ID A4GCT_HUMAN Reviewed; 340 AA. AC Q9UNA3; Q0VDK1; Q0VDK2; DT 25-NOV-2002, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 168. DE RecName: Full=Alpha-1,4-N-acetylglucosaminyltransferase {ECO:0000303|PubMed:10430883}; DE Short=Alpha4GnT {ECO:0000303|PubMed:10430883}; DE EC=2.4.1.- {ECO:0000269|PubMed:10430883}; GN Name=A4GNT {ECO:0000312|HGNC:HGNC:17968}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND RP TISSUE SPECIFICITY. RC TISSUE=Stomach; RX PubMed=10430883; DOI=10.1073/pnas.96.16.8991; RA Nakayama J., Yeh J.-C., Misra A.K., Ito S., Katsuyama T., Fukuda M.; RT "Expression cloning of a human alpha1, 4-N-acetylglucosaminyltransferase RT that forms GlcNAcalpha1-->4Galbeta-->R, a glycan specifically expressed in RT the gastric gland mucous cell-type mucin."; RL Proc. Natl. Acad. Sci. U.S.A. 96:8991-8996(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-218. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). CC -!- FUNCTION: Catalyzes the transfer of N-acetylglucosamine (GlcNAc) CC residues from UDP-N-acetyl-alpha-D-glucosamine donnors to beta (1->4)- CC linked or beta-(1->3)-linked galactose residues on O-glycans like core CC 2 branched O-glycans (PubMed:10430883). Necessary for the synthesis of CC type III mucin which is specifically produced in the stomach, duodenum, CC and pancreatic duct (PubMed:10430883). May protect against CC inflammation-associated gastric adenocarcinomas (By similarity). CC {ECO:0000250|UniProtKB:Q14BT6, ECO:0000269|PubMed:10430883}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-galactoside + UDP-N-acetyl-alpha-D-glucosamine = an CC N-acetyl-alpha-D-glucosaminyl-(1->4)-beta-D-galactosyl derivative + CC UDP + H(+); Xref=Rhea:RHEA:85983, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:28034, ChEBI:CHEBI:57705, ChEBI:CHEBI:58223, CC ChEBI:CHEBI:235336; Evidence={ECO:0000269|PubMed:10430883}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:85984; CC Evidence={ECO:0000269|PubMed:10430883}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 3-O-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl- CC (1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-threonyl-[protein] + UDP- CC N-acetyl-alpha-D-glucosamine = a 3-O-{alpha-D-GlcNAc-(1->4)-beta-D- CC Gal-(1->3)-[beta-D-GlcNAc-(1->6)]-alpha-D-GalNAc}-L-threonyl- CC [protein] + UDP + H(+); Xref=Rhea:RHEA:86035, Rhea:RHEA-COMP:14420, CC Rhea:RHEA-COMP:20700, ChEBI:CHEBI:15378, ChEBI:CHEBI:57705, CC ChEBI:CHEBI:58223, ChEBI:CHEBI:139607, ChEBI:CHEBI:235339; CC Evidence={ECO:0000269|PubMed:10430883}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:86036; CC Evidence={ECO:0000269|PubMed:10430883}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 3-O-{beta-D-Gal-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc- CC (1->6)]-alpha-D-GalNAc}-L-threonyl-[protein] + 2 UDP-N-acetyl-alpha- CC D-glucosamine = a 3-O-{alpha-D-GlcNAc-(1->4)-beta-D-Gal-(1->3)- CC [alpha-D-GlcNAc-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-alpha- CC D-GalNAc}-L-threonyl-[protein] + 2 UDP + 2 H(+); CC Xref=Rhea:RHEA:86039, Rhea:RHEA-COMP:20698, Rhea:RHEA-COMP:20699, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:57705, ChEBI:CHEBI:58223, CC ChEBI:CHEBI:235337, ChEBI:CHEBI:235338; CC Evidence={ECO:0000269|PubMed:10430883}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:86040; CC Evidence={ECO:0000269|PubMed:10430883}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 3-O-{beta-D-Gal-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc- CC (1->6)]-alpha-D-GalNAc}-L-seryl-[protein] + 2 UDP-N-acetyl-alpha-D- CC glucosamine = a 3-O-{alpha-D-GlcNAc-(1->4)-beta-D-Gal-(1->3)-[alpha- CC D-GlcNAc-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-alpha-D- CC GalNAc}-L-seryl-[protein] + 2 UDP + 2 H(+); Xref=Rhea:RHEA:86043, CC Rhea:RHEA-COMP:20707, Rhea:RHEA-COMP:20708, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57705, ChEBI:CHEBI:58223, ChEBI:CHEBI:235340, CC ChEBI:CHEBI:235341; Evidence={ECO:0000269|PubMed:10430883}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:86044; CC Evidence={ECO:0000269|PubMed:10430883}; CC -!- CATALYTIC ACTIVITY: CC Reaction=3-O-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl- CC (1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl-[protein] + UDP-N- CC acetyl-alpha-D-glucosamine = a 3-O-{alpha-D-GlcNAc-(1->4)-beta-D-Gal- CC (1->3)-[beta-D-GlcNAc-(1->6)]-alpha-D-GalNAc}-L-seryl-[protein] + UDP CC + H(+); Xref=Rhea:RHEA:86059, Rhea:RHEA-COMP:14419, Rhea:RHEA- CC COMP:20709, ChEBI:CHEBI:15378, ChEBI:CHEBI:57705, ChEBI:CHEBI:58223, CC ChEBI:CHEBI:139605, ChEBI:CHEBI:235342; CC Evidence={ECO:0000269|PubMed:10430883}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:86060; CC Evidence={ECO:0000269|PubMed:10430883}; CC -!- PATHWAY: Protein modification; protein glycosylation. CC {ECO:0000269|PubMed:10430883}. CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000305}; Single- CC pass type II membrane protein {ECO:0000255}. CC -!- TISSUE SPECIFICITY: Detected in stomach and pancreas. CC {ECO:0000269|PubMed:10430883}. CC -!- DOMAIN: The conserved DXD motif is involved in enzyme activity. CC {ECO:0000250|UniProtKB:Q9JI93}. CC -!- SIMILARITY: Belongs to the glycosyltransferase 32 family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase; Note=Alpha- CC 1,4-N-acetylglucosaminyltransferase; CC URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_532"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF141315; AAD48406.1; -; mRNA. DR EMBL; BC119639; AAI19640.1; -; mRNA. DR EMBL; BC119640; AAI19641.1; -; mRNA. DR CCDS; CCDS3097.1; -. DR RefSeq; NP_057245.1; NM_016161.3. DR RefSeq; XP_016862032.1; XM_017006543.3. DR RefSeq; XP_016862033.1; XM_017006544.2. DR RefSeq; XP_054202697.1; XM_054346722.1. DR RefSeq; XP_054202698.1; XM_054346723.1. DR AlphaFoldDB; Q9UNA3; -. DR SMR; Q9UNA3; -. DR BioGRID; 119330; 59. DR FunCoup; Q9UNA3; 37. DR IntAct; Q9UNA3; 42. DR STRING; 9606.ENSP00000236709; -. DR CAZy; GT32; Glycosyltransferase Family 32. DR GlyCosmos; Q9UNA3; 4 sites, No reported glycans. DR GlyGen; Q9UNA3; 4 sites. DR PhosphoSitePlus; Q9UNA3; -. DR BioMuta; A4GNT; -. DR DMDM; 25452797; -. DR MassIVE; Q9UNA3; -. DR PaxDb; 9606-ENSP00000236709; -. DR PeptideAtlas; Q9UNA3; -. DR Antibodypedia; 2373; 354 antibodies from 34 providers. DR DNASU; 51146; -. DR Ensembl; ENST00000236709.4; ENSP00000236709.3; ENSG00000118017.5. DR GeneID; 51146; -. DR KEGG; hsa:51146; -. DR MANE-Select; ENST00000236709.4; ENSP00000236709.3; NM_016161.3; NP_057245.1. DR UCSC; uc003ers.2; human. DR AGR; HGNC:17968; -. DR ClinPGx; PA134960042; -. DR CTD; 51146; -. DR DisGeNET; 51146; -. DR GeneCards; A4GNT; -. DR HGNC; HGNC:17968; A4GNT. DR HPA; ENSG00000118017; Tissue enriched (stomach). DR OpenTargets; ENSG00000118017; -. DR VEuPathDB; HostDB:ENSG00000118017; -. DR eggNOG; KOG1928; Eukaryota. DR GeneTree; ENSGT00510000047981; -. DR HOGENOM; CLU_049512_2_0_1; -. DR InParanoid; Q9UNA3; -. DR OMA; IWDCMEN; -. DR OrthoDB; 407609at2759; -. DR PAN-GO; Q9UNA3; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9UNA3; -. DR PathwayCommons; Q9UNA3; -. DR Reactome; R-HSA-913709; O-linked glycosylation of mucins. DR SignaLink; Q9UNA3; -. DR UniPathway; UPA00378; -. DR Agora; ENSG00000118017; -. DR BioGRID-ORCS; 51146; 6 hits in 1138 CRISPR screens. DR ChiTaRS; A4GNT; human. DR GenomeRNAi; 51146; -. DR Pharos; Q9UNA3; Tbio. DR PRO; PR:Q9UNA3; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9UNA3; protein. DR Bgee; ENSG00000118017; Expressed in pylorus and 70 other cell types or tissues. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0008375; F:acetylglucosaminyltransferase activity; IDA:MGI. DR GO; GO:0005975; P:carbohydrate metabolic process; TAS:ProtInc. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0009101; P:glycoprotein biosynthetic process; IDA:MGI. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0006493; P:protein O-linked glycosylation; IBA:GO_Central. DR GO; GO:0016266; P:protein O-linked glycosylation via N-acetyl-galactosamine; TAS:Reactome. DR FunFam; 3.90.550.20:FF:000003; Lactosylceramide 4-alpha-galactosyltransferase; 1. DR Gene3D; 3.90.550.20; -; 1. DR InterPro; IPR007652; A1-4-GlycosylTfrase_dom. DR InterPro; IPR051981; Glycosyltransf_32. DR InterPro; IPR007577; GlycoTrfase_DXD_sugar-bd_CS. DR InterPro; IPR029044; Nucleotide-diphossugar_trans. DR PANTHER; PTHR12042:SF16; ALPHA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; 1. DR PANTHER; PTHR12042; LACTOSYLCERAMIDE 4-ALPHA-GALACTOSYLTRANSFERASE ALPHA- 1,4-GALACTOSYLTRANSFERASE; 1. DR Pfam; PF04572; Gb3_synth; 1. DR Pfam; PF04488; Gly_transf_sug; 1. DR SUPFAM; SSF53448; Nucleotide-diphospho-sugar transferases; 1. PE 1: Evidence at protein level; KW Glycoprotein; Glycosyltransferase; Golgi apparatus; Membrane; KW Proteomics identification; Reference proteome; Signal-anchor; Transferase; KW Transmembrane; Transmembrane helix. FT CHAIN 1..340 FT /note="Alpha-1,4-N-acetylglucosaminyltransferase" FT /id="PRO_0000080583" FT TOPO_DOM 1..4 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 5..25 FT /note="Helical; Signal-anchor for type II membrane protein" FT /evidence="ECO:0000255" FT TOPO_DOM 26..340 FT /note="Lumenal" FT /evidence="ECO:0000255" FT MOTIF 167..169 FT /note="DXD motif" FT /evidence="ECO:0000250|UniProtKB:Q9JI93" FT CARBOHYD 99 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 251 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VARIANT 218 FT /note="A -> D (in dbSNP:rs2246945)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_022096" SQ SEQUENCE 340 AA; 39497 MW; 00D667A8394300AB CRC64; MRKELQLSLS VTLLLVCGFL YQFTLKSSCL FCLPSFKSHQ GLEALLSHRR GIVFLETSER MEPPHLVSCS VESAAKIYPE WPVVFFMKGL TDSTPMPSNS TYPAFSFLSA IDNVFLFPLD MKRLLEDTPL FSWYNQINAS AERNWLHISS DASRLAIIWK YGGIYMDTDV ISIRPIPEEN FLAAQASRYS SNGIFGFLPH HPFLWECMEN FVEHYNSAIW GNQGPELMTR MLRVWCKLED FQEVSDLRCL NISFLHPQRF YPISYREWRR YYEVWDTEPS FNVSYALHLW NHMNQEGRAV IRGSNTLVEN LYRKHCPRTY RDLIKGPEGS VTGELGPGNK // ID AAPK2_HUMAN Reviewed; 552 AA. AC P54646; Q9H1E8; Q9UD43; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 16-APR-2002, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-2; DE Short=AMPK subunit alpha-2; DE EC=2.7.11.1 {ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:32029622, ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666}; DE AltName: Full=Acetyl-CoA carboxylase kinase; DE Short=ACACA kinase; DE AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase; DE Short=HMGCR kinase; DE EC=2.7.11.31 {ECO:0000250|UniProtKB:Q09137}; GN Name=PRKAA2 {ECO:0000312|HGNC:HGNC:9377}; Synonyms=AMPK, AMPK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RC TISSUE=Heart; RX PubMed=7959015; DOI=10.1016/0378-1119(94)90174-0; RA Aguan K., Scott J., See C.G., Sarkar N.H.; RT "Characterization and chromosomal localization of the human homologue of a RT rat AMP-activated protein kinase-encoding gene: a major regulator of lipid RT metabolism in mammals."; RL Gene 149:345-350(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Skeletal muscle; RX PubMed=7988703; DOI=10.1016/0014-5793(94)01247-4; RA Beri R.K., Marley A.E., See C.G., Sopwith W.F., Aguan K., Carling D., RA Scott J., Carey F.; RT "Molecular cloning, expression and chromosomal localisation of human AMP- RT activated protein kinase."; RL FEBS Lett. 356:117-121(1994). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [6] RP FUNCTION IN PHOSPHORYLATION OF EP300. RX PubMed=11518699; DOI=10.1074/jbc.c100316200; RA Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.; RT "Regulation of transcription by AMP-activated protein kinase: RT phosphorylation of p300 blocks its interaction with nuclear receptors."; RL J. Biol. Chem. 276:38341-38344(2001). RN [7] RP ACTIVITY REGULATION. RX PubMed=11602624; DOI=10.1172/jci13505; RA Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., RA Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., RA Moller D.E.; RT "Role of AMP-activated protein kinase in mechanism of metformin action."; RL J. Clin. Invest. 108:1167-1174(2001). RN [8] RP FUNCTION IN PHOSPHORYLATION OF CFTR. RX PubMed=12519745; DOI=10.1152/ajpcell.00227.2002; RA Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.; RT "Physiological modulation of CFTR activity by AMP-activated protein kinase RT in polarized T84 cells."; RL Am. J. Physiol. 284:C1297-C1308(2003). RN [9] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [10] RP PHOSPHORYLATION AT THR-172, AND ACTIVITY REGULATION. RX PubMed=15980064; DOI=10.1074/jbc.m503824200; RA Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R., RA Witters L.A.; RT "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated RT protein kinase kinases."; RL J. Biol. Chem. 280:29060-29066(2005). RN [11] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [12] RP FUNCTION IN PHOSPHORYLATION OF FOXO3. RX PubMed=17711846; DOI=10.1074/jbc.m705325200; RA Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., RA Brunet A.; RT "The energy sensor AMP-activated protein kinase directly regulates the RT mammalian FOXO3 transcription factor."; RL J. Biol. Chem. 282:30107-30119(2007). RN [13] RP FUNCTION IN CELL POLARITY. RX PubMed=17486097; DOI=10.1038/nature05828; RA Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H., RA Shong M., Kim J.M., Kim J., Chung J.; RT "Energy-dependent regulation of cell structure by AMP-activated protein RT kinase."; RL Nature 447:1017-1020(2007). RN [14] RP FUNCTION IN PHOSPHORYLATION OF HDAC5. RX PubMed=18184930; DOI=10.2337/db07-0843; RA McGee S.L., van Denderen B.J., Howlett K.F., Mollica J., Schertzer J.D., RA Kemp B.E., Hargreaves M.; RT "AMP-activated protein kinase regulates GLUT4 transcription by RT phosphorylating histone deacetylase 5."; RL Diabetes 57:860-867(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KLC1. RX PubMed=20074060; DOI=10.1042/bst0380205; RA McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G., Rutter G.A.; RT "Cell-wide analysis of secretory granule dynamics in three dimensions in RT living pancreatic beta-cells: evidence against a role for AMPK-dependent RT phosphorylation of KLC1 at Ser517/Ser520 in glucose-stimulated insulin RT granule movement."; RL Biochem. Soc. Trans. 38:205-208(2010). RN [19] RP FUNCTION. RX PubMed=20160076; DOI=10.1073/pnas.0913860107; RA Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K., RA Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B., RA Walker C.L.; RT "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to RT ROS."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010). RN [20] RP PHOSPHORYLATION BY ULK1. RX PubMed=21460634; DOI=10.4161/auto.7.7.15451; RA Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M., RA Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.; RT "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory RT feedback loop."; RL Autophagy 7:696-706(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP FUNCTION IN PHOSPHORYLATION OF ULK1. RX PubMed=21205641; DOI=10.1126/science.1196371; RA Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., RA Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., RA Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.; RT "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects RT energy sensing to mitophagy."; RL Science 331:456-461(2011). RN [23] RP REVIEW ON FUNCTION. RX PubMed=17307971; DOI=10.1161/01.res.0000256090.42690.05; RA Towler M.C., Hardie D.G.; RT "AMP-activated protein kinase in metabolic control and insulin signaling."; RL Circ. Res. 100:328-341(2007). RN [24] RP REVIEW ON FUNCTION. RX PubMed=17712357; DOI=10.1038/nrm2249; RA Hardie D.G.; RT "AMP-activated/SNF1 protein kinases: conserved guardians of cellular RT energy."; RL Nat. Rev. Mol. Cell Biol. 8:774-785(2007). RN [25] RP ACTIVITY REGULATION BY SALICYLATE. RX PubMed=22517326; DOI=10.1126/science.1215327; RA Hawley S.A., Fullerton M.D., Ross F.A., Schertzer J.D., Chevtzoff C., RA Walker K.J., Peggie M.W., Zibrova D., Green K.A., Mustard K.J., Kemp B.E., RA Sakamoto K., Steinberg G.R., Hardie D.G.; RT "The ancient drug salicylate directly activates AMP-activated protein RT kinase."; RL Science 336:918-922(2012). RN [26] RP DEPHOSPHORYLATION AT THR-172. RX PubMed=23088624; DOI=10.1042/bj20121201; RA Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y., Takano-Yamamoto T., RA Tamura S., Kobayashi T.; RT "N-Myristoylation is essential for protein phosphatases PPM1A and PPM1B to RT dephosphorylate their physiological substrates in cells."; RL Biochem. J. 449:741-749(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP PHOSPHORYLATION AT THR-172. RX PubMed=24767988; DOI=10.1016/j.celrep.2014.03.065; RA Lanning N.J., Looyenga B.D., Kauffman A.L., Niemi N.M., Sudderth J., RA DeBerardinis R.J., MacKeigan J.P.; RT "A mitochondrial RNAi screen defines cellular bioenergetic determinants and RT identifies an adenylate kinase as a key regulator of ATP levels."; RL Cell Rep. 7:907-917(2014). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=25687571; DOI=10.1074/mcp.m114.047159; RA Boutchueng-Djidjou M., Collard-Simard G., Fortier S., Hebert S.S., RA Kelly I., Landry C.R., Faure R.L.; RT "The last enzyme of the de novo purine synthesis pathway 5-aminoimidazole- RT 4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) RT plays a central role in insulin signaling and the Golgi/endosomes protein RT network."; RL Mol. Cell. Proteomics 14:1079-1092(2015). RN [30] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT THR-172, INTERACTION WITH RP ACSS2, AND MUTAGENESIS OF THR-172. RX PubMed=28552616; DOI=10.1016/j.molcel.2017.04.026; RA Li X., Yu W., Qian X., Xia Y., Zheng Y., Lee J.H., Li W., Lyu J., Rao G., RA Zhang X., Qian C.N., Rozen S.G., Jiang T., Lu Z.; RT "Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal RT Biogenesis and Autophagy."; RL Mol. Cell 66:684-697(2017). RN [31] RP FUNCTION. RX PubMed=28561066; DOI=10.1038/ncomms15637; RA Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M., RA Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B., RA Proikas-Cezanne T.; RT "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling RT circuits in the control of autophagy."; RL Nat. Commun. 8:15637-15637(2017). RN [32] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32029622; DOI=10.1126/science.aay0542; RA Zhao P., Sun X., Chaggan C., Liao Z., In Wong K., He F., Singh S., RA Loomba R., Karin M., Witztum J.L., Saltiel A.R.; RT "An AMPK-caspase-6 axis controls liver damage in nonalcoholic RT steatohepatitis."; RL Science 367:652-660(2020). RN [33] RP FUNCTION. RX PubMed=34077757; DOI=10.1016/j.molcel.2021.05.005; RA Liu R., Lee J.H., Li J., Yu R., Tan L., Xia Y., Zheng Y., Bian X.L., RA Lorenzi P.L., Chen Q., Lu Z.; RT "Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of RT lipid droplets."; RL Mol. Cell 81:2722-2735(2021). RN [34] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=36732624; DOI=10.1038/s42255-022-00732-4; RA Dai X., Jiang C., Jiang Q., Fang L., Yu H., Guo J., Yan P., Chi F., RA Zhang T., Inuzuka H., Asara J.M., Wang P., Guo J., Wei W.; RT "AMPK-dependent phosphorylation of the GATOR2 component WDR24 suppresses RT glucose-mediated mTORC1 activation."; RL Nat. Metab. 5:265-276(2023). RN [35] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37079666; DOI=10.1126/science.abj5559; RA Malik N., Ferreira B.I., Hollstein P.E., Curtis S.D., Trefts E., RA Weiser Novak S., Yu J., Gilson R., Hellberg K., Fang L., Sheridan A., RA Hah N., Shadel G.S., Manor U., Shaw R.J.; RT "Induction of lysosomal and mitochondrial biogenesis by AMPK RT phosphorylation of FNIP1."; RL Science 380:eabj5559-eabj5559(2023). RN [36] RP FUNCTION, INTERACTION WITH ARF6, AND MUTAGENESIS OF LYS-45 AND THR-172. RX PubMed=36017701; DOI=10.1242/jcs.259609; RA Chen K.J., Hsu J.W., Lee F.S.; RT "AMPK promotes Arf6 activation in a kinase-independent manner upon glucose RT starvation."; RL J. Cell Sci. 135:0-0(2022). RN [37] RP FUNCTION. RX PubMed=36367943; DOI=10.1126/sciadv.abo7956; RA Tilokani L., Russell F.M., Hamilton S., Virga D.M., Segawa M., Paupe V., RA Gruszczyk A.V., Protasoni M., Tabara L.C., Johnson M., Anand H., RA Murphy M.P., Hardie D.G., Polleux F., Prudent J.; RT "AMPK-dependent phosphorylation of MTFR1L regulates mitochondrial RT morphology."; RL Sci. Adv. 8:eabo7956-eabo7956(2022). RN [38] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-279. RX PubMed=20124709; DOI=10.1107/s1744309109052543; RA Littler D.R., Walker J.R., Davis T., Wybenga-Groot L.E., Finerty P.J. Jr., RA Newman E., Mackenzie F., Dhe-Paganon S.; RT "A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP- RT binding site and catalytic loop refolding as a means of regulation."; RL Acta Crystallogr. F 66:143-151(2010). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 6-279 OF MUTANT THR-172 IN RP COMPLEX WITH COMPOUND C, ACTIVITY REGULATION, AND MUTAGENESIS OF THR-172. RX PubMed=21543851; DOI=10.1107/s0907444911010201; RA Handa N., Takagi T., Saijo S., Kishishita S., Takaya D., Toyama M., RA Terada T., Shirouzu M., Suzuki A., Lee S., Yamauchi T., Okada-Iwabu M., RA Iwabu M., Kadowaki T., Minokoshi Y., Yokoyama S.; RT "Structural basis for compound C inhibition of the human AMP-activated RT protein kinase alpha2 subunit kinase domain."; RL Acta Crystallogr. D 67:480-487(2011). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLY-523. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLN-407. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase (AMPK), an CC energy sensor protein kinase that plays a key role in regulating CC cellular energy metabolism (PubMed:17307971, PubMed:17712357). In CC response to reduction of intracellular ATP levels, AMPK activates CC energy-producing pathways and inhibits energy-consuming processes: CC inhibits protein, carbohydrate and lipid biosynthesis, as well as cell CC growth and proliferation (PubMed:17307971, PubMed:17712357). AMPK acts CC via direct phosphorylation of metabolic enzymes, and by longer-term CC effects via phosphorylation of transcription regulators CC (PubMed:17307971, PubMed:17712357). Regulates lipid synthesis by CC phosphorylating and inactivating lipid metabolic enzymes such as ACACA, CC ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol CC synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) CC and hormone-sensitive lipase (LIPE) enzymes, respectively CC (PubMed:7959015). Promotes lipolysis of lipid droplets by mediating CC phosphorylation of isoform 1 of CHKA (CHKalpha2) (PubMed:34077757). CC Regulates insulin-signaling and glycolysis by phosphorylating IRS1, CC PFKFB2 and PFKFB3 (By similarity). Involved in insulin receptor/INSR CC internalization (PubMed:25687571). AMPK stimulates glucose uptake in CC muscle by increasing the translocation of the glucose transporter CC SLC2A4/GLUT4 to the plasma membrane, possibly by mediating CC phosphorylation of TBC1D4/AS160 (By similarity). Regulates CC transcription and chromatin structure by phosphorylating transcription CC regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, CC histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, CC SREBF1, SREBF2 and PPARGC1A (PubMed:11518699, PubMed:11554766, CC PubMed:15866171, PubMed:17711846, PubMed:18184930). Acts as a key CC regulator of glucose homeostasis in liver by phosphorylating CC CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm (By CC similarity). In response to stress, phosphorylates 'Ser-36' of histone CC H2B (H2BS36ph), leading to promote transcription (By similarity). Acts CC as a key regulator of cell growth and proliferation by phosphorylating CC FNIP1, TSC2, RPTOR, WDR24 and ATG1/ULK1: in response to nutrient CC limitation, negatively regulates the mTORC1 complex by phosphorylating CC RPTOR component of the mTORC1 complex and by phosphorylating and CC activating TSC2 (PubMed:14651849, PubMed:20160076, PubMed:21205641). CC Also phosphorylates and inhibits GATOR2 subunit WDR24 in response to CC nutrient limitation, leading to suppress glucose-mediated mTORC1 CC activation (PubMed:36732624). In response to energetic stress, CC phosphorylates FNIP1, inactivating the non-canonical mTORC1 signaling, CC thereby promoting nuclear translocation of TFEB and TFE3, and inducing CC transcription of lysosomal or autophagy genes (PubMed:37079666). In CC response to nutrient limitation, promotes autophagy by phosphorylating CC and activating ATG1/ULK1 (PubMed:21205641). In that process, it also CC activates WDR45/WIPI4 (PubMed:28561066). Phosphorylates CASP6, thereby CC preventing its autoprocessing and subsequent activation CC (PubMed:32029622). AMPK also acts as a regulator of circadian rhythm by CC mediating phosphorylation of CRY1, leading to destabilize it (By CC similarity). May regulate the Wnt signaling pathway by phosphorylating CC CTNNB1, leading to stabilize it (By similarity). Also acts as a CC regulator of cellular polarity by remodeling the actin cytoskeleton; CC probably by indirectly activating myosin (PubMed:17486097). Also CC phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1 (PubMed:12519745, CC PubMed:20074060). Plays an important role in the differential CC regulation of pro-autophagy (composed of PIK3C3, BECN1, PIK3R4 and CC UVRAG or ATG14) and non-autophagy (composed of PIK3C3, BECN1 and CC PIK3R4) complexes, in response to glucose starvation (By similarity). CC Can inhibit the non-autophagy complex by phosphorylating PIK3C3 and can CC activate the pro-autophagy complex by phosphorylating BECN1 (By CC similarity). Upon glucose starvation, promotes ARF6 activation in a CC kinase-independent manner leading to cell migration (PubMed:36017701). CC Upon glucose deprivation mediates the phosphorylation of ACSS2 at 'Ser- CC 659', which exposes the nuclear localization signal of ACSS2, required CC for its interaction with KPNA1 and nuclear translocation CC (PubMed:28552616). Upon stress, regulates mitochondrial fragmentation CC through phosphorylation of MTFR1L (PubMed:36367943). CC {ECO:0000250|UniProtKB:Q09137, ECO:0000250|UniProtKB:Q8BRK8, CC ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17486097, CC ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:18184930, CC ECO:0000269|PubMed:20074060, ECO:0000269|PubMed:20160076, CC ECO:0000269|PubMed:21205641, ECO:0000269|PubMed:25687571, CC ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:28561066, CC ECO:0000269|PubMed:32029622, ECO:0000269|PubMed:34077757, CC ECO:0000269|PubMed:36017701, ECO:0000269|PubMed:36367943, CC ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666, CC ECO:0000269|PubMed:7959015, ECO:0000303|PubMed:17307971, CC ECO:0000303|PubMed:17712357}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:32029622, CC ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[acetyl-CoA carboxylase] + ATP = O-phospho-L-seryl- CC [acetyl-CoA carboxylase] + ADP + H(+); Xref=Rhea:RHEA:20333, CC Rhea:RHEA-COMP:13722, Rhea:RHEA-COMP:13723, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A reductase] + CC ATP = O-phospho-L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A CC reductase] + ADP + H(+); Xref=Rhea:RHEA:23172, Rhea:RHEA-COMP:13692, CC Rhea:RHEA-COMP:13693, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; CC EC=2.7.11.31; Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-172 CC (PubMed:15980064). Binding of AMP to non-catalytic gamma subunit CC (PRKAG1, PRKAG2 or PRKAG3) results in allosteric activation, inducing CC phosphorylation on Thr-172 (PubMed:15980064). AMP-binding to gamma CC subunit also sustains activity by preventing dephosphorylation of Thr- CC 172 (PubMed:15980064). ADP also stimulates Thr-172 phosphorylation, CC without stimulating already phosphorylated AMPK (PubMed:15980064). ATP CC promotes dephosphorylation of Thr-172, rendering the enzyme inactive CC (PubMed:15980064). Under physiological conditions AMPK mainly exists in CC its inactive form in complex with ATP, which is much more abundant than CC AMP. AMPK is activated by antihyperglycemic drug metformin, a drug CC prescribed to patients with type 2 diabetes: in vivo, metformin seems CC to mainly inhibit liver gluconeogenesis. However, metformin can be used CC to activate AMPK in muscle and other cells in culture or ex vivo CC (PubMed:11602624). Selectively inhibited by compound C (6-[4-(2- CC Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a] CC pyrimidine. Activated by resveratrol, a natural polyphenol present in CC red wine, and S17834, a synthetic polyphenol. Salicylate/aspirin CC directly activates kinase activity, primarily by inhibiting Thr-172 CC dephosphorylation. {ECO:0000269|PubMed:11602624, CC ECO:0000269|PubMed:15980064, ECO:0000269|PubMed:21543851, CC ECO:0000269|PubMed:22517326}. CC -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit (PRKAA1 CC or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-catalytic CC subunits (PRKAG1, PRKAG2 or PRKAG3) (PubMed:21543851). Interacts with CC FNIP1 and FNIP2. Associates with internalized insulin receptor/INSR CC complexes on Golgi/endosomal membranes; PRKAA2/AMPK2 together with ATIC CC and HACD3/PTPLAD1 is proposed to be part of a signaling network CC regulating INSR autophosphorylation and endocytosis (PubMed:25687571). CC Interacts with ARF6 (PubMed:36017701). The phosphorylated form at Thr- CC 172 mediated by CamKK2 interacts with ACSS2 (PubMed:28552616). CC {ECO:0000269|PubMed:21543851, ECO:0000269|PubMed:25687571, CC ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:36017701}. CC -!- INTERACTION: CC P54646; Q8IZP0-5: ABI1; NbExp=3; IntAct=EBI-1383852, EBI-11743294; CC P54646; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-1383852, EBI-743598; CC P54646; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-1383852, EBI-11096309; CC P54646; Q13155: AIMP2; NbExp=3; IntAct=EBI-1383852, EBI-745226; CC P54646; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-1383852, EBI-357530; CC P54646; P31749: AKT1; NbExp=3; IntAct=EBI-1383852, EBI-296087; CC P54646; A2BDD9: AMOT; NbExp=3; IntAct=EBI-1383852, EBI-17286414; CC P54646; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-1383852, EBI-746752; CC P54646; Q9NYG5-2: ANAPC11; NbExp=3; IntAct=EBI-1383852, EBI-12224467; CC P54646; Q92624: APPBP2; NbExp=3; IntAct=EBI-1383852, EBI-743771; CC P54646; Q96B67: ARRDC3; NbExp=3; IntAct=EBI-1383852, EBI-2875665; CC P54646; Q5T686: AVPI1; NbExp=3; IntAct=EBI-1383852, EBI-8640233; CC P54646; Q9P1Z2: CALCOCO1; NbExp=3; IntAct=EBI-1383852, EBI-749920; CC P54646; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-1383852, EBI-739580; CC P54646; P0C7W6: CCDC172; NbExp=3; IntAct=EBI-1383852, EBI-2548868; CC P54646; Q9NPC3: CCNB1IP1; NbExp=4; IntAct=EBI-1383852, EBI-745269; CC P54646; Q00587-2: CDC42EP1; NbExp=3; IntAct=EBI-1383852, EBI-11027409; CC P54646; Q01850: CDR2; NbExp=3; IntAct=EBI-1383852, EBI-1181367; CC P54646; O14627: CDX4; NbExp=3; IntAct=EBI-1383852, EBI-10181162; CC P54646; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-1383852, EBI-11523759; CC P54646; O75638-2: CTAG2; NbExp=3; IntAct=EBI-1383852, EBI-12265122; CC P54646; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-1383852, EBI-3867333; CC P54646; Q9NQM4: DNAAF6; NbExp=3; IntAct=EBI-1383852, EBI-10239299; CC P54646; P50570: DNM2; NbExp=3; IntAct=EBI-1383852, EBI-346547; CC P54646; Q92997: DVL3; NbExp=3; IntAct=EBI-1383852, EBI-739789; CC P54646; Q9Y6C2-2: EMILIN1; NbExp=3; IntAct=EBI-1383852, EBI-11748557; CC P54646; O95208-2: EPN2; NbExp=3; IntAct=EBI-1383852, EBI-12135243; CC P54646; Q53EP0-3: FNDC3B; NbExp=3; IntAct=EBI-1383852, EBI-10242151; CC P54646; Q6FG41: FOS; NbExp=3; IntAct=EBI-1383852, EBI-10198738; CC P54646; O75420: GIGYF1; NbExp=3; IntAct=EBI-1383852, EBI-947774; CC P54646; P08151: GLI1; NbExp=3; IntAct=EBI-1383852, EBI-308084; CC P54646; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1383852, EBI-618309; CC P54646; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-1383852, EBI-11163335; CC P54646; O75791: GRAP2; NbExp=3; IntAct=EBI-1383852, EBI-740418; CC P54646; P28799: GRN; NbExp=3; IntAct=EBI-1383852, EBI-747754; CC P54646; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-1383852, EBI-2549423; CC P54646; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-1383852, EBI-10172004; CC P54646; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-1383852, EBI-11522367; CC P54646; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383852, EBI-747204; CC P54646; Q719H9: KCTD1; NbExp=3; IntAct=EBI-1383852, EBI-9027502; CC P54646; Q7L273: KCTD9; NbExp=3; IntAct=EBI-1383852, EBI-4397613; CC P54646; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-1383852, EBI-3437878; CC P54646; Q96L93-6: KIF16B; NbExp=3; IntAct=EBI-1383852, EBI-10988217; CC P54646; Q5T7B8-2: KIF24; NbExp=3; IntAct=EBI-1383852, EBI-10213781; CC P54646; Q9BVG8: KIFC3; NbExp=4; IntAct=EBI-1383852, EBI-2125614; CC P54646; P08779: KRT16; NbExp=3; IntAct=EBI-1383852, EBI-356410; CC P54646; Q15323: KRT31; NbExp=3; IntAct=EBI-1383852, EBI-948001; CC P54646; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-1383852, EBI-11749135; CC P54646; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-1383852, EBI-10172052; CC P54646; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-2686809; CC P54646; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-11985629; CC P54646; P80188: LCN2; NbExp=3; IntAct=EBI-1383852, EBI-11911016; CC P54646; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-1383852, EBI-741037; CC P54646; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383852, EBI-2340269; CC P54646; Q6PF18: MORN3; NbExp=3; IntAct=EBI-1383852, EBI-9675802; CC P54646; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-1383852, EBI-995714; CC P54646; Q5JR59-3: MTUS2; NbExp=4; IntAct=EBI-1383852, EBI-11522433; CC P54646; P12524-2: MYCL; NbExp=3; IntAct=EBI-1383852, EBI-18936665; CC P54646; Q15742: NAB2; NbExp=3; IntAct=EBI-1383852, EBI-8641936; CC P54646; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-1383852, EBI-10172876; CC P54646; Q15233-2: NONO; NbExp=3; IntAct=EBI-1383852, EBI-10203843; CC P54646; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-1383852, EBI-945833; CC P54646; Q96F24: NRBF2; NbExp=3; IntAct=EBI-1383852, EBI-2362014; CC P54646; Q86Y26: NUTM1; NbExp=3; IntAct=EBI-1383852, EBI-10178410; CC P54646; Q494U1-3: PLEKHN1; NbExp=3; IntAct=EBI-1383852, EBI-12014286; CC P54646; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383852, EBI-11320284; CC P54646; Q9Y478: PRKAB1; NbExp=10; IntAct=EBI-1383852, EBI-719769; CC P54646; O43741: PRKAB2; NbExp=18; IntAct=EBI-1383852, EBI-1053424; CC P54646; P54619: PRKAG1; NbExp=14; IntAct=EBI-1383852, EBI-1181439; CC P54646; P31321: PRKAR1B; NbExp=3; IntAct=EBI-1383852, EBI-2805516; CC P54646; P41219: PRPH; NbExp=3; IntAct=EBI-1383852, EBI-752074; CC P54646; Q86YV0: RASAL3; NbExp=3; IntAct=EBI-1383852, EBI-3437896; CC P54646; Q93062: RBPMS; NbExp=3; IntAct=EBI-1383852, EBI-740322; CC P54646; Q04864-2: REL; NbExp=4; IntAct=EBI-1383852, EBI-10829018; CC P54646; Q8HWS3: RFX6; NbExp=3; IntAct=EBI-1383852, EBI-746118; CC P54646; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-1383852, EBI-396669; CC P54646; Q7Z5V6-2: SAXO4; NbExp=3; IntAct=EBI-1383852, EBI-12000762; CC P54646; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-1383852, EBI-748621; CC P54646; Q15477: SKIC2; NbExp=3; IntAct=EBI-1383852, EBI-373226; CC P54646; Q9H6Q3: SLA2; NbExp=3; IntAct=EBI-1383852, EBI-1222854; CC P54646; Q5JUK2: SOHLH1; NbExp=3; IntAct=EBI-1383852, EBI-12288855; CC P54646; O43609: SPRY1; NbExp=3; IntAct=EBI-1383852, EBI-3866665; CC P54646; Q6ZMT1: STAC2; NbExp=3; IntAct=EBI-1383852, EBI-948802; CC P54646; Q15831: STK11; NbExp=3; IntAct=EBI-1383852, EBI-306838; CC P54646; P15884: TCF4; NbExp=3; IntAct=EBI-1383852, EBI-533224; CC P54646; Q96CG3: TIFA; NbExp=3; IntAct=EBI-1383852, EBI-740711; CC P54646; Q08117: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-717810; CC P54646; Q08117-2: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-11741437; CC P54646; Q15645: TRIP13; NbExp=3; IntAct=EBI-1383852, EBI-358993; CC P54646; Q15654: TRIP6; NbExp=3; IntAct=EBI-1383852, EBI-742327; CC P54646; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-1383852, EBI-739485; CC P54646; O75385: ULK1; NbExp=2; IntAct=EBI-1383852, EBI-908831; CC P54646; Q9Y6N9-4: USH1C; NbExp=3; IntAct=EBI-1383852, EBI-11523636; CC P54646; Q495M9: USH1G; NbExp=3; IntAct=EBI-1383852, EBI-8601749; CC P54646; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-1383852, EBI-739895; CC P54646; Q9UK41-2: VPS28; NbExp=3; IntAct=EBI-1383852, EBI-12146727; CC P54646; Q9H9H4: VPS37B; NbExp=3; IntAct=EBI-1383852, EBI-4400866; CC P54646; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-1383852, EBI-2799833; CC P54646; O76024: WFS1; NbExp=3; IntAct=EBI-1383852, EBI-720609; CC P54646; O00308: WWP2; NbExp=3; IntAct=EBI-1383852, EBI-743923; CC P54646; P62258: YWHAE; NbExp=2; IntAct=EBI-1383852, EBI-356498; CC P54646; Q96BR9: ZBTB8A; NbExp=3; IntAct=EBI-1383852, EBI-742740; CC P54646; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-1383852, EBI-12030590; CC P54646; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-1383852, EBI-1640204; CC P54646; Q8NF99: ZNF397; NbExp=3; IntAct=EBI-1383852, EBI-10213894; CC P54646; Q3MJ62: ZSCAN23; NbExp=3; IntAct=EBI-1383852, EBI-5667532; CC P54646; Q9WTK7: Stk11; Xeno; NbExp=2; IntAct=EBI-1383852, EBI-8627450; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q8BRK8}. Nucleus CC {ECO:0000269|PubMed:15866171}. Note=In response to stress, recruited by CC p53/TP53 to specific promoters. {ECO:0000269|PubMed:15866171}. CC -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some sequence CC similarity with the ubiquitin-associated domains and represses kinase CC activity. {ECO:0000250|UniProtKB:Q13131}. CC -!- PTM: Ubiquitinated. {ECO:0000250|UniProtKB:Q8BRK8}. CC -!- PTM: Phosphorylated at Thr-172 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39. Also CC phosphorylated at Thr-172 by CAMKK2; triggered by a rise in CC intracellular calcium ions, without detectable changes in the AMP/ATP CC ratio. CAMKK1 can also phosphorylate Thr-172, but at much lower level. CC Dephosphorylated by protein phosphatase 2A and 2C (PP2A and PP2C). CC Phosphorylated by ULK1; leading to negatively regulate AMPK activity CC and suggesting the existence of a regulatory feedback loop between ULK1 CC and AMPK. Dephosphorylated by PPM1A and PPM1B at Thr-172 (mediated by CC STK11/LKB1). {ECO:0000269|PubMed:15980064, CC ECO:0000269|PubMed:21460634}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U06454; AAA64745.1; -; mRNA. DR EMBL; AL035705; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC069680; AAH69680.1; -; mRNA. DR EMBL; BC069740; AAH69740.1; -; mRNA. DR EMBL; BC069823; AAH69823.1; -; mRNA. DR CCDS; CCDS605.1; -. DR PIR; S51025; S51025. DR RefSeq; NP_006243.2; NM_006252.3. DR PDB; 2H6D; X-ray; 1.85 A; A=6-279. DR PDB; 2LTU; NMR; -; A=282-339. DR PDB; 2YZA; X-ray; 3.02 A; A=6-279. DR PDB; 3AQV; X-ray; 2.08 A; A=6-279. DR PDB; 4CFE; X-ray; 3.02 A; A/C=1-552. DR PDB; 4CFF; X-ray; 3.92 A; A/C=1-552. DR PDB; 4ZHX; X-ray; 2.99 A; A/C=2-552. DR PDB; 5EZV; X-ray; 2.99 A; A/C=2-347, A/C=397-552. DR PDB; 5ISO; X-ray; 2.63 A; A/C=1-552. DR PDB; 6B1U; X-ray; 2.77 A; A/C=2-552. DR PDB; 6B2E; X-ray; 3.80 A; A=2-552. DR PDB; 6BX6; X-ray; 2.90 A; A=6-279. DR PDB; 7MYJ; X-ray; 2.95 A; A/C=2-552. DR PDB; 8BIK; X-ray; 2.50 A; A/D=1-552. DR PDB; 9IC2; X-ray; 2.50 A; A=6-280. DR PDBsum; 2H6D; -. DR PDBsum; 2LTU; -. DR PDBsum; 2YZA; -. DR PDBsum; 3AQV; -. DR PDBsum; 4CFE; -. DR PDBsum; 4CFF; -. DR PDBsum; 4ZHX; -. DR PDBsum; 5EZV; -. DR PDBsum; 5ISO; -. DR PDBsum; 6B1U; -. DR PDBsum; 6B2E; -. DR PDBsum; 6BX6; -. DR PDBsum; 7MYJ; -. DR PDBsum; 8BIK; -. DR PDBsum; 9IC2; -. DR AlphaFoldDB; P54646; -. DR BMRB; P54646; -. DR SMR; P54646; -. DR BioGRID; 111550; 239. DR ComplexPortal; CPX-5787; AMPK complex, alpha2-beta1-gamma1 variant. DR ComplexPortal; CPX-5790; AMPK complex, alpha2-beta2-gamma1 variant. DR ComplexPortal; CPX-5840; AMPK complex, alpha2-beta2-gamma3 variant. DR ComplexPortal; CPX-5843; AMPK complex, alpha2-beta1-gamma3 variant. DR ComplexPortal; CPX-5844; AMPK complex, alpha2-beta1-gamma2 variant. DR ComplexPortal; CPX-5845; AMPK complex, alpha2-beta2-gamma2 variant. DR CORUM; P54646; -. DR DIP; DIP-39796N; -. DR FunCoup; P54646; 2136. DR IntAct; P54646; 181. DR MINT; P54646; -. DR STRING; 9606.ENSP00000360290; -. DR BindingDB; P54646; -. DR ChEMBL; CHEMBL2116; -. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB00131; Adenosine phosphate. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00273; Topiramate. DR DrugCentral; P54646; -. DR TCDB; 8.A.104.1.1; the 5'-amp-activated protein kinase (ampk) family. DR GlyConnect; 985; 2 N-Linked glycans (1 site). DR GlyCosmos; P54646; 1 site, 3 glycans. DR GlyGen; P54646; 2 sites, 3 N-linked glycans (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P54646; -. DR PhosphoSitePlus; P54646; -. DR BioMuta; PRKAA2; -. DR DMDM; 20178276; -. DR jPOST; P54646; -. DR MassIVE; P54646; -. DR PaxDb; 9606-ENSP00000360290; -. DR PeptideAtlas; P54646; -. DR ProteomicsDB; 56689; -. DR Pumba; P54646; -. DR Antibodypedia; 3399; 836 antibodies from 45 providers. DR DNASU; 5563; -. DR Ensembl; ENST00000371244.9; ENSP00000360290.4; ENSG00000162409.13. DR GeneID; 5563; -. DR KEGG; hsa:5563; -. DR MANE-Select; ENST00000371244.9; ENSP00000360290.4; NM_006252.4; NP_006243.2. DR UCSC; uc001cyk.5; human. DR AGR; HGNC:9377; -. DR CIViC; 5563; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33745; -. DR CTD; 5563; -. DR DisGeNET; 5563; -. DR GeneCards; PRKAA2; -. DR HGNC; HGNC:9377; PRKAA2. DR HPA; ENSG00000162409; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MIM; 600497; gene. DR OpenTargets; ENSG00000162409; -. DR VEuPathDB; HostDB:ENSG00000162409; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000156945; -. DR HOGENOM; CLU_000288_59_3_1; -. DR InParanoid; P54646; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; P54646; 4 GO annotations based on evolutionary models. DR PhylomeDB; P54646; -. DR BRENDA; 2.7.11.1; 2681. DR BRENDA; 2.7.11.31; 2681. DR PathwayCommons; P54646; -. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-200425; Carnitine shuttle. DR Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9613354; Lipophagy. DR Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs. DR Reactome; R-HSA-9759194; Nuclear events mediated by NFE2L2. DR SignaLink; P54646; -. DR SIGNOR; P54646; -. DR Agora; ENSG00000162409; -. DR BioGRID-ORCS; 5563; 16 hits in 1188 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; PRKAA2; human. DR EvolutionaryTrace; P54646; -. DR GeneWiki; PRKAA2; -. DR GenomeRNAi; 5563; -. DR Pharos; P54646; Tchem. DR PRO; PR:P54646; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P54646; protein. DR Bgee; ENSG00000162409; Expressed in skeletal muscle tissue of rectus abdominis and 181 other cell types or tissues. DR ExpressionAtlas; P54646; baseline and differential. DR GO; GO:0030424; C:axon; ISS:ARUK-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0010494; C:cytoplasmic stress granule; ISS:ARUK-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; ISS:ARUK-UCL. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0031588; C:nucleotide-activated protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:ComplexPortal. DR GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; ISS:UniProtKB. DR GO; GO:0140823; F:histone H2BS36 kinase activity; ISS:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0071277; P:cellular response to calcium ion; ISS:ARUK-UCL. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071333; P:cellular response to glucose stimulus; ISS:ARUK-UCL. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:ComplexPortal. DR GO; GO:0034599; P:cellular response to oxidative stress; ISS:ARUK-UCL. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB. DR GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB. DR GO; GO:1905691; P:lipid droplet disassembly; IDA:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL. DR GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IDA:UniProt. DR GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904428; P:negative regulation of tubulin deacetylation; IEA:Ensembl. DR GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB. DR GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB. DR GO; GO:0016239; P:positive regulation of macroautophagy; TAS:ParkinsonsUK-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; ISS:ARUK-UCL. DR GO; GO:1990044; P:protein localization to lipid droplet; IDA:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; ISS:UniProtKB. DR GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; ISS:ARUK-UCL. DR GO; GO:0062028; P:regulation of stress granule assembly; IEA:Ensembl. DR GO; GO:0014850; P:response to muscle activity; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd12200; AMPKA2_C; 1. DR CDD; cd14079; STKc_AMPK_alpha; 1. DR CDD; cd14404; UBA_AID_AAPK2; 1. DR FunFam; 1.10.510.10:FF:000079; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000014; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000136; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000003; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00661; -. DR InterPro; IPR032270; AMPK_C. DR InterPro; IPR039148; AMPKA2_C. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049020; PRKAA1/2_AID. DR InterPro; IPR028783; PRKAA2. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346:SF104; 5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2; 1. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR Pfam; PF16579; AdenylateSensor; 1. DR Pfam; PF21147; AMPK_alpha_AID; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Autophagy; Biological rhythms; KW Cholesterol biosynthesis; Cholesterol metabolism; Chromatin regulator; KW Cytoplasm; Fatty acid biosynthesis; Fatty acid metabolism; Kinase; KW Lipid biosynthesis; Lipid metabolism; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Steroid biosynthesis; KW Steroid metabolism; Sterol biosynthesis; Sterol metabolism; Transcription; KW Transcription regulation; Transferase; Ubl conjugation; KW Wnt signaling pathway. FT CHAIN 1..552 FT /note="5'-AMP-activated protein kinase catalytic subunit FT alpha-2" FT /id="PRO_0000085594" FT DOMAIN 16..268 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 291..376 FT /note="AIS" FT /evidence="ECO:0000250|UniProtKB:Q13131" FT REGION 477..521 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 480..490 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 501..510 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 511..521 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 139 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 22..30 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 45 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 172 FT /note="Phosphothreonine; by LKB1 and CaMKK2" FT /evidence="ECO:0000269|PubMed:15980064, FT ECO:0000269|PubMed:24767988, ECO:0000269|PubMed:28552616" FT MOD_RES 258 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q09137" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163" FT MOD_RES 491 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q09137" FT VARIANT 371 FT /note="P -> T (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035623" FT VARIANT 407 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040355" FT VARIANT 523 FT /note="S -> G (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035624" FT MUTAGEN 45 FT /note="K->R: Complete loss of kinase activity." FT /evidence="ECO:0000305|PubMed:36017701" FT MUTAGEN 172 FT /note="T->A: Loss of ARF6 activation. Loss of interaction FT with ACSS2." FT /evidence="ECO:0000269|PubMed:28552616, FT ECO:0000269|PubMed:36017701" FT MUTAGEN 172 FT /note="T->D: Phosphomimetic mutant." FT /evidence="ECO:0000269|PubMed:21543851" FT CONFLICT 180 FT /note="A -> T (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT CONFLICT 271 FT /note="D -> G (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT CONFLICT 403..404 FT /note="HL -> RQ (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT STRAND 16..24 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 26..35 FT /evidence="ECO:0007829|PDB:2H6D" FT TURN 36..38 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 41..48 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 49..54 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 58..69 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 79..84 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 86..94 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 101..108 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 113..133 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 183..185 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 192..209 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 219..228 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:6BX6" FT HELIX 239..248 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 253..255 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 259..264 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 266..269 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 274..276 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 283..286 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 290..299 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 304..312 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 319..335 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 338..341 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 403..408 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 412..425 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 429..434 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 437..443 FT /evidence="ECO:0007829|PDB:8BIK" FT TURN 445..447 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 450..461 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 464..471 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 535..549 FT /evidence="ECO:0007829|PDB:8BIK" SQ SEQUENCE 552 AA; 62320 MW; C46AAFC1D5104975 CRC64; MAEKQKHDGR VKIGHYVLGD TLGVGTFGKV KIGEHQLTGH KVAVKILNRQ KIRSLDVVGK IKREIQNLKL FRHPHIIKLY QVISTPTDFF MVMEYVSGGE LFDYICKHGR VEEMEARRLF QQILSAVDYC HRHMVVHRDL KPENVLLDAH MNAKIADFGL SNMMSDGEFL RTSCGSPNYA APEVISGRLY AGPEVDIWSC GVILYALLCG TLPFDDEHVP TLFKKIRGGV FYIPEYLNRS VATLLMHMLQ VDPLKRATIK DIREHEWFKQ DLPSYLFPED PSYDANVIDD EAVKEVCEKF ECTESEVMNS LYSGDPQDQL AVAYHLIIDN RRIMNQASEF YLASSPPSGS FMDDSAMHIP PGLKPHPERM PPLIADSPKA RCPLDALNTT KPKSLAVKKA KWHLGIRSQS KPYDIMAEVY RAMKQLDFEW KVVNAYHLRV RRKNPVTGNY VKMSLQLYLV DNRSYLLDFK SIDDEVVEQR SGSSTPQRSC SAAGLHRPRS SFDSTTAESH SLSGSLTGSL TGSTLSSVSP RLGSHTMDFF EMCASLITTL AR // ID ACK1_HUMAN Reviewed; 1038 AA. AC Q07912; Q6ZMQ0; Q8N6U7; Q96H59; DT 24-OCT-2003, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 3. DT 28-JAN-2026, entry version 240. DE RecName: Full=Activated CDC42 kinase 1; DE Short=ACK-1; DE EC=2.7.10.2 {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:20333297}; DE EC=2.7.11.1 {ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; DE AltName: Full=Tyrosine kinase non-receptor protein 2; GN Name=TNK2; Synonyms=ACK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDC42. RC TISSUE=Hippocampus; RX PubMed=8497321; DOI=10.1038/363364a0; RA Manser E., Leung T., Salihuddin H., Tan L., Lim L.; RT "A non-receptor tyrosine kinase that inhibits the GTPase activity of RT p21cdc42."; RL Nature 363:364-367(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-725. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP INTERACTION WITH CSPG4. RX PubMed=10587647; DOI=10.1038/70302; RA Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.-L., RA Tachibana K., Lim L., Manser E., Furcht L.T., Iida J.; RT "Melanoma chondroitin sulphate proteoglycan regulates cell spreading RT through Cdc42, Ack-1 and p130cas."; RL Nat. Cell Biol. 1:507-513(1999). RN [6] RP FUNCTION AS MCF2 KINASE, CATALYTIC ACTIVITY, AND COFACTOR. RX PubMed=10652228; DOI=10.1006/bbrc.2000.2106; RA Kato J., Kaziro Y., Satoh T.; RT "Activation of the guanine nucleotide exchange factor Dbl following ACK1- RT dependent tyrosine phosphorylation."; RL Biochem. Biophys. Res. Commun. 268:141-147(2000). RN [7] RP FUNCTION. RX PubMed=11278436; DOI=10.1074/jbc.m008795200; RA Teo M., Tan L., Lim L., Manser E.; RT "The tyrosine kinase ACK1 associates with clathrin-coated vesicles through RT a binding motif shared by arrestin and other adaptors."; RL J. Biol. Chem. 276:18392-18398(2001). RN [8] RP SUBCELLULAR LOCATION. RX PubMed=14733946; DOI=10.1016/j.bbrc.2003.12.137; RA Ahmed I., Calle Y., Sayed M.A., Kamal J.M., Rengaswamy P., Manser E., RA Meiners S., Nur-E-Kamal A.; RT "Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, RT ACK."; RL Biochem. Biophys. Res. Commun. 314:571-579(2004). RN [9] RP AUTOPHOSPHORYLATION, INTERACTION WITH HSP90AB1; MTERK AND WWOX, AND RP MUTAGENESIS OF LYS-158 AND LEU-487. RX PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127; RA Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.; RT "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of RT Ack1 in polyubiquitination of tumor suppressor Wwox."; RL Cancer Res. 65:10514-10523(2005). RN [10] RP INTERACTION WITH SNX9, AND SUBCELLULAR LOCATION. RX PubMed=16137687; DOI=10.1016/j.febslet.2005.07.093; RA Yeow-Fong L., Lim L., Manser E.; RT "SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector RT ACK1."; RL FEBS Lett. 579:5040-5048(2005). RN [11] RP FUNCTION AS WAS KINASE, INTERACTION WITH WASL, CATALYTIC ACTIVITY, AND RP COFACTOR. RX PubMed=16257963; DOI=10.1074/jbc.m506996200; RA Yokoyama N., Lougheed J., Miller W.T.; RT "Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual RT hydroxyamino acid specificity in a tyrosine kinase."; RL J. Biol. Chem. 280:42219-42226(2005). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [13] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=16247015; DOI=10.1073/pnas.0508014102; RA van der Horst E.H., Degenhardt Y.Y., Strelow A., Slavin A., Chinn L., RA Orf J., Rong M., Li S., See L.-H., Nguyen K.Q.C., Hoey T., Wesche H., RA Powers S.; RT "Metastatic properties and genomic amplification of the tyrosine kinase RT gene ACK1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15901-15906(2005). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH BCAR1; CDC42 AND CRK. RX PubMed=17038317; DOI=10.1074/jbc.m604342200; RA Modzelewska K., Newman L.P., Desai R., Keely P.J.; RT "Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas."; RL J. Biol. Chem. 281:37527-37535(2006). RN [16] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT TYR-284. RX PubMed=16472662; DOI=10.1016/s0076-6879(06)06018-6; RA Yokoyama N., Miller W.T.; RT "Purification and enzyme activity of ACK1."; RL Methods Enzymol. 406:250-260(2006). RN [17] RP INTERACTION WITH AR. RX PubMed=17494760; DOI=10.1073/pnas.0700420104; RA Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., RA Earp H.S., Whang Y.E.; RT "Activated Cdc42-associated kinase Ack1 promotes prostate cancer RT progression via androgen receptor tyrosine phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007). RN [18] RP INTERACTION WITH NPHP1. RX PubMed=18477472; DOI=10.1016/j.bbrc.2008.05.016; RA Eley L., Moochhala S.H., Simms R., Hildebrandt F., Sayer J.A.; RT "Nephrocystin-1 interacts directly with Ack1 and is expressed in human RT collecting duct."; RL Biochem. Biophys. Res. Commun. 371:877-882(2008). RN [19] RP FUNCTION. RX PubMed=18435854; DOI=10.1186/bcr2087; RA Howlin J., Rosenkvist J., Andersson T.; RT "TNK2 preserves epidermal growth factor receptor expression on the cell RT surface and enhances migration and invasion of human breast cancer cells."; RL Breast Cancer Res. 10:R36-R36(2008). RN [20] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18262180; DOI=10.1016/j.yexcr.2007.12.017; RA Groevdal L.M., Johannessen L.E., Roedland M.S., Madshus I.H., Stang E.; RT "Dysregulation of Ack1 inhibits down-regulation of the EGF receptor."; RL Exp. Cell Res. 314:1292-1300(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-881, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP INTERACTION WITH NEDD4, AND UBIQUITINATION. RX PubMed=19144635; DOI=10.1074/jbc.m806877200; RA Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E.; RT "Down-regulation of active ACK1 is mediated by association with the E3 RT ubiquitin ligase Nedd4-2."; RL J. Biol. Chem. 284:8185-8194(2009). RN [24] RP FUNCTION, AND INTERACTION WITH AXL; LTK; PDGFRL AND GRB2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-284 AND SER-724, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-284, AND DOMAIN RP SAM-LIKE. RX PubMed=20979614; DOI=10.1186/1471-2091-11-42; RA Prieto-Echaguee V., Gucwa A., Brown D.A., Miller W.T.; RT "Regulation of Ack1 localization and activity by the amino-terminal SAM RT domain."; RL BMC Biochem. 11:42-42(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, VARIANTS LEU-34; GLN-99; LYS-346 AND RP ILE-409, CHARACTERIZATION OF VARIANTS LEU-34; GLN-99; LYS-346 AND ILE-409, RP AND MUTAGENESIS OF LEU-120; LEU-197 AND VAL-365. RX PubMed=20110370; DOI=10.1074/jbc.m109.060459; RA Prieto-Echaguee V., Gucwa A., Craddock B.P., Brown D.A., Miller W.T.; RT "Cancer-associated mutations activate the nonreceptor tyrosine kinase RT Ack1."; RL J. Biol. Chem. 285:10605-10615(2010). RN [28] RP FUNCTION AS AR KINASE, AND ACTIVITY REGULATION. RX PubMed=20383201; DOI=10.1038/onc.2010.103; RA Liu Y., Karaca M., Zhang Z., Gioeli D., Earp H.S., Whang Y.E.; RT "Dasatinib inhibits site-specific tyrosine phosphorylation of androgen RT receptor by Ack1 and Src kinases."; RL Oncogene 29:3208-3216(2010). RN [29] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH AKT1, SUBCELLULAR RP LOCATION, CHARACTERIZATION OF VARIANT LYS-346, PHOSPHORYLATION AT TYR-284, RP AND TISSUE SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [30] RP PHOSPHORYLATION AT TYR-284, TISSUE SPECIFICITY, AND ACTIVITY REGULATION. RX PubMed=20623637; DOI=10.1002/pros.21163; RA Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H., RA Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.; RT "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen RT receptor activity."; RL Prostate 70:1274-1285(2010). RN [31] RP PHOSPHORYLATION AT TYR-284, AND INTERACTION WITH SRC. RX PubMed=21309750; DOI=10.1042/bj20102156; RA Chan W., Sit S.T., Manser E.; RT "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires Src RT for activation."; RL Biochem. J. 435:355-364(2011). RN [32] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284; TYR-518; TYR-827; RP TYR-859 AND TYR-872. RX PubMed=21169560; DOI=10.1091/mbc.e10-07-0637; RA Shen H., Ferguson S.M., Dephoure N., Park R., Yang Y., Volpicelli-Daley L., RA Gygi S., Schlessinger J., De Camilli P.; RT "Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at RT arrested endocytic clathrin-coated pits of cells that lack dynamin."; RL Mol. Biol. Cell 22:493-502(2011). RN [33] RP REVIEW ON TUMOR GROWTH. RX PubMed=20432460; DOI=10.1002/jcp.22162; RA Mahajan K., Mahajan N.P.; RT "Shepherding AKT and androgen receptor by Ack1 tyrosine kinase."; RL J. Cell. Physiol. 224:327-333(2010). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP STRUCTURE BY NMR OF 448-489. RX PubMed=10360579; DOI=10.1038/20732; RA Mott H.R., Owen D., Nietlispach D., Lowe P.N., Manser E., Lim L., RA Laue E.D.; RT "Structure of the small G protein Cdc42 bound to the GTPase-binding domain RT of ACK."; RL Nature 399:384-388(1999). RN [36] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 107-395, AND PHOSPHORYLATION AT RP TYR-284. RX PubMed=15308621; DOI=10.1074/jbc.m406703200; RA Lougheed J.C., Chen R.-H., Mak P., Stout T.J.; RT "Crystal structures of the phosphorylated and unphosphorylated kinase RT domains of the Cdc42-associated tyrosine kinase ACK1."; RL J. Biol. Chem. 279:44039-44045(2004). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 117-392 IN COMPLEX WITH INHIBITOR, RP AND CATALYTIC ACTIVITY. RX PubMed=18993068; DOI=10.1016/j.bmcl.2008.10.092; RA Kopecky D.J., Hao X., Chen Y., Fu J., Jiao X., Jaen J.C., Cardozo M.G., RA Liu J., Wang Z., Walker N.P., Wesche H., Li S., Farrelly E., Xiao S.H., RA Kayser F.; RT "Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4- RT d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors."; RL Bioorg. Med. Chem. Lett. 18:6352-6356(2008). RN [38] RP VARIANTS LEU-34; ARG-71; GLN-99; TRP-99; MET-152; LYS-346; ILE-409; RP SER-507; LEU-725; GLN-748 AND HIS-1038. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [39] RP VARIANT MET-638, INTERACTION WITH NEDD4 AND NEDD4L, AND CHARACTERIZATION OF RP VARIANT MET-638. RX PubMed=23686771; DOI=10.1002/ana.23934; RA Hitomi Y., Heinzen E.L., Donatello S., Dahl H.H., Damiano J.A., RA McMahon J.M., Berkovic S.F., Scheffer I.E., Legros B., Rai M., RA Weckhuysen S., Suls A., De Jonghe P., Pandolfo M., Goldstein D.B., RA Van Bogaert P., Depondt C.; RT "Mutations in TNK2 in severe autosomal recessive infantile onset RT epilepsy."; RL Ann. Neurol. 74:496-501(2013). CC -!- FUNCTION: Non-receptor tyrosine-protein and serine/threonine-protein CC kinase that is implicated in cell spreading and migration, cell CC survival, cell growth and proliferation. Transduces extracellular CC signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, CC MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated CC endocytosis through binding to epidermal growth factor receptor (EGFR) CC and clathrin. Binds to both poly- and mono-ubiquitin and regulates CC ligand-induced degradation of EGFR, thereby contributing to the CC accumulation of EGFR at the limiting membrane of early endosomes. CC Downstream effector of CDC42 which mediates CDC42-dependent cell CC migration via phosphorylation of BCAR1. May be involved both in adult CC synaptic function and plasticity and in brain development. Activates CC AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' CC and 'Tyr-363' thereby promoting its recruitment to androgen-responsive CC enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates CC MCF2, thereby enhancing its activity as a guanine nucleotide exchange CC factor (GEF) toward Rho family proteins. Contributes to the control of CC AXL receptor levels. Confers metastatic properties on cancer cells and CC promotes tumor growth by negatively regulating tumor suppressor such as CC WWOX and positively regulating pro-survival factors such as AKT1 and CC AR. Phosphorylates WASP (PubMed:20110370). CC {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:11278436, CC ECO:0000269|PubMed:16247015, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:18262180, ECO:0000269|PubMed:18435854, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20110370, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20383201}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, CC ECO:0000269|PubMed:20333297}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:20333297}; CC -!- ACTIVITY REGULATION: Inhibited by AIM-100 (4-amino-5,6-biaryl-furo[2,3- CC d]pyrimidine), which suppresses activating phosphorylation at Tyr-284. CC Repressed by dasatinib. {ECO:0000269|PubMed:20383201, CC ECO:0000269|PubMed:20623637}. CC -!- SUBUNIT: Interacts with NEDD4 (via WW3 domain). NEDD4L and EGF promote CC association with NEDD4 (By similarity). Homodimer. Interacts with AR, CC CDC42, WWASL and WWOX. Interacts with CSPG4 (activated). Interacts with CC MERTK (activated); stimulates autophosphorylation. May interact CC (phosphorylated) with HSP90AB1; maintains kinase activity. Interacts CC with NPHP1. Interacts with SNX9 (via SH3 domain). Interacts with SRC CC (via SH2 and SH3 domain). Interacts with EGFR, and this interaction is CC dependent on EGF stimulation and kinase activity of EGFR. Interacts CC (via kinase domain) with AKT1. Part of a collagen stimulated complex CC involved in cell migration composed of CDC42, CRK, TNK2 and CC BCAR1/p130cas. Interacts with BCAR1/p130cas via SH3 domains. Forms CC complexes with GRB2 and numerous receptor tyrosine kinases (RTK) CC including LTK, AXL or PDGFRL, in which GRB2 promotes RTK recruitment by CC TNK2. {ECO:0000250, ECO:0000269|PubMed:10587647, CC ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:18477472, CC ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:19144635, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614, ECO:0000269|PubMed:21309750, CC ECO:0000269|PubMed:23686771, ECO:0000269|PubMed:8497321}. CC -!- INTERACTION: CC Q07912; P29972: AQP1; NbExp=3; IntAct=EBI-603457, EBI-745213; CC Q07912; P56945: BCAR1; NbExp=5; IntAct=EBI-603457, EBI-702093; CC Q07912; P60953-2: CDC42; NbExp=2; IntAct=EBI-603457, EBI-287394; CC Q07912; Q00610: CLTC; NbExp=3; IntAct=EBI-603457, EBI-354967; CC Q07912; P07902: GALT; NbExp=3; IntAct=EBI-603457, EBI-750827; CC Q07912; P62993: GRB2; NbExp=6; IntAct=EBI-603457, EBI-401755; CC Q07912; P08238: HSP90AB1; NbExp=3; IntAct=EBI-603457, EBI-352572; CC Q07912; P16333: NCK1; NbExp=4; IntAct=EBI-603457, EBI-389883; CC Q07912; Q9HC98: NEK6; NbExp=3; IntAct=EBI-603457, EBI-740364; CC Q07912; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-603457, EBI-945833; CC Q07912; O60880: SH2D1A; NbExp=3; IntAct=EBI-603457, EBI-6983382; CC Q07912; Q9Y5X1: SNX9; NbExp=4; IntAct=EBI-603457, EBI-77848; CC Q07912; Q07912: TNK2; NbExp=2; IntAct=EBI-603457, EBI-603457; CC Q07912-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-11994780, EBI-3867333; CC Q07912-2; Q9BQC3: DPH2; NbExp=3; IntAct=EBI-11994780, EBI-10237931; CC Q07912-2; P07902: GALT; NbExp=3; IntAct=EBI-11994780, EBI-750827; CC Q07912-2; Q92569: PIK3R3; NbExp=3; IntAct=EBI-11994780, EBI-79893; CC Q07912-2; O60880: SH2D1A; NbExp=3; IntAct=EBI-11994780, EBI-6983382; CC Q07912-2; O14796: SH2D1B; NbExp=3; IntAct=EBI-11994780, EBI-3923013; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614}. Nucleus {ECO:0000269|PubMed:14733946, CC ECO:0000269|PubMed:20333297}. Endosome {ECO:0000250|UniProtKB:O54967}. CC Cell junction, adherens junction {ECO:0000305}. Cytoplasmic vesicle CC membrane; Peripheral membrane protein; Cytoplasmic side CC {ECO:0000269|PubMed:16137687}. Cytoplasmic vesicle, clathrin-coated CC vesicle {ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:18262180}. CC Membrane, clathrin-coated pit {ECO:0000269|PubMed:21169560}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:20110370}. Cytoplasm, cytosol CC {ECO:0000250|UniProtKB:O54967}. Note=The Tyr-284 phosphorylated form is CC found both in the membrane and nucleus (By similarity). Co-localizes CC with EGFR on endosomes (PubMed:20333297). Nuclear translocation is CC CDC42-dependent (By similarity). Detected in long filamentous cytosolic CC structures where it co-localizes with CTPS1 (By similarity). CC {ECO:0000250|UniProtKB:O54967, ECO:0000269|PubMed:20333297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q07912-1; Sequence=Displayed; CC Name=2; CC IsoId=Q07912-2; Sequence=VSP_008655, VSP_008656; CC Name=3; CC IsoId=Q07912-3; Sequence=VSP_037284, VSP_037285, VSP_037286; CC -!- TISSUE SPECIFICITY: The Tyr-284 phosphorylated form shows a significant CC increase in expression in breast cancers during the progressive stages CC i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), CC invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) CC stages. It also shows a significant increase in expression in prostate CC cancers during the progressive stages. {ECO:0000269|PubMed:16247015, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20623637}. CC -!- DOMAIN: The EBD (EGFR-binding domain) domain is necessary for CC interaction with EGFR. {ECO:0000250}. CC -!- DOMAIN: The SAM-like domain is necessary for NEDD4-mediated CC ubiquitination. Promotes membrane localization and dimerization to CC allow for autophosphorylation. {ECO:0000269|PubMed:20979614}. CC -!- DOMAIN: The UBA domain binds both poly- and mono-ubiquitin. CC {ECO:0000269|PubMed:20979614}. CC -!- PTM: Autophosphorylation regulates kinase activity. Phosphorylation on CC Tyr-518 is required for interaction with SRC and is observed during CC association with clathrin-coated pits. {ECO:0000269|PubMed:15308621, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, CC ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750}. CC -!- PTM: Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be induced CC by EGF and is lysosome-dependent (By similarity). {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08884.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305}; CC Sequence=BAD18675.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L13738; AAA53570.2; -; mRNA. DR EMBL; AK131539; BAD18675.1; ALT_INIT; mRNA. DR EMBL; AC124944; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008884; AAH08884.1; ALT_SEQ; mRNA. DR EMBL; BC028164; AAH28164.1; -; mRNA. DR CCDS; CCDS33927.2; -. [Q07912-3] DR CCDS; CCDS33928.1; -. [Q07912-1] DR PIR; S33596; S33596. DR RefSeq; NP_001010938.2; NM_001010938.2. [Q07912-3] DR RefSeq; NP_001294975.1; NM_001308046.1. DR RefSeq; NP_001374642.1; NM_001387713.1. [Q07912-1] DR RefSeq; NP_001374643.1; NM_001387714.1. [Q07912-1] DR RefSeq; NP_005772.3; NM_005781.4. [Q07912-1] DR RefSeq; XP_047303107.1; XM_047447151.1. [Q07912-1] DR RefSeq; XP_047303116.1; XM_047447160.1. [Q07912-1] DR RefSeq; XP_054200839.1; XM_054344864.1. [Q07912-1] DR RefSeq; XP_054200851.1; XM_054344876.1. [Q07912-1] DR PDB; 1CF4; NMR; -; B=448-489. DR PDB; 1U46; X-ray; 2.00 A; A/B=109-395. DR PDB; 1U4D; X-ray; 2.10 A; A/B=109-395. DR PDB; 1U54; X-ray; 2.80 A; A/B=109-395. DR PDB; 3EQP; X-ray; 2.30 A; A/B=117-392. DR PDB; 3EQR; X-ray; 2.00 A; A/B=117-392. DR PDB; 4EWH; X-ray; 2.50 A; A/B=117-391. DR PDB; 4HZR; X-ray; 1.31 A; A/B=115-389. DR PDB; 4HZS; X-ray; 3.23 A; A/B/C/D=115-453. DR PDB; 4ID7; X-ray; 3.00 A; A=117-389. DR PDB; 5ZXB; X-ray; 2.20 A; A/B=117-391. DR PDB; 6VQM; X-ray; 2.87 A; A/B=109-395. DR PDB; 7KP6; X-ray; 1.79 A; A/B=110-391. DR PDB; 8FE9; X-ray; 3.20 A; A=110-391. DR PDB; 8FZ3; X-ray; 2.78 A; A/B/C/D=958-1038. DR PDB; 8HMT; X-ray; 3.17 A; A/B/C/D=117-389. DR PDB; 8Q5P; X-ray; 1.81 A; B=508-519. DR PDB; 8THA; X-ray; 1.68 A; A=954-1038. DR PDBsum; 1CF4; -. DR PDBsum; 1U46; -. DR PDBsum; 1U4D; -. DR PDBsum; 1U54; -. DR PDBsum; 3EQP; -. DR PDBsum; 3EQR; -. DR PDBsum; 4EWH; -. DR PDBsum; 4HZR; -. DR PDBsum; 4HZS; -. DR PDBsum; 4ID7; -. DR PDBsum; 5ZXB; -. DR PDBsum; 6VQM; -. DR PDBsum; 7KP6; -. DR PDBsum; 8FE9; -. DR PDBsum; 8FZ3; -. DR PDBsum; 8HMT; -. DR PDBsum; 8Q5P; -. DR PDBsum; 8THA; -. DR AlphaFoldDB; Q07912; -. DR SMR; Q07912; -. DR BioGRID; 115485; 135. DR CORUM; Q07912; -. DR DIP; DIP-33858N; -. DR FunCoup; Q07912; 728. DR IntAct; Q07912; 73. DR MINT; Q07912; -. DR STRING; 9606.ENSP00000371341; -. DR BindingDB; Q07912; -. DR ChEMBL; CHEMBL4599; -. DR DrugBank; DB18236; (R)-9b. DR DrugBank; DB00171; ATP. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q07912; -. DR GuidetoPHARMACOLOGY; 2246; -. DR GlyCosmos; Q07912; 2 sites, 1 glycan. DR GlyGen; Q07912; 6 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q07912; -. DR PhosphoSitePlus; Q07912; -. DR BioMuta; TNK2; -. DR DMDM; 229462980; -. DR CPTAC; CPTAC-1779; -. DR CPTAC; CPTAC-2789; -. DR jPOST; Q07912; -. DR MassIVE; Q07912; -. DR PaxDb; 9606-ENSP00000371341; -. DR PeptideAtlas; Q07912; -. DR ProteomicsDB; 58556; -. [Q07912-1] DR ProteomicsDB; 58557; -. [Q07912-2] DR ProteomicsDB; 58558; -. [Q07912-3] DR Pumba; Q07912; -. DR Antibodypedia; 4095; 764 antibodies from 40 providers. DR CPTC; Q07912; 5 antibodies. DR DNASU; 10188; -. DR Ensembl; ENST00000333602.14; ENSP00000329425.6; ENSG00000061938.22. [Q07912-1] DR Ensembl; ENST00000439230.6; ENSP00000395588.1; ENSG00000061938.22. [Q07912-2] DR Ensembl; ENST00000671753.1; ENSP00000499858.1; ENSG00000061938.22. [Q07912-3] DR GeneID; 10188; -. DR KEGG; hsa:10188; -. DR UCSC; uc003fvt.2; human. [Q07912-1] DR AGR; HGNC:19297; -. DR ClinPGx; PA134909759; -. DR CTD; 10188; -. DR DisGeNET; 10188; -. DR GeneCards; TNK2; -. DR HGNC; HGNC:19297; TNK2. DR HPA; ENSG00000061938; Low tissue specificity. DR MalaCards; TNK2; -. DR MIM; 606994; gene. DR OpenTargets; ENSG00000061938; -. DR Orphanet; 391316; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression. DR VEuPathDB; HostDB:ENSG00000061938; -. DR eggNOG; KOG0199; Eukaryota. DR GeneTree; ENSGT00940000160853; -. DR HOGENOM; CLU_000288_7_39_1; -. DR InParanoid; Q07912; -. DR OrthoDB; 635774at2759; -. DR PAN-GO; Q07912; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q07912; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q07912; -. DR Reactome; R-HSA-9842663; Signaling by LTK. DR SignaLink; Q07912; -. DR SIGNOR; Q07912; -. DR Agora; ENSG00000061938; -. DR BioGRID-ORCS; 10188; 11 hits in 1191 CRISPR screens. DR ChiTaRS; TNK2; human. DR EvolutionaryTrace; Q07912; -. DR GeneWiki; TNK2; -. DR GenomeRNAi; 10188; -. DR Pharos; Q07912; Tclin. DR PRO; PR:Q07912; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q07912; protein. DR Bgee; ENSG00000061938; Expressed in right hemisphere of cerebellum and 192 other cell types or tissues. DR ExpressionAtlas; Q07912; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB. DR GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB. DR GO; GO:0097268; C:cytoophidium; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; ISS:UniProtKB. DR GO; GO:0070436; C:Grb2-EGFR complex; IDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0005095; F:GTPase inhibitor activity; TAS:ProtInc. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0050699; F:WW domain binding; ISS:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; IDA:UniProtKB. DR GO; GO:0007264; P:small GTPase-mediated signal transduction; TAS:ProtInc. DR CDD; cd05040; PTKc_Ack_like; 1. DR CDD; cd09539; SAM_TNK-like; 1. DR CDD; cd14274; UBA_ACK1; 1. DR CDD; cd14328; UBA_TNK1; 1. DR DisProt; DP01772; -. DR FunFam; 4.10.680.10:FF:000001; activated CDC42 kinase 1 isoform X1; 1. DR FunFam; 1.10.510.10:FF:000080; Putative activated CDC42 kinase 1; 1. DR FunFam; 3.30.200.20:FF:000107; Putative activated CDC42 kinase 1; 1. DR Gene3D; 4.10.680.10; Cdc42-like binding domain; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00276; -. DR InterPro; IPR055175; ACK/TNK-like_SAM. DR InterPro; IPR030220; Ack1_UBA_dom. DR InterPro; IPR015116; Cdc42-bd-like. DR InterPro; IPR037085; Cdc42-bd-like_dom_sf. DR InterPro; IPR052112; EGFR_SigReg_Kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR021619; Mig-6. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR049587; TNK-like_SAM. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR14254; GENE 33 POLYPEPTIDE; 1. DR PANTHER; PTHR14254:SF6; NON-SPECIFIC PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF09027; GTPase_binding; 1. DR Pfam; PF11555; Inhibitor_Mig-6; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF22931; SAM_TNK; 1. DR Pfam; PF14604; SH3_9; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell junction; KW Cell membrane; Coated pit; Cytoplasm; Cytoplasmic vesicle; Endocytosis; KW Endosome; Kinase; Magnesium; Membrane; Metal-binding; Methylation; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation. FT CHAIN 1..1038 FT /note="Activated CDC42 kinase 1" FT /id="PRO_0000088058" FT DOMAIN 126..385 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 388..448 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 454..466 FT /note="CRIB" FT DOMAIN 958..996 FT /note="UBA" FT REGION 1..110 FT /note="SAM-like domain" FT REGION 90..114 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 497..535 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 623..652 FT /note="Required for interaction with SRC" FT /evidence="ECO:0000269|PubMed:21309750" FT REGION 632..635 FT /note="Required for interaction with NEDD4" FT /evidence="ECO:0000250" FT REGION 659..702 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 718..840 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..876 FT /note="EBD domain" FT /evidence="ECO:0000250" FT REGION 917..957 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 738..749 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 772..783 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 794..805 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 252 FT /note="Proton acceptor" FT BINDING 132..140 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 284 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000269|PubMed:15308621, FT ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, FT ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750, FT ECO:0007744|PubMed:19369195" FT MOD_RES 518 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 827 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 839 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:O54967" FT MOD_RES 859 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 872 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT VAR_SEQ 1 FT /note="M -> MGERSAYQRLAGGEEGPQRLGGGRM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037284" FT VAR_SEQ 485..528 FT /note="LYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPL -> CPFS FT AFSPGHPPAETCGQVLWTGRREACASDPRLHPVSSRTKGL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008655" FT VAR_SEQ 514 FT /note="K -> KREPPPRPPQPAFFTQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037285" FT VAR_SEQ 529..1038 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008656" FT VAR_SEQ 965..994 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037286" FT VARIANT 34 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates; no FT effect on subcellular localization to perinuclear region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032792" FT VARIANT 71 FT /note="K -> R (in dbSNP:rs56036945)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032793" FT VARIANT 99 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; increased autophosphorylation at Y-284; FT increased function in phosphorylation of peptide substrates FT and WASP; no effect on subcellular localization to FT perinuclear region; dbSNP:rs113498671)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032794" FT VARIANT 99 FT /note="R -> W (in dbSNP:rs3747673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032795" FT VARIANT 152 FT /note="T -> M (in dbSNP:rs56161912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032796" FT VARIANT 346 FT /note="E -> K (in an ovarian endometrioid cancer sample; FT somatic mutation; undergoes autoactivation and causes FT phosphorylation on Y-284 leading to activation of AKT1; FT increased autophosphorylation at Y-284; increased function FT in phosphorylation of peptide substrates and WASP; no FT effect on catalytic activity itself as the purified kinase FT domain has activity in vitro comparable to wild-type FT protein; no effect on subcellular localization to FT perinuclear region; dbSNP:rs970946035)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370, ECO:0000269|PubMed:20333297" FT /id="VAR_032797" FT VARIANT 409 FT /note="M -> I (in a gastric adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates and WASP; FT no effect on subcellular localization to perinuclear FT region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032798" FT VARIANT 507 FT /note="P -> S (in dbSNP:rs35759128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032799" FT VARIANT 638 FT /note="V -> M (found in patients with childhood-onset FT epilepsy; uncertain significance; loss of interaction with FT NEDD4 and NEDD4L; increased protein abundance; FT dbSNP:rs201407161)" FT /evidence="ECO:0000269|PubMed:23686771" FT /id="VAR_076966" FT VARIANT 725 FT /note="P -> L (in dbSNP:rs56260729)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_032800" FT VARIANT 748 FT /note="R -> Q (in dbSNP:rs57872314)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032801" FT VARIANT 802 FT /note="P -> L (in dbSNP:rs3749333)" FT /id="VAR_057115" FT VARIANT 1038 FT /note="R -> H (in dbSNP:rs13433937)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032802" FT MUTAGEN 120 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 158 FT /note="K->R: Loss of autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:16288044, FT ECO:0000269|PubMed:20110370" FT MUTAGEN 197 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 365 FT /note="V->R: Increased autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 487 FT /note="L->F: Constantly active kinase." FT /evidence="ECO:0000269|PubMed:16288044" FT CONFLICT 138 FT /note="G -> V (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 304..352 FT /note="TRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPR -> FT PPWRDISASSSTQFPHAVPCFPTSLLAKLLLRHSVPASSREIKLVSILC (in Ref. FT 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 353..1038 FT /note="Missing (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 586 FT /note="A -> P (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 722 FT /note="Missing (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 838..840 FT /note="PRA -> AG (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 123..125 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 126..133 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 140..146 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:3EQP" FT STRAND 152..159 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 164..166 FT /evidence="ECO:0007829|PDB:3EQR" FT HELIX 171..181 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 192..196 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 198..200 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 202..206 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 209..212 FT /evidence="ECO:0007829|PDB:8FE9" FT HELIX 213..219 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 226..245 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 258..262 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 265..268 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 273..276 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:3EQP" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 299..304 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 306..308 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 309..324 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:4HZS" FT TURN 330..333 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 336..344 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 358..367 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 372..374 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 378..387 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 392..394 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 402..404 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 412..417 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 419..421 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 423..432 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 435..439 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 449..451 FT /evidence="ECO:0007829|PDB:1CF4" FT TURN 484..486 FT /evidence="ECO:0007829|PDB:1CF4" SQ SEQUENCE 1038 AA; 114569 MW; 74A1980665BC3E6B CRC64; MQPEEGTGWL LELLSEVQLQ QYFLRLRDDL NVTRLSHFEY VKNEDLEKIG MGRPGQRRLW EAVKRRKALC KRKSWMSKVF SGKRLEAEFP PHHSQSTFRK TSPAPGGPAG EGPLQSLTCL IGEKDLRLLE KLGDGSFGVV RRGEWDAPSG KTVSVAVKCL KPDVLSQPEA MDDFIREVNA MHSLDHRNLI RLYGVVLTPP MKMVTELAPL GSLLDRLRKH QGHFLLGTLS RYAVQVAEGM GYLESKRFIH RDLAARNLLL ATRDLVKIGD FGLMRALPQN DDHYVMQEHR KVPFAWCAPE SLKTRTFSHA SDTWMFGVTL WEMFTYGQEP WIGLNGSQIL HKIDKEGERL PRPEDCPQDI YNVMVQCWAH KPEDRPTFVA LRDFLLEAQP TDMRALQDFE EPDKLHIQMN DVITVIEGRA ENYWWRGQNT RTLCVGPFPR NVVTSVAGLS AQDISQPLQN SFIHTGHGDS DPRHCWGFPD RIDELYLGNP MDPPDLLSVE LSTSRPPQHL GGVKKPTYDP VSEDQDPLSS DFKRLGLRKP GLPRGLWLAK PSARVPGTKA SRGSGAEVTL IDFGEEPVVP ALRPCAPSLA QLAMDACSLL DETPPQSPTR ALPRPLHPTP VVDWDARPLP PPPAYDDVAQ DEDDFEICSI NSTLVGAGVP AGPSQGQTNY AFVPEQARPP PPLEDNLFLP PQGGGKPPSS AQTAEIFQAL QQECMRQLQA PAGSPAPSPS PGGDDKPQVP PRVPIPPRPT RPHVQLSPAP PGEEETSQWP GPASPPRVPP REPLSPQGSR TPSPLVPPGS SPLPPRLSSS PGKTMPTTQS FASDPKYATP QVIQAPGPRA GPCILPIVRD GKKVSSTHYY LLPERPSYLE RYQRFLREAQ SPEEPTPLPV PLLLPPPSTP APAAPTATVR PMPQAALDPK ANFSTNNSNP GARPPPPRAT ARLPQRGCPG DGPEAGRPAD KIQMAMVHGV TTEECQAALQ CHGWSVQRAA QYLKVEQLFG LGLRPRGECH KVLEMFDWNL EQAGCHLLGS WGPAHHKR // ID AKT1_HUMAN Reviewed; 480 AA. AC P31749; B2RAM5; B7Z5R1; Q9BWB6; DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 2. DT 28-JAN-2026, entry version 272. DE RecName: Full=RAC-alpha serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; DE AltName: Full=Protein kinase B; DE Short=PKB; DE AltName: Full=Protein kinase B alpha; DE Short=PKB alpha; DE AltName: Full=Proto-oncogene c-Akt; DE AltName: Full=RAC-PK-alpha; GN Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY. RX PubMed=1851997; DOI=10.1073/pnas.88.10.4171; RA Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.; RT "Molecular cloning and identification of a serine/threonine protein kinase RT of the second-messenger subfamily."; RL Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11508278; DOI=10.1007/s001250100577; RA Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B., RA Permutt M.A.; RT "Isolation and characterization of the human AKT1 gene, identification of RT 13 single nucleotide polymorphisms (SNPs), and their lack of association RT with Type II diabetes."; RL Diabetologia 44:910-913(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Adrenal gland; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-480 (ISOFORM 1), FUNCTION, CATALYTIC RP ACTIVITY, AND TISSUE SPECIFICITY. RC TISSUE=Foreskin; RX PubMed=1718748; DOI=10.1111/j.1432-1033.1991.tb16305.x; RA Coffer P.J., Woodgett J.R.; RT "Molecular cloning and characterisation of a novel putative protein-serine RT kinase related to the cAMP-dependent and protein kinase C families."; RL Eur. J. Biochem. 201:475-481(1991). RN [8] RP ERRATUM OF PUBMED:1718748, AND SEQUENCE REVISION. RX PubMed=1533586; RA Coffer P.J., Woodgett J.R.; RL Eur. J. Biochem. 205:1217-1218(1992). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9829964; DOI=10.1074/jbc.273.49.32377; RA Du K., Montminy M.; RT "CREB is a regulatory target for the protein kinase Akt/PKB."; RL J. Biol. Chem. 273:32377-32379(1998). RN [10] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-473. RX PubMed=9736715; DOI=10.1073/pnas.95.19.11211; RA Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.; RT "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase RT kinase 3 and protein kinase B/AKT by the integrin-linked kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998). RN [11] RP MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND RP SER-473. RX PubMed=8978681; DOI=10.1002/j.1460-2075.1996.tb01045.x; RA Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N., Cohen P., RA Hemmings B.A.; RT "Mechanism of activation of protein kinase B by insulin and IGF-1."; RL EMBO J. 15:6541-6551(1996). RN [12] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1. RX PubMed=9512493; DOI=10.1042/bj3310299; RA Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.; RT "Activation of protein kinase B beta and gamma isoforms by insulin in vivo RT and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison RT with protein kinase B alpha."; RL Biochem. J. 331:299-308(1998). RN [13] RP FUNCTION IN PHOSPHORYLATION OF FOXO1. RX PubMed=10358075; DOI=10.1074/jbc.274.24.17179; RA Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.; RT "Phosphorylation of the transcription factor forkhead family member FKHR by RT protein kinase B."; RL J. Biol. Chem. 274:17179-17183(1999). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2. RX PubMed=10926925; DOI=10.1074/jbc.m001753200; RA Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.; RT "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis RT factor-induced protein kinase C-related kinase 2 (PRK2) cleavage."; RL J. Biol. Chem. 275:34451-34458(2000). RN [16] RP INTERACTION WITH MTCP1; TCL1A AND TCL1B. RX PubMed=10983986; DOI=10.1016/s1097-2765(00)00039-3; RA Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.; RT "The protooncogene TCL1 is an Akt kinase coactivator."; RL Mol. Cell 6:395-407(2000). RN [17] RP INTERACTION WITH TCL1A. RX PubMed=10716693; DOI=10.1073/pnas.97.7.3028; RA Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., RA Russo G., Tsichlis P., Croce C.M.; RT "Tcl1 enhances Akt kinase activity and mediates its nuclear RT translocation."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000). RN [18] RP FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5. RX PubMed=11154276; DOI=10.1128/mcb.21.3.893-901.2001; RA Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.; RT "Akt phosphorylates and negatively regulates apoptosis signal-regulating RT kinase 1."; RL Mol. Cell. Biol. 21:893-901(2001). RN [19] RP INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION. RX PubMed=11598301; DOI=10.1126/science.1062030; RA Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., RA Hemmings B.A.; RT "Carboxyl-terminal modulator protein (CTMP), a negative regulator of RT PKB/Akt and v-Akt at the plasma membrane."; RL Science 294:374-380(2001). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TBC1D4. RX PubMed=11994271; DOI=10.1074/jbc.c200198200; RA Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., RA Lienhard G.E.; RT "A method to identify serine kinase substrates. Akt phosphorylates a novel RT adipocyte protein with a Rab GTPase-activating protein (GAP) domain."; RL J. Biol. Chem. 277:22115-22118(2002). RN [21] RP INTERACTION WITH CDKN1B, AND FUNCTION. RX PubMed=12042314; DOI=10.1074/jbc.m203668200; RA Fujita N., Sato S., Katayama K., Tsuruo T.; RT "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and RT cytoplasmic localization."; RL J. Biol. Chem. 277:28706-28713(2002). RN [22] RP PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474. RX PubMed=12149249; DOI=10.1074/jbc.m203387200; RA Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.; RT "Direct identification of tyrosine 474 as a regulatory phosphorylation site RT for the Akt protein kinase."; RL J. Biol. Chem. 277:38021-38028(2002). RN [23] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=12150915; DOI=10.1016/s1097-2765(02)00568-3; RA Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.; RT "Identification of the tuberous sclerosis complex-2 tumor suppressor gene RT product tuberin as a target of the phosphoinositide 3-kinase/akt pathway."; RL Mol. Cell 10:151-162(2002). RN [24] RP INTERACTION WITH TCL1A. RX PubMed=11839817; DOI=10.1128/mcb.22.5.1513-1525.2002; RA Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F., RA Roumestand C., Stern M.H., Noguchi M.; RT "Identification of Akt association and oligomerization domains of the Akt RT kinase coactivator TCL1."; RL Mol. Cell. Biol. 22:1513-1525(2002). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=12172553; DOI=10.1038/ncb839; RA Inoki K., Li Y., Zhu T., Wu J., Guan K.L.; RT "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR RT signalling."; RL Nat. Cell Biol. 4:648-657(2002). RN [26] RP INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND SER-473. RX PubMed=12244301; DOI=10.1038/nm759; RA Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J., RA Arteaga C.L.; RT "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at RT threonine 157 and modulation of its cellular localization."; RL Nat. Med. 8:1145-1152(2002). RN [27] RP FUNCTION IN PARTICIPATION IN KIT SIGNALING. RX PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4; RA Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.; RT "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent RT phosphorylation site mediating interaction with c-Crk."; RL Exp. Cell Res. 288:110-118(2003). RN [28] RP INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473. RX PubMed=14761976; DOI=10.1074/jbc.m312175200; RA Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.; RT "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt RT activity and mediates cellular invasion."; RL J. Biol. Chem. 279:16441-16451(2004). RN [29] RP PHOSPHORYLATION AT SER-473. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [30] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [31] RP PHOSPHORYLATION AT SER-473. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [32] RP INTERACTION WITH AKTIP. RX PubMed=14749367; DOI=10.1128/mcb.24.4.1493-1504.2004; RA Remy I., Michnick S.W.; RT "Regulation of apoptosis by the Ft1 protein, a new modulator of protein RT kinase B/Akt."; RL Mol. Cell. Biol. 24:1493-1504(2004). RN [33] RP INTERACTION WITH AGAP2. RX PubMed=15118108; DOI=10.1073/pnas.0400921101; RA Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.; RT "PIKE-A is amplified in human cancers and prevents apoptosis by up- RT regulating Akt."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004). RN [34] RP PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING. RX PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422; RA Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., RA Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., RA Serve H.; RT "Constitutive activation of Akt by Flt3 internal tandem duplications is RT necessary for increased survival, proliferation, and myeloid RT transformation."; RL Cancer Res. 65:9643-9650(2005). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001; RA Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K., RA Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.; RT "Akt/PKB regulates actin organization and cell motility via Girdin/APE."; RL Dev. Cell 9:389-402(2005). RN [36] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15861136; DOI=10.1038/sj.emboj.7600648; RA Cartlidge R.A., Knebel A., Peggie M., Alexandrov A., Phizicky E.M., RA Cohen P.; RT "The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK RT in vitro and in cells."; RL EMBO J. 24:1696-1705(2005). RN [37] RP PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [38] RP PHOSPHORYLATION AT SER-473. RX PubMed=17013611; DOI=10.1007/s00401-006-0128-y; RA Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E., RA Simon M., Knobbe C., Bluemcke I., Becker A.J.; RT "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene RT mutations in epilepsy-associated Taylor-type focal cortical dysplasias."; RL Acta Neuropathol. 112:715-725(2006). RN [39] RP INTERACTION WITH WDFY2, AND SUBCELLULAR LOCATION. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [40] RP FUNCTION, AND INTERACTION WITH RARA. RX PubMed=16417524; DOI=10.1042/bj20051794; RA Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L., Weigel N.L., RA Brown P.H., Kurie J.M.; RT "Akt phosphorylates and suppresses the transactivation of retinoic acid RT receptor alpha."; RL Biochem. J. 395:653-662(2006). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [42] RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=16540465; DOI=10.1074/jbc.m601384200; RA Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.; RT "Kinetic mechanism of AKT/PKB enzyme family."; RL J. Biol. Chem. 281:13949-13956(2006). RN [43] RP FUNCTION IN PHOSPHORYLATION OF CDKN1A. RX PubMed=16982699; DOI=10.1128/mcb.00201-06; RA Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D., RA Hemmings B.A., Fernandez A., Lamb N.J.; RT "Only Akt1 is required for proliferation, while Akt2 promotes cell cycle RT exit through p21 binding."; RL Mol. Cell. Biol. 26:8267-8280(2006). RN [44] RP INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17932490; DOI=10.1038/sj.emboj.7601872; RA Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N., RA Rubin M.A., Yelick P.C., Freeman M.R.; RT "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct RT inhibitors of Akt1."; RL EMBO J. 26:4523-4534(2007). RN [45] RP FUNCTION, AND INTERACTION WITH STK4/MST1. RX PubMed=17726016; DOI=10.1074/jbc.m704542200; RA Jang S.W., Yang S.J., Srinivasan S., Ye K.; RT "Akt phosphorylates MstI and prevents its proteolytic activation, blocking RT FOXO3 phosphorylation and nuclear translocation."; RL J. Biol. Chem. 282:30836-30844(2007). RN [46] RP FUNCTION IN PHOSPHORYLATION OF PROHIBITIN. RX PubMed=18507042; RA Han E.K., Mcgonigal T., Butler C., Giranda V.L., Luo Y.; RT "Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is RT an Akt substrate both in vitro and in cells."; RL Anticancer Res. 28:957-963(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND SER-129, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP UBIQUITINATION BY TTC3. RX PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007; RA Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N., RA Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S., RA Obata T., Noguchi M.; RT "The E3 ligase TTC3 facilitates ubiquitination and degradation of RT phosphorylated Akt."; RL Dev. Cell 17:800-810(2009). RN [49] RP FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2. RX PubMed=19592491; DOI=10.1074/jbc.m109.026237; RA Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.; RT "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle RT and cell death in neurons."; RL J. Biol. Chem. 284:24512-24525(2009). RN [50] RP FUNCTION. RX PubMed=19934221; DOI=10.1242/jcs.053728; RA Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.; RT "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin RT dynamics and thereby regulate cell migration."; RL J. Cell Sci. 122:4535-4546(2009). RN [51] RP UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND LYS-14, RP AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17. RX PubMed=19713527; DOI=10.1126/science.1175065; RA Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B., RA Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.; RT "The E3 ligase TRAF6 regulates Akt ubiquitination and activation."; RL Science 325:1134-1138(2009). RN [52] RP FUNCTION, AND INTERACTION WITH STK3/MST2. RX PubMed=20086174; DOI=10.1158/0008-5472.can-09-3147; RA Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.; RT "Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, RT Raf-1, and Akt."; RL Cancer Res. 70:1195-1203(2010). RN [53] RP RETRACTED PAPER. RX PubMed=19940129; DOI=10.1074/jbc.m109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RT "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic RT signaling through phosphorylation of threonine 120."; RL J. Biol. Chem. 285:3815-3824(2010). RN [54] RP RETRACTION NOTICE OF PUBMED:19940129. RX PubMed=27825096; DOI=10.1074/jbc.a109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RL J. Biol. Chem. 291:22858-22858(2016). RN [55] RP FUNCTION, AND INTERACTION WITH CLK2. RX PubMed=20682768; DOI=10.1074/jbc.m110.122044; RA Nam S.Y., Seo H.H., Park H.S., An S., Kim J.Y., Yang K.H., Kim C.S., RA Jeong M., Jin Y.W.; RT "Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls RT cell survival after ionizing radiation."; RL J. Biol. Chem. 285:31157-31163(2010). RN [56] RP FUNCTION IN PHOSPHORYLATION OF PALLD. RX PubMed=20471940; DOI=10.1016/j.molcel.2010.02.031; RA Chin Y.R., Toker A.; RT "The actin-bundling protein palladin is an Akt1-specific substrate that RT regulates breast cancer cell migration."; RL Mol. Cell 38:333-344(2010). RN [57] RP RETRACTED PAPER. RX PubMed=20231902; DOI=10.1371/journal.pone.0009616; RA Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.; RT "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1- RT Akt pathway."; RL PLoS ONE 5:E9616-E9616(2010). RN [58] RP CAUTION, AND RETRACTION NOTICE OF PUBMED:20231902. RX PubMed=37490513; DOI=10.1371/journal.pone.0289329; RG PLOS ONE Editors; RT "Retraction: Regulation of Proapoptotic Mammalian ste20-Like Kinase MST2 by RT the IGF1-Akt Pathway."; RL PLoS ONE 18:e0289329-e0289329(2023). RN [59] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND RP SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE RP SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [60] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [61] RP INTERACTION WITH TRIM13, AND UBIQUITINATION. RX PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001; RA Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H., Kim C.S., RA Kim H.S., Jeong M., An S., Jin Y.W.; RT "Ret finger protein 2 enhances ionizing radiation-induced apoptosis via RT degradation of AKT and MDM2."; RL Eur. J. Cell Biol. 90:420-431(2011). RN [62] RP INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION. RX PubMed=21329884; DOI=10.1016/j.molcel.2011.02.007; RA Rodgers J.T., Vogel R.O., Puigserver P.; RT "Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A RT phosphatase holoenzyme complex on Akt."; RL Mol. Cell 41:471-479(2011). RN [63] RP INTERACTION WITH FAM168A. RX PubMed=23251525; DOI=10.1371/journal.pone.0051413; RA Peng B., Gu Y., Xiong Y., Zheng G., He Z.; RT "Microarray-assisted pathway analysis identifies MT1X & NFkappaB as RT mediators of TCRP1-associated resistance to cisplatin in oral squamous cell RT carcinoma."; RL PLoS ONE 7:E51413-E51413(2012). RN [64] RP PROTEOLYTIC CLEAVAGE. RX PubMed=23152800; DOI=10.1371/journal.pone.0048770; RA Sen T., Sen N., Noordhuis M.G., Ravi R., Wu T.C., Ha P.K., Sidransky D., RA Hoque M.O.; RT "OGDHL is a modifier of AKT-dependent signaling and NF-kappaB function."; RL PLoS ONE 7:e48770-e48770(2012). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [66] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [67] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [68] RP REVIEW ON FUNCTION. RX PubMed=11882383; DOI=10.1016/s0898-6568(01)00271-6; RA Nicholson K.M., Anderson N.G.; RT "The protein kinase B/Akt signalling pathway in human malignancy."; RL Cell. Signal. 14:381-395(2002). RN [69] RP PHOSPHORYLATION AT SER-473. RX PubMed=20978158; DOI=10.1158/1535-7163.mct-10-0730; RA Kunoh T., Noda T., Koseki K., Sekigawa M., Takagi M., Shin-ya K., RA Goshima N., Iemura S., Natsume T., Wada S., Mukai Y., Ohta S., Sasaki R., RA Mizukami T.; RT "A novel human dynactin-associated protein, dynAP, promotes activation of RT Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of RT human cancer cells."; RL Mol. Cancer Ther. 9:2934-2942(2010). RN [70] RP REVIEW ON FUNCTION. RX PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004; RA Hers I., Vincent E.E., Tavare J.M.; RT "Akt signalling in health and disease."; RL Cell. Signal. 23:1515-1527(2011). RN [71] RP REVIEW ON FUNCTION. RX PubMed=21432781; DOI=10.14670/hh-26.651; RA Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.; RT "Akt1 and Akt2: differentiating the aktion."; RL Histol. Histopathol. 26:651-662(2011). RN [72] RP PHOSPHORYLATION AT THR-308 AND SER-473. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [73] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20, DEACETYLATION AT RP LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17 AND LYS-20. RX PubMed=21775285; DOI=10.1126/scisignal.2001465; RA Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., RA Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.; RT "The deacetylase SIRT1 promotes membrane localization and activation of Akt RT and PDK1 during tumorigenesis and cardiac hypertrophy."; RL Sci. Signal. 4:RA46-RA46(2011). RN [74] RP UBIQUITINATION AT LYS-284. RX PubMed=22410793; DOI=10.1038/cr.2012.38; RA Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K., Kim J., RA An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y., Jin Y.W., RA Lee J.H., An S.; RT "Akt is negatively regulated by the MULAN E3 ligase."; RL Cell Res. 22:873-885(2012). RN [75] RP GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR RP LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND THR-312. RX PubMed=22629392; DOI=10.1371/journal.pone.0037427; RA Wang S., Huang X., Sun D., Xin X., Pan Q., Peng S., Liang Z., Luo C., RA Yang Y., Jiang H., Huang M., Chai W., Ding J., Geng M.; RT "Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates RT Akt signaling."; RL PLoS ONE 7:E37427-E37427(2012). RN [76] RP PHOSPHORYLATION AT SER-473, AND DEPHOSPHORYLATION BY CPPED1. RX PubMed=23799035; DOI=10.1371/journal.pone.0065679; RA Zhuo D.X., Zhang X.W., Jin B., Zhang Z., Xie B.S., Wu C.L., Gong K., RA Mao Z.B.; RT "CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell RT apoptosis, and suppresses tumor growth of bladder cancer by directly RT dephosphorylating Akt at Ser473 site."; RL PLoS ONE 8:E65679-E65679(2013). RN [77] RP FUNCTION. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [78] RP INTERACTION WITH SYAP1. RX PubMed=23300339; DOI=10.1126/scisignal.2003295; RA Yao Y., Suraokar M., Darnay B.G., Hollier B.G., Shaiken T.E., Asano T., RA Chen C.H., Chang B.H., Lu Y., Mills G.B., Sarbassov D., Mani S.A., RA Abbruzzese J.L., Reddy S.A.; RT "BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress RT expression of FoxC2 and stimulate adipocyte differentiation."; RL Sci. Signal. 6:RA2-RA2(2013). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-450, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP PHOSPHORYLATION AT SER-477 AND THR-479, AND MUTAGENESIS OF 76-ARG--LEU-78 RP AND 273-ARG--LEU-275. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26440888; DOI=10.1016/j.celrep.2015.09.007; RA Seo G.J., Yang A., Tan B., Kim S., Liang Q., Choi Y., Yuan W., Feng P., RA Park H.S., Jung J.U.; RT "Akt kinase-mediated checkpoint of cGAS DNA sensing pathway."; RL Cell Rep. 13:440-449(2015). RN [82] RP INTERACTION WITH KIF14. RX PubMed=24784001; DOI=10.1016/j.neo.2014.03.008; RA Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R., RA Buckley D.L., Peng Y., John G.B., Li H.C., Sadeghi N., Wright W.E., Lum L., RA Corson T.W., Shay J.W.; RT "KIF14 promotes AKT phosphorylation and contributes to chemoresistance in RT triple-negative breast cancer."; RL Neoplasia 16:247-256(2014). RN [83] RP PHOSPHORYLATION AT SER-473, DEPHOSPHORYLATION, AND INTERACTION WITH PHLPP1 RP AND FKBP5. RX PubMed=28147277; DOI=10.1016/j.celrep.2017.01.009; RA Yu J., Qin B., Wu F., Qin S., Nowsheen S., Shan S., Zayas J., Pei H., RA Lou Z., Wang L.; RT "Regulation of serine-threonine kinase Akt activation by NAD+-dependent RT deacetylase SIRT7."; RL Cell Rep. 18:1229-1240(2017). RN [84] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29343641; DOI=10.1073/pnas.1705954115; RA Choppara S., Malonia S.K., Sankaran G., Green M.R., Santra M.K.; RT "Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:998-1003(2018). RN [85] RP FUNCTION. RX PubMed=30504268; DOI=10.15252/embj.201899435; RA Marchi S., Corricelli M., Branchini A., Vitto V.A.M., Missiroli S., RA Morciano G., Perrone M., Ferrarese M., Giorgi C., Pinotti M., Galluzzi L., RA Kroemer G., Pinton P.; RT "Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels RT and tumor growth."; RL EMBO J. 38:0-0(2019). RN [86] RP FUNCTION. RX PubMed=31204173; DOI=10.1016/j.devcel.2019.05.022; RA Walia V., Cuenca A., Vetter M., Insinna C., Perera S., Lu Q., Ritt D.A., RA Semler E., Specht S., Stauffer J., Morrison D.K., Lorentzen E., RA Westlake C.J.; RT "Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis."; RL Dev. Cell 50:229-246(2019). RN [87] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31548394; DOI=10.1073/pnas.1904774116; RA Padi S.K.R., Singh N., Bearss J.J., Olive V., Song J.H., Cardo-Vila M., RA Kraft A.S., Okumura K.; RT "Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases RT inhibition of mTORC1 and promotes tumor growth."; RL Proc. Natl. Acad. Sci. U.S.A. 116:20505-20510(2019). RN [88] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32322062; DOI=10.1038/s41586-020-2183-2; RA Xu D., Wang Z., Xia Y., Shao F., Xia W., Wei Y., Li X., Qian X., Lee J.H., RA Du L., Zheng Y., Lv G., Leu J.S., Wang H., Xing D., Liang T., Hung M.C., RA Lu Z.; RT "The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis."; RL Nature 580:530-535(2020). RN [89] RP INTERACTION WITH TMEM175, AND FUNCTION. RX PubMed=32228865; DOI=10.7554/elife.53430; RA Oh S., Paknejad N., Hite R.K.; RT "Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175."; RL Elife 9:0-0(2020). RN [90] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=33594058; DOI=10.1038/s41467-021-21206-3; RA Li T., Wang X., Ju E., da Silva S.R., Chen L., Zhang X., Wei S., Gao S.J.; RT "RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 RT for ubiquitination and degradation."; RL Nat. Commun. 12:1055-1055(2021). RN [91] RP INTERACTION WITH SLC9D1, PHOSPHORYLATION AT THR-308 AND SER-473, AND RP SUBCELLULAR LOCATION. RX PubMed=40285646; DOI=10.1002/advs.202504187; RA Li X., Han M., Zhu H., Pan Y., Su C., Liu Y., Liao Z., Zhang B., Chen X.; RT "m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by RT Facilitating the Membrane Translocation and Activation of AKT."; RL Adv. Sci. 12:e2504187-e2504187(2025). RN [92] RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, FUNCTION, INTERACTION WITH RP PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, MUTAGENESIS OF LYS-14; ARG-25 AND RP ARG-86, AND CHARACTERIZATION OF VARIANT CWS6 CYS-25. RX PubMed=12176338; DOI=10.1016/s0960-9822(02)00972-7; RA Thomas C.C., Deak M., Alessi D.R., van Aalten D.M.; RT "High-resolution structure of the pleckstrin homology domain of protein RT kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate."; RL Curr. Biol. 12:1256-1262(2002). RN [93] RP X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, FUNCTION, AND INTERACTION RP WITH PTDINS(1,3,4,5)P4. RX PubMed=12964941; DOI=10.1042/bj20031229; RA Milburn C.C., Deak M., Kelly S.M., Price N.C., Alessi D.R., RA Van Aalten D.M.; RT "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin RT homology domain of protein kinase B induces a conformational change."; RL Biochem. J. 375:531-538(2003). RN [94] {ECO:0007744|PDB:3CQU, ECO:0007744|PDB:3CQW} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=18456494; DOI=10.1016/j.bmcl.2008.04.034; RA Lippa B., Pan G., Corbett M., Li C., Kauffman G.S., Pandit J., Robinson S., RA Wei L., Kozina E., Marr E.S., Borzillo G., Knauth E., Barbacci-Tobin E.G., RA Vincent P., Troutman M., Baker D., Rajamohan F., Kakar S., Clark T., RA Morris J.; RT "Synthesis and structure based optimization of novel Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 18:3359-3363(2008). RN [95] {ECO:0007744|PDB:3OCB} RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=20810279; DOI=10.1016/j.bmcl.2010.08.053; RA Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., RA Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., Risom T., RA Gross S.D., Martinson M., Morales T.H., Vigers G.P., Brandhuber B.J.; RT "Discovery of pyrrolopyrimidine inhibitors of Akt."; RL Bioorg. Med. Chem. Lett. 20:5607-5612(2010). RN [96] {ECO:0007744|PDB:3MV5, ECO:0007744|PDB:3MVH} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=20481595; DOI=10.1021/jm1003842; RA Freeman-Cook K.D., Autry C., Borzillo G., Gordon D., Barbacci-Tobin E., RA Bernardo V., Briere D., Clark T., Corbett M., Jakubczak J., Kakar S., RA Knauth E., Lippa B., Luzzio M.J., Mansour M., Martinelli G., Marx M., RA Nelson K., Pandit J., Rajamohan F., Robinson S., Subramanyam C., Wei L., RA Wythes M., Morris J.; RT "Design of selective, ATP-competitive inhibitors of Akt."; RL J. Med. Chem. 53:4615-4622(2010). RN [97] {ECO:0007744|PDB:3O96} RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND. RX PubMed=20886116; DOI=10.1371/journal.pone.0012913; RA Wu W.I., Voegtli W.C., Sturgis H.L., Dizon F.P., Vigers G.P., RA Brandhuber B.J.; RT "Crystal structure of human AKT1 with an allosteric inhibitor reveals a new RT mode of kinase inhibition."; RL PLoS ONE 5:E12913-E12913(2010). RN [98] {ECO:0007744|PDB:3QKK, ECO:0007744|PDB:3QKL} RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=21392984; DOI=10.1016/j.bmcl.2011.02.073; RA Kallan N.C., Spencer K.L., Blake J.F., Xu R., Heizer J., Bencsik J.R., RA Mitchell I.S., Gloor S.L., Martinson M., Risom T., Gross S.D., RA Morales T.H., Wu W.I., Vigers G.P., Brandhuber B.J., Skelton N.J.; RT "Discovery and SAR of spirochromane Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 21:2410-2414(2011). RN [99] RP VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST CANCER RP LYS-17. RX PubMed=17611497; DOI=10.1038/nature05933; RA Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., RA Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., RA Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., RA Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., RA Thomas J.E.; RT "A transforming mutation in the pleckstrin homology domain of AKT1 in RT cancer."; RL Nature 448:439-444(2007). RN [100] RP CHARACTERIZATION OF VARIANT PROTEUSS LYS-17. RX PubMed=18954143; DOI=10.1021/bi801683k; RA Landgraf K.E., Pilling C., Falke J.J.; RT "Molecular mechanism of an oncogenic mutation that alters membrane RT targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH RT domain."; RL Biochemistry 47:12260-12269(2008). RN [101] RP VARIANT PROTEUSS LYS-17. RX PubMed=21793738; DOI=10.1056/nejmoa1104017; RA Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., RA Turner J., Cannons J.L., Bick D., Blakemore L., Blumhorst C., Brockmann K., RA Calder P., Cherman N., Deardorff M.A., Everman D.B., Golas G., RA Greenstein R.M., Kato B.M., Keppler-Noreuil K.M., Kuznetsov S.A., RA Miyamoto R.T., Newman K., Ng D., O'Brien K., Rothenberg S., RA Schwartzentruber D.J., Singhal V., Tirabosco R., Upton J., Wientroub S., RA Zackai E.H., Hoag K., Whitewood-Neal T., Robey P.G., Schwartzberg P.L., RA Darling T.N., Tosi L.L., Mullikin J.C., Biesecker L.G.; RT "A mosaic activating mutation in AKT1 associated with the Proteus RT syndrome."; RL N. Engl. J. Med. 365:611-619(2011). RN [102] RP VARIANTS CWS6 CYS-25 AND PRO-435. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). CC -!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein CC kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate CC many processes including metabolism, proliferation, cell survival, CC growth and angiogenesis (PubMed:11882383, PubMed:15526160, CC PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). CC This is mediated through serine and/or threonine phosphorylation of a CC range of downstream substrates (PubMed:11882383, PubMed:15526160, CC PubMed:21432781, PubMed:21620960, PubMed:29343641, PubMed:31204173). CC Over 100 substrate candidates have been reported so far, but for most CC of them, no isoform specificity has been reported (PubMed:11882383, CC PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible CC of the regulation of glucose uptake by mediating insulin-induced CC translocation of the SLC2A4/GLUT4 glucose transporter to the cell CC surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' CC negatively modulates its phosphatase activity preventing CC dephosphorylation of the insulin receptor and the attenuation of CC insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers CC the binding of this effector to inhibitory 14-3-3 proteins, which is CC required for insulin-stimulated glucose transport (PubMed:11994271). CC AKT also regulates the storage of glucose in the form of glycogen by CC phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in CC inhibition of its kinase activity (By similarity). Phosphorylation of CC GSK3 isoforms by AKT is also thought to be one mechanism by which cell CC proliferation is driven (By similarity). AKT also regulates cell CC survival via the phosphorylation of MAP3K5 (apoptosis signal-related CC kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 CC kinase activity stimulated by oxidative stress and thereby prevents CC apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein CC synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby CC activating the mTORC1 signaling pathway, and leading to both CC phosphorylation of 4E-BP1 and in activation of RPS6KB1 CC (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling CC pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 CC (PubMed:31548394, PubMed:33594058). AKT plays a role as key modulator CC of the AKT-mTOR signaling pathway controlling the tempo of the process CC of newborn neurons integration during adult neurogenesis, including CC correct neuron positioning, dendritic development and synapse formation CC (By similarity). Part of a positive feedback loop of mTORC2 signaling CC by mediating phosphorylation of MAPKAP1/SIN1, promoting mTORC2 CC activation (By similarity). AKT is involved in the phosphorylation of CC members of the FOXO factors (Forkhead family of transcription factors), CC leading to binding of 14-3-3 proteins and cytoplasmic localization CC (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', CC 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are CC phosphorylated on equivalent sites (PubMed:10358075). AKT has an CC important role in the regulation of NF-kappa-B-dependent gene CC transcription and positively regulates the activity of CREB1 (cyclic CC AMP (cAMP)-response element binding protein) (PubMed:9829964). The CC phosphorylation of CREB1 induces the binding of accessory proteins that CC are necessary for the transcription of pro-survival genes such as BCL2 CC and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate CC lyase (ACLY), thereby potentially regulating ACLY activity and fatty CC acid synthesis (By similarity). Activates the 3B isoform of cyclic CC nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', CC resulting in reduced cyclic AMP levels and inhibition of lipolysis (By CC similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in CC increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating CC protein DLC1 is another substrate and its phosphorylation is implicated CC in the regulation cell proliferation and cell growth (By similarity). CC Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate CC the effects of various growth factors such as platelet-derived growth CC factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like CC growth factor 1 (IGF1) (PubMed:12176338, PubMed:12964941). AKT mediates CC the antiapoptotic effects of IGF1 (By similarity). Essential for the CC SPATA13-mediated regulation of cell migration and adhesion assembly and CC disassembly (PubMed:19934221). May be involved in the regulation of the CC placental development (By similarity). Phosphorylates STK4/MST1 at CC 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, CC nuclear translocation, autophosphorylation and ability to phosphorylate CC FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and CC 'Thr-384' leading to inhibition of its: cleavage, kinase activity, CC autophosphorylation at Thr-180, binding to RASSF1 and nuclear CC translocation (PubMed:20086174). Phosphorylates SRPK2 and enhances its CC kinase activity towards SRSF2 and ACIN1 and promotes its nuclear CC translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and CC negatively regulates its activity (PubMed:10576742). Phosphorylation of CC BAD stimulates its pro-apoptotic activity (PubMed:10926925). CC Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the CC interaction of KAT6A with PML and negatively regulates its acetylation CC activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin CC (PALLD), modulating cytoskeletal organization and cell motility CC (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an CC important role in cell metabolism and proliferation (PubMed:18507042). CC Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces CC its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). CC These recent findings indicate that the AKT1 isoform has a more CC specific role in cell motility and proliferation (PubMed:16139227). CC Phosphorylates CLK2 thereby controlling cell survival to ionizing CC radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing CC the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an CC atypical protein kinase activity using GTP as donor (PubMed:32322062). CC Also acts as an activator of TMEM175 potassium channel activity in CC response to growth factors: forms the lysoK(GF) complex together with CC TMEM175 and acts by promoting TMEM175 channel activation, independently CC of its protein kinase activity (PubMed:32228865). Acts as a regulator CC of mitochondrial calcium uptake by mediating phosphorylation of MICU1 CC in the mitochondrial intermembrane space, impairing MICU1 maturation CC (PubMed:30504268). Acts as an inhibitor of tRNA methylation by CC mediating phosphorylation of the N-terminus of METTL1, thereby CC inhibiting METTL1 methyltransferase activity (PubMed:15861136). In CC response to LPAR1 receptor pathway activation, phosphorylates CC Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which CC induces WDR44 binding to Rab11, thereby switching Rab11 vesicular CC function from preciliary trafficking to endocytic recycling CC (PubMed:31204173). {ECO:0000250|UniProtKB:P31750, CC ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10358075, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10926925, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11994271, CC ECO:0000269|PubMed:12150915, ECO:0000269|PubMed:12172553, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12964941, CC ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:18507042, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20471940, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:30504268, CC ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:32322062, CC ECO:0000269|PubMed:33594058, ECO:0000269|PubMed:9829964, CC ECO:0000303|PubMed:11882383, ECO:0000303|PubMed:15526160, CC ECO:0000303|PubMed:21432781, ECO:0000303|PubMed:21620960}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:1851997, ECO:0000269|PubMed:26440888, CC ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:1851997}; CC -!- ACTIVITY REGULATION: Three specific sites, one in the kinase domain CC (Thr-308) and the two other ones in the C-terminal regulatory region CC (Ser-473 and Tyr-474), need to be phosphorylated for its full CC activation (PubMed:15262962, PubMed:20481595, PubMed:21392984, CC PubMed:9512493, PubMed:9736715). Inhibited by pyrrolopyrimidine CC inhibitors like aniline triazole and spiroindoline (PubMed:18456494, CC PubMed:20810279). {ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20810279, ECO:0000269|PubMed:21392984, CC ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715, CC ECO:0000305|PubMed:20810279}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.8 uM for ATP (for purified and in vitro activated AKT1) CC {ECO:0000269|PubMed:16540465}; CC KM=0.5 uM for peptide substrate (for purified and in vitro activated CC AKT1) {ECO:0000269|PubMed:16540465}; CC KM=143.3 uM for ATP (for recombinant myristoylated AKT1 expressed and CC immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465}; CC KM=2.9 uM for peptide substrate (for recombinant myristoylated AKT1 CC expressed and immunoprecipitated from Rat-1 cells) CC {ECO:0000269|PubMed:16540465}; CC -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20 CC (By similarity). Interacts (via the C-terminus) with CCDC88A (via its CC C-terminus). Interacts with GRB10; the interaction leads to GRB10 CC phosphorylation thus promoting YWHAE-binding (By similarity). Interacts CC with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence CC of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) CC with MTCP1, TCL1A and TCL1B. Interacts with CDKN1B; the interaction CC phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle CC progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, CC PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts CC with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. CC Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to CC its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts CC (via the C-terminus) with THEM4 (via its C-terminus). Interacts with CC and phosphorylated by PDPK1. Interacts with PA2G4 (By similarity). CC Interacts with KIF14; the interaction is detected in the plasma CC membrane upon INS stimulation and promotes AKT1 phosphorylation CC (PubMed:24784001). Interacts with FAM83B; activates the PI3K/AKT CC signaling cascade (PubMed:23676467). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Forms a complex with WDFY2 and FOXO1 CC (By similarity). Interacts with FAM168A (PubMed:23251525). Interacts CC with SYAP1 (via phosphorylated form and BSD domain); this interaction CC is enhanced in a mTORC2-mediated manner in response to epidermal growth CC factor (EGF) stimulation and activates AKT1 (PubMed:23300339). CC Interacts with PKHM3 (By similarity). Interacts with FKBP5/FKBP51; CC promoting interaction between Akt/AKT1 and PHLPP1, thereby enhancing CC dephosphorylation and subsequent activation of Akt/AKT1 CC (PubMed:28147277). Interacts with TMEM175; leading to formation of the CC lysoK(GF) complex (PubMed:32228865). Acts as a negative regulator of CC the cGAS-STING pathway by mediating phosphorylation of CGAS during CC mitosis, leading to its inhibition (PubMed:26440888). Interacts with CC SLC9D1 (when phosphorylated); the interaction facilitates the membrane CC translocation and activation of AKT1 (PubMed:40285646). CC {ECO:0000250|UniProtKB:P31750, ECO:0000250|UniProtKB:P47196, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10716693, CC ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:10983986, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11598301, CC ECO:0000269|PubMed:11839817, ECO:0000269|PubMed:12042314, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12244301, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:14749367, CC ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15118108, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:16417524, CC ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392, CC ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23300339, CC ECO:0000269|PubMed:23676467, ECO:0000269|PubMed:24784001, CC ECO:0000269|PubMed:26440888, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:40285646}. CC -!- INTERACTION: CC P31749; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-296087, EBI-10173507; CC P31749; P31749: AKT1; NbExp=4; IntAct=EBI-296087, EBI-296087; CC P31749; P31751: AKT2; NbExp=3; IntAct=EBI-296087, EBI-296058; CC P31749; Q86V81: ALYREF; NbExp=5; IntAct=EBI-296087, EBI-347640; CC P31749; P32121: ARRB2; NbExp=5; IntAct=EBI-296087, EBI-714559; CC P31749; Q8IXJ9: ASXL1; NbExp=3; IntAct=EBI-296087, EBI-1646500; CC P31749; Q13315: ATM; NbExp=5; IntAct=EBI-296087, EBI-495465; CC P31749; P54253: ATXN1; NbExp=6; IntAct=EBI-296087, EBI-930964; CC P31749; Q99728: BARD1; NbExp=3; IntAct=EBI-296087, EBI-473181; CC P31749; O95999: BCL10; NbExp=5; IntAct=EBI-296087, EBI-958922; CC P31749; Q6W2J9: BCOR; NbExp=3; IntAct=EBI-296087, EBI-950027; CC P31749; P15056: BRAF; NbExp=4; IntAct=EBI-296087, EBI-365980; CC P31749; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-296087, EBI-935503; CC P31749; P62324: BTG1; NbExp=4; IntAct=EBI-296087, EBI-742279; CC P31749; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-296087, EBI-1383687; CC P31749; P20248: CCNA2; NbExp=2; IntAct=EBI-296087, EBI-457097; CC P31749; P30281: CCND3; NbExp=3; IntAct=EBI-296087, EBI-375013; CC P31749; Q16543: CDC37; NbExp=5; IntAct=EBI-296087, EBI-295634; CC P31749; P46527: CDKN1B; NbExp=4; IntAct=EBI-296087, EBI-519280; CC P31749; Q8TAP6: CEP76; NbExp=4; IntAct=EBI-296087, EBI-742887; CC P31749; Q92793: CREBBP; NbExp=3; IntAct=EBI-296087, EBI-81215; CC P31749; Q15438: CYTH1; NbExp=3; IntAct=EBI-296087, EBI-997830; CC P31749; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-296087, EBI-742054; CC P31749; P26358: DNMT1; NbExp=6; IntAct=EBI-296087, EBI-719459; CC P31749; P00533: EGFR; NbExp=4; IntAct=EBI-296087, EBI-297353; CC P31749; Q9UJM3: ERRFI1; NbExp=3; IntAct=EBI-296087, EBI-2941912; CC P31749; Q15910: EZH2; NbExp=3; IntAct=EBI-296087, EBI-530054; CC P31749; Q1W6H9: FAM110C; NbExp=2; IntAct=EBI-296087, EBI-3942563; CC P31749; Q00597: FANCC; NbExp=4; IntAct=EBI-296087, EBI-81625; CC P31749; Q9HB96: FANCE; NbExp=4; IntAct=EBI-296087, EBI-396803; CC P31749; Q969H0: FBXW7; NbExp=5; IntAct=EBI-296087, EBI-359574; CC P31749; Q12778: FOXO1; NbExp=2; IntAct=EBI-296087, EBI-1108782; CC P31749; O43524: FOXO3; NbExp=4; IntAct=EBI-296087, EBI-1644164; CC P31749; P06241: FYN; NbExp=3; IntAct=EBI-296087, EBI-515315; CC P31749; P22466: GAL; NbExp=3; IntAct=EBI-296087, EBI-6624768; CC P31749; P49841: GSK3B; NbExp=5; IntAct=EBI-296087, EBI-373586; CC P31749; P68431: H3C12; NbExp=4; IntAct=EBI-296087, EBI-79722; CC P31749; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-296087, EBI-25830912; CC P31749; P08238: HSP90AB1; NbExp=3; IntAct=EBI-296087, EBI-352572; CC P31749; P42858: HTT; NbExp=3; IntAct=EBI-296087, EBI-466029; CC P31749; P08476: INHBA; NbExp=3; IntAct=EBI-296087, EBI-8077140; CC P31749; Q8WZ60: KLHL6; NbExp=3; IntAct=EBI-296087, EBI-6426464; CC P31749; Q5S007: LRRK2; NbExp=6; IntAct=EBI-296087, EBI-5323863; CC P31749; Q99683: MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263; CC P31749; O15264: MAPK13; NbExp=4; IntAct=EBI-296087, EBI-2116951; CC P31749; Q8TD08: MAPK15; NbExp=3; IntAct=EBI-296087, EBI-1383794; CC P31749; Q9BPZ7: MAPKAP1; NbExp=3; IntAct=EBI-296087, EBI-749938; CC P31749; P10636: MAPT; NbExp=2; IntAct=EBI-296087, EBI-366182; CC P31749; Q07820: MCL1; NbExp=3; IntAct=EBI-296087, EBI-1003422; CC P31749; Q00987: MDM2; NbExp=6; IntAct=EBI-296087, EBI-389668; CC P31749; Q14696: MESD; NbExp=3; IntAct=EBI-296087, EBI-6165891; CC P31749; P42345: MTOR; NbExp=6; IntAct=EBI-296087, EBI-359260; CC P31749; P04198: MYCN; NbExp=3; IntAct=EBI-296087, EBI-878369; CC P31749; P25963: NFKBIA; NbExp=3; IntAct=EBI-296087, EBI-307386; CC P31749; Q9BZQ8: NIBAN1; NbExp=2; IntAct=EBI-296087, EBI-6916466; CC P31749; P04150: NR3C1; NbExp=5; IntAct=EBI-296087, EBI-493507; CC P31749; O15530: PDPK1; NbExp=5; IntAct=EBI-296087, EBI-717097; CC P31749; Q96S96: PEBP4; NbExp=2; IntAct=EBI-296087, EBI-8563667; CC P31749; P19174: PLCG1; NbExp=9; IntAct=EBI-296087, EBI-79387; CC P31749; Q03181: PPARD; NbExp=3; IntAct=EBI-296087, EBI-6426768; CC P31749; O60437: PPL; NbExp=2; IntAct=EBI-296087, EBI-368321; CC P31749; P62136: PPP1CA; NbExp=4; IntAct=EBI-296087, EBI-357253; CC P31749; P67775: PPP2CA; NbExp=4; IntAct=EBI-296087, EBI-712311; CC P31749; P30153: PPP2R1A; NbExp=3; IntAct=EBI-296087, EBI-302388; CC P31749; P54646: PRKAA2; NbExp=3; IntAct=EBI-296087, EBI-1383852; CC P31749; P17612: PRKACA; NbExp=3; IntAct=EBI-296087, EBI-476586; CC P31749; Q05513: PRKCZ; NbExp=2; IntAct=EBI-296087, EBI-295351; CC P31749; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-296087, EBI-743880; CC P31749; Q06124: PTPN11; NbExp=3; IntAct=EBI-296087, EBI-297779; CC P31749; P04049: RAF1; NbExp=3; IntAct=EBI-296087, EBI-365996; CC P31749; P10276: RARA; NbExp=3; IntAct=EBI-296087, EBI-413374; CC P31749; Q9NS23: RASSF1; NbExp=3; IntAct=EBI-296087, EBI-367363; CC P31749; Q6R327: RICTOR; NbExp=3; IntAct=EBI-296087, EBI-1387196; CC P31749; P15880: RPS2; NbExp=3; IntAct=EBI-296087, EBI-443446; CC P31749; P23443: RPS6KB1; NbExp=3; IntAct=EBI-296087, EBI-1775921; CC P31749; Q15047: SETDB1; NbExp=10; IntAct=EBI-296087, EBI-79691; CC P31749; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965; CC P31749; Q13309: SKP2; NbExp=4; IntAct=EBI-296087, EBI-456291; CC P31749; Q13485: SMAD4; NbExp=6; IntAct=EBI-296087, EBI-347263; CC P31749; Q8N3U4: STAG2; NbExp=3; IntAct=EBI-296087, EBI-1057252; CC P31749; Q14849: STARD3; NbExp=3; IntAct=EBI-296087, EBI-9819324; CC P31749; Q13043: STK4; NbExp=13; IntAct=EBI-296087, EBI-367376; CC P31749; Q9UNE7-1: STUB1; NbExp=5; IntAct=EBI-296087, EBI-15687717; CC P31749; P56279: TCL1A; NbExp=8; IntAct=EBI-296087, EBI-749995; CC P31749; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-296087, EBI-750109; CC P31749; Q5T1C6: THEM4; NbExp=4; IntAct=EBI-296087, EBI-7684443; CC P31749; Q92547: TOPBP1; NbExp=2; IntAct=EBI-296087, EBI-308302; CC P31749; P53804: TTC3; NbExp=4; IntAct=EBI-296087, EBI-2681313; CC P31749; P10599: TXN; NbExp=3; IntAct=EBI-296087, EBI-594644; CC P31749; P08670: VIM; NbExp=29; IntAct=EBI-296087, EBI-353844; CC P31749; Q6GPH4: XAF1; NbExp=4; IntAct=EBI-296087, EBI-2815120; CC P31749; P17028: ZNF24; NbExp=3; IntAct=EBI-296087, EBI-707773; CC P31749; P29067: Arrb2; Xeno; NbExp=2; IntAct=EBI-296087, EBI-1636616; CC P31749; P06762: Hmox1; Xeno; NbExp=2; IntAct=EBI-296087, EBI-7410266; CC P31749; Q83730: m005R; Xeno; NbExp=3; IntAct=EBI-296087, EBI-6859930; CC P31749; P03165: X; Xeno; NbExp=3; IntAct=EBI-296087, EBI-7683985; CC P31749-1; Q15118-1: PDK1; NbExp=2; IntAct=EBI-12562306, EBI-12562315; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P31750}. Nucleus CC {ECO:0000269|PubMed:20333297}. Cell membrane CC {ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:40285646}. CC Mitochondrion intermembrane space {ECO:0000250|UniProtKB:P31750}. CC Note=Nucleus after activation by integrin-linked protein kinase 1 CC (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. CC Phosphorylation on Tyr-176 by TNK2 results in its localization to the CC cell membrane where it is targeted for further phosphorylations on Thr- CC 308 and Ser-473 leading to its activation and the activated form CC translocates to the nucleus. Colocalizes with WDFY2 in intracellular CC vesicles (PubMed:16792529). Also localizes to mitochondrial CC intermembrane space in response to rapamycin treatment (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:16792529}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P31749-1; Sequence=Displayed; CC Name=2; CC IsoId=P31749-2; Sequence=VSP_056180; CC -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase CC from the normal to the malignant state (at protein level). Expressed in CC all human cell types so far analyzed. The Tyr-176 phosphorylated form CC shows a significant increase in expression in breast cancers during the CC progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma CC in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node CC metastatic (LNMM) stages. {ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5- CC trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase CC alpha (PIK3CA) activity results in its targeting to the plasma membrane CC (PubMed:12176338, PubMed:12964941). PI(3,4,5)P3 is also required for CC phosphorylation at Thr-308 and subsequent activation (By similarity). CC The PH domain mediates interaction with TNK2 and Tyr-176 is also CC essential for this interaction (PubMed:20333297). CC {ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:12176338, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4. CC {ECO:0000269|PubMed:11598301}. CC -!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating CC phosphorylation at Thr-308 via disrupting the interaction between AKT1 CC and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with CC phosphorylation at this site. {ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:17013611, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20978158, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for CC full activity (PubMed:12149249, PubMed:15047712, PubMed:15262962, CC PubMed:16266983, PubMed:18456494, PubMed:20481595, PubMed:20978158, CC PubMed:8978681, PubMed:9512493, PubMed:9736715). Phosphorylation of the CC activation loop at Thr-308 by PDPK1/PDK1 is a prerequisite for full CC activation (PubMed:9512493). Phosphorylation by mTORC2 in response to CC growth factors plays a key role in AKT1 activation: mTORC2 CC phosphorylates different sites depending on the context, such as Thr- CC 450, Ser-473, Ser-477 or Thr-479, thereby facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:15718470, CC PubMed:24670654). Phosphorylation at Ser-473 by mTORC2 promotes CC ubiquitination and degradation by the proteasome (By similarity). Also CC phosphorylated at Ser-477 and Thr-479 by CDK2, facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:24670654). CC Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to CC the anionic plasma membrane phospholipid PA (PubMed:20333297). This CC phosphorylated form localizes to the cell membrane, where it is CC targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and CC Ser-473 leading to its activation (PubMed:20333297). Phosphorylated at CC Thr-308 and Ser-473 by IKBKE and TBK1 (PubMed:21464307). Ser-473 CC phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE- CC A) (PubMed:14761976). Ser-473 phosphorylation is enhanced in focal CC cortical dysplasias with Taylor-type balloon cells (PubMed:17013611). CC Ser-473 phosphorylation is enhanced by signaling through activated FLT3 CC (PubMed:16266983). Ser-473 is dephosphorylated by PHLPP CC (PubMed:28147277). Dephosphorylated at Thr-308 and Ser-473 by PP2A CC phosphatase (PubMed:21329884). The phosphorylated form of PPP2R5B is CC required for bridging AKT1 with PP2A phosphatase (PubMed:21329884). CC Ser-473 is dephosphorylated by CPPED1, leading to termination of CC signaling (PubMed:23799035). AIM2 acts as an inhibitor of AKT1 by CC inhibiting phosphorylation Ser-473: AIM2 acts both by inhibiting the CC activity of PRKDC/DNA-PK kinase and promoting dephosphorylation by PP2A CC phosphatase (By similarity). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:12149249, ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, CC ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21329884, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked CC polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination CC is critical for phosphorylation and activation (PubMed:19713527). When CC ubiquitinated, it translocates to the plasma membrane, where it becomes CC phosphorylated (PubMed:20059950). When fully phosphorylated and CC translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination CC catalyzed by TTC3, leading to its degradation by the proteasome CC (PubMed:20059950). Also ubiquitinated by TRIM13 leading to its CC proteasomal degradation (PubMed:21333377). Phosphorylated, undergoes CC 'Lys-48'-linked polyubiquitination preferentially at Lys-284 catalyzed CC by MUL1, leading to its proteasomal degradation (PubMed:22410793). CC Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading CC to its degradation by the proteasome (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:19713527, CC ECO:0000269|PubMed:20059950, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:22410793}. CC -!- PTM: Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases CC EP300 and KAT2B. Acetylation results in reduced phosphorylation and CC inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. CC SIRT1-mediated deacetylation relieves the inhibition. CC {ECO:0000269|PubMed:21775285}. CC -!- PTM: Cleavage by caspase-3/CASP3 (By similarity). Cleaved at the CC caspase-3 consensus site Asp-462 during apoptosis, resulting in down- CC regulation of the AKT signaling pathway and decreased cell survival CC (PubMed:23152800). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:23152800}. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:17611497}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- DISEASE: Note=Genetic variations in AKT1 may play a role in CC susceptibility to ovarian cancer. CC -!- DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highly variable, CC severe disorder of asymmetric and disproportionate overgrowth of body CC parts, connective tissue nevi, epidermal nevi, dysregulated adipose CC tissue, and vascular malformations. Many features of Proteus syndrome CC overlap with other overgrowth syndromes. {ECO:0000269|PubMed:18954143, CC ECO:0000269|PubMed:21793738}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:23246288}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. RAC subfamily. {ECO:0000305}. CC -!- CAUTION: PUBMED:20231902 has been retracted because there was evidence CC of data fabrication and/or falsification in multiple figure panels. CC {ECO:0000305|PubMed:20231902, ECO:0000305|PubMed:37490513}. CC -!- CAUTION: PUBMED:19940129 has been retracted because the same data were CC used to represent different experimental conditions. CC {ECO:0000305|PubMed:19940129, ECO:0000305|PubMed:27825096}. CC -!- CAUTION: In light of strong homologies in the primary amino acid CC sequence, the 3 AKT kinases were long surmised to play redundant and CC overlapping roles. More recent studies has brought into question the CC redundancy within AKT kinase isoforms and instead pointed to isoform CC specific functions in different cellular events and diseases. AKT1 is CC more specifically involved in cellular survival pathways, by inhibiting CC apoptotic processes; whereas AKT2 is more specific for the insulin CC receptor signaling pathway. Moreover, while AKT1 and AKT2 are often CC implicated in many aspects of cellular transformation, the 2 isoforms CC act in a complementary opposing manner. The role of AKT3 is less clear, CC though it appears to be predominantly expressed in brain. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/355/AKT1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M63167; AAA36539.1; -; mRNA. DR EMBL; AF283830; AAL55732.1; -; Genomic_DNA. DR EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AK299310; BAH12997.1; -; mRNA. DR EMBL; AK314256; BAG36922.1; -; mRNA. DR EMBL; AB451242; BAG70056.1; -; mRNA. DR EMBL; AB451367; BAG70181.1; -; mRNA. DR EMBL; AL583722; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590327; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000479; AAH00479.1; -; mRNA. DR EMBL; BC084538; AAH84538.1; -; mRNA. DR EMBL; X61037; CAA43372.1; -; mRNA. DR CCDS; CCDS9994.1; -. [P31749-1] DR PIR; A39360; A39360. DR RefSeq; NP_001014431.1; NM_001014431.2. [P31749-1] DR RefSeq; NP_001014432.1; NM_001014432.2. [P31749-1] DR RefSeq; NP_001369359.1; NM_001382430.1. [P31749-1] DR RefSeq; NP_001369360.1; NM_001382431.1. [P31749-1] DR RefSeq; NP_001369361.1; NM_001382432.1. [P31749-1] DR RefSeq; NP_001369362.1; NM_001382433.1. [P31749-1] DR RefSeq; NP_005154.2; NM_005163.2. [P31749-1] DR RefSeq; XP_047287025.1; XM_047431069.1. [P31749-1] DR RefSeq; XP_047287026.1; XM_047431070.1. [P31749-1] DR RefSeq; XP_047287027.1; XM_047431071.1. [P31749-1] DR RefSeq; XP_047287028.1; XM_047431072.1. [P31749-1] DR RefSeq; XP_047287029.1; XM_047431073.1. [P31749-1] DR RefSeq; XP_047287030.1; XM_047431074.1. [P31749-1] DR RefSeq; XP_047287031.1; XM_047431075.1. [P31749-1] DR RefSeq; XP_054231528.1; XM_054375553.1. [P31749-1] DR RefSeq; XP_054231529.1; XM_054375554.1. [P31749-1] DR RefSeq; XP_054231530.1; XM_054375555.1. [P31749-1] DR RefSeq; XP_054231531.1; XM_054375556.1. [P31749-1] DR RefSeq; XP_054231532.1; XM_054375557.1. [P31749-1] DR RefSeq; XP_054231533.1; XM_054375558.1. [P31749-1] DR PDB; 1H10; X-ray; 1.40 A; A=1-123. DR PDB; 1UNP; X-ray; 1.65 A; A=1-121. DR PDB; 1UNQ; X-ray; 0.98 A; A=1-123. DR PDB; 1UNR; X-ray; 1.25 A; A=1-123. DR PDB; 2UVM; X-ray; 1.94 A; A=1-123. DR PDB; 2UZR; X-ray; 1.94 A; A=1-123. DR PDB; 2UZS; X-ray; 2.46 A; A=1-123. DR PDB; 3CQU; X-ray; 2.20 A; A=144-480. DR PDB; 3CQW; X-ray; 2.00 A; A=144-480. DR PDB; 3MV5; X-ray; 2.47 A; A=144-480. DR PDB; 3MVH; X-ray; 2.01 A; A=144-480. DR PDB; 3O96; X-ray; 2.70 A; A=2-443. DR PDB; 3OCB; X-ray; 2.70 A; A/B=144-480. DR PDB; 3OW4; X-ray; 2.60 A; A/B=144-480. DR PDB; 3QKK; X-ray; 2.30 A; A=144-480. DR PDB; 3QKL; X-ray; 1.90 A; A=144-480. DR PDB; 3QKM; X-ray; 2.20 A; A=144-480. DR PDB; 4EJN; X-ray; 2.19 A; A=2-446. DR PDB; 4EKK; X-ray; 2.80 A; A/B=144-480. DR PDB; 4EKL; X-ray; 2.00 A; A=144-480. DR PDB; 4GV1; X-ray; 1.49 A; A=144-480. DR PDB; 5KCV; X-ray; 2.70 A; A=2-446. DR PDB; 6BUU; X-ray; 2.40 A; A/B=144-480. DR PDB; 6CCY; X-ray; 2.18 A; A=144-466. DR PDB; 6HHF; X-ray; 2.90 A; A=2-446. DR PDB; 6HHG; X-ray; 2.30 A; A=2-446. DR PDB; 6HHH; X-ray; 2.70 A; A=2-446. DR PDB; 6HHI; X-ray; 2.70 A; A=2-446. DR PDB; 6HHJ; X-ray; 2.30 A; A=2-446. DR PDB; 6NPZ; X-ray; 2.12 A; A/B=123-480, A/B=144-480. DR PDB; 6S9W; X-ray; 2.30 A; A=2-446. DR PDB; 6S9X; X-ray; 2.60 A; A=2-446. DR PDB; 7APJ; X-ray; 2.05 A; A=1-119, A=136-445. DR PDB; 7MYX; X-ray; 1.39 A; A=1-121. DR PDB; 7NH4; X-ray; 2.30 A; A=2-446. DR PDB; 7NH5; X-ray; 1.90 A; A=2-446. DR PDB; 8JOW; X-ray; 1.40 A; B/D=466-477. DR PDB; 8UVY; X-ray; 2.11 A; A=2-446. DR PDB; 8UW2; X-ray; 2.20 A; A=2-446. DR PDB; 8UW7; X-ray; 1.97 A; A=2-446. DR PDB; 8UW9; X-ray; 1.90 A; A=2-446. DR PDB; 8ZPU; X-ray; 2.80 A; C/D=466-477. DR PDBsum; 1H10; -. DR PDBsum; 1UNP; -. DR PDBsum; 1UNQ; -. DR PDBsum; 1UNR; -. DR PDBsum; 2UVM; -. DR PDBsum; 2UZR; -. DR PDBsum; 2UZS; -. DR PDBsum; 3CQU; -. DR PDBsum; 3CQW; -. DR PDBsum; 3MV5; -. DR PDBsum; 3MVH; -. DR PDBsum; 3O96; -. DR PDBsum; 3OCB; -. DR PDBsum; 3OW4; -. DR PDBsum; 3QKK; -. DR PDBsum; 3QKL; -. DR PDBsum; 3QKM; -. DR PDBsum; 4EJN; -. DR PDBsum; 4EKK; -. DR PDBsum; 4EKL; -. DR PDBsum; 4GV1; -. DR PDBsum; 5KCV; -. DR PDBsum; 6BUU; -. DR PDBsum; 6CCY; -. DR PDBsum; 6HHF; -. DR PDBsum; 6HHG; -. DR PDBsum; 6HHH; -. DR PDBsum; 6HHI; -. DR PDBsum; 6HHJ; -. DR PDBsum; 6NPZ; -. DR PDBsum; 6S9W; -. DR PDBsum; 6S9X; -. DR PDBsum; 7APJ; -. DR PDBsum; 7MYX; -. DR PDBsum; 7NH4; -. DR PDBsum; 7NH5; -. DR PDBsum; 8JOW; -. DR PDBsum; 8UVY; -. DR PDBsum; 8UW2; -. DR PDBsum; 8UW7; -. DR PDBsum; 8UW9; -. DR PDBsum; 8ZPU; -. DR AlphaFoldDB; P31749; -. DR SMR; P31749; -. DR BioGRID; 106710; 600. DR CORUM; P31749; -. DR DIP; DIP-24269N; -. DR ELM; P31749; -. DR FunCoup; P31749; 3098. DR IntAct; P31749; 602. DR MINT; P31749; -. DR STRING; 9606.ENSP00000451828; -. DR BindingDB; P31749; -. DR ChEMBL; CHEMBL4282; -. DR DrugBank; DB08073; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE. DR DrugBank; DB07585; 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. DR DrugBank; DB08568; A-674563. DR DrugBank; DB11648; Afuresertib. DR DrugBank; DB05971; Archexin. DR DrugBank; DB01169; Arsenic trioxide. DR DrugBank; DB00171; ATP. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12218; Capivasertib. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB12795; CMX-2043. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01645; Genistein. DR DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate. DR DrugBank; DB11743; Ipatasertib. DR DrugBank; DB15431; M-2698. DR DrugBank; DB14982; Miransertib. DR DrugBank; DB07584; N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB02709; Resveratrol. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugCentral; P31749; -. DR GuidetoPHARMACOLOGY; 1479; -. DR TCDB; 8.A.104.1.10; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; P31749; 6 sites, 1 glycan. DR GlyGen; P31749; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P31749; -. DR MetOSite; P31749; -. DR PhosphoSitePlus; P31749; -. DR BioMuta; AKT1; -. DR DMDM; 60391226; -. DR CPTAC; CPTAC-3162; -. DR CPTAC; CPTAC-3163; -. DR CPTAC; CPTAC-3164; -. DR CPTAC; CPTAC-3165; -. DR CPTAC; CPTAC-3166; -. DR CPTAC; CPTAC-3167; -. DR CPTAC; CPTAC-5758; -. DR CPTAC; CPTAC-5759; -. DR CPTAC; CPTAC-5805; -. DR CPTAC; CPTAC-5806; -. DR CPTAC; CPTAC-5807; -. DR CPTAC; CPTAC-5808; -. DR CPTAC; CPTAC-783; -. DR CPTAC; CPTAC-784; -. DR CPTAC; non-CPTAC-5328; -. DR CPTAC; non-CPTAC-5329; -. DR CPTAC; non-CPTAC-5332; -. DR CPTAC; non-CPTAC-5527; -. DR CPTAC; non-CPTAC-5528; -. DR CPTAC; non-CPTAC-5719; -. DR CPTAC; non-CPTAC-5720; -. DR jPOST; P31749; -. DR MassIVE; P31749; -. DR PaxDb; 9606-ENSP00000451828; -. DR PeptideAtlas; P31749; -. DR ProteomicsDB; 54800; -. [P31749-1] DR ProteomicsDB; 6712; -. DR Pumba; P31749; -. DR ABCD; P31749; 12 sequenced antibodies. DR Antibodypedia; 135; 5291 antibodies from 58 providers. DR CPTC; P31749; 6 antibodies. DR DNASU; 207; -. DR Ensembl; ENST00000349310.7; ENSP00000270202.4; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000402615.6; ENSP00000385326.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000407796.7; ENSP00000384293.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554581.5; ENSP00000451828.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554848.5; ENSP00000451166.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000555528.5; ENSP00000450688.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000649815.2; ENSP00000497822.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000683722.1; ENSP00000507879.1; ENSG00000142208.20. [P31749-1] DR GeneID; 207; -. DR KEGG; hsa:207; -. DR MANE-Select; ENST00000649815.2; ENSP00000497822.1; NM_001382430.1; NP_001369359.1. DR UCSC; uc001ypk.4; human. [P31749-1] DR AGR; HGNC:391; -. DR CIViC; 207; 18 evidence items across 19 molecular profiles. DR ClinPGx; PA24684; -. DR CTD; 207; -. DR DisGeNET; 207; -. DR GeneCards; AKT1; -. DR GeneReviews; AKT1; -. DR HGNC; HGNC:391; AKT1. DR HPA; ENSG00000142208; Low tissue specificity. DR MalaCards; AKT1; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 164730; gene. DR MIM; 176920; phenotype. DR MIM; 615109; phenotype. DR OpenTargets; ENSG00000142208; -. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 744; Proteus syndrome. DR VEuPathDB; HostDB:ENSG00000142208; -. DR eggNOG; KOG0690; Eukaryota. DR GeneTree; ENSGT00940000158752; -. DR HOGENOM; CLU_000288_11_0_1; -. DR InParanoid; P31749; -. DR OMA; MDMEIYL; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P31749; 3 GO annotations based on evolutionary models. DR PhylomeDB; P31749; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P31749; -. DR Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol. DR Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-203615; eNOS activation. DR Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-389513; Co-inhibition by CTLA4. DR Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma. DR Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9604323; Negative regulation of NOTCH4 signaling. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt). DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856532; Mechanical load activates signaling by PIEZO1 and integrins in osteocytes. DR SABIO-RK; P31749; -. DR SignaLink; P31749; -. DR SIGNOR; P31749; -. DR Agora; ENSG00000142208; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 207; 54 hits in 1212 CRISPR screens. DR ChiTaRS; AKT1; human. DR EvolutionaryTrace; P31749; -. DR GeneWiki; AKT1; -. DR GenomeRNAi; 207; -. DR Pharos; P31749; Tchem. DR PRO; PR:P31749; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P31749; protein. DR Bgee; ENSG00000142208; Expressed in stromal cell of endometrium and 189 other cell types or tissues. DR ExpressionAtlas; P31749; baseline and differential. DR GO; GO:0005938; C:cell cortex; NAS:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; NAS:BHF-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProt. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0033011; C:perinuclear theca; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; IPI:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL. DR GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB. DR GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0099104; F:potassium channel activator activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; ISS:BHF-UCL. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:1904841; F:TORC2 complex binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0160213; P:beta-arrestin-dependent dopamine receptor signaling pathway; NAS:ParkinsonsUK-UCL. DR GO; GO:0030154; P:cell differentiation; TAS:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0036294; P:cellular response to decreased oxygen levels; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB. DR GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProtKB. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB. DR GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; IMP:BHF-UCL. DR GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0072752; P:cellular response to rapamycin; ISS:UniProt. DR GO; GO:0033554; P:cellular response to stress; TAS:Reactome. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl. DR GO; GO:0002430; P:complement receptor mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0060079; P:excitatory postsynaptic potential; NAS:ParkinsonsUK-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl. DR GO; GO:0010761; P:fibroblast migration; NAS:BHF-UCL. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW. DR GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:MGI. DR GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0022605; P:mammalian oogenesis stage; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB. DR GO; GO:0001893; P:maternal placenta development; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:BHF-UCL. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:1902018; P:negative regulation of cilium assembly; IDA:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IMP:BHF-UCL. DR GO; GO:1903384; P:negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IMP:BHF-UCL. DR GO; GO:2000402; P:negative regulation of lymphocyte migration; IMP:BHF-UCL. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0045746; P:negative regulation of Notch signaling pathway; TAS:Reactome. DR GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; ISS:UniProt. DR GO; GO:0150033; P:negative regulation of protein localization to lysosome; IDA:UniProtKB. DR GO; GO:1903318; P:negative regulation of protein maturation; ISS:UniProt. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:ARUK-UCL. DR GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL. DR GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc. DR GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IDA:UniProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:1905786; P:positive regulation of anaphase-promoting complex-dependent catabolic process; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProt. DR GO; GO:0046326; P:positive regulation of D-glucose import; IMP:BHF-UCL. DR GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IDA:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL. DR GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:UniProtKB. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1905552; P:positive regulation of protein localization to endoplasmic reticulum; IDA:UniProt. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:BHF-UCL. DR GO; GO:0051247; P:positive regulation of protein metabolic process; ISS:BHF-UCL. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL. DR GO; GO:0010765; P:positive regulation of sodium ion transport; IEA:Ensembl. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0005979; P:regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW. DR GO; GO:0110002; P:regulation of tRNA methylation; IDA:UniProt. DR GO; GO:2000074; P:regulation of type B pancreatic cell development; TAS:Reactome. DR GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL. DR GO; GO:0032094; P:response to food; IEA:Ensembl. DR GO; GO:0070848; P:response to growth factor; IDA:UniProtKB. DR GO; GO:0060416; P:response to growth hormone; ISS:AgBase. DR GO; GO:0009408; P:response to heat; TAS:ProtInc. DR GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase. DR GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0031929; P:TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR CDD; cd01241; PH_PKB; 1. DR CDD; cd05594; STKc_PKB_alpha; 1. DR DisProt; DP03300; -. DR FunFam; 1.10.510.10:FF:000033; Non-specific serine/threonine protein kinase; 1. DR FunFam; 2.30.29.30:FF:000027; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000838; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00412; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034676; Akt1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR039026; PH_PKB. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Carbohydrate metabolism; Cell membrane; Cytoplasm; Developmental protein; KW Disease variant; Disulfide bond; Glucose metabolism; Glycogen biosynthesis; KW Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane; KW Mitochondrion; Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Sugar transport; Transferase; KW Translation regulation; Transport; Ubl conjugation. FT CHAIN 1..480 FT /note="RAC-alpha serine/threonine-protein kinase" FT /id="PRO_0000085605" FT DOMAIN 5..108 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 150..408 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 409..480 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 113..138 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 450..480 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 274 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 14..19 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 23..25 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 53 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 86 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 156..164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 462 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250|UniProtKB:P31750" FT MOD_RES 14 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 20 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 124 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 126 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 129 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 176 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:20333297" FT MOD_RES 308 FT /note="Phosphothreonine; by IKKE, PDPK1 and TBK1" FT /evidence="ECO:0000269|PubMed:15718470, FT ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:40285646, ECO:0000269|PubMed:8978681, FT ECO:0000269|PubMed:9512493" FT MOD_RES 448 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 450 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 473 FT /note="Phosphoserine; by IKKE, MTOR, PRKDC and TBK1; FT alternate" FT /evidence="ECO:0000269|PubMed:14761976, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, FT ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, FT ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:40285646, FT ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9736715" FT MOD_RES 474 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:12149249" FT MOD_RES 477 FT /note="Phosphoserine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT MOD_RES 479 FT /note="Phosphothreonine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT CARBOHYD 126 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 129 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 305 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 312 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 473 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000250|UniProtKB:P31750" FT DISULFID 60..77 FT /evidence="ECO:0000269|PubMed:20886116" FT DISULFID 296..310 FT /evidence="ECO:0000250|UniProtKB:P31751" FT CROSSLNK 284 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22410793" FT VAR_SEQ 1..62 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056180" FT VARIANT 17 FT /note="E -> K (in PROTEUSS and breast cancer; also detected FT in colorectal and ovarian cancer; somatic mutation; results FT in increased phosphorylation at T-308 and higher basal FT ubiquitination; the mutant protein is more efficiently FT recruited to the plasma membrane; alters FT phosphatidylinositiol phosphates lipid specificity of the FT AKT1 PH domain; dbSNP:rs121434592)" FT /evidence="ECO:0000269|PubMed:17611497, FT ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527, FT ECO:0000269|PubMed:21793738" FT /id="VAR_055422" FT VARIANT 25 FT /note="R -> C (in CWS6; impairs interaction with FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2; dbSNP:rs397514644)" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:23246288" FT /id="VAR_069791" FT VARIANT 167 FT /note="V -> A (in dbSNP:rs11555433)" FT /id="VAR_051617" FT VARIANT 435 FT /note="T -> P (in CWS6; dbSNP:rs397514645)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069792" FT MUTAGEN 8 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation as well FT as IGF1-induced membrane recruitment. Decrease in FT ubiquitination and phosphorylation at T-308 as well as FT impaired association with the membrane; when associated FT with K-17." FT /evidence="ECO:0000269|PubMed:19713527" FT MUTAGEN 14 FT /note="K->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, loss of AKT activation, and loss of binding FT to PIP3 as well as IGF1-induced membrane recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation, loss of FT binding to PIP3 as well as IGF1-induced membrane FT recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 17 FT /note="E->K: Loss of membrane localization; when associated FT with Q-20." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, reduced AKT activation, and reduced binding FT to PIP3 as well as IGF1-induced membrane recruitment. Loss FT of membrane localization; when associated with K-17." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->R: Slight increase of phosphorylation at T-308 FT and S-473." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 25 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 76..78 FT /note="RCL->ACA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 86 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 176 FT /note="Y->F: Significant loss of interaction with TNK2. FT Loss of membrane localization. Significant reduction in FT phosphorylation on Ser-473." FT /evidence="ECO:0000269|PubMed:20333297" FT MUTAGEN 179 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:12172553, FT ECO:0000269|PubMed:33594058" FT MUTAGEN 273..275 FT /note="RDL->ADA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 305 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-312." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 305 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 308 FT /note="T->D: 5-fold activation and 18-fold activation; when FT associated with D-473." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 312 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-305." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 312 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 473 FT /note="S->D: 7-fold activation and 25-fold activation; when FT associated with D-308." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 474 FT /note="Y->F: 55% inhibition of activation." FT /evidence="ECO:0000269|PubMed:12149249" FT CONFLICT 173..174 FT /note="GR -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="L -> Q (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="A -> R (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 246 FT /note="S -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 409 FT /note="A -> T (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="A -> P (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> S (in Ref. 1; AAA36539, 2; AAL55732, 3; FT BAG36922 and 4; BAG70056/BAG70181)" FT /evidence="ECO:0000305" FT HELIX 2..4 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 6..15 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 22..30 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 33..40 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:7APJ" FT HELIX 45..48 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 67..69 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 72..79 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 82..89 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 150..158 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 160..169 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 170..172 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 175..182 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 213..218 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 235..242 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 247..268 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:4EJN" FT STRAND 288..290 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:3MVH" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 318..322 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 330..344 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 374..383 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 396..398 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 399..403 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 406..408 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 413..417 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:3MVH" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:7NH5" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 464..466 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:4GV1" SQ SEQUENCE 480 AA; 55686 MW; 6EAFF4F8AD436714 CRC64; MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA // ID AMGO2_HUMAN Reviewed; 522 AA. AC Q86SJ2; Q4VBP6; Q7Z4A0; Q96CN8; DT 21-JUN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 187. DE RecName: Full=Amphoterin-induced protein 2; DE AltName: Full=AMIGO-2; DE AltName: Full=Alivin-1; DE AltName: Full=Differentially expressed in gastric adenocarcinomas; DE Short=DEGA; DE Flags: Precursor; GN Name=AMIGO2 {ECO:0000312|EMBL:AAH47595.1}; GN Synonyms=ALI1 {ECO:0000312|EMBL:BAC81189.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000312|EMBL:AAO48946.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Fibrosarcoma {ECO:0000269|PubMed:12629050}; RX PubMed=12629050; DOI=10.1083/jcb.200209074; RA Kuja-Panula J., Kiiltomaeki M., Yamashiro T., Rouhiainen A., Rauvala H.; RT "AMIGO, a transmembrane protein implicated in axon tract development, RT defines a novel protein family with leucine-rich repeats."; RL J. Cell Biol. 160:963-973(2003). RN [2] {ECO:0000312|EMBL:BAC81189.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain {ECO:0000312|EMBL:BAC81189.1}; RX PubMed=12843293; DOI=10.1523/jneurosci.23-13-05887.2003; RA Ono T., Sekino-Suzuki N., Kikkawa Y., Yonekawa H., Kawashima S.; RT "Alivin 1, a novel neuronal activity-dependent gene, inhibits apoptosis and RT promotes survival of cerebellar granule neurons."; RL J. Neurosci. 23:5887-5896(2003). RN [3] {ECO:0000305, ECO:0000312|EMBL:AAR83271.1} RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RX PubMed=15107827; DOI=10.1038/sj.onc.1207681; RA Rabenau K.E., O'Toole J.M., Bassi R., Kotanides H., Witte L., Ludwig D.L., RA Pereira D.S.; RT "DEGA/AMIGO-2, a leucine-rich repeat family member, differentially RT expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal RT stability, cell adhesion/migration and tumorigenicity."; RL Oncogene 23:5056-5067(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Stomach; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] {ECO:0000312|EMBL:AAH47595.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis {ECO:0000312|EMBL:AAH47595.1}, and RC Uterus {ECO:0000312|EMBL:AAH14103.2}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). CC -!- FUNCTION: Required for depolarization-dependent survival of cultured CC cerebellar granule neurons. May mediate homophilic as well as CC heterophilic cell-cell interaction with AMIGO1 or AMIGO3. May CC contribute to signal transduction through its intracellular domain. May CC be required for tumorigenesis of a subset of gastric adenocarcinomas. CC -!- SUBUNIT: Binds itself as well as AMIGO1 and AMIGO3. {ECO:0000250}. CC -!- INTERACTION: CC Q86SJ2; O00555: CACNA1A; NbExp=2; IntAct=EBI-3866830, EBI-766279; CC Q86SJ2; Q6PL24: TMED8; NbExp=3; IntAct=EBI-3866830, EBI-11603430; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass type I CC membrane protein {ECO:0000250}. Nucleus {ECO:0000250}. Note=Associated CC with nucleus as well as plasma membrane. Restricted to somata of CC cerebellar as well as hippocampal neurons (By similarity). CC {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Highest levels in breast, ovary, cervix, and CC uterus. Lower levels in lung, colon, and rectum. Differentially CC expressed in 56% of thyroid, 57% of pancreatic and 45% of stomach CC cancers. {ECO:0000269|PubMed:15107827}. CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. AMIGO family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY237005; AAO48946.1; -; mRNA. DR EMBL; AB079074; BAC81188.1; -; mRNA. DR EMBL; AB080610; BAC81189.1; -; mRNA. DR EMBL; AY454159; AAR83271.1; -; mRNA. DR EMBL; AL833007; CAH56293.1; -; mRNA. DR EMBL; BC014103; AAH14103.2; -; mRNA. DR EMBL; BC047595; AAH47595.1; -; mRNA. DR EMBL; BC095477; AAH95477.1; -; mRNA. DR CCDS; CCDS8751.1; -. DR RefSeq; NP_001137140.1; NM_001143668.1. DR RefSeq; NP_001357228.1; NM_001370299.1. DR RefSeq; NP_862830.1; NM_181847.4. DR RefSeq; XP_047284741.1; XM_047428785.1. DR AlphaFoldDB; Q86SJ2; -. DR SMR; Q86SJ2; -. DR BioGRID; 131497; 48. DR FunCoup; Q86SJ2; 22. DR IntAct; Q86SJ2; 9. DR STRING; 9606.ENSP00000266581; -. DR GlyConnect; 1007; 4 N-Linked glycans (1 site). DR GlyCosmos; Q86SJ2; 8 sites, 4 glycans. DR GlyGen; Q86SJ2; 10 sites, 6 N-linked glycans (3 sites). DR iPTMnet; Q86SJ2; -. DR PhosphoSitePlus; Q86SJ2; -. DR SwissPalm; Q86SJ2; -. DR BioMuta; AMIGO2; -. DR DMDM; 68052338; -. DR jPOST; Q86SJ2; -. DR MassIVE; Q86SJ2; -. DR PaxDb; 9606-ENSP00000266581; -. DR PeptideAtlas; Q86SJ2; -. DR ProteomicsDB; 69596; -. DR Pumba; Q86SJ2; -. DR Antibodypedia; 13397; 235 antibodies from 31 providers. DR DNASU; 347902; -. DR Ensembl; ENST00000266581.4; ENSP00000266581.4; ENSG00000139211.8. DR Ensembl; ENST00000429635.1; ENSP00000406020.1; ENSG00000139211.8. DR Ensembl; ENST00000550413.2; ENSP00000449034.1; ENSG00000139211.8. DR GeneID; 347902; -. DR KEGG; hsa:347902; -. DR MANE-Select; ENST00000550413.2; ENSP00000449034.1; NM_001370299.1; NP_001357228.1. DR UCSC; uc001rpk.4; human. DR AGR; HGNC:24073; -. DR ClinPGx; PA142672626; -. DR CTD; 347902; -. DR DisGeNET; 347902; -. DR GeneCards; AMIGO2; -. DR HGNC; HGNC:24073; AMIGO2. DR HPA; ENSG00000139211; Low tissue specificity. DR MIM; 615690; gene. DR OpenTargets; ENSG00000139211; -. DR VEuPathDB; HostDB:ENSG00000139211; -. DR eggNOG; ENOG502R009; Eukaryota. DR GeneTree; ENSGT00950000183146; -. DR HOGENOM; CLU_030478_0_0_1; -. DR InParanoid; Q86SJ2; -. DR OMA; DFVWVGP; -. DR OrthoDB; 676979at2759; -. DR PAN-GO; Q86SJ2; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q86SJ2; -. DR PathwayCommons; Q86SJ2; -. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR SignaLink; Q86SJ2; -. DR Agora; ENSG00000139211; -. DR BioGRID-ORCS; 347902; 22 hits in 1166 CRISPR screens. DR GenomeRNAi; 347902; -. DR Pharos; Q86SJ2; Tbio. DR PRO; PR:Q86SJ2; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q86SJ2; protein. DR Bgee; ENSG00000139211; Expressed in blood vessel layer and 190 other cell types or tissues. DR ExpressionAtlas; Q86SJ2; baseline and differential. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0007420; P:brain development; IBA:GO_Central. DR GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; ISS:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; ISS:UniProtKB. DR GO; GO:0043069; P:negative regulation of programmed cell death; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IBA:GO_Central. DR FunFam; 2.60.40.10:FF:001047; amphoterin-induced protein 2 isoform X1; 1. DR FunFam; 3.80.10.10:FF:000170; amphoterin-induced protein 2 isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR InterPro; IPR031283; AMIGO. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp. DR InterPro; IPR032675; LRR_dom_sf. DR PANTHER; PTHR24368; AMPHOTERIN-INDUCED PROTEIN; 1. DR PANTHER; PTHR24368:SF209; AMPHOTERIN-INDUCED PROTEIN 2; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF13855; LRR_8; 1. DR SMART; SM00409; IG; 1. DR SMART; SM00369; LRR_TYP; 5. DR SMART; SM00082; LRRCT; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF52058; L domain-like; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51450; LRR; 7. PE 1: Evidence at protein level; KW Cell adhesion; Cell membrane; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Leucine-rich repeat; Membrane; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Signal; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..39 FT /evidence="ECO:0000255" FT CHAIN 40..522 FT /note="Amphoterin-induced protein 2" FT /evidence="ECO:0000255" FT /id="PRO_0000014509" FT TOPO_DOM 40..398 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 399..419 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 420..522 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 40..68 FT /note="LRRNT" FT REPEAT 69..90 FT /note="LRR 1" FT REPEAT 94..115 FT /note="LRR 2" FT REPEAT 118..139 FT /note="LRR 3" FT REPEAT 142..163 FT /note="LRR 4" FT REPEAT 166..187 FT /note="LRR 5" FT REPEAT 193..214 FT /note="LRR 6" FT DOMAIN 228..284 FT /note="LRRCT" FT DOMAIN 289..379 FT /note="Ig-like C2-type" FT /evidence="ECO:0000255" FT REGION 501..522 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 58 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 281 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 288 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 373 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 381 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 384 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 41..47 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 45..54 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 232..260 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 234..282 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 310..363 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" SQ SEQUENCE 522 AA; 57934 MW; 20A86E3D82C05B9B CRC64; MSLRVHTLPT LLGAVVRPGC RELLCLLMIT VTVGPGASGV CPTACICATD IVSCTNKNLS KVPGNLFRLI KRLDLSYNRI GLLDSEWIPV SFAKLNTLIL RHNNITSIST GSFSTTPNLK CLDLSSNKLK TVKNAVFQEL KVLEVLLLYN NHISYLDPSA FGGLSQLQKL YLSGNFLTQF PMDLYVGRFK LAELMFLDVS YNRIPSMPMH HINLVPGKQL RGIYLHGNPF VCDCSLYSLL VFWYRRHFSS VMDFKNDYTC RLWSDSRHSR QVLLLQDSFM NCSDSIINGS FRALGFIHEA QVGERLMVHC DSKTGNANTD FIWVGPDNRL LEPDKEMENF YVFHNGSLVI ESPRFEDAGV YSCIAMNKQR LLNETVDVTI NVSNFTVSRS HAHEAFNTAF TTLAACVASI VLVLLYLYLT PCPCKCKTKR QKNMLHQSNA HSSILSPGPA SDASADERKA GAGKRVVFLE PLKDTAAGQN GKVRLFPSEA VIAEGILKST RGKSDSDSVN SVFSDTPFVA ST // ID APC_HUMAN Reviewed; 2843 AA. AC P25054; B7Z2B6; D3DT03; Q15162; Q15163; Q93042; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 16-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 276. DE RecName: Full=Adenomatous polyposis coli protein; DE Short=Protein APC; DE AltName: Full=Deleted in polyposis 2.5; GN Name=APC {ECO:0000312|HGNC:HGNC:583}; Synonyms=DP2.5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A AND 2), AND VARIANT ASP-1822. RC TISSUE=Fetal brain; RX PubMed=1678319; DOI=10.1016/0092-8674(81)90022-2; RA Joslyn G., Carlson M., Thliveris A., Albertsen H., Gelbert L., Samowitz W., RA Groden J., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., RA Wolff E., Burt R., Hughes J.P., Warrington J., McPherson J.D., RA Wasmuth J.J., le Paslier D., Abderrahim H., Cohen D., Leppert M., White R.; RT "Identification of deletion mutations and three new genes at the familial RT polyposis locus."; RL Cell 66:601-613(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), AND VARIANT ASP-1822. RX PubMed=1651562; DOI=10.1126/science.1651562; RA Kinzler K.W., Nilbert M.C., Su L.-K., Vogelstein B., Bryan T.M., Levy D.B., RA Smith K.J., Preisinger A.C., Hedge P., McKechnie D., Finniear R., RA Markham A., Groffen J., Boguski M.S., Altschul S.F., Horii A.K., Ando H., RA Miyoshi Y., Miki Y., Nishisho I., Nakamura Y.; RT "Identification of FAP locus genes from chromosome 5q21."; RL Science 253:661-665(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH ARHGEF4, AND IDENTIFICATION IN A COMPLEX WITH ARHGEF4 AND RP CTNNB1. RX PubMed=10947987; DOI=10.1126/science.289.5482.1194; RA Kawasaki Y., Senda T., Ishidate T., Koyama R., Morishita T., Iwayama Y., RA Higuchi O., Akiyama T.; RT "Asef, a link between the tumor suppressor APC and G-protein signaling."; RL Science 289:1194-1197(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-1822. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1135 (ISOFORM 1B). RC TISSUE=Amygdala {ECO:0000312|EMBL:BAH11802.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1506-1524. RX PubMed=1310068; RA Miki Y., Nishisho I., Horii A., Miyoshi Y., Utsunomiya J., Kinzler K.W., RA Vogelstein B., Nakamura Y.; RT "Disruption of the APC gene by a retrotransposal insertion of L1 sequence RT in a colon cancer."; RL Cancer Res. 52:643-645(1992). RN [8] RP INTERACTION WITH ALPHA- AND BETA-CATENINS. RX PubMed=8259519; DOI=10.1126/science.8259519; RA Su L.-K., Vogelstein B., Kinzler K.W.; RT "Association of the APC tumor suppressor protein with catenins."; RL Science 262:1734-1737(1993). RN [9] RP INTERACTION WITH DLG1. RX PubMed=8638125; DOI=10.1126/science.272.5264.1020; RA Matsumine A., Ogai A., Senda T., Okumura N., Satoh K., Baeg G.-H., RA Kawahara T., Kobayashi S., Okada M., Toyoshima K., Akiyama T.; RT "Binding of APC to the human homolog of the Drosophila discs large tumor RT suppressor protein."; RL Science 272:1020-1023(1996). RN [10] RP INTERACTION WITH DLG3. RC TISSUE=Fetal brain; RX PubMed=9188857; DOI=10.1038/sj.onc.1201087; RA Makino K., Kuwahara H., Masuko N., Nishiyama Y., Morisaki T., Sasaki J., RA Nakao M., Kuwano A., Nakata M., Ushio Y., Saya H.; RT "Cloning and characterization of NE-dlg: a novel human homolog of the RT Drosophila discs large (dlg) tumor suppressor protein interacts with the RT APC protein."; RL Oncogene 14:2425-2433(1997). RN [11] RP INTERACTION WITH APC2. RX PubMed=11691822; RA Jarrett C.R., Blancato J., Cao T., Bressette D.S., Cepeda M., Young P.E., RA King C.R., Byers S.W.; RT "Human APC2 localization and allelic imbalance."; RL Cancer Res. 61:7978-7984(2001). RN [12] RP INTERACTION WITH MAPRE1; MAPRE2 AND MAPRE3. RX PubMed=14514668; DOI=10.1074/jbc.m306194200; RA Bu W., Su L.-K.; RT "Characterization of functional domains of human EB1 family proteins."; RL J. Biol. Chem. 278:49721-49731(2003). RN [13] RP UBIQUITINATION. RX PubMed=15355978; DOI=10.1074/jbc.m404655200; RA Choi J., Park S.Y., Costantini F., Jho E.-H., Joo C.-K.; RT "Adenomatous polyposis coli is down-regulated by the ubiquitin-proteasome RT pathway in a process facilitated by Axin."; RL J. Biol. Chem. 279:49188-49198(2004). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP SUBCELLULAR LOCATION, INTERACTION WITH SCRIB, AND MUTAGENESIS OF THR-2841 RP AND VAL-2843. RX PubMed=16611247; DOI=10.1111/j.1365-2443.2006.00954.x; RA Takizawa S., Nagasaka K., Nakagawa S., Yano T., Nakagawa K., Yasugi T., RA Takeuchi T., Kanda T., Huibregtse J.M., Akiyama T., Taketani Y.; RT "Human scribble, a novel tumor suppressor identified as a target of high- RT risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous RT polyposis coli."; RL Genes Cells 11:453-464(2006). RN [16] RP FUNCTION, INTERACTION WITH MAPRE1 AND ACTIN, AND PHOSPHORYLATION. RX PubMed=17293347; DOI=10.1074/jbc.m610615200; RA Moseley J.B., Bartolini F., Okada K., Wen Y., Gundersen G.G., Goode B.L.; RT "Regulated binding of adenomatous polyposis coli protein to actin."; RL J. Biol. Chem. 282:12661-12668(2007). RN [17] RP FUNCTION, AND INTERACTION WITH SPATA13. RX PubMed=17599059; DOI=10.1038/sj.onc.1210574; RA Kawasaki Y., Sagara M., Shibata Y., Shirouzu M., Yokoyama S., Akiyama T.; RT "Identification and characterization of Asef2, a guanine-nucleotide RT exchange factor specific for Rac1 and Cdc42."; RL Oncogene 26:7620-7627(2007). RN [18] RP DEUBIQUITINATION. RX PubMed=18281465; DOI=10.1101/gad.463208; RA Tran H., Hamada F., Schwarz-Romond T., Bienz M.; RT "Trabid, a new positive regulator of Wnt-induced transcription with RT preference for binding and cleaving K63-linked ubiquitin chains."; RL Genes Dev. 22:528-542(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2671, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780; SER-1042; SER-1360; RP SER-1861; SER-1863; SER-1864; THR-2151; SER-2260; SER-2270; SER-2283; RP SER-2473; SER-2535; SER-2671; SER-2674; THR-2679 AND SER-2789, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY. RX PubMed=19527921; DOI=10.1016/j.canlet.2009.05.016; RA Hosoya K., Yamashita S., Ando T., Nakajima T., Itoh F., Ushijima T.; RT "Adenomatous polyposis coli 1A is likely to be methylated as a passenger in RT human gastric carcinogenesis."; RL Cancer Lett. 285:182-189(2009). RN [23] RP INTERACTION WITH MAPRE1, AND SUBCELLULAR LOCATION. RX PubMed=19632184; DOI=10.1016/j.cell.2009.04.065; RA Honnappa S., Gouveia S.M., Weisbrich A., Damberger F.F., Bhavesh N.S., RA Jawhari H., Grigoriev I., van Rijssel F.J., Buey R.M., Lawera A., RA Jelesarov I., Winkler F.K., Wuthrich K., Akhmanova A., Steinmetz M.O.; RT "An EB1-binding motif acts as a microtubule tip localization signal."; RL Cell 138:366-376(2009). RN [24] RP FUNCTION. RX PubMed=19893577; DOI=10.1038/embor.2009.233; RA Kawasaki Y., Tsuji S., Muroya K., Furukawa S., Shibata Y., Okuno M., RA Ohwada S., Akiyama T.; RT "The adenomatous polyposis coli-associated exchange factors Asef and Asef2 RT are required for adenoma formation in Apc(Min/+)mice."; RL EMBO Rep. 10:1355-1362(2009). RN [25] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19151759; DOI=10.1038/onc.2008.478; RA Sagara M., Kawasaki Y., Iemura S.I., Natsume T., Takai Y., Akiyama T.; RT "Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization RT and are involved in HGF-induced cell migration."; RL Oncogene 28:1357-1365(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744 AND SER-780, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP INTERACTION WITH AMER1. RX PubMed=21498506; DOI=10.1074/jbc.m111.224881; RA Tanneberger K., Pfister A.S., Kriz V., Bryja V., Schambony A., Behrens J.; RT "Structural and functional characterization of the Wnt inhibitor APC RT membrane recruitment 1 (Amer1)."; RL J. Biol. Chem. 286:19204-19214(2011). RN [30] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=21643010; DOI=10.1038/onc.2011.201; RA Rohlin A., Engwall Y., Fritzell K., Goeransson K., Bergsten A., RA Einbeigi Z., Nilbert M., Karlsson P., Bjoerk J., Nordling M.; RT "Inactivation of promoter 1B of APC causes partial gene silencing: evidence RT for a significant role of the promoter in regulation and causative of RT familial adenomatous polyposis."; RL Oncogene 30:4977-4989(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1861; SER-1863 AND SER-1864, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP INTERACTION WITH AMER2. RX PubMed=22128170; DOI=10.1074/jbc.m111.308650; RA Pfister A.S., Tanneberger K., Schambony A., Behrens J.; RT "Amer2 protein is a novel negative regulator of Wnt/beta-Catenin signaling RT involved in neuroectodermal patterning."; RL J. Biol. Chem. 287:1734-1741(2012). RN [33] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-748; SER-908; RP SER-1042; SER-1371; SER-1385; THR-1438; SER-1774; SER-1861; SER-2260; RP SER-2283; SER-2569; SER-2674; SER-2724 AND SER-2789, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH JPT1. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [37] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=27217144; DOI=10.1038/srep26011; RA Yamaguchi K., Nagayama S., Shimizu E., Komura M., Yamaguchi R., Shibuya T., RA Arai M., Hatakeyama S., Ikenoue T., Ueno M., Miyano S., Imoto S., RA Furukawa Y.; RT "Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B RT is responsible for familial adenomatous polyposis."; RL Sci. Rep. 6:26011-26011(2016). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 2-55. RX PubMed=10926498; DOI=10.1006/jmbi.2000.3895; RA Day C.L., Alber T.; RT "Crystal structure of the amino-terminal coiled-coil domain of the APC RT tumor suppressor."; RL J. Mol. Biol. 301:147-156(2000). RN [39] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1021-1035 IN COMPLEX WITH CTNNB1. RX PubMed=11707392; DOI=10.1093/emboj/20.22.6203; RA Eklof Spink K., Fridman S.G., Weis W.I.; RT "Molecular mechanisms of beta-catenin recognition by adenomatous polyposis RT coli revealed by the structure of an APC-beta-catenin complex."; RL EMBO J. 20:6203-6212(2001). RN [40] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2034-2049 IN COMPLEX WITH AXIN1, RP AND INTERACTION WITH AXIN1. RX PubMed=10811618; DOI=10.1093/emboj/19.10.2270; RA Spink K.E., Polakis P., Weis W.I.; RT "Structural basis of the axin-adenomatous polyposis coli interaction."; RL EMBO J. 19:2270-2279(2000). RN [41] RP STRUCTURE BY NMR OF 1578-1596 IN COMPLEX WITH ASAP1, AND INTERACTION WITH RP ASAP1. RX PubMed=20509626; DOI=10.1021/bi100563z; RA Kaieda S., Matsui C., Mimori-Kiyosue Y., Ikegami T.; RT "Structural basis of the recognition of the SAMP motif of adenomatous RT polyposis coli by the Src-homology 3 domain."; RL Biochemistry 49:5143-5153(2010). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 407-775, AND DOMAIN ARM REPEATS. RX PubMed=21871439; DOI=10.1016/j.bbrc.2011.08.044; RA Zhang Z., Lin K., Gao L., Chen L., Shi X., Wu G.; RT "Crystal structure of the armadillo repeat domain of adenomatous polyposis RT coli which reveals its inherent flexibility."; RL Biochem. Biophys. Res. Commun. 412:732-736(2011). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 396-732 IN COMPLEX WITH KHDRBS1, RP INTERACTION WITH KHDRBS1, AND MUTAGENESIS OF LYS-516 AND ARG-549. RX PubMed=22000517; DOI=10.1016/j.str.2011.07.013; RA Morishita E.C., Murayama K., Kato-Murayama M., Ishizuka-Katsura Y., RA Tomabechi Y., Hayashi T., Terada T., Handa N., Shirouzu M., Akiyama T., RA Yokoyama S.; RT "Crystal structures of the armadillo repeat domain of adenomatous polyposis RT coli and its complex with the tyrosine-rich domain of Sam68."; RL Structure 19:1496-1508(2011). RN [44] RP VARIANTS FAP1. RX PubMed=1651563; DOI=10.1126/science.1651563; RA Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., RA Koyama K., Utsunomiya J., Baba S., Hedge P., Markham A., Krush A.J., RA Petersen G.M., Hamilton S.R., Nilbert M.C., Levy D.B., Bryan T.M., RA Preisinger A.C., Smith K.J., Su L.-K., Kinzler K.W., Vogelstein B.; RT "Mutations of chromosome 5q21 genes in FAP and colorectal cancer RT patients."; RL Science 253:665-669(1991). RN [45] RP VARIANT FAP1 GLY-911. RX PubMed=1338904; DOI=10.1093/hmg/1.4.229; RA Miyoshi Y., Nagase H., Ando H., Ichii S., Nakatsuru S., Aoki T., Miki Y., RA Mori T., Nakamura Y.; RT "Somatic mutations of the APC gene in colorectal tumors: mutation cluster RT region in the APC gene."; RL Hum. Mol. Genet. 1:229-233(1992). RN [46] RP VARIANTS FAP1. RX PubMed=1338691; DOI=10.1093/hmg/1.8.559; RA Nakatsuru S., Yanagisawa A., Ichii S., Tahara E., Kato Y., Nakamura Y., RA Horii A.; RT "Somatic mutation of the APC gene in gastric cancer: frequent mutations in RT very well differentiated adenocarcinoma and signet-ring cell carcinoma."; RL Hum. Mol. Genet. 1:559-563(1992). RN [47] RP VARIANTS FAP1 MET-1292 AND TRP-1348, AND VARIANTS ASP-1118; VAL-1304 AND RP SER-2502. RX PubMed=1338764; DOI=10.1002/humu.1380010603; RA Nagase H., Miyoshi Y., Horii A., Aoki T., Petersen G.M., Vogelstein B., RA Maher E., Ogawa M., Maruyama M., Utsunomiya J., Baba S., Nakamura Y.; RT "Screening for germ-line mutations in familial adenomatous polyposis RT patients: 61 new patients and a summary of 150 unrelated patients."; RL Hum. Mutat. 1:467-473(1992). RN [48] RP VARIANTS FAP1 CYS-2621 AND PHE-2839. RX PubMed=1316610; DOI=10.1073/pnas.89.10.4452; RA Miyoshi Y., Ando H., Nagase H., Nishisho I., Horii A., Miki Y., Mori T., RA Utsunomiya J., Baba S., Petersen G.; RT "Germ-line mutations of the APC gene in 53 familial adenomatous polyposis RT patients."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4452-4456(1992). RN [49] RP VARIANTS FAP1 CYS-414; THR-784 AND LEU-1176. RX PubMed=8111410; DOI=10.1002/humu.1380020602; RA Nagase H., Nakamura Y.; RT "Mutations of the APC (adenomatous polyposis coli) gene."; RL Hum. Mutat. 2:425-434(1993). RN [50] RP VARIANT FAP1 TRP-99. RC TISSUE=Peripheral blood lymphocyte; RX PubMed=7833149; DOI=10.1016/0959-8049(94)00294-f; RA Dobbie Z., Spycher M., Huerliman R., Ammann R., Ammann T., Roth J., RA Mueller A., Mueller H., Scott R.J.; RT "Mutational analysis of the first 14 exons of the adenomatous polyposis RT coli (APC) gene."; RL Eur. J. Cancer 30A:1709-1713(1994). RN [51] RP VARIANT FAP1 GLY-722. RX PubMed=7833931; DOI=10.1093/hmg/3.9.1687; RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RT "Four novel mutations of the APC (adenomatous polyposis coli) gene in FAP RT patients."; RL Hum. Mol. Genet. 3:1687-1688(1994). RN [52] RP ERRATUM OF PUBMED:7833931. RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RL Hum. Mol. Genet. 3:1918-1918(1994). RN [53] RP INVOLVEMENT IN FAP1. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [54] RP INVOLVEMENT IN DESMD. RX PubMed=8940264; RA Eccles D.M., van der Luijt R.B., Breukel C., Bullman H., Bunyan D., RA Fisher A., Barber J., du Boulay C., Primrose J., Burn J., Fodde R.; RT "Hereditary desmoid disease due to a frameshift mutation at codon 1924 of RT the APC gene."; RL Am. J. Hum. Genet. 59:1193-1201(1996). RN [55] RP VARIANT HEPATOBLASTOMA CYS-1395. RX PubMed=8764128; RA Oda H., Imai Y., Nakatsuru Y., Hata J., Ishikawa T.; RT "Somatic mutations of the APC gene in sporadic hepatoblastomas."; RL Cancer Res. 56:3320-3323(1996). RN [56] RP VARIANT FAP1 ILE-171. RX PubMed=8990002; RX DOI=10.1002/(sici)1098-1004(1997)9:1<7::aid-humu2>3.0.co;2-8; RA van der Luijt R.B., Meera Khan P., Vasen H.F.A., Tops C.M.J., RA van Leeuwen-Cornelisse I.S.J., Wijnen J.T., van der Klift H.M., Plug R.J., RA Griffioen G., Fodde R.; RT "Molecular analysis of the APC gene in 105 Dutch kindreds with familial RT adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and RT southern analysis."; RL Hum. Mutat. 9:7-16(1997). RN [57] RP VARIANTS COLORECTAL CARCINOMA THR-880; ILE-890 AND VAL-1508. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [58] RP VARIANT LYS-1307. RX PubMed=9731522; DOI=10.1038/1666; RA Redston M., Nathanson K.L., Yuan Z.Q., Neuhausen S.L., Satagopan J., RA Wong N., Yang D., Nafa D., Abrahamson J., Ozcelik H., Antin-Ozerkis D., RA Andrulis I., Daly M., Pinsky L., Schrag D., Gallinger S., Kaback M., RA King M.-C., Woodage T., Brody L.C., Godwin A., Warner E., Weber B., RA Foulkes W., Offit K.; RT "The APC I1307K allele and breast cancer risk."; RL Nat. Genet. 20:13-14(1998). RN [59] RP VARIANTS LYS-1307 AND GLN-1317. RC TISSUE=Peripheral blood; RX PubMed=9724771; DOI=10.1073/pnas.95.18.10722; RA Frayling I.M., Beck N.E., Ilyas M., Dove-Edwin I., Goodman P., Pack K., RA Bell J.A., Williams C.B., Hodgson S.V., Thomas H.J.W., Talbot I.C., RA Bodmer W.F., Tomlinson I.P.M.; RT "The APC variants I1307K and E1317Q are associated with colorectal tumors, RT but not always with a family history."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10722-10727(1998). RN [60] RP VARIANT LYS-1307. RX PubMed=9731533; DOI=10.1038/1722; RA Woodage T., King S.M., Wacholder S., Hartge P., Struewing J.P., McAdams M., RA Laken S.J., Tucker M.A., Brody L.C.; RT "The APC I1307K allele and cancer risk in a community-based study of RT Ashkenazi Jews."; RL Nat. Genet. 20:62-65(1998). RN [61] RP VARIANT LYS-1307. RX PubMed=9973276; DOI=10.1086/302262; RA Gryfe R., Di Nicola N., Lal G., Gallinger S., Redston M.; RT "Inherited colorectal polyposis and cancer risk of the APC I1307K RT polymorphism."; RL Am. J. Hum. Genet. 64:378-384(1999). RN [62] RP VARIANTS GLY-1057; CYS-1171; ASP-1822 AND THR-2738. RX PubMed=9950360; RA Wallis Y.L., Morton D.G., McKeown C.M., Macdonald F.; RT "Molecular analysis of the APC gene in 205 families: extended genotype- RT phenotype correlations in FAP and evidence for the role of APC amino acid RT changes in colorectal cancer predisposition."; RL J. Med. Genet. 36:14-20(1999). RN [63] RP VARIANT FAP1 PRO-1184. RX PubMed=10470088; DOI=10.1038/12511; RA Lamlum H., Ilyas M., Rowan A., Clark S., Johnson V., Bell J.A., RA Frayling I.M., Efstathiou J., Pack K., Payne S., Roylance R., Gorman P., RA Sheer D., Neale K., Phillips R., Talbot I.C., Bodmer W.F., RA Tomlinson I.P.M.; RT "The type of somatic mutation at APC in familial adenomatous polyposis is RT determined by the site of the germline mutation: a new facet to Knudson's RT 'two-hit' hypothesis."; RL Nat. Med. 5:1071-1075(1999). RN [64] RP VARIANTS MDB VAL-1296; ILE-1472 AND GLY-1495. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [65] RP INVOLVEMENT IN DESMD. RX PubMed=10782927; DOI=10.1034/j.1399-0004.2000.570306.x; RA Couture J., Mitri A., Lagace R., Smits R., Berk T., Bouchard H.-L., RA Fodde R., Alman B., Bapat B.; RT "A germline mutation at the extreme 3' end of the APC gene results in a RT severe desmoid phenotype and is associated with overexpression of beta- RT catenin in the desmoid tumor."; RL Clin. Genet. 57:205-212(2000). RN [66] RP VARIANT [LARGE SCALE ANALYSIS] PHE-1254. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [67] RP INVOLVEMENT IN GAPPS. RX PubMed=27087319; DOI=10.1016/j.ajhg.2016.03.001; RA Li J., Woods S.L., Healey S., Beesley J., Chen X., Lee J.S., RA Sivakumaran H., Wayte N., Nones K., Waterfall J.J., Pearson J., Patch A.M., RA Senz J., Ferreira M.A., Kaurah P., Mackenzie R., Heravi-Moussavi A., RA Hansford S., Lannagan T.R.M., Spurdle A.B., Simpson P.T., da Silva L., RA Lakhani S.R., Clouston A.D., Bettington M., Grimpen F., Busuttil R.A., RA Di Costanzo N., Boussioutas A., Jeanjean M., Chong G., Fabre A., RA Olschwang S., Faulkner G.J., Bellos E., Coin L., Rioux K., Bathe O.F., RA Wen X., Martin H.C., Neklason D.W., Davis S.R., Walker R.L., Calzone K.A., RA Avital I., Heller T., Koh C., Pineda M., Rudloff U., Quezado M., RA Pichurin P.N., Hulick P.J., Weissman S.M., Newlin A., Rubinstein W.S., RA Sampson J.E., Hamman K., Goldgar D., Poplawski N., Phillips K., RA Schofield L., Armstrong J., Kiraly-Borri C., Suthers G.K., Huntsman D.G., RA Foulkes W.D., Carneiro F., Lindor N.M., Edwards S.L., French J.D., RA Waddell N., Meltzer P.S., Worthley D.L., Schrader K.A., Chenevix-Trench G.; RT "Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and RT Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis RT Variant."; RL Am. J. Hum. Genet. 98:830-842(2016). RN [68] RP INVOLVEMENT IN GAPPS. RX PubMed=27343414; DOI=10.1016/j.gie.2016.06.023; RA Repak R., Kohoutova D., Podhola M., Rejchrt S., Minarik M., Benesova L., RA Lesko M., Bures J.; RT "The first European family with gastric adenocarcinoma and proximal RT polyposis of the stomach: case report and review of the literature."; RL Gastrointest. Endosc. 84:718-725(2016). RN [69] RP INVOLVEMENT IN MDB. RX PubMed=29753700; DOI=10.1016/s1470-2045(18)30242-0; RA Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., RA Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtler K.W., RA Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., RA Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., RA Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., RA Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., RA Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., RA MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., RA Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., RA Wesenberg F., Feychting M., Lannering B., Schuez J., Johansen C., RA Andersen T.V., Roeoesli M., Kuehni C.E., Grotzer M., Kjaerheim K., RA Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., RA Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., RA Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., RA Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., RA Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M.; RT "Spectrum and prevalence of genetic predisposition in medulloblastoma: a RT retrospective genetic study and prospective validation in a clinical trial RT cohort."; RL Lancet Oncol. 19:785-798(2018). RN [70] RP INVOLVEMENT IN GAPPS. RX PubMed=33242120; DOI=10.1007/s12328-020-01290-6; RA Kanemitsu K., Iwatsuki M., Yamashita K., Komohara Y., Morinaga T., RA Iwagami S., Eto K., Nagai Y., Kurashige J., Baba Y., Yoshida N., Baba H.; RT "Two Asian families with gastric adenocarcinoma and proximal polyposis of RT the stomach successfully treated via laparoscopic total gastrectomy."; RL Clin. J. Gastroenterol. 14:92-97(2021). CC -!- FUNCTION: Tumor suppressor. Promotes rapid degradation of CTNNB1 and CC participates in Wnt signaling as a negative regulator. APC activity is CC correlated with its phosphorylation state. Activates the GEF activity CC of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)- CC induced cell migration. Required for MMP9 up-regulation via the JNK CC signaling pathway in colorectal tumor cells. Associates with both CC microtubules and actin filaments, components of the cytoskeleton CC (PubMed:17293347). Plays a role in mediating the organization of F- CC actin into ordered bundles (PubMed:17293347). Functions downstream of CC Rho GTPases and DIAPH1 to selectively stabilize microtubules (By CC similarity). Acts as a mediator of ERBB2-dependent stabilization of CC microtubules at the cell cortex. It is required for the localization of CC MACF1 to the cell membrane and this localization of MACF1 is critical CC for its function in microtubule stabilization. CC {ECO:0000250|UniProtKB:Q61315, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19151759, ECO:0000269|PubMed:19893577, CC ECO:0000269|PubMed:20937854}. CC -!- SUBUNIT: Forms homooligomers (Probable). Found in a complex consisting CC of ARHGEF4, APC and CTNNB1 (PubMed:10947987). Found in a complex CC composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). The CC complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with APC2 CC (PubMed:11691822). Interacts with DLG1 (via PDZ domains) and DLG3 (via CC PDZ domains) (PubMed:8638125, PubMed:9188857). Interacts with CC alpha- and beta-catenins (PubMed:8259519). Interacts with AXIN1 (via CC RGS domain) (PubMed:10811618). Interacts with ARHGEF4 (via N-terminus) CC (PubMed:10947987). Interacts (via C-terminal residues 2674-2843) with CC MAPRE1 (via C-terminal residues 206-211); the interaction inhibits CC association with and bundling of F-actin (PubMed:14514668, CC PubMed:17293347, PubMed:19632184). Interacts with MAPRE2 and MAPRE3 CC (via C-terminus) (PubMed:14514668). Interacts with DIAPH1; DIAPH1 acts CC as a scaffold protein for MAPRE1 and APC to stabilize microtubules and CC promote cell migration (By similarity). Interacts with DIAPH2 (By CC similarity). Interacts with SCRIB; may mediate APC targeting to CC adherens junctions of epithelial cells (PubMed:16611247). Interacts CC with SPATA13 (via N-terminus and SH3 domain) (PubMed:17599059). CC Interacts with ASAP1 (via SH3 domain) (PubMed:20509626). Interacts (at CC the cell membrane) with AMER1 and AMER2 (via ARM repeats) CC (PubMed:21498506, PubMed:22128170). Interacts with KHDRBS1 CC (PubMed:22000517). Interacts with actin; binds both to F-actin and CC actin filament bundles (PubMed:17293347). CC {ECO:0000250|UniProtKB:P70478, ECO:0000250|UniProtKB:Q61315, CC ECO:0000269|PubMed:10811618, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:11707392, CC ECO:0000269|PubMed:14514668, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20509626, CC ECO:0000269|PubMed:21498506, ECO:0000269|PubMed:22000517, CC ECO:0000269|PubMed:22128170, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:8259519, ECO:0000269|PubMed:8638125, CC ECO:0000269|PubMed:9188857, ECO:0000305}. CC -!- INTERACTION: CC P25054; Q5JTC6: AMER1; NbExp=4; IntAct=EBI-727707, EBI-6169747; CC P25054; Q8N944: AMER3; NbExp=8; IntAct=EBI-727707, EBI-8869590; CC P25054; Q9NR80-3: ARHGEF4; NbExp=5; IntAct=EBI-727707, EBI-13639160; CC P25054; O15169: AXIN1; NbExp=17; IntAct=EBI-727707, EBI-710484; CC P25054; O14936: CASK; NbExp=2; IntAct=EBI-727707, EBI-1215506; CC P25054; P60953: CDC42; NbExp=9; IntAct=EBI-727707, EBI-81752; CC P25054; P49674: CSNK1E; NbExp=8; IntAct=EBI-727707, EBI-749343; CC P25054; P35221: CTNNA1; NbExp=3; IntAct=EBI-727707, EBI-701918; CC P25054; P35222: CTNNB1; NbExp=22; IntAct=EBI-727707, EBI-491549; CC P25054; Q12959: DLG1; NbExp=11; IntAct=EBI-727707, EBI-357481; CC P25054; Q15700: DLG2; NbExp=2; IntAct=EBI-727707, EBI-80426; CC P25054; Q92796: DLG3; NbExp=2; IntAct=EBI-727707, EBI-80440; CC P25054; P78352: DLG4; NbExp=3; IntAct=EBI-727707, EBI-80389; CC P25054; O14640: DVL1; NbExp=6; IntAct=EBI-727707, EBI-723489; CC P25054; P54792: DVL1P1; NbExp=2; IntAct=EBI-727707, EBI-7848109; CC P25054; O14641: DVL2; NbExp=2; IntAct=EBI-727707, EBI-740850; CC P25054; Q96RT1: ERBIN; NbExp=2; IntAct=EBI-727707, EBI-993903; CC P25054; P14923: JUP; NbExp=3; IntAct=EBI-727707, EBI-702484; CC P25054; Q07666: KHDRBS1; NbExp=4; IntAct=EBI-727707, EBI-1364; CC P25054; Q14114: LRP8; NbExp=2; IntAct=EBI-727707, EBI-2681187; CC P25054; Q86UL8: MAGI2; NbExp=5; IntAct=EBI-727707, EBI-311035; CC P25054; Q15691: MAPRE1; NbExp=6; IntAct=EBI-727707, EBI-1004115; CC P25054; Q14160: SCRIB; NbExp=8; IntAct=EBI-727707, EBI-357345; CC P25054; Q96N96: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13618641; CC P25054; Q96N96-1: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13638906; CC P25054; Q96N96-2: SPATA13; NbExp=2; IntAct=EBI-727707, EBI-13639118; CC P25054; O14907: TAX1BP3; NbExp=5; IntAct=EBI-727707, EBI-723259; CC P25054; P63104: YWHAZ; NbExp=2; IntAct=EBI-727707, EBI-347088; CC P25054; Q02248: Ctnnb1; Xeno; NbExp=8; IntAct=EBI-727707, EBI-397872; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:16611247}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. Cell CC projection, lamellipodium {ECO:0000269|PubMed:19151759}. Cell CC projection, ruffle membrane {ECO:0000269|PubMed:19151759}. Cytoplasm CC {ECO:0000269|PubMed:10947987}. Cell membrane CC {ECO:0000269|PubMed:10947987, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:20937854}. Note=Associated with the microtubule CC network at the growing distal tip of microtubules (PubMed:19632184). CC MAPRE1 may be required for targeting to the growing microtubule plus CC ends (PubMed:19632184). Accumulates in the lamellipodium and ruffle CC membrane in response to hepatocyte growth factor (HGF) treatment CC (PubMed:19151759). The MEMO1-RHOA-DIAPH1 signaling pathway controls CC localization of the phosphorylated form to the cell membrane CC (PubMed:20937854). {ECO:0000269|PubMed:19151759, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1A {ECO:0000303|PubMed:19527921}; Synonyms=Long CC {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-1; Sequence=Displayed; CC Name=2; Synonyms=Short {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-2; Sequence=VSP_004115; CC Name=1B {ECO:0000303|PubMed:19527921}; CC IsoId=P25054-3; Sequence=VSP_059027, VSP_059028; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tissues: brain, small CC intestine, colon, thymus, skeletal muscle, heart, prostate, lung, CC spleen, ovary, testis kidney, placenta, blood and liver CC (PubMed:21643010, PubMed:27217144). Isoform 1A: Very strongly expressed CC in brain but has relatively low expression levels in other tissues CC (PubMed:19527921, PubMed:21643010, PubMed:27217144). Isoform 1B: CC Predominant form in all tissues except for brain, including gastric CC mucosa and blood (PubMed:19527921, PubMed:21643010, PubMed:27217144). CC {ECO:0000269|PubMed:19527921, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144}. CC -!- DOMAIN: The microtubule tip localization signal (MtLS) motif; mediates CC interaction with MAPRE1 and targeting to the growing microtubule plus CC ends. {ECO:0000250}. CC -!- DOMAIN: The basic region (residues 2167-2674) mediates the association CC with both microtubule and actin proteins and promotes the bundling of CC F-actin. {ECO:0000269|PubMed:17293347}. CC -!- PTM: Phosphorylated; phosphorylation enhances the F-actin bundling CC activity (PubMed:17293347). Phosphorylated by GSK3B. CC {ECO:0000269|PubMed:17293347}. CC -!- PTM: Ubiquitinated, leading to its degradation by the proteasome. CC Ubiquitination is facilitated by Axin. Deubiquitinated by CC ZRANB1/TRABID. {ECO:0000269|PubMed:15355978, CC ECO:0000269|PubMed:18281465}. CC -!- DISEASE: Familial adenomatous polyposis 1 (FAP1) [MIM:175100]: An CC autosomal dominant cancer predisposition syndrome characterized by CC adenomatous polyps of the colon and rectum, but also of upper CC gastrointestinal tract (ampullary, duodenal and gastric adenomas). This CC is a viciously premalignant disease with one or more polyps progressing CC through dysplasia to malignancy in untreated gene carriers with a CC median age at diagnosis of 40 years. {ECO:0000269|PubMed:10470088, CC ECO:0000269|PubMed:1316610, ECO:0000269|PubMed:1338691, CC ECO:0000269|PubMed:1338764, ECO:0000269|PubMed:1338904, CC ECO:0000269|PubMed:1651563, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144, ECO:0000269|PubMed:7661930, CC ECO:0000269|PubMed:7833149, ECO:0000269|PubMed:7833931, CC ECO:0000269|PubMed:8111410, ECO:0000269|PubMed:8990002}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Desmoid disease, hereditary (DESMD) [MIM:135290]: An autosomal CC dominant disease characterized by multifocal fibromatosis of the CC abdominal wall and mesentery. Desmoid tumors can also affect paraspinal CC muscles, breast, occiput, arms, and lower ribs. CC {ECO:0000269|PubMed:10782927, ECO:0000269|PubMed:8940264}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:29753700}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric adenocarcinoma and proximal polyposis of the stomach CC (GAPPS) [MIM:619182]: A familial gastric polyposis syndrome CC characterized by autosomal dominant transmission of fundic gland CC polyposis with occasional hyperplastic and adenomatous polyps, sparing CC of the gastric antrum, and a significant risk of intestinal-type CC gastric adenocarcinoma development. Colorectal polyposis is not CC observed, and family history does not include colorectal cancer. CC {ECO:0000269|PubMed:27087319, ECO:0000269|PubMed:27343414, CC ECO:0000269|PubMed:33242120}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- MISCELLANEOUS: APC mutations have led to some interesting observations. CC (1) the great majority of the mutations found to date would result in CC truncation of the APC product. (2) almost all the mutations have CC occurred within the first half of the coding sequence, and somatic CC mutations in colorectal tumors are further clustered in a particular CC region, called MCR (mutation cluster region). (3) most identified point CC mutations in the APC gene are transitions from cytosine to other CC nucleotides. (4) the location of germline mutations tends to correlate CC with the number of colorectal polyps in FAP1 patients. Inactivation of CC both alleles of the APC gene seems to be required as an early event to CC develop most adenomas and carcinomas in the colon and rectum as well as CC some of those in the stomach. CC -!- MISCELLANEOUS: [Isoform 1B]: Produced by alternative promoter usage. CC {ECO:0000269|PubMed:19527921}. CC -!- SIMILARITY: Belongs to the adenomatous polyposis coli (APC) family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases Adenomatous CC Polyposis Coli (APC); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/APC"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/118/APC"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M73548; AAA60353.1; -; mRNA. DR EMBL; M73548; AAA60354.1; -; mRNA. DR EMBL; M74088; AAA03586.1; -; mRNA. DR EMBL; AC008575; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC136500; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471086; EAW49002.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49007.1; -; Genomic_DNA. DR EMBL; AK294544; BAH11802.1; -; mRNA. DR EMBL; S78214; AAB21145.2; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS4107.1; -. [P25054-1] DR PIR; A37261; RBHUAP. DR RefSeq; NP_000029.2; NM_000038.5. [P25054-1] DR RefSeq; NP_001120982.1; NM_001127510.3. [P25054-1] DR RefSeq; NP_001120983.2; NM_001127511.3. [P25054-3] DR RefSeq; NP_001341824.1; NM_001354895.2. [P25054-1] DR RefSeq; NP_001341832.1; NM_001354903.2. [P25054-2] DR RefSeq; NP_001394379.1; NM_001407450.1. [P25054-1] DR RefSeq; NP_001394387.1; NM_001407458.1. [P25054-2] DR RefSeq; NP_001394388.1; NM_001407459.1. [P25054-2] DR RefSeq; NP_001394389.1; NM_001407460.1. [P25054-2] DR PDB; 1DEB; X-ray; 2.40 A; A/B=2-55. DR PDB; 1EMU; X-ray; 1.90 A; B=2034-2049. DR PDB; 1JPP; X-ray; 3.10 A; C/D=1021-1035. DR PDB; 1M5I; X-ray; 2.00 A; A=126-250. DR PDB; 1T08; X-ray; 2.10 A; C=1484-1498. DR PDB; 1TH1; X-ray; 2.50 A; C/D=1362-1540. DR PDB; 1V18; X-ray; 2.10 A; B=1482-1528. DR PDB; 2RQU; NMR; -; B=1578-1596. DR PDB; 3AU3; X-ray; 2.10 A; A=396-732. DR PDB; 3NMW; X-ray; 1.60 A; A/B=407-751. DR PDB; 3NMX; X-ray; 2.30 A; A/B/C=407-751. DR PDB; 3NMZ; X-ray; 3.01 A; A/B=303-739. DR PDB; 3QHE; X-ray; 2.40 A; A/C=396-732. DR PDB; 3RL7; X-ray; 2.30 A; G/H/I/J/K/L=2833-2843. DR PDB; 3RL8; X-ray; 2.20 A; F=2833-2843. DR PDB; 3T7U; X-ray; 2.90 A; A/B=407-775. DR PDB; 4G69; X-ray; 2.00 A; B=2833-2843. DR PDB; 4YJE; X-ray; 1.90 A; A=407-751. DR PDB; 4YJL; X-ray; 2.10 A; A/B/C/D/E/F=407-751. DR PDB; 4YK6; X-ray; 1.70 A; A=407-751. DR PDB; 5B6G; X-ray; 1.99 A; A=407-751. DR PDB; 5IZ6; X-ray; 2.15 A; A=407-751. DR PDB; 5IZ8; X-ray; 3.06 A; A/B=407-751. DR PDB; 5IZ9; X-ray; 2.93 A; A=407-751. DR PDB; 5IZA; X-ray; 1.50 A; A=407-751. DR PDB; 5Z8H; X-ray; 1.79 A; A=407-741. DR PDB; 7F6M; X-ray; 2.40 A; A=407-751. DR PDB; 7F7O; X-ray; 2.80 A; A=407-738. DR PDB; 7XTY; X-ray; 2.10 A; C/D=2833-2843. DR PDB; 8GSJ; X-ray; 2.10 A; A=407-738. DR PDB; 8X2Q; X-ray; 2.00 A; A=126-250. DR PDBsum; 1DEB; -. DR PDBsum; 1EMU; -. DR PDBsum; 1JPP; -. DR PDBsum; 1M5I; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 1V18; -. DR PDBsum; 2RQU; -. DR PDBsum; 3AU3; -. DR PDBsum; 3NMW; -. DR PDBsum; 3NMX; -. DR PDBsum; 3NMZ; -. DR PDBsum; 3QHE; -. DR PDBsum; 3RL7; -. DR PDBsum; 3RL8; -. DR PDBsum; 3T7U; -. DR PDBsum; 4G69; -. DR PDBsum; 4YJE; -. DR PDBsum; 4YJL; -. DR PDBsum; 4YK6; -. DR PDBsum; 5B6G; -. DR PDBsum; 5IZ6; -. DR PDBsum; 5IZ8; -. DR PDBsum; 5IZ9; -. DR PDBsum; 5IZA; -. DR PDBsum; 5Z8H; -. DR PDBsum; 7F6M; -. DR PDBsum; 7F7O; -. DR PDBsum; 7XTY; -. DR PDBsum; 8GSJ; -. DR PDBsum; 8X2Q; -. DR BMRB; P25054; -. DR SMR; P25054; -. DR BioGRID; 106821; 370. DR ComplexPortal; CPX-107; Beta-catenin destruction core complex, APC-AXIN1-GSK3A variant. DR ComplexPortal; CPX-109; Beta-catenin destruction core complex, APC-AXIN1-GSK3B variant. DR ComplexPortal; CPX-439; Beta-catenin destruction core complex, APC-AXIN2-GSK3B variant. DR ComplexPortal; CPX-441; Beta-catenin destruction core complex, APC-AXIN2-GSK3A variant. DR CORUM; P25054; -. DR DIP; DIP-33556N; -. DR FunCoup; P25054; 1537. DR IntAct; P25054; 301. DR MINT; P25054; -. DR STRING; 9606.ENSP00000257430; -. DR BindingDB; P25054; -. DR ChEMBL; CHEMBL3233; -. DR GlyCosmos; P25054; 3 sites, 2 glycans. DR GlyGen; P25054; 8 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (4 sites). DR iPTMnet; P25054; -. DR PhosphoSitePlus; P25054; -. DR BioMuta; APC; -. DR DMDM; 97535708; -. DR jPOST; P25054; -. DR MassIVE; P25054; -. DR PaxDb; 9606-ENSP00000257430; -. DR PeptideAtlas; P25054; -. DR ProteomicsDB; 54247; -. [P25054-1] DR ProteomicsDB; 54248; -. [P25054-2] DR ProteomicsDB; 6428; -. DR Pumba; P25054; -. DR Antibodypedia; 1054; 757 antibodies from 45 providers. DR DNASU; 324; -. DR Ensembl; ENST00000257430.9; ENSP00000257430.4; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000507379.6; ENSP00000423224.2; ENSG00000134982.20. [P25054-3] DR Ensembl; ENST00000508376.6; ENSP00000427089.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000509732.6; ENSP00000426541.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000512211.7; ENSP00000423828.3; ENSG00000134982.20. [P25054-1] DR GeneID; 324; -. DR KEGG; hsa:324; -. DR MANE-Select; ENST00000257430.9; ENSP00000257430.4; NM_000038.6; NP_000029.2. DR UCSC; uc003kpy.5; human. [P25054-1] DR UCSC; uc063gan.1; human. DR AGR; HGNC:583; -. DR CIViC; 324; 4 evidence items across 2 molecular profiles. DR ClinPGx; PA24875; -. DR CTD; 324; -. DR DisGeNET; 324; -. DR GeneCards; APC; -. DR GeneReviews; APC; -. DR HGNC; HGNC:583; APC. DR HPA; ENSG00000134982; Tissue enhanced (brain). DR MalaCards; APC; -. DR MIM; 114550; phenotype. DR MIM; 135290; phenotype. DR MIM; 155255; phenotype. DR MIM; 175100; phenotype. DR MIM; 611731; gene. DR MIM; 613659; phenotype. DR MIM; 619182; phenotype. DR OpenTargets; ENSG00000134982; -. DR Orphanet; 261584; 5q22 microdeletion syndrome. DR Orphanet; 220460; Attenuated familial adenomatous polyposis. DR Orphanet; 3258; Cenani-Lenz syndrome. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 314022; Gastric adenocarcinoma and proximal polyposis of the stomach. DR VEuPathDB; HostDB:ENSG00000134982; -. DR eggNOG; KOG2122; Eukaryota. DR GeneTree; ENSGT00530000063749; -. DR HOGENOM; CLU_001012_0_0_1; -. DR InParanoid; P25054; -. DR OMA; DHEKHSP; -. DR OrthoDB; 5918429at2759; -. DR PAN-GO; P25054; 14 GO annotations based on evolutionary models. DR PhylomeDB; P25054; -. DR BioCyc; MetaCyc:ENSG00000134982-MONOMER; -. DR PathwayCommons; P25054; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5467333; APC truncation mutants are not K63 polyubiquitinated. DR Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding. DR Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex. DR Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR SignaLink; P25054; -. DR SIGNOR; P25054; -. DR Agora; ENSG00000134982; -. DR BioGRID-ORCS; 324; 172 hits in 1170 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D8D47D1F; Synthetic Condensate 000297. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; APC; human. DR EvolutionaryTrace; P25054; -. DR GeneWiki; Adenomatous_polyposis_coli; -. DR GenomeRNAi; 324; -. DR Pharos; P25054; Tchem. DR PRO; PR:P25054; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P25054; protein. DR Bgee; ENSG00000134982; Expressed in substantia nigra pars compacta and 207 other cell types or tissues. DR ExpressionAtlas; P25054; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:CACAO. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0070840; F:dynein complex binding; IPI:CAFA. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0051010; F:microtubule plus-end binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IDA:DisProt. DR GO; GO:0019887; F:protein kinase regulator activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:MGI. DR GO; GO:0070830; P:bicellular tight junction assembly; NAS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; NAS:UniProtKB. DR GO; GO:0001708; P:cell fate specification; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0003170; P:heart valve development; ISS:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:MGI. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:MGI. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007026; P:negative regulation of microtubule depolymerization; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007389; P:pattern specification process; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:MGI. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:MGI. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IGI:MGI. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:CAFA. DR GO; GO:0031274; P:positive regulation of pseudopodium assembly; IMP:MGI. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; NAS:ComplexPortal. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:MGI. DR GO; GO:0060632; P:regulation of microtubule-based movement; IEP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IMP:UniProtKB. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR DisProt; DP00519; -. DR FunFam; 1.25.10.10:FF:000035; adenomatous polyposis coli protein 2; 1. DR FunFam; 1.10.287.450:FF:000001; adenomatous polyposis coli protein isoform X1; 1. DR Gene3D; 1.20.5.10; -; 1. DR Gene3D; 1.10.287.450; Helix hairpin bin; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00035; -. DR InterPro; IPR009240; APC_15aa_rpt. DR InterPro; IPR009234; APC_basic_dom. DR InterPro; IPR026831; APC_dom. DR InterPro; IPR026818; Apc_fam. DR InterPro; IPR032038; APC_N. DR InterPro; IPR036149; APC_N_sf. DR InterPro; IPR041257; APC_rep. DR InterPro; IPR009223; APC_rpt. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR009232; EB1-bd. DR InterPro; IPR009224; SAMP. DR PANTHER; PTHR12607:SF11; ADENOMATOUS POLYPOSIS COLI PROTEIN; 1. DR PANTHER; PTHR12607; ADENOMATOUS POLYPOSIS COLI PROTEIN FAMILY; 1. DR Pfam; PF05972; APC_15aa; 4. DR Pfam; PF05956; APC_basic; 1. DR Pfam; PF16689; APC_N_CC; 1. DR Pfam; PF05923; APC_r; 7. DR Pfam; PF18797; APC_rep; 1. DR Pfam; PF16634; APC_u13; 1. DR Pfam; PF16635; APC_u14; 1. DR Pfam; PF16636; APC_u15; 1. DR Pfam; PF16630; APC_u5; 1. DR Pfam; PF16633; APC_u9; 1. DR Pfam; PF00514; Arm; 3. DR Pfam; PF16629; Arm_APC_u3; 1. DR Pfam; PF05937; EB1_binding; 1. DR Pfam; PF05924; SAMP; 3. DR Pfam; PF11414; Suppressor_APC; 1. DR SMART; SM00185; ARM; 7. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF58050; N-terminal coiled coil domain from apc; 1. DR SUPFAM; SSF82931; Tumor suppressor gene product Apc; 1. DR PROSITE; PS50176; ARM_REPEAT; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative promoter usage; KW Alternative splicing; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Cytoskeleton; Disease variant; Membrane; KW Microtubule; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Tumor suppressor; Ubl conjugation; Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..2843 FT /note="Adenomatous polyposis coli protein" FT /id="PRO_0000064627" FT REPEAT 453..495 FT /note="ARM 1" FT REPEAT 505..547 FT /note="ARM 2" FT REPEAT 548..591 FT /note="ARM 3" FT REPEAT 592..638 FT /note="ARM 4" FT REPEAT 639..683 FT /note="ARM 5" FT REPEAT 684..725 FT /note="ARM 6" FT REPEAT 726..767 FT /note="ARM 7" FT REGION 239..305 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 828..878 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 923..943 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 958..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 960..1337 FT /note="Responsible for down-regulation through a process FT mediated by direct ubiquitination" FT REGION 1020..1169 FT /note="Interaction with catenins" FT /evidence="ECO:0000269|PubMed:8259519" FT REGION 1099..1169 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1190..1244 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1311..1376 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1403..1475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1526..1569 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1583..1611 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1664..1717 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1729..1836 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1893 FT /note="Highly charged" FT REGION 1881..1950 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1965..2011 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2035..2059 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000269|PubMed:10811618" FT REGION 2043..2072 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2147..2635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2167..2674 FT /note="Basic region" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2475..2843 FT /note="Interaction with DLG1" FT /evidence="ECO:0000269|PubMed:8638125" FT REGION 2667..2714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2674..2843 FT /note="Interaction with MAPRE1" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2729..2843 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 2..61 FT /evidence="ECO:0000255" FT COILED 127..248 FT /evidence="ECO:0000255" FT MOTIF 2803..2806 FT /note="Microtubule tip localization signal" FT MOTIF 2841..2843 FT /note="PDZ-binding" FT COMPBIAS 241..261 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..282 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 290..299 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 833..843 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 844..857 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 869..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 927..943 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 961..971 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1107..1130 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1146..1159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1190..1224 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1225..1244 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1335..1345 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1355..1366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1448..1466 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1540..1564 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1683..1698 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1735..1744 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1785..1794 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1804..1813 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1881..1896 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1897..1913 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1928..1938 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1939..1950 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1979..1991 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2169..2187 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2203..2223 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2257..2271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2286..2331 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2348..2369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2370..2409 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2418..2427 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2459..2477 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2518..2535 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2555..2568 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2569..2579 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2580..2592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2593..2608 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2620..2635 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2668..2679 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2741..2757 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2763..2774 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2784..2812 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 107 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 744 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 748 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 908 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1038 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1385 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1392 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1438 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1774 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1863 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1971 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1973 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2088 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2093 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2125 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2129 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2132 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2151 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2260 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2283 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2473 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2535 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2569 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2671 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2679 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2710 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2789 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..45 FT /note="MAAASYDQLLKQVEALKMENSNLRQELEDNSNHLTKLETEASNMK -> MYA FT SLGSGPVAPLPASVPPSVLGSWSTGGSRSCVRQETKSPGGARTSGHWASVWQ (in FT isoform 1B)" FT /id="VSP_059027" FT VAR_SEQ 217..244 FT /note="Missing (in isoform 1B)" FT /id="VSP_059028" FT VAR_SEQ 312..412 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:1678319" FT /id="VSP_004115" FT VARIANT 99 FT /note="R -> W (in FAP1; benign; dbSNP:rs139196838)" FT /evidence="ECO:0000269|PubMed:7833149" FT /id="VAR_009613" FT VARIANT 171 FT /note="S -> I (in FAP1)" FT /evidence="ECO:0000269|PubMed:8990002" FT /id="VAR_005032" FT VARIANT 414 FT /note="R -> C (in FAP1; benign; dbSNP:rs137854567)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005033" FT VARIANT 722 FT /note="S -> G (in FAP1)" FT /evidence="ECO:0000269|PubMed:7833931" FT /id="VAR_009614" FT VARIANT 784 FT /note="S -> T (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005034" FT VARIANT 817 FT /note="G -> C (in gastric cancer)" FT /id="VAR_005035" FT VARIANT 870 FT /note="P -> S (in dbSNP:rs33974176)" FT /id="VAR_053976" FT VARIANT 880 FT /note="I -> T (in colorectal carcinoma and gastric cancer; FT from a patient with MMRCS; dbSNP:rs1400295986)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_005036" FT VARIANT 890 FT /note="V -> I (in colorectal carcinoma; from a patient with FT MMRCS; dbSNP:rs779998847)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012975" FT VARIANT 906 FT /note="S -> Y (in colorectal tumor)" FT /id="VAR_005037" FT VARIANT 911 FT /note="E -> G (in FAP1 and colorectal tumor)" FT /evidence="ECO:0000269|PubMed:1338904" FT /id="VAR_005038" FT VARIANT 942 FT /note="N -> D (in gastric cancer)" FT /id="VAR_005039" FT VARIANT 1027 FT /note="Y -> C (in colorectal tumor; dbSNP:rs869312784)" FT /id="VAR_005040" FT VARIANT 1057 FT /note="E -> G (found in a family whose members exhibit FT gastrointestinal cancers and multiple pigmented cutaneous FT lesions; uncertain significance)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_009615" FT VARIANT 1118 FT /note="N -> D (in dbSNP:rs140493115)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005041" FT VARIANT 1120 FT /note="G -> E (in gastric cancer; dbSNP:rs28933379)" FT /id="VAR_005042" FT VARIANT 1171 FT /note="R -> C (in dbSNP:rs201830995)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008992" FT VARIANT 1171 FT /note="R -> H (in gastric cancer; dbSNP:rs372481703)" FT /id="VAR_005043" FT VARIANT 1176 FT /note="P -> L (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005044" FT VARIANT 1184 FT /note="A -> P (in FAP1)" FT /evidence="ECO:0000269|PubMed:10470088" FT /id="VAR_009616" FT VARIANT 1197 FT /note="F -> S (in gastric cancer)" FT /id="VAR_005045" FT VARIANT 1254 FT /note="I -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035794" FT VARIANT 1259 FT /note="I -> T (in gastric cancer)" FT /id="VAR_005046" FT VARIANT 1292 FT /note="T -> M (in FAP1; uncertain significance; FT dbSNP:rs371113837)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005047" FT VARIANT 1296 FT /note="A -> V (in MDB; sporadic; dbSNP:rs1291513037)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017653" FT VARIANT 1304 FT /note="I -> V (in dbSNP:rs770157475)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005048" FT VARIANT 1307 FT /note="I -> K (probable risk factor for colon and breast FT cancer; dbSNP:rs1801155)" FT /evidence="ECO:0000269|PubMed:9724771, FT ECO:0000269|PubMed:9731522, ECO:0000269|PubMed:9731533, FT ECO:0000269|PubMed:9973276" FT /id="VAR_005049" FT VARIANT 1312 FT /note="G -> E (in gastric cancer)" FT /id="VAR_005050" FT VARIANT 1313 FT /note="T -> A (in FAP1 and colorectal tumor; FT dbSNP:rs863225349)" FT /id="VAR_005051" FT VARIANT 1317 FT /note="E -> Q (may contribute to colorectal tumor FT development; dbSNP:rs1801166)" FT /evidence="ECO:0000269|PubMed:9724771" FT /id="VAR_009617" FT VARIANT 1326 FT /note="V -> A (in gastric cancer)" FT /id="VAR_005052" FT VARIANT 1348 FT /note="R -> W (in FAP1)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005053" FT VARIANT 1395 FT /note="S -> C (in hepatoblastoma; dbSNP:rs137854578)" FT /evidence="ECO:0000269|PubMed:8764128" FT /id="VAR_065133" FT VARIANT 1422 FT /note="D -> H (in colorectal tumor)" FT /id="VAR_005054" FT VARIANT 1472 FT /note="V -> I (in MDB; sporadic; dbSNP:rs878853445)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017654" FT VARIANT 1495 FT /note="S -> G (in MDB; sporadic)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017655" FT VARIANT 1496 FT /note="T -> S (in dbSNP:rs2229996)" FT /id="VAR_020141" FT VARIANT 1508 FT /note="A -> V (in colorectal carcinoma from a patient with FT MMRCS)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012976" FT VARIANT 1822 FT /note="V -> D (in dbSNP:rs459552)" FT /evidence="ECO:0000269|PubMed:1651562, FT ECO:0000269|PubMed:1678319, ECO:0000269|PubMed:9950360, FT ECO:0000269|Ref.5" FT /id="VAR_008993" FT VARIANT 1882 FT /note="R -> T (in dbSNP:rs34157245)" FT /id="VAR_053977" FT VARIANT 1973 FT /note="S -> T (in dbSNP:rs4987109)" FT /id="VAR_020142" FT VARIANT 2499 FT /note="V -> L (in dbSNP:rs33941929)" FT /id="VAR_053978" FT VARIANT 2502 FT /note="G -> S (in dbSNP:rs2229995)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005055" FT VARIANT 2621 FT /note="S -> C (in FAP1; benign; dbSNP:rs72541816)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005056" FT VARIANT 2738 FT /note="I -> T (in dbSNP:rs863224552)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008994" FT VARIANT 2839 FT /note="L -> F (in FAP1; dbSNP:rs876658156)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005057" FT MUTAGEN 516 FT /note="K->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 549 FT /note="R->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 2841 FT /note="T->L: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT MUTAGEN 2843 FT /note="V->Q: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT CONFLICT 184 FT /note="M -> L (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 970 FT /note="S -> N (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1309 FT /note="E -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1325..1331 FT /note="AVSQHPR -> SSVHSTLE (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1355 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1591 FT /note="A -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2723 FT /note="N -> T (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2755 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT HELIX 6..53 FT /evidence="ECO:0007829|PDB:1DEB" FT HELIX 132..169 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:8X2Q" FT HELIX 180..204 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 208..238 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 328..338 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 343..350 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 353..360 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 377..393 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 407..426 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:3AU3" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 446..456 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 460..468 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 471..486 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 492..509 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 513..521 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 523..531 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 532..534 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 538..552 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 557..565 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 568..578 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 582..596 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 600..607 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 612..619 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 625..627 FT /evidence="ECO:0007829|PDB:3NMW" FT HELIX 629..646 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 650..658 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 661..668 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 674..687 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 688..690 FT /evidence="ECO:0007829|PDB:5IZ8" FT HELIX 692..700 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 703..708 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 709..712 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 716..731 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 739..742 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 1027..1030 FT /evidence="ECO:0007829|PDB:1JPP" FT HELIX 1470..1479 FT /evidence="ECO:0007829|PDB:1TH1" FT HELIX 1520..1524 FT /evidence="ECO:0007829|PDB:1V18" FT HELIX 2036..2045 FT /evidence="ECO:0007829|PDB:1EMU" FT STRAND 2841..2843 FT /evidence="ECO:0007829|PDB:7XTY" SQ SEQUENCE 2843 AA; 311646 MW; 77E194AE4A91DC5A CRC64; MAAASYDQLL KQVEALKMEN SNLRQELEDN SNHLTKLETE ASNMKEVLKQ LQGSIEDEAM ASSGQIDLLE RLKELNLDSS NFPGVKLRSK MSLRSYGSRE GSVSSRSGEC SPVPMGSFPR RGFVNGSRES TGYLEELEKE RSLLLADLDK EEKEKDWYYA QLQNLTKRID SLPLTENFSL QTDMTRRQLE YEARQIRVAM EEQLGTCQDM EKRAQRRIAR IQQIEKDILR IRQLLQSQAT EAERSSQNKH ETGSHDAERQ NEGQGVGEIN MATSGNGQGS TTRMDHETAS VLSSSSTHSA PRRLTSHLGT KVEMVYSLLS MLGTHDKDDM SRTLLAMSSS QDSCISMRQS GCLPLLIQLL HGNDKDSVLL GNSRGSKEAR ARASAALHNI IHSQPDDKRG RREIRVLHLL EQIRAYCETC WEWQEAHEPG MDQDKNPMPA PVEHQICPAV CVLMKLSFDE EHRHAMNELG GLQAIAELLQ VDCEMYGLTN DHYSITLRRY AGMALTNLTF GDVANKATLC SMKGCMRALV AQLKSESEDL QQVIASVLRN LSWRADVNSK KTLREVGSVK ALMECALEVK KESTLKSVLS ALWNLSAHCT ENKADICAVD GALAFLVGTL TYRSQTNTLA IIESGGGILR NVSSLIATNE DHRQILRENN CLQTLLQHLK SHSLTIVSNA CGTLWNLSAR NPKDQEALWD MGAVSMLKNL IHSKHKMIAM GSAAALRNLM ANRPAKYKDA NIMSPGSSLP SLHVRKQKAL EAELDAQHLS ETFDNIDNLS PKASHRSKQR HKQSLYGDYV FDTNRHDDNR SDNFNTGNMT VLSPYLNTTV LPSSSSSRGS LDSSRSEKDR SLERERGIGL GNYHPATENP GTSSKRGLQI STTAAQIAKV MEEVSAIHTS QEDRSSGSTT ELHCVTDERN ALRRSSAAHT HSNTYNFTKS ENSNRTCSMP YAKLEYKRSS NDSLNSVSSS DGYGKRGQMK PSIESYSEDD ESKFCSYGQY PADLAHKIHS ANHMDDNDGE LDTPINYSLK YSDEQLNSGR QSPSQNERWA RPKHIIEDEI KQSEQRQSRN QSTTYPVYTE STDDKHLKFQ PHFGQQECVS PYRSRGANGS ETNRVGSNHG INQNVSQSLC QEDDYEDDKP TNYSERYSEE EQHEEEERPT NYSIKYNEEK RHVDQPIDYS LKYATDIPSS QKQSFSFSKS SSGQSSKTEH MSSSSENTST PSSNAKRQNQ LHPSSAQSRS GQPQKAATCK VSSINQETIQ TYCVEDTPIC FSRCSSLSSL SSAEDEIGCN QTTQEADSAN TLQIAEIKEK IGTRSAEDPV SEVPAVSQHP RTKSSRLQGS SLSSESARHK AVEFSSGAKS PSKSGAQTPK SPPEHYVQET PLMFSRCTSV SSLDSFESRS IASSVQSEPC SGMVSGIISP SDLPDSPGQT MPPSRSKTPP PPPQTAQTKR EVPKNKAPTA EKRESGPKQA AVNAAVQRVQ VLPDADTLLH FATESTPDGF SCSSSLSALS LDEPFIQKDV ELRIMPPVQE NDNGNETESE QPKESNENQE KEAEKTIDSE KDLLDDSDDD DIEILEECII SAMPTKSSRK AKKPAQTASK LPPPVARKPS QLPVYKLLPS QNRLQPQKHV SFTPGDDMPR VYCVEGTPIN FSTATSLSDL TIESPPNELA AGEGVRGGAQ SGEFEKRDTI PTEGRSTDEA QGGKTSSVTI PELDDNKAEE GDILAECINS AMPKGKSHKP FRVKKIMDQV QQASASSSAP NKNQLDGKKK KPTSPVKPIP QNTEYRTRVR KNADSKNNLN AERVFSDNKD SKKQNLKNNS KVFNDKLPNN EDRVRGSFAF DSPHHYTPIE GTPYCFSRND SLSSLDFDDD DVDLSREKAE LRKAKENKES EAKVTSHTEL TSNQQSANKT QAIAKQPINR GQPKPILQKQ STFPQSSKDI PDRGAATDEK LQNFAIENTP VCFSHNSSLS SLSDIDQENN NKENEPIKET EPPDSQGEPS KPQASGYAPK SFHVEDTPVC FSRNSSLSSL SIDSEDDLLQ ECISSAMPKK KKPSRLKGDN EKHSPRNMGG ILGEDLTLDL KDIQRPDSEH GLSPDSENFD WKAIQEGANS IVSSLHQAAA AACLSRQASS DSDSILSLKS GISLGSPFHL TPDQEEKPFT SNKGPRILKP GEKSTLETKK IESESKGIKG GKKVYKSLIT GKVRSNSEIS GQMKQPLQAN MPSISRGRTM IHIPGVRNSS SSTSPVSKKG PPLKTPASKS PSEGQTATTS PRGAKPSVKS ELSPVARQTS QIGGSSKAPS RSGSRDSTPS RPAQQPLSRP IQSPGRNSIS PGRNGISPPN KLSQLPRTSS PSTASTKSSG SGKMSYTSPG RQMSQQNLTK QTGLSKNASS IPRSESASKG LNQMNNGNGA NKKVELSRMS STKSSGSESD RSERPVLVRQ STFIKEAPSP TLRRKLEESA SFESLSPSSR PASPTRSQAQ TPVLSPSLPD MSLSTHSSVQ AGGWRKLPPN LSPTIEYNDG RPAKRHDIAR SHSESPSRLP INRSGTWKRE HSKHSSSLPR VSTWRRTGSS SSILSASSES SEKAKSEDEK HVNSISGTKQ SKENQVSAKG TWRKIKENEF SPTNSTSQTV SSGATNGAES KTLIYQMAPA VSKTEDVWVR IEDCPINNPR SGRSPTGNTP PVIDSVSEKA NPNIKDSKDN QAKQNVGNGS VPMRTVGLEN RLNSFIQVDA PDQKGTEIKP GQNNPVPVSE TNESSIVERT PFSSSSSSKH SSPSGTVAAR VTPFNYNPSP RKSSADSTSA RPSQIPTPVN NNTKKRDSKT DSTESSGTQS PKRHSGSYLV TSV // ID ASCC1_HUMAN Reviewed; 400 AA. AC Q8N9N2; Q5SW06; Q5SW07; Q96EI8; Q9Y307; DT 19-JUL-2004, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 28-JAN-2026, entry version 190. DE RecName: Full=Activating signal cointegrator 1 complex subunit 1; DE AltName: Full=ASC-1 complex subunit p50 {ECO:0000303|PubMed:12077347}; DE AltName: Full=Trip4 complex subunit p50 {ECO:0000303|PubMed:12077347}; GN Name=ASCC1; ORFNames=CGI-18; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION, RP IDENTIFICATION OF THE ASC-1 COMPLEX, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Cervix carcinoma; RX PubMed=12077347; DOI=10.1128/mcb.22.14.5203-5211.2002; RA Jung D.-J., Sung H.-S., Goo Y.-W., Lee H.M., Park O.K., Jung S.-Y., Lim J., RA Kim H.-J., Lee S.-K., Kim T.S., Lee J.W., Lee Y.C.; RT "Novel transcription coactivator complex containing activating signal RT cointegrator 1."; RL Mol. Cell. Biol. 22:5203-5211(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=10810093; DOI=10.1101/gr.10.5.703; RA Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.; RT "Identification of novel human genes evolutionarily conserved in RT Caenorhabditis elegans by comparative proteomics."; RL Genome Res. 10:703-713(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Astrocyte, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=19074642; DOI=10.1152/ajpgi.90340.2008; RA Almeida-Vega S., Catlow K., Kenny S., Dimaline R., Varro A.; RT "Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ RT and ASC-1."; RL Am. J. Physiol. 296:G414-G423(2009). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [9] RP INVOLVEMENT IN BE, AND VARIANT SER-318. RX PubMed=21791690; DOI=10.1001/jama.2011.1029; RA Orloff M., Peterson C., He X., Ganapathi S., Heald B., Yang Y.R., Bebek G., RA Romigh T., Song J.H., Wu W., David S., Cheng Y., Meltzer S.J., Eng C.; RT "Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett RT esophagus and esophageal adenocarcinoma."; RL JAMA 306:410-419(2011). RN [10] RP INTERACTION WITH ALKBH3. RX PubMed=22055184; DOI=10.1016/j.molcel.2011.08.039; RA Dango S., Mosammaparast N., Sowa M.E., Xiong L.J., Wu F., Park K., RA Rubin M., Gygi S., Harper J.W., Shi Y.; RT "DNA unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA RT alkylation repair and cancer cell proliferation."; RL Mol. Cell 44:373-384(2011). RN [11] RP FUNCTION, INTERACTION WITH CSRP1, SUBCELLULAR LOCATION, AND INVOLVEMENT IN RP SMABF2. RX PubMed=26924529; DOI=10.1016/j.ajhg.2016.01.006; RA Knierim E., Hirata H., Wolf N.I., Morales-Gonzalez S., Schottmann G., RA Tanaka Y., Rudnik-Schoeneborn S., Orgeur M., Zerres K., Vogt S., RA van Riesen A., Gill E., Seifert F., Zwirner A., Kirschner J., Goebel H.H., RA Huebner C., Stricker S., Meierhofer D., Stenzel W., Schuelke M.; RT "Mutations in subunits of the activating signal cointegrator 1 complex are RT associated with prenatal spinal muscular atrophy and congenital bone RT fractures."; RL Am. J. Hum. Genet. 98:473-489(2016). RN [12] RP IDENTIFICATION IN A COMPLEX WITH ASCC1 AND ASCC3, SUBUNIT, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=29144457; DOI=10.1038/nature24484; RA Brickner J.R., Soll J.M., Lombardi P.M., Vaagboe C.B., Mudge M.C., RA Oyeniran C., Rabe R., Jackson J., Sullender M.E., Blazosky E., Byrum A.K., RA Zhao Y., Corbett M.A., Gecz J., Field M., Vindigni A., Slupphaug G., RA Wolberger C., Mosammaparast N.; RT "A ubiquitin-dependent signalling axis specific for ALKBH-mediated DNA RT dealkylation repair."; RL Nature 551:389-393(2017). RN [13] RP FUNCTION, SUBUNIT, INTERACTION WITH ASCC3, AND SUBCELLULAR LOCATION. RX PubMed=29997253; DOI=10.1074/jbc.ra117.000114; RA Soll J.M., Brickner J.R., Mudge M.C., Mosammaparast N.; RT "RNA ligase-like domain in activating signal cointegrator 1 complex subunit RT 1 (ASCC1) regulates ASCC complex function during alkylation damage."; RL J. Biol. Chem. 293:13524-13533(2018). RN [14] RP INTERACTION WITH ZCCHC4. RX PubMed=31799605; DOI=10.1093/nar/gkz1147; RA Pinto R., Vaagboe C.B., Jakobsson M.E., Kim Y., Baltissen M.P., RA O'Donohue M.F., Guzman U.H., Malecki J.M., Wu J., Kirpekar F., Olsen J.V., RA Gleizes P.E., Vermeulen M., Leidel S.A., Slupphaug G., Falnes P.O.; RT "The human methyltransferase ZCCHC4 catalyses N6-methyladenosine RT modification of 28S ribosomal RNA."; RL Nucleic Acids Res. 48:830-846(2020). CC -!- FUNCTION: Plays a role in DNA damage repair as component of the ASCC CC complex (PubMed:29997253). Part of the ASC-1 complex that enhances NF- CC kappa-B, SRF and AP1 transactivation (PubMed:12077347). In cells CC responding to gastrin-activated paracrine signals, it is involved in CC the induction of SERPINB2 expression by gastrin. May also play a role CC in the development of neuromuscular junction. CC {ECO:0000269|PubMed:12077347, ECO:0000269|PubMed:19074642, CC ECO:0000269|PubMed:26924529, ECO:0000269|PubMed:29997253}. CC -!- SUBUNIT: Identified in the ASCC complex that contains ASCC1, ASCC2 and CC ASCC3 (PubMed:29144457, PubMed:29997253). Interacts directly with ASCC3 CC (PubMed:29997253). The ASCC complex interacts with ALKBH3 CC (PubMed:22055184, PubMed:29144457). Part of the ASC-1 complex, that CC contains TRIP4, ASCC1, ASCC2 and ASCC3 (PubMed:12077347). Interacts CC with CSRP1 (PubMed:26924529). Interacts with ZCCHC4 (PubMed:31799605). CC {ECO:0000269|PubMed:12077347, ECO:0000269|PubMed:22055184, CC ECO:0000269|PubMed:26924529, ECO:0000269|PubMed:29144457, CC ECO:0000269|PubMed:29997253, ECO:0000269|PubMed:31799605}. CC -!- INTERACTION: CC Q8N9N2; Q8N3C0: ASCC3; NbExp=4; IntAct=EBI-10268317, EBI-1210710; CC Q8N9N2; Q12933: TRAF2; NbExp=3; IntAct=EBI-10268317, EBI-355744; CC Q8N9N2-2; Q8N3C0: ASCC3; NbExp=4; IntAct=EBI-10962548, EBI-1210710; CC Q8N9N2-2; Q12933: TRAF2; NbExp=3; IntAct=EBI-10962548, EBI-355744; CC Q8N9N2-2; Q13114: TRAF3; NbExp=3; IntAct=EBI-10962548, EBI-357631; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12077347, CC ECO:0000269|PubMed:26924529}. Nucleus speckle CC {ECO:0000269|PubMed:29997253}. Note=Colocalizes with PRPF8 in nuclear CC speckles in the absence of DNA damage. {ECO:0000269|PubMed:29997253}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8N9N2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8N9N2-2; Sequence=VSP_011007, VSP_011008; CC -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:12077347}. CC -!- DISEASE: Barrett esophagus (BE) [MIM:614266]: A condition characterized CC by a metaplastic change in which normal esophageal squamous epithelium CC is replaced by a columnar and intestinal-type epithelium. Patients with CC Barrett esophagus have an increased risk of esophageal adenocarcinoma. CC The main cause of Barrett esophagus is gastroesophageal reflux. The CC retrograde movement of acid and bile salts from the stomach into the CC esophagus causes prolonged injury to the esophageal epithelium and CC induces chronic esophagitis, which in turn is believed to trigger the CC pathologic changes. {ECO:0000269|PubMed:21791690}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Spinal muscular atrophy with congenital bone fractures 2 CC (SMABF2) [MIM:616867]: An autosomal recessive neuromuscular disorder CC characterized by prenatal-onset spinal muscular atrophy, multiple CC congenital contractures consistent with arthrogryposis multiplex CC congenita, respiratory distress, and congenital bone fractures. CC {ECO:0000269|PubMed:26924529}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY013290; AAG45476.1; -; mRNA. DR EMBL; AF132952; AAD27727.1; -; mRNA. DR EMBL; AK094170; BAC04299.1; -; mRNA. DR EMBL; AK023436; BAG51193.1; -; mRNA. DR EMBL; AC022392; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL607035; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471083; EAW54444.1; -; Genomic_DNA. DR EMBL; BC012291; AAH12291.1; -; mRNA. DR CCDS; CCDS31219.1; -. [Q8N9N2-2] DR CCDS; CCDS55713.1; -. [Q8N9N2-1] DR RefSeq; NP_001185727.1; NM_001198798.2. [Q8N9N2-2] DR RefSeq; NP_001185728.1; NM_001198799.3. [Q8N9N2-1] DR RefSeq; NP_001185729.1; NM_001198800.3. [Q8N9N2-2] DR RefSeq; NP_001356022.1; NM_001369093.1. [Q8N9N2-2] DR RefSeq; NP_001356023.1; NM_001369094.1. [Q8N9N2-2] DR RefSeq; NP_001356024.1; NM_001369095.1. [Q8N9N2-2] DR PDB; 8TLY; X-ray; 2.80 A; A/B=162-349. DR PDBsum; 8TLY; -. DR AlphaFoldDB; Q8N9N2; -. DR SMR; Q8N9N2; -. DR BioGRID; 119215; 82. DR ComplexPortal; CPX-6641; ASCC DNA alkylation repair complex. DR CORUM; Q8N9N2; -. DR FunCoup; Q8N9N2; 998. DR IntAct; Q8N9N2; 51. DR STRING; 9606.ENSP00000339404; -. DR BindingDB; Q8N9N2; -. DR GlyGen; Q8N9N2; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q8N9N2; -. DR PhosphoSitePlus; Q8N9N2; -. DR BioMuta; ASCC1; -. DR DMDM; 50400556; -. DR jPOST; Q8N9N2; -. DR MassIVE; Q8N9N2; -. DR PaxDb; 9606-ENSP00000339404; -. DR PeptideAtlas; Q8N9N2; -. DR ProteomicsDB; 72561; -. [Q8N9N2-1] DR ProteomicsDB; 72562; -. [Q8N9N2-2] DR Pumba; Q8N9N2; -. DR Antibodypedia; 29224; 202 antibodies from 23 providers. DR DNASU; 51008; -. DR Ensembl; ENST00000317126.8; ENSP00000320461.4; ENSG00000138303.20. [Q8N9N2-2] DR Ensembl; ENST00000342444.8; ENSP00000339404.4; ENSG00000138303.20. [Q8N9N2-1] DR Ensembl; ENST00000394915.7; ENSP00000378373.3; ENSG00000138303.20. [Q8N9N2-1] DR Ensembl; ENST00000672957.1; ENSP00000500935.1; ENSG00000138303.20. [Q8N9N2-2] DR GeneID; 51008; -. DR KEGG; hsa:51008; -. DR MANE-Select; ENST00000672957.1; ENSP00000500935.1; NM_001198800.3; NP_001185729.1. [Q8N9N2-2] DR UCSC; uc001jst.3; human. [Q8N9N2-1] DR AGR; HGNC:24268; -. DR ClinPGx; PA134974899; -. DR CTD; 51008; -. DR DisGeNET; 51008; -. DR GeneCards; ASCC1; -. DR HGNC; HGNC:24268; ASCC1. DR HPA; ENSG00000138303; Low tissue specificity. DR MalaCards; ASCC1; -. DR MIM; 614215; gene. DR MIM; 614266; phenotype. DR MIM; 616867; phenotype. DR OpenTargets; ENSG00000138303; -. DR Orphanet; 486811; Prenatal-onset spinal muscular atrophy with congenital bone fractures. DR VEuPathDB; HostDB:ENSG00000138303; -. DR eggNOG; KOG0940; Eukaryota. DR eggNOG; KOG2814; Eukaryota. DR GeneTree; ENSGT00390000018119; -. DR HOGENOM; CLU_044606_0_0_1; -. DR InParanoid; Q8N9N2; -. DR OrthoDB; 277832at2759; -. DR PAN-GO; Q8N9N2; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q8N9N2; -. DR PathwayCommons; Q8N9N2; -. DR Reactome; R-HSA-112126; ALKBH3 mediated reversal of alkylation damage. DR SignaLink; Q8N9N2; -. DR Agora; ENSG00000138303; -. DR BioGRID-ORCS; 51008; 26 hits in 1157 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 804901D1; Nuclear speckle. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; ASCC1; human. DR GenomeRNAi; 51008; -. DR Pharos; Q8N9N2; Tbio. DR PRO; PR:Q8N9N2; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q8N9N2; protein. DR Bgee; ENSG00000138303; Expressed in calcaneal tendon and 199 other cell types or tissues. DR ExpressionAtlas; Q8N9N2; baseline and differential. DR GO; GO:1990391; C:DNA repair complex; IPI:ComplexPortal. DR GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:MGI. DR GO; GO:0003723; F:RNA binding; IEA:InterPro. DR GO; GO:0006307; P:DNA alkylation repair; NAS:ComplexPortal. DR GO; GO:0006260; P:DNA replication; NAS:ComplexPortal. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:MGI. DR CDD; cd22419; KH-I_ASCC1; 1. DR FunFam; 3.30.1370.10:FF:000101; Activating signal cointegrator 1 complex subunit 1; 1. DR FunFam; 3.90.1140.10:FF:000005; activating signal cointegrator 1 complex subunit 1; 1. DR Gene3D; 3.90.1140.10; Cyclic phosphodiesterase; 1. DR Gene3D; 3.30.1370.10; K Homology domain, type 1; 1. DR InterPro; IPR019510; AKAP7-like_phosphoesterase. DR InterPro; IPR009210; ASCC1. DR InterPro; IPR009097; Cyclic_Pdiesterase. DR InterPro; IPR047538; KH-I_ASCC1. DR InterPro; IPR004088; KH_dom_type_1. DR InterPro; IPR036612; KH_dom_type_1_sf. DR PANTHER; PTHR13360; ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX SUBUNIT 1; 1. DR PANTHER; PTHR13360:SF1; ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX SUBUNIT 1; 1. DR Pfam; PF10469; AKAP7_NLS; 1. DR Pfam; PF00013; KH_1; 1. DR PIRSF; PIRSF027019; Euk_LigT; 1. DR SUPFAM; SSF54791; Eukaryotic type KH-domain (KH-domain type I); 1. DR SUPFAM; SSF55144; LigT-like; 1. DR PROSITE; PS50084; KH_TYPE_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Direct protein sequencing; DNA damage; KW DNA repair; Neurodegeneration; Nucleus; Proteomics identification; KW Reference proteome; Transcription; Transcription regulation. FT CHAIN 1..400 FT /note="Activating signal cointegrator 1 complex subunit 1" FT /id="PRO_0000050100" FT DOMAIN 86..148 FT /note="KH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117" FT REGION 1..53 FT /note="Required for interaction with ASCC3" FT /evidence="ECO:0000269|PubMed:29997253" FT VAR_SEQ 71..99 FT /note="NLIHLNTSNDCGFQKITLDCQNIYTWKSR -> K (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10810093, FT ECO:0000303|PubMed:12077347, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_011007" FT VAR_SEQ 348..400 FT /note="SFALLPRLEYNDAISAHCNLCLPGSSDSPASASQVAGITGVSDAYSQSLPGK FT S -> LFENFYFGSLKLNSIHISQRFTVDSFGNYASCGQIDFS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10810093, FT ECO:0000303|PubMed:12077347, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_011008" FT VARIANT 34 FT /note="D -> N (in dbSNP:rs11558719)" FT /id="VAR_061278" FT VARIANT 318 FT /note="N -> S (found in patients with Barrett esophagus; FT dbSNP:rs146370051)" FT /evidence="ECO:0000269|PubMed:21791690" FT /id="VAR_066588" FT CONFLICT 11 FT /note="I -> F (in Ref. 1; AAG45476 and 2; AAD27727)" FT /evidence="ECO:0000305" FT CONFLICT 240..243 FT /note="SGGK -> PGR (in Ref. 1; AAG45476 and 2; AAD27727)" FT /evidence="ECO:0000305" FT CONFLICT 250 FT /note="A -> P (in Ref. 1; AAG45476 and 2; AAD27727)" FT /evidence="ECO:0000305" SQ SEQUENCE 400 AA; 45509 MW; DAD067C98CE71DDB CRC64; MEVLRPQLIR IDGRNYRKNP VQEQTYQHEE DEEDFYQGSM ECADEPCDAY EVEQTPQGFR STLRAPSLLY NLIHLNTSND CGFQKITLDC QNIYTWKSRH IVGKRGDTRK KIEMETKTSI SIPKPGQDGE IVITGQHRNG VISARTRIDV LLDTFRRKQP FTHFLAFFLN EVEVQEGFLR FQEEVLAKCS MDHGVDSSIF QNPKKLHLTI GMLVLLSEEE IQQTCEMLQQ CKEEFINDIS GGKPLEVEMA GIEYMNDDPG MVDVLYAKVH MKDGSNRLQE LVDRVLERFQ ASGLIVKEWN SVKLHATVMN TLFRKDPNAE GRYNLYTAEG KYIFKERESF DGRNILKSFA LLPRLEYNDA ISAHCNLCLP GSSDSPASAS QVAGITGVSD AYSQSLPGKS // ID ATM_HUMAN Reviewed; 3056 AA. AC Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 22-JAN-2014, sequence version 4. DT 28-JAN-2026, entry version 269. DE RecName: Full=Serine-protein kinase ATM; DE EC=2.7.11.1 {ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; DE AltName: Full=Ataxia telangiectasia mutated; DE Short=A-T mutated; GN Name=ATM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT ASP-3003. RX PubMed=8589678; DOI=10.1093/hmg/4.11.2025; RA Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., RA Shiloh Y., Rotman G.; RT "The complete sequence of the coding region of the ATM gene reveals RT similarity to cell cycle regulators in different species."; RL Hum. Mol. Genet. 4:2025-2032(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT AT ASP-3003, AND VARIANTS RP CYS-49; ARG-1054; PHE-1420; ILE-2079 AND ALA-2287. RX PubMed=8665503; RA Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L., RA Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R., Russo G., RA Croce C.M., Negrini M.; RT "The ATM gene and susceptibility to breast cancer: analysis of 38 breast RT tumors reveals no evidence for mutation."; RL Cancer Res. 56:2726-2732(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9199932; DOI=10.1101/gr.7.6.592; RA Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A., RA Gilad S., Shiloh Y., Rosenthal A.; RT "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic RT DNA containing the entire ATM gene."; RL Genome Res. 7:592-605(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT 2546-SER--ILE-2548 RP DEL. RX PubMed=8789452; DOI=10.1093/hmg/5.1.145; RA Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T., RA McGuire G.M., Thick J.A., Taylor A.M.R.; RT "Mutations revealed by sequencing the 5' half of the gene for ataxia RT telangiectasia."; RL Hum. Mol. Genet. 5:145-149(1996). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24. RX PubMed=9108147; DOI=10.1093/nar/25.9.1678; RA Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A., RA Elroy-Stein O., Shiloh Y., Rotman G.; RT "Ataxia-telangiectasia: structural diversity of untranslated sequences RT suggests complex post-transcriptional regulation of ATM gene expression."; RL Nucleic Acids Res. 25:1678-1684(1997). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS 2427-LEU-ARG-2428 RP DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND ASP-3003. RC TISSUE=Fibroblast; RX PubMed=7792600; DOI=10.1126/science.7792600; RA Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., RA Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., RA Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., RA Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., RA Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y.; RT "A single ataxia telangiectasia gene with a product similar to PI-3 RT kinase."; RL Science 268:1749-1753(1995). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056. RX PubMed=8521392; RA Rasio D., Negrini M., Croce C.M.; RT "Genomic organization of the ATM locus involved in ataxia-telangiectasia."; RL Cancer Res. 55:6053-6057(1995). RN [12] RP PHOSPHORYLATION. RX PubMed=8969240; DOI=10.1074/jbc.271.52.33693; RA Chen G., Lee E.Y.-H.P.; RT "The product of the ATM gene is a 370-kDa nuclear phosphoprotein."; RL J. Biol. Chem. 271:33693-33697(1996). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=9050866; DOI=10.1073/pnas.94.5.1840; RA Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., RA Tagle D.A.; RT "The ataxia-telangiectasia gene product, a constitutively expressed nuclear RT protein that is not up-regulated following genome damage."; RL Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997). RN [14] RP SUBCELLULAR LOCATION, AND VARIANTS 2546-SER--ILE-2548 DEL AND TYR-2824. RX PubMed=9150358; DOI=10.1038/sj.onc.1201037; RA Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., RA Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., RA Ramsay J., Gatti R.A., Lavin M.F.; RT "Cellular localisation of the ataxia-telangiectasia (ATM) gene product and RT discrimination between mutated and normal forms."; RL Oncogene 14:1911-1921(1997). RN [15] RP CATALYTIC ACTIVITY. RX PubMed=8988033; RA Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.; RT "ATM gene product phosphorylates I kappa B-alpha."; RL Cancer Res. 57:24-27(1997). RN [16] RP INTERACTION WITH ABL1. RX PubMed=9168117; DOI=10.1038/387520a0; RA Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., RA Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., RA Kufe D., Lavin M.F.; RT "Interaction between ATM protein and c-Abl in response to DNA damage."; RL Nature 387:520-523(1997). RN [17] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [18] RP FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY. RX PubMed=9843217; DOI=10.1038/3882; RA Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., RA Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.; RT "ATM associates with and phosphorylates p53: mapping the region of RT interaction."; RL Nat. Genet. 20:398-400(1998). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=9707615; DOI=10.1073/pnas.95.17.10146; RA Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S., RA Darnell R.B., Shiloh Y., Kastan M.B.; RT "ATM binds to beta-adaptin in cytoplasmic vesicles."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TP53. RX PubMed=9733514; DOI=10.1126/science.281.5383.1674; RA Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L., RA Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.; RT "Enhanced phosphorylation of p53 by ATM in response to DNA damage."; RL Science 281:1674-1677(1998). RN [21] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND RP ASN-2875. RX PubMed=9733515; DOI=10.1126/science.281.5383.1677; RA Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., RA Appella E., Kastan M.B., Siliciano J.D.; RT "Activation of the ATM kinase by ionizing radiation and phosphorylation of RT p53."; RL Science 281:1677-1679(1998). RN [22] RP DNA-BINDING. RX PubMed=10500142; DOI=10.1073/pnas.96.20.11134; RA Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J., RA Jackson S.P.; RT "Purification and DNA binding properties of the ataxia-telangiectasia gene RT product ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF BRCA1. RX PubMed=10550055; DOI=10.1126/science.286.5442.1162; RA Cortez D., Wang Y., Qin J., Elledge S.J.; RT "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage RT response to double-strand breaks."; RL Science 286:1162-1166(1999). RN [24] RP IDENTIFICATION OF ATM AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [25] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10766245; DOI=10.1038/35007091; RA Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J., RA Kastan M.B.; RT "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway."; RL Nature 404:613-617(2000). RN [26] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10839545; DOI=10.1038/35013089; RA Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., RA O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., RA Livingston D.M., Weaver D.T.; RT "ATM phosphorylation of Nijmegen breakage syndrome protein is required in a RT DNA damage response."; RL Nature 405:477-482(2000). RN [27] RP FUNCTION IN PHOSPHORYLATION OF CTIP. RX PubMed=10910365; DOI=10.1038/35018134; RA Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y., Lee E.Y.-H.P., RA Lee W.-H.; RT "Functional link of BRCA1 and ataxia telangiectasia gene product in DNA RT damage response."; RL Nature 406:210-215(2000). RN [28] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10802669; DOI=10.1038/75508; RA Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., RA Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.; RT "ATM-dependent phosphorylation of nibrin in response to radiation RT exposure."; RL Nat. Genet. 25:115-119(2000). RN [29] RP FUNCTION IN PHOSPHORYLATION OF CHEK2. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [30] RP FUNCTION IN PHOSPHORYLATION OF TERF1. RX PubMed=11375976; DOI=10.1074/jbc.m011534200; RA Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.; RT "Telomeric protein Pin2/TRF1 as an important ATM target in response to RT double strand DNA breaks."; RL J. Biol. Chem. 276:29282-29291(2001). RN [31] RP INTERACTION WITH RAD17. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [32] RP FUNCTION IN PHOSPHORYLATION OF FANCD2. RX PubMed=12086603; DOI=10.1016/s0092-8674(02)00747-x; RA Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., RA Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.; RT "Convergence of the Fanconi anemia and ataxia telangiectasia signaling RT pathways."; RL Cell 109:459-472(2002). RN [33] RP PHOSPHORYLATION BY NUAK1. RX PubMed=12409306; DOI=10.1074/jbc.m206025200; RA Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H.; RT "Identification of a novel protein kinase mediating Akt survival signaling RT to the ATM protein."; RL J. Biol. Chem. 278:48-53(2003). RN [34] RP PHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF RP SER-1981. RX PubMed=12556884; DOI=10.1038/nature01368; RA Bakkenist C.J., Kastan M.B.; RT "DNA damage activates ATM through intermolecular autophosphorylation and RT dimer dissociation."; RL Nature 421:499-506(2003). RN [35] RP FUNCTION IN DNA DAMAGE RESPONSE. RX PubMed=14871926; DOI=10.1101/gad.1176004; RA Ali A., Zhang J., Bao S., Liu I., Otterness D., Dean N.M., Abraham R.T., RA Wang X.F.; RT "Requirement of protein phosphatase 5 in DNA-damage-induced ATM RT activation."; RL Genes Dev. 18:249-254(2004). RN [36] RP FUNCTION IN PHOSPHORYLATION OF DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [37] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [38] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=15064416; DOI=10.1126/science.1091496; RA Lee J.-H., Paull T.T.; RT "Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 RT complex."; RL Science 304:93-96(2004). RN [39] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [40] RP FUNCTION. RX PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015; RA Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.; RT "ATM-dependent phosphorylation of ATF2 is required for the DNA damage RT response."; RL Mol. Cell 18:577-587(2005). RN [41] RP INTERACTION WITH KAT8. RX PubMed=15923642; DOI=10.1128/mcb.25.12.5292-5305.2005; RA Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R., Paull T.T., RA Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.; RT "Involvement of human MOF in ATM function."; RL Mol. Cell. Biol. 25:5292-5305(2005). RN [42] RP FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY. RX PubMed=16086026; DOI=10.1038/nsmb972; RA Kaygun H., Marzluff W.F.; RT "Regulated degradation of replication-dependent histone mRNAs requires both RT ATR and Upf1."; RL Nat. Struct. Mol. Biol. 12:794-800(2005). RN [43] RP PHOSPHORYLATION AT SER-1981, AND ACETYLATION. RX PubMed=16141325; DOI=10.1073/pnas.0504211102; RA Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.; RT "A role for the Tip60 histone acetyltransferase in the acetylation and RT activation of ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005). RN [44] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP PHOSPHORYLATION AT SER-1981. RX PubMed=15790808; DOI=10.1126/science.1108297; RA Lee J.H., Paull T.T.; RT "ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 RT complex."; RL Science 308:551-554(2005). RN [45] RP PHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, CATALYTIC RP ACTIVITY, MUTAGENESIS OF SER-367; SER-1893 AND SER-1981, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RX PubMed=16858402; DOI=10.1038/sj.emboj.7601231; RA Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.; RT "Involvement of novel autophosphorylation sites in ATM activation."; RL EMBO J. 25:3504-3514(2006). RN [46] RP INTERACTION WITH ATMIN. RX PubMed=17525732; DOI=10.1038/sj.emboj.7601733; RA Kanu N., Behrens A.; RT "ATMIN defines an NBS1-independent pathway of ATM signalling."; RL EMBO J. 26:2933-2941(2007). RN [47] RP ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND RP LYS-3018. RX PubMed=17923702; DOI=10.1128/mcb.01382-07; RA Sun Y., Xu Y., Roy K., Price B.D.; RT "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase RT activity."; RL Mol. Cell. Biol. 27:8502-8509(2007). RN [48] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-1983, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [49] RP INTERACTION WITH CEP164. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [51] RP INTERACTION WITH NABP2. RX PubMed=18449195; DOI=10.1038/nature06883; RA Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K., RA Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J., Pandita R.K., RA Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T., Pandita T.K., RA White M.F., Khanna K.K.; RT "Single-stranded DNA-binding protein hSSB1 is critical for genomic RT stability."; RL Nature 453:677-681(2008). RN [52] RP INTERACTION WITH DDX1. RX PubMed=18710941; DOI=10.1128/mcb.01053-08; RA Li L., Monckton E.A., Godbout R.; RT "A role for DEAD box 1 at DNA double-strand breaks."; RL Mol. Cell. Biol. 28:6413-6425(2008). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [54] RP FUNCTION AS DYRK2 KINASE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [55] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [56] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [57] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [59] RP PHOSPHORYLATION AT SER-1981. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [61] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21757780; DOI=10.1074/jbc.m111.258152; RA Gatei M., Jakob B., Chen P., Kijas A.W., Becherel O.J., Gueven N., RA Birrell G., Lee J.H., Paull T.T., Lerenthal Y., Fazry S., RA Taucher-Scholz G., Kalb R., Schindler D., Waltes R., Doerk T., Lavin M.F.; RT "ATM protein-dependent phosphorylation of Rad50 protein regulates DNA RT repair and cell cycle control."; RL J. Biol. Chem. 286:31542-31556(2011). RN [62] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP FUNCTION. RX PubMed=24534091; DOI=10.1002/embj.201386064; RA Wang Q., Goldstein M., Alexander P., Wakeman T.P., Sun T., Feng J., Lou Z., RA Kastan M.B., Wang X.F.; RT "Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular RT response to DNA double-strand breaks."; RL EMBO J. 33:862-877(2014). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [66] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PEX5, RP AND MUTAGENESIS OF ARG-3047. RX PubMed=26344566; DOI=10.1038/ncb3230; RA Zhang J., Tripathi D.N., Jing J., Alexander A., Kim J., Powell R.T., RA Dere R., Tait-Mulder J., Lee J.H., Paull T.T., Pandita R.K., Charaka V.K., RA Pandita T.K., Kastan M.B., Walker C.L.; RT "ATM functions at the peroxisome to induce pexophagy in response to ROS."; RL Nat. Cell Biol. 17:1259-1269(2015). RN [67] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26240375; DOI=10.1093/nar/gkv754; RA Kijas A.W., Lim Y.C., Bolderson E., Cerosaletti K., Gatei M., Jakob B., RA Tobias F., Taucher-Scholz G., Gueven N., Oakley G., Concannon P., RA Wolvetang E., Khanna K.K., Wiesmueller L., Lavin M.F.; RT "ATM-dependent phosphorylation of MRE11 controls extent of resection during RT homology directed repair by signalling through Exonuclease 1."; RL Nucleic Acids Res. 43:8352-8367(2015). RN [68] RP FUNCTION IN PHOSPHORYLATION OF FBXW7. RX PubMed=26774286; DOI=10.1016/j.molcel.2015.12.010; RA Zhang Q., Karnak D., Tan M., Lawrence T.S., Morgan M.A., Sun Y.; RT "FBXW7 facilitates nonhomologous end-joining via K63-linked RT polyubiquitylation of XRCC4."; RL Mol. Cell 61:419-433(2016). RN [69] RP FUNCTION. RX PubMed=29203878; DOI=10.1038/s41467-017-02114-x; RA Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D., RA Zhu X.D.; RT "ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair RT pathway choice."; RL Nat. Commun. 8:1921-1921(2017). RN [70] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [71] RP FUNCTION. RX PubMed=30612738; DOI=10.1016/j.cell.2018.11.024; RA Jachimowicz R.D., Beleggia F., Isensee J., Velpula B.B., Goergens J., RA Bustos M.A., Doll M.A., Shenoy A., Checa-Rodriguez C., Wiederstein J.L., RA Baranes-Bachar K., Bartenhagen C., Hertwig F., Teper N., Nishi T., RA Schmitt A., Distelmaier F., Luedecke H.J., Albrecht B., Krueger M., RA Schumacher B., Geiger T., Hoon D.S.B., Huertas P., Fischer M., Hucho T., RA Peifer M., Ziv Y., Reinhardt H.C., Wieczorek D., Shiloh Y.; RT "UBQLN4 represses homologous recombination and is overexpressed in RT aggressive tumors."; RL Cell 0:0-0(2019). RN [72] RP FUNCTION IN PHOSPHORYLATION OF UFL1, AND CATALYTIC ACTIVITY. RX PubMed=30886146; DOI=10.1038/s41467-019-09175-0; RA Qin B., Yu J., Nowsheen S., Wang M., Tu X., Liu T., Li H., Wang L., Lou Z.; RT "UFL1 promotes histone H4 ufmylation and ATM activation."; RL Nat. Commun. 10:1242-1242(2019). RN [73] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30952868; DOI=10.1038/s41467-019-09641-9; RA Ha G.H., Ji J.H., Chae S., Park J., Kim S., Lee J.K., Kim Y., Min S., RA Park J.M., Kang T.H., Lee H., Cho H., Lee C.W.; RT "Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at RT DNA double-strand breaks."; RL Nat. Commun. 10:1577-1577(2019). RN [74] RP ACETYLATION AT LYS-3016, PHOSPHORYLATION AT SER-1981, AND MUTAGENESIS OF RP LYS-3016. RX PubMed=30944854; DOI=10.1126/sciadv.aav1118; RA Tang M., Li Z., Zhang C., Lu X., Tu B., Cao Z., Li Y., Chen Y., Jiang L., RA Wang H., Wang L., Wang J., Liu B., Xu X., Wang H., Zhu W.G.; RT "SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA RT damage repair."; RL Sci. Adv. 5:EAAV1118-EAAV1118(2019). RN [75] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=38128537; DOI=10.1016/j.cell.2023.11.022; RA Chen Y., Wu J., Zhai L., Zhang T., Yin H., Gao H., Zhao F., Wang Z., RA Yang X., Jin M., Huang B., Ding X., Li R., Yang J., He Y., Wang Q., RA Wang W., Kloeber J.A., Li Y., Hao B., Zhang Y., Wang J., Tan M., Li K., RA Wang P., Lou Z., Yuan J.; RT "Metabolic regulation of homologous recombination repair by MRE11 RT lactylation."; RL Cell 187:294-311(2024). RN [76] {ECO:0007744|PDB:5NP0, ECO:0007744|PDB:5NP1} RP STRUCTURE BY ELECTRON MICROSCOPY (5.70 ANGSTROMS), CATALYTIC ACTIVITY, AND RP SUBUNIT. RX PubMed=28508083; DOI=10.1126/sciadv.1700933; RA Baretic D., Pollard H.K., Fisher D.I., Johnson C.M., Santhanam B., RA Truman C.M., Kouba T., Fersht A.R., Phillips C., Williams R.L.; RT "Structures of closed and open conformations of dimeric human ATM."; RL Sci. Adv. 3:E1700933-E1700933(2017). RN [77] {ECO:0007744|PDB:7SIC, ECO:0007744|PDB:7SID} RP STRUCTURE BY ELECTRON MICROSCOPY (2.51 ANGSTROMS) IN COMPLEX WITH NBN, RP FUNCTION, INTERACTION WITH NBN, AND ACTIVITY REGULATION. RX PubMed=35076389; DOI=10.7554/elife.74218; RA Warren C., Pavletich N.P.; RT "Structure of the human ATM kinase and mechanism of Nbs1 binding."; RL Elife 11:0-0(2022). RN [78] RP VARIANTS GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827. RX PubMed=8755918; RA McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y., RA Lennox G.G., Taylor A.M.R.; RT "Mutations associated with variant phenotypes in ataxia-telangiectasia."; RL Am. J. Hum. Genet. 59:320-330(1996). RN [79] RP VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438. RX PubMed=8808599; RA Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D., RA Concannon P.; RT "A high frequency of distinct ATM gene mutations in ataxia- RT telangiectasia."; RL Am. J. Hum. Genet. 59:839-846(1996). RN [80] RP VARIANTS 705-TYR--SER-707 DELINS PHE-ILE-PRO AND 2546-SER--ILE-2548 DEL, RP AND VARIANTS CYS-49; LEU-858; ARG-1054; PHE-1420 AND ARG-1691. RX PubMed=8797579; RA Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B., RA Croce C.M., Hammarstroem L.; RT "ATM mutations in cancer families."; RL Cancer Res. 56:4130-4133(1996). RN [81] RP VARIANT AT 705-TYR--SER-707 DELINS PHE-ILE-PRO, AND VARIANTS LEU-858 AND RP ARG-1054. RX PubMed=9043869; DOI=10.1159/000472231; RA Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M., RA James M.R., Negrini M., Webster A.D.B., Hammarstroem L.; RT "Exon-scanning mutation analysis of the ATM gene in patients with ataxia- RT telangiectasia."; RL Eur. J. Hum. Genet. 4:352-355(1996). RN [82] RP VARIANT AT ARG-2867. RX PubMed=8698354; DOI=10.1007/s004390050202; RA Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.; RT "New mutations in the ataxia telangiectasia gene."; RL Hum. Genet. 98:246-249(1996). RN [83] RP VARIANTS 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND RP GLY-2904. RX PubMed=8845835; DOI=10.1093/hmg/5.4.433; RA Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., RA Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O., RA Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F., RA Tatsumi K., Wegner R.-D., Shiloh Y., Bar-Shira A.; RT "Predominance of null mutations in ataxia-telangiectasia."; RL Hum. Mol. Genet. 5:433-439(1996). RN [84] RP POSSIBLE INVOLVEMENT IN TPLL AND BNHL, AND VARIANTS VAL-1040; THR-1407; RP SER-1463; HIS-1682; HIS-1910; LYS-2164; SER-2396; GLY-2424; PRO-2442; RP 2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722; VAL-2725; LEU-2732; LYS-2810 RP DEL; CYS-2832 AND 2871-ARG-HIS-2872 DELINS SER AND VAL-2890. RX PubMed=9288106; DOI=10.1038/ng0997-96; RA Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L., Yaxley J.C., RA Foroni L., Hammarstroem L., Webster A.D.B., Yuille M.A.R.; RT "Clustering of missense mutations in the ataxia-telangiectasia gene in a RT sporadic T-cell leukaemia."; RL Nat. Genet. 17:96-99(1997). RN [85] RP POSSIBLE INVOLVEMENT IN TPLL, AND VARIANTS GLY-2725; PRO-3006 AND CYS-3008. RX PubMed=9334731; DOI=10.1038/nm1097-1155; RA Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., RA Bar-Shira A., James M.R., Lichter P., Doehner H.; RT "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia."; RL Nat. Med. 3:1155-1159(1997). RN [86] RP VARIANT AT CYS-2832. RX PubMed=9443866; DOI=10.1086/301673; RA Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T., Castellvi-Bel S., RA Udar N., Boerresen-Dale A.-L., Chessa L., Bernatowska-Matuszkiewicz E., RA Porras O., Watanabe M., Junker A., Concannon P., Gatti R.A.; RT "Ataxia-telangiectasia: identification and detection of founder-effect RT mutations in the ATM gene in ethnic populations."; RL Am. J. Hum. Genet. 62:86-97(1998). RN [87] RP POSSIBLE INVOLVEMENT IN TALL, AND VARIANTS AT LEU-292; ASP-768; GLN-1001; RP ARG-1691; ILE-1743; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 RP DEL; ASP-2554; GLY-2668 AND CYS-2827. RX PubMed=9463314; DOI=10.1086/301706; RA Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., RA Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., RA Byrd P.J., Taylor A.M.R.; RT "ATM mutations and phenotypes in ataxia-telangiectasia families in the RT British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, RT and breast cancer."; RL Am. J. Hum. Genet. 62:334-345(1998). RN [88] RP VARIANT AT 1812-ALA-PHE-1813 DELINS VAL. RX PubMed=9497252; DOI=10.1086/301755; RA Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M., RA Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.; RT "Genotype-phenotype relationships in ataxia-telangiectasia and variants."; RL Am. J. Hum. Genet. 62:551-561(1998). RN [89] RP VARIANT AT PRO-2656. RX PubMed=9450874; RX DOI=10.1002/(sici)1096-8628(19980113)75:2<141::aid-ajmg4>3.3.co;2-8; RA Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E., RA Ohno K., Hori N., Sato K., Takeshita K.; RT "Ataxia-telangiectasia without immunodeficiency: novel point mutations RT within and adjacent to the phosphatidylinositol 3-kinase-like domain."; RL Am. J. Med. Genet. 75:141-144(1998). RN [90] RP VARIANT TPLL GLY-2486. RX PubMed=9573030; RA Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., RA Stern M.-H.; RT "Inactivation of the ATM gene in T-cell prolymphocytic leukemias."; RL Blood 91:3920-3926(1998). RN [91] RP VARIANTS 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND VARIANT RP VAL-1853. RX PubMed=9872980; DOI=10.1101/gr.8.12.1245; RA Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C., RA Fodor S.P.A., Tagle D.A., Collins F.S.; RT "Strategies for mutational analysis of the large multiexon ATM gene using RT high-density oligonucleotide arrays."; RL Genome Res. 8:1245-1258(1998). RN [92] RP VARIANT AT 2625-ASP-ALA-2626 DELINS GLU-PRO. RX PubMed=9521587; DOI=10.1007/s004390050675; RA van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M., RA van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.; RT "A double missense mutation in the ATM gene of a Dutch family with ataxia RT telangiectasia."; RL Hum. Genet. 102:187-191(1998). RN [93] RP VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853. RX PubMed=9711876; RX DOI=10.1002/(sici)1098-1004(1998)12:3<186::aid-humu6>3.0.co;2-f; RA Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T., Yamauchi M., RA Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K., Nikaido O., RA Hayashi K.; RT "ATM mutations in patients with ataxia telangiectasia screened by a RT hierarchical strategy."; RL Hum. Mutat. 12:186-195(1998). RN [94] RP VARIANTS AT LEU-858; ARG-1054; ASP-1091 AND ARG-1566. RX PubMed=9792409; RX DOI=10.1002/(sici)1098-1004(1998)12:5<330::aid-humu6>3.0.co;2-h; RA Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J., RA Jaspers N.G.J., van 't Veer L.J.; RT "ATM germline mutations in classical ataxia-telangiectasia patients in the RT Dutch population."; RL Hum. Mutat. 12:330-337(1998). RN [95] RP VARIANTS AT ARG-2491 AND GLY-2909. RX PubMed=9792410; RX DOI=10.1002/(sici)1098-1004(1998)12:5<338::aid-humu7>3.0.co;2-9; RA Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T., RA Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J., RA Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.; RT "Ataxia-telangiectasia in the Japanese population: identification of RT R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being RT relatively common mutations."; RL Hum. Mutat. 12:338-343(1998). RN [96] RP VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008. RX PubMed=9488043; DOI=10.1038/sj.onc.1201603; RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RT "ATM is usually rearranged in T-cell prolymphocytic leukaemia."; RL Oncogene 16:789-796(1998). RN [97] RP ERRATUM OF PUBMED:9488043. RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RL Oncogene 16:2955-2955(1998). RN [98] RP POSSIBLE INVOLVEMENT IN BCLL AND MCL, AND VARIANTS ASN-1853; VAL-1853; RP ARG-1953; LYS-2418 INS; PRO-2420; GLY-2423; HIS-3008 AND ASN-3018. RX PubMed=10397742; RA Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.; RT "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic RT lymphocytic leukemia."; RL Blood 94:748-753(1999). RN [99] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS CYS-332; ARG-1691 AND GLY-2424. RX PubMed=9892178; RA Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M., RA Albitar M., Reed J.C., Croce C.M.; RT "ATM mutations in B-cell chronic lymphocytic leukemia."; RL Cancer Res. 59:24-27(1999). RN [100] RP VARIANT AT PRO-1465. RX PubMed=10234507; DOI=10.1038/sj.ejhg.5200288; RA Izatt L., Vessey C., Hodgson S.V., Solomon E.; RT "Rapid and efficient ATM mutation detection by fluorescent chemical RT cleavage of mismatch: identification of four novel mutations."; RL Eur. J. Hum. Genet. 7:310-320(1999). RN [101] RP VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570; ASN-1853 RP AND SER-2765. RX PubMed=10534763; RX DOI=10.1002/(sici)1098-2264(199912)26:4<286::aid-gcc2>3.3.co;2-o; RA Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G., RA Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.; RT "Identification of germline missense mutations and rare allelic variants in RT the ATM gene in early-onset breast cancer."; RL Genes Chromosomes Cancer 26:286-294(1999). RN [102] RP VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227; RP ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49; RP LEU-858; ARG-1054; ASN-1853 AND VAL-1853. RX PubMed=9887333; DOI=10.1093/hmg/8.1.69; RA Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R., Skawran B., RA Stuhrmann M., Wegner R.-D., Sperling K., Banin S., Shiloh Y., Baumer A., RA Bernthaler U., Sennefelder H., Brohm M., Weber B.H.F., Schindler D.; RT "Characterization of ATM gene mutations in 66 ataxia telangiectasia RT families."; RL Hum. Mol. Genet. 8:69-79(1999). RN [103] RP VARIANTS AT 375-GLN--VAL-3056 DEL; 1466-ARG--VAL-3056 DEL; RP 1730-ARG--VAL-3056 DEL; GLY-2016; 2224-MET--ARG-2227 DELINS ILE-SER; RP 2246-CYS--THR-2252 DELINS HIS; VAL-2664 DEL; VAL-2726; 2849-ARG--VAL-3056 RP DEL AND ARG-2855, AND VARIANT CYS-49. RX PubMed=10425038; RX DOI=10.1002/(sici)1098-1004(1999)14:2<156::aid-humu7>3.0.co;2-e; RA Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J., RA Wang Z., Yang Z., Cheng R., Gatti R.A.; RT "New mutations, polymorphisms, and rare variants in the ATM gene detected RT by a novel SSCP strategy."; RL Hum. Mutat. 14:156-162(1999). RN [104] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS THR-350; THR-352; ARG-1054; RP THR-2274 AND ALA-2695. RX PubMed=10023947; DOI=10.1016/s0140-6736(98)10117-4; RA Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., RA Moss P.A.H., Taylor A.M.R.; RT "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic RT lymphocytic leukaemia."; RL Lancet 353:26-29(1999). RN [105] RP VARIANT ARG-1054. RX PubMed=10217116; DOI=10.1016/s0140-6736(05)75199-0; RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RT "Missense mutations at ATM gene and cancer risk."; RL Lancet 353:1276-1276(1999). RN [106] RP ERRATUM OF PUBMED:10217116. RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RL Lancet 354:780-780(1999). RN [107] RP VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548 DEL; RP GLN-2625; CYS-2832; 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND RP VARIANTS VAL-1853 AND ILE-2438. RX PubMed=10817650; RX DOI=10.1002/(sici)1096-8628(20000529)92:3<170::aid-ajmg3>3.0.co;2-#; RA Li A., Swift M.; RT "Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A- RT T patients."; RL Am. J. Med. Genet. 92:170-177(2000). RN [108] RP VARIANTS AT 35-ARG--VAL-3056 DEL; LEU-292; 393-TRP--VAL-3056 DEL; ARG-950; RP LEU-1082; 1171-GLN--VAL-3056 DEL; 1839-GLN--VAL-3056 DEL; GLU-2063; RP CYS-2227; 2246-CYS--THR-2252 DELINS HIS; 2547-ARG--SER-2549 DEL; GLU-2625; RP PRO-2626 AND ARG-2702, AND VARIANT CYS-49. RX PubMed=10873394; DOI=10.1006/mgme.2000.2998; RA Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O., RA Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.; RT "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein RT expression, mutations, and radiosensitivity."; RL Mol. Genet. Metab. 70:122-133(2000). RN [109] RP VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008. RX PubMed=10706620; DOI=10.1073/pnas.050400997; RA Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.; RT "Mantle cell lymphoma is characterized by inactivation of the ATM gene."; RL Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000). RN [110] RP VARIANTS TRP-45 AND CYS-49. RX PubMed=11897822; DOI=10.1136/jmg.39.3.192; RA Allinen M., Launonen V., Laake K., Jansen L., Huusko P., Kaeaeriaeinen H., RA Boerresen-Dale A.L., Winqvist R.; RT "ATM mutations in Finnish breast cancer patients."; RL J. Med. Genet. 39:192-196(2002). RN [111] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140; GLN-250; RP PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514; TYR-540; VAL-546; RP LEU-582; PRO-707; GLN-848; LEU-858; SER-872; TRP-924; ALA-935; ARG-1054; RP PHE-1179; ILE-1321; TYR-1380; SER-1382; PHE-1420; MET-1469; CYS-1475; RP SER-1650; THR-1739; ASN-1853; VAL-1853; ILE-1916; THR-1945; CYS-1961; RP ASP-1991; PHE-2307; PRO-2332; PHE-2356; LEU-2408; PRO-2442; GLN-2443; RP ARG-2464; ARG-2492; ALA-2666; HIS-2719; ARG-2842 AND ASN-2870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [112] RP VARIANTS CYS-49; LEU-858; ARG-1054; VAL-1255; ASN-1853; THR-2105; SER-2396 RP AND HIS-2719. RX PubMed=18384426; DOI=10.1111/j.1399-0004.2008.00987.x; RA Brunet J., Gutierrez-Enriquez S., Torres A., Berez V., Sanjose S., RA Galceran J., Izquierdo A., Menendez J.A., Guma J., Borras J.; RT "ATM germline mutations in Spanish early-onset breast cancer patients RT negative for BRCA1/BRCA2 mutations."; RL Clin. Genet. 73:465-473(2008). RN [113] RP FUNCTION, CHARACTERIZATION OF VARIANTS AT LEU-292; PRO-1465; ILE-1743; RP THR-2274; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; RP ASP-2554; GLY-2668; CYS-2827; 2855-SER-VAL-2856 DELINS ARG-ILE AND RP CYS-3008, CHARACTERIZATION OF VARIANTS VAL-546; ARG-1054; ILE-1322; RP ARG-1691; CYS-1961 AND SER-2765, VARIANT ILE-1322, AND MUTAGENESIS OF RP LYS-1807; VAL-1941; TYR-2019; GLU-2039; LEU-2338; SER-2394; LEU-2452; RP SER-2685; PRO-2699; ASP-2708 AND GLN-2730. RX PubMed=19431188; DOI=10.1002/humu.21034; RA Barone G., Groom A., Reiman A., Srinivasan V., Byrd P.J., Taylor A.M.; RT "Modeling ATM mutant proteins from missense changes confirms retained RT kinase activity."; RL Hum. Mutat. 30:1222-1230(2009). RN [114] RP VARIANTS ALA-661; PRO-707; LEU-858; TRP-924; ARG-1054; ARG-1691 AND RP VAL-1853. RX PubMed=28202063; DOI=10.1186/s12920-017-0244-7; RA Jalkh N., Chouery E., Haidar Z., Khater C., Atallah D., Ali H., RA Marafie M.J., Al-Mulla M.R., Al-Mulla F., Megarbane A.; RT "Next-generation sequencing in familial breast cancer patients from RT Lebanon."; RL BMC Med. Genomics 10:8-8(2017). RN [115] RP VARIANTS AT VAL-323; PRO-1046; ARG-2023; SER-2068; ASP-2080; HIS-2627; RP LEU-2834 AND ASP-3003, CHARACTERIZATION OF VARIANTS AT VAL-323; PRO-1046; RP ARG-2023; SER-2068; ASP-2080; HIS-2627; LEU-2834 AND ASP-3003, AND RP PHOSPHORYLATION. RX PubMed=27664052; DOI=10.1007/s12017-016-8440-8; RA Carranza D., Vega A.K., Torres-Rusillo S., Montero E., Martinez L.J., RA Santamaria M., Santos J.L., Molina I.J.; RT "Molecular and functional characterization of a cohort of Spanish patients RT with ataxia-telangiectasia."; RL NeuroMolecular Med. 19:161-174(2017). RN [116] RP VARIANTS VAL-68; ILE-341; LEU-597; GLY-699; GLY-759; SER-813; GLY-869; RP ILE-897; ASP-1474; VAL-1488; CYS-1961; ALA-2287; PHE-2307; ARG-2464; RP PRO-2524; THR-2531; GLN-2810; HIS-2832; LEU-2974; ASP-3029 AND LEU-3056. RX PubMed=28726808; DOI=10.1038/gim.2017.85; RA Chaffee K.G., Oberg A.L., McWilliams R.R., Majithia N., Allen B.A., RA Kidd J., Singh N., Hartman A.R., Wenstrup R.J., Petersen G.M.; RT "Prevalence of germ-line mutations in cancer genes among pancreatic cancer RT patients with a positive family history."; RL Genet. Med. 20:119-127(2018). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon double strand breaks (DSBs), apoptosis and genotoxic CC stresses such as ionizing ultraviolet A light (UVA), thereby acting as CC a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, CC PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, CC PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, CC PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). CC Recognizes the substrate consensus sequence [ST]-Q (PubMed:10550055, CC PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, CC PubMed:15448695, PubMed:15456891, PubMed:15916964, PubMed:17923702, CC PubMed:24534091, PubMed:9733514). Phosphorylates 'Ser-139' of histone CC variant H2AX at double strand breaks (DSBs), thereby regulating DNA CC damage response mechanism (By similarity). Also plays a role in pre-B CC cell allelic exclusion, a process leading to expression of a single CC immunoglobulin heavy chain allele to enforce clonality and monospecific CC recognition by the B-cell antigen receptor (BCR) expressed on CC individual B-lymphocytes. After the introduction of DNA breaks by the CC RAG complex on one immunoglobulin allele, acts by mediating a CC repositioning of the second allele to pericentromeric heterochromatin, CC preventing accessibility to the RAG complex and recombination of the CC second allele. Also involved in signal transduction and cell cycle CC control. May function as a tumor suppressor. Necessary for activation CC of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FBXW7, FANCD2, CC NFKBIA, BRCA1, CREBBP/CBP, RBBP8/CTIP, FBXO46, MRE11, nibrin (NBN), CC RAD50, RAD17, PELI1, TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C CC (PubMed:10550055, PubMed:10766245, PubMed:10802669, PubMed:10839545, CC PubMed:10910365, PubMed:10973490, PubMed:11375976, PubMed:12086603, CC PubMed:15456891, PubMed:19965871, PubMed:21757780, PubMed:24534091, CC PubMed:26240375, PubMed:26774286, PubMed:30171069, PubMed:30612738, CC PubMed:30886146, PubMed:30952868, PubMed:38128537, PubMed:9733515, CC PubMed:9843217). May play a role in vesicle and/or protein transport. CC Could play a role in T-cell development, gonad and neurological CC function. Plays a role in replication-dependent histone mRNA CC degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in CC response to genotoxic stress prevents its MDM2-mediated ubiquitination CC and subsequent proteasome degradation (PubMed:19965871). Phosphorylates CC ATF2 which stimulates its function in DNA damage response CC (PubMed:15916964). Phosphorylates ERCC6 which is essential for its CC chromatin remodeling activity at DNA double-strand breaks CC (PubMed:29203878). Phosphorylates TTC5/STRAP at 'Ser-203' in the CC cytoplasm in response to DNA damage, which promotes TTC5/STRAP nuclear CC localization (PubMed:15448695). Also involved in pexophagy by mediating CC phosphorylation of PEX5: translocated to peroxisomes in response to CC reactive oxygen species (ROS), and catalyzes phosphorylation of PEX5, CC promoting PEX5 ubiquitination and induction of pexophagy CC (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10550055, ECO:0000269|PubMed:10766245, CC ECO:0000269|PubMed:10802669, ECO:0000269|PubMed:10839545, CC ECO:0000269|PubMed:10910365, ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11375976, ECO:0000269|PubMed:12086603, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926, CC ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:21757780, ECO:0000269|PubMed:24534091, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:26344566, CC ECO:0000269|PubMed:26774286, ECO:0000269|PubMed:29203878, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30612738, CC ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:9733514, ECO:0000269|PubMed:9733515, CC ECO:0000269|PubMed:9843217}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:26240375, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30886146, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:21757780, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:9843217, ECO:0000305|PubMed:15448695}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:24534091, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:8988033, CC ECO:0000269|PubMed:9843217}; CC -!- ACTIVITY REGULATION: Activated by the MRN (MRE11-RAD50-NBS1) complex in CC response to DNA double strand breaks (DSBs), which recruits ATM to DSBs CC and promotes its activation (PubMed:15064416, PubMed:15790808, CC PubMed:35076389). Inhibited by wortmannin (PubMed:9766667). CC {ECO:0000269|PubMed:15064416, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Homodimer (PubMed:12556884, PubMed:15790808, PubMed:28508083). CC Dimers or tetramers in inactive state (PubMed:12556884, CC PubMed:15790808, PubMed:28508083). On DNA damage, autophosphorylation CC dissociates ATM into monomers rendering them catalytically active CC (PubMed:12556884, PubMed:28508083). Binds p53/TP53, ABL1, BRCA1 and CC TERF1 (PubMed:15790808, PubMed:9168117, PubMed:9843217). Interacts with CC NBN (via FxF/Y motif) (PubMed:35076389). Part of the BRCA1-associated CC genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, CC MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). Interacts with RAD17; DNA damage promotes the CC association (PubMed:11418864). Interacts with EEF1E1; the interaction, CC induced on DNA damage, up-regulates TP53 (PubMed:15680327). Interacts CC with KAT8, NABP2, ATMIN and CEP164 (PubMed:15923642, PubMed:17525732, CC PubMed:18283122, PubMed:18449195). Interacts with AP2B1 and AP3B2; the CC interaction occurs in cytoplasmic vesicles (By similarity). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with DDX1 (PubMed:18710941). Interacts with CC BRAT1 (PubMed:22977523). Interacts with CYREN (via XLF motif) (By CC similarity). Interacts (via microbody targeting signal) with PEX5; CC promoting translocation to peroxisomes in response to reactive oxygen CC species (ROS) (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10783165, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15680327, CC ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:15923642, CC ECO:0000269|PubMed:17525732, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:18449195, ECO:0000269|PubMed:18710941, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9168117, CC ECO:0000269|PubMed:9843217}. CC -!- INTERACTION: CC Q13315; Q9NY61: AATF; NbExp=3; IntAct=EBI-495465, EBI-372428; CC Q13315; P00519: ABL1; NbExp=4; IntAct=EBI-495465, EBI-375543; CC Q13315; P31749: AKT1; NbExp=5; IntAct=EBI-495465, EBI-296087; CC Q13315; O43313: ATMIN; NbExp=5; IntAct=EBI-495465, EBI-7422202; CC Q13315; Q6PJG6: BRAT1; NbExp=3; IntAct=EBI-495465, EBI-10826195; CC Q13315; P62508-3: ESRRG; NbExp=3; IntAct=EBI-495465, EBI-12001340; CC Q13315; Q5XUX0: FBXO31; NbExp=2; IntAct=EBI-495465, EBI-6162477; CC Q13315; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-495465, EBI-81279; CC Q13315; Q13007: IL24; NbExp=2; IntAct=EBI-495465, EBI-3915542; CC Q13315; Q14676: MDC1; NbExp=3; IntAct=EBI-495465, EBI-495644; CC Q13315; Q9BQ15: NABP2; NbExp=4; IntAct=EBI-495465, EBI-2120336; CC Q13315; P11245: NAT2; NbExp=2; IntAct=EBI-495465, EBI-9057228; CC Q13315; O60934: NBN; NbExp=2; IntAct=EBI-495465, EBI-494844; CC Q13315; P46531: NOTCH1; NbExp=8; IntAct=EBI-495465, EBI-636374; CC Q13315; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-495465, EBI-3390132; CC Q13315; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-495465, EBI-9009083; CC Q13315; Q9Y4R8: TELO2; NbExp=4; IntAct=EBI-495465, EBI-1043674; CC Q13315; P54274: TERF1; NbExp=3; IntAct=EBI-495465, EBI-710997; CC Q13315; P54274-2: TERF1; NbExp=5; IntAct=EBI-495465, EBI-711018; CC Q13315; Q15554: TERF2; NbExp=2; IntAct=EBI-495465, EBI-706637; CC Q13315; Q12888: TP53BP1; NbExp=2; IntAct=EBI-495465, EBI-396540; CC Q13315; O43156: TTI1; NbExp=5; IntAct=EBI-495465, EBI-1055680; CC Q13315; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-495465, EBI-6904388; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358}. Cytoplasmic vesicle CC {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:Q62388}. Peroxisome matrix CC {ECO:0000269|PubMed:26344566}. Note=Primarily nuclear (PubMed:9050866, CC PubMed:9150358). Found also in endocytic vesicles in association with CC beta-adaptin (PubMed:9707615). Translocated to peroxisomes in response CC to reactive oxygen species (ROS) by PEX5 (PubMed:26344566). CC {ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9707615}. CC -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle, liver, CC lung, placenta, brain, heart, spleen, thymus, testis, ovary, small CC intestine, colon and leukocytes. CC -!- INDUCTION: By ionizing radiation. CC -!- DOMAIN: The FATC domain is required for interaction with KAT5. CC {ECO:0000269|PubMed:16141325}. CC -!- PTM: Phosphorylated by NUAK1/ARK5 (PubMed:12409306). CC Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA CC damage-mediated activation of the kinase (PubMed:12556884, CC PubMed:15790808, PubMed:16141325, PubMed:16858402, PubMed:21144835, CC PubMed:27664052). During the late stages of DNA damage response, CC dephosphorylated following deacetylation by SIRT7, leading to ATM CC deactivation (PubMed:30944854). {ECO:0000269|PubMed:12409306, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:16858402, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:30944854}. CC -!- PTM: Acetylation, on DNA damage, is required for activation of the CC kinase activity, dimer-monomer transition, and subsequent CC autophosphorylation on Ser-1981 (PubMed:12556884, PubMed:16141325, CC PubMed:16858402, PubMed:17923702, PubMed:21144835). Acetylated in vitro CC by KAT5/TIP60 (PubMed:16141325). Deacetylated by SIRT7 during the late CC stages of DNA damage response, promoting ATM dephosphorylation and CC subsequent deactivation (PubMed:30944854). CC {ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854}. CC -!- DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive CC disorder characterized by progressive cerebellar ataxia, dilation of CC the blood vessels in the conjunctiva and eyeballs, immunodeficiency, CC growth retardation and sexual immaturity. Patients have a strong CC predisposition to cancer; about 30% of patients develop tumors, CC particularly lymphomas and leukemias. Cells from affected individuals CC are highly sensitive to damage by ionizing radiation and resistant to CC inhibition of DNA synthesis following irradiation. CC {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038, CC ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, CC ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354, CC ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, CC ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, CC ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866, CC ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314, CC ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587, CC ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409, CC ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980, CC ECO:0000269|PubMed:9887333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in ATM may contribute to T-cell acute CC lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). CC TPLL is characterized by a high white blood cell count, with a CC predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, CC skin lesions and serous effusion. The clinical course is highly CC aggressive, with poor response to chemotherapy and short survival time. CC TPLL occurs both in adults as a sporadic disease and in younger AT CC patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731, CC ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043, CC ECO:0000269|PubMed:9573030}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell non-Hodgkin CC lymphomas (BNHL), including mantle cell lymphoma (MCL). CC {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620, CC ECO:0000269|PubMed:9288106}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell chronic CC lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in CC the elderly. It is characterized by the accumulation of mature CD5+ B- CC lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure. CC {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742, CC ECO:0000269|PubMed:9892178}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA86520.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=EAW67111.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/123/ATM"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated entry; CC URL="https://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33841; AAC50289.1; -; mRNA. DR EMBL; U55757; AAB38309.1; -; Genomic_DNA. DR EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55757; AAB38310.1; -; Genomic_DNA. DR EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U82828; AAB65827.1; -; Genomic_DNA. DR EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF455499; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA. DR EMBL; X91196; CAA62603.1; -; mRNA. DR EMBL; U67092; AAC51298.1; -; Genomic_DNA. DR EMBL; AY220758; AAO26044.1; -; Genomic_DNA. DR EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA. DR EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA. DR CCDS; CCDS31669.1; -. DR PIR; A43100; A43100. DR RefSeq; NP_000042.3; NM_000051.3. DR RefSeq; NP_001338763.1; NM_001351834.2. DR RefSeq; XP_005271619.2; XM_005271562.6. DR RefSeq; XP_006718906.1; XM_006718843.5. DR RefSeq; XP_006718908.1; XM_006718845.1. DR RefSeq; XP_011541142.1; XM_011542840.4. DR RefSeq; XP_016873279.1; XM_017017790.3. DR RefSeq; XP_047282931.1; XM_047426975.1. DR RefSeq; XP_047282932.1; XM_047426976.1. DR RefSeq; XP_054224846.1; XM_054368871.1. DR RefSeq; XP_054224847.1; XM_054368872.1. DR RefSeq; XP_054224848.1; XM_054368873.1. DR RefSeq; XP_054224849.1; XM_054368874.1. DR RefSeq; XP_054224850.1; XM_054368875.1. DR RefSeq; XP_054224851.1; XM_054368876.1. DR PDB; 5NP0; EM; 5.70 A; A/B=1-3056. DR PDB; 5NP1; EM; 5.70 A; A=1-3056. DR PDB; 6HKA; NMR; -; A=3024-3056. DR PDB; 6K9K; EM; 7.82 A; A=1-3056. DR PDB; 6K9L; EM; 4.27 A; A/B=1-3056. DR PDB; 7NI4; EM; 3.00 A; A/B=1-3056. DR PDB; 7NI5; EM; 2.78 A; A/B=1-3056. DR PDB; 7NI6; EM; 2.80 A; A/B=1-3056. DR PDB; 7SIC; EM; 2.51 A; A/B=1-3056. DR PDB; 7SID; EM; 2.53 A; A/C=1-3056. DR PDB; 8OXM; EM; 3.30 A; A/B=1-3056. DR PDB; 8OXO; EM; 3.00 A; A/B=1-3056. DR PDB; 8OXP; EM; 2.60 A; A/B=1-3056. DR PDB; 8OXQ; EM; 2.50 A; A/B=1-3056. DR PDBsum; 5NP0; -. DR PDBsum; 5NP1; -. DR PDBsum; 6HKA; -. DR PDBsum; 6K9K; -. DR PDBsum; 6K9L; -. DR PDBsum; 7NI4; -. DR PDBsum; 7NI5; -. DR PDBsum; 7NI6; -. DR PDBsum; 7SIC; -. DR PDBsum; 7SID; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8OXP; -. DR PDBsum; 8OXQ; -. DR EMDB; EMD-12350; -. DR EMDB; EMD-12351; -. DR EMDB; EMD-12352; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-17267; -. DR EMDB; EMD-17268; -. DR EMDB; EMD-25140; -. DR EMDB; EMD-25141; -. DR EMDB; EMD-3669; -. DR EMDB; EMD-3672; -. DR EMDB; EMD-9949; -. DR EMDB; EMD-9950; -. DR SMR; Q13315; -. DR BioGRID; 106962; 345. DR CORUM; Q13315; -. DR DIP; DIP-182N; -. DR FunCoup; Q13315; 3527. DR IntAct; Q13315; 175. DR MINT; Q13315; -. DR STRING; 9606.ENSP00000278616; -. DR BindingDB; Q13315; -. DR ChEMBL; CHEMBL3797; -. DR DrugBank; DB02289; 2-Aminopropanedioic Acid. DR DrugBank; DB00201; Caffeine. DR GuidetoPHARMACOLOGY; 1934; -. DR GlyCosmos; Q13315; 4 sites, 2 glycans. DR GlyGen; Q13315; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q13315; -. DR PhosphoSitePlus; Q13315; -. DR BioMuta; ATM; -. DR DMDM; 317373479; -. DR CPTAC; CPTAC-2874; -. DR CPTAC; CPTAC-2875; -. DR CPTAC; CPTAC-2876; -. DR CPTAC; CPTAC-3210; -. DR CPTAC; CPTAC-3211; -. DR CPTAC; CPTAC-3212; -. DR CPTAC; CPTAC-3213; -. DR CPTAC; CPTAC-5976; -. DR CPTAC; CPTAC-5977; -. DR CPTAC; CPTAC-5978; -. DR CPTAC; CPTAC-5979; -. DR CPTAC; CPTAC-912; -. DR CPTAC; CPTAC-913; -. DR jPOST; Q13315; -. DR MassIVE; Q13315; -. DR PaxDb; 9606-ENSP00000278616; -. DR PeptideAtlas; Q13315; -. DR ProteomicsDB; 59303; -. DR Pumba; Q13315; -. DR Antibodypedia; 3596; 1462 antibodies from 49 providers. DR CPTC; Q13315; 4 antibodies. DR DNASU; 472; -. DR Ensembl; ENST00000278616.10; ENSP00000278616.4; ENSG00000149311.23. DR Ensembl; ENST00000452508.7; ENSP00000388058.2; ENSG00000149311.23. DR Ensembl; ENST00000601453.3; ENSP00000469471.2; ENSG00000149311.23. DR Ensembl; ENST00000675843.1; ENSP00000501606.1; ENSG00000149311.23. DR Ensembl; ENST00000713844.1; ENSP00000519149.1; ENSG00000149311.23. DR GeneID; 472; -. DR KEGG; hsa:472; -. DR MANE-Select; ENST00000675843.1; ENSP00000501606.1; NM_000051.4; NP_000042.3. DR UCSC; uc001pkb.1; human. DR AGR; HGNC:795; -. DR CIViC; 472; 50 evidence items across 37 molecular profiles. DR ClinPGx; PA61; -. DR CTD; 472; -. DR DisGeNET; 472; -. DR GeneCards; ATM; -. DR GeneReviews; ATM; -. DR HGNC; HGNC:795; ATM. DR HPA; ENSG00000149311; Low tissue specificity. DR MalaCards; ATM; -. DR MIM; 208900; phenotype. DR MIM; 607585; gene. DR OpenTargets; ENSG00000149311; -. DR Orphanet; 100; Ataxia-telangiectasia. DR Orphanet; 370109; Ataxia-telangiectasia variant. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 52416; Mantle cell lymphoma. DR VEuPathDB; HostDB:ENSG00000149311; -. DR eggNOG; KOG0892; Eukaryota. DR GeneTree; ENSGT00670000098061; -. DR HOGENOM; CLU_000178_3_1_1; -. DR InParanoid; Q13315; -. DR OMA; SEVYMKW; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13315; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q13315; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13315; -. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-912446; Meiotic recombination. DR Reactome; R-HSA-9664873; Pexophagy. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q13315; -. DR SIGNOR; Q13315; -. DR Agora; ENSG00000149311; -. DR BioGRID-ORCS; 472; 54 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR ChiTaRS; ATM; human. DR GeneWiki; Ataxia_telangiectasia_mutated; -. DR GenomeRNAi; 472; -. DR Pharos; Q13315; Tchem. DR PRO; PR:Q13315; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q13315; protein. DR Bgee; ENSG00000149311; Expressed in calcaneal tendon and 207 other cell types or tissues. DR ExpressionAtlas; Q13315; baseline and differential. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:1990391; C:DNA repair complex; IDA:MGI. DR GO; GO:0098850; C:extrinsic component of synaptic vesicle membrane; IEA:Ensembl. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL. DR GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB. DR GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:BHF-UCL. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0071500; P:cellular response to nitrosative stress; IDA:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071481; P:cellular response to X-ray; IDA:ParkinsonsUK-UCL. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:CAFA. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000729; P:DNA double-strand break processing; IDA:UniProt. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProt. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IMP:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB. DR GO; GO:1904354; P:negative regulation of telomere capping; IMP:BHF-UCL. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:MGI. DR GO; GO:0000425; P:pexophagy; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; ISS:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:BHF-UCL. DR GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:1904358; P:positive regulation of telomere maintenance via telomere lengthening; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ARUK-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProt. DR GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome. DR GO; GO:2000785; P:regulation of autophagosome assembly; IC:UniProt. DR GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl. DR CDD; cd05171; PIKKc_ATM; 1. DR FunFam; 1.10.1070.11:FF:000011; Serine-protein kinase ATM; 1. DR FunFam; 3.30.1010.10:FF:000015; Serine-protein kinase ATM; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR038980; ATM_plant. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR044107; PIKKc_ATM. DR InterPro; IPR021668; TAN. DR PANTHER; PTHR37079; SERINE/THREONINE-PROTEIN KINASE ATM; 1. DR PANTHER; PTHR37079:SF4; SERINE_THREONINE-PROTEIN KINASE ATM; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF11640; TAN; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01342; TAN; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell cycle; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; Disease variant; DNA damage; KW DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus; KW Peroxisome; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3056 FT /note="Serine-protein kinase ATM" FT /id="PRO_0000088840" FT DOMAIN 1940..2566 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2686..2998 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3024..3056 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1373..1382 FT /note="Interaction with ABL1" FT /evidence="ECO:0000269|PubMed:9168117" FT REGION 2692..2698 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2867..2875 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2887..2911 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 3046..3048 FT /note="Microbody targeting signal; atypical" FT /evidence="ECO:0000269|PubMed:26344566" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 367 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1893 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1981 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16141325, FT ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:30944854, ECO:0007744|PubMed:17525332" FT MOD_RES 1983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 2996 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 3016 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17923702, FT ECO:0000269|PubMed:30944854" FT VARIANT 23 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587779858)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041545" FT VARIANT 35..3056 FT /note="Missing (in AT; dbSNP:rs55861249)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085060" FT VARIANT 45 FT /note="R -> W (found in a patient with breast cancer; FT uncertain significance; dbSNP:rs3218684)" FT /evidence="ECO:0000269|PubMed:11897822" FT /id="VAR_056678" FT VARIANT 49 FT /note="S -> C (in dbSNP:rs1800054)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333" FT /id="VAR_010798" FT VARIANT 68 FT /note="I -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083373" FT VARIANT 126 FT /note="D -> E (in dbSNP:rs2234997)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010799" FT VARIANT 140 FT /note="D -> H (in dbSNP:rs55633650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041546" FT VARIANT 182 FT /note="V -> L (in dbSNP:rs3218707)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010800" FT VARIANT 224 FT /note="K -> E (in AT; uncertain significance; FT dbSNP:rs145053092)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010801" FT VARIANT 250 FT /note="R -> Q (in dbSNP:rs56123940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041547" FT VARIANT 292 FT /note="P -> L (in AT; decrease phosphorylation of target FT proteins; increases protein abundance; dbSNP:rs747727055)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314" FT /id="VAR_010802" FT VARIANT 323 FT /note="I -> V (in AT; loss of protein expression; FT dbSNP:rs587781511)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:27664052" FT /id="VAR_010803" FT VARIANT 332 FT /note="Y -> C (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9892178" FT /id="VAR_010804" FT VARIANT 333 FT /note="S -> F (in dbSNP:rs28904919)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041548" FT VARIANT 337 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs138398778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041549" FT VARIANT 337 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs202160435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041550" FT VARIANT 341 FT /note="V -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083374" FT VARIANT 350 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs371713984)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010805" FT VARIANT 352 FT /note="I -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs369203092)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010806" FT VARIANT 374..3056 FT /note="Missing (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085061" FT VARIANT 393..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085062" FT VARIANT 410 FT /note="V -> A (in dbSNP:rs56128736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041551" FT VARIANT 504 FT /note="N -> S (in dbSNP:rs56365018)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041552" FT VARIANT 514 FT /note="G -> D (in dbSNP:rs2235000)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010807" FT VARIANT 540 FT /note="C -> Y (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041553" FT VARIANT 546 FT /note="L -> V (no effect on phosphorylation of target FT proteins; dbSNP:rs2227924)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188" FT /id="VAR_041554" FT VARIANT 570 FT /note="F -> S (in AT; dbSNP:rs777301065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010808" FT VARIANT 582 FT /note="F -> L (in dbSNP:rs2235006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041555" FT VARIANT 597 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083375" FT VARIANT 661 FT /note="D -> A (found in a patient with familial breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28202063" FT /id="VAR_083376" FT VARIANT 699 FT /note="E -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083377" FT VARIANT 705..707 FT /note="YSS -> FIP (in AT)" FT /evidence="ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869" FT /id="VAR_010809" FT VARIANT 707 FT /note="S -> P (in dbSNP:rs4986761)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063" FT /id="VAR_010810" FT VARIANT 759 FT /note="S -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083378" FT VARIANT 761 FT /note="T -> S (in dbSNP:rs2235011)" FT /id="VAR_056679" FT VARIANT 768 FT /note="N -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010812" FT VARIANT 785 FT /note="R -> C (in AT; dbSNP:rs587778065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010813" FT VARIANT 788 FT /note="S -> R (in dbSNP:rs641252)" FT /id="VAR_056680" FT VARIANT 813 FT /note="N -> S (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083379" FT VARIANT 814 FT /note="D -> E (in dbSNP:rs3218695)" FT /id="VAR_056681" FT VARIANT 848 FT /note="E -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254046)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041556" FT VARIANT 858 FT /note="F -> L (in dbSNP:rs1800056)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010814" FT VARIANT 869 FT /note="A -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083380" FT VARIANT 872 FT /note="P -> S (in dbSNP:rs3218673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041557" FT VARIANT 897 FT /note="F -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083381" FT VARIANT 924 FT /note="R -> W (found in a patient with familial breast FT cancer; uncertain significance; dbSNP:rs55723361)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063" FT /id="VAR_041558" FT VARIANT 935 FT /note="T -> A (in dbSNP:rs35813135)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041559" FT VARIANT 935 FT /note="T -> M (in dbSNP:rs3218708)" FT /id="VAR_056682" FT VARIANT 942 FT /note="L -> F (in dbSNP:rs3218688)" FT /id="VAR_056683" FT VARIANT 950 FT /note="L -> R (in AT; dbSNP:rs786203054)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010815" FT VARIANT 1001 FT /note="L -> Q (in AT; risk factor for T-cell acute FT lymphoblastic leukemia)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010816" FT VARIANT 1040 FT /note="M -> V (in dbSNP:rs3092857)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010817" FT VARIANT 1046 FT /note="L -> P (in AT; loss of protein expression; FT dbSNP:rs568461905)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077237" FT VARIANT 1054 FT /note="P -> R (in AT; likely benign; no effect on FT phosphorylation of target proteins; dbSNP:rs1800057)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869, FT ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333" FT /id="VAR_010818" FT VARIANT 1082 FT /note="H -> L (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010819" FT VARIANT 1091 FT /note="E -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010820" FT VARIANT 1171..3056 FT /note="Missing (in AT; uncertain significance; increases FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085063" FT VARIANT 1179 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041560" FT VARIANT 1255 FT /note="L -> V (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083382" FT VARIANT 1313 FT /note="E -> Q (in dbSNP:rs3092841)" FT /id="VAR_056684" FT VARIANT 1321 FT /note="M -> I (in dbSNP:rs35184530)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041561" FT VARIANT 1322 FT /note="L -> I (no effect on phosphorylation of target FT proteins; dbSNP:rs144535256)" FT /evidence="ECO:0000269|PubMed:19431188" FT /id="VAR_080300" FT VARIANT 1380 FT /note="H -> Y (in dbSNP:rs3092856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041562" FT VARIANT 1382 FT /note="P -> S (in dbSNP:rs55859590)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041563" FT VARIANT 1407 FT /note="I -> T (in T-prolymphocytic leukemia; FT dbSNP:rs1234250980)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010821" FT VARIANT 1420 FT /note="L -> F (in dbSNP:rs1800058)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579" FT /id="VAR_010822" FT VARIANT 1420 FT /note="L -> P (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010823" FT VARIANT 1427 FT /note="A -> T (in dbSNP:rs2229021)" FT /id="VAR_056685" FT VARIANT 1463 FT /note="F -> S (found in B-cell non-Hodgkin lymphoma; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010825" FT VARIANT 1465 FT /note="L -> P (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs730881391)" FT /evidence="ECO:0000269|PubMed:10234507, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010826" FT VARIANT 1466..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs730881369)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085064" FT VARIANT 1469 FT /note="I -> M (in a renal papillary cancer sample; somatic FT mutation; dbSNP:rs775047783)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041564" FT VARIANT 1474 FT /note="H -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083383" FT VARIANT 1475 FT /note="Y -> C (in dbSNP:rs34640941)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041565" FT VARIANT 1488 FT /note="L -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083384" FT VARIANT 1541 FT /note="L -> F (in dbSNP:rs3092849)" FT /id="VAR_056686" FT VARIANT 1566 FT /note="P -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010827" FT VARIANT 1570 FT /note="V -> A (in dbSNP:rs140856217)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010828" FT VARIANT 1650 FT /note="N -> S (in dbSNP:rs55870064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041566" FT VARIANT 1682 FT /note="D -> H (in T-prolymphocytic leukemia; FT dbSNP:rs121434217)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010829" FT VARIANT 1691 FT /note="S -> R (in AT, B-cell chronic lymphocytic leukemia FT and familial cancer patients; no effect on phosphorylation FT of target proteins; dbSNP:rs1800059)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010830" FT VARIANT 1729 FT /note="V -> L (in dbSNP:rs3092907)" FT /id="VAR_056687" FT VARIANT 1730..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs764389018)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085065" FT VARIANT 1739 FT /note="N -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041567" FT VARIANT 1743 FT /note="T -> I (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs587779844)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010831" FT VARIANT 1812..1813 FT /note="AF -> V (in AT)" FT /evidence="ECO:0000269|PubMed:9497252" FT /id="VAR_010832" FT VARIANT 1839..3056 FT /note="Missing (in AT; uncertain significance; reduces FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085066" FT VARIANT 1853 FT /note="D -> N (in dbSNP:rs1801516)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9887333" FT /id="VAR_010833" FT VARIANT 1853 FT /note="D -> V (might contribute to B-cell chronic FT lymphocytic leukemia; dbSNP:rs1801673)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010834" FT VARIANT 1910 FT /note="L -> H (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010835" FT VARIANT 1913 FT /note="V -> G (in AT; dbSNP:rs1060501688)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010836" FT VARIANT 1916 FT /note="M -> I (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041568" FT VARIANT 1945 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041569" FT VARIANT 1953 FT /note="T -> R (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010837" FT VARIANT 1961 FT /note="Y -> C (found in a patient with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; decreased FT phosphorylation of target proteins; dbSNP:rs56399311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808" FT /id="VAR_041570" FT VARIANT 1983 FT /note="S -> N (in dbSNP:rs659243)" FT /evidence="ECO:0000269|PubMed:16554811" FT /id="VAR_041571" FT VARIANT 1991 FT /note="E -> D (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs587782274)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041572" FT VARIANT 2016 FT /note="D -> G (in AT; uncertain significance; FT dbSNP:rs587781302)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010838" FT VARIANT 2023 FT /note="G -> R (in AT; loss of protein expression; FT dbSNP:rs11212587)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077238" FT VARIANT 2034 FT /note="R -> Q (in dbSNP:rs3218670)" FT /id="VAR_056688" FT VARIANT 2063 FT /note="G -> E (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs866290641)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010839" FT VARIANT 2067 FT /note="A -> D (in AT; dbSNP:rs397514577)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010840" FT VARIANT 2068 FT /note="L -> S (in AT; decreased protein abundance; loss of FT DNA damage induced protein autophosphorylation; FT dbSNP:rs1555114558)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077239" FT VARIANT 2079 FT /note="V -> I (in dbSNP:rs1800060)" FT /evidence="ECO:0000269|PubMed:8665503" FT /id="VAR_010841" FT VARIANT 2080 FT /note="Y -> D (in AT; loss of DNA damage induced protein FT autophosphorylation; dbSNP:rs1064795467)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077240" FT VARIANT 2105 FT /note="R -> T (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083385" FT VARIANT 2139 FT /note="E -> G (in T-prolymphocytic leukemia; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:9488043" FT /id="VAR_010842" FT VARIANT 2164 FT /note="E -> K (in T-prolymphocytic leukemia; FT dbSNP:rs1317619286)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010843" FT VARIANT 2218 FT /note="S -> C (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010844" FT VARIANT 2224..2227 FT /note="MALR -> IS (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010845" FT VARIANT 2227 FT /note="R -> C (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs564652222)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010846" FT VARIANT 2246..2252 FT /note="CIKDILT -> H (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10873394" FT /id="VAR_010847" FT VARIANT 2274 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT uncertain significance; no effect on phosphorylation of FT target proteins; dbSNP:rs567060474)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010848" FT VARIANT 2287 FT /note="G -> A (found in a patient with familial pancreatic FT cancer; uncertain significance; dbSNP:rs1800061)" FT /evidence="ECO:0000269|PubMed:28726808, FT ECO:0000269|PubMed:8665503" FT /id="VAR_010849" FT VARIANT 2307 FT /note="L -> F (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; FT dbSNP:rs56009889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041573" FT VARIANT 2332 FT /note="L -> P (in dbSNP:rs4988111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041574" FT VARIANT 2335 FT /note="T -> K (in dbSNP:rs3092831)" FT /id="VAR_056689" FT VARIANT 2356 FT /note="I -> F (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs876658517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041575" FT VARIANT 2396 FT /note="T -> S (found in a patient with T-prolymphocytic FT leukemia; uncertain significance; also found in a patient FT with early-onset breast cancer; uncertain significance; FT dbSNP:rs370559102)" FT /evidence="ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010850" FT VARIANT 2408 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs730881315)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041576" FT VARIANT 2418 FT /note="K -> KK (in mantle cell lymphoma)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010851" FT VARIANT 2420 FT /note="A -> P (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010852" FT VARIANT 2423 FT /note="E -> G (in mantle cell lymphoma; dbSNP:rs121434221)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010853" FT VARIANT 2424 FT /note="V -> G (in AT; also found in B-cell chronic FT lymphocytic leukemia and T-prolymphocytic leukemia; risk FT factor for breast cancer; decreased phosphorylation of FT target proteins; dbSNP:rs28904921)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010854" FT VARIANT 2427..2428 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia; lack of phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8845835, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010855" FT VARIANT 2438 FT /note="T -> I (in dbSNP:rs147604227)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:8808599" FT /id="VAR_010856" FT VARIANT 2442 FT /note="Q -> P (in T-prolymphocytic leukemia; also in a lung FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010857" FT VARIANT 2443 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587782310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041577" FT VARIANT 2464 FT /note="C -> R (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a small cell FT lung cancer sample; uncertain significance; FT dbSNP:rs55801750)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041578" FT VARIANT 2470 FT /note="Y -> D (in AT; dbSNP:rs876659365)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010858" FT VARIANT 2486 FT /note="R -> G (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9573030" FT /id="VAR_010859" FT VARIANT 2491 FT /note="W -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010860" FT VARIANT 2492 FT /note="L -> R (in dbSNP:rs56399857)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041579" FT VARIANT 2524 FT /note="A -> P (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083386" FT VARIANT 2531 FT /note="M -> T (found in patients with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083387" FT VARIANT 2546..2548 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia and T-cell acute lymphoblastic leukemia; lack of FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, FT ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9150358, FT ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314" FT /id="VAR_010861" FT VARIANT 2547..2549 FT /note="Missing (in AT; dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085067" FT VARIANT 2554 FT /note="H -> D (in AT; lack of phosphorylation of target FT proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010862" FT VARIANT 2570 FT /note="E -> G (in dbSNP:rs28904920)" FT /id="VAR_056690" FT VARIANT 2625..2626 FT /note="DA -> EP (in AT; dbSNP:rs267606668)" FT /evidence="ECO:0000269|PubMed:9521587" FT /id="VAR_010864" FT VARIANT 2625 FT /note="D -> E (in AT; uncertain significance; FT dbSNP:rs1196903858)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085068" FT VARIANT 2625 FT /note="D -> Q (in AT; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010863" FT VARIANT 2626 FT /note="A -> P (in AT; uncertain significance; FT dbSNP:rs267606669)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085069" FT VARIANT 2627 FT /note="Y -> H (in AT; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077241" FT VARIANT 2640 FT /note="T -> I (in dbSNP:rs4988125)" FT /id="VAR_056691" FT VARIANT 2656 FT /note="L -> P (in AT; dbSNP:rs121434218)" FT /evidence="ECO:0000269|PubMed:9450874" FT /id="VAR_010865" FT VARIANT 2662 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010866" FT VARIANT 2664 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs1471563800)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085070" FT VARIANT 2666 FT /note="T -> A (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs745775382)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041580" FT VARIANT 2668 FT /note="E -> G (in AT; uncertain significance; no effect on FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010868" FT VARIANT 2695 FT /note="G -> A (in T-prolymphocytic leukemia and B-cell FT chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010869" FT VARIANT 2702 FT /note="I -> R (in AT; dbSNP:rs876659735)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010870" FT VARIANT 2709 FT /note="G -> S (in dbSNP:rs3218680)" FT /id="VAR_056692" FT VARIANT 2719 FT /note="R -> H (found in a patient with early-onset breast FT cancer; uncertain significance; dbSNP:rs55982963)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426" FT /id="VAR_041581" FT VARIANT 2722 FT /note="L -> R (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010871" FT VARIANT 2725 FT /note="D -> G (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs1555128314)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010872" FT VARIANT 2725 FT /note="D -> V (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010873" FT VARIANT 2726 FT /note="A -> V (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010874" FT VARIANT 2732 FT /note="F -> L (in T-prolymphocytic leukemia; FT dbSNP:rs876659619)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010875" FT VARIANT 2765 FT /note="G -> S (may contribute to breast cancer; lack of FT phosphorylation of target proteins; dbSNP:rs748634900)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010876" FT VARIANT 2810 FT /note="K -> Q (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083388" FT VARIANT 2810 FT /note="Missing (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010877" FT VARIANT 2824 FT /note="C -> Y (in AT; dbSNP:rs876660927)" FT /evidence="ECO:0000269|PubMed:9150358" FT /id="VAR_010878" FT VARIANT 2827 FT /note="F -> C (in AT; mild; decreased phosphorylation of FT target proteins; dbSNP:rs121434216)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314" FT /id="VAR_010879" FT VARIANT 2829 FT /note="P -> L (in AT; dbSNP:rs938431501)" FT /evidence="ECO:0000269|PubMed:9711876" FT /id="VAR_010880" FT VARIANT 2832 FT /note="R -> C (in AT; also found in B-cell non-Hodgkin FT lymphoma; increases protein abundance; dbSNP:rs587779872)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9443866" FT /id="VAR_010881" FT VARIANT 2832 FT /note="R -> H (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083389" FT VARIANT 2834 FT /note="F -> L (in AT; decreased protein abundance)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077242" FT VARIANT 2842 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041582" FT VARIANT 2849..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587778080)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085071" FT VARIANT 2849 FT /note="R -> P (in AT; dbSNP:rs587782202)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010882" FT VARIANT 2855..2856 FT /note="SV -> RI (in AT; lack of phosphorylation of target FT proteins; dbSNP:rs587781353)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9872980" FT /id="VAR_010884" FT VARIANT 2855 FT /note="S -> R (in AT; uncertain significance; FT dbSNP:rs780905851)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010883" FT VARIANT 2860 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8845835" FT /id="VAR_010885" FT VARIANT 2867 FT /note="G -> R (in AT)" FT /evidence="ECO:0000269|PubMed:8698354, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010886" FT VARIANT 2870 FT /note="D -> N (in dbSNP:rs55798854)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041583" FT VARIANT 2871..2872 FT /note="RH -> S (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010887" FT VARIANT 2890 FT /note="L -> V (in T-prolymphocytic leukemia; FT dbSNP:rs587779874)" FT /evidence="ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9488043" FT /id="VAR_010888" FT VARIANT 2904 FT /note="E -> G (in AT; dbSNP:rs786202826)" FT /evidence="ECO:0000269|PubMed:8845835" FT /id="VAR_010889" FT VARIANT 2909 FT /note="R -> G (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010890" FT VARIANT 2974 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083390" FT VARIANT 3003 FT /note="N -> D (in AT; decreased protein abundance; FT dbSNP:rs1137889)" FT /evidence="ECO:0000269|PubMed:27664052, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, FT ECO:0000269|PubMed:8665503" FT /id="VAR_077243" FT VARIANT 3006 FT /note="A -> P (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs876658767)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010892" FT VARIANT 3008 FT /note="R -> C (in AT; also found in T-prolymphocytic FT leukemia and mantle cell lymphoma; lack of phosphorylation FT of target proteins; dbSNP:rs587782292)" FT /evidence="ECO:0000269|PubMed:10706620, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043, FT ECO:0000269|PubMed:9872980" FT /id="VAR_010893" FT VARIANT 3008 FT /note="R -> H (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs587781894)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010894" FT VARIANT 3018 FT /note="K -> N (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010895" FT VARIANT 3029 FT /note="G -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083391" FT VARIANT 3056 FT /note="V -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083392" FT MUTAGEN 367 FT /note="S->A: Loss of IR-induced S-367 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-1893 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1807 FT /note="K->E: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1893 FT /note="S->A: Loss of IR-induced S-1893 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1941 FT /note="V->L: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1981 FT /note="S->A: Loss of IR-induced S-1981 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1893 FT autophosphorylation. No dimer disruption." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 1981 FT /note="S->D,E: Disrupts the dimer." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 2019 FT /note="Y->C: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2039 FT /note="E->K: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2338 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2394 FT /note="S->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2452 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2685 FT /note="S->T: No effect on phosphorylation of target FT proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2699 FT /note="P->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2708 FT /note="D->N: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2730 FT /note="Q->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2870 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 2875 FT /note="N->K: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 3016 FT /note="K->Q: Mimics acetylation, preventing FT dephosphorylation and subsequent ATM deactivation during FT the late stage of DNA damage response." FT /evidence="ECO:0000269|PubMed:30944854" FT MUTAGEN 3016 FT /note="K->R: Loss of DNA damage-inducible acetylation. FT Retains constitutive kinase activity, but blocks DNA FT damage-induced kinase activation. Disrupts dimer and FT abolishes S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3018 FT /note="K->R: Retains DNA damage-inducible acetylation and FT S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3047 FT /note="R->Q: Abolished interaction with PEX5 and FT translocation to peroxisomes in response to reactive oxygen FT species (ROS)." FT /evidence="ECO:0000269|PubMed:26344566" FT CONFLICT 46 FT /note="H -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="N -> I (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 313 FT /note="Y -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 488 FT /note="W -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="T -> A (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="K -> N (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="Q -> K (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="E -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="Q -> L (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1049 FT /note="L -> W (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1089 FT /note="A -> V (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT HELIX 6..17 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 20..33 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 36..41 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 57..73 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 90..108 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 109..112 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 117..129 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 130..133 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 135..148 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 149..151 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 153..158 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 161..176 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 183..201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 210..222 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 229..242 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 244..246 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 248..268 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 273..290 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 292..294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 298..300 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 306..323 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 343..356 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 410..422 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 424..426 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 429..431 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 432..442 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 445..447 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 452..466 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 474..492 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 493..496 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 498..500 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 501..513 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 521..524 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 525..527 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 528..530 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 536..548 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 572..580 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 605..607 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 608..615 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 617..619 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 620..628 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 684..704 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 713..731 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 732..735 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 737..741 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 744..765 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 771..786 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 792..794 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 795..806 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 809..822 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 892..911 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 920..930 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 941..953 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 957..959 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 973..979 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 980..982 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 984..994 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 995..997 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 998..1002 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1009..1030 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1031..1033 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1036..1052 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1060..1063 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1066..1069 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1070..1076 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1077..1079 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1083..1092 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1093..1096 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1113..1132 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1144..1164 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1169..1181 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1187..1201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1206..1212 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1214..1223 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1227..1229 FT /evidence="ECO:0007829|PDB:7NI5" FT TURN 1231..1233 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1236..1238 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1244..1261 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1265..1275 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1279..1285 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1287..1294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1295..1297 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1299..1303 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1306..1322 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1325..1327 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1328..1330 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1332..1338 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1340..1348 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1383..1396 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1397..1399 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1404..1408 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1413..1428 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1432..1450 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1453..1455 FT /evidence="ECO:0007829|PDB:7SID" FT TURN 1456..1460 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1461..1477 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1485..1508 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1513..1515 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1517..1527 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1528..1530 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1532..1545 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1546..1551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1553..1560 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1567..1569 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1572..1582 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1583..1585 FT /evidence="ECO:0007829|PDB:7NI6" FT HELIX 1590..1601 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1607..1610 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1611..1623 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1625..1634 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1635..1637 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 1639..1641 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1643..1658 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1661..1663 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1664..1677 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1694..1702 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1706..1721 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1723..1725 FT /evidence="ECO:0007829|PDB:8OXO" FT HELIX 1727..1742 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1744..1753 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1754..1756 FT /evidence="ECO:0007829|PDB:7NI4" FT HELIX 1759..1763 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1764..1767 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1785..1789 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1792..1795 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1802..1815 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1822..1825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1828..1831 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1835..1851 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1857..1874 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1903..1917 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1922..1924 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1927..1930 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1938..1947 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1951..1973 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1986..1997 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2001..2012 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2016..2019 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2023..2028 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 2029..2038 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2042..2051 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2057..2070 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2074..2087 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2093..2105 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2124..2136 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2140..2159 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2166..2168 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2170..2190 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2195..2210 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2211..2214 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2217..2236 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2240..2242 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2245..2264 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2269..2281 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2290..2301 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2305..2322 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2328..2348 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2353..2359 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2361..2370 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2377..2406 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2408..2421 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2437..2475 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2481..2483 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2484..2493 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2494..2496 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2498..2507 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2508..2510 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2513..2516 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2520..2525 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2529..2531 FT /evidence="ECO:0007829|PDB:7SID" FT STRAND 2533..2535 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2537..2551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2553..2564 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2565..2567 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2568..2572 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2593..2612 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2614..2632 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2637..2640 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2652..2655 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2659..2663 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2665..2667 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2673..2675 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2682..2686 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2688..2692 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2695..2697 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2700..2706 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2707..2709 FT /evidence="ECO:0007829|PDB:7NI4" FT STRAND 2711..2717 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2723..2740 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2743..2748 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2757..2759 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2761..2763 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2765..2768 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2773..2775 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2776..2780 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2783..2785 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2787..2791 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2798..2807 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2808..2810 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2813..2825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2833..2838 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2842..2866 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2873..2875 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2876..2879 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2880..2882 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2885..2887 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2894..2899 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2900..2902 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2906..2908 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2912..2916 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2920..2925 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2926..2940 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2942..2953 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2964..2970 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3002..3017 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 3020..3025 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3028..3040 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3042..3047 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3050..3052 FT /evidence="ECO:0007829|PDB:8OXQ" SQ SEQUENCE 3056 AA; 350687 MW; C0B4866E1E3199E2 CRC64; MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV // ID AVR2A_HUMAN Reviewed; 513 AA. AC P27037; B2RAB8; B4DWQ2; D3DP85; Q53TH4; Q6NWV2; Q92474; DT 01-AUG-1992, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1992, sequence version 1. DT 28-JAN-2026, entry version 236. DE RecName: Full=Activin receptor type-2A {ECO:0000305|PubMed:1314589}; DE EC=2.7.11.30 {ECO:0000269|PubMed:25368322}; DE AltName: Full=Activin receptor type IIA; DE Short=ACTR-IIA; DE Short=ACTRIIA; DE Flags: Precursor; GN Name=ACVR2A {ECO:0000312|HGNC:HGNC:173}; Synonyms=ACVR2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=1311955; DOI=10.1016/0167-4781(92)90472-c; RA Matzuk M.M., Bradley A.; RT "Cloning of the human activin receptor cDNA reveals high evolutionary RT conservation."; RL Biochim. Biophys. Acta 1130:105-108(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION. RC TISSUE=Testis; RX PubMed=1314589; DOI=10.1016/0006-291x(92)91194-u; RA Donaldson C.J., Mathews L.S., Vale W.W.; RT "Molecular cloning and binding properties of the human type II activin RT receptor."; RL Biochem. Biophys. Res. Commun. 184:310-316(1992). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary gland; RA Geiser A.G.; RL Submitted (DEC-1991) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Iimura T., Oida S.; RL Submitted (NOV-1994) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Colon, and Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP FUNCTION, AND INTERACTION WITH ACTIVIN A/INHBA. RX PubMed=10652306; DOI=10.1074/jbc.275.5.3206; RA Gray P.C., Greenwald J., Blount A.L., Kunitake K.S., Donaldson C.J., RA Choe S., Vale W.; RT "Identification of a binding site on the type II activin receptor for RT activin and inhibin."; RL J. Biol. Chem. 275:3206-3212(2000). RN [10] RP INTERACTION WITH BMP7. RX PubMed=12667445; DOI=10.1016/s1097-2765(03)00094-7; RA Greenwald J., Groppe J., Gray P., Wiater E., Kwiatkowski W., Vale W., RA Choe S.; RT "The BMP7/ActRII extracellular domain complex provides new insights into RT the cooperative nature of receptor assembly."; RL Mol. Cell 11:605-617(2003). RN [11] RP FUNCTION, AND INTERACTION WITH ACVR1. RX PubMed=17911401; DOI=10.1677/joe-07-0281; RA Renlund N., O'Neill F.H., Zhang L., Sidis Y., Teixeira J.; RT "Activin receptor-like kinase-2 inhibits activin signaling by blocking the RT binding of activin to its type II receptor."; RL J. Endocrinol. 195:95-103(2007). RN [12] RP INTERACTION WITH TSC22D1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [13] RP CATALYTIC ACTIVITY. RX PubMed=25368322; DOI=10.1074/jbc.m114.604397; RA Horbelt D., Boergermann J.H., Chaikuad A., Alfano I., Williams E., RA Lukonin I., Timmel T., Bullock A.N., Knaus P.; RT "Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 RT signaling and promote functional myoblast differentiation."; RL J. Biol. Chem. 290:3390-3404(2015). RN [14] RP X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) OF 191-488 IN COMPLEX WITH RP DORSOMORPHIN. RG Structural genomics consortium (SGC); RT "Crystal structure of activin receptor type-IIa (ACVR2A) kinase domain in RT complex with dorsomorphin."; RL Submitted (FEB-2011) to the PDB data bank. RN [15] RP VARIANTS ARG-258 AND ASN-306. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [16] RP VARIANT THR-367. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). CC -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two CC type II and two type I transmembrane serine/threonine kinases. Type II CC receptors phosphorylate and activate type I receptors which CC autophosphorylate, then bind and activate SMAD transcriptional CC regulators. Receptor for activin A, activin B and inhibin A CC (PubMed:17911401, PubMed:10652306). Mediates induction of adipogenesis CC by GDF6 (By similarity). {ECO:0000250|UniProtKB:P27038, CC ECO:0000269|PubMed:1314589, ECO:0000269|PubMed:17911401}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC Evidence={ECO:0000269|PubMed:25368322}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44881; CC Evidence={ECO:0000269|PubMed:25368322}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC Evidence={ECO:0000269|PubMed:25368322}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18674; CC Evidence={ECO:0000269|PubMed:25368322}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Part of a complex consisting of MAGI2/ARIP1, ACVR2A, ACVR1B CC and SMAD3 (By similarity). Interacts with MAGI2/ARIP1 (By similarity). CC Interacts with type I receptor ACVR1 (PubMed:17911401). Interacts with CC BMP7 (PubMed:12667445). Interacts with TSC22D1/TSC-22 CC (PubMed:21791611). Interacts with activin A/INHBA (PubMed:10652306). CC {ECO:0000250|UniProtKB:P27038, ECO:0000269|PubMed:10652306, CC ECO:0000269|PubMed:12667445, ECO:0000269|PubMed:17911401, CC ECO:0000269|PubMed:21791611}. CC -!- INTERACTION: CC P27037; Q12959: DLG1; NbExp=2; IntAct=EBI-296189, EBI-357481; CC P27037; P78352: DLG4; NbExp=3; IntAct=EBI-296189, EBI-80389; CC P27037; Q6P0Q8: MAST2; NbExp=3; IntAct=EBI-296189, EBI-493777; CC P27037; Q14160: SCRIB; NbExp=4; IntAct=EBI-296189, EBI-357345; CC P27037; Q96L92: SNX27; NbExp=3; IntAct=EBI-296189, EBI-2514865; CC P27037; Q9WVQ1: Magi2; Xeno; NbExp=2; IntAct=EBI-296189, EBI-297151; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P27038}; CC Single-pass type I membrane protein {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P27037-1; Sequence=Displayed; CC Name=2; CC IsoId=P27037-2; Sequence=VSP_054689; CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/567/ACVR2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X63128; CAA44839.1; -; mRNA. DR EMBL; M93415; AAA35504.1; -; mRNA. DR EMBL; X62381; CAA44245.1; -; mRNA. DR EMBL; D31770; BAA06548.1; -; mRNA. DR EMBL; AK301629; BAG63114.1; -; mRNA. DR EMBL; AK314124; BAG36815.1; -; mRNA. DR EMBL; AC009480; AAX93050.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11561.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11562.1; -; Genomic_DNA. DR EMBL; BC067418; AAH67418.1; -; mRNA. DR EMBL; BC067417; AAH67417.1; -; mRNA. DR EMBL; BC069707; AAH69707.1; -; mRNA. DR CCDS; CCDS33301.1; -. [P27037-1] DR CCDS; CCDS63030.1; -. [P27037-2] DR PIR; JQ1486; JQ1486. DR RefSeq; NP_001265508.1; NM_001278579.2. [P27037-1] DR RefSeq; NP_001265509.1; NM_001278580.2. [P27037-2] DR RefSeq; NP_001607.1; NM_001616.5. [P27037-1] DR RefSeq; XP_047302248.1; XM_047446292.1. [P27037-2] DR RefSeq; XP_054200482.1; XM_054344507.1. [P27037-2] DR PDB; 3Q4T; X-ray; 1.96 A; A/B=191-488. DR PDB; 3SOC; X-ray; 1.95 A; A/B=191-488. DR PDB; 4ASX; X-ray; 2.05 A; A/B=191-488. DR PDB; 5NH3; X-ray; 2.35 A; A/B=20-135. DR PDB; 7U5P; X-ray; 3.14 A; A/C/E/G=1-121. DR PDBsum; 3Q4T; -. DR PDBsum; 3SOC; -. DR PDBsum; 4ASX; -. DR PDBsum; 5NH3; -. DR PDBsum; 7U5P; -. DR AlphaFoldDB; P27037; -. DR SMR; P27037; -. DR BioGRID; 106607; 133. DR CORUM; P27037; -. DR DIP; DIP-520N; -. DR FunCoup; P27037; 1596. DR IntAct; P27037; 92. DR MINT; P27037; -. DR STRING; 9606.ENSP00000241416; -. DR BindingDB; P27037; -. DR ChEMBL; CHEMBL5616; -. DR DrugBank; DB12118; Sotatercept. DR DrugCentral; P27037; -. DR GuidetoPHARMACOLOGY; 1791; -. DR GlyCosmos; P27037; 2 sites, No reported glycans. DR GlyGen; P27037; 2 sites, 2 N-linked glycans (2 sites). DR iPTMnet; P27037; -. DR PhosphoSitePlus; P27037; -. DR BioMuta; ACVR2A; -. DR DMDM; 114722; -. DR jPOST; P27037; -. DR MassIVE; P27037; -. DR PaxDb; 9606-ENSP00000241416; -. DR PeptideAtlas; P27037; -. DR ProteomicsDB; 5369; -. DR ProteomicsDB; 54373; -. [P27037-1] DR ABCD; P27037; 1 sequenced antibody. DR Antibodypedia; 18817; 493 antibodies from 39 providers. DR DNASU; 92; -. DR Ensembl; ENST00000241416.12; ENSP00000241416.7; ENSG00000121989.16. [P27037-1] DR Ensembl; ENST00000404590.1; ENSP00000384338.1; ENSG00000121989.16. [P27037-1] DR Ensembl; ENST00000535787.5; ENSP00000439988.1; ENSG00000121989.16. [P27037-2] DR GeneID; 92; -. DR KEGG; hsa:92; -. DR MANE-Select; ENST00000241416.12; ENSP00000241416.7; NM_001616.5; NP_001607.1. DR UCSC; uc002twg.5; human. [P27037-1] DR AGR; HGNC:173; -. DR ClinPGx; PA24494; -. DR CTD; 92; -. DR DisGeNET; 92; -. DR GeneCards; ACVR2A; -. DR HGNC; HGNC:173; ACVR2A. DR HPA; ENSG00000121989; Low tissue specificity. DR MalaCards; ACVR2A; -. DR MIM; 102581; gene. DR OpenTargets; ENSG00000121989; -. DR VEuPathDB; HostDB:ENSG00000121989; -. DR eggNOG; KOG3653; Eukaryota. DR GeneTree; ENSGT00940000157233; -. DR HOGENOM; CLU_000288_8_4_1; -. DR InParanoid; P27037; -. DR OMA; CNQNFTW; -. DR OrthoDB; 9513784at2759; -. DR PAN-GO; P27037; 6 GO annotations based on evolutionary models. DR PhylomeDB; P27037; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P27037; -. DR Reactome; R-HSA-1181150; Signaling by NODAL. DR Reactome; R-HSA-1433617; Regulation of signaling by NODAL. DR Reactome; R-HSA-1502540; Signaling by Activin. DR Reactome; R-HSA-201451; Signaling by BMP. DR Reactome; R-HSA-9839406; TGFBR3 regulates activin signaling. DR SignaLink; P27037; -. DR SIGNOR; P27037; -. DR Agora; ENSG00000121989; -. DR BioGRID-ORCS; 92; 40 hits in 1181 CRISPR screens. DR ChiTaRS; ACVR2A; human. DR EvolutionaryTrace; P27037; -. DR GeneWiki; ACVR2A; -. DR GenomeRNAi; 92; -. DR Pharos; P27037; Tchem. DR PRO; PR:P27037; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P27037; protein. DR Bgee; ENSG00000121989; Expressed in buccal mucosa cell and 202 other cell types or tissues. DR GO; GO:0048179; C:activin receptor complex; IBA:GO_Central. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:HGNC-UCL. DR GO; GO:0034673; C:inhibin-betaglycan-ActRII complex; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; ISS:UniProt. DR GO; GO:0043235; C:receptor complex; IPI:BHF-UCL. DR GO; GO:0048185; F:activin binding; IEA:Ensembl. DR GO; GO:0017002; F:activin receptor activity; IDA:UniProtKB. DR GO; GO:0016361; F:activin receptor activity, type I; IDA:UniProt. DR GO; GO:0016362; F:activin receptor activity, type II; IDA:UniProt. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0098821; F:BMP receptor activity; ISS:UniProtKB. DR GO; GO:0015026; F:coreceptor activity; IDA:BHF-UCL. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0034711; F:inhibin binding; IEA:Ensembl. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0030165; F:PDZ domain binding; IEA:Ensembl. DR GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0032924; P:activin receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl. DR GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL. DR GO; GO:0007178; P:cell surface receptor protein serine/threonine kinase signaling pathway; TAS:ProtInc. DR GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl. DR GO; GO:0048706; P:embryonic skeletal system development; IEA:Ensembl. DR GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl. DR GO; GO:0007498; P:mesoderm development; IEA:Ensembl. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; IDA:UniProt. DR GO; GO:0007389; P:pattern specification process; IBA:GO_Central. DR GO; GO:0043084; P:penile erection; IEA:Ensembl. DR GO; GO:0032927; P:positive regulation of activin receptor signaling pathway; IDA:HGNC-UCL. DR GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL. DR GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IDA:HGNC-UCL. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:MGI. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0045428; P:regulation of nitric oxide biosynthetic process; IEA:Ensembl. DR GO; GO:0060011; P:Sertoli cell proliferation; IEA:Ensembl. DR GO; GO:0042713; P:sperm ejaculation; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd14141; STKc_ACVR2a; 1. DR CDD; cd23631; TFP_LU_ECD_ACVR2A; 1. DR FunFam; 1.10.510.10:FF:000099; Serine/threonine-protein kinase receptor; 1. DR FunFam; 2.10.60.10:FF:000002; Serine/threonine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000094; Serine/threonine-protein kinase receptor; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000472; Activin_recp. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR PANTHER; PTHR23255:SF64; ACTIVIN RECEPTOR TYPE-2A; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF01064; Activin_recp; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR00653; ACTIVIN2R. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Disulfide bond; Glycoprotein; Kinase; Magnesium; Manganese; Membrane; KW Metal-binding; Nucleotide-binding; Proteomics identification; Receptor; KW Reference proteome; Serine/threonine-protein kinase; Signal; Transferase; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..19 FT /evidence="ECO:0000255" FT CHAIN 20..513 FT /note="Activin receptor type-2A" FT /id="PRO_0000024398" FT TOPO_DOM 20..135 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 136..161 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 162..513 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 192..485 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 322 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 198..206 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 219 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 30..60 FT /evidence="ECO:0000250|UniProtKB:P27038" FT DISULFID 50..78 FT /evidence="ECO:0000250|UniProtKB:P27038" FT DISULFID 85..104 FT /evidence="ECO:0000250|UniProtKB:P27038" FT DISULFID 91..103 FT /evidence="ECO:0000250|UniProtKB:P27038" FT DISULFID 105..110 FT /evidence="ECO:0000250|UniProtKB:P27038" FT VAR_SEQ 1..108 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054689" FT VARIANT 258 FT /note="S -> R (in dbSNP:rs34917571)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032809" FT VARIANT 306 FT /note="D -> N (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs764255410)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032810" FT VARIANT 367 FT /note="A -> T (found in a clear cell renal carcinoma case; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064692" FT CONFLICT 13 FT /note="L -> V (in Ref. 4; BAA06548)" FT /evidence="ECO:0000305" FT CONFLICT 204..206 FT /note="GCV -> PSL (in Ref. 4; BAA06548)" FT /evidence="ECO:0000305" FT CONFLICT 348 FT /note="E -> V (in Ref. 4; BAA06548)" FT /evidence="ECO:0000305" FT CONFLICT 507 FT /note="P -> L (in Ref. 8; AAH67417)" FT /evidence="ECO:0000305" FT STRAND 28..34 FT /evidence="ECO:0007829|PDB:5NH3" FT HELIX 37..40 FT /evidence="ECO:0007829|PDB:5NH3" FT STRAND 44..49 FT /evidence="ECO:0007829|PDB:5NH3" FT STRAND 58..67 FT /evidence="ECO:0007829|PDB:5NH3" FT STRAND 70..80 FT /evidence="ECO:0007829|PDB:5NH3" FT HELIX 83..85 FT /evidence="ECO:0007829|PDB:7U5P" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:5NH3" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:5NH3" FT HELIX 110..112 FT /evidence="ECO:0007829|PDB:5NH3" FT STRAND 191..199 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 205..211 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 214..221 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 226..236 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 249..256 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 258..268 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 275..281 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 286..303 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 307..310 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 313..315 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 317..319 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 327..330 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 336..338 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 363..365 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 368..371 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 379..398 FT /evidence="ECO:0007829|PDB:3SOC" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 416..419 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 425..432 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 443..446 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 449..461 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 466..468 FT /evidence="ECO:0007829|PDB:3SOC" FT HELIX 472..485 FT /evidence="ECO:0007829|PDB:3SOC" SQ SEQUENCE 513 AA; 57848 MW; A89822E880979618 CRC64; MGAAAKLAFA VFLISCSSGA ILGRSETQEC LFFNANWEKD RTNQTGVEPC YGDKDKRRHC FATWKNISGS IEIVKQGCWL DDINCYDRTD CVEKKDSPEV YFCCCEGNMC NEKFSYFPEM EVTQPTSNPV TPKPPYYNIL LYSLVPLMLI AGIVICAFWV YRHHKMAYPP VLVPTQDPGP PPPSPLLGLK PLQLLEVKAR GRFGCVWKAQ LLNEYVAVKI FPIQDKQSWQ NEYEVYSLPG MKHENILQFI GAEKRGTSVD VDLWLITAFH EKGSLSDFLK ANVVSWNELC HIAETMARGL AYLHEDIPGL KDGHKPAISH RDIKSKNVLL KNNLTACIAD FGLALKFEAG KSAGDTHGQV GTRRYMAPEV LEGAINFQRD AFLRIDMYAM GLVLWELASR CTAADGPVDE YMLPFEEEIG QHPSLEDMQE VVVHKKKRPV LRDYWQKHAG MAMLCETIEE CWDHDAEARL SAGCVGERIT QMQRLTNIIT TEDIVTVVTM VTNVDFPPKE SSL // ID BMR1A_HUMAN Reviewed; 532 AA. AC P36894; A8K6U9; Q8NEN8; DT 01-JUN-1994, integrated into UniProtKB/Swiss-Prot. DT 15-MAR-2005, sequence version 2. DT 28-JAN-2026, entry version 257. DE RecName: Full=Bone morphogenetic protein receptor type-1A; DE Short=BMP type-1A receptor; DE Short=BMPR-1A; DE EC=2.7.11.30; DE AltName: Full=Activin receptor-like kinase 3; DE Short=ALK-3; DE AltName: Full=Serine/threonine-protein kinase receptor R5; DE Short=SKR5; DE AltName: CD_antigen=CD292; DE Flags: Precursor; GN Name=BMPR1A; Synonyms=ACVRLK3, ALK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-2. RC TISSUE=Placenta; RX PubMed=8397373; RA ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H., RA Heldin C.-H., Miyazono K.; RT "Activin receptor-like kinases: a novel subclass of cell-surface receptors RT with predicted serine/threonine kinase activity."; RL Oncogene 8:2879-2887(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-2. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INTERACTION WITH BMP4. RX PubMed=8006002; DOI=10.1016/s0021-9258(17)32506-1; RA ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., RA Riddle D.L., Ichijo H., Heldin C.H., Miyazono K.; RT "Identification of type I receptors for osteogenic protein-1 and bone RT morphogenetic protein-4."; RL J. Biol. Chem. 269:16985-16988(1994). RN [5] RP INTERACTION WITH TGFBR3, AND SUBCELLULAR LOCATION. RX PubMed=19726563; DOI=10.1091/mbc.e09-07-0539; RA Lee N.Y., Kirkbride K.C., Sheu R.D., Blobe G.C.; RT "The transforming growth factor-beta type III receptor mediates distinct RT subcellular trafficking and downstream signaling of activin-like kinase RT (ALK)3 and ALK6 receptors."; RL Mol. Biol. Cell 20:4362-4370(2009). RN [6] RP INTERACTION WITH TSC22D1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [7] RP INTERACTION WITH BMP2, AND MUTAGENESIS OF 107-ASP--GLN-109. RX PubMed=22799562; DOI=10.1021/bi300942x; RA Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.; RT "Structure of the Alk1 extracellular domain and characterization of its RT bone morphogenetic protein (BMP) binding properties."; RL Biochemistry 51:6328-6341(2012). RN [8] RP INTERACTION WITH GDF5. RX PubMed=24098149; DOI=10.1371/journal.pgen.1003846; RA Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C., Nickel J., RA Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T., Mundlos S., RA Doelken S.C., Seemann P.; RT "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2."; RL PLoS Genet. 9:E1003846-E1003846(2013). RN [9] RP INTERACTION WITH BMP2 AND BMP6. RX PubMed=31800957; DOI=10.1182/blood.2019002620; RA Wang C.Y., Xu Y., Traeger L., Dogan D.Y., Xiao X., Steinbicker A.U., RA Babitt J.L.; RT "Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from RT binding to the BMP type I receptor ALK3."; RL Blood 135:453-456(2020). RN [10] RP INTERACTION WITH SCUBE3. RX PubMed=33308444; DOI=10.1016/j.ajhg.2020.11.015; RG Genomics England Research Consortium; RA Lin Y.C., Niceta M., Muto V., Vona B., Pagnamenta A.T., Maroofian R., RA Beetz C., van Duyvenvoorde H., Dentici M.L., Lauffer P., Vallian S., RA Ciolfi A., Pizzi S., Bauer P., Gruening N.M., Bellacchio E., RA Del Fattore A., Petrini S., Shaheen R., Tiosano D., Halloun R., RA Pode-Shakked B., Albayrak H.M., Isik E., Wit J.M., Dittrich M., RA Freire B.L., Bertola D.R., Jorge A.A.L., Barel O., Sabir A.H., RA Al Tenaiji A.M.J., Taji S.M., Al-Sannaa N., Al-Abdulwahed H., Digilio M.C., RA Irving M., Anikster Y., Bhavani G.S.L., Girisha K.M., Haaf T., Taylor J.C., RA Dallapiccola B., Alkuraya F.S., Yang R.B., Tartaglia M.; RT "SCUBE3 loss-of-function causes a recognizable recessive developmental RT disorder due to defective bone morphogenetic protein signaling."; RL Am. J. Hum. Genet. 108:115-133(2021). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 55-143 IN COMPLEX WITH BMP2, RP DISULFIDE BOND, AND INTERACTION WITH BMP2. RX PubMed=10881198; DOI=10.1038/75903; RA Kirsch T., Sebald W., Dreyer M.K.; RT "Crystal structure of the BMP-2-BRIA ectodomain complex."; RL Nat. Struct. Biol. 7:492-496(2000). RN [12] {ECO:0007744|PDB:1REW} RP X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 24-152, AND INTERACTION WITH RP BMP2. RX PubMed=15064755; DOI=10.1038/nsmb756; RA Keller S., Nickel J., Zhang J.L., Sebald W., Mueller T.D.; RT "Molecular recognition of BMP-2 and BMP receptor IA."; RL Nat. Struct. Mol. Biol. 11:481-488(2004). RN [13] {ECO:0007744|PDB:2H62, ECO:0007744|PDB:2H64} RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 24-152, AND INTERACTION WITH RP BMP2. RX PubMed=17295905; DOI=10.1186/1472-6807-7-6; RA Weber D., Kotzsch A., Nickel J., Harth S., Seher A., Mueller U., Sebald W., RA Mueller T.D.; RT "A silent H-bond can be mutationally activated for high-affinity RT interaction of BMP-2 and activin type IIB receptor."; RL BMC Struct. Biol. 7:6-6(2007). RN [14] RP DISEASE. RX PubMed=11381269; DOI=10.1038/88919; RA Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., RA Petersen G.M., Velculescu V.E., Traverso G., Vogelstein B.; RT "Germline mutations of the gene encoding bone morphogenetic protein RT receptor 1A in juvenile polyposis."; RL Nat. Genet. 28:184-187(2001). RN [15] RP STRUCTURE BY NMR OF 51-152, DISULFIDE BONDS, AND INTERACTION WITH BMP2. RX PubMed=18937504; DOI=10.1021/bi801059j; RA Klages J., Kotzsch A., Coles M., Sebald W., Nickel J., Muller T., RA Kessler H.; RT "The solution structure of BMPR-IA reveals a local disorder-to-order RT transition upon BMP-2 binding."; RL Biochemistry 47:11930-11939(2008). RN [16] RP VARIANTS JPS ARG-124; ASP-338 AND TYR-376. RX PubMed=11536076; DOI=10.1086/323703; RA Zhou X.-P., Woodford-Richens K., Lehtonen R., Kurose K., Aldred M., RA Hampel H., Launonen V., Virta S., Pilarski R., Salovaara R., Bodmer W.F., RA Conrad B.A., Dunlop M., Hodgson S.V., Iwama T., Jaervinen H., RA Kellokumpu I., Kim J.C., Leggett B., Markie D., Mecklin J.-P., Neale K., RA Phillips R., Piris J., Rozen P., Houlston R.S., Aaltonen L.A., RA Tomlinson I.P.M., Eng C.; RT "Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile RT polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes."; RL Am. J. Hum. Genet. 69:704-711(2001). RN [17] RP VARIANTS JPS ASP-62; TYR-82 AND CYS-443. RX PubMed=12417513; DOI=10.1007/bf02557528; RA Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L., RA Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M., RA Vogelstein B., Howe J.R.; RT "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis."; RL Ann. Surg. Oncol. 9:901-906(2002). RN [18] RP VARIANT JPS ARG-130. RX PubMed=12136244; DOI=10.1007/s00439-002-0748-9; RA Friedl W., Uhlhaas S., Schulmann K., Stolte M., Loff S., Back W., RA Mangold E., Stern M., Knaebel H.P., Sutter C., Weber R.G., Pistorius S., RA Burger B., Propping P.; RT "Juvenile polyposis: massive gastric polyposis is more common in MADH4 RT mutation carriers than in BMPR1A mutation carriers."; RL Hum. Genet. 111:108-111(2002). RN [19] RP VARIANT JPS THR-470. RX PubMed=12630959; DOI=10.1034/j.1399-0004.2003.00008.x; RA Kim I.J., Park J.H., Kang H.C., Kim K.H., Kim J.H., Ku J.L., Kang S.B., RA Park S.Y., Lee J.S., Park J.G.; RT "Identification of a novel BMPR1A germline mutation in a Korean juvenile RT polyposis patient without SMAD4 mutation."; RL Clin. Genet. 63:126-130(2003). RN [20] RP INVOLVEMENT IN JUVENILE POLYPOSIS OF INFANCY. RX PubMed=16685657; DOI=10.1086/504301; RA Delnatte C., Sanlaville D., Mougenot J.-F., Vermeesch J.-R., Houdayer C., RA Blois M.-C., Genevieve D., Goulet O., Fryns J.-P., Jaubert F., Vekemans M., RA Lyonnet S., Romana S., Eng C., Stoppa-Lyonnet D.; RT "Contiguous gene deletion within chromosome arm 10q is associated with RT juvenile polyposis of infancy, reflecting cooperation between the BMPR1A RT and PTEN tumor-suppressor genes."; RL Am. J. Hum. Genet. 78:1066-1074(2006). RN [21] RP INVOLVEMENT IN HMPS2. RX PubMed=16525031; DOI=10.1136/jmg.2005.034827; RA Cao X., Eu K.W., Kumarasinghe M.P., Li H.H., Loi C., Cheah P.Y.; RT "Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 RT by genomewide high-density single nucleotide polymorphism (SNP) scan and RT identification of BMPR1A loss of function."; RL J. Med. Genet. 43:E13-E13(2006). RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] THR-2; TYR-58; CYS-443; MET-450 AND RP GLN-486. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP VARIANT THR-460. RX PubMed=25860647; DOI=10.1007/s10689-015-9803-2; RA Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E., Steinsbekk K.S., RA Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.; RT "A novel POLE mutation associated with cancers of colon, pancreas, ovaries RT and small intestine."; RL Fam. Cancer 14:437-448(2015). CC -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two CC type II and two type I transmembrane serine/threonine kinases. Type II CC receptors phosphorylate and activate type I receptors which CC autophosphorylate, then bind and activate SMAD transcriptional CC regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively CC regulates chondrocyte differentiation through GDF5 interaction. CC Mediates induction of adipogenesis by GDF6. May promote the expression CC of HAMP, potentially via its interaction with BMP2 (By similarity). CC {ECO:0000250|UniProtKB:P36895}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with low affinity with GDF5; positively regulates CC chondrocyte differentiation (PubMed:24098149). Interacts with BMP4 CC (PubMed:8006002). Interacts with SCUBE3 (PubMed:33308444). Interacts CC with TSC22D1/TSC-22 (PubMed:21791611). Interacts with BMP2; the CC interaction may induce HAMP expression (PubMed:10881198, CC PubMed:15064755, PubMed:17295905, PubMed:18937504, PubMed:31800957). CC Interacts with BMP6 (PubMed:31800957). Interacts with heterodimers CC composed of BMP2 and BMP6 in vitro; the interaction may induce HAMP CC expression (PubMed:31800957). Interacts with TGFBR3 (PubMed:19726563). CC {ECO:0000269|PubMed:10881198, ECO:0000269|PubMed:15064755, CC ECO:0000269|PubMed:17295905, ECO:0000269|PubMed:18937504, CC ECO:0000269|PubMed:19726563, ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:24098149, ECO:0000269|PubMed:31800957, CC ECO:0000269|PubMed:33308444, ECO:0000269|PubMed:8006002}. CC -!- INTERACTION: CC P36894; P12643: BMP2; NbExp=17; IntAct=EBI-1029237, EBI-1029262; CC P36894; P12644: BMP4; NbExp=2; IntAct=EBI-1029237, EBI-1998134; CC P36894; P43026: GDF5; NbExp=4; IntAct=EBI-1029237, EBI-8571476; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19726563}; CC Single-pass type I membrane protein {ECO:0000255}. Cell surface CC {ECO:0000250|UniProtKB:P36895}. CC -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle. CC -!- PTM: Glycosylated. {ECO:0000250|UniProtKB:P36895}. CC -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal CC dominant gastrointestinal hamartomatous polyposis syndrome in which CC patients are at risk for developing gastrointestinal cancers. The CC lesions are typified by a smooth histological appearance, predominant CC stroma, cystic spaces and lack of a smooth muscle core. Multiple CC juvenile polyps usually occur in a number of Mendelian disorders. CC Sometimes, these polyps occur without associated features as in JPS; CC here, polyps tend to occur in the large bowel and are associated with CC an increased risk of colon and other gastrointestinal cancers. CC {ECO:0000269|PubMed:11536076, ECO:0000269|PubMed:12136244, CC ECO:0000269|PubMed:12417513, ECO:0000269|PubMed:12630959}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Polyposis syndrome, mixed hereditary 2 (HMPS2) [MIM:610069]: A CC disease is characterized by atypical juvenile polyps, colonic adenomas, CC and colorectal carcinomas. {ECO:0000269|PubMed:16525031}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC {ECO:0000269|PubMed:11381269, ECO:0000269|PubMed:16525031}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z22535; CAA80257.1; -; mRNA. DR EMBL; AK291764; BAF84453.1; -; mRNA. DR EMBL; BC028383; AAH28383.1; -; mRNA. DR CCDS; CCDS7378.1; -. DR PIR; I37163; I37163. DR RefSeq; NP_001393490.1; NM_001406561.1. DR RefSeq; NP_001393491.1; NM_001406562.1. DR RefSeq; NP_001393492.1; NM_001406563.1. DR RefSeq; NP_001393493.1; NM_001406564.1. DR RefSeq; NP_001393494.1; NM_001406565.1. DR RefSeq; NP_001393495.1; NM_001406566.1. DR RefSeq; NP_001393496.1; NM_001406567.1. DR RefSeq; NP_001393497.1; NM_001406568.1. DR RefSeq; NP_001393498.1; NM_001406569.1. DR RefSeq; NP_001393499.1; NM_001406570.1. DR RefSeq; NP_001393500.1; NM_001406571.1. DR RefSeq; NP_001393501.1; NM_001406572.1. DR RefSeq; NP_001393502.1; NM_001406573.1. DR RefSeq; NP_001393503.1; NM_001406574.1. DR RefSeq; NP_001393504.1; NM_001406575.1. DR RefSeq; NP_001393505.1; NM_001406576.1. DR RefSeq; NP_001393506.1; NM_001406577.1. DR RefSeq; NP_001393507.1; NM_001406578.1. DR RefSeq; NP_001393508.1; NM_001406579.1. DR RefSeq; NP_001393509.1; NM_001406580.1. DR RefSeq; NP_001393510.1; NM_001406581.1. DR RefSeq; NP_001393511.1; NM_001406582.1. DR RefSeq; NP_004320.2; NM_004329.2. DR RefSeq; XP_047281636.1; XM_047425680.1. DR RefSeq; XP_054222620.1; XM_054366645.1. DR PDB; 1ES7; X-ray; 2.90 A; B/D=55-143. DR PDB; 1REW; X-ray; 1.86 A; C/D=24-152. DR PDB; 2GOO; X-ray; 2.20 A; B/E=24-152. DR PDB; 2H62; X-ray; 1.85 A; C=24-152. DR PDB; 2H64; X-ray; 1.92 A; B=24-152. DR PDB; 2K3G; NMR; -; A=51-152. DR PDB; 2QJ9; X-ray; 2.44 A; C/D=24-152. DR PDB; 2QJA; X-ray; 2.60 A; C/D=24-152. DR PDB; 2QJB; X-ray; 2.50 A; C/D=24-152. DR PDB; 3NH7; X-ray; 2.70 A; A/B/C/D=24-152. DR PDB; 3QB4; X-ray; 2.28 A; B/D=24-152. DR PDBsum; 1ES7; -. DR PDBsum; 1REW; -. DR PDBsum; 2GOO; -. DR PDBsum; 2H62; -. DR PDBsum; 2H64; -. DR PDBsum; 2K3G; -. DR PDBsum; 2QJ9; -. DR PDBsum; 2QJA; -. DR PDBsum; 2QJB; -. DR PDBsum; 3NH7; -. DR PDBsum; 3QB4; -. DR AlphaFoldDB; P36894; -. DR BMRB; P36894; -. DR SMR; P36894; -. DR BioGRID; 107125; 266. DR CORUM; P36894; -. DR DIP; DIP-5793N; -. DR FunCoup; P36894; 1712. DR IntAct; P36894; 128. DR MINT; P36894; -. DR STRING; 9606.ENSP00000361107; -. DR BindingDB; P36894; -. DR ChEMBL; CHEMBL5275; -. DR DrugBank; DB11639; Dibotermin alfa. DR DrugCentral; P36894; -. DR GuidetoPHARMACOLOGY; 1786; -. DR GlyCosmos; P36894; 1 site, No reported glycans. DR GlyGen; P36894; 2 sites. DR iPTMnet; P36894; -. DR PhosphoSitePlus; P36894; -. DR SwissPalm; P36894; -. DR BioMuta; BMPR1A; -. DR DMDM; 61252444; -. DR jPOST; P36894; -. DR MassIVE; P36894; -. DR PaxDb; 9606-ENSP00000361107; -. DR PeptideAtlas; P36894; -. DR ProteomicsDB; 55228; -. DR ABCD; P36894; 1 sequenced antibody. DR Antibodypedia; 4524; 791 antibodies from 39 providers. DR DNASU; 657; -. DR Ensembl; ENST00000372037.8; ENSP00000361107.2; ENSG00000107779.17. DR Ensembl; ENST00000480152.3; ENSP00000483569.2; ENSG00000107779.17. DR Ensembl; ENST00000635816.2; ENSP00000489707.1; ENSG00000107779.17. DR Ensembl; ENST00000636056.2; ENSP00000490273.1; ENSG00000107779.17. DR Ensembl; ENST00000638429.1; ENSP00000492290.1; ENSG00000107779.17. DR Ensembl; ENST00000713672.1; ENSP00000518974.1; ENSG00000107779.17. DR Ensembl; ENST00000713675.1; ENSP00000518977.1; ENSG00000107779.17. DR GeneID; 657; -. DR KEGG; hsa:657; -. DR MANE-Select; ENST00000372037.8; ENSP00000361107.2; NM_004329.3; NP_004320.2. DR UCSC; uc001kdy.4; human. DR AGR; HGNC:1076; -. DR ClinPGx; PA25386; -. DR CTD; 657; -. DR DisGeNET; 657; -. DR GeneCards; BMPR1A; -. DR GeneReviews; BMPR1A; -. DR HGNC; HGNC:1076; BMPR1A. DR HPA; ENSG00000107779; Low tissue specificity. DR MalaCards; BMPR1A; -. DR MIM; 174900; phenotype. DR MIM; 601299; gene. DR MIM; 610069; phenotype. DR MIM; 612242; phenotype. DR OpenTargets; ENSG00000107779; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli. DR Orphanet; 157794; Hereditary mixed polyposis syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR VEuPathDB; HostDB:ENSG00000107779; -. DR eggNOG; KOG2052; Eukaryota. DR GeneTree; ENSGT00940000156225; -. DR HOGENOM; CLU_000288_8_1_1; -. DR InParanoid; P36894; -. DR OMA; GSCPNNV; -. DR OrthoDB; 69842at2759; -. DR PAN-GO; P36894; 8 GO annotations based on evolutionary models. DR PhylomeDB; P36894; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P36894; -. DR Reactome; R-HSA-201451; Signaling by BMP. DR SignaLink; P36894; -. DR SIGNOR; P36894; -. DR Agora; ENSG00000107779; -. DR BioGRID-ORCS; 657; 88 hits in 1193 CRISPR screens. DR ChiTaRS; BMPR1A; human. DR EvolutionaryTrace; P36894; -. DR GeneWiki; BMPR1A; -. DR GenomeRNAi; 657; -. DR Pharos; P36894; Tchem. DR PRO; PR:P36894; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P36894; protein. DR Bgee; ENSG00000107779; Expressed in secondary oocyte and 211 other cell types or tissues. DR ExpressionAtlas; P36894; baseline and differential. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL. DR GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL. DR GO; GO:0036122; F:BMP binding; IPI:BHF-UCL. DR GO; GO:0098821; F:BMP receptor activity; IDA:ARUK-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL. DR GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL. DR GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IDA:UniProt. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0001525; P:angiogenesis; IMP:BHF-UCL. DR GO; GO:1990262; P:anti-Mullerian hormone receptor signaling pathway; IDA:UniProt. DR GO; GO:0060928; P:atrioventricular node cell development; ISS:BHF-UCL. DR GO; GO:0003171; P:atrioventricular valve development; ISS:BHF-UCL. DR GO; GO:0030509; P:BMP signaling pathway; IDA:HGNC-UCL. DR GO; GO:0003161; P:cardiac conduction system development; ISS:BHF-UCL. DR GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0048589; P:developmental growth; IEA:Ensembl. DR GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL. DR GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl. DR GO; GO:0009953; P:dorsal/ventral pattern formation; IBA:GO_Central. DR GO; GO:0007398; P:ectoderm development; IEA:Ensembl. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; ISS:BHF-UCL. DR GO; GO:0003272; P:endocardial cushion formation; ISS:BHF-UCL. DR GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:1905285; P:fibrous ring of heart morphogenesis; ISS:BHF-UCL. DR GO; GO:0060914; P:heart formation; IEA:Ensembl. DR GO; GO:0035137; P:hindlimb morphogenesis; IEA:Ensembl. DR GO; GO:0006955; P:immune response; IMP:BHF-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0048368; P:lateral mesoderm development; IEA:Ensembl. DR GO; GO:0030324; P:lung development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0048382; P:mesendoderm development; IEA:Ensembl. DR GO; GO:0001707; P:mesoderm formation; IEA:Ensembl. DR GO; GO:0003183; P:mitral valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001880; P:Mullerian duct regression; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; ISS:BHF-UCL. DR GO; GO:0051148; P:negative regulation of muscle cell differentiation; IEA:Ensembl. DR GO; GO:0050768; P:negative regulation of neurogenesis; IEA:Ensembl. DR GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IMP:BHF-UCL. DR GO; GO:0014032; P:neural crest cell development; IEA:Ensembl. DR GO; GO:0021998; P:neural plate mediolateral regionalization; IEA:Ensembl. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0048352; P:paraxial mesoderm structural organization; IEA:Ensembl. DR GO; GO:0061626; P:pharyngeal arch artery morphogenesis; ISS:BHF-UCL. DR GO; GO:0021983; P:pituitary gland development; IEA:Ensembl. DR GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL. DR GO; GO:1904414; P:positive regulation of cardiac ventricle development; ISS:BHF-UCL. DR GO; GO:1900006; P:positive regulation of dendrite development; TAS:UniProt. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0032915; P:positive regulation of transforming growth factor beta2 production; ISS:BHF-UCL. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0060043; P:regulation of cardiac muscle cell proliferation; ISS:BHF-UCL. DR GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IEA:Ensembl. DR GO; GO:0060021; P:roof of mouth development; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0048863; P:stem cell differentiation; ISS:UniProt. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:FlyBase. DR GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0003223; P:ventricular compact myocardium morphogenesis; ISS:BHF-UCL. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL. DR CDD; cd14220; STKc_BMPR1a; 1. DR CDD; cd23612; TFP_LU_ECD_BMPR1A; 1. DR DisProt; DP01990; -. DR FunFam; 1.10.510.10:FF:000018; Receptor protein serine/threonine kinase; 1. DR FunFam; 2.10.60.10:FF:000001; Receptor protein serine/threonine kinase; 1. DR FunFam; 3.30.200.20:FF:000055; Receptor protein serine/threonine kinase; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000472; Activin_recp. DR InterPro; IPR003605; GS_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR PANTHER; PTHR23255:SF50; BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1A; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF01064; Activin_recp; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF08515; TGF_beta_GS; 1. DR SMART; SM00467; GS; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS51256; GS; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell membrane; Disease variant; Disulfide bond; KW Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding; KW Nucleotide-binding; Proteomics identification; Receptor; KW Reference proteome; Serine/threonine-protein kinase; Signal; Transferase; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..532 FT /note="Bone morphogenetic protein receptor type-1A" FT /id="PRO_0000024410" FT TOPO_DOM 24..152 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 153..176 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 177..532 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 204..233 FT /note="GS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00585" FT DOMAIN 234..525 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 107..109 FT /note="Mediates specificity for BMP ligand" FT /evidence="ECO:0000269|PubMed:22799562" FT ACT_SITE 362 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 240..248 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT CARBOHYD 73 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..82 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 63..67 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 76..100 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 110..124 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 125..130 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT VARIANT 2 FT /note="P -> T (in dbSNP:rs11528010)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8397373" FT /id="VAR_041397" FT VARIANT 58 FT /note="F -> Y (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041398" FT VARIANT 62 FT /note="Y -> D (in JPS)" FT /evidence="ECO:0000269|PubMed:12417513" FT /id="VAR_022828" FT VARIANT 82 FT /note="C -> Y (in JPS)" FT /evidence="ECO:0000269|PubMed:12417513" FT /id="VAR_022829" FT VARIANT 124 FT /note="C -> R (in JPS; dbSNP:rs199476087)" FT /evidence="ECO:0000269|PubMed:11536076" FT /id="VAR_015533" FT VARIANT 130 FT /note="C -> R (in JPS; dbSNP:rs1131691168)" FT /evidence="ECO:0000269|PubMed:12136244" FT /id="VAR_022830" FT VARIANT 338 FT /note="A -> D (in JPS; dbSNP:rs199476086)" FT /evidence="ECO:0000269|PubMed:11536076" FT /id="VAR_015534" FT VARIANT 376 FT /note="C -> Y (in JPS; dbSNP:rs199476088)" FT /evidence="ECO:0000269|PubMed:11536076" FT /id="VAR_015535" FT VARIANT 443 FT /note="R -> C (in JPS; dbSNP:rs35619497)" FT /evidence="ECO:0000269|PubMed:12417513, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022831" FT VARIANT 450 FT /note="V -> M (in dbSNP:rs55932635)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041399" FT VARIANT 460 FT /note="M -> T (found in a patient with tubular adenoma and FT rectal neuroendocrine tumor; uncertain significance; FT dbSNP:rs758309022)" FT /evidence="ECO:0000269|PubMed:25860647" FT /id="VAR_077353" FT VARIANT 470 FT /note="M -> T (in JPS; dbSNP:rs199476089)" FT /evidence="ECO:0000269|PubMed:12630959" FT /id="VAR_022832" FT VARIANT 486 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs752802257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041400" FT MUTAGEN 107..109 FT /note="DFQ->REL: Affinity for BMP2 decreased by over 200- FT fold." FT /evidence="ECO:0000269|PubMed:22799562" FT STRAND 59..62 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 64..66 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 75..88 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 90..92 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 94..101 FT /evidence="ECO:0007829|PDB:2H62" FT HELIX 106..111 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 116..118 FT /evidence="ECO:0007829|PDB:2QJA" FT STRAND 120..125 FT /evidence="ECO:0007829|PDB:2H62" FT HELIX 130..133 FT /evidence="ECO:0007829|PDB:2H62" SQ SEQUENCE 532 AA; 60198 MW; 00CE2DDDA3A44170 CRC64; MPQLYIYIRL LGAYLFIISR VQGQNLDSML HGTGMKSDSD QKKSENGVTL APEDTLPFLK CYCSGHCPDD AINNTCITNG HCFAIIEEDD QGETTLASGC MKYEGSDFQC KDSPKAQLRR TIECCRTNLC NQYLQPTLPP VVIGPFFDGS IRWLVLLISM AVCIIAMIIF SSCFCYKHYC KSISSRRRYN RDLEQDEAFI PVGESLKDLI DQSQSSGSGS GLPLLVQRTI AKQIQMVRQV GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDF LKCATLDTRA LLKLAYSAAC GLCHLHTEIY GTQGKPAIAH RDLKSKNILI KKNGSCCIAD LGLAVKFNSD TNEVDVPLNT RVGTKRYMAP EVLDESLNKN HFQPYIMADI YSFGLIIWEM ARRCITGGIV EEYQLPYYNM VPSDPSYEDM REVVCVKRLR PIVSNRWNSD ECLRAVLKLM SECWAHNPAS RLTALRIKKT LAKMVESQDV KI // ID BMR1B_HUMAN Reviewed; 502 AA. AC O00238; B2R953; B4DSV1; P78366; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1997, sequence version 1. DT 28-JAN-2026, entry version 235. DE RecName: Full=Bone morphogenetic protein receptor type-1B; DE Short=BMP type-1B receptor; DE Short=BMPR-1B; DE EC=2.7.11.30 {ECO:0000250|UniProtKB:P36898}; DE AltName: CD_antigen=CDw293; DE Flags: Precursor; GN Name=BMPR1B; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Prostate; RX PubMed=9178898; DOI=10.1038/sj.onc.1200964; RA Ide H., Katoh M., Sasaki H., Yoshida T., Aoki K., Nawa Y., Osada Y., RA Sugimura T., Terada M.; RT "Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and RT its expression in prostate cancer in comparison with other BMPRs."; RL Oncogene 14:1377-1382(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Ovary; RX PubMed=10051328; DOI=10.1007/s003359900990; RA Astroem A.-K., Jin D.F., Imamura T., Roijer E., Rosenzweig B., Miyazono K., RA ten Dijke P., Stenman G.; RT "Chromosomal localization of three human genes encoding bone morphogenetic RT protein receptors."; RL Mamm. Genome 10:299-302(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=PNS; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP INTERACTION WITH TGFBR3, AND SUBCELLULAR LOCATION. RX PubMed=19726563; DOI=10.1091/mbc.e09-07-0539; RA Lee N.Y., Kirkbride K.C., Sheu R.D., Blobe G.C.; RT "The transforming growth factor-beta type III receptor mediates distinct RT subcellular trafficking and downstream signaling of activin-like kinase RT (ALK)3 and ALK6 receptors."; RL Mol. Biol. Cell 20:4362-4370(2009). RN [8] RP INTERACTION WITH TSC22D1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [9] RP INTERACTION WITH GDF5. RX PubMed=24098149; DOI=10.1371/journal.pgen.1003846; RA Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C., Nickel J., RA Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T., Mundlos S., RA Doelken S.C., Seemann P.; RT "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2."; RL PLoS Genet. 9:E1003846-E1003846(2013). RN [10] RP INTERACTION WITH SCUBE3. RX PubMed=33308444; DOI=10.1016/j.ajhg.2020.11.015; RG Genomics England Research Consortium; RA Lin Y.C., Niceta M., Muto V., Vona B., Pagnamenta A.T., Maroofian R., RA Beetz C., van Duyvenvoorde H., Dentici M.L., Lauffer P., Vallian S., RA Ciolfi A., Pizzi S., Bauer P., Gruening N.M., Bellacchio E., RA Del Fattore A., Petrini S., Shaheen R., Tiosano D., Halloun R., RA Pode-Shakked B., Albayrak H.M., Isik E., Wit J.M., Dittrich M., RA Freire B.L., Bertola D.R., Jorge A.A.L., Barel O., Sabir A.H., RA Al Tenaiji A.M.J., Taji S.M., Al-Sannaa N., Al-Abdulwahed H., Digilio M.C., RA Irving M., Anikster Y., Bhavani G.S.L., Girisha K.M., Haaf T., Taylor J.C., RA Dallapiccola B., Alkuraya F.S., Yang R.B., Tartaglia M.; RT "SCUBE3 loss-of-function causes a recognizable recessive developmental RT disorder due to defective bone morphogenetic protein signaling."; RL Am. J. Hum. Genet. 108:115-133(2021). RN [11] RP VARIANTS BDA2 LYS-200 AND TRP-486, AND CHARACTERIZATION OF VARIANTS BDA2 RP LYS-200 AND TRP-486. RX PubMed=14523231; DOI=10.1073/pnas.2133476100; RA Lehmann K., Seemann P., Stricker S., Sammar M., Meyer B., Suering K., RA Majewski F., Tinschert S., Grzeschik K.-H., Mueller D., Knaus P., RA Nuernberg P., Mundlos S.; RT "Mutations in bone morphogenetic protein receptor 1B cause brachydactyly RT type A2."; RL Proc. Natl. Acad. Sci. U.S.A. 100:12277-12282(2003). RN [12] RP INVOLVEMENT IN AMD3. RX PubMed=15805157; DOI=10.1136/jmg.2004.023564; RA Demirhan O., Tuerkmen S., Schwabe G.C., Soyupak S., Akguel E., Tastemir D., RA Karahan D., Mundlos S., Lehmann K.; RT "A homozygous BMPR1B mutation causes a new subtype of acromesomelic RT chondrodysplasia with genital anomalies."; RL J. Med. Genet. 42:314-317(2005). RN [13] RP VARIANT BRACHYDACTYLY TYPE C/BDA2 GLN-486. RX PubMed=16957682; DOI=10.1038/sj.ejhg.5201708; RA Lehmann K., Seemann P., Boergermann J., Morin G., Reif S., Knaus P., RA Mundlos S.; RT "A novel R486Q mutation in BMPR1B resulting in either a brachydactyly type RT C/symphalangism-like phenotype or brachydactyly type A2."; RL Eur. J. Hum. Genet. 14:1248-1254(2006). RN [14] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-31; TRP-149; HIS-224; ASN-297 AND RP GLN-371. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [15] RP VARIANT AMD3 ARG-53, AND CHARACTERIZATION OF VARIANT AMD3 ARG-53. RX PubMed=24129431; DOI=10.1038/ejhg.2013.222; RA Graul-Neumann L.M., Deichsel A., Wille U., Kakar N., Koll R., Bassir C., RA Ahmad J., Cormier-Daire V., Mundlos S., Kubisch C., Borck G., Klopocki E., RA Mueller T.D., Doelken S.C., Seemann P.; RT "Homozygous missense and nonsense mutations in BMPR1B cause acromesomelic RT chondrodysplasia-type Grebe."; RL Eur. J. Hum. Genet. 22:726-733(2014). RN [16] RP INVOLVEMENT IN BDA1D, VARIANT BDA1D ASN-325, AND CHARACTERIZATION OF RP VARIANT BDA1D ASN-325. RX PubMed=25758993; DOI=10.1038/ejhg.2015.38; RA Racacho L., Byrnes A.M., MacDonald H., Dranse H.J., Nikkel S.M., RA Allanson J., Rosser E., Underhill T.M., Bulman D.E.; RT "Two novel disease-causing variants in BMPR1B are associated with RT brachydactyly type A1."; RL Eur. J. Hum. Genet. 23:1640-1645(2015). RN [17] RP VARIANT AMD3 CYS-31, AND CHARACTERIZATION OF VARIANT AMD3 CYS-31. RX PubMed=26105076; DOI=10.1186/s13023-015-0299-5; RA Stange K., Desir J., Kakar N., Mueller T.D., Budde B.S., Gordon C.T., RA Horn D., Seemann P., Borck G.; RT "A hypomorphic BMPR1B mutation causes du Pan acromesomelic dysplasia."; RL Orphanet J. Rare Dis. 10:84-84(2015). CC -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two CC type II and two type I transmembrane serine/threonine kinases. Type II CC receptors phosphorylate and activate type I receptors which CC autophosphorylate, then bind and activate SMAD transcriptional CC regulators. Receptor for BMP7/OP-1 and GDF5. Positively regulates CC chondrocyte differentiation through GDF5 interaction. CC {ECO:0000250|UniProtKB:P36898}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44881; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18674; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with high affinity with GDF5; positively regulates CC chondrocyte differentiation (PubMed:24098149). Interacts with SCUBE3 CC (PubMed:33308444). Interacts with TSC22D1/TSC-22 (PubMed:21791611). CC Interacts with TGFBR3 (PubMed:19726563). {ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:24098149, ECO:0000269|PubMed:33308444}. CC -!- INTERACTION: CC O00238; P12643: BMP2; NbExp=3; IntAct=EBI-7527193, EBI-1029262; CC O00238; P43026: GDF5; NbExp=7; IntAct=EBI-7527193, EBI-8571476; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19726563}; CC Single-pass type I membrane protein {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O00238-1; Sequence=Displayed; CC Name=2; CC IsoId=O00238-2; Sequence=VSP_045100; CC -!- PTM: Autophosphorylated. {ECO:0000250|UniProtKB:P36898}. CC -!- DISEASE: Acromesomelic dysplasia 3 (AMD3) [MIM:609441]: A form of CC acromesomelic dysplasia, a skeletal disorder characterized by short CC stature, very short limbs and hand/foot malformations. The severity of CC limb abnormalities increases from proximal to distal with profoundly CC affected hands and feet showing brachydactyly and/or rudimentary CC fingers (knob-like fingers). AMD3 is an autosomal recessive form CC characterized by bilateral aplasia of the fibula, severe brachydactyly, CC and fusion of carpal and tarsal bones. {ECO:0000269|PubMed:15805157, CC ECO:0000269|PubMed:24129431, ECO:0000269|PubMed:26105076}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Brachydactyly A2 (BDA2) [MIM:112600]: A form of brachydactyly. CC Brachydactyly defines a group of inherited malformations characterized CC by shortening of the digits due to abnormal development of the CC phalanges and/or the metacarpals. In brachydactyly type A2 shortening CC of the middle phalanges is confined to the index finger and the second CC toe, all other digits being more or less normal. Because of a rhomboid CC or triangular shape of the affected middle phalanx, the end of the CC second finger usually deviates radially. {ECO:0000269|PubMed:14523231, CC ECO:0000269|PubMed:16957682}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Brachydactyly A1, D (BDA1D) [MIM:616849]: A form of CC brachydactyly type A1. Brachydactyly defines a group of inherited CC malformations characterized by shortening of the digits due to abnormal CC development of the phalanges and/or the metacarpals. Brachydactyly type CC A1 is characterized by middle phalanges of all the digits rudimentary CC or fused with the terminal phalanges. The proximal phalanges of the CC thumbs and big toes are short. BDA1D inheritance is autosomal dominant. CC {ECO:0000269|PubMed:25758993}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D89675; BAA19765.1; -; mRNA. DR EMBL; U89326; AAC28131.1; -; mRNA. DR EMBL; AK299930; BAG61763.1; -; mRNA. DR EMBL; AK313642; BAG36400.1; -; mRNA. DR EMBL; AC004061; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092609; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC093634; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC105395; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471057; EAX06060.1; -; Genomic_DNA. DR EMBL; BC047773; AAH47773.1; -; mRNA. DR EMBL; BC069796; AAH69796.1; -; mRNA. DR EMBL; BC069803; AAH69803.1; -; mRNA. DR CCDS; CCDS3642.1; -. [O00238-1] DR CCDS; CCDS58919.1; -. [O00238-2] DR RefSeq; NP_001194.1; NM_001203.3. [O00238-1] DR RefSeq; NP_001243721.1; NM_001256792.2. [O00238-1] DR RefSeq; NP_001243722.1; NM_001256793.2. [O00238-2] DR RefSeq; NP_001243723.1; NM_001256794.1. [O00238-1] DR RefSeq; XP_011530503.1; XM_011532201.3. [O00238-1] DR RefSeq; XP_016864047.1; XM_017008558.2. [O00238-1] DR RefSeq; XP_016864048.1; XM_017008559.2. [O00238-1] DR RefSeq; XP_016864049.1; XM_017008560.2. [O00238-1] DR RefSeq; XP_047272047.1; XM_047416091.1. [O00238-1] DR RefSeq; XP_047272049.1; XM_047416093.1. [O00238-1] DR RefSeq; XP_047272050.1; XM_047416094.1. [O00238-1] DR RefSeq; XP_047272051.1; XM_047416095.1. [O00238-1] DR RefSeq; XP_054206712.1; XM_054350737.1. [O00238-1] DR RefSeq; XP_054206713.1; XM_054350738.1. [O00238-1] DR RefSeq; XP_054206714.1; XM_054350739.1. [O00238-1] DR RefSeq; XP_054206715.1; XM_054350740.1. [O00238-1] DR RefSeq; XP_054206716.1; XM_054350741.1. [O00238-1] DR RefSeq; XP_054206717.1; XM_054350742.1. [O00238-1] DR RefSeq; XP_054206718.1; XM_054350743.1. [O00238-1] DR PDB; 3MDY; X-ray; 2.05 A; A/C=168-502. DR PDBsum; 3MDY; -. DR AlphaFoldDB; O00238; -. DR SMR; O00238; -. DR BioGRID; 107126; 80. DR FunCoup; O00238; 929. DR IntAct; O00238; 15. DR MINT; O00238; -. DR STRING; 9606.ENSP00000401907; -. DR BindingDB; O00238; -. DR ChEMBL; CHEMBL5476; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O00238; -. DR GuidetoPHARMACOLOGY; 1789; -. DR GlyGen; O00238; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O00238; -. DR PhosphoSitePlus; O00238; -. DR BioMuta; BMPR1B; -. DR CPTAC; CPTAC-2846; -. DR CPTAC; CPTAC-2847; -. DR jPOST; O00238; -. DR MassIVE; O00238; -. DR PaxDb; 9606-ENSP00000401907; -. DR PeptideAtlas; O00238; -. DR ProteomicsDB; 47802; -. [O00238-1] DR Antibodypedia; 4045; 661 antibodies from 36 providers. DR DNASU; 658; -. DR Ensembl; ENST00000264568.8; ENSP00000264568.4; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000394931.1; ENSP00000378389.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000440890.7; ENSP00000401907.2; ENSG00000138696.12. [O00238-2] DR Ensembl; ENST00000509540.6; ENSP00000421671.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000512312.5; ENSP00000425444.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000515059.6; ENSP00000426617.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000672698.1; ENSP00000500035.1; ENSG00000138696.12. [O00238-1] DR GeneID; 658; -. DR KEGG; hsa:658; -. DR MANE-Select; ENST00000515059.6; ENSP00000426617.1; NM_001203.3; NP_001194.1. DR UCSC; uc003htm.5; human. [O00238-1] DR AGR; HGNC:1077; -. DR ClinPGx; PA25387; -. DR CTD; 658; -. DR DisGeNET; 658; -. DR GeneCards; BMPR1B; -. DR GeneReviews; BMPR1B; -. DR HGNC; HGNC:1077; BMPR1B. DR HPA; ENSG00000138696; Tissue enhanced (cervix, prostate). DR MalaCards; BMPR1B; -. DR MIM; 112600; phenotype. DR MIM; 603248; gene. DR MIM; 609441; phenotype. DR MIM; 616849; phenotype. DR OpenTargets; ENSG00000138696; -. DR Orphanet; 2098; Acromesomelic dysplasia, Grebe type. DR Orphanet; 93388; Brachydactyly type A1. DR Orphanet; 93396; Brachydactyly type A2. DR Orphanet; 93384; Brachydactyly type C. DR Orphanet; 2639; Fibular aplasia-complex brachydactyly syndrome. DR VEuPathDB; HostDB:ENSG00000138696; -. DR eggNOG; KOG2052; Eukaryota. DR GeneTree; ENSGT00940000155919; -. DR HOGENOM; CLU_000288_8_1_1; -. DR InParanoid; O00238; -. DR OMA; RRTIACC; -. DR OrthoDB; 69842at2759; -. DR PAN-GO; O00238; 8 GO annotations based on evolutionary models. DR PhylomeDB; O00238; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; O00238; -. DR Reactome; R-HSA-201451; Signaling by BMP. DR SignaLink; O00238; -. DR SIGNOR; O00238; -. DR Agora; ENSG00000138696; -. DR BioGRID-ORCS; 658; 17 hits in 1178 CRISPR screens. DR ChiTaRS; BMPR1B; human. DR EvolutionaryTrace; O00238; -. DR GeneWiki; BMPR1B; -. DR GenomeRNAi; 658; -. DR Pharos; O00238; Tchem. DR PRO; PR:O00238; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; O00238; protein. DR Bgee; ENSG00000138696; Expressed in calcaneal tendon and 160 other cell types or tissues. DR ExpressionAtlas; O00238; baseline and differential. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; ISS:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL. DR GO; GO:0036122; F:BMP binding; IPI:BHF-UCL. DR GO; GO:0098821; F:BMP receptor activity; IDA:ARUK-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL. DR GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL. DR GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IBA:GO_Central. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:UniProtKB. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL. DR GO; GO:0030509; P:BMP signaling pathway; IDA:HGNC-UCL. DR GO; GO:0001502; P:cartilage condensation; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0002063; P:chondrocyte development; ISS:AgBase. DR GO; GO:0009953; P:dorsal/ventral pattern formation; IBA:GO_Central. DR GO; GO:0060350; P:endochondral bone morphogenesis; ISS:AgBase. DR GO; GO:0001654; P:eye development; ISS:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:1902731; P:negative regulation of chondrocyte proliferation; ISS:AgBase. DR GO; GO:0001649; P:osteoblast differentiation; IMP:BHF-UCL. DR GO; GO:0001550; P:ovarian cumulus expansion; ISS:UniProtKB. DR GO; GO:0042698; P:ovulation cycle; ISS:UniProtKB. DR GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL. DR GO; GO:0061036; P:positive regulation of cartilage development; ISS:AgBase. DR GO; GO:0032332; P:positive regulation of chondrocyte differentiation; ISS:UniProtKB. DR GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0030166; P:proteoglycan biosynthetic process; ISS:AgBase. DR GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl. DR CDD; cd14219; STKc_BMPR1b; 1. DR CDD; cd23613; TFP_LU_ECD_BMPR1B; 1. DR FunFam; 1.10.510.10:FF:000018; Receptor protein serine/threonine kinase; 1. DR FunFam; 2.10.60.10:FF:000001; Receptor protein serine/threonine kinase; 1. DR FunFam; 3.30.200.20:FF:000055; Receptor protein serine/threonine kinase; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000472; Activin_recp. DR InterPro; IPR003605; GS_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR PANTHER; PTHR23255:SF62; BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF01064; Activin_recp; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF08515; TGF_beta_GS; 1. DR PRINTS; PR00653; ACTIVIN2R. DR SMART; SM00467; GS; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS51256; GS; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Chondrogenesis; Disease variant; Disulfide bond; Dwarfism; Kinase; KW Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding; KW Proteomics identification; Receptor; Reference proteome; KW Serine/threonine-protein kinase; Signal; Transferase; Transmembrane; KW Transmembrane helix. FT SIGNAL 1..13 FT /evidence="ECO:0000255" FT CHAIN 14..502 FT /note="Bone morphogenetic protein receptor type-1B" FT /id="PRO_0000024412" FT TOPO_DOM 14..126 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 127..148 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 149..502 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 174..203 FT /note="GS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00585" FT DOMAIN 204..494 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..25 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 332 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 210..218 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 231 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DISULFID 32..53 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 34..38 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 47..71 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 81..95 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 96..102 FT /evidence="ECO:0000250|UniProtKB:P36898" FT VAR_SEQ 1 FT /note="M -> MGWLEELNWQLHIFLLILLSMHTRANFLDNM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045100" FT VARIANT 31 FT /note="R -> C (in AMD3; uncertain significance; mouse FT BMPR1B construct containing this mutation shows reduced FT GDF5-dependent receptor activation, mouse BMPR1B construct FT containing this mutation shows no loss of cell membrane FT localization; dbSNP:rs745854387)" FT /evidence="ECO:0000269|PubMed:26105076" FT /id="VAR_075520" FT VARIANT 31 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs200035802)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041401" FT VARIANT 53 FT /note="C -> R (in AMD3; mouse BMPR1B construct containing FT this mutation shows loss of GDF5-dependent receptor FT activation, chicken BMPR1B construct containing this FT mutation does not show reduced chondrocyte differentiation, FT mouse BMPR1B construct containing this mutation shows no FT loss of cell membrane localization; dbSNP:rs863225041)" FT /evidence="ECO:0000269|PubMed:24129431" FT /id="VAR_075521" FT VARIANT 149 FT /note="R -> W (in dbSNP:rs34231464)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041402" FT VARIANT 200 FT /note="I -> K (in BDA2; in animal models loss of kinase FT activity and loss of positive regulation of chondrocyte FT differentiation; dbSNP:rs121434417)" FT /evidence="ECO:0000269|PubMed:14523231" FT /id="VAR_023819" FT VARIANT 224 FT /note="R -> H (in dbSNP:rs35973133)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041403" FT VARIANT 297 FT /note="D -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041404" FT VARIANT 325 FT /note="K -> N (in BDA1D; acts in a dominant-negative FT manner; dbSNP:rs869025614)" FT /evidence="ECO:0000269|PubMed:25758993" FT /id="VAR_076406" FT VARIANT 371 FT /note="R -> Q (in dbSNP:rs34970181)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041405" FT VARIANT 486 FT /note="R -> Q (in brachydactyly type C and BDA2; with also FT additional features of symphalangism-1; dbSNP:rs121434419)" FT /evidence="ECO:0000269|PubMed:16957682" FT /id="VAR_037967" FT VARIANT 486 FT /note="R -> W (in BDA2; in animal models no effect on FT kinase activity but strongly decreased positive regulation FT of chondrocyte differentiation; dbSNP:rs121434418)" FT /evidence="ECO:0000269|PubMed:14523231" FT /id="VAR_023820" FT HELIX 176..186 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 190..192 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 194..197 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 200..203 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 205..213 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 216..223 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 226..234 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 235..237 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 238..248 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 261..268 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 270..272 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 274..279 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 287..293 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 298..316 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 337..340 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 346..348 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 375..377 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 380..383 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 393..411 FT /evidence="ECO:0007829|PDB:3MDY" FT TURN 426..430 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 437..444 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 455..459 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 461..473 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 484..496 FT /evidence="ECO:0007829|PDB:3MDY" FT TURN 497..499 FT /evidence="ECO:0007829|PDB:3MDY" SQ SEQUENCE 502 AA; 56930 MW; B283D9BF45535C79 CRC64; MLLRSAGKLN VGTKKEDGES TAPTPRPKVL RCKCHHHCPE DSVNNICSTD GYCFTMIEED DSGLPVVTSG CLGLEGSDFQ CRDTPIPHQR RSIECCTERN ECNKDLHPTL PPLKNRDFVD GPIHHRALLI SVTVCSLLLV LIILFCYFRY KRQETRPRYS IGLEQDETYI PPGESLRDLI EQSQSSGSGS GLPLLVQRTI AKQIQMVKQI GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDY LKSTTLDAKS MLKLAYSSVS GLCHLHTEIF STQGKPAIAH RDLKSKNILV KKNGTCCIAD LGLAVKFISD TNEVDIPPNT RVGTKRYMPP EVLDESLNRN HFQSYIMADM YSFGLILWEV ARRCVSGGIV EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS RLTALRVKKT LAKMSESQDI KL // ID BRD2_HUMAN Reviewed; 801 AA. AC P25440; A2AAU0; B0S7P0; B1AZT1; O00699; O00700; Q15310; Q5STC9; Q63HQ9; AC Q658Y7; Q6P3U2; Q969U4; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 2. DT 28-JAN-2026, entry version 228. DE RecName: Full=Bromodomain-containing protein 2 {ECO:0000305}; DE AltName: Full=O27.1.1; GN Name=BRD2 {ECO:0000303|PubMed:16227282, ECO:0000312|HGNC:HGNC:1103}; GN Synonyms=KIAA9001 {ECO:0000303|Ref.3}, RING3 {ECO:0000303|PubMed:8781126}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=T-cell; RX PubMed=1352711; DOI=10.3109/10425179209020804; RA Beck S., Hanson I., Kelly A., Pappin D.J.C., Trowsdale J.; RT "A homologue of the Drosophila female sterile homeotic (fsh) gene in the RT class II region of the human MHC."; RL DNA Seq. 2:203-210(1992). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SEQUENCE REVISION TO N-TERMINUS. RX PubMed=8781126; DOI=10.1007/bf02602785; RA Thorpe K.L., Abdulla S., Kaufman J., Trowsdale J., Beck S.; RT "Phylogeny and structure of the RING3 gene."; RL Immunogenetics 44:391-396(1996). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Bone marrow; RA Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarabayasi Y., Sato S., RA Nagase T., Seki T., Ishikawa K., Tabata S.; RL Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4). RC TISSUE=Bone marrow, and Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PHE-238. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=PNS; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INTERACTION WITH HERPES VIRUS 8 PROTEIN LANA1 (MICROBIAL INFECTION). RX PubMed=16227282; DOI=10.1128/jvi.79.21.13618-13629.2005; RA Viejo-Borbolla A., Ottinger M., Bruening E., Buerger A., Koenig R., RA Kati E., Sheldon J.A., Schulz T.F.; RT "Brd2/RING3 interacts with a chromatin-binding domain in the Kaposi's RT Sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA- RT 1) that is required for multiple functions of LANA-1."; RL J. Virol. 79:13618-13629(2005). RN [9] RP FUNCTION, INTERACTION WITH ACETYLATED CHROMATIN, AND SUBCELLULAR LOCATION. RX PubMed=18406326; DOI=10.1016/j.molcel.2008.01.018; RA LeRoy G., Rickards B., Flint S.J.; RT "The double bromodomain proteins Brd2 and Brd3 couple histone acetylation RT to transcription."; RL Mol. Cell 30:51-60(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298; SER-301; SER-305 AND RP SER-633, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-298 AND SER-301, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT THR-6; SER-298 AND SER-301, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298 AND SER-633, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298; SER-301 AND SER-305, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [19] RP FUNCTION. RX PubMed=35410381; DOI=10.1038/s41588-022-01044-9; RA Xie L., Dong P., Qi Y., Hsieh T.S., English B.P., Jung S., Chen X., RA De Marzio M., Casellas R., Chang H.Y., Zhang B., Tjian R., Liu Z.; RT "BRD2 compartmentalizes the accessible genome."; RL Nat. Genet. 54:481-491(2022). RN [20] {ECO:0007744|PDB:2G4A} RP STRUCTURE BY NMR OF 348-455, FUNCTION, SUBUNIT, AND MUTAGENESIS OF VAL-376; RP LEU-381; LEU-383 AND ASN-429. RX PubMed=17848202; DOI=10.1186/1472-6807-7-57; RA Huang H., Zhang J., Shen W., Wang X., Wu J., Wu J., Shi Y.; RT "Solution structure of the second bromodomain of Brd2 and its specific RT interaction with acetylated histone tails."; RL BMC Struct. Biol. 7:57-57(2007). RN [21] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 73-194, FUNCTION, RP HOMODIMERIZATION, INTERACTION WITH E2F1 AND HISTONE H4, AND MUTAGENESIS OF RP GLN-78; 142-MET-GLN-143; TYR-153; ILE-154; GLU-170; LEU-174; VAL-177 AND RP GLN-182. RX PubMed=17148447; DOI=10.1074/jbc.m605971200; RA Nakamura Y., Umehara T., Nakano K., Jang M.K., Shirouzu M., Morita S., RA Uda-Tochio H., Hamana H., Terada T., Adachi N., Matsumoto T., Tanaka A., RA Horikoshi M., Ozato K., Padmanabhan B., Yokoyama S.; RT "Crystal structure of the human BRD2 bromodomain: insights into RT dimerization and recognition of acetylated histone h4."; RL J. Biol. Chem. 282:4193-4201(2007). RN [22] {ECO:0007744|PDB:2E3K} RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 348-455, FUNCTION, RP HOMODIMERIZATION, DOMAIN, AND MUTAGENESIS OF 111-PRO-ASP-112; RP 112-ASP--ILE-116; TYR-113; ILE-154; 156-ASN--ASP-160; ASN-156; RP 157-LYS--ASP-160; PRO-158 AND ASP-160. RX PubMed=20709061; DOI=10.1016/j.febslet.2010.08.013; RA Umehara T., Nakamura Y., Wakamori M., Ozato K., Yokoyama S., RA Padmanabhan B.; RT "Structural implications for K5/K12-di-acetylated histone H4 recognition by RT the second bromodomain of BRD2."; RL FEBS Lett. 584:3901-3908(2010). RN [23] {ECO:0007744|PDB:1X0J, ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVR, ECO:0007744|PDB:2DVS} RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 73-194, FUNCTION, RP HOMODIMERIZATION, AND DOMAIN. RX PubMed=20048151; DOI=10.1074/jbc.m109.062422; RA Umehara T., Nakamura Y., Jang M.K., Nakano K., Tanaka A., Ozato K., RA Padmanabhan B., Yokoyama S.; RT "Structural basis for acetylated histone H4 recognition by the human BRD2 RT bromodomain."; RL J. Biol. Chem. 285:7610-7618(2010). RN [24] RP X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 344-452, FUNCTION, AND ACTIVITY RP REGULATION. RX PubMed=20871596; DOI=10.1038/nature09504; RA Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., RA Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., RA McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., RA Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., RA Bradner J.E.; RT "Selective inhibition of BET bromodomains."; RL Nature 468:1067-1073(2010). RN [25] {ECO:0007744|PDB:5U5S} RP STRUCTURE BY NMR OF 344-455 IN COMPLEX WITH STAT3, FUNCTION, SUBCELLULAR RP LOCATION, AND INTERACTION WITH STAT3. RX PubMed=28262505; DOI=10.1016/j.molcel.2016.12.022; RA Cheung K.L., Zhang F., Jaganathan A., Sharma R., Zhang Q., Konuma T., RA Shen T., Lee J.Y., Ren C., Chen C.H., Lu G., Olson M.R., Zhang W., RA Kaplan M.H., Littman D.R., Walsh M.J., Xiong H., Zeng L., Zhou M.M.; RT "Distinct roles of Brd2 and Brd4 in potentiating the transcriptional RT program for th17 cell differentiation."; RL Mol. Cell 65:1068-1080(2017). RN [26] {ECO:0007744|PDB:6E6J, ECO:0007744|PDB:6ONY} RP X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS) OF 73-194 IN COMPLEX WITH ABBV-744 RP INHIBITOR, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=31969702; DOI=10.1038/s41586-020-1930-8; RA Faivre E.J., McDaniel K.F., Albert D.H., Mantena S.R., Plotnik J.P., RA Wilcox D., Zhang L., Bui M.H., Sheppard G.S., Wang L., Sehgal V., Lin X., RA Huang X., Lu X., Uziel T., Hessler P., Lam L.T., Bellin R.J., Mehta G., RA Fidanze S., Pratt J.K., Liu D., Hasvold L.A., Sun C., Panchal S.C., RA Nicolette J.J., Fossey S.L., Park C.H., Longenecker K., Bigelow L., RA Torrent M., Rosenberg S.H., Kati W.M., Shen Y.; RT "Selective inhibition of the BD2 bromodomain of BET proteins in prostate RT cancer."; RL Nature 578:306-310(2020). RN [27] {ECO:0007744|PDB:6SWO, ECO:0007744|PDB:6SWP} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 344-455 IN COMPLEX WITH GSK778 RP AND GSK046, AND ACTIVITY REGULATION. RX PubMed=32193360; DOI=10.1126/science.aaz8455; RA Gilan O., Rioja I., Knezevic K., Bell M.J., Yeung M.M., Harker N.R., RA Lam E.Y.N., Chung C.W., Bamborough P., Petretich M., Urh M., Atkinson S.J., RA Bassil A.K., Roberts E.J., Vassiliadis D., Burr M.L., Preston A.G.S., RA Wellaway C., Werner T., Gray J.R., Michon A.M., Gobbetti T., Kumar V., RA Soden P.E., Haynes A., Vappiani J., Tough D.F., Taylor S., Dawson S.J., RA Bantscheff M., Lindon M., Drewes G., Demont E.H., Daniels D.L., Grandi P., RA Prinjha R.K., Dawson M.A.; RT "Selective targeting of BD1 and BD2 of the BET proteins in cancer and RT immunoinflammation."; RL Science 368:387-394(2020). RN [28] {ECO:0007744|PDB:8SB6} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 86-206 IN COMPLEX WITH RP N6-ACETYL-N6-METHYLLYSINE, FUNCTION, AND MUTAGENESIS OF ASN-156. RX PubMed=37731000; DOI=10.1038/s41586-023-06565-9; RA Lu-Culligan W.J., Connor L.J., Xie Y., Ekundayo B.E., Rose B.T., RA Machyna M., Pintado-Urbanc A.P., Zimmer J.T., Vock I.W., Bhanu N.V., RA King M.C., Garcia B.A., Bleichert F., Simon M.D.; RT "Acetyl-methyllysine marks chromatin at active transcription start sites."; RL Nature 622:173-179(2023). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-30; GLY-49; SER-49; PRO-212; PHE-238; RP GLN-260; VAL-474; GLY-558; THR-569; PRO-599 AND LEU-714. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Chromatin reader protein that specifically recognizes and CC binds histone H4 acetylated at 'Lys-5' and 'Lys-12' (H4K5ac and CC H4K12ac, respectively), thereby controlling gene expression and CC remodeling chromatin structures (PubMed:17148447, PubMed:17848202, CC PubMed:18406326, PubMed:20048151, PubMed:20709061, PubMed:20871596). CC Recruits transcription factors and coactivators to target gene sites, CC and activates RNA polymerase II machinery for transcriptional CC elongation (PubMed:28262505). Plays a key role in genome CC compartmentalization via its association with CTCF and cohesin: CC recruited to chromatin by CTCF and promotes formation of topologically CC associating domains (TADs) via its ability to bind acetylated histones, CC contributing to CTCF boundary formation and enhancer insulation CC (PubMed:35410381). Also recognizes and binds acetylated non-histone CC proteins, such as STAT3 (PubMed:28262505). Involved in inflammatory CC response by regulating differentiation of naive CD4(+) T-cells into T- CC helper Th17: recognizes and binds STAT3 acetylated at 'Lys-87', CC promoting STAT3 recruitment to chromatin (PubMed:28262505). In addition CC to acetylated lysines, also recognizes and binds lysine residues on CC histones that are both methylated and acetylated on the same side chain CC to form N6-acetyl-N6-methyllysine (Kacme), an epigenetic mark of active CC chromatin associated with increased transcriptional initiation CC (PubMed:37731000). Specifically binds histone H4 acetyl-methylated at CC 'Lys-5' and 'Lys-12' (H4K5acme and H4K12acme, respectively) CC (PubMed:37731000). {ECO:0000269|PubMed:17148447, CC ECO:0000269|PubMed:17848202, ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:20048151, ECO:0000269|PubMed:20709061, CC ECO:0000269|PubMed:20871596, ECO:0000269|PubMed:28262505, CC ECO:0000269|PubMed:35410381, ECO:0000269|PubMed:37731000}. CC -!- ACTIVITY REGULATION: Inhibited by JQ1, a thieno-triazolo-1,4-diazepine CC derivative, which specifically inhibits members of the BET family CC (BRD2, BRD3 and BRD4) (PubMed:20871596). The first bromo domain is CC inhibited by GSK778 (iBET-BD1), which specifically inhibits the first CC bromo domain of members of the BET family (BRD2, BRD3 and BRD4) CC (PubMed:32193360). The second bromo domain is inhibited by ABBV-744, CC which specifically inhibits the second bromo domain of members of the CC BET family (BRD2, BRD3 and BRD4) (PubMed:31969702). The second bromo CC domain is inhibited by GSK046 (iBET-BD2), which specifically inhibits CC the second bromo domain of members of the BET family (BRD2, BRD3 and CC BRD4) (PubMed:32193360). {ECO:0000269|PubMed:20871596, CC ECO:0000269|PubMed:31969702, ECO:0000269|PubMed:32193360}. CC -!- SUBUNIT: Homodimer (PubMed:17148447, PubMed:17848202, PubMed:20048151, CC PubMed:20709061). Interacts with E2F1 (PubMed:17148447). Interacts with CC (acetylated) STAT3; promoting STAT3 recruitment to chromatin CC (PubMed:28262505). Interacts with CTCF; promoting BRD2 recruitment to CC chromatin (By similarity). {ECO:0000250|UniProtKB:Q7JJ13, CC ECO:0000269|PubMed:17148447, ECO:0000269|PubMed:17848202, CC ECO:0000269|PubMed:20048151, ECO:0000269|PubMed:20709061, CC ECO:0000269|PubMed:28262505}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein CC LANA1. {ECO:0000269|PubMed:16227282}. CC -!- INTERACTION: CC P25440; P62805: H4C9; NbExp=5; IntAct=EBI-2874802, EBI-302023; CC P25440; Q13761: RUNX3; NbExp=8; IntAct=EBI-2874802, EBI-925990; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:25593309}. Chromosome {ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:25593309, ECO:0000269|PubMed:28262505}. CC Note=Detected on chromatin and nucleosomes. CC {ECO:0000269|PubMed:18406326}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P25440-1; Sequence=Displayed; CC Name=2; CC IsoId=P25440-2; Sequence=VSP_022600; CC Name=3; CC IsoId=P25440-3; Sequence=VSP_055029; CC Name=4; CC IsoId=P25440-4; Sequence=VSP_055028; CC -!- DOMAIN: The first bromo domain specifically recognizes histone H4 CC acetylated at 'Lys-12' (H4K12ac) (PubMed:20048151). It also CC specifically binds histone H4 acetyl-methylated at 'Lys-5' and 'Lys-12' CC (H4K5acme and H4K12acme, respectively) (PubMed:37731000). The second CC bromo domain recognizes and binds histone H4 acetylated at 'Lys-5' and CC 'Lys-12' (H4K5ac and H4K12ac, respectively) (PubMed:20709061). CC {ECO:0000269|PubMed:20048151, ECO:0000269|PubMed:20709061, CC ECO:0000269|PubMed:37731000}. CC -!- MISCELLANEOUS: Some specific inhibitors of BRD2 that prevent binding to CC acetylated histone are promising therapeutic molecules for the CC treatment of cancers or inflammatory diseases (PubMed:31969702, CC PubMed:32193360). ABBV-744, a small molecule, has been tested on tumors CC with success: ABBV-744 antiproliferative activity is mainly restricted CC to cell lines of acute myeloid leukaemia and prostate cancer and is CC able to displace BRD4 from chromatin (PubMed:31969702). GSK046 (iBET- CC BD2), which specifically inhibits the second bromo domain, is a CC promising therapeutic small molecule for the treatment of inflammatory CC and autoimmune diseases (PubMed:32193360). CC {ECO:0000269|PubMed:31969702, ECO:0000269|PubMed:32193360}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA68890.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X62083; CAA43996.1; -; mRNA. DR EMBL; M80613; AAA68890.1; ALT_INIT; mRNA. DR EMBL; X96670; CAA65450.1; -; Genomic_DNA. DR EMBL; Z96104; CAC69989.1; -; Genomic_DNA. DR EMBL; D42040; BAA07641.1; -; mRNA. DR EMBL; BX647233; CAH56179.1; -; mRNA. DR EMBL; BX648109; CAH56171.1; -; mRNA. DR EMBL; AL832722; CAH56208.1; -; mRNA. DR EMBL; AL645941; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL662845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL805913; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX005422; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX908719; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CR936909; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL935042; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX03662.1; -; Genomic_DNA. DR EMBL; CH471081; EAX03663.1; -; Genomic_DNA. DR EMBL; BC063840; AAH63840.1; -; mRNA. DR CCDS; CCDS4762.1; -. [P25440-1] DR CCDS; CCDS56420.1; -. [P25440-2] DR PIR; A56619; A56619. DR RefSeq; NP_001106653.1; NM_001113182.3. [P25440-1] DR RefSeq; NP_001186384.1; NM_001199455.1. [P25440-2] DR RefSeq; NP_001186385.1; NM_001199456.2. [P25440-3] DR RefSeq; NP_001278915.1; NM_001291986.2. [P25440-4] DR RefSeq; NP_005095.1; NM_005104.4. [P25440-1] DR PDB; 1X0J; X-ray; 1.80 A; A/B/C=73-194. DR PDB; 2DVQ; X-ray; 2.04 A; A/B/C=73-194. DR PDB; 2DVR; X-ray; 2.30 A; A/B/C=73-194. DR PDB; 2DVS; X-ray; 2.04 A; A/B/C=73-194. DR PDB; 2DVV; X-ray; 1.80 A; A=348-455. DR PDB; 2E3K; X-ray; 2.30 A; A/B/C/D=348-455. DR PDB; 2G4A; NMR; -; A=348-455. DR PDB; 2YDW; X-ray; 1.90 A; A/B/C=67-200. DR PDB; 2YEK; X-ray; 1.98 A; A/B/C=67-200. DR PDB; 3AQA; X-ray; 2.30 A; A/B/C=73-194. DR PDB; 3ONI; X-ray; 1.61 A; A=344-455. DR PDB; 4A9E; X-ray; 1.91 A; A/B/C=67-200. DR PDB; 4A9F; X-ray; 1.73 A; A/B/C=67-200. DR PDB; 4A9H; X-ray; 2.05 A; A/B/C=67-200. DR PDB; 4A9I; X-ray; 2.25 A; A/B/C=67-200. DR PDB; 4A9J; X-ray; 1.90 A; A/B/C=67-200. DR PDB; 4A9M; X-ray; 2.06 A; A/B/C=67-200. DR PDB; 4A9N; X-ray; 1.85 A; A/B/C=67-200. DR PDB; 4A9O; X-ray; 1.78 A; A/B/C=67-200. DR PDB; 4AKN; X-ray; 1.82 A; A/B/C=67-200. DR PDB; 4ALG; X-ray; 1.60 A; A=67-200. DR PDB; 4ALH; X-ray; 1.78 A; A/B/C=67-200. DR PDB; 4J1P; X-ray; 1.08 A; A=344-455. DR PDB; 4MR5; X-ray; 1.63 A; A=344-455. DR PDB; 4MR6; X-ray; 1.67 A; A=344-455. DR PDB; 4QEU; X-ray; 1.50 A; A=344-455. DR PDB; 4QEV; X-ray; 1.80 A; A=344-455. DR PDB; 4QEW; X-ray; 1.70 A; A=344-455. DR PDB; 4UYF; X-ray; 1.60 A; A/B/C=67-200. DR PDB; 4UYG; X-ray; 2.50 A; A/B/C/D/E/F=338-473. DR PDB; 4UYH; X-ray; 1.73 A; A/B/C=67-200. DR PDB; 5BT5; X-ray; 1.40 A; A=344-455. DR PDB; 5DFB; X-ray; 1.40 A; A=344-455. DR PDB; 5DFC; X-ray; 1.50 A; A=344-455. DR PDB; 5DFD; X-ray; 1.50 A; A=344-455. DR PDB; 5DW1; X-ray; 1.55 A; A/B/C/D=345-455. DR PDB; 5EK9; X-ray; 2.08 A; A/B=344-455. DR PDB; 5HEL; X-ray; 1.45 A; A=71-194. DR PDB; 5HEM; X-ray; 1.65 A; A/B=71-194. DR PDB; 5HEN; X-ray; 1.79 A; A/B/C=71-194. DR PDB; 5HFQ; X-ray; 1.40 A; A=344-455. DR PDB; 5IBN; X-ray; 0.94 A; A=348-455. DR PDB; 5IG6; X-ray; 0.91 A; A=348-454. DR PDB; 5N2L; X-ray; 1.89 A; A/B/C/D=344-455. DR PDB; 5O38; X-ray; 1.20 A; A=344-455. DR PDB; 5O39; X-ray; 1.74 A; A=344-455. DR PDB; 5O3A; X-ray; 2.40 A; A=344-455. DR PDB; 5O3B; X-ray; 1.95 A; A/B/C/D=344-455. DR PDB; 5O3C; X-ray; 1.60 A; A=344-455. DR PDB; 5O3D; X-ray; 1.60 A; A=345-455. DR PDB; 5O3E; X-ray; 1.40 A; A=344-455. DR PDB; 5O3F; X-ray; 1.75 A; A=344-455. DR PDB; 5O3G; X-ray; 1.85 A; A/B=344-455. DR PDB; 5O3H; X-ray; 1.40 A; A=344-455. DR PDB; 5O3I; X-ray; 1.20 A; A=344-455. DR PDB; 5S9O; X-ray; 2.49 A; A/B=73-194. DR PDB; 5U5S; NMR; -; A=344-455. DR PDB; 5U6V; X-ray; 1.77 A; A=347-455. DR PDB; 5UEW; X-ray; 1.83 A; A/B=347-454. DR PDB; 5XHE; X-ray; 1.40 A; A=348-455. DR PDB; 5XHK; X-ray; 1.28 A; A=348-455. DR PDB; 6CUI; NMR; -; A=621-750. DR PDB; 6DB0; X-ray; 1.70 A; A/B/C=67-200. DR PDB; 6DBC; X-ray; 1.05 A; A=348-455. DR PDB; 6DDI; X-ray; 1.50 A; A/B/C=67-200. DR PDB; 6DDJ; X-ray; 1.05 A; A=348-455. DR PDB; 6E6J; X-ray; 2.44 A; A/B/C/D/E/F=348-455. DR PDB; 6FFE; X-ray; 1.76 A; A=344-455. DR PDB; 6FFF; X-ray; 1.67 A; A=344-455. DR PDB; 6FFG; X-ray; 1.59 A; A=344-455. DR PDB; 6I80; X-ray; 1.14 A; A/B=348-455. DR PDB; 6I81; X-ray; 1.74 A; A=348-455. DR PDB; 6JKE; X-ray; 1.50 A; A/B/C=73-194. DR PDB; 6K04; X-ray; 1.25 A; A=344-455. DR PDB; 6K05; X-ray; 1.94 A; A/B/C=73-194. DR PDB; 6MO7; X-ray; 1.85 A; A/B/C=71-194. DR PDB; 6MO8; X-ray; 1.80 A; A/B/C=71-194. DR PDB; 6MO9; X-ray; 1.80 A; A/B/C=71-194. DR PDB; 6MOA; X-ray; 1.27 A; A=346-455. DR PDB; 6ONY; X-ray; 1.98 A; A/B=73-194. DR PDB; 6SWO; X-ray; 1.60 A; AAA=344-455. DR PDB; 6SWP; X-ray; 1.60 A; AAA=344-455. DR PDB; 6TQ1; X-ray; 1.90 A; AAA/BBB/CCC=67-200. DR PDB; 6TQ2; X-ray; 2.26 A; AAA/BBB/CCC=67-200. DR PDB; 6U61; X-ray; 2.29 A; A/B=65-194. DR PDB; 6U71; X-ray; 1.47 A; A=347-455. DR PDB; 6U8H; X-ray; 2.07 A; A=65-194. DR PDB; 6ULQ; X-ray; 2.70 A; A/B/C=65-194. DR PDB; 6ULT; X-ray; 2.80 A; A/B/C/D/E/F/G/H=347-454. DR PDB; 6VIY; X-ray; 1.90 A; A/B=348-455. DR PDB; 6WWB; X-ray; 1.31 A; A=348-455. DR PDB; 6YTM; X-ray; 1.56 A; A/B=345-455. DR PDB; 6Z7F; X-ray; 1.60 A; AAA=344-455. DR PDB; 6Z8P; X-ray; 1.55 A; AAA=344-455. DR PDB; 6ZB0; X-ray; 1.61 A; AAA=344-455. DR PDB; 6ZB1; X-ray; 1.60 A; AAA=344-455. DR PDB; 6ZB2; X-ray; 2.28 A; AAA=344-455. DR PDB; 7DPN; X-ray; 1.80 A; A/B/C=73-194. DR PDB; 7DPO; X-ray; 2.30 A; A=348-455. DR PDB; 7ENV; X-ray; 2.45 A; A/B/C=73-194. DR PDB; 7ENZ; X-ray; 1.70 A; A=348-455. DR PDB; 7EO5; X-ray; 2.00 A; A=348-455. DR PDB; 7JX7; X-ray; 1.75 A; A=347-455. DR PDB; 7L6D; X-ray; 1.55 A; A=344-455. DR PDB; 7L9G; X-ray; 1.36 A; A=344-455. DR PDB; 7L9J; X-ray; 1.85 A; A=344-455. DR PDB; 7L9K; X-ray; 1.95 A; A/B=344-455. DR PDB; 7LAK; X-ray; 1.83 A; A=73-194. DR PDB; 7NPY; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NPZ; X-ray; 1.28 A; AAA=344-455. DR PDB; 7NQ0; X-ray; 1.30 A; AAA=344-455. DR PDB; 7NQ1; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQ2; X-ray; 1.74 A; AAA=344-455. DR PDB; 7NQ3; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQ5; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQ7; X-ray; 1.70 A; AAA=344-455. DR PDB; 7NQ8; X-ray; 1.60 A; A=344-455. DR PDB; 7NQ9; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQI; X-ray; 1.60 A; A=344-455. DR PDB; 7NQJ; X-ray; 1.73 A; A=344-455. DR PDB; 7OE4; X-ray; 1.65 A; AAA=344-455. DR PDB; 7OE5; X-ray; 1.60 A; AAA=344-455. DR PDB; 7OE6; X-ray; 1.76 A; AAA=344-455. DR PDB; 7OE8; X-ray; 1.30 A; A=344-455. DR PDB; 7OE9; X-ray; 1.60 A; A=344-455. DR PDB; 7OEP; X-ray; 1.80 A; AAA=344-455. DR PDB; 7OER; X-ray; 1.60 A; AAA=344-455. DR PDB; 7OES; X-ray; 1.60 A; AAA=344-455. DR PDB; 7OET; X-ray; 1.41 A; AAA=344-455. DR PDB; 7OGY; X-ray; 1.60 A; AAA=344-455. DR PDB; 7Q5O; X-ray; 1.52 A; A=346-454. DR PDB; 7USG; X-ray; 1.20 A; A=348-455. DR PDB; 7USH; X-ray; 1.27 A; A=348-455. DR PDB; 7USI; X-ray; 2.50 A; A/B/C/D/E/F=73-183. DR PDB; 7UU0; X-ray; 1.30 A; A=344-455. DR PDB; 7VRH; X-ray; 2.20 A; A/B/C=73-194. DR PDB; 7VRI; X-ray; 1.50 A; A=348-455. DR PDB; 7VRK; X-ray; 2.48 A; A/B/C=73-194. DR PDB; 7VRM; X-ray; 1.10 A; A=348-455. DR PDB; 7VRO; X-ray; 2.35 A; A/B/C=73-194. DR PDB; 7VRQ; X-ray; 1.15 A; A=348-455. DR PDB; 7VRZ; X-ray; 2.05 A; A/B/C=73-194. DR PDB; 7VS0; X-ray; 1.25 A; A=348-455. DR PDB; 7VS1; X-ray; 1.25 A; A=348-455. DR PDB; 7VSF; X-ray; 2.50 A; A/B/C=73-194. DR PDB; 7WLN; X-ray; 2.85 A; A/B/C/D=344-455. DR PDB; 7WMQ; X-ray; 2.37 A; A/B/C/D=344-455. DR PDB; 7WMU; X-ray; 1.73 A; A=344-455. DR PDB; 7WN5; X-ray; 1.70 A; A/B=344-455. DR PDB; 7WNA; X-ray; 2.60 A; A/B/C/D/E/F=344-455. DR PDB; 7WNI; X-ray; 3.12 A; A/B=344-455. DR PDB; 8B5G; X-ray; 1.62 A; AAA=344-455. DR PDB; 8B5H; X-ray; 1.60 A; AAA=344-455. DR PDB; 8B5I; X-ray; 1.60 A; AAA=344-455. DR PDB; 8B5J; X-ray; 1.60 A; AAA=344-455. DR PDB; 8CV7; X-ray; 1.60 A; A/B=347-455. DR PDB; 8DNQ; X-ray; 1.84 A; A/B=65-194. DR PDB; 8PX2; X-ray; 1.62 A; A=344-455. DR PDB; 8PX8; X-ray; 1.60 A; A=344-455. DR PDB; 8SB6; X-ray; 1.80 A; A/B/C=86-206. DR PDB; 8UGU; X-ray; 2.34 A; A/B/C/D=348-455. DR PDB; 8UGV; X-ray; 1.99 A; A/B=348-455. DR PDB; 8WYG; X-ray; 3.13 A; A/B/C/D=344-455. DR PDB; 8Z69; X-ray; 1.77 A; A/B/C/D=344-455. DR PDB; 9FBX; X-ray; 1.60 A; A=344-455. DR PDBsum; 1X0J; -. DR PDBsum; 2DVQ; -. DR PDBsum; 2DVR; -. DR PDBsum; 2DVS; -. DR PDBsum; 2DVV; -. DR PDBsum; 2E3K; -. DR PDBsum; 2G4A; -. DR PDBsum; 2YDW; -. DR PDBsum; 2YEK; -. DR PDBsum; 3AQA; -. DR PDBsum; 3ONI; -. DR PDBsum; 4A9E; -. DR PDBsum; 4A9F; -. DR PDBsum; 4A9H; -. DR PDBsum; 4A9I; -. DR PDBsum; 4A9J; -. DR PDBsum; 4A9M; -. DR PDBsum; 4A9N; -. DR PDBsum; 4A9O; -. DR PDBsum; 4AKN; -. DR PDBsum; 4ALG; -. DR PDBsum; 4ALH; -. DR PDBsum; 4J1P; -. DR PDBsum; 4MR5; -. DR PDBsum; 4MR6; -. DR PDBsum; 4QEU; -. DR PDBsum; 4QEV; -. DR PDBsum; 4QEW; -. DR PDBsum; 4UYF; -. DR PDBsum; 4UYG; -. DR PDBsum; 4UYH; -. DR PDBsum; 5BT5; -. DR PDBsum; 5DFB; -. DR PDBsum; 5DFC; -. DR PDBsum; 5DFD; -. DR PDBsum; 5DW1; -. DR PDBsum; 5EK9; -. DR PDBsum; 5HEL; -. DR PDBsum; 5HEM; -. DR PDBsum; 5HEN; -. DR PDBsum; 5HFQ; -. DR PDBsum; 5IBN; -. DR PDBsum; 5IG6; -. DR PDBsum; 5N2L; -. DR PDBsum; 5O38; -. DR PDBsum; 5O39; -. DR PDBsum; 5O3A; -. DR PDBsum; 5O3B; -. DR PDBsum; 5O3C; -. DR PDBsum; 5O3D; -. DR PDBsum; 5O3E; -. DR PDBsum; 5O3F; -. DR PDBsum; 5O3G; -. DR PDBsum; 5O3H; -. DR PDBsum; 5O3I; -. DR PDBsum; 5S9O; -. DR PDBsum; 5U5S; -. DR PDBsum; 5U6V; -. DR PDBsum; 5UEW; -. DR PDBsum; 5XHE; -. DR PDBsum; 5XHK; -. DR PDBsum; 6CUI; -. DR PDBsum; 6DB0; -. DR PDBsum; 6DBC; -. DR PDBsum; 6DDI; -. DR PDBsum; 6DDJ; -. DR PDBsum; 6E6J; -. DR PDBsum; 6FFE; -. DR PDBsum; 6FFF; -. DR PDBsum; 6FFG; -. DR PDBsum; 6I80; -. DR PDBsum; 6I81; -. DR PDBsum; 6JKE; -. DR PDBsum; 6K04; -. DR PDBsum; 6K05; -. DR PDBsum; 6MO7; -. DR PDBsum; 6MO8; -. DR PDBsum; 6MO9; -. DR PDBsum; 6MOA; -. DR PDBsum; 6ONY; -. DR PDBsum; 6SWO; -. DR PDBsum; 6SWP; -. DR PDBsum; 6TQ1; -. DR PDBsum; 6TQ2; -. DR PDBsum; 6U61; -. DR PDBsum; 6U71; -. DR PDBsum; 6U8H; -. DR PDBsum; 6ULQ; -. DR PDBsum; 6ULT; -. DR PDBsum; 6VIY; -. DR PDBsum; 6WWB; -. DR PDBsum; 6YTM; -. DR PDBsum; 6Z7F; -. DR PDBsum; 6Z8P; -. DR PDBsum; 6ZB0; -. DR PDBsum; 6ZB1; -. DR PDBsum; 6ZB2; -. DR PDBsum; 7DPN; -. DR PDBsum; 7DPO; -. DR PDBsum; 7ENV; -. DR PDBsum; 7ENZ; -. DR PDBsum; 7EO5; -. DR PDBsum; 7JX7; -. DR PDBsum; 7L6D; -. DR PDBsum; 7L9G; -. DR PDBsum; 7L9J; -. DR PDBsum; 7L9K; -. DR PDBsum; 7LAK; -. DR PDBsum; 7NPY; -. DR PDBsum; 7NPZ; -. DR PDBsum; 7NQ0; -. DR PDBsum; 7NQ1; -. DR PDBsum; 7NQ2; -. DR PDBsum; 7NQ3; -. DR PDBsum; 7NQ5; -. DR PDBsum; 7NQ7; -. DR PDBsum; 7NQ8; -. DR PDBsum; 7NQ9; -. DR PDBsum; 7NQI; -. DR PDBsum; 7NQJ; -. DR PDBsum; 7OE4; -. DR PDBsum; 7OE5; -. DR PDBsum; 7OE6; -. DR PDBsum; 7OE8; -. DR PDBsum; 7OE9; -. DR PDBsum; 7OEP; -. DR PDBsum; 7OER; -. DR PDBsum; 7OES; -. DR PDBsum; 7OET; -. DR PDBsum; 7OGY; -. DR PDBsum; 7Q5O; -. DR PDBsum; 7USG; -. DR PDBsum; 7USH; -. DR PDBsum; 7USI; -. DR PDBsum; 7UU0; -. DR PDBsum; 7VRH; -. DR PDBsum; 7VRI; -. DR PDBsum; 7VRK; -. DR PDBsum; 7VRM; -. DR PDBsum; 7VRO; -. DR PDBsum; 7VRQ; -. DR PDBsum; 7VRZ; -. DR PDBsum; 7VS0; -. DR PDBsum; 7VS1; -. DR PDBsum; 7VSF; -. DR PDBsum; 7WLN; -. DR PDBsum; 7WMQ; -. DR PDBsum; 7WMU; -. DR PDBsum; 7WN5; -. DR PDBsum; 7WNA; -. DR PDBsum; 7WNI; -. DR PDBsum; 8B5G; -. DR PDBsum; 8B5H; -. DR PDBsum; 8B5I; -. DR PDBsum; 8B5J; -. DR PDBsum; 8CV7; -. DR PDBsum; 8DNQ; -. DR PDBsum; 8PX2; -. DR PDBsum; 8PX8; -. DR PDBsum; 8SB6; -. DR PDBsum; 8UGU; -. DR PDBsum; 8UGV; -. DR PDBsum; 8WYG; -. DR PDBsum; 8Z69; -. DR PDBsum; 9FBX; -. DR AlphaFoldDB; P25440; -. DR SASBDB; P25440; -. DR SMR; P25440; -. DR BioGRID; 111973; 446. DR DIP; DIP-60835N; -. DR FunCoup; P25440; 3292. DR IntAct; P25440; 79. DR MINT; P25440; -. DR STRING; 9606.ENSP00000378702; -. DR BindingDB; P25440; -. DR ChEMBL; CHEMBL1293289; -. DR DrugBank; DB19199; ABBV-744. DR DrugBank; DB15189; Birabresib. DR GuidetoPHARMACOLOGY; 1944; -. DR GlyCosmos; P25440; 6 sites, 2 glycans. DR GlyGen; P25440; 8 sites, 2 O-linked glycans (8 sites). DR iPTMnet; P25440; -. DR PhosphoSitePlus; P25440; -. DR BioMuta; BRD2; -. DR DMDM; 12230989; -. DR CPTAC; CPTAC-1598; -. DR jPOST; P25440; -. DR MassIVE; P25440; -. DR PaxDb; 9606-ENSP00000378704; -. DR PeptideAtlas; P25440; -. DR ProteomicsDB; 54271; -. [P25440-1] DR ProteomicsDB; 54272; -. [P25440-2] DR ProteomicsDB; 65931; -. DR Pumba; P25440; -. DR ABCD; P25440; 1 sequenced antibody. DR Antibodypedia; 28816; 415 antibodies from 39 providers. DR DNASU; 6046; -. DR Ensembl; ENST00000374825.9; ENSP00000363958.4; ENSG00000204256.16. [P25440-1] DR Ensembl; ENST00000374831.8; ENSP00000363964.4; ENSG00000204256.16. [P25440-1] DR Ensembl; ENST00000383108.6; ENSP00000372588.2; ENSG00000234507.9. [P25440-1] DR Ensembl; ENST00000395287.5; ENSP00000378702.1; ENSG00000204256.16. [P25440-2] DR Ensembl; ENST00000399527.5; ENSP00000382443.1; ENSG00000215077.10. [P25440-2] DR Ensembl; ENST00000399528.5; ENSP00000382444.1; ENSG00000215077.10. [P25440-1] DR Ensembl; ENST00000399529.7; ENSP00000382445.3; ENSG00000215077.10. [P25440-1] DR Ensembl; ENST00000414731.6; ENSP00000391246.2; ENSG00000234704.9. DR Ensembl; ENST00000436979.5; ENSP00000405634.1; ENSG00000235307.12. [P25440-3] DR Ensembl; ENST00000438194.6; ENSP00000401791.2; ENSG00000234507.9. [P25440-1] DR Ensembl; ENST00000442863.5; ENSP00000410994.1; ENSG00000234507.9. [P25440-2] DR Ensembl; ENST00000448067.5; ENSP00000412885.1; ENSG00000235307.12. [P25440-2] DR Ensembl; ENST00000449085.4; ENSP00000409145.3; ENSG00000204256.16. [P25440-1] DR Ensembl; ENST00000449118.5; ENSP00000399009.1; ENSG00000234704.9. DR Ensembl; ENST00000549126.4; ENSP00000449380.2; ENSG00000235307.12. [P25440-1] DR Ensembl; ENST00000552587.4; ENSP00000449609.1; ENSG00000235307.12. [P25440-1] DR Ensembl; ENST00000678250.1; ENSP00000502900.1; ENSG00000204256.16. [P25440-1] DR GeneID; 6046; -. DR KEGG; hsa:6046; -. DR MANE-Select; ENST00000374825.9; ENSP00000363958.4; NM_005104.4; NP_005095.1. DR UCSC; uc003ocn.4; human. [P25440-1] DR AGR; HGNC:1103; -. DR ClinPGx; PA25414; -. DR CTD; 6046; -. DR DisGeNET; 6046; -. DR GeneCards; BRD2; -. DR HGNC; HGNC:1103; BRD2. DR HPA; ENSG00000204256; Low tissue specificity. DR MIM; 601540; gene. DR OpenTargets; ENSG00000204256; -. DR VEuPathDB; HostDB:ENSG00000204256; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000153385; -. DR HOGENOM; CLU_001499_0_4_1; -. DR InParanoid; P25440; -. DR OMA; GGMDQHT; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; P25440; 5 GO annotations based on evolutionary models. DR PhylomeDB; P25440; -. DR PathwayCommons; P25440; -. DR Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF. DR SignaLink; P25440; -. DR SIGNOR; P25440; -. DR Agora; ENSG00000204256; -. DR BioGRID-ORCS; 6046; 296 hits in 1214 CRISPR screens. DR ChiTaRS; BRD2; human. DR EvolutionaryTrace; P25440; -. DR GeneWiki; BRD2; -. DR GenomeRNAi; 6046; -. DR Pharos; P25440; Tchem. DR PRO; PR:P25440; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; P25440; protein. DR Bgee; ENSG00000204256; Expressed in ventricular zone and 98 other cell types or tissues. DR ExpressionAtlas; P25440; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0140033; F:acetylation-dependent protein binding; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IBA:GO_Central. DR GO; GO:0140015; F:histone H3K14ac reader activity; IDA:GO_Central. DR GO; GO:0140011; F:histone H4K12ac reader activity; IDA:UniProtKB. DR GO; GO:0140012; F:histone H4K5ac reader activity; IDA:UniProtKB. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:FlyBase. DR GO; GO:0140588; P:chromatin looping; IDA:UniProtKB. DR GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central. DR GO; GO:0001843; P:neural tube closure; IEA:Ensembl. DR GO; GO:0006334; P:nucleosome assembly; IMP:UniProtKB. DR GO; GO:2000330; P:positive regulation of T-helper 17 cell lineage commitment; IDA:UniProtKB. DR GO; GO:0071168; P:protein localization to chromatin; IDA:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; TAS:ProtInc. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF240; BROMODOMAIN-CONTAINING PROTEIN 2; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Bromodomain; KW Chromatin regulator; Chromosome; Host-virus interaction; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Transcription; Transcription regulation. FT CHAIN 1..801 FT /note="Bromodomain-containing protein 2" FT /id="PRO_0000211180" FT DOMAIN 74..180 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 344..453 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 632..714 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 53..73 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 268..349 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 456..647 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 737..801 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 555..559 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 285..298 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 316..332 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 481..514 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 544..566 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 592..612 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 763..795 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 112 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 155 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 156 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:61930" FT /evidence="ECO:0000269|PubMed:20048151, FT ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVS" FT BINDING 156 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 157 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 160 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:61930" FT /evidence="ECO:0000269|PubMed:20048151, FT ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVS" FT BINDING 161 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:61930" FT /evidence="ECO:0000269|PubMed:20048151, FT ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVS" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:20068231" FT MOD_RES 6 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 37 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 298 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 301 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:24275569" FT MOD_RES 305 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 633 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..120 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_055028" FT VAR_SEQ 1..47 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_055029" FT VAR_SEQ 615 FT /note="L -> LQAGVQWRDLGLLQPPLLGFKRFSCLSLPSSQDYRL (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_022600" FT VARIANT 30 FT /note="G -> E (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041904" FT VARIANT 49 FT /note="A -> G (in dbSNP:rs3918144)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041905" FT VARIANT 49 FT /note="A -> S (in dbSNP:rs55669504)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041906" FT VARIANT 212 FT /note="A -> P (in dbSNP:rs35952031)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041907" FT VARIANT 238 FT /note="L -> F (in dbSNP:rs176250)" FT /evidence="ECO:0000269|PubMed:14574404, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022132" FT VARIANT 260 FT /note="P -> Q (in dbSNP:rs35294809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041908" FT VARIANT 474 FT /note="A -> V (in dbSNP:rs3918143)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_029300" FT VARIANT 547 FT /note="R -> K (in dbSNP:rs1049369)" FT /id="VAR_029301" FT VARIANT 558 FT /note="R -> G (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041909" FT VARIANT 569 FT /note="A -> T (in dbSNP:rs34530779)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041910" FT VARIANT 599 FT /note="A -> P (in dbSNP:rs55952113)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041911" FT VARIANT 714 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041912" FT MUTAGEN 78 FT /note="Q->A: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 111..112 FT /note="PD->AA: Abolished binding to histone H4 acetylated FT at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 112..116 FT /note="DYHKI->AHYA: Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 113 FT /note="Y->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 142..143 FT /note="MQ->AA: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 153 FT /note="Y->K: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 154 FT /note="I->A: Partial loss of homodimerization; when FT associated with A-182. Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17148447, FT ECO:0000269|PubMed:20709061" FT MUTAGEN 156..160 FT /note="NKPTD->AKPTA: Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 156 FT /note="N->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac). Abolished binding to histone H4 acetyl- FT methylated." FT /evidence="ECO:0000269|PubMed:20709061, FT ECO:0000269|PubMed:37731000" FT MUTAGEN 157..160 FT /note="KPTD->APTA: Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 158 FT /note="P->D: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 160 FT /note="D->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 170 FT /note="E->A: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 174 FT /note="L->E: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 177 FT /note="V->E: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 182 FT /note="Q->A: Partial loss of homodimerization; when FT associated with A-154." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 376 FT /note="V->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT MUTAGEN 381 FT /note="L->A: Reduced binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT MUTAGEN 383 FT /note="L->A: Reduced binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT MUTAGEN 429 FT /note="N->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT CONFLICT 490 FT /note="S -> F (in Ref. 4; CAH56179)" FT /evidence="ECO:0000305" FT HELIX 77..84 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 86..91 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 105..108 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 113..116 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 123..131 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 138..155 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 161..177 FT /evidence="ECO:0007829|PDB:5HEL" FT STRAND 186..189 FT /evidence="ECO:0007829|PDB:6ULQ" FT HELIX 348..360 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 363..365 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 366..369 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 370..372 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 378..381 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 386..389 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 396..404 FT /evidence="ECO:0007829|PDB:5IG6" FT TURN 406..408 FT /evidence="ECO:0007829|PDB:2G4A" FT HELIX 411..428 FT /evidence="ECO:0007829|PDB:5IG6" FT STRAND 431..433 FT /evidence="ECO:0007829|PDB:7WNI" FT HELIX 434..450 FT /evidence="ECO:0007829|PDB:5IG6" FT STRAND 628..631 FT /evidence="ECO:0007829|PDB:6CUI" FT TURN 634..638 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 644..654 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 659..670 FT /evidence="ECO:0007829|PDB:6CUI" FT TURN 674..678 FT /evidence="ECO:0007829|PDB:6CUI" FT STRAND 681..683 FT /evidence="ECO:0007829|PDB:6CUI" FT TURN 688..690 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 693..707 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 725..743 FT /evidence="ECO:0007829|PDB:6CUI" SQ SEQUENCE 801 AA; 88061 MW; 9A075EEB13507D8E CRC64; MLQNVTPHNK LPGEGNAGLL GLGPEAAAPG KRIRKPSLLY EGFESPTMAS VPALQLTPAN PPPPEVSNPK KPGRVTNQLQ YLHKVVMKAL WKHQFAWPFR QPVDAVKLGL PDYHKIIKQP MDMGTIKRRL ENNYYWAASE CMQDFNTMFT NCYIYNKPTD DIVLMAQTLE KIFLQKVASM PQEEQELVVT IPKNSHKKGA KLAALQGSVT SAHQVPAVSS VSHTALYTPP PEIPTTVLNI PHPSVISSPL LKSLHSAGPP LLAVTAAPPA QPLAKKKGVK RKADTTTPTP TAILAPGSPA SPPGSLEPKA ARLPPMRRES GRPIKPPRKD LPDSQQQHQS SKKGKLSEQL KHCNGILKEL LSKKHAAYAW PFYKPVDASA LGLHDYHDII KHPMDLSTVK RKMENRDYRD AQEFAADVRL MFSNCYKYNP PDHDVVAMAR KLQDVFEFRY AKMPDEPLEP GPLPVSTAMP PGLAKSSSES SSEESSSESS SEEEEEEDEE DEEEEESESS DSEEERAHRL AELQEQLRAV HEQLAALSQG PISKPKRKRE KKEKKKKRKA EKHRGRAGAD EDDKGPRAPR PPQPKKSKKA SGSGGGSAAL GPSGFGPSGG SGTKLPKKAT KTAPPALPTG YDSEEEEESR PMSYDEKRQL SLDINKLPGE KLGRVVHIIQ AREPSLRDSN PEEIEIDFET LKPSTLRELE RYVLSCLRKK PRKPYTIKKP VGKTKEELAL EKKRELEKRL QDVSGQLNST KKPPKKANEK TESSSAQQVA VSRLSASSSS SDSSSSSSSS SSSDTSDSDS G // ID BRD3_HUMAN Reviewed; 726 AA. AC Q15059; B1APD9; Q4G5Y3; Q5T1R7; Q8N5M3; Q92645; DT 11-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 213. DE RecName: Full=Bromodomain-containing protein 3; DE AltName: Full=RING3-like protein; GN Name=BRD3 {ECO:0000303|PubMed:18406326, ECO:0000312|HGNC:HGNC:1104}; GN Synonyms=KIAA0043 {ECO:0000303|PubMed:7584044}, RING3L; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Bone marrow; RX PubMed=7584044; DOI=10.1093/dnares/1.5.223; RA Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S., Seki N., RA Kawarabayasi Y., Ishikawa K., Tabata S.; RT "Prediction of the coding sequences of unidentified human genes. II. The RT coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of RT cDNA clones from human cell line KG-1."; RL DNA Res. 1:223-229(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=16008511; DOI=10.1089/dna.2005.24.432; RA Ishii H., Mimori K., Mori M., Vecchione A.; RT "Differentially expressed genes in endothelial differentiation."; RL DNA Cell Biol. 24:432-437(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Colon; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 363-726, AND TISSUE SPECIFICITY. RX PubMed=9373153; DOI=10.1016/s0378-1119(97)00415-0; RA Thorpe K.L., Gorman P., Thomas C., Sheer D., Trowsdale J., Beck S.; RT "Chromosomal localization, gene structure and transcription pattern of the RT ORFX gene, a homologue of the MHC-linked RING3 gene."; RL Gene 200:177-183(1997). RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ACETYLATED CHROMATIN. RX PubMed=18406326; DOI=10.1016/j.molcel.2008.01.018; RA LeRoy G., Rickards B., Flint S.J.; RT "The double bromodomain proteins Brd2 and Brd3 couple histone acetylation RT to transcription."; RL Mol. Cell 30:51-60(2008). RN [8] RP CHROMOSOMAL TRANSLOCATION WITH NUTM1. RX PubMed=17934517; DOI=10.1038/sj.onc.1210852; RA French C.A., Ramirez C.L., Kolmakova J., Hickman T.T., Cameron M.J., RA Thyne M.E., Kutok J.L., Toretsky J.A., Tadavarthy A.K., Kees U.R., RA Fletcher J.A., Aster J.C.; RT "BRD-NUT oncoproteins: a family of closely related nuclear proteins that RT block epithelial differentiation and maintain the growth of carcinoma RT cells."; RL Oncogene 27:2237-2242(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-563, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP ACTIVITY REGULATION. RX PubMed=20871596; DOI=10.1038/nature09504; RA Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., RA Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., RA McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., RA Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., RA Bradner J.E.; RT "Selective inhibition of BET bromodomains."; RL Nature 468:1067-1073(2010). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-563, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-281, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-414, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [19] RP ACTIVITY REGULATION. RX PubMed=31969702; DOI=10.1038/s41586-020-1930-8; RA Faivre E.J., McDaniel K.F., Albert D.H., Mantena S.R., Plotnik J.P., RA Wilcox D., Zhang L., Bui M.H., Sheppard G.S., Wang L., Sehgal V., Lin X., RA Huang X., Lu X., Uziel T., Hessler P., Lam L.T., Bellin R.J., Mehta G., RA Fidanze S., Pratt J.K., Liu D., Hasvold L.A., Sun C., Panchal S.C., RA Nicolette J.J., Fossey S.L., Park C.H., Longenecker K., Bigelow L., RA Torrent M., Rosenberg S.H., Kati W.M., Shen Y.; RT "Selective inhibition of the BD2 bromodomain of BET proteins in prostate RT cancer."; RL Nature 578:306-310(2020). RN [20] RP FUNCTION. RX PubMed=32895492; DOI=10.1038/s41556-020-0572-2; RA Daneshvar K., Ardehali M.B., Klein I.A., Hsieh F.K., Kratkiewicz A.J., RA Mahpour A., Cancelliere S.O.L., Zhou C., Cook B.M., Li W., Pondick J.V., RA Gupta S.K., Moran S.P., Young R.A., Kingston R.E., Mullen A.C.; RT "lncRNA DIGIT and BRD3 protein form phase-separated condensates to regulate RT endoderm differentiation."; RL Nat. Cell Biol. 22:1211-1222(2020). RN [21] RP ACTIVITY REGULATION. RX PubMed=32193360; DOI=10.1126/science.aaz8455; RA Gilan O., Rioja I., Knezevic K., Bell M.J., Yeung M.M., Harker N.R., RA Lam E.Y.N., Chung C.W., Bamborough P., Petretich M., Urh M., Atkinson S.J., RA Bassil A.K., Roberts E.J., Vassiliadis D., Burr M.L., Preston A.G.S., RA Wellaway C., Werner T., Gray J.R., Michon A.M., Gobbetti T., Kumar V., RA Soden P.E., Haynes A., Vappiani J., Tough D.F., Taylor S., Dawson S.J., RA Bantscheff M., Lindon M., Drewes G., Demont E.H., Daniels D.L., Grandi P., RA Prinjha R.K., Dawson M.A.; RT "Selective targeting of BD1 and BD2 of the BET proteins in cancer and RT immunoinflammation."; RL Science 368:387-394(2020). RN [22] RP STRUCTURE BY NMR OF 25-415. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the first and second bromodomain from human RT bromodomain containing protein 3."; RL Submitted (FEB-2009) to the PDB data bank. RN [23] RP X-RAY CRYSTALLOGRAPHY (1.36 ANGSTROMS) OF 24-416, FUNCTION, SUBUNIT, AND RP DOMAIN. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [24] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 307-416 IN COMPLEX WITH RP ACETYLATED HISTONE H3 PEPTIDE, FUNCTION, AND DOMAIN. RX PubMed=27105114; DOI=10.1016/j.molcel.2016.03.028; RA Li Y., Sabari B.R., Panchenko T., Wen H., Zhao D., Guan H., Wan L., RA Huang H., Tang Z., Zhao Y., Roeder R.G., Shi X., Allis C.D., Li H.; RT "Molecular coupling of histone crotonylation and active transcription by RT AF9 YEATS domain."; RL Mol. Cell 62:181-193(2016). RN [25] {ECO:0007744|PDB:6BGG, ECO:0007744|PDB:6BGH} RP STRUCTURE BY NMR OF 557-644 IN COMPLEX WITH CHD4 AND SMARCA4, FUNCTION, RP DOMAIN, AND INTERACTION WITH CHD4; NSD3 AND SMARCA4. RX PubMed=29567837; DOI=10.1074/jbc.ra117.000678; RA Wai D.C.C., Szyszka T.N., Campbell A.E., Kwong C., Wilkinson-White L.E., RA Silva A.P.G., Low J.K.K., Kwan A.H., Gamsjaeger R., Chalmers J.D., RA Patrick W.M., Lu B., Vakoc C.R., Blobel G.A., Mackay J.P.; RT "The BRD3 ET domain recognizes a short peptide motif through a mechanism RT that is conserved across chromatin remodelers and transcriptional RT regulators."; RL J. Biol. Chem. 293:7160-7175(2018). RN [26] {ECO:0007744|PDB:7JMY, ECO:0007744|PDB:7JQ8, ECO:0007744|PDB:7JYN, ECO:0007744|PDB:7JYZ} RP STRUCTURE BY NMR OF 554-640 IN COMPLEX WITH NSD3, INTERACTION WITH NSD3, RP AND INTERACTION WITH INTEGRASE PROTEIN OF MLV VIRUS (MICROBIAL INFECTION). RX PubMed=33592170; DOI=10.1016/j.str.2021.01.010; RA Aiyer S., Swapna G.V.T., Ma L.C., Liu G., Hao J., Chalmers G., Jacobs B.C., RA Montelione G.T., Roth M.J.; RT "A common binding motif in the ET domain of BRD3 forms polymorphic RT structural interfaces with host and viral proteins."; RL Structure 29:886-898(2021). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-36; THR-161; VAL-172; GLN-435; HIS-441 RP AND PRO-447. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Chromatin reader that recognizes and binds acetylated CC histones, thereby controlling gene expression and remodeling chromatin CC structures (PubMed:18406326, PubMed:22464331, PubMed:27105114, CC PubMed:32895492). Recruits transcription factors and coactivators to CC target gene sites, and activates RNA polymerase II machinery for CC transcriptional elongation (PubMed:29567837, PubMed:32895492). In CC vitro, binds acetylated lysine residues on the N-terminus of histone CC H2A, H2B, H3 and H4 (PubMed:18406326). Involved in endoderm CC differentiation via its association with long non-coding RNA (lncRNA) CC DIGIT: BRD3 undergoes liquid-liquid phase separation upon binding to CC lncRNA DIGIT, promoting binding to histone H3 acetylated at 'Lys-18' CC (H3K18ac) to induce endoderm gene expression (PubMed:32895492). Also CC binds non-histones acetylated proteins, such as GATA1 and GATA2: CC regulates transcription by promoting the binding of the transcription CC factor GATA1 to its targets (By similarity). CC {ECO:0000250|UniProtKB:Q8K2F0, ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:27105114, CC ECO:0000269|PubMed:29567837, ECO:0000269|PubMed:32895492}. CC -!- ACTIVITY REGULATION: Inhibited by JQ1, a thieno-triazolo-1,4-diazepine CC derivative, which specifically inhibits members of the BET family CC (BRD2, BRD3 and BRD4) (PubMed:20871596). The first bromo domain is CC inhibited by GSK778 (iBET-BD1), which specifically inhibits the first CC bromo domain of members of the BET family (BRD2, BRD3 and BRD4) CC (PubMed:32193360). The second bromo domain is inhibited by ABBV-744, CC which specifically inhibits the second bromo domain of members of the CC BET family (BRD2, BRD3 and BRD4) (PubMed:31969702). The second bromo CC domain is inhibited by GSK046 (iBET-BD2), which specifically inhibits CC the second bromo domain of members of the BET family (BRD2, BRD3 and CC BRD4) (PubMed:32193360). {ECO:0000269|PubMed:20871596, CC ECO:0000269|PubMed:31969702, ECO:0000269|PubMed:32193360}. CC -!- SUBUNIT: Interacts (via bromo domain 1) with GATA1 acetylated at 'Lys- CC 312' and 'Lys-315' (By similarity). Interacts (via bromo domain 1) with CC GATA2 acetylated on lysine residues (By similarity). Interacts (via NET CC domain) with CHD4 (via KIKL motif) (PubMed:29567837). Interacts (via CC NET domain) with SMARCA4 (via KIKL motif) (PubMed:29567837). Interacts CC (via NET domain) with NSD3 (via KIKL motif) (PubMed:29567837, CC PubMed:33592170). {ECO:0000250|UniProtKB:Q8K2F0, CC ECO:0000269|PubMed:29567837, ECO:0000269|PubMed:33592170}. CC -!- SUBUNIT: (Microbial infection) Interacts with the Integrase protein of CC Moloney murine leukemia virus (MLV). {ECO:0000269|PubMed:33592170}. CC -!- INTERACTION: CC Q15059; P01106: MYC; NbExp=3; IntAct=EBI-1383460, EBI-447544; CC Q15059-2; O00505: KPNA3; NbExp=3; IntAct=EBI-13468085, EBI-358297; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:25593309}. Chromosome CC {ECO:0000269|PubMed:18406326}. Note=Detected on chromatin. CC {ECO:0000269|PubMed:18406326}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q15059-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15059-2; Sequence=VSP_010247, VSP_010248; CC -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:9373153}. CC -!- DOMAIN: The Bromo domains specifically recognize and bind acetylated CC histones. {ECO:0000269|PubMed:27105114}. CC -!- DOMAIN: The NET domain recognizes and binds the 'KIKL' motif found in CC chromatin proteins. {ECO:0000269|PubMed:29567837}. CC -!- DISEASE: Note=A chromosomal aberration involving BRD3 is found in a CC rare, aggressive, and lethal carcinoma arising in midline organs of CC young people. Translocation t(15;9)(q14;q34) with NUTM1 which produces CC a BRD3-NUTM1 fusion protein. {ECO:0000269|PubMed:17934517}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA05393.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26362; BAA05393.2; ALT_INIT; mRNA. DR EMBL; AY513270; AAS82952.1; -; mRNA. DR EMBL; AL445931; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471090; EAW88113.1; -; Genomic_DNA. DR EMBL; CH471090; EAW88114.1; -; Genomic_DNA. DR EMBL; BC032124; AAH32124.1; -; mRNA. DR EMBL; Z81330; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS6980.1; -. [Q15059-1] DR RefSeq; NP_031397.1; NM_007371.4. [Q15059-1] DR RefSeq; XP_006717354.1; XM_006717291.4. [Q15059-1] DR RefSeq; XP_011517354.1; XM_011519052.3. [Q15059-1] DR RefSeq; XP_047279859.1; XM_047423903.1. [Q15059-1] DR RefSeq; XP_047279860.1; XM_047423904.1. [Q15059-1] DR RefSeq; XP_054219849.1; XM_054363874.1. [Q15059-1] DR RefSeq; XP_054219850.1; XM_054363875.1. [Q15059-1] DR RefSeq; XP_054219851.1; XM_054363876.1. [Q15059-1] DR RefSeq; XP_054219852.1; XM_054363877.1. [Q15059-1] DR PDB; 2E7N; NMR; -; A=306-415. DR PDB; 2NXB; X-ray; 1.40 A; A/B=24-144. DR PDB; 2OO1; X-ray; 1.70 A; A/B/C/D=307-416. DR PDB; 2YW5; NMR; -; A=25-155. DR PDB; 3S91; X-ray; 2.06 A; A=24-144. DR PDB; 3S92; X-ray; 1.36 A; A=306-416. DR PDB; 5A7C; X-ray; 1.90 A; A/B/C/D=306-416. DR PDB; 5HFR; X-ray; 1.70 A; A/B/C/D=306-416. DR PDB; 5HJC; X-ray; 2.60 A; A=307-416. DR PDB; 6BGG; NMR; -; B=557-644. DR PDB; 6BGH; NMR; -; A=557-643. DR PDB; 6I41; X-ray; 1.90 A; B=245-253. DR PDB; 6I5P; X-ray; 1.81 A; B/D/F/H=245-253. DR PDB; 6I68; X-ray; 1.85 A; B/D/F/H=245-253. DR PDB; 6I7A; X-ray; 2.20 A; B/D/F/H=245-253. DR PDB; 6QJU; X-ray; 1.20 A; A/B=24-144. DR PDB; 6U4A; X-ray; 1.88 A; A/B=25-147. DR PDB; 6ULP; X-ray; 2.80 A; A/B=307-419. DR PDB; 7JMY; NMR; -; A=554-640. DR PDB; 7JQ8; NMR; -; A=554-640. DR PDB; 7JYN; NMR; -; A=554-640. DR PDB; 7JYZ; NMR; -; B=554-640. DR PDB; 7L72; X-ray; 1.50 A; A=306-416. DR PDB; 7L9L; X-ray; 1.55 A; A=306-416. DR PDB; 7LAY; X-ray; 1.45 A; A/B=24-144. DR PDB; 7LAZ; X-ray; 2.30 A; A/B=24-144. DR PDB; 7LB4; X-ray; 2.00 A; A/B=306-416. DR PDB; 7LBT; X-ray; 2.70 A; A/B/C/D=306-416. DR PDB; 7R8R; X-ray; 1.80 A; A=24-144. DR PDB; 7RJK; X-ray; 1.85 A; A/B=24-144. DR PDB; 7RJL; X-ray; 1.50 A; A/B=24-144. DR PDB; 7RJM; X-ray; 2.10 A; A/B=24-144. DR PDB; 7RJN; X-ray; 1.95 A; A/B=24-144. DR PDB; 7S3P; X-ray; 2.89 A; A/B/C/D/E/F/G/H/I/J/K=306-416. DR PDB; 7TO7; X-ray; 1.93 A; A/B/D/E=25-147. DR PDB; 7TO8; X-ray; 1.50 A; A/B=25-147. DR PDB; 7TO9; X-ray; 1.60 A; A/B=25-147. DR PDB; 7TOA; X-ray; 1.41 A; A/B=32-147. DR PDB; 7UG5; X-ray; 1.80 A; A/B/C/D=306-416. DR PDB; 8B5A; X-ray; 1.92 A; A=307-416. DR PDB; 8CV5; X-ray; 1.47 A; A=307-419. DR PDBsum; 2E7N; -. DR PDBsum; 2NXB; -. DR PDBsum; 2OO1; -. DR PDBsum; 2YW5; -. DR PDBsum; 3S91; -. DR PDBsum; 3S92; -. DR PDBsum; 5A7C; -. DR PDBsum; 5HFR; -. DR PDBsum; 5HJC; -. DR PDBsum; 6BGG; -. DR PDBsum; 6BGH; -. DR PDBsum; 6I41; -. DR PDBsum; 6I5P; -. DR PDBsum; 6I68; -. DR PDBsum; 6I7A; -. DR PDBsum; 6QJU; -. DR PDBsum; 6U4A; -. DR PDBsum; 6ULP; -. DR PDBsum; 7JMY; -. DR PDBsum; 7JQ8; -. DR PDBsum; 7JYN; -. DR PDBsum; 7JYZ; -. DR PDBsum; 7L72; -. DR PDBsum; 7L9L; -. DR PDBsum; 7LAY; -. DR PDBsum; 7LAZ; -. DR PDBsum; 7LB4; -. DR PDBsum; 7LBT; -. DR PDBsum; 7R8R; -. DR PDBsum; 7RJK; -. DR PDBsum; 7RJL; -. DR PDBsum; 7RJM; -. DR PDBsum; 7RJN; -. DR PDBsum; 7S3P; -. DR PDBsum; 7TO7; -. DR PDBsum; 7TO8; -. DR PDBsum; 7TO9; -. DR PDBsum; 7TOA; -. DR PDBsum; 7UG5; -. DR PDBsum; 8B5A; -. DR PDBsum; 8CV5; -. DR AlphaFoldDB; Q15059; -. DR SASBDB; Q15059; -. DR SMR; Q15059; -. DR BioGRID; 113715; 504. DR DIP; DIP-39755N; -. DR FunCoup; Q15059; 2558. DR IntAct; Q15059; 36. DR MINT; Q15059; -. DR STRING; 9606.ENSP00000305918; -. DR BindingDB; Q15059; -. DR ChEMBL; CHEMBL1795186; -. DR DrugBank; DB19199; ABBV-744. DR GuidetoPHARMACOLOGY; 2725; -. DR GlyCosmos; Q15059; 5 sites, 1 glycan. DR GlyGen; Q15059; 9 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q15059; -. DR PhosphoSitePlus; Q15059; -. DR BioMuta; BRD3; -. DR DMDM; 12643726; -. DR jPOST; Q15059; -. DR MassIVE; Q15059; -. DR PaxDb; 9606-ENSP00000305918; -. DR PeptideAtlas; Q15059; -. DR ProteomicsDB; 60414; -. [Q15059-1] DR ProteomicsDB; 60415; -. [Q15059-2] DR Pumba; Q15059; -. DR ABCD; Q15059; 1 sequenced antibody. DR Antibodypedia; 31966; 413 antibodies from 34 providers. DR DNASU; 8019; -. DR Ensembl; ENST00000303407.12; ENSP00000305918.6; ENSG00000169925.18. [Q15059-1] DR Ensembl; ENST00000371834.6; ENSP00000360900.2; ENSG00000169925.18. [Q15059-2] DR GeneID; 8019; -. DR KEGG; hsa:8019; -. DR MANE-Select; ENST00000303407.12; ENSP00000305918.6; NM_007371.4; NP_031397.1. DR UCSC; uc004cew.4; human. [Q15059-1] DR AGR; HGNC:1104; -. DR ClinPGx; PA25415; -. DR CTD; 8019; -. DR DisGeNET; 8019; -. DR GeneCards; BRD3; -. DR HGNC; HGNC:1104; BRD3. DR HPA; ENSG00000169925; Low tissue specificity. DR MalaCards; BRD3; -. DR MIM; 601541; gene. DR OpenTargets; ENSG00000169925; -. DR VEuPathDB; HostDB:ENSG00000169925; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000153385; -. DR HOGENOM; CLU_001499_0_4_1; -. DR InParanoid; Q15059; -. DR OMA; KMNIPHY; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; Q15059; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q15059; -. DR PathwayCommons; Q15059; -. DR SignaLink; Q15059; -. DR SIGNOR; Q15059; -. DR Agora; ENSG00000169925; -. DR BioGRID-ORCS; 8019; 18 hits in 1176 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR ChiTaRS; BRD3; human. DR EvolutionaryTrace; Q15059; -. DR GeneWiki; BRD3; -. DR GenomeRNAi; 8019; -. DR Pharos; Q15059; Tchem. DR PRO; PR:Q15059; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q15059; protein. DR Bgee; ENSG00000169925; Expressed in nipple and 220 other cell types or tissues. DR ExpressionAtlas; Q15059; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProt. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IBA:GO_Central. DR GO; GO:0140017; F:histone H3K18cr reader activity; IDA:UniProtKB. DR GO; GO:0140038; F:histone H3K27cr reader activity; IDA:UniProtKB. DR GO; GO:0140019; F:histone H3K9cr reader activity; IDA:UniProtKB. DR GO; GO:0062072; F:histone H3K9me2/3 reader activity; IDA:UniProtKB. DR GO; GO:0140566; F:histone reader activity; IDA:GO_Central. DR GO; GO:0106222; F:lncRNA binding; IDA:UniProtKB. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central. DR GO; GO:0035987; P:endodermal cell differentiation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProt. DR GO; GO:0071168; P:protein localization to chromatin; IDA:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR DisProt; DP03059; -. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF246; BROMODOMAIN-CONTAINING PROTEIN 3; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Bromodomain; KW Chromatin regulator; Chromosomal rearrangement; Chromosome; Coiled coil; KW Isopeptide bond; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Transcription; Transcription regulation; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..726 FT /note="Bromodomain-containing protein 3" FT /id="PRO_0000211181" FT DOMAIN 34..140 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 306..415 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 562..644 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 78..80 FT /note="Acetylated histone H3 binding" FT /evidence="ECO:0000269|PubMed:27105114" FT REGION 149..169 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 237..305 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 421..462 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 477..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 637..726 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 453..524 FT /evidence="ECO:0000255" FT COILED 645..684 FT /evidence="ECO:0000255" FT COMPBIAS 15..26 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 248..261 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 487..503 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 504..521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 523..540 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 655..673 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 692..726 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 647..648 FT /note="Breakpoint for translocation to form BDR3-NUTM1 FT fusion protein" FT /evidence="ECO:0000269|PubMed:17934517" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 281 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 563 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT CROSSLNK 414 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 549..556 FT /note="QLKKGGKQ -> DHFLTCGV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_010247" FT VAR_SEQ 557..726 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_010248" FT VARIANT 36 FT /note="T -> N (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041913" FT VARIANT 161 FT /note="A -> T (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041914" FT VARIANT 172 FT /note="A -> V (in dbSNP:rs34609592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041915" FT VARIANT 435 FT /note="K -> Q (in dbSNP:rs36093130)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041916" FT VARIANT 441 FT /note="R -> H (in dbSNP:rs56017928)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041917" FT VARIANT 447 FT /note="S -> P (in dbSNP:rs55754444)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041918" FT STRAND 29..31 FT /evidence="ECO:0007829|PDB:2YW5" FT HELIX 37..44 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 46..52 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:6QJU" FT TURN 65..69 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 73..76 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 83..91 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 98..115 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 121..137 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 310..323 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 328..331 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 332..334 FT /evidence="ECO:0007829|PDB:3S92" FT TURN 340..344 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 348..351 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 358..366 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 373..390 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 396..413 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 558..561 FT /evidence="ECO:0007829|PDB:6BGH" FT HELIX 567..569 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 574..585 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 589..602 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 604..608 FT /evidence="ECO:0007829|PDB:6BGG" FT STRAND 611..613 FT /evidence="ECO:0007829|PDB:6BGH" FT STRAND 615..617 FT /evidence="ECO:0007829|PDB:6BGG" FT TURN 618..620 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 623..636 FT /evidence="ECO:0007829|PDB:6BGG" FT TURN 640..642 FT /evidence="ECO:0007829|PDB:6BGG" SQ SEQUENCE 726 AA; 79542 MW; 64F526FC3C1033AA CRC64; MSTATTVAPA GIPATPGPVN PPPPEVSNPS KPGRKTNQLQ YMQNVVVKTL WKHQFAWPFY QPVDAIKLNL PDYHKIIKNP MDMGTIKKRL ENNYYWSASE CMQDFNTMFT NCYIYNKPTD DIVLMAQALE KIFLQKVAQM PQEEVELLPP APKGKGRKPA AGAQSAGTQQ VAAVSSVSPA TPFQSVPPTV SQTPVIAATP VPTITANVTS VPVPPAAAPP PPATPIVPVV PPTPPVVKKK GVKRKADTTT PTTSAITASR SESPPPLSDP KQAKVVARRE SGGRPIKPPK KDLEDGEVPQ HAGKKGKLSE HLRYCDSILR EMLSKKHAAY AWPFYKPVDA EALELHDYHD IIKHPMDLST VKRKMDGREY PDAQGFAADV RLMFSNCYKY NPPDHEVVAM ARKLQDVFEM RFAKMPDEPV EAPALPAPAA PMVSKGAESS RSSEESSSDS GSSDSEEERA TRLAELQEQL KAVHEQLAAL SQAPVNKPKK KKEKKEKEKK KKDKEKEKEK HKVKAEEEKK AKVAPPAKQA QQKKAPAKKA NSTTTAGRQL KKGGKQASAS YDSEEEEEGL PMSYDEKRQL SLDINRLPGE KLGRVVHIIQ SREPSLRDSN PDEIEIDFET LKPTTLRELE RYVKSCLQKK QRKPFSASGK KQAAKSKEEL AQEKKKELEK RLQDVSGQLS SSKKPARKEK PGSAPSGGPS RLSSSSSSES GSSSSSGSSS DSSDSE // ID BRDT_HUMAN Reviewed; 947 AA. AC Q58F21; A6NF68; B7Z811; B7Z890; B7ZAX7; D3DT32; O14789; Q05DQ4; Q6P5T1; AC Q7Z4A6; Q8IWI6; DT 30-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 14-APR-2009, sequence version 4. DT 28-JAN-2026, entry version 165. DE RecName: Full=Bromodomain testis-specific protein; DE AltName: Full=Cancer/testis antigen 9; DE Short=CT9; DE AltName: Full=RING3-like protein; GN Name=BRDT; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP VARIANTS LYS-62 AND LEU-696. RX PubMed=9367677; DOI=10.1006/geno.1997.5000; RA Jones M.H., Numata M., Shimane M.; RT "Identification and characterization of BRDT: a testis-specific gene RT related to the bromodomain genes RING3 and Drosophila fsh."; RL Genomics 45:529-534(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ALTERNATIVE SPLICING, RP TISSUE SPECIFICITY, AND VARIANTS LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=15647849; RA Zheng Y., Yuan W., Zhou Z., Xu M., Sha J.-H.; RT "Molecular cloning and expression of a novel alternative splice variant of RT BRDT gene."; RL Int. J. Mol. Med. 15:315-321(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANTS RP LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS LYS-62 AND RP LEU-696. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-462 (ISOFORM 1), AND VARIANTS RP LYS-62; ASN-238 AND LYS-410. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP TISSUE SPECIFICITY, AND IDENTIFICATION AS A CANCER/TESTIS ANTIGEN. RX PubMed=10704737; DOI=10.1016/s0304-3835(99)00385-7; RA Scanlan M.J., Altorki N.K., Gure A.O., Williamson B., Jungbluth A., RA Chen Y.-T., Old L.J.; RT "Expression of cancer-testis antigens in lung cancer: definition of RT bromodomain testis-specific gene (BRDT) as a new CT gene, CT9."; RL Cancer Lett. 150:155-164(2000). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-2; GLN-6; VAL-89; ASN-238; TYR-288; RP LYS-357; LYS-410 AND ALA-542. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=20538714; DOI=10.1530/rep-10-0139; RA Steilmann C., Cavalcanti M.C., Bartkuhn M., Pons-Kuhnemann J., RA Schuppe H.C., Weidner W., Steger K., Paradowska A.; RT "The interaction of modified histones with the bromodomain testis-specific RT (BRDT) gene and its mRNA level in sperm of fertile donors and subfertile RT men."; RL Reproduction 140:435-443(2010). RN [10] RP SUBCELLULAR LOCATION, AND MOTIF NUCLEAR LOCALIZATION SIGNAL. RX PubMed=22971749; DOI=10.1248/bpb.b12-00527; RA Fukazawa H., Masumi A.; RT "The conserved 12-amino acid stretch in the inter-bromodomain region of BET RT family proteins functions as a nuclear localization signal."; RL Biol. Pharm. Bull. 35:2064-2068(2012). RN [11] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [12] {ECO:0007744|PDB:2RFJ} RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 21-137, FUNCTION, SUBUNIT, AND RP DOMAIN. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [13] {ECO:0007744|PDB:4FLP} RP X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 21-137 IN COMPLEX WITH JQ1, RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=22901802; DOI=10.1016/j.cell.2012.06.045; RA Matzuk M.M., McKeown M.R., Filippakopoulos P., Li Q., Ma L., Agno J.E., RA Lemieux M.E., Picaud S., Yu R.N., Qi J., Knapp S., Bradner J.E.; RT "Small-molecule inhibition of BRDT for male contraception."; RL Cell 150:673-684(2012). RN [14] RP VARIANT SPGF21 ASP-928, AND CHARACTERIZATION OF VARIANT SPGF21 ASP-928. RX PubMed=28199965; DOI=10.18632/oncotarget.15251; RA Li L., Sha Y., Wang X., Li P., Wang J., Kee K., Wang B.; RT "Whole-exome sequencing identified a homozygous BRDT mutation in a patient RT with acephalic spermatozoa."; RL Oncotarget 8:19914-19922(2017). CC -!- FUNCTION: Testis-specific chromatin protein that specifically binds CC histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, CC respectively) and plays a key role in spermatogenesis (PubMed:22464331, CC PubMed:22901802). Required in late pachytene spermatocytes: plays a CC role in meiotic and post-meiotic cells by binding to acetylated CC histones at the promoter of specific meiotic and post-meiotic genes, CC facilitating their activation at the appropriate time CC (PubMed:22901802). In the post-meiotic phase of spermatogenesis, binds CC to hyperacetylated histones and participates in their general removal CC from DNA (PubMed:22901802). Also recognizes and binds a subset of CC butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' CC (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' CC (H4K5ac) (By similarity). Also acts as a component of the splicing CC machinery in pachytene spermatocytes and round spermatids and CC participates in 3'-UTR truncation of specific mRNAs in post-meiotic CC spermatids (By similarity). Required for chromocenter organization, a CC structure comprised of peri-centromeric heterochromatin. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:22901802, CC ECO:0000269|PubMed:9367677}. CC -!- SUBUNIT: Interacts with mRNA splicing machinery proteins SRSF2, DDX5, CC HNRNPK and TARDBP. Interacts with the acetylated N-terminus of histone CC H1, H2, H3 and H4. Interacts with P-TEFb components CDK9 and CC CCNT1/cyclin-T1. Interacts with SMARCE1 (By similarity). Interacts with CC the acetylated N-terminus of histone H1.4, H2A, H2B, H3 and H4. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20538714, CC ECO:0000269|PubMed:22901802, ECO:0000269|PubMed:22971749, CC ECO:0000269|PubMed:25593309}. Note=Detected on chromatin. CC {ECO:0000250|UniProtKB:Q91Y44}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; CC IsoId=Q58F21-1; Sequence=Displayed; CC Name=2; Synonyms=BRDT-NY; CC IsoId=Q58F21-2; Sequence=VSP_019118; CC Name=3; CC IsoId=Q58F21-3; Sequence=VSP_044511; CC Name=4; CC IsoId=Q58F21-4; Sequence=VSP_044510; CC Name=5; CC IsoId=Q58F21-5; Sequence=VSP_044509; CC -!- TISSUE SPECIFICITY: Testis-specific. A 3-fold higher expression is seen CC in adult testis than in embryo testis. Expression seems to be CC correlated with histone H4 hyperacetylation during the haploid phase of CC spermatogenesis (spermiogenesis). No expression, or very low expression CC is seen in patients' testes with abnormal spermatogenesis. Expressed in CC cancers such as non-small cell lung cancer and squamous cell carcinomas CC of the head and neck as well as of esophagus, but not in melanoma or in CC cancers of the colon, breast, kidney and bladder. CC {ECO:0000269|PubMed:10704737, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:9367677}. CC -!- DEVELOPMENTAL STAGE: Expressed in embryo testis. CC -!- DOMAIN: Bromo domains mediate interaction with histones that have CC acetylated lysine residues at specific positions (PubMed:22464331). CC Bromo domain 1 mediates binding with histone H4 acetylated at 'Lys-5' CC and 'Lys-8' (H4K5ac and H4K8ac, respectively) (PubMed:22901802). The CC bromo domains also recognize and bind a subset of butyrylated histones: CC able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is CC not able to bind H4 butyrylated at 'Lys-5' (H4K5ac) (By similarity). CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- PTM: Ubiquitinated in a SPOP-dependent manner, leading to proteasomal CC degradation. {ECO:0000250|UniProtKB:Q91Y44}. CC -!- DISEASE: Spermatogenic failure 21 (SPGF21) [MIM:617644]: An infertility CC disorder caused by spermatogenesis defects and characterized by CC acephalic spermatozoa in the semen of affected individuals. SPGF21 CC inheritance is autosomal recessive. {ECO:0000269|PubMed:28199965}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: BRDT is a promising target for male contraception. CC Inhibition by thienodiazepine inhibitor (+)-JQ1 that binds Asn-109, CC prevents recognition of acetylated histone H4, causing a complete and CC reversible contraceptive effect in male mice (PubMed:22901802). CC {ECO:0000305|PubMed:22901802}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH05281.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH47900.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH62700.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=Asking life to be patient CC - Issue 144 of November 2012; CC URL="https://www.proteinspotlight.org/back_issues/144"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF019085; AAB87862.1; -; mRNA. DR EMBL; AY338951; AAQ16198.1; -; mRNA. DR EMBL; AK303008; BAH13876.1; -; mRNA. DR EMBL; AK302758; BAH13797.1; -; mRNA. DR EMBL; AK316442; BAH14813.1; -; mRNA. DR EMBL; AC114486; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471097; EAW73106.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73107.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73108.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73110.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73111.1; -; Genomic_DNA. DR EMBL; BC005281; AAH05281.1; ALT_SEQ; mRNA. DR EMBL; BC017582; AAH17582.1; -; mRNA. DR EMBL; BC047900; AAH47900.1; ALT_SEQ; mRNA. DR EMBL; BC062700; AAH62700.1; ALT_SEQ; mRNA. DR CCDS; CCDS55615.1; -. [Q58F21-4] DR CCDS; CCDS55616.1; -. [Q58F21-5] DR CCDS; CCDS735.1; -. [Q58F21-1] DR RefSeq; NP_001229734.2; NM_001242805.2. [Q58F21-1] DR RefSeq; NP_001229735.2; NM_001242806.2. [Q58F21-3] DR RefSeq; NP_001229736.2; NM_001242807.2. [Q58F21-4] DR RefSeq; NP_001229737.2; NM_001242808.2. [Q58F21-4] DR RefSeq; NP_001229739.2; NM_001242810.2. [Q58F21-5] DR RefSeq; NP_001717.3; NM_001726.4. [Q58F21-1] DR RefSeq; NP_997072.2; NM_207189.4. [Q58F21-1] DR RefSeq; XP_006710918.1; XM_006710855.5. [Q58F21-1] DR RefSeq; XP_006710919.1; XM_006710856.5. [Q58F21-1] DR RefSeq; XP_011540334.1; XM_011542032.4. [Q58F21-1] DR RefSeq; XP_011540336.1; XM_011542034.4. [Q58F21-1] DR RefSeq; XP_011540337.1; XM_011542035.4. [Q58F21-1] DR RefSeq; XP_011540338.1; XM_011542036.4. [Q58F21-1] DR RefSeq; XP_047284905.1; XM_047428949.1. [Q58F21-1] DR RefSeq; XP_047284911.1; XM_047428955.1. [Q58F21-1] DR RefSeq; XP_047284923.1; XM_047428967.1. [Q58F21-1] DR PDB; 2RFJ; X-ray; 2.05 A; A/B/C=21-137. DR PDB; 4FLP; X-ray; 2.23 A; A/B=21-137. DR PDB; 4KCX; X-ray; 2.00 A; A/B=21-137. DR PDB; 5VBQ; X-ray; 1.65 A; A/B=29-137. DR PDB; 5VBR; X-ray; 1.90 A; A/B=29-137. DR PDB; 7BJY; X-ray; 2.22 A; A/B=29-137. DR PDB; 7L73; X-ray; 1.46 A; A=29-137. DR PDB; 7L99; X-ray; 1.90 A; A/B/C/D=269-380. DR PDB; 7L9A; X-ray; 2.27 A; A/B=269-380. DR PDB; 7LEJ; X-ray; 1.73 A; A=266-378. DR PDB; 7LEK; X-ray; 2.75 A; A/B/C/D=266-378. DR PDB; 7LEL; X-ray; 2.15 A; A/B/C/D=266-378. DR PDB; 7LEM; X-ray; 1.89 A; A/B=29-137. DR PDB; 7MRC; X-ray; 1.55 A; A/B=29-137. DR PDB; 7MRD; X-ray; 1.39 A; A/B=29-137. DR PDB; 7MRG; X-ray; 1.99 A; A/B=29-137. DR PDB; 7MRH; X-ray; 1.98 A; A/B=29-137. DR PDB; 7UBO; X-ray; 1.82 A; A/B/C/D=29-137. DR PDB; 7UUU; X-ray; 1.52 A; A=29-137. DR PDB; 8CZA; X-ray; 2.96 A; A/B/C/D/E/F=29-137. DR PDB; 8YHS; X-ray; 1.50 A; A=21-137. DR PDBsum; 2RFJ; -. DR PDBsum; 4FLP; -. DR PDBsum; 4KCX; -. DR PDBsum; 5VBQ; -. DR PDBsum; 5VBR; -. DR PDBsum; 7BJY; -. DR PDBsum; 7L73; -. DR PDBsum; 7L99; -. DR PDBsum; 7L9A; -. DR PDBsum; 7LEJ; -. DR PDBsum; 7LEK; -. DR PDBsum; 7LEL; -. DR PDBsum; 7LEM; -. DR PDBsum; 7MRC; -. DR PDBsum; 7MRD; -. DR PDBsum; 7MRG; -. DR PDBsum; 7MRH; -. DR PDBsum; 7UBO; -. DR PDBsum; 7UUU; -. DR PDBsum; 8CZA; -. DR PDBsum; 8YHS; -. DR AlphaFoldDB; Q58F21; -. DR SASBDB; Q58F21; -. DR SMR; Q58F21; -. DR BioGRID; 107143; 78. DR FunCoup; Q58F21; 517. DR IntAct; Q58F21; 2. DR STRING; 9606.ENSP00000387822; -. DR BindingDB; Q58F21; -. DR ChEMBL; CHEMBL1795185; -. DR DrugBank; DB17021; JQ1. DR DrugCentral; Q58F21; -. DR GuidetoPHARMACOLOGY; 2729; -. DR GlyGen; Q58F21; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q58F21; -. DR PhosphoSitePlus; Q58F21; -. DR BioMuta; BRDT; -. DR DMDM; 226694198; -. DR jPOST; Q58F21; -. DR MassIVE; Q58F21; -. DR PaxDb; 9606-ENSP00000387822; -. DR PeptideAtlas; Q58F21; -. DR ProteomicsDB; 1029; -. DR ProteomicsDB; 62618; -. [Q58F21-1] DR ProteomicsDB; 62619; -. [Q58F21-2] DR Antibodypedia; 3212; 136 antibodies from 22 providers. DR DNASU; 676; -. DR Ensembl; ENST00000362005.7; ENSP00000354568.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000370389.6; ENSP00000359416.2; ENSG00000137948.19. [Q58F21-5] DR Ensembl; ENST00000394530.7; ENSP00000378038.3; ENSG00000137948.19. [Q58F21-4] DR Ensembl; ENST00000399546.7; ENSP00000387822.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000402388.1; ENSP00000384051.1; ENSG00000137948.19. [Q58F21-1] DR GeneID; 676; -. DR KEGG; hsa:676; -. DR MANE-Select; ENST00000399546.7; ENSP00000387822.3; NM_207189.4; NP_997072.2. DR UCSC; uc001dol.5; human. [Q58F21-1] DR AGR; HGNC:1105; -. DR ClinPGx; PA25418; -. DR CTD; 676; -. DR DisGeNET; 676; -. DR GeneCards; BRDT; -. DR HGNC; HGNC:1105; BRDT. DR HPA; ENSG00000137948; Tissue enriched (testis). DR MalaCards; BRDT; -. DR MIM; 602144; gene. DR MIM; 617644; phenotype. DR OpenTargets; ENSG00000137948; -. DR VEuPathDB; HostDB:ENSG00000137948; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000154549; -. DR HOGENOM; CLU_001499_0_0_1; -. DR InParanoid; Q58F21; -. DR OMA; DFKTMFL; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; Q58F21; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q58F21; -. DR PathwayCommons; Q58F21; -. DR SignaLink; Q58F21; -. DR SIGNOR; Q58F21; -. DR Agora; ENSG00000137948; -. DR BioGRID-ORCS; 676; 15 hits in 1166 CRISPR screens. DR ChiTaRS; BRDT; human. DR EvolutionaryTrace; Q58F21; -. DR GeneWiki; BRDT; -. DR GenomeRNAi; 676; -. DR Pharos; Q58F21; Tchem. DR PRO; PR:Q58F21; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q58F21; protein. DR Bgee; ENSG00000137948; Expressed in left testis and 97 other cell types or tissues. DR ExpressionAtlas; Q58F21; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0140008; F:histone H4 reader activity; IEA:Ensembl. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc. DR GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB. DR GO; GO:0007141; P:male meiosis I; ISS:UniProtKB. DR GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0043484; P:regulation of RNA splicing; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW. DR GO; GO:0035092; P:sperm DNA condensation; ISS:UniProtKB. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR DisProt; DP03058; -. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR031354; BRD4_CDT. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF175; BROMODOMAIN TESTIS-SPECIFIC PROTEIN; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF17105; BRD4_CDT; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Bromodomain; KW Chromatin regulator; Coiled coil; Differentiation; Disease variant; KW Meiosis; mRNA processing; mRNA splicing; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Spermatogenesis; KW Transcription; Transcription regulation; Ubl conjugation. FT CHAIN 1..947 FT /note="Bromodomain testis-specific protein" FT /id="PRO_0000239225" FT DOMAIN 27..133 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 267..376 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 500..582 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 202..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 395..420 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 444..511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 610..698 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 882..924 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 417..470 FT /evidence="ECO:0000255" FT COILED 591..621 FT /evidence="ECO:0000255" FT MOTIF 209..220 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22971749" FT COMPBIAS 217..228 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 447..462 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 470..481 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 482..494 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..662 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 674..692 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 885..924 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 109 FT /ligand="JQ1" FT /ligand_id="ChEBI:CHEBI:137113" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:22901802, FT ECO:0007744|PDB:4FLP" FT SITE 109 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT SITE 114 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT MOD_RES 187 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT VAR_SEQ 1..73 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_044509" FT VAR_SEQ 1 FT /note="M -> MTCTCRQDSKQLRM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15647849" FT /id="VSP_019118" FT VAR_SEQ 65..110 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044510" FT VAR_SEQ 148 FT /note="K -> KGKAG (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044511" FT VARIANT 2 FT /note="S -> F (in dbSNP:rs55806733)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041924" FT VARIANT 6 FT /note="R -> Q (in dbSNP:rs56273490)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041925" FT VARIANT 62 FT /note="Q -> K (in dbSNP:rs10783071)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15647849, FT ECO:0000269|PubMed:9367677, ECO:0000269|Ref.5" FT /id="VAR_026584" FT VARIANT 89 FT /note="A -> V (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs781375003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041926" FT VARIANT 238 FT /note="K -> N (in dbSNP:rs1156281)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026585" FT VARIANT 288 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041927" FT VARIANT 336 FT /note="K -> T (in dbSNP:rs1064567)" FT /id="VAR_047327" FT VARIANT 357 FT /note="E -> K (in dbSNP:rs34674879)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041928" FT VARIANT 410 FT /note="N -> K (in dbSNP:rs3088232)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026586" FT VARIANT 542 FT /note="P -> A (in dbSNP:rs55912588)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041929" FT VARIANT 605 FT /note="R -> Q (in dbSNP:rs35327986)" FT /id="VAR_047328" FT VARIANT 696 FT /note="P -> L (in dbSNP:rs10747493)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15647849, ECO:0000269|PubMed:9367677, FT ECO:0000269|Ref.5" FT /id="VAR_047329" FT VARIANT 928 FT /note="G -> D (in SPGF21; uncertain significance; no effect FT on protein expression; dbSNP:rs754258809)" FT /evidence="ECO:0000269|PubMed:28199965" FT /id="VAR_079306" FT CONFLICT 42 FT /note="D -> N (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="P -> S (in Ref. 6; AAH05281)" FT /evidence="ECO:0000305" FT CONFLICT 80 FT /note="K -> I (in Ref. 6; AAH62700)" FT /evidence="ECO:0000305" FT CONFLICT 265 FT /note="K -> E (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 336 FT /note="K -> S (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 462 FT /note="E -> K (in Ref. 6; AAH17582)" FT /evidence="ECO:0000305" FT CONFLICT 477 FT /note="Q -> R (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 552 FT /note="I -> M (in Ref. 2; AAQ16198)" FT /evidence="ECO:0000305" FT CONFLICT 686 FT /note="N -> H (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 893 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 915 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT HELIX 29..37 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 39..45 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:7MRD" FT STRAND 53..55 FT /evidence="ECO:0007829|PDB:2RFJ" FT TURN 58..62 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 66..69 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 76..84 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 91..108 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 114..131 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 266..284 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 289..292 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:7LEJ" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:7L99" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 319..327 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 334..351 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 357..373 FT /evidence="ECO:0007829|PDB:7LEJ" SQ SEQUENCE 947 AA; 107954 MW; 09C0FD8690E217BB CRC64; MSLPSRQTAI IVNPPPPEYI NTKKNGRLTN QLQYLQKVVL KDLWKHSFSW PFQRPVDAVK LQLPDYYTII KNPMDLNTIK KRLENKYYAK ASECIEDFNT MFSNCYLYNK PGDDIVLMAQ ALEKLFMQKL SQMPQEEQVV GVKERIKKGT QQNIAVSSAK EKSSPSATEK VFKQQEIPSV FPKTSISPLN VVQGASVNSS SQTAAQVTKG VKRKADTTTP ATSAVKASSE FSPTFTEKSV ALPPIKENMP KNVLPDSQQQ YNVVKTVKVT EQLRHCSEIL KEMLAKKHFS YAWPFYNPVD VNALGLHNYY DVVKNPMDLG TIKEKMDNQE YKDAYKFAAD VRLMFMNCYK YNPPDHEVVT MARMLQDVFE THFSKIPIEP VESMPLCYIK TDITETTGRE NTNEASSEGN SSDDSEDERV KRLAKLQEQL KAVHQQLQVL SQVPFRKLNK KKEKSKKEKK KEKVNNSNEN PRKMCEQMRL KEKSKRNQPK KRKQQFIGLK SEDEDNAKPM NYDEKRQLSL NINKLPGDKL GRVVHIIQSR EPSLSNSNPD EIEIDFETLK ASTLRELEKY VSACLRKRPL KPPAKKIMMS KEELHSQKKQ ELEKRLLDVN NQLNSRKRQT KSDKTQPSKA VENVSRLSES SSSSSSSSES ESSSSDLSSS DSSDSESEMF PKFTEVKPND SPSKENVKKM KNECIPPEGR TGVTQIGYCV QDTTSANTTL VHQTTPSHVM PPNHHQLAFN YQELEHLQTV KNISPLQILP PSGDSEQLSN GITVMHPSGD SDTTMLESEC QAPVQKDIKI KNADSWKSLG KPVKPSGVMK SSDELFNQFR KAAIEKEVKA RTQELIRKHL EQNTKELKAS QENQRDLGNG LTVESFSNKI QNKCSGEEQK EHQQSSEAQD KSKLWLLKDR DLARQKEQER RRREAMVGTI DMTLQSDIMT MFENNFD // ID BRSK1_HUMAN Reviewed; 778 AA. AC Q8TDC3; F1DG44; Q5J5B5; Q8NDD0; Q8NDR4; Q8TDC2; Q96AV4; Q96JL4; DT 29-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 21-SEP-2011, sequence version 2. DT 28-JAN-2026, entry version 200. DE RecName: Full=Serine/threonine-protein kinase BRSK1; DE EC=2.7.11.1; DE AltName: Full=Brain-selective kinase 1; DE EC=2.7.11.26; DE AltName: Full=Brain-specific serine/threonine-protein kinase 1; DE Short=BR serine/threonine-protein kinase 1; DE AltName: Full=Serine/threonine-protein kinase SAD-B; DE AltName: Full=Synapses of Amphids Defective homolog 1; DE Short=SAD1 homolog; DE Short=hSAD1; GN Name=BRSK1; Synonyms=KIAA1811, SAD1, SADB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF THR-189. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-59. RC TISSUE=Testis; RX PubMed=15150265; DOI=10.1074/jbc.m404728200; RA Lu R., Niida H., Nakanishi M.; RT "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint RT function."; RL J. Biol. Chem. 279:31164-31170(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=16630837; DOI=10.1016/j.neuron.2006.03.018; RA Inoue E., Mochida S., Takagi H., Higa S., Deguchi-Tawarada M., RA Takao-Rikitsu E., Inoue M., Yao I., Takeuchi K., Kitajima I., Setou M., RA Ohtsuka T., Takai Y.; RT "SAD: a presynaptic kinase associated with synaptic vesicles and the active RT zone cytomatrix that regulates neurotransmitter release."; RL Neuron 50:261-275(2006). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RX PubMed=19648910; DOI=10.1038/ncb1921; RA Alvarado-Kristensson M., Rodriguez M.J., Silio V., Valpuesta J.M., RA Carrera A.C.; RT "SADB phosphorylation of gamma-tubulin regulates centrosome duplication."; RL Nat. Cell Biol. 11:1081-1092(2009). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RA She X.Y., Yu L., Guo J.H.; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 35-778. RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 64-778. RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 287-778. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF GLY-327. RX PubMed=18339622; DOI=10.1074/jbc.m710381200; RA Bright N.J., Carling D., Thornton C.; RT "Investigating the regulation of brain-specific kinases 1 and 2 by RT phosphorylation."; RL J. Biol. Chem. 283:14946-14954(2008). RN [11] RP PHOSPHORYLATION. RX PubMed=19958286; DOI=10.1042/bj20091372; RA Fogarty S., Hawley S.A., Green K.A., Saner N., Mustard K.J., Hardie D.G.; RT "Calmodulin-dependent protein kinase kinase-beta activates AMPK without RT forming a stable complex: synergistic effects of Ca2+ and AMP."; RL Biochem. J. 426:109-118(2010). RN [12] RP FUNCTION. RX PubMed=20026642; DOI=10.1242/jcs.058230; RA Muller M., Lutter D., Puschel A.W.; RT "Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and SadB- RT deficient neurons disrupts neuronal polarity."; RL J. Cell Sci. 123:286-294(2010). RN [13] RP CATALYTIC ACTIVITY, AND FUNCTION IN MAPT PHOSPHORYLATION. RX PubMed=21985311; DOI=10.1111/j.1471-4159.2011.07523.x; RA Yoshida H., Goedert M.; RT "Phosphorylation of microtubule-associated protein tau by AMPK-related RT kinases."; RL J. Neurochem. 120:165-176(2012). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-508, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-303; ILE-319; GLU-391; ASN-531; SER-749 RP AND ALA-764. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that plays a key role in CC polarization of neurons and centrosome duplication. Phosphorylates CC CDC25B, CDC25C, MAPT/TAU, RIMS1, TUBG1, TUBG2 and WEE1. Following CC phosphorylation and activation by STK11/LKB1, acts as a key regulator CC of polarization of cortical neurons, probably by mediating CC phosphorylation of microtubule-associated proteins such as MAPT/TAU at CC 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by CC mediating phosphorylation of WEE1 at 'Ser-642' in postmitotic neurons, CC leading to down-regulate WEE1 activity in polarized neurons. In CC neurons, localizes to synaptic vesicles and plays a role in CC neurotransmitter release, possibly by phosphorylating RIMS1. Also acts CC as a positive regulator of centrosome duplication by mediating CC phosphorylation of gamma-tubulin (TUBG1 and TUBG2) at 'Ser-131', CC leading to translocation of gamma-tubulin and its associated proteins CC to the centrosome. Involved in the UV-induced DNA damage checkpoint CC response, probably by inhibiting CDK1 activity through phosphorylation CC and activation of WEE1, and inhibition of CDC25B and CDC25C. CC {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15150265, CC ECO:0000269|PubMed:20026642, ECO:0000269|PubMed:21985311}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] CC + ADP + H(+); Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA- CC COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau CC protein] + ADP + H(+); Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703, CC Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.26; Evidence={ECO:0000269|PubMed:21985311}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-189 by CC STK11/LKB1. {ECO:0000269|PubMed:14976552}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15150265}. Nucleus CC {ECO:0000269|PubMed:15150265}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250}. Synapse CC {ECO:0000250|UniProtKB:B2DD29}. Presynaptic active zone CC {ECO:0000250|UniProtKB:B2DD29}. Cytoplasmic vesicle, secretory vesicle, CC synaptic vesicle {ECO:0000250|UniProtKB:B2DD29}. Note=Nuclear in the CC absence of DNA damage. Translocated to the nucleus in response to CC UV- or MMS-induced DNA damage (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=SADB-Long, L; CC IsoId=Q8TDC3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8TDC3-2; Sequence=VSP_008158; CC Name=3; Synonyms=SADB-short, S; CC IsoId=Q8TDC3-3; Sequence=VSP_041742; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in brain and CC testis. Protein levels remain constant throughout the cell cycle. CC {ECO:0000269|PubMed:15150265}. CC -!- PTM: Phosphorylated at Thr-189 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39. Not CC phosphorylated at Thr-189 by CaMKK2. In contrast, it is phosphorylated CC and activated by CaMKK1. May be inactivated via dephosphorylation of CC Thr-189 by PP2C. {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:19958286}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16681.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY458602; AAS10354.1; -; mRNA. DR EMBL; AY505124; AAS86442.1; -; mRNA. DR EMBL; HQ830199; ADX95745.1; -; mRNA. DR EMBL; AF479826; AAL87697.1; -; mRNA. DR EMBL; AF479827; AAL87698.1; -; mRNA. DR EMBL; AC008974; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC020922; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL831945; CAD38595.1; -; mRNA. DR EMBL; AL834275; CAD38950.2; -; mRNA. DR EMBL; AB058714; BAB47440.1; -; mRNA. DR EMBL; BC016681; AAH16681.1; ALT_INIT; mRNA. DR CCDS; CCDS12921.1; -. [Q8TDC3-1] DR RefSeq; NP_115806.1; NM_032430.2. [Q8TDC3-1] DR AlphaFoldDB; Q8TDC3; -. DR SMR; Q8TDC3; -. DR BioGRID; 124084; 36. DR FunCoup; Q8TDC3; 1370. DR IntAct; Q8TDC3; 29. DR MINT; Q8TDC3; -. DR STRING; 9606.ENSP00000310649; -. DR BindingDB; Q8TDC3; -. DR ChEMBL; CHEMBL5650; -. DR DrugCentral; Q8TDC3; -. DR GlyGen; Q8TDC3; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q8TDC3; -. DR PhosphoSitePlus; Q8TDC3; -. DR SwissPalm; Q8TDC3; -. DR BioMuta; BRSK1; -. DR DMDM; 347595639; -. DR jPOST; Q8TDC3; -. DR MassIVE; Q8TDC3; -. DR PaxDb; 9606-ENSP00000310649; -. DR PeptideAtlas; Q8TDC3; -. DR ProteomicsDB; 74264; -. [Q8TDC3-1] DR ProteomicsDB; 74265; -. [Q8TDC3-2] DR ProteomicsDB; 74266; -. [Q8TDC3-3] DR Antibodypedia; 19545; 448 antibodies from 37 providers. DR DNASU; 84446; -. DR Ensembl; ENST00000309383.6; ENSP00000310649.1; ENSG00000160469.17. [Q8TDC3-1] DR Ensembl; ENST00000585418.1; ENSP00000467357.1; ENSG00000160469.17. [Q8TDC3-3] DR Ensembl; ENST00000590333.5; ENSP00000468190.1; ENSG00000160469.17. [Q8TDC3-2] DR GeneID; 84446; -. DR KEGG; hsa:84446; -. DR MANE-Select; ENST00000309383.6; ENSP00000310649.1; NM_032430.2; NP_115806.1. DR UCSC; uc002qkf.4; human. [Q8TDC3-1] DR AGR; HGNC:18994; -. DR ClinPGx; PA134888976; -. DR CTD; 84446; -. DR DisGeNET; 84446; -. DR GeneCards; BRSK1; -. DR HGNC; HGNC:18994; BRSK1. DR HPA; ENSG00000160469; Group enriched (brain, pituitary gland). DR MalaCards; BRSK1; -. DR MIM; 609235; gene. DR OpenTargets; ENSG00000160469; -. DR VEuPathDB; HostDB:ENSG00000160469; -. DR eggNOG; KOG0588; Eukaryota. DR GeneTree; ENSGT00940000161254; -. DR HOGENOM; CLU_000288_156_2_1; -. DR InParanoid; Q8TDC3; -. DR OMA; QHSQRNR; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q8TDC3; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q8TDC3; -. DR PathwayCommons; Q8TDC3; -. DR SignaLink; Q8TDC3; -. DR SIGNOR; Q8TDC3; -. DR Agora; ENSG00000160469; -. DR BioGRID-ORCS; 84446; 8 hits in 1189 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; BRSK1; human. DR GeneWiki; BRSK1; -. DR GenomeRNAi; 84446; -. DR Pharos; Q8TDC3; Tchem. DR PRO; PR:Q8TDC3; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q8TDC3; protein. DR Bgee; ENSG00000160469; Expressed in right frontal lobe and 121 other cell types or tissues. DR ExpressionAtlas; Q8TDC3; baseline and differential. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0098981; C:cholinergic synapse; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0150034; C:distal axon; ISS:ARUK-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0048786; C:presynaptic active zone; TAS:ARUK-UCL. DR GO; GO:0008021; C:synaptic vesicle; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IC:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; ISS:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB. DR GO; GO:0008306; P:associative learning; ISS:ARUK-UCL. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0051298; P:centrosome duplication; ISS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:MGI. DR GO; GO:0090176; P:microtubule cytoskeleton organization involved in establishment of planar polarity; ISS:ARUK-UCL. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0007269; P:neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:MGI. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050770; P:regulation of axonogenesis; ISS:ARUK-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0048167; P:regulation of synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:2000807; P:regulation of synaptic vesicle clustering; TAS:ARUK-UCL. DR GO; GO:0010807; P:regulation of synaptic vesicle priming; IEA:Ensembl. DR GO; GO:0009411; P:response to UV; IDA:UniProtKB. DR GO; GO:0099504; P:synaptic vesicle cycle; ISS:ARUK-UCL. DR CDD; cd14081; STKc_BRSK1_2; 1. DR CDD; cd14340; UBA_BRSK; 1. DR FunFam; 1.10.510.10:FF:000064; BR serine/threonine-protein kinase 2; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR048622; BRSK1_2-like_UBA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF36; SERINE_THREONINE-PROTEIN KINASE BRSK1 ISOFORM X1-RELATED; 1. DR Pfam; PF21122; KA1_BRSK; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF21115; UBA_BRSK; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Cell projection; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; DNA damage; Kinase; Magnesium; KW Metal-binding; Methylation; Neurogenesis; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..778 FT /note="Serine/threonine-protein kinase BRSK1" FT /id="PRO_0000085669" FT DOMAIN 34..285 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 314..356 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 362..548 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 719..778 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..12 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 362..383 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 430..457 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 491..508 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 509..533 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 156 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 40..48 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 189 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:18339622" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 443 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 450 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 466 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 481 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 484 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 498 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 508 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 525 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 529 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 535 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 550 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 583 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 586 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 587 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 601 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT VAR_SEQ 1..26 FT /note="MSSGAKEGGGGSPAYHLPHPHPHPPQ -> MVAGLTLGKGPESPDGDVSVPE FT RKDEVAGGGGEEEEAEERGR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14976552, ECO:0000303|Ref.5" FT /id="VSP_008158" FT VAR_SEQ 344..778 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:19648910" FT /id="VSP_041742" FT VARIANT 303 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs144130246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040394" FT VARIANT 319 FT /note="V -> I (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs2088591390)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040395" FT VARIANT 391 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040396" FT VARIANT 531 FT /note="T -> N (in dbSNP:rs55892637)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040397" FT VARIANT 749 FT /note="G -> S (in dbSNP:rs12978445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040398" FT VARIANT 764 FT /note="P -> A (in dbSNP:rs55796422)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040399" FT MUTAGEN 59 FT /note="K->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15150265" FT MUTAGEN 189 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 327 FT /note="G->A: Abolishes activation of kinase activity." FT /evidence="ECO:0000269|PubMed:18339622" FT CONFLICT 762 FT /note="G -> A (in Ref. 9; AAH16681)" FT /evidence="ECO:0000305" SQ SEQUENCE 778 AA; 85087 MW; 8D1818D4E54398BB CRC64; MSSGAKEGGG GSPAYHLPHP HPHPPQHAQY VGPYRLEKTL GKGQTGLVKL GVHCITGQKV AIKIVNREKL SESVLMKVER EIAILKLIEH PHVLKLHDVY ENKKYLYLVL EHVSGGELFD YLVKKGRLTP KEARKFFRQI VSALDFCHSY SICHRDLKPE NLLLDEKNNI RIADFGMASL QVGDSLLETS CGSPHYACPE VIKGEKYDGR RADMWSCGVI LFALLVGALP FDDDNLRQLL EKVKRGVFHM PHFIPPDCQS LLRGMIEVEP EKRLSLEQIQ KHPWYLGGKH EPDPCLEPAP GRRVAMRSLP SNGELDPDVL ESMASLGCFR DRERLHRELR SEEENQEKMI YYLLLDRKER YPSCEDQDLP PRNDVDPPRK RVDSPMLSRH GKRRPERKSM EVLSITDAGG GGSPVPTRRA LEMAQHSQRS RSVSGASTGL SSSPLSSPRS PVFSFSPEPG AGDEARGGGS PTSKTQTLPS RGPRGGGAGE QPPPPSARST PLPGPPGSPR SSGGTPLHSP LHTPRASPTG TPGTTPPPSP GGGVGGAAWR SRLNSIRNSF LGSPRFHRRK MQVPTAEEMS SLTPESSPEL AKRSWFGNFI SLDKEEQIFL VLKDKPLSSI KADIVHAFLS IPSLSHSVLS QTSFRAEYKA SGGPSVFQKP VRFQVDISSS EGPEPSPRRD GSGGGGIYSV TFTLISGPSR RFKRVVETIQ AQLLSTHDQP SVQALADEKN GAQTRPAGAP PRSLQPPPGR PDPELSSSPR RGPPKDKKLL ATNGTPLP // ID CADH1_HUMAN Reviewed; 882 AA. AC P12830; A8K1U7; Q13799; Q14216; Q15855; Q16194; Q4PJ14; Q9UII8; DT 01-OCT-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1993, sequence version 3. DT 28-JAN-2026, entry version 271. DE RecName: Full=Cadherin-1 {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=CAM 120/80; DE AltName: Full=Epithelial cadherin {ECO:0000305}; DE Short=E-cadherin {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=Uvomorulin {ECO:0000303|PubMed:8459805}; DE AltName: CD_antigen=CD324; DE Contains: DE RecName: Full=E-Cad/CTF1; DE Contains: DE RecName: Full=E-Cad/CTF2; DE Contains: DE RecName: Full=E-Cad/CTF3; DE Flags: Precursor; GN Name=CDH1 {ECO:0000312|HGNC:HGNC:1748}; GN Synonyms=CDHE, UVO {ECO:0000312|HGNC:HGNC:1748}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=8459805; DOI=10.1007/bf00996219; RA Bussemakers M.J.G., Mees S.G.M., van Bokhoven A., Debruyne F.M.J., RA Schalken J.A.; RT "Molecular cloning and characterization of the human E-cadherin cDNA."; RL Mol. Biol. Rep. 17:123-128(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT 274-GLY--PRO-277 DEL. RX PubMed=8127895; DOI=10.1073/pnas.91.5.1858; RA Oda T., Kanai Y., Oyama T., Yoshiura K., Shimoyama Y., Birchmeier W., RA Sugimura T., Hirohashi S.; RT "E-cadherin gene mutations in human gastric carcinoma cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1858-1862(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Liver; RX PubMed=8185635; DOI=10.1006/bbrc.1994.1656; RA Rimm D.L., Morrow J.S.; RT "Molecular cloning of human E-cadherin suggests a novel subdivision of the RT cadherin superfamily."; RL Biochem. Biophys. Res. Commun. 200:1754-1761(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 586-591, RP PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION. RC TISSUE=Epidermal carcinoma; RX PubMed=10597309; DOI=10.1038/sj.onc.1203191; RA Ito K., Okamoto I., Araki N., Kawano Y., Nakao M., Fujiyama S., Tomita K., RA Mimori T., Saya H.; RT "Calcium influx triggers the sequential proteolysis of extracellular and RT cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from RT cell-cell contacts."; RL Oncogene 18:7080-7090(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Shibamoto S., Fukudome Y., Yanagihara K.; RT "Mutant E-cadherin."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Hippocampus, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-478; THR-617; MET-832 RP AND LYS-880. RG NIEHS SNPs program; RL Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=8093045; DOI=10.1006/bbrc.1994.2321; RA Bussemakers M.J.G., Giroldi L.A., van Bokhoven A., Schalken J.A.; RT "Transcriptional regulation of the human E-cadherin gene in human prostate RT cancer cell lines: characterization of the human E-cadherin gene RT promoter."; RL Biochem. Biophys. Res. Commun. 203:1284-1290(1994). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RC TISSUE=Placenta; RX PubMed=7543680; DOI=10.1073/pnas.92.16.7416; RA Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S.; RT "Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in RT human carcinomas."; RL Proc. Natl. Acad. Sci. U.S.A. 92:7416-7419(1995). RN [12] RP INTERACTION WITH CTNNB1 AND PKP2. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [13] RP INTERACTION WITH PIP5K1C. RX PubMed=17261850; DOI=10.1083/jcb.200606023; RA Ling K., Bairstow S.F., Carbonara C., Turbin D.A., Huntsman D.G., RA Anderson R.A.; RT "Type I gamma phosphatidylinositol phosphate kinase modulates adherens RT junction and E-cadherin trafficking via a direct interaction with mu 1B RT adaptin."; RL J. Cell Biol. 176:343-353(2007). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-882. RC TISSUE=Placenta; RX PubMed=7601454; DOI=10.1016/0888-7543(95)80212-5; RA Berx G., Staes K., van Hengel J., Molemans F., Bussemakers M.J.G., RA van Bokhoven A., van Roy F.; RT "Cloning and characterization of the human invasion suppressor gene E- RT cadherin (CDH1)."; RL Genomics 26:281-289(1995). RN [15] RP PROTEIN SEQUENCE OF 155-174, AND FUNCTION AS L.MONOCYTOGENES RECEPTOR RP (MICROBIAL INFECTION). RX PubMed=8601315; DOI=10.1016/s0092-8674(00)81070-3; RA Mengaud J., Ohayon H., Gounon P., Mege R.M., Cossart P.; RT "E-cadherin is the receptor for internalin, a surface protein required for RT entry of L. monocytogenes into epithelial cells."; RL Cell 84:923-932(1996). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 172-311 (ISOFORM 1/2), AND TISSUE RP SPECIFICITY. RC TISSUE=Liver; RX PubMed=3263290; DOI=10.1111/j.1432-0436.1988.tb00593.x; RA Mansouri A., Spurr N., Goodfellow P.N., Kemler R.; RT "Characterization and chromosomal localization of the gene encoding the RT human cell adhesion molecule uvomorulin."; RL Differentiation 38:67-71(1988). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 265-392 (ISOFORM 1). RC TISSUE=Liver; RA Frixen U.H.; RL Submitted (MAR-1990) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 337-476, AND VARIANTS ALA-370 AND RP ASP-473. RX PubMed=8033105; RA Becker K.-F., Atkinson M.J., Reich U., Becker I., Nekarda H., Siewert J.R., RA Hoefler H.; RT "E-cadherin gene mutations provide clues to diffuse type gastric RT carcinomas."; RL Cancer Res. 54:3845-3852(1994). RN [19] RP PROTEIN SEQUENCE OF 701-714 AND 732-742, PROTEOLYTIC PROCESSING BY RP GAMMA-SECRETASE/PS1 AND A MEMBRANE-BOUND METALLOPROTEINASE, AND MUTAGENESIS RP OF 759-GLY--GLY-761. RX PubMed=11953314; DOI=10.1093/emboj/21.8.1948; RA Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S., Nagy V., RA Baki L., Wen P., Efthimiopoulos S., Shao Z., Wisniewski T., Robakis N.K.; RT "A presenilin-1/gamma-secretase cleavage releases the E-cadherin RT intracellular domain and regulates disassembly of adherens junctions."; RL EMBO J. 21:1948-1956(2002). RN [20] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION). RX PubMed=23532847; DOI=10.1074/jbc.m113.459875; RA Sumitomo T., Nakata M., Higashino M., Terao Y., Kawabata S.; RT "Group A streptococcal cysteine protease cleaves epithelial junctions and RT contributes to bacterial translocation."; RL J. Biol. Chem. 288:13317-13324(2013). RN [21] RP DOMAIN CATENIN-BINDING. RX PubMed=2349235; DOI=10.1073/pnas.87.11.4246; RA Ozawa M., Ringwald M., Kemler R.; RT "Uvomorulin-catenin complex formation is regulated by a specific domain in RT the cytoplasmic region of the cell adhesion molecule."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4246-4250(1990). RN [22] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [23] RP FUNCTION AS L.MONOCYTOGENES RECEPTOR (MICROBIAL INFECTION), AND MUTAGENESIS RP OF PRO-170. RX PubMed=10406800; DOI=10.1093/emboj/18.14.3956; RA Lecuit M., Dramsi S., Gottardi C., Fedor-Chaiken M., Gumbiner B., RA Cossart P.; RT "A single amino acid in E-cadherin responsible for host specificity towards RT the human pathogen Listeria monocytogenes."; RL EMBO J. 18:3956-3963(1999). RN [24] RP PROTEOLYTIC PROCESSING. RX PubMed=11076937; DOI=10.1074/jbc.m006102200; RA Steinhusen U., Weiske J., Badock V., Tauber R., Bommert K., Huber O.; RT "Cleavage and shedding of E-cadherin after induction of apoptosis."; RL J. Biol. Chem. 276:4972-4980(2001). RN [25] RP INTERACTION WITH PSEN1. RX PubMed=11226248; DOI=10.1073/pnas.041603398; RA Baki L., Marambaud P., Efthimiopoulos S., Georgakopoulos A., Wen P., RA Cui W., Shioi J., Koo E., Ozawa M., Friedrich V.L., Robakis N.K.; RT "Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 RT association, and regulates stability and function of the cadherin/catenin RT adhesion complex."; RL Proc. Natl. Acad. Sci. U.S.A. 98:2381-2386(2001). RN [26] RP INTERCHAIN DISULFIDE BOND. RX PubMed=11856755; DOI=10.1074/jbc.m200916200; RA Makagiansar I.T., Nguyen P.D., Ikesue A., Kuczera K., Dentler W., RA Urbauer J.L., Galeva N., Alterman M., Siahaan T.J.; RT "Disulfide bond formation promotes the cis- and trans-dimerization of the RT E-cadherin-derived first repeat."; RL J. Biol. Chem. 277:16002-16010(2002). RN [27] RP FUNCTION. RX PubMed=11976333; DOI=10.1074/jbc.m201984200; RA Meigs T.E., Fedor-Chaiken M., Kaplan D.D., Brackenbury R., Casey P.J.; RT "Galpha12 and Galpha13 negatively regulate the adhesive functions of RT cadherin."; RL J. Biol. Chem. 277:24594-24600(2002). RN [28] RP INTERACTION WITH DLGAP5, AND SUBCELLULAR LOCATION. RX PubMed=14699157; DOI=10.1074/jbc.m309843200; RA Laprise P., Viel A., Rivard N.; RT "Human homolog of disc-large is required for adherens junction assembly and RT differentiation of human intestinal epithelial cells."; RL J. Biol. Chem. 279:10157-10166(2004). RN [29] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [30] RP INTERACTION WITH CTNND1. RX PubMed=15240885; DOI=10.1073/pnas.0401366101; RA Krakstad B.F., Ardawatia V.V., Aragay A.M.; RT "A role for Galpha12/Galpha13 in p120ctn regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10314-10319(2004). RN [31] RP INTERACTION WITH PSEN1 AND CTNNB1, AND MUTAGENESIS OF 759-GLY--GLY-761. RX PubMed=16126725; DOI=10.1074/jbc.m507503200; RA Serban G., Kouchi Z., Baki L., Georgakopoulos A., Litterst C.M., Shioi J., RA Robakis N.K.; RT "Cadherins mediate both the association between PS1 and beta-catenin and RT the effects of PS1 on beta-catenin stability."; RL J. Biol. Chem. 280:36007-36012(2005). RN [32] RP SUBCELLULAR LOCATION. RX PubMed=15689490; DOI=10.1091/mbc.e04-10-0867; RA Lock J.G., Stow J.L.; RT "Rab11 in recycling endosomes regulates the sorting and basolateral RT transport of E-cadherin."; RL Mol. Biol. Cell 16:1744-1755(2005). RN [33] RP FUNCTION OF E-CAD/CTF2. RX PubMed=16417575; DOI=10.1111/j.1471-4159.2005.03616.x; RA Agiostratidou G., Muros R.M., Shioi J., Marambaud P., Robakis N.K.; RT "The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic RT degradation of A beta precursors."; RL J. Neurochem. 96:1182-1188(2006). RN [34] RP INDUCTION. RX PubMed=17893710; DOI=10.1038/cr.2007.79; RA Meng Y.G., Han W.-D., Zhao Y.-L., Huang K., Si Y.-L., Wu Z.-Q., Mu Y.-M.; RT "Induction of the LRP16 gene by estrogen promotes the invasive growth of RT Ishikawa human endometrial cancer cells through the downregulation of E- RT cadherin."; RL Cell Res. 17:869-880(2007). RN [35] RP INVOLVEMENT IN LBC. RX PubMed=17660459; DOI=10.1136/jmg.2007.051268; RA Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M.J., RA Harris L.N., Pinheiro H.C., Troussard A., Miron P., Tung N., Oliveira C., RA Collins L., Schnitt S., Garber J.E., Huntsman D.; RT "Germline E-cadherin mutations in familial lobular breast cancer."; RL J. Med. Genet. 44:726-731(2007). RN [36] RP SUBCELLULAR LOCATION. RX PubMed=18343367; DOI=10.1016/j.yexcr.2008.01.031; RA Kanno M., Isa Y., Aoyama Y., Yamamoto Y., Nagai M., Ozawa M., Kitajima Y.; RT "P120-catenin is a novel desmoglein 3 interacting partner: identification RT of the p120-catenin association site of desmoglein 3."; RL Exp. Cell Res. 314:1683-1692(2008). RN [37] RP GLYCOSYLATION AT ASN-558; ASN-570; ASN-622 AND ASN-637, AND MUTAGENESIS OF RP ASN-637. RX PubMed=18491227; DOI=10.1007/s10719-008-9133-9; RA Zhou F., Su J., Fu L., Yang Y., Zhang L., Wang L., Zhao H., Zhang D., RA Li Z., Zha X.; RT "Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded RT incorrectly and arrested in endoplasmic reticulum, then sequentially RT degraded by ERAD."; RL Glycoconj. J. 25:727-740(2008). RN [38] RP INTERACTION WITH LIMA1. RX PubMed=18093941; DOI=10.1073/pnas.0710504105; RA Abe K., Takeichi M.; RT "EPLIN mediates linkage of the cadherin catenin complex to F-actin and RT stabilizes the circumferential actin belt."; RL Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008). RN [39] RP REVIEW ON CADHERINS. RX PubMed=20066110; DOI=10.1101/cshperspect.a003053; RA Shapiro L., Weis W.I.; RT "Structure and biochemistry of cadherins and catenins."; RL Cold Spring Harb. Perspect. Biol. 1:A3053-A3053(2009). RN [40] RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=19403558; DOI=10.1093/hmg/ddp194; RA Pinho S.S., Reis C.A., Paredes J., Magalhaes A.M., Ferreira A.C., RA Figueiredo J., Xiaogang W., Carneiro F., Gaertner F., Seruca R.; RT "The role of N-acetylglucosaminyltransferase III and V in the post- RT transcriptional modifications of E-cadherin."; RL Hum. Mol. Genet. 18:2599-2608(2009). RN [41] RP INTERACTION WITH TBC1D2. RX PubMed=20116244; DOI=10.1016/j.cub.2009.12.053; RA Frasa M.A., Maximiano F.C., Smolarczyk K., Francis R.E., Betson M.E., RA Lozano E., Goldenring J., Seabra M.C., Rak A., Ahmadian M.R., Braga V.M.; RT "Armus is a Rac1 effector that inactivates Rab7 and regulates E-cadherin RT degradation."; RL Curr. Biol. 20:198-208(2010). RN [42] RP SUBCELLULAR LOCATION, AND INTERACTION WITH DDR1. RX PubMed=20432435; DOI=10.1002/jcp.22134; RA Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L., Hwang C.C., RA Wang H.M., Wang C.Z.; RT "DDR1 regulates the stabilization of cell surface E-cadherin and E- RT cadherin-mediated cell aggregation."; RL J. Cell. Physiol. 224:387-397(2010). RN [43] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [44] RP SUBCELLULAR LOCATION. RX PubMed=20859650; DOI=10.1007/s00018-010-0531-3; RA Gosavi P., Kundu S.T., Khapare N., Sehgal L., Karkhanis M.S., Dalal S.N.; RT "E-cadherin and plakoglobin recruit plakophilin3 to the cell border to RT initiate desmosome assembly."; RL Cell. Mol. Life Sci. 68:1439-1454(2011). RN [45] RP UBIQUITINATION BY CBLL1. RX PubMed=21283129; DOI=10.1038/cr.2011.17; RA Zhou W.J., Geng Z.H., Chi S., Zhang W., Niu X.F., Lan S.J., Ma L., Yang X., RA Wang L.J., Ding Y.Q., Geng J.G.; RT "Slit-Robo signaling induces malignant transformation through Hakai- RT mediated E-cadherin degradation during colorectal epithelial cell RT carcinogenesis."; RL Cell Res. 21:609-626(2011). RN [46] RP UBIQUITINATION BY A SKP2-CONTAINING SCF COMPLEX, AND PHOSPHORYLATION BY RP CSNK1A1. RX PubMed=22770219; DOI=10.1016/j.cell.2012.05.038; RA Inuzuka H., Gao D., Finley L.W., Yang W., Wan L., Fukushima H., Chin Y.R., RA Zhai B., Shaik S., Lau A.W., Wang Z., Gygi S.P., Nakayama K., RA Teruya-Feldstein J., Toker A., Haigis M.C., Pandolfi P.P., Wei W.; RT "Acetylation-dependent regulation of Skp2 function."; RL Cell 150:179-193(2012). RN [47] RP PHOSPHORYLATION AT TYR-753; TYR-754 AND TYR-755, AND MUTAGENESIS OF RP TYR-754. RX PubMed=22252131; DOI=10.1038/emboj.2011.496; RA Mukherjee M., Chow S.Y., Yusoff P., Seetharaman J., Ng C., Sinniah S., RA Koh X.W., Asgar N.F., Li D., Yim D., Jackson R.A., Yew J., Qian J., Iyu A., RA Lim Y.P., Zhou X., Sze S.K., Guy G.R., Sivaraman J.; RT "Structure of a novel phosphotyrosine-binding domain in Hakai that targets RT E-cadherin."; RL EMBO J. 31:1308-1319(2012). RN [48] RP INTERACTION WITH DSG3, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-770 AND SER-793, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [50] RP IDENTIFICATION IN A COMPLEX WITH PKP3 AND RAP1A, INTERACTION WITH PKP3 AND RP RAP1A, AND SUBCELLULAR LOCATION. RX PubMed=25208567; DOI=10.1091/mbc.e14-05-0968; RA Todorovic V., Koetsier J.L., Godsel L.M., Green K.J.; RT "Plakophilin 3 mediates Rap1-dependent desmosome assembly and adherens RT junction maturation."; RL Mol. Biol. Cell 25:3749-3764(2014). RN [51] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=27760340; DOI=10.1016/j.immuni.2016.09.014; RA Cronan M.R., Beerman R.W., Rosenberg A.F., Saelens J.W., Johnson M.G., RA Oehlers S.H., Sisk D.M., Jurcic Smith K.L., Medvitz N.A., Miller S.E., RA Trinh L.A., Fraser S.E., Madden J.F., Turner J., Stout J.E., Lee S., RA Tobin D.M.; RT "Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma RT Formation and Promotes Infection."; RL Immunity 45:861-876(2016). RN [52] RP SUBCELLULAR LOCATION. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [53] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-175. RX PubMed=29999492; DOI=10.7554/elife.37629; RA Shafraz O., Ruebsam M., Stahley S.N., Caldara A.L., Kowalczyk A.P., RA Niessen C.M., Sivasankar S.; RT "E-cadherin binds to desmoglein to facilitate desmosome assembly."; RL Elife 7:0-0(2018). RN [54] RP INTERACTION WITH SPEF1. RX PubMed=31473225; DOI=10.1053/j.gastro.2019.08.031; RA Tapia R., Perez-Yepez E.A., Carlino M.J., Karandikar U.C., Kralicek S.E., RA Estes M.K., Hecht G.A.; RT "Sperm Flagellar 1 Binds Actin in Intestinal Epithelial Cells and RT Contributes to Formation of Filopodia and Lamellipodia."; RL Gastroenterology 157:1544-1555(2019). RN [55] RP INDUCTION. RX PubMed=31835537; DOI=10.3390/ijms20246221; RA Uttagomol J., Ahmad U.S., Rehman A., Huang Y., Laly A.C., Kang A., RA Soetaert J., Chance R., Teh M.T., Connelly J.T., Wan H.; RT "Evidence for the Desmosomal Cadherin Desmoglein-3 in Regulating YAP and RT Phospho-YAP in Keratinocyte Responses to Mechanical Forces."; RL Int. J. Mol. Sci. 20:0-0(2019). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=33596089; DOI=10.1091/mbc.e20-12-0775; RA Raya-Sandino A., Luissint A.C., Kusters D.H.M., Narayanan V., Flemming S., RA Garcia-Hernandez V., Godsel L.M., Green K.J., Hagen S.J., Conway D.E., RA Parkos C.A., Nusrat A.; RT "Regulation of intestinal epithelial intercellular adhesion and barrier RT function by desmosomal cadherin desmocollin-2."; RL Mol. Biol. Cell 32:753-768(2021). RN [57] RP SUBCELLULAR LOCATION. RX PubMed=36309486; DOI=10.1038/s41419-022-05326-2; RA Myo Min K.K., Rojas-Canales D., Penko D., DeNichilo M., Cockshell M.P., RA Ffrench C.B., Thompson E.J., Asplund O., Drogemuller C.J., Prasad R.B., RA Groop L., Grey S.T., Thomas H.E., Loudovaris T., Kay T.W., Mahoney M.G., RA Jessup C.F., Coates P.T., Bonder C.S.; RT "Desmoglein-2 is important for islet function and beta-cell survival."; RL Cell Death Dis. 13:911-911(2022). RN [58] {ECO:0007744|PDB:1O6S} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), SUBUNIT (MICROBIAL RP INFECTION), AND MUTAGENESIS OF TRP-156 AND PRO-170. RX PubMed=12526809; DOI=10.1016/s0092-8674(02)01136-4; RA Schubert W.-D., Urbanke C., Ziehm T., Beier V., Machner M.P., Domann E., RA Wehland J., Chakraborty T., Heinz D.W.; RT "Structure of internalin, a major invasion protein of Listeria RT monocytogenes, in complex with its human receptor E-cadherin."; RL Cell 111:825-836(2002). RN [59] RP REVIEW ON VARIANTS. RX PubMed=9744472; RX DOI=10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-d; RA Berx G., Becker K.-F., Hoefler H., van Roy F.; RT "Mutations of the human E-cadherin (CDH1) gene."; RL Hum. Mutat. 12:226-237(1998). RN [60] {ECO:0007744|PDB:2OMV, ECO:0007744|PDB:2OMY} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), AND SUBUNIT RP (MICROBIAL INFECTION). RX PubMed=17540170; DOI=10.1016/j.cell.2007.03.049; RA Wollert T., Pasche B., Rochon M., Deppenmeier S., van den Heuvel J., RA Gruber A.D., Heinz D.W., Lengeling A., Schubert W.D.; RT "Extending the host range of Listeria monocytogenes by rational protein RT design."; RL Cell 129:891-902(2007). RN [61] {ECO:0007744|PDB:2OMU, ECO:0007744|PDB:2OMZ} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, AND SUBUNIT (MICROBIAL INFECTION). RX PubMed=17715295; DOI=10.1073/pnas.0702199104; RA Wollert T., Heinz D.W., Schubert W.D.; RT "Thermodynamically reengineering the listerial invasion complex InlA/E- RT cadherin."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13960-13965(2007). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 155-367, AND CALCIUM-BINDING RP SITES. RX PubMed=17850815; DOI=10.1016/j.jmb.2007.08.011; RA Parisini E., Higgins J.M., Liu J.H., Brenner M.B., Wang J.H.; RT "The crystal structure of human E-cadherin domains 1 and 2, and comparison RT with other cadherins in the context of adhesion mechanism."; RL J. Mol. Biol. 373:401-411(2007). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 155-253 IN COMPLEX WITH KLRG1. RX PubMed=19604491; DOI=10.1016/j.immuni.2009.04.019; RA Li Y., Hofmann M., Wang Q., Teng L., Chlewicki L.K., Pircher H., RA Mariuzza R.A.; RT "Structure of natural killer cell receptor KLRG1 bound to E-cadherin RT reveals basis for MHC-independent missing self recognition."; RL Immunity 31:35-46(2009). RN [64] RP VARIANT LOBULAR BREAST CARCINOMA SER-315. RX PubMed=7961105; DOI=10.1111/j.1349-7006.1994.tb02902.x; RA Kanai Y., Oda T., Tsuda H., Ochiai A., Hirohashi S.; RT "Point mutation of the E-cadherin gene in invasive lobular carcinoma of the RT breast."; RL Jpn. J. Cancer Res. 85:1035-1039(1994). RN [65] RP VARIANTS THR-617 AND VAL-711, AND VARIANT OVARIAN CANCER GLY-838. RX PubMed=8075649; DOI=10.1038/ng0594-98; RA Risinger J.I., Berchuck A., Kohler M.F., Boyd J.; RT "Mutations of the E-cadherin gene in human gynecologic cancers."; RL Nat. Genet. 7:98-102(1994). RN [66] RP VARIANT PRO-193. RX PubMed=8797891; DOI=10.1111/j.1349-7006.1996.tb02109.x; RA Muta H., Noguchi M., Kanai Y., Ochiai A., Nawata H., Hirohashi S.; RT "E-cadherin gene mutations in signet ring cell carcinoma of the stomach."; RL Jpn. J. Cancer Res. 87:843-848(1996). RN [67] RP VARIANTS ASP-400 DEL AND 418-ASP--PHE-423 DEL. RX PubMed=9045944; DOI=10.1111/j.1349-7006.1996.tb03125.x; RA Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Iwaya T., RA Terashima M., Saito K., Satodate R.; RT "Inactivation of the E-cadherin gene in primary gastric carcinomas and RT gastric carcinoma cell lines."; RL Jpn. J. Cancer Res. 87:1153-1159(1996). RN [68] RP VARIANT THYROID CANCER THR-592. RX PubMed=8985087; RX DOI=10.1002/(sici)1097-0215(19970106)70:1<32::aid-ijc5>3.0.co;2-7; RA Soares P., Berx G., van Roy F., Sobrinho-Simoes M.; RT "E-cadherin gene alterations are rare events in thyroid tumors."; RL Int. J. Cancer 70:32-38(1997). RN [69] RP VARIANT DGLBC ASP-336, AND VARIANT ILE-470. RX PubMed=9537325; DOI=10.1038/32918; RA Guilford P.J., Hopkins J.B.W., Harraway J., McLeod M., McLeod N., RA Harawira P., Taite H., Scoular R., Miller A., Reeve A.E.; RT "E-cadherin germline mutations in familial gastric cancer."; RL Nature 392:402-405(1998). RN [70] RP VARIANTS DGLBC GLY-244 AND ALA-487. RX PubMed=10319582; DOI=10.1007/s100380050137; RA Yoon K.-A., Ku J.-L., Yang H.-K., Kim W.H., Park S.Y., Park J.-G.; RT "Germline mutations of E-cadherin gene in Korean familial gastric cancer RT patients."; RL J. Hum. Genet. 44:177-180(1999). RN [71] RP VARIANT ALA-340. RX PubMed=10896919; DOI=10.1136/gut.47.2.262; RA Kim H.C., Wheeler J.M.D., Kim J.C., Ilyas M., Beck N.E., Kim B.S., RA Park K.C., Bodmer W.F.; RT "The E-cadherin gene (CDH1) variants T340A and L599V in gastric and RT colorectal cancer patients in Korea."; RL Gut 47:262-267(2000). RN [72] RP VARIANT ALA-270. RX PubMed=11705864; RA Ikonen T., Matikainen M., Mononen N., Hyytinen E.R., Helin H.J., RA Tommola S., Tammela T.L., Pukkala E., Schleutker J., Kallioniemi O.-P., RA Koivisto P.A.; RT "Association of E-cadherin germ-line alterations with prostate cancer."; RL Clin. Cancer Res. 7:3465-3471(2001). RN [73] RP VARIANT THR-592. RX PubMed=11562785; DOI=10.3892/ijmm.8.4.439; RA Salahshor S., Hou H., Diep C.B., Loukola A., Zhang H., Liu T., Chen J., RA Iselius L., Rubio C., Lothe R.A., Aaltonen L., Sun X.F., Lindmark G., RA Lindblom A.; RT "A germline E-cadherin mutation in a family with gastric and colon RT cancer."; RL Int. J. Mol. Med. 8:439-443(2001). RN [74] RP VARIANT ALA-340. RX PubMed=11968083; DOI=10.1002/humu.10068; RA Oliveira C., Bordin M.C., Grehan N., Huntsman D., Suriano G., Machado J.C., RA Kiviluoto T., Aaltonen L., Jackson C.E., Seruca R., Caldas C.; RT "Screening E-cadherin in gastric cancer families reveals germline mutations RT only in hereditary diffuse gastric cancer kindred."; RL Hum. Mutat. 19:510-517(2002). RN [75] RP VARIANT DGLBC MET-832. RX PubMed=12216071; DOI=10.1002/ijc.10633; RA Yabuta T., Shinmura K., Tani M., Yamaguchi S., Yoshimura K., Katai H., RA Nakajima T., Mochiki E., Tsujinaka T., Takami M., Hirose K., Yamaguchi A., RA Takenoshita S., Yokota J.; RT "E-cadherin gene variants in gastric cancer families whose probands are RT diagnosed with diffuse gastric cancer."; RL Int. J. Cancer 101:434-441(2002). RN [76] RP VARIANTS THR-617 AND VAL-634, AND CHARACTERIZATION OF VARIANTS ALA-340; RP THR-617 AND VAL-634. RX PubMed=12588804; DOI=10.1093/hmg/ddg048; RA Suriano G., Oliveira C., Ferreira P., Machado J.C., Bordin M.C., RA De Wever O., Bruyneel E.A., Moguilevsky N., Grehan N., Porter T.R., RA Richards F.M., Hruban R.H., Roviello F., Huntsman D., Mareel M., RA Carneiro F., Caldas C., Seruca R.; RT "Identification of CDH1 germline missense mutations associated with RT functional inactivation of the E-cadherin protein in young gastric cancer RT probands."; RL Hum. Mol. Genet. 12:575-582(2003). RN [77] RP VARIANTS ILE-282 AND ASN-777. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [78] RP INVOLVEMENT IN BCDS1, VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, RP CHARACTERIZATION OF VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, AND RP SUBCELLULAR LOCATION. RX PubMed=28301459; DOI=10.1038/gim.2017.11; RA Ghoumid J., Stichelbout M., Jourdain A.S., Frenois F., Lejeune-Dumoulin S., RA Alex-Cordier M.P., Lebrun M., Guerreschi P., Duquennoy-Martinot V., RA Vinchon M., Ferri J., Jung M., Vicaire S., Vanlerberghe C., Escande F., RA Petit F., Manouvrier-Hanu S.; RT "Blepharocheilodontic syndrome is a CDH1 pathway-related disorder due to RT mutations in CDH1 and CTNND1."; RL Genet. Med. 19:1013-1021(2017). CC -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins CC (PubMed:11976333). They preferentially interact with themselves in a CC homophilic manner in connecting cells; cadherins may thus contribute to CC the sorting of heterogeneous cell types. CDH1 is involved in mechanisms CC regulating cell-cell adhesions, mobility and proliferation of CC epithelial cells (PubMed:11976333). Promotes organization of radial CC actin fiber structure and cellular response to contractile forces, via CC its interaction with AMOTL2 which facilitates anchoring of radial actin CC fibers to CDH1 junction complexes at the cell membrane (By similarity). CC Plays a role in the early stages of desmosome cell-cell junction CC formation via facilitating the recruitment of DSG2 and DSP to desmosome CC plaques (PubMed:29999492). Has a potent invasive suppressor role. It is CC a ligand for integrin alpha-E/beta-7. {ECO:0000250|UniProtKB:F1PAA9, CC ECO:0000269|PubMed:11976333, ECO:0000269|PubMed:16417575, CC ECO:0000269|PubMed:29999492}. CC -!- FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta CC precursors. Has a strong inhibitory effect on APP C99 and C83 CC production. {ECO:0000269|PubMed:16417575}. CC -!- FUNCTION: (Microbial infection) Serves as a receptor for Listeria CC monocytogenes; internalin A (InlA) binds to this protein and promotes CC uptake of the bacteria. {ECO:0000269|PubMed:10406800, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:8601315}. CC -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:11856755). Component of an CC E-cadherin/ catenin adhesion complex composed of at least E- CC cadherin/CDH1, beta-catenin/CTNNB1 or gamma-catenin/JUP, and CC potentially alpha-catenin/CTNNA1; the complex is located to adherens CC junctions (PubMed:16126725, PubMed:7982500). Found in a complex CC composed of CDH1, RAP1A and PKP3; PKP3 acts as a scaffold protein CC within the complex, the complex is required for CDH1 localization to CC mature desmosome cell junctions (PubMed:25208567). Interacts with the CC TRPV4 and CTNNB1 complex (By similarity). Interacts with CTNND1 CC (PubMed:15240885). The stable association of CTNNA1 is controversial as CC CTNNA1 was shown not to bind to F-actin when assembled in the complex CC (By similarity). Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1 (By similarity). CC Interaction with PSEN1, cleaves CDH1 resulting in the disassociation of CC cadherin-based adherens junctions (CAJs) (PubMed:11226248, CC PubMed:16126725). Interacts with AJAP1 and DLGAP5 (PubMed:14595118, CC PubMed:14699157). Interacts with TBC1D2 (PubMed:20116244). Interacts CC with LIMA1 (PubMed:18093941). Interacts with CAV1. Interacts with CC PIP5K1C (PubMed:17261850). Interacts with RAB8B (By similarity). CC Interacts with RAPGEF2 (By similarity). Interacts with DDR1; this CC stabilizes CDH1 at the cell surface and inhibits its internalization CC (PubMed:20432435). Interacts with KLRG1 (PubMed:19604491). Forms a CC ternary complex composed of ADAM10, CADH1 and EPHA4; within the CC complex, CADH1 is cleaved by ADAM10 which disrupts adherens junctions CC (By similarity). Interacts with SPEF1 (PubMed:31473225). Interacts with CC CTNNB1 and PKP2 (PubMed:11790773). Interacts with AMOTL2; the CC interaction may facilitate binding of radial actin fibers to cell CC junction complexes (By similarity). Interacts with DSG3; the CC interaction is required for CDH1 localization to developing adherens CC junctions (PubMed:22294297). {ECO:0000250, CC ECO:0000250|UniProtKB:F1PAA9, ECO:0000250|UniProtKB:P09803, CC ECO:0000250|UniProtKB:Q9R0T4, ECO:0000269|PubMed:11226248, CC ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:11856755, CC ECO:0000269|PubMed:12526809, ECO:0000269|PubMed:14595118, CC ECO:0000269|PubMed:14699157, ECO:0000269|PubMed:15240885, CC ECO:0000269|PubMed:16126725, ECO:0000269|PubMed:17261850, CC ECO:0000269|PubMed:18093941, ECO:0000269|PubMed:19604491, CC ECO:0000269|PubMed:20116244, ECO:0000269|PubMed:20432435, CC ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:25208567, CC ECO:0000269|PubMed:31473225, ECO:0000269|PubMed:7982500}. CC -!- SUBUNIT: (Microbial infection) Interacts with L.monocytogenes InlA CC (PubMed:12526809, PubMed:17540170, PubMed:17715295). The formation of CC the complex between InlA and cadherin-1 is calcium-dependent CC (PubMed:12526809). {ECO:0000269|PubMed:12526809, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:17715295}. CC -!- INTERACTION: CC P12830; O94983-5: CAMTA2; NbExp=3; IntAct=EBI-727477, EBI-10176008; CC P12830; P30260: CDC27; NbExp=2; IntAct=EBI-727477, EBI-994813; CC P12830; P12830: CDH1; NbExp=8; IntAct=EBI-727477, EBI-727477; CC P12830; Q6UXH1-2: CRELD2; NbExp=3; IntAct=EBI-727477, EBI-21670927; CC P12830; P35221: CTNNA1; NbExp=8; IntAct=EBI-727477, EBI-701918; CC P12830; P35222: CTNNB1; NbExp=23; IntAct=EBI-727477, EBI-491549; CC P12830; O60716: CTNND1; NbExp=9; IntAct=EBI-727477, EBI-701927; CC P12830; P49184: DNASE1L1; NbExp=3; IntAct=EBI-727477, EBI-20894690; CC P12830; Q9H8V3: ECT2; NbExp=3; IntAct=EBI-727477, EBI-1054039; CC P12830; P00533: EGFR; NbExp=4; IntAct=EBI-727477, EBI-297353; CC P12830; P16422: EPCAM; NbExp=3; IntAct=EBI-727477, EBI-1171184; CC P12830; P11362: FGFR1; NbExp=3; IntAct=EBI-727477, EBI-1028277; CC P12830; Q7Z6Z7-2: HUWE1; NbExp=3; IntAct=EBI-727477, EBI-10975491; CC P12830; Q9UHB6: LIMA1; NbExp=2; IntAct=EBI-727477, EBI-351479; CC P12830; P43356: MAGEA2B; NbExp=3; IntAct=EBI-727477, EBI-5650739; CC P12830; Q7Z434: MAVS; NbExp=3; IntAct=EBI-727477, EBI-995373; CC P12830; P08581: MET; NbExp=2; IntAct=EBI-727477, EBI-1039152; CC P12830; Q8NCR3: MFI; NbExp=3; IntAct=EBI-727477, EBI-744790; CC P12830; Q8TB02: MGC39372; NbExp=3; IntAct=EBI-727477, EBI-25834188; CC P12830; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-727477, EBI-3446748; CC P12830; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-727477, EBI-11750983; CC P12830; Q8N323: NXPE1; NbExp=3; IntAct=EBI-727477, EBI-25834085; CC P12830; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-727477, EBI-473160; CC P12830; Q8NBT0: POC1A; NbExp=3; IntAct=EBI-727477, EBI-2557132; CC P12830; P62136: PPP1CA; NbExp=2; IntAct=EBI-727477, EBI-357253; CC P12830; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-727477, EBI-2860740; CC P12830; P17612: PRKACA; NbExp=3; IntAct=EBI-727477, EBI-476586; CC P12830; Q15139: PRKD1; NbExp=7; IntAct=EBI-727477, EBI-1181072; CC P12830; Q9Y617: PSAT1; NbExp=3; IntAct=EBI-727477, EBI-709652; CC P12830; P49768: PSEN1; NbExp=2; IntAct=EBI-727477, EBI-297277; CC P12830; P50454: SERPINH1; NbExp=3; IntAct=EBI-727477, EBI-350723; CC P12830; Q02978: SLC25A11; NbExp=3; IntAct=EBI-727477, EBI-359174; CC P12830; P12931: SRC; NbExp=2; IntAct=EBI-727477, EBI-621482; CC P12830; P48775: TDO2; NbExp=3; IntAct=EBI-727477, EBI-743494; CC P12830; P37173: TGFBR2; NbExp=3; IntAct=EBI-727477, EBI-296151; CC P12830; Q9BT49: THAP7; NbExp=3; IntAct=EBI-727477, EBI-741350; CC P12830; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-727477, EBI-1220488; CC P12830; Q9ULW0: TPX2; NbExp=3; IntAct=EBI-727477, EBI-1037322; CC P12830; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-727477, EBI-25830993; CC P12830; Q9BQ29; NbExp=3; IntAct=EBI-727477, EBI-22013570; CC P12830; A0A0S2C3P2: cagA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-55025805; CC P12830; Q9JIY2: Cbll1; Xeno; NbExp=21; IntAct=EBI-727477, EBI-7644904; CC P12830; P0DJM0: inlA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-1035388; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:18343367, ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:27760340, ECO:0000269|PubMed:28169360}. Cell CC membrane {ECO:0000269|PubMed:19403558, ECO:0000269|PubMed:20859650, CC ECO:0000269|PubMed:28301459, ECO:0000269|PubMed:36309486}; Single-pass CC type I membrane protein. Endosome {ECO:0000269|PubMed:15689490}. Golgi CC apparatus, trans-Golgi network {ECO:0000269|PubMed:15689490}. Cytoplasm CC {ECO:0000269|PubMed:22294297}. Cell junction, desmosome CC {ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492, CC ECO:0000269|PubMed:33596089}. Note=Colocalizes with DLGAP5 at sites of CC cell-cell contact in intestinal epithelial cells. Anchored to actin CC microfilaments through association with alpha-, beta- and gamma- CC catenin. Sequential proteolysis induced by apoptosis or calcium influx, CC results in translocation from sites of cell-cell contact to the CC cytoplasm. Colocalizes with RAB11A endosomes during its transport from CC the Golgi apparatus to the plasma membrane. Recruited to desmosomes at CC the initial assembly phase and also accumulates progressively at mature CC desmosome cell-cell junctions (PubMed:25208567, PubMed:29999492). CC Localizes to cell-cell contacts as keratinocyte differentiation CC progresses (By similarity). {ECO:0000250|UniProtKB:P09803, CC ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P12830-1; Sequence=Displayed; CC Name=2; CC IsoId=P12830-2; Sequence=VSP_055586; CC -!- TISSUE SPECIFICITY: Expressed in granuloma macrophages (at protein CC level) (PubMed:27760340). Expressed in the skin (at protein level) CC (PubMed:22294297). Expressed in the liver (PubMed:3263290). CC {ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:27760340, CC ECO:0000269|PubMed:3263290}. CC -!- INDUCTION: Induced in the hours following cyclic mechanical strain in CC keratinocytes (PubMed:31835537). Expression is repressed by MACROD1 CC (PubMed:17893710). {ECO:0000269|PubMed:17893710, CC ECO:0000269|PubMed:31835537}. CC -!- DOMAIN: Three calcium ions are usually bound at the interface of each CC cadherin domain and strengthen the connections, imparting a strong CC curvature to the full-length ectodomain. {ECO:0000269|PubMed:2349235}. CC -!- PTM: During apoptosis or with calcium influx, cleaved by a membrane- CC bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 CC (PubMed:10597309, PubMed:11076937, PubMed:11953314). Processing by the CC metalloproteinase, induced by calcium influx, causes disruption of CC cell-cell adhesion and the subsequent release of beta-catenin into the CC cytoplasm (PubMed:10597309). The residual membrane-tethered cleavage CC product is rapidly degraded via an intracellular proteolytic pathway CC (PubMed:10597309). Cleavage by caspase-3 releases the cytoplasmic tail CC resulting in disintegration of the actin microfilament system CC (PubMed:11076937). The gamma-secretase-mediated cleavage promotes CC disassembly of adherens junctions (PubMed:11953314). During development CC of the cochlear organ of Corti, cleavage by ADAM10 at adherens CC junctions promotes pillar cell separation (By similarity). CC {ECO:0000250|UniProtKB:P09803, ECO:0000269|PubMed:10597309, CC ECO:0000269|PubMed:11076937, ECO:0000269|PubMed:11953314}. CC -!- PTM: N-glycosylation at Asn-637 is essential for expression, folding CC and trafficking. Addition of bisecting N-acetylglucosamine by MGAT3 CC modulates its cell membrane location (PubMed:19403558). CC {ECO:0000269|PubMed:18491227, ECO:0000269|PubMed:19403558}. CC -!- PTM: Ubiquitinated by a SCF complex containing SKP2, which requires CC prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by CBLL1/HAKAI, CC requires prior phosphorylation at Tyr-754. CC {ECO:0000269|PubMed:21283129, ECO:0000269|PubMed:22252131, CC ECO:0000269|PubMed:22770219}. CC -!- PTM: O-glycosylated. O-manosylated by TMTC1, TMTC2, TMTC3 or TMTC4. CC Thr-285 and Thr-509 are O-mannosylated by TMTC2 or TMTC4 but not TMTC1 CC or TMTC3. {ECO:0000250|UniProtKB:P09803}. CC -!- PTM: (Microbial infection) Cleaved by S.pyogenes SpeB protease; leading CC to its degradation (PubMed:23532847). Degradation by SpeB promotes CC bacterial translocation across the host epithelial barrier CC (PubMed:23532847). {ECO:0000269|PubMed:23532847}. CC -!- DISEASE: Diffuse gastric and lobular breast cancer syndrome (DGLBC) CC [MIM:137215]: A cancer predisposition syndrome with increased CC susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a CC malignant disease characterized by poorly differentiated infiltrating CC lesions resulting in thickening of the stomach. Malignant tumors start CC in the stomach, can spread to the esophagus or the small intestine, and CC can extend through the stomach wall to nearby lymph nodes and organs. CC It also can metastasize to other parts of the body. In addition to CC gastric cancer, most female mutation carriers develop lobular carcinoma CC of the breast. {ECO:0000269|PubMed:10319582, CC ECO:0000269|PubMed:12216071, ECO:0000269|PubMed:9537325}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. Heterozygous CDH1 germline mutations are CC responsible for familial cases of diffuse gastric cancer. Somatic CC mutations has also been found in patients with sporadic diffuse gastric CC cancer and lobular breast cancer. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast CC cancer that begins in the milk-producing glands (lobules) of the CC breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in CC this entry may be involved in disease pathogenesis. CC -!- DISEASE: Blepharocheilodontic syndrome 1 (BCDS1) [MIM:119580]: A form CC of blepharocheilodontic syndrome, a rare autosomal dominant disorder. CC It is characterized by lower eyelid ectropion, upper eyelid CC distichiasis, euryblepharon, bilateral cleft lip and palate, and CC features of ectodermal dysplasia, including hair anomalies, conical CC teeth and tooth agenesis. An additional rare manifestation is CC imperforate anus. There is considerable phenotypic variability among CC affected individuals. {ECO:0000269|PubMed:28301459}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: May play a role in blister formation in Pemphigus CC vulgaris patients, expression is lost at sites of cell-cell contact CC between the basal and suprabasal layers in blisters and immediately CC adjacent to blisters. {ECO:0000269|PubMed:22294297}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA61259.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/166/CDH1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=E-cadherin entry; CC URL="https://en.wikipedia.org/wiki/E-cadherin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z13009; CAA78353.1; -; mRNA. DR EMBL; Z18923; CAA79356.1; -; mRNA. DR EMBL; L08599; AAA61259.1; ALT_FRAME; mRNA. DR EMBL; AB025105; BAA88956.1; -; mRNA. DR EMBL; AK290012; BAF82701.1; -; mRNA. DR EMBL; AK312551; BAG35448.1; -; mRNA. DR EMBL; DQ090940; AAY68225.1; -; Genomic_DNA. DR EMBL; AC099314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471092; EAW83243.1; -; Genomic_DNA. DR EMBL; CH471092; EAW83244.1; -; Genomic_DNA. DR EMBL; L34545; AAA21764.1; -; Genomic_DNA. DR EMBL; D49685; BAA08537.1; -; Genomic_DNA. DR EMBL; Z35402; CAA84586.1; -; Genomic_DNA. DR EMBL; Z35403; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35404; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35405; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35406; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35407; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35408; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35409; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35410; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35411; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35412; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35413; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35414; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35415; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; X12790; CAA31279.1; -; mRNA. DR EMBL; X52279; CAA36522.1; -; mRNA. DR EMBL; S72492; AAD14108.1; -; Genomic_DNA. DR EMBL; S72397; AAD14108.1; JOINED; Genomic_DNA. DR EMBL; S72491; AAD14108.1; JOINED; Genomic_DNA. DR CCDS; CCDS10869.1; -. [P12830-1] DR CCDS; CCDS82005.1; -. [P12830-2] DR PIR; S37654; IJHUCE. DR RefSeq; NP_001304113.1; NM_001317184.2. [P12830-2] DR RefSeq; NP_001304114.1; NM_001317185.1. DR RefSeq; NP_001304115.1; NM_001317186.1. DR RefSeq; NP_004351.1; NM_004360.5. [P12830-1] DR PDB; 1O6S; X-ray; 1.80 A; B=156-255. DR PDB; 2O72; X-ray; 2.00 A; A=155-367. DR PDB; 2OMT; X-ray; 2.00 A; B=156-255. DR PDB; 2OMU; X-ray; 1.80 A; B=156-255. DR PDB; 2OMV; X-ray; 1.90 A; B=156-255. DR PDB; 2OMX; X-ray; 1.70 A; B=156-258. DR PDB; 2OMY; X-ray; 1.70 A; B=156-254. DR PDB; 2OMZ; X-ray; 1.60 A; B=156-254. DR PDB; 3FF7; X-ray; 1.80 A; A/B=155-253. DR PDB; 3FF8; X-ray; 2.00 A; A/B=155-254. DR PDB; 3L6X; X-ray; 2.40 A; B=756-773. DR PDB; 3L6Y; X-ray; 3.00 A; B/D/F=756-773. DR PDB; 4ZT1; X-ray; 1.92 A; A/B=157-367. DR PDB; 4ZTE; X-ray; 2.13 A; A/B=157-367. DR PDB; 6CXY; X-ray; 2.20 A; C=155-371. DR PDB; 6OLE; EM; 3.10 A; y=693-730. DR PDB; 6OLF; EM; 3.90 A; y=693-730. DR PDB; 6OLG; EM; 3.40 A; A=693-730. DR PDB; 6VEL; X-ray; 2.65 A; C=155-371. DR PDB; 7STZ; X-ray; 2.95 A; C/D=155-698. DR PDB; 8H62; X-ray; 1.91 A; B=155-367. DR PDBsum; 1O6S; -. DR PDBsum; 2O72; -. DR PDBsum; 2OMT; -. DR PDBsum; 2OMU; -. DR PDBsum; 2OMV; -. DR PDBsum; 2OMX; -. DR PDBsum; 2OMY; -. DR PDBsum; 2OMZ; -. DR PDBsum; 3FF7; -. DR PDBsum; 3FF8; -. DR PDBsum; 3L6X; -. DR PDBsum; 3L6Y; -. DR PDBsum; 4ZT1; -. DR PDBsum; 4ZTE; -. DR PDBsum; 6CXY; -. DR PDBsum; 6OLE; -. DR PDBsum; 6OLF; -. DR PDBsum; 6OLG; -. DR PDBsum; 6VEL; -. DR PDBsum; 7STZ; -. DR PDBsum; 8H62; -. DR AlphaFoldDB; P12830; -. DR EMDB; EMD-25883; -. DR EMDB; EMD-25884; -. DR EMDB; EMD-25886; -. DR EMDB; EMD-25892; -. DR SMR; P12830; -. DR BioGRID; 107434; 777. DR CORUM; P12830; -. DR DIP; DIP-477N; -. DR ELM; P12830; -. DR FunCoup; P12830; 811. DR IntAct; P12830; 146. DR MINT; P12830; -. DR STRING; 9606.ENSP00000261769; -. DR BindingDB; P12830; -. DR ChEMBL; CHEMBL2321609; -. DR TCDB; 8.A.204.1.1; the cadhesin (cdh) family. DR UniLectin; P12830; -. DR GlyCosmos; P12830; 13 sites, No reported glycans. DR GlyGen; P12830; 16 sites, 2 O-linked glycans (3 sites). DR iPTMnet; P12830; -. DR PhosphoSitePlus; P12830; -. DR SwissPalm; P12830; -. DR BioMuta; CDH1; -. DR DMDM; 399166; -. DR CPTAC; CPTAC-1599; -. DR CPTAC; CPTAC-5772; -. DR CPTAC; CPTAC-5773; -. DR CPTAC; non-CPTAC-5366; -. DR CPTAC; non-CPTAC-5367; -. DR CPTAC; non-CPTAC-5370; -. DR CPTAC; non-CPTAC-5541; -. DR CPTAC; non-CPTAC-5542; -. DR jPOST; P12830; -. DR MassIVE; P12830; -. DR PaxDb; 9606-ENSP00000261769; -. DR PeptideAtlas; P12830; -. DR ProteomicsDB; 52879; -. [P12830-1] DR ProteomicsDB; 84533; -. DR Pumba; P12830; -. DR TopDownProteomics; P12830-2; -. [P12830-2] DR ABCD; P12830; 29 sequenced antibodies. DR Antibodypedia; 1347; 3254 antibodies from 63 providers. DR CPTC; P12830; 4 antibodies. DR DNASU; 999; -. DR Ensembl; ENST00000261769.10; ENSP00000261769.4; ENSG00000039068.21. [P12830-1] DR Ensembl; ENST00000422392.6; ENSP00000414946.2; ENSG00000039068.21. [P12830-2] DR GeneID; 999; -. DR KEGG; hsa:999; -. DR MANE-Select; ENST00000261769.10; ENSP00000261769.4; NM_004360.5; NP_004351.1. DR UCSC; uc002ewg.2; human. [P12830-1] DR AGR; HGNC:1748; -. DR CIViC; 999; 4 evidence items across 4 molecular profiles. DR ClinPGx; PA26282; -. DR CTD; 999; -. DR DisGeNET; 999; -. DR GeneCards; CDH1; -. DR GeneReviews; CDH1; -. DR HGNC; HGNC:1748; CDH1. DR HPA; ENSG00000039068; Tissue enhanced (parathyroid). DR MalaCards; CDH1; -. DR MIM; 119580; phenotype. DR MIM; 137215; phenotype. DR MIM; 167000; phenotype. DR MIM; 192090; gene. DR MIM; 608089; phenotype. DR OpenTargets; ENSG00000039068; -. DR Orphanet; 1997; Blepharo-cheilo-odontic syndrome. DR Orphanet; 199306; Cleft lip/palate. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 26106; Hereditary diffuse gastric cancer. DR VEuPathDB; HostDB:ENSG00000039068; -. DR eggNOG; KOG3594; Eukaryota. DR GeneTree; ENSGT00940000157175; -. DR HOGENOM; CLU_005284_2_1_1; -. DR InParanoid; P12830; -. DR OrthoDB; 6079678at2759; -. DR PAN-GO; P12830; 8 GO annotations based on evolutionary models. DR PhylomeDB; P12830; -. DR PathwayCommons; P12830; -. DR Reactome; R-HSA-1474228; Degradation of the extracellular matrix. DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9764562; Regulation of CDH1 mRNA translation by microRNAs. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR Reactome; R-HSA-9926550; Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P12830; -. DR SIGNOR; P12830; -. DR Agora; ENSG00000039068; -. DR BioGRID-ORCS; 999; 47 hits in 1173 CRISPR screens. DR ChiTaRS; CDH1; human. DR EvolutionaryTrace; P12830; -. DR GeneWiki; CDH1_(gene); -. DR GenomeRNAi; 999; -. DR Pharos; P12830; Tbio. DR PRO; PR:P12830; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; P12830; protein. DR Bgee; ENSG00000039068; Expressed in jejunal mucosa and 158 other cell types or tissues. DR ExpressionAtlas; P12830; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0043296; C:apical junction complex; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0030057; C:desmosome; IDA:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; TAS:Reactome. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0016600; C:flotillin complex; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005765; C:lysosomal membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005802; C:trans-Golgi network; IMP:BHF-UCL. DR GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0098631; F:cell adhesion mediator activity; IDA:UniProt. DR GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0032794; F:GTPase activating protein binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:1990782; F:protein tyrosine kinase binding; IEA:Ensembl. DR GO; GO:0034332; P:adherens junction organization; IMP:UniProtKB. DR GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0000902; P:cell morphogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IDA:BHF-UCL. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IDA:BHF-UCL. DR GO; GO:0007043; P:cell-cell junction assembly; IBA:GO_Central. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0071285; P:cellular response to lithium ion; IDA:UniProtKB. DR GO; GO:0002159; P:desmosome assembly; IMP:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; NAS:UniProtKB. DR GO; GO:0030517; P:negative regulation of axon extension; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:ARUK-UCL. DR GO; GO:0022408; P:negative regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0031175; P:neuron projection development; IEA:Ensembl. DR GO; GO:0021983; P:pituitary gland development; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; IMP:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB. DR GO; GO:0099576; P:regulation of protein catabolic process at postsynapse, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0071503; P:response to heparin; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0007416; P:synapse assembly; IBA:GO_Central. DR CDD; cd00031; CA_like; 1. DR CDD; cd11304; Cadherin_repeat; 3. DR FunFam; 2.60.40.60:FF:000011; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000191; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000019; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000022; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000027; Cadherin 2; 1. DR FunFam; 4.10.900.10:FF:000001; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000031; Cadherin 3; 1. DR Gene3D; 2.60.40.60; Cadherins; 6. DR Gene3D; 4.10.900.10; TCF3-CBD (Catenin binding domain); 1. DR InterPro; IPR039808; Cadherin. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR020894; Cadherin_CS. DR InterPro; IPR014868; Cadherin_pro_dom. DR InterPro; IPR000233; Cadherin_Y-type_LIR. DR InterPro; IPR027397; Catenin-bd_sf. DR PANTHER; PTHR24027:SF319; CADHERIN-1; 1. DR PANTHER; PTHR24027; CADHERIN-23; 1. DR Pfam; PF01049; CADH_Y-type_LIR; 1. DR Pfam; PF00028; Cadherin; 5. DR Pfam; PF08758; Cadherin_pro; 1. DR PRINTS; PR00205; CADHERIN. DR SMART; SM00112; CA; 4. DR SMART; SM01055; Cadherin_pro; 1. DR SUPFAM; SSF49313; Cadherin-like; 6. DR PROSITE; PS00232; CADHERIN_1; 3. DR PROSITE; PS50268; CADHERIN_2; 5. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell junction; KW Cell membrane; Cleavage on pair of basic residues; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Endosome; Glycoprotein; Golgi apparatus; Membrane; KW Metal-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix; KW Ubl conjugation. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT PROPEP 23..154 FT /evidence="ECO:0000255" FT /id="PRO_0000003715" FT CHAIN 155..882 FT /note="Cadherin-1" FT /id="PRO_0000003716" FT CHAIN 701..882 FT /note="E-Cad/CTF1" FT /id="PRO_0000236067" FT CHAIN 732..882 FT /note="E-Cad/CTF2" FT /id="PRO_0000236068" FT CHAIN 751..882 FT /note="E-Cad/CTF3" FT /id="PRO_0000236069" FT TOPO_DOM 155..709 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 710..730 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 731..882 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 155..262 FT /note="Cadherin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 263..375 FT /note="Cadherin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 376..486 FT /note="Cadherin 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 487..593 FT /note="Cadherin 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 594..697 FT /note="Cadherin 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT REGION 747..767 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 758..769 FT /note="Required for binding CTNND1 and PSEN1" FT REGION 811..882 FT /note="Required for binding alpha, beta and gamma catenins" FT COMPBIAS 755..767 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 288 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT SITE 364..365 FT /note="Cleavage; by S.pyogenes SpeB" FT /evidence="ECO:0000269|PubMed:23532847" FT SITE 700..701 FT /note="Cleavage; by a metalloproteinase" FT SITE 731..732 FT /note="Cleavage; by gamma-secretase/PS1" FT SITE 750..751 FT /note="Cleavage; by caspase-3" FT MOD_RES 753 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 754 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 755 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 793 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 838 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 840 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 846 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 280 FT /note="O-linked (Man...) serine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 285 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 358 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 470 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 472 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 509 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 558 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 570 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 576 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 578 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 580 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 622 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 637 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT DISULFID 163 FT /note="Interchain" FT VAR_SEQ 380..440 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_055586" FT VARIANT 72 FT /note="D -> N (in dbSNP:rs35606263)" FT /id="VAR_048500" FT VARIANT 123 FT /note="H -> Y (in a gastric cancer sample; FT dbSNP:rs1555514482)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001306" FT VARIANT 193 FT /note="T -> P (in a diffuse gastric cancer sample; FT dbSNP:rs1597891014)" FT /evidence="ECO:0000269|PubMed:8797891" FT /id="VAR_001307" FT VARIANT 244 FT /note="D -> G (in DGLBC; likely benign; FT dbSNP:rs1064794231)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008712" FT VARIANT 254 FT /note="D -> Y (in BCDS1; abolishes protein abundance; loss FT of cell membrane localization; dbSNP:rs1555515445)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079392" FT VARIANT 257 FT /note="D -> V (in BCDS1; slightly decreases protein FT abundance; loss of cell membrane localization; FT dbSNP:rs1555515446)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079393" FT VARIANT 270 FT /note="S -> A (in dbSNP:rs587776399)" FT /evidence="ECO:0000269|PubMed:11705864" FT /id="VAR_013970" FT VARIANT 274..277 FT /note="Missing (found in gastric carcinoma cell lines)" FT /evidence="ECO:0000269|PubMed:8127895" FT /id="VAR_001308" FT VARIANT 282 FT /note="M -> I (in a breast cancer sample; somatic mutation; FT dbSNP:rs200932258)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033026" FT VARIANT 315 FT /note="N -> S (in lobular breast carcinoma)" FT /evidence="ECO:0000269|PubMed:7961105" FT /id="VAR_001309" FT VARIANT 336 FT /note="E -> D (in DGLBC; likely pathogenic; FT dbSNP:rs267606712)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001310" FT VARIANT 340 FT /note="T -> A (found in gastric and colorectal cancer FT samples; cells exhibited decreased aggregation increased FT invasiveness and non-uniform migration in vitro compared to FT cells transfected with wild-type sequence; FT dbSNP:rs116093741)" FT /evidence="ECO:0000269|PubMed:10896919, FT ECO:0000269|PubMed:11968083, ECO:0000269|PubMed:12588804" FT /id="VAR_013971" FT VARIANT 370 FT /note="D -> A (in a diffuse gastric cancer sample; FT dbSNP:rs2152132676)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001311" FT VARIANT 393 FT /note="I -> N (in dbSNP:rs34466743)" FT /id="VAR_048501" FT VARIANT 400 FT /note="Missing (in a gastric carcinoma sample; loss of FT heterozygosity)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001312" FT VARIANT 418..423 FT /note="Missing (in a gastric carcinoma sample)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001313" FT VARIANT 454 FT /note="Missing (in BCDS1; decreases protein abundance; loss FT of cell membrane localization)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079394" FT VARIANT 463 FT /note="E -> Q (in a gastric carcinoma sample; FT dbSNP:rs1960961009)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001314" FT VARIANT 470 FT /note="T -> I (in dbSNP:rs370864592)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001315" FT VARIANT 473 FT /note="V -> D (in a diffuse gastric cancer sample; FT dbSNP:rs2152134881)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001317" FT VARIANT 473 FT /note="V -> I (in dbSNP:rs36087757)" FT /id="VAR_048502" FT VARIANT 478 FT /note="L -> P (in dbSNP:rs35520415)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023357" FT VARIANT 487 FT /note="V -> A (in DGLBC; dbSNP:rs1960965342)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008713" FT VARIANT 592 FT /note="A -> T (in dbSNP:rs35187787)" FT /evidence="ECO:0000269|PubMed:11562785, FT ECO:0000269|PubMed:8985087" FT /id="VAR_001318" FT VARIANT 598 FT /note="R -> Q (in a gastric cancer sample; FT dbSNP:rs780759537)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001319" FT VARIANT 617 FT /note="A -> T (detected in an endometrial cancer sample; FT loss of heterozygosity; cells exhibited an intermediate FT phenotype concerning aggregation invasiveness and migration FT in vitro compared to cells transfected with wild-type FT sequence; dbSNP:rs33935154)" FT /evidence="ECO:0000269|PubMed:12588804, FT ECO:0000269|PubMed:8075649, ECO:0000269|Ref.7" FT /id="VAR_001320" FT VARIANT 630 FT /note="L -> V (in dbSNP:rs2276331)" FT /id="VAR_021868" FT VARIANT 634 FT /note="A -> V (found in a gastric cancer sample; cells FT exhibited decreased aggregation increased invasiveness and FT non-uniform migration in vitro compared to cells FT transfected with wild-type sequence; dbSNP:rs121964878)" FT /evidence="ECO:0000269|PubMed:12588804" FT /id="VAR_055431" FT VARIANT 695 FT /note="C -> R (in dbSNP:rs9282655)" FT /id="VAR_021869" FT VARIANT 711 FT /note="L -> V (detected in an endometrial cancer sample; FT dbSNP:rs121964871)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001321" FT VARIANT 777 FT /note="D -> N (in dbSNP:rs372989292)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033027" FT VARIANT 832 FT /note="V -> M (in DGLBC; benign; dbSNP:rs35572355)" FT /evidence="ECO:0000269|PubMed:12216071, ECO:0000269|Ref.7" FT /id="VAR_023358" FT VARIANT 838 FT /note="S -> G (in an ovarian carcinoma sample; somatic FT mutation; loss of heterozygosity; dbSNP:rs121964872)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001322" FT VARIANT 880 FT /note="E -> K (in dbSNP:rs34507583)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023359" FT MUTAGEN 156 FT /note="W->A,S: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 156 FT /note="W->D: Protein is partially unfolded, no longer binds FT L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->A,E,V: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->E: No longer adheres to L.monocytogenes InlA FT coated beads, nor do cells take up InlA coated beads." FT /evidence="ECO:0000269|PubMed:10406800" FT MUTAGEN 175 FT /note="L->D: Reduces localization to desmosome cell-cell FT junctions. Also reduces the localization of DSG2 and DSP to FT desmosome cell-cell junctions." FT /evidence="ECO:0000269|PubMed:29999492" FT MUTAGEN 637 FT /note="N->Q: CDH1 becomes a substrate for ERAD and is FT retro-translocated from ER to cytoplasm." FT /evidence="ECO:0000269|PubMed:18491227" FT MUTAGEN 754 FT /note="Y->F: Abolishes binding to CBLL1." FT /evidence="ECO:0000269|PubMed:22252131" FT MUTAGEN 759..761 FT /note="GGG->AAA: Binds to CTNNB1 but abolishes interaction FT of CTNNB1 with PSEN1. Abolishes gamma-secretase cleavage." FT /evidence="ECO:0000269|PubMed:11953314, FT ECO:0000269|PubMed:16126725" FT CONFLICT 10 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 29 FT /note="H -> L (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 47 FT /note="E -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 70..71 FT /note="SL -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 483 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 530 FT /note="A -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 543 FT /note="S -> F (in Ref. 2; CAA79356)" FT /evidence="ECO:0000305" FT CONFLICT 615 FT /note="I -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 634..636 FT /note="ASA -> RVP (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="R -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 882 FT /note="D -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT STRAND 163..166 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 169..177 FT /evidence="ECO:0007829|PDB:2OMZ" FT HELIX 181..184 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 189..195 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 213..216 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 222..224 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 241..243 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 246..253 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 265..272 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 292..294 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 301..309 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 316..319 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 321..323 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 325..328 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 335..337 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 340..348 FT /evidence="ECO:0007829|PDB:8H62" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 356..366 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 374..384 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 394..396 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 410..417 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 423..428 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 429..432 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 433..440 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 448..460 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 470..477 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 485..498 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 522..527 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 533..535 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 537..539 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 541..544 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 557..568 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 576..586 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 594..596 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 599..607 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 610..615 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 622..625 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 627..633 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 638..644 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 648..656 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 660..673 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 675..691 FT /evidence="ECO:0007829|PDB:7STZ" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:3L6X" SQ SEQUENCE 882 AA; 97456 MW; E427118043A13C67 CRC64; MGPWSRSLSA LLLLLQVSSW LCQEPEPCHP GFDAESYTFT VPRRHLERGR VLGRVNFEDC TGRQRTAYFS LDTRFKVGTD GVITVKRPLR FHNPQIHFLV YAWDSTYRKF STKVTLNTVG HHHRPPPHQA SVSGIQAELL TFPNSSPGLR RQKRDWVIPP ISCPENEKGP FPKNLVQIKS NKDKEGKVFY SITGQGADTP PVGVFIIERE TGWLKVTEPL DRERIATYTL FSHAVSSNGN AVEDPMEILI TVTDQNDNKP EFTQEVFKGS VMEGALPGTS VMEVTATDAD DDVNTYNAAI AYTILSQDPE LPDKNMFTIN RNTGVISVVT TGLDRESFPT YTLVVQAADL QGEGLSTTAT AVITVTDTND NPPIFNPTTY KGQVPENEAN VVITTLKVTD ADAPNTPAWE AVYTILNDDG GQFVVTTNPV NNDGILKTAK GLDFEAKQQY ILHVAVTNVV PFEVSLTTST ATVTVDVLDV NEAPIFVPPE KRVEVSEDFG VGQEITSYTA QEPDTFMEQK ITYRIWRDTA NWLEINPDTG AISTRAELDR EDFEHVKNST YTALIIATDN GSPVATGTGT LLLILSDVND NAPIPEPRTI FFCERNPKPQ VINIIDADLP PNTSPFTAEL THGASANWTI QYNDPTQESI ILKPKMALEV GDYKINLKLM DNQNKDQVTT LEVSVCDCEG AAGVCRKAQP VEAGLQIPAI LGILGGILAL LILILLLLLF LRRRAVVKEP LLPPEDDTRD NVYYYDEEGG GEEDQDFDLS QLHRGLDARP EVTRNDVAPT LMSVPRYLPR PANPDEIGNF IDENLKAADT DPTAPPYDSL LVFDYEGSGS EAASLSSLNS SESDKDQDYD YLNEWGNRFK KLADMYGGGE DD // ID CASPA_HUMAN Reviewed; 521 AA. AC Q92851; Q68HC0; Q6KF62; Q6KF63; Q8IUP5; Q8WYQ8; Q99845; Q9Y2U6; Q9Y2U7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 3. DT 28-JAN-2026, entry version 241. DE RecName: Full=Caspase-10; DE Short=CASP-10; DE EC=3.4.22.63 {ECO:0000269|PubMed:16916640}; DE AltName: Full=Apoptotic protease Mch-4; DE AltName: Full=FAS-associated death domain protein interleukin-1B-converting enzyme 2; DE Short=FLICE2; DE AltName: Full=ICE-like apoptotic protease 4; DE Contains: DE RecName: Full=Caspase-10 subunit p23/17; DE Contains: DE RecName: Full=Caspase-10 subunit p12; DE Flags: Precursor; GN Name=CASP10; Synonyms=MCH4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), AND VARIANT ILE-479 (ISOFORM B). RC TISSUE=T-cell; RX PubMed=8755496; DOI=10.1073/pnas.93.15.7464; RA Fernandes-Alnemri T., Armstrong R.C., Krebs J.F., Srinivasula S.M., RA Wang L., Bullrich F., Fritz L.C., Trapani J.A., Tomaselli K.J., Litwack G., RA Alnemri E.S.; RT "In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic RT cysteine protease containing two FADD-like domains."; RL Proc. Natl. Acad. Sci. U.S.A. 93:7464-7469(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A). RX PubMed=9045686; DOI=10.1074/jbc.272.10.6578; RA Vincenz C., Dixit V.M.; RT "Fas-associated death domain protein interleukin-1beta-converting enzyme 2 RT (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55- RT mediated death signaling."; RL J. Biol. Chem. 272:6578-6583(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS C AND D), VARIANT ILE-410, AND VARIANT RP ILE-522 (ISOFORM D). RC TISSUE=Spleen, and Thymus; RX PubMed=10187817; DOI=10.1074/jbc.274.15.10301; RA Ng P.W., Porter A.G., Janicke R.U.; RT "Molecular cloning and characterization of two novel pro-apoptotic isoforms RT of caspase-10."; RL J. Biol. Chem. 274:10301-10308(1999). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS A AND B), RP AND VARIANT ILE-479 (ISOFORM B). RX PubMed=11161814; DOI=10.1006/geno.2000.6392; RA Hadano S., Yanagisawa Y., Skaug J., Fichter K., Nasir J., Martindale D., RA Koop B.F., Scherer S.W., Nicholson D.W., Rouleau G.A., Ikeda J.-E., RA Hayden M.R.; RT "Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and RT ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical RT region at chromosome 2q33-q34: candidate genes for ALS2."; RL Genomics 71:200-213(2001). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), AND VARIANT ILE-455 (ISOFORM RP 6). RC TISSUE=Blood; RA Vonarbourg C., Fischer A., Rieux-Laucat F.; RT "A novel human caspase 10 isoform participating in Fas-induced apoptosis."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7), AND FUNCTION (ISOFORM 7). RX PubMed=17822854; DOI=10.1016/j.bbagen.2007.07.010; RA Wang H., Wang P., Sun X., Luo Y., Wang X., Ma D., Wu J.; RT "Cloning and characterization of a novel caspase-10 isoform that activates RT NF-kappa B activity."; RL Biochim. Biophys. Acta 1770:1528-1537(2007). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-239; ILE-410; SER-444; RP CYS-446 AND ILE-522 (ISOFORM 2). RG NIEHS SNPs program; RL Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM D). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC PROCESSING. RX PubMed=8962078; DOI=10.1073/pnas.93.25.14486; RA Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., Litwack G., Alnemri E.S.; RT "Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease RT Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like RT cysteine proteases."; RL Proc. Natl. Acad. Sci. U.S.A. 93:14486-14491(1996). RN [12] RP FUNCTION, SELF-ASSOCIATION, INTERACTION WITH FADD, INTERACTION WITH CASP8, RP IDENTIFICATION IN A COMPLEX WITH FAS; FADD AND CASP8, AND MUTAGENESIS OF RP CYS-401. RX PubMed=11717445; DOI=10.1073/pnas.241358198; RA Wang J., Chun H.J., Wong W., Spencer D.M., Lenardo M.J.; RT "Caspase-10 is an initiator caspase in death receptor signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 98:13884-13888(2001). RN [13] RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8; RA Hillman R.T., Green R.E., Brenner S.E.; RT "An unappreciated role for RNA surveillance."; RL Genome Biol. 5:R8.1-R8.16(2004). RN [14] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=15069192; DOI=10.1073/pnas.0307459101; RA McDonald E.R. III, El-Deiry W.S.; RT "Suppression of caspase-8- and -10-associated RING proteins results in RT sensitization to death ligands and inhibition of tumor cell growth."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6170-6175(2004). RN [15] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=16916640; DOI=10.1016/j.molcel.2006.06.020; RA Denault J.B., Bekes M., Scott F.L., Sexton K.M., Bogyo M., Salvesen G.S.; RT "Engineered hybrid dimers: tracking the activation pathway of caspase-7."; RL Mol. Cell 23:523-533(2006). RN [16] RP INTERACTION WITH RIOK3. RX PubMed=19557502; DOI=10.1007/s11010-009-0180-8; RA Shan J., Wang P., Zhou J., Wu D., Shi H., Huo K.; RT "RIOK3 interacts with caspase-10 and negatively regulates the NF-kappaB RT signaling pathway."; RL Mol. Cell. Biochem. 332:113-120(2009). RN [17] RP VARIANT ALPS2A PHE-285, VARIANT ILE-410, AND ALTERNATIVE SPLICING (ISOFORMS RP B AND D). RX PubMed=10412980; DOI=10.1016/s0092-8674(00)80605-4; RA Wang J., Zheng L., Lobito A., Chan F.K., Dale J., Sneller M., Yao X., RA Puck J.M., Straus S.E., Lenardo M.J.; RT "Inherited human caspase 10 mutations underlie defective lymphocyte and RT dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type RT II."; RL Cell 98:47-58(1999). RN [18] RP VARIANT NHL VAL-414. RX PubMed=12010812; DOI=10.1182/blood.v99.11.4094; RA Shin M.S., Kim H.S., Kang C.S., Park W.S., Kim S.Y., Lee S.N., Lee J.H., RA Park J.Y., Jang J.J., Kim C.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H.; RT "Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas."; RL Blood 99:4094-4099(2002). RN [19] RP VARIANT GASC THR-147, AND CHARACTERIZATION OF VARIANT GASC THR-147. RX PubMed=11973654; DOI=10.1038/sj.onc.1205394; RA Park W.S., Lee J.H., Shin M.S., Park J.Y., Kim H.S., Lee J.H., Kim Y.S., RA Lee S.N., Xiao W., Park C.H., Lee S.H., Yoo N.J., Lee J.Y.; RT "Inactivating mutations of the caspase-10 gene in gastric cancer."; RL Oncogene 21:2919-2925(2002). RN [20] RP VARIANTS LEU-406; ILE-410 AND CYS-446, AND CHARACTERIZATION OF VARIANTS RP LEU-406; ILE-410 AND CYS-446. RX PubMed=16446975; DOI=10.1007/s00439-006-0138-9; RA Zhu S., Hsu A.P., Vacek M.M., Zheng L., Schaeffer A.A., Dale J.K., RA Davis J., Fischer R.E., Straus S.E., Boruchov D., Saulsbury F.T., RA Lenardo M.J., Puck J.M.; RT "Genetic alterations in caspase-10 may be causative or protective in RT autoimmune lymphoproliferative syndrome."; RL Hum. Genet. 119:284-294(2006). RN [21] RP VARIANT ILE-522 (ISOFORM D), AND RISK FACTOR FOR CUTANEOUS MELANOMA. RX PubMed=18563783; DOI=10.1002/humu.20803; RA Li C., Zhao H., Hu Z., Liu Z., Wang L.-E., Gershenwald J.E., Prieto V.G., RA Lee J.E., Duvic M., Grimm E.A., Wei Q.; RT "Genetic variants and haplotypes of the caspase-8 and caspase-10 genes RT contribute to susceptibility to cutaneous melanoma."; RL Hum. Mutat. 29:1443-1451(2008). RN [22] RP VARIANTS CYS-21 AND PRO-285. RX PubMed=19900088; DOI=10.1080/00313020903041143; RA Kim M.S., Oh J.E., Min C.K., Lee S., Chung N.G., Yoo N.J., Lee S.H.; RT "Mutational analysis of CASP10 gene in acute leukaemias and multiple RT myelomas."; RL Pathology 41:484-487(2009). RN [23] RP VARIANT THR-14. RX PubMed=20025484; DOI=10.3109/00313020903434371; RA Oh J.E., Kim M.S., Ahn C.H., Kim S.S., Han J.Y., Lee S.H., Yoo N.J.; RT "Mutational analysis of CASP10 gene in colon, breast, lung and RT hepatocellular carcinomas."; RL Pathology 42:73-76(2010). RN [24] RP VARIANT LEU-406. RX PubMed=27378136; DOI=10.1016/j.imlet.2016.07.001; RA Tripodi S.I., Mazza C., Moratto D., Ramenghi U., Caorsi R., Gattorno M., RA Badolato R.; RT "Atypical presentation of autoimmune lymphoproliferative syndrome due to RT CASP10 mutation."; RL Immunol. Lett. 177:22-24(2016). RN [25] RP VARIANT LEU-406. RX PubMed=27535533; DOI=10.1038/nature19057; RG Exome Aggregation Consortium; RA Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., RA O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., RA Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J., RA Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M., RA Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N., RA Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P., RA Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A., RA Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G., RA Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M., RA Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C., RA Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M., RA McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M., RA Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P., RA Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G., RA Daly M.J., MacArthur D.G.; RT "Analysis of protein-coding genetic variation in 60,706 humans."; RL Nature 536:285-291(2016). CC -!- FUNCTION: Involved in the activation cascade of caspases responsible CC for apoptosis execution. Recruited to both Fas- and TNFR-1 receptors in CC a FADD dependent manner. May participate in the granzyme B apoptotic CC pathways. Cleaves and activates effector caspases CASP3, CASP4, CASP6, CC CASP7, CASP8 and CASP9. Hydrolyzes the small- molecule substrates, Tyr- CC Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC. CC {ECO:0000269|PubMed:11717445, ECO:0000269|PubMed:16916640}. CC -!- FUNCTION: Isoform 7 can enhance NF-kappaB activity but promotes only CC slight apoptosis. {ECO:0000269|PubMed:17822854}. CC -!- FUNCTION: Isoform C is proteolytically inactive. CC {ECO:0000269|PubMed:11717445}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Strict requirement for Asp at position P1 and has a preferred CC cleavage sequence of Leu-Gln-Thr-Asp-|-Gly.; EC=3.4.22.63; CC Evidence={ECO:0000269|PubMed:16916640}; CC -!- SUBUNIT: Heterotetramer that consists of two anti-parallel arranged CC heterodimers, each one formed by a 23/17 kDa (p23/17) (depending on the CC splicing events) and a 12 kDa (p12) subunit (By similarity). Self- CC associates. Interacts with FADD and CASP8. Found in a Fas signaling CC complex consisting of FAS, FADD, CASP8 and CASP10. Interacts with RFFL CC and RNF34; negatively regulate CASP10 through proteasomal degradation. CC Interacts with RIOK3. {ECO:0000250, ECO:0000269|PubMed:11717445, CC ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:19557502}. CC -!- INTERACTION: CC Q92851; Q14790: CASP8; NbExp=6; IntAct=EBI-495095, EBI-78060; CC Q92851; O15519: CFLAR; NbExp=3; IntAct=EBI-495095, EBI-514941; CC Q92851; Q13158: FADD; NbExp=4; IntAct=EBI-495095, EBI-494804; CC Q92851; O14730: RIOK3; NbExp=6; IntAct=EBI-495095, EBI-1047061; CC Q92851; Q13546: RIPK1; NbExp=2; IntAct=EBI-495095, EBI-358507; CC Q92851; P98170: XIAP; NbExp=3; IntAct=EBI-495095, EBI-517127; CC Q92851-4; PRO_0000004678 [O15519]: CFLAR; NbExp=3; IntAct=EBI-6621134, EBI-4478097; CC Q92851-4; P98170: XIAP; NbExp=3; IntAct=EBI-6621134, EBI-517127; CC Q92851-7; O14730: RIOK3; NbExp=3; IntAct=EBI-12737837, EBI-1047061; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=A; Synonyms=10-A; CC IsoId=Q92851-1; Sequence=Displayed; CC Name=B; Synonyms=10-B, 10-S; CC IsoId=Q92851-2; Sequence=VSP_000819, VSP_000820; CC Name=D; Synonyms=10-D, 10-L; CC IsoId=Q92851-4; Sequence=VSP_000820; CC Name=C; Synonyms=10-C; CC IsoId=Q92851-3; Sequence=VSP_000821, VSP_000822; CC Name=5; CC IsoId=Q92851-5; Sequence=VSP_000819; CC Name=6; CC IsoId=Q92851-6; Sequence=VSP_037229, VSP_000820; CC Name=7; Synonyms=10-G, 10g; CC IsoId=Q92851-7; Sequence=VSP_053333, VSP_053334; CC -!- TISSUE SPECIFICITY: Detectable in most tissues. Lowest expression is CC seen in brain, kidney, prostate, testis and colon. CC -!- PTM: Cleavage by granzyme B and autocatalytic activity generate the two CC active subunits. CC -!- DISEASE: Autoimmune lymphoproliferative syndrome 2A (ALPS2A) CC [MIM:603909]: A disorder of apoptosis that manifests in early childhood CC and results in the accumulation of autoreactive lymphocytes. It is CC characterized by non-malignant lymphadenopathy with hepatosplenomegaly, CC and autoimmune hemolytic anemia, thrombocytopenia and neutropenia. CC {ECO:0000269|PubMed:10412980}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:12010812}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:11973654}. Note=The CC gene represented in this entry is involved in disease pathogenesis. CC -!- MISCELLANEOUS: [Isoform B]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform C]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=CASP10base; Note=CASP10 mutation db; CC URL="https://databases.lovd.nl/shared/genes/CASP10"; CC -!- WEB RESOURCE: Name=Autoimmune Lymphoproliferative Syndrome Database CC (ALPSbase); Note=Caspase-10 mutations causing ALPS type II; CC URL="https://www.niaid.nih.gov/diseases-conditions/autoimmune-lymphoproliferative-syndrome-alps"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U60519; AAC50644.1; -; mRNA. DR EMBL; U86214; AAB46730.1; -; mRNA. DR EMBL; AF111344; AAD28402.1; -; mRNA. DR EMBL; AF111345; AAD28403.1; -; mRNA. DR EMBL; AB038979; BAB32553.1; -; Genomic_DNA. DR EMBL; AB038979; BAB32554.1; -; Genomic_DNA. DR EMBL; AJ487678; CAD32371.1; -; mRNA. DR EMBL; AJ487679; CAD32372.1; -; mRNA. DR EMBL; AY690601; AAU00989.1; -; mRNA. DR EMBL; EF050529; ABJ53426.1; -; Genomic_DNA. DR EMBL; AC007283; AAY24291.1; -; Genomic_DNA. DR EMBL; CH471063; EAW70248.1; -; Genomic_DNA. DR EMBL; CH471063; EAW70249.1; -; Genomic_DNA. DR EMBL; BC042844; AAH42844.1; -; mRNA. DR CCDS; CCDS2338.1; -. [Q92851-1] DR CCDS; CCDS2339.1; -. [Q92851-2] DR CCDS; CCDS2340.1; -. [Q92851-4] DR CCDS; CCDS56159.1; -. [Q92851-6] DR CCDS; CCDS56160.1; -. [Q92851-5] DR CCDS; CCDS77506.1; -. [Q92851-7] DR RefSeq; NP_001193453.1; NM_001206524.2. [Q92851-6] DR RefSeq; NP_001193471.1; NM_001206542.2. [Q92851-5] DR RefSeq; NP_001221.2; NM_001230.4. [Q92851-2] DR RefSeq; NP_001293012.1; NM_001306083.2. [Q92851-7] DR RefSeq; NP_116756.2; NM_032974.4. [Q92851-1] DR RefSeq; NP_116758.1; NM_032976.4. [Q92851-3] DR RefSeq; NP_116759.2; NM_032977.3. [Q92851-4] DR AlphaFoldDB; Q92851; -. DR SMR; Q92851; -. DR BioGRID; 107293; 98. DR CORUM; Q92851; -. DR FunCoup; Q92851; 364. DR IntAct; Q92851; 26. DR MINT; Q92851; -. DR STRING; 9606.ENSP00000286186; -. DR BindingDB; Q92851; -. DR ChEMBL; CHEMBL5037; -. DR MEROPS; C14.011; -. DR iPTMnet; Q92851; -. DR PhosphoSitePlus; Q92851; -. DR BioMuta; CASP10; -. DR DMDM; 12644463; -. DR CPTAC; CPTAC-1039; -. DR jPOST; Q92851; -. DR MassIVE; Q92851; -. DR PaxDb; 9606-ENSP00000286186; -. DR PeptideAtlas; Q92851; -. DR ProteomicsDB; 66146; -. DR ProteomicsDB; 75543; -. [Q92851-1] DR ProteomicsDB; 75544; -. [Q92851-2] DR ProteomicsDB; 75545; -. [Q92851-3] DR ProteomicsDB; 75546; -. [Q92851-4] DR ProteomicsDB; 75547; -. [Q92851-5] DR ProteomicsDB; 75548; -. [Q92851-6] DR Pumba; Q92851; -. DR Antibodypedia; 1700; 590 antibodies from 47 providers. DR DNASU; 843; -. DR Ensembl; ENST00000272879.9; ENSP00000272879.5; ENSG00000003400.17. [Q92851-1] DR Ensembl; ENST00000286186.11; ENSP00000286186.6; ENSG00000003400.17. [Q92851-4] DR Ensembl; ENST00000313728.12; ENSP00000314599.7; ENSG00000003400.17. [Q92851-6] DR Ensembl; ENST00000346817.10; ENSP00000237865.7; ENSG00000003400.17. [Q92851-2] DR Ensembl; ENST00000374650.8; ENSP00000363781.3; ENSG00000003400.17. [Q92851-7] DR Ensembl; ENST00000448480.1; ENSP00000396835.1; ENSG00000003400.17. [Q92851-5] DR Ensembl; ENST00000492363.6; ENSP00000512459.1; ENSG00000003400.17. [Q92851-3] DR GeneID; 843; -. DR KEGG; hsa:843; -. DR MANE-Select; ENST00000286186.11; ENSP00000286186.6; NM_032977.4; NP_116759.2. [Q92851-4] DR UCSC; uc002uxi.2; human. [Q92851-1] DR AGR; HGNC:1500; -. DR ClinPGx; PA26084; -. DR CTD; 843; -. DR DisGeNET; 843; -. DR GeneCards; CASP10; -. DR GeneReviews; CASP10; -. DR HGNC; HGNC:1500; CASP10. DR HPA; ENSG00000003400; Low tissue specificity. DR MalaCards; CASP10; -. DR MIM; 601762; gene. DR MIM; 603909; phenotype. DR MIM; 605027; phenotype. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000003400; -. DR Orphanet; 3261; Autoimmune lymphoproliferative syndrome. DR VEuPathDB; HostDB:ENSG00000003400; -. DR eggNOG; KOG3573; Eukaryota. DR GeneTree; ENSGT00940000160994; -. DR HOGENOM; CLU_088972_0_0_1; -. DR InParanoid; Q92851; -. DR OMA; CRDCISH; -. DR OrthoDB; 6114029at2759; -. DR PAN-GO; Q92851; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q92851; -. DR BioCyc; MetaCyc:HS00093-MONOMER; -. DR BRENDA; 3.4.22.63; 2681. DR PathwayCommons; Q92851; -. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-75157; FasL/ CD95L signaling. DR Reactome; R-HSA-75158; TRAIL signaling. DR Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10. DR SignaLink; Q92851; -. DR SIGNOR; Q92851; -. DR Agora; ENSG00000003400; -. DR BioGRID-ORCS; 843; 6 hits in 1156 CRISPR screens. DR ChiTaRS; CASP10; human. DR GeneWiki; Caspase_10; -. DR GenomeRNAi; 843; -. DR Pharos; Q92851; Tchem. DR PRO; PR:Q92851; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q92851; protein. DR Bgee; ENSG00000003400; Expressed in colonic epithelium and 126 other cell types or tissues. DR ExpressionAtlas; Q92851; baseline and differential. DR GO; GO:0031265; C:CD95 death-inducing signaling complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0097342; C:ripoptosome; IDA:UniProtKB. DR GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB. DR GO; GO:0035877; F:death effector domain binding; IPI:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IBA:GO_Central. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IDA:UniProt. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central. DR GO; GO:0051604; P:protein maturation; IDA:UniProt. DR GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW. DR CDD; cd00032; CASc; 1. DR CDD; cd08341; DED_Caspase_10_r1; 1. DR CDD; cd08814; DED_Caspase_10_r2; 1. DR FunFam; 1.10.533.10:FF:000038; Caspase 10; 1. DR FunFam; 1.10.533.10:FF:000070; Caspase 10; 1. DR FunFam; 3.40.50.1460:FF:000014; Caspase 10, apoptosis-related cysteine peptidase; 1. DR Gene3D; 3.40.50.1460; -; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 2. DR InterPro; IPR035701; CASP10_DED2. DR InterPro; IPR029030; Caspase-like_dom_sf. DR InterPro; IPR033139; Caspase_cys_AS. DR InterPro; IPR016129; Caspase_his_AS. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR001875; DED_dom. DR InterPro; IPR011600; Pept_C14_caspase. DR InterPro; IPR002138; Pept_C14_p10. DR InterPro; IPR001309; Pept_C14_p20. DR InterPro; IPR015917; Pept_C14A. DR PANTHER; PTHR48169:SF7; CASPASE 10; 1. DR PANTHER; PTHR48169; DED DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF01335; DED; 2. DR Pfam; PF00656; Peptidase_C14; 1. DR PRINTS; PR00376; IL1BCENZYME. DR SMART; SM00115; CASc; 1. DR SMART; SM00031; DED; 2. DR SUPFAM; SSF52129; Caspase-like; 1. DR SUPFAM; SSF47986; DEATH domain; 2. DR PROSITE; PS01122; CASPASE_CYS; 1. DR PROSITE; PS01121; CASPASE_HIS; 1. DR PROSITE; PS50207; CASPASE_P10; 1. DR PROSITE; PS50208; CASPASE_P20; 1. DR PROSITE; PS50168; DED; 2. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; Direct protein sequencing; KW Disease variant; Hydrolase; Protease; Proteomics identification; KW Reference proteome; Repeat; Thiol protease; Zymogen. FT PROPEP 1..219 FT /id="PRO_0000004644" FT CHAIN 220..415 FT /note="Caspase-10 subunit p23/17" FT /id="PRO_0000004645" FT CHAIN 416..521 FT /note="Caspase-10 subunit p12" FT /id="PRO_0000004646" FT DOMAIN 19..97 FT /note="DED 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT DOMAIN 114..187 FT /note="DED 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT REGION 231..269 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 231..248 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 259..268 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 358 FT /evidence="ECO:0000250" FT ACT_SITE 401 FT /evidence="ECO:0000250" FT VAR_SEQ 229..271 FT /note="Missing (in isoform B and isoform 5)" FT /evidence="ECO:0000303|PubMed:8755496, ECO:0000303|Ref.5" FT /id="VSP_000819" FT VAR_SEQ 229..247 FT /note="QESWQNKHAGSNGNRATNG -> EGVFVFLNEGDRGNSPDDL (in FT isoform 7)" FT /evidence="ECO:0000303|PubMed:17822854" FT /id="VSP_053333" FT VAR_SEQ 241..307 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_037229" FT VAR_SEQ 241..273 FT /note="GNRATNGAPSLVSRGMQGASANTLNSETSTKRA -> EGSCVQDESEPQRPL FT CHCQQPQLYLPEGQTRNP (in isoform C)" FT /evidence="ECO:0000303|PubMed:10187817" FT /id="VSP_000821" FT VAR_SEQ 248..521 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:17822854" FT /id="VSP_053334" FT VAR_SEQ 274..521 FT /note="Missing (in isoform C)" FT /evidence="ECO:0000303|PubMed:10187817" FT /id="VSP_000822" FT VAR_SEQ 473..521 FT /note="MLKFLEKTMEIRGRKRTVWGAKQISATSLPTAISAQTPRPPMRRWSSVS -> FT HEDILSILTAVNDDVSRRVDKQGTKKQMPQPAFTLRKKLVFPVPLDALSL (in FT isoform B, isoform D and isoform 6)" FT /evidence="ECO:0000303|PubMed:10187817, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8755496, FT ECO:0000303|Ref.5" FT /id="VSP_000820" FT VARIANT 14 FT /note="K -> T (found in a colon cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:20025484" FT /id="VAR_065233" FT VARIANT 21 FT /note="R -> C (found in a multiple myeloma sample; somatic FT mutation; dbSNP:rs559979934)" FT /evidence="ECO:0000269|PubMed:19900088" FT /id="VAR_065234" FT VARIANT 147 FT /note="M -> T (in GASC; somatic mutation; impairs CASP10- FT mediated apoptosis; dbSNP:rs121909776)" FT /evidence="ECO:0000269|PubMed:11973654" FT /id="VAR_037428" FT VARIANT 239 FT /note="S -> C (in dbSNP:rs41473647)" FT /id="VAR_055361" FT VARIANT 285 FT /note="L -> F (in ALPS2A; dbSNP:rs17860403)" FT /evidence="ECO:0000269|PubMed:10412980" FT /id="VAR_014071" FT VARIANT 285 FT /note="L -> P (found in a T-acute lymphoblastic leukemia FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:19900088" FT /id="VAR_065235" FT VARIANT 406 FT /note="I -> L (the mutant protein has defective apoptosis FT and exerts a dominant-negative effect when cotransfected FT with the wild-type protein; dbSNP:rs80358239)" FT /evidence="ECO:0000269|PubMed:16446975, FT ECO:0000269|PubMed:27378136, ECO:0000269|PubMed:27535533" FT /id="VAR_037429" FT VARIANT 410 FT /note="V -> I (does not interfere with apoptosis in a FT dominant negative manner; dbSNP:rs13010627)" FT /evidence="ECO:0000269|PubMed:10187817, FT ECO:0000269|PubMed:10412980, ECO:0000269|PubMed:16446975" FT /id="VAR_014072" FT VARIANT 414 FT /note="A -> V (in NHL; somatic mutation; dbSNP:rs28936699)" FT /evidence="ECO:0000269|PubMed:12010812" FT /id="VAR_037430" FT VARIANT 444 FT /note="P -> S (in dbSNP:rs41513147)" FT /id="VAR_055362" FT VARIANT 446 FT /note="Y -> C (risk factor for ALPS2A; does not interfere FT with apoptosis in a dominant negative manner; FT dbSNP:rs17860405)" FT /evidence="ECO:0000269|PubMed:16446975" FT /id="VAR_037431" FT MUTAGEN 401 FT /note="C->A: Abolishes proteolytic activity." FT /evidence="ECO:0000269|PubMed:11717445" FT CONFLICT 68 FT /note="E -> G (in Ref. 2; AAB46730)" FT /evidence="ECO:0000305" FT CONFLICT 268 FT /note="T -> A (in Ref. 3; AAD28403)" FT /evidence="ECO:0000305" FT VARIANT Q92851-2:479 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000269|PubMed:11161814, FT ECO:0000269|PubMed:8755496" FT /id="VAR_082802" FT VARIANT Q92851-4:522 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000305" FT /id="VAR_082803" FT VARIANT Q92851-6:455 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000305" FT /id="VAR_082804" SQ SEQUENCE 521 AA; 58951 MW; 840348AE602B8243 CRC64; MKSQGQHWYS SSDKNCKVSF REKLLIIDSN LGVQDVENLK FLCIGLVPNK KLEKSSSASD VFEHLLAEDL LSEEDPFFLA ELLYIIRQKK LLQHLNCTKE EVERLLPTRQ RVSLFRNLLY ELSEGIDSEN LKDMIFLLKD SLPKTEMTSL SFLAFLEKQG KIDEDNLTCL EDLCKTVVPK LLRNIEKYKR EKAIQIVTPP VDKEAESYQG EEELVSQTDV KTFLEALPQE SWQNKHAGSN GNRATNGAPS LVSRGMQGAS ANTLNSETST KRAAVYRMNR NHRGLCVIVN NHSFTSLKDR QGTHKDAEIL SHVFQWLGFT VHIHNNVTKV EMEMVLQKQK CNPAHADGDC FVFCILTHGR FGAVYSSDEA LIPIREIMSH FTALQCPRLA EKPKLFFIQA CQGEEIQPSV SIEADALNPE QAPTSLQDSI PAEADFLLGL ATVPGYVSFR HVEEGSWYIQ SLCNHLKKLV PRMLKFLEKT MEIRGRKRTV WGAKQISATS LPTAISAQTP RPPMRRWSSV S // ID CDK12_HUMAN Reviewed; 1490 AA. AC Q9NYV4; A7E2B2; B4DYX4; B9EIQ6; O94978; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 2. DT 28-JAN-2026, entry version 215. DE RecName: Full=Cyclin-dependent kinase 12; DE EC=2.7.11.22; DE EC=2.7.11.23 {ECO:0000305|PubMed:20952539}; DE AltName: Full=Cdc2-related kinase, arginine/serine-rich; DE Short=CrkRS; DE AltName: Full=Cell division cycle 2-related protein kinase 7; DE Short=CDC2-related protein kinase 7; DE AltName: Full=Cell division protein kinase 12; DE Short=hCDK12; GN Name=CDK12; Synonyms=CRK7, CRKRS, KIAA0904; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND FUNCTION. RX PubMed=11683387; DOI=10.1242/jcs.114.14.2591; RA Ko T.K., Kelly E., Pines J.; RT "CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with RT SC35 speckles."; RL J. Cell Sci. 114:2591-2603(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=10048485; DOI=10.1093/dnares/5.6.355; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:355-364(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-681 AND SER-685, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-57; TYR-73; SER-400; SER-423; RP THR-514; SER-681; SER-685 AND THR-692, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; SER-301; SER-303; RP SER-318; SER-323; SER-325; SER-332; SER-333; SER-334; SER-345; SER-383; RP SER-385; SER-400; SER-681; SER-685 AND THR-692, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [13] RP FUNCTION. RX PubMed=19651820; DOI=10.1093/carcin/bgp187; RA Iorns E., Martens-de Kemp S.R., Lord C.J., Ashworth A.; RT "CRK7 modifies the MAPK pathway and influences the response to endocrine RT therapy."; RL Carcinogenesis 30:1696-1701(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-420; SER-423; SER-681; RP SER-685; THR-692 AND SER-1053, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-383; SER-385; RP SER-681; SER-685 AND THR-1244, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [16] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=20952539; DOI=10.1101/gad.1968210; RA Bartkowiak B., Liu P., Phatnani H.P., Fuda N.J., Cooper J.J., Price D.H., RA Adelman K., Lis J.T., Greenleaf A.L.; RT "CDK12 is a transcription elongation-associated CTD kinase, the metazoan RT ortholog of yeast Ctk1."; RL Genes Dev. 24:2303-2316(2010). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-385; RP SER-400; SER-423; SER-681; SER-685; THR-893 AND SER-1083, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [19] RP CHROMOSOMAL REARRANGEMENT WITH ERBB2, AND POSSIBLE INVOLVEMENT IN GASTRIC RP CANCER. RX PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749; RA Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D., RA Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H., RA Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.; RT "Genetic and structural variation in the gastric cancer kinome revealed RT through targeted deep sequencing."; RL Cancer Res. 71:29-39(2011). RN [20] RP FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=22012619; DOI=10.1101/gad.16962311; RA Blazek D., Kohoutek J., Bartholomeeusen K., Johansen E., Hulinkova P., RA Luo Z., Cimermancic P., Ule J., Peterlin B.M.; RT "The Cyclin K/Cdk12 complex maintains genomic stability via regulation of RT expression of DNA damage response genes."; RL Genes Dev. 25:2158-2172(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-274; RP SER-276; SER-301; SER-303; SER-310; SER-312; SER-332; SER-333; SER-334; RP SER-338; SER-423; SER-681; SER-685; THR-893 AND SER-1083, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-265; RP SER-274; SER-276; SER-318; SER-323; SER-325; SER-332; SER-333; SER-334; RP SER-341; SER-343; SER-345; SER-423; THR-514; SER-614; SER-681; THR-692; RP SER-889; THR-893; SER-1053 AND SER-1083, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-423; SER-681 AND SER-685, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-263; LYS-509 AND LYS-655, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [25] RP INTERACTION WITH HHV-1 TRANSCRIPTIONAL REGULATOR ICP22 (MICROBIAL RP INFECTION). RX PubMed=34696162; DOI=10.3390/vaccines9101054; RA Isa N.F., Bensaude O., Aziz N.C., Murphy S.; RT "HSV-1 ICP22 Is a Selective Viral Repressor of Cellular RNA Polymerase II- RT Mediated Transcription Elongation."; RL Vaccines (Basel) 9:0-0(2021). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 714-1063 IN COMPLEX WITH THE ATP RP ANALOG ADP; TRANSITION STATE ANALOG AND CCNK, FUNCTION, CATALYTIC ACTIVITY, RP SUBUNIT, INTERACTION WITH CCNK, PHOSPHORYLATION AT THR-893, IDENTIFICATION RP BY MASS SPECTROMETRY, MUTAGENESIS OF ASP-877, AND ACTIVITY REGULATION. RX PubMed=24662513; DOI=10.1038/ncomms4505; RA Boesken C.A., Farnung L., Hintermair C., Merzel Schachter M., RA Vogel-Bachmayr K., Blazek D., Anand K., Fisher R.P., Eick D., Geyer M.; RT "The structure and substrate specificity of human Cdk12/Cyclin K."; RL Nat. Commun. 5:3505-3505(2014). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-530; HIS-912; GLN-1189 AND LEU-1275. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Cyclin-dependent kinase that phosphorylates the C-terminal CC domain (CTD) of the large subunit of RNA polymerase II (POLR2A), CC thereby acting as a key regulator of transcription elongation. CC Regulates the expression of genes involved in DNA repair and is CC required for the maintenance of genomic stability. Preferentially CC phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated CC at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA CC splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation CC of MAP kinase activity, possibly leading to affect the response to CC estrogen inhibitors. {ECO:0000269|PubMed:11683387, CC ECO:0000269|PubMed:19651820, ECO:0000269|PubMed:20952539, CC ECO:0000269|PubMed:22012619, ECO:0000269|PubMed:24662513}. CC -!- CATALYTIC ACTIVITY: CC Reaction=[DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed CC RNA polymerase] + ADP + H(+); Xref=Rhea:RHEA:10216, Rhea:RHEA- CC COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, CC ChEBI:CHEBI:456216; EC=2.7.11.23; CC Evidence={ECO:0000305|PubMed:20952539}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- ACTIVITY REGULATION: Inhibited by the ATP analog flavopiridol, CC purvalanol A, purvalanol B, staurosporine and CR8. CC {ECO:0000269|PubMed:24662513}. CC -!- SUBUNIT: Interacts with CCNL1 and CCNL2 (By similarity). Interacts with CC CCNK. {ECO:0000250, ECO:0000269|PubMed:22012619, CC ECO:0000269|PubMed:24662513}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 1 CC (HHV-1) transcriptional regulator ICP22. {ECO:0000269|PubMed:34696162}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11683387}. Nucleus CC speckle {ECO:0000269|PubMed:11683387}. Note=Colocalized with nuclear CC speckles throughout interphase. {ECO:0000269|PubMed:11683387}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9NYV4-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9NYV4-2; Sequence=VSP_030284; CC Name=3; CC IsoId=Q9NYV4-3; Sequence=VSP_040908, VSP_040909, VSP_040910; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:11683387}. CC -!- PTM: Phosphorylation at Thr-893 increases kinase activity. CC {ECO:0000269|PubMed:24662513}. CC -!- DISEASE: Note=Chromosomal aberrations involving CDK12 may be a cause CC gastric cancer. Deletions within 17q12 region producing fusion CC transcripts with ERBB2, leading to CDK12-ERBB2 fusion leading to CC trunctated CDK12 protein not in-frame with ERBB2. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA74927.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF227198; AAF36401.1; -; mRNA. DR EMBL; AB020711; BAA74927.2; ALT_INIT; mRNA. DR EMBL; AK302645; BAG63886.1; -; mRNA. DR EMBL; AC009283; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471152; EAW60577.1; -; Genomic_DNA. DR EMBL; BC140854; AAI40855.1; -; mRNA. DR EMBL; BC150265; AAI50266.1; -; mRNA. DR CCDS; CCDS11337.1; -. [Q9NYV4-1] DR CCDS; CCDS45666.1; -. [Q9NYV4-2] DR RefSeq; NP_055898.1; NM_015083.4. [Q9NYV4-2] DR RefSeq; NP_057591.2; NM_016507.4. [Q9NYV4-1] DR PDB; 4CXA; X-ray; 3.15 A; A/C=715-1052. DR PDB; 4NST; X-ray; 2.20 A; A/C=714-1063. DR PDB; 4UN0; X-ray; 3.15 A; C/D=715-1038. DR PDB; 5ACB; X-ray; 2.70 A; C/D=715-1052. DR PDB; 6B3E; X-ray; 3.06 A; A/C=717-1036. DR PDB; 6CKX; X-ray; 2.80 A; A/C=714-1063. DR PDB; 6TD3; X-ray; 3.46 A; B/E/H=712-1051. DR PDB; 7NXK; X-ray; 3.00 A; A/C=714-1063. DR PDB; 8BU1; X-ray; 2.98 A; B/E/H=712-1051. DR PDB; 8BU2; X-ray; 3.13 A; B/E/H=712-1051. DR PDB; 8BU3; X-ray; 3.42 A; B/E/H=712-1051. DR PDB; 8BU4; X-ray; 3.09 A; B/E/H=712-1051. DR PDB; 8BU5; X-ray; 3.13 A; B/E/H=712-1051. DR PDB; 8BU6; X-ray; 3.45 A; B/E/H=712-1051. DR PDB; 8BU7; X-ray; 3.25 A; B/E/H=712-1051. DR PDB; 8BU9; X-ray; 3.51 A; B/E/H=712-1051. DR PDB; 8BUA; X-ray; 3.19 A; B/E/H=712-1051. DR PDB; 8BUB; X-ray; 3.42 A; B/E/H=712-1051. DR PDB; 8BUC; X-ray; 3.85 A; B/E/H=712-1051. DR PDB; 8BUD; X-ray; 3.20 A; B/E/H=712-1051. DR PDB; 8BUE; X-ray; 3.25 A; B/E/H=712-1051. DR PDB; 8BUF; X-ray; 3.30 A; B/E/H=712-1051. DR PDB; 8BUG; X-ray; 3.53 A; B/E/H=712-1051. DR PDB; 8BUH; X-ray; 3.79 A; B/E/H=712-1051. DR PDB; 8BUI; X-ray; 3.50 A; B/E/H=712-1051. DR PDB; 8BUJ; X-ray; 3.62 A; B/E/H=712-1051. DR PDB; 8BUK; X-ray; 3.41 A; B/E/H=712-1051. DR PDB; 8BUL; X-ray; 3.40 A; B/E/H=712-1052. DR PDB; 8BUM; X-ray; 3.36 A; B/E/H=712-1051. DR PDB; 8BUN; X-ray; 3.08 A; B/E/H=712-1051. DR PDB; 8BUO; X-ray; 3.58 A; B/E/H=712-1051. DR PDB; 8BUP; X-ray; 3.41 A; B/E/H=712-1051. DR PDB; 8BUQ; X-ray; 3.20 A; B/E/H=712-1051. DR PDB; 8BUR; X-ray; 3.64 A; B/E/H=712-1051. DR PDB; 8BUS; X-ray; 3.26 A; B/E/H=712-1051. DR PDB; 8BUT; X-ray; 3.25 A; B/E/H=712-1051. DR PDB; 8P81; X-ray; 2.68 A; A=714-1063. DR PDB; 9FMR; X-ray; 3.90 A; B/E/H=714-1063. DR PDB; 9JK1; X-ray; 2.72 A; A/B=715-1052. DR PDBsum; 4CXA; -. DR PDBsum; 4NST; -. DR PDBsum; 4UN0; -. DR PDBsum; 5ACB; -. DR PDBsum; 6B3E; -. DR PDBsum; 6CKX; -. DR PDBsum; 6TD3; -. DR PDBsum; 7NXK; -. DR PDBsum; 8BU1; -. DR PDBsum; 8BU2; -. DR PDBsum; 8BU3; -. DR PDBsum; 8BU4; -. DR PDBsum; 8BU5; -. DR PDBsum; 8BU6; -. DR PDBsum; 8BU7; -. DR PDBsum; 8BU9; -. DR PDBsum; 8BUA; -. DR PDBsum; 8BUB; -. DR PDBsum; 8BUC; -. DR PDBsum; 8BUD; -. DR PDBsum; 8BUE; -. DR PDBsum; 8BUF; -. DR PDBsum; 8BUG; -. DR PDBsum; 8BUH; -. DR PDBsum; 8BUI; -. DR PDBsum; 8BUJ; -. DR PDBsum; 8BUK; -. DR PDBsum; 8BUL; -. DR PDBsum; 8BUM; -. DR PDBsum; 8BUN; -. DR PDBsum; 8BUO; -. DR PDBsum; 8BUP; -. DR PDBsum; 8BUQ; -. DR PDBsum; 8BUR; -. DR PDBsum; 8BUS; -. DR PDBsum; 8BUT; -. DR PDBsum; 8P81; -. DR PDBsum; 9FMR; -. DR PDBsum; 9JK1; -. DR AlphaFoldDB; Q9NYV4; -. DR SMR; Q9NYV4; -. DR BioGRID; 119715; 286. DR ComplexPortal; CPX-241; Cyclin K-CDK12 complex. DR CORUM; Q9NYV4; -. DR DIP; DIP-39768N; -. DR FunCoup; Q9NYV4; 3170. DR IntAct; Q9NYV4; 109. DR MINT; Q9NYV4; -. DR STRING; 9606.ENSP00000398880; -. DR BindingDB; Q9NYV4; -. DR ChEMBL; CHEMBL3559692; -. DR DrugCentral; Q9NYV4; -. DR GuidetoPHARMACOLOGY; 1965; -. DR CarbonylDB; Q9NYV4; -. DR GlyConnect; 2877; 1 O-GlcNAc glycan (2 sites). DR GlyCosmos; Q9NYV4; 6 sites, 1 glycan. DR GlyGen; Q9NYV4; 18 sites, 2 N-linked glycans (1 site), 1 O-linked glycan (17 sites). DR iPTMnet; Q9NYV4; -. DR PhosphoSitePlus; Q9NYV4; -. DR SwissPalm; Q9NYV4; -. DR BioMuta; CDK12; -. DR DMDM; 308153421; -. DR CPTAC; non-CPTAC-2958; -. DR CPTAC; non-CPTAC-2959; -. DR jPOST; Q9NYV4; -. DR MassIVE; Q9NYV4; -. DR PaxDb; 9606-ENSP00000398880; -. DR PeptideAtlas; Q9NYV4; -. DR ProteomicsDB; 83279; -. [Q9NYV4-1] DR ProteomicsDB; 83280; -. [Q9NYV4-2] DR ProteomicsDB; 83281; -. [Q9NYV4-3] DR Pumba; Q9NYV4; -. DR Antibodypedia; 2096; 236 antibodies from 32 providers. DR CPTC; Q9NYV4; 2 antibodies. DR DNASU; 51755; -. DR Ensembl; ENST00000430627.6; ENSP00000407720.2; ENSG00000167258.17. [Q9NYV4-2] DR Ensembl; ENST00000447079.6; ENSP00000398880.4; ENSG00000167258.17. [Q9NYV4-1] DR GeneID; 51755; -. DR KEGG; hsa:51755; -. DR MANE-Select; ENST00000447079.6; ENSP00000398880.4; NM_016507.4; NP_057591.2. DR UCSC; uc002hrw.6; human. [Q9NYV4-1] DR AGR; HGNC:24224; -. DR CIViC; 51755; 4 evidence items across 2 molecular profiles. DR ClinPGx; PA165431656; -. DR CTD; 51755; -. DR DisGeNET; 51755; -. DR GeneCards; CDK12; -. DR HGNC; HGNC:24224; CDK12. DR HPA; ENSG00000167258; Low tissue specificity. DR MalaCards; CDK12; -. DR MIM; 615514; gene. DR OpenTargets; ENSG00000167258; -. DR VEuPathDB; HostDB:ENSG00000167258; -. DR eggNOG; KOG0600; Eukaryota. DR GeneTree; ENSGT00940000157595; -. DR InParanoid; Q9NYV4; -. DR OMA; HWGAPAQ; -. DR OrthoDB; 28397at2759; -. DR PAN-GO; Q9NYV4; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q9NYV4; -. DR BRENDA; 2.7.11.22; 2681. DR BRENDA; 2.7.11.23; 2681. DR PathwayCommons; Q9NYV4; -. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR SignaLink; Q9NYV4; -. DR SIGNOR; Q9NYV4; -. DR Agora; ENSG00000167258; -. DR BioGRID-ORCS; 51755; 350 hits in 1217 CRISPR screens. DR ChiTaRS; CDK12; human. DR EvolutionaryTrace; Q9NYV4; -. DR GeneWiki; CRKRS; -. DR GenomeRNAi; 51755; -. DR Pharos; Q9NYV4; Tchem. DR PRO; PR:Q9NYV4; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9NYV4; protein. DR Bgee; ENSG00000167258; Expressed in buccal mucosa cell and 175 other cell types or tissues. DR ExpressionAtlas; Q9NYV4; baseline and differential. DR GO; GO:0002944; C:cyclin K-CDK12 complex; IPI:MGI. DR GO; GO:0008024; C:cyclin/CDK positive transcription elongation factor complex; IBA:GO_Central. DR GO; GO:0019908; C:nuclear cyclin-dependent protein kinase holoenzyme complex; ISS:UniProtKB. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0030332; F:cyclin binding; IPI:MGI. DR GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IDA:HGNC-UCL. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IDA:GO_Central. DR GO; GO:0071391; P:cellular response to estrogen stimulus; IMP:HGNC-UCL. DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW. DR GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IMP:HGNC-UCL. DR GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:HGNC-UCL. DR GO; GO:2000737; P:negative regulation of stem cell differentiation; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB. DR GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0043405; P:regulation of MAP kinase activity; IMP:UniProtKB. DR GO; GO:0008380; P:RNA splicing; ISS:UniProtKB. DR GO; GO:0006366; P:transcription by RNA polymerase II; IDA:GO_Central. DR CDD; cd07864; STKc_CDK12; 1. DR DisProt; DP03248; -. DR FunFam; 1.10.510.10:FF:000102; cyclin-dependent kinase 12 isoform X1; 1. DR FunFam; 3.30.200.20:FF:000074; cyclin-dependent kinase 12 isoform X2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050108; CDK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24056; CELL DIVISION PROTEIN KINASE; 1. DR PANTHER; PTHR24056:SF126; CYCLIN-DEPENDENT KINASE 12; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Chromosomal rearrangement; KW Host-virus interaction; Isopeptide bond; Kinase; mRNA processing; KW mRNA splicing; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..1490 FT /note="Cyclin-dependent kinase 12" FT /id="PRO_0000085715" FT DOMAIN 727..1020 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..703 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1047..1098 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1161..1189 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1220..1348 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1441..1460 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1466..1490 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 34..49 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 72..84 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 87..106 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 107..119 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 120..134 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 142..162 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 184..195 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 196..205 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 226..235 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 250..276 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 287..305 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 313..350 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 366..381 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 428..458 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 466..478 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 479..525 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 526..570 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 577..593 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 601..616 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 654..666 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1071..1083 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1161..1171 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1268..1281 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1473..1490 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 859 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 733..741 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 756 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 814..819 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 1040 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 57 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 73 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 236 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 249 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 274 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 276 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 301 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 303 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 310 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 312 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 318 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 323 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 332 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 334 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 338 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 343 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 345 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 383 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 385 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231" FT MOD_RES 400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231" FT MOD_RES 420 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 514 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 614 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 644 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q3MJK5" FT MOD_RES 681 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 685 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:24275569" FT MOD_RES 692 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 889 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 893 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:24662513, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1053 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1083 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1244 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 1246 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q14AX6" FT CROSSLNK 263 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 509 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 655 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 349 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_040908" FT VAR_SEQ 1205..1274 FT /note="DMQNILAVLLSQLMKTQEPAGSLEENNSDKNSGPQGPRRTPTMPQEEAAACP FT PHILPPEKRPPEPPGPPP -> ILWYMQRPNCKTMGSWGQEPLGPAAQEQAFTGGAQLS FT LLLMENSIGGLQESHQEGEEGEEFLTNPETSVS (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_040909" FT VAR_SEQ 1254..1262 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10048485, FT ECO:0000303|PubMed:15489334" FT /id="VSP_030284" FT VAR_SEQ 1275..1490 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_040910" FT VARIANT 530 FT /note="P -> A (in dbSNP:rs56121596)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041968" FT VARIANT 912 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041969" FT VARIANT 1189 FT /note="L -> Q (in dbSNP:rs56362165)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041970" FT VARIANT 1275 FT /note="P -> L (in dbSNP:rs34070318)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041971" FT MUTAGEN 877 FT /note="D->N: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:24662513" FT CONFLICT 133 FT /note="S -> G (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 268 FT /note="S -> G (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 639 FT /note="D -> G (in Ref. 1; AAF36401)" FT /evidence="ECO:0000305" FT CONFLICT 737 FT /note="T -> I (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 745 FT /note="K -> R (in Ref. 1; AAF36401)" FT /evidence="ECO:0000305" FT CONFLICT 822 FT /note="G -> V (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 1195 FT /note="T -> M (in Ref. 1; AAF36401, 2; BAA74927 and 6; FT AAI50266)" FT /evidence="ECO:0000305" FT STRAND 715..717 FT /evidence="ECO:0007829|PDB:8BU5" FT TURN 719..721 FT /evidence="ECO:0007829|PDB:8P81" FT HELIX 724..726 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 727..735 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 737..746 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 747..749 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 752..758 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 762..767 FT /evidence="ECO:0007829|PDB:8P81" FT HELIX 769..778 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 789..794 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 802..804 FT /evidence="ECO:0007829|PDB:8P81" FT STRAND 809..814 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 817..819 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 820..826 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 833..852 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 855..857 FT /evidence="ECO:0007829|PDB:8BUP" FT HELIX 862..864 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 865..867 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 869..871 FT /evidence="ECO:0007829|PDB:8BUB" FT STRAND 873..875 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8BU7" FT STRAND 881..883 FT /evidence="ECO:0007829|PDB:8BUI" FT STRAND 886..888 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 899..901 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 904..907 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 916..931 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 941..952 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 957..959 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 961..965 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 967..971 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 982..985 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 986..988 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 991..1000 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 1005..1007 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1011..1014 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1018..1021 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1025..1027 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 1035..1037 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1041..1045 FT /evidence="ECO:0007829|PDB:4NST" SQ SEQUENCE 1490 AA; 164155 MW; D6B04B998ECDE58E CRC64; MPNSERHGGK KDGSGGASGT LQPSSGGGSS NSRERHRLVS KHKRHKSKHS KDMGLVTPEA ASLGTVIKPL VEYDDISSDS DTFSDDMAFK LDRRENDERR GSDRSDRLHK HRHHQHRRSR DLLKAKQTEK EKSQEVSSKS GSMKDRISGS SKRSNEETDD YGKAQVAKSS SKESRSSKLH KEKTRKEREL KSGHKDRSKS HRKRETPKSY KTVDSPKRRS RSPHRKWSDS SKQDDSPSGA SYGQDYDLSP SRSHTSSNYD SYKKSPGSTS RRQSVSPPYK EPSAYQSSTR SPSPYSRRQR SVSPYSRRRS SSYERSGSYS GRSPSPYGRR RSSSPFLSKR SLSRSPLPSR KSMKSRSRSP AYSRHSSSHS KKKRSSSRSR HSSISPVRLP LNSSLGAELS RKKKERAAAA AAAKMDGKES KGSPVFLPRK ENSSVEAKDS GLESKKLPRS VKLEKSAPDT ELVNVTHLNT EVKNSSDTGK VKLDENSEKH LVKDLKAQGT RDSKPIALKE EIVTPKETET SEKETPPPLP TIASPPPPLP TTTPPPQTPP LPPLPPIPAL PQQPPLPPSQ PAFSQVPASS TSTLPPSTHS KTSAVSSQAN SQPPVQVSVK TQVSVTAAIP HLKTSTLPPL PLPPLLPGDD DMDSPKETLP SKPVKKEKEQ RTRHLLTDLP LPPELPGGDL SPPDSPEPKA ITPPQQPYKK RPKICCPRYG ERRQTESDWG KRCVDKFDII GIIGEGTYGQ VYKAKDKDTG ELVALKKVRL DNEKEGFPIT AIREIKILRQ LIHRSVVNMK EIVTDKQDAL DFKKDKGAFY LVFEYMDHDL MGLLESGLVH FSEDHIKSFM KQLMEGLEYC HKKNFLHRDI KCSNILLNNS GQIKLADFGL ARLYNSEESR PYTNKVITLW YRPPELLLGE ERYTPAIDVW SCGCILGELF TKKPIFQANL ELAQLELISR LCGSPCPAVW PDVIKLPYFN TMKPKKQYRR RLREEFSFIP SAALDLLDHM LTLDPSKRCT AEQTLQSDFL KDVELSKMAP PDLPHWQDCH ELWSKKRRRQ RQSGVVVEEP PPSKTSRKET TSGTSTEPVK NSSPAPPQPA PGKVESGAGD AIGLADITQQ LNQSELAVLL NLLQSQTDLS IPQMAQLLNI HSNPEMQQQL EALNQSISAL TEATSQQQDS ETMAPEESLK EAPSAPVILP SAEQTTLEAS STPADMQNIL AVLLSQLMKT QEPAGSLEEN NSDKNSGPQG PRRTPTMPQE EAAACPPHIL PPEKRPPEPP GPPPPPPPPP LVEGDLSSAP QELNPAVTAA LLQLLSQPEA EPPGHLPHEH QALRPMEYST RPRPNRTYGN TDGPETGFSA IDTDERNSGP ALTESLVQTL VKNRTFSGSL SHLGESSSYQ GTGSVQFPGD QDLRFARVPL ALHPVVGQPF LKAEGSSNSV VHAETKLQNY GELGPGTTGA SSSGAGLHWG GPTQSSAYGK LYRGPTRVPP RGGRGRGVPY // ID CEMIP_HUMAN Reviewed; 1361 AA. AC Q8WUJ3; Q6L9J5; Q9H1K5; Q9NPN9; Q9ULM1; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 13-APR-2004, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Cell migration-inducing and hyaluronan-binding protein; DE EC=3.2.1.35 {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; DE AltName: Full=Hyaluronan binding protein involved in hyaluronan depolymerization {ECO:0000303|PubMed:23509262}; DE Flags: Precursor; GN Name=CEMIP {ECO:0000312|HGNC:HGNC:29213}; GN Synonyms=HYBID {ECO:0000303|PubMed:23509262}, KIAA1199; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS CYS-187; HIS-187 AND TYR-783, AND RP VARIANTS ARG-783; ILE-1109 AND ALA-1169. RX PubMed=14577002; DOI=10.1007/s10038-003-0079-2; RA Abe S., Usami S., Nakamura Y.; RT "Mutations in the gene encoding KIAA1199 protein, an inner-ear protein RT expressed in Deiters' cells and the fibrocytes, as the cause of RT nonsyndromic hearing loss."; RL J. Hum. Genet. 48:564-570(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16157444; DOI=10.1016/j.canlet.2005.07.028; RA Michishita E., Garces G., Barrett J.C., Horikawa I.; RT "Upregulation of the KIAA1199 gene is associated with cellular mortality."; RL Cancer Lett. 239:71-77(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 349-1361 (ISOFORM 1), AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 558-1361. RG The European IMAGE consortium; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 862-1361. RX PubMed=11247670; DOI=10.1006/geno.2000.6466; RA Wines M.E., Lee L., Katari M.S., Zhang L., DeRossi C., Shi Y., Perkins S., RA Feldman M., McCombie W.R., Holdener B.C.; RT "Identification of mesoderm development (mesd) candidate genes by RT comparative mapping and genome sequence analysis."; RL Genomics 72:88-98(2001). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12471561; DOI=10.1086/345398; RA Abe S., Katagiri T., Saito-Hisaminato A., Usami S., Inoue Y., Tsunoda T., RA Nakamura Y.; RT "Identification of CRYM as a candidate responsible for nonsyndromic RT deafness, through cDNA microarray analysis of human cochlear and vestibular RT tissues."; RL Am. J. Hum. Genet. 72:73-82(2003). RN [9] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=19434458; DOI=10.1245/s10434-009-0469-6; RA Matsuzaki S., Tanaka F., Mimori K., Tahara K., Inoue H., Mori M.; RT "Clinicopathologic significance of KIAA1199 overexpression in human gastric RT cancer."; RL Ann. Surg. Oncol. 16:2042-2051(2009). RN [10] RP PROBABLE FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21772334; DOI=10.1038/bjc.2011.268; RA Birkenkamp-Demtroder K., Maghnouj A., Mansilla F., Thorsen K., RA Andersen C.L., Oster B., Hahn S., Orntoft T.F.; RT "Repression of KIAA1199 attenuates Wnt-signalling and decreases the RT proliferation of colon cancer cells."; RL Br. J. Cancer 105:552-561(2011). RN [11] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=22970280; DOI=10.1371/journal.pone.0044661; RA Kuscu C., Evensen N., Kim D., Hu Y.J., Zucker S., Cao J.; RT "Transcriptional and epigenetic regulation of KIAA1199 gene expression in RT human breast cancer."; RL PLoS ONE 7:E44661-E44661(2012). RN [12] RP FUNCTION IN CANCER, INTERACTION WITH HSPA5, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [13] RP INTERACTION WITH EPHA2 AND ITPR3, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [14] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, HYALURONIC ACID-BINDING, INTERACTION WITH CLATHRIN, SUBCELLULAR RP LOCATION, INDUCTION, AND CHARACTERIZATION OF VARIANTS CYS-187; HIS-187; RP ARG-783 AND ILE-1109. RX PubMed=23509262; DOI=10.1073/pnas.1215432110; RA Yoshida H., Nagaoka A., Kusaka-Kikushima A., Tobiishi M., Kawabata K., RA Sayo T., Sakai S., Sugiyama Y., Enomoto H., Okada Y., Inoue S.; RT "KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding RT protein involved in hyaluronan depolymerization."; RL Proc. Natl. Acad. Sci. U.S.A. 110:5612-5617(2013). RN [15] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, GLYCOSYLATION, RP SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND SIGNAL SEQUENCE CLEAVAGE RP SITE. RX PubMed=24269685; DOI=10.1016/j.febslet.2013.11.017; RA Yoshida H., Nagaoka A., Nakamura S., Tobiishi M., Sugiyama Y., Inoue S.; RT "N-Terminal signal sequence is required for cellular trafficking and RT hyaluronan-depolymerization of KIAA1199."; RL FEBS Lett. 588:111-116(2014). CC -!- FUNCTION: Mediates depolymerization of hyaluronic acid (HA) via the CC cell membrane-associated clathrin-coated pit endocytic pathway. Binds CC to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to CC produce an intermediate-sized product, a process that may occur through CC rapid vesicle endocytosis and recycling without intracytoplasmic CC accumulation or digestion in lysosomes. Involved in hyaluronan CC catabolism in the dermis of the skin and arthritic synovium. Positively CC regulates epithelial-mesenchymal transition (EMT), and hence tumor cell CC growth, invasion and cancer dissemination. In collaboration with CC HSPA5/BIP, promotes cancer cell migration in a calcium and PKC- CC dependent manner. May be involved in hearing. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:24269685}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D- CC glucosamine and D-glucuronate residues in hyaluronate.; EC=3.2.1.35; CC Evidence={ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; CC -!- ACTIVITY REGULATION: Activity is up-regulated by histamine. CC {ECO:0000269|PubMed:23509262}. CC -!- SUBUNIT: Interacts with EPHA2 and ITPR3. Interacts with HSPA5/BIP; the CC interaction induces calcium leakage from the endoplasmic reticulum and CC cell migration. Interacts with clathrin heavy chain/CLTC. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23936024, CC ECO:0000269|PubMed:23990668}. CC -!- INTERACTION: CC Q8WUJ3; P53621: COPA; NbExp=2; IntAct=EBI-310606, EBI-356273; CC Q8WUJ3; Q93100: PHKB; NbExp=2; IntAct=EBI-310606, EBI-740559; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Endoplasmic reticulum. Cell CC membrane. Membrane, clathrin-coated pit. Secreted. Note=Retained in the CC endoplasmic reticulum (ER) in a HSPA5/BIP-dependent manner. Colocalized CC with clathrin heavy chain/CLTC in clathrin-coated vesicles. Strongly CC detected in the cytoplasm of breast carcinoma cells, whereas poorly CC detected in adjacent normal epithelial cells, stromal cells, or benign CC breast tissues. Localized in the nucleus and cytoplasm of colon CC adenocarcinomas. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WUJ3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WUJ3-2; Sequence=VSP_009814, VSP_009815; CC -!- TISSUE SPECIFICITY: Expressed in dermal and in synovial fibroblasts. CC Strongly expressed in gastric cancers compared with the paired normal CC tissues. Strongly expressed in both ductal carcinoma and invasive CC breast cancer cells compared with benign epithelial cells (at protein CC level). Strongly expressed in brain, placenta, prostate, breast, lung CC and testis. Expressed in fibroblasts, epithelial cells and cancer CC cells. In ear, it is specifically expressed in inner ear. Expressed in CC cochlea and vestibule tissues. Strongly expressed in gastric cancers CC compared with the paired normal tissues. Strongly expressed in colon CC adenocarcinomas compared with normal colonic mucosas. Strongly CC expressed in breast cancer as compared to normal breast tissue. CC {ECO:0000269|PubMed:10574462, ECO:0000269|PubMed:12471561, CC ECO:0000269|PubMed:16157444, ECO:0000269|PubMed:19434458, CC ECO:0000269|PubMed:21772334, ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:23990668}. CC -!- INDUCTION: Up-regulated by histamine. Up-regulated by the adapter CC protein complex 1 (AP-1) and NF-kappaB/RELA. Down-regulated by CC transforming growth factor TGFB1. {ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23509262}. CC -!- DOMAIN: The signal sequence is essential in mediating its proper CC translocation, hyaluronic acid (HA) degradation activity and secretion. CC -!- PTM: N-glycosylated; glycosylation is not necessary for HA-binding. CC {ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:24269685}. CC -!- SIMILARITY: Belongs to the CEMIP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB103330; BAD02451.1; -; mRNA. DR EMBL; CH471136; EAW99111.1; -; Genomic_DNA. DR EMBL; BC020256; AAH20256.1; -; mRNA. DR EMBL; AB033025; BAA86513.1; -; mRNA. DR EMBL; AL359061; CAB94391.1; -; mRNA. DR EMBL; AY007811; AAG41059.1; -; mRNA. DR CCDS; CCDS10315.1; -. [Q8WUJ3-1] DR RefSeq; NP_001280227.1; NM_001293298.2. [Q8WUJ3-1] DR RefSeq; NP_001280233.1; NM_001293304.2. [Q8WUJ3-1] DR RefSeq; NP_061159.1; NM_018689.3. [Q8WUJ3-1] DR RefSeq; XP_047288856.1; XM_047432900.1. [Q8WUJ3-1] DR RefSeq; XP_054234488.1; XM_054378513.1. [Q8WUJ3-1] DR AlphaFoldDB; Q8WUJ3; -. DR SMR; Q8WUJ3; -. DR BioGRID; 121452; 96. DR FunCoup; Q8WUJ3; 405. DR IntAct; Q8WUJ3; 15. DR MINT; Q8WUJ3; -. DR STRING; 9606.ENSP00000378177; -. DR CarbonylDB; Q8WUJ3; -. DR GlyCosmos; Q8WUJ3; 7 sites, No reported glycans. DR GlyGen; Q8WUJ3; 8 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q8WUJ3; -. DR PhosphoSitePlus; Q8WUJ3; -. DR BioMuta; CEMIP; -. DR DMDM; 46396475; -. DR jPOST; Q8WUJ3; -. DR MassIVE; Q8WUJ3; -. DR PaxDb; 9606-ENSP00000378177; -. DR PeptideAtlas; Q8WUJ3; -. DR ProteomicsDB; 74690; -. [Q8WUJ3-1] DR ProteomicsDB; 74691; -. [Q8WUJ3-2] DR Antibodypedia; 27890; 248 antibodies from 26 providers. DR DNASU; 57214; -. DR Ensembl; ENST00000220244.7; ENSP00000220244.3; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000356249.9; ENSP00000348583.5; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000394685.8; ENSP00000378177.3; ENSG00000103888.18. [Q8WUJ3-1] DR GeneID; 57214; -. DR KEGG; hsa:57214; -. DR MANE-Select; ENST00000394685.8; ENSP00000378177.3; NM_001293298.2; NP_001280227.1. DR UCSC; uc002bfw.2; human. [Q8WUJ3-1] DR AGR; HGNC:29213; -. DR ClinPGx; PA134967531; -. DR CTD; 57214; -. DR DisGeNET; 57214; -. DR GeneCards; CEMIP; -. DR HGNC; HGNC:29213; CEMIP. DR HPA; ENSG00000103888; Tissue enhanced (endometrium). DR MIM; 608366; gene. DR OpenTargets; ENSG00000103888; -. DR VEuPathDB; HostDB:ENSG00000103888; -. DR eggNOG; ENOG502QT0K; Eukaryota. DR GeneTree; ENSGT00940000153636; -. DR HOGENOM; CLU_005606_1_0_1; -. DR InParanoid; Q8WUJ3; -. DR OMA; YGRADED; -. DR OrthoDB; 120976at2759; -. DR PAN-GO; Q8WUJ3; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8WUJ3; -. DR PathwayCommons; Q8WUJ3; -. DR Reactome; R-HSA-2160916; Hyaluronan degradation. DR SignaLink; Q8WUJ3; -. DR Agora; ENSG00000103888; -. DR BioGRID-ORCS; 57214; 16 hits in 1143 CRISPR screens. DR ChiTaRS; CEMIP; human. DR GeneWiki; KIAA1199; -. DR GenomeRNAi; 57214; -. DR Pharos; Q8WUJ3; Tbio. DR PRO; PR:Q8WUJ3; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q8WUJ3; protein. DR Bgee; ENSG00000103888; Expressed in choroid plexus epithelium and 132 other cell types or tissues. DR ExpressionAtlas; Q8WUJ3; baseline and differential. DR GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:UniProtKB. DR GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell. DR GO; GO:0030665; C:clathrin-coated vesicle membrane; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0032050; F:clathrin heavy chain binding; IDA:UniProtKB. DR GO; GO:0046923; F:ER retention sequence binding; IDA:UniProtKB. DR GO; GO:0005540; F:hyaluronic acid binding; IDA:UniProtKB. DR GO; GO:0004415; F:hyalurononglucosaminidase activity; IMP:UniProtKB. DR GO; GO:0030214; P:hyaluronan catabolic process; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:1900020; P:positive regulation of protein kinase C activity; IDA:UniProtKB. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd13941; PANDER_like_KIAA1199; 1. DR CDD; cd13938; PANDER_like_TMEM2; 1. DR InterPro; IPR052252; CEMIP/CEMIP2. DR InterPro; IPR055401; CEMIP_beta-hel_dom. DR InterPro; IPR055400; CEMIP_X. DR InterPro; IPR019316; G8_domain. DR InterPro; IPR039477; ILEI/PANDER_dom. DR InterPro; IPR011050; Pectin_lyase_fold/virulence. DR InterPro; IPR039473; TMEM2_PANDER-like. DR InterPro; IPR025155; WxxW_domain. DR PANTHER; PTHR15535:SF15; CELL MIGRATION-INDUCING AND HYALURONAN-BINDING PROTEIN; 1. DR PANTHER; PTHR15535; TRANSMEMBRANE PROTEIN 2-RELATED; 1. DR Pfam; PF24606; CEMIP_beta-hel; 1. DR Pfam; PF24605; CEMIP_X; 1. DR Pfam; PF10162; G8; 1. DR Pfam; PF15711; ILEI; 2. DR Pfam; PF13330; Mucin2_WxxW; 2. DR SMART; SM01225; G8; 1. DR SUPFAM; SSF51126; Pectin lyase-like; 1. DR PROSITE; PS51484; G8; 1. DR PROSITE; PS52031; GG_LECTIN; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Coated pit; Cytoplasm; KW Endoplasmic reticulum; Glycoprotein; Glycosidase; Hyaluronic acid; KW Hydrolase; Lectin; Membrane; Nucleus; Proteomics identification; KW Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..30 FT /evidence="ECO:0000269|PubMed:24269685" FT CHAIN 31..1361 FT /note="Cell migration-inducing and hyaluronan-binding FT protein" FT /id="PRO_0000021538" FT DOMAIN 44..166 FT /note="G8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00817" FT DOMAIN 176..317 FT /note="GG-type lectin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REPEAT 572..594 FT /note="PbH1 1" FT REPEAT 595..617 FT /note="PbH1 2" FT REPEAT 719..741 FT /note="PbH1 3" FT REPEAT 798..819 FT /note="PbH1 4" FT DOMAIN 1227..1361 FT /note="GG-type lectin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REGION 295..591 FT /note="Necessary for its endoplasmic reticulum (ER) FT retention and interaction with HSPA5" FT /evidence="ECO:0000269|PubMed:23990668" FT CARBOHYD 119 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 165 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 312 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 370 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 420 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 889 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 921 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 978..992 FT /note="NWLVRHPDCINVPDW -> KWHSLASKAASGPSG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009814" FT VAR_SEQ 993..1361 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009815" FT VARIANT 187 FT /note="R -> C (in a family with non-syndromic hearing loss; FT reduces hyaluronic acid degradation activity; FT dbSNP:rs368854657)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018165" FT VARIANT 187 FT /note="R -> H (in two unrelated families with non-syndromic FT hearing loss; reduces hyaluronic acid (HA) degradation FT activity; dbSNP:rs144446375)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018166" FT VARIANT 783 FT /note="H -> R (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs12441101)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018167" FT VARIANT 783 FT /note="H -> Y (in a sporadic case of non-syndromic hearing FT loss; dbSNP:rs996035812)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018168" FT VARIANT 1109 FT /note="V -> I (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs751807711)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018169" FT VARIANT 1169 FT /note="P -> A (in dbSNP:rs16972583)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018170" FT CONFLICT 558..564 FT /note="HFHLAGD -> TRPPTRP (in Ref. 6; CAB94391)" FT /evidence="ECO:0000305" FT CONFLICT 862 FT /note="H -> T (in Ref. 7; AAG41059)" FT /evidence="ECO:0000305" SQ SEQUENCE 1361 AA; 152998 MW; 40CDFFB84F99516C CRC64; MGAAGRQDFL FKAMLTISWL TLTCFPGATS TVAAGCPDQS PELQPWNPGH DQDHHVHIGQ GKTLLLTSSA TVYSIHISEG GKLVIKDHDE PIVLRTRHIL IDNGGELHAG SALCPFQGNF TIILYGRADE GIQPDPYYGL KYIGVGKGGA LELHGQKKLS WTFLNKTLHP GGMAEGGYFF ERSWGHRGVI VHVIDPKSGT VIHSDRFDTY RSKKESERLV QYLNAVPDGR ILSVAVNDEG SRNLDDMARK AMTKLGSKHF LHLGFRHPWS FLTVKGNPSS SVEDHIEYHG HRGSAAARVF KLFQTEHGEY FNVSLSSEWV QDVEWTEWFD HDKVSQTKGG EKISDLWKAH PGKICNRPID IQATTMDGVN LSTEVVYKKG QDYRFACYDR GRACRSYRVR FLCGKPVRPK LTVTIDTNVN STILNLEDNV QSWKPGDTLV IASTDYSMYQ AEEFQVLPCR SCAPNQVKVA GKPMYLHIGE EIDGVDMRAE VGLLSRNIIV MGEMEDKCYP YRNHICNFFD FDTFGGHIKF ALGFKAAHLE GTELKHMGQQ LVGQYPIHFH LAGDVDERGG YDPPTYIRDL SIHHTFSRCV TVHGSNGLLI KDVVGYNSLG HCFFTEDGPE ERNTFDHCLG LLVKSGTLLP SDRDSKMCKM ITEDSYPGYI PKPRQDCNAV STFWMANPNN NLINCAAAGS EETGFWFIFH HVPTGPSVGM YSPGYSEHIP LGKFYNNRAH SNYRAGMIID NGVKTTEASA KDKRPFLSII SARYSPHQDA DPLKPREPAI IRHFIAYKNQ DHGAWLRGGD VWLDSCRFAD NGIGLTLASG GTFPYDDGSK QEIKNSLFVG ESGNVGTEMM DNRIWGPGGL DHSGRTLPIG QNFPIRGIQL YDGPINIQNC TFRKFVALEG RHTSALAFRL NNAWQSCPHN NVTGIAFEDV PITSRVFFGE PGPWFNQLDM DGDKTSVFHD VDGSVSEYPG SYLTKNDNWL VRHPDCINVP DWRGAICSGC YAQMYIQAYK TSNLRMKIIK NDFPSHPLYL EGALTRSTHY QQYQPVVTLQ KGYTIHWDQT APAELAIWLI NFNKGDWIRV GLCYPRGTTF SILSDVHNRL LKQTSKTGVF VRTLQMDKVE QSYPGRSHYY WDEDSGLLFL KLKAQNEREK FAFCSMKGCE RIKIKALIPK NAGVSDCTAT AYPKFTERAV VDVPMPKKLF GSQLKTKDHF LEVKMESSKQ HFFHLWNDFA YIEVDGKKYP SSEDGIQVVV IDGNQGRVVS HTSFRNSILQ GIPWQLFNYV ATIPDNSIVL MASKGRYVSR GPWTRVLEKL GADRGLKLKE QMAFVGFKGS FRPIWVTLDT EDHKAKIFQV VPIPVVKKKK L // ID CTHR1_HUMAN Reviewed; 243 AA. AC Q96CG8; G3V141; Q6UW91; Q8IX63; DT 10-MAY-2005, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 167. DE RecName: Full=Collagen triple helix repeat-containing protein 1; DE Flags: Precursor; GN Name=CTHRC1; ORFNames=UNQ762/PRO1550; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Aorta; RX PubMed=15618538; DOI=10.1161/01.res.0000154262.07264.12; RA Pyagay P., Heroult M., Wang Q., Lehnert W., Belden J., Liaw L., RA Friesel R.E., Lindner V.; RT "Collagen triple helix repeat containing 1, a novel secreted protein in RT injured and diseased arteries, inhibits collagen expression and promotes RT cell migration."; RL Circ. Res. 96:261-268(2005). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Sanuki N., Fujiki K., Kanai A., Tanaka Y., Iwata T.; RT "Novel polypeptide found in human cornea cDNA library."; RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 31-45 (ISOFORM 1). RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [8] RP INVOLVEMENT IN BE, AND VARIANT PRO-44. RX PubMed=21791690; DOI=10.1001/jama.2011.1029; RA Orloff M., Peterson C., He X., Ganapathi S., Heald B., Yang Y.R., Bebek G., RA Romigh T., Song J.H., Wu W., David S., Cheng Y., Meltzer S.J., Eng C.; RT "Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett RT esophagus and esophageal adenocarcinoma."; RL JAMA 306:410-419(2011). CC -!- FUNCTION: May act as a negative regulator of collagen matrix CC deposition. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular CC matrix {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q96CG8-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96CG8-2; Sequence=VSP_013622, VSP_013623; CC Name=3; CC IsoId=Q96CG8-3; Sequence=VSP_013622; CC -!- TISSUE SPECIFICITY: Isoform 1 is expressed in calcified atherosclerotic CC plaque and chondrocyte-like cells. {ECO:0000269|PubMed:15618538}. CC -!- PTM: N-glycosylated. {ECO:0000250}. CC -!- DISEASE: Barrett esophagus (BE) [MIM:614266]: A condition characterized CC by a metaplastic change in which normal esophageal squamous epithelium CC is replaced by a columnar and intestinal-type epithelium. Patients with CC Barrett esophagus have an increased risk of esophageal adenocarcinoma. CC The main cause of Barrett esophagus is gastroesophageal reflux. The CC retrograde movement of acid and bile salts from the stomach into the CC esophagus causes prolonged injury to the esophageal epithelium and CC induces chronic esophagitis, which in turn is believed to trigger the CC pathologic changes. {ECO:0000269|PubMed:21791690}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40193/CTHRC1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY136825; AAN15749.1; -; mRNA. DR EMBL; AF395488; AAO17919.1; -; mRNA. DR EMBL; AY358914; AAQ89273.1; -; mRNA. DR EMBL; AC012213; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC069351; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW91876.1; -; Genomic_DNA. DR EMBL; BC014245; AAH14245.1; -; mRNA. DR CCDS; CCDS59110.1; -. [Q96CG8-3] DR CCDS; CCDS6299.1; -. [Q96CG8-1] DR RefSeq; NP_001243028.1; NM_001256099.2. [Q96CG8-3] DR RefSeq; NP_612464.1; NM_138455.4. [Q96CG8-1] DR AlphaFoldDB; Q96CG8; -. DR BioGRID; 125461; 33. DR FunCoup; Q96CG8; 247. DR IntAct; Q96CG8; 14. DR STRING; 9606.ENSP00000330523; -. DR GlyCosmos; Q96CG8; 1 site, No reported glycans. DR GlyGen; Q96CG8; 3 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q96CG8; -. DR PhosphoSitePlus; Q96CG8; -. DR BioMuta; CTHRC1; -. DR DMDM; 67462315; -. DR jPOST; Q96CG8; -. DR MassIVE; Q96CG8; -. DR PaxDb; 9606-ENSP00000330523; -. DR PeptideAtlas; Q96CG8; -. DR ProteomicsDB; 32251; -. DR ProteomicsDB; 76186; -. [Q96CG8-1] DR ProteomicsDB; 76187; -. [Q96CG8-2] DR Antibodypedia; 26375; 323 antibodies from 35 providers. DR DNASU; 115908; -. DR Ensembl; ENST00000330295.10; ENSP00000330523.5; ENSG00000164932.14. [Q96CG8-1] DR Ensembl; ENST00000520337.1; ENSP00000430550.1; ENSG00000164932.14. [Q96CG8-3] DR GeneID; 115908; -. DR KEGG; hsa:115908; -. DR MANE-Select; ENST00000330295.10; ENSP00000330523.5; NM_138455.4; NP_612464.1. DR UCSC; uc003ylk.5; human. [Q96CG8-1] DR AGR; HGNC:18831; -. DR ClinPGx; PA38701; -. DR CTD; 115908; -. DR DisGeNET; 115908; -. DR GeneCards; CTHRC1; -. DR HGNC; HGNC:18831; CTHRC1. DR HPA; ENSG00000164932; Tissue enhanced (adipose tissue, gallbladder, placenta, urinary bladder). DR MalaCards; CTHRC1; -. DR MIM; 610635; gene. DR MIM; 614266; phenotype. DR OpenTargets; ENSG00000164932; -. DR VEuPathDB; HostDB:ENSG00000164932; -. DR eggNOG; ENOG502QSJD; Eukaryota. DR GeneTree; ENSGT00390000018094; -. DR HOGENOM; CLU_099891_0_0_1; -. DR InParanoid; Q96CG8; -. DR OMA; CADYPKG; -. DR OrthoDB; 5985978at2759; -. DR PAN-GO; Q96CG8; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q96CG8; -. DR PathwayCommons; Q96CG8; -. DR SignaLink; Q96CG8; -. DR Agora; ENSG00000164932; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 115908; 11 hits in 1145 CRISPR screens. DR GenomeRNAi; 115908; -. DR Pharos; Q96CG8; Tbio. DR PRO; PR:Q96CG8; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q96CG8; protein. DR Bgee; ENSG00000164932; Expressed in tibia and 164 other cell types or tissues. DR ExpressionAtlas; Q96CG8; baseline and differential. DR GO; GO:0005581; C:collagen trimer; IEA:UniProtKB-KW. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0031012; C:extracellular matrix; HDA:BHF-UCL. DR GO; GO:0005576; C:extracellular region; HDA:BHF-UCL. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0043005; C:neuron projection; IBA:GO_Central. DR GO; GO:0016528; C:sarcoplasm; IEA:Ensembl. DR GO; GO:0005109; F:frizzled binding; IEA:Ensembl. DR GO; GO:0004666; F:prostaglandin-endoperoxide synthase activity; IBA:GO_Central. DR GO; GO:0017147; F:Wnt-protein binding; IEA:Ensembl. DR GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl. DR GO; GO:0019371; P:cyclooxygenase pathway; IBA:GO_Central. DR GO; GO:0090177; P:establishment of planar polarity involved in neural tube closure; IEA:Ensembl. DR GO; GO:0060122; P:inner ear receptor cell stereocilium organization; IEA:Ensembl. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0043932; P:ossification involved in bone remodeling; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0033687; P:osteoblast proliferation; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl. DR GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl. DR GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; IEA:Ensembl. DR InterPro; IPR057873; CTHRC1_C. DR Pfam; PF25815; CTHRC1_C; 1. PE 1: Evidence at protein level; KW Alternative splicing; Collagen; Direct protein sequencing; KW Extracellular matrix; Glycoprotein; Proteomics identification; KW Reference proteome; Secreted; Signal. FT SIGNAL 1..30 FT CHAIN 31..243 FT /note="Collagen triple helix repeat-containing protein 1" FT /id="PRO_0000021038" FT DOMAIN 57..90 FT /note="Collagen-like" FT REGION 62..85 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 186 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..50 FT /note="MRPQGPAASPQRLRGLLLLLLLQLPAPSSASEIPKGKQKAQLRQREVVDL FT -> MWPPGRSITVKLREKTVSRKLEMNGPSAFQGLICGK (in isoform 2 and FT isoform 3)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_013622" FT VAR_SEQ 243 FT /note="K -> IYML (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_013623" FT VARIANT 44 FT /note="Q -> P (found in patients with Barrett esophagus; FT dbSNP:rs387907029)" FT /evidence="ECO:0000269|PubMed:21791690" FT /id="VAR_066589" FT CONFLICT 73 FT /note="G -> V (in Ref. 3; AAQ89273)" FT /evidence="ECO:0000305" SQ SEQUENCE 243 AA; 26224 MW; A11FFEB1C66867F9 CRC64; MRPQGPAASP QRLRGLLLLL LLQLPAPSSA SEIPKGKQKA QLRQREVVDL YNGMCLQGPA GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFEE SWTPNYKQCS WSSLNYGIDL GKIAECTFTK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE LPK // ID DCLK1_HUMAN Reviewed; 740 AA. AC O15075; B7Z3E9; Q5VZY8; Q5VZZ0; Q5VZZ1; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2000, sequence version 2. DT 28-JAN-2026, entry version 221. DE RecName: Full=Serine/threonine-protein kinase DCLK1; DE EC=2.7.11.1; DE AltName: Full=Doublecortin domain-containing protein 3A; DE AltName: Full=Doublecortin-like and CAM kinase-like 1; DE AltName: Full=Doublecortin-like kinase 1; GN Name=DCLK1; Synonyms=DCAMKL1, DCDC3A, KIAA0369; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4). RX PubMed=9747029; DOI=10.1007/s100380050063; RA Omori Y., Suzuki M., Ozaki K., Harada Y., Nakamura Y., Takahashi E., RA Fujiwara T.; RT "Expression and chromosomal localization of KIAA0369, a putative kinase RT structurally related to Doublecortin."; RL J. Hum. Genet. 43:169-177(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Fetal brain; RX PubMed=10036192; DOI=10.1006/geno.1998.5718; RA Sossey-Alaoui K., Srivastava A.K.; RT "DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is similar RT to doublecortin (DCX)."; RL Genomics 56:121-126(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP TISSUE SPECIFICITY. RX PubMed=10051403; DOI=10.1006/geno.1998.5673; RA Matsumoto N., Pilz D.T., Ledbetter D.H.; RT "Genomic structure, chromosomal mapping, and expression pattern of human RT DCAMKL1 (KIAA0369), a homologue of DCX (XLIS)."; RL Genomics 56:179-183(1999). RN [9] RP INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x; RA Leong W.F., Chow V.T.; RT "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal RT differential cellular gene expression in response to enterovirus 71 RT infection."; RL Cell. Microbiol. 8:565-580(2006). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [11] RP STRUCTURE BY NMR OF 51-156. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the N-terminal DCX domain of human doublecortin-like RT kinase."; RL Submitted (NOV-2003) to the PDB data bank. RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-29; MET-46; GLN-93; PHE-291 AND RP HIS-292. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Probable kinase that may be involved in a calcium-signaling CC pathway controlling neuronal migration in the developing brain. May CC also participate in functions of the mature nervous system. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC O15075; Q96M94: KLHL15; NbExp=2; IntAct=EBI-2684263, EBI-2510129; CC O15075-2; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-12324841, EBI-396137; CC O15075-2; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-12324841, EBI-2349927; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Comment=Additional isoforms seem to exist. Type A (AS and AL) and CC type B (BS and BL) isoforms differ respectively by the presence or CC absence of the doublecortin domain. An alternative splicing occurring CC in 3' of the mRNA produces the long (L) instead of the short (S) CC isoforms.; CC Name=2; Synonyms=AL; CC IsoId=O15075-1; Sequence=Displayed; CC Name=1; Synonyms=AS; CC IsoId=O15075-2; Sequence=VSP_004907; CC Name=3; Synonyms=BS; CC IsoId=O15075-3; Sequence=VSP_004905, VSP_004906, VSP_004907; CC Name=4; Synonyms=BL; CC IsoId=O15075-4; Sequence=VSP_004905, VSP_004906; CC -!- TISSUE SPECIFICITY: In fetal tissues, highly expressed in brain, CC detectable in lung and liver, but not in kidney. In adult tissues, CC expressed ubiquitously in the brain, detectable in the heart, liver, CC spleen, thymus, prostate, testis, ovary, small intestine and colon. The CC type A isoforms seem to be expressed predominantly in fetal brain CC whereas type B isoforms are expressed abundantly in both fetal and CC adult brain. {ECO:0000269|PubMed:10051403}. CC -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71) infection CC (at protein level). {ECO:0000269|PubMed:16548883}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA20824.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB002367; BAA20824.2; ALT_INIT; mRNA. DR EMBL; AL157760; CAH70167.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70170.1; -; Genomic_DNA. DR EMBL; AK295777; BAH12185.1; -; mRNA. DR EMBL; AL157760; CAH70168.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70261.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70262.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL157694; CAH70656.1; -; Genomic_DNA. DR EMBL; AL157760; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL157694; CAH70657.1; -; Genomic_DNA. DR EMBL; AL157760; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAI15720.1; -; Genomic_DNA. DR EMBL; AL157694; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAI15721.1; -; Genomic_DNA. DR EMBL; AL157694; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; CH471075; EAX08550.1; -; Genomic_DNA. DR EMBL; CH471075; EAX08551.1; -; Genomic_DNA. DR EMBL; BC152456; AAI52457.1; -; mRNA. DR CCDS; CCDS55895.1; -. [O15075-4] DR CCDS; CCDS73561.1; -. [O15075-3] DR CCDS; CCDS81762.1; -. [O15075-1] DR CCDS; CCDS9354.1; -. [O15075-2] DR RefSeq; NP_001182344.1; NM_001195415.2. [O15075-3] DR RefSeq; NP_001182345.1; NM_001195416.2. [O15075-4] DR RefSeq; NP_001317000.1; NM_001330071.2. [O15075-1] DR RefSeq; NP_001317001.1; NM_001330072.2. [O15075-1] DR RefSeq; NP_004725.1; NM_004734.5. [O15075-2] DR PDB; 1MFW; X-ray; 1.60 A; A=49-154. DR PDB; 1MG4; X-ray; 1.50 A; A=49-154. DR PDB; 1UF0; NMR; -; A=54-156. DR PDB; 5JZJ; X-ray; 1.71 A; A/B=372-649. DR PDB; 5JZN; X-ray; 2.85 A; A/B=372-649. DR PDB; 6KYQ; X-ray; 2.14 A; A/B=379-704. DR PDB; 6KYR; X-ray; 2.21 A; A/B=379-704. DR PDB; 7F3G; X-ray; 2.10 A; A/B=372-649. DR PDB; 7KX6; X-ray; 2.50 A; A/B=372-649. DR PDB; 7KX8; X-ray; 3.10 A; A/B=372-686. DR PDB; 7KXW; X-ray; 3.00 A; A/B=372-649. DR PDBsum; 1MFW; -. DR PDBsum; 1MG4; -. DR PDBsum; 1UF0; -. DR PDBsum; 5JZJ; -. DR PDBsum; 5JZN; -. DR PDBsum; 6KYQ; -. DR PDBsum; 6KYR; -. DR PDBsum; 7F3G; -. DR PDBsum; 7KX6; -. DR PDBsum; 7KX8; -. DR PDBsum; 7KXW; -. DR AlphaFoldDB; O15075; -. DR SMR; O15075; -. DR BioGRID; 114635; 123. DR FunCoup; O15075; 1256. DR IntAct; O15075; 121. DR MINT; O15075; -. DR STRING; 9606.ENSP00000353846; -. DR BindingDB; O15075; -. DR ChEMBL; CHEMBL5683; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O15075; -. DR GuidetoPHARMACOLOGY; 2005; -. DR CarbonylDB; O15075; -. DR GlyGen; O15075; 1 site, 1 N-linked glycan (1 site). DR iPTMnet; O15075; -. DR PhosphoSitePlus; O15075; -. DR SwissPalm; O15075; -. DR BioMuta; DCLK1; -. DR jPOST; O15075; -. DR MassIVE; O15075; -. DR PaxDb; 9606-ENSP00000255448; -. DR PeptideAtlas; O15075; -. DR ProteomicsDB; 48428; -. [O15075-1] DR ProteomicsDB; 48429; -. [O15075-2] DR ProteomicsDB; 48430; -. [O15075-3] DR ProteomicsDB; 48431; -. [O15075-4] DR Pumba; O15075; -. DR Antibodypedia; 23046; 446 antibodies from 40 providers. DR DNASU; 9201; -. DR Ensembl; ENST00000255448.8; ENSP00000255448.4; ENSG00000133083.16. [O15075-2] DR Ensembl; ENST00000360631.8; ENSP00000353846.3; ENSG00000133083.16. [O15075-1] DR Ensembl; ENST00000379893.5; ENSP00000369223.1; ENSG00000133083.16. [O15075-4] DR Ensembl; ENST00000615680.5; ENSP00000484452.1; ENSG00000133083.16. [O15075-3] DR GeneID; 9201; -. DR KEGG; hsa:9201; -. DR MANE-Select; ENST00000360631.8; ENSP00000353846.3; NM_001330071.2; NP_001317000.1. DR UCSC; uc001uve.4; human. [O15075-1] DR AGR; HGNC:2700; -. DR ClinPGx; PA162383325; -. DR CTD; 9201; -. DR DisGeNET; 9201; -. DR GeneCards; DCLK1; -. DR HGNC; HGNC:2700; DCLK1. DR HPA; ENSG00000133083; Tissue enhanced (brain). DR MIM; 604742; gene. DR OpenTargets; ENSG00000133083; -. DR VEuPathDB; HostDB:ENSG00000133083; -. DR eggNOG; KOG0032; Eukaryota. DR eggNOG; KOG3757; Eukaryota. DR GeneTree; ENSGT00940000154956; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; O15075; -. DR OMA; CWEFEGS; -. DR OrthoDB; 1738954at2759; -. DR PAN-GO; O15075; 1 GO annotation based on evolutionary models. DR PhylomeDB; O15075; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O15075; -. DR SignaLink; O15075; -. DR SIGNOR; O15075; -. DR Agora; ENSG00000133083; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 9201; 13 hits in 1181 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; DCLK1; human. DR EvolutionaryTrace; O15075; -. DR GeneWiki; DCLK1; -. DR GenomeRNAi; 9201; -. DR Pharos; O15075; Tchem. DR PRO; PR:O15075; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; O15075; protein. DR Bgee; ENSG00000133083; Expressed in endothelial cell and 188 other cell types or tissues. DR ExpressionAtlas; O15075; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; TAS:ProtInc. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0048675; P:axon extension; IBA:GO_Central. DR GO; GO:0007417; P:central nervous system development; TAS:ProtInc. DR GO; GO:0016197; P:endosomal transport; NAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0007399; P:nervous system development; TAS:ProtInc. DR GO; GO:0034504; P:protein localization to nucleus; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0009615; P:response to virus; IEP:UniProtKB. DR CDD; cd17140; DCX1_DCLK1; 1. DR CDD; cd17069; DCX2; 1. DR CDD; cd14183; STKc_DCKL1; 1. DR FunFam; 3.10.20.230:FF:000003; Neuronal migration protein doublecortin; 1. DR FunFam; 1.10.510.10:FF:000066; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000057; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.10.20.230:FF:000001; serine/threonine-protein kinase DCLK1 isoform X1; 1. DR Gene3D; 3.10.20.230; Doublecortin domain; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003533; Doublecortin_dom. DR InterPro; IPR036572; Doublecortin_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF03607; DCX; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00537; DCX; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF89837; Doublecortin (DC); 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50309; DC; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Developmental protein; KW Differentiation; Kinase; Neurogenesis; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..740 FT /note="Serine/threonine-protein kinase DCLK1" FT /id="PRO_0000085919" FT DOMAIN 57..143 FT /note="Doublecortin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00072" FT DOMAIN 186..269 FT /note="Doublecortin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00072" FT DOMAIN 390..647 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 287..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 697..740 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 297..313 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 347..362 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 366..377 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 697..707 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 511 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 396..404 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 419 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 32 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 36 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 46 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 305 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 307 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 330 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 332 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 334 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 337 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 347 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 352 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 353 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08875" FT MOD_RES 355 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 376 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 520 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 726 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 735 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 738 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT VAR_SEQ 1..307 FT /note="Missing (in isoform 3 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9747029" FT /id="VSP_004905" FT VAR_SEQ 308..313 FT /note="PASTSS -> MLELIE (in isoform 3 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9747029" FT /id="VSP_004906" FT VAR_SEQ 687..740 FT /note="TTALDKERQVFRRRRNQDVRSRYKAQPAPPELNSESEDYSPSSSETVRSPNS FT PF -> LDHGFTIKRSGSLDYYQQPGMYWIRPPLLIRRGRFSDEDATRM (in FT isoform 1 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10036192, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9205841, ECO:0000303|PubMed:9747029" FT /id="VSP_004907" FT VARIANT 29 FT /note="G -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045673" FT VARIANT 46 FT /note="T -> M (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045674" FT VARIANT 93 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1366698690)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045675" FT VARIANT 291 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045676" FT VARIANT 292 FT /note="R -> H (in dbSNP:rs56185003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045677" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:1MFW" FT STRAND 56..63 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 72..76 FT /evidence="ECO:0007829|PDB:1MG4" FT TURN 78..80 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 84..95 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 98..101 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 120..122 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 128..135 FT /evidence="ECO:0007829|PDB:1MG4" FT TURN 142..145 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 148..151 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 384..389 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 390..398 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 400..409 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 415..422 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 423..425 FT /evidence="ECO:0007829|PDB:6KYQ" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 436..440 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 451..456 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 473..480 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 485..504 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 514..516 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 517..521 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 523..525 FT /evidence="ECO:0007829|PDB:7KX6" FT STRAND 527..531 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 551..553 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 556..560 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 568..582 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 596..603 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 610..615 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 618..627 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 632..634 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 638..643 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 645..647 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 662..668 FT /evidence="ECO:0007829|PDB:6KYQ" FT TURN 678..682 FT /evidence="ECO:0007829|PDB:6KYQ" FT HELIX 683..686 FT /evidence="ECO:0007829|PDB:6KYQ" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:6KYQ" SQ SEQUENCE 740 AA; 82224 MW; D7B6D855099A315C CRC64; MSFGRDMELE HFDERDKAQR YSRGSRVNGL PSPTHSAHCS FYRTRTLQTL SSEKKAKKVR FYRNGDRYFK GIVYAISPDR FRSFEALLAD LTRTLSDNVN LPQGVRTIYT IDGLKKISSL DQLVEGESYV CGSIEPFKKL EYTKNVNPNW SVNVKTTSAS RAVSSLATAK GSPSEVRENK DFIRPKLVTI IRSGVKPRKA VRILLNKKTA HSFEQVLTDI TDAIKLDSGV VKRLYTLDGK QVMCLQDFFG DDDIFIACGP EKFRYQDDFL LDESECRVVK STSYTKIASS SRRSTTKSPG PSRRSKSPAS TSSVNGTPGS QLSTPRSGKS PSPSPTSPGS LRKQRSSQHG GSSTSLASTK VCSSMDENDG PGEEVSEEGF QIPATITERY KVGRTIGDGN FAVVKECVER STAREYALKI IKKSKCRGKE HMIQNEVSIL RRVKHPNIVL LIEEMDVPTE LYLVMELVKG GDLFDAITST NKYTERDASG MLYNLASAIK YLHSLNIVHR DIKPENLLVY EHQDGSKSLK LGDFGLATIV DGPLYTVCGT PTYVAPEIIA ETGYGLKVDI WAAGVITYIL LCGFPPFRGS GDDQEVLFDQ ILMGQVDFPS PYWDNVSDSA KELITMMLLV DVDQRFSAVQ VLEHPWVNDD GLPENEHQLS VAGKIKKHFN TGPKPNSTAA GVSVIATTAL DKERQVFRRR RNQDVRSRYK AQPAPPELNS ESEDYSPSSS ETVRSPNSPF // ID DSE_HUMAN Reviewed; 958 AA. AC Q9UL01; Q5R3K6; DT 07-FEB-2006, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 175. DE RecName: Full=Dermatan-sulfate epimerase; DE Short=DS epimerase; DE EC=5.1.3.19 {ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}; DE AltName: Full=Chondroitin-glucuronate 5-epimerase; DE AltName: Full=Squamous cell carcinoma antigen recognized by T-cells 2; DE Short=SART-2; DE Flags: Precursor; GN Name=DSE; Synonyms=SART2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10679095; DOI=10.4049/jimmunol.164.5.2565; RA Nakao M., Shichijo S., Imaizumi T., Inoue Y., Matsunaga K., Yamada A., RA Kikuchi M., Tsuda N., Ohta K., Takamori S., Yamana H., Fujita H., Itoh K.; RT "Identification of a gene coding for a new squamous cell carcinoma antigen RT recognized by the CTL."; RL J. Immunol. 164:2565-2574(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, RP PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=7092807; DOI=10.1042/bj2010489; RA Malmstroem A., Aberg L.; RT "Biosynthesis of dermatan sulphate. Assay and properties of the uronosyl C- RT 5 epimerase."; RL Biochem. J. 201:489-493(1982). RN [5] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=16505484; DOI=10.1074/jbc.m513373200; RA Maccarana M., Olander B., Malmstroem J., Tiedemann K., Aebersold R., RA Lindahl U., Li J.-P., Malmstroem A.; RT "Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is RT identical to SART2."; RL J. Biol. Chem. 281:11560-11568(2006). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVE SITE, GLYCOSYLATION AT RP ASN-183; ASN-336; ASN-642 AND ASN-648, AND MUTAGENESIS OF HIS-203; HIS-205; RP TYR-256; TYR-261; LYS-331 AND HIS-450. RX PubMed=19004833; DOI=10.1074/jbc.m805479200; RA Pacheco B., Maccarana M., Goodlett D.R., Malmstroem A., Malmstroem L.; RT "Identification of the active site of DS-epimerase 1 and requirement of N- RT glycosylation for enzyme function."; RL J. Biol. Chem. 284:1741-1747(2009). RN [7] {ECO:0007744|PDB:6HZN} RP X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 23-775 IN COMPLEX WITH MANGANESE RP IONS, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVE SITE, GLYCOSYLATION AT RP ASN-183; ASN-336; ASN-411; ASN-642 AND ASN-648, AND MUTAGENESIS OF TRP-98; RP ASP-147; PRO-383; HIS-452; GLU-470 AND TYR-473. RX DOI=10.1039/D0SC05971D; RA Hasan M., Khakzad H., Happonen L., Sundin A., Unge J., Mueller U., RA Malmstrom J., Westergren-Thorsson G., Malmstrom L., Ellervik U., RA Malmstrom A., Tykesson E.; RT "The structure of human dermatan sulfate epimerase 1 emphasizes the RT importance of C5-epimerization of glucuronic acid in higher organisms."; RL Chem. Sci. 11:0-0(2020). RN [8] RP VARIANT EDSMC2 LEU-268, AND CHARACTERIZATION OF VARIANT EDSMC2 LEU-268. RX PubMed=23704329; DOI=10.1093/hmg/ddt227; RA Mueller T., Mizumoto S., Suresh I., Komatsu Y., Vodopiutz J., Dundar M., RA Straub V., Lingenhel A., Melmer A., Lechner S., Zschocke J., Sugahara K., RA Janecke A.R.; RT "Loss of dermatan sulfate epimerase (DSE) function results in RT musculocontractural Ehlers-Danlos syndrome."; RL Hum. Mol. Genet. 22:3761-3772(2013). CC -!- FUNCTION: Converts D-glucuronic acid to L-iduronic acid (IdoUA) CC residues. Plays an important role in the biosynthesis of the CC glycosaminoglycan/mucopolysaccharide dermatan sulfate. CC {ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, CC ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}. CC -!- CATALYTIC ACTIVITY: CC Reaction=chondroitin 4'-sulfate = dermatan 4'-sulfate; CC Xref=Rhea:RHEA:21084, Rhea:RHEA-COMP:9829, Rhea:RHEA-COMP:9965, CC ChEBI:CHEBI:58422, ChEBI:CHEBI:58465; EC=5.1.3.19; CC Evidence={ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, CC ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:7092807}; CC Note=Also has weak activity in the presence of Mg(2+) or Ca(2+) ions. CC {ECO:0000269|PubMed:7092807}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=0.12 mM for chondroitin {ECO:0000269|PubMed:7092807}; CC pH dependence: CC Optimum pH is 5.5. {ECO:0000269|PubMed:7092807}; CC -!- PATHWAY: Glycan metabolism; chondroitin sulfate biosynthesis. CC {ECO:0000305|PubMed:16505484, ECO:0000305|PubMed:19004833, CC ECO:0000305|PubMed:7092807, ECO:0000305|Ref.7}. CC -!- PATHWAY: Glycan metabolism; heparan sulfate biosynthesis. CC {ECO:0000305|PubMed:16505484, ECO:0000305|PubMed:19004833, CC ECO:0000305|PubMed:7092807, ECO:0000305|Ref.7}. CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:10679095, ECO:0000305|PubMed:7092807}; Multi-pass CC membrane protein {ECO:0000305}. Golgi apparatus membrane CC {ECO:0000269|PubMed:10679095}; Multi-pass membrane protein CC {ECO:0000305}. Cytoplasmic vesicle membrane CC {ECO:0000269|PubMed:10679095}; Multi-pass membrane protein CC {ECO:0000305}. Microsome membrane {ECO:0000269|PubMed:7092807}; Multi- CC pass membrane protein {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Ubiquitously expressed with higher expression in CC kidney and ovary and lower expression in brain, colon and thymus. Also CC expressed in renal cell carcinomas, brain tumors, and in a part of CC melanomas and adenocarcinomas from organs other than the breast. CC Expressed in squamous cell carcinomas (SCC), glioma, and some CC adenocarcinoma cell lines, but not in breast cancer cell lines or any CC normal tissues (at protein level). {ECO:0000269|PubMed:10679095}. CC -!- PTM: N-glycosylated (PubMed:19004833, Ref.7). Glycosylation is CC important for enzymatic activity (PubMed:19004833). CC {ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7}. CC -!- DISEASE: Ehlers-Danlos syndrome, musculocontractural type 2 (EDSMC2) CC [MIM:615539]: A form of Ehlers-Danlos syndrome characterized by CC progressive multisystem manifestations, including joint dislocations CC and deformities, skin hyperextensibility, skin bruisability and CC fragility with recurrent large subcutaneous hematomas, cardiac CC valvular, respiratory, gastrointestinal, and ophthalmologic CC complications. Motor developmental delay is associated with muscle CC hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in CC histology in adulthood. {ECO:0000269|PubMed:23704329}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the dermatan-sulfate isomerase family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF098066; AAF00087.1; -; mRNA. DR EMBL; Z84488; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039245; AAH39245.1; -; mRNA. DR CCDS; CCDS5107.1; -. DR RefSeq; NP_001074445.1; NM_001080976.3. DR RefSeq; NP_001309866.1; NM_001322937.2. DR RefSeq; NP_001309867.1; NM_001322938.2. DR RefSeq; NP_001309868.1; NM_001322939.1. DR RefSeq; NP_001309869.1; NM_001322940.1. DR RefSeq; NP_001309870.1; NM_001322941.1. DR RefSeq; NP_001309872.1; NM_001322943.1. DR RefSeq; NP_001309873.1; NM_001322944.1. DR RefSeq; NP_037484.1; NM_013352.4. DR PDB; 6HZN; X-ray; 2.41 A; A=23-775. DR PDBsum; 6HZN; -. DR AlphaFoldDB; Q9UL01; -. DR SMR; Q9UL01; -. DR BioGRID; 118977; 39. DR FunCoup; Q9UL01; 1086. DR IntAct; Q9UL01; 32. DR MINT; Q9UL01; -. DR STRING; 9606.ENSP00000494147; -. DR GlyCosmos; Q9UL01; 5 sites, No reported glycans. DR GlyGen; Q9UL01; 6 sites, 2 N-linked glycans (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q9UL01; -. DR PhosphoSitePlus; Q9UL01; -. DR BioMuta; DSE; -. DR DMDM; 74762778; -. DR jPOST; Q9UL01; -. DR MassIVE; Q9UL01; -. DR PaxDb; 9606-ENSP00000332151; -. DR PeptideAtlas; Q9UL01; -. DR ProteomicsDB; 84921; -. DR Antibodypedia; 3106; 80 antibodies from 20 providers. DR DNASU; 29940; -. DR Ensembl; ENST00000331677.7; ENSP00000332151.2; ENSG00000111817.20. DR Ensembl; ENST00000452085.7; ENSP00000404049.2; ENSG00000111817.20. DR Ensembl; ENST00000644252.3; ENSP00000494147.2; ENSG00000111817.20. DR GeneID; 29940; -. DR KEGG; hsa:29940; -. DR MANE-Select; ENST00000644252.3; ENSP00000494147.2; NM_013352.4; NP_037484.1. DR UCSC; uc003pws.5; human. DR AGR; HGNC:21144; -. DR ClinPGx; PA162384080; -. DR CTD; 29940; -. DR DisGeNET; 29940; -. DR GeneCards; DSE; -. DR GeneReviews; DSE; -. DR HGNC; HGNC:21144; DSE. DR HPA; ENSG00000111817; Low tissue specificity. DR MalaCards; DSE; -. DR MIM; 605942; gene. DR MIM; 615539; phenotype. DR OpenTargets; ENSG00000111817; -. DR Orphanet; 2953; Musculocontractural Ehlers-Danlos syndrome. DR VEuPathDB; HostDB:ENSG00000111817; -. DR eggNOG; ENOG502QPWZ; Eukaryota. DR GeneTree; ENSGT00390000006522; -. DR HOGENOM; CLU_308813_0_0_1; -. DR InParanoid; Q9UL01; -. DR OMA; FFIHAVC; -. DR OrthoDB; 5946629at2759; -. DR PAN-GO; Q9UL01; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UL01; -. DR BioCyc; MetaCyc:HS03472-MONOMER; -. DR BRENDA; 5.1.3.19; 2681. DR PathwayCommons; Q9UL01; -. DR Reactome; R-HSA-2022923; DS-GAG biosynthesis. DR SignaLink; Q9UL01; -. DR UniPathway; UPA00755; -. DR UniPathway; UPA00756; -. DR Agora; ENSG00000111817; -. DR BioGRID-ORCS; 29940; 10 hits in 1149 CRISPR screens. DR ChiTaRS; DSE; human. DR GeneWiki; DSE_(gene); -. DR GenomeRNAi; 29940; -. DR Pharos; Q9UL01; Tbio. DR PRO; PR:Q9UL01; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q9UL01; protein. DR Bgee; ENSG00000111817; Expressed in parietal pleura and 198 other cell types or tissues. DR ExpressionAtlas; Q9UL01; baseline and differential. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HGNC-UCL. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:HGNC-UCL. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0047757; F:chondroitin-glucuronate 5-epimerase activity; IDA:HGNC-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0050654; P:chondroitin sulfate proteoglycan metabolic process; IBA:GO_Central. DR GO; GO:0050651; P:dermatan sulfate proteoglycan biosynthetic process; IDA:UniProtKB. DR GO; GO:0050655; P:dermatan sulfate proteoglycan metabolic process; IBA:GO_Central. DR GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IEA:UniProtKB-UniPathway. DR FunFam; 1.50.10.100:FF:000001; dermatan-sulfate epimerase isoform X1; 1. DR FunFam; 2.70.98.70:FF:000001; dermatan-sulfate epimerase isoform X1; 1. DR Gene3D; 2.70.98.70; -; 1. DR Gene3D; 1.50.10.100; Chondroitin AC/alginate lyase; 1. DR InterPro; IPR008929; Chondroitin_lyas. DR InterPro; IPR052447; Dermatan-Sulfate_Isomerase. DR PANTHER; PTHR15532; -; 1. DR PANTHER; PTHR15532:SF3; DERMATAN-SULFATE EPIMERASE; 1. DR SUPFAM; SSF48230; Chondroitin AC/alginate lyase; 1. PE 1: Evidence at protein level; KW 3D-structure; Cytoplasmic vesicle; Disease variant; Ehlers-Danlos syndrome; KW Endoplasmic reticulum; Glycoprotein; Golgi apparatus; Isomerase; Manganese; KW Membrane; Metal-binding; Microsome; Proteomics identification; KW Reference proteome; Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..958 FT /note="Dermatan-sulfate epimerase" FT /id="PRO_0000223311" FT TOPO_DOM 23..902 FT /note="Lumenal" FT /evidence="ECO:0000305" FT TRANSMEM 903..923 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 924..933 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 934..954 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 955..958 FT /note="Lumenal" FT /evidence="ECO:0000305" FT ACT_SITE 205 FT /note="Proton donor" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT ACT_SITE 261 FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT ACT_SITE 473 FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT BINDING 452 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT BINDING 470 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT BINDING 481 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT SITE 450 FT /note="Critical for catalysis" FT /evidence="ECO:0000269|PubMed:19004833" FT CARBOHYD 183 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) (high mannose) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 411 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT CARBOHYD 642 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 648 FT /note="N-linked (GlcNAc...) (paucimannose) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT VARIANT 25 FT /note="T -> I (in dbSNP:rs10485183)" FT /id="VAR_034481" FT VARIANT 34 FT /note="P -> L (in dbSNP:rs35548455)" FT /id="VAR_053833" FT VARIANT 268 FT /note="S -> L (in EDSMC2; shows a loss of epimerase FT activity towards partially desulfated dermatan sulfate; FT patient-derived fibroblasts show also a significant FT reduction in activity; dbSNP:rs398122361)" FT /evidence="ECO:0000269|PubMed:23704329" FT /id="VAR_070911" FT VARIANT 282 FT /note="I -> V (in dbSNP:rs34994230)" FT /id="VAR_053834" FT MUTAGEN 98 FT /note="W->A: Severely impairs catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 147 FT /note="D->A: Impairs catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 203 FT /note="H->A,N: Severely impairs catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 205 FT /note="H->A,N: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 256 FT /note="Y->A: Moderately reduced catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 261 FT /note="Y->A,F: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 331 FT /note="K->A: No significant effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 383 FT /note="P->A: Very low levels of protein expression and no FT detectable catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 450 FT /note="H->A,N: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 452 FT /note="H->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 470 FT /note="E->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 473 FT /note="Y->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 53..61 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 65..80 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 82..85 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 91..94 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 101..115 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 120..134 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 149..165 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 171..191 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 192..194 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 196..198 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 205..222 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 226..247 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 258..280 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 288..298 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 323..332 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 338..349 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 352..354 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 360..366 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 367..373 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 384..387 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 391..394 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 395..398 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 399..403 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 414..418 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 424..432 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 437..439 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 442..445 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 457..461 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 484..488 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 515..518 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 524..531 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 534..540 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 542..544 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 547..549 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 551..562 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 565..574 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 582..592 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 602..609 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 612..620 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 629..633 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 639..641 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 644..652 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 655..665 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 671..678 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 680..691 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 693..701 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 704..707 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 709..713 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 723..725 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 738..746 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 750..765 FT /evidence="ECO:0007829|PDB:6HZN" SQ SEQUENCE 958 AA; 109773 MW; A3D05C6194B4D2F9 CRC64; MRTHTRGAPS VFFIYLLCFV SAYITDENPE VMIPFTNANY DSHPMLYFSR AEVAELQLRA ASSHEHIAAR LTEAVHTMLS SPLEYLPPWD PKDYSARWNE IFGNNLGALA MFCVLYPENI EARDMAKDYM ERMAAQPSWL VKDAPWDEVP LAHSLVGFAT AYDFLYNYLS KTQQEKFLEV IANASGYMYE TSYRRGWGFQ YLHNHQPTNC MALLTGSLVL MNQGYLQEAY LWTKQVLTIM EKSLVLLREV TDGSLYEGVA YGSYTTRSLF QYMFLVQRHF NINHFGHPWL KQHFAFMYRT ILPGFQRTVA IADSNYNWFY GPESQLVFLD KFVMRNGSGN WLADQIRRNR VVEGPGTPSK GQRWCTLHTE FLWYDGSLKS VPPPDFGTPT LHYFEDWGVV TYGSALPAEI NRSFLSFKSG KLGGRAIYDI VHRNKYKDWI KGWRNFNAGH EHPDQNSFTF APNGVPFITE ALYGPKYTFF NNVLMFSPAV SKSCFSPWVG QVTEDCSSKW SKYKHDLAAS CQGRVVAAEE KNGVVFIRGE GVGAYNPQLN LKNVQRNLIL LHPQLLLLVD QIHLGEESPL ETAASFFHNV DVPFEETVVD GVHGAFIRQR DGLYKMYWMD DTGYSEKATF ASVTYPRGYP YNGTNYVNVT MHLRSPITRA AYLFIGPSID VQSFTVHGDS QQLDVFIATS KHAYATYLWT GEATGQSAFA QVIADRHKIL FDRNSAIKSS IVPEVKDYAA IVEQNLQHFK PVFQLLEKQI LSRVRNTASF RKTAERLLRF SDKRQTEEAI DRIFAISQQQ QQQSKSKKNR RAGKRYKFVD AVPDIFAQIE VNEKKIRQKA QILAQKELPI DEDEEMKDLL DFADVTYEKH KNGGLIKGRF GQARMVTTTH SRAPSLSASY TRLFLILNIA IFFVMLAMQL TYFQRAQSLH GQRCLYAVLL IDSCILLWLY SSCSQSQC // ID EPCAM_HUMAN Reviewed; 314 AA. AC P16422; P18180; Q6FG26; Q6FG49; Q96C47; Q9UCD0; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 13-NOV-2007, sequence version 2. DT 28-JAN-2026, entry version 223. DE RecName: Full=Epithelial cell adhesion molecule; DE Short=Ep-CAM; DE AltName: Full=Adenocarcinoma-associated antigen; DE AltName: Full=Cell surface glycoprotein Trop-1; DE AltName: Full=Epithelial cell surface antigen; DE AltName: Full=Epithelial glycoprotein; DE Short=EGP; DE AltName: Full=Epithelial glycoprotein 314; DE Short=EGP314; DE Short=hEGP314; DE AltName: Full=KS 1/4 antigen; DE AltName: Full=KSA; DE AltName: Full=Major gastrointestinal tumor-associated protein GA733-2; DE AltName: Full=Tumor-associated calcium signal transducer 1; DE AltName: CD_antigen=CD326; DE Flags: Precursor; GN Name=EPCAM; Synonyms=GA733-2, M1S2, M4S1, MIC18, TACSTD1, TROP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RC TISSUE=Lung adenocarcinoma; RX PubMed=2463074; RA Strnad J., Hamilton A.E., Beavers L.S., Gamboa G.C., Apelgren L.D., RA Taber L.D., Sportsman J.R., Bumol T.F., Sharp J.D., Gadski R.A.; RT "Molecular cloning and characterization of a human RT adenocarcinoma/epithelial cell surface antigen complementary DNA."; RL Cancer Res. 49:314-317(1989). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RX PubMed=2469722; RA Perez M.S., Walker L.E.; RT "Isolation and characterization of a cDNA encoding the KS1/4 epithelial RT carcinoma marker."; RL J. Immunol. 142:3662-3667(1989). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RX PubMed=2108441; DOI=10.1073/pnas.87.7.2755; RA Simon B., Podolsky D.K., Moldenhauer G., Isselbacher K.J., RA Gattoni-Celli S., Brand S.J.; RT "Epithelial glycoprotein is a member of a family of epithelial cell surface RT antigens homologous to nidogen, a matrix adhesion protein."; RL Proc. Natl. Acad. Sci. U.S.A. 87:2755-2759(1990). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Colon carcinoma; RX PubMed=2333300; DOI=10.1073/pnas.87.9.3542; RA Szala S., Froehlich M., Scollon M., Kasai Y., Steplewski Z., Koprowski H., RA Linnenbach A.J.; RT "Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:3542-3546(1990). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Lymphoma; RX PubMed=8382772; DOI=10.1128/mcb.13.3.1507-1515.1993; RA Linnenbach A.J., Seng B.A., Wu S., Robbins S., Scollon M., Pyrc J.J., RA Druck T., Huebner K.; RT "Retroposition in a family of carcinoma-associated antigen genes."; RL Mol. Cell. Biol. 13:1507-1515(1993). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-115. RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PRELIMINARY PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 81-126. RC TISSUE=Placenta; RX PubMed=2911574; DOI=10.1073/pnas.86.1.27; RA Linnenbach A.J., Wojcierowski J., Wu S., Pyrc J.J., Ross A.H., RA Dietzschold B., Speicher D., Koprowski H.; RT "Sequence investigation of the major gastrointestinal tumor-associated RT antigen gene family, GA733."; RL Proc. Natl. Acad. Sci. U.S.A. 86:27-31(1989). RN [11] RP PROTEIN SEQUENCE OF 82-100, AND SUBUNIT. RX PubMed=7693697; DOI=10.1016/s0021-9258(20)80515-8; RA Bjoerk P., Joensson U., Svedberg H., Larsson K., Lind P., Dillner J., RA Hedlund G., Dohlsten M., Kalland T.; RT "Isolation, partial characterization, and molecular cloning of a human RT colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse RT monoclonal antibody."; RL J. Biol. Chem. 268:24232-24241(1993). RN [12] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-74 AND ASN-111. RX PubMed=11080501; DOI=10.1074/jbc.m008839200; RA Chong J.M., Speicher D.W.; RT "Determination of disulfide bond assignments and N-glycosylation sites of RT the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, RT KSA, and Ep-CAM)."; RL J. Biol. Chem. 276:5804-5813(2001). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15195135; DOI=10.1038/sj.onc.1207610; RA Muenz M., Kieu C., Mack B., Schmitt B., Zeidler R., Gires O.; RT "The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell RT proliferation."; RL Oncogene 23:5748-5758(2004). RN [14] RP FUNCTION. RX PubMed=15922867; DOI=10.1016/j.canlet.2004.11.048; RA Muenz M., Zeidler R., Gires O.; RT "The tumour-associated antigen EpCAM upregulates the fatty acid binding RT protein E-FABP."; RL Cancer Lett. 225:151-157(2005). RN [15] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CLDN7. RX PubMed=16054130; DOI=10.1016/j.yexcr.2005.06.013; RA Ladwein M., Pape U.F., Schmidt D.S., Schnoelzer M., Fiedler S., RA Langbein L., Franke W.W., Moldenhauer G., Zoeller M.; RT "The cell-cell adhesion molecule EpCAM interacts directly with the tight RT junction protein claudin-7."; RL Exp. Cell Res. 309:345-357(2005). RN [16] RP GLYCOSYLATION AT ASN-74; ASN-111 AND ASN-198, AND MUTAGENESIS OF ASN-74; RP ASN-111 AND ASN-198. RX PubMed=18508581; DOI=10.2741/3075; RA Munz M., Fellinger K., Hofmann T., Schmitt B., Gires O.; RT "Glycosylation is crucial for stability of tumour and cancer stem cell RT antigen EpCAM."; RL Front. Biosci. 13:5195-5201(2008). RN [17] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-198. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [18] RP INVOLVEMENT IN LYNCH8. RX PubMed=19098912; DOI=10.1038/ng.283; RA Ligtenberg M.J., Kuiper R.P., Chan T.L., Goossens M., Hebeda K.M., RA Voorendt M., Lee T.Y., Bodmer D., Hoenselaar E., Hendriks-Cornelissen S.J., RA Tsui W.Y., Kong C.K., Brunner H.G., van Kessel A.G., Yuen S.T., RA van Krieken J.H., Leung S.Y., Hoogerbrugge N.; RT "Heritable somatic methylation and inactivation of MSH2 in families with RT Lynch syndrome due to deletion of the 3' exons of TACSTD1."; RL Nat. Genet. 41:112-117(2009). RN [19] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=20064925; DOI=10.1074/jbc.m109.077081; RA Lu T.Y., Lu R.M., Liao M.Y., Yu J., Chung C.H., Kao C.F., Wu H.C.; RT "Epithelial cell adhesion molecule regulation is associated with the RT maintenance of the undifferentiated phenotype of human embryonic stem RT cells."; RL J. Biol. Chem. 285:8719-8732(2010). RN [20] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19785009; DOI=10.1002/stem.221; RA Ng V.Y., Ang S.N., Chan J.X., Choo A.B.; RT "Characterization of epithelial cell adhesion molecule as a surface marker RT on undifferentiated human embryonic stem cells."; RL Stem Cells 28:29-35(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP VARIANT DIAR5 TYR-66, AND INVOLVEMENT IN DIAR5. RX PubMed=18572020; DOI=10.1053/j.gastro.2008.05.036; RA Sivagnanam M., Mueller J.L., Lee H., Chen Z., Nelson S.F., Turner D., RA Zlotkin S.H., Pencharz P.B., Ngan B.Y., Libiger O., Schork N.J., RA Lavine J.E., Taylor S., Newbury R.O., Kolodner R.D., Hoffman H.M.; RT "Identification of EpCAM as the gene for congenital tufting enteropathy."; RL Gastroenterology 135:429-437(2008). RN [23] RP VARIANTS DIAR5 76-SER--ALA-314 DEL; ARG-103; CYS-105; ILE-120 AND RP 132-GLU--ALA-314 DEL, AND INVOLVEMENT IN DIAR5. RX PubMed=24142340; DOI=10.1007/s00439-013-1380-6; RA Salomon J., Goulet O., Canioni D., Brousse N., Lemale J., Tounian P., RA Coulomb A., Marinier E., Hugot J.P., Ruemmele F., Dufier J.L., Roche O., RA Bodemer C., Colomb V., Talbotec C., Lacaille F., Campeotto F., RA Cerf-Bensussan N., Janecke A.R., Mueller T., Koletzko S., Bonnefont J.P., RA Lyonnet S., Munnich A., Poirier F., Smahi A.; RT "Genetic characterization of congenital tufting enteropathy: epcam RT associated phenotype and involvement of SPINT2 in the syndromic form."; RL Hum. Genet. 133:299-310(2014). CC -!- FUNCTION: May act as a physical homophilic interaction molecule between CC intestinal epithelial cells (IECs) and intraepithelial lymphocytes CC (IELs) at the mucosal epithelium for providing immunological barrier as CC a first line of defense against mucosal infection. Plays a role in CC embryonic stem cells proliferation and differentiation. Up-regulates CC the expression of FABP5, MYC and cyclins A and E. CC {ECO:0000269|PubMed:15195135, ECO:0000269|PubMed:15922867, CC ECO:0000269|PubMed:19785009, ECO:0000269|PubMed:20064925}. CC -!- SUBUNIT: Monomer. Interacts with phosphorylated CLDN7. CC {ECO:0000269|PubMed:16054130, ECO:0000269|PubMed:7693697}. CC -!- INTERACTION: CC P16422; P27797: CALR; NbExp=3; IntAct=EBI-1171184, EBI-1049597; CC P16422; P12830: CDH1; NbExp=3; IntAct=EBI-1171184, EBI-727477; CC P16422; Q15078: CDK5R1; NbExp=3; IntAct=EBI-1171184, EBI-746189; CC P16422; P36957: DLST; NbExp=3; IntAct=EBI-1171184, EBI-351007; CC P16422; Q8TDX7: NEK7; NbExp=3; IntAct=EBI-1171184, EBI-1055945; CC -!- SUBCELLULAR LOCATION: Lateral cell membrane CC {ECO:0000269|PubMed:15195135, ECO:0000269|PubMed:16054130, CC ECO:0000269|PubMed:19785009}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:16054130}. Cell junction, tight junction CC {ECO:0000269|PubMed:16054130}. Note=Colocalizes with CLDN7 at the CC lateral cell membrane and tight junction. CC {ECO:0000269|PubMed:16054130}. CC -!- TISSUE SPECIFICITY: Highly and selectively expressed by CC undifferentiated rather than differentiated embryonic stem cells (ESC). CC Levels rapidly diminish as soon as ESC's differentiate (at protein CC levels). Expressed in almost all epithelial cell membranes but not on CC mesodermal or neural cell membranes. Found on the surface of CC adenocarcinoma. {ECO:0000269|PubMed:20064925}. CC -!- PTM: Hyperglycosylated in carcinoma tissue as compared with autologous CC normal epithelia. Glycosylation at Asn-198 is crucial for protein CC stability. {ECO:0000269|PubMed:11080501, ECO:0000269|PubMed:18508581, CC ECO:0000269|PubMed:19159218}. CC -!- DISEASE: Diarrhea 5, with tufting enteropathy, congenital (DIAR5) CC [MIM:613217]: An intractable diarrhea of infancy characterized by CC villous atrophy and absence of inflammation, with intestinal epithelial CC cell dysplasia manifesting as focal epithelial tufts in the duodenum CC and jejunum. {ECO:0000269|PubMed:18572020, CC ECO:0000269|PubMed:24142340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lynch syndrome 8 (LYNCH8) [MIM:613244]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:19098912}. Note=The disease is caused by variants CC affecting the gene represented in this entry. LYNCH8 results from CC heterozygous deletion of 3-prime exons of EPCAM and intergenic regions CC directly upstream of MSH2, resulting in transcriptional read-through CC and epigenetic silencing of MSH2 in tissues expressing EPCAM. CC -!- SIMILARITY: Belongs to the EPCAM family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42459/TACSTD1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M32325; AAA36151.1; -; mRNA. DR EMBL; X14758; CAA32870.1; -; mRNA. DR EMBL; M26481; AAA59543.1; -; mRNA. DR EMBL; M32306; AAA35723.1; -; mRNA. DR EMBL; M33011; AAA35861.1; -; mRNA. DR EMBL; M93036; AAB00775.1; -; Genomic_DNA. DR EMBL; M93029; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93030; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93031; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93032; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93033; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93034; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93035; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; CR542259; CAG47055.1; -; mRNA. DR EMBL; CR542283; CAG47078.1; -; mRNA. DR EMBL; AC079775; AAY15095.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00218.1; -; Genomic_DNA. DR EMBL; BC014785; AAH14785.1; -; mRNA. DR CCDS; CCDS1833.1; -. DR PIR; B48149; B48149. DR RefSeq; NP_002345.2; NM_002354.3. DR PDB; 4MZV; X-ray; 1.86 A; A=24-265. DR PDB; 6I07; X-ray; 2.35 A; C/D=24-265. DR PDBsum; 4MZV; -. DR PDBsum; 6I07; -. DR AlphaFoldDB; P16422; -. DR SMR; P16422; -. DR BioGRID; 110250; 42. DR CORUM; P16422; -. DR FunCoup; P16422; 328. DR IntAct; P16422; 26. DR MINT; P16422; -. DR STRING; 9606.ENSP00000263735; -. DR ChEMBL; CHEMBL3580493; -. DR DrugBank; DB06607; Catumaxomab. DR DrugBank; DB06072; Citatuzumab Bogatox. DR DrugBank; DB11075; Hypromellose. DR DrugBank; DB05831; ING-1. DR DrugBank; DB05319; Oportuzumab monatox. DR DrugBank; DB09336; Technetium Tc-99m nofetumomab merpentan. DR GlyConnect; 1217; 34 N-Linked glycans (3 sites). DR GlyCosmos; P16422; 3 sites, 34 glycans. DR GlyGen; P16422; 6 sites, 63 N-linked glycans (3 sites), 2 O-linked glycans (3 sites). DR iPTMnet; P16422; -. DR MetOSite; P16422; -. DR PhosphoSitePlus; P16422; -. DR SwissPalm; P16422; -. DR BioMuta; EPCAM; -. DR DMDM; 160266056; -. DR CPTAC; CPTAC-502; -. DR CPTAC; CPTAC-503; -. DR jPOST; P16422; -. DR MassIVE; P16422; -. DR PaxDb; 9606-ENSP00000263735; -. DR PeptideAtlas; P16422; -. DR ProteomicsDB; 53359; -. DR Pumba; P16422; -. DR ABCD; P16422; 30 sequenced antibodies. DR Antibodypedia; 3539; 5006 antibodies from 64 providers. DR DNASU; 4072; -. DR Ensembl; ENST00000263735.9; ENSP00000263735.4; ENSG00000119888.12. DR GeneID; 4072; -. DR KEGG; hsa:4072; -. DR MANE-Select; ENST00000263735.9; ENSP00000263735.4; NM_002354.3; NP_002345.2. DR UCSC; uc002rvx.4; human. DR AGR; HGNC:11529; -. DR CIViC; 4072; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA35493; -. DR CTD; 4072; -. DR DisGeNET; 4072; -. DR GeneCards; EPCAM; -. DR GeneReviews; EPCAM; -. DR HGNC; HGNC:11529; EPCAM. DR HPA; ENSG00000119888; Tissue enhanced (intestine). DR MalaCards; EPCAM; -. DR MIM; 185535; gene. DR MIM; 613217; phenotype. DR MIM; 613244; phenotype. DR OpenTargets; ENSG00000119888; -. DR Orphanet; 92050; Congenital tufting enteropathy. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000119888; -. DR eggNOG; ENOG502QVSU; Eukaryota. DR GeneTree; ENSGT00390000018245; -. DR HOGENOM; CLU_075326_0_0_1; -. DR InParanoid; P16422; -. DR OMA; CQCKSIG; -. DR OrthoDB; 8953056at2759; -. DR PAN-GO; P16422; 2 GO annotations based on evolutionary models. DR PhylomeDB; P16422; -. DR BRENDA; 2.4.1.37; 2681. DR BRENDA; 2.4.1.40; 2681. DR PathwayCommons; P16422; -. DR Reactome; R-HSA-202733; Cell surface interactions at the vascular wall. DR Reactome; R-HSA-9638630; Attachment of bacteria to epithelial cells. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P16422; -. DR SIGNOR; P16422; -. DR Agora; ENSG00000119888; -. DR BioGRID-ORCS; 4072; 34 hits in 1164 CRISPR screens. DR ChiTaRS; EPCAM; human. DR EvolutionaryTrace; P16422; -. DR GeneWiki; Epithelial_cell_adhesion_molecule; -. DR GenomeRNAi; 4072; -. DR Pharos; P16422; Tbio. DR PRO; PR:P16422; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P16422; protein. DR Bgee; ENSG00000119888; Expressed in jejunal mucosa and 176 other cell types or tissues. DR ExpressionAtlas; P16422; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:MGI. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:MGI. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098641; F:cadherin binding involved in cell-cell adhesion; IBA:GO_Central. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IMP:UniProtKB. DR GO; GO:0048863; P:stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR CDD; cd00191; TY; 1. DR FunFam; 4.10.800.10:FF:000015; Epithelial cell adhesion molecule; 1. DR Gene3D; 4.10.800.10; Thyroglobulin type-1; 1. DR InterPro; IPR049420; EPCAM-Trop-2_C. DR InterPro; IPR043406; EPCAM/Trop-2. DR InterPro; IPR041630; EpCAM_N. DR InterPro; IPR000716; Thyroglobulin_1. DR InterPro; IPR036857; Thyroglobulin_1_sf. DR PANTHER; PTHR14168:SF2; EPITHELIAL CELL ADHESION MOLECULE; 1. DR PANTHER; PTHR14168; TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER; 1. DR Pfam; PF21283; EPCAM-Trop-2_C; 1. DR Pfam; PF18635; EpCAM_N; 1. DR Pfam; PF00086; Thyroglobulin_1; 1. DR SMART; SM00211; TY; 1. DR SUPFAM; SSF57610; Thyroglobulin type-1 domain; 1. DR PROSITE; PS00484; THYROGLOBULIN_1_1; 1. DR PROSITE; PS51162; THYROGLOBULIN_1_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Cell junction; Cell membrane; Direct protein sequencing; KW Disease variant; Disulfide bond; Glycoprotein; KW Hereditary nonpolyposis colorectal cancer; Membrane; KW Proteomics identification; Reference proteome; Repeat; Signal; KW Tight junction; Transmembrane; Transmembrane helix; Tumor antigen. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..314 FT /note="Epithelial cell adhesion molecule" FT /id="PRO_0000022467" FT TOPO_DOM 24..265 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 266..288 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 289..314 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 63..135 FT /note="Thyroglobulin type-1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500" FT CARBOHYD 74 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:11080501, FT ECO:0000269|PubMed:18508581" FT CARBOHYD 111 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:11080501, FT ECO:0000269|PubMed:18508581" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18508581, FT ECO:0000269|PubMed:19159218" FT DISULFID 27..46 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 29..59 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 38..48 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 66..99 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 110..116 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 118..135 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT VARIANT 66 FT /note="C -> Y (in DIAR5; dbSNP:rs267606785)" FT /evidence="ECO:0000269|PubMed:18572020" FT /id="VAR_063829" FT VARIANT 76..314 FT /note="Missing (in DIAR5; likely pathogenic)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089317" FT VARIANT 103 FT /note="G -> R (in DIAR5; uncertain significance; FT dbSNP:rs1346393896)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089318" FT VARIANT 105 FT /note="F -> C (in DIAR5; uncertain significance)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089319" FT VARIANT 115 FT /note="M -> T (in dbSNP:rs1126497)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2108441, ECO:0000269|PubMed:2463074, FT ECO:0000269|PubMed:2469722" FT /id="VAR_018329" FT VARIANT 120 FT /note="N -> I (in DIAR5; uncertain significance; FT dbSNP:rs2103747763)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089320" FT VARIANT 132..314 FT /note="Missing (in DIAR5; likely pathogenic)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089321" FT MUTAGEN 74 FT /note="N->A: Changed glycosylation pattern. Complete loss FT of glycosylation and substantial decrease in protein FT expression; when associated with A-111 and A-198." FT /evidence="ECO:0000269|PubMed:18508581" FT MUTAGEN 111 FT /note="N->A: Changed glycosylation pattern. Complete loss FT of glycosylation and substantial decrease in protein FT expression; when associated with A-74 and A-198." FT /evidence="ECO:0000269|PubMed:18508581" FT MUTAGEN 198 FT /note="N->A: Decreased glycosylation, reduced protein FT stability and significant decrease in protein expression. FT Complete loss of glycosylation and substantial decrease in FT protein expression; when associated with A-74 and A-111." FT /evidence="ECO:0000269|PubMed:18508581" FT CONFLICT 277 FT /note="I -> M (in Ref. 1; AAA36151/CAA32870 and 2; FT AAA59543)" FT /evidence="ECO:0000305" FT CONFLICT 303 FT /note="K -> R (in Ref. 6; CAG47055)" FT /evidence="ECO:0000305" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 46..50 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 65..72 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 107..111 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 141..150 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 159..173 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 178..180 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 181..187 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 199..201 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 209..220 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 226..228 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 234..237 FT /evidence="ECO:0007829|PDB:6I07" FT HELIX 244..246 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 248..255 FT /evidence="ECO:0007829|PDB:4MZV" SQ SEQUENCE 314 AA; 34932 MW; 023FCE418B2F1079 CRC64; MAPPQVLAFG LLLAAATATF AAAQEECVCE NYKLAVNCFV NNNRQCQCTS VGAQNTVICS KLAAKCLVMK AEMNGSKLGR RAKPEGALQN NDGLYDPDCD ESGLFKAKQC NGTSMCWCVN TAGVRRTDKD TEITCSERVR TYWIIIELKH KAREKPYDSK SLRTALQKEI TTRYQLDPKF ITSILYENNV ITIDLVQNSS QKTQNDVDIA DVAYYFEKDV KGESLFHSKK MDLTVNGEQL DLDPGQTLIY YVDEKAPEFS MQGLKAGVIA VIVVVVIAVV AGIVVLVISR KKRMAKYEKA EIKEMGEMHR ELNA // ID EPHA2_HUMAN Reviewed; 976 AA. AC P29317; B5A968; Q8N3Z2; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 2. DT 28-JAN-2026, entry version 259. DE RecName: Full=Ephrin type-A receptor 2; DE EC=2.7.10.1; DE AltName: Full=Epithelial cell kinase; DE AltName: Full=Tyrosine-protein kinase receptor ECK; DE Flags: Precursor; GN Name=EPHA2; Synonyms=ECK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND RP AUTOPHOSPHORYLATION. RC TISSUE=Epithelium; RX PubMed=2174105; DOI=10.1128/mcb.10.12.6316-6324.1990; RA Lindberg R.A., Hunter T.; RT "cDNA cloning and characterization of eck, an epithelial cell receptor RT protein-tyrosine kinase in the eph/elk family of protein kinases."; RL Mol. Cell. Biol. 10:6316-6324(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [7] RP FUNCTION IN INTEGRIN-MEDIATED CELL ADHESION, FUNCTION IN CELL MIGRATION, RP PHOSPHORYLATION, INTERACTION WITH PTK2/FAK1 AND PTPN11, AND SUBCELLULAR RP LOCATION. RX PubMed=10655584; DOI=10.1038/35000008; RA Miao H., Burnett E., Kinch M., Simon E., Wang B.; RT "Activation of EphA2 kinase suppresses integrin function and causes focal- RT adhesion-kinase dephosphorylation."; RL Nat. Cell Biol. 2:62-69(2000). RN [8] RP ONCOGENICITY. RX PubMed=11280802; RA Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S.; RT "EphA2 overexpression causes tumorigenesis of mammary epithelial cells."; RL Cancer Res. 61:2301-2306(2001). RN [9] RP INTERACTION WITH ACP1, AND DEPHOSPHORYLATION BY ACP1. RX PubMed=12167657; DOI=10.1074/jbc.m207127200; RA Kikawa K.D., Vidale D.R., Van Etten R.L., Kinch M.S.; RT "Regulation of the EphA2 kinase by the low molecular weight tyrosine RT phosphatase induces transformation."; RL J. Biol. Chem. 277:39274-39279(2002). RN [10] RP FUNCTION IN CELL-CELL INTERACTION, INTERACTION WITH CLDN4, AND MUTAGENESIS RP OF LYS-646. RX PubMed=16236711; DOI=10.1074/jbc.m503786200; RA Tanaka M., Kamata R., Sakai R.; RT "EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates RT paracellular permeability."; RL J. Biol. Chem. 280:42375-42382(2005). RN [11] RP TISSUE SPECIFICITY. RX PubMed=17332925; RA Liu D.-P., Wang Y., Koeffler H.P., Xie D.; RT "Ephrin-A1 is a negative regulator in glioma through down-regulation of RT EphA2 and FAK."; RL Int. J. Oncol. 30:865-871(2007). RN [12] RP INTERACTION WITH INPPL1. RX PubMed=17135240; DOI=10.1074/jbc.m608509200; RA Zhuang G., Hunter S., Hwang Y., Chen J.; RT "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via RT phosphatidylinositol 3-Kinase-dependent Rac1 activation."; RL J. Biol. Chem. 282:2683-2694(2007). RN [13] RP FUNCTION IN APOPTOSIS, AND INDUCTION BY UV. RX PubMed=18339848; DOI=10.1158/0008-5472.can-07-2372; RA Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.; RT "EphA2 is an essential mediator of UV radiation-induced apoptosis."; RL Cancer Res. 68:1691-1696(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-579 AND THR-647, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=18794797; DOI=10.1038/onc.2008.328; RA Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.; RT "Soluble monomeric EphrinA1 is released from tumor cells and is a RT functional ligand for the EphA2 receptor."; RL Oncogene 27:7260-7273(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND SER-901, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP DISEASE, FUNCTION IN CELL MIGRATION, SUBCELLULAR LOCATION, MUTAGENESIS OF RP ASP-739 AND SER-897, AND PHOSPHORYLATION AT SER-897 BY PKB. RX PubMed=19573808; DOI=10.1016/j.ccr.2009.04.009; RA Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P., RA Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., Wang B.; RT "EphA2 mediates ligand-dependent inhibition and ligand-independent RT promotion of cell migration and invasion via a reciprocal regulatory loop RT with Akt."; RL Cancer Cell 16:9-20(2009). RN [18] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [19] RP UBIQUITINATION BY STUB1. RX PubMed=19567782; DOI=10.1158/1541-7786.mcr-08-0582; RA Annamalai B., Liu X., Gopal U., Isaacs J.S.; RT "Hsp90 is an essential regulator of EphA2 receptor stability and signaling: RT implications for cancer cell migration and metastasis."; RL Mol. Cancer Res. 7:1021-1032(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-628; THR-647 AND RP SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH ARHGEF16; DOCK4 AND ELMO2. RX PubMed=20679435; DOI=10.1083/jcb.201005141; RA Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S., RA Negishi M., Katoh H.; RT "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent RT mechanism."; RL J. Cell Biol. 190:461-477(2010). RN [22] RP FUNCTION IN KERATINOCYTE ADHESION AND DIFFERENTIATION, AND SUBCELLULAR RP LOCATION. RX PubMed=20861311; DOI=10.1091/mbc.e10-03-0242; RA Lin S., Gordon K., Kaplan N., Getsios S.; RT "Ligand targeting of EphA2 enhances keratinocyte adhesion and RT differentiation via desmoglein 1."; RL Mol. Biol. Cell 21:3902-3914(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP SUBCELLULAR LOCATION. RX PubMed=20223987; DOI=10.1126/science.1181729; RA Salaita K., Nair P.M., Petit R.S., Neve R.M., Das D., Gray J.W., RA Groves J.T.; RT "Restriction of receptor movement alters cellular response: physical force RT sensing by EphA2."; RL Science 327:1380-1385(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21516087; DOI=10.1038/nm.2341; RA Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., RA Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., RA Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., RA Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., RA McKeating J.A., Brino L., Baumert T.F.; RT "EGFR and EphA2 are host factors for hepatitis C virus entry and possible RT targets for antiviral therapy."; RL Nat. Med. 17:589-595(2011). RN [27] RP INTERACTION WITH ANKS1A. RX PubMed=22332920; DOI=10.1021/bi300141h; RA Mercurio F.A., Marasco D., Pirone L., Pedone E.M., Pellecchia M., Leone M.; RT "Solution structure of the first Sam domain of Odin and binding studies RT with the EphA2 receptor."; RL Biochemistry 51:2136-2145(2012). RN [28] RP INTERACTION WITH HHV-8 GLYCOPROTEIN L/GLYCOPROTEIN H (MICROBIAL INFECTION). RX PubMed=22635007; DOI=10.1038/nm.2805; RA Hahn A.S., Kaufmann J.K., Wies E., Naschberger E., Panteleev-Ivlev J., RA Schmidt K., Holzer A., Schmidt M., Chen J., Konig S., Ensser A., Myoung J., RA Brockmeyer N.H., Sturzl M., Fleckenstein B., Neipel F.; RT "The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's RT sarcoma-associated herpesvirus."; RL Nat. Med. 18:961-966(2012). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; SER-892; SER-897 AND RP SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [30] RP FUNCTION IN CELL MIGRATION, PHOSPHORYLATION AT TYR-930, DEPHOSPHORYLATION RP AT TYR-930 BY PTPRF, AND INTERACTION WITH NCK1. RX PubMed=23358419; DOI=10.1128/mcb.01708-12; RA Lee H., Bennett A.M.; RT "Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate RT screen identifies EphA2 as a target for LAR in cell migration."; RL Mol. Cell. Biol. 33:1430-1441(2013). RN [31] RP INTERACTION WITH CEMIP. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [32] RP PHOSPHORYLATION AT SER-897 BY RPS6KA1 AND RPS6KA3, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=26158630; DOI=10.1038/ncomms8679; RA Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S., RA Fukuoka J., Koizumi K., Saiki I., Sakurai H.; RT "Crucial roles of RSK in cell motility by catalysing serine phosphorylation RT of EphA2."; RL Nat. Commun. 6:7679-7679(2015). RN [33] RP PHOSPHORYLATION AT SER-897 BY PKA, PHOSPHORYLATION AT SER-901, AND RP FUNCTION. RX PubMed=27385333; DOI=10.1091/mbc.e16-01-0048; RA Barquilla A., Lamberto I., Noberini R., Heynen-Genel S., Brill L.M., RA Pasquale E.B.; RT "Protein kinase A can block EphA2 receptor-mediated cell repulsion by RT increasing EphA2 S897 phosphorylation."; RL Mol. Biol. Cell 27:2757-2770(2016). RN [34] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292383; DOI=10.1038/s41564-017-0080-8; RA Zhang H., Li Y., Wang H.B., Zhang A., Chen M.L., Fang Z.X., Dong X.D., RA Li S.B., Du Y., Xiong D., He J.Y., Li M.Z., Liu Y.M., Zhou A.J., Zhong Q., RA Zeng Y.X., Kieff E., Zhang Z., Gewurz B.E., Zhao B., Zeng M.S.; RT "Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus RT entry."; RL Nat. Microbiol. 3:1-8(2018). RN [35] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292384; DOI=10.1038/s41564-017-0081-7; RA Chen J., Sathiyamoorthy K., Zhang X., Schaller S., Perez White B.E., RA Jardetzky T.S., Longnecker R.; RT "Ephrin receptor A2 is a functional entry receptor for Epstein-Barr RT virus."; RL Nat. Microbiol. 3:172-180(2018). RN [36] RP INTERACTION WITH TIMD4, AND SUBCELLULAR LOCATION. RX PubMed=34067457; DOI=10.3390/cells10061290; RA Moon B., Yang S., Kim K., Lee J., Jeong D., Park D.; RT "EphA2 Interacts with Tim-4 through Association between Its FN3 Domain and RT the IgV Domain of Tim-4."; RL Cells 10:0-0(2021). RN [37] RP FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN CYTOMEGALOVIRUS RP PROTEINS GH AND GL (MICROBIAL INFECTION). RX PubMed=37146061; DOI=10.1371/journal.ppat.1011304; RA Dong X.D., Li Y., Li Y., Sun C., Liu S.X., Duan H., Cui R., Zhong Q., RA Mou Y.G., Wen L., Yang B., Zeng M.S., Luo M.H., Zhang H.; RT "EphA2 is a functional entry receptor for HCMV infection of glioblastoma RT cells."; RL PLoS Pathog. 19:e1011304-e1011304(2023). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [39] RP STRUCTURE BY NMR OF 902-976. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin type-A RT receptor 2 precursor (EC 2.7.10.1)."; RL Submitted (JAN-2008) to the PDB data bank. RN [40] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY CRYSTALLOGRAPHY RP (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1, SUBUNIT, DISULFIDE BOND, RP AND MUTAGENESIS OF ARG-103. RX PubMed=19525919; DOI=10.1038/embor.2009.91; RA Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M., Nguyen M., RA Rajashankar K.R., Wang B., Nikolov D.B.; RT "Ligand recognition by A-class Eph receptors: crystal structures of the RT EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex."; RL EMBO Rep. 10:722-728(2009). RN [41] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND. RG Structural genomics consortium (SGC); RT "Ephrin A1 bound to the ligand binding domain of the human ephrin A2 RT (EPHA2) receptor protein kinase."; RL Submitted (FEB-2009) to the PDB data bank. RN [42] RP STRUCTURE BY NMR OF 523-563. RA Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.; RT "Left-handed dimer of EPHA2 transmembrane domain helix packing diversity RT among receptor tyrosine kinases."; RL Submitted (AUG-2009) to the PDB data bank. RN [43] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 23-202 IN COMPLEX WITH EFNA1, AND RP SUBUNIT. RX PubMed=20505120; DOI=10.1073/pnas.1004148107; RA Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K., Atapattu L., RA Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B., Dhe-Paganon S.; RT "Architecture of Eph receptor clusters."; RL Proc. Natl. Acad. Sci. U.S.A. 107:10860-10865(2010). RN [44] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND RP HIS-876. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [45] RP VARIANT CTRCT6 TRP-948. RX PubMed=19005574; RA Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X., RA Hejtmancik J.F.; RT "The EPHA2 gene is associated with cataracts linked to chromosome 1p."; RL Mol. Vis. 14:2042-2055(2008). RN [46] RP VARIANT CTRCT6 ILE-940. RX PubMed=19306328; DOI=10.1002/humu.20995; RA Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E., RA Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J., Zhang X.; RT "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal RT dominant congenital cataract."; RL Hum. Mutat. 30:E603-E611(2009). RN [47] RP VARIANT CTRCT6 GLN-721, AND CHARACTERIZATION OF VARIANT CTRCT6 GLN-721. RX PubMed=19649315; DOI=10.1371/journal.pgen.1000584; RA Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H., RA Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P., RA Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J., RA Elston R.C., Iyengar S.K., Wang B.; RT "EPHA2 is associated with age-related cortical cataract in mice and RT humans."; RL PLoS Genet. 5:E1000584-E1000584(2009). RN [48] RP CHARACTERIZATION OF VARIANTS CTRCT6 ILE-940 AND CTRCT6 TRP-948. RX PubMed=22570727; DOI=10.1371/journal.pone.0036564; RA Park J.E., Son A.I., Hua R., Wang L., Zhang X., Zhou R.; RT "Human cataract mutations in EPHA2 SAM domain alter receptor stability and RT function."; RL PLoS ONE 7:E36564-E36564(2012). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane- CC bound ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Activated by the ligand ephrin- CC A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation CC and differentiation of cells. Regulates cell adhesion and CC differentiation through DSG1/desmoglein-1 and inhibition of the CC ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also CC participate in UV radiation-induced apoptosis and have a ligand- CC independent stimulatory effect on chemotactic cell migration. During CC development, may function in distinctive aspects of pattern formation CC and subsequently in development of several fetal tissues. Involved for CC instance in angiogenesis, in early hindbrain development and epithelial CC proliferation and branching morphogenesis during mammary gland CC development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens CC fiber cells shape and interactions and be important for lens CC transparency development and maintenance. With ephrin-A2/EFNA2 may play CC a role in bone remodeling through regulation of osteoclastogenesis and CC osteoblastogenesis. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:18339848, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C CC virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV CC entry by promoting the formation of the CD81-CLDN1 receptor complexes CC that are essential for HCV entry and by enhancing membrane fusion of CC cells expressing HCV envelope glycoproteins. CC {ECO:0000269|PubMed:21516087}. CC -!- FUNCTION: Acts as a receptor for human cytomegalovirus (HCMV) to CC mediate viral entry and fusion in glioblastoma cells. CC {ECO:0000269|PubMed:37146061}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:2174105}; CC -!- SUBUNIT: Homodimer. Interacts with SLA. Interacts (phosphorylated form) CC with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3); CC critical for the EFNA1-induced activation of RAC1 which stimulates cell CC migration (By similarity). Interacts with INPPL1; regulates activated CC EPHA2 endocytosis and degradation. Interacts (inactivated form) with CC PTK2/FAK1 and interacts (EFNA1 ligand-activated form) with PTPN11; CC regulates integrin-mediated adhesion. Interacts with ARHGEF16, DOCK4 CC and ELMO2; mediates ligand-independent activation of RAC1 which CC stimulates cell migration. Interacts with CLDN4; phosphorylates CLDN4 CC and may regulate tight junctions. Interacts with ACP1. Interacts (via CC SAM domain) with ANKS1A (via SAM domain). Interacts with CEMIP. CC Interacts with NCK1; may regulate EPHA2 activity in cell migration and CC adhesion. Interacts with TIMD4 (PubMed:34067457). CC {ECO:0000250|UniProtKB:Q03145, ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:12167657, ECO:0000269|PubMed:16236711, CC ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:19525919, CC ECO:0000269|PubMed:20505120, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:22332920, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:34067457}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 8/HHV- CC 8 glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC triggers EPHA2 phosphorylation and endocytosis, allowing virus entry. CC {ECO:0000269|PubMed:22635007}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) glycoprotein L/gL and glycoprotein H/gH heterodimer. CC {ECO:0000269|PubMed:37146061}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus/HHV-4 CC glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC facilitates virus internalization and fusion. CC {ECO:0000269|PubMed:29292383, ECO:0000269|PubMed:29292384}. CC -!- INTERACTION: CC P29317; P30530: AXL; NbExp=2; IntAct=EBI-702104, EBI-2850927; CC P29317; P35222: CTNNB1; NbExp=2; IntAct=EBI-702104, EBI-491549; CC P29317; P20827: EFNA1; NbExp=9; IntAct=EBI-702104, EBI-715194; CC P29317; P52803: EFNA5; NbExp=8; IntAct=EBI-702104, EBI-1753674; CC P29317; P98172: EFNB1; NbExp=3; IntAct=EBI-702104, EBI-538287; CC P29317; P29320: EPHA3; NbExp=3; IntAct=EBI-702104, EBI-1641575; CC P29317; P54756: EPHA5; NbExp=3; IntAct=EBI-702104, EBI-1383718; CC P29317; Q9UF33: EPHA6; NbExp=4; IntAct=EBI-702104, EBI-3950019; CC P29317; Q15375: EPHA7; NbExp=7; IntAct=EBI-702104, EBI-1383428; CC P29317; P08238: HSP90AB1; NbExp=2; IntAct=EBI-702104, EBI-352572; CC P29317; O15357-1: INPPL1; NbExp=3; IntAct=EBI-702104, EBI-15963021; CC P29317; P29376: LTK; NbExp=3; IntAct=EBI-702104, EBI-6596163; CC P29317; Q05397: PTK2; NbExp=3; IntAct=EBI-702104, EBI-702142; CC P29317; Q06124: PTPN11; NbExp=3; IntAct=EBI-702104, EBI-297779; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20223987, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:34067457}; Single-pass CC type I membrane protein {ECO:0000255}. Cell projection, ruffle membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell projection, lamellipodium membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell junction, focal adhesion CC {ECO:0000269|PubMed:10655584}. Note=Present at regions of cell-cell CC contacts but also at the leading edge of migrating cells CC (PubMed:19573808, PubMed:20861311). Relocates from the plasma membrane CC to the cytoplasmic and perinuclear regions in cancer cells CC (PubMed:18794797). {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311, CC ECO:0000269|PubMed:26158630}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29317-1; Sequence=Displayed; CC Name=2; CC IsoId=P29317-2; Sequence=VSP_056014, VSP_056015; CC -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and glioma CC cell lines (at protein level). Expressed most highly in tissues that CC contain a high proportion of epithelial cells, e.g. skin, intestine, CC lung, and ovary. {ECO:0000269|PubMed:17332925}. CC -!- INDUCTION: Up-regulated by UV irradiation via a TP53-independent, MAPK- CC dependent mechanism. {ECO:0000269|PubMed:18339848}. CC -!- PTM: Autophosphorylates. Phosphorylated on tyrosine upon binding and CC activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-594 are CC required for binding VAV2 and VAV3 while phosphorylated residues Tyr- CC 735 and Tyr-930 are required for binding PI3-kinase p85 subunit CC (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated residues are critical CC for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which CC transduce downstream signaling to activate RAC1 GTPase and cell CC migration. Dephosphorylation of Tyr-930 by PTPRF prevents the CC interaction of EPHA2 with NCK1. Phosphorylated at Ser-897 by PKB; CC serum-induced phosphorylation which targets EPHA2 to the cell leading CC edge and stimulates cell migration. Phosphorylation by PKB is inhibited CC by EFNA1-activated EPHA2 which regulates PKB activity via a reciprocal CC regulatory loop. Phosphorylated at Ser-897 in response to TNF by CC RPS6KA1 and RPS6KA3; RPS6KA-EPHA2 signaling pathway controls cell CC migration (PubMed:26158630). Phosphorylated at Ser-897 by PKA; blocks CC cell retraction induced by EPHA2 kinase activity (PubMed:27385333). CC Dephosphorylated by ACP1. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:18794797, ECO:0000269|PubMed:19573808, CC ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:26158630, CC ECO:0000269|PubMed:27385333}. CC -!- PTM: Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by the CC HSP90 chaperone and regulates the receptor stability and activity CC through proteasomal degradation. ANKS1A prevents ubiquitination and CC degradation (By similarity). {ECO:0000250}. CC -!- DISEASE: Cataract 6, multiple types (CTRCT6) [MIM:116600]: An CC opacification of the crystalline lens of the eye that frequently CC results in visual impairment or blindness. Opacities vary in CC morphology, are often confined to a portion of the lens, and may be CC static or progressive. CTRCT6 includes posterior polar and age-related CC cortical cataracts, among others. Posterior polar cataract is a CC subcapsular opacity, usually disk-shaped, located at the back of the CC lens. Age-related cortical cataract is a developmental punctate opacity CC restricted to the cortex. The cataract is white or cerulean, increases CC in number with age, but rarely affects vision. CC {ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:19306328, CC ECO:0000269|PubMed:19649315, ECO:0000269|PubMed:22570727}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Overexpressed in several cancer types and promotes CC malignancy. {ECO:0000269|PubMed:19573808}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40462/EPHA2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M59371; AAA53375.1; -; mRNA. DR EMBL; EU826606; ACF47642.1; -; mRNA. DR EMBL; AL451042; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471167; EAW51769.1; -; Genomic_DNA. DR EMBL; BC037166; AAH37166.1; -; mRNA. DR CCDS; CCDS169.1; -. [P29317-1] DR PIR; A36355; A36355. DR RefSeq; NP_004422.2; NM_004431.4. [P29317-1] DR PDB; 1MQB; X-ray; 2.30 A; A/B=596-900. DR PDB; 2E8N; NMR; -; A=902-976. DR PDB; 2K9Y; NMR; -; A/B=523-563. DR PDB; 2KSO; NMR; -; A=908-972. DR PDB; 2X10; X-ray; 3.00 A; A=27-534. DR PDB; 2X11; X-ray; 4.83 A; A=27-534. DR PDB; 3C8X; X-ray; 1.95 A; A=23-202. DR PDB; 3CZU; X-ray; 2.65 A; A=23-202. DR PDB; 3FL7; X-ray; 2.50 A; A=23-531. DR PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201. DR PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201. DR PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971. DR PDB; 3MBW; X-ray; 2.81 A; A=23-326. DR PDB; 3MX0; X-ray; 3.51 A; A/C=27-435. DR PDB; 3SKJ; X-ray; 2.50 A; E/F=23-202. DR PDB; 4P2K; X-ray; 1.50 A; A=590-876. DR PDB; 4PDO; X-ray; 2.10 A; A/B=590-876. DR PDB; 4TRL; X-ray; 2.45 A; A=590-876. DR PDB; 5EK7; X-ray; 1.90 A; A/B=583-876. DR PDB; 5I9U; X-ray; 1.89 A; A=596-900. DR PDB; 5I9V; X-ray; 1.46 A; A=596-900. DR PDB; 5I9W; X-ray; 1.36 A; A=596-900. DR PDB; 5I9X; X-ray; 1.43 A; A=596-900. DR PDB; 5I9Y; X-ray; 1.23 A; A=596-900. DR PDB; 5I9Z; X-ray; 1.70 A; A=596-900. DR PDB; 5IA0; X-ray; 1.95 A; A/B/C=596-900. DR PDB; 5IA1; X-ray; 2.04 A; A=596-900. DR PDB; 5IA2; X-ray; 1.62 A; A=596-900. DR PDB; 5IA3; X-ray; 1.79 A; A=596-900. DR PDB; 5IA4; X-ray; 1.80 A; A=596-900. DR PDB; 5IA5; X-ray; 1.78 A; A=596-900. DR PDB; 5NJZ; X-ray; 1.77 A; A=596-900. DR PDB; 5NK0; X-ray; 1.60 A; A=596-900. DR PDB; 5NK1; X-ray; 1.55 A; A=596-900. DR PDB; 5NK2; X-ray; 1.65 A; A=596-900. DR PDB; 5NK3; X-ray; 1.59 A; A=596-900. DR PDB; 5NK4; X-ray; 1.45 A; A=596-900. DR PDB; 5NK5; X-ray; 1.33 A; A=596-900. DR PDB; 5NK6; X-ray; 1.27 A; A=596-900. DR PDB; 5NK7; X-ray; 1.89 A; A=596-900. DR PDB; 5NK8; X-ray; 1.76 A; A=596-900. DR PDB; 5NK9; X-ray; 1.59 A; A=596-900. DR PDB; 5NKA; X-ray; 1.38 A; A=596-900. DR PDB; 5NKB; X-ray; 1.50 A; A=596-900. DR PDB; 5NKC; X-ray; 1.45 A; A=596-900. DR PDB; 5NKD; X-ray; 1.41 A; A=596-900. DR PDB; 5NKE; X-ray; 1.39 A; A=596-900. DR PDB; 5NKF; X-ray; 1.10 A; A=596-900. DR PDB; 5NKG; X-ray; 1.10 A; A=596-900. DR PDB; 5NKH; X-ray; 1.29 A; A=596-900. DR PDB; 5NKI; X-ray; 1.68 A; A=596-900. DR PDB; 5NZ9; NMR; -; A=945-969. DR PDB; 6B9L; X-ray; 3.20 A; A/B/C/D=27-200. DR PDB; 6F7M; NMR; -; A=945-969. DR PDB; 6F7N; NMR; -; A=951-963. DR PDB; 6FNF; X-ray; 1.56 A; A=596-900. DR PDB; 6FNG; X-ray; 1.04 A; A=596-900. DR PDB; 6FNH; X-ray; 1.38 A; A/B/C=596-900. DR PDB; 6HES; X-ray; 1.13 A; A=596-900. DR PDB; 6HET; X-ray; 1.21 A; A=596-900. DR PDB; 6HEU; X-ray; 1.72 A; A=596-900. DR PDB; 6HEV; X-ray; 1.28 A; A=596-900. DR PDB; 6HEW; X-ray; 1.27 A; A=596-900. DR PDB; 6HEX; X-ray; 1.41 A; A=596-900. DR PDB; 6HEY; X-ray; 1.37 A; A=596-900. DR PDB; 6NJZ; X-ray; 1.90 A; A/B=28-200. DR PDB; 6NK0; X-ray; 1.53 A; A/B=28-200. DR PDB; 6NK1; X-ray; 1.55 A; A/B=28-200. DR PDB; 6NK2; X-ray; 2.20 A; A/B=28-200. DR PDB; 6NKP; X-ray; 2.03 A; A/B=28-200. DR PDB; 6Q7B; X-ray; 1.01 A; A=596-900. DR PDB; 6Q7C; X-ray; 1.05 A; A=596-900. DR PDB; 6Q7D; X-ray; 0.98 A; A=596-900. DR PDB; 6Q7E; X-ray; 1.06 A; A=596-900. DR PDB; 6Q7F; X-ray; 1.20 A; A=596-900. DR PDB; 6Q7G; X-ray; 1.05 A; A=596-900. DR PDB; 6RW2; X-ray; 2.26 A; A=27-201. DR PDB; 7B7N; X-ray; 2.69 A; E=23-202. DR PDB; 7CZE; X-ray; 3.00 A; I/J/K/L=26-200. DR PDB; 7CZF; X-ray; 3.20 A; A/D=28-206. DR PDB; 7KJA; X-ray; 1.75 A; A/B=590-976. DR PDB; 7KJB; X-ray; 2.80 A; A=590-976. DR PDB; 7KJC; X-ray; 2.30 A; A/B=590-976. DR PDB; 8BIN; X-ray; 1.50 A; A=596-900. DR PDB; 8BIO; X-ray; 1.60 A; A=596-900. DR PDB; 8BK0; X-ray; 1.70 A; A=596-900. DR PDB; 8BM8; X-ray; 1.68 A; A=596-900. DR PDB; 8BOC; X-ray; 1.90 A; A=596-900. DR PDB; 8BOD; X-ray; 1.50 A; A=596-900. DR PDB; 8BOF; X-ray; 1.82 A; A=596-900. DR PDB; 8BOG; X-ray; 1.47 A; A=596-900. DR PDB; 8BOH; X-ray; 1.42 A; A=596-900. DR PDB; 8BOI; X-ray; 1.63 A; A=596-900. DR PDB; 8BOK; X-ray; 2.02 A; A=596-900. DR PDB; 8BOM; X-ray; 1.12 A; A=596-900. DR PDB; 8QQY; X-ray; 1.80 A; A=596-900. DR PDB; 8T9B; X-ray; 4.20 A; I/J/K/L=436-529. DR PDB; 8TRS; X-ray; 1.90 A; D=199-326. DR PDB; 8TRT; X-ray; 3.00 A; D/E=199-326. DR PDB; 8TRV; X-ray; 3.25 A; A/B=23-326. DR PDB; 8TV1; X-ray; 2.60 A; C=23-326. DR PDB; 8TV5; X-ray; 4.60 A; C/F=23-326. DR PDB; 8XPV; X-ray; 1.55 A; A=596-900. DR PDBsum; 1MQB; -. DR PDBsum; 2E8N; -. DR PDBsum; 2K9Y; -. DR PDBsum; 2KSO; -. DR PDBsum; 2X10; -. DR PDBsum; 2X11; -. DR PDBsum; 3C8X; -. DR PDBsum; 3CZU; -. DR PDBsum; 3FL7; -. DR PDBsum; 3HEI; -. DR PDBsum; 3HPN; -. DR PDBsum; 3KKA; -. DR PDBsum; 3MBW; -. DR PDBsum; 3MX0; -. DR PDBsum; 3SKJ; -. DR PDBsum; 4P2K; -. DR PDBsum; 4PDO; -. DR PDBsum; 4TRL; -. DR PDBsum; 5EK7; -. DR PDBsum; 5I9U; -. DR PDBsum; 5I9V; -. DR PDBsum; 5I9W; -. DR PDBsum; 5I9X; -. DR PDBsum; 5I9Y; -. DR PDBsum; 5I9Z; -. DR PDBsum; 5IA0; -. DR PDBsum; 5IA1; -. DR PDBsum; 5IA2; -. DR PDBsum; 5IA3; -. DR PDBsum; 5IA4; -. DR PDBsum; 5IA5; -. DR PDBsum; 5NJZ; -. DR PDBsum; 5NK0; -. DR PDBsum; 5NK1; -. DR PDBsum; 5NK2; -. DR PDBsum; 5NK3; -. DR PDBsum; 5NK4; -. DR PDBsum; 5NK5; -. DR PDBsum; 5NK6; -. DR PDBsum; 5NK7; -. DR PDBsum; 5NK8; -. DR PDBsum; 5NK9; -. DR PDBsum; 5NKA; -. DR PDBsum; 5NKB; -. DR PDBsum; 5NKC; -. DR PDBsum; 5NKD; -. DR PDBsum; 5NKE; -. DR PDBsum; 5NKF; -. DR PDBsum; 5NKG; -. DR PDBsum; 5NKH; -. DR PDBsum; 5NKI; -. DR PDBsum; 5NZ9; -. DR PDBsum; 6B9L; -. DR PDBsum; 6F7M; -. DR PDBsum; 6F7N; -. DR PDBsum; 6FNF; -. DR PDBsum; 6FNG; -. DR PDBsum; 6FNH; -. DR PDBsum; 6HES; -. DR PDBsum; 6HET; -. DR PDBsum; 6HEU; -. DR PDBsum; 6HEV; -. DR PDBsum; 6HEW; -. DR PDBsum; 6HEX; -. DR PDBsum; 6HEY; -. DR PDBsum; 6NJZ; -. DR PDBsum; 6NK0; -. DR PDBsum; 6NK1; -. DR PDBsum; 6NK2; -. DR PDBsum; 6NKP; -. DR PDBsum; 6Q7B; -. DR PDBsum; 6Q7C; -. DR PDBsum; 6Q7D; -. DR PDBsum; 6Q7E; -. DR PDBsum; 6Q7F; -. DR PDBsum; 6Q7G; -. DR PDBsum; 6RW2; -. DR PDBsum; 7B7N; -. DR PDBsum; 7CZE; -. DR PDBsum; 7CZF; -. DR PDBsum; 7KJA; -. DR PDBsum; 7KJB; -. DR PDBsum; 7KJC; -. DR PDBsum; 8BIN; -. DR PDBsum; 8BIO; -. DR PDBsum; 8BK0; -. DR PDBsum; 8BM8; -. DR PDBsum; 8BOC; -. DR PDBsum; 8BOD; -. DR PDBsum; 8BOF; -. DR PDBsum; 8BOG; -. DR PDBsum; 8BOH; -. DR PDBsum; 8BOI; -. DR PDBsum; 8BOK; -. DR PDBsum; 8BOM; -. DR PDBsum; 8QQY; -. DR PDBsum; 8T9B; -. DR PDBsum; 8TRS; -. DR PDBsum; 8TRT; -. DR PDBsum; 8TRV; -. DR PDBsum; 8TV1; -. DR PDBsum; 8TV5; -. DR PDBsum; 8XPV; -. DR AlphaFoldDB; P29317; -. DR BMRB; P29317; -. DR SMR; P29317; -. DR BioGRID; 108288; 748. DR CORUM; P29317; -. DR DIP; DIP-96N; -. DR FunCoup; P29317; 946. DR IntAct; P29317; 207. DR MINT; P29317; -. DR STRING; 9606.ENSP00000351209; -. DR BindingDB; P29317; -. DR ChEMBL; CHEMBL2068; -. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR DrugBank; DB08896; Regorafenib. DR DrugCentral; P29317; -. DR GuidetoPHARMACOLOGY; 1822; -. DR GlyConnect; 777; 3 N-Linked glycans (1 site). DR GlyCosmos; P29317; 2 sites, 4 glycans. DR GlyGen; P29317; 4 sites, 6 N-linked glycans (2 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P29317; -. DR PhosphoSitePlus; P29317; -. DR SwissPalm; P29317; -. DR BioMuta; EPHA2; -. DR DMDM; 229462861; -. DR CPTAC; CPTAC-1784; -. DR CPTAC; CPTAC-2783; -. DR CPTAC; CPTAC-3201; -. DR jPOST; P29317; -. DR MassIVE; P29317; -. DR PaxDb; 9606-ENSP00000351209; -. DR PeptideAtlas; P29317; -. DR ProteomicsDB; 54535; -. [P29317-1] DR Pumba; P29317; -. DR ABCD; P29317; 32 sequenced antibodies. DR Antibodypedia; 4183; 1411 antibodies from 48 providers. DR DNASU; 1969; -. DR Ensembl; ENST00000358432.8; ENSP00000351209.5; ENSG00000142627.14. [P29317-1] DR GeneID; 1969; -. DR KEGG; hsa:1969; -. DR MANE-Select; ENST00000358432.8; ENSP00000351209.5; NM_004431.5; NP_004422.2. DR UCSC; uc001aya.2; human. [P29317-1] DR AGR; HGNC:3386; -. DR ClinPGx; PA27818; -. DR CTD; 1969; -. DR DisGeNET; 1969; -. DR GeneCards; EPHA2; -. DR HGNC; HGNC:3386; EPHA2. DR HPA; ENSG00000142627; Tissue enhanced (esophagus). DR MalaCards; EPHA2; -. DR MIM; 116600; phenotype. DR MIM; 176946; gene. DR OpenTargets; ENSG00000142627; -. DR Orphanet; 98991; Early-onset nuclear cataract. DR Orphanet; 98993; Early-onset posterior polar cataract. DR Orphanet; 441447; Early-onset posterior subcapsular cataract. DR Orphanet; 98994; Total early-onset cataract. DR VEuPathDB; HostDB:ENSG00000142627; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160786; -. DR HOGENOM; CLU_000288_141_4_1; -. DR InParanoid; P29317; -. DR OMA; CLECPVH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29317; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29317; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29317; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9013408; RHOG GTPase cycle. DR Reactome; R-HSA-9013420; RHOU GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR Reactome; R-HSA-9013424; RHOV GTPase cycle. DR Reactome; R-HSA-9696264; RND3 GTPase cycle. DR Reactome; R-HSA-9696270; RND2 GTPase cycle. DR Reactome; R-HSA-9696273; RND1 GTPase cycle. DR SignaLink; P29317; -. DR SIGNOR; P29317; -. DR Agora; ENSG00000142627; -. DR BioGRID-ORCS; 1969; 20 hits in 1214 CRISPR screens. DR ChiTaRS; EPHA2; human. DR EvolutionaryTrace; P29317; -. DR GeneWiki; EPH_receptor_A2; -. DR GenomeRNAi; 1969; -. DR Pharos; P29317; Tclin. DR PRO; PR:P29317; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29317; protein. DR Bgee; ENSG00000142627; Expressed in lower esophagus mucosa and 143 other cell types or tissues. DR ExpressionAtlas; P29317; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell. DR GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0070160; C:tight junction; IDA:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IPI:ARUK-UCL. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW. DR GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl. DR GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IEA:Ensembl. DR GO; GO:0046849; P:bone remodeling; ISS:UniProtKB. DR GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISS:UniProtKB. DR GO; GO:0046058; P:cAMP metabolic process; IMP:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0048870; P:cell motility; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB. DR GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB. DR GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0032682; P:negative regulation of chemokine production; IEA:Ensembl. DR GO; GO:1901491; P:negative regulation of lymphangiogenesis; IEA:Ensembl. DR GO; GO:0021915; P:neural tube development; IEA:Ensembl. DR GO; GO:0060035; P:notochord cell development; IEA:Ensembl. DR GO; GO:0014028; P:notochord formation; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB. DR GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl. DR GO; GO:1903348; P:positive regulation of bicellular tight junction assembly; IMP:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:ARUK-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:UniProtKB. DR GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl. DR GO; GO:0072659; P:protein localization to plasma membrane; IMP:ARUK-UCL. DR GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB. DR GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0010591; P:regulation of lamellipodium assembly; IMP:UniProtKB. DR GO; GO:0070848; P:response to growth factor; IMP:UniProtKB. DR GO; GO:0001501; P:skeletal system development; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd10480; EphR_LBD_A2; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05063; PTKc_EphR_A2; 1. DR CDD; cd09543; SAM_EPH-A2; 1. DR DisProt; DP03145; -. DR FunFam; 1.10.150.50:FF:000029; Ephrin type-A receptor 1; 1. DR FunFam; 1.20.5.510:FF:000004; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.120.260:FF:000023; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.10:FF:000724; ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.1770:FF:000002; ephrin type-A receptor 2; 1. DR FunFam; 1.10.510.10:FF:000019; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.510; Single helix bin; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034263; EphA2_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF20; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; Apoptosis; ATP-binding; KW Cataract; Cell adhesion; Cell junction; Cell membrane; Cell projection; KW Differentiation; Disease variant; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Kinase; KW Membrane; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..976 FT /note="Ephrin type-A receptor 2" FT /id="PRO_0000016800" FT TOPO_DOM 24..537 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 538..558 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 559..976 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 28..206 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 438..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 613..875 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 904..968 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 1..206 FT /note="Mediates interaction with CLDN4" FT /evidence="ECO:0000269|PubMed:16236711" FT REGION 606..906 FT /note="Mediates interaction with ARHGEF16 and ELMO2" FT /evidence="ECO:0000269|PubMed:20679435" FT REGION 886..976 FT /note="Negatively regulates interaction with ARHGEF16" FT /evidence="ECO:0000269|PubMed:20679435" FT MOTIF 974..976 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 739 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 619..627 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 646 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 570 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195" FT MOD_RES 575 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 579 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 594 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 628 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 647 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 735 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 772 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 869 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 892 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 897 FT /note="Phosphoserine; by PKB/AKT1, RPS6KA1, RPS6KA3 AND FT PKA" FT /evidence="ECO:0000269|PubMed:19573808, FT ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:23186163" FT MOD_RES 901 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 921 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 930 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23358419" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 435 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT DISULFID 70..188 FT DISULFID 105..115 FT VAR_SEQ 477..497 FT /note="GDSNSYNVRRTEGFSVTLDDL -> VTPRGAGLALAGPTAGDRLVT (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056014" FT VAR_SEQ 498..976 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056015" FT VARIANT 99 FT /note="K -> N (in dbSNP:rs1058372)" FT /id="VAR_055989" FT VARIANT 391 FT /note="G -> R (in dbSNP:rs34192549)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042121" FT VARIANT 511 FT /note="T -> M (in dbSNP:rs55747232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042122" FT VARIANT 568 FT /note="R -> H (in dbSNP:rs56198600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042123" FT VARIANT 631 FT /note="M -> T (in dbSNP:rs34021505)" FT /id="VAR_055990" FT VARIANT 721 FT /note="R -> Q (in CTRCT6; retained in the cytoplasm and FT constitutively active it alters EPHA2 signaling; FT dbSNP:rs116506614)" FT /evidence="ECO:0000269|PubMed:19649315" FT /id="VAR_062532" FT VARIANT 777 FT /note="G -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs922655349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042124" FT VARIANT 876 FT /note="R -> H (in dbSNP:rs35903225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042125" FT VARIANT 940 FT /note="T -> I (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853200)" FT /evidence="ECO:0000269|PubMed:19306328, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058907" FT VARIANT 948 FT /note="G -> W (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853199)" FT /evidence="ECO:0000269|PubMed:19005574, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058908" FT MUTAGEN 103 FT /note="R->E: Significantly reduced response to EFNA1." FT /evidence="ECO:0000269|PubMed:19525919" FT MUTAGEN 646 FT /note="K->M: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16236711" FT MUTAGEN 739 FT /note="D->N: Increases serum-induced chemotaxis. Loss of FT EFNA1-dependent regulation of cell migration." FT /evidence="ECO:0000269|PubMed:19573808" FT MUTAGEN 897 FT /note="S->A,D: Loss of serum-induced phosphorylation by FT PKB. Loss of serum-induced chemotaxis." FT /evidence="ECO:0000269|PubMed:19573808" FT CONFLICT 94..99 FT /note="IFIELK -> NNFELN (in Ref. 1; AAA53375)" FT /evidence="ECO:0000305" FT STRAND 28..33 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 34..37 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:6NK0" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:6NK1" FT STRAND 53..57 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 59..62 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 92..103 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 105..107 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:3HEI" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 119..128 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 136..138 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 140..145 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 148..151 FT /evidence="ECO:0007829|PDB:6RW2" FT HELIX 153..157 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 164..170 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 175..199 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:8TRS" FT HELIX 221..224 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 225..227 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:3MBW" FT STRAND 244..247 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 253..257 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 272..275 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 284..287 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 295..298 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 304..306 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 335..338 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 343..348 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 384..387 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 389..392 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 394..400 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 407..415 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 419..421 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 427..433 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 453..457 FT /evidence="ECO:0007829|PDB:3FL7" FT TURN 460..465 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 467..475 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 483..493 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 502..510 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 522..525 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 536..556 FT /evidence="ECO:0007829|PDB:2K9Y" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:2K9Y" FT HELIX 591..594 FT /evidence="ECO:0007829|PDB:5EK7" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:4PDO" FT TURN 601..604 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 610..612 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 613..622 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 625..632 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:5NKH" FT STRAND 641..648 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 654..669 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 678..682 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 684..693 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 700..706 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:6Q7E" FT HELIX 713..732 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 742..744 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 753..755 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 762..766 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 770..772 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 776..778 FT /evidence="ECO:0007829|PDB:5NKH" FT HELIX 781..783 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 786..791 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 796..811 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 823..831 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 844..853 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 858..860 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 864..876 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 878..881 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 882..884 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 889..892 FT /evidence="ECO:0007829|PDB:8QQY" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 919..921 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 922..927 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 933..936 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 941..946 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 952..969 FT /evidence="ECO:0007829|PDB:7KJA" SQ SEQUENCE 976 AA; 108266 MW; 845D7E1BBCCAACCC CRC64; MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY SLLGLKDQVN TVGIPI // ID EPHA8_HUMAN Reviewed; 1005 AA. AC P29322; Q6IN80; Q8IUX6; Q9NUA9; Q9P269; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 235. DE RecName: Full=Ephrin type-A receptor 8; DE EC=2.7.10.1; DE AltName: Full=EPH- and ELK-related kinase; DE AltName: Full=EPH-like kinase 3; DE Short=EK3; DE Short=hEK3; DE AltName: Full=Tyrosine-protein kinase receptor EEK; DE Flags: Precursor; GN Name=EPHA8; Synonyms=EEK, HEK3, KIAA1459; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-1005 (ISOFORM 1), AND VARIANT RP GLN-612. RC TISSUE=Brain; RX PubMed=10819331; DOI=10.1093/dnares/7.2.143; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:143-150(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 706-726. RX PubMed=1648701; RA Chan J., Watt V.M.; RT "eek and erk, new members of the eph subclass of receptor protein-tyrosine RT kinases."; RL Oncogene 6:1057-1061(1991). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP INTERACTION WITH FYN. RX PubMed=10498895; DOI=10.1038/sj.onc.1202917; RA Choi S., Park S.; RT "Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn RT binding to the Tyr-615 site by enhancing tyrosine kinase activity."; RL Oncogene 18:5413-5422(1999). RN [7] RP INTERACTION WITH PIK3CG. RX PubMed=11416136; DOI=10.1128/mcb.21.14.4579-4597.2001; RA Gu C., Park S.; RT "The EphA8 receptor regulates integrin activity through p110gamma RT phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent RT manner."; RL Mol. Cell. Biol. 21:4579-4597(2001). RN [8] RP INTERACTION WITH ANKS1B. RX PubMed=17875921; DOI=10.1128/mcb.00794-07; RA Shin J., Gu C., Park E., Park S.; RT "Identification of phosphotyrosine binding domain-containing proteins as RT novel downstream targets of the EphA8 signaling function."; RL Mol. Cell. Biol. 27:8113-8126(2007). RN [9] RP INTERACTION WITH TIAM1. RX PubMed=20496116; DOI=10.1007/s10059-010-0075-2; RA Yoo S., Shin J., Park S.; RT "EphA8-ephrinA5 signaling and clathrin-mediated endocytosis is regulated by RT Tiam-1, a Rac-specific guanine nucleotide exchange factor."; RL Mol. Cells 29:603-609(2010). RN [10] RP STRUCTURE BY NMR OF 437-534 AND 932-1000. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain and of sterile alpha motif RT (SAM) domain of EPH receptor A8 protein."; RL Submitted (NOV-2005) to the PDB data bank. RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] SER-45; LEU-60; LYS-123; CYS-179; LEU-198 RP AND LEU-860. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, CC EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. CC With EFNA5 may regulate integrin-mediated cell adhesion and migration CC on fibronectin substrate but also neurite outgrowth. During development CC of the nervous system also plays a role in axon guidance. Downstream CC effectors of the EPHA8 signaling pathway include FYN which promotes CC cell adhesion upon activation by EPHA8 and the MAP kinases in the CC stimulation of neurite outgrowth (By similarity). {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses. May also form CC heterodimers with other ephrin receptors (By similarity). Interacts CC with FYN; possible downstream effector of EPHA8 in regulation of cell CC adhesion. Interacts with PIK3CG; regulates integrin-mediated cell CC adhesion to substrate. Interacts with TIAM1; regulates clathrin- CC mediated endocytosis of EPHA8. Interacts with ANKS1A and ANKS1B; EPHA8 CC kinase activity-independent but stimulated by EPHA8 ubiquitination. CC {ECO:0000250, ECO:0000269|PubMed:10498895, ECO:0000269|PubMed:11416136, CC ECO:0000269|PubMed:17875921, ECO:0000269|PubMed:20496116}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:O09127}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection CC {ECO:0000250|UniProtKB:O09127}. Early endosome membrane CC {ECO:0000250|UniProtKB:O09127}. Note=Undergoes clathrin-mediated CC endocytosis upon EFNA5-binding and is targeted to early endosomes. CC {ECO:0000250|UniProtKB:O09127}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29322-1; Sequence=Displayed; CC Name=2; CC IsoId=P29322-2; Sequence=VSP_041946, VSP_041947; CC -!- PTM: Phosphorylated. Phosphorylation is stimulated upon binding of its CC ligands including EFNA2, EFNA3 and EFNA5. Autophosphorylation on Tyr- CC 616 is critical for association with FYN. Autophosphorylation on Tyr- CC 839 modulates tyrosine kinase activity (By similarity). {ECO:0000250}. CC -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor CC stability and activity through proteasomal degradation. ANKS1A prevents CC ubiquitination and degradation (By similarity). {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA41980.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL035703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC038796; AAH38796.1; -; mRNA. DR EMBL; BC072417; AAH72417.2; -; mRNA. DR EMBL; AB040892; BAA95983.1; -; mRNA. DR EMBL; X59291; CAA41980.1; ALT_INIT; Genomic_DNA. DR CCDS; CCDS225.1; -. [P29322-1] DR CCDS; CCDS30626.1; -. [P29322-2] DR PIR; S23361; S23361. DR RefSeq; NP_001006944.1; NM_001006943.3. [P29322-2] DR RefSeq; NP_065387.1; NM_020526.5. [P29322-1] DR PDB; 1UCV; NMR; -; A=933-1000. DR PDB; 1X5L; NMR; -; A=437-534. DR PDB; 3KUL; X-ray; 2.15 A; A/B=602-909. DR PDBsum; 1UCV; -. DR PDBsum; 1X5L; -. DR PDBsum; 3KUL; -. DR AlphaFoldDB; P29322; -. DR BMRB; P29322; -. DR SMR; P29322; -. DR BioGRID; 108360; 162. DR CORUM; P29322; -. DR FunCoup; P29322; 354. DR IntAct; P29322; 151. DR MINT; P29322; -. DR STRING; 9606.ENSP00000166244; -. DR BindingDB; P29322; -. DR ChEMBL; CHEMBL4134; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P29322; -. DR GuidetoPHARMACOLOGY; 1828; -. DR GlyCosmos; P29322; 3 sites, No reported glycans. DR GlyGen; P29322; 4 sites, 1 O-linked glycan (1 site). DR iPTMnet; P29322; -. DR PhosphoSitePlus; P29322; -. DR BioMuta; EPHA8; -. DR DMDM; 19857975; -. DR CPTAC; CPTAC-2820; -. DR CPTAC; CPTAC-3204; -. DR jPOST; P29322; -. DR MassIVE; P29322; -. DR PaxDb; 9606-ENSP00000166244; -. DR PeptideAtlas; P29322; -. DR ProteomicsDB; 54538; -. [P29322-1] DR ProteomicsDB; 54539; -. [P29322-2] DR Antibodypedia; 4046; 174 antibodies from 33 providers. DR DNASU; 2046; -. DR Ensembl; ENST00000166244.8; ENSP00000166244.3; ENSG00000070886.12. [P29322-1] DR Ensembl; ENST00000374644.8; ENSP00000363775.4; ENSG00000070886.12. [P29322-2] DR GeneID; 2046; -. DR KEGG; hsa:2046; -. DR MANE-Select; ENST00000166244.8; ENSP00000166244.3; NM_020526.5; NP_065387.1. DR UCSC; uc001bfw.4; human. [P29322-1] DR AGR; HGNC:3391; -. DR ClinPGx; PA27823; -. DR CTD; 2046; -. DR DisGeNET; 2046; -. DR GeneCards; EPHA8; -. DR HGNC; HGNC:3391; EPHA8. DR HPA; ENSG00000070886; Tissue enriched (choroid). DR MIM; 176945; gene. DR OpenTargets; ENSG00000070886; -. DR VEuPathDB; HostDB:ENSG00000070886; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160469; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P29322; -. DR OMA; MRMNIDD; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29322; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29322; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29322; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29322; -. DR SIGNOR; P29322; -. DR Agora; ENSG00000070886; -. DR BioGRID-ORCS; 2046; 11 hits in 1180 CRISPR screens. DR ChiTaRS; EPHA8; human. DR EvolutionaryTrace; P29322; -. DR GeneWiki; EPHA8; -. DR GenomeRNAi; 2046; -. DR Pharos; P29322; Tchem. DR PRO; PR:P29322; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29322; protein. DR Bgee; ENSG00000070886; Expressed in endothelial cell and 47 other cell types or tissues. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0043005; C:neuron projection; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0031175; P:neuron projection development; ISS:UniProtKB. DR GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0030155; P:regulation of cell adhesion; ISS:UniProtKB. DR GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; ISS:UniProtKB. DR GO; GO:0006929; P:substrate-dependent cell migration; ISS:UniProtKB. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09550; SAM_EPH-A8; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000130; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.40.10:FF:000190; Ephrin type-A receptor 7; 1. DR FunFam; 1.10.150.50:FF:000058; ephrin type-A receptor 8; 1. DR FunFam; 3.30.200.20:FF:000143; Ephrin type-B receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF7; EPHRIN TYPE-A RECEPTOR 8; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Cell projection; Developmental protein; Endosome; KW Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..1005 FT /note="Ephrin type-A receptor 8" FT /id="PRO_0000016822" FT TOPO_DOM 28..542 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 543..563 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 564..1005 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..209 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..438 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 439..534 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 635..896 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 930..994 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 564..570 FT /note="Mediates interaction with ANKS1A and ANKS1B" FT /evidence="ECO:0000250" FT REGION 589..644 FT /note="Mediates interaction with PIK3CG and required for FT endocytosis" FT /evidence="ECO:0000250" FT MOTIF 1003..1005 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 760 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 641..649 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 667 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 616 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT MOD_RES 839 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT CARBOHYD 340 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 432 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 439..495 FT /note="APSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEKDKEMQSYSTL FT KAVTT -> GRRRNSVPQRPGPPASPASDPSRDQSSAGDVLWAFRQVPLWPCAPHQDPE FT LEALHCL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041946" FT VAR_SEQ 496..1005 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041947" FT VARIANT 45 FT /note="G -> S (in dbSNP:rs45498698)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042153" FT VARIANT 60 FT /note="V -> L (in dbSNP:rs56402644)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042154" FT VARIANT 123 FT /note="N -> K (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042155" FT VARIANT 179 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1557556639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042156" FT VARIANT 198 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042157" FT VARIANT 321 FT /note="P -> L (in dbSNP:rs56656925)" FT /id="VAR_061292" FT VARIANT 444 FT /note="V -> M (in dbSNP:rs2295021)" FT /id="VAR_022107" FT VARIANT 612 FT /note="E -> Q (in dbSNP:rs999765)" FT /evidence="ECO:0000269|PubMed:10819331" FT /id="VAR_024514" FT VARIANT 860 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042158" FT CONFLICT 237 FT /note="S -> L (in Ref. 3; BAA95983)" FT /evidence="ECO:0000305" FT STRAND 456..460 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 472..482 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 488..499 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 507..510 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:1X5L" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 635..643 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 644..646 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 647..654 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 662..669 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 675..688 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 699..703 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 705..707 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 710..714 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 721..726 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 727..730 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 734..753 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 766..768 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 774..776 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 802..804 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 807..812 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 817..832 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 833..835 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 838..841 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 844..852 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 865..874 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 879..881 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 885..897 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 935..941 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 945..947 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 948..953 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 959..962 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 967..973 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 978..995 FT /evidence="ECO:0007829|PDB:1UCV" SQ SEQUENCE 1005 AA; 111003 MW; 6FBF85535E4212B3 CRC64; MAPARGRLPP ALWVVTAAAA AATCVSAARG EVNLLDTSTI HGDWGWLTYP AHGWDSINEV DESFQPIHTY QVCNVMSPNQ NNWLRTSWVP RDGARRVYAE IKFTLRDCNS MPGVLGTCKE TFNLYYLESD RDLGASTQES QFLKIDTIAA DESFTGADLG VRRLKLNTEV RSVGPLSKRG FYLAFQDIGA CLAILSLRIY YKKCPAMVRN LAAFSEAVTG ADSSSLVEVR GQCVRHSEER DTPKMYCSAE GEWLVPIGKC VCSAGYEERR DACVACELGF YKSAPGDQLC ARCPPHSHSA APAAQACHCD LSYYRAALDP PSSACTRPPS APVNLISSVN GTSVTLEWAP PLDPGGRSDI TYNAVCRRCP WALSRCEACG SGTRFVPQQT SLVQASLLVA NLLAHMNYSF WIEAVNGVSD LSPEPRRAAV VNITTNQAAP SQVVVIRQER AGQTSVSLLW QEPEQPNGII LEYEIKYYEK DKEMQSYSTL KAVTTRATVS GLKPGTRYVF QVRARTSAGC GRFSQAMEVE TGKPRPRYDT RTIVWICLTL ITGLVVLLLL LICKKRHCGY SKAFQDSDEE KMHYQNGQAP PPVFLPLHHP PGKLPEPQFY AEPHTYEEPG RAGRSFTREI EASRIHIEKI IGSGDSGEVC YGRLRVPGQR DVPVAIKALK AGYTERQRRD FLSEASIMGQ FDHPNIIRLE GVVTRGRLAM IVTEYMENGS LDTFLRTHDG QFTIMQLVGM LRGVGAGMRY LSDLGYVHRD LAARNVLVDS NLVCKVSDFG LSRVLEDDPD AAYTTTGGKI PIRWTAPEAI AFRTFSSASD VWSFGVVMWE VLAYGERPYW NMTNRDVISS VEEGYRLPAP MGCPHALHQL MLDCWHKDRA QRPRFSQIVS VLDALIRSPE SLRATATVSR CPPPAFVRSC FDLRGGSGGG GGLTVGDWLD SIRMGRYRDH FAAGGYSSLG MVLRMNAQDV RALGITLMGH QKKILGSIQT MRAQLTSTQG PRRHL // ID EPHAA_HUMAN Reviewed; 1008 AA. AC Q5JZY3; A4FU89; J3KPB5; Q6NW42; DT 27-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 03-APR-2013, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=Ephrin type-A receptor 10; DE EC=2.7.10.1; DE Flags: Precursor; GN Name=EPHA10; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), RP ALTERNATIVE SPLICING, FUNCTION, AND TISSUE SPECIFICITY. RC TISSUE=Testis; RX PubMed=15777695; DOI=10.1016/j.bbagen.2005.01.011; RA Aasheim H.-C., Patzke S., Hjorthaug H.S., Finne E.F.; RT "Characterization of a novel Eph receptor tyrosine kinase, EphA10, RT expressed in testis."; RL Biochim. Biophys. Acta 1723:1-7(2005). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 501-1008 (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INVOLVEMENT IN DFNA88. RX PubMed=36048850; DOI=10.1093/hmg/ddac223; RA Huang S., Ma L., Liu X., He C., Li J., Hu Z., Jiang L., Liu Y., Liu X., RA Feng Y., Cai X.; RT "A non-coding variant in 5' untranslated region drove up-regulation of RT pseudo-kinase EPHA10 and caused non-syndromic hearing loss in humans."; RL Hum. Mol. Genet. 32:720-731(2023). RN [5] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-150; LYS-220; ILE-281; PRO-630; ARG-775 RP AND THR-956. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor for members of the ephrin-A family. Binds to EFNA3, CC EFNA4 and EFNA5. {ECO:0000269|PubMed:15777695}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC -!- INTERACTION: CC Q5JZY3-3; Q8N9N5: BANP; NbExp=3; IntAct=EBI-10244652, EBI-744695; CC Q5JZY3-3; Q13557: CAMK2D; NbExp=3; IntAct=EBI-10244652, EBI-351018; CC Q5JZY3-3; Q13643: FHL3; NbExp=3; IntAct=EBI-10244652, EBI-741101; CC Q5JZY3-3; Q12800: TFCP2; NbExp=3; IntAct=EBI-10244652, EBI-717422; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane {ECO:0000305}; Single- CC pass type I membrane protein {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane {ECO:0000305}; Single- CC pass type I membrane protein {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q5JZY3-1; Sequence=Displayed; CC Name=2; Synonyms=Epha10s; CC IsoId=Q5JZY3-2; Sequence=VSP_015772, VSP_015773; CC Name=3; Synonyms=Epha10*; CC IsoId=Q5JZY3-3; Sequence=VSP_015774, VSP_015775; CC -!- TISSUE SPECIFICITY: Mainly expressed in testis. CC {ECO:0000269|PubMed:15777695}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- DISEASE: Deafness, autosomal dominant, 88 (DFNA88) [MIM:620283]: A form CC of non-syndromic, sensorineural hearing loss. Sensorineural hearing CC loss results from damage to the neural receptors of the inner ear, the CC nerve pathways to the brain, or the area of the brain that receives CC sound information. DFNA88 is characterized by postlingual, progressive CC and severe hearing loss with tinnitus. {ECO:0000269|PubMed:36048850}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAI12934.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ872185; CAI43321.1; -; Genomic_DNA. DR EMBL; AJ781169; CAG77605.1; -; mRNA. DR EMBL; AC104336; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC067734; AAH67734.1; -; mRNA. DR EMBL; BC112933; AAI12934.1; ALT_INIT; mRNA. DR CCDS; CCDS41305.1; -. [Q5JZY3-1] DR CCDS; CCDS425.1; -. [Q5JZY3-2] DR RefSeq; NP_001092909.1; NM_001099439.2. [Q5JZY3-1] DR RefSeq; NP_775912.2; NM_173641.3. [Q5JZY3-2] DR AlphaFoldDB; Q5JZY3; -. DR SMR; Q5JZY3; -. DR BioGRID; 129927; 85. DR FunCoup; Q5JZY3; 264. DR IntAct; Q5JZY3; 84. DR STRING; 9606.ENSP00000362139; -. DR ChEMBL; CHEMBL2363043; -. DR GlyCosmos; Q5JZY3; 2 sites, No reported glycans. DR GlyGen; Q5JZY3; 2 sites. DR iPTMnet; Q5JZY3; -. DR PhosphoSitePlus; Q5JZY3; -. DR BioMuta; EPHA10; -. DR DMDM; 476007830; -. DR jPOST; Q5JZY3; -. DR MassIVE; Q5JZY3; -. DR PaxDb; 9606-ENSP00000362139; -. DR PeptideAtlas; Q5JZY3; -. DR ProteomicsDB; 63538; -. [Q5JZY3-1] DR ProteomicsDB; 63539; -. [Q5JZY3-2] DR ProteomicsDB; 63540; -. [Q5JZY3-3] DR Antibodypedia; 51311; 274 antibodies from 31 providers. DR DNASU; 284656; -. DR Ensembl; ENST00000319637.6; ENSP00000316395.6; ENSG00000183317.18. [Q5JZY3-2] DR Ensembl; ENST00000373048.9; ENSP00000362139.4; ENSG00000183317.18. [Q5JZY3-1] DR GeneID; 284656; -. DR KEGG; hsa:284656; -. DR MANE-Select; ENST00000373048.9; ENSP00000362139.4; NM_001099439.2; NP_001092909.1. DR UCSC; uc001cbw.5; human. [Q5JZY3-1] DR AGR; HGNC:19987; -. DR ClinPGx; PA134938798; -. DR CTD; 284656; -. DR DisGeNET; 284656; -. DR GeneCards; EPHA10; -. DR HGNC; HGNC:19987; EPHA10. DR HPA; ENSG00000183317; Tissue enhanced (brain, intestine, testis). DR MalaCards; EPHA10; -. DR MIM; 611123; gene. DR MIM; 620283; phenotype. DR OpenTargets; ENSG00000183317; -. DR VEuPathDB; HostDB:ENSG00000183317; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160752; -. DR HOGENOM; CLU_000288_141_4_1; -. DR InParanoid; Q5JZY3; -. DR OMA; ATQLVCM; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q5JZY3; 8 GO annotations based on evolutionary models. DR PathwayCommons; Q5JZY3; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; Q5JZY3; -. DR SIGNOR; Q5JZY3; -. DR Agora; ENSG00000183317; -. DR BioGRID-ORCS; 284656; 11 hits in 1186 CRISPR screens. DR ChiTaRS; EPHA10; human. DR GeneWiki; EPHA10; -. DR GenomeRNAi; 284656; -. DR Pharos; Q5JZY3; Tbio. DR PRO; PR:Q5JZY3; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q5JZY3; protein. DR Bgee; ENSG00000183317; Expressed in sperm and 129 other cell types or tissues. DR ExpressionAtlas; Q5JZY3; baseline and differential. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; IBA:GO_Central. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IBA:GO_Central. DR CDD; cd10487; EphR_LBD_A10; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05064; PTKc_EphR_A10; 1. DR FunFam; 1.10.510.10:FF:000360; Ephrin type-A receptor 10; 1. DR FunFam; 2.60.40.10:FF:001125; Ephrin type-A receptor 10; 1. DR FunFam; 1.10.150.50:FF:000066; ephrin type-A receptor 10; 1. DR FunFam; 3.30.200.20:FF:000505; ephrin type-A receptor 10; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF16; EPHRIN TYPE-A RECEPTOR 10; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF07647; SAM_2; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell membrane; Deafness; Glycoprotein; KW Kinase; Membrane; Non-syndromic deafness; Nucleotide-binding; KW Proteomics identification; Receptor; Reference proteome; Repeat; Secreted; KW Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase. FT SIGNAL 1..33 FT /evidence="ECO:0000255" FT CHAIN 34..1008 FT /note="Ephrin type-A receptor 10" FT /id="PRO_0000042157" FT TOPO_DOM 34..565 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 566..586 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 587..1008 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 35..216 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 340..452 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 456..554 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 645..900 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 933..997 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 322..342 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 311 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 486 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 284..295 FT /note="ACPPGFYKVSPR -> GIQLAGGRGVGV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:15777695" FT /id="VSP_015772" FT VAR_SEQ 296..1008 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:15777695" FT /id="VSP_015773" FT VAR_SEQ 889..892 FT /note="ERPR -> LPPH (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_015774" FT VAR_SEQ 893..1008 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_015775" FT VARIANT 103 FT /note="V -> L (in dbSNP:rs34557762)" FT /id="VAR_055992" FT VARIANT 150 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs771803475)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042159" FT VARIANT 220 FT /note="T -> K (in dbSNP:rs56276182)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042160" FT VARIANT 281 FT /note="F -> I (in dbSNP:rs4653328)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042161" FT VARIANT 629 FT /note="L -> P (in dbSNP:rs17511304)" FT /id="VAR_055993" FT VARIANT 630 FT /note="L -> P (in dbSNP:rs1645827659)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042162" FT VARIANT 645 FT /note="V -> I (in dbSNP:rs12405650)" FT /id="VAR_055994" FT VARIANT 749 FT /note="G -> E (in dbSNP:rs6671088)" FT /id="VAR_055995" FT VARIANT 775 FT /note="H -> R (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042163" FT VARIANT 807 FT /note="R -> Q (in dbSNP:rs6670599)" FT /id="VAR_055996" FT VARIANT 956 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042164" FT CONFLICT 458 FT /note="D -> G (in Ref. 1; CAI43321)" FT /evidence="ECO:0000305" FT CONFLICT 503 FT /note="T -> A (in Ref. 1; CAI43321)" FT /evidence="ECO:0000305" SQ SEQUENCE 1008 AA; 109716 MW; 82D60740B7B6B9BD CRC64; METCAGPHPL RLFLCRMQLC LALLLGPWRP GTAEEVILLD SKASQAELGW TALPSNGWEE ISGVDEHDRP IRTYQVCNVL EPNQDNWLQT GWISRGRGQR IFVELQFTLR DCSSIPGAAG TCKETFNVYY LETEADLGRG RPRLGGSRPR KIDTIAADES FTQGDLGERK MKLNTEVREI GPLSRRGFHL AFQDVGACVA LVSVRVYYKQ CRATVRGLAT FPATAAESAF STLVEVAGTC VAHSEGEPGS PPRMHCGADG EWLVPVGRCS CSAGFQERGD FCEACPPGFY KVSPRRPLCS PCPEHSRALE NASTFCVCQD SYARSPTDPP SASCTRPPSA PRDLQYSLSR SPLVLRLRWL PPADSGGRSD VTYSLLCLRC GREGPAGACE PCGPRVAFLP RQAGLRERAA TLLHLRPGAR YTVRVAALNG VSGPAAAAGT TYAQVTVSTG PGAPWEEDEI RRDRVEPQSV SLSWREPIPA GAPGANDTEY EIRYYEKGQS EQTYSMVKTG APTVTVTNLK PATRYVFQIR AASPGPSWEA QSFNPSIEVQ TLGEAASGSR DQSPAIVVTV VTISALLVLG SVMSVLAIWR RPCSYGKGGG DAHDEEELYF HFKVPTRRTF LDPQSCGDLL QAVHLFAKEL DAKSVTLERS LGGGRFGELC CGCLQLPGRQ ELLVAVHMLR DSASDSQRLG FLAEALTLGQ FDHSHIVRLE GVVTRGSTLM IVTEYMSHGA LDGFLRRHEG QLVAGQLMGL LPGLASAMKY LSEMGYVHRG LAARHVLVSS DLVCKISGFG RGPRDRSEAV YTTMSGRSPA LWAAPETLQF GHFSSASDVW SFGIIMWEVM AFGERPYWDM SGQDVIKAVE DGFRLPPPRN CPNLLHRLML DCWQKDPGER PRFSQIHSIL SKMVQDPEPP KCALTTCPRP PTPLADRAFS TFPSFGSVGA WLEALDLCRY KDSFAAAGYG SLEAVAEMTA QDLVSLGISL AEHREALLSG ISALQARVLQ LQGQGVQV // ID EPHB1_HUMAN Reviewed; 984 AA. AC P54762; A8K593; B3KTB2; B5A969; O43569; O95142; O95143; Q0VG87; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1996, sequence version 1. DT 28-JAN-2026, entry version 236. DE RecName: Full=Ephrin type-B receptor 1; DE EC=2.7.10.1; DE AltName: Full=ELK; DE AltName: Full=EPH tyrosine kinase 2; DE AltName: Full=EPH-like kinase 6; DE Short=EK6; DE Short=hEK6; DE AltName: Full=Neuronally-expressed EPH-related tyrosine kinase; DE Short=NET; DE AltName: Full=Tyrosine-protein kinase receptor EPH-2; DE Flags: Precursor; GN Name=EPHB1; Synonyms=ELK, EPHT2, HEK6, NET; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=8666391; DOI=10.1006/geno.1995.9985; RA Tang X.X., Biegel J.A., Nycum L.M., Yoshioka A., Brodeur G.M., RA Pleasure D.E., Ikegaki N.; RT "cDNA cloning, molecular characterization, and chromosomal localization of RT NET(EPHT2), a human EPH-related receptor protein-tyrosine kinase gene RT preferentially expressed in brain."; RL Genomics 29:426-437(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CELL ADHESION, FUNCTION RP IN JUN CASCADE ACTIVATION, INTERACTION WITH NCK1, MUTAGENESIS OF TYR-594 RP AND LYS-651, AND VARIANT TRP-973. RC TISSUE=Kidney; RX PubMed=9430661; DOI=10.1074/jbc.273.3.1303; RA Stein E., Huynh-Do U., Lane A.A., Cerretti D.P., Daniel T.O.; RT "Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to RT c-Jun kinase."; RL J. Biol. Chem. 273:1303-1308(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 18-32. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [8] RP INTERACTION WITH GRB2 AND GRB10, MUTAGENESIS OF TYR-928, AND RP PHOSPHORYLATION AT TYR-928. RX PubMed=8798570; DOI=10.1074/jbc.271.38.23588; RA Stein E., Cerretti D.P., Daniel T.O.; RT "Ligand activation of ELK receptor tyrosine kinase promotes its association RT with Grb10 and Grb2 in vascular endothelial cells."; RL J. Biol. Chem. 271:23588-23593(1996). RN [9] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [10] RP FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, INTERACTION WITH ACP1, RP AND MUTAGENESIS OF TYR-928. RX PubMed=9499402; DOI=10.1101/gad.12.5.667; RA Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., RA Van Etten R.L., Daniel T.O.; RT "Eph receptors discriminate specific ligand oligomers to determine RT alternative signaling complexes, attachment, and assembly responses."; RL Genes Dev. 12:667-678(1998). RN [11] RP INTERACTION WITH EPHB6. RX PubMed=11713248; DOI=10.1074/jbc.m108011200; RA Freywald A., Sharfe N., Roifman C.M.; RT "The kinase-null EphB6 receptor undergoes transphosphorylation in a complex RT with EphB1."; RL J. Biol. Chem. 277:3823-3828(2002). RN [12] RP INTERACTION WITH GRB7, FUNCTION, PHOSPHORYLATION AT TYR-928, AND RP MUTAGENESIS OF TYR-928. RX PubMed=12223469; DOI=10.1074/jbc.m203165200; RA Han D.C., Shen T.L., Miao H., Wang B., Guan J.L.; RT "EphB1 associates with Grb7 and regulates cell migration."; RL J. Biol. Chem. 277:45655-45661(2002). RN [13] RP FUNCTION IN CELL MIGRATION, FUNCTION IN ERK CASCADE ACTIVATION, INTERACTION RP WITH GRB2; SHC1 AND SRC, AND MUTAGENESIS OF TYR-600 AND TYR-778. RX PubMed=12925710; DOI=10.1083/jcb.200302073; RA Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.; RT "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote RT chemotaxis."; RL J. Cell Biol. 162:661-671(2003). RN [14] RP FUNCTION IN ERK CASCADE ACTIVATION, UBIQUITINATION BY CBL, INTERACTION WITH RP CBL, MUTAGENESIS OF LYS-651, AUTOPHOSPHORYLATION, IDENTIFICATION OF EFNB1 RP AS LIGAND, AND SUBCELLULAR LOCATION. RX PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x; RA Fasen K., Cerretti D.P., Huynh-Do U.; RT "Ligand binding induces Cbl-dependent EphB1 receptor degradation through RT the lysosomal pathway."; RL Traffic 9:251-266(2008). RN [15] RP STRUCTURE BY NMR OF 899-984. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C-terminal SAM-domain of mouse ephrin type-B RT receptor 1 precursor (EC 2.7.1.112)."; RL Submitted (JUL-2007) to the PDB data bank. RN [16] RP STRUCTURE BY NMR OF 434-528. RG RIKEN structural genomics initiative (RSGI); RT "Solution structures of the FN3 domain of human ephrin type-B receptor 1."; RL Submitted (FEB-2009) to the PDB data bank. RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-18; MET-387; THR-707; VAL-719; GLN-743; RP THR-912 AND MET-981. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Cognate/functional CC ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During CC nervous system development, regulates retinal axon guidance redirecting CC ipsilaterally ventrotemporal retinal ganglion cells axons at the optic CC chiasm midline. This probably requires repulsive interaction with CC EFNB2. In the adult nervous system together with EFNB3, regulates CC chemotaxis, proliferation and polarity of the hippocampus neural CC progenitors. In addition to its role in axon guidance also plays an CC important redundant role with other ephrin-B receptors in development CC and maturation of dendritic spines and synapse formation. May also CC regulate angiogenesis. More generally, may play a role in targeted cell CC migration and adhesion. Upon activation by EFNB1 and probably other CC ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades CC to regulate cell migration and adhesion respectively. Involved in the CC maintenance of the pool of satellite cells (muscle stem cells) by CC promoting their self-renewal and reducing their activation and CC differentiation (By similarity). {ECO:0000250|UniProtKB:Q8CBF3, CC ECO:0000269|PubMed:12223469, ECO:0000269|PubMed:12925710, CC ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:9430661, CC ECO:0000269|PubMed:9499402}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts with EPHB6; transphosphorylates EPHB6 to form an active CC signaling complex. Interacts with PICK1 (By similarity). Interacts CC (through Tyr-594) with NCK1 (via SH2 domain); activates the JUN cascade CC to regulate cell adhesion (By similarity). The ligand-activated form CC interacts (through Tyr-928) with GRB7 and GRB10 (via SH2 domains). The CC ligand-activated form interacts (residues within the catalytic domain) CC with GRB2 (via SH2 domain). Interacts with GRB2, SHC1 and SRC; CC activates the MAPK/ERK cascade to regulate cell migration. Interacts CC with CBL; regulates receptor degradation through ubiquitination. CC Interacts with ACP1. {ECO:0000250|UniProtKB:Q8CBF3, CC ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:12223469, CC ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:18034775, CC ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9430661, CC ECO:0000269|PubMed:9499402}. CC -!- INTERACTION: CC P54762; Q13322: GRB10; NbExp=2; IntAct=EBI-80252, EBI-80275; CC P54762; P62993: GRB2; NbExp=2; IntAct=EBI-80252, EBI-401755; CC P54762; Q14451: GRB7; NbExp=4; IntAct=EBI-80252, EBI-970191; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18034775}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:18034775}. CC Early endosome membrane {ECO:0000269|PubMed:18034775}. Cell projection, CC dendrite {ECO:0000250|UniProtKB:Q8CBF3}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P54762-1; Sequence=Displayed; CC Name=2; CC IsoId=P54762-5; Sequence=VSP_056017; CC Name=3; CC IsoId=P54762-6; Sequence=VSP_056018, VSP_056019; CC -!- TISSUE SPECIFICITY: Preferentially expressed in brain. CC -!- PTM: Phosphorylated. Autophosphorylation is stimulated by the ligand CC EFNB1. Required for interaction with SH2 domain-containing interactors, CC for activation of the MAPK/ERK and JUN signaling cascades and for CC ubiquitination by CBL. {ECO:0000269|PubMed:12223469, CC ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:8798570}. CC -!- PTM: Ubiquitinated; (EFNB1)ligand-induced poly- and/or multi- CC ubiquitination by CBL is regulated by SRC and leads to lysosomal CC degradation. {ECO:0000269|PubMed:18034775}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB94627.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305}; CC Sequence=AAB94628.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305}; CC Sequence=AAD02031.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L40636; AAB08520.1; -; mRNA. DR EMBL; AF037331; AAD02030.1; -; mRNA. DR EMBL; AF037332; AAD02031.1; ALT_SEQ; mRNA. DR EMBL; AF037333; AAB94627.1; ALT_SEQ; mRNA. DR EMBL; AF037334; AAB94628.1; ALT_SEQ; mRNA. DR EMBL; EU826607; ACF47643.1; -; mRNA. DR EMBL; AK095305; BAG53024.1; -; mRNA. DR EMBL; AK291208; BAF83897.1; -; mRNA. DR EMBL; AC016931; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC016951; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC063918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC073244; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092969; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC111744; AAI11745.1; -; mRNA. DR CCDS; CCDS46921.1; -. [P54762-1] DR RefSeq; NP_004432.1; NM_004441.5. [P54762-1] DR PDB; 2DJS; NMR; -; A=434-528. DR PDB; 2EAO; NMR; -; A=899-984. DR PDB; 3ZFX; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I=602-896. DR PDB; 5MJA; X-ray; 2.14 A; A/B=602-896. DR PDB; 5MJB; X-ray; 2.23 A; A/B=602-896. DR PDB; 6UMW; X-ray; 1.98 A; A=602-896. DR PDB; 7KPL; X-ray; 2.71 A; A=611-889. DR PDB; 7KPM; X-ray; 1.61 A; A=611-889. DR PDBsum; 2DJS; -. DR PDBsum; 2EAO; -. DR PDBsum; 3ZFX; -. DR PDBsum; 5MJA; -. DR PDBsum; 5MJB; -. DR PDBsum; 6UMW; -. DR PDBsum; 7KPL; -. DR PDBsum; 7KPM; -. DR AlphaFoldDB; P54762; -. DR SMR; P54762; -. DR BioGRID; 108361; 30. DR FunCoup; P54762; 1441. DR IntAct; P54762; 45. DR MINT; P54762; -. DR STRING; 9606.ENSP00000381097; -. DR BindingDB; P54762; -. DR ChEMBL; CHEMBL5072; -. DR DrugBank; DB09093; Chlortetracycline. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P54762; -. DR GuidetoPHARMACOLOGY; 1830; -. DR GlyCosmos; P54762; 3 sites, No reported glycans. DR GlyGen; P54762; 4 sites, 1 N-linked glycan (1 site). DR iPTMnet; P54762; -. DR PhosphoSitePlus; P54762; -. DR SwissPalm; P54762; -. DR BioMuta; EPHB1; -. DR DMDM; 1706663; -. DR CPTAC; CPTAC-2920; -. DR CPTAC; CPTAC-2921; -. DR jPOST; P54762; -. DR MassIVE; P54762; -. DR PaxDb; 9606-ENSP00000381097; -. DR PeptideAtlas; P54762; -. DR ProteomicsDB; 3673; -. DR ProteomicsDB; 56716; -. [P54762-1] DR Antibodypedia; 33398; 561 antibodies from 40 providers. DR DNASU; 2047; -. DR Ensembl; ENST00000398015.8; ENSP00000381097.3; ENSG00000154928.20. [P54762-1] DR Ensembl; ENST00000493838.1; ENSP00000419574.1; ENSG00000154928.20. [P54762-5] DR GeneID; 2047; -. DR KEGG; hsa:2047; -. DR MANE-Select; ENST00000398015.8; ENSP00000381097.3; NM_004441.5; NP_004432.1. DR UCSC; uc003eqt.4; human. [P54762-1] DR AGR; HGNC:3392; -. DR ClinPGx; PA27824; -. DR CTD; 2047; -. DR DisGeNET; 2047; -. DR GeneCards; EPHB1; -. DR HGNC; HGNC:3392; EPHB1. DR HPA; ENSG00000154928; Tissue enhanced (brain). DR MalaCards; EPHB1; -. DR MIM; 600600; gene. DR OpenTargets; ENSG00000154928; -. DR VEuPathDB; HostDB:ENSG00000154928; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000155297; -. DR HOGENOM; CLU_000288_141_0_1; -. DR InParanoid; P54762; -. DR OMA; AVAAMEX; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54762; 8 GO annotations based on evolutionary models. DR PhylomeDB; P54762; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54762; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54762; -. DR SIGNOR; P54762; -. DR Agora; ENSG00000154928; -. DR BioGRID-ORCS; 2047; 6 hits in 1191 CRISPR screens. DR ChiTaRS; EPHB1; human. DR EvolutionaryTrace; P54762; -. DR GeneWiki; EPH_receptor_B1; -. DR GenomeRNAi; 2047; -. DR Pharos; P54762; Tchem. DR PRO; PR:P54762; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P54762; protein. DR Bgee; ENSG00000154928; Expressed in cortical plate and 138 other cell types or tissues. DR ExpressionAtlas; P54762; baseline and differential. DR GO; GO:0030424; C:axon; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0032433; C:filopodium tip; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0045121; C:membrane raft; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0031589; P:cell-substrate adhesion; IDA:UniProtKB. DR GO; GO:0021952; P:central nervous system projection neuron axonogenesis; ISS:UniProtKB. DR GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0021934; P:hindbrain tangential cell migration; IEA:Ensembl. DR GO; GO:0001771; P:immunological synapse formation; IEA:Ensembl. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:1902725; P:negative regulation of satellite cell differentiation; ISS:UniProtKB. DR GO; GO:1902723; P:negative regulation of skeletal muscle satellite cell proliferation; ISS:UniProtKB. DR GO; GO:0061351; P:neural precursor cell proliferation; ISS:UniProtKB. DR GO; GO:0022008; P:neurogenesis; ISS:UniProtKB. DR GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; ISS:UniProtKB. DR GO; GO:0014719; P:skeletal muscle satellite cell activation; ISS:UniProtKB. DR CDD; cd10476; EphR_LBD_B1; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09551; SAM_EPH-B1; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000004; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.40.10:FF:000110; Ephrin type-B receptor 2; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034231; EphB1_rcpt_lig-bd. DR InterPro; IPR042819; EphB1_SAM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF17; EPHRIN TYPE-B RECEPTOR 1; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Cell projection; Direct protein sequencing; Endosome; KW Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..17 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 18..984 FT /note="Ephrin type-B receptor 1" FT /id="PRO_0000016824" FT TOPO_DOM 18..540 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 541..563 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 564..984 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 19..201 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 322..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 433..528 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 619..882 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 911..975 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 982..984 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 744 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 625..633 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 651 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 600 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:P54753" FT MOD_RES 928 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 334 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 426 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 480 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..439 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056017" FT VAR_SEQ 158..242 FT /note="VNTEVRSFGPLTRNGFYLAFQDYGACMSLLSVRVFFKKCPSIVQNFAVFPET FT MTGAESTSLVIARGTCIPNAEEVDVPIKLYCNG -> LALQGHSRPARKLKAAPTAPPT FT AAPLQRRLPSAPVGPVITERTLTLQKWHALASHQVPAMLSPSSMRRPSFWSGTLQGRQV FT GGMM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056018" FT VAR_SEQ 243..984 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056019" FT VARIANT 18 FT /note="M -> V (in dbSNP:rs55650774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042165" FT VARIANT 87 FT /note="T -> S (in dbSNP:rs1042794)" FT /id="VAR_011801" FT VARIANT 152 FT /note="G -> R (in dbSNP:rs1042793)" FT /id="VAR_011802" FT VARIANT 367 FT /note="R -> G (in dbSNP:rs1042789)" FT /id="VAR_011803" FT VARIANT 387 FT /note="T -> M (in dbSNP:rs56396912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042166" FT VARIANT 485 FT /note="R -> S (in dbSNP:rs1042788)" FT /id="VAR_011804" FT VARIANT 707 FT /note="S -> T (in an ovarian undifferentiated carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042167" FT VARIANT 719 FT /note="I -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042168" FT VARIANT 743 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1338928289)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042169" FT VARIANT 847 FT /note="M -> T (in dbSNP:rs1042785)" FT /id="VAR_011805" FT VARIANT 912 FT /note="A -> T (in dbSNP:rs56345346)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042170" FT VARIANT 973 FT /note="R -> W (in dbSNP:rs1042784)" FT /evidence="ECO:0000269|PubMed:9430661" FT /id="VAR_058479" FT VARIANT 981 FT /note="T -> M (in dbSNP:rs56186270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042171" FT MUTAGEN 594 FT /note="Y->F: Loss of interaction with NCK1." FT /evidence="ECO:0000269|PubMed:9430661" FT MUTAGEN 600 FT /note="Y->F: Loss of interaction with SHC1 and SRC." FT /evidence="ECO:0000269|PubMed:12925710" FT MUTAGEN 651 FT /note="K->R: Kinase-dead mutant. Unable to FT autophosphorylate, to interact with SH2 domain-containing FT interactors, to activate the MAPK/ERK and JUN signaling FT cascades. Not ubiquitinated by CBL." FT /evidence="ECO:0000269|PubMed:18034775, FT ECO:0000269|PubMed:9430661" FT MUTAGEN 778 FT /note="Y->F: Loss of interaction with SHC1." FT /evidence="ECO:0000269|PubMed:12925710" FT MUTAGEN 928 FT /note="Y->F: Disrupts binding with the GRB10 SH2 domain, FT providing evidence for phosphorylation. Disrupts FT interaction with GRB7 and ACP1." FT /evidence="ECO:0000269|PubMed:12223469, FT ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9499402" FT CONFLICT 12 FT /note="A -> E (in Ref. 2; AAD02030/AAB94627/AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 185 FT /note="S -> I (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 274 FT /note="T -> R (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 336 FT /note="T -> S (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 752 FT /note="V -> L (in Ref. 6; AAI11745)" FT /evidence="ECO:0000305" FT CONFLICT 813 FT /note="V -> H (in Ref. 2; AAD02030/AAB94627)" FT /evidence="ECO:0000305" FT CONFLICT 819 FT /note="S -> Y (in Ref. 2; AAD02030/AAB94627)" FT /evidence="ECO:0000305" FT CONFLICT 881 FT /note="M -> I (in Ref. 4; BAF83897)" FT /evidence="ECO:0000305" FT CONFLICT 903 FT /note="L -> H (in Ref. 4; BAF83897)" FT /evidence="ECO:0000305" FT STRAND 441..445 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 447..453 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 464..473 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 482..495 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 501..512 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 514..517 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 521..524 FT /evidence="ECO:0007829|PDB:2DJS" FT HELIX 616..618 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 619..627 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 632..638 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 646..652 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 659..673 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 683..687 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 689..692 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 694..698 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 705..710 FT /evidence="ECO:0007829|PDB:7KPM" FT TURN 711..714 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 718..737 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 747..749 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 758..760 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 783..786 FT /evidence="ECO:0007829|PDB:5MJB" FT HELIX 788..790 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 793..798 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 803..818 FT /evidence="ECO:0007829|PDB:7KPM" FT TURN 824..827 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 830..838 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 851..860 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 865..867 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 871..883 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 885..887 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 889..891 FT /evidence="ECO:0007829|PDB:3ZFX" FT HELIX 916..921 FT /evidence="ECO:0007829|PDB:2EAO" FT TURN 922..924 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 926..928 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 929..935 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 940..943 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 948..954 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 959..975 FT /evidence="ECO:0007829|PDB:2EAO" SQ SEQUENCE 984 AA; 109885 MW; 8044160E24E93A92 CRC64; MALDYLLLLL LASAVAAMEE TLMDTRTATA ELGWTANPAS GWEEVSGYDE NLNTIRTYQV CNVFEPNQNN WLLTTFINRR GAHRIYTEMR FTVRDCSSLP NVPGSCKETF NLYYYETDSV IATKKSAFWS EAPYLKVDTI AADESFSQVD FGGRLMKVNT EVRSFGPLTR NGFYLAFQDY GACMSLLSVR VFFKKCPSIV QNFAVFPETM TGAESTSLVI ARGTCIPNAE EVDVPIKLYC NGDGEWMVPI GRCTCKPGYE PENSVACKAC PAGTFKASQE AEGCSHCPSN SRSPAEASPI CTCRTGYYRA DFDPPEVACT SVPSGPRNVI SIVNETSIIL EWHPPRETGG RDDVTYNIIC KKCRADRRSC SRCDDNVEFV PRQLGLTECR VSISSLWAHT PYTFDIQAIN GVSSKSPFPP QHVSVNITTN QAAPSTVPIM HQVSATMRSI TLSWPQPEQP NGIILDYEIR YYEKEHNEFN SSMARSQTNT ARIDGLRPGM VYVVQVRART VAGYGKFSGK MCFQTLTDDD YKSELREQLP LIAGSAAAGV VFVVSLVAIS IVCSRKRAYS KEAVYSDKLQ HYSTGRGSPG MKIYIDPFTY EDPNEAVREF AKEIDVSFVK IEEVIGAGEF GEVYKGRLKL PGKREIYVAI KTLKAGYSEK QRRDFLSEAS IMGQFDHPNI IRLEGVVTKS RPVMIITEFM ENGALDSFLR QNDGQFTVIQ LVGMLRGIAA GMKYLAEMNY VHRDLAARNI LVNSNLVCKV SDFGLSRYLQ DDTSDPTYTS SLGGKIPVRW TAPEAIAYRK FTSASDVWSY GIVMWEVMSF GERPYWDMSN QDVINAIEQD YRLPPPMDCP AALHQLMLDC WQKDRNSRPR FAEIVNTLDK MIRNPASLKT VATITAVPSQ PLLDRSIPDF TAFTTVDDWL SAIKMVQYRD SFLTAGFTSL QLVTQMTSED LLRIGITLAG HQKKILNSIH SMRVQISQSP TAMA // ID EPHB4_HUMAN Reviewed; 987 AA. AC P54760; B5A970; B5A971; B5A972; Q7Z635; Q9BTA5; Q9BXP0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 243. DE RecName: Full=Ephrin type-B receptor 4; DE EC=2.7.10.1; DE AltName: Full=Hepatoma transmembrane kinase; DE AltName: Full=Tyrosine-protein kinase TYRO11; DE Flags: Precursor; GN Name=EPHB4; Synonyms=HTK, MYK1, TYRO11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, RP AUTOPHOSPHORYLATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=8188704; DOI=10.1016/s0021-9258(17)36776-5; RA Bennett B.D., Wang Z., Kuang W.J., Wang A., Groopman J.E., Goeddel D.V., RA Scadden D.T.; RT "Cloning and characterization of HTK, a novel transmembrane tyrosine kinase RT of the EPH subfamily."; RL J. Biol. Chem. 269:14211-14218(1994). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11239002; DOI=10.1093/nar/29.6.1352; RA Wilson M.D., Riemer C., Martindale D.W., Schnupf P., Boright A.P., RA Cheung T.L., Hardy D.M., Schwartz S., Scherer S.W., Tsui L.-C., Miller W., RA Koop B.F.; RT "Comparative analysis of the gene-dense ACHE/TFR2 region on human RT chromosome 7q22 with the orthologous region on mouse chromosome 5."; RL Nucleic Acids Res. 29:1352-1365(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-162. RC TISSUE=Ovary, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=12734395; DOI=10.1242/jcs.00426; RA Fueller T., Korff T., Kilian A., Dandekar G., Augustin H.G.; RT "Forward EphB4 signaling in endothelial cells controls cellular repulsion RT and segregation from ephrinB2 positive cells."; RL J. Cell Sci. 116:2461-2470(2003). RN [7] RP FUNCTION IN ANGIOGENESIS. RX PubMed=16424904; DOI=10.1038/sj.emboj.7600949; RA Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J., RA Hammes H.P., Grobholz R., Ullrich A., Vajkoczy P.; RT "EphB4 controls blood vascular morphogenesis during postnatal RT angiogenesis."; RL EMBO J. 25:628-641(2006). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-976, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911; THR-976 AND TYR-987, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-769; SER-770 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-943, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 17-196 IN COMPLEX WITH EFNB2, RP MUTAGENESIS OF LEU-95, AND DISULFIDE BOND. RX PubMed=16867992; DOI=10.1074/jbc.m605766200; RA Chrencik J.E., Brooun A., Kraus M.L., Recht M.I., Kolatkar A.R., Han G.W., RA Seifert J.M., Widmer H., Auer M., Kuhn P.; RT "Structural and biophysical characterization of the EphB4*ephrinB2 protein- RT protein interaction and receptor specificity."; RL J. Biol. Chem. 281:28185-28192(2006). RN [16] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 17-196 IN COMPLEX WITH RP ANTAGONISTIC PEPTIDE, AND DISULFIDE BOND. RX PubMed=16472751; DOI=10.1016/j.str.2005.11.011; RA Chrencik J.E., Brooun A., Recht M.I., Kraus M.L., Koolpe M., Kolatkar A.R., RA Bruce R.H., Martiny-Baron G., Widmer H., Pasquale E.B., Kuhn P.; RT "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 RT antagonist peptide complex reveals the determinants for receptor RT specificity."; RL Structure 14:321-330(2006). RN [17] RP STRUCTURE BY NMR OF 434-529. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain from human ephrin type-B RT receptor 4."; RL Submitted (JUL-2007) to the PDB data bank. RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-67; ILE-113; LEU-346; VAL-371; GLU-576; RP HIS-678; THR-882; TRP-889 AND ASP-890. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [19] RP INVOLVEMENT IN LMPHM7, VARIANTS LMPHM7 GLN-739 AND SER-782, RP CHARACTERIZATION OF VARIANTS LMPHM7 GLU-739 AND SER-782, AND FUNCTION. RX PubMed=27400125; DOI=10.1172/jci85794; RA Martin-Almedina S., Martinez-Corral I., Holdhus R., Vicente A., Fotiou E., RA Lin S., Petersen K., Simpson M.A., Hoischen A., Gilissen C., Jeffery H., RA Atton G., Karapouliou C., Brice G., Gordon K., Wiseman J.W., Wedin M., RA Rockson S.G., Jeffery S., Mortimer P.S., Snyder M.P., Berland S., RA Mansour S., Makinen T., Ostergaard P.; RT "EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic- RT related hydrops fetalis."; RL J. Clin. Invest. 126:3080-3088(2016). RN [20] RP VARIANTS CMAVM2 LYS-59; PRO-74; TYR-115 DEL; 130-TRP--TYR-987 DEL; RP 161-VAL-LYS-162 DELINS LEU; PRO-187; 244-GLN--TYR-987 DEL; ARG-268; RP 352-ARG--TYR-987 DEL; 375-GLY--TYR-987 DEL; 431-ARG--TYR-987 DEL; GLY-469; RP ARG-516; 520-GLN--TYR-987 DEL; 596-TYR--TYR-987 DEL; TRP-656; LYS-664; RP THR-725; 739-ARG--TYR-987 DEL; ASP-745; ARG-789; SER-789; 806-TYR--TYR-987 RP DEL; ARG-807; LEU-820; THR-820; TRP-838; ARG-845; TYR-856; TRP-864 AND RP PRO-874, CHARACTERIZATION OF VARIANTS CMAVM2 LYS-664; TRP-838; ARG-845 AND RP TRP-864, INVOLVEMENT IN CMAVM2, AND SUBCELLULAR LOCATION. RX PubMed=28687708; DOI=10.1161/circulationaha.116.026886; RA Amyere M., Revencu N., Helaers R., Pairet E., Baselga E., Cordisco M., RA Chung W., Dubois J., Lacour J.P., Martorell L., Mazereeuw-Hautier J., RA Pyeritz R.E., Amor D.J., Bisdorff A., Blei F., Bombei H., Dompmartin A., RA Brooks D., Dupont J., Gonzalez-Ensenat M.A., Frieden I., Gerard M., RA Kvarnung M., Hanson-Kahn A.K., Hudgins L., Leaute-Labreze C., McCuaig C., RA Metry D., Parent P., Paul C., Petit F., Phan A., Quere I., Salhi A., RA Turner A., Vabres P., Vicente A., Wargon O., Watanabe S., Weibel L., RA Wilson A., Willing M., Mulliken J.B., Boon L.M., Vikkula M.; RT "Germline loss-of-function mutations in EPHB4 cause a second form of RT capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RT RAS-MAPK signaling."; RL Circulation 136:1037-1048(2017). RN [21] RP VARIANT CMAVM2 GLY-802, AND INVOLVEMENT IN CMAVM2. RX PubMed=28730721; DOI=10.1111/pde.13208; RA Yu J., Streicher J.L., Medne L., Krantz I.D., Yan A.C.; RT "EPHB4 mutation implicated in capillary malformation-arteriovenous RT malformation syndrome: A case report."; RL Pediatr. Dermatol. 34:E227-E230(2017). RN [22] RP VARIANTS CMAVM2 ARG-107 AND GLU-870, AND INVOLVEMENT IN CMAVM2. RX PubMed=29444212; DOI=10.1093/brain/awy020; RA Vivanti A., Ozanne A., Grondin C., Saliou G., Quevarec L., Maurey H., RA Aubourg P., Benachi A., Gut M., Gut I., Martinovic J., Senat M.V., Tawk M., RA Melki J.; RT "Loss of function mutations in EPHB4 are responsible for vein of Galen RT aneurysmal malformation."; RL Brain 141:979-988(2018). RN [23] RP VARIANT GLY-509, CHARACTERIZATION OF VARIANT GLY-509, VARIANTS CMAVM2 RP ASN-650 AND LEU-867, CHARACTERIZATION OF VARIANTS CMAVM2 ASN-650 AND RP LEU-867, INVOLVEMENT IN CMAVM2, FUNCTION, AND INTERACTION WITH RASA1. RX PubMed=30578106; DOI=10.1016/j.neuron.2018.11.041; RA Duran D., Zeng X., Jin S.C., Choi J., Nelson-Williams C., Yatsula B., RA Gaillard J., Furey C.G., Lu Q., Timberlake A.T., Dong W., Sorscher M.A., RA Loring E., Klein J., Allocco A., Hunt A., Conine S., Karimy J.K., RA Youngblood M.W., Zhang J., DiLuna M.L., Matouk C.C., Mane S., RA Tikhonova I.R., Castaldi C., Lopez-Giraldez F., Knight J., Haider S., RA Soban M., Alper S.L., Komiyama M., Ducruet A.F., Zabramski J.M., Dardik A., RA Walcott B.P., Stapleton C.J., Aagaard-Kienitz B., Rodesch G., Jackson E., RA Smith E.R., Orbach D.B., Berenstein A., Bilguvar K., Vikkula M., Gunel M., RA Lifton R.P., Kahle K.T.; RT "Mutations in chromatin modifier and ephrin signaling genes in vein of RT Galen malformation."; RL Neuron 101:429-443(2019). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Together with its CC cognate ligand/functional ligand EFNB2 it is involved in the regulation CC of cell adhesion and migration, and plays a central role in heart CC morphogenesis, angiogenesis and blood vessel remodeling and CC permeability. EPHB4-mediated forward signaling controls cellular CC repulsion and segregation from EFNB2-expressing cells. CC {ECO:0000269|PubMed:12734395, ECO:0000269|PubMed:16424904, CC ECO:0000269|PubMed:27400125, ECO:0000269|PubMed:30578106}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts with RASA1; the interaction depends on EPHB4 tyrosine- CC phosphorylation (PubMed:30578106). {ECO:0000250, CC ECO:0000269|PubMed:30578106}. CC -!- INTERACTION: CC P54760; P52799: EFNB2; NbExp=7; IntAct=EBI-702121, EBI-7532268; CC P54760; P54756: EPHA5; NbExp=2; IntAct=EBI-702121, EBI-1383718; CC P54760; Q9UF33: EPHA6; NbExp=2; IntAct=EBI-702121, EBI-3950019; CC P54760; Q15375: EPHA7; NbExp=3; IntAct=EBI-702121, EBI-1383428; CC P54760; P01588: EPO; NbExp=6; IntAct=EBI-702121, EBI-1027362; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28687708, CC ECO:0000269|PubMed:8188704}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:8188704}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P54760-1; Sequence=Displayed; CC Name=2; CC IsoId=P54760-2; Sequence=VSP_056024, VSP_056025; CC Name=3; CC IsoId=P54760-3; Sequence=VSP_056020, VSP_056021; CC Name=4; CC IsoId=P54760-4; Sequence=VSP_056022, VSP_056023; CC -!- TISSUE SPECIFICITY: Abundantly expressed in placenta but also detected CC in kidney, liver, lung, pancreas, skeletal muscle and heart. Expressed CC in primitive and myeloid, but not lymphoid, hematopoietic cells. Also CC observed in cell lines derived from liver, breast, colon, lung, CC melanocyte and cervix. {ECO:0000269|PubMed:8188704}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal heart, lung, liver and to a CC lower extent in brain. Not expressed in adult brain. CC {ECO:0000269|PubMed:8188704}. CC -!- PTM: Phosphorylated; autophosphorylation is stimulated by EFNB2. CC -!- DISEASE: Lymphatic malformation 7 (LMPHM7) [MIM:617300]: A form of CC primary lymphedema, a disease characterized by swelling of body parts CC due to developmental anomalies and functional defects of the lymphatic CC system. Patients with lymphedema may suffer from recurrent local CC infections. LMPHM7 is an autosomal dominant form with variable CC expressivity. Some individuals present with severe non-immune hydrops CC fetalis, which may cause perinatal demise or fully resolve after the CC neonatal period. Others present with no edema and have milder clinical CC features, such as atrial septal defect or varicose veins as adults. CC {ECO:0000269|PubMed:27400125}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Capillary malformation-arteriovenous malformation 2 (CMAVM2) CC [MIM:618196]: An autosomal dominant disorder characterized by multiple, CC round to oval or more irregularly shaped macules that are pinkish red CC in color and are randomly distributed across the body. These capillary CC malformations are associated with either arteriovenous malformation, CC arteriovenous fistula, or Parkes Weber syndrome. CC {ECO:0000269|PubMed:28687708, ECO:0000269|PubMed:28730721, CC ECO:0000269|PubMed:29444212, ECO:0000269|PubMed:30578106}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07695; AAA20598.1; -; mRNA. DR EMBL; AF312032; AAK21010.1; -; Genomic_DNA. DR EMBL; EU826608; ACF47644.1; -; mRNA. DR EMBL; EU826609; ACF47645.1; -; mRNA. DR EMBL; EU826610; ACF47646.1; -; mRNA. DR EMBL; BC004264; AAH04264.1; -; mRNA. DR EMBL; BC052804; AAH52804.1; -; mRNA. DR CCDS; CCDS5706.1; -. [P54760-1] DR PIR; A54092; A54092. DR RefSeq; NP_004435.3; NM_004444.4. [P54760-1] DR PDB; 2BBA; X-ray; 1.65 A; A=17-196. DR PDB; 2E7H; NMR; -; A=434-529. DR PDB; 2HLE; X-ray; 2.05 A; A=17-196. DR PDB; 2QKQ; X-ray; 2.10 A; A/B=896-977. DR PDB; 2VWU; X-ray; 2.00 A; A=598-899. DR PDB; 2VWV; X-ray; 1.90 A; A=598-899. DR PDB; 2VWW; X-ray; 1.90 A; A=598-899. DR PDB; 2VWX; X-ray; 1.65 A; A=598-899. DR PDB; 2VWY; X-ray; 1.65 A; A=598-899. DR PDB; 2VWZ; X-ray; 1.65 A; A=598-899. DR PDB; 2VX0; X-ray; 2.10 A; A=598-899. DR PDB; 2VX1; X-ray; 1.65 A; A=598-899. DR PDB; 2X9F; X-ray; 1.75 A; A=598-899. DR PDB; 2XVD; X-ray; 1.70 A; A=598-899. DR PDB; 2YN8; X-ray; 2.11 A; A/B=598-892. DR PDB; 3ZEW; X-ray; 2.50 A; A/B=598-892. DR PDB; 4AW5; X-ray; 2.33 A; A=605-890. DR PDB; 4BB4; X-ray; 1.65 A; A=598-899. DR PDB; 6FNI; X-ray; 1.47 A; A=598-892. DR PDB; 6FNJ; X-ray; 1.24 A; A/B=598-892. DR PDB; 6FNK; X-ray; 1.05 A; A=598-892. DR PDB; 6FNL; X-ray; 1.27 A; A=598-892. DR PDB; 6FNM; X-ray; 1.16 A; A=598-892. DR PDBsum; 2BBA; -. DR PDBsum; 2E7H; -. DR PDBsum; 2HLE; -. DR PDBsum; 2QKQ; -. DR PDBsum; 2VWU; -. DR PDBsum; 2VWV; -. DR PDBsum; 2VWW; -. DR PDBsum; 2VWX; -. DR PDBsum; 2VWY; -. DR PDBsum; 2VWZ; -. DR PDBsum; 2VX0; -. DR PDBsum; 2VX1; -. DR PDBsum; 2X9F; -. DR PDBsum; 2XVD; -. DR PDBsum; 2YN8; -. DR PDBsum; 3ZEW; -. DR PDBsum; 4AW5; -. DR PDBsum; 4BB4; -. DR PDBsum; 6FNI; -. DR PDBsum; 6FNJ; -. DR PDBsum; 6FNK; -. DR PDBsum; 6FNL; -. DR PDBsum; 6FNM; -. DR AlphaFoldDB; P54760; -. DR BMRB; P54760; -. DR SASBDB; P54760; -. DR SMR; P54760; -. DR BioGRID; 108364; 154. DR FunCoup; P54760; 1222. DR IntAct; P54760; 108. DR MINT; P54760; -. DR STRING; 9606.ENSP00000350896; -. DR BindingDB; P54760; -. DR ChEMBL; CHEMBL5147; -. DR DrugBank; DB07256; 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE. DR DrugBank; DB07252; 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07251; N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE. DR DrugBank; DB07250; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07253; N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine. DR DrugBank; DB07255; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07249; N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine. DR DrugBank; DB07254; N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE. DR DrugBank; DB11973; Tesevatinib. DR DrugCentral; P54760; -. DR GuidetoPHARMACOLOGY; 1833; -. DR TCDB; 8.A.23.1.15; the basigin (basigin) family. DR GlyConnect; 1214; 3 N-Linked glycans (1 site). DR GlyCosmos; P54760; 3 sites, 3 glycans. DR GlyGen; P54760; 4 sites, 10 N-linked glycans (3 sites). DR iPTMnet; P54760; -. DR PhosphoSitePlus; P54760; -. DR SwissPalm; P54760; -. DR BioMuta; EPHB4; -. DR DMDM; 19860819; -. DR CPTAC; CPTAC-2788; -. DR CPTAC; CPTAC-2841; -. DR CPTAC; CPTAC-2919; -. DR jPOST; P54760; -. DR MassIVE; P54760; -. DR PaxDb; 9606-ENSP00000350896; -. DR PeptideAtlas; P54760; -. DR ProteomicsDB; 56715; -. [P54760-1] DR Pumba; P54760; -. DR Antibodypedia; 4623; 752 antibodies from 43 providers. DR CPTC; P54760; 2 antibodies. DR DNASU; 2050; -. DR Ensembl; ENST00000358173.8; ENSP00000350896.3; ENSG00000196411.11. [P54760-1] DR Ensembl; ENST00000616502.4; ENSP00000482702.1; ENSG00000196411.11. [P54760-3] DR GeneID; 2050; -. DR KEGG; hsa:2050; -. DR MANE-Select; ENST00000358173.8; ENSP00000350896.3; NM_004444.5; NP_004435.3. DR UCSC; uc011kkg.2; human. [P54760-1] DR AGR; HGNC:3395; -. DR CIViC; 2050; 1 evidence item across 1 molecular profile. DR ClinPGx; PA27827; -. DR CTD; 2050; -. DR DisGeNET; 2050; -. DR GeneCards; EPHB4; -. DR GeneReviews; EPHB4; -. DR HGNC; HGNC:3395; EPHB4. DR HPA; ENSG00000196411; Low tissue specificity. DR MalaCards; EPHB4; -. DR MIM; 600011; gene. DR MIM; 617300; phenotype. DR MIM; 618196; phenotype. DR OpenTargets; ENSG00000196411; -. DR Orphanet; 693912; EPHB4-related capillary malformation-arteriovenous malformation. DR Orphanet; 568065; EPHB4-related lymphatic-related hydrops fetalis. DR Orphanet; 90186; Meige disease. DR Orphanet; 1053; Vein of Galen aneurysmal malformation. DR VEuPathDB; HostDB:ENSG00000196411; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160057; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P54760; -. DR OMA; STKCRAC; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54760; 9 GO annotations based on evolutionary models. DR PhylomeDB; P54760; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54760; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54760; -. DR SIGNOR; P54760; -. DR Agora; ENSG00000196411; -. DR BioGRID-ORCS; 2050; 13 hits in 1190 CRISPR screens. DR ChiTaRS; EPHB4; human. DR EvolutionaryTrace; P54760; -. DR GeneWiki; EPH_receptor_B4; -. DR GenomeRNAi; 2050; -. DR Pharos; P54760; Tchem. DR PRO; PR:P54760; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P54760; protein. DR Bgee; ENSG00000196411; Expressed in olfactory bulb and 209 other cell types or tissues. DR ExpressionAtlas; P54760; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001525; P:angiogenesis; IDA:UniProt. DR GO; GO:0007155; P:cell adhesion; IDA:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IDA:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB. DR CDD; cd10474; EphR_LBD_B4; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09554; SAM_EPH-B4; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000071; Ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.10:FF:000787; ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.1770:FF:000003; ephrin type-B receptor 4; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR037636; EPH-B4_SAM. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034290; EphB4_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF19; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; ATP-binding; KW Cell membrane; Developmental protein; Disease variant; Disulfide bond; KW Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Repeat; Signal; KW Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..15 FT /evidence="ECO:0000255" FT CHAIN 16..987 FT /note="Ephrin type-B receptor 4" FT /id="PRO_0000016834" FT TOPO_DOM 16..539 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 540..560 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 561..987 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 17..202 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 323..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 436..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 615..899 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 907..971 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 965..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 985..987 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT COMPBIAS 976..987 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 647 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 769 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 911 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 943 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 976 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 203 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 335 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 426 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..184 FT DISULFID 97..107 FT VAR_SEQ 270..306 FT /note="ACAQGTFKPLSGEGSCQPCPANSHSNTIGSAVCQCRV -> GRRGSQQRAVP FT EDVRKPGRAAGAEAGSQLPGAGTGAL (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056020" FT VAR_SEQ 307..987 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056021" FT VAR_SEQ 406..414 FT /note="VTALNGVSS -> YLLQCLTSG (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056022" FT VAR_SEQ 415..987 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056023" FT VAR_SEQ 507..516 FT /note="VRARSEAGYG -> RARAGGSSWP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056024" FT VAR_SEQ 517..987 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056025" FT VARIANT 59 FT /note="E -> K (in CMAVM2; uncertain significance; FT dbSNP:rs1584667224)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081689" FT VARIANT 67 FT /note="P -> L (in dbSNP:rs34653459)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042181" FT VARIANT 74 FT /note="R -> P (in CMAVM2; uncertain significance; FT dbSNP:rs61735971)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081690" FT VARIANT 107 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1562974383)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081691" FT VARIANT 113 FT /note="V -> I (in dbSNP:rs55866373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042182" FT VARIANT 115 FT /note="Missing (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081692" FT VARIANT 130..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081693" FT VARIANT 161..162 FT /note="VK -> L (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081694" FT VARIANT 162 FT /note="K -> R (in dbSNP:rs17854760)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_071163" FT VARIANT 187 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584666053)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081695" FT VARIANT 244..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081696" FT VARIANT 268 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs201816920)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081697" FT VARIANT 346 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267601191)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042183" FT VARIANT 352..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081698" FT VARIANT 371 FT /note="A -> V (in dbSNP:rs55720981)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042184" FT VARIANT 375..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081699" FT VARIANT 431..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081700" FT VARIANT 469 FT /note="V -> G (in CMAVM2; uncertain significance; FT dbSNP:rs1584662591)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081701" FT VARIANT 509 FT /note="A -> G (does not affect tyrosine phosphorylation; FT does not affect interaction with RASA1; dbSNP:rs146937374)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081702" FT VARIANT 516 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs776305185)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081703" FT VARIANT 520..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081704" FT VARIANT 576 FT /note="D -> E (in dbSNP:rs36050247)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042185" FT VARIANT 596..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081705" FT VARIANT 650 FT /note="K -> N (in CMAVM2; highly decreased tyrosine FT phosphorylation; highly decreased interaction with RASA1; FT dbSNP:rs1584658113)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081706" FT VARIANT 656 FT /note="R -> W (in CMAVM2; uncertain significance; FT dbSNP:rs745584371)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081707" FT VARIANT 664 FT /note="E -> K (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1562969219)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081708" FT VARIANT 678 FT /note="R -> H (in dbSNP:rs55692440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042186" FT VARIANT 725 FT /note="A -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1159930961)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081709" FT VARIANT 739..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081710" FT VARIANT 739 FT /note="R -> Q (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519263)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078063" FT VARIANT 745 FT /note="N -> D (in CMAVM2; dbSNP:rs1584654433)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081711" FT VARIANT 782 FT /note="I -> S (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519264)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078064" FT VARIANT 789 FT /note="P -> R (in CMAVM2; uncertain significance; FT dbSNP:rs753075600)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081712" FT VARIANT 789 FT /note="P -> S (in CMAVM2; uncertain significance; FT dbSNP:rs1417508111)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081713" FT VARIANT 802 FT /note="D -> G (in CMAVM2; dbSNP:rs776410552)" FT /evidence="ECO:0000269|PubMed:28730721" FT /id="VAR_081714" FT VARIANT 806..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081715" FT VARIANT 807 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1330628156)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081716" FT VARIANT 820 FT /note="P -> L (in CMAVM2; uncertain significance; FT dbSNP:rs1584653650)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081717" FT VARIANT 820 FT /note="P -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1584653653)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081718" FT VARIANT 838 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs764827256)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081719" FT VARIANT 845 FT /note="C -> R (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1584653054)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081720" FT VARIANT 856 FT /note="C -> Y (in CMAVM2; dbSNP:rs1584653005)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081721" FT VARIANT 864 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs769965440)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081722" FT VARIANT 867 FT /note="F -> L (in CMAVM2; loss of tyrosine phosphorylation; FT loss of interaction with RASA1; dbSNP:rs1584652949)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081723" FT VARIANT 870 FT /note="V -> E (in CMAVM2; uncertain significance; FT dbSNP:rs1584652920)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081724" FT VARIANT 874 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584652900)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081725" FT VARIANT 882 FT /note="A -> T (in dbSNP:rs34918225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042187" FT VARIANT 889 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs762016655)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042188" FT VARIANT 890 FT /note="E -> D (in dbSNP:rs35638378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042189" FT MUTAGEN 95 FT /note="L->R: Reduces binding affinity for EFNB2." FT /evidence="ECO:0000269|PubMed:16867992" FT CONFLICT 62 FT /note="D -> E (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 308 FT /note="Y -> D (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 464 FT /note="V -> W (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 926..927 FT /note="ES -> AR (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT STRAND 17..22 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 23..25 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 33..36 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 43..48 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 54..61 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 70..74 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 84..95 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 109..121 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 135..142 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2HLE" FT TURN 151..153 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 154..156 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 160..166 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 171..182 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 184..196 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 449..453 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 460..462 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 466..473 FT /evidence="ECO:0007829|PDB:2E7H" FT TURN 479..481 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 482..496 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 503..510 FT /evidence="ECO:0007829|PDB:2E7H" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 615..623 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 625..634 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 637..639 FT /evidence="ECO:0007829|PDB:6FNJ" FT STRAND 642..649 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 655..668 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 679..683 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 685..694 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 701..707 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 708..710 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 761..763 FT /evidence="ECO:0007829|PDB:6FNI" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:2VWX" FT HELIX 784..786 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 789..794 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 799..814 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 815..817 FT /evidence="ECO:0007829|PDB:6FNI" FT TURN 820..823 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 826..834 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 847..856 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 861..863 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 867..879 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 881..884 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 912..918 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 922..924 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 925..930 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 936..939 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 944..950 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 955..965 FT /evidence="ECO:0007829|PDB:2QKQ" SQ SEQUENCE 987 AA; 108270 MW; 11A004622F194706 CRC64; MELRVLLCWA SLAAALEETL LNTKLETADL KWVTFPQVDG QWEELSGLDE EQHSVRTYEV CDVQRAPGQA HWLRTGWVPR RGAVHVYATL RFTMLECLSL PRAGRSCKET FTVFYYESDA DTATALTPAW MENPYIKVDT VAAEHLTRKR PGAEATGKVN VKTLRLGPLS KAGFYLAFQD QGACMALLSL HLFYKKCAQL TVNLTRFPET VPRELVVPVA GSCVVDAVPA PGPSPSLYCR EDGQWAEQPV TGCSCAPGFE AAEGNTKCRA CAQGTFKPLS GEGSCQPCPA NSHSNTIGSA VCQCRVGYFR ARTDPRGAPC TTPPSAPRSV VSRLNGSSLH LEWSAPLESG GREDLTYALR CRECRPGGSC APCGGDLTFD PGPRDLVEPW VVVRGLRPDF TYTFEVTALN GVSSLATGPV PFEPVNVTTD REVPPAVSDI RVTRSSPSSL SLAWAVPRAP SGAVLDYEVK YHEKGAEGPS SVRFLKTSEN RAELRGLKRG ASYLVQVRAR SEAGYGPFGQ EHHSQTQLDE SEGWREQLAL IAGTAVVGVV LVLVVIVVAV LCLRKQSNGR EAEYSDKHGQ YLIGHGTKVY IDPFTYEDPN EAVREFAKEI DVSYVKIEEV IGAGEFGEVC RGRLKAPGKK ESCVAIKTLK GGYTERQRRE FLSEASIMGQ FEHPNIIRLE GVVTNSMPVM ILTEFMENGA LDSFLRLNDG QFTVIQLVGM LRGIASGMRY LAEMSYVHRD LAARNILVNS NLVCKVSDFG LSRFLEENSS DPTYTSSLGG KIPIRWTAPE AIAFRKFTSA SDAWSYGIVM WEVMSFGERP YWDMSNQDVI NAIEQDYRLP PPPDCPTSLH QLMLDCWQKD RNARPRFPQV VSALDKMIRN PASLKIVARE NGGASHPLLD QRQPHYSAFG SVGEWLRAIK MGRYEESFAA AGFGSFELVS QISAEDLLRI GVTLAGHQKK ILASVQHMKS QAKPGTPGGT GGPAPQY // ID ERBB2_HUMAN Reviewed; 1255 AA. AC P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-1987, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Receptor tyrosine-protein kinase erbB-2; DE EC=2.7.10.1; DE AltName: Full=Metastatic lymph node gene 19 protein; DE Short=MLN 19; DE AltName: Full=Proto-oncogene Neu; DE AltName: Full=Proto-oncogene c-ErbB-2; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER2; DE AltName: Full=p185erbB2; DE AltName: CD_antigen=CD340; DE Flags: Precursor; GN Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003577; DOI=10.1038/319230a0; RA Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., RA Saito T., Toyoshima K.; RT "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal RT growth factor receptor."; RL Nature 319:230-234(1986). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT ALA-1170. RX PubMed=2999974; DOI=10.1126/science.2999974; RA Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., RA Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A., RA Ullrich A.; RT "Tyrosine kinase receptor with extensive homology to EGF receptor shares RT chromosomal location with neu oncogene."; RL Science 230:1132-1139(1985). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND RP ALA-1170. RG NIEHS SNPs program; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Brain; RA Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A., RA Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y., RA Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T., RA Sugano S., Nomura N., Isogai T.; RT "NEDO human cDNA sequencing project focused on splicing variants."; RL Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1). RX PubMed=3039351; DOI=10.1128/mcb.7.7.2597-2601.1987; RA Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.; RT "Human HER2 (neu) promoter: evidence for multiple mechanisms for RT transcriptional initiation."; RL Mol. Cell. Biol. 7:2597-2601(1987). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6). RC TISSUE=Fetal brain; RX PubMed=24722188; DOI=10.1038/ncomms4650; RA Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M., RA Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I., RA Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A., RA Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D., RA Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.; RT "Protein interaction network of alternatively spliced isoforms from brain RT links genetic risk factors for autism."; RL Nat. Commun. 5:3650-3650(2014). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031. RX PubMed=2995967; DOI=10.1073/pnas.82.19.6497; RA Semba K., Kamata N., Toyoshima K., Yamamoto T.; RT "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB- RT 1/epidermal growth factor-receptor gene and is amplified in a human RT salivary gland adenocarcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909. RC TISSUE=Mammary carcinoma; RX PubMed=2992089; DOI=10.1126/science.2992089; RA King C.R., Kraus M.H., Aaronson S.A.; RT "Amplification of a novel v-erbB-related gene in a human mammary RT carcinoma."; RL Science 229:974-976(1985). RN [11] RP NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170. RX PubMed=8104414; DOI=10.1089/dna.1993.12.611; RA Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.; RT "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene."; RL DNA Cell Biol. 12:611-615(1993). RN [12] RP INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [13] RP IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A RP COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [14] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012; RA Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z., Ali-Seyed M., RA Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K., Hung M.C.; RT "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine RT kinase receptor ErbB-2."; RL Cancer Cell 6:251-261(2004). RN [16] RP INTERACTION WITH PLXNB1. RX PubMed=15210733; DOI=10.1083/jcb.200312094; RA Swiercz J.M., Kuner R., Offermanns S.; RT "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine RT kinase ErbB-2."; RL J. Cell Biol. 165:869-880(2004). RN [17] RP INTERACTION WITH MEMO1. RX PubMed=15156151; DOI=10.1038/ncb1134; RA Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.; RT "Memo mediates ErbB2-driven cell motility."; RL Nat. Cell Biol. 6:515-522(2004). RN [18] RP SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION WITH RP KPNB1; RANBP2; CRM1; EEA1 AND CLTC. RX PubMed=16314522; DOI=10.1128/mcb.25.24.11005-11018.2005; RA Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G., RA Wang S.C., Hung M.C.; RT "Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell RT surface receptor."; RL Mol. Cell. Biol. 25:11005-11018(2005). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [20] RP FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION, RP AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712. RX PubMed=16794579; DOI=10.1038/sj.emboj.7601191; RA Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., RA Baselga J., Arribas J.; RT "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative RT initiation of translation."; RL EMBO J. 25:3234-3244(2006). RN [21] RP INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [22] RP PHOSPHORYLATION AT TYR-1248. RX PubMed=17554007; DOI=10.1523/jneurosci.5381-06.2007; RA Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A., RA Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L., RA Offermanns S., Kuner R.; RT "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and RT patterning of the developing nervous system in vivo."; RL J. Neurosci. 27:6333-6347(2007). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP INTERACTION WITH PTK6, AND ACTIVITY REGULATION. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [26] RP FUNCTION IN NUCLEUS. RX PubMed=19372587; DOI=10.1158/1541-7786.mcr-08-0316; RA Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.; RT "ErbB2-mediated Src and signal transducer and activator of transcription 3 RT activation leads to transcriptional up-regulation of p21Cip1 and RT chemoresistance in breast cancer cells."; RL Mol. Cancer Res. 7:592-600(2009). RN [27] RP INTERACTION WITH CPNE3. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [28] RP FUNCTION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP CHROMOSOMAL REARRANGEMENT WITH CDK12. RX PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749; RA Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D., RA Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H., RA Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.; RT "Genetic and structural variation in the gastric cancer kinome revealed RT through targeted deep sequencing."; RL Cancer Res. 71:29-39(2011). RN [31] RP FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR RP LOCATION. RX PubMed=21555369; DOI=10.1158/0008-5472.can-10-3504; RA Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H., Chen H.Y., RA Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P., Lien H.C., Tsai C.H., RA Hung M.C.; RT "Nuclear ErbB2 enhances translation and cell growth by activating RT transcription of ribosomal RNA genes."; RL Cancer Res. 71:4269-4279(2011). RN [32] RP INTERACTION WITH EGFR. RX PubMed=21190959; DOI=10.1210/en.2010-0940; RA Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N., Qiu X., RA Kumar U.; RT "Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in RT the presence of somatostatin receptor 5 modulate signaling pathways."; RL Endocrinology 152:931-945(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182; SER-1054; SER-1083 AND RP THR-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH HSP90AA1 AND HSP90AB1. RX PubMed=26517842; DOI=10.1371/journal.pone.0141786; RA Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C., RA Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K., RA Trepel J.B., Neckers L.; RT "Client proteins and small molecule inhibitors display distinct binding RT preferences for constitutive and stress-induced HSP90 isoforms and their RT conformationally restricted mutants."; RL PLoS ONE 10:E0141786-E0141786(2015). RN [37] RP PHOSPHORYLATION AT TYR-1112; TYR-1139; TYR-1196 AND TYR-1248, AND RP DEPHOSPHORYLATION BY PTPN12. RX PubMed=27134172; DOI=10.1016/j.celrep.2016.04.016; RA Li H., Yang F., Liu C., Xiao P., Xu Y., Liang Z., Liu C., Wang H., Wang W., RA Zheng W., Zhang W., Ma X., He D., Song X., Cui F., Xu Z., Yi F., Sun J.P., RA Yu X.; RT "Crystal structure and substrate specificity of PTPN12."; RL Cell Rep. 15:1345-1358(2016). RN [38] RP INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION. RX PubMed=31138794; DOI=10.1038/s41467-019-10275-0; RA Pietilae M., Sahgal P., Peuhu E., Jaentti N.Z., Paatero I., Naervae E., RA Al-Akhrass H., Lilja J., Georgiadou M., Andersen O.M., Padzik A., Sihto H., RA Joensuu H., Blomqvist M., Saarinen I., Bostroem P.J., Taimen P., Ivaska J.; RT "SORLA regulates endosomal trafficking and oncogenic fitness of HER2."; RL Nat. Commun. 10:2340-2340(2019). RN [39] RP INTERACTION WITH SH3BGRL, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT RP TYR-877 AND TYR-1196. RX PubMed=32381043; DOI=10.1186/s13046-020-01577-z; RA Li H., Zhang M., Wei Y., Haider F., Lin Y., Guan W., Liu Y., Zhang S., RA Yuan R., Yang X., Yang S., Wang H.; RT "SH3BGRL confers innate drug resistance in breast cancer by stabilizing RT HER2 activation on cell membrane."; RL J. Exp. Clin. Cancer Res. 39:81-81(2020). RN [40] RP SUBCELLULAR LOCATION. RX PubMed=34380438; DOI=10.1186/s12860-021-00379-1; RA Di Pisa F., Pesenti E., Bono M., Mazzarello A.N., Bernardi C., RA Lisanti M.P., Renzone G., Scaloni A., Ciccone E., Fais F., Bruno S., RA Scartezzini P., Ghiotto F.; RT "SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates RT migration in the MDA-MB-231 cell line."; RL BMC Mol. Cell Biol. 22:41-41(2021). RN [41] RP INTERACTION WITH ROR1. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA AND RP BETA-2 MICROGLOBULIN. RX PubMed=10593938; DOI=10.1074/jbc.274.51.36422; RA Kuhns J.J., Batalia M.A., Yan S., Collins E.J.; RT "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of RT interactions with the center of the peptide."; RL J. Biol. Chem. 274:36422-36427(1999). RN [43] RP X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH ERBIN, RP AND INTERACTION WITH ERBIN. RX PubMed=12444095; DOI=10.1074/jbc.c200571200; RA Birrane G., Chung J., Ladias J.A.; RT "Novel mode of ligand recognition by the Erbin PDZ domain."; RL J. Biol. Chem. 278:1399-1402(2003). RN [44] RP STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION WITH RP GRB7. RX PubMed=12975581; DOI=10.1023/a:1025498409113; RA Ivancic M., Daly R.J., Lyons B.A.; RT "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and RT structural basis for Grb7 binding to ErbB2."; RL J. Biomol. NMR 27:205-219(2003). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN. RX PubMed=12610629; DOI=10.1038/nature01392; RA Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., RA Denney D.W. Jr., Leahy D.J.; RT "Structure of the extracellular region of HER2 alone and in complex with RT the Herceptin Fab."; RL Nature 421:756-760(2003). RN [46] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF RP 317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187; ASN-259 AND RP ASN-530. RX PubMed=15093539; DOI=10.1016/s1535-6108(04)00083-2; RA Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., RA Sliwkowski M.X.; RT "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab RT complex."; RL Cancer Cell 5:317-328(2004). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND RP ASN-530. RX PubMed=19299620; DOI=10.1126/science.1165480; RA Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., RA Peale F., Ross S., Wiesmann C., Fuh G.; RT "Variants of the antibody herceptin that interact with HER2 and VEGF at the RT antigen binding site."; RL Science 323:1610-1614(2009). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH ENGINEERED RP ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-68; ASN-259 AND RP ASN-571. RX PubMed=20696930; DOI=10.1073/pnas.1005025107; RA Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.; RT "Structural basis for high-affinity HER2 receptor binding by an engineered RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH RP INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ACTIVITY REGULATION. RX PubMed=21454582; DOI=10.1074/jbc.m110.206193; RA Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G., Jennings A., RA Iwamoto K., Habuka N., Hirokawa A., Ishikawa T., Tanaka T., Miki H., RA Ohta Y., Sogabe S.; RT "Structural analysis of the mechanism of inhibition and allosteric RT activation of the kinase domain of HER2 protein."; RL J. Biol. Chem. 286:18756-18765(2011). RN [50] RP VARIANTS VAL-654 AND VAL-655. RX PubMed=8095488; DOI=10.1006/geno.1993.1081; RA Ehsani A., Low J., Wallace R.B., Wu A.M.; RT "Characterization of a new allele of the human ERBB2 gene by allele- RT specific competition hybridization."; RL Genomics 15:426-429(1993). RN [51] RP INVOLVEMENT IN CANCER, VARIANT GASC SER-776, VARIANT OC SER-857, VARIANT RP GLM LYS-914, AND VARIANTS LNCR PRO-755; ALA-TYR-VAL-MET-774 INS AND RP VAL-GLY-SER-779 INS. RX PubMed=15457249; DOI=10.1038/431525b; RG Cancer genome project and collaborative group; RA Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., RA Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M., RA Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A., Drozd A., RA Edwards K., Forbes S., Foster R., Gray K., Greenman C., Halliday K., RA Hills K., Kosmidou V., Lugg R., Menzies A., Perry J., Petty R., Raine K., RA Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., Varian J., RA West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., RA Knowles M., Leung S.Y., Louis D.N., Looijenga L.H., Malkowicz B., RA Pierotti M.A., Teh B., Chenevix-Trench G., Weber B.L., Yuen S.T., RA Harris G., Goldstraw P., Nicholson A.G., Futreal P.A., Wooster R., RA Stratton M.R.; RT "Lung cancer: intragenic ERBB2 kinase mutations in tumours."; RL Nature 431:525-526(2004). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170 AND RP ASP-1216, VARIANT GASC SER-776, AND VARIANT OC SER-857. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP INVOLVEMENT IN VSCN2, VARIANT VSCN2 VAL-710, CHARACTERIZATION OF VARIANT RP VSCN2 VAL-710, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=33497358; DOI=10.1172/jci145837; RA Le T.L., Galmiche L., Levy J., Suwannarat P., Hellebrekers D.M., RA Morarach K., Boismoreau F., Theunissen T.E., Lefebvre M., Pelet A., RA Martinovic J., Gelot A., Guimiot F., Calleroz A., Gitiaux C., Hully M., RA Goulet O., Chardot C., Drunat S., Capri Y., Bole-Feysot C., Nitschke P., RA Whalen S., Mouthon L., Babcock H.E., Hofstra R., de Coo I.F., Tabet A.C., RA Molina T.J., Keren B., Brooks A., Smeets H.J., Marklund U., Gordon C.T., RA Lyonnet S., Amiel J., Bondurand N.; RT "Dysregulation of the NRG1/ERBB pathway causes a developmental disorder RT with gastrointestinal dysmotility in humans."; RL J. Clin. Invest. 131:0-0(2021). CC -!- FUNCTION: Protein tyrosine kinase that is part of several cell surface CC receptor complexes, but that apparently needs a coreceptor for ligand CC binding. Essential component of a neuregulin-receptor complex, although CC neuregulins do not interact with it alone. GP30 is a potential ligand CC for this receptor. Regulates outgrowth and stabilization of peripheral CC microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 CC signaling pathway elicits the phosphorylation and thus the inhibition CC of GSK3B at cell membrane. This prevents the phosphorylation of APC and CC CLASP2, allowing its association with the cell membrane. In turn, CC membrane-bound APC allows the localization of MACF1 to the cell CC membrane, which is required for microtubule capture and stabilization. CC {ECO:0000305}. CC -!- FUNCTION: In the nucleus is involved in transcriptional regulation. CC Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter CC and activates its transcription. Implicated in transcriptional CC activation of CDKN1A; the function involves STAT3 and SRC. Involved in CC the transcription of rRNA genes by RNA Pol I and enhances protein CC synthesis and cell growth. {ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:15380516, ECO:0000269|PubMed:21555369}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:21454582}; CC -!- ACTIVITY REGULATION: Activated by dimerization. Not activated by EGF, CC TGF-alpha and amphiregulin. Interaction with PTK6 increases its CC intrinsic kinase activity. {ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:21454582}. CC -!- SUBUNIT: Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and CC ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:16978839, CC PubMed:21190959). Part of a complex with EGFR and either PIK3C2A or CC PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196 CC (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts CC (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151). CC Interacts with MUC1; the interaction is enhanced by heregulin (HRG) CC (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with CC GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated CC on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1, CC RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6 CC (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369). CC Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts CC (preferentially with the tyrosine phosphorylated form) with CPNE3; this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction CC suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with CC SORL1; this interaction regulates ERBB2 subcellular distribution by CC promoting its recycling after internalization from endosomes back to CC the plasma membrane, hence stimulates ERBB2-mediated signaling CC (PubMed:31138794). Interacts with SH3BGRL (PubMed:32381043). Interacts CC with ROR1 (PubMed:36949068). {ECO:0000250|UniProtKB:P70424, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:12975581, CC ECO:0000269|PubMed:15093539, ECO:0000269|PubMed:15156151, CC ECO:0000269|PubMed:15210733, ECO:0000269|PubMed:16314522, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21190959, CC ECO:0000269|PubMed:21454582, ECO:0000269|PubMed:21555369, CC ECO:0000269|PubMed:26517842, ECO:0000269|PubMed:31138794, CC ECO:0000269|PubMed:32381043, ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC P04626; P00519: ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543; CC P04626; P42684: ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694; CC P04626; P15309: ACP3; NbExp=2; IntAct=EBI-641062, EBI-1222012; CC P04626; P60709: ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944; CC P04626; Q92625: ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612; CC P04626; O00213: APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694; CC P04626; O75815: BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336; CC P04626; Q9HB71: CACYBP; NbExp=2; IntAct=EBI-641062, EBI-1047302; CC P04626; Q16543: CDC37; NbExp=5; IntAct=EBI-641062, EBI-295634; CC P04626; Q9NSE2: CISH; NbExp=4; IntAct=EBI-641062, EBI-617866; CC P04626; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194; CC P04626; P46109: CRKL; NbExp=2; IntAct=EBI-641062, EBI-910; CC P04626; Q93034: CUL5; NbExp=2; IntAct=EBI-641062, EBI-1057139; CC P04626; Q99704: DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360; CC P04626; Q8TEW6: DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542; CC P04626; Q15075: EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113; CC P04626; P98172: EFNB1; NbExp=12; IntAct=EBI-641062, EBI-538287; CC P04626; P00533: EGFR; NbExp=25; IntAct=EBI-641062, EBI-297353; CC P04626; P04626: ERBB2; NbExp=12; IntAct=EBI-641062, EBI-641062; CC P04626; P21860: ERBB3; NbExp=30; IntAct=EBI-641062, EBI-720706; CC P04626; Q15303: ERBB4; NbExp=5; IntAct=EBI-641062, EBI-80371; CC P04626; Q9UJM3: ERRFI1; NbExp=4; IntAct=EBI-641062, EBI-2941912; CC P04626; P09769: FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732; CC P04626; P06241: FYN; NbExp=2; IntAct=EBI-641062, EBI-515315; CC P04626; O75791: GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418; CC P04626; P62993: GRB2; NbExp=8; IntAct=EBI-641062, EBI-401755; CC P04626; Q14451: GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191; CC P04626; P07900: HSP90AA1; NbExp=6; IntAct=EBI-641062, EBI-296047; CC P04626; P08238: HSP90AB1; NbExp=5; IntAct=EBI-641062, EBI-352572; CC P04626; P14625: HSP90B1; NbExp=2; IntAct=EBI-641062, EBI-359129; CC P04626; P11021: HSPA5; NbExp=3; IntAct=EBI-641062, EBI-354921; CC P04626; P46940: IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509; CC P04626; P35568: IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592; CC P04626; Q08881: ITK; NbExp=2; IntAct=EBI-641062, EBI-968552; CC P04626; P23458: JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438; CC P04626; Q14974: KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758; CC P04626; Q96JA1: LRIG1; NbExp=7; IntAct=EBI-641062, EBI-2865191; CC P04626; O75367: MACROH2A1; NbExp=6; IntAct=EBI-641062, EBI-2868511; CC P04626; O75367-3: MACROH2A1; NbExp=3; IntAct=EBI-641062, EBI-6250866; CC P04626; Q9UQF2: MAPK8IP1; NbExp=4; IntAct=EBI-641062, EBI-78404; CC P04626; Q13387: MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813; CC P04626; P42679: MATK; NbExp=2; IntAct=EBI-641062, EBI-751664; CC P04626; Q9Y316: MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564; CC P04626; O43639: NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635; CC P04626; Q02297-7: NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927; CC P04626; O00750: PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107; CC P04626; P27986: PIK3R1; NbExp=12; IntAct=EBI-641062, EBI-79464; CC P04626; O00459: PIK3R2; NbExp=8; IntAct=EBI-641062, EBI-346930; CC P04626; Q92569: PIK3R3; NbExp=10; IntAct=EBI-641062, EBI-79893; CC P04626; P19174: PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387; CC P04626; P16885: PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403; CC P04626; O95602: POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472; CC P04626; Q13882: PTK6; NbExp=4; IntAct=EBI-641062, EBI-1383632; CC P04626; Q06124: PTPN11; NbExp=4; IntAct=EBI-641062, EBI-297779; CC P04626; Q05209: PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035; CC P04626; Q99952: PTPN18; NbExp=6; IntAct=EBI-641062, EBI-1384210; CC P04626; Q99952-1: PTPN18; NbExp=5; IntAct=EBI-641062, EBI-12739708; CC P04626; P23467: PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766; CC P04626; P08575: PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341; CC P04626; Q12913: PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500; CC P04626; Q15262: PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052; CC P04626; Q16827: PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739; CC P04626; Q15256: PTPRR; NbExp=2; IntAct=EBI-641062, EBI-2265659; CC P04626; P49792: RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138; CC P04626; P20936: RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476; CC P04626; O95980: RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742; CC P04626; Q9NP31: SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630; CC P04626; P29353: SHC1; NbExp=16; IntAct=EBI-641062, EBI-78835; CC P04626; P98077: SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023; CC P04626; Q92529: SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084; CC P04626; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854; CC P04626; O15524: SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198; CC P04626; O43791: SPOP; NbExp=6; IntAct=EBI-641062, EBI-743549; CC P04626; P12931: SRC; NbExp=11; IntAct=EBI-641062, EBI-621482; CC P04626; P42224: STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697; CC P04626; P40763: STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675; CC P04626; P31948: STIP1; NbExp=2; IntAct=EBI-641062, EBI-1054052; CC P04626; Q7KZ85: SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547; CC P04626; P43405: SYK; NbExp=7; IntAct=EBI-641062, EBI-78302; CC P04626; Q9Y490: TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036; CC P04626; Q63HR2: TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753; CC P04626; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488; CC P04626; Q96D37: VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353; CC P04626; P52735: VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549; CC P04626; O14980: XPO1; NbExp=3; IntAct=EBI-641062, EBI-355867; CC P04626; P62258: YWHAE; NbExp=2; IntAct=EBI-641062, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:32381043}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection, CC ruffle membrane {ECO:0000269|PubMed:34380438}; Single-pass type I CC membrane protein {ECO:0000255}. Note=Internalized from the cell CC membrane in response to EGF stimulation. {ECO:0000269|PubMed:32381043}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:31138794, ECO:0000269|PubMed:33497358}; Single-pass CC type I membrane protein {ECO:0000255}. Early endosome CC {ECO:0000269|PubMed:31138794}. Cytoplasm, perinuclear region. Nucleus. CC Note=Translocation to the nucleus requires endocytosis, probably CC endosomal sorting and is mediated by importin beta-1/KPNB1. Also CC detected in VPS35-positive endosome-to-TGN retrograde vesicles CC (PubMed:31138794). {ECO:0000269|PubMed:31138794}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=6; CC Name=1; Synonyms=ERBB2, HER2; CC IsoId=P04626-1; Sequence=Displayed; CC Name=2; Synonyms=CTF-611; CC IsoId=P04626-2; Sequence=VSP_039249; CC Name=3; Synonyms=CTF-687; CC IsoId=P04626-3; Sequence=VSP_039250; CC Name=4; CC IsoId=P04626-4; Sequence=VSP_039248; CC Name=5; CC IsoId=P04626-5; Sequence=VSP_054787; CC Name=6; Synonyms=B; CC IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues including CC primary breast tumors and tumors from small bowel, esophagus, kidney CC and mouth. {ECO:0000269|PubMed:15380516}. CC -!- PTM: Autophosphorylated. Autophosphorylation occurs in trans, i.e. one CC subunit of the dimeric receptor phosphorylates tyrosine residues on the CC other subunit (Probable). Ligand-binding increases phosphorylation on CC tyrosine residues (PubMed:27134172, PubMed:33497358). Signaling via CC SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). CC Dephosphorylated by PTPN12 (PubMed:27134172). CC {ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:27134172, CC ECO:0000269|PubMed:33497358, ECO:0000305}. CC -!- POLYMORPHISM: There are four alleles due to the variations in positions CC 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; CC allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val- CC 654/Val-655) has a frequency of 0.012. CC -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15457249}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15457249}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The protein represented in this CC entry is involved in disease pathogenesis. CC -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause CC gastric cancer. Deletions within 17q12 region producing fusion CC transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to CC truncated CDK12 protein not in-frame with ERBB2. CC {ECO:0000269|PubMed:21097718}. CC -!- DISEASE: Visceral neuropathy, familial, 2, autosomal recessive (VSCN2) CC [MIM:619465]: An autosomal recessive disorder characterized by CC intestinal dysmotility due to aganglionosis (Hirschsprung disease), CC hypoganglionosis, and/or chronic intestinal pseudoobstruction. Patients CC also show peripheral axonal neuropathy, hypotonia, mild developmental CC delay, unilateral ptosis, and sensorineural hearing loss. CC {ECO:0000269|PubMed:33497358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative initiation at Met- CC 611 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met- CC 687 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform CC 1. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/162/ERBB2"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry; CC URL="https://en.wikipedia.org/wiki/ERBB2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AH001455; AAA35808.1; -; Genomic_DNA. DR EMBL; X03363; CAA27060.1; -; mRNA. DR EMBL; M11730; AAA75493.1; -; mRNA. DR EMBL; M12036; AAA35978.1; -; Genomic_DNA. DR EMBL; AY208911; AAO18082.1; -; Genomic_DNA. DR EMBL; AK295195; BAG58195.1; -; mRNA. DR EMBL; CH471152; EAW60597.1; -; Genomic_DNA. DR EMBL; BC167147; AAI67147.1; -; mRNA. DR EMBL; M16792; AAA58637.1; -; Genomic_DNA. DR EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; KJ534964; AHW56604.1; -; mRNA. DR EMBL; L29395; AAA35809.1; -; Genomic_DNA. DR EMBL; M95667; AAC37531.1; -; Genomic_DNA. DR CCDS; CCDS32642.1; -. [P04626-1] DR CCDS; CCDS45667.1; -. [P04626-5] DR CCDS; CCDS74052.1; -. [P04626-4] DR PIR; A24571; A24571. DR RefSeq; NP_001005862.1; NM_001005862.3. [P04626-5] DR RefSeq; NP_001276865.1; NM_001289936.2. [P04626-4] DR RefSeq; NP_001276867.1; NM_001289938.1. DR RefSeq; NP_001369711.1; NM_001382782.1. [P04626-5] DR RefSeq; NP_001369712.1; NM_001382783.1. [P04626-5] DR RefSeq; NP_004439.2; NM_004448.4. [P04626-1] DR RefSeq; XP_047291546.1; XM_047435590.1. [P04626-4] DR PDB; 1MFG; X-ray; 1.25 A; B=1247-1255. DR PDB; 1MFL; X-ray; 1.88 A; B=1247-1255. DR PDB; 1MW4; NMR; -; B=1135-1144. DR PDB; 1N8Z; X-ray; 2.52 A; C=23-629. DR PDB; 1QR1; X-ray; 2.40 A; C/F=654-662. DR PDB; 1S78; X-ray; 3.25 A; A/B=23-646. DR PDB; 2A91; X-ray; 2.50 A; A=22-530. DR PDB; 2JWA; NMR; -; A/B=641-684. DR PDB; 2KS1; NMR; -; A=641-684. DR PDB; 2L4K; NMR; -; B=1135-1144. DR PDB; 2N2A; NMR; -; A/B=644-700. DR PDB; 3BE1; X-ray; 2.90 A; A=23-646. DR PDB; 3H3B; X-ray; 2.45 A; A/B=23-214. DR PDB; 3MZW; X-ray; 2.90 A; A=23-646. DR PDB; 3N85; X-ray; 3.20 A; A=23-646. DR PDB; 3PP0; X-ray; 2.25 A; A/B=703-1029. DR PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028. DR PDB; 3WLW; X-ray; 3.09 A; A/B=23-586. DR PDB; 3WSQ; X-ray; 3.50 A; A=23-586. DR PDB; 4GFU; X-ray; 2.00 A; F=1246-1252. DR PDB; 4HRL; X-ray; 2.55 A; C=24-219. DR PDB; 4HRM; X-ray; 3.20 A; A/C=24-219. DR PDB; 4HRN; X-ray; 2.65 A; C/D=529-625. DR PDB; 4NND; X-ray; 2.50 A; C/E/F/H=1109-1114. DR PDB; 5K33; X-ray; 3.30 A; C=23-629. DR PDB; 5KWG; X-ray; 4.30 A; C=23-653. DR PDB; 5MY6; X-ray; 2.25 A; A=24-645. DR PDB; 5O4G; X-ray; 3.00 A; C=23-628. DR PDB; 5OB4; NMR; -; A/B=641-684. DR PDB; 5TQS; X-ray; 1.88 A; E/F/G/H=1218-1228. DR PDB; 6ATT; X-ray; 3.77 A; A=23-652. DR PDB; 6BGT; X-ray; 2.70 A; C=1-652. DR PDB; 6J71; X-ray; 2.92 A; A=22-639. DR PDB; 6LBX; X-ray; 2.03 A; B=531-626. DR PDB; 6OGE; EM; 4.36 A; A=23-644. DR PDB; 7JXH; X-ray; 3.27 A; A/B/C/D/E/F/G/H=703-1024. DR PDB; 7MN5; EM; 2.93 A; B=1-1029. DR PDB; 7MN6; EM; 3.09 A; B=1-1029. DR PDB; 7MN8; EM; 3.45 A; B=1-1029. DR PDB; 7PCD; X-ray; 1.77 A; A=703-1029. DR PDB; 7QVK; X-ray; 3.10 A; AAA=23-646. DR PDB; 8FFJ; EM; 7.50 A; X=23-644. DR PDB; 8HGO; EM; 3.31 A; B=1-693. DR PDB; 8HGP; EM; 4.53 A; B=1-693. DR PDB; 8JYQ; X-ray; 1.75 A; C/F=611-618. DR PDB; 8JYR; X-ray; 1.69 A; A=23-216. DR PDB; 8PWH; EM; 3.17 A; E=23-646. DR PDB; 8Q6J; EM; 3.30 A; E=23-646. DR PDB; 8U4K; EM; 4.27 A; B=24-629. DR PDB; 8U4L; EM; 3.31 A; B=24-629. DR PDB; 8U8X; X-ray; 1.69 A; A=694-1029. DR PDB; 8VB5; X-ray; 1.48 A; A=703-1029. DR PDB; 8VQD; EM; 2.61 A; A=23-652. DR PDB; 8VQE; EM; 2.67 A; A/B=23-652. DR PDB; 9IUT; X-ray; 2.09 A; C/F=611-618. DR PDB; 9L1S; EM; 3.00 A; A=23-652. DR PDBsum; 1MFG; -. DR PDBsum; 1MFL; -. DR PDBsum; 1MW4; -. DR PDBsum; 1N8Z; -. DR PDBsum; 1QR1; -. DR PDBsum; 1S78; -. DR PDBsum; 2A91; -. DR PDBsum; 2JWA; -. DR PDBsum; 2KS1; -. DR PDBsum; 2L4K; -. DR PDBsum; 2N2A; -. DR PDBsum; 3BE1; -. DR PDBsum; 3H3B; -. DR PDBsum; 3MZW; -. DR PDBsum; 3N85; -. DR PDBsum; 3PP0; -. DR PDBsum; 3RCD; -. DR PDBsum; 3WLW; -. DR PDBsum; 3WSQ; -. DR PDBsum; 4GFU; -. DR PDBsum; 4HRL; -. DR PDBsum; 4HRM; -. DR PDBsum; 4HRN; -. DR PDBsum; 4NND; -. DR PDBsum; 5K33; -. DR PDBsum; 5KWG; -. DR PDBsum; 5MY6; -. DR PDBsum; 5O4G; -. DR PDBsum; 5OB4; -. DR PDBsum; 5TQS; -. DR PDBsum; 6ATT; -. DR PDBsum; 6BGT; -. DR PDBsum; 6J71; -. DR PDBsum; 6LBX; -. DR PDBsum; 6OGE; -. DR PDBsum; 7JXH; -. DR PDBsum; 7MN5; -. DR PDBsum; 7MN6; -. DR PDBsum; 7MN8; -. DR PDBsum; 7PCD; -. DR PDBsum; 7QVK; -. DR PDBsum; 8FFJ; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8JYQ; -. DR PDBsum; 8JYR; -. DR PDBsum; 8PWH; -. DR PDBsum; 8Q6J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR PDBsum; 8U8X; -. DR PDBsum; 8VB5; -. DR PDBsum; 8VQD; -. DR PDBsum; 8VQE; -. DR PDBsum; 9IUT; -. DR PDBsum; 9L1S; -. DR AlphaFoldDB; P04626; -. DR BMRB; P04626; -. DR EMDB; EMD-17993; -. DR EMDB; EMD-18188; -. DR EMDB; EMD-18189; -. DR EMDB; EMD-18190; -. DR EMDB; EMD-20055; -. DR EMDB; EMD-29044; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR EMDB; EMD-43439; -. DR EMDB; EMD-43440; -. DR EMDB; EMD-62753; -. DR SMR; P04626; -. DR BioGRID; 108376; 731. DR CORUM; P04626; -. DR DIP; DIP-8N; -. DR ELM; P04626; -. DR FunCoup; P04626; 2287. DR IntAct; P04626; 558. DR MINT; P04626; -. DR STRING; 9606.ENSP00000269571; -. DR BindingDB; P04626; -. DR ChEMBL; CHEMBL1824; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12302; CP-724714. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB14967; Margetuximab. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB06226; Nelipepimut-S. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB06366; Pertuzumab. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB12183; Sapitinib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB11973; Tesevatinib. DR DrugBank; DB00072; Trastuzumab. DR DrugBank; DB05773; Trastuzumab emtansine. DR DrugBank; DB11652; Tucatinib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB15471; Zanidatamab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P04626; -. DR GuidetoPHARMACOLOGY; 2019; -. DR MoonDB; P04626; Predicted. DR TCDB; 8.A.23.1.39; the basigin (basigin) family. DR CarbonylDB; P04626; -. DR GlyConnect; 1710; 13 N-Linked glycans (5 sites), 1 O-Linked glycan (1 site). DR GlyCosmos; P04626; 9 sites, 13 glycans. DR GlyGen; P04626; 10 sites, 27 N-linked glycans (7 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P04626; -. DR PhosphoSitePlus; P04626; -. DR SwissPalm; P04626; -. DR BioMuta; ERBB2; -. DR DMDM; 119533; -. DR CPTAC; CPTAC-192; -. DR CPTAC; CPTAC-193; -. DR CPTAC; CPTAC-194; -. DR CPTAC; CPTAC-195; -. DR CPTAC; CPTAC-3045; -. DR CPTAC; CPTAC-3046; -. DR CPTAC; CPTAC-5777; -. DR CPTAC; CPTAC-5827; -. DR CPTAC; CPTAC-5839; -. DR CPTAC; CPTAC-5864; -. DR CPTAC; CPTAC-693; -. DR CPTAC; non-CPTAC-5384; -. DR CPTAC; non-CPTAC-5385; -. DR CPTAC; non-CPTAC-5386; -. DR CPTAC; non-CPTAC-5547; -. DR CPTAC; non-CPTAC-5732; -. DR CPTAC; non-CPTAC-5733; -. DR jPOST; P04626; -. DR MassIVE; P04626; -. DR PaxDb; 9606-ENSP00000269571; -. DR PeptideAtlas; P04626; -. DR ProteomicsDB; 51718; -. [P04626-1] DR ProteomicsDB; 51719; -. [P04626-2] DR ProteomicsDB; 51720; -. [P04626-3] DR ProteomicsDB; 51721; -. [P04626-4] DR Pumba; P04626; -. DR ABCD; P04626; 341 sequenced antibodies. DR Antibodypedia; 740; 6685 antibodies from 63 providers. DR CPTC; P04626; 4 antibodies. DR DNASU; 2064; -. DR Ensembl; ENST00000269571.10; ENSP00000269571.4; ENSG00000141736.15. [P04626-1] DR Ensembl; ENST00000584601.5; ENSP00000462438.1; ENSG00000141736.15. [P04626-5] DR GeneID; 2064; -. DR KEGG; hsa:2064; -. DR MANE-Select; ENST00000269571.10; ENSP00000269571.4; NM_004448.4; NP_004439.2. DR UCSC; uc060esv.1; human. [P04626-1] DR AGR; HGNC:3430; -. DR CIViC; 2064; 2 clinical assertions and 302 evidence items across 174 molecular profiles. DR ClinPGx; PA27844; -. DR CTD; 2064; -. DR DisGeNET; 2064; -. DR GeneCards; ERBB2; -. DR HGNC; HGNC:3430; ERBB2. DR HPA; ENSG00000141736; Low tissue specificity. DR MalaCards; ERBB2; -. DR MIM; 137800; phenotype. DR MIM; 164870; gene. DR MIM; 167000; phenotype. DR MIM; 211980; phenotype. DR MIM; 613659; phenotype. DR MIM; 619465; phenotype. DR OpenTargets; ENSG00000141736; -. DR Orphanet; 99976; Adenocarcinoma of the oesophagus and oesophagogastric junction. DR Orphanet; 2800; Extramammary Paget disease. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 213726; Serous carcinoma of the corpus uteri. DR VEuPathDB; HostDB:ENSG00000141736; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000158232; -. DR InParanoid; P04626; -. DR OMA; DRHCLPC; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P04626; 10 GO annotations based on evolutionary models. DR PhylomeDB; P04626; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P04626; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9652282; Drug-mediated inhibition of ERBB2 signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665233; Resistance of ERBB2 KD mutants to trastuzumab. DR Reactome; R-HSA-9665244; Resistance of ERBB2 KD mutants to sapitinib. DR Reactome; R-HSA-9665245; Resistance of ERBB2 KD mutants to tesevatinib. DR Reactome; R-HSA-9665246; Resistance of ERBB2 KD mutants to neratinib. DR Reactome; R-HSA-9665247; Resistance of ERBB2 KD mutants to osimertinib. DR Reactome; R-HSA-9665249; Resistance of ERBB2 KD mutants to afatinib. DR Reactome; R-HSA-9665250; Resistance of ERBB2 KD mutants to AEE788. DR Reactome; R-HSA-9665251; Resistance of ERBB2 KD mutants to lapatinib. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9665737; Drug resistance in ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P04626; -. DR SIGNOR; P04626; -. DR Agora; ENSG00000141736; -. DR BioGRID-ORCS; 2064; 92 hits in 1209 CRISPR screens. DR ChiTaRS; ERBB2; human. DR EvolutionaryTrace; P04626; -. DR GeneWiki; HER2/neu; -. DR GenomeRNAi; 2064; -. DR Pharos; P04626; Tclin. DR PRO; PR:P04626; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04626; protein. DR Bgee; ENSG00000141736; Expressed in lower esophagus mucosa and 186 other cell types or tissues. DR ExpressionAtlas; P04626; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0038143; C:ERBB3:ERBB2 complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0043209; C:myelin sheath; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0002116; C:semaphorin receptor complex; ISS:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; ISS:BHF-UCL. DR GO; GO:0043125; F:ErbB-3 class receptor binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; TAS:ProtInc. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:BHF-UCL. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0042060; P:wound healing; IDA:BHF-UCL. DR CDD; cd00064; FU; 3. DR CDD; cd05109; PTKc_HER2; 1. DR CDD; cd12094; TM_ErbB2; 1. DR DisProt; DP01484; -. DR FunFam; 1.20.5.100:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000009; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000010; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000184; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 4.10.1140.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 1.20.5.100; Cytochrome c1, transmembrane anchor, C-terminal; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 4.10.1140.10; membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor like domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00293; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF137; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative initiation; Alternative splicing; KW ATP-binding; Cell membrane; Cell projection; Chromosomal rearrangement; KW Cytoplasm; Disease variant; Disulfide bond; Endosome; Glycoprotein; Kinase; KW Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Signal; KW Transcription; Transcription regulation; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..1255 FT /note="Receptor tyrosine-protein kinase erbB-2" FT /id="PRO_0000016669" FT TOPO_DOM 23..652 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 653..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1255 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 720..987 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 676..689 FT /note="Required for interaction with KPNB1 and EEA1" FT /evidence="ECO:0000269|PubMed:16314522" FT REGION 1035..1179 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1195..1197 FT /note="Interaction with PIK3C2B" FT /evidence="ECO:0000305" FT REGION 1196..1255 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..689 FT /note="Nuclear localization signal" FT COMPBIAS 1146..1155 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 845 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 726..734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 753 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 182 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 877 FT /note="Phosphotyrosine" FT /evidence="ECO:0000305|PubMed:32381043" FT MOD_RES 1054 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 1078 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P06494" FT MOD_RES 1083 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1107 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1112 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1139 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1166 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1196 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172, FT ECO:0000305|PubMed:32381043" FT MOD_RES 1248 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17554007, FT ECO:0000269|PubMed:27134172, ECO:0007744|PubMed:17081983" FT CARBOHYD 68 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW" FT CARBOHYD 124 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 187 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255, ECO:0007744|PDB:1N8Z, FT ECO:0007744|PDB:1S78, ECO:0007744|PDB:2A91, FT ECO:0007744|PDB:3N85" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85" FT CARBOHYD 530 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0007744|PDB:1S78" FT CARBOHYD 571 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:3MZW" FT CARBOHYD 629 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 26..53 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 162..192 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 195..204 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 199..212 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 220..227 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 224..235 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 236..244 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 240..252 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 255..264 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 268..295 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 299..311 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 315..331 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 334..338 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 342..367 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 475..504 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 511..520 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 515..528 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 531..540 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 544..560 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 563..576 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 567..584 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 587..596 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:4HRN" FT DISULFID 600..623 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3N85" FT DISULFID 626..634 FT /evidence="ECO:0007744|PDB:3N85" FT DISULFID 630..642 FT /evidence="ECO:0007744|PDB:3N85" FT VAR_SEQ 1..686 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_039250" FT VAR_SEQ 1..610 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_039249" FT VAR_SEQ 1..30 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_054787" FT VAR_SEQ 1..23 FT /note="MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_039248" FT VAR_SEQ 633..648 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055902" FT VAR_SEQ 771..883 FT /note="AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDL FT LNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADG FT GK -> TISNLFSNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLWGCRGEP FT RVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTRAGGSTQHLQRDTYGREPRVPGSGR FT ASVNQKAKSAEALMCPQGAGKA (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055903" FT VAR_SEQ 884..1255 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055904" FT VARIANT 452 FT /note="W -> C (in dbSNP:rs4252633)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_016317" FT VARIANT 654 FT /note="I -> V (in allele B3; dbSNP:rs1801201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488" FT /id="VAR_004077" FT VARIANT 655 FT /note="I -> V (in allele B2 and allele B3; FT dbSNP:rs1136201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488, ECO:0000269|Ref.3" FT /id="VAR_004078" FT VARIANT 710 FT /note="A -> V (in VSCN2; almost complete loss of ERBB2 and FT ERBB3 phosphorylation in the presence or in the absence of FT NRG1 stimulation, suggesting alteration of downstream FT signaling; does not affect the subcellular localization at FT the cell membrane; dbSNP:rs2145813505)" FT /evidence="ECO:0000269|PubMed:33497358" FT /id="VAR_086107" FT VARIANT 755 FT /note="L -> P (in LNCR; uncertain significance; somatic FT mutation; dbSNP:rs121913469)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055432" FT VARIANT 768 FT /note="L -> S (in dbSNP:rs56366519)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042097" FT VARIANT 774 FT /note="M -> MAYVM (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055433" FT VARIANT 776 FT /note="G -> S (in GASC; uncertain significance; somatic FT mutation; dbSNP:rs28933369)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042098" FT VARIANT 779 FT /note="S -> SVGS (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055434" FT VARIANT 857 FT /note="N -> S (in OC; uncertain significance; somatic FT mutation; dbSNP:rs28933370)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042099" FT VARIANT 914 FT /note="E -> K (in GLM; uncertain significance; somatic FT mutation; dbSNP:rs28933368)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055435" FT VARIANT 1170 FT /note="P -> A (in dbSNP:rs1058808)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2999974, ECO:0000269|PubMed:8104414, FT ECO:0000269|Ref.3" FT /id="VAR_016318" FT VARIANT 1216 FT /note="A -> D (in dbSNP:rs55943169)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042100" FT MUTAGEN 317..318 FT /note="LH->AA: Reduces dimerization with ERBB3." FT /evidence="ECO:0000269|PubMed:15093539" FT MUTAGEN 611 FT /note="M->A: Prevents synthesis of isoform 2." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 687 FT /note="M->A: Prevents synthesis of isoform 3." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 706 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 712 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT STRAND 25..27 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 39..50 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 55..64 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 84..88 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 92..95 FT /evidence="ECO:0007829|PDB:3H3B" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 112..117 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 123..125 FT /evidence="ECO:0007829|PDB:8PWH" FT TURN 130..132 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 152..156 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 175..177 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 209..211 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 217..219 FT /evidence="ECO:0007829|PDB:1N8Z" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 227..231 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 240..248 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 271..274 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 284..286 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 294..298 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 319..323 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 329..333 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:2A91" FT HELIX 348..350 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 358..360 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 361..364 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 368..376 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 378..382 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 385..387 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 394..400 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 405..408 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 410..413 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 417..421 FT /evidence="ECO:0007829|PDB:8PWH" FT HELIX 423..425 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 430..435 FT /evidence="ECO:0007829|PDB:3WLW" FT TURN 438..440 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 441..447 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 463..469 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 476..479 FT /evidence="ECO:0007829|PDB:8VQE" FT HELIX 482..485 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 493..499 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 501..506 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3N85" FT HELIX 516..518 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 520..524 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 532..536 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 539..542 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 545..551 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 553..556 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 559..562 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 565..567 FT /evidence="ECO:0007829|PDB:3WSQ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 575..580 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 583..592 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 602..604 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 605..608 FT /evidence="ECO:0007829|PDB:8PWH" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:8JYQ" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 630..632 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:6J71" FT HELIX 651..678 FT /evidence="ECO:0007829|PDB:2JWA" FT HELIX 684..690 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 691..697 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 720..729 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 732..739 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 748..755 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 762..765 FT /evidence="ECO:0007829|PDB:3RCD" FT HELIX 770..775 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 787..799 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 806..813 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 814..816 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 819..838 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 848..850 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 851..855 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 866..870 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 886..888 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 891..896 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 901..916 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 922..925 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 928..930 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 931..936 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 949..958 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 963..965 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 969..980 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 983..985 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 989..992 FT /evidence="ECO:0007829|PDB:3PP0" FT HELIX 1003..1007 FT /evidence="ECO:0007829|PDB:3PP0" FT TURN 1008..1011 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 1140..1142 FT /evidence="ECO:0007829|PDB:1MW4" SQ SEQUENCE 1255 AA; 137910 MW; 39E9DFDA04DCF962 CRC64; MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV // ID ERN1_HUMAN Reviewed; 977 AA. AC O75460; A1L457; A8K8N8; A8MXS7; Q59EE2; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-2008, sequence version 2. DT 28-JAN-2026, entry version 226. DE RecName: Full=Serine/threonine-protein kinase/endoribonuclease IRE1 {ECO:0000305}; DE AltName: Full=Endoplasmic reticulum-to-nucleus signaling 1 {ECO:0000303|PubMed:9637683}; DE AltName: Full=Inositol-requiring protein 1 {ECO:0000303|PubMed:9637683}; DE Short=hIRE1p {ECO:0000303|PubMed:9637683}; DE AltName: Full=Ire1-alpha {ECO:0000303|PubMed:11779464}; DE Short=IRE1a {ECO:0000303|PubMed:11779464}; DE Includes: DE RecName: Full=Serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; DE Includes: DE RecName: Full=Endoribonuclease; DE EC=3.1.26.- {ECO:0000269|PubMed:21317875, ECO:0000305|PubMed:30118681}; DE Flags: Precursor; GN Name=ERN1 {ECO:0000312|HGNC:HGNC:3449}; GN Synonyms=IRE1 {ECO:0000312|EMBL:AAC25991.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAC25991.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP COFACTOR, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AUTOPHOSPHORYLATION, RP GLYCOSYLATION, AND MUTAGENESIS OF LYS-599. RC TISSUE=Liver {ECO:0000312|EMBL:AAC25991.1}; RX PubMed=9637683; DOI=10.1101/gad.12.12.1812; RA Tirasophon W., Welihinda A.A., Kaufman R.J.; RT "A stress response pathway from the endoplasmic reticulum to the nucleus RT requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in RT mammalian cells."; RL Genes Dev. 12:1812-1824(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Endothelial cell; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 2-977 (ISOFORM 2). RC TISSUE=Brain, and Leukocyte; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=11779464; DOI=10.1016/s0092-8674(01)00611-0; RA Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K.; RT "XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress RT to produce a highly active transcription factor."; RL Cell 107:881-891(2001). RN [8] RP INTERACTION WITH TAOK3 AND TRAF2. RX PubMed=11278723; DOI=10.1074/jbc.m010677200; RA Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T., Tohyama M.; RT "Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, RT through tumor necrosis factor receptor-associated factor 2-dependent RT mechanism in response to the ER stress."; RL J. Biol. Chem. 276:13935-13940(2001). RN [9] {ECO:0000305} RP FUNCTION, AND MUTAGENESIS OF LYS-599. RX PubMed=11175748; DOI=10.1038/35055065; RA Iwawaki T., Hosoda A., Okuda T., Kamigori Y., Nomura-Furuwatari C., RA Kimata Y., Tsuru A., Kohno K.; RT "Translational control by the ER transmembrane kinase/ribonuclease IRE1 RT under ER stress."; RL Nat. Cell Biol. 3:158-164(2001). RN [10] {ECO:0000305} RP FUNCTION, HOMODIMERIZATION, ACTIVITY REGULATION, INTERACTION WITH HSPA5, RP AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=12637535; DOI=10.1074/jbc.m300418200; RA Liu C.Y., Xu Z., Kaufman R.J.; RT "Structure and intermolecular interactions of the luminal dimerization RT domain of human IRE1alpha."; RL J. Biol. Chem. 278:17680-17687(2003). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-973, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP FUNCTION, AND INTERACTION WITH TMBIM6. RX PubMed=19328063; DOI=10.1016/j.molcel.2009.02.017; RA Lisbona F., Rojas-Rivera D., Thielen P., Zamorano S., Todd D., Martinon F., RA Glavic A., Kress C., Lin J.H., Walter P., Reed J.C., Glimcher L.H., RA Hetz C.; RT "BAX inhibitor-1 is a negative regulator of the ER stress sensor RT IRE1alpha."; RL Mol. Cell 33:679-691(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP ADP-RIBOSYLATION BY PARP16. RX PubMed=23103912; DOI=10.1038/ncb2593; RA Jwa M., Chang P.; RT "PARP16 is a tail-anchored endoplasmic reticulum protein required for the RT PERK-and IRE1alpha-mediated unfolded protein response."; RL Nat. Cell Biol. 14:1223-1230(2012). RN [15] RP SUBUNIT, AND INTERACTION WITH DNAJB9 AND HSPA5. RX PubMed=29198525; DOI=10.1016/j.cell.2017.10.040; RA Amin-Wetzel N., Saunders R.A., Kamphuis M.J., Rato C., Preissler S., RA Harding H.P., Ron D.; RT "A J-Protein co-chaperone recruits bip to monomerize IRE1 and repress the RT unfolded protein response."; RL Cell 171:1625-1637(2017). RN [16] RP INTERACTION WITH RNF13. RX PubMed=23378536; DOI=10.1074/jbc.m112.368829; RA Arshad M., Ye Z., Gu X., Wong C.K., Liu Y., Li D., Zhou L., Zhang Y., RA Bay W.P., Yu V.C., Li P.; RT "RNF13, a RING finger protein, mediates endoplasmic reticulum stress- RT induced apoptosis through the inositol-requiring enzyme (IRE1alpha)/c-Jun RT NH2-terminal kinase pathway."; RL J. Biol. Chem. 288:8726-8736(2013). RN [17] RP INTERACTION WITH LACC1. RX PubMed=31875558; DOI=10.1016/j.celrep.2019.11.105; RA Huang C., Hedl M., Ranjan K., Abraham C.; RT "LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes RT in human macrophages and LACC1 risk variants modulate these outcomes."; RL Cell Rep. 29:4525-4539(2019). RN [18] RP FUNCTION. RX PubMed=21884936; DOI=10.1016/j.cell.2011.07.021; RA Gee H.Y., Noh S.H., Tang B.L., Kim K.H., Lee M.G.; RT "Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional RT secretion pathway."; RL Cell 146:746-760(2011). RN [19] RP FUNCTION, INTERACTION WITH PDIA6, SUBUNIT, AND MUTAGENESIS OF CYS-148. RX PubMed=24508390; DOI=10.1016/j.molcel.2014.01.004; RA Eletto D., Eletto D., Dersh D., Gidalevitz T., Argon Y.; RT "Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling RT via disulfide-dependent association."; RL Mol. Cell 53:562-576(2014). RN [20] RP FUNCTION, INTERACTION WITH DDRGK1, AND PHOSPHORYLATION. RX PubMed=28128204; DOI=10.1038/ncomms14186; RA Liu J., Wang Y., Song L., Zeng L., Yi W., Liu T., Chen H., Wang M., Ju Z., RA Cong Y.S.; RT "A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via RT regulation of IRE1alpha stability."; RL Nat. Commun. 8:14186-14186(2017). RN [21] RP FUNCTION. RX PubMed=28067262; DOI=10.1038/srep39887; RA Piao H., Kim J., Noh S.H., Kweon H.S., Kim J.Y., Lee M.G.; RT "Sec16A is critical for both conventional and unconventional secretion of RT CFTR."; RL Sci. Rep. 7:39887-39887(2017). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND PHOSPHORYLATION AT SER-724 AND RP SER-729. RX PubMed=30118681; DOI=10.1016/j.molcel.2018.06.038; RA Chang T.K., Lawrence D.A., Lu M., Tan J., Harnoss J.M., Marsters S.A., RA Liu P., Sandoval W., Martin S.E., Ashkenazi A.; RT "Coordination between Two Branches of the Unfolded Protein Response RT Determines Apoptotic Cell Fate."; RL Mol. Cell 71:629-636.e5(2018). RN [23] RP INTERACTION WITH P4HB, AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=32149426; DOI=10.15252/embj.2019103841; RA Yu J., Li T., Liu Y., Wang X., Zhang J., Wang X., Shi G., Lou J., Wang L., RA Wang C.C., Wang L.; RT "Phosphorylation switches protein disulfide isomerase activity to maintain RT proteostasis and attenuate ER stress."; RL EMBO J. 39:e103841-e103841(2020). RN [24] RP FUNCTION, INTERACTION WITH MANF AND HSPA5, INDUCTION, AND PHOSPHORYLATION RP AT SER-724. RX PubMed=36739529; DOI=10.1016/j.celrep.2023.112066; RA Kovaleva V., Yu L.Y., Ivanova L., Shpironok O., Nam J., Eesmaa A., RA Kumpula E.P., Sakson S., Toots U., Ustav M., Huiskonen J.T., RA Voutilainen M.H., Lindholm P., Karelson M., Saarma M.; RT "MANF regulates neuronal survival and UPR through its ER-located receptor RT IRE1alpha."; RL Cell Rep. 42:112066-112066(2023). RN [25] {ECO:0007744|PDB:2HZ6} RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 24-390, SUBUNIT, AND MUTAGENESIS RP OF GLN-105; ASP-123 AND TRP-125. RX PubMed=16973740; DOI=10.1073/pnas.0606480103; RA Zhou J., Liu C.Y., Back S.H., Clark R.L., Peisach D., Xu Z., Kaufman R.J.; RT "The crystal structure of human IRE1 luminal domain reveals a conserved RT dimerization interface required for activation of the unfolded protein RT response."; RL Proc. Natl. Acad. Sci. U.S.A. 103:14343-14348(2006). RN [26] {ECO:0007744|PDB:3P23} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 547-977 IN COMPLEX WITH ADP, RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, AND RP COFACTOR. RX PubMed=21317875; DOI=10.1038/emboj.2011.18; RA Ali M.M., Bagratuni T., Davenport E.L., Nowak P.R., Silva-Santisteban M.C., RA Hardcastle A., McAndrews C., Rowlands M.G., Morgan G.J., Aherne W., RA Collins I., Davies F.E., Pearl L.H.; RT "Structure of the Ire1 autophosphorylation complex and implications for the RT unfolded protein response."; RL EMBO J. 30:894-905(2011). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] SER-244; MET-418; ARG-474; TRP-635; RP SER-700; PHE-769 AND LEU-830. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase and endoribonuclease that CC acts as a key sensor for the endoplasmic reticulum unfolded protein CC response (UPR) (PubMed:11175748, PubMed:11779464, PubMed:12637535, CC PubMed:19328063, PubMed:21317875, PubMed:28128204, PubMed:30118681, CC PubMed:36739529, PubMed:9637683). In unstressed cells, the endoplasmic CC reticulum luminal domain is maintained in its inactive monomeric state CC by binding to the endoplasmic reticulum chaperone HSPA5/BiP CC (PubMed:21317875). Accumulation of misfolded proteins in the CC endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal CC domain to homodimerize, promoting autophosphorylation of the kinase CC domain and subsequent activation of the endoribonuclease activity CC (PubMed:21317875). The endoribonuclease activity is specific for XBP1 CC mRNA and excises 26 nucleotides from XBP1 mRNA (PubMed:11779464, CC PubMed:21317875, PubMed:24508390). The resulting spliced transcript of CC XBP1 encodes a transcriptional activator protein that up-regulates CC expression of UPR target genes (PubMed:11779464, PubMed:21317875, CC PubMed:24508390). Acts as an upstream signal for ER stress-induced CC GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CC CFTR to cell membrane by modulating the expression and localization of CC SEC16A (PubMed:21884936, PubMed:28067262). CC {ECO:0000269|PubMed:11175748, ECO:0000269|PubMed:11779464, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:21884936, CC ECO:0000269|PubMed:28067262, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:30118681, ECO:0000269|PubMed:36739529, CC ECO:0000269|PubMed:9637683, ECO:0000305|PubMed:24508390}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- ACTIVITY REGULATION: The kinase domain is activated by trans- CC autophosphorylation following homodimerization (PubMed:12637535, CC PubMed:9637683). Kinase activity is required for activation of the CC endoribonuclease domain (PubMed:12637535, PubMed:9637683). CC Endoribonuclease activity is specifically inhibited by hydroxy-aryl- CC aldehydes (HAA) (By similarity). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:9637683}. CC -!- SUBUNIT: Monomer (PubMed:16973740, PubMed:29198525). Homodimer; CC disulfide-linked; homodimerization takes place in response to CC endoplasmic reticulum stress and promotes activation of the kinase and CC endoribonuclease activities (PubMed:12637535, PubMed:16973740, CC PubMed:21317875, PubMed:24508390, PubMed:30118681). Dimer formation is CC driven by hydrophobic interactions within the N-terminal luminal CC domains and stabilized by disulfide bridges (PubMed:12637535). CC Interacts (via the luminal region) with DNAJB9/ERdj4; interaction takes CC place in unstressed cells and promotes recruitment of HSPA5/BiP CC (PubMed:29198525). Interacts (via the luminal region) with HSPA5/BiP; CC HSPA5/BiP is a negative regulator of the unfolded protein response CC (UPR) that prevents homodimerization of ERN1/IRE1 and subsequent CC activation of the protein (PubMed:12637535, PubMed:29198525, CC PubMed:36739529). Interaction with HSPA5 also competitively inhibits CC ERN1 interaction with MANF (PubMed:36739529). Interacts with PDIA6, a CC negative regulator of the UPR; the interaction is direct and disrupts CC homodimerization (PubMed:24508390). Interacts with DAB2IP (via PH CC domain); the interaction occurs in a endoplasmic reticulum stress- CC induced dependent manner and is required for subsequent recruitment of CC TRAF2 to ERN1/IRE1 (By similarity). Interacts with TAOK3 and TRAF2 CC (PubMed:11278723). Interacts with RNF13 (PubMed:23378536). Interacts CC with LACC1 (PubMed:31875558). Interacts (when unphosphorylated) with CC DDRGK1; interaction is dependent on UFM1 and takes place in response to CC endoplasmic reticulum stress, regulating ERN1/IRE1-alpha stability CC (PubMed:28128204). Interacts (via N-terminus) with P4HB/PDIA1; the CC interaction is enhanced by phosphorylation of P4HB by FAM20C in CC response to endoplasmic reticulum stress and results in attenuation of CC ERN1 activity (PubMed:32149426). Interacts with TMBIM6; this CC interaction inhibits ERN1 activity (PubMed:19328063). Interacts (via CC luminal domain) with MANF (via C-terminus); the interaction is CC decreased in the presence of increasing concentrations of Ca(2+) CC (PubMed:36739529). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:11278723, ECO:0000269|PubMed:12637535, CC ECO:0000269|PubMed:16973740, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:23378536, CC ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:29198525, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:31875558, ECO:0000269|PubMed:32149426, CC ECO:0000269|PubMed:36739529}. CC -!- INTERACTION: CC O75460; Q07812: BAX; NbExp=2; IntAct=EBI-371750, EBI-516580; CC O75460; O75460: ERN1; NbExp=2; IntAct=EBI-371750, EBI-371750; CC O75460; P11021: HSPA5; NbExp=3; IntAct=EBI-371750, EBI-354921; CC O75460; Q86TM6: SYVN1; NbExp=2; IntAct=EBI-371750, EBI-947849; CC O75460; Q9H2K8: TAOK3; NbExp=3; IntAct=EBI-371750, EBI-1384100; CC O75460; Q12933: TRAF2; NbExp=3; IntAct=EBI-371750, EBI-355744; CC O75460; Q969M3: YIPF5; NbExp=3; IntAct=EBI-371750, EBI-2124787; CC O75460; O08734: Bak1; Xeno; NbExp=2; IntAct=EBI-371750, EBI-822441; CC O75460; Q07813: Bax; Xeno; NbExp=2; IntAct=EBI-371750, EBI-700711; CC O75460; P20029: Hspa5; Xeno; NbExp=2; IntAct=EBI-371750, EBI-772325; CC O75460-1; O75460-1: ERN1; NbExp=5; IntAct=EBI-15600828, EBI-15600828; CC O75460-1; P11021: HSPA5; NbExp=4; IntAct=EBI-15600828, EBI-354921; CC O75460-1; Q13438: OS9; NbExp=2; IntAct=EBI-15600828, EBI-725454; CC O75460-1; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-15600828, EBI-358766; CC O75460-1; Q86TM6: SYVN1; NbExp=3; IntAct=EBI-15600828, EBI-947849; CC O75460-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-25852368, EBI-18899653; CC O75460-2; Q96MA6: AK8; NbExp=3; IntAct=EBI-25852368, EBI-8466265; CC O75460-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-25852368, EBI-5280499; CC O75460-2; Q9UBL3: ASH2L; NbExp=3; IntAct=EBI-25852368, EBI-540797; CC O75460-2; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-25852368, EBI-9089489; CC O75460-2; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-25852368, EBI-742750; CC O75460-2; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-25852368, EBI-12300031; CC O75460-2; P38936: CDKN1A; NbExp=3; IntAct=EBI-25852368, EBI-375077; CC O75460-2; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-25852368, EBI-11526226; CC O75460-2; Q92782-2: DPF1; NbExp=3; IntAct=EBI-25852368, EBI-23669343; CC O75460-2; O77932: DXO; NbExp=3; IntAct=EBI-25852368, EBI-372173; CC O75460-2; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-618189; CC O75460-2; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-9088619; CC O75460-2; P52655: GTF2A1; NbExp=3; IntAct=EBI-25852368, EBI-389518; CC O75460-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-25852368, EBI-6509505; CC O75460-2; Q92615: LARP4B; NbExp=3; IntAct=EBI-25852368, EBI-1052558; CC O75460-2; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-25852368, EBI-2802743; CC O75460-2; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-25852368, EBI-25830200; CC O75460-2; Q8N2H9-4: PELI3; NbExp=3; IntAct=EBI-25852368, EBI-25852006; CC O75460-2; O15534: PER1; NbExp=3; IntAct=EBI-25852368, EBI-2557276; CC O75460-2; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-25852368, EBI-21503705; CC O75460-2; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-25852368, EBI-26412802; CC O75460-2; Q14181: POLA2; NbExp=3; IntAct=EBI-25852368, EBI-712752; CC O75460-2; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-25852368, EBI-13292283; CC O75460-2; O14544: SOCS6; NbExp=3; IntAct=EBI-25852368, EBI-3929549; CC O75460-2; Q496A3: SPATS1; NbExp=3; IntAct=EBI-25852368, EBI-3923692; CC O75460-2; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-25852368, EBI-9089156; CC O75460-2; P49459: UBE2A; NbExp=3; IntAct=EBI-25852368, EBI-2339348; CC O75460-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-25852368, EBI-10316321; CC O75460-2; Q9BYN7-2: ZNF341; NbExp=3; IntAct=EBI-25852368, EBI-16435478; CC O75460-2; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-25852368, EBI-18036029; CC O75460-2; Q9BRT8: ZNG1A; NbExp=3; IntAct=EBI-25852368, EBI-1054417; CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:9637683}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:9637683}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O75460-1; Sequence=Displayed; CC Name=2; CC IsoId=O75460-2; Sequence=VSP_034582, VSP_034583; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. High levels observed in CC pancreatic tissue. {ECO:0000269|PubMed:9637683}. CC -!- INDUCTION: Induced by the ER stressor tunicamycin. CC {ECO:0000269|PubMed:36739529}. CC -!- PTM: Autophosphorylated following homodimerization. Autophosphorylation CC promotes activation of the endoribonuclease domain (PubMed:12637535, CC PubMed:21317875, PubMed:28128204, PubMed:9637683). In response to ER CC stress, phosphorylated at Ser-724, Ser-729 and possibly Ser-726; CC phosphorylation promotes oligomerization and endoribonuclease activity CC (PubMed:30118681). Dephosphorylated at Ser-724, Ser-729 and possibly CC Ser-726 by RPAP2 to abort failed ER-stress adaptation and trigger CC apoptosis (PubMed:30118681). Phosphorylated at Ser-724; in response to CC the ER stressor tunicamycin (PubMed:36739529). CC {ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:21317875, CC ECO:0000269|PubMed:28128204, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:36739529, ECO:0000269|PubMed:9637683}. CC -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases both CC kinase and endonuclease activities. {ECO:0000269|PubMed:23103912}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059198; AAC25991.1; -; mRNA. DR EMBL; AK292403; BAF85092.1; -; mRNA. DR EMBL; DA254477; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AB209869; BAD93106.1; -; mRNA. DR EMBL; AC005803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC025362; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471109; EAW94214.1; -; Genomic_DNA. DR EMBL; BC130405; AAI30406.1; -; mRNA. DR EMBL; BC130407; AAI30408.1; -; mRNA. DR EMBL; BI912495; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS45762.1; -. [O75460-1] DR RefSeq; NP_001424.3; NM_001433.5. [O75460-1] DR PDB; 2HZ6; X-ray; 3.10 A; A=24-390. DR PDB; 3P23; X-ray; 2.70 A; A/B/C/D=547-977. DR PDB; 4U6R; X-ray; 2.50 A; A=547-977. DR PDB; 4YZ9; X-ray; 2.46 A; A/B/C=562-966. DR PDB; 4YZC; X-ray; 2.49 A; A/B=562-966. DR PDB; 4YZD; X-ray; 3.10 A; A/B/C=562-966. DR PDB; 4Z7G; X-ray; 2.60 A; A/B=562-977. DR PDB; 4Z7H; X-ray; 2.90 A; A/B=562-977. DR PDB; 5HGI; X-ray; 2.58 A; A=547-977. DR PDB; 6HV0; X-ray; 2.73 A; A=562-977. DR PDB; 6HX1; X-ray; 2.14 A; A=562-964. DR PDB; 6SHC; X-ray; 3.55 A; A=24-390. DR PDB; 6URC; X-ray; 2.20 A; A/B=547-977. DR PDB; 6W39; X-ray; 1.74 A; A/B=547-977. DR PDB; 6W3A; X-ray; 2.61 A; A/B=547-977. DR PDB; 6W3B; X-ray; 2.57 A; A=547-977. DR PDB; 6W3C; X-ray; 2.30 A; A/B/C/D=547-977. DR PDB; 6W3E; X-ray; 2.74 A; A/B=547-977. DR PDB; 6W3K; X-ray; 2.08 A; A=547-977. DR PDB; 6XDB; X-ray; 2.45 A; A=547-977. DR PDB; 6XDD; X-ray; 2.40 A; A/B=547-977. DR PDB; 6XDF; X-ray; 2.54 A; A/B=547-977. DR PDB; 7BMK; X-ray; 1.85 A; A/B=547-977. DR PDB; 8UVL; X-ray; 2.43 A; A=547-977. DR PDBsum; 2HZ6; -. DR PDBsum; 3P23; -. DR PDBsum; 4U6R; -. DR PDBsum; 4YZ9; -. DR PDBsum; 4YZC; -. DR PDBsum; 4YZD; -. DR PDBsum; 4Z7G; -. DR PDBsum; 4Z7H; -. DR PDBsum; 5HGI; -. DR PDBsum; 6HV0; -. DR PDBsum; 6HX1; -. DR PDBsum; 6SHC; -. DR PDBsum; 6URC; -. DR PDBsum; 6W39; -. DR PDBsum; 6W3A; -. DR PDBsum; 6W3B; -. DR PDBsum; 6W3C; -. DR PDBsum; 6W3E; -. DR PDBsum; 6W3K; -. DR PDBsum; 6XDB; -. DR PDBsum; 6XDD; -. DR PDBsum; 6XDF; -. DR PDBsum; 7BMK; -. DR PDBsum; 8UVL; -. DR AlphaFoldDB; O75460; -. DR SMR; O75460; -. DR BioGRID; 108391; 71. DR CORUM; O75460; -. DR DIP; DIP-31711N; -. DR FunCoup; O75460; 1464. DR IntAct; O75460; 74. DR MINT; O75460; -. DR STRING; 9606.ENSP00000401445; -. DR BindingDB; O75460; -. DR ChEMBL; CHEMBL1163101; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07382; N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine. DR DrugCentral; O75460; -. DR GuidetoPHARMACOLOGY; 2020; -. DR TCDB; 8.A.104.1.9; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; O75460; 1 site, No reported glycans. DR GlyGen; O75460; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O75460; -. DR PhosphoSitePlus; O75460; -. DR BioMuta; ERN1; -. DR CPTAC; CPTAC-3100; -. DR CPTAC; CPTAC-3101; -. DR jPOST; O75460; -. DR MassIVE; O75460; -. DR PaxDb; 9606-ENSP00000401445; -. DR PeptideAtlas; O75460; -. DR ProteomicsDB; 50021; -. [O75460-1] DR Pumba; O75460; -. DR Antibodypedia; 4011; 736 antibodies from 44 providers. DR DNASU; 2081; -. DR Ensembl; ENST00000433197.4; ENSP00000401445.2; ENSG00000178607.17. [O75460-1] DR Ensembl; ENST00000606895.2; ENSP00000475519.1; ENSG00000178607.17. [O75460-2] DR GeneID; 2081; -. DR KEGG; hsa:2081; -. DR MANE-Select; ENST00000433197.4; ENSP00000401445.2; NM_001433.5; NP_001424.3. DR UCSC; uc002jdz.3; human. [O75460-1] DR AGR; HGNC:3449; -. DR ClinPGx; PA27861; -. DR CTD; 2081; -. DR DisGeNET; 2081; -. DR GeneCards; ERN1; -. DR HGNC; HGNC:3449; ERN1. DR HPA; ENSG00000178607; Tissue enhanced (adrenal gland, pancreas). DR MIM; 604033; gene. DR OpenTargets; ENSG00000178607; -. DR VEuPathDB; HostDB:ENSG00000178607; -. DR eggNOG; KOG1027; Eukaryota. DR GeneTree; ENSGT00940000159761; -. DR HOGENOM; CLU_004875_1_1_1; -. DR InParanoid; O75460; -. DR OMA; NYWVERF; -. DR OrthoDB; 63989at2759; -. DR PAN-GO; O75460; 6 GO annotations based on evolutionary models. DR PhylomeDB; O75460; -. DR PathwayCommons; O75460; -. DR Reactome; R-HSA-381070; IRE1alpha activates chaperones. DR SignaLink; O75460; -. DR SIGNOR; O75460; -. DR Agora; ENSG00000178607; -. DR BioGRID-ORCS; 2081; 13 hits in 1188 CRISPR screens. DR ChiTaRS; ERN1; human. DR EvolutionaryTrace; O75460; -. DR GeneWiki; ERN1; -. DR GenomeRNAi; 2081; -. DR Pharos; O75460; Tchem. DR PRO; PR:O75460; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O75460; protein. DR Bgee; ENSG00000178607; Expressed in parotid gland and 159 other cell types or tissues. DR GO; GO:1990597; C:AIP1-IRE1 complex; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB. DR GO; GO:1990332; C:Ire1 complex; NAS:ParkinsonsUK-UCL. DR GO; GO:1990630; C:IRE1-RACK1-PP2A complex; IDA:ParkinsonsUK-UCL. DR GO; GO:1990604; C:IRE1-TRAF2-ASK1 complex; IDA:ParkinsonsUK-UCL. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0005637; C:nuclear inner membrane; IEA:Ensembl. DR GO; GO:0043531; F:ADP binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0030544; F:Hsp70 protein binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0051879; F:Hsp90 protein binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; IDA:UniProtKB. DR GO; GO:0051082; F:unfolded protein binding; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IDA:ParkinsonsUK-UCL. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0034620; P:cellular response to unfolded protein; IDA:ParkinsonsUK-UCL. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IDA:ParkinsonsUK-UCL. DR GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB. DR GO; GO:1901142; P:insulin metabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISS:UniProtKB. DR GO; GO:0036498; P:IRE1-mediated unfolded protein response; IDA:UniProtKB. DR GO; GO:0006402; P:mRNA catabolic process; TAS:ParkinsonsUK-UCL. DR GO; GO:0070054; P:mRNA splicing, via endonucleolytic cleavage and ligation; IDA:UniProtKB. DR GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:ParkinsonsUK-UCL. DR GO; GO:0033120; P:positive regulation of RNA splicing; IDA:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL. DR GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:ParkinsonsUK-UCL. DR CDD; cd09769; Luminal_IRE1; 1. DR CDD; cd10422; RNase_Ire1; 1. DR CDD; cd13982; STKc_IRE1; 1. DR FunFam; 2.130.10.10:FF:000225; Endoplasmic reticulum to nucleus-signaling 1; 1. DR FunFam; 3.30.200.20:FF:000077; Putative Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.20.1440.180:FF:000001; Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.10.510.10:FF:000215; serine/threonine-protein kinase/endoribonuclease IRE1 isoform X1; 1. DR Gene3D; 1.20.1440.180; KEN domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR045133; IRE1/2-like. DR InterPro; IPR010513; KEN_dom. DR InterPro; IPR038357; KEN_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR018391; PQQ_b-propeller_rpt. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR011047; Quinoprotein_ADH-like_sf. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR PANTHER; PTHR13954; IRE1-RELATED; 1. DR PANTHER; PTHR13954:SF17; SERINE_THREONINE-PROTEIN KINASE_ENDORIBONUCLEASE IRE1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF06479; Ribonuc_2-5A; 1. DR SMART; SM00564; PQQ; 5. DR SMART; SM00580; PUG; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50998; Quinoprotein alcohol dehydrogenase-like; 1. DR PROSITE; PS51392; KEN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis; KW ATP-binding; Disulfide bond; Endoplasmic reticulum; Glycoprotein; KW Hydrolase; Kinase; Magnesium; Membrane; Metal-binding; KW Multifunctional enzyme; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Unfolded protein response. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..977 FT /note="Serine/threonine-protein kinase/endoribonuclease FT IRE1" FT /id="PRO_0000024327" FT TOPO_DOM 19..443 FT /note="Lumenal" FT /evidence="ECO:0000255" FT TRANSMEM 444..464 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 465..977 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 571..832 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 835..963 FT /note="KEN" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00725" FT REGION 410..434 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 491..559 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 906..907 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT COMPBIAS 410..419 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 513..552 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 688 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 577..585 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 599 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683, FT ECO:0007744|PDB:3P23" FT BINDING 643..645 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 690..693 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 711 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT SITE 892 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681, FT ECO:0000269|PubMed:36739529" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681" FT MOD_RES 973 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 176 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 19..70 FT /note="IFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEE FT -> VSDRGAWGGGQLATAGSGPGQRRGAGAGVRAGSATAAARCPVSPAVGGSGRA (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034582" FT VAR_SEQ 71..977 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034583" FT VARIANT 244 FT /note="N -> S (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs1397145500)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040488" FT VARIANT 418 FT /note="V -> M (in dbSNP:rs55869215)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040489" FT VARIANT 474 FT /note="L -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs186305118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040490" FT VARIANT 635 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs146710304)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040491" FT VARIANT 700 FT /note="N -> S (in dbSNP:rs918253870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040492" FT VARIANT 769 FT /note="S -> F (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040493" FT VARIANT 830 FT /note="P -> L (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs1279653488)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040494" FT MUTAGEN 105 FT /note="Q->E: Impaired ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 109 FT /note="C->S: No effect on dimerization. No effect on FT interaction with P4HB; when associated with S-148 and S- FT 332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 123 FT /note="D->P: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 125 FT /note="W->A: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 148 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-332. Abolishes interaction with PDIA6. FT Prolonged splicing of XBP1, probably due to prolonged FT activation of PDIA6. Inhibits formation of oxidized FT multimeric forms of ERN1 in response to ER stress. No FT effect on interaction with P4HB; when associated with S-109 FT and S-332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:32149426" FT MUTAGEN 332 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-148. No effect on interaction with P4HB; FT when associated with S-109 and S-148." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 599 FT /note="K->A: Loss of autophosphorylation and of FT endoribonuclease activity. Inhibition of growth arrest." FT /evidence="ECO:0000269|PubMed:11175748, FT ECO:0000269|PubMed:9637683" FT CONFLICT 190..191 FT /note="DV -> EG (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 768 FT /note="I -> V (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 816 FT /note="D -> G (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 824..825 FT /note="KH -> ND (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 880 FT /note="V -> D (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="M -> T (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 924 FT /note="S -> T (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT STRAND 32..37 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 52..57 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 77..79 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 82..84 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 100..104 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 120..128 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 154..164 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 168..172 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 176..182 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 205..209 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 216..221 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 226..231 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 243..246 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 247..264 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 273..279 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 286..288 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 297..300 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 359..361 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 564..566 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 569..578 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 581..583 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 585..591 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 594..601 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 603..605 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 606..619 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 628..633 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 645..648 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 649..654 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 655..657 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 658..661 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 665..681 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 694..697 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 701..703 FT /evidence="ECO:0007829|PDB:6W3E" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 711..716 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:6HV0" FT STRAND 723..727 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:6HV0" FT TURN 732..736 FT /evidence="ECO:0007829|PDB:6HV0" FT HELIX 740..743 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 744..746 FT /evidence="ECO:0007829|PDB:6XDF" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 778..780 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 781..787 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 793..795 FT /evidence="ECO:0007829|PDB:4YZC" FT HELIX 800..812 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 817..819 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 823..827 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 830..832 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 835..848 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 849..851 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 854..856 FT /evidence="ECO:0007829|PDB:4YZ9" FT HELIX 857..863 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 866..869 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 880..884 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 887..890 FT /evidence="ECO:0007829|PDB:6W3K" FT HELIX 897..909 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 911..913 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 916..922 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 927..936 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 940..947 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 948..951 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 952..954 FT /evidence="ECO:0007829|PDB:3P23" FT HELIX 955..957 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 958..960 FT /evidence="ECO:0007829|PDB:6W39" SQ SEQUENCE 977 AA; 109735 MW; A2DF808CCE015536 CRC64; MPARRLLLLL TLLLPGLGIF GSTSTVTLPE TLLFVSTLDG SLHAVSKRTG SIKWTLKEDP VLQVPTHVEE PAFLPDPNDG SLYTLGSKNN EGLTKLPFTI PELVQASPCR SSDGILYMGK KQDIWYVIDL LTGEKQQTLS SAFADSLCPS TSLLYLGRTE YTITMYDTKT RELRWNATYF DYAASLPEDD VDYKMSHFVS NGDGLVVTVD SESGDVLWIQ NYASPVVAFY VWQREGLRKV MHINVAVETL RYLTFMSGEV GRITKWKYPF PKETEAKSKL TPTLYVGKYS TSLYASPSMV HEGVAVVPRG STLPLLEGPQ TDGVTIGDKG ECVITPSTDV KFDPGLKSKN KLNYLRNYWL LIGHHETPLS ASTKMLERFP NNLPKHRENV IPADSEKKSF EEVINLVDQT SENAPTTVSR DVEEKPAHAP ARPEAPVDSM LKDMATIILS TFLLIGWVAF IITYPLSMHQ QQQLQHQQFQ KELEKIQLLQ QQQQQLPFHP PGDTAQDGEL LDTSGPYSES SGTSSPSTSP RASNHSLCSG SSASKAGSSP SLEQDDGDEE TSVVIVGKIS FCPKDVLGHG AEGTIVYRGM FDNRDVAVKR ILPECFSFAD REVQLLRESD EHPNVIRYFC TEKDRQFQYI AIELCAATLQ EYVEQKDFAH LGLEPITLLQ QTTSGLAHLH SLNIVHRDLK PHNILISMPN AHGKIKAMIS DFGLCKKLAV GRHSFSRRSG VPGTEGWIAP EMLSEDCKEN PTYTVDIFSA GCVFYYVISE GSHPFGKSLQ RQANILLGAC SLDCLHPEKH EDVIARELIE KMIAMDPQKR PSAKHVLKHP FFWSLEKQLQ FFQDVSDRIE KESLDGPIVK QLERGGRAVV KMDWRENITV PLQTDLRKFR TYKGGSVRDL LRAMRNKKHH YRELPAEVRE TLGSLPDDFV CYFTSRFPHL LAHTYRAMEL CSHERLFQPY YFHEPPEPQP PVTPDAL // ID FABP6_HUMAN Reviewed; 128 AA. AC P51161; Q07DR7; Q8TBI3; Q9UGI7; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 2. DT 28-JAN-2026, entry version 205. DE RecName: Full=Gastrotropin; DE Short=GT; DE AltName: Full=Fatty acid-binding protein 6; DE AltName: Full=Ileal lipid-binding protein; DE Short=ILBP; DE AltName: Full=Intestinal 15 kDa protein; DE Short=I-15P; DE AltName: Full=Intestinal bile acid-binding protein; DE Short=I-BABP; GN Name=FABP6; Synonyms=ILBP, ILLBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Ileum; RX PubMed=7619861; DOI=10.1016/0005-2760(95)00098-w; RA Oelkers P., Dawson P.A.; RT "Cloning and chromosomal localization of the human ileal lipid-binding RT protein."; RL Biochim. Biophys. Acta 1257:199-202(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BILE ACID-BINDING, AND TISSUE RP SPECIFICITY. RC TISSUE=Ileum; RX PubMed=7588781; DOI=10.1111/j.1432-1033.1995.406_2.x; RA Fujita M., Fujii H., Kanda T., Sato E., Hatakeyama K., Ono T.; RT "Molecular cloning, expression, and characterization of a human intestinal RT 15-kDa protein."; RL Eur. J. Biochem. 233:406-413(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), ALTERNATIVE RP PROMOTER USAGE, SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=17909007; DOI=10.1158/0008-5472.can-06-3690; RA Fang C., Dean J., Smith J.W.; RT "A novel variant of ileal bile acid binding protein is up-regulated through RT nuclear factor-kappaB activation in colorectal adenocarcinoma."; RL Cancer Res. 67:9039-9046(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS RP HIS-33 AND TYR-55. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19 (ISOFORM 1). RA Barley N.F., Shaw-Smith C.J., Chakravarty P., Howard A., Legon S., RA Walters J.R.; RT "The human ileal bile acid binding protein gene: promoter sequence and RT effects of CDX2 on expression."; RL Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP BILE ACID-BINDING. RX PubMed=11461829; DOI=10.1016/s1357-2725(01)00070-x; RA Zimmerman A.W., van Moerkerk H.T., Veerkamp J.H.; RT "Ligand specificity and conformational stability of human fatty acid- RT binding proteins."; RL Int. J. Biochem. Cell Biol. 33:865-876(2001). RN [8] RP STRUCTURE BY NMR IN COMPLEX WITH TAUROCHOLATE, AND DOMAIN. RX PubMed=12486725; DOI=10.1002/prot.10289; RA Kurz M., Brachvogel V., Matter H., Stengelin S., Thuering H., Kramer W.; RT "Insights into the bile acid transportation system: the human ileal lipid- RT binding protein-cholyltaurine complex and its comparison with homologous RT structures."; RL Proteins 50:312-328(2003). RN [9] RP STRUCTURE BY NMR IN COMPLEX WITH GLYCOCHOLATE AND GLYCOCHENODEOXYCHOLATE, RP AND DOMAIN. RX PubMed=26613247; DOI=10.1111/febs.13610; RA Horvath G., Bencsura A., Simon A., Tochtrop G.P., DeKoster G.T., RA Covey D.F., Cistola D.P., Toke O.; RT "Structural determinants of ligand binding in the ternary complex of human RT ileal bile acid binding protein with glycocholate and RT glycochenodeoxycholate obtained from solution NMR."; RL FEBS J. 283:541-555(2016). RN [10] RP VARIANT MET-79. RX PubMed=19744871; DOI=10.1016/j.ymgme.2009.08.001; RA Fisher E., Grallert H., Klapper M., Pfaefflin A., Schrezenmeir J., RA Illig T., Boeing H., Doering F.; RT "Evidence for the Thr79Met polymorphism of the ileal fatty acid binding RT protein (FABP6) to be associated with type 2 diabetes in obese RT individuals."; RL Mol. Genet. Metab. 98:400-405(2009). CC -!- FUNCTION: Binds to bile acids and is involved in enterohepatic bile CC acid metabolism. Required for efficient apical to basolateral transport CC of conjugated bile acids in ileal enterocytes (By similarity). In vitro CC binds to bile acids in the order: deoxycholic acid > cholic acid > CC chenodeoxycholic acid and respective BA conjugation modifies affinities CC in the order taurine-conjugated > glycine-conjugated > unconjugated CC bile acids. Stimulates gastric acid and pepsinogen secretion (By CC similarity). {ECO:0000250|UniProtKB:P10289, CC ECO:0000250|UniProtKB:P51162, ECO:0000269|PubMed:12486725, CC ECO:0000269|PubMed:7588781}. CC -!- FUNCTION: [Isoform 2]: Essential for the survival of colon cancer cells CC to bile acid-induced apoptosis. {ECO:0000269|PubMed:17909007}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm CC {ECO:0000250|UniProtKB:P80020}. Membrane; Peripheral membrane protein CC {ECO:0000250|UniProtKB:P50119}; Cytoplasmic side CC {ECO:0000250|UniProtKB:P50119}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm CC {ECO:0000269|PubMed:17909007}. Note=Localized close to nucleus on the CC apical side of both normal and neoplastic cells. CC {ECO:0000269|PubMed:17909007}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage; Named isoforms=2; CC Name=1; CC IsoId=P51161-1; Sequence=Displayed; CC Name=2; Synonyms=IBABP-L; CC IsoId=P51161-2; Sequence=VSP_038039; CC -!- TISSUE SPECIFICITY: Isoform 1 is expressed in the jejunum, ileum, cecum CC and ascending colon intestine. Isoform 2 is xpressed in the CC gallbladder, duodenum, jejunum, ileum, cecum, ascending, transverse and CC descending colon, sigmoid colon and rectum. Isoform 2 is expressed in CC colorectal adenocarcinomas and their adjacent normal mucosa (at protein CC level). {ECO:0000269|PubMed:17909007, ECO:0000269|PubMed:7588781, CC ECO:0000269|PubMed:7619861}. CC -!- INDUCTION: Isoform 1 is up-regulated by chenodeoxycholic acid (CDCA) CC via the FXR transcription pathway. Isoform 2 is up-regulated by NF- CC kappa-B and in all stages of colorectal adenocarcinoma. Isoform 1 is CC not up-regulated in all stages of colorectal adenocarcinoma. CC {ECO:0000269|PubMed:17909007}. CC -!- DOMAIN: Forms a beta-barrel structure that accommodates the hydrophobic CC ligand in its interior. Can bind at least two ligands per molecule, CC however, the stoichiometry is debated. {ECO:0000305|PubMed:12486725, CC ECO:0000305|PubMed:26613247}. CC -!- SIMILARITY: Belongs to the calycin superfamily. Fatty-acid binding CC protein (FABP) family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH22489.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U19869; AAB82751.1; -; mRNA. DR EMBL; X90908; CAA62415.1; -; mRNA. DR EMBL; DQ132786; ABA12611.1; -; mRNA. DR EMBL; AC008609; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC112191; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC022489; AAH22489.1; ALT_INIT; mRNA. DR EMBL; AJ250902; CAB65728.1; -; Genomic_DNA. DR CCDS; CCDS43393.1; -. [P51161-2] DR CCDS; CCDS4349.1; -. [P51161-1] DR PIR; S63983; S63983. DR RefSeq; NP_001035532.1; NM_001040442.1. [P51161-2] DR RefSeq; NP_001124430.1; NM_001130958.2. [P51161-2] DR RefSeq; NP_001436.1; NM_001445.3. [P51161-1] DR PDB; 1O1U; NMR; -; A=2-128. DR PDB; 1O1V; NMR; -; A=2-128. DR PDB; 2MM3; NMR; -; A=2-128. DR PDB; 5L8I; X-ray; 1.88 A; A/B/C=1-128. DR PDB; 5L8N; X-ray; 2.12 A; A/B/C=1-128. DR PDB; 5L8O; X-ray; 2.39 A; A/B/C=1-128. DR PDBsum; 1O1U; -. DR PDBsum; 1O1V; -. DR PDBsum; 2MM3; -. DR PDBsum; 5L8I; -. DR PDBsum; 5L8N; -. DR PDBsum; 5L8O; -. DR AlphaFoldDB; P51161; -. DR BMRB; P51161; -. DR SMR; P51161; -. DR BioGRID; 108470; 6. DR FunCoup; P51161; 1163. DR IntAct; P51161; 2. DR STRING; 9606.ENSP00000377549; -. DR BindingDB; P51161; -. DR ChEMBL; CHEMBL4523235; -. DR DrugBank; DB02659; Cholic Acid. DR DrugBank; DB02691; Glycocholic acid. DR DrugBank; DB04348; Taurocholic acid. DR SwissLipids; SLP:000001518; -. DR iPTMnet; P51161; -. DR PhosphoSitePlus; P51161; -. DR BioMuta; FABP6; -. DR DMDM; 1708457; -. DR jPOST; P51161; -. DR MassIVE; P51161; -. DR PaxDb; 9606-ENSP00000377549; -. DR PeptideAtlas; P51161; -. DR ProteomicsDB; 56292; -. [P51161-1] DR ProteomicsDB; 56293; -. [P51161-2] DR Antibodypedia; 1989; 238 antibodies from 31 providers. DR DNASU; 2172; -. DR Ensembl; ENST00000393980.8; ENSP00000377549.4; ENSG00000170231.17. [P51161-2] DR Ensembl; ENST00000402432.4; ENSP00000385433.4; ENSG00000170231.17. [P51161-1] DR GeneID; 2172; -. DR KEGG; hsa:2172; -. DR MANE-Select; ENST00000402432.4; ENSP00000385433.4; NM_001445.3; NP_001436.1. DR UCSC; uc003lxx.2; human. [P51161-1] DR AGR; HGNC:3561; -. DR ClinPGx; PA27962; -. DR CTD; 2172; -. DR DisGeNET; 2172; -. DR GeneCards; FABP6; -. DR HGNC; HGNC:3561; FABP6. DR HPA; ENSG00000170231; Tissue enriched (intestine). DR MIM; 600422; gene. DR OpenTargets; ENSG00000170231; -. DR VEuPathDB; HostDB:ENSG00000170231; -. DR eggNOG; KOG4015; Eukaryota. DR GeneTree; ENSGT00940000157139; -. DR HOGENOM; CLU_113772_4_0_1; -. DR InParanoid; P51161; -. DR OrthoDB; 10016075at2759; -. DR PAN-GO; P51161; 4 GO annotations based on evolutionary models. DR PhylomeDB; P51161; -. DR PathwayCommons; P51161; -. DR Reactome; R-HSA-159418; Recycling of bile acids and salts. DR Reactome; R-HSA-163560; Triglyceride catabolism. DR Reactome; R-HSA-9623433; NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis. DR SIGNOR; P51161; -. DR Agora; ENSG00000170231; -. DR BioGRID-ORCS; 2172; 6 hits in 1149 CRISPR screens. DR ChiTaRS; FABP6; human. DR EvolutionaryTrace; P51161; -. DR GeneWiki; FABP6; -. DR GenomeRNAi; 2172; -. DR Pharos; P51161; Tbio. DR PRO; PR:P51161; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P51161; protein. DR Bgee; ENSG00000170231; Expressed in ileal mucosa and 137 other cell types or tissues. DR ExpressionAtlas; P51161; baseline and differential. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005504; F:fatty acid binding; IBA:GO_Central. DR GO; GO:0008289; F:lipid binding; TAS:ProtInc. DR GO; GO:0015908; P:fatty acid transport; IBA:GO_Central. DR GO; GO:0006629; P:lipid metabolic process; NAS:ProtInc. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR CDD; cd19446; FABP6; 1. DR FunFam; 2.40.128.20:FF:000006; Fatty acid-binding protein, liver; 1. DR Gene3D; 2.40.128.20; -; 1. DR InterPro; IPR012674; Calycin. DR InterPro; IPR000463; Fatty_acid-bd. DR InterPro; IPR031259; ILBP. DR PANTHER; PTHR11955; FATTY ACID BINDING PROTEIN; 1. DR Pfam; PF14651; Lipocalin_7; 1. DR PRINTS; PR00178; FATTYACIDBP. DR SUPFAM; SSF50814; Lipocalins; 1. DR PROSITE; PS00214; FABP; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative promoter usage; Cytoplasm; KW Lipid transport; Lipid-binding; Membrane; Proteomics identification; KW Reference proteome; Transport. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P10289" FT CHAIN 2..128 FT /note="Gastrotropin" FT /id="PRO_0000067380" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000250|UniProtKB:P10289" FT VAR_SEQ 1 FT /note="M -> MKTVTMMMVVEMQALTQVLRAVLSACTWVSRKGDLQRMKQTHKGKPP FT SSM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17909007" FT /id="VSP_038039" FT VARIANT 33 FT /note="R -> H (in dbSNP:rs17856662)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_039578" FT VARIANT 55 FT /note="S -> Y (in dbSNP:rs17852045)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_039579" FT VARIANT 79 FT /note="T -> M (probable risk factor for type 2 diabetes FT obese individuals; dbSNP:rs1130435)" FT /evidence="ECO:0000269|PubMed:19744871" FT /id="VAR_039580" FT STRAND 5..14 FT /evidence="ECO:0007829|PDB:5L8I" FT HELIX 15..22 FT /evidence="ECO:0007829|PDB:5L8I" FT HELIX 26..33 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 37..44 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 47..54 FT /evidence="ECO:0007829|PDB:5L8I" FT TURN 55..57 FT /evidence="ECO:0007829|PDB:5L8O" FT STRAND 59..65 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 68..72 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:5L8N" FT STRAND 80..83 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 90..95 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 98..104 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 106..115 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 118..127 FT /evidence="ECO:0007829|PDB:5L8I" SQ SEQUENCE 128 AA; 14371 MW; 173CBC5DBEDADDE1 CRC64; MAFTGKFEME SEKNYDEFMK LLGISSDVIE KARNFKIVTE VQQDGQDFTW SQHYSGGHTM TNKFTVGKES NIQTMGGKTF KATVQMEGGK LVVNFPNYHQ TSEIVGDKLV EVSTIGGVTY ERVSKRLA // ID FGFR4_HUMAN Reviewed; 802 AA. AC P22455; G3JVM2; G3JVM5; G3JVM7; G3JVM9; O43785; Q14309; Q71TW8; Q8TDA0; AC Q96KE5; DT 01-AUG-1991, integrated into UniProtKB/Swiss-Prot. DT 27-APR-2001, sequence version 2. DT 28-JAN-2026, entry version 248. DE RecName: Full=Fibroblast growth factor receptor 4; DE Short=FGFR-4; DE EC=2.7.10.1; DE AltName: CD_antigen=CD334; DE Flags: Precursor; GN Name=FGFR4; Synonyms=JTK2, TKF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1709094; DOI=10.1002/j.1460-2075.1991.tb07654.x; RA Partanen J.M., Maekelae T.P., Eerola E., Korhonen J., Hirvonen H., RA Claesson-Welsh L., Alitalo K.; RT "FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct RT expression pattern."; RL EMBO J. 10:1347-1354(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS RECEPTOR FOR FGF1 RP AND FGF2. RC TISSUE=Mammary gland; RX PubMed=7680645; DOI=10.1016/s0021-9258(18)53334-2; RA Ron D., Reich R., Chedid M., Lengel C., Cohen O.E., Chan A.M., Neufeld G., RA Miki T., Tronick S.R.; RT "Fibroblast growth factor receptor 4 is a high affinity receptor for both RT acidic and basic fibroblast growth factor but not for keratinocyte growth RT factor."; RL J. Biol. Chem. 268:5388-5394(1993). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT LEU-136, TISSUE RP SPECIFICITY, AND SUBCELLULAR LOCATION. RC TISSUE=Intestine; RX PubMed=10631118; DOI=10.1006/bbrc.1999.2010; RA Takaishi S., Sawada M., Morita Y., Seno H., Fukuzawa H., Chiba T.; RT "Identification of a novel alternative splicing of human FGF receptor 4: RT soluble-form splice variant expressed in human gastrointestinal epithelial RT cells."; RL Biochem. Biophys. Res. Commun. 267:658-662(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9457674; DOI=10.1007/s003359900703; RA Kostrzewa M., Muller U.; RT "Genomic structure and complete sequence of the human FGFR4 gene."; RL Mamm. Genome 9:131-135(1998). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS ILE-10 AND LEU-136, RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=21882254; DOI=10.1002/mc.20848; RA Marshall A.D., van der Ent M.A., Grosveld G.C.; RT "PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma."; RL Mol. Carcinog. 51:807-815(2012). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-136. RA Lind D.L., Cox D.R.; RT "Sequence variation in fibroblast growth factor receptors 3 and 4."; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-10; LEU-136 AND RP ARG-388. RG NIEHS SNPs program; RL Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-136. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 609-676. RC TISSUE=Blood; RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [12] RP RETRACTED PAPER. RX PubMed=11781352; DOI=10.1172/jci14036; RA Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.; RT "Targeted expression of a human pituitary tumor-derived isoform of FGF RT receptor-4 recapitulates pituitary tumorigenesis."; RL J. Clin. Invest. 109:69-78(2002). RN [13] RP RETRACTION NOTICE OF PUBMED:11781352. RX PubMed=26237043; DOI=10.1172/jci83399; RA Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.; RL J. Clin. Invest. 125:3303-3303(2015). RN [14] RP PROTEIN SEQUENCE OF 22-38. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [15] RP FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF SIGNALING VIA PLCG1 AND RP PIK3R1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-754, AND MUTAGENESIS RP OF TYR-754. RX PubMed=7518429; DOI=10.1016/s0021-9258(17)32309-8; RA Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G., Alitalo K.; RT "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). RT Comparison with FGFR-1."; RL J. Biol. Chem. 269:18320-18326(1994). RN [16] RP INTERACTION WITH FGF1; FGF2; FGF4; FGF6; FGF8 AND FGF9, AND FUNCTION IN RP CELL PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [17] RP FUNCTION IN CELL DIFFERENTIATION, MUTAGENESIS OF LYS-503, CATALYTIC RP ACTIVITY, AND IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1; FRS2; RP SRC; SHC; GAP43 AND CTTN. RX PubMed=11433297; DOI=10.1038/35083041; RA Cavallaro U., Niedermeyer J., Fuxa M., Christofori G.; RT "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor RT signalling."; RL Nat. Cell Biol. 3:650-657(2001). RN [18] RP INVOLVEMENT IN CANCER. RX PubMed=11830541; RA Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M., RA Knyazeva T., Mueller S., Gaertner S., Sures I., Wang H., Imyanitov E., RA Haering H.U., Knayzev P., Iacobelli S., Hoefler H., Ullrich A.; RT "Cancer progression and tumor cell motility are associated with the FGFR4 RT Arg(388) allele."; RL Cancer Res. 62:840-847(2002). RN [19] RP INTERACTION WITH FGF1; FGF17; FGF18; FGF19; FGF21 AND FGF23, AND FUNCTION RP IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [20] RP INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN SIGNALING AND IN RP REGULATION OF CYP7A1 AND BILE ACID SYNTHESIS. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [21] RP FUNCTION IN STAT1 PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF RP LYS-503, GLYCOSYLATION, AND PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [22] RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=18756523; DOI=10.1002/ijc.23578; RA Ma Z., Tsuchiya N., Yuasa T., Inoue T., Kumazawa T., Narita S., RA Horikawa Y., Tsuruta H., Obara T., Saito M., Satoh S., Ogawa O., RA Habuchi T.; RT "Polymorphisms of fibroblast growth factor receptor 4 have association with RT the development of prostate cancer and benign prostatic hyperplasia and the RT progression of prostate cancer in a Japanese population."; RL Int. J. Cancer 123:2574-2579(2008). RN [23] RP CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF PLCG1; RP FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ACTIVITY REGULATION, UBIQUITINATION, AND RP SUBCELLULAR LOCATION. RX PubMed=18480409; DOI=10.1091/mbc.e07-12-1219; RA Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.; RT "Ubiquitination of fibroblast growth factor receptor 1 is required for its RT intracellular sorting but not for its endocytosis."; RL Mol. Biol. Cell 19:3390-3403(2008). RN [24] RP CATALYTIC ACTIVITY, FUNCTION AS FGF2 RECEPTOR AND IN STIMULATION OF CELL RP PROLIFERATION, SUBCELLULAR LOCATION, INTERACTION WITH FGF2 AND HIP1, RP PHOSPHORYLATION AT TYR-642 AND TYR-643, INVOLVEMENT IN CANCER, AND RP CHARACTERIZATION OF VARIANT ARG-388. RX PubMed=18670643; DOI=10.1593/neo.08450; RA Wang J., Yu W., Cai Y., Ren C., Ittmann M.M.; RT "Altered fibroblast growth factor receptor 4 stability promotes prostate RT cancer progression."; RL Neoplasia 10:847-856(2008). RN [25] RP INVOLVEMENT IN CANCER. RX PubMed=20638838; DOI=10.1016/j.ejca.2010.06.017; RA Xu W., Li Y., Wang X., Chen B., Wang Y., Liu S., Xu J., Zhao W., Wu J.; RT "FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis RT including 8555 subjects."; RL Eur. J. Cancer 46:3332-3338(2010). RN [26] RP FUNCTION IN FGF19 SIGNALING AND IN REGULATION OF BILE ACID SYNTHESIS VIA RP CYP7A1, INTERACTION WITH FGF19; KL AND KLB, AUTOPHOSPHORYLATION, RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=20683963; DOI=10.1002/hep.23708; RA Triantis V., Saeland E., Bijl N., Oude-Elferink R.P., Jansen P.L.; RT "Glycosylation of fibroblast growth factor receptor 4 is a key regulator of RT fibroblast growth factor 19-mediated down-regulation of cytochrome P450 RT 7A1."; RL Hepatology 52:656-666(2010). RN [27] RP FUNCTION IN HEPATOCYTE PROLIFERATION AND FGF19 SIGNALING. RX PubMed=20018895; DOI=10.1074/jbc.m109.068783; RA Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R., Gupte J., RA Hager T., Wang Z., Lindberg R., Li Y.; RT "FGF19-induced hepatocyte proliferation is mediated through FGFR4 RT activation."; RL J. Biol. Chem. 285:5165-5170(2010). RN [28] RP FUNCTION IN DOWN-REGULATION OF MMP14, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH MMP14. RX PubMed=20798051; DOI=10.1073/pnas.0914459107; RA Sugiyama N., Varjosalo M., Meller P., Lohi J., Chan K.M., Zhou Z., RA Alitalo K., Taipale J., Keski-Oja J., Lehti K.; RT "FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a RT membrane type 1 matrix metalloproteinase-FGFR4 complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15786-15791(2010). RN [29] RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=21349172; DOI=10.1186/1471-2407-11-84; RA Xu B., Tong N., Chen S.Q., Hua L.X., Wang Z.J., Zhang Z.D., Chen M.; RT "FGFR4 Gly388Arg polymorphism contributes to prostate cancer development RT and progression: a meta-analysis of 2618 cases and 2305 controls."; RL BMC Cancer 11:84-84(2011). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP INVOLVEMENT IN CANCER. RX PubMed=21412156; DOI=10.1097/cej.0b013e3283457274; RA Frullanti E., Berking C., Harbeck N., Jezequel P., Haugen A., Mawrin C., RA Parise O. Jr., Sasaki H., Tsuchiya N., Dragani T.A.; RT "Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer RT prognostic factor."; RL Eur. J. Cancer Prev. 20:340-347(2011). RN [32] RP FUNCTION IN FGF19 SIGNALING, FUNCTION IN STIMULATION OF CELL PROLIFERATION RP AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND INTERACTION WITH FGF19; RP KLB AND SULFATED GLYCOSAMINOGLYCANS. RX PubMed=21653700; DOI=10.1074/jbc.m111.251140; RA Nakamura M., Uehara Y., Asada M., Honda E., Nagai N., Kimata K., Suzuki M., RA Imamura T.; RT "Sulfated glycosaminoglycans are required for specific and sensitive RT fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and RT betaKlotho."; RL J. Biol. Chem. 286:26418-26423(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [35] RP INTERACTION WITH STAT3, INVOLVEMENT IN CANCER, CHARACTERIZATION OF VARIANT RP ARG-388, AND PHOSPHORYLATION AT TYR-390. RX PubMed=26675719; DOI=10.1038/nature16449; RA Ulaganathan V.K., Sperl B., Rapp U.R., Ullrich A.; RT "Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding RT site."; RL Nature 528:570-574(2015). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-10; LEU-136; ALA-179; SER-426; ASN-516; RP MET-550; THR-712 AND ASN-772. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [37] RP REVIEW ON LIGAND SELECTIVITY AND SIGNALING. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [38] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [39] RP CHARACTERIZATION OF VARIANT ARG-388, AND FUNCTION IN TUMOR CELL INVASION. RX PubMed=20876804; DOI=10.1158/0008-5472.can-10-1223; RA Sugiyama N., Varjosalo M., Meller P., Lohi J., Hyytiainen M., Kilpinen S., RA Kallioniemi O., Ingvarsen S., Engelholm L.H., Taipale J., Alitalo K., RA Keski-Oja J., Lehti K.; RT "Fibroblast growth factor receptor 4 regulates tumor invasion by coupling RT fibroblast growth factor signaling to extracellular matrix degradation."; RL Cancer Res. 70:7851-7861(2010). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays a role in the regulation of CC cell proliferation, differentiation and migration, and in regulation of CC lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D CC metabolism and phosphate homeostasis. Required for normal down- CC regulation of the expression of CYP7A1, the rate-limiting enzyme in CC bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and CC FRS2. Ligand binding leads to the activation of several signaling CC cascades. Activation of PLCG1 leads to the production of the cellular CC signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and CC its lysosomal degradation. FGFR4 signaling is down-regulated by CC receptor internalization and degradation; MMP14 promotes CC internalization and degradation of FGFR4. Mutations that lead to CC constitutive kinase activation or impair normal FGFR4 inactivation lead CC to aberrant signaling. {ECO:0000269|PubMed:11433297, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409, CC ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20018895, CC ECO:0000269|PubMed:20683963, ECO:0000269|PubMed:20798051, CC ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21653700, CC ECO:0000269|PubMed:7518429, ECO:0000269|PubMed:7680645, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:18670643}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. CC {ECO:0000269|PubMed:18480409}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with FGF1, CC FGF2, FGF4, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, FGF19, FGF21 and CC FGF23 (in vitro). Binding affinity for FGF family members is enhanced CC by interactions between FGFs and heparan sulfate proteoglycans. CC Interacts with KLB; this strongly increases the affinity for FGF19 and CC FGF23. Affinity for FGF19 is strongly increased by KLB and sulfated CC glycosaminoglycans. KLB and KL both interact with the core-glycosylated CC FGFR4 in the endoplasmic reticulum and promote its degradation, so that CC only FGFR4 with fully mature N-glycans is expressed at the cell CC surface. Identified in a complex with NCAM1, CDH2, PLCG1, FRS2, SRC, CC SHC1, GAP43 and CTTN. Interacts with MMP14 and HIP1 (PubMed:11433297, CC PubMed:16597617, PubMed:17623664, PubMed:18670643, PubMed:20683963, CC PubMed:20798051, PubMed:21653700, PubMed:7518429, PubMed:8663044). CC Interacts with STAT3 (PubMed:26675719). {ECO:0000269|PubMed:11433297, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17623664, CC ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20683963, CC ECO:0000269|PubMed:20798051, ECO:0000269|PubMed:21653700, CC ECO:0000269|PubMed:26675719, ECO:0000269|PubMed:7518429, CC ECO:0000269|PubMed:8663044}. CC -!- INTERACTION: CC P22455; P11362: FGFR1; NbExp=3; IntAct=EBI-6256193, EBI-1028277; CC P22455; P50281: MMP14; NbExp=6; IntAct=EBI-6256193, EBI-992788; CC P22455; P07949: RET; NbExp=2; IntAct=EBI-6256193, EBI-2480756; CC P22455; P34741: SDC2; NbExp=2; IntAct=EBI-6256193, EBI-1172957; CC P22455; Q03167: TGFBR3; NbExp=2; IntAct=EBI-6256193, EBI-2852679; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Endosome. Endoplasmic reticulum. Note=Internalized from the CC cell membrane to recycling endosomes, and from there back to the cell CC membrane. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P22455-1; Sequence=Displayed; CC Name=2; Synonyms=Soluble-form; CC IsoId=P22455-2; Sequence=VSP_035108; CC -!- TISSUE SPECIFICITY: Expressed in gastrointestinal epithelial cells, CC pancreas, and gastric and pancreatic cancer cell lines. CC {ECO:0000269|PubMed:10631118}. CC -!- PTM: N-glycosylated. Full maturation of the glycan chains in the Golgi CC is essential for high affinity interaction with FGF19. CC -!- PTM: Ubiquitinated. Subject to proteasomal degradation when not fully CC glycosylated. {ECO:0000269|PubMed:18480409}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on tyrosine residues. Autophosphorylation CC occurs in trans between the two FGFR molecules present in the dimer. CC {ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:18670643, CC ECO:0000269|PubMed:7518429}. CC -!- DISEASE: Note=FGFR4 variants may be involved in the pathogenesis of CC various cancers. Variant Arg-388 predisposes cancer patients to CC accelerated disease progression and may be associated with poor CC prognosis. It has been found in prostate cancer as well as cancers of CC the breast, colon, head and neck, larynx, lung, skin. CC {ECO:0000269|PubMed:11830541, ECO:0000269|PubMed:18670643, CC ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20638838, CC ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21349172, CC ECO:0000269|PubMed:21412156, ECO:0000269|PubMed:21882254, CC ECO:0000269|PubMed:26675719}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: An additional N-terminally truncated cytoplasmic isoform was CC previously reported to exist. However, the paper was subsequently CC retracted due to concerns regarding duplication of panels in some CC figures. {ECO:0000305|PubMed:11781352, ECO:0000305|PubMed:26237043}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/512/FGFR4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X57205; CAA40490.1; -; mRNA. DR EMBL; L03840; AAB59389.1; -; mRNA. DR EMBL; AF202063; AAF27432.1; -; mRNA. DR EMBL; Y13901; CAA74200.1; -; Genomic_DNA. DR EMBL; AF359246; AAK51435.1; -; mRNA. DR EMBL; JN007471; AEO19712.1; -; mRNA. DR EMBL; JN007472; AEO19713.1; -; mRNA. DR EMBL; JN007473; AEO19714.1; -; mRNA. DR EMBL; JN007474; AEO19715.1; -; mRNA. DR EMBL; JN007475; AEO19716.1; -; mRNA. DR EMBL; JN007476; AEO19717.1; -; mRNA. DR EMBL; JN007477; AEO19718.1; -; mRNA. DR EMBL; JN007478; AEO19719.1; -; mRNA. DR EMBL; JN007479; AEO19720.1; -; mRNA. DR EMBL; JN007480; AEO19721.1; -; mRNA. DR EMBL; JN007481; AEO19722.1; -; mRNA. DR EMBL; JN007482; AEO19723.1; -; mRNA. DR EMBL; AF487555; AAM13666.1; -; Genomic_DNA. DR EMBL; EF571596; ABQ01235.1; -; Genomic_DNA. DR EMBL; AC027314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471195; EAW85036.1; -; Genomic_DNA. DR EMBL; BC011847; AAH11847.1; -; mRNA. DR EMBL; M59373; AAA63208.1; -; mRNA. DR CCDS; CCDS4410.1; -. [P22455-1] DR CCDS; CCDS4411.1; -. [P22455-2] DR PIR; S15345; TVHUF4. DR RefSeq; NP_001278909.1; NM_001291980.1. DR RefSeq; NP_001341913.1; NM_001354984.2. [P22455-1] DR RefSeq; NP_002002.3; NM_002011.4. [P22455-1] DR RefSeq; NP_075252.2; NM_022963.3. [P22455-2] DR RefSeq; NP_998812.1; NM_213647.3. [P22455-1] DR PDB; 4QQ5; X-ray; 2.20 A; A=445-753. DR PDB; 4QQC; X-ray; 2.40 A; A=445-753. DR PDB; 4QQJ; X-ray; 1.68 A; A=445-753. DR PDB; 4QQT; X-ray; 1.50 A; A=445-753. DR PDB; 4QRC; X-ray; 1.90 A; A=445-753. DR PDB; 4R6V; X-ray; 2.35 A; A=445-753. DR PDB; 4TYE; X-ray; 2.80 A; A=447-753. DR PDB; 4TYG; X-ray; 2.40 A; A=447-753. DR PDB; 4TYI; X-ray; 3.40 A; A=447-753. DR PDB; 4TYJ; X-ray; 2.45 A; A=447-753. DR PDB; 4UXQ; X-ray; 1.85 A; A=447-753. DR PDB; 4XCU; X-ray; 1.71 A; A=449-751. DR PDB; 5JKG; X-ray; 2.35 A; A=445-753. DR PDB; 5NUD; X-ray; 2.50 A; A/B=449-753. DR PDB; 5NWZ; X-ray; 2.37 A; A/B=449-753. DR PDB; 5XFF; X-ray; 2.70 A; A=445-753. DR PDB; 5XFJ; X-ray; 3.25 A; A=445-753. DR PDB; 6IUO; X-ray; 2.30 A; A=445-753. DR PDB; 6IUP; X-ray; 2.00 A; A=445-753. DR PDB; 6J6Y; X-ray; 2.15 A; A/D=141-244. DR PDB; 6JPE; X-ray; 1.60 A; A=445-753. DR PDB; 6JPJ; X-ray; 2.64 A; A=445-753. DR PDB; 6NVG; X-ray; 1.99 A; A=450-751. DR PDB; 6NVH; X-ray; 1.90 A; A=450-751. DR PDB; 6NVI; X-ray; 2.12 A; A=450-751. DR PDB; 6NVJ; X-ray; 2.30 A; A=450-751. DR PDB; 6NVK; X-ray; 2.30 A; A=450-751. DR PDB; 6V9C; X-ray; 1.90 A; A=449-751. DR PDB; 6YI8; X-ray; 2.13 A; A/B=447-753. DR PDB; 7DTZ; X-ray; 2.01 A; A=445-753. DR PDB; 7F3M; X-ray; 2.29 A; A=445-753. DR PDB; 7N1J; X-ray; 2.99 A; A/C=245-355. DR PDB; 7TYD; X-ray; 2.86 A; A/C=245-355. DR PDB; 7V29; X-ray; 1.98 A; A/B=445-753. DR PDB; 7VJL; X-ray; 2.90 A; A/B=453-753. DR PDB; 7WCT; X-ray; 2.11 A; A=445-753. DR PDB; 7WCW; X-ray; 2.32 A; A=445-753. DR PDB; 7WCX; X-ray; 2.17 A; A=445-753. DR PDB; 7YBO; X-ray; 2.31 A; A=445-753. DR PDB; 7YBP; X-ray; 2.24 A; A=445-753. DR PDB; 7YBX; X-ray; 2.23 A; A=445-753. DR PDB; 7YC1; X-ray; 2.54 A; A=445-753. DR PDB; 7YC3; X-ray; 1.99 A; A=445-753. DR PDB; 7YSW; EM; 3.03 A; C/E=142-354. DR PDB; 8KH6; X-ray; 1.62 A; A=445-753. DR PDB; 8KH7; X-ray; 1.52 A; A=445-753. DR PDB; 8KH8; X-ray; 1.49 A; A=445-753. DR PDB; 8KH9; X-ray; 1.42 A; A=454-753. DR PDB; 8W5C; X-ray; 2.30 A; A/B=453-752. DR PDB; 8XLQ; X-ray; 1.95 A; A=445-753. DR PDBsum; 4QQ5; -. DR PDBsum; 4QQC; -. DR PDBsum; 4QQJ; -. DR PDBsum; 4QQT; -. DR PDBsum; 4QRC; -. DR PDBsum; 4R6V; -. DR PDBsum; 4TYE; -. DR PDBsum; 4TYG; -. DR PDBsum; 4TYI; -. DR PDBsum; 4TYJ; -. DR PDBsum; 4UXQ; -. DR PDBsum; 4XCU; -. DR PDBsum; 5JKG; -. DR PDBsum; 5NUD; -. DR PDBsum; 5NWZ; -. DR PDBsum; 5XFF; -. DR PDBsum; 5XFJ; -. DR PDBsum; 6IUO; -. DR PDBsum; 6IUP; -. DR PDBsum; 6J6Y; -. DR PDBsum; 6JPE; -. DR PDBsum; 6JPJ; -. DR PDBsum; 6NVG; -. DR PDBsum; 6NVH; -. DR PDBsum; 6NVI; -. DR PDBsum; 6NVJ; -. DR PDBsum; 6NVK; -. DR PDBsum; 6V9C; -. DR PDBsum; 6YI8; -. DR PDBsum; 7DTZ; -. DR PDBsum; 7F3M; -. DR PDBsum; 7N1J; -. DR PDBsum; 7TYD; -. DR PDBsum; 7V29; -. DR PDBsum; 7VJL; -. DR PDBsum; 7WCT; -. DR PDBsum; 7WCW; -. DR PDBsum; 7WCX; -. DR PDBsum; 7YBO; -. DR PDBsum; 7YBP; -. DR PDBsum; 7YBX; -. DR PDBsum; 7YC1; -. DR PDBsum; 7YC3; -. DR PDBsum; 7YSW; -. DR PDBsum; 8KH6; -. DR PDBsum; 8KH7; -. DR PDBsum; 8KH8; -. DR PDBsum; 8KH9; -. DR PDBsum; 8W5C; -. DR PDBsum; 8XLQ; -. DR AlphaFoldDB; P22455; -. DR EMDB; EMD-34084; -. DR SMR; P22455; -. DR BioGRID; 108555; 519. DR CORUM; P22455; -. DR DIP; DIP-5149N; -. DR FunCoup; P22455; 1427. DR IntAct; P22455; 421. DR MINT; P22455; -. DR STRING; 9606.ENSP00000292408; -. DR BindingDB; P22455; -. DR ChEMBL; CHEMBL3973; -. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB16167; Fisogatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB15169; H3B-6527. DR DrugBank; DB01109; Heparin. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB16845; Roblitinib. DR DrugCentral; P22455; -. DR GuidetoPHARMACOLOGY; 1811; -. DR TCDB; 8.A.23.1.9; the basigin (basigin) family. DR GlyConnect; 1938; 7 N-Linked glycans (4 sites). DR GlyCosmos; P22455; 8 sites, 8 glycans. DR GlyGen; P22455; 8 sites, 9 N-linked glycans (5 sites), 1 O-linked glycan (1 site). DR iPTMnet; P22455; -. DR PhosphoSitePlus; P22455; -. DR SwissPalm; P22455; -. DR BioMuta; FGFR4; -. DR DMDM; 13432140; -. DR CPTAC; CPTAC-1768; -. DR CPTAC; CPTAC-3178; -. DR CPTAC; CPTAC-3179; -. DR jPOST; P22455; -. DR MassIVE; P22455; -. DR PaxDb; 9606-ENSP00000292408; -. DR PeptideAtlas; P22455; -. DR ProteomicsDB; 53990; -. [P22455-1] DR ProteomicsDB; 53991; -. [P22455-2] DR ABCD; P22455; 1 sequenced antibody. DR Antibodypedia; 3922; 892 antibodies from 48 providers. DR DNASU; 2264; -. DR Ensembl; ENST00000292408.9; ENSP00000292408.4; ENSG00000160867.16. [P22455-1] DR Ensembl; ENST00000393637.5; ENSP00000377254.1; ENSG00000160867.16. [P22455-2] DR Ensembl; ENST00000502906.5; ENSP00000424960.1; ENSG00000160867.16. [P22455-1] DR GeneID; 2264; -. DR KEGG; hsa:2264; -. DR MANE-Select; ENST00000292408.9; ENSP00000292408.4; NM_213647.3; NP_998812.1. DR UCSC; uc003mfl.4; human. [P22455-1] DR AGR; HGNC:3691; -. DR CIViC; 2264; 11 evidence items across 6 molecular profiles. DR ClinPGx; PA28130; -. DR CTD; 2264; -. DR DisGeNET; 2264; -. DR GeneCards; FGFR4; -. DR HGNC; HGNC:3691; FGFR4. DR HPA; ENSG00000160867; Tissue enhanced (liver, lung). DR MalaCards; FGFR4; -. DR MIM; 134935; gene. DR OpenTargets; ENSG00000160867; -. DR VEuPathDB; HostDB:ENSG00000160867; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000161469; -. DR HOGENOM; CLU_000288_74_3_1; -. DR InParanoid; P22455; -. DR OMA; WYKEGNR; -. DR OrthoDB; 5984265at2759; -. DR PAN-GO; P22455; 9 GO annotations based on evolutionary models. DR PhylomeDB; P22455; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P22455; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1307965; betaKlotho-mediated ligand binding. DR Reactome; R-HSA-1839128; FGFR4 mutant receptor activation. DR Reactome; R-HSA-190322; FGFR4 ligand binding and activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P22455; -. DR SIGNOR; P22455; -. DR Agora; ENSG00000160867; -. DR BioGRID-ORCS; 2264; 21 hits in 1192 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR4; human. DR EvolutionaryTrace; P22455; -. DR GeneWiki; Fibroblast_growth_factor_receptor_4; -. DR GenomeRNAi; 2264; -. DR Pharos; P22455; Tclin. DR PRO; PR:P22455; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P22455; protein. DR Bgee; ENSG00000160867; Expressed in right lobe of liver and 112 other cell types or tissues. DR ExpressionAtlas; P22455; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0030133; C:transport vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0008201; F:heparin binding; IDA:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0055062; P:phosphate ion homeostasis; ISS:UniProtKB. DR GO; GO:0043085; P:positive regulation of catalytic activity; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0045862; P:positive regulation of proteolysis; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0070857; P:regulation of bile acid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB. DR GO; GO:0019216; P:regulation of lipid metabolic process; ISS:UniProtKB. DR CDD; cd05857; IgI_2_FGFR; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000730; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000334; Fibroblast growth factor receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF343; FIBROBLAST GROWTH FACTOR RECEPTOR 4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Direct protein sequencing; Disulfide bond; Endoplasmic reticulum; Endosome; KW Glycoprotein; Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..21 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 22..802 FT /note="Fibroblast growth factor receptor 4" FT /id="PRO_0000016787" FT TOPO_DOM 22..369 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 370..390 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 391..802 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 22..118 FT /note="Ig-like C2-type 1" FT DOMAIN 152..240 FT /note="Ig-like C2-type 2" FT DOMAIN 249..349 FT /note="Ig-like C2-type 3" FT DOMAIN 467..755 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 119..148 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 612 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 473..481 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 503 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 390 FT /note="Phosphotyrosine; in variant R-388" FT /evidence="ECO:0000269|PubMed:26675719" FT MOD_RES 573 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 642 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18670643" FT MOD_RES 643 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18670643" FT MOD_RES 754 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:7518429" FT CARBOHYD 112 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 258 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 290 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 311 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 57..101 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 172..224 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 271..333 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 353..416 FT /note="EEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPA FT TVQKLSRFPLAR -> GTGRIPHLTCDSLTPAGRTKSPTL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10631118" FT /id="VSP_035108" FT VARIANT 10 FT /note="V -> I (in dbSNP:rs1966265)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21882254, ECO:0000269|Ref.7" FT /id="VAR_029185" FT VARIANT 136 FT /note="P -> L (in dbSNP:rs376618)" FT /evidence="ECO:0000269|PubMed:10631118, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21882254, FT ECO:0000269|Ref.6, ECO:0000269|Ref.7, ECO:0000269|Ref.9" FT /id="VAR_042211" FT VARIANT 179 FT /note="T -> A (in dbSNP:rs55675160)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042212" FT VARIANT 388 FT /note="G -> R (in cancer cells, may be associated with FT accelerated disease progression and increased tumor cell FT motility, possibly due to increased stability of the FT protease MMP14; leads to phosphorylation at residue Y-390, FT resulting in prolonged FGFR4 activity; increases FT interaction with STAT3, resulting in STAT3 phosphorylation FT and signaling activation.; dbSNP:rs351855)" FT /evidence="ECO:0000269|PubMed:18670643, FT ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20876804, FT ECO:0000269|PubMed:21349172, ECO:0000269|PubMed:21882254, FT ECO:0000269|PubMed:26675719, ECO:0000269|Ref.7" FT /id="VAR_014797" FT VARIANT 426 FT /note="G -> S (in dbSNP:rs55879131)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046102" FT VARIANT 516 FT /note="D -> N (in dbSNP:rs34158682)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042213" FT VARIANT 529 FT /note="R -> Q (in dbSNP:rs34284947)" FT /id="VAR_049720" FT VARIANT 550 FT /note="V -> M (in breast pleomorphic lobular sample; FT somatic mutation; dbSNP:rs774571806)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046103" FT VARIANT 712 FT /note="P -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046104" FT VARIANT 772 FT /note="S -> N (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046105" FT MUTAGEN 503 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11433297, FT ECO:0000269|PubMed:17311277" FT MUTAGEN 754 FT /note="Y->F: Loss of interaction with PLCG1." FT /evidence="ECO:0000269|PubMed:7518429" FT CONFLICT 121 FT /note="L -> S (in Ref. 3; AAF27432)" FT /evidence="ECO:0000305" FT CONFLICT 194 FT /note="E -> G (in Ref. 3; AAF27432)" FT /evidence="ECO:0000305" FT CONFLICT 297 FT /note="D -> V (in Ref. 1; CAA40490)" FT /evidence="ECO:0000305" FT STRAND 145..150 FT /evidence="ECO:0007829|PDB:6J6Y" FT HELIX 152..155 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 159..163 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 168..171 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 174..178 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 181..186 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 201..203 FT /evidence="ECO:0007829|PDB:6J6Y" FT TURN 204..207 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 208..213 FT /evidence="ECO:0007829|PDB:6J6Y" FT HELIX 216..218 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 232..242 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 259..262 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 267..271 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 280..286 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 292..294 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 302..306 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 316..320 FT /evidence="ECO:0007829|PDB:7TYD" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 329..336 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 341..351 FT /evidence="ECO:0007829|PDB:7TYD" FT HELIX 445..448 FT /evidence="ECO:0007829|PDB:4QQ5" FT TURN 458..460 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 467..475 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 480..487 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 489..493 FT /evidence="ECO:0007829|PDB:6NVH" FT STRAND 497..504 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 511..527 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:5XFJ" FT STRAND 536..540 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 542..544 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 547..551 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 558..563 FT /evidence="ECO:0007829|PDB:8KH9" FT TURN 570..572 FT /evidence="ECO:0007829|PDB:6YI8" FT TURN 577..580 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 586..605 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 615..617 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 618..620 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 626..628 FT /evidence="ECO:0007829|PDB:8KH9" FT TURN 631..635 FT /evidence="ECO:0007829|PDB:4XCU" FT HELIX 637..639 FT /evidence="ECO:0007829|PDB:4QQT" FT STRAND 642..644 FT /evidence="ECO:0007829|PDB:4UXQ" FT HELIX 652..655 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 658..663 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 668..683 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 689..692 FT /evidence="ECO:0007829|PDB:6NVH" FT HELIX 695..703 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 716..725 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 730..732 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 736..750 FT /evidence="ECO:0007829|PDB:8KH9" SQ SEQUENCE 802 AA; 87954 MW; B22B259831BB889F CRC64; MRLLLALLGV LLSVPGPPVL SLEASEEVEL EPCLAPSLEQ QEQELTVALG QPVRLCCGRA ERGGHWYKEG SRLAPAGRVR GWRGRLEIAS FLPEDAGRYL CLARGSMIVL QNLTLITGDS LTSSNDDEDP KSHRDPSNRH SYPQQAPYWT HPQRMEKKLH AVPAGNTVKF RCPAAGNPTP TIRWLKDGQA FHGENRIGGI RLRHQHWSLV MESVVPSDRG TYTCLVENAV GSIRYNYLLD VLERSPHRPI LQAGLPANTT AVVGSDVELL CKVYSDAQPH IQWLKHIVIN GSSFGADGFP YVQVLKTADI NSSEVEVLYL RNVSAEDAGE YTCLAGNSIG LSYQSAWLTV LPEEDPTWTA AAPEARYTDI ILYASGSLAL AVLLLLAGLY RGQALHGRHP RPPATVQKLS RFPLARQFSL ESGSSGKSSS SLVRGVRLSS SGPALLAGLV SLDLPLDPLW EFPRDRLVLG KPLGEGCFGQ VVRAEAFGMD PARPDQASTV AVKMLKDNAS DKDLADLVSE MEVMKLIGRH KNIINLLGVC TQEGPLYVIV ECAAKGNLRE FLRARRPPGP DLSPDGPRSS EGPLSFPVLV SCAYQVARGM QYLESRKCIH RDLAARNVLV TEDNVMKIAD FGLARGVHHI DYYKKTSNGR LPVKWMAPEA LFDRVYTHQS DVWSFGILLW EIFTLGGSPY PGIPVEELFS LLREGHRMDR PPHCPPELYG LMRECWHAAP SQRPTFKQLV EALDKVLLAV SEEYLDLRLT FGPYSPSGGD ASSTCSSSDS VFSHDPLPLG SSSFPFGSGV QT // ID G3ST1_HUMAN Reviewed; 423 AA. AC Q99999; Q96C63; DT 26-JUL-2002, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1997, sequence version 1. DT 28-JAN-2026, entry version 186. DE RecName: Full=Galactosylceramide sulfotransferase {ECO:0000305}; DE Short=GalCer sulfotransferase {ECO:0000303|PubMed:10785389}; DE EC=2.8.2.11 {ECO:0000269|PubMed:8830034}; DE AltName: Full=3'-phosphoadenosine-5'-phosphosulfate:GalCer sulfotransferase {ECO:0000303|PubMed:8830034}; DE AltName: Full=3'-phosphoadenylylsulfate:galactosylceramide 3'-sulfotransferase {ECO:0000303|PubMed:9030544}; DE AltName: Full=Cerebroside sulfotransferase {ECO:0000250|UniProtKB:Q9JHE4}; GN Name=GAL3ST1 {ECO:0000312|HGNC:HGNC:24240}; GN Synonyms=CST {ECO:0000250|UniProtKB:Q9JHE4}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 7-14; 86-101; 102-105; RP 187-192; 278-286; 372-379 AND 416-423, CATALYTIC ACTIVITY, FUNCTION, AND RP TISSUE SPECIFICITY. RC TISSUE=Renal cell carcinoma; RX PubMed=9030544; DOI=10.1074/jbc.272.8.4864; RA Honke K., Tsuda M., Hirahara Y., Ishii A., Makita A., Wada Y.; RT "Molecular cloning and expression of cDNA encoding human 3'- RT phosphoadenylylsulfate:galactosylceramide 3'-sulfotransferase."; RL J. Biol. Chem. 272:4864-4868(1997). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY. RC TISSUE=Kidney proximal tubule; RX PubMed=10785389; DOI=10.1046/j.1432-1327.2000.01281.x; RA Tsuda M., Egashira M., Niikawa N., Wada Y., Honke K.; RT "Cancer-associated alternative usage of multiple promoters of human GalCer RT sulfotransferase gene."; RL Eur. J. Biochem. 267:2672-2679(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-29. RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-29. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY. RX PubMed=8830034; DOI=10.1093/oxfordjournals.jbchem.a021258; RA Honke K., Yamane M., Ishii A., Kobayashi T., Makita A.; RT "Purification and characterization of 3'-phosphoadenosine-5'- RT phosphosulfate:GalCer sulfotransferase from human renal cancer cells."; RL J. Biochem. 119:421-427(1996). CC -!- FUNCTION: Catalyzes the transfer of a sulfate group to position 3 of CC non-reducing beta-galactosyl residues in glycerolipids and CC sphingolipids, therefore participates in the biosynthesis of CC sulfoglycolipids (PubMed:8830034, PubMed:9030544). Catalyzes the CC synthesis of galactosylceramide sulfate (sulfatide), a major lipid CC component of the myelin sheath and of monogalactosylalkylacylglycerol CC sulfate (seminolipid), present in spermatocytes (PubMed:8830034). Seems CC to prefer beta-glycosides at the non-reducing termini of sugar chains CC attached to a lipid moiety (PubMed:8830034). Also acts on CC lactosylceramide, galactosyl 1-alkyl-2-sn-glycerol and galactosyl CC diacylglycerol (in vitro) (PubMed:8830034). CC {ECO:0000269|PubMed:8830034, ECO:0000269|PubMed:9030544}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine + 3'- CC phosphoadenylyl sulfate = an N-acyl-1-beta-D-(3-O-sulfo)-galactosyl- CC sphing-4-enine + adenosine 3',5'-bisphosphate + H(+); CC Xref=Rhea:RHEA:20613, ChEBI:CHEBI:15378, ChEBI:CHEBI:18390, CC ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:75956; EC=2.8.2.11; CC Evidence={ECO:0000269|PubMed:8830034}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20614; CC Evidence={ECO:0000305|PubMed:8830034}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1-O-alkyl-2-acyl-3-O-(beta-D-galactosyl)-sn-glycerol + 3'- CC phosphoadenylyl sulfate = a 1-O-alkyl-2-acyl-3-(beta-D-3- CC sulfogalactosyl)-sn-glycerol + adenosine 3',5'-bisphosphate + H(+); CC Xref=Rhea:RHEA:41744, ChEBI:CHEBI:15378, ChEBI:CHEBI:58339, CC ChEBI:CHEBI:58343, ChEBI:CHEBI:78428, ChEBI:CHEBI:78429; EC=2.8.2.11; CC Evidence={ECO:0000269|PubMed:8830034}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41745; CC Evidence={ECO:0000305|PubMed:8830034}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-Gal-(1<->1')-ceramide + 3'-phosphoadenylyl sulfate = CC 1-(3-O-sulfo-beta-D-galactosyl)-ceramide + adenosine 3',5'- CC bisphosphate + H(+); Xref=Rhea:RHEA:43304, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:82953, CC ChEBI:CHEBI:143593; Evidence={ECO:0000269|PubMed:9030544}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43305; CC Evidence={ECO:0000269|PubMed:9030544}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-3-O-(beta-D-galactosyl)-sn-glycerol + 3'- CC phosphoadenylyl sulfate = 1,2-diacyl-3-(3-O-sulfo-beta-D-galactosyl)- CC sn-glycerol + adenosine 3',5'-bisphosphate + H(+); CC Xref=Rhea:RHEA:41748, ChEBI:CHEBI:15378, ChEBI:CHEBI:17615, CC ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:157618; CC Evidence={ECO:0000269|PubMed:8830034}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41749; CC Evidence={ECO:0000305|PubMed:8830034}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + 3'- CC phosphoadenylyl sulfate = beta-D-3-sulfogalactosyl-(1->4)-beta-D- CC glucosyl-(1<->1')-N-acylsphing-4-enine + adenosine 3',5'-bisphosphate CC + H(+); Xref=Rhea:RHEA:41736, ChEBI:CHEBI:15378, ChEBI:CHEBI:17950, CC ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:78426; CC Evidence={ECO:0000269|PubMed:8830034}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41737; CC Evidence={ECO:0000305|PubMed:8830034}; CC -!- PATHWAY: Lipid metabolism; sphingolipid metabolism. CC {ECO:0000269|PubMed:8830034}. CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000305}; Single- CC pass type II membrane protein {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Expressed in kidney proximal tubule, gastric mucosa CC and adenocarcinoma (PubMed:10785389, PubMed:9030544). Highly expressed CC in renal cell carcinoma cell lines (PubMed:8830034, PubMed:9030544). CC {ECO:0000269|PubMed:10785389, ECO:0000269|PubMed:8830034, CC ECO:0000269|PubMed:9030544}. CC -!- SIMILARITY: Belongs to the galactose-3-O-sulfotransferase family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D88667; BAA13673.1; -; mRNA. DR EMBL; AB029901; BAA89503.1; -; Genomic_DNA. DR EMBL; CR456350; CAG30236.1; -; mRNA. DR EMBL; BC014649; AAH14649.1; -; mRNA. DR EMBL; BC019077; AAH19077.1; -; mRNA. DR CCDS; CCDS13879.1; -. DR RefSeq; NP_001305032.1; NM_001318103.2. DR RefSeq; NP_001305033.1; NM_001318104.2. DR RefSeq; NP_001305034.1; NM_001318105.2. DR RefSeq; NP_001305035.1; NM_001318106.2. DR RefSeq; NP_001305036.1; NM_001318107.1. DR RefSeq; NP_001305037.1; NM_001318108.2. DR RefSeq; NP_001305038.2; NM_001318109.2. DR RefSeq; NP_001305039.1; NM_001318110.2. DR RefSeq; NP_001305040.1; NM_001318111.2. DR RefSeq; NP_001305041.1; NM_001318112.2. DR RefSeq; NP_001305042.1; NM_001318113.2. DR RefSeq; NP_001305043.1; NM_001318114.1. DR RefSeq; NP_001305044.1; NM_001318115.2. DR RefSeq; NP_001305045.1; NM_001318116.2. DR RefSeq; NP_004852.1; NM_004861.3. DR AlphaFoldDB; Q99999; -. DR BioGRID; 114891; 24. DR FunCoup; Q99999; 641. DR IntAct; Q99999; 13. DR MINT; Q99999; -. DR STRING; 9606.ENSP00000385207; -. DR SwissLipids; SLP:000000746; -. DR GlyCosmos; Q99999; 5 sites, 2 glycans. DR GlyGen; Q99999; 5 sites, 15 N-linked glycans (1 site), 2 O-linked glycans (3 sites). DR iPTMnet; Q99999; -. DR PhosphoSitePlus; Q99999; -. DR BioMuta; GAL3ST1; -. DR jPOST; Q99999; -. DR MassIVE; Q99999; -. DR PaxDb; 9606-ENSP00000385735; -. DR PeptideAtlas; Q99999; -. DR ProteomicsDB; 78572; -. DR Antibodypedia; 243; 145 antibodies from 21 providers. DR DNASU; 9514; -. DR Ensembl; ENST00000338911.6; ENSP00000343234.5; ENSG00000128242.14. DR Ensembl; ENST00000401975.5; ENSP00000384388.1; ENSG00000128242.14. DR Ensembl; ENST00000402321.5; ENSP00000385735.1; ENSG00000128242.14. DR Ensembl; ENST00000402369.5; ENSP00000384122.1; ENSG00000128242.14. DR Ensembl; ENST00000406361.6; ENSP00000385207.1; ENSG00000128242.14. DR Ensembl; ENST00000406955.5; ENSP00000385825.1; ENSG00000128242.14. DR GeneID; 9514; -. DR KEGG; hsa:9514; -. DR MANE-Select; ENST00000406361.6; ENSP00000385207.1; NM_001318104.2; NP_001305033.1. DR UCSC; uc003aih.2; human. DR AGR; HGNC:24240; -. DR ClinPGx; PA134889661; -. DR CTD; 9514; -. DR DisGeNET; 9514; -. DR GeneCards; GAL3ST1; -. DR HGNC; HGNC:24240; GAL3ST1. DR HPA; ENSG00000128242; Group enriched (brain, intestine, kidney). DR MIM; 602300; gene. DR OpenTargets; ENSG00000128242; -. DR VEuPathDB; HostDB:ENSG00000128242; -. DR eggNOG; ENOG502QTXT; Eukaryota. DR GeneTree; ENSGT00950000182923; -. DR HOGENOM; CLU_040616_1_1_1; -. DR InParanoid; Q99999; -. DR OMA; CAPKVDI; -. DR OrthoDB; 514299at2759; -. DR PAN-GO; Q99999; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q99999; -. DR BioCyc; MetaCyc:HS05164-MONOMER; -. DR BRENDA; 2.8.2.11; 2681. DR PathwayCommons; Q99999; -. DR Reactome; R-HSA-9840309; Glycosphingolipid biosynthesis. DR SignaLink; Q99999; -. DR UniPathway; UPA00222; -. DR Agora; ENSG00000128242; -. DR BioGRID-ORCS; 9514; 17 hits in 1141 CRISPR screens. DR GeneWiki; GAL3ST1; -. DR GenomeRNAi; 9514; -. DR Pharos; Q99999; Tbio. DR PRO; PR:Q99999; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; Q99999; protein. DR Bgee; ENSG00000128242; Expressed in C1 segment of cervical spinal cord and 131 other cell types or tissues. DR ExpressionAtlas; Q99999; baseline and differential. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; TAS:ProtInc. DR GO; GO:0001733; F:galactosylceramide sulfotransferase activity; IDA:UniProtKB. DR GO; GO:0008146; F:sulfotransferase activity; TAS:ProtInc. DR GO; GO:0006682; P:galactosylceramide biosynthetic process; IBA:GO_Central. DR GO; GO:0006681; P:galactosylceramide metabolic process; ISS:UniProtKB. DR GO; GO:0046486; P:glycerolipid metabolic process; IDA:UniProtKB. DR GO; GO:0006688; P:glycosphingolipid biosynthetic process; TAS:Reactome. DR GO; GO:0042552; P:myelination; IBA:GO_Central. DR GO; GO:0006487; P:protein N-linked glycosylation; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0006665; P:sphingolipid metabolic process; IDA:UniProtKB. DR FunFam; 3.40.50.300:FF:000807; galactosylceramide sulfotransferase isoform X1; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR009729; Gal-3-0_sulfotransfrase. DR InterPro; IPR027417; P-loop_NTPase. DR PANTHER; PTHR14647; GALACTOSE-3-O-SULFOTRANSFERASE; 1. DR PANTHER; PTHR14647:SF56; GALACTOSYLCERAMIDE SULFOTRANSFERASE; 1. DR Pfam; PF06990; Gal-3-0_sulfotr; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. PE 1: Evidence at protein level; KW Direct protein sequencing; Glycoprotein; Golgi apparatus; Lipid metabolism; KW Membrane; Proteomics identification; Reference proteome; Signal-anchor; KW Sphingolipid metabolism; Transferase; Transmembrane; Transmembrane helix. FT CHAIN 1..423 FT /note="Galactosylceramide sulfotransferase" FT /id="PRO_0000085201" FT TOPO_DOM 1..14 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 15..35 FT /note="Helical; Signal-anchor for type II membrane protein" FT /evidence="ECO:0000255" FT TOPO_DOM 36..423 FT /note="Lumenal" FT /evidence="ECO:0000255" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 312 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VARIANT 29 FT /note="V -> M (in dbSNP:rs2267161)" FT /evidence="ECO:0000269|PubMed:15461802, FT ECO:0000269|PubMed:15489334" FT /id="VAR_013684" FT CONFLICT 281..282 FT /note="RR -> LN (in Ref. 1; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 418 FT /note="R -> L (in Ref. 1; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 422 FT /note="R -> E (in Ref. 1; AA sequence)" FT /evidence="ECO:0000305" SQ SEQUENCE 423 AA; 48764 MW; 0FD4F2E374447C56 CRC64; MLPPQKKPWE SMAKGLVLGA LFTSFLLLVY SYAVPPLHAG LASTTPEAAA SCSPPALEPE AVIRANGSAG ECQPRRNIVF LKTHKTASST LLNILFRFGQ KHRLKFAFPN GRNDFDYPTF FARSLVQDYR PGACFNIICN HMRFHYDEVR GLVPTNAIFI TVLRDPARLF ESSFHYFGPV VPLTWKLSAG DKLTEFLQDP DRYYDPNGFN AHYLRNLLFF DLGYDNSLDP SSPQVQEHIL EVERRFHLVL LQEYFDESLV LLKDLLCWEL EDVLYFKLNA RRDSPVPRLS GELYGRATAW NMLDSHLYRH FNASFWRKVE AFGRERMARE VAALRHANER MRTICIDGGH AVDAAAIQDE AMQPWQPLGT KSILGYNLKK SIGQRHAQLC RRMLTPEIQY LMDLGANLWV TKLWKFIRDF LRW // ID GPX7_HUMAN Reviewed; 187 AA. AC Q96SL4; O95337; Q5T501; DT 04-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 189. DE RecName: Full=Glutathione peroxidase 7; DE Short=GPx-7; DE Short=GSHPx-7; DE EC=1.11.1.9; DE AltName: Full=CL683; DE Flags: Precursor; GN Name=GPX7; Synonyms=GPX6; ORFNames=UNQ469/PRO828; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Fetal brain; RA Gu S., Lin S., Ying K., Xie Y., Mao Y.; RT "Cloning and characterizing a novel human glutathione peroxidase-GPX6."; RL Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 75-187. RA Barrow I.K.-P., Boguski M.S., Touchman J.W., Spencer F.; RT "Full-insert sequence of mapped XREF EST."; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [8] RP FUNCTION, TISSUE SPECIFICITY, AND INVOLVEMENT IN BE. RX PubMed=22157330; DOI=10.1136/gutjnl-2011-301078; RA Peng D., Belkhiri A., Hu T., Chaturvedi R., Asim M., Wilson K.T., Zaika A., RA El-Rifai W.; RT "Glutathione peroxidase 7 protects against oxidative DNA damage in RT oesophageal cells."; RL Gut 61:1250-1260(2012). RN [9] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 20-177. RG Structural genomics consortium (SGC); RT "Crystal structure of human glutathione peroxidase 7."; RL Submitted (MAR-2007) to the PDB data bank. CC -!- FUNCTION: It protects esophageal epithelia from hydrogen peroxide- CC induced oxidative stress. It suppresses acidic bile acid-induced CC reactive oxygen species (ROS) and protects against oxidative DNA damage CC and double-strand breaks. {ECO:0000269|PubMed:22157330}. CC -!- CATALYTIC ACTIVITY: CC Reaction=2 glutathione + H2O2 = glutathione disulfide + 2 H2O; CC Xref=Rhea:RHEA:16833, ChEBI:CHEBI:15377, ChEBI:CHEBI:16240, CC ChEBI:CHEBI:57925, ChEBI:CHEBI:58297; EC=1.11.1.9; CC -!- INTERACTION: CC Q96SL4; Q12797-6: ASPH; NbExp=3; IntAct=EBI-749411, EBI-12092171; CC Q96SL4; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-749411, EBI-739624; CC Q96SL4; Q9UBL6-2: CPNE7; NbExp=5; IntAct=EBI-749411, EBI-12012272; CC Q96SL4; G5E9A7: DMWD; NbExp=3; IntAct=EBI-749411, EBI-10976677; CC Q96SL4; O43681: GET3; NbExp=6; IntAct=EBI-749411, EBI-2515857; CC Q96SL4; P42858: HTT; NbExp=3; IntAct=EBI-749411, EBI-466029; CC Q96SL4; P61601: NCALD; NbExp=3; IntAct=EBI-749411, EBI-749635; CC Q96SL4; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-749411, EBI-741158; CC Q96SL4; O43765: SGTA; NbExp=7; IntAct=EBI-749411, EBI-347996; CC Q96SL4; Q96EQ0: SGTB; NbExp=5; IntAct=EBI-749411, EBI-744081; CC Q96SL4; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-749411, EBI-5235340; CC Q96SL4; Q9BQ70: TCF25; NbExp=3; IntAct=EBI-749411, EBI-745182; CC Q96SL4; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-749411, EBI-947187; CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Expressed in esophageal epithelial cells; CC expression is up-regulated after exposure to acidic bile acids. CC {ECO:0000269|PubMed:22157330}. CC -!- DISEASE: Barrett esophagus (BE) [MIM:614266]: A condition characterized CC by a metaplastic change in which normal esophageal squamous epithelium CC is replaced by a columnar and intestinal-type epithelium. Patients with CC Barrett esophagus have an increased risk of esophageal adenocarcinoma. CC The main cause of Barrett esophagus is gastroesophageal reflux. The CC retrograde movement of acid and bile salts from the stomach into the CC esophagus causes prolonged injury to the esophageal epithelium and CC induces chronic esophagitis, which in turn is believed to trigger the CC pathologic changes. {ECO:0000269|PubMed:22157330}. Note=The disease is CC caused by variants affecting the gene represented in this entry. The CC pathologic mechanisms leading to Barrett esophagus involve GPX7 CC dysfunction that results in higher levels of hydrogen peroxide and ROS- CC induced oxidative stress and DNA damage in esophageal cells. CC -!- SIMILARITY: Belongs to the glutathione peroxidase family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC72961.1; Type=Erroneous translation; Note=Wrong choice of frame.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF320068; AAN76501.1; -; mRNA. DR EMBL; AY358402; AAQ88768.1; -; mRNA. DR EMBL; AK027683; BAB55294.1; -; mRNA. DR EMBL; DQ096732; AAY88741.1; -; Genomic_DNA. DR EMBL; AL356976; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032788; AAH32788.1; -; mRNA. DR EMBL; AF091092; AAC72961.1; ALT_SEQ; mRNA. DR CCDS; CCDS569.1; -. DR RefSeq; NP_056511.2; NM_015696.4. DR PDB; 2P31; X-ray; 2.00 A; A/B=20-177. DR PDBsum; 2P31; -. DR AlphaFoldDB; Q96SL4; -. DR SMR; Q96SL4; -. DR BioGRID; 109139; 70. DR FunCoup; Q96SL4; 216. DR IntAct; Q96SL4; 59. DR STRING; 9606.ENSP00000354677; -. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB00143; Glutathione. DR DrugBank; DB03310; Glutathione disulfide. DR PeroxiBase; 3606; HsGPx07. DR GlyGen; Q96SL4; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96SL4; -. DR PhosphoSitePlus; Q96SL4; -. DR BioMuta; GPX7; -. DR DMDM; 33516901; -. DR jPOST; Q96SL4; -. DR MassIVE; Q96SL4; -. DR PaxDb; 9606-ENSP00000354677; -. DR PeptideAtlas; Q96SL4; -. DR ProteomicsDB; 78126; -. DR Pumba; Q96SL4; -. DR Antibodypedia; 19147; 224 antibodies from 35 providers. DR DNASU; 2882; -. DR Ensembl; ENST00000361314.5; ENSP00000354677.4; ENSG00000116157.6. DR GeneID; 2882; -. DR KEGG; hsa:2882; -. DR MANE-Select; ENST00000361314.5; ENSP00000354677.4; NM_015696.5; NP_056511.2. DR UCSC; uc001cue.4; human. DR AGR; HGNC:4559; -. DR ClinPGx; PA28955; -. DR CTD; 2882; -. DR DisGeNET; 2882; -. DR GeneCards; GPX7; -. DR HGNC; HGNC:4559; GPX7. DR HPA; ENSG00000116157; Low tissue specificity. DR MIM; 614266; phenotype. DR MIM; 615784; gene. DR OpenTargets; ENSG00000116157; -. DR VEuPathDB; HostDB:ENSG00000116157; -. DR eggNOG; KOG1651; Eukaryota. DR GeneTree; ENSGT00940000159127; -. DR HOGENOM; CLU_029507_0_1_1; -. DR InParanoid; Q96SL4; -. DR OMA; QCGLTKQ; -. DR OrthoDB; 446890at2759; -. DR PAN-GO; Q96SL4; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q96SL4; -. DR BRENDA; 1.11.1.9; 2681. DR PathwayCommons; Q96SL4; -. DR Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species. DR SignaLink; Q96SL4; -. DR Agora; ENSG00000116157; -. DR BioGRID-ORCS; 2882; 8 hits in 1144 CRISPR screens. DR ChiTaRS; GPX7; human. DR EvolutionaryTrace; Q96SL4; -. DR GeneWiki; GPX7; -. DR GenomeRNAi; 2882; -. DR Pharos; Q96SL4; Tbio. DR PRO; PR:Q96SL4; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q96SL4; protein. DR Bgee; ENSG00000116157; Expressed in adrenal tissue and 125 other cell types or tissues. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0004096; F:catalase activity; IDA:CACAO. DR GO; GO:0004602; F:glutathione peroxidase activity; IEA:UniProtKB-EC. DR GO; GO:0004601; F:peroxidase activity; EXP:Reactome. DR GO; GO:0034599; P:cellular response to oxidative stress; TAS:Reactome. DR CDD; cd00340; GSH_Peroxidase; 1. DR FunFam; 3.40.30.10:FF:000049; Glutathione peroxidase; 1. DR Gene3D; 3.40.30.10; Glutaredoxin; 1. DR InterPro; IPR013376; Glut_perox_Gpx7. DR InterPro; IPR000889; Glutathione_peroxidase. DR InterPro; IPR029759; GPX_AS. DR InterPro; IPR029760; GPX_CS. DR InterPro; IPR036249; Thioredoxin-like_sf. DR NCBIfam; TIGR02540; gpx7; 1. DR PANTHER; PTHR11592; GLUTATHIONE PEROXIDASE; 1. DR PANTHER; PTHR11592:SF5; GLUTATHIONE PEROXIDASE 7; 1. DR Pfam; PF00255; GSHPx; 1. DR PIRSF; PIRSF000303; Glutathion_perox; 1. DR PRINTS; PR01011; GLUTPROXDASE. DR SUPFAM; SSF52833; Thioredoxin-like; 1. DR PROSITE; PS00460; GLUTATHIONE_PEROXID_1; 1. DR PROSITE; PS00763; GLUTATHIONE_PEROXID_2; 1. DR PROSITE; PS51355; GLUTATHIONE_PEROXID_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Oxidoreductase; Peroxidase; Proteomics identification; KW Reference proteome; Secreted; Signal. FT SIGNAL 1..19 FT /evidence="ECO:0000255" FT CHAIN 20..187 FT /note="Glutathione peroxidase 7" FT /id="PRO_0000013084" FT ACT_SITE 57 FT /evidence="ECO:0000250" FT CONFLICT 75..77 FT /note="GPH -> HED (in Ref. 7)" FT /evidence="ECO:0000305" FT HELIX 25..27 FT /evidence="ECO:0007829|PDB:2P31" FT STRAND 29..32 FT /evidence="ECO:0007829|PDB:2P31" FT STRAND 37..39 FT /evidence="ECO:0007829|PDB:2P31" FT HELIX 40..43 FT /evidence="ECO:0007829|PDB:2P31" FT STRAND 46..53 FT /evidence="ECO:0007829|PDB:2P31" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:2P31" FT HELIX 60..74 FT /evidence="ECO:0007829|PDB:2P31" FT HELIX 75..77 FT /evidence="ECO:0007829|PDB:2P31" FT STRAND 79..85 FT /evidence="ECO:0007829|PDB:2P31" FT HELIX 97..108 FT /evidence="ECO:0007829|PDB:2P31" FT HELIX 127..136 FT /evidence="ECO:0007829|PDB:2P31" FT STRAND 146..149 FT /evidence="ECO:0007829|PDB:2P31" FT STRAND 155..159 FT /evidence="ECO:0007829|PDB:2P31" FT HELIX 165..173 FT /evidence="ECO:0007829|PDB:2P31" SQ SEQUENCE 187 AA; 20996 MW; 0ACB80AC2522EFCD CRC64; MVAATVAAAW LLLWAAACAQ QEQDFYDFKA VNIRGKLVSL EKYRGSVSLV VNVASECGFT DQHYRALQQL QRDLGPHHFN VLAFPCNQFG QQEPDSNKEI ESFARRTYSV SFPMFSKIAV TGTGAHPAFK YLAQTSGKEP TWNFWKYLVA PDGKVVGAWD PTVSVEEVRP QITALVRKLI LLKREDL // ID GRK6_HUMAN Reviewed; 576 AA. AC P43250; O60541; Q13652; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2002, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=G protein-coupled receptor kinase 6; DE EC=2.7.11.16; DE AltName: Full=G protein-coupled receptor kinase GRK6; GN Name=GRK6; Synonyms=GPRK6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GRK6A). RX PubMed=8366096; DOI=10.1016/s0021-9258(19)36546-9; RA Benovic J.L., Gomez J.; RT "Molecular cloning and expression of GRK6. A new member of the G protein- RT coupled receptor kinase family."; RL J. Biol. Chem. 268:19521-19527(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GRK6B AND GRK6C). RX PubMed=10506199; DOI=10.1074/jbc.274.41.29381; RA Premont R.T., Macrae A.D., Aparicio S.A., Kendall H.E., Welch J.E., RA Lefkowitz R.J.; RT "The GRK4 subfamily of G protein-coupled receptor kinases. Alternative RT splicing, gene organization, and sequence conservation."; RL J. Biol. Chem. 274:29381-29389(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GRK6A). RC TISSUE=Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 33-576, AND TISSUE SPECIFICITY. RX PubMed=8415712; DOI=10.1073/pnas.90.20.9398; RA Haribabu B., Snyderman R.; RT "Identification of additional members of human G-protein-coupled receptor RT kinase multigene family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:9398-9402(1993). RN [6] RP PALMITOYLATION AT CYS-561; CYS-562 AND CYS-565, AND MUTAGENESIS OF CYS-561; RP CYS-562 AND CYS-565. RX PubMed=7961702; DOI=10.1016/s0021-9258(18)46852-4; RA Stoffel R.H., Randall R.R., Premont R.T., Lefkowitz R.J., Inglese J.; RT "Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid RT modification diversity in the GRK family."; RL J. Biol. Chem. 269:27791-27794(1994). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-484 AND THR-485, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP FUNCTION IN PHOSPHORYLATION OF LRP6. RX PubMed=19801552; DOI=10.1074/jbc.m109.047456; RA Chen M., Philipp M., Wang J., Premont R.T., Garrison T.R., Caron M.G., RA Lefkowitz R.J., Chen W.; RT "G Protein-coupled receptor kinases phosphorylate LRP6 in the Wnt RT pathway."; RL J. Biol. Chem. 284:35040-35048(2009). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-484 AND THR-485, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [10] RP FUNCTION IN PHOSPHORYLATION OF CXCR4. RX PubMed=20048153; DOI=10.1074/jbc.m109.091173; RA Busillo J.M., Armando S., Sengupta R., Meucci O., Bouvier M., Benovic J.L.; RT "Site-specific phosphorylation of CXCR4 is dynamically regulated by RT multiple kinases and results in differential modulation of CXCR4 RT signaling."; RL J. Biol. Chem. 285:7805-7817(2010). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS). RX PubMed=16613860; DOI=10.1074/jbc.m601327200; RA Lodowski D.T., Tesmer V.M., Benovic J.L., Tesmer J.J.; RT "The structure of G protein-coupled receptor kinase (GRK)-6 defines a RT second lineage of GRKs."; RL J. Biol. Chem. 281:16785-16793(2006). RN [12] RP X-RAY CRYSTALLOGRAPHY (2.72 ANGSTROMS) IN COMPLEX WITH AMP AND RP SANGIVAMYCIN, AND MUTAGENESIS OF ILE-6; VAL-7; ASN-9 AND LEU-12. RX PubMed=20729810; DOI=10.1038/emboj.2010.206; RA Boguth C.A., Singh P., Huang C.C., Tesmer J.J.; RT "Molecular basis for activation of G protein-coupled receptor kinases."; RL EMBO J. 29:3249-3259(2010). RN [13] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-31; MET-73 AND MET-275. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Specifically phosphorylates the activated forms of G protein- CC coupled receptors. Such receptor phosphorylation initiates beta- CC arrestin-mediated receptor desensitization, internalization, and CC signaling events leading to their desensitization. Seems to be involved CC in the desensitization of D2-like dopamine receptors in striatum and CC chemokine receptor CXCR4 which is critical for CXCL12-induced cell CC chemotaxis (By similarity). Phosphorylates rhodopsin (RHO) (in vitro) CC and a non G-protein-coupled receptor: LRP6 during Wnt signaling (in CC vitro). {ECO:0000250, ECO:0000269|PubMed:19801552, CC ECO:0000269|PubMed:20048153}. CC -!- CATALYTIC ACTIVITY: CC Reaction=[G-protein-coupled receptor] + ATP = [G-protein-coupled CC receptor]-phosphate + ADP + H(+); Xref=Rhea:RHEA:12008, Rhea:RHEA- CC COMP:11260, Rhea:RHEA-COMP:11261, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, CC ChEBI:CHEBI:456216; EC=2.7.11.16; CC -!- SUBUNIT: Interacts with GIT1. {ECO:0000250|UniProtKB:P97711}. CC -!- INTERACTION: CC P43250; P05067: APP; NbExp=3; IntAct=EBI-722747, EBI-77613; CC P43250; P32298: GRK4; NbExp=2; IntAct=EBI-722747, EBI-5774453; CC P43250; P08238: HSP90AB1; NbExp=2; IntAct=EBI-722747, EBI-352572; CC P43250; P52205: ROM1; Xeno; NbExp=9; IntAct=EBI-722747, EBI-8176947; CC P43250-2; P05067: APP; NbExp=3; IntAct=EBI-6428342, EBI-77613; CC -!- SUBCELLULAR LOCATION: Membrane; Lipid-anchor. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=GRK6A; CC IsoId=P43250-1; Sequence=Displayed; CC Name=GRK6B; CC IsoId=P43250-2; Sequence=VSP_004938; CC Name=GRK6C; CC IsoId=P43250-3; Sequence=VSP_041813, VSP_041814; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:8415712}. CC -!- PTM: It is uncertain whether palmitoylation is on Cys-561 and/or Cys- CC 562 and/or Cys-565. {ECO:0000269|PubMed:7961702}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. GPRK subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L16862; AAA60175.1; -; mRNA. DR EMBL; AF040751; AAC09273.1; -; mRNA. DR EMBL; AF040752; AAC09274.1; -; mRNA. DR EMBL; AC145098; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC009277; AAH09277.1; -; mRNA. DR EMBL; U00686; AAA03565.1; -; mRNA. DR CCDS; CCDS34303.1; -. [P43250-1] DR CCDS; CCDS43406.1; -. [P43250-3] DR PIR; A48765; A48765. DR RefSeq; NP_001004105.1; NM_001004105.3. [P43250-3] DR RefSeq; NP_001004106.1; NM_001004106.3. [P43250-1] DR RefSeq; NP_002073.2; NM_002082.4. [P43250-2] DR PDB; 2ACX; X-ray; 2.60 A; A/B=1-576. DR PDB; 3NYN; X-ray; 2.72 A; A/B=2-576. DR PDB; 3NYO; X-ray; 2.92 A; A/B=2-576. DR PDBsum; 2ACX; -. DR PDBsum; 3NYN; -. DR PDBsum; 3NYO; -. DR AlphaFoldDB; P43250; -. DR SMR; P43250; -. DR BioGRID; 109128; 143. DR FunCoup; P43250; 2317. DR IntAct; P43250; 141. DR MINT; P43250; -. DR STRING; 9606.ENSP00000347655; -. DR BindingDB; P43250; -. DR ChEMBL; CHEMBL6144; -. DR DrugCentral; P43250; -. DR GuidetoPHARMACOLOGY; 1470; -. DR CarbonylDB; P43250; -. DR iPTMnet; P43250; -. DR PhosphoSitePlus; P43250; -. DR SwissPalm; P43250; -. DR BioMuta; GRK6; -. DR DMDM; 20141386; -. DR jPOST; P43250; -. DR MassIVE; P43250; -. DR PaxDb; 9606-ENSP00000433511; -. DR PeptideAtlas; P43250; -. DR ProteomicsDB; 55602; -. [P43250-1] DR ProteomicsDB; 55603; -. [P43250-2] DR ProteomicsDB; 55604; -. [P43250-3] DR Pumba; P43250; -. DR ABCD; P43250; 1 sequenced antibody. DR Antibodypedia; 17408; 406 antibodies from 38 providers. DR DNASU; 2870; -. DR Ensembl; ENST00000355472.10; ENSP00000347655.5; ENSG00000198055.12. [P43250-1] DR Ensembl; ENST00000355958.9; ENSP00000348230.5; ENSG00000198055.12. [P43250-3] DR Ensembl; ENST00000528793.5; ENSP00000433511.1; ENSG00000198055.12. [P43250-2] DR GeneID; 2870; -. DR KEGG; hsa:2870; -. DR MANE-Select; ENST00000355472.10; ENSP00000347655.5; NM_001004106.3; NP_001004106.1. DR UCSC; uc003mgq.3; human. [P43250-1] DR AGR; HGNC:4545; -. DR ClinPGx; PA28942; -. DR CTD; 2870; -. DR DisGeNET; 2870; -. DR GeneCards; GRK6; -. DR HGNC; HGNC:4545; GRK6. DR HPA; ENSG00000198055; Tissue enhanced (bone). DR MIM; 600869; gene. DR OpenTargets; ENSG00000198055; -. DR VEuPathDB; HostDB:ENSG00000198055; -. DR eggNOG; KOG0986; Eukaryota. DR GeneTree; ENSGT00940000158544; -. DR InParanoid; P43250; -. DR OMA; NYLNPKC; -. DR OrthoDB; 354826at2759; -. DR PAN-GO; P43250; 5 GO annotations based on evolutionary models. DR PhylomeDB; P43250; -. DR BRENDA; 2.7.11.16; 2681. DR PathwayCommons; P43250; -. DR Reactome; R-HSA-418555; G alpha (s) signalling events. DR SignaLink; P43250; -. DR SIGNOR; P43250; -. DR Agora; ENSG00000198055; -. DR BioGRID-ORCS; 2870; 16 hits in 1189 CRISPR screens. DR ChiTaRS; GRK6; human. DR EvolutionaryTrace; P43250; -. DR GeneWiki; GRK6; -. DR GenomeRNAi; 2870; -. DR Pharos; P43250; Tchem. DR PRO; PR:P43250; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P43250; protein. DR Bgee; ENSG00000198055; Expressed in granulocyte and 203 other cell types or tissues. DR ExpressionAtlas; P43250; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0047696; F:beta-adrenergic receptor kinase activity; IDA:CACAO. DR GO; GO:0004703; F:G protein-coupled receptor kinase activity; IBA:GO_Central. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome. DR GO; GO:0008277; P:regulation of G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0009966; P:regulation of signal transduction; IBA:GO_Central. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd05630; STKc_GRK6; 1. DR DisProt; DP03187; -. DR FunFam; 1.10.167.10:FF:000009; G protein-coupled receptor kinase; 2. DR FunFam; 1.10.510.10:FF:000074; G protein-coupled receptor kinase; 1. DR Gene3D; 6.10.250.2260; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.167.10; Regulator of G-protein Signalling 4, domain 2; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000239; GPCR_kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016137; RGS. DR InterPro; IPR036305; RGS_sf. DR InterPro; IPR044926; RGS_subdomain_2. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24355:SF15; G PROTEIN-COUPLED RECEPTOR KINASE 6; 1. DR PANTHER; PTHR24355; G PROTEIN-COUPLED RECEPTOR KINASE/RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00615; RGS; 1. DR PRINTS; PR00717; GPCRKINASE. DR SMART; SM00315; RGS; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF48097; Regulator of G-protein signaling, RGS; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50132; RGS; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Kinase; Lipoprotein; KW Membrane; Nucleotide-binding; Palmitate; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Wnt signaling pathway. FT CHAIN 1..576 FT /note="G protein-coupled receptor kinase 6" FT /id="PRO_0000085974" FT DOMAIN 53..171 FT /note="RGS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00171" FT DOMAIN 186..448 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 449..514 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 1..185 FT /note="N-terminal" FT ACT_SITE 311 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 192..200 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 215 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 264..270 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 315..318 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 484 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 485 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 566 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70293" FT MOD_RES 568 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70293" FT LIPID 561 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:7961702" FT LIPID 562 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:7961702" FT LIPID 565 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:7961702" FT VAR_SEQ 560..576 FT /note="DCCGNCSDSEEELPTRL -> RIAVETAATARKSSPPASSPQPEAPTSSWR FT (in isoform GRK6B)" FT /evidence="ECO:0000303|PubMed:10506199" FT /id="VSP_004938" FT VAR_SEQ 560 FT /note="D -> R (in isoform GRK6C)" FT /evidence="ECO:0000303|PubMed:10506199" FT /id="VSP_041813" FT VAR_SEQ 561..576 FT /note="Missing (in isoform GRK6C)" FT /evidence="ECO:0000303|PubMed:10506199" FT /id="VSP_041814" FT VARIANT 31 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs141014084)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040524" FT VARIANT 73 FT /note="T -> M (in dbSNP:rs56382815)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040525" FT VARIANT 275 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040526" FT MUTAGEN 6 FT /note="I->A: 12-13 fold defects in kinase activity; 180- FT fold defects in kinase activity; when associated with A-7." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 7 FT /note="V->A: 12-13 fold defects in kinase activity; 180- FT fold defects in kinase activity; when associated with A-6." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 9 FT /note="N->A: 140-fold defects in kinase activity." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 12 FT /note="L->A: 1100-fold defects in kinase activity." FT /evidence="ECO:0000269|PubMed:20729810" FT MUTAGEN 561 FT /note="C->S: Abolishes palmitoylation; when associated with FT S-562 and S-565." FT /evidence="ECO:0000269|PubMed:7961702" FT MUTAGEN 562 FT /note="C->S: Abolishes palmitoylation; when associated with FT S-561 and S-565." FT /evidence="ECO:0000269|PubMed:7961702" FT MUTAGEN 565 FT /note="C->S: Abolishes palmitoylation; when associated with FT S-561 and S-562." FT /evidence="ECO:0000269|PubMed:7961702" FT CONFLICT 60..61 FT /note="QP -> HA (in Ref. 1; AAA60175)" FT /evidence="ECO:0000305" FT CONFLICT 104..105 FT /note="QL -> HV (in Ref. 1; AAA60175)" FT /evidence="ECO:0000305" FT HELIX 3..18 FT /evidence="ECO:0007829|PDB:3NYN" FT STRAND 23..25 FT /evidence="ECO:0007829|PDB:3NYN" FT HELIX 30..33 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 43..48 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 53..57 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 61..71 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 75..91 FT /evidence="ECO:0007829|PDB:2ACX" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 98..109 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 112..114 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 117..120 FT /evidence="ECO:0007829|PDB:3NYN" FT HELIX 123..135 FT /evidence="ECO:0007829|PDB:2ACX" FT TURN 139..142 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 143..153 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 156..162 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 165..177 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 183..185 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 186..195 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 198..205 FT /evidence="ECO:0007829|PDB:2ACX" FT TURN 206..208 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 211..218 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 219..224 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 228..240 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 249..254 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 256..263 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 271..276 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 277..280 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 285..304 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 317..319 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 349..351 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 354..357 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 361..364 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 365..380 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 384..386 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 388..390 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 394..403 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 410..412 FT /evidence="ECO:0007829|PDB:3NYN" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 428..430 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 435..437 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 438..443 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 446..448 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 453..457 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 477..479 FT /evidence="ECO:0007829|PDB:3NYO" FT HELIX 493..502 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 508..517 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 520..525 FT /evidence="ECO:0007829|PDB:2ACX" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:2ACX" FT HELIX 549..555 FT /evidence="ECO:0007829|PDB:3NYN" SQ SEQUENCE 576 AA; 65991 MW; 3BF8C3B1CDE2BD74 CRC64; MELENIVANT VLLKAREGGG GNRKGKSKKW RQMLQFPHIS QCEELRLSLE RDYHSLCERQ PIGRLLFREF CATRPELSRC VAFLDGVAEY EVTPDDKRKA CGRQLTQNFL SHTGPDLIPE VPRQLVTNCT QRLEQGPCKD LFQELTRLTH EYLSVAPFAD YLDSIYFNRF LQWKWLERQP VTKNTFRQYR VLGKGGFGEV CACQVRATGK MYACKKLEKK RIKKRKGEAM ALNEKQILEK VNSRFVVSLA YAYETKDALC LVLTLMNGGD LKFHIYHMGQ AGFPEARAVF YAAEICCGLE DLHRERIVYR DLKPENILLD DHGHIRISDL GLAVHVPEGQ TIKGRVGTVG YMAPEVVKNE RYTFSPDWWA LGCLLYEMIA GQSPFQQRKK KIKREEVERL VKEVPEEYSE RFSPQARSLC SQLLCKDPAE RLGCRGGSAR EVKEHPLFKK LNFKRLGAGM LEPPFKPDPQ AIYCKDVLDI EQFSTVKGVE LEPTDQDFYQ KFATGSVPIP WQNEMVETEC FQELNVFGLD GSVPPDLDWK GQPPAPPKKG LLQRLFSRQD CCGNCSDSEE ELPTRL // ID HNRDL_HUMAN Reviewed; 420 AA. AC O14979; Q6SPF2; Q7KZ74; Q7KZ75; Q96IM0; Q96S43; DT 15-MAY-2007, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 3. DT 28-JAN-2026, entry version 212. DE RecName: Full=Heterogeneous nuclear ribonucleoprotein D-like; DE Short=hnRNP D-like; DE Short=hnRNP DL; DE AltName: Full=AU-rich element RNA-binding factor; DE AltName: Full=JKT41-binding protein; DE AltName: Full=Protein laAUF1; GN Name=HNRNPDL; Synonyms=HNRPDL, JKTBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE RP SPECIFICITY, RNA-BINDING, AND DNA-BINDING. RC TISSUE=Erythroleukemia, and Placenta; RX PubMed=9538234; DOI=10.1093/oxfordjournals.jbchem.a021964; RA Tsuchiya N., Kamei D., Takano A., Matsui T., Yamada M.; RT "Cloning and characterization of a cDNA encoding a novel heterogeneous RT nuclear ribonucleoprotein-like protein and its expression in myeloid RT leukemia cells."; RL J. Biochem. 123:499-507(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), INDUCTION, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=10072754; DOI=10.1016/s0378-1119(99)00020-7; RA Kamei D., Tsuchiya N., Yamazaki M., Meguro H., Yamada M.; RT "Two forms of expression and genomic structure of the human heterogeneous RT nuclear ribonucleoprotein D-like JKTBP gene (HNRPDL)."; RL Gene 228:13-22(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), SUBCELLULAR LOCATION, AND RP RNA-BINDING. RX PubMed=11705999; DOI=10.1074/jbc.m108477200; RA Kawamura H., Tomozoe Y., Akagi T., Kamei D., Ochiai M., Yamada M.; RT "Identification of the nucleocytoplasmic shuttling sequence of RT heterogeneous nuclear ribonucleoprotein D-like protein JKTBP and its RT interaction with mRNA."; RL J. Biol. Chem. 277:2732-2739(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, Ovary, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 123-420. RC TISSUE=Brain; RX PubMed=15190078; DOI=10.1074/jbc.m403160200; RA Boopathi E., Lenka N., Prabu S.K., Fang J.-K., Wilkinson F., Atchison M., RA Giallongo A., Avadhani N.G.; RT "Regulation of murine cytochrome c oxidase Vb gene expression during RT myogenesis: YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein RT (JKTBP1) reciprocally regulate transcription activity by physical RT interaction with the BERF-1/ZBP-89 factor."; RL J. Biol. Chem. 279:35242-35254(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 131-420, INTERACTION WITH TNPO1, MUTAGENESIS RP OF GLY-404, INDUCTION, AND RNA-BINDING. RX PubMed=9524220; DOI=10.1016/s0167-4781(97)00223-6; RA Doi A., Shiosaka T., Takaoka Y., Yanagisawa K., Fujita S.; RT "Molecular cloning of the cDNA encoding A + U-rich element RNA binding RT factor."; RL Biochim. Biophys. Acta 1396:51-56(1998). RN [9] RP PROTEIN SEQUENCE OF 150-180; 190-209; 234-269; 275-289 AND 406-420, RP METHYLATION AT LYS-161 AND ARG-408, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Colon carcinoma, and Ovarian carcinoma; RA Bienvenut W.V., Zebisch A., Lilla S., von Kriegsheim A., Lempens A., RA Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [10] RP PROTEIN SEQUENCE OF 235-269 AND 275-289. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP SUBCELLULAR LOCATION, AND RNA-BINDING. RX PubMed=12406575; DOI=10.1016/s0378-1119(02)00926-5; RA Kamei D., Yamada M.; RT "Interactions of heterogeneous nuclear ribonucleoprotein D-like protein RT JKTBP and its domains with high-affinity binding sites."; RL Gene 298:49-57(2002). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-216, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [20] RP INVOLVEMENT IN LGMDD3, AND VARIANTS LGMDD3 ASN-378 AND HIS-378. RX PubMed=24647604; DOI=10.1093/hmg/ddu127; RA Vieira N.M., Naslavsky M.S., Licinio L., Kok F., Schlesinger D., RA Vainzof M., Sanchez N., Kitajima J.P., Gal L., Cavacana N., Serafini P.R., RA Chuartzman S., Vasquez C., Mimbacas A., Nigro V., Pavanello R.C., RA Schuldiner M., Kunkel L.M., Zatz M.; RT "A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular RT dystrophy 1G (LGMD1G)."; RL Hum. Mol. Genet. 23:4103-4110(2014). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-25, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [23] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-209, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- FUNCTION: Acts as a transcriptional regulator. Promotes transcription CC repression. Promotes transcription activation in differentiated CC myotubes (By similarity). Binds to double- and single-stranded DNA CC sequences. Binds to the transcription suppressor CATR sequence of the CC COX5B promoter (By similarity). Binds with high affinity to RNA CC molecules that contain AU-rich elements (AREs) found within the 3'-UTR CC of many proto-oncogenes and cytokine mRNAs. Binds both to nuclear and CC cytoplasmic poly(A) mRNAs. Binds to poly(G) and poly(A), but not to CC poly(U) or poly(C) RNA homopolymers. Binds to the 5'-ACUAGC-3' RNA CC consensus sequence. {ECO:0000250, ECO:0000269|PubMed:9538234}. CC -!- SUBUNIT: Interacts with ZNF148 (By similarity). Interacts with TNPO1. CC {ECO:0000250, ECO:0000269|PubMed:9524220}. CC -!- INTERACTION: CC O14979; P22626: HNRNPA2B1; NbExp=2; IntAct=EBI-299727, EBI-299649; CC O14979; Q14103: HNRNPD; NbExp=2; IntAct=EBI-299727, EBI-299674; CC O14979; Q15637: SF1; NbExp=4; IntAct=EBI-299727, EBI-744603; CC O14979; P09234: SNRPC; NbExp=4; IntAct=EBI-299727, EBI-766589; CC O14979; Q13148: TARDBP; NbExp=3; IntAct=EBI-299727, EBI-372899; CC O14979; O76024: WFS1; NbExp=3; IntAct=EBI-299727, EBI-720609; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. Cytoplasm {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. Note=Shuttles between the nucleus and the CC cytoplasm in a TNPO1-dependent manner. {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=JKTBP2 {ECO:0000303|PubMed:10072754}; CC IsoId=O14979-1; Sequence=Displayed; CC Name=2; Synonyms=JKTBP1 {ECO:0000303|PubMed:10072754}; CC IsoId=O14979-2; Sequence=VSP_025410; CC Name=3; CC IsoId=O14979-3; Sequence=VSP_025410, VSP_025411; CC -!- TISSUE SPECIFICITY: Expressed in heart, brain, placenta, lung, liver, CC skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, CC ovary, small intestine, colon and leukocytes. Expressed in myeloid CC leukemia, gastric adenocarcinoma, cervical carcinoma, hepatoma, CC fibrosarcoma, colon adenocarcinoma, epidermoid carcinoma, osteosarcoma CC and urinary bladder carcinoma cells. {ECO:0000269|PubMed:10072754, CC ECO:0000269|PubMed:9538234}. CC -!- INDUCTION: Up-regulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) CC in macrophages and retinoic acid (RA) in granulocytes (at protein CC level). Down-regulated by IL4/interleukin-4. CC {ECO:0000269|PubMed:10072754, ECO:0000269|PubMed:9524220}. CC -!- PTM: Dimethylation of Arg-408 is probably of the asymmetric type. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal dominant 3 (LGMDD3) CC [MIM:609115]: An autosomal dominant degenerative myopathy characterized CC by slowly progressive wasting and weakness of the proximal muscles of CC arms and legs around the pelvic or shoulder girdles, elevated creatine CC kinase levels and dystrophic features on muscle biopsy. LGMDD3 is CC characterized by a mild late-onset and is associated with progressive CC fingers and toes flexion limitation. Affected individuals may also CC develop cataracts before age 50. {ECO:0000269|PubMed:24647604}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SEQUENCE CAUTION: CC Sequence=BAA22860.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB017019; BAA75241.1; -; mRNA. DR EMBL; D89092; BAA24361.1; -; mRNA. DR EMBL; AB066484; BAB62188.1; -; mRNA. DR EMBL; CR407623; CAG28551.1; -; mRNA. DR EMBL; AC124016; AAY40914.1; -; Genomic_DNA. DR EMBL; AB017018; BAA75239.1; -; Genomic_DNA. DR EMBL; AB017018; BAA75240.1; -; Genomic_DNA. DR EMBL; BC007392; AAH07392.2; -; mRNA. DR EMBL; BC011714; AAH11714.1; -; mRNA. DR EMBL; BC071944; AAH71944.1; -; mRNA. DR EMBL; AY453824; AAR17782.1; -; mRNA. DR EMBL; D89678; BAA22860.1; ALT_INIT; mRNA. DR CCDS; CCDS3593.1; -. [O14979-1] DR PIR; JW0079; JW0079. DR RefSeq; NP_001193929.1; NM_001207000.1. DR RefSeq; NP_112740.1; NM_031372.4. [O14979-1] DR PDB; 7ZIR; EM; 2.50 A; A/B/C/D/E=121-420. DR PDBsum; 7ZIR; -. DR AlphaFoldDB; O14979; -. DR EMDB; EMD-14738; -. DR SMR; O14979; -. DR BioGRID; 115308; 392. DR CORUM; O14979; -. DR FunCoup; O14979; 3959. DR IntAct; O14979; 166. DR MINT; O14979; -. DR STRING; 9606.ENSP00000483254; -. DR GlyGen; O14979; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14979; -. DR MetOSite; O14979; -. DR PhosphoSitePlus; O14979; -. DR SwissPalm; O14979; -. DR BioMuta; HNRNPDL; -. DR jPOST; O14979; -. DR MassIVE; O14979; -. DR PaxDb; 9606-ENSP00000483254; -. DR PeptideAtlas; O14979; -. DR ProteomicsDB; 48353; -. [O14979-1] DR ProteomicsDB; 48354; -. [O14979-2] DR ProteomicsDB; 48355; -. [O14979-3] DR Pumba; O14979; -. DR Antibodypedia; 25039; 160 antibodies from 24 providers. DR DNASU; 9987; -. DR Ensembl; ENST00000295470.10; ENSP00000295470.5; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000349655.8; ENSP00000338552.5; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000502762.4; ENSP00000422040.1; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000507721.5; ENSP00000480156.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000602300.5; ENSP00000473677.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000621267.4; ENSP00000483254.1; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000630114.2; ENSP00000486452.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000630827.1; ENSP00000485954.1; ENSG00000152795.19. [O14979-2] DR GeneID; 9987; -. DR KEGG; hsa:9987; -. DR MANE-Select; ENST00000295470.10; ENSP00000295470.5; NM_031372.4; NP_112740.1. DR UCSC; uc003hmr.4; human. [O14979-1] DR AGR; HGNC:5037; -. DR ClinPGx; PA29362; -. DR CTD; 9987; -. DR DisGeNET; 9987; -. DR GeneCards; HNRNPDL; -. DR HGNC; HGNC:5037; HNRNPDL. DR HPA; ENSG00000152795; Low tissue specificity. DR MalaCards; HNRNPDL; -. DR MIM; 607137; gene. DR MIM; 609115; phenotype. DR OpenTargets; ENSG00000152795; -. DR Orphanet; 55596; HNRNPDL-related limb-girdle muscular dystrophy D3. DR VEuPathDB; HostDB:ENSG00000152795; -. DR eggNOG; KOG0118; Eukaryota. DR GeneTree; ENSGT00940000154426; -. DR HOGENOM; CLU_012062_1_1_1; -. DR InParanoid; O14979; -. DR OMA; QVDTEMN; -. DR OrthoDB; 1875751at2759; -. DR PAN-GO; O14979; 4 GO annotations based on evolutionary models. DR PhylomeDB; O14979; -. DR PathwayCommons; O14979; -. DR Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation. DR SignaLink; O14979; -. DR Agora; ENSG00000152795; -. DR BioGRID-ORCS; 9987; 19 hits in 1107 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; D0F20FEF; Synthetic Condensate 000090. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; HNRNPDL; human. DR GeneWiki; HNRPDL; -. DR GenomeRNAi; 9987; -. DR Pharos; O14979; Tbio. DR PRO; PR:O14979; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; O14979; protein. DR Bgee; ENSG00000152795; Expressed in primordial germ cell in gonad and 212 other cell types or tissues. DR ExpressionAtlas; O14979; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005681; C:spliceosomal complex; NAS:UniProtKB. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB. DR GO; GO:0008143; F:poly(A) binding; IDA:UniProtKB. DR GO; GO:0034046; F:poly(G) binding; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB. DR GO; GO:0010468; P:regulation of gene expression; IDA:UniProtKB. DR GO; GO:0006396; P:RNA processing; NAS:UniProtKB. DR CDD; cd12758; RRM1_hnRPDL; 1. DR CDD; cd12585; RRM2_hnRPDL; 1. DR FunFam; 3.30.70.330:FF:000220; Heterogeneous nuclear ribonucleoprotein D-like protein; 1. DR FunFam; 3.30.70.330:FF:000030; Heterogeneous nuclear ribonucleoprotein d0 isoform; 1. DR Gene3D; 3.30.70.330; -; 2. DR InterPro; IPR034847; hnRPDL_RRM1. DR InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf. DR InterPro; IPR035979; RBD_domain_sf. DR InterPro; IPR000504; RRM_dom. DR PANTHER; PTHR48033:SF2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D-LIKE; 1. DR PANTHER; PTHR48033; RNA-BINDING (RRM/RBD/RNP MOTIFS) FAMILY PROTEIN; 1. DR Pfam; PF00076; RRM_1; 2. DR SMART; SM00360; RRM; 2. DR SUPFAM; SSF54928; RNA-binding domain, RBD; 2. DR PROSITE; PS50102; RRM; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm; KW Direct protein sequencing; Disease variant; DNA-binding; Isopeptide bond; KW Limb-girdle muscular dystrophy; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW RNA-binding; Transcription; Transcription regulation; Ubl conjugation. FT CHAIN 1..420 FT /note="Heterogeneous nuclear ribonucleoprotein D-like" FT /id="PRO_0000287239" FT DOMAIN 148..230 FT /note="RRM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT DOMAIN 233..312 FT /note="RRM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT REGION 1..83 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 96..120 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 313..348 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 342..420 FT /note="Necessary for interaction with TNPO1" FT /evidence="ECO:0000269|PubMed:9524220" FT REGION 396..420 FT /note="Necessary for its nuclear import and export" FT REGION 398..420 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 36..52 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 323..342 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 25 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 161 FT /note="N6-methyllysine" FT /evidence="ECO:0000269|Ref.9" FT MOD_RES 216 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 241 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 408 FT /note="Dimethylated arginine; alternate" FT /evidence="ECO:0000269|Ref.9" FT MOD_RES 408 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z130" FT CROSSLNK 209 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..119 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10072754, FT ECO:0000303|PubMed:11705999, ECO:0000303|PubMed:9538234" FT /id="VSP_025410" FT VAR_SEQ 341..397 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11705999" FT /id="VSP_025411" FT VARIANT 378 FT /note="D -> H (in LGMDD3; dbSNP:rs587777669)" FT /evidence="ECO:0000269|PubMed:24647604" FT /id="VAR_072567" FT VARIANT 378 FT /note="D -> N (in LGMDD3; dbSNP:rs587777669)" FT /evidence="ECO:0000269|PubMed:24647604" FT /id="VAR_072568" FT MUTAGEN 404 FT /note="G->A: Reduces significantly its nuclear FT localization." FT /evidence="ECO:0000269|PubMed:9524220" FT STRAND 358..362 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 380..383 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 388..394 FT /evidence="ECO:0007829|PDB:7ZIR" SQ SEQUENCE 420 AA; 46438 MW; 00F631863859D0CA CRC64; MEVPPRLSHV PPPLFPSAPA TLASRSLSHW RPRPPRQLAP LLPSLAPSSA RQGARRAQRH VTAQQPSRLA GGAAIKGGRR RRPDLFRRHF KSSSIQRSAA AAAATRTARQ HPPADSSVTM EDMNEYSNIE EFAEGSKINA SKNQQDDGKM FIGGLSWDTS KKDLTEYLSR FGEVVDCTIK TDPVTGRSRG FGFVLFKDAA SVDKVLELKE HKLDGKLIDP KRAKALKGKE PPKKVFVGGL SPDTSEEQIK EYFGAFGEIE NIELPMDTKT NERRGFCFIT YTDEEPVKKL LESRYHQIGS GKCEIKVAQP KEVYRQQQQQ QKGGRGAAAG GRGGTRGRGR GQGQNWNQGF NNYYDQGYGN YNSAYGGDQN YSGYGGYDYT GYNYGNYGYG QGYADYSGQQ STYGKASRGG GNHQNNYQPY // ID INSR_HUMAN Reviewed; 1382 AA. AC P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9; DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 4. DT 28-JAN-2026, entry version 294. DE RecName: Full=Insulin receptor; DE Short=IR; DE EC=2.7.10.1; DE AltName: CD_antigen=CD220; DE Contains: DE RecName: Full=Insulin receptor subunit alpha; DE Contains: DE RecName: Full=Insulin receptor subunit beta; DE Flags: Precursor; GN Name=INSR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2; HIS-171; RP THR-448 AND LYS-492. RX PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4; RA Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.-H., RA Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.; RT "The human insulin receptor cDNA: the structural basis for hormone- RT activated transmembrane signalling."; RL Cell 40:747-758(1985). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49 AND RP 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2. RX PubMed=2983222; DOI=10.1038/313756a0; RA Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J., RA Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A., Seeburg P.H., RA Grunfeld C., Rosen O.M., Ramachandran J.; RT "Human insulin receptor and its relationship to the tyrosine kinase family RT of oncogenes."; RL Nature 313:756-761(1985). RN [3] RP SEQUENCE REVISION TO 899-900. RA Chen E.Y.; RL Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2. RC TISSUE=Fetal liver; RX PubMed=2210055; DOI=10.2337/diacare.39.1.123; RA Seino S., Seino M., Bell G.I.; RT "Human insulin-receptor gene. Partial sequence and amplification of exons RT by polymerase chain reaction."; RL Diabetes 39:123-128(1990). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT GLY-2. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=3680248; DOI=10.1016/s0021-9258(18)47714-9; RA Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene. Evidence for promoter activity."; RL J. Biol. Chem. 262:16186-16191(1987). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5; RA Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene."; RL Diabetes Res. Clin. Pract. 7:S31-S33(1989). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2777789; DOI=10.1016/s0021-9258(18)71612-8; RA Tewari D.S., Cook D.M., Taub R.; RT "Characterization of the promoter region and 3' end of the human insulin RT receptor gene."; RL J. Biol. Chem. 264:16238-16245(1989). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RC TISSUE=Skin fibroblast; RX PubMed=2280779; DOI=10.1210/mend-4-4-647; RA McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D., RA Taylor S.I.; RT "Structural and functional analysis of the insulin receptor promoter."; RL Mol. Endocrinol. 4:647-656(1990). RN [11] RP PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780, ACTIVITY RP REGULATION, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=2211730; DOI=10.1016/s0021-9258(17)44805-8; RA Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.; RT "Substructural analysis of the insulin receptor by microsequence analyses RT of limited tryptic fragments isolated by sodium dodecyl sulfate- RT polyacrylamide gel electrophoresis in the absence or presence of RT dithiothreitol."; RL J. Biol. Chem. 265:18673-18681(1990). RN [12] RP PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A HYBRID RP RECEPTOR WITH IGF1R. RC TISSUE=Placenta; RX PubMed=8257688; DOI=10.1021/bi00212a019; RA Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A., RA Fujita-Yamaguchi Y.; RT "Characterization of human placental insulin-like growth factor-I/insulin RT hybrid receptors by protein microsequencing and purification."; RL Biochemistry 32:13531-13536(1993). RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE RP SPLICING. RX PubMed=2538124; DOI=10.1016/0006-291x(89)92439-x; RA Seino S., Bell G.I.; RT "Alternative splicing of human insulin receptor messenger RNA."; RL Biochem. Biophys. Res. Commun. 159:312-316(1989). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE SPECIFICITY, RP LIGAND-BINDING, AND AUTOPHOSPHORYLATION. RX PubMed=2369896; DOI=10.1002/j.1460-2075.1990.tb07416.x; RA Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A.; RT "Functionally distinct insulin receptors generated by tissue-specific RT alternative splicing."; RL EMBO J. 9:2409-2413(1990). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085. RX PubMed=2566545; DOI=10.2337/diab.38.6.737; RA Elbein S.C.; RT "Molecular and clinical characterization of an insertional polymorphism of RT the insulin-receptor gene."; RL Diabetes 38:737-743(1989). RN [17] RP PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND RP PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361. RC TISSUE=Placenta; RX PubMed=3166375; DOI=10.1042/bj2520607; RA Tavare J.M., Denton R.M.; RT "Studies on the autophosphorylation of the insulin receptor from human RT placenta. Analysis of the sites phosphorylated by two-dimensional peptide RT mapping."; RL Biochem. J. 252:607-615(1988). RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123. RX PubMed=2544997; DOI=10.1126/science.2544997; RA Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A., RA Nakamura F., Ebina Y., Tatibana M., Makino H.; RT "Human diabetes associated with a deletion of the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:63-66(1989). RN [19] RP PARTIAL PROTEIN SEQUENCE. RX PubMed=3447155; RA Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.; RT "Partial amino acid sequence analyses of human placental insulin RT receptor."; RL Protein Seq. Data Anal. 1:3-6(1987). RN [20] RP MUTAGENESIS OF LYS-1057. RX PubMed=3101064; DOI=10.1073/pnas.84.3.704; RA Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S., Siddle K., RA Pierce S.B., Roth R.A., Rutter W.J.; RT "Replacement of lysine residue 1030 in the putative ATP-binding region of RT the insulin receptor abolishes insulin- and antibody-stimulated glucose RT uptake and receptor kinase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987). RN [21] RP MUTAGENESIS OF TYR-999. RX PubMed=2842060; DOI=10.1016/s0092-8674(88)80008-4; RA White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J., Ullrich A., RA Kahn C.R.; RT "Mutation of the insulin receptor at tyrosine 960 inhibits signal RT transmission but does not affect its tyrosine kinase activity."; RL Cell 54:641-649(1988). RN [22] RP AUTOPHOSPHORYLATION. RX PubMed=1321605; DOI=10.1016/s0006-291x(05)80799-5; RA Dickens M., Tavare J.M.; RT "Analysis of the order of autophosphorylation of human insulin receptor RT tyrosines 1158, 1162 and 1163."; RL Biochem. Biophys. Res. Commun. 186:244-250(1992). RN [23] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541. RX PubMed=1472036; DOI=10.1016/0006-291x(92)92250-2; RA Schaeffer L., Ljungqvist L.; RT "Identification of a disulfide bridge connecting the alpha-subunits of the RT extracellular domain of the insulin receptor."; RL Biochem. Biophys. Res. Commun. 189:650-653(1992). RN [24] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=8452530; DOI=10.1042/bj2900419; RA Soos M.A., Field C.E., Siddle K.; RT "Purified hybrid insulin/insulin-like growth factor-I receptors bind RT insulin-like growth factor-I, but not insulin, with high affinity."; RL Biochem. J. 290:419-426(1993). RN [25] RP FUNCTION, AND INTERACTION WITH PIK3R1. RX PubMed=8276809; DOI=10.1016/s0021-9258(17)42304-0; RA Van Horn D.J., Myers M.G. Jr., Backer J.M.; RT "Direct activation of the phosphatidylinositol 3'-kinase by the insulin RT receptor."; RL J. Biol. Chem. 269:29-32(1994). RN [26] RP INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992; RP ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002. RX PubMed=7559478; DOI=10.1074/jbc.270.40.23258; RA He W., O'Neill T.J., Gustafson T.A.; RT "Distinct modes of interaction of SHC and insulin receptor substrate-1 with RT the insulin receptor NPEY region via non-SH2 domains."; RL J. Biol. Chem. 270:23258-23262(1995). RN [27] RP INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996; RP PRO-997; GLU-998; TYR-999 AND LYS-1057. RX PubMed=7537849; DOI=10.1128/mcb.15.5.2500; RA Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.; RT "Phosphotyrosine-dependent interaction of SHC and insulin receptor RT substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 RT domain."; RL Mol. Cell. Biol. 15:2500-2508(1995). RN [28] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9355755; DOI=10.1042/bj3270209; RA Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.; RT "Insulin receptor/IGF-I receptor hybrids are widely distributed in RT mammalian tissues: quantification of individual receptor species by RT selective immunoprecipitation and immunoblotting."; RL Biochem. J. 327:209-215(1997). RN [29] RP FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND RP INTERACTION WITH STAT5B; IRS1 AND IRS2. RX PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x; RA Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I., RA Van Obberghen E.; RT "Identification of Stat 5B as a substrate of the insulin receptor."; RL Eur. J. Biochem. 250:411-417(1997). RN [30] RP INTERACTION WITH PTPRF. RX PubMed=8995282; DOI=10.1074/jbc.272.11.7519; RA Ahmad F., Goldstein B.J.; RT "Functional association between the insulin receptor and the transmembrane RT protein-tyrosine phosphatase LAR in intact cells."; RL J. Biol. Chem. 272:448-457(1997). RN [31] RP INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE. RX PubMed=8999839; DOI=10.1074/jbc.272.3.1639; RA Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., RA Gustafson T.A., Kusari J.; RT "Protein-tyrosine phosphatase 1B complexes with the insulin receptor in RT vivo and is tyrosine-phosphorylated in the presence of insulin."; RL J. Biol. Chem. 272:1639-1645(1997). RN [32] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9202395; DOI=10.1016/s0303-7207(97)04050-1; RA Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D., RA Sesti G.; RT "Distribution of insulin/insulin-like growth factor-I hybrid receptors in RT human tissues."; RL Mol. Cell. Endocrinol. 129:121-126(1997). RN [33] RP TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM SHORT). RX PubMed=10207053; DOI=10.1128/mcb.19.5.3278; RA Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., RA Goldfine I.D., Belfiore A., Vigneri R.; RT "Insulin receptor isoform A, a newly recognized, high-affinity insulin-like RT growth factor II receptor in fetal and cancer cells."; RL Mol. Cell. Biol. 19:3278-3288(1999). RN [34] RP INTERACTION WITH ENPP1, AND ACTIVITY REGULATION. RX PubMed=10615944; DOI=10.2337/diabetes.49.1.13; RA Maddux B.A., Goldfine I.D.; RT "Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs RT via direct interaction with the receptor alpha-subunit."; RL Diabetes 49:13-19(2000). RN [35] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=10734133; DOI=10.1074/jbc.275.13.9792; RA Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S., RA Hooft van Huijsduijnen R.; RT "Identification of tyrosine phosphatases that dephosphorylate the insulin RT receptor. A brute force approach based on 'substrate-trapping' mutants."; RL J. Biol. Chem. 275:9792-9796(2000). RN [36] RP INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND TYR-1190. RX PubMed=10803466; DOI=10.1038/sj.onc.1203469; RA Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.; RT "Evidence for an interaction between the insulin receptor and Grb7. A role RT for two of its binding domains, PIR and SH2."; RL Oncogene 19:2052-2059(2000). RN [37] RP INTERACTION WITH SORBS1. RX PubMed=11374898; DOI=10.1006/geno.2001.6541; RA Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y., RA Chuang L.-M.; RT "Cloning, mapping, and characterization of the human sorbin and SH3 domain RT containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin RT signaling in the hepatoma cell line Hep3B."; RL Genomics 74:12-20(2001). RN [38] RP CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ACTIVITY RP REGULATION. RX PubMed=11598120; DOI=10.1074/jbc.m107236200; RA Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.; RT "Multiple activation loop conformations and their regulatory properties in RT the insulin receptor's kinase domain."; RL J. Biol. Chem. 276:46933-46940(2001). RN [39] RP INTERACTION WITH GRB14, AND ACTIVITY REGULATION. RX PubMed=11726652; DOI=10.1074/jbc.m106574200; RA Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J., RA Burnol A.F.; RT "Inhibition of insulin receptor catalytic activity by the molecular adapter RT Grb14."; RL J. Biol. Chem. 277:4845-4852(2002). RN [40] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=12138094; DOI=10.1074/jbc.m202766200; RA Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.; RT "Insulin/insulin-like growth factor I hybrid receptors have different RT biological characteristics depending on the insulin receptor isoform RT involved."; RL J. Biol. Chem. 277:39684-39695(2002). RN [41] RP INTERACTION WITH GRB10, AND ACTIVITY REGULATION. RX PubMed=12493740; DOI=10.1074/jbc.m208518200; RA Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q., Shoelson S.E., RA Liu F.; RT "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)- RT phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the RT association of IRS-1/IRS-2 with the insulin receptor."; RL J. Biol. Chem. 278:8460-8467(2003). RN [42] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2. RX PubMed=12612081; DOI=10.1128/mcb.23.6.2096-2108.2003; RA Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A., RA Meng T.C., Tonks N.K., Tiganis T.; RT "Regulation of insulin receptor signaling by the protein tyrosine RT phosphatase TCPTP."; RL Mol. Cell. Biol. 23:2096-2108(2003). RN [43] RP INTERACTION WITH SOCS7. RX PubMed=16127460; DOI=10.1172/jci23853; RA Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., RA Rothman P.B.; RT "Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of RT Langerhans."; RL J. Clin. Invest. 115:2462-2471(2005). RN [44] RP FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=16314505; DOI=10.1128/mcb.25.24.10803-10814.2005; RA Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I., Corbo V., RA Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S., Formisano P., RA Beguinot F.; RT "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the RT insulin receptor is necessary for insulin metabolic signaling."; RL Mol. Cell. Biol. 25:10803-10814(2005). RN [45] RP DEPHOSPHORYLATION BY PTPRE. RX PubMed=15738637; DOI=10.2108/zsj.22.169; RA Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N., RA Miyazaki H.; RT "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a RT negative regulator of insulin signaling in primary hepatocytes and liver."; RL Zool. Sci. 22:169-175(2005). RN [46] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=16831875; DOI=10.1074/jbc.m605189200; RA Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C., RA Mathiasen I.S., Brandt J.; RT "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth RT factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity RT irrespective of the IR splice variant."; RL J. Biol. Chem. 281:25869-25874(2006). RN [47] RP REVIEW ON SIGNALING PATHWAYS. RX PubMed=16493415; DOI=10.1038/nrm1837; RA Taniguchi C.M., Emanuelli B., Kahn C.R.; RT "Critical nodes in signalling pathways: insights into insulin action."; RL Nat. Rev. Mol. Cell Biol. 7:85-96(2006). RN [48] RP REVIEW ON REGULATION OF INSR FUNCTION. RX PubMed=17347799; DOI=10.1007/s00018-007-6359-9; RA Youngren J.F.; RT "Regulation of insulin receptor function."; RL Cell. Mol. Life Sci. 64:873-891(2007). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND SER-407, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [50] RP DOMAIN, AND INSULIN-BINDING SITE. RX PubMed=19459609; DOI=10.1021/bi900261q; RA Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.; RT "A thermodynamic study of ligand binding to the first three domains of the RT human insulin receptor: relationship between the receptor alpha-chain C- RT terminal peptide and the site 1 insulin mimetic peptides."; RL Biochemistry 48:5492-5500(2009). RN [51] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [53] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [54] RP INTERACTION WITH NCK1, AND PHOSPHORYLATION AT TYR-1189 AND TYR-1190. RX PubMed=21707536; DOI=10.1042/bj20110799; RA Wu C.L., Buszard B., Teng C.H., Chen W.L., Warr C.G., Tiganis T., RA Meng T.C.; RT "Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling."; RL Biochem. J. 439:151-159(2011). RN [55] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [56] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [57] RP PHOSPHORYLATION AT TYR-1185 AND TYR-1190. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [58] RP MUTAGENESIS OF LYS-1079, AND UBIQUITINATION AT LYS-1079. RX PubMed=27577745; DOI=10.1038/ncomms12639; RA Nagarajan A., Petersen M.C., Nasiri A.R., Butrico G., Fung A., Ruan H.B., RA Kursawe R., Caprio S., Thibodeau J., Bourgeois-Daigneault M.C., Sun L., RA Gao G., Bhanot S., Jurczak M.J., Green M.R., Shulman G.I., Wajapeyee N.; RT "MARCH1 regulates insulin sensitivity by controlling cell surface insulin RT receptor levels."; RL Nat. Commun. 7:12639-12639(2016). RN [59] RP INTERACTION WITH SORL1. RX PubMed=27322061; DOI=10.1172/jci84708; RA Schmidt V., Schulz N., Yan X., Schuermann A., Kempa S., Kern M., RA Blueher M., Poy M.N., Olivecrona G., Willnow T.E.; RT "SORLA facilitates insulin receptor signaling in adipocytes and exacerbates RT obesity."; RL J. Clin. Invest. 126:2706-2720(2016). RN [60] RP SUBUNIT. RX PubMed=27617429; DOI=10.1038/nsmb.3292; RA Menting J.G., Gajewiak J., MacRaild C.A., Chou D.H., Disotuar M.M., RA Smith N.A., Miller C., Erchegyi J., Rivier J.E., Olivera B.M., Forbes B.E., RA Smith B.J., Norton R.S., Safavi-Hemami H., Lawrence M.C.; RT "A minimized human insulin-receptor-binding motif revealed in a Conus RT geographus venom insulin."; RL Nat. Struct. Mol. Biol. 23:916-920(2016). RN [61] RP S-NITROSYLATION AT CYS-1083, AND MUTAGENESIS OF CYS-462; CYS-825; CYS-834 RP AND CYS-1083. RX PubMed=38056462; DOI=10.1016/j.cell.2023.11.009; RA Zhou H.L., Grimmett Z.W., Venetos N.M., Stomberski C.T., Qian Z., RA McLaughlin P.J., Bansal P.K., Zhang R., Reynolds J.D., Premont R.T., RA Stamler J.S.; RT "An enzyme that selectively S-nitrosylates proteins to regulate insulin RT signaling."; RL Cell 0:0-0(2023). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310. RX PubMed=7997262; DOI=10.1038/372746a0; RA Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.; RT "Crystal structure of the tyrosine kinase domain of the human insulin RT receptor."; RL Nature 372:746-754(1994). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE, RP AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190. RX PubMed=9312016; DOI=10.1093/emboj/16.18.5572; RA Hubbard S.R.; RT "Crystal structure of the activated insulin receptor tyrosine kinase in RT complex with peptide substrate and ATP analog."; RL EMBO J. 16:5572-5581(1997). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG, AND CATALYTIC ACTIVITY. RX PubMed=11124964; DOI=10.1074/jbc.m010161200; RA Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A., RA Hubbard S.R.; RT "Crystallographic and solution studies of an activation loop mutant of the RT insulin receptor tyrosine kinase: insights into kinase mechanism."; RL J. Biol. Chem. 276:10049-10055(2001). RN [65] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT ASN-1159, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF TYR-1011. RX PubMed=12707268; DOI=10.1074/jbc.m302425200; RA Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.; RT "Structural and biochemical evidence for an autoinhibitory role for RT tyrosine 984 in the juxtamembrane region of the insulin receptor."; RL J. Biol. Chem. 278:26007-26014(2003). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=14690593; DOI=10.1016/s1097-2765(03)00487-8; RA Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.; RT "Structural basis for recruitment of the adaptor protein APS to the RT activated insulin receptor."; RL Mol. Cell 12:1379-1389(2003). RN [67] RP X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH GRB14, RP INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT RP TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001; RA Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J., Hubbard S.R.; RT "Structural basis for inhibition of the insulin receptor by the adaptor RT protein Grb14."; RL Mol. Cell 20:325-333(2005). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH PTPN1, RP AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16271887; DOI=10.1016/j.str.2005.07.019; RA Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.; RT "Crystal structure of a complex between protein tyrosine phosphatase 1B and RT the insulin receptor tyrosine kinase."; RL Structure 13:1643-1651(2005). RN [69] RP X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH INSULIN RP ANALOG, DOMAIN, AND DISULFIDE BONDS. RX PubMed=16957736; DOI=10.1038/nature05106; RA McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., RA Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., RA Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E., RA Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G., RA Fernley R.T., Epa V.C., Ward C.W.; RT "Structure of the insulin receptor ectodomain reveals a folded-over RT conformation."; RL Nature 443:218-221(2006). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT ASN-43; RP ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND ASN-445, AND RP DISULFIDE BONDS. RX PubMed=16894147; DOI=10.1073/pnas.0605395103; RA Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D., RA Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.; RT "The first three domains of the insulin receptor differ structurally from RT the insulin-like growth factor 1 receptor in the regions governing ligand RT specificity."; RL Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006). RN [71] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP AND RP IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190, AND INTERACTION WITH IRS2. RX PubMed=18278056; DOI=10.1038/nsmb.1388; RA Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.; RT "Structural and biochemical characterization of the KRLB region in insulin RT receptor substrate-2."; RL Nat. Struct. Mol. Biol. 15:251-258(2008). RN [72] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH RP INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=18767165; DOI=10.1002/prot.22207; RA Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S., RA Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.; RT "Identification of a key element for hydrogen-bonding patterns between RT protein kinases and their inhibitors."; RL Proteins 73:795-801(2008). RN [73] RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077; RA Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B., RA Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M., Shewchuk L.M., RA Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C., Groy A., Rowand J.L., RA Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.; RT "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R RT tyrosine kinase inhibitors towards JNK selectivity."; RL Bioorg. Med. Chem. Lett. 19:360-364(2009). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046; RA Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M., Yang B., RA Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A., Atkins C., Gerding R., RA Hassell A.M., Lei H., Mook R.A. Jr., Moorthy G., Rowand J.L., Stevens K.L., RA Kumar R., Shotwell J.B.; RT "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent RT inhibitors of the IGF-1R receptor tyrosine kinase."; RL Bioorg. Med. Chem. Lett. 19:469-473(2009). RN [75] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110; RA Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B., Tang J., RA Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M., Shewchuck L.M., RA Kumar R., Lei H., Chamberlain S.D.; RT "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent RT inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine RT kinase."; RL Bioorg. Med. Chem. Lett. 19:3136-3140(2009). RN [76] RP X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING REGION, RP AND DISULFIDE BONDS. RX PubMed=20348418; DOI=10.1073/pnas.1001813107; RA Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G., RA Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W., RA Weiss M.A., Lawrence M.C.; RT "Structural resolution of a tandem hormone-binding element in the insulin RT receptor and its implications for design of peptide agonists."; RL Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010). RN [77] RP X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH INSULIN, RP DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND ASN-282, AND RP DISULFIDE BONDS. RX PubMed=23302862; DOI=10.1038/nature11781; RA Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K., RA Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J., Chan S.J., RA Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A., Ward C.W., RA Lawrence M.C.; RT "How insulin engages its primary binding site on the insulin receptor."; RL Nature 493:241-245(2013). RN [78] RP VARIANT IRAN TYPE A SER-762. RX PubMed=3283938; DOI=10.1126/science.3283938; RA Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H., RA Imura H., Bell G.I., Steiner D.F.; RT "Insulin-resistant diabetes due to a point mutation that prevents insulin RT proreceptor processing."; RL Science 240:784-787(1988). RN [79] RP VARIANT LEPRCH GLU-487. RX PubMed=2834824; DOI=10.1126/science.2834824; RA Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B., Kadowaki H., RA Beitz L., McKeon C., Taylor S.I.; RT "Two mutant alleles of the insulin receptor gene in a patient with extreme RT insulin resistance."; RL Science 240:787-790(1988). RN [80] RP VARIANT LEPRCH PRO-260. RX PubMed=2479553; DOI=10.1002/j.1460-2075.1989.tb08387.x; RA Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D., RA Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.; RT "A leucine-to-proline mutation in the insulin receptor in a family with RT insulin resistance."; RL EMBO J. 8:2503-2507(1989). RN [81] RP VARIANT IRAN TYPE A VAL-1035. RX PubMed=2544998; DOI=10.1126/science.2544998; RA Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K., Accili D., RA Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F., Taylor S.I., RA Kasuga M.; RT "Human diabetes associated with a mutation in the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:66-68(1989). RN [82] RP VARIANT IRAN TYPE A THR-1161. RX PubMed=2168397; DOI=10.1016/s0021-9258(18)77212-8; RA Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.; RT "A naturally occurring mutation of insulin receptor alanine 1134 impairs RT tyrosine kinase function and is associated with dominantly inherited RT insulin resistance."; RL J. Biol. Chem. 265:14979-14985(1990). RN [83] RP CHARACTERIZATION OF VARIANT RMS LYS-42. RX PubMed=2121734; DOI=10.1016/s0021-9258(17)30636-1; RA Kadowaki T., Kadowaki H., Accili D., Taylor S.I.; RT "Substitution of lysine for asparagine at position 15 in the alpha-subunit RT of the human insulin receptor. A mutation that impairs transport of RT receptors to the cell surface and decreases the affinity of insulin RT binding."; RL J. Biol. Chem. 265:19143-19150(1990). RN [84] RP VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A RP SER-489. RX PubMed=2365819; DOI=10.1172/jci114693; RA Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J., RA Gorden P., Taylor S.I.; RT "Five mutant alleles of the insulin receptor gene in patients with genetic RT forms of insulin resistance."; RL J. Clin. Invest. 86:254-264(1990). RN [85] RP VARIANT IRAN TYPE A SER-1227. RX PubMed=1963473; DOI=10.1210/mend-4-8-1183; RA Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.; RT "Functional properties of a naturally occurring Trp1200-->Ser1200 mutation RT of the insulin receptor."; RL Mol. Endocrinol. 4:1183-1191(1990). RN [86] RP VARIANT GLU-1095. RX PubMed=2040394; DOI=10.2337/diab.40.6.777; RA O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S., Moller D.E.; RT "Detection of mutations in insulin-receptor gene in NIDDM patients by RT analysis of single-stranded conformation polymorphisms."; RL Diabetes 40:777-782(1991). RN [87] RP VARIANT IRAN TYPE A GLN-1020. RX PubMed=2002058; DOI=10.1016/s0021-9258(19)67781-1; RA Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O., RA Olefsky J.M.; RT "Insulin resistance and diabetes due to different mutations in the tyrosine RT kinase domain of both insulin receptor gene alleles."; RL J. Biol. Chem. 266:5260-5267(1991). RN [88] RP VARIANT INS RESISTANCE ILE-1180. RX PubMed=1890161; DOI=10.1210/jcem-73-4-894; RA Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P., RA Imperato-Mcginley J., Taylor S.I.; RT "A mutation in the tyrosine kinase domain of the insulin receptor RT associated with insulin resistance in an obese woman."; RL J. Clin. Endocrinol. Metab. 73:894-901(1991). RN [89] RP VARIANTS LEPRCH ALA-55 AND ARG-393. RX PubMed=1607067; DOI=10.2337/diab.41.4.408; RA Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E., RA Pizzo P., Moghetti P., Muggeo M., Roth J.; RT "Detection of mutations in insulin receptor gene by denaturing gradient gel RT electrophoresis."; RL Diabetes 41:408-415(1992). RN [90] RP VARIANT T2D GLN-1191. RX PubMed=1607076; DOI=10.2337/diab.41.4.521; RA Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G., RA Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.; RT "NIDDM associated with mutation in tyrosine kinase domain of insulin RT receptor gene."; RL Diabetes 41:521-526(1992). RN [91] RP VARIANT IRAN TYPE A LEU-1205. RX PubMed=1563582; DOI=10.1007/bf00400927; RA Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y., RA Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I., RA Kadowaki T.; RT "Detection of mutations in the insulin receptor gene in patients with RT insulin resistance by analysis of single-stranded conformational RT polymorphisms."; RL Diabetologia 35:261-266(1992). RN [92] RP VARIANT LEPRCH ARG-58. RX PubMed=1730625; DOI=10.1016/s0021-9258(18)48459-1; RA van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J., RA Lindhout D., Maassen J.A.; RT "An Arg for Gly substitution at position 31 in the insulin receptor, linked RT to insulin resistance, inhibits receptor processing and transport."; RL J. Biol. Chem. 267:66-71(1992). RN [93] RP VARIANT T2D GLN-1158. RX PubMed=1470163; RA Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T., Hagino H., RA Shii K.; RT "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of RT insulin receptor observed in insulin resistant diabetes."; RL Nihon Geka Gakkai Zasshi 93:968-971(1992). RN [94] RP VARIANT MET-1012. RX PubMed=8432414; DOI=10.2337/diab.42.3.429; RA Elbein S.C., Sorensen L.K., Schumacher M.C.; RT "Methionine for valine substitution in exon 17 of the insulin receptor gene RT in a pedigree with familial NIDDM."; RL Diabetes 42:429-434(1993). RN [95] RP VARIANT IRAN TYPE A ASP-1075. RX PubMed=8243830; DOI=10.2337/diab.42.12.1837; RA Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K., RA Itazu T., Kobayashi M.; RT "Ala1048-->Asp mutation in the kinase domain of insulin receptor causes RT defective kinase activity and insulin resistance."; RL Diabetes 42:1837-1844(1993). RN [96] RP VARIANT MET-1012. RX PubMed=8458533; DOI=10.1007/bf00400701; RA van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J., RA van Maldergem L., Herwig J., Maassen J.A.; RT "Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli RT type, express normal insulin receptors."; RL Diabetologia 36:172-174(1993). RN [97] RP VARIANT INS RESISTANCE LEU-1220. RX PubMed=8390949; DOI=10.1007/bf00402277; RA Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K., RA Imamura T., Naitou K., Itazu T., Kobayashi M.; RT "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the RT insulin receptor associated with type A syndrome of insulin resistance."; RL Diabetologia 36:414-422(1993). RN [98] RP VARIANT INS RESISTANCE LEU-220. RX PubMed=8242067; DOI=10.1093/hmg/2.9.1437; RA Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R., RA Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I., Micossi P., RA Barbetti F.; RT "Substitution of Leu for Pro-193 in the insulin receptor in a patient with RT a genetic form of severe insulin resistance."; RL Hum. Mol. Genet. 2:1437-1441(1993). RN [99] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162. RX PubMed=8096518; DOI=10.1016/s0021-9258(18)53063-5; RA Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P., Taylor S.I.; RT "Substitution of glutamic acid for alanine 1135 in the putative 'catalytic RT loop' of the tyrosine kinase domain of the human insulin receptor. A RT mutation that impairs proteolytic processing into subunits and inhibits RT receptor tyrosine kinase activity."; RL J. Biol. Chem. 268:8060-8069(1993). RN [100] RP VARIANT IRAN TYPE A VAL-409. RX PubMed=8388389; DOI=10.1016/s0021-9258(18)82120-2; RA Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J., RA Taylor S.I., Accili D., van Obberghen E.; RT "Antibodies to the extracellular receptor domain restore the hormone- RT insensitive kinase and conformation of the mutant insulin receptor valine RT 382."; RL J. Biol. Chem. 268:11272-11277(1993). RN [101] RP VARIANT LEPRCH MET-146. RX PubMed=8326490; DOI=10.1136/jmg.30.6.470; RA Al-Gazali L.I., Khalil M., Devadas K.; RT "A syndrome of insulin resistance resembling leprechaunism in five sibs of RT consanguineous parents."; RL J. Med. Genet. 30:470-475(1993). RN [102] RP VARIANT LEPRCH PRO-113. RX PubMed=8419945; DOI=10.1073/pnas.90.1.60; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Activation of glucose transport by a natural mutation in the human insulin RT receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993). RN [103] RP VARIANT IRAN TYPE A GLN-1201. RX PubMed=8288049; DOI=10.2337/diab.43.2.247; RA Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F., Eberle A., RA Morrow L.A., Moses A.C., Flier J.S.; RT "Prevalence of mutations in the insulin receptor gene in subjects with RT features of the type A syndrome of insulin resistance."; RL Diabetes 43:247-255(1994). RN [104] RP VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND GLN-1378, RP AND VARIANT MET-1012. RX PubMed=8314008; DOI=10.2337/diab.43.3.357; RA Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.; RT "Molecular scanning of the insulin receptor gene in syndromes of insulin RT resistance."; RL Diabetes 43:357-368(1994). RN [105] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201. RX PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0; RA Moritz W., Froesch E.R., Boeni-Schnetzler M.; RT "Functional properties of a heterozygous mutation (Arg1174-->Gln) in the RT tyrosine kinase domain of the insulin receptor from a type A insulin RT resistant patient."; RL FEBS Lett. 351:276-280(1994). RN [106] RP VARIANT LEPRCH SER-439. RX PubMed=8188715; DOI=10.1016/s0021-9258(17)36788-1; RA van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J., Moller W., RA Maassen J.A.; RT "A mutation in the insulin receptor that impairs proreceptor processing but RT not insulin binding."; RL J. Biol. Chem. 269:14297-14302(1994). RN [107] RP CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220. RX PubMed=7983039; DOI=10.1016/s0021-9258(18)47384-x; RA Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T., RA Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.; RT "Two naturally occurring mutations in the kinase domain of insulin receptor RT accelerate degradation of the insulin receptor and impair the kinase RT activity."; RL J. Biol. Chem. 269:31019-31027(1994). RN [108] RP VARIANT LEPRCH MET-146. RX PubMed=7815442; DOI=10.1136/jmg.31.9.715; RA Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T., Taylor S.I.; RT "Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor RT gene in five sibs with familial insulin resistance."; RL J. Med. Genet. 31:715-716(1994). RN [109] RP VARIANT T2D ALA-858, AND VARIANT CYS-1361. RX PubMed=7657032; DOI=10.2337/diab.44.9.1081; RA Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T., Ito K., RA Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T., Kagawa S., RA Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.; RT "Frequency of mutations of insulin receptor gene in Japanese patients with RT NIDDM."; RL Diabetes 44:1081-1086(1995). RN [110] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=7538143; DOI=10.1210/jcem.80.5.7538143; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Two mutations in the insulin receptor gene of a patient with RT leprechaunism: application to prenatal diagnosis."; RL J. Clin. Endocrinol. Metab. 80:1496-1501(1995). RN [111] RP VARIANT PHE-1023. RX PubMed=8890729; DOI=10.1530/eje.0.1350357; RA Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.; RT "In-frame exon 2 deletion in insulin receptor RNA in a family with extreme RT insulin resistance in association with defective insulin binding: a case RT report."; RL Eur. J. Endocrinol. 135:357-363(1996). RN [112] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=8636294; DOI=10.1210/jcem.81.2.8636294; RA Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J., RA Flori E., Besmond C., Capeau J., Caron M.; RT "Deletion of Asn281 in the alpha-subunit of the human insulin receptor RT causes constitutive activation of the receptor and insulin RT desensitization."; RL J. Clin. Endocrinol. Metab. 81:719-727(1996). RN [113] RP VARIANT MET-1012. RX PubMed=9199575; DOI=10.1086/515464; RA Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A., RA Rasmussen S.K., Pedersen O.; RT "The Val985Met insulin-receptor variant in the Danish Caucasian population: RT lack of associations with non-insulin-dependent diabetes mellitus or RT insulin resistance."; RL Am. J. Hum. Genet. 60:1532-1535(1997). RN [114] RP VARIANTS IRAN TYPE A GLY-86 AND PRO-89. RX PubMed=9175790; DOI=10.1006/bbrc.1997.6695; RA Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P., RA Renard E., Bringer J., Jaffiol C., Grigorescu F.; RT "Identification of two novel insulin receptor mutations, Asp59Gly and RT Leu62Pro, in type A syndrome of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 234:764-768(1997). RN [115] RP CHARACTERIZATION OF VARIANT LEPRCH MET-937. RX PubMed=9299395; DOI=10.1006/bbrc.1997.7181; RA Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y., Quin J.D., RA MacCuish A.C., Koda N., Fukushima Y., Taylor S.I., Akanuma Y., Yazaki Y., RA Kadowaki T.; RT "Four mutant alleles of the insulin receptor gene associated with genetic RT syndromes of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 237:516-520(1997). RN [116] RP VARIANTS LEPRCH TRP-1119 AND LYS-1206. RX PubMed=9249867; RX DOI=10.1002/(sici)1097-0223(199707)17:7<657::aid-pd132>3.3.co;2-#; RA Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A., RA Conteville P., Magre J., Besmond C., Goossens M., Capeau J., Amselem S.; RT "Molecular analysis of the insulin receptor gene for prenatal diagnosis of RT leprechaunism in two families."; RL Prenat. Diagn. 17:657-663(1997). RN [117] RP VARIANTS LEPRCH TYR-301 AND TRP-1201. RX PubMed=9703342; DOI=10.2337/diab.47.8.1362; RA Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M., O'Rahilly S.; RT "Multiple molecular mechanisms of insulin receptor dysfunction in a patient RT with Donohue syndrome."; RL Diabetes 47:1362-1364(1998). RN [118] RP VARIANTS RMS THR-1143 AND TRP-1158. RX PubMed=10443650; DOI=10.1210/jcem.84.8.5902; RA Longo N., Wang Y., Pasquali M.; RT "Progressive decline in insulin levels in Rabson-Mendenhall syndrome."; RL J. Clin. Endocrinol. Metab. 84:2623-2629(1999). RN [119] RP VARIANTS IRAN TYPE A LEU-167 AND VAL-1055. RX PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x; RA Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J., Carrascosa A., RA Potau N.; RT "Identification of three novel mutations in the insulin receptor gene in RT type A insulin resistant patients."; RL Clin. Genet. 57:67-69(2000). RN [120] RP VARIANT IRAN TYPE A TYR-280. RX PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x; RA Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F., Kaino Y., RA Kida K., Makino H.; RT "Identification of novel C253Y missense and Y864X nonsense mutations in the RT insulin receptor gene in type A insulin-resistant patients."; RL Clin. Genet. 59:194-197(2001). RN [121] RP VARIANT IRAN TYPE A CYS-279. RX PubMed=12107746; DOI=10.1007/s00125-002-0798-5; RA Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J., De Meyts P., RA Maeder C., Kahn C.R., Carpentier J.-L.; RT "An arginine to cysteine(252) mutation in insulin receptors from a patient RT with severe insulin resistance inhibits receptor internalisation but RT preserves signalling events."; RL Diabetologia 45:657-667(2002). RN [122] RP CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL; THR-925 RP AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND TRP-1201. RX PubMed=12023989; DOI=10.1093/hmg/11.12.1465; RA Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A., RA Giannella-Neto D.; RT "Genotype-phenotype correlation in inherited severe insulin resistance."; RL Hum. Mol. Genet. 11:1465-1475(2002). RN [123] RP VARIANT LEPRCH VAL-362 DEL. RX PubMed=12538626; DOI=10.1210/en.2002-220815; RA George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S., Saudek V., RA Siddle K., Hansen L., O'Rahilly S.; RT "Deletion of V335 from the L2 domain of the insulin receptor results in a RT conformationally abnormal receptor that is unable to bind insulin and RT causes Donohue's syndrome in a human subject."; RL Endocrinology 144:631-637(2003). RN [124] RP VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458 AND RP TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND RP CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458. RX PubMed=12970295; DOI=10.1210/jc.2003-030034; RA Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M., RA D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.; RT "Identification and functional assessment of novel and known insulin RT receptor mutations in five patients with syndromes of severe insulin RT resistance."; RL J. Clin. Endocrinol. Metab. 88:4251-4257(2003). RN [125] RP VARIANT HHF5 GLN-1201. RX PubMed=15161766; DOI=10.2337/diabetes.53.6.1592; RA Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K., Lindholm J., RA Pedersen O., Bech-Nielsen H.; RT "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia RT linked to a mutation in the human insulin receptor gene."; RL Diabetes 53:1592-1598(2004). RN [126] RP VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS RP ARG-236 AND SER-386. RX PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x; RA Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J., RA Didi M., O'Rahilly S.; RT "Functional characterization of a novel insulin receptor mutation RT contributing to Rabson-Mendenhall syndrome."; RL Clin. Endocrinol. (Oxf.) 66:21-26(2007). RN [127] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012; RP VAL-1065 AND ALA-1282. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [128] RP VARIANTS LEPRCH CYS-818 AND 890-ARG--SER-1382 DEL. RX PubMed=22768670; DOI=10.1515/jpem-2011-0448; RA Nobile S., Semple R.K., Carnielli V.P.; RT "A novel mutation of the insulin receptor gene in a preterm infant with RT Donohue syndrome and heart failure."; RL J. Pediatr. Endocrinol. Metab. 25:363-366(2012). RN [129] RP VARIANTS LEPRCH THR-56 AND TYR-286, AND CHARACTERIZATION OF VARIANTS LEPRCH RP THR-56 AND TYR-286. RX PubMed=24498630; DOI=10.1002/mgg3.43; RA Falik Zaccai T.C., Kalfon L., Klar A., Elisha M.B., Hurvitz H., RA Weingarten G., Chechik E., Fleisher Sheffer V., Haj Yahya R., Meidan G., RA Gross-Kieselstein E., Bauman D., Hershkovitz S., Yaron Y., Orr-Urtreger A., RA Wertheimer E.; RT "Two novel mutations identified in familial cases with Donohue syndrome."; RL Mol. Genet. Genomic Med. 2:64-72(2014). RN [130] RP VARIANTS RMS CYS-256; LEU-635; ILE-835; VAL-842; LEU-874; SER-878 AND RP 999-TYR--SER-1382 DEL, VARIANTS IRAN TYPE A ASP-489 AND MET-1054, VARIANTS RP LEPRCH PHE-657; ARG-659 AND CYS-818, CHARACTERIZATION OF VARIANTS LEPRCH RP PHE-657; ARG-659; CYS-818; THR-925; TRP-926 AND MET-937, AND RP CHARACTERIZATION OF VARIANTS RMS LEU-635; ILE-835; VAL-842; LEU-874 AND RP SER-878. RX PubMed=28765322; DOI=10.2337/db17-0301; RA Hosoe J., Kadowaki H., Miya F., Aizu K., Kawamura T., Miyata I., RA Satomura K., Ito T., Hara K., Tanaka M., Ishiura H., Tsuji S., Suzuki K., RA Takakura M., Boroevich K.A., Tsunoda T., Yamauchi T., Shojima N., RA Kadowaki T.; RT "Structural Basis and Genotype-Phenotype Correlations of INSR Mutations RT Causing Severe Insulin Resistance."; RL Diabetes 66:2713-2723(2017). CC -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic CC actions of insulin. Binding of insulin leads to phosphorylation of CC several intracellular substrates, including, insulin receptor CC substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling CC intermediates. Each of these phosphorylated proteins serve as docking CC proteins for other signaling proteins that contain Src-homology-2 CC domains (SH2 domain) that specifically recognize different CC phosphotyrosine residues, including the p85 regulatory subunit of PI3K CC and SHP2. Phosphorylation of IRSs proteins lead to the activation of CC two main signaling pathways: the PI3K-AKT/PKB pathway, which is CC responsible for most of the metabolic actions of insulin, and the Ras- CC MAPK pathway, which regulates expression of some genes and cooperates CC with the PI3K pathway to control cell growth and differentiation. CC Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to CC the activation of PI3K and the generation of phosphatidylinositol-(3, CC 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates CC several PIP3-dependent serine/threonine kinases, such as PDPK1 and CC subsequently AKT/PKB. The net effect of this pathway is to produce a CC translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic CC vesicles to the cell membrane to facilitate glucose transport. CC Moreover, upon insulin stimulation, activated AKT/PKB is responsible CC for: anti-apoptotic effect of insulin by inducing phosphorylation of CC BAD; regulates the expression of gluconeogenic and lipogenic enzymes by CC controlling the activity of the winged helix or forkhead (FOX) class of CC transcription factors. Another pathway regulated by PI3K-AKT/PKB CC activation is mTORC1 signaling pathway which regulates cell growth and CC metabolism and integrates signals from insulin. AKT mediates insulin- CC stimulated protein synthesis by phosphorylating TSC2 thereby activating CC mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in CC mediating cell growth, survival and cellular differentiation of CC insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers CC the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to CC binding insulin, the insulin receptor can bind insulin-like growth CC factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII CC binding. When present in a hybrid receptor with IGF1R, binds IGF1. CC PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR CC isoform Long are activated with a high affinity by IGF1, with low CC affinity by IGF2 and not significantly activated by insulin, and that CC hybrid receptors composed of IGF1R and INSR isoform Short are activated CC by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that CC hybrid receptors composed of IGF1R and INSR isoform Long and hybrid CC receptors composed of IGF1R and INSR isoform Short have similar binding CC characteristics, both bind IGF1 and have a low affinity for insulin. In CC adipocytes, inhibits lipolysis (By similarity). CC {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, CC ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11598120, CC ECO:0000269|PubMed:12707268, ECO:0000269|PubMed:18278056, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:9312016}; CC -!- ACTIVITY REGULATION: Activated in response to insulin. CC Autophosphorylation activates the kinase activity. PTPN1, PTPRE and CC PTPRF dephosphorylate important tyrosine residues, thereby reducing CC INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the CC catalytic activity of the INSR, they block access of substrates to the CC activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR CC activity, they bind to the activated INRS and interfere with the CC phosphorylation of INSR substrates. {ECO:0000269|PubMed:10615944, CC ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:11726652, CC ECO:0000269|PubMed:12493740, ECO:0000269|PubMed:2211730}. CC -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide CC bonds. The alpha chains carry the insulin-binding regions, while the CC beta chains carry the kinase domain. Forms a hybrid receptor with CC IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta CC chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts CC with SORBS1 but dissociates from it following insulin stimulation. CC Binds SH2B2. Activated form of INSR interacts (via Tyr-999) with the CC PTB/PID domains of IRS1 and SHC1. The sequences surrounding the CC phosphorylated NPXY motif contribute differentially to either IRS1 or CC SHC1 recognition. Interacts (via tyrosines in the C-terminus) with IRS2 CC (via PTB domain and 591-786 AA); the 591-786 would be the primary CC anchor of IRS2 to INSR while the PTB domain would have a stabilizing CC action on the interaction with INSR. Interacts with the SH2 domains of CC the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when CC autophosphorylated on tyrosine residues. Interacts with SOCS7. CC Interacts (via the phosphorylated Tyr-999), with SOCS3. Interacts (via CC the phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts CC with CAV2 (tyrosine-phosphorylated form); the interaction is increased CC with 'Tyr-27'phosphorylation of CAV2 (By similarity). Interacts with CC ARRB2 (By similarity). Interacts with GRB10; this interaction blocks CC the association between IRS1/IRS2 and INSR, significantly reduces CC insulin-stimulated tyrosine phosphorylation of IRS1 and IRS2 and thus CC decreases insulin signaling. Interacts with GRB7. Interacts with PDPK1. CC Interacts (via Tyr-1190) with GRB14 (via BPS domain); this interaction CC protects the tyrosines in the activation loop from dephosphorylation, CC but promotes dephosphorylation of Tyr-999, this results in decreased CC interaction with, and phosphorylation of, IRS1. Interacts (via subunit CC alpha) with ENPP1 (via 485-599 AA); this interaction blocks CC autophosphorylation. Interacts with PTPRE; this interaction is CC dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR. Interacts CC with STAT5B (via SH2 domain). Interacts with PTPRF. Interacts with CC ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is proposed to CC be part of a signaling netwok regulating INSR autophosphorylation and CC endocytosis (By similarity). Interacts with the cone snail venom CC insulin Con-Ins G1 (PubMed:27617429). Interacts with the insulin CC receptor SORL1; this interaction strongly increases its surface CC exposure, hence strengthens insulin signal reception (PubMed:27322061). CC Interacts (tyrosine phosphorylated) with CCDC88A/GIV (via SH2-like CC region); binding requires autophosphorylation of the INSR C-terminal CC region (PubMed:25187647). Interacts with GNAI3; the interaction is CC probably mediated by CCDC88A/GIV (PubMed:25187647). Interacts with CC LMBRD1 (By similarity). Interacts (in response to insulin stimulation) CC with NCK1; this interaction may recruit PTPN1 to mediate INSR CC dephosphorylation (PubMed:21707536). Interacts with CD248; this CC interaction diminishes INSR autophosphorylation (By similarity). CC {ECO:0000250|UniProtKB:P15127, ECO:0000250|UniProtKB:P15208, CC ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:10803466, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11374898, CC ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740, CC ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16127460, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16957736, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:21707536, CC ECO:0000269|PubMed:2211730, ECO:0000269|PubMed:23302862, CC ECO:0000269|PubMed:25187647, ECO:0000269|PubMed:27322061, CC ECO:0000269|PubMed:27617429, ECO:0000269|PubMed:7537849, CC ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839, CC ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}. CC -!- INTERACTION: CC P06213; Q99490: AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824; CC P06213; Q8NEJ0: DUSP18; NbExp=2; IntAct=EBI-475899, EBI-10698945; CC P06213; Q13322: GRB10; NbExp=4; IntAct=EBI-475899, EBI-80275; CC P06213; P05019: IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275; CC P06213; P08069: IGF1R; NbExp=5; IntAct=EBI-475899, EBI-475981; CC P06213; P14616: INSRR; NbExp=6; IntAct=EBI-475899, EBI-6424336; CC P06213; P35568: IRS1; NbExp=5; IntAct=EBI-475899, EBI-517592; CC P06213; Q9Y4H2: IRS2; NbExp=4; IntAct=EBI-475899, EBI-1049582; CC P06213; Q15323: KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001; CC P06213; Q13257: MAD2L1; NbExp=4; IntAct=EBI-475899, EBI-78203; CC P06213; P27986: PIK3R1; NbExp=9; IntAct=EBI-475899, EBI-79464; CC P06213; P19174: PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387; CC P06213; P18031: PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788; CC P06213; Q06124: PTPN11; NbExp=3; IntAct=EBI-475899, EBI-297779; CC P06213; Q15262: PTPRK; NbExp=2; IntAct=EBI-475899, EBI-474052; CC P06213; Q15256: PTPRR; NbExp=2; IntAct=EBI-475899, EBI-2265659; CC P06213; Q9NRF2: SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491; CC P06213; P29353: SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835; CC P06213; P01317: INS; Xeno; NbExp=5; IntAct=EBI-475899, EBI-3989070; CC P06213; P35570: Irs1; Xeno; NbExp=5; IntAct=EBI-475899, EBI-520230; CC P06213-1; P32121: ARRB2; NbExp=2; IntAct=EBI-15558981, EBI-714559; CC P06213-1; P06213-1: INSR; NbExp=4; IntAct=EBI-15558981, EBI-15558981; CC P06213-1; P18031: PTPN1; NbExp=2; IntAct=EBI-15558981, EBI-968788; CC P06213-1; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-15558981, EBI-21501656; CC P06213-1; P81122: Irs2; Xeno; NbExp=8; IntAct=EBI-15558981, EBI-1369862; CC P06213-1; Q1XH17: Trim72; Xeno; NbExp=2; IntAct=EBI-15558981, EBI-16034016; CC P06213-2; P01308: INS; NbExp=6; IntAct=EBI-9984921, EBI-7090529; CC P06213-2; Q13257: MAD2L1; NbExp=3; IntAct=EBI-9984921, EBI-78203; CC P06213-2; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-9984921, EBI-21501656; CC P06213-2; P01317: INS; Xeno; NbExp=2; IntAct=EBI-9984921, EBI-3989070; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P15208}; CC Single-pass type I membrane protein {ECO:0000305}. Late endosome CC {ECO:0000250|UniProtKB:P15208}. Lysosome CC {ECO:0000250|UniProtKB:P15208}. Note=Binding of insulin to INSR induces CC internalization and lysosomal degradation of the receptor, a means for CC down-regulating this signaling pathway after stimulation. In the CC presence of SORL1, internalized INSR molecules are redirected back to CC the cell surface, thereby preventing their lysosomal catabolism and CC strengthening insulin signal reception. {ECO:0000250|UniProtKB:P15208}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; Synonyms=HIR-B; CC IsoId=P06213-1; Sequence=Displayed; CC Name=Short; Synonyms=HIR-A; CC IsoId=P06213-2; Sequence=VSP_002898; CC -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are predominantly CC expressed in tissue targets of insulin metabolic effects: liver, CC adipose tissue and skeletal muscle but are also expressed in the CC peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta CC vascular endothelium, fibroblasts, monocytes, granulocytes, CC erythrocytes and skin. Isoform Short is preferentially expressed in CC fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found CC as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose CC tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at CC protein level). Overexpressed in several tumors, including breast, CC colon, lung, ovary, and thyroid carcinomas. CC {ECO:0000269|PubMed:10207053, ECO:0000269|PubMed:2369896, CC ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}. CC -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-identical CC regions from two alpha chains, primarily via the C-terminal region of CC the first INSR alpha chain. Residues from the leucine-rich N-terminus CC of the other INSR alpha chain also contribute to this insulin binding CC site. A secondary insulin-binding site is formed by residues at the CC junction of fibronectin type-III domain 1 and 2. CC {ECO:0000269|PubMed:16957736, ECO:0000269|PubMed:19459609, CC ECO:0000269|PubMed:23302862}. CC -!- PTM: After being transported from the endoplasmic reticulum to the CC Golgi apparatus, the single glycosylated precursor is further CC glycosylated and then cleaved, followed by its transport to the plasma CC membrane. {ECO:0000269|PubMed:1472036, ECO:0000269|PubMed:16894147, CC ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973, CC ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to insulin CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Phosphorylation of CC Tyr-999 is required for binding to IRS1, SHC1 and STAT5B CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Dephosphorylated by CC PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190 (PubMed:14690593, CC PubMed:16246733, PubMed:16271887, PubMed:18278056, PubMed:18767165, CC PubMed:3166375, PubMed:9312016). May also be phosphorylated at Tyr-1185 CC and Tyr-1190 by mTORC2 (PubMed:26584640). Dephosphorylated by PTPRF and CC PTPN1 (PubMed:8995282). Dephosphorylated by PTPN2; down-regulates CC insulin-induced signaling (PubMed:10734133, PubMed:12612081). CC Dephosphorylation at Tyr-1189 and Tyr-1190 requires the SH2/SH3 adapter CC protein NCK1, probably to recruit its interaction partner PTPN1 CC (PubMed:21707536). {ECO:0000269|PubMed:10734133, CC ECO:0000269|PubMed:12612081, ECO:0000269|PubMed:14690593, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:21707536, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:8995282, CC ECO:0000269|PubMed:9312016}. CC -!- PTM: S-nitrosylation at Cys-1083 by BLVRB inhibits the receptor CC tyrosine kinase, thereby inhibiting insulin signaling. CC {ECO:0000269|PubMed:38056462}. CC -!- PTM: Ubiquitinated by MARCHF1; leading to degradation thereby reducing CC surface INSR expression. {ECO:0000269|PubMed:27577745}. CC -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin CC resistance syndrome characterized by insulin-resistant diabetes CC mellitus with pineal hyperplasia and somatic abnormalities. Typical CC features include coarse, senile-appearing facies, dental and skin CC abnormalities, abdominal distension, and phallic enlargement. CC Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650, CC ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797, CC ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:8314008}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most CC severe form of insulin resistance syndrome, characterized by CC intrauterine and postnatal growth retardation and death in early CC infancy. Inheritance is autosomal recessive. CC {ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:12538626, CC ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067, CC ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:22768670, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:24498630, CC ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:7538143, CC ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715, CC ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945, CC ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867, CC ECO:0000269|PubMed:9299395, ECO:0000269|PubMed:9703342}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Type 2 diabetes mellitus (T2D) [MIM:125853]: A multifactorial CC disorder of glucose homeostasis caused by a lack of sensitivity to CC insulin. Affected individuals usually have an obese body habitus and CC manifestations of a metabolic syndrome characterized by diabetes, CC insulin resistance, hypertension and hypertriglyceridemia. The disease CC results in long-term complications that affect the eyes, kidneys, CC nerves, and blood vessels. {ECO:0000269|PubMed:1470163, CC ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Hyperinsulinemic hypoglycemia, familial, 5 (HHF5) CC [MIM:609968]: A form of hyperinsulinemic hypoglycemia, a clinically and CC genetically heterogeneous disorder characterized by inappropriate CC insulin secretion from the pancreatic beta-cells in the presence of low CC blood glucose levels. HHF5 clinical features include loss of CC consciousness due to hypoglycemia and hypoglycemic seizures. HHF5 CC inheritance is autosomal dominant. {ECO:0000269|PubMed:15161766}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans CC type A (IRAN type A) [MIM:610549]: Characterized by the association of CC severe insulin resistance (manifested by marked hyperinsulinemia and a CC failure to respond to exogenous insulin) with the skin lesion CC acanthosis nigricans and ovarian hyperandrogenism in adolescent female CC subjects. Women frequently present with hirsutism, acne, amenorrhea or CC oligomenorrhea, and virilization. This syndrome is different from the CC type B that has been demonstrated to be secondary to the presence of CC circulating autoantibodies against the insulin receptor. CC {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, CC ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, CC ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, CC ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938, CC ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, CC ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, CC ECO:0000269|PubMed:9175790}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry; CC URL="https://en.wikipedia.org/wiki/Insulin_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M10051; AAA59174.1; -; mRNA. DR EMBL; X02160; CAA26096.1; -; mRNA. DR EMBL; M32972; AAA59452.1; -; Genomic_DNA. DR EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117172; AAI17173.1; -; mRNA. DR EMBL; J03466; AAA59175.1; -; Genomic_DNA. DR EMBL; J05043; AAA59190.1; -; Genomic_DNA. DR EMBL; M76592; AAC37604.1; -; Genomic_DNA. DR EMBL; AB208861; BAD92098.1; -; mRNA. DR EMBL; M24555; AAA59178.1; -; mRNA. DR EMBL; M29929; AAA59176.1; -; Genomic_DNA. DR EMBL; M29930; AAA59177.1; -; Genomic_DNA. DR EMBL; M27197; AAA86791.1; -; Genomic_DNA. DR EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA. DR CCDS; CCDS12176.1; -. [P06213-1] DR CCDS; CCDS42487.1; -. [P06213-2] DR PIR; A37348; INHUR. DR RefSeq; NP_000199.2; NM_000208.4. [P06213-1] DR RefSeq; NP_001073285.1; NM_001079817.3. [P06213-2] DR PDB; 1GAG; X-ray; 2.70 A; A=1005-1310. DR PDB; 1I44; X-ray; 2.40 A; A=1005-1310. DR PDB; 1IR3; X-ray; 1.90 A; A=1005-1310. DR PDB; 1IRK; X-ray; 2.10 A; A=1005-1310. DR PDB; 1P14; X-ray; 1.90 A; A=1005-1310. DR PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310. DR PDB; 2AUH; X-ray; 3.20 A; A=1005-1310. DR PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310. DR PDB; 2HR7; X-ray; 2.32 A; A/B=28-512. DR PDB; 2MFR; NMR; -; A=940-988. DR PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310. DR PDB; 3BU3; X-ray; 1.65 A; A=1005-1310. DR PDB; 3BU5; X-ray; 2.10 A; A=1005-1310. DR PDB; 3BU6; X-ray; 1.95 A; A=1005-1310. DR PDB; 3EKK; X-ray; 2.10 A; A=1005-1310. DR PDB; 3EKN; X-ray; 2.20 A; A=1005-1310. DR PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322. DR PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744. DR PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744. DR PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744. DR PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310. DR PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744. DR PDB; 4XLV; X-ray; 2.30 A; A=983-1310. DR PDB; 4XSS; X-ray; 3.00 A; E=28-337. DR PDB; 4XST; X-ray; 3.00 A; E=28-337. DR PDB; 4ZXB; X-ray; 3.30 A; E=28-956. DR PDB; 5E1S; X-ray; 2.26 A; A=1005-1310. DR PDB; 5HHW; X-ray; 1.79 A; A=1005-1310. DR PDB; 5J3H; X-ray; 3.27 A; E=28-337. DR PDB; 5KQV; X-ray; 4.40 A; E/F=28-746. DR PDB; 5U1M; X-ray; 1.80 A; B=991-999. DR PDB; 6HN4; EM; 4.20 A; E/F=28-955. DR PDB; 6HN5; EM; 3.20 A; E/F=28-955. DR PDB; 6PXV; EM; 3.20 A; A/C=28-1382. DR PDB; 6PXW; EM; 3.10 A; A/B=28-1382. DR PDB; 6SOF; EM; 4.30 A; A/C=28-746, B/D=795-956. DR PDB; 6VEP; X-ray; 2.90 A; E/K/Q/W=28-337, F/L/R/X=731-746. DR PDB; 6VEQ; X-ray; 3.25 A; E/K=28-337, F/L=731-746. DR PDB; 7BW7; EM; 4.10 A; A/C=28-1382. DR PDB; 7BW8; EM; 3.80 A; A/C=28-1382. DR PDB; 7BWA; EM; 4.90 A; A/C=28-1382. DR PDB; 7KD6; X-ray; 2.60 A; E/K/Q/W=28-337. DR PDB; 7MQO; EM; 3.40 A; E/F=28-956. DR PDB; 7MQR; EM; 4.10 A; E/F=28-955. DR PDB; 7MQS; EM; 4.40 A; E/F=28-955. DR PDB; 7PG0; EM; 7.60 A; A/B=1-1382. DR PDB; 7PG2; EM; 6.70 A; A/B=1-1382. DR PDB; 7PG3; EM; 7.30 A; A/B=1-1382. DR PDB; 7PG4; EM; 9.10 A; A/B=1-1382. DR PDB; 7PHT; NMR; -; A=953-982. DR PDB; 7QID; EM; 5.00 A; A/C=28-746, B/D=763-956. DR PDB; 7S0Q; EM; 3.70 A; B=28-955. DR PDB; 7S8V; EM; 3.73 A; B=28-955. DR PDB; 7U6D; EM; 5.03 A; B/C=28-955. DR PDB; 7U6E; EM; 3.00 A; E/F=28-955. DR PDB; 7YQ3; EM; 3.60 A; E/F=28-946. DR PDB; 7YQ4; EM; 3.95 A; E/F=28-946. DR PDB; 7YQ5; EM; 4.27 A; E/F=28-946. DR PDB; 7YQ6; EM; 4.18 A; E/F=28-946. DR PDB; 8DWN; X-ray; 2.15 A; A=1005-1310. DR PDB; 8GUY; EM; 4.18 A; E/F=28-946. DR PDB; 8U4B; EM; 3.90 A; A/B=1-1382. DR PDB; 8U4C; EM; 3.60 A; A/B=1-1382. DR PDB; 8U4E; EM; 4.20 A; A/B=1-1382. DR PDB; 8VJB; EM; 3.60 A; A/B=1-1382. DR PDB; 8VJC; EM; 3.80 A; A/B=1-1382. DR PDB; 8X06; EM; 3.24 A; A/B=1-1382. DR PDB; 8X2M; EM; 3.31 A; A/B=1-1382. DR PDB; 8XJS; EM; 3.24 A; A/B=1-1382. DR PDB; 8XK1; EM; 3.31 A; A/B=1-1382. DR PDB; 8XKM; EM; 5.00 A; A/B=1-1382. DR PDB; 8XKR; EM; 3.53 A; A/B=1-1382. DR PDB; 8YSZ; EM; 3.38 A; A/B=1-1382. DR PDB; 8YYL; EM; 4.01 A; A/B=1-1382. DR PDB; 8YYS; EM; 4.14 A; A/B=1-1382. DR PDB; 8YYT; EM; 3.60 A; A/B=1-1382. DR PDBsum; 1GAG; -. DR PDBsum; 1I44; -. DR PDBsum; 1IR3; -. DR PDBsum; 1IRK; -. DR PDBsum; 1P14; -. DR PDBsum; 1RQQ; -. DR PDBsum; 2AUH; -. DR PDBsum; 2B4S; -. DR PDBsum; 2HR7; -. DR PDBsum; 2MFR; -. DR PDBsum; 2Z8C; -. DR PDBsum; 3BU3; -. DR PDBsum; 3BU5; -. DR PDBsum; 3BU6; -. DR PDBsum; 3EKK; -. DR PDBsum; 3EKN; -. DR PDBsum; 3ETA; -. DR PDBsum; 3W11; -. DR PDBsum; 3W12; -. DR PDBsum; 3W13; -. DR PDBsum; 4IBM; -. DR PDBsum; 4OGA; -. DR PDBsum; 4XLV; -. DR PDBsum; 4XSS; -. DR PDBsum; 4XST; -. DR PDBsum; 4ZXB; -. DR PDBsum; 5E1S; -. DR PDBsum; 5HHW; -. DR PDBsum; 5J3H; -. DR PDBsum; 5KQV; -. DR PDBsum; 5U1M; -. DR PDBsum; 6HN4; -. DR PDBsum; 6HN5; -. DR PDBsum; 6PXV; -. DR PDBsum; 6PXW; -. DR PDBsum; 6SOF; -. DR PDBsum; 6VEP; -. DR PDBsum; 6VEQ; -. DR PDBsum; 7BW7; -. DR PDBsum; 7BW8; -. DR PDBsum; 7BWA; -. DR PDBsum; 7KD6; -. DR PDBsum; 7MQO; -. DR PDBsum; 7MQR; -. DR PDBsum; 7MQS; -. DR PDBsum; 7PG0; -. DR PDBsum; 7PG2; -. DR PDBsum; 7PG3; -. DR PDBsum; 7PG4; -. DR PDBsum; 7PHT; -. DR PDBsum; 7QID; -. DR PDBsum; 7S0Q; -. DR PDBsum; 7S8V; -. DR PDBsum; 7U6D; -. DR PDBsum; 7U6E; -. DR PDBsum; 7YQ3; -. DR PDBsum; 7YQ4; -. DR PDBsum; 7YQ5; -. DR PDBsum; 7YQ6; -. DR PDBsum; 8DWN; -. DR PDBsum; 8GUY; -. DR PDBsum; 8U4B; -. DR PDBsum; 8U4C; -. DR PDBsum; 8U4E; -. DR PDBsum; 8VJB; -. DR PDBsum; 8VJC; -. DR PDBsum; 8X06; -. DR PDBsum; 8X2M; -. DR PDBsum; 8XJS; -. DR PDBsum; 8XK1; -. DR PDBsum; 8XKM; -. DR PDBsum; 8XKR; -. DR PDBsum; 8YSZ; -. DR PDBsum; 8YYL; -. DR PDBsum; 8YYS; -. DR PDBsum; 8YYT; -. DR AlphaFoldDB; P06213; -. DR BMRB; P06213; -. DR EMDB; EMD-10273; -. DR EMDB; EMD-10311; -. DR EMDB; EMD-13385; -. DR EMDB; EMD-13386; -. DR EMDB; EMD-13387; -. DR EMDB; EMD-13388; -. DR EMDB; EMD-20522; -. DR EMDB; EMD-20523; -. DR EMDB; EMD-23766; -. DR EMDB; EMD-23767; -. DR EMDB; EMD-23949; -. DR EMDB; EMD-23950; -. DR EMDB; EMD-24791; -. DR EMDB; EMD-24927; -. DR EMDB; EMD-26363; -. DR EMDB; EMD-30225; -. DR EMDB; EMD-30227; -. DR EMDB; EMD-30229; -. DR EMDB; EMD-30230; -. DR EMDB; EMD-30231; -. DR EMDB; EMD-34018; -. DR EMDB; EMD-34019; -. DR EMDB; EMD-34021; -. DR EMDB; EMD-34281; -. DR EMDB; EMD-37970; -. DR EMDB; EMD-38017; -. DR EMDB; EMD-38404; -. DR EMDB; EMD-38413; -. DR EMDB; EMD-38420; -. DR EMDB; EMD-38423; -. DR EMDB; EMD-39566; -. DR EMDB; EMD-39675; -. DR EMDB; EMD-39677; -. DR EMDB; EMD-39678; -. DR EMDB; EMD-41877; -. DR EMDB; EMD-41878; -. DR EMDB; EMD-41880; -. DR EMDB; EMD-43279; -. DR EMDB; EMD-43280; -. DR EMDB; EMD-61431; -. DR EMDB; EMD-61432; -. DR EMDB; EMD-61490; -. DR EMDB; EMD-7461; -. DR EMDB; EMD-7462; -. DR EMDB; EMD-7463; -. DR SASBDB; P06213; -. DR SMR; P06213; -. DR BioGRID; 109854; 380. DR DIP; DIP-480N; -. DR ELM; P06213; -. DR FunCoup; P06213; 1946. DR IntAct; P06213; 709. DR MINT; P06213; -. DR STRING; 9606.ENSP00000303830; -. DR BindingDB; P06213; -. DR ChEMBL; CHEMBL1981; -. DR DrugBank; DB08513; [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID. DR DrugBank; DB03909; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate. DR DrugBank; DB05120; AT1391. DR DrugBank; DB16028; Azemiglitazone. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB09129; Chromic chloride. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11564; Insulin argine. DR DrugBank; DB01306; Insulin aspart. DR DrugBank; DB09456; Insulin beef. DR DrugBank; DB09564; Insulin degludec. DR DrugBank; DB01307; Insulin detemir. DR DrugBank; DB00047; Insulin glargine. DR DrugBank; DB01309; Insulin glulisine. DR DrugBank; DB00030; Insulin human. DR DrugBank; DB16693; Insulin icodec. DR DrugBank; DB00046; Insulin lispro. DR DrugBank; DB11567; Insulin peglispro. DR DrugBank; DB00071; Insulin pork. DR DrugBank; DB11568; Insulin tregopil. DR DrugBank; DB16637; KW-2450 free base. DR DrugBank; DB06075; Linsitinib. DR DrugBank; DB01277; Mecasermin. DR DrugBank; DB14751; Mecasermin rinfabate. DR DrugBank; DB11721; Mitoglitazone. DR DrugBank; DB05115; NN344. DR DrugBank; DB12518; Raclopride. DR DrugBank; DB06156; Tesofensine. DR DrugCentral; P06213; -. DR GuidetoPHARMACOLOGY; 1800; -. DR GlyConnect; 1402; 8 N-Linked glycans (6 sites). DR GlyCosmos; P06213; 21 sites, 11 glycans. DR GlyGen; P06213; 25 sites, 79 N-linked glycans (13 sites), 4 O-linked glycans (6 sites). DR iPTMnet; P06213; -. DR PhosphoSitePlus; P06213; -. DR SwissPalm; P06213; -. DR BioMuta; INSR; -. DR DMDM; 308153655; -. DR CPTAC; CPTAC-1771; -. DR CPTAC; CPTAC-1772; -. DR CPTAC; CPTAC-2814; -. DR CPTAC; CPTAC-3053; -. DR jPOST; P06213; -. DR MassIVE; P06213; -. DR PaxDb; 9606-ENSP00000303830; -. DR PeptideAtlas; P06213; -. DR ProteomicsDB; 51872; -. [P06213-1] DR ProteomicsDB; 51873; -. [P06213-2] DR Pumba; P06213; -. DR ABCD; P06213; 3 sequenced antibodies. DR Antibodypedia; 3403; 2189 antibodies from 53 providers. DR DNASU; 3643; -. DR Ensembl; ENST00000302850.10; ENSP00000303830.4; ENSG00000171105.15. [P06213-1] DR Ensembl; ENST00000341500.9; ENSP00000342838.4; ENSG00000171105.15. [P06213-2] DR GeneID; 3643; -. DR KEGG; hsa:3643; -. DR MANE-Select; ENST00000302850.10; ENSP00000303830.4; NM_000208.4; NP_000199.2. DR UCSC; uc002mgd.2; human. [P06213-1] DR AGR; HGNC:6091; -. DR ClinPGx; PA202; -. DR CTD; 3643; -. DR DisGeNET; 3643; -. DR GeneCards; INSR; -. DR GeneReviews; INSR; -. DR HGNC; HGNC:6091; INSR. DR HPA; ENSG00000171105; Low tissue specificity. DR MalaCards; INSR; -. DR MIM; 125853; phenotype. DR MIM; 147670; gene. DR MIM; 246200; phenotype. DR MIM; 262190; phenotype. DR MIM; 609968; phenotype. DR MIM; 610549; phenotype. DR OpenTargets; ENSG00000171105; -. DR Orphanet; 508; Donohue syndrome. DR Orphanet; 263458; Hyperinsulinism due to INSR deficiency. DR Orphanet; 2297; Insulin-resistance syndrome type A. DR Orphanet; 769; Rabson-Mendenhall syndrome. DR VEuPathDB; HostDB:ENSG00000171105; -. DR eggNOG; KOG4258; Eukaryota. DR GeneTree; ENSGT00940000155404; -. DR HOGENOM; CLU_000288_166_0_1; -. DR InParanoid; P06213; -. DR OMA; AVESNTW; -. DR OrthoDB; 5809444at2759; -. DR PAN-GO; P06213; 12 GO annotations based on evolutionary models. DR PhylomeDB; P06213; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P06213; -. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-74713; IRS activation. DR Reactome; R-HSA-74749; Signal attenuation. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-74752; Signaling by Insulin receptor. DR Reactome; R-HSA-77387; Insulin receptor recycling. DR SABIO-RK; P06213; -. DR SignaLink; P06213; -. DR SIGNOR; P06213; -. DR Agora; ENSG00000171105; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 3643; 15 hits in 1203 CRISPR screens. DR ChiTaRS; INSR; human. DR EvolutionaryTrace; P06213; -. DR GeneWiki; Insulin_receptor; -. DR GenomeRNAi; 3643; -. DR Pharos; P06213; Tclin. DR PRO; PR:P06213; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P06213; protein. DR Bgee; ENSG00000171105; Expressed in buccal mucosa cell and 209 other cell types or tissues. DR ExpressionAtlas; P06213; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0032590; C:dendrite membrane; ISS:ARUK-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; ISS:ARUK-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005899; C:insulin receptor complex; IDA:UniProtKB. DR GO; GO:0005770; C:late endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0032809; C:neuronal cell body membrane; ISS:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:BHF-UCL. DR GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL. DR GO; GO:0005525; F:GTP binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043559; F:insulin binding; IDA:UniProtKB. DR GO; GO:0005009; F:insulin receptor activity; IDA:UniProtKB. DR GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB. DR GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL. DR GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL. DR GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB. DR GO; GO:0019904; F:protein domain specific binding; IPI:CAFA. DR GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL. DR GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL. DR GO; GO:0097062; P:dendritic spine maintenance; ISS:ARUK-UCL. DR GO; GO:0008544; P:epidermis development; IEA:Ensembl. DR GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL. DR GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007612; P:learning; TAS:ARUK-UCL. DR GO; GO:0008584; P:male gonad development; IEA:Ensembl. DR GO; GO:0030238; P:male sex determination; IEA:Ensembl. DR GO; GO:0007613; P:memory; TAS:ARUK-UCL. DR GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IGI:BHF-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0046326; P:positive regulation of D-glucose import; IDA:BHF-UCL. DR GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISS:ARUK-UCL. DR GO; GO:0002092; P:positive regulation of receptor internalization; IDA:CACAO. DR GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0031623; P:receptor internalization; IEA:Ensembl. DR GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:BHF-UCL. DR GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL. DR GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:BHF-UCL. DR GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL. DR CDD; cd00063; FN3; 2. DR CDD; cd00064; FU; 1. DR CDD; cd05061; PTKc_InsR; 1. DR FunFam; 1.10.510.10:FF:000050; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.10.220.10:FF:000005; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000087; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000108; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001010; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000026; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000001; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000002; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR040969; Insulin_TMD. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF535; INSULIN RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF17870; Insulin_TMD; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR PIRSF; PIRSF000620; Insulin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 3. DR SMART; SM00261; FU; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 3. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Carbohydrate metabolism; KW Cell membrane; Cleavage on pair of basic residues; Diabetes mellitus; KW Direct protein sequencing; Disease variant; Disulfide bond; Endosome; KW Glycoprotein; Isopeptide bond; Kinase; Lysosome; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; S-nitrosylation; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000269|PubMed:2211730, FT ECO:0000269|PubMed:2983222, ECO:0000269|PubMed:8257688" FT CHAIN 28..758 FT /note="Insulin receptor subunit alpha" FT /id="PRO_0000016687" FT CHAIN 763..1382 FT /note="Insulin receptor subunit beta" FT /id="PRO_0000016689" FT TOPO_DOM 28..758 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TOPO_DOM 763..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..979 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 980..1382 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 624..726 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 757..842 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 853..947 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1023..1298 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 686..708 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..741 FT /note="Insulin-binding" FT REGION 746..766 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 999 FT /note="Important for interaction with IRS1, SHC1 and FT STAT5B" FT /evidence="ECO:0000269|PubMed:9428692" FT REGION 1360..1382 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1361..1364 FT /note="PIK3R1-binding" FT ACT_SITE 1159 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000269|PubMed:9312016" FT BINDING 1033 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1057 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1104..1110 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1163..1164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1177 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT SITE 66 FT /note="Insulin-binding" FT /evidence="ECO:0000305" FT MOD_RES 400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 401 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 407 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 992 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 999 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1011 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 1083 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:38056462" FT MOD_RES 1185 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1189 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016" FT MOD_RES 1190 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1355 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1361 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222" FT CARBOHYD 52 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 105 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 242 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23302862" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 364 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 424 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 445 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19349973" FT CARBOHYD 541 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:1472036, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 633 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 651 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 698 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 769 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2983222" FT CARBOHYD 782 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 920 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 933 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 35..53 FT DISULFID 153..182 FT DISULFID 186..209 FT DISULFID 196..215 FT DISULFID 219..228 FT DISULFID 223..234 FT DISULFID 235..243 FT DISULFID 239..252 FT DISULFID 255..264 FT DISULFID 268..280 FT DISULFID 286..311 FT DISULFID 293..301 FT DISULFID 315..328 FT DISULFID 331..335 FT DISULFID 339..360 FT DISULFID 462..495 FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 551 FT /note="Interchain" FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 674..899 FT DISULFID 825..834 FT CROSSLNK 1079 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:27577745" FT VAR_SEQ 745..756 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:2983222, ECO:0000303|Ref.13" FT /id="VSP_002898" FT VARIANT 2 FT /note="A -> G (in dbSNP:rs7508518)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2210055, ECO:0000269|PubMed:2280779, FT ECO:0000269|PubMed:2777789, ECO:0000269|PubMed:2806055, FT ECO:0000269|PubMed:2859121, ECO:0000269|PubMed:2983222, FT ECO:0000269|PubMed:3680248" FT /id="VAR_058395" FT VARIANT 42 FT /note="N -> K (in RMS; impairs transport to the plasma FT membrane and reduces the affinity to bind insulin; FT dbSNP:rs121913143)" FT /evidence="ECO:0000269|PubMed:2121734, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004079" FT VARIANT 55 FT /note="V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004080" FT VARIANT 56 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; dbSNP:rs1555689937)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079535" FT VARIANT 58 FT /note="G -> R (in LEPRCH; Helmond; inhibits processing and FT transport; dbSNP:rs52836744)" FT /evidence="ECO:0000269|PubMed:1730625" FT /id="VAR_004081" FT VARIANT 86 FT /note="D -> G (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015907" FT VARIANT 89 FT /note="L -> P (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015908" FT VARIANT 113 FT /note="R -> P (in LEPRCH; Atlanta-1; abolishes insulin FT binding; dbSNP:rs121913153)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:8419945" FT /id="VAR_004082" FT VARIANT 119 FT /note="A -> V (in LEPRCH; markedly impairs insulin binding; FT dbSNP:rs1347473020)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015909" FT VARIANT 120 FT /note="L -> Q (in LEPRCH; inhibits receptor processing)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031518" FT VARIANT 146 FT /note="I -> M (in LEPRCH; mild; dbSNP:rs121913159)" FT /evidence="ECO:0000269|PubMed:7815442, FT ECO:0000269|PubMed:8326490" FT /id="VAR_015539" FT VARIANT 167 FT /note="V -> L (in IRAN type A; dbSNP:rs938519025)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015910" FT VARIANT 171 FT /note="Y -> H (in dbSNP:rs1051692)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_058396" FT VARIANT 220 FT /note="P -> L (in Ins resistance; severe; FT dbSNP:rs749094324)" FT /evidence="ECO:0000269|PubMed:8242067" FT /id="VAR_004083" FT VARIANT 228 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041429" FT VARIANT 236 FT /note="H -> R (in RMS and LEPRCH; Winnipeg; may impair FT receptor processing; dbSNP:rs121913145)" FT /evidence="ECO:0000269|PubMed:17201797, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004084" FT VARIANT 256 FT /note="R -> C (in RMS; dbSNP:rs781007453)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079536" FT VARIANT 260 FT /note="L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)" FT /evidence="ECO:0000269|PubMed:2479553" FT /id="VAR_004085" FT VARIANT 279 FT /note="R -> C (in IRAN type A; inhibits receptor FT internalization; dbSNP:rs1568470274)" FT /evidence="ECO:0000269|PubMed:12107746" FT /id="VAR_015540" FT VARIANT 279 FT /note="R -> H (in IRAN type A; interferes with receptor FT processing; dbSNP:rs1329693158)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031519" FT VARIANT 280 FT /note="C -> Y (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:11260230" FT /id="VAR_015911" FT VARIANT 286 FT /note="C -> Y (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079537" FT VARIANT 301 FT /note="C -> Y (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9703342" FT /id="VAR_015912" FT VARIANT 308 FT /note="Missing (in LEPRCH; abolishes insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:8636294" FT /id="VAR_015913" FT VARIANT 350 FT /note="S -> L (in RMS and LEPRCH; dbSNP:rs1974095413)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:8314008" FT /id="VAR_015914" FT VARIANT 362 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:12538626" FT /id="VAR_015541" FT VARIANT 386 FT /note="G -> S (in RMS; may impair receptor processing; FT dbSNP:rs764221583)" FT /evidence="ECO:0000269|PubMed:17201797" FT /id="VAR_031520" FT VARIANT 393 FT /note="G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004086" FT VARIANT 409 FT /note="F -> V (in IRAN type A; dbSNP:rs121913142)" FT /evidence="ECO:0000269|PubMed:8388389" FT /id="VAR_004087" FT VARIANT 439 FT /note="W -> S (in LEPRCH; impairs transport of the receptor FT to the cell surface; dbSNP:rs121913158)" FT /evidence="ECO:0000269|PubMed:8188715" FT /id="VAR_015542" FT VARIANT 448 FT /note="I -> T (in dbSNP:rs1051691)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015915" FT VARIANT 458 FT /note="N -> D (in LEPRCH; partially inhibits receptor FT processing and autophosphorylation; strongly impairs ERK FT phosphorylation; induces wild-type levels of IRS-1 FT phosphorylation; dbSNP:rs121913160)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031521" FT VARIANT 487 FT /note="K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)" FT /evidence="ECO:0000269|PubMed:2834824" FT /id="VAR_004088" FT VARIANT 489 FT /note="N -> D (in IRAN type A; uncertain significance; FT dbSNP:rs1135401742)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079538" FT VARIANT 489 FT /note="N -> S (in IRAN type A; dbSNP:rs121913147)" FT /evidence="ECO:0000269|PubMed:2365819" FT /id="VAR_004089" FT VARIANT 492 FT /note="Q -> K" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015916" FT VARIANT 635 FT /note="S -> L (in RMS; decreases post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079539" FT VARIANT 657 FT /note="V -> F (in LEPRCH; impairs post-translational FT processing; dbSNP:rs1135401737)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079540" FT VARIANT 659 FT /note="W -> R (in LEPRCH; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079541" FT VARIANT 695 FT /note="Q -> R (in dbSNP:rs55906835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041430" FT VARIANT 762 FT /note="R -> S (in IRAN type A; dbSNP:rs121913138)" FT /evidence="ECO:0000269|PubMed:3283938" FT /id="VAR_004090" FT VARIANT 811 FT /note="G -> S (in dbSNP:rs35045353)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041431" FT VARIANT 818 FT /note="Y -> C (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:22768670, FT ECO:0000269|PubMed:28765322" FT /id="VAR_079542" FT VARIANT 830 FT /note="P -> L (in dbSNP:rs2162771)" FT /id="VAR_055986" FT VARIANT 835 FT /note="S -> I (in RMS; impairs post-translational FT processing; dbSNP:rs1135401739)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079543" FT VARIANT 842 FT /note="A -> V (in RMS; decreases post-translational FT processing; dbSNP:rs1135401738)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079544" FT VARIANT 858 FT /note="T -> A (in T2D; dbSNP:rs182552223)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015917" FT VARIANT 874 FT /note="P -> L (in RMS; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079545" FT VARIANT 878 FT /note="N -> S (in RMS; impairs post-translational FT processing; dbSNP:rs887190835)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079546" FT VARIANT 890..1382 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:22768670" FT /id="VAR_079547" FT VARIANT 925 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; abolishes insulin binding; dbSNP:rs1599881881)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015918" FT VARIANT 926 FT /note="R -> W (in LEPRCH; markedly impairs insulin FT binding;impairs post-translational processing; FT dbSNP:rs911929963)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015919" FT VARIANT 937 FT /note="T -> M (in LEPRCH; impaired receptor processing; FT impairs post-translational processing; dbSNP:rs1972802448)" FT /evidence="ECO:0000269|PubMed:28765322, FT ECO:0000269|PubMed:9299395" FT /id="VAR_015920" FT VARIANT 997 FT /note="P -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015921" FT VARIANT 999..1382 FT /note="Missing (in RMS)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079548" FT VARIANT 1012 FT /note="V -> M (in dbSNP:rs1799816)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8432414, FT ECO:0000269|PubMed:8458533, ECO:0000269|PubMed:9199575" FT /id="VAR_004091" FT VARIANT 1020 FT /note="R -> Q (in IRAN type A; dbSNP:rs121913148)" FT /evidence="ECO:0000269|PubMed:2002058" FT /id="VAR_004092" FT VARIANT 1023 FT /note="I -> F" FT /evidence="ECO:0000269|PubMed:8890729" FT /id="VAR_015922" FT VARIANT 1035 FT /note="G -> V (in IRAN type A; dbSNP:rs121913135)" FT /evidence="ECO:0000269|PubMed:2544998" FT /id="VAR_004093" FT VARIANT 1054 FT /note="V -> M (in IRAN type A; uncertain significance; FT dbSNP:rs1135401741)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079549" FT VARIANT 1055 FT /note="A -> V (in IRAN type A; dbSNP:rs1599874183)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015923" FT VARIANT 1065 FT /note="L -> V (in dbSNP:rs56395521)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041432" FT VARIANT 1075 FT /note="A -> D (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:8243830" FT /id="VAR_004094" FT VARIANT 1095 FT /note="K -> E (in a subject with non-insulin dependent FT diabetes mellitus; dbSNP:rs909008899)" FT /evidence="ECO:0000269|PubMed:2040394" FT /id="VAR_015924" FT VARIANT 1119 FT /note="R -> W (in LEPRCH; dbSNP:rs1229730671)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:9249867" FT /id="VAR_015925" FT VARIANT 1143 FT /note="I -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015926" FT VARIANT 1158 FT /note="R -> Q (in T2D)" FT /evidence="ECO:0000269|PubMed:1470163" FT /id="VAR_015927" FT VARIANT 1158 FT /note="R -> W (in RMS; abolishes insulin binding; FT dbSNP:rs111993466)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015928" FT VARIANT 1161 FT /note="A -> T (in IRAN type A; dbSNP:rs121913139)" FT /evidence="ECO:0000269|PubMed:2168397" FT /id="VAR_004095" FT VARIANT 1162 FT /note="A -> E (in IRAN type A; impairs proteolytic FT processing; dbSNP:rs121913154)" FT /evidence="ECO:0000269|PubMed:8096518" FT /id="VAR_004096" FT VARIANT 1180 FT /note="M -> I (in a patient with insulin resistance; FT dbSNP:rs121913157)" FT /evidence="ECO:0000269|PubMed:1890161" FT /id="VAR_004097" FT VARIANT 1191 FT /note="R -> Q (in T2D; dbSNP:rs121913150)" FT /evidence="ECO:0000269|PubMed:1607076" FT /id="VAR_004098" FT VARIANT 1201 FT /note="R -> Q (in HHF5 and IRAN type A; interferes with FT kinase activation by insulin; dbSNP:rs121913156)" FT /evidence="ECO:0000269|PubMed:15161766, FT ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049" FT /id="VAR_015929" FT VARIANT 1201 FT /note="R -> W (in LEPRCH and RMS; reduces insulin binding FT possibly due to reduced receptor levels on the cell FT surface; dbSNP:rs1568426700)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:9703342" FT /id="VAR_015930" FT VARIANT 1205 FT /note="P -> L (in IRAN type A; moderate; FT dbSNP:rs1295645322)" FT /evidence="ECO:0000269|PubMed:1563582, FT ECO:0000269|PubMed:8314008" FT /id="VAR_004099" FT VARIANT 1206 FT /note="E -> D (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity)" FT /evidence="ECO:0000269|PubMed:7983039" FT /id="VAR_015931" FT VARIANT 1206 FT /note="E -> K (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9249867" FT /id="VAR_015932" FT VARIANT 1220 FT /note="W -> L (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity; dbSNP:rs52800171)" FT /evidence="ECO:0000269|PubMed:7983039, FT ECO:0000269|PubMed:8390949" FT /id="VAR_004100" FT VARIANT 1227 FT /note="W -> S (in IRAN type A; dbSNP:rs121913140)" FT /evidence="ECO:0000269|PubMed:1963473" FT /id="VAR_004101" FT VARIANT 1282 FT /note="T -> A (in dbSNP:rs55875349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041433" FT VARIANT 1361 FT /note="Y -> C (in dbSNP:rs13306449)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015933" FT VARIANT 1378 FT /note="R -> Q (in IRAN type A; dbSNP:rs52826008)" FT /evidence="ECO:0000269|PubMed:8314008" FT /id="VAR_015934" FT MUTAGEN 462 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 825 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 834 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 991 FT /note="L->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 992 FT /note="Y->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996..997 FT /note="NP->AA: Abolishes interaction with IRS1. Severely FT disrupts, but does not abolish interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996 FT /note="N->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 997 FT /note="P->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 998 FT /note="E->A: Does not affect interaction with IRS1, SHC1 or FT PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849" FT MUTAGEN 999 FT /note="Y->E: Abolishes interaction with IRS1 and SHC1." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 999 FT /note="Y->F: Has no effect on insulin-stimulated FT autophosphorylation, but inhibits the biological activity FT of the receptor. Abolishes interaction with IRS1 and almost FT completely prevents interaction with SHC1. Has no effect on FT interaction with PIK3R1. Abolishes interaction with FT STAT5B." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 1000 FT /note="L->A,R: Severely reduces interaction with SHC1. Has FT no effect on interaction with IRS1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1002 FT /note="A->D: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1011 FT /note="Y->A: Increases kinase activity." FT /evidence="ECO:0000269|PubMed:12707268" FT MUTAGEN 1057 FT /note="K->A: Abolishes the kinase activity and abolishes FT interaction with IRS1, SHC1, GRB7 and PIK3R1." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1057 FT /note="K->M,R: Abolishes the kinase activity." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1079 FT /note="K->R: Increased cell surface stability." FT /evidence="ECO:0000269|PubMed:27577745" FT MUTAGEN 1083 FT /note="C->A: Reduced S-nitrosylation by BLVRB, leading to FT increased receptor tyrosine kinase activity." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 1159 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1163 FT /note="R->Q: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1189 FT /note="Y->F: Reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT MUTAGEN 1190 FT /note="Y->F: Strongly reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT CONFLICT 601 FT /note="D -> N (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 830 FT /note="P -> E (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1278 FT /note="K -> N (in Ref. 2; CAA26096)" FT /evidence="ECO:0000305" FT STRAND 33..42 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 45..50 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 53..65 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 88..93 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 103..105 FT /evidence="ECO:0007829|PDB:8X2M" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 118..124 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 141..149 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 171..175 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 187..192 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 224..226 FT /evidence="ECO:0007829|PDB:8X06" FT STRAND 230..232 FT /evidence="ECO:0007829|PDB:7MQO" FT STRAND 243..247 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 305..307 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 310..314 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 323..325 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 327..330 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 338..348 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 351..355 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 356..359 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 377..385 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 390..393 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 395..399 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8X06" FT TURN 422..424 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 425..430 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 437..439 FT /evidence="ECO:0007829|PDB:7U6E" FT TURN 441..443 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 447..450 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 452..458 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 463..472 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 476..478 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 481..483 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 486..490 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 498..500 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 524..526 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 527..536 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 538..540 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 552..554 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 570..573 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 577..580 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 588..597 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 601..603 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 608..610 FT /evidence="ECO:0007829|PDB:4ZXB" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 626..631 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 633..636 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 654..658 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 666..669 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 732..740 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 798..803 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 805..809 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 817..827 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 838..843 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 867..870 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 881..890 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 896..901 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 902..908 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 910..913 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 918..931 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 940..944 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 953..979 FT /evidence="ECO:0007829|PDB:2MFR" FT STRAND 992..995 FT /evidence="ECO:0007829|PDB:5U1M" FT TURN 1003..1005 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1009..1011 FT /evidence="ECO:0007829|PDB:1IR3" FT HELIX 1014..1016 FT /evidence="ECO:0007829|PDB:1IRK" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1023..1031 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1033..1043 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1046..1048 FT /evidence="ECO:0007829|PDB:2Z8C" FT STRAND 1050..1057 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1065..1078 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1089..1093 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1095..1098 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1100..1104 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1111..1117 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1119..1121 FT /evidence="ECO:0007829|PDB:3ETA" FT HELIX 1133..1152 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1154..1156 FT /evidence="ECO:0007829|PDB:2AUH" FT HELIX 1162..1164 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1165..1167 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1173..1175 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1181..1183 FT /evidence="ECO:0007829|PDB:1IRK" FT TURN 1185..1187 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1190..1192 FT /evidence="ECO:0007829|PDB:5HHW" FT STRAND 1194..1198 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1200..1202 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1205..1210 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1215..1230 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1236..1239 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1242..1250 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1263..1272 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1277..1279 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1283..1290 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1291..1293 FT /evidence="ECO:0007829|PDB:5HHW" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1303..1305 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1307..1309 FT /evidence="ECO:0007829|PDB:8DWN" SQ SEQUENCE 1382 AA; 156333 MW; 709A955660739066 CRC64; MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN PS // ID IRF1_HUMAN Reviewed; 325 AA. AC P10914; Q96GG7; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 16-APR-2002, sequence version 2. DT 28-JAN-2026, entry version 213. DE RecName: Full=Interferon regulatory factor 1; DE Short=IRF-1; GN Name=IRF1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2726461; DOI=10.1093/nar/17.8.3292; RA Maruyama M., Fujita T., Taniguchi T.; RT "Sequence of a cDNA coding for human IRF-1."; RL Nucleic Acids Res. 17:3292-3292(1989). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=3409321; DOI=10.1016/s0092-8674(88)91307-4; RA Miyamoto M., Fujita T., Kimura Y., Maruyama M., Harada H., Sudo Y., RA Miyata T., Taniguchi T.; RT "Regulated expression of a gene encoding a nuclear factor, IRF-1, that RT specifically binds to IFN-beta gene regulatory elements."; RL Cell 54:903-913(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=1382447; DOI=10.1089/dna.1992.11.605; RA Cha Y., Sims S.H., Romine M.F., Kaufmann M., Deisseroth A.B.; RT "Human interferon regulatory factor 1: intron-exon organization."; RL DNA Cell Biol. 11:605-611(1992). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION. RX PubMed=7687740; DOI=10.1128/mcb.13.8.4531-4538.1993; RA Tanaka N., Kawakami T., Taniguchi T.; RT "Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and RT IRF-2, regulators of cell growth and the interferon system."; RL Mol. Cell. Biol. 13:4531-4538(1993). RN [7] RP INVOLVEMENT IN LEUKEMIAS. RX PubMed=8438156; DOI=10.1126/science.8438156; RA Willman C.L., Sever C.E., Pallavicini M.G., Harada H., Tanaka N., RA Slovak M.L., Yamamoto H., Harada K., Meeker T.C., List A.F., Taniguchi T.; RT "Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and RT preleukemic myelodysplasia."; RL Science 259:968-971(1993). RN [8] RP INDUCTION. RX PubMed=7507207; DOI=10.1128/mcb.14.2.1500-1509.1994; RA Harada H., Takahashi E., Itoh S., Harada K., Hori T.A., Taniguchi T.; RT "Structure and regulation of the human interferon regulatory factor 1 (IRF- RT 1) and IRF-2 genes: implications for a gene network in the interferon RT system."; RL Mol. Cell. Biol. 14:1500-1509(1994). RN [9] RP PHOSPHORYLATION. RX PubMed=10094406; DOI=10.1023/a:1006850009017; RA Lin R., Hiscott J.; RT "A role for casein kinase II phosphorylation in the regulation of IRF-1 RT transcriptional activity."; RL Mol. Cell. Biochem. 191:169-180(1999). RN [10] RP REVIEW ON FUNCTION. RX PubMed=11244049; DOI=10.1146/annurev.immunol.19.1.623; RA Taniguchi T., Ogasawara K., Takaoka A., Tanaka N.; RT "IRF family of transcription factors as regulators of host defense."; RL Annu. Rev. Immunol. 19:623-655(2001). RN [11] RP REVIEW ON FUNCTION. RX PubMed=11846971; DOI=10.1089/107999002753452610; RA Kroeger A., Koester M., Schroeder K., Hauser H., Mueller P.P.; RT "Activities of IRF-1."; RL J. Interferon Cytokine Res. 22:5-14(2002). RN [12] RP REVIEW ON FUNCTION. RX PubMed=11846974; DOI=10.1089/107999002753452647; RA Romeo G., Fiorucci G., Chiantore M.V., Percario Z.A., Vannucchi S., RA Affabris E.; RT "IRF-1 as a negative regulator of cell proliferation."; RL J. Interferon Cytokine Res. 22:39-47(2002). RN [13] RP FUNCTION, AND INDUCTION BY IFN. RX PubMed=15226432; DOI=10.1128/mcb.24.14.6298-6310.2004; RA Oshima S., Nakamura T., Namiki S., Okada E., Tsuchiya K., Okamoto R., RA Yamazaki M., Yokota T., Aida M., Yamaguchi Y., Kanai T., Handa H., RA Watanabe M.; RT "Interferon regulatory factor 1 (IRF-1) and IRF-2 distinctively up-regulate RT gene expression and production of interleukin-7 in human intestinal RT epithelial cells."; RL Mol. Cell. Biol. 24:6298-6310(2004). RN [14] RP FUNCTION, AND INTERACTION WITH EP300. RX PubMed=15509808; DOI=10.1128/mcb.24.22.10083-10098.2004; RA Dornan D., Eckert M., Wallace M., Shimizu H., Ramsay E., Hupp T.R., RA Ball K.L.; RT "Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent RT acetylation of p53."; RL Mol. Cell. Biol. 24:10083-10098(2004). RN [15] RP REVIEW ON FUNCTION. RX PubMed=16932750; DOI=10.1038/nri1900; RA Honda K., Taniguchi T.; RT "IRFs: master regulators of signalling by Toll-like receptors and cytosolic RT pattern-recognition receptors."; RL Nat. Rev. Immunol. 6:644-658(2006). RN [16] RP FUNCTION, AND INDUCTION BY IFN. RX PubMed=17516545; DOI=10.1002/jcp.21128; RA Su Z.Z., Sarkar D., Emdad L., Barral P.M., Fisher P.B.; RT "Central role of interferon regulatory factor-1 (IRF-1) in controlling RT retinoic acid inducible gene-I (RIG-I) expression."; RL J. Cell. Physiol. 213:502-510(2007). RN [17] RP FUNCTION. RX PubMed=18084608; DOI=10.1593/neo.07640; RA Maratheftis C.I., Giannouli S., Spachidou M.P., Panayotou G., RA Voulgarelis M.; RT "RNA interference of interferon regulatory factor-1 gene expression in THP- RT 1 cell line leads to Toll-like receptor-4 overexpression/activation as well RT as up-modulation of annexin-II."; RL Neoplasia 9:1012-1020(2007). RN [18] RP SUMOYLATION AT LYS-275 AND LYS-299, UBIQUITINATION AT LYS-275 AND LYS-299, RP FUNCTION, INDUCTION BY IFN, AND MUTAGENESIS OF LYS-275 AND LYS-299. RX PubMed=17942705; DOI=10.1073/pnas.0609852104; RA Park J., Kim K., Lee E.-J., Seo Y.-J., Lim S.-N., Park K., Rho S.B., RA Lee S.-H., Lee J.-H.; RT "Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1- RT mediated apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 104:17028-17033(2007). RN [19] RP FUNCTION. RX PubMed=18497060; DOI=10.1007/978-0-387-69080-3_35; RA Bowie M.L., Ibarra C., Seewalt V.L.; RT "IRF-1 promotes apoptosis in p53-damaged basal-type human mammary RT epithelial cells: a model for early basal-type mammary carcinogenesis."; RL Adv. Exp. Med. Biol. 617:367-374(2008). RN [20] RP FUNCTION. RX PubMed=18641303; DOI=10.4049/jimmunol.181.3.1673; RA Fragale A., Gabriele L., Stellacci E., Borghi P., Perrotti E., Ilari R., RA Lanciotti A., Remoli A.L., Venditti M., Belardelli F., Battistini A.; RT "IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell RT differentiation by repressing Foxp3 expression."; RL J. Immunol. 181:1673-1682(2008). RN [21] RP FUNCTION, AND INDUCTION BY HIV AND IFN. RX PubMed=19404407; DOI=10.1371/journal.pone.0005397; RA Huang Y., Walstrom A., Zhang L., Zhao Y., Cui M., Ye L., Zheng J.C.; RT "Type I interferons and interferon regulatory factors regulate TNF-related RT apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages."; RL PLoS ONE 4:E5397-E5397(2009). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20049431; DOI=10.1007/s00262-009-0804-6; RA Savitsky D., Tamura T., Yanai H., Taniguchi T.; RT "Regulation of immunity and oncogenesis by the IRF transcription factor RT family."; RL Cancer Immunol. Immunother. 59:489-510(2010). RN [23] RP FUNCTION, AND INDUCTION BY IFN. RX PubMed=19851330; DOI=10.1038/cdd.2009.156; RA Gao J., Senthil M., Ren B., Yan J., Xing Q., Yu J., Zhang L., Yim J.H.; RT "IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial RT apoptotic pathway in IRF-1-induced apoptosis in cancer cells."; RL Cell Death Differ. 17:699-709(2010). RN [24] RP FUNCTION, AND INDUCTION BY HPV16 E5. RX PubMed=21389130; DOI=10.1128/jvi.02114-10; RA Muto V., Stellacci E., Lamberti A.G., Perrotti E., Carrabba A., Matera G., RA Sgarbanti M., Battistini A., Liberto M.C., Foca A.; RT "Human papillomavirus type 16 E5 protein induces expression of beta RT interferon through interferon regulatory factor 1 in human keratinocytes."; RL J. Virol. 85:5070-5080(2011). RN [25] RP FUNCTION. RX PubMed=22200613; DOI=10.1016/j.canlet.2011.12.027; RA Armstrong M.J., Stang M.T., Liu Y., Gao J., Ren B., Zuckerbraun B.S., RA Mahidhara R.S., Xing Q., Pizzoferrato E., Yim J.H.; RT "Interferon regulatory factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent RT cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in RT cancer cells."; RL Cancer Lett. 319:56-65(2012). RN [26] RP FUNCTION, INDUCTION BY N-METHYL-N'-NITRO-N-NITROSOGUANIDINE, ACETYLATION AT RP LYS-78, AND MUTAGENESIS OF LYS-78. RX PubMed=22367195; DOI=10.1074/jbc.m111.313429; RA Qi H., Zhu H., Lou M., Fan Y., Liu H., Shen J., Li Z., Lv X., Shan J., RA Zhu L., Chin Y.E., Shao J.; RT "Interferon regulatory factor 1 transactivates the expression of human DNA RT polymerase eta in response to the carcinogen N-methyl-N'-nitro-N- RT nitrosoguanidine."; RL J. Biol. Chem. 287:12622-12633(2012). RN [27] RP FUNCTION. RX PubMed=32385160; DOI=10.1073/pnas.1921484117; RA Somerville T.D.D., Xu Y., Wu X.S., Maia-Silva D., Hur S.K., RA de Almeida L.M.N., Preall J.B., Koo P.K., Vakoc C.R.; RT "ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell RT identity in pancreatic cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 117:11471-11482(2020). RN [28] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SPOP. RX PubMed=37622993; DOI=10.7554/elife.89951; RA Schwartz I., Vunjak M., Budroni V., Cantoran Garcia A., Mastrovito M., RA Soderholm A., Hinterndorfer M., de Almeida M., Hacker K., Wang J., RA Froussios K., Jude J., Decker T., Zuber J., Versteeg G.A.; RT "SPOP targets the immune transcription factor IRF1 for proteasomal RT degradation."; RL Elife 12:0-0(2023). RN [29] RP VARIANT GASC LEU-8, AND CHARACTERIZATION OF VARIANT GASC LEU-8. RX PubMed=9679752; RX DOI=10.1002/(sici)1097-0215(19980812)77:4<522::aid-ijc8>3.0.co;2-w; RA Nozawa H., Oda E., Ueda S., Tamura G., Maesawa C., Muto T., Taniguchi T., RA Tanaka N.; RT "Functionally inactivating point mutation in the tumor-suppressor IRF-1 RT gene identified in human gastric cancer."; RL Int. J. Cancer 77:522-527(1998). RN [30] RP VARIANT GASC ARG-11. RX PubMed=10395927; DOI=10.1016/s0167-4781(99)00078-0; RA Eason D.D., Shepherd A.T., Blanck G.; RT "Interferon regulatory factor 1 tryptophan 11 to arginine point mutation RT abolishes DNA binding."; RL Biochim. Biophys. Acta 1446:140-144(1999). RN [31] RP VARIANT IMD117 129-ARG--PRO-325 DEL, CHARACTERIZATION OF VARIANT IMD117 RP 129-ARG--PRO-325 DEL, INVOLVEMENT IN IMD117, MUTAGENESIS OF ALA-67, AND RP FUNCTION. RX PubMed=36736301; DOI=10.1016/j.cell.2022.12.038; RA Rosain J., Neehus A.L., Manry J., Yang R., Le Pen J., Daher W., Liu Z., RA Chan Y.H., Tahuil N., Tuerel O., Bourgey M., Ogishi M., Doisne J.M., RA Izquierdo H.M., Shirasaki T., Le Voyer T., Guerin A., Bastard P., RA Moncada-Velez M., Han J.E., Khan T., Rapaport F., Hong S.H., Cheung A., RA Haake K., Mindt B.C., Perez L., Philippot Q., Lee D., Zhang P., Rinchai D., RA Al Ali F., Ahmad Ata M.M., Rahman M., Peel J.N., Heissel S., Molina H., RA Kendir-Demirkol Y., Bailey R., Zhao S., Bohlen J., Mancini M., RA Seeleuthner Y., Roelens M., Lorenzo L., Soudee C., Paz M.E.J., RA Gonzalez M.L., Jeljeli M., Soulier J., Romana S., L'Honneur A.S., RA Materna M., Martinez-Barricarte R., Pochon M., Oleaga-Quintas C., RA Michev A., Migaud M., Levy R., Alyanakian M.A., Rozenberg F., Croft C.A., RA Vogt G., Emile J.F., Kremer L., Ma C.S., Fritz J.H., Lemon S.M., RA Spaan A.N., Manel N., Abel L., MacDonald M.R., Boisson-Dupuis S., Marr N., RA Tangye S.G., Di Santo J.P., Zhang Q., Zhang S.Y., Rice C.M., Beziat V., RA Lachmann N., Langlais D., Casanova J.L., Gros P., Bustamante J.; RT "Human IRF1 governs macrophagic IFN-gamma immunity to mycobacteria."; RL Cell 186:621-645(2023). CC -!- FUNCTION: Transcriptional regulator which displays a remarkable CC functional diversity in the regulation of cellular responses CC (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, CC PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:22367195, CC PubMed:32385160). Regulates transcription of IFN and IFN-inducible CC genes, host response to viral and bacterial infections, regulation of CC many genes expressed during hematopoiesis, inflammation, immune CC responses and cell proliferation and differentiation, regulation of the CC cell cycle and induction of growth arrest and programmed cell death CC following DNA damage (PubMed:15226432, PubMed:15509808, CC PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, CC PubMed:19851330, PubMed:22367195, PubMed:7687740). Stimulates both CC innate and acquired immune responses through the activation of specific CC target genes and can act as a transcriptional activator and repressor CC regulating target genes by binding to an interferon-stimulated response CC element (ISRE) in their promoters (PubMed:15226432, PubMed:15509808, CC PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, CC PubMed:19851330, PubMed:21389130, PubMed:22367195). Has an essentail CC role in IFNG-dependent immunity to mycobacteria (PubMed:36736301). CC Competes with the transcriptional repressor ZBED2 for binding to a CC common consensus sequence in gene promoters (PubMed:32385160). Its CC target genes for transcriptional activation activity include: genes CC involved in anti-viral response, such as IFN-alpha/beta, RIGI, CC TNFSF10/TRAIL, ZBP1, OAS1/2, PIAS1/GBP, EIF2AK2/PKR and RSAD2/viperin; CC antibacterial response, such as GBP2, GBP5 and NOS2/INOS; anti- CC proliferative response, such as p53/TP53, LOX and CDKN1A; apoptosis, CC such as BBC3/PUMA, CASP1, CASP7 and CASP8; immune response, such as CC IL7, IL12A/B and IL15, PTGS2/COX2 and CYBB; DNA damage responses and CC DNA repair, such as POLQ/POLH; MHC class I expression, such as TAP1, CC PSMB9/LMP2, PSME1/PA28A, PSME2/PA28B and B2M and MHC class II CC expression, such as CIITA; metabolic enzymes, such as ACOD1/IRG1 CC (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, CC PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:22367195). CC Represses genes involved in anti-proliferative response, such as CC BIRC5/survivin, CCNB1, CCNE1, CDK1, CDK2 and CDK4 and in immune CC response, such as FOXP3, IL4, ANXA2 and TLR4 (PubMed:18641303, CC PubMed:22200613). Stimulates p53/TP53-dependent transcription through CC enhanced recruitment of EP300 leading to increased acetylation of CC p53/TP53 (PubMed:15509808, PubMed:18084608). Plays an important role in CC immune response directly affecting NK maturation and activity, CC macrophage production of IL12, Th1 development and maturation of CD8+ CC T-cells (PubMed:11244049, PubMed:11846971, PubMed:11846974, CC PubMed:16932750). Also implicated in the differentiation and maturation CC of dendritic cells and in the suppression of regulatory T (Treg) cells CC development (PubMed:11244049, PubMed:11846971, PubMed:11846974, CC PubMed:16932750). Acts as a tumor suppressor and plays a role not only CC in antagonism of tumor cell growth but also in stimulating an immune CC response against tumor cells (PubMed:20049431). CC {ECO:0000269|PubMed:15226432, ECO:0000269|PubMed:15509808, CC ECO:0000269|PubMed:17516545, ECO:0000269|PubMed:17942705, CC ECO:0000269|PubMed:18084608, ECO:0000269|PubMed:18497060, CC ECO:0000269|PubMed:18641303, ECO:0000269|PubMed:19404407, CC ECO:0000269|PubMed:19851330, ECO:0000269|PubMed:21389130, CC ECO:0000269|PubMed:22200613, ECO:0000269|PubMed:22367195, CC ECO:0000269|PubMed:32385160, ECO:0000269|PubMed:36736301, CC ECO:0000269|PubMed:7687740, ECO:0000303|PubMed:11244049, CC ECO:0000303|PubMed:11846971, ECO:0000303|PubMed:11846974, CC ECO:0000303|PubMed:16932750, ECO:0000303|PubMed:20049431}. CC -!- ACTIVITY REGULATION: Activated by MYD88. CC {ECO:0000250|UniProtKB:P15314}. CC -!- SUBUNIT: Monomer (By similarity). Homodimer (By similarity). Interacts CC with EP300 (PubMed:15509808). Interacts with MYD88 (By similarity). CC Interacts with PIAS3 (By similarity). Interacts with SPOP CC (PubMed:37622993). {ECO:0000250|UniProtKB:P15314, CC ECO:0000269|PubMed:15509808, ECO:0000269|PubMed:37622993}. CC -!- INTERACTION: CC P10914; Q14653: IRF3; NbExp=5; IntAct=EBI-1055781, EBI-2650369; CC P10914; Q16236: NFE2L2; NbExp=3; IntAct=EBI-1055781, EBI-2007911; CC P10914; P63165: SUMO1; NbExp=2; IntAct=EBI-1055781, EBI-80140; CC P10914; P03129: E7; Xeno; NbExp=4; IntAct=EBI-1055781, EBI-866453; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:37622993}. Cytoplasm CC {ECO:0000250|UniProtKB:P15314}. Note=MYD88-associated IRF1 migrates CC into the nucleus more efficiently than non-MYD88-associated IRF1. CC {ECO:0000250|UniProtKB:P15314}. CC -!- INDUCTION: By viruses and IFN (PubMed:7507207). Induced by HPV16 E5 CC (PubMed:21389130). Induced by HIV (PubMed:19404407). By interferon CC (IFN) (PubMed:15226432, PubMed:17516545, PubMed:17942705, CC PubMed:19404407, PubMed:19851330, PubMed:32385160). Induced by N- CC methyl-N'-nitro-N-nitrosoguanidine (PubMed:22367195). CC {ECO:0000269|PubMed:15226432, ECO:0000269|PubMed:17516545, CC ECO:0000269|PubMed:17942705, ECO:0000269|PubMed:19404407, CC ECO:0000269|PubMed:19851330, ECO:0000269|PubMed:21389130, CC ECO:0000269|PubMed:22367195, ECO:0000269|PubMed:32385160, CC ECO:0000269|PubMed:7507207}. CC -!- PTM: Phosphorylated by CK2 and this positively regulates its activity. CC {ECO:0000269|PubMed:10094406}. CC -!- PTM: Sumoylation represses the transcriptional activity and displays CC enhanced resistance to protein degradation (PubMed:17942705). CC Sumoylated by UBE2I/UBC9 and SUMO1 (By similarity). Inactivates the CC tumor suppressor activity (PubMed:17942705). Elevated levels in tumor CC cells (PubMed:17942705). Major site is Lys-275 (PubMed:17942705). CC Sumoylation is enhanced by PIAS3 (By similarity). Desumoylated by SENP1 CC in tumor cells and appears to compete with ubiquitination on C-terminal CC sites (PubMed:17942705). {ECO:0000250|UniProtKB:P15314, CC ECO:0000269|PubMed:17942705}. CC -!- PTM: Ubiquitinated in a SPOP-depedent manner (PubMed:37622993). Appears CC to compete with sumoylation on C-terminal sites. CC {ECO:0000269|PubMed:17942705, ECO:0000269|PubMed:37622993}. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:10395927, CC ECO:0000269|PubMed:9679752}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Immunodeficiency 117 (IMD117) [MIM:620668]: An autosomal CC recessive immunologic disorder characterized by increased CC susceptibility to disseminated mycobacterial infection apparent in CC early childhood, after exposure to weakly virulent mycobacteria. CC Affected individuals develop mycobacterial disease after BCG (bacille CC Calmette-Guerin) vaccination. Immunologic workup shows impaired CC development of myeloid and lymphoid cell subsets that secrete and CC respond to gamma-interferon. {ECO:0000269|PubMed:36736301}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: Deletion or rearrangement of IRF1 are found in CC preleukemic myelodysplastic syndrome (MDS) and acute myelogenous CC leukemia (AML). CC -!- SIMILARITY: Belongs to the IRF family. {ECO:0000255|PROSITE- CC ProRule:PRU00840}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40990/IRF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X14454; CAA32624.1; -; mRNA. DR EMBL; L05072; AAA36043.1; -; Genomic_DNA. DR EMBL; BT019756; AAV38561.1; -; mRNA. DR EMBL; BC009483; AAH09483.1; -; mRNA. DR CCDS; CCDS4155.1; -. DR PIR; B31595; B31595. DR PIR; I52998; I52998. DR RefSeq; NP_002189.1; NM_002198.3. DR AlphaFoldDB; P10914; -. DR SMR; P10914; -. DR BioGRID; 109867; 69. DR CORUM; P10914; -. DR DIP; DIP-40988N; -. DR FunCoup; P10914; 2329. DR IntAct; P10914; 33. DR MINT; P10914; -. DR STRING; 9606.ENSP00000245414; -. DR iPTMnet; P10914; -. DR PhosphoSitePlus; P10914; -. DR BioMuta; IRF1; -. DR DMDM; 20178295; -. DR jPOST; P10914; -. DR MassIVE; P10914; -. DR PaxDb; 9606-ENSP00000245414; -. DR PeptideAtlas; P10914; -. DR ProteomicsDB; 52676; -. DR Antibodypedia; 3180; 485 antibodies from 38 providers. DR DNASU; 3659; -. DR Ensembl; ENST00000245414.9; ENSP00000245414.4; ENSG00000125347.16. DR Ensembl; ENST00000405885.6; ENSP00000384406.1; ENSG00000125347.16. DR GeneID; 3659; -. DR KEGG; hsa:3659; -. DR MANE-Select; ENST00000245414.9; ENSP00000245414.4; NM_002198.3; NP_002189.1. DR AGR; HGNC:6116; -. DR ClinPGx; PA29915; -. DR CTD; 3659; -. DR DisGeNET; 3659; -. DR GeneCards; IRF1; -. DR HGNC; HGNC:6116; IRF1. DR HPA; ENSG00000125347; Tissue enhanced (bone). DR MalaCards; IRF1; -. DR MIM; 147575; gene. DR MIM; 613659; phenotype. DR MIM; 620668; phenotype. DR OpenTargets; ENSG00000125347; -. DR Orphanet; 699615; Severe mendelian susceptibility to mycobacterial diseases due to complete IRF1 deficiency. DR VEuPathDB; HostDB:ENSG00000125347; -. DR eggNOG; ENOG502QVVN; Eukaryota. DR GeneTree; ENSGT00940000156288; -. DR HOGENOM; CLU_056386_1_0_1; -. DR InParanoid; P10914; -. DR OMA; HSGYTIH; -. DR OrthoDB; 6538197at2759; -. DR PAN-GO; P10914; 5 GO annotations based on evolutionary models. DR PhylomeDB; P10914; -. DR PathwayCommons; P10914; -. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-877300; Interferon gamma signaling. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR SignaLink; P10914; -. DR SIGNOR; P10914; -. DR Agora; ENSG00000125347; -. DR BioGRID-ORCS; 3659; 25 hits in 1185 CRISPR screens. DR ChiTaRS; IRF1; human. DR GeneWiki; IRF1; -. DR GenomeRNAi; 3659; -. DR Pharos; P10914; Tbio. DR PRO; PR:P10914; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P10914; protein. DR Bgee; ENSG00000125347; Expressed in granulocyte and 182 other cell types or tissues. DR ExpressionAtlas; P10914; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0003677; F:DNA binding; TAS:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:MGI. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0043374; P:CD8-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0035458; P:cellular response to interferon-beta; IDA:BHF-UCL. DR GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0002376; P:immune system process; IBA:GO_Central. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0045590; P:negative regulation of regulatory T cell differentiation; ISS:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0032728; P:positive regulation of interferon-beta production; IMP:UniProtKB. DR GO; GO:0032735; P:positive regulation of interleukin-12 production; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB. DR GO; GO:0032481; P:positive regulation of type I interferon production; ISS:UniProtKB. DR GO; GO:0002819; P:regulation of adaptive immune response; TAS:UniProtKB. DR GO; GO:2000564; P:regulation of CD8-positive, alpha-beta T cell proliferation; ISS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB. DR GO; GO:0045088; P:regulation of innate immune response; TAS:UniProtKB. DR GO; GO:0034124; P:regulation of MyD88-dependent toll-like receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:MGI. DR GO; GO:0034138; P:toll-like receptor 3 signaling pathway; IDA:MGI. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; ISS:UniProtKB. DR CDD; cd00103; IRF; 1. DR FunFam; 1.10.10.10:FF:000065; Interferon regulatory factor; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR InterPro; IPR019817; Interferon_reg_fac_CS. DR InterPro; IPR001346; Interferon_reg_fact_DNA-bd_dom. DR InterPro; IPR017431; IRF1/IRF2. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR PANTHER; PTHR11949; INTERFERON REGULATORY FACTOR; 1. DR PANTHER; PTHR11949:SF3; INTERFERON REGULATORY FACTOR 1; 1. DR Pfam; PF00605; IRF; 1. DR PIRSF; PIRSF038196; IFN_RF1/2; 1. DR PRINTS; PR00267; INTFRNREGFCT. DR SMART; SM00348; IRF; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS00601; IRF_1; 1. DR PROSITE; PS51507; IRF_2; 1. PE 1: Evidence at protein level; KW Acetylation; Activator; Antiviral defense; Cytoplasm; Disease variant; KW DNA-binding; Immunity; Innate immunity; Isopeptide bond; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repressor; KW Transcription; Transcription regulation; Tumor suppressor; Ubl conjugation. FT CHAIN 1..325 FT /note="Interferon regulatory factor 1" FT /id="PRO_0000154545" FT DNA_BIND 5..113 FT /note="IRF tryptophan pentad repeat" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00840" FT REGION 92..165 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 141..157 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 78 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22367195" FT CROSSLNK 275 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT CROSSLNK 299 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT VARIANT 8 FT /note="M -> L (in GASC; somatic mutation; produces a FT protein with markedly reduced transcriptional activity but FT unaltered DNA-binding activity; dbSNP:rs121912469)" FT /evidence="ECO:0000269|PubMed:9679752" FT /id="VAR_065134" FT VARIANT 11 FT /note="W -> R (in GASC; the mutation abolishes DNA binding FT and transactivating activities; dbSNP:rs121912470)" FT /evidence="ECO:0000269|PubMed:10395927" FT /id="VAR_065135" FT VARIANT 129..325 FT /note="Missing (in IMD117; likely pathogenic; lack of a FT detectable protein in homozygous patient cells; no effect FT on nuclear localization; no effect on DNA binding; loss of FT transcriptional activity)" FT /evidence="ECO:0000269|PubMed:36736301" FT /id="VAR_089208" FT MUTAGEN 67 FT /note="A->P: No effect on transcriptional activity." FT /evidence="ECO:0000269|PubMed:36736301" FT MUTAGEN 78 FT /note="K->R: Loss of acetylation. Partial loss of DNA- FT binding and transcriptional activity." FT /evidence="ECO:0000269|PubMed:22367195" FT MUTAGEN 275 FT /note="K->R: Some loss of sumoylation. Partial inhibition FT of acetylation and activity. Abolishes sumoylation, FT diminished ubiquitination, higher resistance to FT degradation, and increased apoptotic activity; when FT associated with R-299." FT /evidence="ECO:0000269|PubMed:17942705" FT MUTAGEN 299 FT /note="K->R: Large loss of sumoylation. Abolishes FT sumoylation, diminished ubiquitination, higher resistance FT to degradation, and increased apoptotic activity; when FT associated with R-275." FT /evidence="ECO:0000269|PubMed:17942705" FT CONFLICT 5 FT /note="R -> W (in Ref. 1; no nucleotide entry and 2; no FT nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 34..35 FT /note="FQ -> LE (in Ref. 1; no nucleotide entry and 2; no FT nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 220 FT /note="T -> I (in Ref. 1; no nucleotide entry and 2; no FT nucleotide entry)" FT /evidence="ECO:0000305" SQ SEQUENCE 325 AA; 36502 MW; 2E06245A212D1541 CRC64; MPITRMRMRP WLEMQINSNQ IPGLIWINKE EMIFQIPWKH AAKHGWDINK DACLFRSWAI HTGRYKAGEK EPDPKTWKAN FRCAMNSLPD IEEVKDQSRN KGSSAVRVYR MLPPLTKNQR KERKSKSSRD AKSKAKRKSC GDSSPDTFSD GLSSSTLPDD HSSYTVPGYM QDLEVEQALT PALSPCAVSS TLPDWHIPVE VVPDSTSDLY NFQVSPMPST SEATTDEDEE GKLPEDIMKL LEQSEWQPTN VDGKGYLLNE PGVQPTSVYG DFSCKEEPEI DSPGGDIGLS LQRVFTDLKN MDATWLDSLL TPVRLPSIQA IPCAP // ID ITK_HUMAN Reviewed; 620 AA. AC Q08881; B2R752; Q32ML7; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1994, sequence version 1. DT 28-JAN-2026, entry version 239. DE RecName: Full=Tyrosine-protein kinase ITK/TSK; DE EC=2.7.10.2; DE AltName: Full=Interleukin-2-inducible T-cell kinase; DE Short=IL-2-inducible T-cell kinase; DE AltName: Full=Kinase EMT; DE AltName: Full=T-cell-specific kinase; DE AltName: Full=Tyrosine-protein kinase Lyk; GN Name=ITK; Synonyms=EMT, LYK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION. RX PubMed=8504851; DOI=10.1016/0014-5793(93)81520-a; RA Tanaka N., Asao H., Ohtani K., Nakamura M., Sugamura K.; RT "A novel human tyrosine kinase gene inducible in T cells by interleukin RT 2."; RL FEBS Lett. 324:1-5(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Thymus; RX PubMed=8364206; RA Gibson S., Leung B., Squire J.A., Hill M., Arima N., Goss P., Hogg D., RA Mills G.B.; RT "Identification, cloning, and characterization of a novel human T-cell- RT specific tyrosine kinase located at the hematopoietin complex on chromosome RT 5q."; RL Blood 82:1561-1572(1993). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 171-192, AND PHOSPHORYLATION AT TYR-180. RX PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1; RA Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A., RA Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.; RT "Identification of phosphorylation sites within the SH3 domains of Tec RT family tyrosine kinases."; RL Biochim. Biophys. Acta 1645:123-132(2003). RN [7] RP PHOSPHORYLATION BY LCK. RX PubMed=9312162; DOI=10.1074/jbc.272.40.25401; RA Heyeck S.D., Wilcox H.M., Bunnell S.C., Berg L.J.; RT "Lck phosphorylates the activation loop tyrosine of the Itk kinase domain RT and activates Itk kinase activity."; RL J. Biol. Chem. 272:25401-25408(1997). RN [8] RP INDUCTION. RX PubMed=9701039; DOI=10.1093/intimm/10.7.1009; RA King P.D., Sadra A., Teng J.M., Bell G.M., Dupont B.; RT "CD2-mediated activation of the Tec-family tyrosine kinase ITK is RT controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail."; RL Int. Immunol. 10:1009-1016(1998). RN [9] RP DOMAIN. RX PubMed=10795735; DOI=10.1016/s1074-7613(00)80189-2; RA Yang W.C., Collette Y., Nunes J.A., Olive D.; RT "Tec kinases: a family with multiple roles in immunity."; RL Immunity 12:373-382(2000). RN [10] RP FUNCTION IN PHOSPHORYLATION OF LAT. RX PubMed=12186560; DOI=10.1021/bi025554o; RA Perez-Villar J.J., Whitney G.S., Sitnick M.T., Dunn R.J., Venkatesan S., RA O'Day K., Schieven G.L., Lin T.A., Kanner S.B.; RT "Phosphorylation of the linker for activation of T-cells by Itk promotes RT recruitment of Vav."; RL Biochemistry 41:10732-10740(2002). RN [11] RP FUNCTION. RX PubMed=12682224; DOI=10.4049/jimmunol.170.8.3971; RA Grasis J.A., Browne C.D., Tsoukas C.D.; RT "Inducible T cell tyrosine kinase regulates actin-dependent cytoskeletal RT events induced by the T cell antigen receptor."; RL J. Immunol. 170:3971-3976(2003). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [13] RP INTERACTION WITH PPIA/CYPA, AND MUTAGENESIS OF PRO-288. RX PubMed=15308100; DOI=10.1016/j.immuni.2004.07.005; RA Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y., RA Sokolskaja E., Andreotti A., Luban J.; RT "Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline- RT directed conformational switch in Itk."; RL Immunity 21:189-201(2004). RN [14] RP INTERACTION WITH VAV1. RX PubMed=15661896; DOI=10.4049/jimmunol.174.3.1385; RA Dombroski D., Houghtling R.A., Labno C.M., Precht P., Takesono A., RA Caplen N.J., Billadeau D.D., Wange R.L., Burkhardt J.K., Schwartzberg P.L.; RT "Kinase-independent functions for Itk in TCR-induced regulation of Vav and RT the actin cytoskeleton."; RL J. Immunol. 174:1385-1392(2005). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=17060314; DOI=10.1074/jbc.m609180200; RA Qi Q., Sahu N., August A.; RT "Tec kinase Itk forms membrane clusters specifically in the vicinity of RT recruiting receptors."; RL J. Biol. Chem. 281:38529-38534(2006). RN [16] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [17] RP AUTOPHOSPHORYLATION. RX PubMed=19523959; DOI=10.1016/j.jmb.2009.06.023; RA Joseph R.E., Severin A., Min L., Fulton D.B., Andreotti A.H.; RT "SH2-dependent autophosphorylation within the Tec family kinase Itk."; RL J. Mol. Biol. 391:164-177(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-512 AND SER-565, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP UBIQUITINATION. RX PubMed=20596523; DOI=10.1371/journal.pone.0011332; RA Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B., RA Spruck C.; RT "Development and validation of a method for profiling post-translational RT modification activities using protein microarrays."; RL PLoS ONE 5:E11332-E11332(2010). RN [20] RP FUNCTION IN PHOSPHORYLATION OF LCP2. RX PubMed=21725281; DOI=10.1038/emboj.2011.213; RA Sela M., Bogin Y., Beach D., Oellerich T., Lehne J., Smith-Garvin J.E., RA Okumura M., Starosvetsky E., Kosoff R., Libman E., Koretzky G., RA Kambayashi T., Urlaub H., Wienands J., Chernoff J., Yablonski D.; RT "Sequential phosphorylation of SLP-76 at tyrosine 173 is required for RT activation of T and mast cells."; RL EMBO J. 30:3160-3172(2011). RN [21] RP STRUCTURE BY NMR OF 113-239. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the BTK motif and the SH3 domain of tyrosine-protein RT kinase ITK from human."; RL Submitted (OCT-2007) to the PDB data bank. RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-19; LEU-23; GLN-451; TRP-581 AND RP ILE-587. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP VARIANT LPFS1 TRP-335, AND CHARACTERIZATION OF VARIANT LPSA1 TRP-335. RX PubMed=19425169; DOI=10.1172/jci37901; RA Huck K., Feyen O., Niehues T., Rueschendorf F., Huebner N., Laws H.-J., RA Telieps T., Knapp S., Wacker H.-H., Meindl A., Jumaa H., Borkhardt A.; RT "Girls homozygous for an IL-2-inducible T cell kinase mutation that leads RT to protein deficiency develop fatal EBV-associated lymphoproliferation."; RL J. Clin. Invest. 119:1350-1358(2009). CC -!- FUNCTION: Tyrosine kinase that plays an essential role in regulation of CC the adaptive immune response. Regulates the development, function and CC differentiation of conventional T-cells and nonconventional NKT-cells. CC When antigen presenting cells (APC) activate T-cell receptor (TCR), a CC series of phosphorylation lead to the recruitment of ITK to the cell CC membrane, in the vicinity of the stimulated TCR receptor, where it is CC phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation CC and full activation. Once activated, phosphorylates PLCG1, leading to CC the activation of this lipase and subsequent cleavage of its CC substrates. In turn, the endoplasmic reticulum releases calcium in the CC cytoplasm and the nuclear activator of activated T-cells (NFAT) CC translocates into the nucleus to perform its transcriptional duty. CC Phosphorylates 2 essential adapter proteins: the linker for activation CC of T-cells/LAT protein and LCP2. Then, a large number of signaling CC molecules such as VAV1 are recruited and ultimately lead to lymphokine CC production, T-cell proliferation and differentiation (PubMed:12186560, CC PubMed:12682224, PubMed:21725281). Required for TCR-mediated calcium CC response in gamma-delta T-cells, may also be involved in the modulation CC of the transcriptomic signature in the Vgamma2-positive subset of CC immature gamma-delta T-cells (By similarity). Phosphorylates TBX21 at CC 'Tyr-530' and mediates its interaction with GATA3 (By similarity). CC {ECO:0000250|UniProtKB:Q03526, ECO:0000269|PubMed:12186560, CC ECO:0000269|PubMed:12682224, ECO:0000269|PubMed:21725281}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250}; CC -!- SUBUNIT: Homooligomerizes; this association negatively regulates kinase CC activity (By similarity). Interacts with PPIA/CYPA; this interaction CC regulates TCR signal strength via a proline-directed conformational CC switch in ITK. Interacts with THEMIS (By similarity). Interacts with CC FASLG. Interacts with VAV1; this interaction is important for VAV1 CC localization and TCR-induced actin polarization. Interacts with TBX21 CC (By similarity). {ECO:0000250|UniProtKB:Q03526, CC ECO:0000269|PubMed:15308100, ECO:0000269|PubMed:15661896, CC ECO:0000269|PubMed:19807924}. CC -!- INTERACTION: CC Q08881; P04626: ERBB2; NbExp=2; IntAct=EBI-968552, EBI-641062; CC Q08881; P48023: FASLG; NbExp=3; IntAct=EBI-968552, EBI-495538; CC Q08881; P08238: HSP90AB1; NbExp=3; IntAct=EBI-968552, EBI-352572; CC Q08881; Q13094: LCP2; NbExp=4; IntAct=EBI-968552, EBI-346946; CC Q08881; P31947: SFN; NbExp=2; IntAct=EBI-968552, EBI-476295; CC Q08881; P62258: YWHAE; NbExp=2; IntAct=EBI-968552, EBI-356498; CC Q08881; P10686: Plcg1; Xeno; NbExp=2; IntAct=EBI-968552, EBI-520788; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17060314}. Nucleus CC {ECO:0000250|UniProtKB:Q03526}. Note=Localizes in the vicinity of cell CC surface receptors in the plasma membrane after receptor stimulation. CC -!- TISSUE SPECIFICITY: T-cell lines and natural killer cell lines. CC -!- INDUCTION: Through a myriad of surface receptors including the TCR/CD3 CC signaling complex, coreceptors, or chemokine receptors. CC {ECO:0000269|PubMed:8504851, ECO:0000269|PubMed:9701039}. CC -!- DOMAIN: The N-terminal PH domain allows ITK to be recruited to the CC plasma membrane by an activated PI3 kinase. This domain also contains a CC proline-rich region (PRR). The adjoining domain is a SH3 domain, which CC binds to PRR (from itself or from other proteins). Next, a SH2 domain CC is required for binding tyrosine-phosphorylated substrates. In the C- CC terminal region, the kinase domain is required for tyrosine CC phosphorylation. {ECO:0000269|PubMed:10795735}. CC -!- PTM: Phosphorylated at Tyr-512 in the activation loop of the kinase CC domain by LCK. Subsequent autophosphorylation at Tyr-180 leads to the CC kinase activation. The autophosphorylated Tyr-180 lies within the CC substrate binding sequence of the SH3 domain. CC {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:9312162}. CC -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}. CC -!- DISEASE: Lymphoproliferative syndrome 1 (LPFS1) [MIM:613011]: A rare CC immunodeficiency characterized by extreme susceptibility to infection CC with Epstein-Barr virus (EBV). Inadequate immune response to EBV can CC have a fatal outcome. Clinical features include splenomegaly, CC lymphadenopathy, anemia, thrombocytopenia, pancytopenia, recurrent CC infections. There is an increased risk for lymphoma. CC {ECO:0000269|PubMed:19425169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/43329/ITK"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D13720; BAA02873.1; -; mRNA. DR EMBL; L10717; AAA36748.1; -; mRNA. DR EMBL; S65186; AAB28072.2; -; mRNA. DR EMBL; AK312846; BAG35699.1; -; mRNA. DR EMBL; CH471062; EAW61608.1; -; Genomic_DNA. DR EMBL; BC109077; AAI09078.1; -; mRNA. DR EMBL; BC109078; AAI09079.1; -; mRNA. DR CCDS; CCDS4336.1; -. DR PIR; S33253; S33253. DR RefSeq; NP_005537.3; NM_005546.3. DR PDB; 1SM2; X-ray; 2.30 A; A/B=357-620. DR PDB; 1SNU; X-ray; 2.50 A; A/B=357-620. DR PDB; 1SNX; X-ray; 3.20 A; A/B=357-620. DR PDB; 2E6I; NMR; -; A=113-169. DR PDB; 2LMJ; NMR; -; A=171-231. DR PDB; 2YUQ; NMR; -; A=162-239. DR PDB; 3MIY; X-ray; 1.67 A; A/B=357-620. DR PDB; 3MJ1; X-ray; 1.72 A; A=357-620. DR PDB; 3MJ2; X-ray; 1.90 A; A=357-620. DR PDB; 3QGW; X-ray; 2.10 A; A/B=357-620. DR PDB; 3QGY; X-ray; 2.10 A; A/B=357-620. DR PDB; 3T9T; X-ray; 1.65 A; A=354-620. DR PDB; 3V5J; X-ray; 2.59 A; A/B=357-620. DR PDB; 3V5L; X-ray; 1.86 A; A/B/C/D=357-620. DR PDB; 3V8T; X-ray; 2.00 A; A/B=357-620. DR PDB; 3V8W; X-ray; 2.27 A; A/B=357-620. DR PDB; 4HCT; X-ray; 1.48 A; A=354-620. DR PDB; 4HCU; X-ray; 1.43 A; A=354-620. DR PDB; 4HCV; X-ray; 1.48 A; A=354-620. DR PDB; 4KIO; X-ray; 2.18 A; A/B/C/D=357-620. DR PDB; 4L7S; X-ray; 2.03 A; A/B=357-620. DR PDB; 4M0Y; X-ray; 1.70 A; A=354-620. DR PDB; 4M0Z; X-ray; 2.00 A; A=354-620. DR PDB; 4M12; X-ray; 2.15 A; A=354-620. DR PDB; 4M13; X-ray; 1.85 A; A=354-620. DR PDB; 4M14; X-ray; 1.55 A; A=354-620. DR PDB; 4M15; X-ray; 1.52 A; A=354-620. DR PDB; 4MF0; X-ray; 2.67 A; A/B=357-620. DR PDB; 4MF1; X-ray; 2.11 A; A/B=357-620. DR PDB; 4PP9; X-ray; 2.58 A; A/B=357-620. DR PDB; 4PPA; X-ray; 2.67 A; A/B=357-620. DR PDB; 4PPB; X-ray; 2.82 A; A/B=357-620. DR PDB; 4PPC; X-ray; 2.95 A; A/B=357-620. DR PDB; 4PQN; X-ray; 1.71 A; A=357-620. DR PDB; 4QD6; X-ray; 2.45 A; A/B=357-620. DR PDB; 4RFM; X-ray; 2.10 A; A=357-620. DR PDBsum; 1SM2; -. DR PDBsum; 1SNU; -. DR PDBsum; 1SNX; -. DR PDBsum; 2E6I; -. DR PDBsum; 2LMJ; -. DR PDBsum; 2YUQ; -. DR PDBsum; 3MIY; -. DR PDBsum; 3MJ1; -. DR PDBsum; 3MJ2; -. DR PDBsum; 3QGW; -. DR PDBsum; 3QGY; -. DR PDBsum; 3T9T; -. DR PDBsum; 3V5J; -. DR PDBsum; 3V5L; -. DR PDBsum; 3V8T; -. DR PDBsum; 3V8W; -. DR PDBsum; 4HCT; -. DR PDBsum; 4HCU; -. DR PDBsum; 4HCV; -. DR PDBsum; 4KIO; -. DR PDBsum; 4L7S; -. DR PDBsum; 4M0Y; -. DR PDBsum; 4M0Z; -. DR PDBsum; 4M12; -. DR PDBsum; 4M13; -. DR PDBsum; 4M14; -. DR PDBsum; 4M15; -. DR PDBsum; 4MF0; -. DR PDBsum; 4MF1; -. DR PDBsum; 4PP9; -. DR PDBsum; 4PPA; -. DR PDBsum; 4PPB; -. DR PDBsum; 4PPC; -. DR PDBsum; 4PQN; -. DR PDBsum; 4QD6; -. DR PDBsum; 4RFM; -. DR AlphaFoldDB; Q08881; -. DR BMRB; Q08881; -. DR SMR; Q08881; -. DR BioGRID; 109907; 55. DR CORUM; Q08881; -. DR DIP; DIP-29974N; -. DR FunCoup; Q08881; 1866. DR IntAct; Q08881; 45. DR MINT; Q08881; -. DR STRING; 9606.ENSP00000398655; -. DR BindingDB; Q08881; -. DR ChEMBL; CHEMBL2959; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q08881; -. DR GuidetoPHARMACOLOGY; 2046; -. DR GlyGen; Q08881; 1 site. DR iPTMnet; Q08881; -. DR PhosphoSitePlus; Q08881; -. DR BioMuta; ITK; -. DR DMDM; 585361; -. DR CPTAC; CPTAC-2862; -. DR CPTAC; CPTAC-2863; -. DR jPOST; Q08881; -. DR MassIVE; Q08881; -. DR PaxDb; 9606-ENSP00000398655; -. DR PeptideAtlas; Q08881; -. DR ProteomicsDB; 58650; -. DR Pumba; Q08881; -. DR ABCD; Q08881; 4 sequenced antibodies. DR Antibodypedia; 16533; 527 antibodies from 42 providers. DR DNASU; 3702; -. DR Ensembl; ENST00000422843.8; ENSP00000398655.4; ENSG00000113263.15. DR GeneID; 3702; -. DR KEGG; hsa:3702; -. DR MANE-Select; ENST00000422843.8; ENSP00000398655.4; NM_005546.4; NP_005537.3. DR UCSC; uc003lwo.2; human. DR AGR; HGNC:6171; -. DR ClinPGx; PA29968; -. DR CTD; 3702; -. DR DisGeNET; 3702; -. DR GeneCards; ITK; -. DR HGNC; HGNC:6171; ITK. DR HPA; ENSG00000113263; Tissue enriched (lymphoid). DR MalaCards; ITK; -. DR MIM; 186973; gene. DR MIM; 613011; phenotype. DR OpenTargets; ENSG00000113263; -. DR Orphanet; 538963; Combined immunodeficiency due to ITK deficiency. DR VEuPathDB; HostDB:ENSG00000113263; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000158850; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q08881; -. DR OMA; GYWLEKT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q08881; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q08881; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q08881; -. DR Reactome; R-HSA-202433; Generation of second messenger molecules. DR Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization. DR SignaLink; Q08881; -. DR SIGNOR; Q08881; -. DR Agora; ENSG00000113263; -. DR BioGRID-ORCS; 3702; 17 hits in 1184 CRISPR screens. DR CD-CODE; F345034F; Signaling cluster. DR ChiTaRS; ITK; human. DR EvolutionaryTrace; Q08881; -. DR GeneWiki; ITK_(gene); -. DR GenomeRNAi; 3702; -. DR Pharos; Q08881; Tclin. DR PRO; PR:Q08881; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q08881; protein. DR Bgee; ENSG00000113263; Expressed in granulocyte and 129 other cell types or tissues. DR ExpressionAtlas; Q08881; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB. DR GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central. DR GO; GO:0006968; P:cellular defense response; TAS:ProtInc. DR GO; GO:0046629; P:gamma-delta T cell activation; ISS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0001865; P:NK T cell differentiation; IBA:GO_Central. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042110; P:T cell activation; TAS:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB. DR CDD; cd01238; PH_Btk; 1. DR CDD; cd05112; PTKc_Itk; 1. DR CDD; cd10396; SH2_Tec_Itk; 1. DR CDD; cd11908; SH3_ITK; 1. DR FunFam; 1.10.510.10:FF:000052; Tyrosine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000244; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000176; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000061; Tyrosine-protein kinase; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042785; ITK_PTKc. DR InterPro; IPR035583; ITK_SH3. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001562; Znf_Btk_motif. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF00779; BTK; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00107; BTK; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. DR PROSITE; PS51113; ZF_BTK; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Cytoplasm; KW Direct protein sequencing; Disease variant; Immunity; Kinase; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..620 FT /note="Tyrosine-protein kinase ITK/TSK" FT /id="PRO_0000088106" FT DOMAIN 4..111 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 171..231 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 239..338 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 363..615 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 113..149 FT /note="Btk-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT ACT_SITE 482 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 133 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 143 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 369..377 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 391 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 180 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12573241" FT MOD_RES 512 FT /note="Phosphotyrosine; by LCK" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 565 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT VARIANT 19 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1753502279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041710" FT VARIANT 23 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041711" FT VARIANT 193 FT /note="R -> Q (in dbSNP:rs17054374)" FT /id="VAR_051696" FT VARIANT 335 FT /note="R -> W (in LPFS1; shows nearly undetectable mutant FT ITK protein consistent with severe protein instability; FT dbSNP:rs121908191)" FT /evidence="ECO:0000269|PubMed:19425169" FT /id="VAR_063424" FT VARIANT 451 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs779372373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041712" FT VARIANT 581 FT /note="R -> W (in dbSNP:rs34482255)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041713" FT VARIANT 587 FT /note="V -> I (in dbSNP:rs56005928)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041714" FT MUTAGEN 288 FT /note="P->G: Complete loss of interaction with PPIA/CYPA." FT /evidence="ECO:0000269|PubMed:15308100" FT CONFLICT 171..172 FT /note="PE -> GS (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 331 FT /note="V -> W (in Ref. 2; AAB28072)" FT /evidence="ECO:0000305" FT STRAND 127..133 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 148..152 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 171..173 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 175..180 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 197..205 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 208..212 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 218..221 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 226..228 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 360..362 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 363..371 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:4KIO" FT STRAND 376..382 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 383..385 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 386..393 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 395..397 FT /evidence="ECO:0007829|PDB:3T9T" FT HELIX 400..411 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 421..425 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 427..436 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 443..448 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 449..452 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 456..475 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 485..487 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 496..498 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 503..506 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 510..513 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 522..524 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 527..532 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 537..552 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:4PQN" FT TURN 558..561 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 564..572 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 581..583 FT /evidence="ECO:0007829|PDB:3V8W" FT HELIX 585..594 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 605..617 FT /evidence="ECO:0007829|PDB:4HCU" SQ SEQUENCE 620 AA; 71831 MW; DAE396BD2309319D CRC64; MNNFILLEEQ LIKKSQQKRR TSPSNFKVRF FVLTKASLAY FEDRHGKKRT LKGSIELSRI KCVEIVKSDI SIPCHYKYPF QVVHDNYLLY VFAPDRESRQ RWVLALKEET RNNNSLVPKY HPNFWMDGKW RCCSQLEKLA TGCAQYDPTK NASKKPLPPT PEDNRRPLWE PEETVVIALY DYQTNDPQEL ALRRNEEYCL LDSSEIHWWR VQDRNGHEGY VPSSYLVEKS PNNLETYEWY NKSISRDKAE KLLLDTGKEG AFMVRDSRTA GTYTVSVFTK AVVSENNPCI KHYHIKETND NPKRYYVAEK YVFDSIPLLI NYHQHNGGGL VTRLRYPVCF GRQKAPVTAG LRYGKWVIDP SELTFVQEIG SGQFGLVHLG YWLNKDKVAI KTIREGAMSE EDFIEEAEVM MKLSHPKLVQ LYGVCLEQAP ICLVFEFMEH GCLSDYLRTQ RGLFAAETLL GMCLDVCEGM AYLEEACVIH RDLAARNCLV GENQVIKVSD FGMTRFVLDD QYTSSTGTKF PVKWASPEVF SFSRYSSKSD VWSFGVLMWE VFSEGKIPYE NRSNSEVVED ISTGFRLYKP RLASTHVYQI MNHCWKERPE DRPAFSRLLR QLAEIAESGL // ID JAK3_HUMAN Reviewed; 1124 AA. AC P52333; Q13259; Q13260; Q13611; Q8N1E8; Q99699; Q9Y6S2; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 2. DT 28-JAN-2026, entry version 245. DE RecName: Full=Tyrosine-protein kinase JAK3 {ECO:0000305}; DE EC=2.7.10.2; DE AltName: Full=Janus kinase 3; DE Short=JAK-3; DE AltName: Full=Leukocyte janus kinase; DE Short=L-JAK; GN Name=JAK3 {ECO:0000312|HGNC:HGNC:6193}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=8022790; DOI=10.1073/pnas.91.14.6374; RA Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.-Q., Lal B.K., RA Lloyd A.R., Kelvin D.J., Staples J.E., Ortaldo J.R., O'Shea J.J.; RT "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase RT expressed in natural killer cells and activated leukocytes."; RL Proc. Natl. Acad. Sci. U.S.A. 91:6374-6378(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING (ISOFORM RP 2). RX PubMed=7559633; DOI=10.1074/jbc.270.42.25028; RA Lai K.S., Jin Y., Graham D.K., Witthuhn B.A., Ihle J.N., Liu E.T.; RT "A kinase-deficient splice variant of the human JAK3 is expressed in RT hematopoietic and epithelial cancer cells."; RL J. Biol. Chem. 270:25028-25036(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=8921370; DOI=10.1006/geno.1996.0520; RA Riedy M.C., Dutra A.S., Blake T.B., Modi W., Lal B.K., Davis J., Bosse A., RA O'Shea J.J., Johnston J.A.; RT "Genomic sequence, organization, and chromosomal localization of human RT JAK3."; RL Genomics 37:57-61(1996). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-132 AND ILE-722. RG SeattleSNPs variation discovery resource; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 36-191. RX PubMed=8662778; DOI=10.1074/jbc.271.24.13976; RA Verbsky J.W., Bach E.A., Fang Y.F., Yang L., Randolph D.A., Fields L.E.; RT "Expression of Janus kinase 3 in human endothelial and other non-lymphoid RT and non-myeloid cells."; RL J. Biol. Chem. 271:13976-13980(1996). RN [9] RP FUNCTION IN IL2 SIGNALING PATHWAY. RX PubMed=8022485; DOI=10.1038/370151a0; RA Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., RA Ortaldo J.R., McVicar D.W., O'Shea J.J.; RT "Phosphorylation and activation of the Jak-3 Janus kinase in response to RT interleukin-2."; RL Nature 370:151-153(1994). RN [10] RP FUNCTION IN IL7 SIGNALING PATHWAY. RX PubMed=7662955; RA Sharfe N., Dadi H.K., Roifman C.M.; RT "JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of RT phosphatidylinositol-3' kinase."; RL Blood 86:2077-2085(1995). RN [11] RP TISSUE SPECIFICITY. RX PubMed=7535338; DOI=10.1084/jem.181.4.1425; RA Musso T., Johnston J.A., Linnekin D., Varesio L., Rowe T.K., O'Shea J.J., RA McVicar D.W.; RT "Regulation of JAK3 expression in human monocytes: phosphorylation in RT response to interleukins 2, 4, and 7."; RL J. Exp. Med. 181:1425-1431(1995). RN [12] RP INTERACTION WITH STAM2. RC TISSUE=Fetal brain; RX PubMed=10899310; DOI=10.1016/s0014-5793(00)01760-9; RA Endo K., Takeshita T., Kasai H., Sasaki Y., Tanaka N., Asao H., Kikuchi K., RA Yamada M., Chenb M., O'Shea J.J., Sugamura K.; RT "STAM2, a new member of the STAM family, binding to the Janus kinases."; RL FEBS Lett. 477:55-61(2000). RN [13] RP INTERACTION WITH SHB. RX PubMed=12200137; DOI=10.1016/s0006-291x(02)02016-8; RA Lindholm C.K.; RT "IL-2 receptor signaling through the Shb adapter protein in T and NK RT cells."; RL Biochem. Biophys. Res. Commun. 296:929-936(2002). RN [14] RP FUNCTION IN CYTOKINE SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION AT RP TYR-980 AND TYR-981 BY PTPN2. RX PubMed=11909529; DOI=10.1016/s0960-9822(02)00697-8; RA Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J.; RT "The T cell protein tyrosine phosphatase is a negative regulator of janus RT family kinases 1 and 3."; RL Curr. Biol. 12:446-453(2002). RN [15] RP DOMAIN. RX PubMed=12351625; DOI=10.1074/jbc.m205156200; RA Saharinen P., Silvennoinen O.; RT "The pseudokinase domain is required for suppression of basal activity of RT Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of RT signal transduction."; RL J. Biol. Chem. 277:47954-47963(2002). RN [16] RP PHOSPHORYLATION AT TYR-785, AND MUTAGENESIS OF TYR-785. RX PubMed=15121872; DOI=10.1128/mcb.24.10.4557-4570.2004; RA Kurzer J.H., Argetsinger L.S., Zhou Y.J., Kouadio J.L., O'Shea J.J., RA Carter-Su C.; RT "Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation RT of JAK2 by SH2-B beta."; RL Mol. Cell. Biol. 24:4557-4570(2004). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [18] RP PHOSPHORYLATION AT TYR-904 AND TYR-939, AND MUTAGENESIS OF LYS-855; TYR-904 RP AND TYR-939. RX PubMed=18250158; DOI=10.1128/mcb.01789-07; RA Cheng H., Ross J.A., Frost J.A., Kirken R.A.; RT "Phosphorylation of human Jak3 at tyrosines 904 and 939 positively RT regulates its activity."; RL Mol. Cell. Biol. 28:2271-2282(2008). RN [19] RP REVIEW ON FUNCTION. RX PubMed=19290934; DOI=10.1111/j.1600-065x.2008.00754.x; RA Ghoreschi K., Laurence A., O'Shea J.J.; RT "Janus kinases in immune cell signaling."; RL Immunol. Rev. 228:273-287(2009). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [22] RP FUNCTION IN IL15 SIGNALING PATHWAY. RX PubMed=20440074; DOI=10.1172/jci41344; RA Malamut G., El Machhour R., Montcuquet N., Martin-Lanneree S., RA Dusanter-Fourt I., Verkarre V., Mention J.J., Rahmi G., Kiyono H., RA Butz E.A., Brousse N., Cellier C., Cerf-Bensussan N., Meresse B.; RT "IL-15 triggers an antiapoptotic pathway in human intraepithelial RT lymphocytes that is a potential new target in celiac disease-associated RT inflammation and lymphomagenesis."; RL J. Clin. Invest. 120:2131-2143(2010). RN [23] RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 814-1103 IN COMPLEX WITH RP STAUROSPORINE ANALOG AFN941, AND PHOSPHORYLATION AT TYR-980 AND TYR-981. RX PubMed=15831699; DOI=10.1182/blood-2005-02-0707; RA Boggon T.J., Li Y., Manley P.W., Eck M.J.; RT "Crystal structure of the Jak3 kinase domain in complex with a RT staurosporine analog."; RL Blood 106:996-1002(2005). RN [24] RP VARIANT T(-)B(+)NK(-) SCID CYS-100. RX PubMed=7659163; DOI=10.1038/377065a0; RA Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F., RA Ugazio A.G., Johnston J.A., Candotti F., O'Shea J.J., Vezzoni P., RA Notarangelo L.D.; RT "Mutations of Jak-3 gene in patients with autosomal severe combined immune RT deficiency (SCID)."; RL Nature 377:65-68(1995). RN [25] RP VARIANTS T(-)B(+)NK(-) SCID GLY-481; 586-LEU--MET-592 DEL AND ARG-759. RX PubMed=9354668; RA Candotti F., Oakes S.A., Johnston J.A., Giliani S., Schumacher R.F., RA Mella P., Fiorini M., Ugazio A.G., Badolato R., Notarangelo L.D., Bozzi F., RA Macchi P., Strina D., Vezzoni P., Blaese R.M., O'Shea J.J., Villa A.; RT "Structural and functional basis for JAK3-deficient severe combined RT immunodeficiency."; RL Blood 90:3996-4003(1997). RN [26] RP VARIANT T(-)B(+)NK(-) SCID TRP-582. RX PubMed=9753072; DOI=10.1111/j.1365-2141.1998.tb08990.x; RA Bozzi F., Lefranc G., Villa A., Badolato R., Schumacher R.F., Khalil G., RA Loiselet J., Bresciani S., O'Shea J.J., Vezzoni P., Notarangelo L.D., RA Candotti F.; RT "Molecular and biochemical characterization of JAK3 deficiency in a patient RT with severe combined immunodeficiency over 20 years after bone marrow RT transplantation: implications for treatment."; RL Br. J. Haematol. 102:1363-1366(1998). RN [27] RP VARIANTS T(-)B(+)NK(-) SCID ARG-151 AND SER-910, AND VARIANT ILE-722. RX PubMed=10982185; DOI=10.1007/s004390051012; RA Schumacher R.F., Mella P., Badolato R., Fiorini M., Savoldi G., Giliani S., RA Villa A., Candotti F., Tampalini A., O'Shea J.J., Notarangelo L.D.; RT "Complete genomic organization of the human JAK3 gene and mutation analysis RT in severe combined immunodeficiency by single-strand conformation RT polymorphism."; RL Hum. Genet. 106:73-79(2000). RN [28] RP VARIANTS T(-)B(+)NK(-) SCID ALA-58 DEL; GLU-169 AND SER-589, AND VARIANT RP ILE-722. RX PubMed=14615376; DOI=10.1182/blood-2003-06-2104; RA Roberts J.L., Lengi A., Brown S.M., Chen M., Zhou Y.-J., O'Shea J.J., RA Buckley R.H.; RT "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular RT analyses of 10 patients and outcomes of stem cell transplantation."; RL Blood 103:2009-2018(2004). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-12; HIS-40; THR-132; ARG-151; VAL-521; RP PRO-527; PHE-688 AND ILE-722. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine kinase involved in various processes CC such as cell growth, development, or differentiation. Mediates CC essential signaling events in both innate and adaptive immunity and CC plays a crucial role in hematopoiesis during T-cells development. In CC the cytoplasm, plays a pivotal role in signal transduction via its CC association with type I receptors sharing the common subunit gamma such CC as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to CC cell surface receptors, phosphorylates specific tyrosine residues on CC the cytoplasmic tails of the receptor, creating docking sites for STATs CC proteins. Subsequently, phosphorylates the STATs proteins once they are CC recruited to the receptor. Phosphorylated STATs then form homodimer or CC heterodimers and translocate to the nucleus to activate gene CC transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 CC molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits CC inducing the tyrosine phosphorylation of both receptor subunits on CC their cytoplasmic domain. Then, STAT5A and STAT5B are recruited, CC phosphorylated and activated by JAK1 and JAK3. Once activated, CC dimerized STAT5 translocates to the nucleus and promotes the CC transcription of specific target genes in a cytokine-specific fashion. CC {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:20440074, CC ECO:0000269|PubMed:7662955, ECO:0000269|PubMed:8022485}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Interacts with STAM2 and MYO18A (PubMed:10899310). Interacts CC with SHB (PubMed:12200137). Interacts with CD69 (By similarity). CC {ECO:0000250|UniProtKB:Q62137, ECO:0000269|PubMed:10899310, CC ECO:0000269|PubMed:12200137, ECO:0000269|PubMed:15831699}. CC -!- INTERACTION: CC P52333; Q969H0: FBXW7; NbExp=5; IntAct=EBI-518246, EBI-359574; CC P52333; Q07666: KHDRBS1; NbExp=2; IntAct=EBI-518246, EBI-1364; CC P52333; Q9UNF1: MAGED2; NbExp=5; IntAct=EBI-518246, EBI-725832; CC P52333; P55209: NAP1L1; NbExp=4; IntAct=EBI-518246, EBI-356392; CC P52333; Q13485: SMAD4; NbExp=3; IntAct=EBI-518246, EBI-347263; CC P52333; P51532: SMARCA4; NbExp=5; IntAct=EBI-518246, EBI-302489; CC -!- SUBCELLULAR LOCATION: Endomembrane system {ECO:0000250}; Peripheral CC membrane protein {ECO:0000250}. Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=2; Synonyms=JAK3S, Spleen-JAK3; CC IsoId=P52333-1; Sequence=Displayed; CC Name=1; Synonyms=JAK3B, Breast-JAK3; CC IsoId=P52333-2; Sequence=VSP_004989; CC Name=3; CC IsoId=P52333-4; Sequence=VSP_054165, VSP_054166; CC -!- TISSUE SPECIFICITY: In NK cells and an NK-like cell line but not in CC resting T-cells or in other tissues. The S-form is more commonly seen CC in hematopoietic lines, whereas the B-form is detected in cells both of CC hematopoietic and epithelial origins. {ECO:0000269|PubMed:7535338}. CC -!- DOMAIN: Possesses two phosphotransferase domains. The second one CC probably contains the catalytic domain (By similarity), while the CC presence of slight differences suggest a different role for domain 1. CC {ECO:0000250, ECO:0000269|PubMed:12351625}. CC -!- PTM: Tyrosine phosphorylated in response to IL-2 and IL-4. CC Dephosphorylation of Tyr-980 and Tyr-981 by PTPN2 negatively regulates CC cytokine-mediated signaling (Probable). {ECO:0000305|PubMed:11909529, CC ECO:0000305|PubMed:15121872, ECO:0000305|PubMed:15831699, CC ECO:0000305|PubMed:18250158}. CC -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-cell- CC negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) CC [MIM:600802]: A form of severe combined immunodeficiency (SCID), a CC genetically and clinically heterogeneous group of rare congenital CC disorders characterized by impairment of both humoral and cell-mediated CC immunity, leukopenia, and low or absent antibody levels. Patients CC present in infancy recurrent, persistent infections by opportunistic CC organisms. The common characteristic of all types of SCID is absence of CC T-cell-mediated cellular immunity due to a defect in T-cell CC development. {ECO:0000269|PubMed:10982185, ECO:0000269|PubMed:14615376, CC ECO:0000269|PubMed:7659163, ECO:0000269|PubMed:9354668, CC ECO:0000269|PubMed:9753072}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 1]: May be inactive as it lacks some part of CC the kinase domain. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. JAK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC50227.1; Type=Miscellaneous discrepancy; Note=Wrong choice of CDS. Was erroneously described as an isoform JAK3M while it is a fragmentary mRNA of INSL3.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41032/JAK3"; CC -!- WEB RESOURCE: Name=JAK3base; Note=JAK3 mutation db; CC URL="https://databases.lovd.nl/shared/genes/JAK3"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U09607; AAA19626.1; -; mRNA. DR EMBL; U31601; AAC50226.1; -; mRNA. DR EMBL; U31602; AAC50227.1; ALT_SEQ; mRNA. DR EMBL; U70065; AAC50950.1; -; Genomic_DNA. DR EMBL; AF513860; AAM44860.1; -; Genomic_DNA. DR EMBL; AC007201; AAD22741.1; -; Genomic_DNA. DR EMBL; CH471106; EAW84639.1; -; Genomic_DNA. DR EMBL; BC028068; AAH28068.1; -; mRNA. DR EMBL; U57096; AAC50542.1; -; mRNA. DR CCDS; CCDS12366.1; -. [P52333-1] DR PIR; A55747; A55747. DR RefSeq; NP_000206.2; NM_000215.3. [P52333-1] DR RefSeq; NP_001427368.1; NM_001440439.1. [P52333-1] DR PDB; 1YVJ; X-ray; 2.55 A; A=814-1103. DR PDB; 3LXK; X-ray; 2.00 A; A=806-1124. DR PDB; 3LXL; X-ray; 1.74 A; A=806-1124. DR PDB; 3PJC; X-ray; 2.20 A; A=812-1124. DR PDB; 3ZC6; X-ray; 2.42 A; A/B/C/D=813-1100. DR PDB; 3ZEP; X-ray; 2.35 A; A/B/C/D=813-1047, A/B/C/D=813-1100. DR PDB; 4HVD; X-ray; 1.85 A; A=811-1124. DR PDB; 4HVG; X-ray; 2.75 A; A=811-1124. DR PDB; 4HVH; X-ray; 2.30 A; A=811-1124. DR PDB; 4HVI; X-ray; 2.40 A; A=811-1124. DR PDB; 4I6Q; X-ray; 1.85 A; A=811-1124. DR PDB; 4QPS; X-ray; 1.80 A; A/C=811-1103. DR PDB; 4QT1; X-ray; 2.40 A; A=811-1124. DR PDB; 4RIO; X-ray; 2.69 A; A=810-1100. DR PDB; 4V0G; X-ray; 3.00 A; A/B=816-1098. DR PDB; 4Z16; X-ray; 2.90 A; A/B/C/D=811-1124. DR PDB; 5LWM; X-ray; 1.55 A; A=812-1103. DR PDB; 5LWN; X-ray; 1.60 A; A=812-1103. DR PDB; 5TOZ; X-ray; 1.98 A; A=812-1124. DR PDB; 5TTS; X-ray; 2.34 A; A=812-1124. DR PDB; 5TTU; X-ray; 1.72 A; A=812-1124. DR PDB; 5TTV; X-ray; 1.93 A; A=812-1124. DR PDB; 5VO6; X-ray; 2.65 A; A=812-1100. DR PDB; 5W86; X-ray; 2.61 A; A/B/C/D=814-1100. DR PDB; 5WFJ; X-ray; 2.48 A; A=810-1100. DR PDB; 6AAK; X-ray; 2.67 A; A/B/C/D=814-1100. DR PDB; 6DA4; X-ray; 2.90 A; A=812-1124. DR PDB; 6DB3; X-ray; 1.97 A; A=812-1124. DR PDB; 6DB4; X-ray; 1.66 A; A=812-1124. DR PDB; 6DUD; X-ray; 1.66 A; A=812-1124. DR PDB; 6GL9; X-ray; 1.70 A; A/B=812-1103. DR PDB; 6GLA; X-ray; 1.92 A; A/B=812-1103. DR PDB; 6GLB; X-ray; 2.00 A; A/B=812-1103. DR PDB; 6HZV; X-ray; 2.46 A; A/B/C/D=815-1099. DR PDB; 6NY4; X-ray; 2.33 A; A=810-1100. DR PDB; 7APF; X-ray; 1.95 A; A/B=812-1103. DR PDB; 7APG; X-ray; 2.40 A; A/B/C/D=812-1103. DR PDB; 7C3N; X-ray; 1.98 A; A=812-1124. DR PDB; 7Q6H; X-ray; 1.75 A; AAA=806-1124. DR PDB; 7UYV; X-ray; 2.15 A; A/B/C/D=810-1100. DR PDB; 8EXM; X-ray; 2.35 A; D=973-988. DR PDB; 9R5Z; X-ray; 1.80 A; A/B=812-1103. DR PDBsum; 1YVJ; -. DR PDBsum; 3LXK; -. DR PDBsum; 3LXL; -. DR PDBsum; 3PJC; -. DR PDBsum; 3ZC6; -. DR PDBsum; 3ZEP; -. DR PDBsum; 4HVD; -. DR PDBsum; 4HVG; -. DR PDBsum; 4HVH; -. DR PDBsum; 4HVI; -. DR PDBsum; 4I6Q; -. DR PDBsum; 4QPS; -. DR PDBsum; 4QT1; -. DR PDBsum; 4RIO; -. DR PDBsum; 4V0G; -. DR PDBsum; 4Z16; -. DR PDBsum; 5LWM; -. DR PDBsum; 5LWN; -. DR PDBsum; 5TOZ; -. DR PDBsum; 5TTS; -. DR PDBsum; 5TTU; -. DR PDBsum; 5TTV; -. DR PDBsum; 5VO6; -. DR PDBsum; 5W86; -. DR PDBsum; 5WFJ; -. DR PDBsum; 6AAK; -. DR PDBsum; 6DA4; -. DR PDBsum; 6DB3; -. DR PDBsum; 6DB4; -. DR PDBsum; 6DUD; -. DR PDBsum; 6GL9; -. DR PDBsum; 6GLA; -. DR PDBsum; 6GLB; -. DR PDBsum; 6HZV; -. DR PDBsum; 6NY4; -. DR PDBsum; 7APF; -. DR PDBsum; 7APG; -. DR PDBsum; 7C3N; -. DR PDBsum; 7Q6H; -. DR PDBsum; 7UYV; -. DR PDBsum; 8EXM; -. DR PDBsum; 9R5Z; -. DR AlphaFoldDB; P52333; -. DR SMR; P52333; -. DR BioGRID; 109921; 125. DR CORUM; P52333; -. DR DIP; DIP-274N; -. DR FunCoup; P52333; 855. DR IntAct; P52333; 97. DR MINT; P52333; -. DR STRING; 9606.ENSP00000432511; -. DR BindingDB; P52333; -. DR ChEMBL; CHEMBL2148; -. DR DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one. DR DrugBank; DB14973; Abrocitinib. DR DrugBank; DB11817; Baricitinib. DR DrugBank; DB15499; Cerdulatinib. DR DrugBank; DB12566; Decernotinib. DR DrugBank; DB16133; Delgocitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16191; Ifidancitinib. DR DrugBank; DB11763; Momelotinib. DR DrugBank; DB11697; Pacritinib. DR DrugBank; DB11708; Peficitinib. DR DrugBank; DB06321; R-348. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB08877; Ruxolitinib. DR DrugBank; DB08895; Tofacitinib. DR DrugBank; DB15035; Zanubrutinib. DR DrugBank; DB17064; ZM-39923. DR DrugCentral; P52333; -. DR GuidetoPHARMACOLOGY; 2049; -. DR GlyGen; P52333; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P52333; -. DR PhosphoSitePlus; P52333; -. DR BioMuta; JAK3; -. DR DMDM; 50403745; -. DR CPTAC; CPTAC-2905; -. DR CPTAC; CPTAC-2906; -. DR jPOST; P52333; -. DR MassIVE; P52333; -. DR PaxDb; 9606-ENSP00000391676; -. DR PeptideAtlas; P52333; -. DR ProteomicsDB; 56482; -. [P52333-1] DR ProteomicsDB; 56483; -. [P52333-2] DR ProteomicsDB; 71591; -. DR Antibodypedia; 35352; 492 antibodies from 38 providers. DR DNASU; 3718; -. DR Ensembl; ENST00000458235.7; ENSP00000391676.1; ENSG00000105639.21. [P52333-1] DR Ensembl; ENST00000527670.5; ENSP00000432511.1; ENSG00000105639.21. [P52333-1] DR Ensembl; ENST00000534444.1; ENSP00000436421.1; ENSG00000105639.21. [P52333-2] DR GeneID; 3718; -. DR KEGG; hsa:3718; -. DR MANE-Select; ENST00000458235.7; ENSP00000391676.1; NM_000215.4; NP_000206.2. DR UCSC; uc002nhn.5; human. [P52333-1] DR AGR; HGNC:6193; -. DR CIViC; 3718; 3 evidence items across 8 molecular profiles. DR ClinPGx; PA29990; -. DR CTD; 3718; -. DR DisGeNET; 3718; -. DR GeneCards; JAK3; -. DR HGNC; HGNC:6193; JAK3. DR HPA; ENSG00000105639; Tissue enhanced (lymphoid). DR MalaCards; JAK3; -. DR MIM; 600173; gene. DR MIM; 600802; phenotype. DR OpenTargets; ENSG00000105639; -. DR Orphanet; 35078; T-B+ severe combined immunodeficiency due to JAK3 deficiency. DR VEuPathDB; HostDB:ENSG00000105639; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000161827; -. DR HOGENOM; CLU_008155_1_0_1; -. DR InParanoid; P52333; -. DR OMA; MENQCHG; -. DR OrthoDB; 1915767at2759; -. DR PAN-GO; P52333; 10 GO annotations based on evolutionary models. DR PhylomeDB; P52333; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P52333; -. DR Reactome; R-HSA-1266695; Interleukin-7 signaling. DR Reactome; R-HSA-201556; Signaling by ALK. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-8854691; Interleukin-20 family signaling. DR Reactome; R-HSA-8983432; Interleukin-15 signaling. DR Reactome; R-HSA-8985947; Interleukin-9 signaling. DR Reactome; R-HSA-9020558; Interleukin-2 signaling. DR Reactome; R-HSA-9020958; Interleukin-21 signaling. DR Reactome; R-HSA-912526; Interleukin receptor SHC signaling. DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR SignaLink; P52333; -. DR SIGNOR; P52333; -. DR Agora; ENSG00000105639; -. DR BioGRID-ORCS; 3718; 15 hits in 1191 CRISPR screens. DR EvolutionaryTrace; P52333; -. DR GeneWiki; Janus_kinase_3; -. DR GenomeRNAi; 3718; -. DR Pharos; P52333; Tclin. DR PRO; PR:P52333; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P52333; protein. DR Bgee; ENSG00000105639; Expressed in granulocyte and 150 other cell types or tissues. DR ExpressionAtlas; P52333; baseline and differential. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IC:UniProt. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0005768; C:endosome; TAS:Reactome. DR GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProt. DR GO; GO:0019897; C:extrinsic component of plasma membrane; IC:UniProt. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005131; F:growth hormone receptor binding; IBA:GO_Central. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProt. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IBA:GO_Central. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central. DR GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; ISS:BHF-UCL. DR GO; GO:0060397; P:growth hormone receptor signaling pathway via JAK-STAT; IBA:GO_Central. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0035723; P:interleukin-15-mediated signaling pathway; IDA:UniProt. DR GO; GO:0038110; P:interleukin-2-mediated signaling pathway; IDA:UniProt. DR GO; GO:0035771; P:interleukin-4-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0038111; P:interleukin-7-mediated signaling pathway; IDA:UniProt. DR GO; GO:0038113; P:interleukin-9-mediated signaling pathway; IDA:UniProt. DR GO; GO:0035556; P:intracellular signal transduction; ISS:BHF-UCL. DR GO; GO:0002731; P:negative regulation of dendritic cell cytokine production; ISS:BHF-UCL. DR GO; GO:0010561; P:negative regulation of glycoprotein biosynthetic process; ISS:BHF-UCL. DR GO; GO:0032693; P:negative regulation of interleukin-10 production; ISS:BHF-UCL. DR GO; GO:0032695; P:negative regulation of interleukin-12 production; ISS:BHF-UCL. DR GO; GO:0050868; P:negative regulation of T cell activation; ISS:BHF-UCL. DR GO; GO:0045626; P:negative regulation of T-helper 1 cell differentiation; ISS:BHF-UCL. DR GO; GO:2000329; P:negative regulation of T-helper 17 cell lineage commitment; IDA:UniProt. DR GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central. DR GO; GO:0046425; P:regulation of receptor signaling pathway via JAK-STAT; TAS:UniProtKB. DR GO; GO:0070232; P:regulation of T cell apoptotic process; ISS:BHF-UCL. DR GO; GO:0070672; P:response to interleukin-15; TAS:BHF-UCL. DR GO; GO:0070669; P:response to interleukin-2; TAS:BHF-UCL. DR GO; GO:0070670; P:response to interleukin-4; IDA:BHF-UCL. DR GO; GO:0071104; P:response to interleukin-9; TAS:BHF-UCL. DR GO; GO:0043029; P:T cell homeostasis; ISS:BHF-UCL. DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; TAS:UniProtKB. DR CDD; cd14208; PTK_Jak3_rpt1; 1. DR CDD; cd05081; PTKc_Jak3_rpt2; 1. DR CDD; cd10380; SH2_Jak3; 1. DR FunFam; 1.10.510.10:FF:000110; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000084; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000135; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000073; Tyrosine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000114; Tyrosine-protein kinase JAK2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR019749; Band_41_domain. DR InterPro; IPR000299; FERM_domain. DR InterPro; IPR041155; FERM_F1. DR InterPro; IPR041046; FERM_F2. DR InterPro; IPR051286; JAK. DR InterPro; IPR041381; JAK1-3/TYK2_PHL_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2. DR InterPro; IPR020775; Tyr_kinase_non-rcpt_Jak3. DR PANTHER; PTHR45807; TYROSINE-PROTEIN KINASE HOPSCOTCH; 1. DR PANTHER; PTHR45807:SF3; TYROSINE-PROTEIN KINASE JAK3; 1. DR Pfam; PF18379; FERM_F1; 1. DR Pfam; PF18377; FERM_F2; 1. DR Pfam; PF17887; Jak1_Phl; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 2. DR Pfam; PF21990; SH2_1; 1. DR PIRSF; PIRSF000636; TyrPK_Jak; 1. DR PRINTS; PR01823; JANUSKINASE. DR PRINTS; PR01826; JANUSKINASE3. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00295; B41; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00219; TyrKc; 2. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR SUPFAM; SSF55550; SH2 domain; 1. DR PROSITE; PS50057; FERM_3; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Alternative splicing; ATP-binding; KW Cytoplasm; Disease variant; Immunity; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; SCID; SH2 domain; Transferase; KW Tyrosine-protein kinase. FT CHAIN 1..1124 FT /note="Tyrosine-protein kinase JAK3" FT /id="PRO_0000088115" FT DOMAIN 24..356 FT /note="FERM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00084" FT DOMAIN 375..475 FT /note="SH2; atypical" FT DOMAIN 521..781 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 822..1111 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..223 FT /note="Interaction with cytokine/interferon/growth hormone FT receptors" FT /evidence="ECO:0000250" FT ACT_SITE 949 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 828..836 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 855 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 17 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62137" FT MOD_RES 785 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15121872" FT MOD_RES 904 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:18250158" FT MOD_RES 939 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:18250158" FT MOD_RES 980 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15831699" FT MOD_RES 981 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15831699" FT VAR_SEQ 597..619 FT /note="TMVQEFVHLGAIDMYLRKRGHLV -> ESPPPTHPTPASPKSRLFFPPLF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_054165" FT VAR_SEQ 620..1124 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_054166" FT VAR_SEQ 1071..1124 FT /note="HELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLS FT FS -> SAAGLASVSQSVDWAGVSGKPAGA (in isoform 1)" FT /evidence="ECO:0000303|PubMed:7559633" FT /id="VSP_004989" FT VARIANT 12 FT /note="P -> L (in dbSNP:rs56061056)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041722" FT VARIANT 40 FT /note="R -> H (in dbSNP:rs56384680)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041723" FT VARIANT 58 FT /note="Missing (in T(-)B(+)NK(-) SCID)" FT /evidence="ECO:0000269|PubMed:14615376" FT /id="VAR_019337" FT VARIANT 100 FT /note="Y -> C (in T(-)B(+)NK(-) SCID; dbSNP:rs137852624)" FT /evidence="ECO:0000269|PubMed:7659163" FT /id="VAR_006284" FT VARIANT 132 FT /note="P -> T (in dbSNP:rs3212723)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_019336" FT VARIANT 151 FT /note="P -> R (in T(-)B(+)NK(-) SCID; likely benign; FT dbSNP:rs55778349)" FT /evidence="ECO:0000269|PubMed:10982185, FT ECO:0000269|PubMed:17344846" FT /id="VAR_010492" FT VARIANT 169 FT /note="D -> E (in T(-)B(+)NK(-) SCID; dbSNP:rs147181709)" FT /evidence="ECO:0000269|PubMed:14615376" FT /id="VAR_019338" FT VARIANT 481 FT /note="E -> G (in T(-)B(+)NK(-) SCID)" FT /evidence="ECO:0000269|PubMed:9354668" FT /id="VAR_010493" FT VARIANT 521 FT /note="L -> V (in dbSNP:rs55666418)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041724" FT VARIANT 527 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041725" FT VARIANT 582 FT /note="R -> W (in T(-)B(+)NK(-) SCID; dbSNP:rs193922361)" FT /evidence="ECO:0000269|PubMed:9753072" FT /id="VAR_010494" FT VARIANT 586..592 FT /note="Missing (in T(-)B(+)NK(-) SCID; lack of FT phosphorylation in response to cytokine stimulation)" FT /evidence="ECO:0000269|PubMed:9354668" FT /id="VAR_010495" FT VARIANT 589 FT /note="G -> S (in T(-)B(+)NK(-) SCID; dbSNP:rs886039394)" FT /evidence="ECO:0000269|PubMed:14615376" FT /id="VAR_019339" FT VARIANT 688 FT /note="I -> F (in dbSNP:rs35785705)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041726" FT VARIANT 722 FT /note="V -> I (in dbSNP:rs3213409)" FT /evidence="ECO:0000269|PubMed:10982185, FT ECO:0000269|PubMed:14615376, ECO:0000269|PubMed:17344846, FT ECO:0000269|Ref.4" FT /id="VAR_010496" FT VARIANT 759 FT /note="C -> R (in T(-)B(+)NK(-) SCID; constitutive FT phosphorylation)" FT /evidence="ECO:0000269|PubMed:9354668" FT /id="VAR_010497" FT VARIANT 910 FT /note="L -> S (in T(-)B(+)NK(-) SCID)" FT /evidence="ECO:0000269|PubMed:10982185" FT /id="VAR_010498" FT MUTAGEN 785 FT /note="Y->F: Strong decrease of JAK3 phosphorylation." FT /evidence="ECO:0000269|PubMed:15121872" FT MUTAGEN 855 FT /note="K->A: More than 90% loss of STAT5a activation." FT /evidence="ECO:0000269|PubMed:18250158" FT MUTAGEN 904 FT /note="Y->F: About 40% loss of STAT5a activation." FT /evidence="ECO:0000269|PubMed:18250158" FT MUTAGEN 939 FT /note="Y->F: About 80% loss of STAT5a activation." FT /evidence="ECO:0000269|PubMed:18250158" FT CONFLICT 34 FT /note="G -> A (in Ref. 1; AAA19626)" FT /evidence="ECO:0000305" FT CONFLICT 45 FT /note="F -> S (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 103 FT /note="R -> RS (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 147 FT /note="Missing (in Ref. 8; AAC50542)" FT /evidence="ECO:0000305" FT CONFLICT 187 FT /note="T -> A (in Ref. 8; AAC50542)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="R -> A (in Ref. 1; AAA19626 and 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 222 FT /note="R -> P (in Ref. 1; AAA19626 and 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 271 FT /note="L -> F (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 287 FT /note="Missing (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 610 FT /note="M -> I (in Ref. 2; AAC50226)" FT /evidence="ECO:0000305" FT CONFLICT 845..846 FT /note="GD -> AH (in Ref. 1; AAA19626)" FT /evidence="ECO:0000305" FT CONFLICT 895..897 FT /note="RQS -> EPE (in Ref. 3; AAC50950)" FT /evidence="ECO:0000305" FT CONFLICT 896..897 FT /note="QS -> PE (in Ref. 1; AAA19626)" FT /evidence="ECO:0000305" FT STRAND 816..818 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 819..821 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 822..830 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 832..841 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 845..847 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 849..859 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 862..877 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 886..891 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 893..896 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 898..903 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 910..917 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 918..920 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 923..942 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 952..954 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 955..959 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 962..965 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 968..970 FT /evidence="ECO:0007829|PDB:3LXL" FT STRAND 979..982 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 991..993 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 996..1001 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 1003..1005 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1006..1021 FT /evidence="ECO:0007829|PDB:5LWM" FT TURN 1022..1024 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1026..1028 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1030..1037 FT /evidence="ECO:0007829|PDB:5LWM" FT STRAND 1042..1044 FT /evidence="ECO:0007829|PDB:4QPS" FT HELIX 1046..1055 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1068..1077 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1082..1084 FT /evidence="ECO:0007829|PDB:5LWM" FT HELIX 1088..1102 FT /evidence="ECO:0007829|PDB:5LWM" SQ SEQUENCE 1124 AA; 125099 MW; 895D8563439B2B7C CRC64; MAPPSEETPL IPQRSCSLLS TEAGALHVLL PARGPGPPQR LSFSFGDHLA EDLCVQAAKA SGILPVYHSL FALATEDLSC WFPPSHIFSV EDASTQVLLY RIRFYFPNWF GLEKCHRFGL RKDLASAILD LPVLEHLFAQ HRSDLVSGRL PVGLSLKEQG ECLSLAVLDL ARMAREQAQR PGELLKTVSY KACLPPSLRD LIQGLSFVTR RRIRRTVRRA LRRVAACQAD RHSLMAKYIM DLERLDPAGA AETFHVGLPG ALGGHDGLGL LRVAGDGGIA WTQGEQEVLQ PFCDFPEIVD ISIKQAPRVG PAGEHRLVTV TRTDNQILEA EFPGLPEALS FVALVDGYFR LTTDSQHFFC KEVAPPRLLE EVAEQCHGPI TLDFAINKLK TGGSRPGSYV LRRSPQDFDS FLLTVCVQNP LGPDYKGCLI RRSPTGTFLL VGLSRPHSSL RELLATCWDG GLHVDGVAVT LTSCCIPRPK EKSNLIVVQR GHSPPTSSLV QPQSQYQLSQ MTFHKIPADS LEWHENLGHG SFTKIYRGCR HEVVDGEARK TEVLLKVMDA KHKNCMESFL EAASLMSQVS YRHLVLLHGV CMAGDSTMVQ EFVHLGAIDM YLRKRGHLVP ASWKLQVVKQ LAYALNYLED KGLPHGNVSA RKVLLAREGA DGSPPFIKLS DPGVSPAVLS LEMLTDRIPW VAPECLREAQ TLSLEADKWG FGATVWEVFS GVTMPISALD PAKKLQFYED RQQLPAPKWT ELALLIQQCM AYEPVQRPSF RAVIRDLNSL ISSDYELLSD PTPGALAPRD GLWNGAQLYA CQDPTIFEER HLKYISQLGK GNFGSVELCR YDPLGDNTGA LVAVKQLQHS GPDQQRDFQR EIQILKALHS DFIVKYRGVS YGPGRQSLRL VMEYLPSGCL RDFLQRHRAR LDASRLLLYS SQICKGMEYL GSRRCVHRDL AARNILVESE AHVKIADFGL AKLLPLDKDY YVVREPGQSP IFWYAPESLS DNIFSRQSDV WSFGVVLYEL FTYCDKSCSP SAEFLRMMGC ERDVPALCRL LELLEEGQRL PAPPACPAEV HELMKLCWAP SPQDRPSFSA LGPQLDMLWS GSRGCETHAF TAHPEGKHHS LSFS // ID KIT_HUMAN Reviewed; 976 AA. AC P10721; B5A956; D5LXN2; D5M931; F5H8F8; Q6IQ28; Q99662; Q9UM99; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1989, sequence version 1. DT 28-JAN-2026, entry version 265. DE RecName: Full=Mast/stem cell growth factor receptor Kit; DE Short=SCFR; DE EC=2.7.10.1; DE AltName: Full=Piebald trait protein; DE Short=PBT; DE AltName: Full=Proto-oncogene c-Kit; DE AltName: Full=Tyrosine-protein kinase Kit; DE AltName: Full=p145 c-kit; DE AltName: Full=v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; DE AltName: CD_antigen=CD117; DE Flags: Precursor; GN Name=KIT; Synonyms=SCFR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, AND SUBCELLULAR LOCATION. RC TISSUE=Fetal brain, and Term placenta; RX PubMed=2448137; DOI=10.1002/j.1460-2075.1987.tb02655.x; RA Yarden Y., Kuang W.-J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J., RA Chen E., Schlessinger J., Francke U., Ullrich A.; RT "Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase RT for an unidentified ligand."; RL EMBO J. 6:3341-3351(1987). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1 AND RP 2). RX PubMed=1279499; RA Giebel L.B., Strunk K.M., Holmes S.A., Spritz R.A.; RT "Organization and nucleotide sequence of the human KIT (mast/stem cell RT growth factor receptor) proto-oncogene."; RL Oncogene 7:2207-2217(1992). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RC TISSUE=Colon carcinoma; RX PubMed=7505199; RA Toyota M., Hinoda Y., Itoh F., Takaoka A., Imai K., Yachi A.; RT "Complementary DNA cloning and characterization of truncated form of c-kit RT in human colon carcinoma cells."; RL Cancer Res. 54:272-275(1994). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9027509; DOI=10.1006/geno.1996.4482; RA Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V., Hu W.X., RA Galibert F.; RT "Sequence analysis of two genomic regions containing the KIT and the FMS RT receptor tyrosine kinase genes."; RL Genomics 39:216-226(1997). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RC TISSUE=Prostate cancer; RX PubMed=15039213; DOI=10.1016/s0002-9440(10)63212-9; RA Paronetto M.P., Farini D., Sammarco I., Maturo G., Vespasiani G., RA Geremia R., Rossi P., Sette C.; RT "Expression of a truncated form of the c-Kit tyrosine kinase receptor and RT activation of Src kinase in human prostatic cancer."; RL Am. J. Pathol. 164:1243-1251(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND RP INDUCTION. RX PubMed=20658618; DOI=10.1002/pbc.22603; RA Neumann I., Foell J.L., Bremer M., Volkmer I., Korholz D., Burdach S., RA Staege M.S.; RT "Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib RT mesylate."; RL Pediatr. Blood Cancer 55:464-470(2010). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Staege M.S., Neumann I., Volkmer I.; RT "Sequence of KIT mRNA from all-trans retinoic acid treated neuroblastoma RT cell lines."; RL Submitted (MAR-2010) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-411 (ISOFORMS 1/2). RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22. RX PubMed=7506248; DOI=10.1111/j.1349-7006.1993.tb02813.x; RA Yamamoto K., Tojo A., Aoki N., Shibuya M.; RT "Characterization of the promoter region of the human c-kit proto- RT oncogene."; RL Jpn. J. Cancer Res. 84:1136-1144(1993). RN [13] RP FUNCTION IN PHOSPHORYLATION OF PIK3R1; RAF1 AND MAPK1, INTERACTION WITH RP GRB2; PIK3R1 AND PIK3 CATALYTIC SUBUNIT, ACTIVITY REGULATION, AND RP PHOSPHORYLATION. RX PubMed=7520444; DOI=10.1016/s0021-9258(17)31874-4; RA Blume-Jensen P., Ronnstrand L., Gout I., Waterfield M.D., Heldin C.H.; RT "Modulation of Kit/stem cell factor receptor-induced signaling by protein RT kinase C."; RL J. Biol. Chem. 269:21793-21802(1994). RN [14] RP PHOSPHORYLATION AT SER-741; SER-746; SER-821 AND SER-959, ACTIVITY RP REGULATION, PARTIAL PROTEIN SEQUENCE, AND MUTAGENESIS OF SER-741 AND RP SER-746. RX PubMed=7539802; DOI=10.1074/jbc.270.23.14192; RA Blume-Jensen P., Wernstedt C., Heldin C.H., Ronnstrand L.; RT "Identification of the major phosphorylation sites for protein kinase C in RT kit/stem cell factor receptor in vitro and in intact cells."; RL J. Biol. Chem. 270:14192-14200(1995). RN [15] RP INTERACTION WITH PIK3R1; MATK/CHK; FYN AND SHC1, AND PHOSPHORYLATION AT RP TYR-568; TYR-570 AND TYR-721. RX PubMed=9038210; DOI=10.1074/jbc.272.9.5915; RA Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.; RT "Direct association of Csk homologous kinase (CHK) with the RT diphosphorylated site Tyr568/570 of the activated c-KIT in RT megakaryocytes."; RL J. Biol. Chem. 272:5915-5920(1997). RN [16] RP INTERACTION WITH LYN. RX PubMed=9341198; DOI=10.1074/jbc.272.43.27450; RA Linnekin D., DeBerry C.S., Mou S.; RT "Lyn associates with the juxtamembrane region of c-Kit and is activated by RT stem cell factor in hematopoietic cell lines and normal progenitor cells."; RL J. Biol. Chem. 272:27450-27455(1997). RN [17] RP INTERACTION WITH PTPN6, AUTOPHOSPHORYLATION, AND FUNCTION IN RP PHOSPHORYLATION OF PTPN6. RX PubMed=9528781; DOI=10.1128/mcb.18.4.2089; RA Kozlowski M., Larose L., Lee F., Le D.M., Rottapel R., Siminovitch K.A.; RT "SHP-1 binds and negatively modulates the c-Kit receptor by interaction RT with tyrosine 569 in the c-Kit juxtamembrane domain."; RL Mol. Cell. Biol. 18:2089-2099(1998). RN [18] RP INTERACTION WITH GRB2 AND GRB7, PARTIAL PROTEIN SEQUENCE, RP AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-703 AND TYR-936. RX PubMed=10377264; DOI=10.1042/bj3410211; RA Thommes K., Lennartsson J., Carlberg M., Ronnstrand L.; RT "Identification of Tyr-703 and Tyr-936 as the primary association sites for RT Grb2 and Grb7 in the c-Kit/stem cell factor receptor."; RL Biochem. J. 341:211-216(1999). RN [19] RP INTERACTION WITH PTPRU, AND FUNCTION IN PHOSPHORYLATION OF PTPRU. RX PubMed=10397721; RA Taniguchi Y., London R., Schinkmann K., Jiang S., Avraham H.; RT "The receptor protein tyrosine phosphatase, PTP-RO, is upregulated during RT megakaryocyte differentiation and is associated with the c-Kit receptor."; RL Blood 94:539-549(1999). RN [20] RP INTERACTION WITH MPDZ, CHARACTERIZATION OF VARIANT VAL-816, AND MUTAGENESIS RP OF LYS-623. RX PubMed=11018522; DOI=10.1016/s0014-5793(00)02036-6; RA Mancini A., Koch A., Stefan M., Niemann H., Tamura T.; RT "The direct association of the multiple PDZ domain containing proteins RT (MUPP-1) with the human c-Kit C-terminus is regulated by tyrosine kinase RT activity."; RL FEBS Lett. 482:54-58(2000). RN [21] RP INTERACTION WITH LYN; TEC AND DOK1. RX PubMed=11825908; DOI=10.1074/jbc.m200277200; RA Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B., Resh M.D.; RT "Phosphatidylinositol 3-kinase and Src family kinases are required for RT phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling."; RL J. Biol. Chem. 277:13732-13738(2002). RN [22] RP INTERACTION WITH SH2B2/APS, FUNCTION IN PHOSPHORYLATION OF SH2B2/APS, AND RP MUTAGENESIS OF ILE-571 AND LEU-939. RX PubMed=12444928; DOI=10.1042/bj20020716; RA Wollberg P., Lennartsson J., Gottfridsson E., Yoshimura A., Ronnstrand L.; RT "The adapter protein APS associates with the multifunctional docking sites RT Tyr-568 and Tyr-936 in c-Kit."; RL Biochem. J. 370:1033-1038(2003). RN [23] RP PHOSPHORYLATION AT SER-891 AND TYR-900, PARTIAL PROTEIN SEQUENCE, RP INTERACTION WITH CRK AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF CRK; AKT1 RP AND MAP KINASES, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4; RA Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.; RT "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent RT phosphorylation site mediating interaction with c-Crk."; RL Exp. Cell Res. 288:110-118(2003). RN [24] RP FUNCTION, AND ALTERNATIVE SPLICING. RX PubMed=12511554; DOI=10.1074/jbc.m211726200; RA Voytyuk O., Lennartsson J., Mogi A., Caruana G., Courtneidge S., RA Ashman L.K., Ronnstrand L.; RT "Src family kinases are involved in the differential signaling from two RT splice forms of c-Kit."; RL J. Biol. Chem. 278:9159-9166(2003). RN [25] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-130. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [26] RP INTERACTION WITH FES/FPS, AND CHARACTERIZATION OF VARIANT VAL-816. RX PubMed=17595334; DOI=10.1182/blood-2007-02-076471; RA Voisset E., Lopez S., Dubreuil P., De Sepulveda P.; RT "The tyrosine kinase FES is an essential effector of KITD816V proliferation RT signal."; RL Blood 110:2593-2599(2007). RN [27] RP INTERACTION WITH GRB2 AND CBL, UBIQUITINATION, AND FUNCTION IN RP PHOSPHORYLATION OF CBL. RX PubMed=17904548; DOI=10.1016/j.yexcr.2007.08.021; RA Sun J., Pedersen M., Bengtsson S., Ronnstrand L.; RT "Grb2 mediates negative regulation of stem cell factor receptor/c-Kit RT signaling by recruitment of Cbl."; RL Exp. Cell Res. 313:3935-3942(2007). RN [28] RP FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS AND CELL SURVIVAL, FUNCTION IN RP PHOSPHORYLATION OF CBL, PHOSPHORYLATION AT TYR-568; TYR-703; TYR-721 AND RP TYR-936, UBIQUITINATION, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT VAL-816. RX PubMed=19265199; DOI=10.1074/jbc.m808058200; RA Sun J., Pedersen M., Ronnstrand L.; RT "The D816V mutation of c-Kit circumvents a requirement for Src family RT kinases in c-Kit signal transduction."; RL J. Biol. Chem. 284:11039-11047(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-959, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [30] RP SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY. RX PubMed=20601678; DOI=10.1093/humrep/deq168; RA Muciaccia B., Sette C., Paronetto M.P., Barchi M., Pensini S., RA D'Agostino A., Gandini L., Geremia R., Stefanini M., Rossi P.; RT "Expression of a truncated form of KIT tyrosine kinase in human spermatozoa RT correlates with sperm DNA integrity."; RL Hum. Reprod. 25:2188-2202(2010). RN [31] RP PHOSPHORYLATION AT TYR-547; TYR-553; TYR-703; TYR-721; TYR-730; TYR-823 AND RP TYR-900, IDENTIFICATION BY MASS SPECTROMETRY, MUTAGENESIS OF TYR-823, AND RP CHARACTERIZATION OF VARIANT HIS-816. RX PubMed=20147452; DOI=10.1093/jb/mvq015; RA DiNitto J.P., Deshmukh G.D., Zhang Y., Jacques S.L., Coli R., Worrall J.W., RA Diehl W., English J.M., Wu J.C.; RT "Function of activation loop tyrosine phosphorylation in the mechanism of RT c-Kit auto-activation and its implication in sunitinib resistance."; RL J. Biochem. 147:601-609(2010). RN [32] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, RP SUBUNIT, AND CHARACTERIZATION OF VARIANT VAL-816. RX PubMed=21640708; DOI=10.1016/j.bbrc.2011.05.111; RA Kim S.Y., Kang J.J., Lee H.H., Kang J.J., Kim B., Kim C.G., Park T.K., RA Kang H.; RT "Mechanism of activation of human c-KIT kinase by internal tandem RT duplications of the juxtamembrane domain and point mutations at aspartic RT acid 816."; RL Biochem. Biophys. Res. Commun. 410:224-228(2011). RN [33] RP FUNCTION IN ACTIVATION AND PHOSPHORYLATION OF STAT1; STAT3; STAT5A AND RP STAT5B. RX PubMed=21135090; DOI=10.1074/jbc.m110.182642; RA Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.; RT "Mechanisms of STAT protein activation by oncogenic KIT mutants in RT neoplastic mast cells."; RL J. Biol. Chem. 286:5956-5966(2011). RN [34] RP REVIEW. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [35] RP REVIEW ON KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [36] RP REVIEW. RX PubMed=15625120; DOI=10.1634/stemcells.2004-0117; RA Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R.; RT "Normal and oncogenic forms of the receptor tyrosine kinase kit."; RL Stem Cells 23:16-43(2005). RN [37] RP REVIEW. RX PubMed=18381929; DOI=10.1158/1078-0432.ccr-07-5134; RA Kent D., Copley M., Benz C., Dykstra B., Bowie M., Eaves C.; RT "Regulation of hematopoietic stem cells by the steel factor/KIT signaling RT pathway."; RL Clin. Cancer Res. 14:1926-1930(2008). RN [38] RP REVIEW. RX PubMed=21057534; DOI=10.1038/onc.2010.494; RA Pittoni P., Piconese S., Tripodo C., Colombo M.P.; RT "Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary RT off-target of tyrosine kinase inhibitors."; RL Oncogene 30:757-769(2011). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 549-931 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS, SUBUNIT, PHOSPHORYLATION AT TYR-568 AND TYR-570, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12824176; DOI=10.1074/jbc.c300186200; RA Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C., RA Nowakowski J., Kassel D.B., Cronin C.N., McRee D.E.; RT "Structure of a c-kit product complex reveals the basis for kinase RT transactivation."; RL J. Biol. Chem. 278:31461-31464(2003). RN [40] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 565-935 IN COMPLEXES WITH RP INHIBITOR IMATINIB AND PHOSPHATE, AND ACTIVITY REGULATION. RX PubMed=15123710; DOI=10.1074/jbc.m403319200; RA Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., RA Scheibe D.N., Snell G.P., Zou H., Sang B.C., Wilson K.P.; RT "Structural basis for the autoinhibition and STI-571 inhibition of c-Kit RT tyrosine kinase."; RL J. Biol. Chem. 279:31655-31663(2004). RN [41] RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 1-519 IN COMPLEX WITH KITLG/SCF, RP INTERACTION WITH KITLG/SCF, SUBUNIT, DISULFIDE BONDS, CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, MUTAGENESIS OF ARG-381 AND GLU-386, AND GLYCOSYLATION RP AT ASN-130; ASN-283; ASN-293; ASN-300; ASN-320; ASN-352 AND ASN-367. RX PubMed=17662946; DOI=10.1016/j.cell.2007.05.055; RA Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I., Schlessinger J.; RT "Structural basis for activation of the receptor tyrosine kinase KIT by RT stem cell factor."; RL Cell 130:323-334(2007). RN [42] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 544-935 IN COMPLEX WITH SUNITINIB, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, CHARACTERIZATION OF VARIANTS RP HIS-816 AND VAL-816, AND ACTIVITY REGULATION. RX PubMed=19164557; DOI=10.1073/pnas.0812413106; RA Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W., RA DiNitto J.P., English J.M., Greig M.J., He Y.A., Jacques S.L., Lunney E.A., RA McTigue M., Molina D., Quenzer T., Wells P.A., Yu X., Zhang Y., Zou A., RA Emmett M.R., Marshall A.G., Zhang H.M., Demetri G.D.; RT "KIT kinase mutants show unique mechanisms of drug resistance to imatinib RT and sunitinib in gastrointestinal stromal tumor patients."; RL Proc. Natl. Acad. Sci. U.S.A. 106:1542-1547(2009). RN [43] RP X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 564-574 IN COMPLEX WITH SOCS6, RP AND PHOSPHORYLATION AT TYR-568. RX PubMed=21030588; DOI=10.1074/jbc.m110.173526; RA Zadjali F., Pike A.C., Vesterlund M., Sun J., Wu C., Li S.S., RA Ronnstrand L., Knapp S., Bullock A.N., Flores-Morales A.; RT "Structural basis for c-KIT inhibition by the suppressor of cytokine RT signaling 6 (SOCS6) ubiquitin ligase."; RL J. Biol. Chem. 286:480-490(2011). RN [44] RP VARIANT PBT LYS-583. RX PubMed=1376329; DOI=10.1172/jci115772; RA Fleischman R.A.; RT "Human piebald trait resulting from a dominant negative mutant allele of RT the c-kit membrane receptor gene."; RL J. Clin. Invest. 89:1713-1717(1992). RN [45] RP VARIANT PBT LEU-584. RX PubMed=1370874; RA Spritz R.A., Giebel L.B., Holmes S.A.; RT "Dominant negative and loss of function mutations of the c-kit (mast/stem RT cell growth factor receptor) proto-oncogene in human piebaldism."; RL Am. J. Hum. Genet. 50:261-269(1992). RN [46] RP VARIANT PBT ARG-664. RX PubMed=1717985; DOI=10.1073/pnas.88.19.8696; RA Giebel L.B., Spritz R.A.; RT "Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene RT in human piebaldism."; RL Proc. Natl. Acad. Sci. U.S.A. 88:8696-8699(1991). RN [47] RP VARIANT MAST CELL LEUKEMIA VAL-816. RX PubMed=7691885; DOI=10.1172/jci116761; RA Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., RA Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y., Matsuzawa Y., RA Kitamura Y., Kanakura Y.; RT "Identification of mutations in the coding sequence of the proto-oncogene RT c-kit in a human mast cell leukemia cell line causing ligand-independent RT activation of c-kit product."; RL J. Clin. Invest. 92:1736-1744(1993). RN [48] RP VARIANTS PBT GLY-791 AND VAL-812. RX PubMed=7687267; DOI=10.1111/1523-1747.ep12358440; RA Spritz R.A., Holmes S.A., Itin P., Kuester W.; RT "Novel mutations of the KIT (mast/stem cell growth factor receptor) proto- RT oncogene in human piebaldism."; RL J. Invest. Dermatol. 101:22-25(1993). RN [49] RP VARIANT PBT 893-GLU--PRO-896 DEL. RX PubMed=8680409; DOI=10.1002/humu.1380060409; RA Riva P., Milani N., Gandolfi P., Larizza L.; RT "A 12-bp deletion (7818del12) in the c-kit protooncogene in a large Italian RT kindred with piebaldism."; RL Hum. Mutat. 6:343-345(1995). RN [50] RP VARIANT MAST CELL DISEASE GLY-820. RX PubMed=9029028; DOI=10.1046/j.1365-2141.1997.d01-2042.x; RA Pignon J.-M., Giraudier S., Duquesnoy P., Jouault H., Imbert M., RA Vainchenker W., Vernant J.-P., Tulliez M.; RT "A new c-kit mutation in a case of aggressive mast cell disease."; RL Br. J. Haematol. 96:374-376(1997). RN [51] RP VARIANT PBT GLY-796. RX PubMed=9450866; RX DOI=10.1002/(sici)1096-8628(19980106)75:1<101::aid-ajmg20>3.0.co;2-p; RA Spritz R.A., Beighton P.; RT "Piebaldism with deafness: molecular evidence for an expanded syndrome."; RL Am. J. Med. Genet. 75:101-103(1998). RN [52] RP VARIANT ACUTE MYELOID LEUKEMIA TYR-816. RX PubMed=9657776; RA Beghini A., Larizza L., Cairoli R., Morra E.; RT "c-kit activating mutations and mast cell proliferation in human RT leukemia."; RL Blood 92:701-702(1998). RN [53] RP VARIANT PBT PRO-847. RX PubMed=9699740; DOI=10.1046/j.1523-1747.1998.00269.x; RA Nomura K., Hatayama I., Narita T., Kaneko T., Shiraishi M.; RT "A novel KIT gene missense mutation in a Japanese family with piebaldism."; RL J. Invest. Dermatol. 111:337-338(1998). RN [54] RP VARIANT GIST VAL-559 DEL. RX PubMed=9697690; DOI=10.1038/1209; RA Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K., Nakamura H., RA Kanakura Y., Tanaka T., Takabayashi A., Matsuda H., Kitamura Y.; RT "Familial gastrointestinal stromal tumours with germline mutation of the RT KIT gene."; RL Nat. Genet. 19:323-324(1998). RN [55] RP VARIANTS GIST ILE-550; 550-LYS--LYS-558 DEL; 551-PRO--VAL-555 DEL; ASP-559 RP AND 559-VAL-VAL-560 DEL. RX PubMed=9438854; DOI=10.1126/science.279.5350.577; RA Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., RA Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., RA Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y.; RT "Gain-of-function mutations of c-kit in human gastrointestinal stromal RT tumors."; RL Science 279:577-580(1998). RN [56] RP VARIANT HIS-816, AND CHARACTERIZATION OF VARIANT HIS-816. RX PubMed=10362788; DOI=10.1016/s0002-9440(10)65419-3; RA Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A.; RT "Activating c-kit gene mutations in human germ cell tumors."; RL Am. J. Pathol. 154:1643-1647(1999). RN [57] RP VARIANTS MASTSYS VAL-816 AND TYR-816, VARIANTS MASTC PHE-816 AND LYS-839, RP CHARACTERIZATION OF VARIANTS MASTSYS VAL-816 AND TYR-816, CHARACTERIZATION RP OF VARIANTS MASTC PHE-816 AND LYS-839, AND INVOLVEMENT IN MASTSYS AND RP MASTC. RX PubMed=9990072; DOI=10.1073/pnas.96.4.1609; RA Longley B.J. Jr., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.-Z., RA Heitjan D., Ma Y.; RT "Activating and dominant inactivating c-KIT catalytic domain mutations in RT distinct clinical forms of human mastocytosis."; RL Proc. Natl. Acad. Sci. U.S.A. 96:1609-1614(1999). RN [58] RP VARIANTS PBT CYS-584; ARG-601 AND PRO-656. RX PubMed=11074500; RX DOI=10.1002/1096-8628(20001106)95:1<79::aid-ajmg16>3.0.co;2-4; RA Syrris P., Malik N.M., Murday V.A., Patton M.A., Carter N.D., Hughes H.E., RA Metcalfe K.; RT "Three novel mutations of the proto-oncogene KIT cause human piebaldism."; RL Am. J. Med. Genet. 95:79-81(2000). RN [59] RP VARIANT GIST ALA-559. RX PubMed=11505412; RX DOI=10.1002/1097-0142(20010801)92:3<657::aid-cncr1367>3.0.co;2-d; RA Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G., RA Capella C., Larizza L.; RT "Germline mutation in the juxtamembrane domain of the kit gene in a family RT with gastrointestinal stromal tumors and urticaria pigmentosa."; RL Cancer 92:657-662(2001). RN [60] RP VARIANT MASTC ASP-533, AND INVOLVEMENT IN MASTC. RX PubMed=15173254; DOI=10.1136/jmg.2003.015156; RA Tang X., Boxer M., Drummond A., Ogston P., Hodgins M., Burden A.D.; RT "A germline mutation in KIT in familial diffuse cutaneous mastocytosis."; RL J. Med. Genet. 41:E88-E88(2004). RN [61] RP VARIANT GIST 550-LYS--LYS-558 DEL. RX PubMed=15824741; DOI=10.1038/sj.onc.1208587; RA Chen L.L., Sabripour M., Wu E.F., Prieto V.G., Fuller G.N., Frazier M.L.; RT "A mutation-created novel intra-exonic pre-mRNA splice site causes RT constitutive activation of KIT in human gastrointestinal stromal tumors."; RL Oncogene 24:4271-4280(2005). RN [62] RP VARIANTS TYR-816; LYS-822 AND PRO-829. RX PubMed=16175573; DOI=10.1002/gcc.20265; RA Bignell G., Smith R., Hunter C., Stephens P., Davies H., Greenman C., RA Teague J., Butler A., Edkins S., Stevens C., O'meara S., Parker A., RA Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J., RA Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., RA Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., RA Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., RA Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., RA Yates A., Gillis A.J.M., Stoop H.J., van Gurp R.J.H.L.M., Oosterhuis J.W., RA Looijenga L.H.J., Futreal P.A., Wooster R., Stratton M.R.; RT "Sequence analysis of the protein kinase gene family in human testicular RT germ-cell tumors of adolescents and adults."; RL Genes Chromosomes Cancer 45:42-46(2006). RN [63] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-532; LEU-541; SER-691; ASN-715; RP ASN-737; TRP-804; TYR-816; LYS-822 AND PRO-829. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [64] RP VARIANT LEU-541, VARIANTS MASTC ILE-816; TYR-816 AND VAL-816, AND RP CHARACTERIZATION OF VARIANTS MASTC ILE-816; TYR-816 AND VAL-816. RX PubMed=19865100; DOI=10.1038/jid.2009.281; RA Bodemer C., Hermine O., Palmerini F., Yang Y., Grandpeix-Guyodo C., RA Leventhal P.S., Hadj-Rabia S., Nasca L., Georgin-Lavialle S., RA Cohen-Akenine A., Launay J.M., Barete S., Feger F., Arock M., Catteau B., RA Sans B., Stalder J.F., Skowron F., Thomas L., Lorette G., Plantin P., RA Bordigoni P., Lortholary O., de Prost Y., Moussy A., Sobol H., Dubreuil P.; RT "Pediatric mastocytosis is a clonal disease associated with D816V and other RT activating c-KIT mutations."; RL J. Invest. Dermatol. 130:804-815(2010). RN [65] RP VARIANT MASTC ILE-822, CHARACTERIZATION OF VARIANT MASTC ILE-822, AND RP INVOLVEMENT IN MASTC. RX PubMed=21689725; DOI=10.1016/j.exphem.2011.05.009; RA Wasag B., Niedoszytko M., Piskorz A., Lange M., Renke J., Jassem E., RA Biernat W., Debiec-Rychter M., Limon J.; RT "Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis."; RL Exp. Hematol. 39:859-865(2011). RN [66] RP VARIANT MASTC CYS-451, AND INVOLVEMENT IN MASTC. RX PubMed=24289326; DOI=10.1111/ced.12225; RA Wang H.J., Lin Z.M., Zhang J., Yin J.H., Yang Y.; RT "A new germline mutation in KIT associated with diffuse cutaneous RT mastocytosis in a Chinese family."; RL Clin. Exp. Dermatol. 39:146-149(2014). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for the cytokine KITLG/SCF and plays an essential role in the CC regulation of cell survival and proliferation, hematopoiesis, stem cell CC maintenance, gametogenesis, mast cell development, migration and CC function, and in melanogenesis. In response to KITLG/SCF binding, KIT CC can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, CC SH2B2/APS and CBL. Activates the AKT1 signaling pathway by CC phosphorylation of PIK3R1, the regulatory subunit of CC phosphatidylinositol 3-kinase. Activated KIT also transmits signals via CC GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or CC MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, CC STAT5A and STAT5B. Activation of PLCG1 leads to the production of the CC cellular signaling molecules diacylglycerol and inositol 1,4,5- CC trisphosphate. KIT signaling is modulated by protein phosphatases, and CC by rapid internalization and degradation of the receptor. Activated KIT CC promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and CC PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and CC STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), CC LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1. CC {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12444928, CC ECO:0000269|PubMed:12511554, ECO:0000269|PubMed:12878163, CC ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19265199, CC ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:21640708, CC ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9528781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:17662946, ECO:0000269|PubMed:19164557, CC ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:2448137}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. KITLG/SCF binding leads to dimerization and activation CC by autophosphorylation on tyrosine residues. Activity is down-regulated CC by PRKCA-mediated phosphorylation on serine residues. Inhibited by CC imatinib/STI-571 (Gleevec) and sunitinib; these compounds maintain the CC kinase in an inactive conformation. {ECO:0000269|PubMed:15123710, CC ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21640708, CC ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:7539802}. CC -!- SUBUNIT: Monomer in the absence of bound KITLG/SCF. Homodimer in the CC presence of bound KITLG/SCF, forming a heterotetramer with two CC KITLG/SCF molecules. Interacts (via phosphorylated tyrosine residues) CC with the adapter proteins GRB2 and GRB7 (via SH2 domain), and CC SH2B2/APS. Interacts (via C-terminus) with MPDZ (via the tenth PDZ CC domain). Interacts (via phosphorylated tyrosine residues) with PIK3R1 CC and PIK3 catalytic subunit. Interacts (via phosphorylated tyrosine) CC with CRK (isoform Crk-II), FYN, SHC1 and MATK/CHK (via SH2 domain). CC Interacts with LYN and FES/FPS. Interacts (via phosphorylated tyrosine CC residues) with the protein phosphatases PTPN6/SHP-1 (via SH2 domain), CC PTPN11/SHP-2 (via SH2 domain) and PTPRU. Interacts with PLCG1. CC Interacts with DOK1 and TEC. Interacts (KITLG/SCF-bound) with IL1RL1. CC Interacts with IL1RAP (independent of stimulation with KITLG/SCF). A CC mast cell-specific KITLG/SCF-induced interleukin-33 signaling complex CC contains IL1RL1, IL1RAP, KIT and MYD88. {ECO:0000250|UniProtKB:P05532, CC ECO:0000269|PubMed:10377264, ECO:0000269|PubMed:10397721, CC ECO:0000269|PubMed:11018522, ECO:0000269|PubMed:11825908, CC ECO:0000269|PubMed:12444928, ECO:0000269|PubMed:12824176, CC ECO:0000269|PubMed:12878163, ECO:0000269|PubMed:17595334, CC ECO:0000269|PubMed:17662946, ECO:0000269|PubMed:17904548, CC ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21030588, CC ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7520444, CC ECO:0000269|PubMed:9038210, ECO:0000269|PubMed:9341198, CC ECO:0000269|PubMed:9528781}. CC -!- INTERACTION: CC P10721; P00519: ABL1; NbExp=2; IntAct=EBI-1379503, EBI-375543; CC P10721; P42684: ABL2; NbExp=2; IntAct=EBI-1379503, EBI-1102694; CC P10721; O75815: BCAR3; NbExp=3; IntAct=EBI-1379503, EBI-702336; CC P10721; P51451: BLK; NbExp=5; IntAct=EBI-1379503, EBI-2105445; CC P10721; Q8WV28: BLNK; NbExp=2; IntAct=EBI-1379503, EBI-2623522; CC P10721; P46108: CRK; NbExp=4; IntAct=EBI-1379503, EBI-886; CC P10721; P07332: FES; NbExp=2; IntAct=EBI-1379503, EBI-1055635; CC P10721; P09769: FGR; NbExp=2; IntAct=EBI-1379503, EBI-1383732; CC P10721; O75791: GRAP2; NbExp=2; IntAct=EBI-1379503, EBI-740418; CC P10721; P62993: GRB2; NbExp=6; IntAct=EBI-1379503, EBI-401755; CC P10721; Q14451: GRB7; NbExp=4; IntAct=EBI-1379503, EBI-970191; CC P10721; P08631: HCK; NbExp=2; IntAct=EBI-1379503, EBI-346340; CC P10721; Q96JZ2: HSH2D; NbExp=5; IntAct=EBI-1379503, EBI-3919324; CC P10721; P21583: KITLG; NbExp=2; IntAct=EBI-1379503, EBI-1379527; CC P10721; P06239: LCK; NbExp=8; IntAct=EBI-1379503, EBI-1348; CC P10721; P07948: LYN; NbExp=7; IntAct=EBI-1379503, EBI-79452; CC P10721; P16333: NCK1; NbExp=3; IntAct=EBI-1379503, EBI-389883; CC P10721; O43639: NCK2; NbExp=2; IntAct=EBI-1379503, EBI-713635; CC P10721; P27986: PIK3R1; NbExp=19; IntAct=EBI-1379503, EBI-79464; CC P10721; O00459: PIK3R2; NbExp=19; IntAct=EBI-1379503, EBI-346930; CC P10721; Q92569: PIK3R3; NbExp=31; IntAct=EBI-1379503, EBI-79893; CC P10721; P19174: PLCG1; NbExp=31; IntAct=EBI-1379503, EBI-79387; CC P10721; P16885: PLCG2; NbExp=8; IntAct=EBI-1379503, EBI-617403; CC P10721; Q13882: PTK6; NbExp=4; IntAct=EBI-1379503, EBI-1383632; CC P10721; Q06124: PTPN11; NbExp=29; IntAct=EBI-1379503, EBI-297779; CC P10721; Q92729: PTPRU; NbExp=2; IntAct=EBI-1379503, EBI-7052301; CC P10721; P20936: RASA1; NbExp=16; IntAct=EBI-1379503, EBI-1026476; CC P10721; Q9UQQ2: SH2B3; NbExp=2; IntAct=EBI-1379503, EBI-7879749; CC P10721; O14796: SH2D1B; NbExp=8; IntAct=EBI-1379503, EBI-3923013; CC P10721; Q9NP31: SH2D2A; NbExp=10; IntAct=EBI-1379503, EBI-490630; CC P10721; Q8N5H7: SH2D3C; NbExp=4; IntAct=EBI-1379503, EBI-745980; CC P10721; P78314: SH3BP2; NbExp=3; IntAct=EBI-1379503, EBI-727062; CC P10721; Q15464: SHB; NbExp=2; IntAct=EBI-1379503, EBI-4402156; CC P10721; P29353: SHC1; NbExp=8; IntAct=EBI-1379503, EBI-78835; CC P10721; P98077: SHC2; NbExp=5; IntAct=EBI-1379503, EBI-7256023; CC P10721; Q92529: SHC3; NbExp=3; IntAct=EBI-1379503, EBI-79084; CC P10721; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-1379503, EBI-1222854; CC P10721; O14508: SOCS2; NbExp=4; IntAct=EBI-1379503, EBI-617737; CC P10721; O14543: SOCS3; NbExp=3; IntAct=EBI-1379503, EBI-714146; CC P10721; O14544: SOCS6; NbExp=12; IntAct=EBI-1379503, EBI-3929549; CC P10721; P12931: SRC; NbExp=5; IntAct=EBI-1379503, EBI-621482; CC P10721; Q9ULZ2: STAP1; NbExp=3; IntAct=EBI-1379503, EBI-6083058; CC P10721; Q9HBL0: TNS1; NbExp=2; IntAct=EBI-1379503, EBI-3389814; CC P10721; Q63HR2: TNS2; NbExp=2; IntAct=EBI-1379503, EBI-949753; CC P10721; Q68CZ2: TNS3; NbExp=5; IntAct=EBI-1379503, EBI-1220488; CC P10721; P42681: TXK; NbExp=3; IntAct=EBI-1379503, EBI-7877438; CC P10721; P07947: YES1; NbExp=7; IntAct=EBI-1379503, EBI-515331; CC P10721; P43403: ZAP70; NbExp=2; IntAct=EBI-1379503, EBI-1211276; CC P10721; Q8VBX6: Mpdz; Xeno; NbExp=4; IntAct=EBI-1379503, EBI-8026435; CC P10721; P35235: Ptpn11; Xeno; NbExp=2; IntAct=EBI-1379503, EBI-397236; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane; Single-pass type I CC membrane protein. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm CC {ECO:0000269|PubMed:20601678}. Note=Detected in the cytoplasm of CC spermatozoa, especially in the equatorial and subacrosomal region of CC the sperm head. {ECO:0000269|PubMed:20601678}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=GNNK(+), KitA(+); CC IsoId=P10721-1; Sequence=Displayed; CC Name=2; Synonyms=GNNK(-), Kit(+); CC IsoId=P10721-2; Sequence=VSP_038385; CC Name=3; Synonyms=TR-KIT {ECO:0000303|PubMed:20601678}; CC IsoId=P10721-4; Sequence=VSP_060976; CC -!- TISSUE SPECIFICITY: [Isoform 3]: In testis, detected in spermatogonia CC in the basal layer and in interstitial Leydig cells but not in Sertoli CC cells or spermatocytes inside the seminiferous tubules (at protein CC level) (PubMed:20601678). Expression is maintained in ejaculated CC spermatozoa (at protein level) (PubMed:20601678). CC {ECO:0000269|PubMed:20601678}. CC -!- INDUCTION: Up-regulated by cis-retinoic acid in neuroblastoma cell CC lines. {ECO:0000269|PubMed:20658618}. CC -!- PTM: Ubiquitinated by SOCS6. KIT is rapidly ubiquitinated after CC autophosphorylation induced by KITLG/SCF binding, leading to CC internalization and degradation. {ECO:0000269|PubMed:17904548, CC ECO:0000269|PubMed:19265199}. CC -!- PTM: Autophosphorylated on tyrosine residues. KITLG/SCF binding CC enhances autophosphorylation. Isoform 1 shows low levels of tyrosine CC phosphorylation in the absence of added KITLG/SCF (in vitro). Kinase CC activity is down-regulated by phosphorylation on serine residues by CC protein kinase C family members. Phosphorylation at Tyr-568 is required CC for interaction with PTPN11/SHP-2, CRK (isoform Crk-II) and members of CC the SRC tyrosine-protein kinase family. Phosphorylation at Tyr-570 is CC required for interaction with PTPN6/SHP-1. Phosphorylation at Tyr-703, CC Tyr-823 and Tyr-936 is important for interaction with GRB2. CC Phosphorylation at Tyr-721 is important for interaction with PIK3R1. CC Phosphorylation at Tyr-823 and Tyr-936 is important for interaction CC with GRB7. {ECO:0000269|PubMed:10377264, ECO:0000269|PubMed:12824176, CC ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:20147452, CC ECO:0000269|PubMed:21030588, ECO:0000269|PubMed:9038210}. CC -!- DISEASE: Piebald trait (PBT) [MIM:172800]: Autosomal dominant genetic CC developmental abnormality of pigmentation characterized by congenital CC patches of white skin and hair that lack melanocytes. CC {ECO:0000269|PubMed:11074500, ECO:0000269|PubMed:1370874, CC ECO:0000269|PubMed:1376329, ECO:0000269|PubMed:1717985, CC ECO:0000269|PubMed:7687267, ECO:0000269|PubMed:8680409, CC ECO:0000269|PubMed:9450866, ECO:0000269|PubMed:9699740}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]: Common CC mesenchymal neoplasms arising in the gastrointestinal tract, most often CC in the stomach. They are histologically, immunohistochemically, and CC genetically different from typical leiomyomas, leiomyosarcomas, and CC schwannomas. Most GISTs are composed of a fairly uniform population of CC spindle-shaped cells. Some tumors are dominated by epithelioid cells or CC contain a mixture of spindle and epithelioid morphologies. Primary CC GISTs in the gastrointestinal tract commonly metastasize in the omentum CC and mesenteries, often as multiple nodules. However, primary tumors may CC also occur outside of the gastrointestinal tract, in other intra- CC abdominal locations, especially in the omentum and mesentery. CC {ECO:0000269|PubMed:11505412, ECO:0000269|PubMed:15824741, CC ECO:0000269|PubMed:9438854, ECO:0000269|PubMed:9697690}. Note=The gene CC represented in this entry is involved in disease pathogenesis. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. Somatic mutations that lead to constitutive activation of CC KIT are detected in AML patients. These mutations fall into two CC classes, the most common being in-frame internal tandem duplications of CC variable length in the juxtamembrane region that disrupt the normal CC regulation of the kinase activity. Likewise, point mutations in the CC kinase domain can result in a constitutively activated kinase. CC -!- DISEASE: Mastocytosis, cutaneous (MASTC) [MIM:154800]: A form of CC mastocytosis, a heterogeneous group of disorders associated with CC abnormal proliferation and accumulation of mast cells in various CC tissues, especially in the skin and hematopoietic organs. MASTC is an CC autosomal dominant form characterized by macules, papules, nodules, or CC diffuse infiltration of the skin, often associated with localized CC hyperpigmentation. Gentle rubbing of the lesions induces histamine CC release from mechanically activated mast cells, causing local wheals, CC erythema, and often pruritus, a phenomenon termed Darier sign. CC {ECO:0000269|PubMed:15173254, ECO:0000269|PubMed:19865100, CC ECO:0000269|PubMed:21689725, ECO:0000269|PubMed:24289326, CC ECO:0000269|PubMed:9990072}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Mastocytosis, systemic (MASTSYS) [MIM:154800]: A severe form CC of mastocytosis characterized by abnormal proliferation and CC accumulation of mast cells in several organs, resulting in a systemic CC disease that may affect bone, gastrointestinal tract, lymphatics, CC spleen, and liver. In some cases, it is associated with a clonal CC hematologic non-mast-cell lineage disease, such as a myelodysplastic or CC myeloproliferative disorder. It can also lead to mast cell leukemia, CC which carries a high risk of mortality. {ECO:0000269|PubMed:9990072}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: Numerous proteins are phosphorylated in response to KIT CC signaling, but it is not evident to determine which are directly CC phosphorylated by KIT under in vivo conditions. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=ACF47630.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/127/KIT"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=CD117 entry; CC URL="https://en.wikipedia.org/wiki/CD117"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=two's company - Issue 163 of CC August 2014; CC URL="https://www.proteinspotlight.org/back_issues/163/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X06182; CAA29548.1; -; mRNA. DR EMBL; X69301; CAA49159.1; -; Genomic_DNA. DR EMBL; X69302; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69303; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69304; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69305; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69306; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69307; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69308; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69309; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69310; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69311; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69312; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69313; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69314; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69315; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; X69316; CAA49159.1; JOINED; Genomic_DNA. DR EMBL; U63834; AAC50968.1; -; Genomic_DNA. DR EMBL; U63834; AAC50969.1; -; Genomic_DNA. DR EMBL; GU983671; ADF36702.1; -; mRNA. DR EMBL; HM015525; ADF50068.1; -; mRNA. DR EMBL; HM015526; ADF50069.1; -; mRNA. DR EMBL; AK304031; BAG64945.1; -; mRNA. DR EMBL; AC006552; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092545; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC071593; AAH71593.1; -; mRNA. DR EMBL; EU826594; ACF47630.1; ALT_SEQ; mRNA. DR EMBL; S67773; AAB29529.1; -; Genomic_DNA. DR CCDS; CCDS3496.1; -. [P10721-1] DR CCDS; CCDS47058.1; -. [P10721-2] DR PIR; S01426; TVHUKT. DR RefSeq; NP_000213.1; NM_000222.3. [P10721-1] DR RefSeq; NP_001087241.1; NM_001093772.2. [P10721-2] DR PDB; 1PKG; X-ray; 2.90 A; A/B=549-935. DR PDB; 1T45; X-ray; 1.90 A; A=547-693, A=754-935. DR PDB; 1T46; X-ray; 1.60 A; A=565-693, A=754-935. DR PDB; 2E9W; X-ray; 3.50 A; A/B=26-514. DR PDB; 2EC8; X-ray; 3.00 A; A=1-519. DR PDB; 2IUH; X-ray; 2.00 A; B=718-728. DR PDB; 2VIF; X-ray; 1.45 A; P=564-574. DR PDB; 3G0E; X-ray; 1.60 A; A=544-693, A=754-935. DR PDB; 3G0F; X-ray; 2.60 A; A/B=544-693, A/B=754-935. DR PDB; 4HVS; X-ray; 1.90 A; A=551-934. DR PDB; 4K94; X-ray; 2.40 A; C=308-518. DR PDB; 4K9E; X-ray; 2.70 A; C=308-518. DR PDB; 4PGZ; X-ray; 2.40 A; A/B/C=308-518. DR PDB; 4U0I; X-ray; 2.00 A; A=563-693, A=754-935. DR PDB; 6GQJ; X-ray; 2.33 A; A/B=551-933. DR PDB; 6GQK; X-ray; 2.31 A; A/B=551-687, A/B=771-934. DR PDB; 6GQL; X-ray; 2.01 A; A/B=551-934. DR PDB; 6GQM; X-ray; 2.00 A; A/B=551-934. DR PDB; 6HH1; X-ray; 2.25 A; A=565-702, A=802-929. DR PDB; 6ITT; X-ray; 2.10 A; A/B=547-693, A/B=754-935. DR PDB; 6ITV; X-ray; 1.88 A; A=547-693, A=754-935. DR PDB; 6KLA; X-ray; 2.11 A; A=547-693, A=754-935. DR PDB; 6MOB; X-ray; 1.80 A; A=566-693, A=754-935. DR PDB; 6XV9; X-ray; 3.38 A; A/B=551-687, A/B=766-934. DR PDB; 6XVA; X-ray; 2.30 A; A/B=551-687, A/B=766-934. DR PDB; 6XVB; X-ray; 2.15 A; A/B=551-687, A/B=766-934. DR PDB; 7KHG; X-ray; 2.15 A; A=545-934. DR PDB; 7KHJ; X-ray; 2.80 A; A/B=545-934. DR PDB; 7KHK; X-ray; 2.34 A; A/B=545-934. DR PDB; 7ZW8; X-ray; 2.12 A; A=551-935. DR PDB; 7ZY6; X-ray; 3.09 A; A=551-935. DR PDB; 8DFM; EM; 3.45 A; A/B=32-976. DR PDB; 8DFP; EM; 3.17 A; A/B=32-976. DR PDB; 8DFQ; EM; 3.96 A; A/B=32-976. DR PDB; 8PQ9; X-ray; 1.70 A; A/C=551-687, A/C=766-934. DR PDB; 8PQA; X-ray; 1.65 A; A/C=551-687, A/C=766-934. DR PDB; 8PQB; X-ray; 1.87 A; A=551-687, A=766-934. DR PDB; 8PQC; X-ray; 1.77 A; A/B=551-687, A/B=766-934. DR PDB; 8PQD; X-ray; 1.50 A; A/B=551-687, A/B=766-934. DR PDB; 8PQE; X-ray; 2.00 A; A/B=551-687, A/B=766-934. DR PDB; 8PQF; X-ray; 1.90 A; A/C=551-687, A/C=766-934. DR PDB; 8PQG; X-ray; 2.40 A; A/C=551-687, A/C=766-934. DR PDB; 8S13; X-ray; 2.00 A; A=551-687, A=766-934. DR PDB; 8S14; X-ray; 1.50 A; A=551-687, A=766-934. DR PDB; 8S15; X-ray; 2.40 A; A=551-687, A=766-934. DR PDB; 8S16; X-ray; 1.85 A; A/B=551-687, A/B=766-934. DR PDB; 8S17; X-ray; 2.20 A; A/B=551-687, A/B=766-934. DR PDB; 8S18; X-ray; 2.10 A; A/B=551-687, A/B=766-934. DR PDB; 8S19; X-ray; 2.30 A; A/B=551-687, A/B=766-934. DR PDB; 8S1A; X-ray; 1.85 A; A/B=551-687, A/B=766-934. DR PDB; 8S1B; X-ray; 2.00 A; A/B=551-687, A/B=766-934. DR PDBsum; 1PKG; -. DR PDBsum; 1T45; -. DR PDBsum; 1T46; -. DR PDBsum; 2E9W; -. DR PDBsum; 2EC8; -. DR PDBsum; 2IUH; -. DR PDBsum; 2VIF; -. DR PDBsum; 3G0E; -. DR PDBsum; 3G0F; -. DR PDBsum; 4HVS; -. DR PDBsum; 4K94; -. DR PDBsum; 4K9E; -. DR PDBsum; 4PGZ; -. DR PDBsum; 4U0I; -. DR PDBsum; 6GQJ; -. DR PDBsum; 6GQK; -. DR PDBsum; 6GQL; -. DR PDBsum; 6GQM; -. DR PDBsum; 6HH1; -. DR PDBsum; 6ITT; -. DR PDBsum; 6ITV; -. DR PDBsum; 6KLA; -. DR PDBsum; 6MOB; -. DR PDBsum; 6XV9; -. DR PDBsum; 6XVA; -. DR PDBsum; 6XVB; -. DR PDBsum; 7KHG; -. DR PDBsum; 7KHJ; -. DR PDBsum; 7KHK; -. DR PDBsum; 7ZW8; -. DR PDBsum; 7ZY6; -. DR PDBsum; 8DFM; -. DR PDBsum; 8DFP; -. DR PDBsum; 8DFQ; -. DR PDBsum; 8PQ9; -. DR PDBsum; 8PQA; -. DR PDBsum; 8PQB; -. DR PDBsum; 8PQC; -. DR PDBsum; 8PQD; -. DR PDBsum; 8PQE; -. DR PDBsum; 8PQF; -. DR PDBsum; 8PQG; -. DR PDBsum; 8S13; -. DR PDBsum; 8S14; -. DR PDBsum; 8S15; -. DR PDBsum; 8S16; -. DR PDBsum; 8S17; -. DR PDBsum; 8S18; -. DR PDBsum; 8S19; -. DR PDBsum; 8S1A; -. DR PDBsum; 8S1B; -. DR AlphaFoldDB; P10721; -. DR EMDB; EMD-27408; -. DR EMDB; EMD-27410; -. DR EMDB; EMD-27411; -. DR SMR; P10721; -. DR BioGRID; 110015; 108. DR CORUM; P10721; -. DR DIP; DIP-1055N; -. DR FunCoup; P10721; 1086. DR IntAct; P10721; 106. DR MINT; P10721; -. DR STRING; 9606.ENSP00000288135; -. DR BindingDB; P10721; -. DR ChEMBL; CHEMBL1936; -. DR DrugBank; DB12742; Amuvatinib. DR DrugBank; DB09103; Ancestim. DR DrugBank; DB15233; Avapritinib. DR DrugBank; DB18041; Bezuclastinib. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB17140; JNJ-28312141. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB06080; Linifanib. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB05575; Motesanib. DR DrugBank; DB04868; Nilotinib. DR DrugBank; DB05913; OSI-930. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB12978; Pexidartinib. DR DrugBank; DB01962; Phosphonotyrosine. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB05146; XL820. DR DrugCentral; P10721; -. DR GuidetoPHARMACOLOGY; 1805; -. DR CarbonylDB; P10721; -. DR GlyConnect; 1492; 3 N-Linked glycans (2 sites). DR GlyCosmos; P10721; 10 sites, 4 glycans. DR GlyGen; P10721; 12 sites, 26 N-linked glycans (6 sites). DR iPTMnet; P10721; -. DR PhosphoSitePlus; P10721; -. DR BioMuta; KIT; -. DR DMDM; 125472; -. DR CPTAC; CPTAC-3066; -. DR CPTAC; CPTAC-3067; -. DR jPOST; P10721; -. DR MassIVE; P10721; -. DR PaxDb; 9606-ENSP00000288135; -. DR PeptideAtlas; P10721; -. DR ProteomicsDB; 52640; -. [P10721-1] DR ProteomicsDB; 52641; -. [P10721-2] DR Pumba; P10721; -. DR ABCD; P10721; 2 sequenced antibodies. DR Antibodypedia; 1392; 5560 antibodies from 59 providers. DR DNASU; 3815; -. DR Ensembl; ENST00000288135.6; ENSP00000288135.6; ENSG00000157404.18. [P10721-1] DR Ensembl; ENST00000687295.1; ENSP00000509450.1; ENSG00000157404.18. [P10721-2] DR GeneID; 3815; -. DR KEGG; hsa:3815; -. DR MANE-Select; ENST00000288135.6; ENSP00000288135.6; NM_000222.3; NP_000213.1. DR UCSC; uc010igr.4; human. [P10721-1] DR AGR; HGNC:6342; -. DR CIViC; 3815; 1 clinical assertion and 310 evidence items across 136 molecular profiles. DR ClinPGx; PA30128; -. DR CTD; 3815; -. DR DisGeNET; 3815; -. DR GeneCards; KIT; -. DR HGNC; HGNC:6342; KIT. DR HPA; ENSG00000157404; Tissue enhanced (breast). DR MalaCards; KIT; -. DR MIM; 154800; phenotype. DR MIM; 164920; gene. DR MIM; 172800; phenotype. DR MIM; 273300; phenotype. DR MIM; 601626; phenotype. DR MIM; 606764; phenotype. DR OpenTargets; ENSG00000157404; -. DR Orphanet; 566393; Acute mast cell leukemia. DR Orphanet; 98834; Acute myeloblastic leukemia with maturation. DR Orphanet; 98829; Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22). DR Orphanet; 102724; Acute myeloid leukemia with t(8;21)(q22;q22) translocation. DR Orphanet; 280785; Bullous diffuse cutaneous mastocytosis. DR Orphanet; 566396; Chronic mast cell leukemia. DR Orphanet; 79455; Cutaneous mastocytoma. DR Orphanet; 44890; Gastrointestinal stromal tumor. DR Orphanet; 158778; Isolated bone marrow mastocytosis. DR Orphanet; 158772; Nodular urticaria pigmentosa. DR Orphanet; 2884; Piebaldism. DR Orphanet; 158769; Plaque-form urticaria pigmentosa. DR Orphanet; 280794; Pseudoxanthomatous diffuse cutaneous mastocytosis. DR Orphanet; 158775; Smoldering systemic mastocytosis. DR Orphanet; 98849; Systemic mastocytosis with associated hematologic neoplasm. DR Orphanet; 90389; Telangiectasia macularis eruptiva perstans. DR Orphanet; 842; Testicular seminomatous germ cell tumor. DR Orphanet; 158766; Typical urticaria pigmentosa. DR VEuPathDB; HostDB:ENSG00000157404; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000155626; -. DR HOGENOM; CLU_000288_49_0_1; -. DR InParanoid; P10721; -. DR OMA; ANEECEW; -. DR OrthoDB; 6077854at2759; -. DR PAN-GO; P10721; 10 GO annotations based on evolutionary models. DR PhylomeDB; P10721; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P10721; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1433559; Regulation of KIT signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9669914; Dasatinib-resistant KIT mutants. DR Reactome; R-HSA-9669917; Imatinib-resistant KIT mutants. DR Reactome; R-HSA-9669921; KIT mutants bind TKIs. DR Reactome; R-HSA-9669924; Masitinib-resistant KIT mutants. DR Reactome; R-HSA-9669926; Nilotinib-resistant KIT mutants. DR Reactome; R-HSA-9669929; Regorafenib-resistant KIT mutants. DR Reactome; R-HSA-9669933; Signaling by kinase domain mutants of KIT. DR Reactome; R-HSA-9669934; Sunitinib-resistant KIT mutants. DR Reactome; R-HSA-9669935; Signaling by juxtamembrane domain KIT mutants. DR Reactome; R-HSA-9669936; Sorafenib-resistant KIT mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9680187; Signaling by extracellular domain mutants of KIT. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR SignaLink; P10721; -. DR SIGNOR; P10721; -. DR Agora; ENSG00000157404; -. DR BioGRID-ORCS; 3815; 9 hits in 1192 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; KIT; human. DR EvolutionaryTrace; P10721; -. DR GeneWiki; CD117; -. DR GenomeRNAi; 3815; -. DR Pharos; P10721; Tclin. DR PRO; PR:P10721; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P10721; protein. DR Bgee; ENSG00000157404; Expressed in lateral nuclear group of thalamus and 193 other cell types or tissues. DR GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl. DR GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl. DR GO; GO:0005615; C:extracellular space; IDA:BHF-UCL. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019955; F:cytokine binding; IDA:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0002020; F:protease binding; IEA:Ensembl. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome. DR GO; GO:0042169; F:SH2 domain binding; IEA:Ensembl. DR GO; GO:0005020; F:stem cell factor receptor activity; IEA:Ensembl. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0030183; P:B cell differentiation; IBA:GO_Central. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; ISS:UniProtKB. DR GO; GO:0048565; P:digestive tract development; ISS:UniProtKB. DR GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl. DR GO; GO:0035162; P:embryonic hemopoiesis; ISS:UniProtKB. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB. DR GO; GO:0038162; P:erythropoietin-mediated signaling pathway; ISS:UniProtKB. DR GO; GO:0038093; P:Fc receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0008354; P:germ cell migration; IEA:Ensembl. DR GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IBA:GO_Central. DR GO; GO:0035701; P:hematopoietic stem cell migration; IEA:Ensembl. DR GO; GO:0030097; P:hemopoiesis; TAS:UniProtKB. DR GO; GO:0002327; P:immature B cell differentiation; ISS:UniProtKB. DR GO; GO:0006954; P:inflammatory response; ISS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl. DR GO; GO:0038109; P:Kit signaling pathway; IDA:UniProtKB. DR GO; GO:0030032; P:lamellipodium assembly; ISS:UniProtKB. DR GO; GO:0002320; P:lymphoid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0008584; P:male gonad development; IEP:UniProtKB. DR GO; GO:0002551; P:mast cell chemotaxis; IDA:UniProtKB. DR GO; GO:0043303; P:mast cell degranulation; IMP:UniProtKB. DR GO; GO:0060374; P:mast cell differentiation; ISS:UniProtKB. DR GO; GO:0070662; P:mast cell proliferation; TAS:UniProtKB. DR GO; GO:0035855; P:megakaryocyte development; ISS:UniProtKB. DR GO; GO:0097326; P:melanocyte adhesion; ISS:UniProtKB. DR GO; GO:0030318; P:melanocyte differentiation; ISS:UniProtKB. DR GO; GO:0097324; P:melanocyte migration; ISS:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0051093; P:negative regulation of developmental process; IEA:Ensembl. DR GO; GO:0043069; P:negative regulation of programmed cell death; IEA:Ensembl. DR GO; GO:2000242; P:negative regulation of reproductive process; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; ISS:UniProtKB. DR GO; GO:0043473; P:pigmentation; ISS:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IBA:GO_Central. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IBA:GO_Central. DR GO; GO:1904343; P:positive regulation of colon smooth muscle contraction; IEA:Ensembl. DR GO; GO:0002732; P:positive regulation of dendritic cell cytokine production; ISS:UniProtKB. DR GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB. DR GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0032765; P:positive regulation of mast cell cytokine production; IDA:UniProtKB. DR GO; GO:0070668; P:positive regulation of mast cell proliferation; IEA:Ensembl. DR GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; TAS:UniProtKB. DR GO; GO:0031274; P:positive regulation of pseudopodium assembly; IEA:Ensembl. DR GO; GO:0120072; P:positive regulation of pyloric antrum smooth muscle contraction; IEA:Ensembl. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:1904349; P:positive regulation of small intestine smooth muscle contraction; IEA:Ensembl. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:1905065; P:positive regulation of vascular associated smooth muscle cell differentiation; IDA:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:1904251; P:regulation of bile acid metabolic process; IEA:Ensembl. DR GO; GO:0042127; P:regulation of cell population proliferation; TAS:UniProtKB. DR GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB. DR GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0007286; P:spermatid development; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB. DR GO; GO:0048863; P:stem cell differentiation; ISS:UniProtKB. DR GO; GO:0019827; P:stem cell population maintenance; TAS:UniProtKB. DR GO; GO:0030217; P:T cell differentiation; ISS:UniProtKB. DR GO; GO:0043586; P:tongue development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd00096; Ig; 2. DR CDD; cd05860; IgI_4_SCFR; 1. DR CDD; cd05104; PTKc_Kit; 1. DR DisProt; DP02247; -. DR FunFam; 1.10.510.10:FF:000177; Mast/stem cell growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000422; Mast/stem cell growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000429; Mast/stem cell growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000469; Mast/stem cell growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000544; Mast/stem cell growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000815; Mast/stem cell growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000025; Platelet-derived growth factor receptor alpha; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 5. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR027263; SCGF_receptor. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR PANTHER; PTHR24416:SF46; MAST_STEM CELL GROWTH FACTOR RECEPTOR KIT; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF500951; SCGF_recepter; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Magnesium; Membrane; Metal-binding; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..976 FT /note="Mast/stem cell growth factor receptor Kit" FT /id="PRO_0000016754" FT TOPO_DOM 26..524 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 525..545 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 546..976 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 27..112 FT /note="Ig-like C2-type 1" FT DOMAIN 121..205 FT /note="Ig-like C2-type 2" FT DOMAIN 212..308 FT /note="Ig-like C2-type 3" FT DOMAIN 317..410 FT /note="Ig-like C2-type 4" FT DOMAIN 413..507 FT /note="Ig-like C2-type 5" FT DOMAIN 589..937 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 568..570 FT /note="Important for interaction with phosphotyrosine- FT binding proteins" FT ACT_SITE 792 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 568 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT BINDING 596..603 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 623 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 671..677 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 796 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 797 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT BINDING 810 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT SITE 936 FT /note="Important for interaction with phosphotyrosine- FT binding proteins" FT MOD_RES 547 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:20147452" FT MOD_RES 553 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:20147452" FT MOD_RES 568 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12824176, FT ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:21030588, FT ECO:0000269|PubMed:9038210" FT MOD_RES 570 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12824176, FT ECO:0000269|PubMed:9038210" FT MOD_RES 703 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10377264, FT ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:20147452" FT MOD_RES 721 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19265199, FT ECO:0000269|PubMed:20147452, ECO:0000269|PubMed:9038210" FT MOD_RES 730 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:20147452" FT MOD_RES 741 FT /note="Phosphoserine; by PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:7539802" FT MOD_RES 746 FT /note="Phosphoserine; by PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:7539802" FT MOD_RES 821 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:7539802" FT MOD_RES 823 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:20147452" FT MOD_RES 891 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:12878163" FT MOD_RES 900 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12878163, FT ECO:0000269|PubMed:20147452" FT MOD_RES 936 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10377264, FT ECO:0000269|PubMed:19265199" FT MOD_RES 959 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:7539802, FT ECO:0007744|PubMed:19369195" FT CARBOHYD 130 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:17662946" FT CARBOHYD 145 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 283 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:17662946" FT CARBOHYD 293 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:17662946" FT CARBOHYD 300 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:17662946" FT CARBOHYD 320 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:17662946" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:17662946" FT CARBOHYD 367 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:17662946" FT CARBOHYD 463 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 486 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 58..97 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:17662946" FT DISULFID 136..186 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:17662946" FT DISULFID 151..183 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:17662946" FT DISULFID 233..290 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:17662946" FT DISULFID 428..491 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:17662946" FT VAR_SEQ 1..744 FT /note="MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGD FT EIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFV FT RDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGI FT MIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEF FT TVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVF FT MCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQ FT WIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFN FT VYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSS FT GPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTP FT LLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWE FT FPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELK FT VLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAA FT LYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRI -> MSLPLSFPFLTF FT MVVIAKKNPLFLT (in isoform 3)" FT /id="VSP_060976" FT VAR_SEQ 510..513 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:20658618, ECO:0000303|Ref.7" FT /id="VSP_038385" FT VARIANT 451 FT /note="S -> C (in MASTC; uncertain significance; FT dbSNP:rs1060502556)" FT /evidence="ECO:0000269|PubMed:24289326" FT /id="VAR_081062" FT VARIANT 532 FT /note="V -> I (in dbSNP:rs55792975)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042021" FT VARIANT 533 FT /note="A -> D (in MASTC; uncertain significance; FT dbSNP:rs753212327)" FT /evidence="ECO:0000269|PubMed:15173254" FT /id="VAR_081063" FT VARIANT 541 FT /note="M -> L (in dbSNP:rs3822214)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19865100" FT /id="VAR_042022" FT VARIANT 541 FT /note="M -> V (in dbSNP:rs3822214)" FT /id="VAR_061289" FT VARIANT 550..558 FT /note="Missing (in GIST; somatic mutation)" FT /evidence="ECO:0000269|PubMed:15824741, FT ECO:0000269|PubMed:9438854" FT /id="VAR_033124" FT VARIANT 550 FT /note="K -> I (in GIST; somatic mutation; FT dbSNP:rs2109775477)" FT /evidence="ECO:0000269|PubMed:9438854" FT /id="VAR_033123" FT VARIANT 551..555 FT /note="Missing (in GIST; somatic mutation; FT dbSNP:rs2109775521)" FT /evidence="ECO:0000269|PubMed:9438854" FT /id="VAR_033125" FT VARIANT 559..560 FT /note="Missing (in GIST; somatic mutation; FT dbSNP:rs121913685)" FT /evidence="ECO:0000269|PubMed:9438854" FT /id="VAR_033128" FT VARIANT 559 FT /note="V -> A (in GIST; dbSNP:rs121913517)" FT /evidence="ECO:0000269|PubMed:11505412" FT /id="VAR_033126" FT VARIANT 559 FT /note="V -> D (in GIST; somatic mutation; FT dbSNP:rs121913517)" FT /evidence="ECO:0000269|PubMed:9438854" FT /id="VAR_033127" FT VARIANT 559 FT /note="Missing (in GIST; dbSNP:rs121913685)" FT /evidence="ECO:0000269|PubMed:9697690" FT /id="VAR_007965" FT VARIANT 583 FT /note="E -> K (in PBT; dbSNP:rs121913680)" FT /evidence="ECO:0000269|PubMed:1376329" FT /id="VAR_004104" FT VARIANT 584 FT /note="F -> C (in PBT; dbSNP:rs28933371)" FT /evidence="ECO:0000269|PubMed:11074500" FT /id="VAR_033129" FT VARIANT 584 FT /note="F -> L (in PBT; dbSNP:rs794726671)" FT /evidence="ECO:0000269|PubMed:1370874" FT /id="VAR_004105" FT VARIANT 601 FT /note="G -> R (in PBT; dbSNP:rs2109779521)" FT /evidence="ECO:0000269|PubMed:11074500" FT /id="VAR_033130" FT VARIANT 656 FT /note="L -> P (in PBT)" FT /evidence="ECO:0000269|PubMed:11074500" FT /id="VAR_033131" FT VARIANT 664 FT /note="G -> R (in PBT; dbSNP:rs121913679)" FT /evidence="ECO:0000269|PubMed:1717985" FT /id="VAR_004106" FT VARIANT 691 FT /note="C -> S (in dbSNP:rs35200131)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042023" FT VARIANT 715 FT /note="S -> N (in dbSNP:rs56094246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042024" FT VARIANT 737 FT /note="D -> N (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751005114)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042025" FT VARIANT 791 FT /note="R -> G (in PBT; dbSNP:rs1722708855)" FT /evidence="ECO:0000269|PubMed:7687267" FT /id="VAR_004107" FT VARIANT 796 FT /note="R -> G (in PBT; with sensorineural deafness; FT dbSNP:rs121913684)" FT /evidence="ECO:0000269|PubMed:9450866" FT /id="VAR_033132" FT VARIANT 804 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs145602440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042026" FT VARIANT 812 FT /note="G -> V (in PBT; dbSNP:rs2109801595)" FT /evidence="ECO:0000269|PubMed:7687267" FT /id="VAR_004108" FT VARIANT 816 FT /note="D -> F (in MASTC; sporadic case; somatic mutation; FT constitutively activated and is much more rapidly FT autophosphorylated than wild type; requires 2 nucleotide FT substitutions; dbSNP:rs1057519709)" FT /evidence="ECO:0000269|PubMed:9990072" FT /id="VAR_033133" FT VARIANT 816 FT /note="D -> H (in a testicular tumor; seminoma; somatic FT mutation; constitutively activated; dbSNP:rs121913506)" FT /evidence="ECO:0000269|PubMed:10362788, FT ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:20147452" FT /id="VAR_033134" FT VARIANT 816 FT /note="D -> I (in MASTC; somatic mutation; constitutively FT activated; requires 2 nucleotide substitutions; FT dbSNP:rs1057519709)" FT /evidence="ECO:0000269|PubMed:19865100" FT /id="VAR_081064" FT VARIANT 816 FT /note="D -> V (in MASTSYS, MASTC and mast cell leukemia; FT somatic mutation; constitutively activated; loss of FT interaction with MPDZ; dbSNP:rs121913507)" FT /evidence="ECO:0000269|PubMed:11018522, FT ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:19164557, FT ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:19865100, FT ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7691885, FT ECO:0000269|PubMed:9990072" FT /id="VAR_004109" FT VARIANT 816 FT /note="D -> Y (in MASTSYS and MASTC; also found in acute FT myeloid leukemia and a germ cell tumor of the testis; FT somatic mutation; constitutively activated; FT dbSNP:rs121913506)" FT /evidence="ECO:0000269|PubMed:16175573, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19865100, FT ECO:0000269|PubMed:9657776, ECO:0000269|PubMed:9990072" FT /id="VAR_023828" FT VARIANT 820 FT /note="D -> G (in mast cell disease; systemic; FT dbSNP:rs121913682)" FT /evidence="ECO:0000269|PubMed:9029028" FT /id="VAR_033135" FT VARIANT 822 FT /note="N -> I (in MASTC; constitutively activated; FT dbSNP:rs993022333)" FT /evidence="ECO:0000269|PubMed:21689725" FT /id="VAR_081065" FT VARIANT 822 FT /note="N -> K (in a germ cell tumor of the testis; somatic FT mutation; dbSNP:rs121913514)" FT /evidence="ECO:0000269|PubMed:16175573, FT ECO:0000269|PubMed:17344846" FT /id="VAR_023829" FT VARIANT 829 FT /note="A -> P (in a germ cell tumor of the testis; somatic FT mutation; dbSNP:rs1057519713)" FT /evidence="ECO:0000269|PubMed:16175573, FT ECO:0000269|PubMed:17344846" FT /id="VAR_023830" FT VARIANT 839 FT /note="E -> K (in MASTC; sporadic case; somatic mutation; FT dominant negative mutation; loss of autophosphorylation; FT dbSNP:rs121913509)" FT /evidence="ECO:0000269|PubMed:9990072" FT /id="VAR_033136" FT VARIANT 847 FT /note="T -> P (in PBT; dbSNP:rs121913687)" FT /evidence="ECO:0000269|PubMed:9699740" FT /id="VAR_033137" FT VARIANT 893..896 FT /note="Missing (in PBT; severe)" FT /evidence="ECO:0000269|PubMed:8680409" FT /id="VAR_004110" FT MUTAGEN 381 FT /note="R->A: Reduces autophosphorylation in response to FT KITLG/SCF." FT /evidence="ECO:0000269|PubMed:17662946" FT MUTAGEN 386 FT /note="E->A: Reduces autophosphorylation in response to FT KITLG/SCF." FT /evidence="ECO:0000269|PubMed:17662946" FT MUTAGEN 571 FT /note="I->A: Reduction in SH2B2/APS binding. Abolishes FT SH2B2/APS binding; when associated with A-939." FT /evidence="ECO:0000269|PubMed:12444928" FT MUTAGEN 623 FT /note="K->M: Stronger interaction with MPDZ." FT /evidence="ECO:0000269|PubMed:11018522" FT MUTAGEN 741 FT /note="S->A: Abolishes down-regulation of kinase activity FT by PKC/PRKCA-mediated phosphorylation; when associated with FT A-746." FT /evidence="ECO:0000269|PubMed:7539802" FT MUTAGEN 746 FT /note="S->A: Abolishes down-regulation of kinase activity FT by PKC/PRKCA-mediated phosphorylation; when associated with FT A-741." FT /evidence="ECO:0000269|PubMed:7539802" FT MUTAGEN 823 FT /note="Y->F: No decrease in activity. Leads to FT autophosphorylation at Tyr-900." FT /evidence="ECO:0000269|PubMed:20147452" FT MUTAGEN 939 FT /note="L->A: Reduction in SH2B2/APS binding. Abolishes FT SH2B2/APS binding; when associated with A-571." FT /evidence="ECO:0000269|PubMed:12444928" FT CONFLICT 764 FT /note="L -> I (in Ref. 10; AAH71593)" FT /evidence="ECO:0000305" FT CONFLICT 838 FT /note="P -> H (in Ref. 10; AAH71593)" FT /evidence="ECO:0000305" FT STRAND 38..41 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 54..59 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 63..72 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 79..86 FT /evidence="ECO:0007829|PDB:2EC8" FT HELIX 89..91 FT /evidence="ECO:0007829|PDB:8DFP" FT STRAND 93..99 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 104..110 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:8DFP" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 146..149 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 151..153 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 161..165 FT /evidence="ECO:0007829|PDB:2EC8" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 169..174 FT /evidence="ECO:0007829|PDB:2EC8" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 183..188 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:8DFP" FT STRAND 200..205 FT /evidence="ECO:0007829|PDB:8DFP" FT STRAND 213..215 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 219..224 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 229..239 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 243..248 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 258..263 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 265..267 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 269..279 FT /evidence="ECO:0007829|PDB:2EC8" FT TURN 282..284 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 286..293 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 298..310 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 312..319 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 321..325 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 331..341 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 344..350 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 356..364 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 367..369 FT /evidence="ECO:0007829|PDB:2EC8" FT STRAND 372..379 FT /evidence="ECO:0007829|PDB:4K94" FT HELIX 384..386 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 388..395 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 400..409 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 411..420 FT /evidence="ECO:0007829|PDB:4K94" FT HELIX 422..424 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 425..434 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 437..444 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 445..449 FT /evidence="ECO:0007829|PDB:4PGZ" FT STRAND 452..454 FT /evidence="ECO:0007829|PDB:4PGZ" FT STRAND 458..462 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 465..468 FT /evidence="ECO:0007829|PDB:4PGZ" FT STRAND 472..479 FT /evidence="ECO:0007829|PDB:4K94" FT HELIX 481..483 FT /evidence="ECO:0007829|PDB:4PGZ" FT STRAND 485..494 FT /evidence="ECO:0007829|PDB:4K94" FT STRAND 499..506 FT /evidence="ECO:0007829|PDB:4K94" FT HELIX 550..552 FT /evidence="ECO:0007829|PDB:7KHG" FT STRAND 558..564 FT /evidence="ECO:0007829|PDB:3G0E" FT STRAND 567..570 FT /evidence="ECO:0007829|PDB:3G0E" FT HELIX 573..575 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 580..582 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 589..597 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 599..609 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 611..613 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 617..625 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 627..629 FT /evidence="ECO:0007829|PDB:6HH1" FT HELIX 631..647 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 656..660 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 662..664 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 667..671 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 674..677 FT /evidence="ECO:0007829|PDB:7KHK" FT HELIX 678..685 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 686..689 FT /evidence="ECO:0007829|PDB:3G0E" FT STRAND 719..721 FT /evidence="ECO:0007829|PDB:2IUH" FT HELIX 754..756 FT /evidence="ECO:0007829|PDB:4HVS" FT STRAND 757..759 FT /evidence="ECO:0007829|PDB:4HVS" FT HELIX 760..762 FT /evidence="ECO:0007829|PDB:4HVS" FT HELIX 766..785 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 788..790 FT /evidence="ECO:0007829|PDB:3G0F" FT HELIX 795..797 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 798..801 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 802..804 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 805..808 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 812..814 FT /evidence="ECO:0007829|PDB:1T46" FT TURN 818..820 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 821..824 FT /evidence="ECO:0007829|PDB:8PQD" FT STRAND 827..831 FT /evidence="ECO:0007829|PDB:1T46" FT HELIX 833..835 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 838..843 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 848..863 FT /evidence="ECO:0007829|PDB:8PQD" FT TURN 864..866 FT /evidence="ECO:0007829|PDB:1T46" FT STRAND 869..872 FT /evidence="ECO:0007829|PDB:6ITT" FT HELIX 877..885 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 897..906 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 911..913 FT /evidence="ECO:0007829|PDB:8PQD" FT HELIX 917..930 FT /evidence="ECO:0007829|PDB:8PQD" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:1T45" SQ SEQUENCE 976 AA; 109865 MW; 81B0CD76817F3454 CRC64; MRGARGAWDF LCVLLLLLRV QTGSSQPSVS PGEPSPPSIH PGKSDLIVRV GDEIRLLCTD PGFVKWTFEI LDETNENKQN EWITEKAEAT NTGKYTCTNK HGLSNSIYVF VRDPAKLFLV DRSLYGKEDN DTLVRCPLTD PEVTNYSLKG CQGKPLPKDL RFIPDPKAGI MIKSVKRAYH RLCLHCSVDQ EGKSVLSEKF ILKVRPAFKA VPVVSVSKAS YLLREGEEFT VTCTIKDVSS SVYSTWKREN SQTKLQEKYN SWHHGDFNYE RQATLTISSA RVNDSGVFMC YANNTFGSAN VTTTLEVVDK GFINIFPMIN TTVFVNDGEN VDLIVEYEAF PKPEHQQWIY MNRTFTDKWE DYPKSENESN IRYVSELHLT RLKGTEGGTY TFLVSNSDVN AAIAFNVYVN TKPEILTYDR LVNGMLQCVA AGFPEPTIDW YFCPGTEQRC SASVLPVDVQ TLNSSGPPFG KLVVQSSIDS SAFKHNGTVE CKAYNDVGKT SAYFNFAFKG NNKEQIHPHT LFTPLLIGFV IVAGMMCIIV MILTYKYLQK PMYEVQWKVV EEINGNNYVY IDPTQLPYDH KWEFPRNRLS FGKTLGAGAF GKVVEATAYG LIKSDAAMTV AVKMLKPSAH LTEREALMSE LKVLSYLGNH MNIVNLLGAC TIGGPTLVIT EYCCYGDLLN FLRRKRDSFI CSKQEDHAEA ALYKNLLHSK ESSCSDSTNE YMDMKPGVSY VVPTKADKRR SVRIGSYIER DVTPAIMEDD ELALDLEDLL SFSYQVAKGM AFLASKNCIH RDLAARNILL THGRITKICD FGLARDIKND SNYVVKGNAR LPVKWMAPES IFNCVYTFES DVWSYGIFLW ELFSLGSSPY PGMPVDSKFY KMIKEGFRML SPEHAPAEMY DIMKTCWDAD PLKRPTFKQI VQLIEKQISE STNHIYSNLA NCSPNRQKPV VDHSVRINSV GSTASSSQPL LVHDDV // ID KLF6_HUMAN Reviewed; 283 AA. AC Q99612; B2RE86; B4DDN0; D3DRR1; F5H3M5; Q5VUT7; Q5VUT8; Q9BT79; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2000, sequence version 3. DT 28-JAN-2026, entry version 221. DE RecName: Full=Krueppel-like factor 6; DE AltName: Full=B-cell-derived protein 1; DE AltName: Full=Core promoter element-binding protein; DE AltName: Full=GC-rich sites-binding factor GBF; DE AltName: Full=Proto-oncogene BCD1; DE AltName: Full=Suppressor of tumorigenicity 12 protein; DE AltName: Full=Transcription factor Zf9; GN Name=KLF6; Synonyms=BCD1, COPEB, CPBP, ST12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP PRELIMINARY NUCLEOTIDE SEQUENCE (ISOFORM 1). RX PubMed=9000136; RA El Rouby S., Newcomb E.W.; RT "Identification of Bcd, a novel proto-oncogene expressed in B-cells."; RL Oncogene 13:2623-2630(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=9083102; DOI=10.1074/jbc.272.14.9573; RA Koritschoner N.P., Bocco J.L., Panzetta-Dutari G.M., Dumur C.I., Flury A., RA Patrito L.C.; RT "A novel human zinc finger protein that interacts with the core promoter RT element of a TATA box-less gene."; RL J. Biol. Chem. 272:9573-9580(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Hepatic stellate cell; RX PubMed=9689109; DOI=10.1073/pnas.95.16.9500; RA Ratziu V., Lalazar A., Wong L., Dang Q., Collins C., Shaulian E., RA Jensen S., Friedman S.L.; RT "Zf9, a Kruppel-like transcription factor up-regulated in vivo during early RT hepatic fibrosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:9500-9505(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION. RC TISSUE=Leukocyte; RX PubMed=9685731; DOI=10.1093/oxfordjournals.jbchem.a022124; RA Suzuki T., Yamamoto T., Kurabayashi M., Nagai R., Yazaki Y., Horikoshi M.; RT "Isolation and initial characterization of GBF, a novel DNA-binding zinc RT finger protein that binds to the GC-rich binding sites of the HIV-1 RT promoter."; RL J. Biochem. 124:389-395(1998). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Koritschoner N.P.; RT "Genomic organization of the human COPEB/CPBP locus."; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP INACTIVATION OF 9AATAD MOTIF. RX PubMed=31375868; DOI=10.1007/s00018-019-03251-w; RA Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.; RT "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with RT valines and intron reservoirs."; RL Cell. Mol. Life Sci. 77:1793-1810(2020). RN [12] RP INVOLVEMENT IN PC, VARIANTS ARG-64; PRO-116; ASP-123 AND PRO-169, AND RP CHARACTERIZATION OF VARIANTS ARG-64; PRO-116; ASP-123 AND PRO-169. RX PubMed=11752579; DOI=10.1126/science.1066326; RA Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., RA Glucksman M.J., Narla J., Eng F.J., Chan A.M., Ferrari A.C., RA Martignetti J.A., Friedman S.L.; RT "KLF6, a candidate tumor suppressor gene mutated in prostate cancer."; RL Science 294:2563-2566(2001). RN [13] RP INVOLVEMENT IN GASC, AND VARIANTS ARG-155; THR-172; LEU-180 AND LYS-198. RX PubMed=15824733; DOI=10.1038/sj.onc.1208670; RA Cho Y.G., Kim C.J., Park C.H., Yang Y.M., Kim S.Y., Nam S.W., Lee S.H., RA Yoo N.J., Lee J.Y., Park W.S.; RT "Genetic alterations of the KLF6 gene in gastric cancer."; RL Oncogene 24:4588-4590(2005). RN [14] RP INTERACTION WITH ZZEF1. RX PubMed=33227311; DOI=10.1016/j.jmb.2020.11.021; RA Yu Y., Tencer A., Xuan H., Kutateladze T.G., Shi X.; RT "ZZEF1 is a Histone Reader and Transcriptional Coregulator of Krueppel-Like RT Factors."; RL J. Mol. Biol. 433:166722-166722(2021). CC -!- FUNCTION: Transcriptional activator (By similarity). Binds a GC box CC motif. Could play a role in B-cell growth and development. CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with ZZEF1. {ECO:0000269|PubMed:33227311}. CC -!- INTERACTION: CC Q99612; P41250: GARS1; NbExp=3; IntAct=EBI-714994, EBI-724143; CC Q99612; P02545: LMNA; NbExp=3; IntAct=EBI-714994, EBI-351935; CC Q99612; Q04206: RELA; NbExp=6; IntAct=EBI-714994, EBI-73886; CC Q99612; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-714994, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q99612-1; Sequence=Displayed; CC Name=2; CC IsoId=Q99612-2; Sequence=VSP_015715; CC Name=3; CC IsoId=Q99612-3; Sequence=VSP_045808; CC -!- TISSUE SPECIFICITY: Highly expressed in placenta followed by spleen, CC thymus, prostate, testis, small intestine and colon. Weakly expressed CC in pancreas, lung, liver, heart and skeletal muscle. Also expressed in CC fetal brain, spleen and thymus. CC -!- DOMAIN: The acidic N-terminal part may favor interaction with the basic CC domain of transcription factors. CC -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large CC number of yeast and animal transcription factors. In KLF6, the motif is CC inactive. {ECO:0000269|PubMed:31375868}. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15824733}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:11752579}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein CC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC23699.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA33050.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44002/KLF6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U44975; AAC23699.1; ALT_INIT; mRNA. DR EMBL; AF001461; AAC39929.1; -; mRNA. DR EMBL; AB017493; BAA33050.1; ALT_INIT; mRNA. DR EMBL; AF284036; AAM73548.1; -; Genomic_DNA. DR EMBL; BT006778; AAP35424.1; -; mRNA. DR EMBL; AL513303; CAH74049.1; -; Genomic_DNA. DR EMBL; AL450322; CAH74049.1; JOINED; Genomic_DNA. DR EMBL; AK293259; BAG56791.1; -; mRNA. DR EMBL; AK316596; BAG38183.1; -; mRNA. DR EMBL; AL513303; CAH74050.1; -; Genomic_DNA. DR EMBL; AL450322; CAH74050.1; JOINED; Genomic_DNA. DR EMBL; AL450322; CAH71010.1; -; Genomic_DNA. DR EMBL; AL513303; CAH71010.1; JOINED; Genomic_DNA. DR EMBL; AL450322; CAH71011.1; -; Genomic_DNA. DR EMBL; AL513303; CAH71011.1; JOINED; Genomic_DNA. DR EMBL; CH471072; EAW86477.1; -; Genomic_DNA. DR EMBL; CH471072; EAW86479.1; -; Genomic_DNA. DR EMBL; BC000311; AAH00311.1; -; mRNA. DR CCDS; CCDS53490.1; -. [Q99612-3] DR CCDS; CCDS7060.1; -. [Q99612-1] DR PIR; JE0235; JE0235. DR RefSeq; NP_001153596.1; NM_001160124.1. DR RefSeq; NP_001153597.1; NM_001160125.2. [Q99612-3] DR RefSeq; NP_001291.3; NM_001300.5. [Q99612-1] DR AlphaFoldDB; Q99612; -. DR SMR; Q99612; -. DR BioGRID; 107711; 94. DR FunCoup; Q99612; 2033. DR IntAct; Q99612; 81. DR STRING; 9606.ENSP00000419923; -. DR GlyGen; Q99612; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q99612; -. DR PhosphoSitePlus; Q99612; -. DR BioMuta; KLF6; -. DR DMDM; 7387592; -. DR jPOST; Q99612; -. DR MassIVE; Q99612; -. DR PaxDb; 9606-ENSP00000419923; -. DR PeptideAtlas; Q99612; -. DR ProteomicsDB; 26317; -. DR ProteomicsDB; 78355; -. [Q99612-1] DR ProteomicsDB; 78356; -. [Q99612-2] DR Antibodypedia; 4619; 229 antibodies from 37 providers. DR DNASU; 1316; -. DR Ensembl; ENST00000469435.1; ENSP00000419079.1; ENSG00000067082.16. [Q99612-2] DR Ensembl; ENST00000497571.6; ENSP00000419923.1; ENSG00000067082.16. [Q99612-1] DR Ensembl; ENST00000542957.1; ENSP00000445301.1; ENSG00000067082.16. [Q99612-3] DR GeneID; 1316; -. DR KEGG; hsa:1316; -. DR MANE-Select; ENST00000497571.6; ENSP00000419923.1; NM_001300.6; NP_001291.3. DR UCSC; uc001iha.4; human. [Q99612-1] DR AGR; HGNC:2235; -. DR ClinPGx; PA26751; -. DR CTD; 1316; -. DR DisGeNET; 1316; -. DR GeneCards; KLF6; -. DR HGNC; HGNC:2235; KLF6. DR HPA; ENSG00000067082; Tissue enhanced (bone). DR MalaCards; KLF6; -. DR MIM; 176807; phenotype. DR MIM; 602053; gene. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000067082; -. DR VEuPathDB; HostDB:ENSG00000067082; -. DR eggNOG; KOG1721; Eukaryota. DR GeneTree; ENSGT00940000158085; -. DR HOGENOM; CLU_002678_33_4_1; -. DR InParanoid; Q99612; -. DR OMA; HKCHFNG; -. DR OrthoDB; 4748970at2759; -. DR PAN-GO; Q99612; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q99612; -. DR PathwayCommons; Q99612; -. DR SignaLink; Q99612; -. DR SIGNOR; Q99612; -. DR Agora; ENSG00000067082; -. DR BioGRID-ORCS; 1316; 31 hits in 1184 CRISPR screens. DR ChiTaRS; KLF6; human. DR GeneWiki; KLF6; -. DR GenomeRNAi; 1316; -. DR Pharos; Q99612; Tbio. DR PRO; PR:Q99612; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q99612; protein. DR Bgee; ENSG00000067082; Expressed in nipple and 214 other cell types or tissues. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; TAS:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030183; P:B cell differentiation; NAS:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR CDD; cd21586; KLF6_N; 1. DR FunFam; 3.30.160.60:FF:000021; Basic krueppel-like factor 3; 1. DR FunFam; 3.30.160.60:FF:000018; Krueppel-like factor 15; 1. DR FunFam; 3.30.160.60:FF:000624; zinc finger protein 697; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 3. DR InterPro; IPR036236; Znf_C2H2_sf. DR InterPro; IPR013087; Znf_C2H2_type. DR PANTHER; PTHR23235:SF50; KRUEPPEL-LIKE FACTOR 6; 1. DR PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1. DR Pfam; PF00096; zf-C2H2; 3. DR SMART; SM00355; ZnF_C2H2; 3. DR SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 2. DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3. DR PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3. PE 1: Evidence at protein level; KW Activator; Alternative splicing; DNA-binding; Metal-binding; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Transcription; KW Transcription regulation; Zinc; Zinc-finger. FT CHAIN 1..283 FT /note="Krueppel-like factor 6" FT /id="PRO_0000047171" FT ZN_FING 200..224 FT /note="C2H2-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 230..254 FT /note="C2H2-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 260..282 FT /note="C2H2-type 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT REGION 106..198 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 62..70 FT /note="9aaTAD; inactive" FT /evidence="ECO:0000269|PubMed:31375868" FT COMPBIAS 133..148 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 183..196 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 227..283 FT /note="EKPYRCSWEGCEWRFARSDELTRHFRKHTGAKPFKCSHCDRCFSRSDHLALH FT MKRHL -> QCPRGPRRAAAGGRHCIAPALEGAGPGCTGCGQGRQILTSSDVFHQSIRS FT FWSSE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_015715" FT VAR_SEQ 227..283 FT /note="EKPYRCSWEGCEWRFARSDELTRHFRKHTGAKPFKCSHCDRCFSRSDHLALH FT MKRHL -> VFPGLTTWPCT (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_045808" FT VARIANT 64 FT /note="W -> R (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909142)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065136" FT VARIANT 116 FT /note="S -> P (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909139)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065137" FT VARIANT 123 FT /note="A -> D (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909141)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065138" FT VARIANT 155 FT /note="S -> R (found in gastric cancer samples; somatic FT mutation; dbSNP:rs121909144)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065139" FT VARIANT 169 FT /note="L -> P (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909143)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065140" FT VARIANT 172 FT /note="P -> T (found in gastric cancer samples; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065141" FT VARIANT 180 FT /note="S -> L (found in gastric cancer samples; somatic FT mutation; dbSNP:rs372338890)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065142" FT VARIANT 198 FT /note="R -> K (found in gastric cancer samples; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065143" FT CONFLICT 276 FT /note="A -> G (in Ref. 3; AAC39929)" FT /evidence="ECO:0000305" SQ SEQUENCE 283 AA; 31865 MW; 84294A7E6D0A0231 CRC64; MDVLPMCSIF QELQIVHETG YFSALPSLEE YWQQTCLELE RYLQSEPCYV SASEIKFDSQ EDLWTKIILA REKKEESELK ISSSPPEDTL ISPSFCYNLE TNSLNSDVSS ESSDSSEELS PTAKFTSDPI GEVLVSSGKL SSSVTSTPPS SPELSREPSQ LWGCVPGELP SPGKVRSGTS GKPGDKGNGD ASPDGRRRVH RCHFNGCRKV YTKSSHLKAH QRTHTGEKPY RCSWEGCEWR FARSDELTRH FRKHTGAKPF KCSHCDRCFS RSDHLALHMK RHL // ID KPCD2_HUMAN Reviewed; 878 AA. AC Q9BZL6; B4DTS2; M0QZW1; M0R2R2; Q8NCK8; Q8TB08; Q9P0T6; Q9Y3X8; DT 27-MAR-2002, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 3. DT 28-JAN-2026, entry version 231. DE RecName: Full=Serine/threonine-protein kinase D2; DE EC=2.7.11.13 {ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}; DE AltName: Full=nPKC-D2; GN Name=PRKD2; Synonyms=PKD2; ORFNames=HSPC187; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, COFACTOR, RP TISSUE SPECIFICITY, AND PHOSPHORYLATION AT SER-876. RC TISSUE=Pancreas; RX PubMed=11062248; DOI=10.1074/jbc.m008719200; RA Sturany S., Van Lint J., Mueller F., Wilda M., Hameister H., Hoecker M., RA Brey A., Gern U., Vandenheede J., Gress T., Adler G., Seufferlein T.; RT "Molecular cloning and characterization of the human protein kinase D2. A RT novel member of the protein kinase d family of serine threonine kinases."; RL J. Biol. Chem. 276:3310-3318(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Mammary gland, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 337-878 (ISOFORM 1/2). RC TISSUE=Uterus; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 574-878 (ISOFORM 1/2). RC TISSUE=Umbilical cord blood; RX PubMed=11042152; DOI=10.1101/gr.140200; RA Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G., RA Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W., RA Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.; RT "Cloning and functional analysis of cDNAs with open reading frames for 300 RT previously undefined genes expressed in CD34+ hematopoietic stem/progenitor RT cells."; RL Genome Res. 10:1546-1560(2000). RN [6] RP CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-706; SER-710 AND SER-876. RX PubMed=12058027; DOI=10.1074/jbc.m200934200; RA Sturany S., Van Lint J., Gilchrist A., Vandenheede J.R., Adler G., RA Seufferlein T.; RT "Mechanism of activation of protein kinase D2(PKD2) by the CCK(B)/gastrin RT receptor."; RL J. Biol. Chem. 277:29431-29436(2002). RN [7] RP FUNCTION IN NF-KAPPA-B ACTIVATION, PHOSPHORYLATION AT TYR-438, AND RP MUTAGENESIS OF TYR-438. RX PubMed=15604256; DOI=10.1158/0008-5472.can-04-0981; RA Mihailovic T., Marx M., Auer A., Van Lint J., Schmid M., Weber C., RA Seufferlein T.; RT "Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl RT in Bcr-Abl+ human myeloid leukemia cells."; RL Cancer Res. 64:8939-8944(2004). RN [8] RP FUNCTION IN TRAFFICKING. RX PubMed=14743217; DOI=10.1038/ncb1090; RA Yeaman C., Ayala M.I., Wright J.R., Bard F., Bossard C., Ang A., Maeda Y., RA Seufferlein T., Mellman I., Nelson W.J., Malhotra V.; RT "Protein kinase D regulates basolateral membrane protein exit from trans- RT Golgi network."; RL Nat. Cell Biol. 6:106-112(2004). RN [9] RP FUNCTION IN ADAPTIVE IMMUNE RESPONSE. RX PubMed=17077180; DOI=10.1093/intimm/dxl108; RA Irie A., Harada K., Tsukamoto H., Kim J.R., Araki N., Nishimura Y.; RT "Protein kinase D2 contributes to either IL-2 promoter regulation or RT induction of cell death upon TCR stimulation depending on its activity in RT Jurkat cells."; RL Int. Immunol. 18:1737-1747(2006). RN [10] RP FUNCTION. RX PubMed=16928771; DOI=10.1152/ajpcell.00308.2006; RA Chiu T.T., Leung W.Y., Moyer M.P., Strieter R.M., Rozengurt E.; RT "Protein kinase D2 mediates lysophosphatidic acid-induced interleukin 8 RT production in nontransformed human colonic epithelial cells through NF- RT kappaB."; RL Am. J. Physiol. 292:C767-C777(2007). RN [11] RP FUNCTION IN PHOSPHORYLATION OF HDAC7, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-244. RX PubMed=17962809; DOI=10.1038/sj.emboj.7601891; RA von Blume J., Knippschild U., Dequiedt F., Giamas G., Beck A., Auer A., RA Van Lint J., Adler G., Seufferlein T.; RT "Phosphorylation at Ser244 by CK1 determines nuclear localization and RT substrate targeting of PKD2."; RL EMBO J. 26:4619-4633(2007). RN [12] RP FUNCTION IN CELL ADHESION. RX PubMed=17951978; DOI=10.1254/jphs.fp0070858; RA Ge X., Low B., Liang M., Fu J.; RT "Angiotensin II directly triggers endothelial exocytosis via protein kinase RT C-dependent protein kinase D2 activation."; RL J. Pharmacol. Sci. 105:168-176(2007). RN [13] RP PHORBOL-ESTER BINDING, AND MUTAGENESIS OF PRO-275. RX PubMed=18076381; DOI=10.1042/bj20071334; RA Chen J., Deng F., Li J., Wang Q.J.; RT "Selective binding of phorbol esters and diacylglycerol by individual C1 RT domains of the PKD family."; RL Biochem. J. 411:333-342(2008). RN [14] RP FUNCTION IN SECRETORY PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=18262756; DOI=10.1016/j.cellsig.2008.01.003; RA von Wichert G., Edenfeld T., von Blume J., Krisp H., Krndija D., Schmid H., RA Oswald F., Lother U., Walther P., Adler G., Seufferlein T.; RT "Protein kinase D2 regulates chromogranin A secretion in human BON RT neuroendocrine tumour cells."; RL Cell. Signal. 20:925-934(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-710 AND SER-876, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-200; SER-203; SER-206; RP SER-214 AND SER-710, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [18] RP FUNCTION, AND INTERACTION WITH LCK. RX PubMed=19192391; DOI=10.5483/bmbrep.2009.42.1.035; RA Li Q., Sun X., Wu J., Lin Z., Luo Y.; RT "PKD2 interacts with Lck and regulates NFAT activity in T cells."; RL BMB Rep. 42:35-40(2009). RN [19] RP FUNCTION IN ANGIOGENESIS. RX PubMed=19001381; DOI=10.1074/jbc.m807546200; RA Hao Q., Wang L., Zhao Z.J., Tang H.; RT "Identification of protein kinase D2 as a pivotal regulator of endothelial RT cell proliferation, migration, and angiogenesis."; RL J. Biol. Chem. 284:799-806(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206; SER-518; SER-710; RP TYR-717 AND SER-876, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; SER-198; SER-200; RP SER-203; SER-206 AND SER-710, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP FUNCTION, INTERACTION WITH CIB1 ISOFORM 2, AND MUTAGENESIS OF SER-244; RP ASP-695; SER-706 AND SER-710. RX PubMed=23503467; DOI=10.1038/onc.2013.43; RA Armacki M., Joodi G., Nimmagadda S.C., de Kimpe L., Pusapati G.V., RA Vandoninck S., Van Lint J., Illing A., Seufferlein T.; RT "A novel splice variant of calcium and integrin-binding protein 1 mediates RT protein kinase D2-stimulated tumour growth by regulating angiogenesis."; RL Oncogene 33:1167-1180(2014). RN [28] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION, INTERACTION RP WITH PRKCD, MOTIF, PHOSPHORYLATION AT SER-706; SER-710 AND TYR-717, AND RP MUTAGENESIS OF TYR-87; TYR-438; SER-706; SER-710; TYR-717 AND RP 724-LEU--GLN-726. RX PubMed=28428613; DOI=10.1038/s41598-017-00800-w; RA Cobbaut M., Derua R., Doeppler H., Lou H.J., Vandoninck S., Storz P., RA Turk B.E., Seufferlein T., Waelkens E., Janssens V., Van Lint J.; RT "Differential regulation of PKD isoforms in oxidative stress conditions RT through phosphorylation of a conserved Tyr in the P+1 loop."; RL Sci. Rep. 7:887-887(2017). RN [29] RP STRUCTURE BY NMR OF 395-509. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the PH domain of protein kinase C, D2 type from RT human."; RL Submitted (NOV-2005) to the PDB data bank. RN [30] RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 526-534. RX PubMed=18836451; DOI=10.1038/ni.1660; RA Mohammed F., Cobbold M., Zarling A.L., Salim M., Barrett-Wilt G.A., RA Shabanowitz J., Hunt D.F., Engelhard V.H., Willcox B.E.; RT "Phosphorylation-dependent interaction between antigenic peptides and MHC RT class I: a molecular basis for the presentation of transformed self."; RL Nat. Immunol. 9:1236-1243(2008). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] MET-324; VAL-496; GLY-604; ARG-773; GLU-848 RP AND GLU-870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that converts transient CC diacylglycerol (DAG) signals into prolonged physiological effects CC downstream of PKC, and is involved in the regulation of cell CC proliferation via MAPK1/3 (ERK1/2) signaling, oxidative stress-induced CC NF-kappa-B activation, inhibition of HDAC7 transcriptional repression, CC signaling downstream of T-cell antigen receptor (TCR) and cytokine CC production, and plays a role in Golgi membrane trafficking, CC angiogenesis, secretory granule release and cell adhesion CC (PubMed:14743217, PubMed:15604256, PubMed:16928771, PubMed:17077180, CC PubMed:17951978, PubMed:17962809, PubMed:18262756, PubMed:19001381, CC PubMed:19192391, PubMed:23503467, PubMed:28428613). May potentiate CC mitogenesis induced by the neuropeptide bombesin by mediating an CC increase in the duration of MAPK1/3 (ERK1/2) signaling, which leads to CC accumulation of immediate-early gene products including FOS that CC stimulate cell cycle progression (By similarity). In response to CC oxidative stress, is phosphorylated at Tyr-438 and Tyr-717 by ABL1, CC which leads to the activation of PRKD2 without increasing its catalytic CC activity, and mediates activation of NF-kappa-B (PubMed:15604256, CC PubMed:28428613). In response to the activation of the gastrin receptor CC CCKBR, is phosphorylated at Ser-244 by CSNK1D and CSNK1E, translocates CC to the nucleus, phosphorylates HDAC7, leading to nuclear export of CC HDAC7 and inhibition of HDAC7 transcriptional repression of NR4A1/NUR77 CC (PubMed:17962809). Upon TCR stimulation, is activated independently of CC ZAP70, translocates from the cytoplasm to the nucleus and is required CC for interleukin-2 (IL2) promoter up-regulation (PubMed:17077180). CC During adaptive immune responses, is required in peripheral T- CC lymphocytes for the production of the effector cytokines IL2 and IFNG CC after TCR engagement and for optimal induction of antibody responses to CC antigens (By similarity). In epithelial cells stimulated with CC lysophosphatidic acid (LPA), is activated through a PKC-dependent CC pathway and mediates LPA-stimulated interleukin-8 (IL8) secretion via a CC NF-kappa-B-dependent pathway (PubMed:16928771). During TCR-induced T- CC cell activation, interacts with and is activated by the tyrosine kinase CC LCK, which results in the activation of the NFAT transcription factors CC (PubMed:19192391). In the trans-Golgi network (TGN), regulates the CC fission of transport vesicles that are on their way to the plasma CC membrane and in polarized cells is involved in the transport of CC proteins from the TGN to the basolateral membrane (PubMed:14743217). CC Plays an important role in endothelial cell proliferation and migration CC prior to angiogenesis, partly through modulation of the expression of CC KDR/VEGFR2 and FGFR1, two key growth factor receptors involved in CC angiogenesis (PubMed:19001381). In secretory pathway, is required for CC the release of chromogranin-A (CHGA)-containing secretory granules from CC the TGN (PubMed:18262756). Downstream of PRKCA, plays important roles CC in angiotensin-2-induced monocyte adhesion to endothelial cells CC (PubMed:17951978). Plays a regulatory role in angiogenesis and tumor CC growth by phosphorylating a downstream mediator CIB1 isoform 2, CC resulting in vascular endothelial growth factor A (VEGFA) secretion CC (PubMed:23503467). {ECO:0000250|UniProtKB:Q8BZ03, CC ECO:0000269|PubMed:14743217, ECO:0000269|PubMed:15604256, CC ECO:0000269|PubMed:16928771, ECO:0000269|PubMed:17077180, CC ECO:0000269|PubMed:17951978, ECO:0000269|PubMed:17962809, CC ECO:0000269|PubMed:18262756, ECO:0000269|PubMed:19001381, CC ECO:0000269|PubMed:19192391, ECO:0000269|PubMed:23503467, CC ECO:0000269|PubMed:28428613}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:28428613}; CC -!- ACTIVITY REGULATION: Activated by DAG and phorbol esters CC (PubMed:12058027, PubMed:17962809, PubMed:28428613). Phorbol-ester/DAG- CC type domains bind DAG, mediating translocation to membranes CC (PubMed:17962809). Autophosphorylation of Ser-710 and phosphorylation CC of Ser-706 by PKC relieves auto-inhibition by the PH domain CC (PubMed:17962809). Catalytic activity is further increased by CC phosphorylation at Tyr-717 in response to oxidative stress CC (PubMed:28428613). {ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}. CC -!- SUBUNIT: Interacts (via C-terminus) with LCK (PubMed:19192391). CC Interacts (via N-terminal AP-rich region) with CIB1 isoform 2 CC (PubMed:23503467). Interacts (via N-terminus and zing-finger domain 1 CC and 2) with PRKCD in response to oxidative stress; the interaction is CC independent of PRKD2 tyrosine phosphorylation (PubMed:28428613). CC {ECO:0000269|PubMed:19192391, ECO:0000269|PubMed:23503467, CC ECO:0000269|PubMed:28428613}. CC -!- INTERACTION: CC Q9BZL6; Q02410: APBA1; NbExp=3; IntAct=EBI-1384325, EBI-368690; CC Q9BZL6; Q9BQQ3: GORASP1; NbExp=2; IntAct=EBI-1384325, EBI-2561458; CC Q9BZL6; Q8WUI4: HDAC7; NbExp=6; IntAct=EBI-1384325, EBI-1048378; CC Q9BZL6; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-1384325, EBI-311035; CC Q9BZL6; Q15599: NHERF2; NbExp=3; IntAct=EBI-1384325, EBI-1149760; CC Q9BZL6; P26045: PTPN3; NbExp=2; IntAct=EBI-1384325, EBI-1047946; CC Q9BZL6; Q04917: YWHAH; NbExp=3; IntAct=EBI-1384325, EBI-306940; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17962809}. Cell CC membrane {ECO:0000250|UniProtKB:Q15139}. Nucleus CC {ECO:0000269|PubMed:17962809}. Golgi apparatus, trans-Golgi network CC {ECO:0000269|PubMed:18262756}. Note=Translocation to the cell membrane CC is required for kinase activation. Accumulates in the nucleus upon CK1- CC mediated phosphorylation after activation of G-protein-coupled CC receptors. Nuclear accumulation is regulated by blocking nuclear export CC of active PRKD2 rather than by increasing import. CC {ECO:0000269|PubMed:17962809}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9BZL6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BZL6-2; Sequence=VSP_057279; CC Name=3; CC IsoId=Q9BZL6-3; Sequence=VSP_059398; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:11062248}. CC -!- PTM: Phosphorylation of Ser-876 correlates with the activation status CC of the kinase (PubMed:11062248). Ser-706 or/and Ser-710 are probably CC phosphorylated by PKC (PubMed:12058027, PubMed:28428613). CC Phosphorylation at Ser-244 by CSNK1D and CSNK1E promotes nuclear CC localization and substrate targeting (PubMed:17962809). Phosphorylation CC at Ser-244, Ser-706 and Ser-710 is required for nuclear localization CC (PubMed:17962809). Phosphorylated at Tyr-438 by ABL1 in response to CC oxidative stress (PubMed:15604256). Phosphorylated at Tyr-717 by ABL1 CC specifically in response to oxidative stress; requires prior CC phosphorylation at Ser-706 or/and Ser-710 (PubMed:28428613). CC {ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:15604256, ECO:0000269|PubMed:17962809, CC ECO:0000269|PubMed:28428613}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. PKD subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF36107.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF309082; AAK01149.1; -; mRNA. DR EMBL; AK074673; BAC11127.1; -; mRNA. DR EMBL; AK095884; BAG53158.1; -; mRNA. DR EMBL; AK300339; BAG62084.1; -; mRNA. DR EMBL; AC008635; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC093503; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KC877745; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL050147; CAB43292.1; -; mRNA. DR EMBL; AF151021; AAF36107.1; ALT_FRAME; mRNA. DR CCDS; CCDS12689.1; -. [Q9BZL6-1] DR CCDS; CCDS59401.1; -. [Q9BZL6-2] DR PIR; T08777; T08777. DR RefSeq; NP_001073349.1; NM_001079880.2. [Q9BZL6-1] DR RefSeq; NP_001073350.1; NM_001079881.2. [Q9BZL6-1] DR RefSeq; NP_001073351.1; NM_001079882.2. [Q9BZL6-2] DR RefSeq; NP_057541.2; NM_016457.4. [Q9BZL6-1] DR RefSeq; XP_005258773.2; XM_005258716.3. [Q9BZL6-2] DR RefSeq; XP_047294523.1; XM_047438567.1. [Q9BZL6-2] DR RefSeq; XP_047294524.1; XM_047438568.1. [Q9BZL6-2] DR RefSeq; XP_054176459.1; XM_054320484.1. [Q9BZL6-1] DR RefSeq; XP_054176460.1; XM_054320485.1. [Q9BZL6-1] DR RefSeq; XP_054176461.1; XM_054320486.1. [Q9BZL6-2] DR RefSeq; XP_054176462.1; XM_054320487.1. [Q9BZL6-2] DR RefSeq; XP_054176463.1; XM_054320488.1. [Q9BZL6-2] DR PDB; 2COA; NMR; -; A=398-509. DR PDB; 3BGM; X-ray; 1.60 A; C=526-534. DR PDB; 4NNX; X-ray; 2.10 A; C=526-534. DR PDB; 4NNY; X-ray; 1.90 A; C=526-534. DR PDBsum; 2COA; -. DR PDBsum; 3BGM; -. DR PDBsum; 4NNX; -. DR PDBsum; 4NNY; -. DR AlphaFoldDB; Q9BZL6; -. DR BMRB; Q9BZL6; -. DR SMR; Q9BZL6; -. DR BioGRID; 117384; 316. DR FunCoup; Q9BZL6; 2691. DR IntAct; Q9BZL6; 161. DR MINT; Q9BZL6; -. DR STRING; 9606.ENSP00000393978; -. DR BindingDB; Q9BZL6; -. DR ChEMBL; CHEMBL4900; -. DR DrugCentral; Q9BZL6; -. DR GuidetoPHARMACOLOGY; 2173; -. DR GlyGen; Q9BZL6; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q9BZL6; -. DR PhosphoSitePlus; Q9BZL6; -. DR BioMuta; PRKD2; -. DR DMDM; 296434570; -. DR CPTAC; CPTAC-1364; -. DR jPOST; Q9BZL6; -. DR MassIVE; Q9BZL6; -. DR PaxDb; 9606-ENSP00000393978; -. DR PeptideAtlas; Q9BZL6; -. DR ProteomicsDB; 79872; -. [Q9BZL6-1] DR Pumba; Q9BZL6; -. DR Antibodypedia; 18122; 622 antibodies from 42 providers. DR DNASU; 25865; -. DR Ensembl; ENST00000291281.9; ENSP00000291281.3; ENSG00000105287.14. [Q9BZL6-1] DR Ensembl; ENST00000433867.5; ENSP00000393978.1; ENSG00000105287.14. [Q9BZL6-1] DR Ensembl; ENST00000595515.5; ENSP00000470804.1; ENSG00000105287.14. [Q9BZL6-3] DR Ensembl; ENST00000600194.5; ENSP00000472744.1; ENSG00000105287.14. [Q9BZL6-2] DR Ensembl; ENST00000601806.5; ENSP00000469106.1; ENSG00000105287.14. [Q9BZL6-2] DR GeneID; 25865; -. DR KEGG; hsa:25865; -. DR MANE-Select; ENST00000291281.9; ENSP00000291281.3; NM_016457.5; NP_057541.2. DR UCSC; uc002pfi.4; human. [Q9BZL6-1] DR UCSC; uc010xye.3; human. DR AGR; HGNC:17293; -. DR ClinPGx; PA134903505; -. DR CTD; 25865; -. DR DisGeNET; 25865; -. DR GeneCards; PRKD2; -. DR HGNC; HGNC:17293; PRKD2. DR HPA; ENSG00000105287; Low tissue specificity. DR MIM; 607074; gene. DR OpenTargets; ENSG00000105287; -. DR VEuPathDB; HostDB:ENSG00000105287; -. DR eggNOG; KOG4236; Eukaryota. DR GeneTree; ENSGT00950000183024; -. DR HOGENOM; CLU_009772_1_0_1; -. DR InParanoid; Q9BZL6; -. DR OMA; ASYMGRP; -. DR OrthoDB; 74314at2759; -. DR PAN-GO; Q9BZL6; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9BZL6; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q9BZL6; -. DR Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis. DR SignaLink; Q9BZL6; -. DR SIGNOR; Q9BZL6; -. DR Agora; ENSG00000105287; -. DR BioGRID-ORCS; 25865; 31 hits in 1202 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PRKD2; human. DR EvolutionaryTrace; Q9BZL6; -. DR GeneWiki; PRKD2; -. DR GenomeRNAi; 25865; -. DR Pharos; Q9BZL6; Tchem. DR PRO; PR:Q9BZL6; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q9BZL6; protein. DR Bgee; ENSG00000105287; Expressed in vena cava and 201 other cell types or tissues. DR ExpressionAtlas; Q9BZL6; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IGI:BHF-UCL. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0061154; P:endothelial tube morphogenesis; TAS:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB. DR GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB. DR GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IMP:BHF-UCL. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0032743; P:positive regulation of interleukin-2 production; ISS:UniProtKB. DR GO; GO:0032757; P:positive regulation of interleukin-8 production; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:CACAO. DR GO; GO:0070232; P:regulation of T cell apoptotic process; IMP:BHF-UCL. DR GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome. DR GO; GO:0050852; P:T cell receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL. DR CDD; cd20840; C1_PKD2_rpt1; 1. DR CDD; cd20843; C1_PKD2_rpt2; 1. DR CDD; cd01239; PH_PKD; 1. DR CDD; cd14082; STKc_PKD; 1. DR FunFam; 1.10.510.10:FF:000151; Serine/threonine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000056; Serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000137; Serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000007; Serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000019; Serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR015727; Protein_Kinase_C_mu-related. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR057764; Ubiquitin_PRKD1-3_N. DR PANTHER; PTHR22968; PROTEIN KINASE C, MU; 1. DR PANTHER; PTHR22968:SF12; SERINE_THREONINE-PROTEIN KINASE D2; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF25525; Ubiquitin_PRKD1_N; 1. DR PIRSF; PIRSF000552; PKC_mu_nu_D2; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00233; PH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Alternative splicing; Angiogenesis; KW ATP-binding; Cell adhesion; Cell membrane; Cytoplasm; Golgi apparatus; KW Immunity; Kinase; Magnesium; Membrane; Metal-binding; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..878 FT /note="Serine/threonine-protein kinase D2" FT /id="PRO_0000055716" FT DOMAIN 397..509 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 551..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 138..188 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 264..314 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 224..247 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 343..373 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 844..869 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 724..726 FT /note="Important for ABL1-mediated Tyr-717 phosphorylation" FT /evidence="ECO:0000269|PubMed:28428613" FT COMPBIAS 1..12 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14..35 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 236..245 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 674 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 557..565 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 580 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 30 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O94806" FT MOD_RES 87 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q15139" FT MOD_RES 197 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 198 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 203 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 206 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163" FT MOD_RES 212 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BZ03" FT MOD_RES 214 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 244 FT /note="Phosphoserine; by CSNK1D and CSNK1E" FT /evidence="ECO:0000269|PubMed:17962809" FT MOD_RES 407 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q15139" FT MOD_RES 438 FT /note="Phosphotyrosine; by ABL1" FT /evidence="ECO:0000269|PubMed:15604256, FT ECO:0000305|PubMed:28428613" FT MOD_RES 518 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 706 FT /note="Phosphoserine; by PKC" FT /evidence="ECO:0000269|PubMed:12058027, FT ECO:0000269|PubMed:28428613" FT MOD_RES 710 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:12058027, FT ECO:0000269|PubMed:28428613, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 717 FT /note="Phosphotyrosine; by ABL1" FT /evidence="ECO:0000269|PubMed:28428613, FT ECO:0007744|PubMed:19369195" FT MOD_RES 876 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11062248, FT ECO:0000269|PubMed:12058027, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT VAR_SEQ 1..157 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_057279" FT VAR_SEQ 779 FT /note="G -> GGAWGPPTPWA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_059398" FT VARIANT 324 FT /note="V -> M (in dbSNP:rs45455991)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042330" FT VARIANT 496 FT /note="A -> V (in dbSNP:rs55716765)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042331" FT VARIANT 604 FT /note="S -> G (in dbSNP:rs34325043)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042332" FT VARIANT 773 FT /note="W -> R (in dbSNP:rs55933311)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042333" FT VARIANT 835 FT /note="A -> V (in dbSNP:rs314665)" FT /id="VAR_061531" FT VARIANT 848 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042334" FT VARIANT 870 FT /note="G -> E (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042335" FT MUTAGEN 87 FT /note="Y->F: Loss of phosphorylation. No effect on the FT interaction with PRKCD. No effect on Ser-706 or/and Ser-710 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 244 FT /note="S->E: Constitutive kinase activity; when associated FT with E-706 and E-710." FT /evidence="ECO:0000269|PubMed:23503467" FT MUTAGEN 275 FT /note="P->G: Increase in ability to bind phorbol ester, FT slight increase in ability to bind DAG." FT /evidence="ECO:0000269|PubMed:18076381" FT MUTAGEN 438 FT /note="Y->D: Slight increase in Tyr-717 phosphorylation. No FT effect on Ser-706 or/and Ser-710 phosphorylation. Increase FT in Tyr-717 phosphorylation; when associated with E-706 and FT E-710." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 438 FT /note="Y->F: Loss of phosphorylation. No effect on FT phosphorylation of Tyr-717 and on Ser-706 or/and Ser-710 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:15604256, FT ECO:0000269|PubMed:28428613" FT MUTAGEN 695 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:23503467" FT MUTAGEN 706 FT /note="S->A: Abolishes phosphorylation. Loss of Tyr-717 FT phosphorylation and any other tyrosine phosphorylation, and FT increases NF-kappa-B activation in response to oxidative FT stress; when associated with A-710." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 706 FT /note="S->E: Constitutive kinase activity; when associated FT with E-710 or with E-244 and E-710. Increases Tyr-717 FT phosphorylation; when associated with E-710 or with E-710 FT and D-438." FT /evidence="ECO:0000269|PubMed:23503467, FT ECO:0000269|PubMed:28428613" FT MUTAGEN 710 FT /note="S->A: Abolishes phosphorylation. Loss of Tyr-717 FT phosphorylation and any other tyrosine phosphorylation, and FT increases NF-kappa-B activation in response to oxidative FT stress; when associated with A-706." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 710 FT /note="S->E: Constitutive kinase activity; when associated FT with E-706 or with E-244 and E-706. when associated with E- FT 710 or with E-244 and E-710. Increases Tyr-717 FT phosphorylation; when associated with E-710 or with E-710 FT and D-438." FT /evidence="ECO:0000269|PubMed:23503467, FT ECO:0000269|PubMed:28428613" FT MUTAGEN 717 FT /note="Y->F: Abolishes phosphorylation. Decreases substrate FT affinity and increases catalytic efficiency. Increases Ser- FT 706 or/and Ser-710 phosphorylation. Increases NF-kappa-B FT activation in response to oxidative stress." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 724..726 FT /note="LNQ->RNK: Reduced catalytic activity. Severe FT reduction in Tyr-717 phosphorylation by ABL1 in response to FT oxidative stress. No effect on Ser-706 or/and Ser-710 FT phosphorylation and on NF-kappa-B activation in response to FT oxidative stress." FT /evidence="ECO:0000269|PubMed:28428613" FT CONFLICT 790 FT /note="V -> L (in Ref. 5; AAF36107)" FT /evidence="ECO:0000305" FT STRAND 399..406 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 415..421 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 423..433 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 438..442 FT /evidence="ECO:0007829|PDB:2COA" FT TURN 443..445 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 448..452 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 456..458 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 465..470 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 486..488 FT /evidence="ECO:0007829|PDB:2COA" FT HELIX 495..507 FT /evidence="ECO:0007829|PDB:2COA" SQ SEQUENCE 878 AA; 96722 MW; 8BAB45E8F99D23E7 CRC64; MATAPSYPAG LPGSPGPGSP PPPGGLELQS PPPLLPQIPA PGSGVSFHIQ IGLTREFVLL PAASELAHVK QLACSIVDQK FPECGFYGLY DKILLFKHDP TSANLLQLVR SSGDIQEGDL VEVVLSASAT FEDFQIRPHA LTVHSYRAPA FCDHCGEMLF GLVRQGLKCD GCGLNYHKRC AFSIPNNCSG ARKRRLSSTS LASGHSVRLG TSESLPCTAE ELSRSTTELL PRRPPSSSSS SSASSYTGRP IELDKMLLSK VKVPHTFLIH SYTRPTVCQA CKKLLKGLFR QGLQCKDCKF NCHKRCATRV PNDCLGEALI NGDVPMEEAT DFSEADKSAL MDESEDSGVI PGSHSENALH ASEEEEGEGG KAQSSLGYIP LMRVVQSVRH TTRKSSTTLR EGWVVHYSNK DTLRKRHYWR LDCKCITLFQ NNTTNRYYKE IPLSEILTVE SAQNFSLVPP GTNPHCFEIV TANATYFVGE MPGGTPGGPS GQGAEAARGW ETAIRQALMP VILQDAPSAP GHAPHRQASL SISVSNSQIQ ENVDIATVYQ IFPDEVLGSG QFGVVYGGKH RKTGRDVAVK VIDKLRFPTK QESQLRNEVA ILQSLRHPGI VNLECMFETP EKVFVVMEKL HGDMLEMILS SEKGRLPERL TKFLITQILV ALRHLHFKNI VHCDLKPENV LLASADPFPQ VKLCDFGFAR IIGEKSFRRS VVGTPAYLAP EVLLNQGYNR SLDMWSVGVI MYVSLSGTFP FNEDEDINDQ IQNAAFMYPA SPWSHISAGA IDLINNLLQV KMRKRYSVDK SLSHPWLQEY QTWLDLRELE GKMGERYITH ESDDARWEQF AAEHPLPGSG LPTDRDLGGA CPPQDHDMQG LAERISVL // ID KS6A3_HUMAN Reviewed; 740 AA. AC P51812; B2R9V4; Q4VAP3; Q59H26; Q5JPK8; Q7Z3Z7; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1996, sequence version 1. DT 28-JAN-2026, entry version 235. DE RecName: Full=Ribosomal protein S6 kinase alpha-3; DE Short=S6K-alpha-3; DE EC=2.7.11.1 {ECO:0000269|PubMed:17213202}; DE AltName: Full=90 kDa ribosomal protein S6 kinase 3; DE Short=p90-RSK 3; DE Short=p90RSK3; DE AltName: Full=Insulin-stimulated protein kinase 1; DE Short=ISPK-1; DE AltName: Full=MAP kinase-activated protein kinase 1b; DE Short=MAPK-activated protein kinase 1b; DE Short=MAPKAP kinase 1b; DE Short=MAPKAPK-1b; DE AltName: Full=Ribosomal S6 kinase 2; DE Short=RSK-2; DE AltName: Full=pp90RSK2; GN Name=RPS6KA3; Synonyms=ISPK1, MAPKAPK1B, RSK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta, and T-cell; RX PubMed=7813820; DOI=10.2337/diab.44.1.90; RA Bjoerbaek C., Vik T.A., Echwald S.M., Webb G.C., Wang J.P., Yang P.-Y., RA Vestergaard H., Richmond K., Hansen T., Erikson R.L., Miklos G.L.G., RA Cohen P.T.W., Pedersen O.; RT "Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene and RT analysis of coding regions and mRNA levels of the ISPK-1 and the protein RT phosphatase-1 genes in muscle from NIDDM patients."; RL Diabetes 44:90-97(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2-582. RC TISSUE=Skeletal muscle; RX PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351; RA Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.; RT "Human rsk isoforms: cloning and characterization of tissue-specific RT expression."; RL Am. J. Physiol. 266:C351-C359(1994). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-735. RX PubMed=12777533; DOI=10.1093/molbev/msg134; RA Kitano T., Schwarz C., Nickel B., Paeaebo S.; RT "Gene diversity patterns at 10 X-chromosomal loci in humans and RT chimpanzees."; RL Mol. Biol. Evol. 20:1281-1289(2003). RN [8] RP FUNCTION IN PHOSPHORYLATION OF GSK3B. RX PubMed=8250835; DOI=10.1042/bj2960015; RA Sutherland C., Leighton I.A., Cohen P.; RT "Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new RT kinase connections in insulin and growth-factor signalling."; RL Biochem. J. 296:15-19(1993). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9770464; DOI=10.1073/pnas.95.21.12202; RA De Cesare D., Jacquot S., Hanauer A., Sassone-Corsi P.; RT "Rsk-2 activity is necessary for epidermal growth factor-induced RT phosphorylation of CREB protein and transcription of c-fos gene."; RL Proc. Natl. Acad. Sci. U.S.A. 95:12202-12207(1998). RN [10] RP FUNCTION IN PHOSPHORYLATION OF HISTONE H3. RX PubMed=10436156; DOI=10.1126/science.285.5429.886; RA Sassone-Corsi P., Mizzen C.A., Cheung P., Crosio C., Monaco L., Jacquot S., RA Hanauer A., Allis C.D.; RT "Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation RT of histone H3."; RL Science 285:886-891(1999). RN [11] RP FUNCTION IN PHOSPHORYLATION OF DAPK1. RX PubMed=16213824; DOI=10.1016/j.cub.2005.08.050; RA Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.; RT "The tumor suppressor DAP kinase is a target of RSK-mediated survival RT signaling."; RL Curr. Biol. 15:1762-1767(2005). RN [12] RP FUNCTION IN PHOSPHORYLATION OF NR4A1/NUR77. RX PubMed=16223362; DOI=10.1042/bj20050967; RA Wingate A.D., Campbell D.G., Peggie M., Arthur J.S.; RT "Nur77 is phosphorylated in cells by RSK in response to mitogenic RT stimulation."; RL Biochem. J. 393:715-724(2006). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION WITH NFATC4, RP AND SUBCELLULAR LOCATION. RX PubMed=17213202; DOI=10.1074/jbc.m611322200; RA Cho Y.-Y., Yao K., Bode A.M., Bergen H.R. III, Madden B.J., Oh S.-M., RA Ermakova S., Kang B.S., Choi H.S., Shim J.-H., Dong Z.; RT "RSK2 mediates muscle cell differentiation through regulation of NFAT3."; RL J. Biol. Chem. 282:8380-8392(2007). RN [15] RP FUNCTION IN PHOSPHORYLATION OF RPS6. RX PubMed=17360704; DOI=10.1074/jbc.m700906200; RA Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J., RA Sonenberg N., Blenis J.; RT "RAS/ERK signaling promotes site-specific ribosomal protein S6 RT phosphorylation via RSK and stimulates cap-dependent translation."; RL J. Biol. Chem. 282:14056-14064(2007). RN [16] RP FUNCTION IN MTOR SIGNALING. RX PubMed=18722121; DOI=10.1016/j.cub.2008.07.078; RA Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P., RA Roux P.P.; RT "Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK- RT mediated raptor phosphorylation."; RL Curr. Biol. 18:1269-1277(2008). RN [17] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=18508509; DOI=10.2741/3003; RA Carriere A., Ray H., Blenis J., Roux P.P.; RT "The RSK factors of activating the Ras/MAPK signaling cascade."; RL Front. Biosci. 13:4258-4275(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375; RP SER-386; SER-415; SER-556 AND SER-715, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [19] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=18813292; DOI=10.1038/nrm2509; RA Anjum R., Blenis J.; RT "The RSK family of kinases: emerging roles in cellular signalling."; RL Nat. Rev. Mol. Cell Biol. 9:747-758(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369 AND SER-375, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375; RP SER-386; SER-415 AND SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-415, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365 AND SER-369, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-415 AND RP SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-369; SER-386; SER-415 AND RP SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [28] RP FUNCTION IN PHOSPHORYLATION OF EPHA2. RX PubMed=26158630; DOI=10.1038/ncomms8679; RA Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S., RA Fukuoka J., Koizumi K., Saiki I., Sakurai H.; RT "Crucial roles of RSK in cell motility by catalysing serine phosphorylation RT of EphA2."; RL Nat. Commun. 6:7679-7679(2015). RN [29] RP VARIANTS CLS VAL-75 AND ALA-227. RX PubMed=8955270; DOI=10.1038/384567a0; RA Trivier E., de Cesare D., Jacquot S., Pannetier S., Zackai E., Young I., RA Mandel J.-L., Sassone-Corsi P., Hanauer A.; RT "Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome."; RL Nature 384:567-570(1996). RN [30] RP VARIANTS CLS PHE-82; GLN-127; TYR-154; VAL-225 AND ASP-431, AND VARIANT RP SER-38. RX PubMed=9837815; DOI=10.1086/302153; RA Jacquot S., Merienne K., de Cesare D., Pannetier S., Mandel J.-L., RA Sassone-Corsi P., Hanauer A.; RT "Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive RT allelic heterogeneity and a high rate of De novo mutations."; RL Am. J. Hum. Genet. 63:1631-1640(1998). RN [31] RP VARIANTS CLS TRP-114 AND GLN-729. RX PubMed=10094187; DOI=10.1038/sj.ejhg.5200231; RA Abidi F., Jacquot S., Lassiter C., Trivier E., Hanauer A., Schwartz C.E.; RT "Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS)."; RL Eur. J. Hum. Genet. 7:20-26(1999). RN [32] RP VARIANT CLS LYS-189. RX PubMed=10528858; DOI=10.1136/jmg.36.10.775; RA Manouvrier-Hanu S., Amiel J., Jacquot S., Merienne K., Moerman A., RA Coeslier A., Labarriere F., Vallee L., Croquette M.F., Hanauer A.; RT "Unreported RSK2 missense mutation in two male sibs with an unusually mild RT form of Coffin-Lowry syndrome."; RL J. Med. Genet. 36:775-778(1999). RN [33] RP VARIANT XLID19 TRP-383, AND CHARACTERIZATION OF VARIANT XLID19 TRP-383. RX PubMed=10319851; DOI=10.1038/8719; RA Merienne K., Jacquot S., Pannetier S., Zeniou M., Bankier A., Gecz J., RA Mandel J.L., Mulley J., Sassone-Corsi P., Hanauer A.; RT "A missense mutation in RPS6KA3 (RSK2) responsible for non-specific mental RT retardation."; RL Nat. Genet. 22:13-14(1999). RN [34] RP VARIANT CLS SER-268. RX PubMed=14986828; DOI=10.1046/j.1399-0004.2003.00166.x; RA Martinez-Garay I., Ballesta M.J., Oltra S., Orellana C., Palomeque A., RA Molto M.D., Prieto F., Martinez F.; RT "Intronic L1 insertion and F268S, novel mutations in RPS6KA3 (RSK2) causing RT Coffin-Lowry syndrome."; RL Clin. Genet. 64:491-496(2003). RN [35] RP VARIANT CLS ILE-477 DEL. RX PubMed=15214012; DOI=10.1002/ajmg.a.30056; RA Facher J.J., Regier E.J., Jacobs G.H., Siwik E., Delaunoy J.P., Robin N.H.; RT "Cardiomyopathy in Coffin-Lowry syndrome."; RL Am. J. Med. Genet. A 128:176-178(2004). RN [36] RP VARIANTS XLID19 SER-115; GLY-152 DEL AND ASP-202 DEL. RX PubMed=17100996; DOI=10.1111/j.1399-0004.2006.00723.x; RA Field M., Tarpey P., Boyle J., Edkins S., Goodship J., Luo Y., Moon J., RA Teague J., Stratton M.R., Futreal P.A., Wooster R., Raymond F.L., RA Turner G.; RT "Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and RT nonsyndromic X-linked mental retardation."; RL Clin. Genet. 70:509-515(2006). RN [37] RP VARIANT [LARGE SCALE ANALYSIS] VAL-416. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [38] RP VARIANTS [LARGE SCALE ANALYSIS] SER-38; CYS-483; PHE-608 AND CYS-723. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK CC (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and CC stress-induced activation of the transcription factors CREB1, ETV1/ER81 CC and NR4A1/NUR77, regulates translation through RPS6 and EIF4B CC phosphorylation, and mediates cellular proliferation, survival, and CC differentiation by modulating mTOR signaling and repressing pro- CC apoptotic function of BAD and DAPK1 (PubMed:16213824, PubMed:16223362, CC PubMed:17360704, PubMed:9770464). In fibroblast, is required for EGF- CC stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which CC results in the subsequent transcriptional activation of several CC immediate-early genes (PubMed:10436156, PubMed:9770464). In response to CC mitogenic stimulation (EGF and PMA), phosphorylates and activates CC NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP CC (PubMed:16223362). Upon insulin-derived signal, acts indirectly on the CC transcription regulation of several genes by phosphorylating GSK3B at CC 'Ser-9' and inhibiting its activity (PubMed:8250835). Phosphorylates CC RPS6 in response to serum or EGF via an mTOR-independent mechanism and CC promotes translation initiation by facilitating assembly of the CC preinitiation complex (PubMed:17360704). In response to insulin, CC phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and CC stimulating cap-dependent translation (PubMed:18508509, CC PubMed:18813292). Is involved in the mTOR nutrient-sensing pathway by CC directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits CC TSC2 ability to suppress mTOR signaling, and mediates phosphorylation CC of RPTOR, which regulates mTORC1 activity and may promote rapamycin- CC sensitive signaling independently of the PI3K/AKT pathway CC (PubMed:18722121). Mediates cell survival by phosphorylating the pro- CC apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic CC function (PubMed:16213824). Promotes the survival of hepatic stellate CC cells by phosphorylating CEBPB in response to the hepatotoxin carbon CC tetrachloride (CCl4) (PubMed:18508509, PubMed:18813292). Is involved in CC cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, CC which promotes CDKN1B association with 14-3-3 proteins and prevents its CC translocation to the nucleus and inhibition of G1 progression (By CC similarity). In LPS-stimulated dendritic cells, is involved in TLR4- CC induced macropinocytosis, and in myeloma cells, acts as effector of CC FGFR3-mediated transformation signaling, after direct phosphorylation CC at Tyr-529 by FGFR3 (By similarity). Negatively regulates EGF-induced CC MAPK1/3 phosphorylation via phosphorylation of SOS1 (By similarity). CC Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and CC YWHAE binding sites and which contribute to the negative regulation of CC MAPK1/3 phosphorylation (By similarity). Phosphorylates EPHA2 at 'Ser- CC 897', the RPS6KA-EPHA2 signaling pathway controls cell migration CC (PubMed:26158630). Acts as a regulator of osteoblast differentiation by CC mediating phosphorylation of ATF4, thereby promoting ATF4 CC transactivation activity (By similarity). CC {ECO:0000250|UniProtKB:P18654, ECO:0000269|PubMed:10436156, CC ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362, CC ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121, CC ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:8250835, CC ECO:0000269|PubMed:9770464, ECO:0000303|PubMed:18508509, CC ECO:0000303|PubMed:18813292}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17213202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation, CC phosphorylated at Thr-577 in the C-terminal kinase domain (CTKD) by CC MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates CC Ser-386, allowing binding of PDPK1, which in turn phosphorylates Ser- CC 227 in the N-terminal kinase domain (NTDK) leading to the full CC activation of the protein and subsequent phosphorylation of the CC substrates by the NTKD. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=3.56 uM for NFATC4 {ECO:0000269|PubMed:17213202}; CC Vmax=11.5 umol/min/ug enzyme toward ATP CC {ECO:0000269|PubMed:17213202}; CC -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in CC quiescent cells. Transiently dissociates following mitogenic CC stimulation (By similarity). Interacts with NFATC4, ETV1/ER81 and CC FGFR1. {ECO:0000250, ECO:0000269|PubMed:17213202}. CC -!- INTERACTION: CC P51812; Q02410: APBA1; NbExp=2; IntAct=EBI-1046616, EBI-368690; CC P51812; P46379-2: BAG6; NbExp=3; IntAct=EBI-1046616, EBI-10988864; CC P51812; P67870: CSNK2B; NbExp=8; IntAct=EBI-1046616, EBI-348169; CC P51812; Q12959: DLG1; NbExp=3; IntAct=EBI-1046616, EBI-357481; CC P51812; P09471: GNAO1; NbExp=3; IntAct=EBI-1046616, EBI-715087; CC P51812; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1046616, EBI-352572; CC P51812; O14901: KLF11; NbExp=3; IntAct=EBI-1046616, EBI-948266; CC P51812; Q86UL8: MAGI2; NbExp=3; IntAct=EBI-1046616, EBI-311035; CC P51812; P28482: MAPK1; NbExp=12; IntAct=EBI-1046616, EBI-959949; CC P51812; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-1046616, EBI-11750983; CC P51812; Q15599: NHERF2; NbExp=2; IntAct=EBI-1046616, EBI-1149760; CC P51812; Q6P4D5-2: PABIR3; NbExp=3; IntAct=EBI-1046616, EBI-9091052; CC P51812; Q5T2W1: PDZK1; NbExp=2; IntAct=EBI-1046616, EBI-349819; CC P51812; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-1046616, EBI-9090282; CC P51812; Q14160: SCRIB; NbExp=2; IntAct=EBI-1046616, EBI-357345; CC P51812; Q7Z698: SPRED2; NbExp=4; IntAct=EBI-1046616, EBI-7082156; CC P51812; Q9P202: WHRN; NbExp=2; IntAct=EBI-1046616, EBI-310886; CC P51812; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-1046616, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17213202}. Cytoplasm CC {ECO:0000269|PubMed:17213202}. CC -!- TISSUE SPECIFICITY: Expressed in many tissues, highest levels in CC skeletal muscle. CC -!- PTM: Activated by phosphorylation at Ser-227 by PDPK1. CC Autophosphorylated on Ser-386, as part of the activation process. May CC be phosphorylated at Thr-365 and Ser-369 by MAPK1/ERK2 and MAPK3/ERK1. CC Can also be activated via phosphorylation at Ser-386 by MAPKAPK2. CC -!- PTM: N-terminal myristoylation results in an activated kinase in the CC absence of added growth factors. CC -!- DISEASE: Coffin-Lowry syndrome (CLS) [MIM:303600]: An X-linked disorder CC characterized by intellectual disability associated with facial and CC digital dysmorphisms, progressive skeletal malformations, growth CC retardation, hearing deficit and paroxysmal movement disorders. CC {ECO:0000269|PubMed:10094187, ECO:0000269|PubMed:10528858, CC ECO:0000269|PubMed:14986828, ECO:0000269|PubMed:15214012, CC ECO:0000269|PubMed:8955270, ECO:0000269|PubMed:9837815}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Intellectual developmental disorder, X-linked 19 (XLID19) CC [MIM:300844]: A disorder characterized by significantly below average CC general intellectual functioning associated with impairments in CC adaptive behavior and manifested during the developmental period. CC {ECO:0000269|PubMed:10319851, ECO:0000269|PubMed:17100996}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. S6 kinase subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92170.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U08316; AAA81952.1; -; mRNA. DR EMBL; AK313932; BAG36651.1; -; mRNA. DR EMBL; AB208933; BAD92170.1; ALT_INIT; mRNA. DR EMBL; AL732366; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL807772; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC096301; AAH96301.1; -; mRNA. DR EMBL; BC096302; AAH96302.1; -; mRNA. DR EMBL; BC096303; AAH96303.1; -; mRNA. DR EMBL; L07599; AAC82495.1; -; mRNA. DR EMBL; AB102662; BAC81131.1; -; mRNA. DR CCDS; CCDS14197.1; -. DR PIR; I38556; I38556. DR RefSeq; NP_004577.1; NM_004586.3. DR PDB; 4D9T; X-ray; 2.40 A; A=399-740. DR PDB; 4D9U; X-ray; 2.40 A; A=399-740. DR PDB; 4JG6; X-ray; 2.60 A; A=399-740. DR PDB; 4JG7; X-ray; 3.00 A; A=399-740. DR PDB; 4JG8; X-ray; 3.10 A; A=399-740. DR PDB; 4NUS; X-ray; 2.39 A; A=39-359. DR PDB; 4NW5; X-ray; 1.94 A; A=39-359. DR PDB; 4NW6; X-ray; 1.74 A; A=39-359. DR PDB; 5D9K; X-ray; 2.55 A; A/B=39-366. DR PDB; 5D9L; X-ray; 2.15 A; A=39-359. DR PDB; 7OPO; X-ray; 2.75 A; A/C/E/G/I/K=39-351. DR PDB; 8EQ5; X-ray; 1.80 A; A=46-346. DR PDB; 8R58; X-ray; 2.31 A; A=39-351. DR PDB; 8XEY; X-ray; 2.65 A; A=400-740. DR PDB; 8XFY; X-ray; 3.20 A; A/B/C/D/E/F/G/H/I/J=40-359. DR PDBsum; 4D9T; -. DR PDBsum; 4D9U; -. DR PDBsum; 4JG6; -. DR PDBsum; 4JG7; -. DR PDBsum; 4JG8; -. DR PDBsum; 4NUS; -. DR PDBsum; 4NW5; -. DR PDBsum; 4NW6; -. DR PDBsum; 5D9K; -. DR PDBsum; 5D9L; -. DR PDBsum; 7OPO; -. DR PDBsum; 8EQ5; -. DR PDBsum; 8R58; -. DR PDBsum; 8XEY; -. DR PDBsum; 8XFY; -. DR AlphaFoldDB; P51812; -. DR SMR; P51812; -. DR BioGRID; 112111; 215. DR DIP; DIP-38247N; -. DR FunCoup; P51812; 2985. DR IntAct; P51812; 146. DR MINT; P51812; -. DR STRING; 9606.ENSP00000368884; -. DR BindingDB; P51812; -. DR ChEMBL; CHEMBL2345; -. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P51812; -. DR GuidetoPHARMACOLOGY; 1528; -. DR GlyCosmos; P51812; 1 site, 1 glycan. DR GlyGen; P51812; 6 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P51812; -. DR MetOSite; P51812; -. DR PhosphoSitePlus; P51812; -. DR BioMuta; RPS6KA3; -. DR DMDM; 1730070; -. DR CPTAC; CPTAC-2899; -. DR CPTAC; CPTAC-2900; -. DR jPOST; P51812; -. DR MassIVE; P51812; -. DR PaxDb; 9606-ENSP00000368884; -. DR PeptideAtlas; P51812; -. DR ProteomicsDB; 56408; -. DR Pumba; P51812; -. DR Antibodypedia; 1004; 599 antibodies from 40 providers. DR DNASU; 6197; -. DR Ensembl; ENST00000379565.9; ENSP00000368884.3; ENSG00000177189.15. DR GeneID; 6197; -. DR KEGG; hsa:6197; -. DR MANE-Select; ENST00000379565.9; ENSP00000368884.3; NM_004586.3; NP_004577.1. DR UCSC; uc004czu.4; human. DR AGR; HGNC:10432; -. DR ClinPGx; PA34847; -. DR CTD; 6197; -. DR DisGeNET; 6197; -. DR GeneCards; RPS6KA3; -. DR GeneReviews; RPS6KA3; -. DR HGNC; HGNC:10432; RPS6KA3. DR HPA; ENSG00000177189; Low tissue specificity. DR MalaCards; RPS6KA3; -. DR MIM; 300075; gene. DR MIM; 300844; phenotype. DR MIM; 303600; phenotype. DR OpenTargets; ENSG00000177189; -. DR Orphanet; 192; Coffin-Lowry syndrome. DR Orphanet; 276630; Symptomatic form of Coffin-Lowry syndrome in female carriers. DR Orphanet; 777; X-linked non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000177189; -. DR eggNOG; KOG0603; Eukaryota. DR GeneTree; ENSGT00940000159370; -. DR HOGENOM; CLU_000288_58_3_1; -. DR InParanoid; P51812; -. DR OMA; QTDEVFY; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P51812; 4 GO annotations based on evolutionary models. DR PhylomeDB; P51812; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P51812; -. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-199920; CREB phosphorylation. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-437239; Recycling pathway of L1. DR Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. DR Reactome; R-HSA-444257; RSK activation. DR Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK. DR SABIO-RK; P51812; -. DR SignaLink; P51812; -. DR SIGNOR; P51812; -. DR Agora; ENSG00000177189; -. DR BioGRID-ORCS; 6197; 25 hits in 814 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; RPS6KA3; human. DR EvolutionaryTrace; P51812; -. DR GeneWiki; RPS6KA3; -. DR GenomeRNAi; 6197; -. DR Pharos; P51812; Tchem. DR PRO; PR:P51812; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51812; protein. DR Bgee; ENSG00000177189; Expressed in cartilage tissue and 204 other cell types or tissues. DR ExpressionAtlas; P51812; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central. DR GO; GO:0007417; P:central nervous system development; TAS:ProtInc. DR GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0045597; P:positive regulation of cell differentiation; TAS:UniProtKB. DR GO; GO:0030307; P:positive regulation of cell growth; TAS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0043555; P:regulation of translation in response to stress; TAS:UniProtKB. DR GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0001501; P:skeletal system development; TAS:ProtInc. DR GO; GO:0002224; P:toll-like receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central. DR CDD; cd14176; STKc_RSK2_C; 1. DR CDD; cd05582; STKc_RSK_N; 1. DR FunFam; 1.10.510.10:FF:000010; Ribosomal protein S6 kinase; 1. DR FunFam; 1.10.510.10:FF:000041; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000013; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000121; Ribosomal protein S6 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016239; Ribosomal_S6_kinase_II. DR InterPro; IPR041905; RPS6KA3_C. DR InterPro; IPR041906; RSK_N. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cytoplasm; Disease variant; KW Intellectual disability; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; KW Stress response; Transferase. FT CHAIN 1..740 FT /note="Ribosomal protein S6 kinase alpha-3" FT /id="PRO_0000086203" FT DOMAIN 68..327 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 328..397 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 422..679 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 18..27 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 193 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 539 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 74..82 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 100 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 428..436 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 451 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 227 FT /note="Phosphoserine; by PDPK1" FT /evidence="ECO:0000250|UniProtKB:P18654, ECO:0000305" FT MOD_RES 365 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 369 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 375 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195" FT MOD_RES 386 FT /note="Phosphoserine; by autocatalysis and MAPKAPK2" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:24275569" FT MOD_RES 415 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 529 FT /note="Phosphotyrosine; by FGFR3" FT /evidence="ECO:0000250|UniProtKB:P18654" FT MOD_RES 556 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 715 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VARIANT 38 FT /note="I -> S (in dbSNP:rs56218010)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9837815" FT /id="VAR_006188" FT VARIANT 75 FT /note="G -> V (in CLS; dbSNP:rs122454124)" FT /evidence="ECO:0000269|PubMed:8955270" FT /id="VAR_006189" FT VARIANT 82 FT /note="V -> F (in CLS; dbSNP:rs122454126)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006190" FT VARIANT 114 FT /note="R -> W (in CLS; dbSNP:rs122454127)" FT /evidence="ECO:0000269|PubMed:10094187" FT /id="VAR_006191" FT VARIANT 115 FT /note="T -> S (in XLID19; dbSNP:rs387906703)" FT /evidence="ECO:0000269|PubMed:17100996" FT /id="VAR_065892" FT VARIANT 127 FT /note="H -> Q (in CLS)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006192" FT VARIANT 152 FT /note="Missing (in XLID19; dbSNP:rs398122813)" FT /evidence="ECO:0000269|PubMed:17100996" FT /id="VAR_065893" FT VARIANT 154 FT /note="D -> Y (in CLS)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006193" FT VARIANT 189 FT /note="I -> K (in CLS; dbSNP:rs122454130)" FT /evidence="ECO:0000269|PubMed:10528858" FT /id="VAR_065894" FT VARIANT 202 FT /note="Missing (in XLID19)" FT /evidence="ECO:0000269|PubMed:17100996" FT /id="VAR_065895" FT VARIANT 225 FT /note="A -> V (in CLS; dbSNP:rs879027948)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006194" FT VARIANT 227 FT /note="S -> A (in CLS; dbSNP:rs122454125)" FT /evidence="ECO:0000269|PubMed:8955270" FT /id="VAR_006195" FT VARIANT 268 FT /note="F -> S (in CLS; dbSNP:rs122454131)" FT /evidence="ECO:0000269|PubMed:14986828" FT /id="VAR_065896" FT VARIANT 383 FT /note="R -> W (in XLID19; kinase activity is decreased but FT not abolished; dbSNP:rs122454129)" FT /evidence="ECO:0000269|PubMed:10319851" FT /id="VAR_065897" FT VARIANT 416 FT /note="I -> V (in a breast cancer sample; somatic mutation; FT dbSNP:rs148050184)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035627" FT VARIANT 431 FT /note="G -> D (in CLS)" FT /evidence="ECO:0000269|PubMed:9837815" FT /id="VAR_006196" FT VARIANT 477 FT /note="Missing (in CLS)" FT /evidence="ECO:0000269|PubMed:15214012" FT /id="VAR_065898" FT VARIANT 483 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1271090915)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040629" FT VARIANT 608 FT /note="L -> F (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040630" FT VARIANT 723 FT /note="R -> C (in dbSNP:rs35026425)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040631" FT VARIANT 729 FT /note="R -> Q (in CLS; dbSNP:rs28935171)" FT /evidence="ECO:0000269|PubMed:10094187" FT /id="VAR_006197" FT CONFLICT 89 FT /note="S -> L (in Ref. 5; AAH96303)" FT /evidence="ECO:0000305" FT CONFLICT 410 FT /note="Missing (in Ref. 3; BAD92170)" FT /evidence="ECO:0000305" FT CONFLICT 424 FT /note="V -> L (in Ref. 6; AAC82495)" FT /evidence="ECO:0000305" FT CONFLICT 480 FT /note="K -> N (in Ref. 6; AAC82495)" FT /evidence="ECO:0000305" FT CONFLICT 494 FT /note="Missing (in Ref. 6; AAC82495)" FT /evidence="ECO:0000305" FT STRAND 50..56 FT /evidence="ECO:0007829|PDB:8EQ5" FT HELIX 65..67 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 68..76 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 78..87 FT /evidence="ECO:0007829|PDB:4NW6" FT TURN 91..94 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:4NW6" FT TURN 105..107 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 109..124 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 133..139 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 142..148 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:5D9K" FT HELIX 155..162 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 167..186 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 189..192 FT /evidence="ECO:0007829|PDB:5D9L" FT HELIX 196..198 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4NUS" FT STRAND 207..209 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:5D9L" FT HELIX 217..223 FT /evidence="ECO:0007829|PDB:4NUS" FT TURN 224..226 FT /evidence="ECO:0007829|PDB:4NUS" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 237..240 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 249..263 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 273..282 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 293..302 FT /evidence="ECO:0007829|PDB:4NW6" FT STRAND 304..306 FT /evidence="ECO:0007829|PDB:8EQ5" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:4NW6" FT TURN 315..318 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 319..322 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 332..336 FT /evidence="ECO:0007829|PDB:4NW6" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:5D9L" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:4JG7" FT HELIX 412..414 FT /evidence="ECO:0007829|PDB:4D9U" FT TURN 419..421 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 422..430 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 432..441 FT /evidence="ECO:0007829|PDB:4D9T" FT TURN 442..445 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 446..454 FT /evidence="ECO:0007829|PDB:4D9T" FT TURN 455..457 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 461..470 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 479..484 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 486..494 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 501..506 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 513..532 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 542..544 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 545..551 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 554..556 FT /evidence="ECO:0007829|PDB:4D9T" FT STRAND 557..559 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 571..573 FT /evidence="ECO:0007829|PDB:8XEY" FT HELIX 587..613 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 626..635 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 643..645 FT /evidence="ECO:0007829|PDB:4D9U" FT STRAND 646..648 FT /evidence="ECO:0007829|PDB:4JG6" FT HELIX 650..659 FT /evidence="ECO:0007829|PDB:4D9T" FT TURN 664..666 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 670..673 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 677..680 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 682..684 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 696..710 FT /evidence="ECO:0007829|PDB:4D9T" FT HELIX 711..713 FT /evidence="ECO:0007829|PDB:4JG8" SQ SEQUENCE 740 AA; 83736 MW; 486AE8357CEAB6C8 CRC64; MPLAQLADPW QKMAVESPSD SAENGQQIMD EPMGEEEINP QTEEVSIKEI AITHHVKEGH EKADPSQFEL LKVLGQGSFG KVFLVKKISG SDARQLYAMK VLKKATLKVR DRVRTKMERD ILVEVNHPFI VKLHYAFQTE GKLYLILDFL RGGDLFTRLS KEVMFTEEDV KFYLAELALA LDHLHSLGII YRDLKPENIL LDEEGHIKLT DFGLSKESID HEKKAYSFCG TVEYMAPEVV NRRGHTQSAD WWSFGVLMFE MLTGTLPFQG KDRKETMTMI LKAKLGMPQF LSPEAQSLLR MLFKRNPANR LGAGPDGVEE IKRHSFFSTI DWNKLYRREI HPPFKPATGR PEDTFYFDPE FTAKTPKDSP GIPPSANAHQ LFRGFSFVAI TSDDESQAMQ TVGVHSIVQQ LHRNSIQFTD GYEVKEDIGV GSYSVCKRCI HKATNMEFAV KIIDKSKRDP TEEIEILLRY GQHPNIITLK DVYDDGKYVY VVTELMKGGE LLDKILRQKF FSEREASAVL FTITKTVEYL HAQGVVHRDL KPSNILYVDE SGNPESIRIC DFGFAKQLRA ENGLLMTPCY TANFVAPEVL KRQGYDAACD IWSLGVLLYT MLTGYTPFAN GPDDTPEEIL ARIGSGKFSL SGGYWNSVSD TAKDLVSKML HVDPHQRLTA ALVLRHPWIV HWDQLPQYQL NRQDAPHLVK GAMAATYSAL NRNQSPVLEP VGRSTLAQRR GIKKITSTAL // ID M3K9_HUMAN Reviewed; 1104 AA. AC P80192; A3KN85; Q0D2G7; Q6EH31; Q9H2N5; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 214. DE RecName: Full=Mitogen-activated protein kinase kinase kinase 9; DE EC=2.7.11.25; DE AltName: Full=Mixed lineage kinase 1; GN Name=MAP3K9; Synonyms=MLK1, PRKE1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-304; THR-305; SER-308 AND THR-312, AND MUTAGENESIS RP OF LYS-171; THR-304; THR-305; SER-308 AND THR-312. RX PubMed=15610029; DOI=10.1021/bi049866y; RA Durkin J.T., Holskin B.P., Kopec K.K., Reed M.S., Spais C.M., Steffy B.M., RA Gessner G., Angeles T.S., Pohl J., Ator M.A., Meyer S.L.; RT "Phosphoregulation of mixed-lineage kinase 1 activity by multiple RT phosphorylation in the activation loop."; RL Biochemistry 43:16348-16355(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] OF 53-1104 (ISOFORM 2). RA McNee J.J., Dower S.K., Guesdon F.; RT "cDNA sequence and gene organisation of mixed lineage kinase 1."; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 142-535, AND TISSUE SPECIFICITY. RC TISSUE=Colon epithelium; RX PubMed=8477742; DOI=10.1111/j.1432-1033.1993.tb17810.x; RA Dorow D.S., Devereux L., Dietzsch E., de Kretser T.; RT "Identification of a new family of human epithelial protein kinases RT containing two leucine/isoleucine-zipper domains."; RL Eur. J. Biochem. 213:701-710(1993). RN [5] RP ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND PHOSPHORYLATION OF RP MAP2K4/MKK4. RX PubMed=11325962; DOI=10.1074/jbc.m011601200; RA Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., RA Xu Z., Meyer S.L., Savage M.J., Greene L.A., Scott R.W., Vaught J.L.; RT "Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase RT family."; RL J. Biol. Chem. 276:25302-25308(2001). RN [6] RP FUNCTION IN THE APOPTOSIS PATHWAY. RX PubMed=11416147; DOI=10.1128/mcb.21.14.4713-4724.2001; RA Xu Z., Maroney A.C., Dobrzanski P., Kukekov N.V., Greene L.A.; RT "The MLK family mediates c-Jun N-terminal kinase activation in neuronal RT apoptosis."; RL Mol. Cell. Biol. 21:4713-4724(2001). RN [7] RP ACTIVITY REGULATION. RX PubMed=11755341; DOI=10.1016/s0960-894x(01)00690-4; RA Murakata C., Kaneko M., Gessner G., Angeles T.S., Ator M.A., O'Kane T.M., RA McKenna B.A., Thomas B.A., Mathiasen J.R., Saporito M.S., RA Bozyczko-Coyne D., Hudkins R.L.; RT "Mixed lineage kinase activity of indolocarbazole analogues."; RL Bioorg. Med. Chem. Lett. 12:147-150(2002). RN [8] RP POSSIBLE ROLE IN ESOPHAGEAL CANCER. RX PubMed=18241037; DOI=10.1002/ijc.23397; RA Chen J., Guo L., Peiffer D.A., Zhou L., Chan O.T., Bibikova M., RA Wickham-Garcia E., Lu S.H., Zhan Q., Wang-Rodriguez J., Jiang W., Fan J.B.; RT "Genomic profiling of 766 cancer-related genes in archived esophageal RT normal and carcinoma tissues."; RL Int. J. Cancer 122:2249-2254(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 136-406. RX PubMed=18714982; DOI=10.1021/jm8005838; RA Hudkins R.L., Diebold J.L., Tao M., Josef K.A., Park C.H., Angeles T.S., RA Aimone L.D., Husten J., Ator M.A., Meyer S.L., Holskin B.P., Durkin J.T., RA Fedorov A.A., Fedorov E.V., Almo S.C., Mathiasen J.R., Bozyczko-Coyne D., RA Saporito M.S., Scott R.W., Mallamo J.P.; RT "Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective RT dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed- RT lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4- RT phenyltetrahydropyridine models."; RL J. Med. Chem. 51:5680-5689(2008). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-246; CYS-467; GLN-497 AND CYS-646. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. Plays an important role CC in the cascades of cellular responses evoked by changes in the CC environment. Once activated, acts as an upstream activator of the CC MKK/JNK signal transduction cascade through the phosphorylation of CC MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The CC MKK/JNK signaling pathway regulates stress response via activator CC protein-1 (JUN) and GATA4 transcription factors. Also plays a role in CC mitochondrial death signaling pathway, including the release cytochrome CC c, leading to apoptosis. {ECO:0000269|PubMed:11416147, CC ECO:0000269|PubMed:15610029}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Homodimerization via the leucine zipper domains is CC required for autophosphorylation of multiple sites in the activation CC loop and subsequent activation. Autophosphorylation at Thr-312 is the CC key step in activation of MAP3K9/MLK1 and is required for full CC phosphorylation. Autophosphorylation at Thr-304 and Ser-308 have been CC shown to be of secondary importance in the activation of MAP3K9/MLK1. CC CEP-1347 and many indolocarbazole analogs have been shown to act as CC inhibitors of MAP3K9/MLK1 activity. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:11755341, ECO:0000269|PubMed:15610029}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=62 uM for ATP {ECO:0000269|PubMed:11325962}; CC KM=7 uM for myelin basic protein (MBP) as substrate CC {ECO:0000269|PubMed:11325962}; CC -!- SUBUNIT: Homodimer. {ECO:0000250}. CC -!- INTERACTION: CC P80192; P08238: HSP90AB1; NbExp=2; IntAct=EBI-3951604, EBI-352572; CC P80192; Q92993: KAT5; NbExp=3; IntAct=EBI-3951604, EBI-399080; CC P80192; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-3951604, EBI-11742507; CC P80192; P17252: PRKCA; NbExp=3; IntAct=EBI-3951604, EBI-1383528; CC P80192; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-3951604, EBI-9090795; CC P80192; P62258: YWHAE; NbExp=3; IntAct=EBI-3951604, EBI-356498; CC P80192; P61981: YWHAG; NbExp=4; IntAct=EBI-3951604, EBI-359832; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P80192-1; Sequence=Displayed; CC Name=2; CC IsoId=P80192-4; Sequence=VSP_013765; CC -!- TISSUE SPECIFICITY: Expressed in epithelial tumor cell lines of CC colonic, breast and esophageal origin. {ECO:0000269|PubMed:8477742}. CC -!- PTM: Autophosphorylation on serine and threonine residues within the CC activation loop plays a role in enzyme activation. Thr-312 is likely to CC be the main autophosphorylation site. Autophosphorylation also occurs CC on Thr-304 and Ser-308. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:15610029}. CC -!- DISEASE: Note=May play a role in esophageal cancer susceptibility CC and/or development. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAI11408.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY327900; AAQ23054.1; -; mRNA. DR EMBL; BC111407; AAI11408.1; ALT_INIT; mRNA. DR EMBL; BC133706; AAI33707.1; -; mRNA. DR EMBL; AF251442; AAG44591.1; -; mRNA. DR CCDS; CCDS32112.1; -. [P80192-4] DR CCDS; CCDS61488.1; -. [P80192-1] DR PIR; S32467; JU0229. DR RefSeq; NP_001271159.1; NM_001284230.2. [P80192-1] DR RefSeq; NP_149132.2; NM_033141.3. [P80192-4] DR PDB; 3DTC; X-ray; 2.60 A; A=136-406. DR PDB; 4UY9; X-ray; 2.81 A; A/B=135-456. DR PDBsum; 3DTC; -. DR PDBsum; 4UY9; -. DR AlphaFoldDB; P80192; -. DR SMR; P80192; -. DR BioGRID; 110439; 29. DR FunCoup; P80192; 485. DR IntAct; P80192; 32. DR STRING; 9606.ENSP00000451263; -. DR BindingDB; P80192; -. DR ChEMBL; CHEMBL2872; -. DR DrugBank; DB08703; 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P80192; -. DR GuidetoPHARMACOLOGY; 2084; -. DR GlyGen; P80192; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P80192; -. DR PhosphoSitePlus; P80192; -. DR BioMuta; MAP3K9; -. DR DMDM; 116242625; -. DR CPTAC; CPTAC-860; -. DR CPTAC; CPTAC-861; -. DR jPOST; P80192; -. DR MassIVE; P80192; -. DR PaxDb; 9606-ENSP00000451263; -. DR PeptideAtlas; P80192; -. DR ProteomicsDB; 57671; -. [P80192-1] DR ProteomicsDB; 57672; -. [P80192-4] DR Antibodypedia; 75; 343 antibodies from 33 providers. DR DNASU; 4293; -. DR Ensembl; ENST00000554752.7; ENSP00000451612.2; ENSG00000006432.17. [P80192-1] DR Ensembl; ENST00000555993.6; ENSP00000451263.2; ENSG00000006432.17. [P80192-4] DR GeneID; 4293; -. DR KEGG; hsa:4293; -. DR MANE-Select; ENST00000554752.7; ENSP00000451612.2; NM_001284230.2; NP_001271159.1. DR UCSC; uc001xml.5; human. [P80192-1] DR AGR; HGNC:6861; -. DR ClinPGx; PA30607; -. DR CTD; 4293; -. DR DisGeNET; 4293; -. DR GeneCards; MAP3K9; -. DR HGNC; HGNC:6861; MAP3K9. DR HPA; ENSG00000006432; Tissue enhanced (retina). DR MIM; 600136; gene. DR OpenTargets; ENSG00000006432; -. DR VEuPathDB; HostDB:ENSG00000006432; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000158243; -. DR InParanoid; P80192; -. DR OMA; GCGPYRE; -. DR OrthoDB; 339325at2759; -. DR PAN-GO; P80192; 1 GO annotation based on evolutionary models. DR PhylomeDB; P80192; -. DR PathwayCommons; P80192; -. DR SABIO-RK; P80192; -. DR SignaLink; P80192; -. DR SIGNOR; P80192; -. DR Agora; ENSG00000006432; -. DR BioGRID-ORCS; 4293; 8 hits in 1178 CRISPR screens. DR ChiTaRS; MAP3K9; human. DR EvolutionaryTrace; P80192; -. DR GeneWiki; MAP3K9; -. DR GenomeRNAi; 4293; -. DR Pharos; P80192; Tchem. DR PRO; PR:P80192; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P80192; protein. DR Bgee; ENSG00000006432; Expressed in buccal mucosa cell and 161 other cell types or tissues. DR ExpressionAtlas; P80192; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004706; F:JUN kinase kinase kinase activity; ISS:UniProtKB. DR GO; GO:0004708; F:MAP kinase kinase activity; NAS:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd12059; SH3_MLK1-3; 1. DR CDD; cd14145; STKc_MLK1; 1. DR DisProt; DP02571; -. DR FunFam; 1.10.510.10:FF:000076; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 2.30.30.40:FF:000079; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 3.30.200.20:FF:000085; Mitogen-activated protein kinase kinase kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR035779; MLK1-3_SH3. DR InterPro; IPR016231; MLK1-4. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR PANTHER; PTHR44329:SF35; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF14604; SH3_9; 1. DR PIRSF; PIRSF000556; MAPKKK9_11; 1. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00326; SH3; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Kinase; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; SH3 domain; KW Stress response; Transcription; Transcription regulation; Transferase. FT CHAIN 1..1104 FT /note="Mitogen-activated protein kinase kinase kinase 9" FT /id="PRO_0000086258" FT DOMAIN 52..116 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 144..412 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 12..47 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 430..451 FT /note="Leucine-zipper 1" FT REGION 465..486 FT /note="Leucine-zipper 2" FT REGION 532..636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 675..742 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 781..819 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 890..1038 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 12..22 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 29..39 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 566..575 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 723..739 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 785..797 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 893..910 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 929..944 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1014..1038 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 268 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 150..158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 171 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 304 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 305 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 308 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 312 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 675 FT /note="M -> MALLAASWVVPIDIE (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_013765" FT VARIANT 246 FT /note="A -> V (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040698" FT VARIANT 467 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs773256562)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040699" FT VARIANT 497 FT /note="R -> Q (in dbSNP:rs56196343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040700" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34322726)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040701" FT MUTAGEN 171 FT /note="K->A: Loss of kinase activity and threonine FT phosphorylation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 304 FT /note="T->A: Reduces threonine phosphorylation. Impairs JNK FT activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 305 FT /note="T->A: Little effect on threonine phosphorylation. FT Mildly impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 308 FT /note="S->A: Impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 312 FT /note="T->A: Loss of threonine phosphorylation. Strongly FT impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT CONFLICT 356 FT /note="A -> R (in Ref. 4)" FT /evidence="ECO:0000305" FT CONFLICT 433 FT /note="M -> T (in Ref. 1; AAQ23054)" FT /evidence="ECO:0000305" FT CONFLICT 511..535 FT /note="KLKDGNRISLPSDFQHKFTVQASPT -> AQPVLPFPHGHSRCPGGTGSSWG FT GQ (in Ref. 4)" FT /evidence="ECO:0000305" FT STRAND 143..153 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 156..163 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 166..172 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 185..197 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 206..210 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 228..232 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 239..258 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 259..262 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 271..273 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 274..278 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 290..292 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 299..301 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 318..323 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 328..344 FT /evidence="ECO:0007829|PDB:3DTC" FT TURN 348..351 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 354..362 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 376..385 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 390..392 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 396..404 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 410..412 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 418..439 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:4UY9" SQ SEQUENCE 1104 AA; 121895 MW; 0F059C867FCE7276 CRC64; MEPSRALLGC LASAAAAAPP GEDGAGAGAE EEEEEEEEAA AAVGPGELGC DAPLPYWTAV FEYEAAGEDE LTLRLGDVVE VLSKDSQVSG DEGWWTGQLN QRVGIFPSNY VTPRSAFSSR CQPGGEDPSC YPPIQLLEID FAELTLEEII GIGGFGKVYR AFWIGDEVAV KAARHDPDED ISQTIENVRQ EAKLFAMLKH PNIIALRGVC LKEPNLCLVM EFARGGPLNR VLSGKRIPPD ILVNWAVQIA RGMNYLHDEA IVPIIHRDLK SSNILILQKV ENGDLSNKIL KITDFGLARE WHRTTKMSAA GTYAWMAPEV IRASMFSKGS DVWSYGVLLW ELLTGEVPFR GIDGLAVAYG VAMNKLALPI PSTCPEPFAK LMEDCWNPDP HSRPSFTNIL DQLTTIEESG FFEMPKDSFH CLQDNWKHEI QEMFDQLRAK EKELRTWEEE LTRAALQQKN QEELLRRREQ ELAEREIDIL ERELNIIIHQ LCQEKPRVKK RKGKFRKSRL KLKDGNRISL PSDFQHKFTV QASPTMDKRK SLINSRSSPP ASPTIIPRLR AIQLTPGESS KTWGRSSVVP KEEGEEEEKR APKKKGRTWG PGTLGQKELA SGDEGSPQRR EKANGLSTPS ESPHFHLGLK SLVDGYKQWS SSAPNLVKGP RSSPALPGFT SLMEMEDEDS EGPGSGESRL QHSPSQSYLC IPFPRGEDGD GPSSDGIHEE PTPVNSATST PQLTPTNSLK RGGAHHRRCE VALLGCGAVL AATGLGFDLL EAGKCQLLPL EEPEPPAREE KKRREGLFQR SSRPRRSTSP PSRKLFKKEE PMLLLGDPSA SLTLLSLSSI SECNSTRSLL RSDSDEIVVY EMPVSPVEAP PLSPCTHNPL VNVRVERFKR DPNQSLTPTH VTLTTPSQPS SHRRTPSDGA LKPETLLASR SPSSNGLSPS PGAGMLKTPS PSRDPGEFPR LPDPNVVFPP TPRRWNTQQD STLERPKTLE FLPRPRPSAN RQRLDPWWFV SPSHARSTSP ANSSSTETPS NLDSCFASSS STVEERPGLP ALLPFQAGPL PPTERTLLDL DAEGQSQDST VPLCRAELNT HRPAPYEIQQ EFWS // ID MARK1_HUMAN Reviewed; 795 AA. AC Q9P0L2; D3DTB0; D3DTB1; Q2HIY1; Q5VTF9; Q5VTG0; Q96SW9; Q9P251; DT 12-APR-2005, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 2. DT 28-JAN-2026, entry version 205. DE RecName: Full=Serine/threonine-protein kinase MARK1; DE EC=2.7.11.1; DE EC=2.7.11.26; DE AltName: Full=MAP/microtubule affinity-regulating kinase 1; DE AltName: Full=PAR1 homolog c; DE Short=Par-1c; DE Short=Par1c; GN Name=MARK1 {ECO:0000312|HGNC:HGNC:6896}; GN Synonyms=KIAA1477 {ECO:0000312|EMBL:BAA96001.1}, GN MARK {ECO:0000312|EMBL:AAF72103.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-215, AND MUTAGENESIS OF THR-215. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Zhou H.J., Huang X.W., Zhou Y., Hu S.L., Yuan J.G., Qiang B.Q.; RT "Cloning and isolating human MARK."; RL Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases. RN [3] {ECO:0000305, ECO:0000312|EMBL:BAA96001.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain {ECO:0000269|PubMed:10819331}; RX PubMed=10819331; DOI=10.1093/dnares/7.2.143; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:143-150(2000). RN [4] {ECO:0000305, ECO:0000312|EMBL:BAB55152.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [6] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] {ECO:0000305} RP TISSUE SPECIFICITY. RX PubMed=9108484; DOI=10.1016/s0092-8674(00)80208-1; RA Drewes G., Ebneth A., Preuss U., Mandelkow E.-M., Mandelkow E.; RT "MARK - a novel family of protein kinases that phosphorylate microtubule- RT associated proteins and trigger microtubule disruption."; RL Cell 89:297-308(1997). RN [9] RP NEUROFIBRILLARY TANGLES IN ALZHEIMER BRAIN. RX PubMed=11089574; DOI=10.1093/jnen/59.11.966; RA Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M., RA Hyman B.T.; RT "Microtubule-affinity regulating kinase (MARK) is tightly associated with RT neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy RT transfer study."; RL J. Neuropathol. Exp. Neurol. 59:966-971(2000). RN [10] RP FUNCTION. RX PubMed=11433294; DOI=10.1038/35083016; RA Sun T.-Q., Lu B., Feng J.-J., Reinhard C., Jan Y.N., Fantl W.J., RA Williams L.T.; RT "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt RT signalling."; RL Nat. Cell Biol. 3:628-636(2001). RN [11] RP PHOSPHORYLATION AT THR-208, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=17573348; DOI=10.1074/jbc.m700590200; RA Kojima Y., Miyoshi H., Clevers H.C., Oshima M., Aoki M., Taketo M.M.; RT "Suppression of tubulin polymerization by the LKB1-microtubule-associated RT protein/microtubule affinity-regulating kinase signaling."; RL J. Biol. Chem. 282:23532-23540(2007). RN [12] RP POSSIBLE INVOLVEMENT IN AUTISM. RX PubMed=18492799; DOI=10.1093/hmg/ddn154; RA Maussion G., Carayol J., Lepagnol-Bestel A.M., Tores F., Loe-Mie Y., RA Milbreta U., Rousseau F., Fontaine K., Renaud J., Moalic J.M., Philippi A., RA Chedotal A., Gorwood P., Ramoz N., Hager J., Simonneau M.; RT "Convergent evidence identifying MAP/microtubule affinity-regulating kinase RT 1 (MARK1) as a susceptibility gene for autism."; RL Hum. Mol. Genet. 17:2541-2551(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-5 AND SER-403, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [17] RP REVIEW. RX PubMed=19559622; DOI=10.1016/j.tibs.2009.03.008; RA Matenia D., Mandelkow E.M.; RT "The tau of MARK: a polarized view of the cytoskeleton."; RL Trends Biochem. Sci. 34:332-342(2009). RN [18] RP REVIEW. RX PubMed=20071654; DOI=10.1096/fj.09-148064; RA Marx A., Nugoor C., Panneerselvam S., Mandelkow E.; RT "Structure and function of polarity-inducing kinase family MARK/Par-1 RT within the branch of AMPK/Snf1-related kinases."; RL FASEB J. 24:1637-1648(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [22] RP FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION. RX PubMed=23666762; DOI=10.1007/s12017-013-8232-3; RA Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G., RA Landegren U., Sunnemark D., Kamali-Moghaddam M.; RT "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in RT Alzheimer's disease."; RL NeuroMolecular Med. 15:458-469(2013). RN [23] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 45-371. RX PubMed=16803889; DOI=10.1074/jbc.m604865200; RA Marx A., Nugoor C., Muller J., Panneerselvam S., Timm T., Bilang M., RA Mylonas E., Svergun D.I., Mandelkow E.M., Mandelkow E.; RT "Structural variations in the catalytic and ubiquitin-associated domains of RT microtubule-associated protein/microtubule affinity regulating kinase RT (MARK) 1 and MARK2."; RL J. Biol. Chem. 281:27586-27599(2006). RN [24] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 683-795, DOMAIN KA1, SUBCELLULAR RP LOCATION, AND MUTAGENESIS OF ARG-698; ARG-701; 771-ARG--LYS-773 AND RP 773-LYS-ARG-774. RX PubMed=21145462; DOI=10.1016/j.cell.2010.11.028; RA Moravcevic K., Mendrola J.M., Schmitz K.R., Wang Y.H., Slochower D., RA Janmey P.A., Lemmon M.A.; RT "Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by RT binding acidic phospholipids."; RL Cell 143:966-977(2010). RN [25] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-233; THR-355; MET-530; LEU-578 AND RP GLY-691. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved CC in cell polarity and microtubule dynamics regulation. Phosphorylates CC DCX, MAP2 and MAP4. Phosphorylates the microtubule-associated protein CC MAPT/TAU (PubMed:23666762). Involved in cell polarity by CC phosphorylating the microtubule-associated proteins MAP2, MAP4 and CC MAPT/TAU at KXGS motifs, causing detachment from microtubules, and CC their disassembly. Involved in the regulation of neuronal migration CC through its dual activities in regulating cellular polarity and CC microtubule dynamics, possibly by phosphorylating and regulating DCX. CC Also acts as a positive regulator of the Wnt signaling pathway, CC probably by mediating phosphorylation of dishevelled proteins (DVL1, CC DVL2 and/or DVL3). {ECO:0000269|PubMed:11433294, CC ECO:0000269|PubMed:17573348, ECO:0000269|PubMed:23666762}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] CC + ADP + H(+); Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA- CC COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau CC protein] + ADP + H(+); Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703, CC Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.26; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Inhibited by phosphorylation at Ser-219 (By CC similarity). Activated by phosphorylation on Thr-215. {ECO:0000250, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}. CC -!- SUBUNIT: Interacts with MAPT/TAU. {ECO:0000269|PubMed:23666762}. CC -!- INTERACTION: CC Q9P0L2; P05067: APP; NbExp=3; IntAct=EBI-968587, EBI-77613; CC Q9P0L2; P63172: DYNLT1; NbExp=3; IntAct=EBI-968587, EBI-1176455; CC Q9P0L2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-968587, EBI-6509505; CC Q9P0L2; O95988: TCL1B; NbExp=5; IntAct=EBI-968587, EBI-727338; CC Q9P0L2; Q8IY57-5: YAF2; NbExp=3; IntAct=EBI-968587, EBI-12111538; CC Q9P0L2; P61981: YWHAG; NbExp=4; IntAct=EBI-968587, EBI-359832; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21145462}; CC Peripheral membrane protein {ECO:0000269|PubMed:21145462}. Cytoplasm, CC cytoskeleton {ECO:0000250}. Cytoplasm {ECO:0000269|PubMed:23666762}. CC Cell projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Appears CC to localize to an intracellular network. {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9P0L2-1; Sequence=Displayed; CC Name=2 {ECO:0000305}; CC IsoId=Q9P0L2-2; Sequence=VSP_051702, VSP_051704; CC Name=3 {ECO:0000305}; CC IsoId=Q9P0L2-3; Sequence=VSP_051703, VSP_051704; CC -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle, brain, CC fetal brain and fetal kidney. {ECO:0000269|PubMed:9108484}. CC -!- DOMAIN: The UBA domain does not seem to bind ubiquitin and ubiquitin- CC like and might play a role in regulating the enzyme conformation and CC localization. Activation of the kinase activity following CC phosphorylation at Thr-208 is accompanied by a conformational change CC that alters the orientation of the UBA domain with respect to the CC catalytic domain (By similarity). {ECO:0000250}. CC -!- DOMAIN: The KA1 domain mediates binding to phospholipids and targeting CC to membranes. Binds phosphatidic acid (PA), phosphatidylserine (PtdSer) CC and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). CC {ECO:0000269|PubMed:21145462}. CC -!- PTM: Phosphorylation at Thr-613 by PRKCZ/aPKC in polarized epithelial CC cells inhibits the kinase activity (By similarity). Phosphorylated at CC Thr-215 by STK11/LKB1 in complex with STE20-related adapter-alpha CC (STRADA) pseudo kinase and CAB39. Phosphorylation at Thr-215 by TAOK1 CC activates the kinase activity, leading to phosphorylation and CC detachment of MAPT/TAU from microtubules. Phosphorylation at Ser-219 by CC GSK3-beta (GSK3B) inhibits the kinase activity. {ECO:0000250, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}. CC -!- DISEASE: Note=Genetic variations in MARK1 may be associated with CC susceptibility to autism. MARK1 is overexpressed in the prefrontal CC cortex of patients with autism and causes changes in the function of CC cortical dendrites. CC -!- MISCELLANEOUS: Phosphorylation of MAPT/tau by MARK1 could play a role CC in early steps of Alzheimer disease. Pathological aggregation of CC MAPT/tau to neurofibrillary tangles, filamentous structures consisting CC of paired helical filaments (PHFs), is one of the hallmarks of CC Alzheimer disease. Hyperphosphorylation by MARK1 could be the initial CC step for this abnormal aggregation of tau in Alzheimer disease and CC animal models of tauopathy (PubMed:11089574). CC {ECO:0000305|PubMed:11089574}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA96001.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAB55152.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF154845; AAF72103.1; -; mRNA. DR EMBL; AB040910; BAA96001.1; ALT_INIT; mRNA. DR EMBL; AK027493; BAB55152.1; ALT_FRAME; mRNA. DR EMBL; AC096640; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL592406; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471100; EAW93299.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93300.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93302.1; -; Genomic_DNA. DR EMBL; BC113869; AAI13870.1; -; mRNA. DR EMBL; BC114478; AAI14479.1; -; mRNA. DR CCDS; CCDS31029.2; -. [Q9P0L2-1] DR CCDS; CCDS65789.1; -. [Q9P0L2-3] DR RefSeq; NP_001273057.1; NM_001286128.2. [Q9P0L2-3] DR RefSeq; NP_061120.3; NM_018650.4. [Q9P0L2-1] DR PDB; 2HAK; X-ray; 2.60 A; A/B/C/D/E/F/G/H=45-371. DR PDB; 3OSE; X-ray; 1.70 A; A=683-795. DR PDB; 6C9D; X-ray; 2.50 A; A/B=45-795. DR PDBsum; 2HAK; -. DR PDBsum; 3OSE; -. DR PDBsum; 6C9D; -. DR AlphaFoldDB; Q9P0L2; -. DR SASBDB; Q9P0L2; -. DR SMR; Q9P0L2; -. DR BioGRID; 110309; 84. DR DIP; DIP-39777N; -. DR FunCoup; Q9P0L2; 1289. DR IntAct; Q9P0L2; 53. DR MINT; Q9P0L2; -. DR STRING; 9606.ENSP00000483424; -. DR BindingDB; Q9P0L2; -. DR ChEMBL; CHEMBL5940; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P0L2; -. DR GuidetoPHARMACOLOGY; 2097; -. DR CarbonylDB; Q9P0L2; -. DR iPTMnet; Q9P0L2; -. DR PhosphoSitePlus; Q9P0L2; -. DR BioMuta; MARK1; -. DR DMDM; 124056494; -. DR jPOST; Q9P0L2; -. DR MassIVE; Q9P0L2; -. DR PaxDb; 9606-ENSP00000483424; -. DR PeptideAtlas; Q9P0L2; -. DR ProteomicsDB; 83571; -. [Q9P0L2-1] DR ProteomicsDB; 83572; -. [Q9P0L2-2] DR ProteomicsDB; 83573; -. [Q9P0L2-3] DR Pumba; Q9P0L2; -. DR Antibodypedia; 2072; 432 antibodies from 33 providers. DR DNASU; 4139; -. DR Ensembl; ENST00000366917.6; ENSP00000355884.5; ENSG00000116141.18. [Q9P0L2-1] DR Ensembl; ENST00000366918.8; ENSP00000355885.4; ENSG00000116141.18. [Q9P0L2-3] DR GeneID; 4139; -. DR KEGG; hsa:4139; -. DR MANE-Select; ENST00000366917.6; ENSP00000355884.5; NM_018650.5; NP_061120.3. DR UCSC; uc001hmm.6; human. [Q9P0L2-1] DR AGR; HGNC:6896; -. DR ClinPGx; PA30639; -. DR CTD; 4139; -. DR DisGeNET; 4139; -. DR GeneCards; MARK1; -. DR HGNC; HGNC:6896; MARK1. DR HPA; ENSG00000116141; Low tissue specificity. DR MIM; 606511; gene. DR OpenTargets; ENSG00000116141; -. DR VEuPathDB; HostDB:ENSG00000116141; -. DR eggNOG; KOG0586; Eukaryota. DR GeneTree; ENSGT00940000157560; -. DR InParanoid; Q9P0L2; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q9P0L2; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P0L2; -. DR PathwayCommons; Q9P0L2; -. DR SignaLink; Q9P0L2; -. DR SIGNOR; Q9P0L2; -. DR Agora; ENSG00000116141; -. DR BioGRID-ORCS; 4139; 14 hits in 1190 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; MARK1; human. DR EvolutionaryTrace; Q9P0L2; -. DR GeneWiki; MARK1; -. DR GenomeRNAi; 4139; -. DR Pharos; Q9P0L2; Tchem. DR PRO; PR:Q9P0L2; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9P0L2; protein. DR Bgee; ENSG00000116141; Expressed in cortical plate and 178 other cell types or tissues. DR ExpressionAtlas; Q9P0L2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB. DR GO; GO:0030425; C:dendrite; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0015630; C:microtubule cytoskeleton; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0070300; F:phosphatidic acid binding; IDA:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IMP:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0051654; P:establishment of mitochondrion localization; ISS:ARUK-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; ISS:ARUK-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:ARUK-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050773; P:regulation of dendrite development; ISS:ARUK-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0150052; P:regulation of postsynapse assembly; IEA:Ensembl. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd12196; MARK1-3_C; 1. DR CDD; cd14072; STKc_MARK; 1. DR CDD; cd14405; UBA_MARK1; 1. DR FunFam; 1.10.510.10:FF:001032; KP78b, isoform A; 1. DR FunFam; 1.10.8.10:FF:000011; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000001; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR001772; KA1_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049508; MARK1-4_cat. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF21; SERINE_THREONINE-PROTEIN KINASE MARK1; 1. DR Pfam; PF02149; KA1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00165; UBA; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50032; KA1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Autism; KW Autism spectrum disorder; Cell membrane; Cell projection; Cytoplasm; KW Cytoskeleton; Kinase; Lipid-binding; Magnesium; Membrane; Metal-binding; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Wnt signaling pathway. FT CHAIN 1..795 FT /note="Serine/threonine-protein kinase MARK1" FT /id="PRO_0000086298" FT DOMAIN 60..311 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 325..370 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 746..795 FT /note="KA1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00565" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 377..495 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 539..700 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31..40 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 380..403 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 447..459 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 462..473 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 486..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 590..599 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 647..657 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 661..676 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 683..697 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 182 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:Q9H0K1, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 66..74 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:Q9H0K1, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 89 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:O08678, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 5 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 208 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17573348" FT MOD_RES 215 FT /note="Phosphothreonine; by LKB1 and TAOK1" FT /evidence="ECO:0000269|PubMed:14976552" FT MOD_RES 219 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000250|UniProtKB:O08678" FT MOD_RES 382 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 390 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 393 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 403 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08678" FT MOD_RES 475 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 588 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 613 FT /note="Phosphothreonine; by PKC/PRKCZ" FT /evidence="ECO:0000250" FT MOD_RES 666 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT VAR_SEQ 1..135 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_051702" FT VAR_SEQ 120..141 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10819331" FT /id="VSP_051703" FT VAR_SEQ 663..677 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10819331, FT ECO:0000303|PubMed:14702039" FT /id="VSP_051704" FT VARIANT 233 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040760" FT VARIANT 355 FT /note="N -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040761" FT VARIANT 530 FT /note="V -> M (in dbSNP:rs56212551)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040762" FT VARIANT 578 FT /note="P -> L (in dbSNP:rs55691439)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040763" FT VARIANT 645 FT /note="R -> G (in dbSNP:rs12123778)" FT /id="VAR_030018" FT VARIANT 691 FT /note="E -> G (in dbSNP:rs55688276)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040764" FT MUTAGEN 215 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 215 FT /note="T->E: Constitutively active." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 698 FT /note="R->S: Impairs phospholipid-binding, targeting to FT membrane and vesicle-binding; when associated with S-701." FT /evidence="ECO:0000269|PubMed:21145462" FT MUTAGEN 701 FT /note="R->S: Impairs phospholipid-binding, targeting to FT membrane and vesicle-binding; when associated with S-698." FT /evidence="ECO:0000269|PubMed:21145462" FT MUTAGEN 771..773 FT /note="RFK->AFA: Impairs phospholipid-binding." FT /evidence="ECO:0000269|PubMed:21145462" FT CONFLICT 16 FT /note="E -> V (in Ref. 2; AAF72103)" FT /evidence="ECO:0000305" FT CONFLICT 20 FT /note="S -> T (in Ref. 2; AAF72103)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="D -> N (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 544 FT /note="V -> A (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 763 FT /note="P -> A (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 794 FT /note="K -> M (in Ref. 3; BAA96001)" FT /evidence="ECO:0000305" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 60..68 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 70..79 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 80..82 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 85..92 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 98..111 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 122..127 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 129..136 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 146..151 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 156..175 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 185..187 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 188..190 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 196..198 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 201..203 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 220..222 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 225..228 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 236..252 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 262..271 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 282..291 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 296..298 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 302..305 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 316..318 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 333..341 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 346..355 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 360..368 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 706..708 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 714..727 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 731..736 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 739..745 FT /evidence="ECO:0007829|PDB:3OSE" FT TURN 747..750 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 753..762 FT /evidence="ECO:0007829|PDB:3OSE" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 767..777 FT /evidence="ECO:0007829|PDB:3OSE" FT HELIX 779..792 FT /evidence="ECO:0007829|PDB:3OSE" SQ SEQUENCE 795 AA; 89003 MW; 71BF6EB76912631B CRC64; MSARTPLPTV NERDTENHTS VDGYTEPHIQ PTKSSSRQNI PRCRNSITSA TDEQPHIGNY RLQKTIGKGN FAKVKLARHV LTGREVAVKI IDKTQLNPTS LQKLFREVRI MKILNHPNIV KLFEVIETEK TLYLVMEYAS GGEVFDYLVA HGRMKEKEAR AKFRQIVSAV QYCHQKYIVH RDLKAENLLL DGDMNIKIAD FGFSNEFTVG NKLDTFCGSP PYAAPELFQG KKYDGPEVDV WSLGVILYTL VSGSLPFDGQ NLKELRERVL RGKYRIPFYM STDCENLLKK LLVLNPIKRG SLEQIMKDRW MNVGHEEEEL KPYTEPDPDF NDTKRIDIMV TMGFARDEIN DALINQKYDE VMATYILLGR KPPEFEGGES LSSGNLCQRS RPSSDLNNST LQSPAHLKVQ RSISANQKQR RFSDHAGPSI PPAVSYTKRP QANSVESEQK EEWDKDVARK LGSTTVGSKS EMTASPLVGP ERKKSSTIPS NNVYSGGSMA RRNTYVCERT TDRYVALQNG KDSSLTEMSV SSISSAGSSV ASAVPSARPR HQKSMSTSGH PIKVTLPTIK DGSEAYRPGT TQRVPAASPS AHSISTATPD RTRFPRGSSS RSTFHGEQLR ERRSVAYNGP PASPSHETGA FAHARRGTST GIISKITSKF VRRDPSEGEA SGRTDTSRST SGEPKERDKE EGKDSKPRSL RFTWSMKTTS SMDPNDMMRE IRKVLDANNC DYEQKERFLL FCVHGDARQD SLVQWEMEVC KLPRLSLNGV RFKRISGTSI AFKNIASKIA NELKL // ID MINK1_HUMAN Reviewed; 1332 AA. AC Q8N4C8; D3DTK3; D3DTK4; Q5U8Z0; Q9P1X1; Q9P2R8; DT 28-MAR-2003, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 209. DE RecName: Full=Misshapen-like kinase 1; DE EC=2.7.11.1; DE AltName: Full=GCK family kinase MiNK; DE AltName: Full=MAPK/ERK kinase kinase kinase 6; DE Short=MEK kinase kinase 6; DE Short=MEKKK 6; DE AltName: Full=Misshapen/NIK-related kinase; DE AltName: Full=Mitogen-activated protein kinase kinase kinase kinase 6; GN Name=MINK1 {ECO:0000312|HGNC:HGNC:17565}; GN Synonyms=B55, MAP4K6 {ECO:0000250|UniProtKB:Q9JM52}, GN MINK {ECO:0000312|EMBL:BAA94838.1}, YSK2, ZC3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606 {ECO:0000312|EMBL:AAH34673.1}; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RX PubMed=10708748; DOI=10.1016/s0014-5793(00)01247-3; RA Dan I., Watanabe N.M., Kobayashi T., Yamashita-Suzuki K., Fukagaya Y., RA Kajikawa E., Kimura W.K., Nakashima T.M., Matsumoto K., Ninomiya-Tsuji J., RA Kusumi A.; RT "Molecular cloning of MINK, a novel member of mammalian GCK family kinases, RT which is up-regulated during postnatal mouse cerebral development."; RL FEBS Lett. 469:19-23(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH NCK1, TISSUE SPECIFICITY, ALTERNATIVE SPLICING, RP AUTOPHOSPHORYLATION, AND VARIANTS ALA-771 AND LEU-775. RX PubMed=15469942; DOI=10.1074/jbc.m404497200; RA Hu Y., Leo C., Yu S., Huang B.C., Wang H., Shen M., Luo Y., RA Daniel-Issakani S., Payan D.G., Xu X.; RT "Identification and functional characterization of a novel human RT misshapen/Nck interacting kinase-related kinase, hMINK beta."; RL J. Biol. Chem. 279:54387-54397(2004). RN [3] RP ERRATUM OF PUBMED:15469942. RA Hu Y., Leo C., Yu S., Huang B.C., Wang H., Shen M., Luo Y., RA Daniel-Issakani S., Payan D.G., Xu X.; RL J. Biol. Chem. 280:5128-5128(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS ALA-771 RP AND LEU-775. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION, AND INDUCTION. RX PubMed=16337592; DOI=10.1016/j.molcel.2005.10.038; RA Nicke B., Bastien J., Khanna S.J., Warne P.H., Cowling V., Cook S.J., RA Peters G., Delpuech O., Schulze A., Berns K., Mullenders J., RA Beijersbergen R.L., Bernards R., Ganesan T.S., Downward J., Hancock D.C.; RT "Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth RT arrest in human ovarian surface epithelial cells."; RL Mol. Cell 20:673-685(2005). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [9] RP FUNCTION, INTERACTION WITH RAP2A, AND SUBCELLULAR LOCATION. RX PubMed=18930710; DOI=10.1016/j.bbrc.2008.10.038; RA Nonaka H., Takei K., Umikawa M., Oshiro M., Kuninaka K., Bayarjargal M., RA Asato T., Yamashiro Y., Uechi Y., Endo S., Suzuki T., Kariya K.; RT "MINK is a Rap2 effector for phosphorylation of the postsynaptic scaffold RT protein TANC1."; RL Biochem. Biophys. Res. Commun. 377:573-578(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-641; SER-763 AND SER-782, RP VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763; SER-777; SER-778 AND RP SER-782, VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, VARIANT [LARGE SCALE RP ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-778, VARIANT [LARGE SCALE RP ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP FUNCTION. RX PubMed=21690388; DOI=10.1073/pnas.1104128108; RA Kaneko S., Chen X., Lu P., Yao X., Wright T.G., Rajurkar M., Kariya K., RA Mao J., Ip Y.T., Xu L.; RT "Smad inhibition by the Ste20 kinase Misshapen."; RL Proc. Natl. Acad. Sci. U.S.A. 108:11127-11132(2011). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-641; SER-701; SER-754; RP SER-763 AND SER-778, VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-509, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [23] RP FUNCTION. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] THR-514; ILE-863; VAL-1010 AND VAL-1200. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [25] RP VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). CC -!- FUNCTION: Serine/threonine kinase which acts as a negative regulator of CC Ras-related Rap2-mediated signal transduction to control neuronal CC structure and AMPA receptor trafficking (PubMed:10708748, CC PubMed:16337592). Required for normal synaptic density, dendrite CC complexity, as well as surface AMPA receptor expression in hippocampal CC neurons (By similarity). Can activate the JNK and MAPK14/p38 pathways CC and mediates stimulation of the stress-activated protein kinase CC MAPK14/p38 MAPK downstream of the Raf/ERK pathway. Phosphorylates TANC1 CC upon stimulation by RAP2A, MBP and SMAD1 (PubMed:18930710, CC PubMed:21690388). Has an essential function in negative selection of CC thymocytes, perhaps by coupling NCK1 to activation of JNK1 (By CC similarity). Activator of the Hippo signaling pathway which plays a CC pivotal role in organ size control and tumor suppression by restricting CC proliferation and promoting apoptosis. MAP4Ks act in parallel to and CC are partially redundant with STK3/MST2 and STK4/MST2 in the CC phosphorylation and activation of LATS1/2, and establish MAP4Ks as CC components of the expanded Hippo pathway (PubMed:26437443). CC {ECO:0000250|UniProtKB:F1LP90, ECO:0000250|UniProtKB:Q9JM52, CC ECO:0000269|PubMed:10708748, ECO:0000269|PubMed:16337592, CC ECO:0000269|PubMed:18930710, ECO:0000269|PubMed:21690388, CC ECO:0000269|PubMed:26437443}. CC -!- FUNCTION: Isoform 4 can activate the JNK pathway. Involved in the CC regulation of actin cytoskeleton reorganization, cell-matrix adhesion, CC cell-cell adhesion and cell migration. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9JM52}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9JM52}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q9JM52}; CC -!- SUBUNIT: Interacts with TANC1 (By similarity). Interacts with RAP2A. CC Isoform 4 interacts with NCK1. {ECO:0000250, CC ECO:0000269|PubMed:15469942, ECO:0000269|PubMed:18930710}. CC -!- INTERACTION: CC Q8N4C8; Q00613: HSF1; NbExp=2; IntAct=EBI-2133481, EBI-719620; CC Q8N4C8; O95819: MAP4K4; NbExp=3; IntAct=EBI-2133481, EBI-2511133; CC Q8N4C8; P10114: RAP2A; NbExp=3; IntAct=EBI-2133481, EBI-602366; CC Q8N4C8; P31947: SFN; NbExp=3; IntAct=EBI-2133481, EBI-476295; CC Q8N4C8; P62258: YWHAE; NbExp=3; IntAct=EBI-2133481, EBI-356498; CC Q8N4C8-4; Q5VY09: IER5; NbExp=2; IntAct=EBI-11475194, EBI-1774000; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15469942, CC ECO:0000269|PubMed:18930710}. Postsynaptic density {ECO:0000250}. Cell CC projection, axon {ECO:0000250}. Cell projection, dendrite CC {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Golgi apparatus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=3 {ECO:0000269|PubMed:10708748}; Synonyms=MINK-alpha; CC IsoId=Q8N4C8-1; Sequence=Displayed; CC Name=1 {ECO:0000269|PubMed:10708748}; Synonyms=MiNK-1, MINK-delta; CC IsoId=Q8N4C8-2; Sequence=VSP_007059; CC Name=2 {ECO:0000269|PubMed:10708748}; Synonyms=MiNK-2, MINK-gamma; CC IsoId=Q8N4C8-3; Sequence=VSP_007059, VSP_007060; CC Name=4; Synonyms=MINK-beta; CC IsoId=Q8N4C8-4; Sequence=VSP_041871; CC Name=5; Synonyms=MINK-eta; CC IsoId=Q8N4C8-5; Sequence=VSP_041871, VSP_007059; CC -!- TISSUE SPECIFICITY: Expressed in the brain, isoform 2 is more abundant CC than isoform 1. Isoform 3 is ubiquitously expressed. Isoform 1 is most CC abundant in the skeletal muscle. Isoform 4 is ubiquitously expressed CC with relative high levels in brain, skeletal muscle, pancreas and CC testis. {ECO:0000269|PubMed:15469942}. CC -!- INDUCTION: Activated after Ras induction via a mechanism involving CC reactive oxygen species. {ECO:0000269|PubMed:16337592}. CC -!- PTM: Autophosphorylated. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB041926; BAA94838.1; -; mRNA. DR EMBL; AB035698; BAA90753.1; -; mRNA. DR EMBL; AY775058; AAV41830.1; -; mRNA. DR EMBL; AC233723; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90401.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90403.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90399.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90400.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90402.1; -; Genomic_DNA. DR EMBL; BC034673; AAH34673.1; -; mRNA. DR CCDS; CCDS45588.1; -. [Q8N4C8-1] DR CCDS; CCDS45589.1; -. [Q8N4C8-3] DR CCDS; CCDS45590.1; -. [Q8N4C8-4] DR RefSeq; NP_001020108.1; NM_001024937.4. [Q8N4C8-4] DR RefSeq; NP_001308165.1; NM_001321236.1. DR RefSeq; NP_056531.1; NM_015716.5. [Q8N4C8-2] DR RefSeq; NP_722549.2; NM_153827.4. [Q8N4C8-1] DR RefSeq; NP_733763.1; NM_170663.5. [Q8N4C8-3] DR RefSeq; XP_047292132.1; XM_047436176.1. [Q8N4C8-5] DR AlphaFoldDB; Q8N4C8; -. DR SMR; Q8N4C8; -. DR BioGRID; 119075; 184. DR FunCoup; Q8N4C8; 2105. DR IntAct; Q8N4C8; 101. DR MINT; Q8N4C8; -. DR STRING; 9606.ENSP00000347427; -. DR BindingDB; Q8N4C8; -. DR ChEMBL; CHEMBL5518; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q8N4C8; -. DR GuidetoPHARMACOLOGY; 2103; -. DR GlyCosmos; Q8N4C8; 1 site, 1 glycan. DR GlyGen; Q8N4C8; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q8N4C8; -. DR PhosphoSitePlus; Q8N4C8; -. DR SwissPalm; Q8N4C8; -. DR BioMuta; MINK1; -. DR DMDM; 296437370; -. DR jPOST; Q8N4C8; -. DR MassIVE; Q8N4C8; -. DR PaxDb; 9606-ENSP00000347427; -. DR PeptideAtlas; Q8N4C8; -. DR ProteomicsDB; 71917; -. [Q8N4C8-1] DR ProteomicsDB; 71918; -. [Q8N4C8-2] DR ProteomicsDB; 71919; -. [Q8N4C8-3] DR ProteomicsDB; 71920; -. [Q8N4C8-4] DR ProteomicsDB; 71921; -. [Q8N4C8-5] DR Pumba; Q8N4C8; -. DR Antibodypedia; 5678; 234 antibodies from 32 providers. DR DNASU; 50488; -. DR Ensembl; ENST00000347992.11; ENSP00000269296.7; ENSG00000141503.18. [Q8N4C8-3] DR Ensembl; ENST00000355280.11; ENSP00000347427.6; ENSG00000141503.18. [Q8N4C8-1] DR Ensembl; ENST00000453408.7; ENSP00000406487.3; ENSG00000141503.18. [Q8N4C8-4] DR GeneID; 50488; -. DR KEGG; hsa:50488; -. DR MANE-Select; ENST00000355280.11; ENSP00000347427.6; NM_153827.5; NP_722549.2. DR UCSC; uc010vsl.3; human. [Q8N4C8-1] DR AGR; HGNC:17565; -. DR ClinPGx; PA134910641; -. DR CTD; 50488; -. DR DisGeNET; 50488; -. DR GeneCards; MINK1; -. DR HGNC; HGNC:17565; MINK1. DR HPA; ENSG00000141503; Low tissue specificity. DR MalaCards; MINK1; -. DR MIM; 609426; gene. DR OpenTargets; ENSG00000141503; -. DR VEuPathDB; HostDB:ENSG00000141503; -. DR eggNOG; KOG0587; Eukaryota. DR GeneTree; ENSGT00950000183196; -. DR InParanoid; Q8N4C8; -. DR OMA; QIPPGDR; -. DR OrthoDB; 8957712at2759; -. DR PAN-GO; Q8N4C8; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q8N4C8; -. DR PathwayCommons; Q8N4C8; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR SignaLink; Q8N4C8; -. DR SIGNOR; Q8N4C8; -. DR Agora; ENSG00000141503; -. DR BioGRID-ORCS; 50488; 16 hits in 1191 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; MINK1; human. DR GeneWiki; MINK1; -. DR GenomeRNAi; 50488; -. DR Pharos; Q8N4C8; Tchem. DR PRO; PR:Q8N4C8; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q8N4C8; protein. DR Bgee; ENSG00000141503; Expressed in CA1 field of hippocampus and 208 other cell types or tissues. DR ExpressionAtlas; Q8N4C8; baseline and differential. DR GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; ISS:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0007420; P:brain development; ISS:UniProtKB. DR GO; GO:0007268; P:chemical synaptic transmission; ISS:UniProtKB. DR GO; GO:0048813; P:dendrite morphogenesis; ISS:UniProtKB. DR GO; GO:0007254; P:JNK cascade; TAS:ProtInc. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:0048812; P:neuron projection morphogenesis; IBA:GO_Central. DR GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB. DR GO; GO:1900745; P:positive regulation of p38MAPK cascade; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IMP:CACAO. DR GO; GO:2000311; P:regulation of AMPA receptor activity; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0022407; P:regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0001952; P:regulation of cell-matrix adhesion; IMP:UniProtKB. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR CDD; cd06636; STKc_MAP4K4_6_N; 1. DR FunFam; 1.10.510.10:FF:000003; TRAF2 and NCK-interacting protein kinase isoform 4; 1. DR FunFam; 3.30.200.20:FF:000006; TRAF2 and NCK-interacting protein kinase isoform 4; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR001180; CNH_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051700; STE20_Ser-Thr_kinase. DR PANTHER; PTHR47096; MISSHAPEN LIKE KINASE 1; 1. DR PANTHER; PTHR47096:SF1; MISSHAPEN LIKE KINASE 1; 1. DR Pfam; PF00780; CNH; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00036; CNH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50219; CNH; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell projection; Cytoplasm; KW Golgi apparatus; Kinase; Methylation; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..1332 FT /note="Misshapen-like kinase 1" FT /id="PRO_0000086329" FT DOMAIN 25..289 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 1019..1306 FT /note="CNH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00795" FT REGION 300..347 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 363..383 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 395..887 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 866..1332 FT /note="Mediates interaction with RAP2A" FT /evidence="ECO:0000269|PubMed:18930710" FT REGION 902..943 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 317..333 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 371..380 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 396..466 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 479..497 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 518..528 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 547..561 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..608 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 670..682 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 716..729 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 736..748 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 804..821 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 828..841 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 915..929 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 153 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 31..39 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 54 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 324 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT MOD_RES 326 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT MOD_RES 501 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT MOD_RES 509 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 641 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 701 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 754 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 763 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18088087, ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 777 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 778 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 782 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976" FT MOD_RES 891 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT VAR_SEQ 581..600 FT /note="Missing (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:15469942" FT /id="VSP_041871" FT VAR_SEQ 696..732 FT /note="Missing (in isoform 1, isoform 2 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10708748" FT /id="VSP_007059" FT VAR_SEQ 800 FT /note="A -> ASYKRAIGE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10708748" FT /id="VSP_007060" FT VARIANT 514 FT /note="A -> T (in dbSNP:rs56131206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040799" FT VARIANT 771 FT /note="V -> A (in dbSNP:rs11556634)" FT /evidence="ECO:0000269|PubMed:15469942, FT ECO:0000269|PubMed:15489334" FT /id="VAR_046058" FT VARIANT 775 FT /note="P -> L (in dbSNP:rs11556635)" FT /evidence="ECO:0000269|PubMed:15469942, FT ECO:0000269|PubMed:15489334, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT /id="VAR_046059" FT VARIANT 863 FT /note="V -> I (in dbSNP:rs2302319)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046060" FT VARIANT 1010 FT /note="E -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046061" FT VARIANT 1200 FT /note="I -> V" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040800" SQ SEQUENCE 1332 AA; 149822 MW; 3E3B182CDDB3659C CRC64; MGDPAPARSL DDIDLSALRD PAGIFELVEV VGNGTYGQVY KGRHVKTGQL AAIKVMDVTE DEEEEIKQEI NMLKKYSHHR NIATYYGAFI KKSPPGNDDQ LWLVMEFCGA GSVTDLVKNT KGNALKEDCI AYICREILRG LAHLHAHKVI HRDIKGQNVL LTENAEVKLV DFGVSAQLDR TVGRRNTFIG TPYWMAPEVI ACDENPDATY DYRSDIWSLG ITAIEMAEGA PPLCDMHPMR ALFLIPRNPP PRLKSKKWSK KFIDFIDTCL IKTYLSRPPT EQLLKFPFIR DQPTERQVRI QLKDHIDRSR KKRGEKEETE YEYSGSEEED DSHGEEGEPS SIMNVPGEST LRREFLRLQQ ENKSNSEALK QQQQLQQQQQ RDPEAHIKHL LHQRQRRIEE QKEERRRVEE QQRREREQRK LQEKEQQRRL EDMQALRREE ERRQAEREQE YKRKQLEEQR QSERLQRQLQ QEHAYLKSLQ QQQQQQQLQK QQQQQLLPGD RKPLYHYGRG MNPADKPAWA REVEERTRMN KQQNSPLAKS KPGSTGPEPP IPQASPGPPG PLSQTPPMQR PVEPQEGPHK SLVAHRVPLK PYAAPVPRSQ SLQDQPTRNL AAFPASHDPD PAIPAPTATP SARGAVIRQN SDPTSEGPGP SPNPPAWVRP DNEAPPKVPQ RTSSIATALN TSGAGGSRPA QAVRARPRSN SAWQIYLQRR AERGTPKPPG PPAQPPGPPN ASSNPDLRRS DPGWERSDSV LPASHGHLPQ AGSLERNRVG VSSKPDSSPV LSPGNKAKPD DHRSRPGRPA DFVLLKERTL DEAPRPPKKA MDYSSSSEEV ESSEDDEEEG EGGPAEGSRD TPGGRSDGDT DSVSTMVVHD VEEITGTQPP YGGGTMVVQR TPEEERNLLH ADSNGYTNLP DVVQPSHSPT ENSKGQSPPS KDGSGDYQSR GLVKAPGKSS FTMFVDLGIY QPGGSGDSIP ITALVGGEGT RLDQLQYDVR KGSVVNVNPT NTRAHSETPE IRKYKKRFNS EILCAALWGV NLLVGTENGL MLLDRSGQGK VYGLIGRRRF QQMDVLEGLN LLITISGKRN KLRVYYLSWL RNKILHNDPE VEKKQGWTTV GDMEGCGHYR VVKYERIKFL VIALKSSVEV YAWAPKPYHK FMAFKSFADL PHRPLLVDLT VEEGQRLKVI YGSSAGFHAV DVDSGNSYDI YIPVHIQSQI TPHAIIFLPN TDGMEMLLCY EDEGVYVNTY GRIIKDVVLQ WGEMPTSVAY ICSNQIMGWG EKAIEIRSVE TGHLDGVFMH KRAQRLKFLC ERNDKVFFAS VRSGGSSQVY FMTLNRNCIM NW // ID MK14_HUMAN Reviewed; 360 AA. AC Q16539; A6ZJ92; A8K6P4; B0LPH0; B5TY32; O60776; Q13083; Q14084; Q8TDX0; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 28-JAN-2026, entry version 267. DE RecName: Full=Mitogen-activated protein kinase 14 {ECO:0000305}; DE Short=MAP kinase 14; DE Short=MAPK 14; DE EC=2.7.11.24 {ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:15284239, ECO:0000269|PubMed:35857590, ECO:0000269|PubMed:7493921}; DE AltName: Full=Cytokine suppressive anti-inflammatory drug-binding protein; DE Short=CSAID-binding protein; DE Short=CSBP; DE AltName: Full=MAP kinase MXI2; DE AltName: Full=MAX-interacting protein 2; DE AltName: Full=Mitogen-activated protein kinase p38 alpha; DE Short=MAP kinase p38 alpha; DE AltName: Full=Stress-activated protein kinase 2a; DE Short=SAPK2a; GN Name=MAPK14 {ECO:0000312|HGNC:HGNC:6876}; GN Synonyms=CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS CSBP1 AND CSBP2), AND PARTIAL PROTEIN RP SEQUENCE. RC TISSUE=Peripheral blood; RX PubMed=7997261; DOI=10.1038/372739a0; RA Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., RA McNulty D., Blumenthal M.J., Heys R.J., Landvatter S.W., Strickler J.E., RA McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., RA Adams J.L., Young P.R.; RT "A protein kinase involved in the regulation of inflammatory cytokine RT biosynthesis."; RL Nature 372:739-746(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CSBP2). RC TISSUE=Liver; RX PubMed=7696354; DOI=10.1016/0167-4889(95)00002-a; RA Han J., Richter B., Li Z., Kravchenko V.V., Ulevitch R.J.; RT "Molecular cloning of human p38 MAP kinase."; RL Biochim. Biophys. Acta 1265:224-227(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MXI2). RX PubMed=7479834; DOI=10.1073/pnas.92.23.10531; RA Zervos A.S., Faccio L., Gatto J.P., Kyriakis J.M., Brent R.; RT "Mxi2, a mitogen-activated protein kinase that recognizes and RT phosphorylates Max protein."; RL Proc. Natl. Acad. Sci. U.S.A. 92:10531-10534(1995). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CSBP2). RC TISSUE=B-cell; RX PubMed=10727080; DOI=10.3109/10425179909033952; RA Herbison C.E., Sayer D.C., Bellgard M., Allcock R.J.N., Christiansen F.T., RA Price P.; RT "Structure and polymorphism of two stress-activated protein kinase genes RT centromeric of the MHC: SAPK2a and SAPK4."; RL DNA Seq. 10:229-243(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EXIP), AND ACTIVITY REGULATION. RC TISSUE=Renal cell carcinoma; RX PubMed=11866441; DOI=10.1006/bbrc.2002.6529; RA Sudo T., Yagasaki Y., Hama H., Watanabe N., Osada H.; RT "Exip, a new alternative splicing variant of p38 alpha, can induce an RT earlier onset of apoptosis in HeLa cells."; RL Biochem. Biophys. Res. Commun. 291:838-843(2002). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RX PubMed=19906316; DOI=10.1186/1471-2164-10-518; RA Wang P., Yu P., Gao P., Shi T., Ma D.; RT "Discovery of novel human transcript variants by analysis of intronic RT single-block EST with polyadenylation site."; RL BMC Genomics 10:518-518(2009). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP PROTEIN SEQUENCE OF 2-10. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [15] RP PROTEIN SEQUENCE OF 174-186. RX PubMed=7923354; DOI=10.1016/0092-8674(94)90278-x; RA Freshney N.W., Rawlinson L., Guesdon F., Jones E., Cowley S., Hsuan J., RA Saklatvala J.; RT "Interleukin-1 activates a novel protein kinase cascade that results in the RT phosphorylation of Hsp27."; RL Cell 78:1039-1049(1994). RN [16] RP PHOSPHORYLATION AT THR-180 AND TYR-182, ACTIVITY REGULATION, AND RP SUBCELLULAR LOCATION. RX PubMed=7535770; DOI=10.1074/jbc.270.13.7420; RA Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., RA Davis R.J.; RT "Pro-inflammatory cytokines and environmental stress cause p38 mitogen- RT activated protein kinase activation by dual phosphorylation on tyrosine and RT threonine."; RL J. Biol. Chem. 270:7420-7426(1995). RN [17] RP MUTAGENESIS OF ALA-34; LYS-53; ASP-168; THR-175; THR-180 AND TYR-182, AND RP CATALYTIC ACTIVITY. RX PubMed=7493921; DOI=10.1074/jbc.270.49.29043; RA Kumar S., McLaughlin M.M., McDonnell P.C., Lee J.C., Livi G.P., Young P.R.; RT "Human mitogen-activated protein kinase CSBP1, but not CSBP2, complements a RT hog1 deletion in yeast."; RL J. Biol. Chem. 270:29043-29046(1995). RN [18] RP PHOSPHORYLATION BY MAP2K3/MKK3 AND MAP2K6/MKK6, AND ACTIVITY REGULATION. RX PubMed=8622669; DOI=10.1128/mcb.16.3.1247; RA Raingeaud J., Whitmarsh A.J., Barrett T., Derijard B., Davis R.J.; RT "MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen- RT activated protein kinase signal transduction pathway."; RL Mol. Cell. Biol. 16:1247-1255(1996). RN [19] RP FUNCTION IN ACTIVATION OF RPS6KA5/MSK1. RX PubMed=9687510; DOI=10.1093/emboj/17.15.4426; RA Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.; RT "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly RT activated by MAPK and SAPK2/p38, and may mediate activation of CREB."; RL EMBO J. 17:4426-4441(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF ATF2; ELK1 AND MBP, AND ACTIVITY REGULATION. RX PubMed=9430721; DOI=10.1074/jbc.273.3.1741; RA Enslen H., Raingeaud J., Davis R.J.; RT "Selective activation of p38 mitogen-activated protein (MAP) kinase RT isoforms by the MAP kinase kinases MKK3 and MKK6."; RL J. Biol. Chem. 273:1741-1748(1998). RN [21] RP INTERACTION WITH RPS6KA4, FUNCTION IN PHOSPHORYLATION OF RPS6KA4, AND RP SUBCELLULAR LOCATION. RX PubMed=9792677; DOI=10.1074/jbc.273.45.29661; RA Pierrat B., Correia J.D.S., Mary J.L., Tomas-Zuber M., Lesslauer W.; RT "RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under RT dominant control of p38alpha mitogen-activated protein kinase RT (p38alphaMAPK)."; RL J. Biol. Chem. 273:29661-29671(1998). RN [22] RP INTERACTION WITH DUSP10, AND ACTIVITY REGULATION. RX PubMed=10391943; DOI=10.1074/jbc.274.28.19949; RA Tanoue T., Moriguchi T., Nishida E.; RT "Molecular cloning and characterization of a novel dual specificity RT phosphatase, MKP-5."; RL J. Biol. Chem. 274:19949-19956(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF MEF2A. RX PubMed=9858528; DOI=10.1128/mcb.19.1.21; RA Zhao M., New L., Kravchenko V.V., Kato Y., Gram H., di Padova F., RA Olson E.N., Ulevitch R.J., Han J.-D.; RT "Regulation of the MEF2 family of transcription factors by p38."; RL Mol. Cell. Biol. 19:21-30(1999). RN [24] RP FUNCTION IN PHOSPHORYLATION OF MEF2A AND MEF2C. RX PubMed=10330143; DOI=10.1128/mcb.19.6.4028; RA Yang S.-H., Galanis A., Sharrocks A.D.; RT "Targeting of p38 mitogen-activated protein kinases to MEF2 transcription RT factors."; RL Mol. Cell. Biol. 19:4028-4038(1999). RN [25] RP FUNCTION. RC TISSUE=Hepatoma; RX PubMed=10943842; DOI=10.1016/s0092-8674(00)00027-1; RA Tamura K., Sudo T., Senftleben U., Dadak A.M., Johnson R., Karin M.; RT "Requirement for p38alpha in erythropoietin expression: a role for stress RT kinases in erythropoiesis."; RL Cell 102:221-231(2000). RN [26] RP FUNCTION (ISOFORM MXI2), COFACTOR, AND ACTIVITY REGULATION. RX PubMed=10838079; DOI=10.1016/s0014-5793(00)01598-2; RA Sanz V., Arozarena I., Crespo P.; RT "Distinct carboxy-termini confer divergent characteristics to the mitogen- RT activated protein kinase p38alpha and its splice isoform Mxi2."; RL FEBS Lett. 474:169-174(2000). RN [27] RP INTERACTION WITH CSNK2A1 AND CSNK2B, AND FUNCTION IN ACTIVATION OF CASEIN RP KINASE II. RX PubMed=10747897; DOI=10.1074/jbc.m000312200; RA Sayed M., Kim S.O., Salh B.S., Issinger O.G., Pelech S.L.; RT "Stress-induced activation of protein kinase CK2 by direct interaction with RT p38 mitogen-activated protein kinase."; RL J. Biol. Chem. 275:16569-16573(2000). RN [28] RP INTERACTION WITH MA2PK6/MKK6, PHOSPHORYLATION BY MAP2K6/MKK6, RP AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-54, AND CATALYTIC ACTIVITY. RX PubMed=11010976; DOI=10.1074/jbc.m007835200; RA Alonso G., Ambrosino C., Jones M., Nebreda A.R.; RT "Differential activation of p38 mitogen-activated protein kinase isoforms RT depending on signal strength."; RL J. Biol. Chem. 275:40641-40648(2000). RN [29] RP INTERACTION WITH DUSP1, AND ACTIVITY REGULATION. RX PubMed=11278799; DOI=10.1074/jbc.m010966200; RA Slack D.N., Seternes O.M., Gabrielsen M., Keyse S.M.; RT "Distinct binding determinants for ERK2/p38alpha and JNK map kinases RT mediate catalytic activation and substrate selectivity of map kinase RT phosphatase-1."; RL J. Biol. Chem. 276:16491-16500(2001). RN [30] RP INTERACTION WITH DUSP16, AND ACTIVITY REGULATION. RX PubMed=11359773; DOI=10.1074/jbc.m101981200; RA Tanoue T., Yamamoto T., Maeda R., Nishida E.; RT "A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 RT alpha and beta MAPKs."; RL J. Biol. Chem. 276:26629-26639(2001). RN [31] RP FUNCTION AS MKNK2 KINASE. RX PubMed=11154262; DOI=10.1128/mcb.21.3.743-754.2001; RA Scheper G.C., Morrice N.A., Kleijn M., Proud C.G.; RT "The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a RT eukaryotic initiation factor 4E kinase with high levels of basal activity RT in mammalian cells."; RL Mol. Cell. Biol. 21:743-754(2001). RN [32] RP INTERACTION WITH CDC25B AND CDC25C, AND FUNCTION IN PHOSPHORYLATION OF RP CDC25B AND CDC25C. RX PubMed=11333986; DOI=10.1038/35075107; RA Bulavin D.V., Higashimoto Y., Popoff I.J., Gaarde W.A., Basrur V., RA Potapova O., Appella E., Fornace A.J. Jr.; RT "Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 RT kinase."; RL Nature 411:102-107(2001). RN [33] RP INTERACTION WITH TAB1, AUTOPHOSPHORYLATION, ACTIVITY REGULATION, AND RP CATALYTIC ACTIVITY. RX PubMed=11847341; DOI=10.1126/science.1067289; RA Ge B., Gram H., Di Padova F., Huang B., New L., Ulevitch R.J., Luo Y., RA Han J.; RT "MAPKK-independent activation of p38alpha mediated by TAB1-dependent RT autophosphorylation of p38alpha."; RL Science 295:1291-1294(2002). RN [34] RP MUTAGENESIS OF TYR-69; ASP-176; ASP-177; ALA-320; PHE-327 AND TRP-337. RX PubMed=15284239; DOI=10.1074/jbc.m404595200; RA Diskin R., Askari N., Capone R., Engelberg D., Livnah O.; RT "Active mutants of the human p38alpha mitogen-activated protein kinase."; RL J. Biol. Chem. 279:47040-47049(2004). RN [35] RP FUNCTION IN PHOSPHORYLATION OF S100A9. RX PubMed=15905572; DOI=10.4049/jimmunol.174.11.7257; RA Lominadze G., Rane M.J., Merchant M., Cai J., Ward R.A., McLeish K.R.; RT "Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils."; RL J. Immunol. 174:7257-7267(2005). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [37] RP PHOSPHORYLATION AT TYR-323, AND ACTIVITY REGULATION. RX PubMed=15735648; DOI=10.1038/ni1177; RA Salvador J.M., Mittelstadt P.R., Guszczynski T., Copeland T.D., RA Yamaguchi H., Appella E., Fornace A.J. Jr., Ashwell J.D.; RT "Alternative p38 activation pathway mediated by T cell receptor-proximal RT tyrosine kinases."; RL Nat. Immunol. 6:390-395(2005). RN [38] RP INTERACTION WITH TAB1, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15735649; DOI=10.1038/ni1176; RA Salvador J.M., Mittelstadt P.R., Belova G.I., Fornace A.J. Jr., RA Ashwell J.D.; RT "The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 RT activation pathway."; RL Nat. Immunol. 6:396-402(2005). RN [39] RP INTERACTION WITH SUPT20H. RX PubMed=16751104; DOI=10.1016/j.cell.2006.03.048; RA Zohn I.E., Li Y., Skolnik E.Y., Anderson K.V., Han J., Niswander L.; RT "p38 and a p38-interacting protein are critical for downregulation of E- RT cadherin during mouse gastrulation."; RL Cell 125:957-969(2006). RN [40] RP FUNCTION IN STRESS-INDUCED INTERNALIZATION OF EGFR. RX PubMed=16932740; DOI=10.1038/sj.emboj.7601297; RA Zwang Y., Yarden Y.; RT "p38 MAP kinase mediates stress-induced internalization of EGFR: RT implications for cancer chemotherapy."; RL EMBO J. 25:4195-4206(2006). RN [41] RP FUNCTION IN PHOSPHORYLATION OF SIAH2, AND ACTIVITY REGULATION. RX PubMed=17003045; DOI=10.1074/jbc.m606568200; RA Khurana A., Nakayama K., Williams S., Davis R.J., Mustelin T., Ronai Z.; RT "Regulation of the ring finger E3 ligase Siah2 by p38 MAPK."; RL J. Biol. Chem. 281:35316-35326(2006). RN [42] RP INTERACTION WITH NP60. RX PubMed=16352664; DOI=10.1242/jcs.02699; RA Fu J., Yang Z., Wei J., Han J., Gu J.; RT "Nuclear protein NP60 regulates p38 MAPK activity."; RL J. Cell Sci. 119:115-123(2006). RN [43] RP FUNCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=17724032; DOI=10.1074/jbc.m703857200; RA Qi X., Pohl N.M., Loesch M., Hou S., Li R., Qin J.Z., Cuenda A., Chen G.; RT "p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin- RT proteasome pathways in regulating Ras transformation and stress response."; RL J. Biol. Chem. 282:31398-31408(2007). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-263, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [45] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [46] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-16, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [50] RP FUNCTION IN INHIBITION OF AUTOPHAGY. RX PubMed=19893488; DOI=10.1038/emboj.2009.321; RA Webber J.L., Tooze S.A.; RT "Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and RT p38IP."; RL EMBO J. 29:27-40(2010). RN [51] RP FUNCTION IN PHOSPHORYLATION OF TIAR. RX PubMed=20932473; DOI=10.1016/j.molcel.2010.09.018; RA Reinhardt H.C., Hasskamp P., Schmedding I., Morandell S., van Vugt M.A., RA Wang X., Linding R., Ong S.E., Weaver D., Carr S.A., Yaffe M.B.; RT "DNA damage activates a spatially distinct late cytoplasmic cell-cycle RT checkpoint network controlled by MK2-mediated RNA stabilization."; RL Mol. Cell 40:34-49(2010). RN [52] RP INTERACTION WITH ADAM17, AND FUNCTION IN PHOSPHORYLATION OF ADAM17. RX PubMed=20188673; DOI=10.1016/j.molcel.2010.01.034; RA Xu P., Derynck R.; RT "Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase RT regulates EGF receptor-dependent cell proliferation."; RL Mol. Cell 37:551-566(2010). RN [53] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-2; THR-180 AND TYR-182, CLEAVAGE OF INITIATOR METHIONINE RP [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE RP SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP IDENTIFICATION IN A COMPLEX WITH AKAP13; PKN1; ZAK AND MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [56] RP FUNCTION (MICROBIAL INFECTION). RC TISSUE=T-cell; RX PubMed=21586573; DOI=10.1074/jbc.m111.234062; RA Peng H., Wang X., Barnes P.F., Tang H., Townsend J.C., Samten B.; RT "The Mycobacterium tuberculosis early secreted antigenic target of 6 kDa RT inhibits T cell interferon-gamma production through the p38 mitogen- RT activated protein kinase pathway."; RL J. Biol. Chem. 286:24508-24518(2011). RN [57] RP ACETYLATION AT LYS-53 AND LYS-152 BY KAT2B/PCAF AND EP300, AND RP DEACETYLATION BY HDAC3. RX PubMed=21444723; DOI=10.1128/mcb.01205-10; RA Pillai V.B., Sundaresan N.R., Samant S.A., Wolfgeher D., Trivedi C.M., RA Gupta M.P.; RT "Acetylation of a conserved lysine residue in the ATP binding pocket of p38 RT augments its kinase activity during hypertrophy of cardiomyocytes."; RL Mol. Cell. Biol. 31:2349-2363(2011). RN [58] RP INTERACTION WITH CDK5RAP3 AND PPM1D, AND DEPHOSPHORYLATION BY PPM1D. RX PubMed=21283629; DOI=10.1371/journal.pone.0016427; RA An H., Lu X., Liu D., Yarbrough W.G.; RT "LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating RT p38 association with the wild-type p53 induced phosphatase 1 (WIP1)."; RL PLoS ONE 6:E16427-E16427(2011). RN [59] RP REVIEW ON FUNCTION. RX PubMed=12452429; DOI=10.1515/bc.2002.173; RA Shi Y., Gaestel M.; RT "In the cellular garden of forking paths: how p38 MAPKs signal for RT downstream assistance."; RL Biol. Chem. 383:1519-1536(2002). RN [60] RP REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION. RX PubMed=20626350; DOI=10.1042/bj20100323; RA Cuadrado A., Nebreda A.R.; RT "Mechanisms and functions of p38 MAPK signalling."; RL Biochem. J. 429:403-417(2010). RN [61] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [62] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [64] RP SUBCELLULAR LOCATION. RX PubMed=30878395; DOI=10.1016/j.yjmcc.2019.03.005; RA Li C., Li J., Xue K., Zhang J., Wang C., Zhang Q., Chen X., Gao C., Yu X., RA Sun L.; RT "MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 RT after myocardial infarction."; RL J. Mol. Cell. Cardiol. 129:281-292(2019). RN [65] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=35857590; DOI=10.1126/science.abl6324; RA Robinson K.S., Toh G.A., Rozario P., Chua R., Bauernfried S., Sun Z., RA Firdaus M.J., Bayat S., Nadkarni R., Poh Z.S., Tham K.C., Harapas C.R., RA Lim C.K., Chu W., Tay C.W.S., Tan K.Y., Zhao T., Bonnard C., Sobota R., RA Connolly J.E., Common J., Masters S.L., Chen K.W., Ho L., Wu B., RA Hornung V., Zhong F.L.; RT "ZAKalpha-driven ribotoxic stress response activates the human NLRP1 RT inflammasome."; RL Science 377:328-335(2022). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS). RX PubMed=8910361; DOI=10.1074/jbc.271.44.27696; RA Wilson K.P., Fitzgibbon M.J., Caron P.R., Griffith J.P., Chen W., RA McCaffrey P.G., Chambers S.P., Su M.S.-S.; RT "Crystal structure of p38 mitogen-activated protein kinase."; RL J. Biol. Chem. 271:27696-27700(1996). RN [67] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS). RX PubMed=9095200; DOI=10.1038/nsb0497-311; RA Tong L., Pav S., White D.M., Rogers S., Crane K.M., Cywin C.L., Brown M.L., RA Pargellis C.A.; RT "A highly specific inhibitor of human p38 MAP kinase binds in the ATP RT pocket."; RL Nat. Struct. Biol. 4:311-316(1997). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS). RX PubMed=9753691; DOI=10.1016/s0969-2126(98)00113-0; RA Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., RA Abdel-Meguid S., Adams J.L., Goldsmith E.J.; RT "Structural basis of inhibitor selectivity in MAP kinases."; RL Structure 6:1117-1128(1998). RN [69] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS). RX PubMed=10633045; DOI=10.1021/jm990401t; RA Shewchuk L., Hassell A., Wisely B., Rocque W., Holmes W., Veal J., RA Kuyper L.F.; RT "Binding mode of the 4-anilinoquinazoline class of protein kinase RT inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to RT cyclin-dependent kinase 2 and p38 kinase."; RL J. Med. Chem. 43:133-138(2000). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=11896401; DOI=10.1038/nsb770; RA Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., RA Grob P.M., Hickey E.R., Moss N., Pav S., Regan J.; RT "Inhibition of p38 MAP kinase by utilizing a novel allosteric binding RT site."; RL Nat. Struct. Biol. 9:268-272(2002). RN [71] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=12482439; DOI=10.1016/s0960-894x(02)00752-7; RA Stelmach J.E., Liu L., Patel S.B., Pivnichny J.V., Scapin G., Singh S., RA Hop C.E., Wang Z., Strauss J.R., Cameron P.M., Nichols E.A., O'Keefe S.J., RA O'Neill E.A., Schmatz D.M., Schwartz C.D., Thompson C.M., Zaller D.M., RA Doherty J.B.; RT "Design and synthesis of potent, orally bioavailable dihydroquinazolinone RT inhibitors of p38 MAP kinase."; RL Bioorg. Med. Chem. Lett. 13:277-280(2003). RN [72] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=14561090; DOI=10.1021/jm0301787; RA Trejo A., Arzeno H., Browner M., Chanda S., Cheng S., Comer D.D., RA Dalrymple S.A., Dunten P., Lafargue J., Lovejoy B., Freire-Moar J., Lim J., RA Mcintosh J., Miller J., Papp E., Reuter D., Roberts R., Sanpablo F., RA Saunders J., Song K., Villasenor A., Warren S.D., Welch M., Weller P., RA Whiteley P.E., Zeng L., Goldstein D.M.; RT "Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase."; RL J. Med. Chem. 46:4702-4713(2003). RN [73] {ECO:0007744|PDB:1OUK, ECO:0007744|PDB:1OUY, ECO:0007744|PDB:1OVE} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH INHIBITOR. RX PubMed=12897767; DOI=10.1038/nsb949; RA Fitzgerald C.E., Patel S.B., Becker J.W., Cameron P.M., Zaller D., RA Pikounis V.B., O'Keefe S.J., Scapin G.; RT "Structural basis for p38alpha MAP kinase quinazolinone and pyridol- RT pyrimidine inhibitor specificity."; RL Nat. Struct. Biol. 10:764-769(2003). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=14726206; DOI=10.1016/j.bbapap.2003.09.009; RA Patel S.B., Cameron P.M., Frantz-Wattley B., O'Neill E., Becker J.W., RA Scapin G.; RT "Lattice stabilization and enhanced diffraction in human p38 alpha crystals RT by protein engineering."; RL Biochim. Biophys. Acta 1696:67-73(2004). RN [75] {ECO:0007744|PDB:2BAJ, ECO:0007744|PDB:2BAK, ECO:0007744|PDB:2BAL, ECO:0007744|PDB:2BAQ} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 2-359 IN COMPLEX WITH INHIBITOR. RX PubMed=16342939; DOI=10.1021/bi051714v; RA Sullivan J.E., Holdgate G.A., Campbell D., Timms D., Gerhardt S., Breed J., RA Breeze A.L., Bermingham A., Pauptit R.A., Norman R.A., Embrey K.J., RA Read J., VanScyoc W.S., Ward W.H.; RT "Prevention of MKK6-dependent activation by binding to p38alpha MAP RT kinase."; RL Biochemistry 44:16475-16490(2005). RN [76] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-359, AND ACTIVITY REGULATION. RX PubMed=15837335; DOI=10.1016/j.bmcl.2005.02.010; RA Tamayo N., Liao L., Goldberg M., Powers D., Tudor Y.Y., Yu V., Wong L.M., RA Henkle B., Middleton S., Syed R., Harvey T., Jang G., Hungate R., RA Dominguez C.; RT "Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase."; RL Bioorg. Med. Chem. Lett. 15:2409-2413(2005). RN [77] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=16169718; DOI=10.1016/j.bmcl.2005.08.038; RA Michelotti E.L., Moffett K.K., Nguyen D., Kelly M.J., Shetty R., Chai X., RA Northrop K., Namboodiri V., Campbell B., Flynn G.A., Fujimoto T., RA Hollinger F.P., Bukhtiyarova M., Springman E.B., Karpusas M.; RT "Two classes of p38alpha MAP kinase inhibitors having a common RT diphenylether core but exhibiting divergent binding modes."; RL Bioorg. Med. Chem. Lett. 15:5274-5279(2005). RN [78] {ECO:0007744|PDB:1W7H, ECO:0007744|PDB:1WBO} RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 2-359 IN COMPLEX WITH INHIBITOR. RX PubMed=15658854; DOI=10.1021/jm0495778; RA Hartshorn M.J., Murray C.W., Cleasby A., Frederickson M., Tickle I.J., RA Jhoti H.; RT "Fragment-based lead discovery using X-ray crystallography."; RL J. Med. Chem. 48:403-413(2005). RN [79] RP X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) OF 2-359 IN COMPLEX WITH MAPKAPK2. RX PubMed=17255097; DOI=10.1074/jbc.m611165200; RA ter Haar E., Prabhakar P., Liu X., Lepre C.; RT "Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer."; RL J. Biol. Chem. 282:9733-9739(2007). RN [80] RP ERRATUM OF PUBMED:17255097. RA ter Haar E., Prabhakar P., Liu X., Lepre C.; RL J. Biol. Chem. 282:14684-14684(2007). RN [81] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-51; ARG-322 AND GLY-343. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. MAPK14 is one of the CC four p38 MAPKs which play an important role in the cascades of cellular CC responses evoked by extracellular stimuli such as pro-inflammatory CC cytokines or physical stress leading to direct activation of CC transcription factors. Accordingly, p38 MAPKs phosphorylate a broad CC range of proteins and it has been estimated that they may have CC approximately 200 to 300 substrates each. Some of the targets are CC downstream kinases which are activated through phosphorylation and CC further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 CC can directly phosphorylate and activate transcription factors such as CC CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but CC can also phosphorylate histone H3 and the nucleosomal protein HMGN1 CC (PubMed:9687510, PubMed:9792677). RPS6KA5/MSK1 and RPS6KA4/MSK2 play CC important roles in the rapid induction of immediate-early genes in CC response to stress or mitogenic stimuli, either by inducing chromatin CC remodeling or by recruiting the transcription machinery CC (PubMed:9687510, PubMed:9792677). On the other hand, two other kinase CC targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of CC gene expression mostly at the post-transcriptional level, by CC phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating CC EEF2K, which is important for the elongation of mRNA during CC translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by CC p38 MAPKs, regulate protein synthesis by phosphorylating the initiation CC factor EIF4E2 (PubMed:11154262). MAPK14 also interacts with casein CC kinase II, leading to its activation through autophosphorylation and CC further phosphorylation of TP53/p53 (PubMed:10747897). In the CC cytoplasm, the p38 MAPK pathway is an important regulator of protein CC turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis CC whose proteasome-mediated degradation is regulated by p38 MAPK CC phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin CC ligase SIAH2, regulating its activity towards EGLN3 (PubMed:17003045). CC MAPK14 may also inhibit the lysosomal degradation pathway of autophagy CC by interfering with the intracellular trafficking of the transmembrane CC protein ATG9 (PubMed:19893488). Another function of MAPK14 is to CC regulate the endocytosis of membrane receptors by different mechanisms CC that impinge on the small GTPase RAB5A. In addition, clathrin-mediated CC EGFR internalization induced by inflammatory cytokines and UV CC irradiation depends on MAPK14-mediated phosphorylation of EGFR itself CC as well as of RAB5A effectors (PubMed:16932740). Ectodomain shedding of CC transmembrane proteins is regulated by p38 MAPKs as well. In response CC to inflammatory stimuli, p38 MAPKs phosphorylate the membrane- CC associated metalloprotease ADAM17 (PubMed:20188673). Such CC phosphorylation is required for ADAM17-mediated ectodomain shedding of CC TGF-alpha family ligands, which results in the activation of EGFR CC signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. CC FGFR1 can be translocated from the extracellular space into the cytosol CC and nucleus of target cells, and regulates processes such as rRNA CC synthesis and cell growth. FGFR1 translocation requires p38 MAPK CC activation. In the nucleus, many transcription factors are CC phosphorylated and activated by p38 MAPKs in response to different CC stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, CC DDIT3, TP53/p53 and MEF2C and MEF2A (PubMed:10330143, PubMed:9430721, CC PubMed:9858528). The p38 MAPKs are emerging as important modulators of CC gene expression by regulating chromatin modifiers and remodelers. The CC promoters of several genes involved in the inflammatory response, such CC as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of CC histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated CC myeloid cells. This phosphorylation enhances the accessibility of the CC cryptic NF-kappa-B-binding sites marking promoters for increased NF- CC kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required CC for binding to 14-3-3 proteins and leads to initiation of a G2 delay CC after ultraviolet radiation (PubMed:11333986). Phosphorylates TIAR CC following DNA damage, releasing TIAR from GADD45A mRNA and preventing CC mRNA degradation (PubMed:20932473). The p38 MAPKs may also have kinase- CC independent roles, which are thought to be due to the binding to CC targets in the absence of phosphorylation. Protein O-Glc-N-acylation CC catalyzed by the OGT is regulated by MAPK14, and, although OGT does not CC seem to be phosphorylated by MAPK14, their interaction increases upon CC MAPK14 activation induced by glucose deprivation. This interaction may CC regulate OGT activity by recruiting it to specific targets such as CC neurofilament H, stimulating its O-Glc-N-acylation. Required in mid- CC fetal development for the growth of embryo-derived blood vessels in the CC labyrinth layer of the placenta. Also plays an essential role in CC developmental and stress-induced erythropoiesis, through regulation of CC EPO gene expression (PubMed:10943842). Isoform MXI2 activation is CC stimulated by mitogens and oxidative stress and only poorly CC phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early CC onset of apoptosis. Phosphorylates S100A9 at 'Thr-113' CC (PubMed:15905572). Phosphorylates NLRP1 downstream of MAP3K20/ZAK in CC response to UV-B irradiation and ribosome collisions, promoting CC activation of the NLRP1 inflammasome and pyroptosis (PubMed:35857590). CC {ECO:0000269|PubMed:10330143, ECO:0000269|PubMed:10747897, CC ECO:0000269|PubMed:10943842, ECO:0000269|PubMed:11154262, CC ECO:0000269|PubMed:11333986, ECO:0000269|PubMed:15905572, CC ECO:0000269|PubMed:16932740, ECO:0000269|PubMed:17003045, CC ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:19893488, CC ECO:0000269|PubMed:20188673, ECO:0000269|PubMed:20932473, CC ECO:0000269|PubMed:35857590, ECO:0000269|PubMed:9430721, CC ECO:0000269|PubMed:9687510, ECO:0000269|PubMed:9792677, CC ECO:0000269|PubMed:9858528}. CC -!- FUNCTION: (Microbial infection) Activated by phosphorylation by CC M.tuberculosis EsxA in T-cells leading to inhibition of IFN-gamma CC production; phosphorylation is apparent within 15 minutes and is CC inhibited by kinase-specific inhibitors SB203580 and siRNA CC (PubMed:21586573). {ECO:0000269|PubMed:21586573}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10838079}; CC -!- ACTIVITY REGULATION: Activated by cell stresses such as DNA damage, CC heat shock, osmotic shock, anisomycin and sodium arsenite, as well as CC pro-inflammatory stimuli such as bacterial lipopolysaccharide (LPS) and CC interleukin-1. Activation occurs through dual phosphorylation of Thr- CC 180 and Tyr-182 by either of two dual specificity kinases, MAP2K3/MKK3 CC or MAP2K6/MKK6, and potentially also MAP2K4/MKK4, as well as by TAB1- CC mediated autophosphorylation. MAPK14 phosphorylated on both Thr-180 and CC Tyr-182 is 10-20-fold more active than MAPK14 phosphorylated only on CC Thr-180, whereas MAPK14 phosphorylated on Tyr-182 alone is inactive. CC whereas Thr-180 is necessary for catalysis, Tyr-182 may be required for CC auto-activation and substrate recognition. Phosphorylated at Tyr-323 by CC ZAP70 in an alternative activation pathway in response to TCR signaling CC in T-cells. This alternative pathway is inhibited by GADD45A. Inhibited CC by dual specificity phosphatases, such as DUSP1, DUSP10, and DUSP16. CC Specifically inhibited by the binding of pyridinyl-imidazole compounds, CC which are cytokine-suppressive anti-inflammatory drugs (CSAID). Isoform CC Mxi2 is 100-fold less sensitive to these agents than the other isoforms CC and is not inhibited by DUSP1. Isoform Exip is not activated by MAP2K6. CC SB203580 is an inhibitor of MAPK14. {ECO:0000269|PubMed:10391943, CC ECO:0000269|PubMed:10838079, ECO:0000269|PubMed:11278799, CC ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:11847341, CC ECO:0000269|PubMed:11866441, ECO:0000269|PubMed:11896401, CC ECO:0000269|PubMed:12482439, ECO:0000269|PubMed:14561090, CC ECO:0000269|PubMed:14726206, ECO:0000269|PubMed:15735648, CC ECO:0000269|PubMed:15735649, ECO:0000269|PubMed:15837335, CC ECO:0000269|PubMed:16169718, ECO:0000269|PubMed:17003045, CC ECO:0000269|PubMed:7535770, ECO:0000269|PubMed:8622669, CC ECO:0000269|PubMed:9430721}. CC -!- SUBUNIT: Component of a signaling complex containing at least AKAP13, CC PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13 interacts CC directly with PKN1, which in turn recruits MAPK14, MAP2K3 and ZAK CC (PubMed:21224381). Binds to a kinase interaction motif within the CC protein tyrosine phosphatase, PTPRR (By similarity). This interaction CC retains MAPK14 in the cytoplasm and prevents nuclear accumulation (By CC similarity). Interacts with SPAG9 and GADD45A (By similarity). CC Interacts with CDC25B, CDC25C, DUSP1, DUSP10, DUSP16, NP60, SUPT20H and CC TAB1. Interacts with casein kinase II subunits CSNK2A1 and CSNK2B. CC Interacts with PPM1D. Interacts with CDK5RAP3; recruits PPM1D to MAPK14 CC and may regulate its dephosphorylation (PubMed:21283629). Interacts CC with DUSP2; this interaction does not lead to catalytic activation of CC DUSP2 and dephosphorylation of MAPK14 (By similarity). CC {ECO:0000250|UniProtKB:P47811, ECO:0000269|PubMed:10391943, CC ECO:0000269|PubMed:10747897, ECO:0000269|PubMed:11010976, CC ECO:0000269|PubMed:11278799, ECO:0000269|PubMed:11333986, CC ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:11847341, CC ECO:0000269|PubMed:12897767, ECO:0000269|PubMed:15658854, CC ECO:0000269|PubMed:15735649, ECO:0000269|PubMed:16342939, CC ECO:0000269|PubMed:16352664, ECO:0000269|PubMed:16751104, CC ECO:0000269|PubMed:17255097, ECO:0000269|PubMed:20188673, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:21283629, CC ECO:0000269|PubMed:9792677}. CC -!- INTERACTION: CC Q16539; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-73946, EBI-9087876; CC Q16539; P28562: DUSP1; NbExp=4; IntAct=EBI-73946, EBI-975493; CC Q16539; Q9BY84: DUSP16; NbExp=4; IntAct=EBI-73946, EBI-3443956; CC Q16539; Q16829: DUSP7; NbExp=2; IntAct=EBI-73946, EBI-1265847; CC Q16539; Q99956: DUSP9; NbExp=6; IntAct=EBI-73946, EBI-3906678; CC Q16539; P68104: EEF1A1; NbExp=3; IntAct=EBI-73946, EBI-352162; CC Q16539; Q969H0: FBXW7; NbExp=5; IntAct=EBI-73946, EBI-359574; CC Q16539; P46734: MAP2K3; NbExp=7; IntAct=EBI-73946, EBI-602462; CC Q16539; P52564: MAP2K6; NbExp=3; IntAct=EBI-73946, EBI-448135; CC Q16539; P27361: MAPK3; NbExp=5; IntAct=EBI-73946, EBI-73995; CC Q16539; P49137: MAPKAPK2; NbExp=16; IntAct=EBI-73946, EBI-993299; CC Q16539; Q16644: MAPKAPK3; NbExp=16; IntAct=EBI-73946, EBI-1384657; CC Q16539; Q6PJG2: MIDEAS; NbExp=3; IntAct=EBI-73946, EBI-2795569; CC Q16539; Q9BUB5: MKNK1; NbExp=7; IntAct=EBI-73946, EBI-73837; CC Q16539; Q9HBH9: MKNK2; NbExp=5; IntAct=EBI-73946, EBI-2864341; CC Q16539; P35813: PPM1A; NbExp=2; IntAct=EBI-73946, EBI-989143; CC Q16539; Q15256: PTPRR; NbExp=4; IntAct=EBI-73946, EBI-2265659; CC Q16539; P06400: RB1; NbExp=4; IntAct=EBI-73946, EBI-491274; CC Q16539; O75676: RPS6KA4; NbExp=10; IntAct=EBI-73946, EBI-73933; CC Q16539; O75582: RPS6KA5; NbExp=4; IntAct=EBI-73946, EBI-73869; CC Q16539; Q8NEM7: SUPT20H; NbExp=5; IntAct=EBI-73946, EBI-946984; CC Q16539; Q15750: TAB1; NbExp=4; IntAct=EBI-73946, EBI-358643; CC Q16539; Q92574: TSC1; NbExp=2; IntAct=EBI-73946, EBI-1047085; CC Q16539; Q07352: ZFP36L1; NbExp=2; IntAct=EBI-73946, EBI-721823; CC Q16539; O43257: ZNHIT1; NbExp=7; IntAct=EBI-73946, EBI-347522; CC Q16539-1; P22736-1: NR4A1; NbExp=5; IntAct=EBI-15834191, EBI-16085263; CC Q16539-1; Q15256-1: PTPRR; NbExp=6; IntAct=EBI-15834191, EBI-16067395; CC Q16539-1; P54830-1: Ptpn5; Xeno; NbExp=6; IntAct=EBI-15834191, EBI-16067443; CC Q16539-3; P28482: MAPK1; NbExp=5; IntAct=EBI-6932370, EBI-959949; CC Q16539-3; P49790: NUP153; NbExp=2; IntAct=EBI-6932370, EBI-286779; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:7535770}. Nucleus CC {ECO:0000269|PubMed:30878395, ECO:0000269|PubMed:7535770}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=CSBP2; CC IsoId=Q16539-1; Sequence=Displayed; CC Name=CSBP1; CC IsoId=Q16539-2; Sequence=VSP_004842; CC Name=Mxi2; CC IsoId=Q16539-3; Sequence=VSP_004844; CC Name=Exip; Synonyms=Exon skip; CC IsoId=Q16539-4; Sequence=VSP_004843, VSP_004845; CC Name=5; CC IsoId=Q16539-5; Sequence=VSP_057194; CC -!- TISSUE SPECIFICITY: Brain, heart, placenta, pancreas and skeletal CC muscle. Expressed to a lesser extent in lung, liver and kidney. CC -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues CC whose phosphorylation activates the MAP kinases. CC -!- PTM: Dually phosphorylated on Thr-180 and Tyr-182 by the MAP2Ks CC MAP2K3/MKK3, MAP2K4/MKK4 and MAP2K6/MKK6 in response to inflammatory CC citokines, environmental stress or growth factors, which activates the CC enzyme. Dual phosphorylation can also be mediated by TAB1-mediated CC autophosphorylation. TCR engagement in T-cells also leads to Tyr-323 CC phosphorylation by ZAP70. Dephosphorylated and inactivated by DUPS1, CC DUSP10 and DUSP16. PPM1D also mediates dephosphorylation and CC inactivation of MAPK14 (PubMed:21283629). {ECO:0000269|PubMed:11010976, CC ECO:0000269|PubMed:15735648, ECO:0000269|PubMed:17724032, CC ECO:0000269|PubMed:21283629, ECO:0000269|PubMed:7535770, CC ECO:0000269|PubMed:8622669}. CC -!- PTM: Acetylated at Lys-53 and Lys-152 by KAT2B and EP300. Acetylation CC at Lys-53 increases the affinity for ATP and enhances kinase activity. CC Lys-53 and Lys-152 are deacetylated by HDAC3. CC {ECO:0000269|PubMed:21444723}. CC -!- PTM: Ubiquitinated. Ubiquitination leads to degradation by the CC proteasome pathway. {ECO:0000269|PubMed:17724032}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MAP kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=P38 mitogen-activated protein CC kinases entry; CC URL="https://en.wikipedia.org/wiki/P38_mitogen-activated_protein_kinases"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41292/MAPK14"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L35263; AAA57455.1; -; mRNA. DR EMBL; L35264; AAA57456.1; -; mRNA. DR EMBL; L35253; AAA74301.1; -; mRNA. DR EMBL; U19775; AAC50329.1; -; mRNA. DR EMBL; AF100544; AAF36770.1; -; mRNA. DR EMBL; AB074150; BAB85654.1; -; mRNA. DR EMBL; FJ032367; ACI00233.1; -; mRNA. DR EMBL; AK291709; BAF84398.1; -; mRNA. DR EMBL; BT006933; AAP35579.1; -; mRNA. DR EMBL; CR536505; CAG38743.1; -; mRNA. DR EMBL; EU332860; ABY87549.1; -; Genomic_DNA. DR EMBL; Z95152; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX03869.1; -; Genomic_DNA. DR EMBL; BC000092; AAH00092.1; -; mRNA. DR EMBL; BC031574; AAH31574.1; -; mRNA. DR CCDS; CCDS4815.1; -. [Q16539-2] DR CCDS; CCDS4816.1; -. [Q16539-1] DR CCDS; CCDS4817.1; -. [Q16539-4] DR PIR; S53536; S53536. DR RefSeq; NP_001306.1; NM_001315.3. [Q16539-2] DR RefSeq; NP_620581.1; NM_139012.3. [Q16539-1] DR RefSeq; NP_620582.1; NM_139013.3. [Q16539-3] DR RefSeq; NP_620583.1; NM_139014.3. [Q16539-4] DR PDB; 1A9U; X-ray; 2.50 A; A=1-360. DR PDB; 1BL6; X-ray; 2.50 A; A=1-360. DR PDB; 1BL7; X-ray; 2.50 A; A=1-360. DR PDB; 1BMK; X-ray; 2.40 A; A=1-360. DR PDB; 1DI9; X-ray; 2.60 A; A=1-360. DR PDB; 1IAN; X-ray; 2.00 A; A=2-360. DR PDB; 1KV1; X-ray; 2.50 A; A=1-360. DR PDB; 1KV2; X-ray; 2.80 A; A=1-360. DR PDB; 1M7Q; X-ray; 2.40 A; A=1-360. DR PDB; 1OUK; X-ray; 2.50 A; A=1-360. DR PDB; 1OUY; X-ray; 2.50 A; A=1-360. DR PDB; 1OVE; X-ray; 2.10 A; A=1-360. DR PDB; 1OZ1; X-ray; 2.10 A; A=1-360. DR PDB; 1R39; X-ray; 2.30 A; A=1-360. DR PDB; 1R3C; X-ray; 2.00 A; A=1-360. DR PDB; 1W7H; X-ray; 2.21 A; A=2-360. DR PDB; 1W82; X-ray; 2.20 A; A=2-360. DR PDB; 1W83; X-ray; 2.50 A; A=2-360. DR PDB; 1W84; X-ray; 2.20 A; A=2-360. DR PDB; 1WBN; X-ray; 2.40 A; A=2-360. DR PDB; 1WBO; X-ray; 2.16 A; A=2-360. DR PDB; 1WBS; X-ray; 1.80 A; A=2-360. DR PDB; 1WBT; X-ray; 2.00 A; A=2-360. DR PDB; 1WBV; X-ray; 2.00 A; A=2-360. DR PDB; 1WBW; X-ray; 2.41 A; A=2-360. DR PDB; 1WFC; X-ray; 2.30 A; A=1-360. DR PDB; 1YQJ; X-ray; 2.00 A; A=2-360. DR PDB; 1ZYJ; X-ray; 2.00 A; A=1-360. DR PDB; 1ZZ2; X-ray; 2.00 A; A=1-360. DR PDB; 1ZZL; X-ray; 2.00 A; A=4-354. DR PDB; 2BAJ; X-ray; 2.25 A; A=2-360. DR PDB; 2BAK; X-ray; 2.20 A; A=2-360. DR PDB; 2BAL; X-ray; 2.10 A; A=2-360. DR PDB; 2BAQ; X-ray; 2.80 A; A=2-360. DR PDB; 2FSL; X-ray; 1.70 A; X=2-360. DR PDB; 2FSM; X-ray; 1.86 A; X=2-360. DR PDB; 2FSO; X-ray; 1.83 A; X=2-360. DR PDB; 2FST; X-ray; 1.45 A; X=2-360. DR PDB; 2GFS; X-ray; 1.75 A; A=2-360. DR PDB; 2I0H; X-ray; 2.00 A; A=1-360. DR PDB; 2LGC; NMR; -; A=2-354. DR PDB; 2NPQ; X-ray; 1.80 A; A=2-360. DR PDB; 2OKR; X-ray; 2.00 A; A/D=2-360. DR PDB; 2ONL; X-ray; 4.00 A; A/B=2-360. DR PDB; 2QD9; X-ray; 1.70 A; A=2-360. DR PDB; 2RG5; X-ray; 2.40 A; A=2-360. DR PDB; 2RG6; X-ray; 1.72 A; A=2-360. DR PDB; 2Y8O; X-ray; 1.95 A; A=1-360. DR PDB; 2YIS; X-ray; 2.00 A; A=2-360. DR PDB; 2YIW; X-ray; 2.00 A; A=2-360. DR PDB; 2YIX; X-ray; 2.30 A; A=4-354. DR PDB; 2ZAZ; X-ray; 1.80 A; A=1-360. DR PDB; 2ZB0; X-ray; 2.10 A; A=1-360. DR PDB; 2ZB1; X-ray; 2.50 A; A=1-360. DR PDB; 3BV2; X-ray; 2.40 A; A=2-360. DR PDB; 3BV3; X-ray; 2.59 A; A=2-360. DR PDB; 3BX5; X-ray; 2.40 A; A=2-360. DR PDB; 3C5U; X-ray; 2.80 A; A=2-360. DR PDB; 3CTQ; X-ray; 1.95 A; A=5-352. DR PDB; 3D7Z; X-ray; 2.10 A; A=1-360. DR PDB; 3D83; X-ray; 1.90 A; A=1-360. DR PDB; 3DS6; X-ray; 2.90 A; A/B/C/D=1-360. DR PDB; 3DT1; X-ray; 2.80 A; A=1-360. DR PDB; 3E92; X-ray; 2.00 A; A=1-360. DR PDB; 3E93; X-ray; 2.00 A; A=1-360. DR PDB; 3FC1; X-ray; 2.40 A; X=1-360. DR PDB; 3FI4; X-ray; 2.20 A; A=1-360. DR PDB; 3FKL; X-ray; 2.00 A; A=1-360. DR PDB; 3FKN; X-ray; 2.00 A; A=1-360. DR PDB; 3FKO; X-ray; 2.00 A; A=1-360. DR PDB; 3FL4; X-ray; 1.80 A; A=1-360. DR PDB; 3FLN; X-ray; 1.90 A; C=1-360. DR PDB; 3FLQ; X-ray; 1.90 A; A=1-360. DR PDB; 3FLS; X-ray; 2.30 A; A=1-360. DR PDB; 3FLW; X-ray; 2.10 A; A=1-360. DR PDB; 3FLY; X-ray; 1.80 A; A=1-360. DR PDB; 3FLZ; X-ray; 2.23 A; A=1-360. DR PDB; 3FMH; X-ray; 1.90 A; A=1-360. DR PDB; 3FMJ; X-ray; 2.00 A; A=1-360. DR PDB; 3FMK; X-ray; 1.70 A; A=1-360. DR PDB; 3FML; X-ray; 2.10 A; A=1-360. DR PDB; 3FMM; X-ray; 2.00 A; A=1-360. DR PDB; 3FMN; X-ray; 1.90 A; A=1-360. DR PDB; 3FSF; X-ray; 2.10 A; A=1-360. DR PDB; 3FSK; X-ray; 2.00 A; A=1-360. DR PDB; 3GC7; X-ray; 1.80 A; A=1-360. DR PDB; 3GCP; X-ray; 2.25 A; A=2-360. DR PDB; 3GCQ; X-ray; 2.00 A; A=2-360. DR PDB; 3GCS; X-ray; 2.10 A; A=2-360. DR PDB; 3GCU; X-ray; 2.10 A; A/B=2-360. DR PDB; 3GCV; X-ray; 2.30 A; A=2-360. DR PDB; 3GFE; X-ray; 2.10 A; A=1-360. DR PDB; 3GI3; X-ray; 2.40 A; A=1-360. DR PDB; 3HA8; X-ray; 2.48 A; A=1-360. DR PDB; 3HEC; X-ray; 2.50 A; A=5-352. DR PDB; 3HEG; X-ray; 2.20 A; A=5-352. DR PDB; 3HL7; X-ray; 1.88 A; A=1-360. DR PDB; 3HLL; X-ray; 1.95 A; A=1-360. DR PDB; 3HP2; X-ray; 2.15 A; A=1-360. DR PDB; 3HP5; X-ray; 2.30 A; A=1-360. DR PDB; 3HRB; X-ray; 2.20 A; A=2-360. DR PDB; 3HUB; X-ray; 2.25 A; A=2-360. DR PDB; 3HUC; X-ray; 1.80 A; A=2-360. DR PDB; 3HV3; X-ray; 2.00 A; A=2-360. DR PDB; 3HV4; X-ray; 2.60 A; A/B=2-360. DR PDB; 3HV5; X-ray; 2.25 A; A/B=2-360. DR PDB; 3HV6; X-ray; 1.95 A; A=2-360. DR PDB; 3HV7; X-ray; 2.40 A; A=2-360. DR PDB; 3HVC; X-ray; 2.10 A; A=1-360. DR PDB; 3IPH; X-ray; 2.10 A; A=1-360. DR PDB; 3ITZ; X-ray; 2.25 A; A=1-360. DR PDB; 3IW5; X-ray; 2.50 A; A=2-360. DR PDB; 3IW6; X-ray; 2.10 A; A=2-360. DR PDB; 3IW7; X-ray; 2.40 A; A=2-360. DR PDB; 3IW8; X-ray; 2.00 A; A=2-360. DR PDB; 3K3I; X-ray; 1.70 A; A=5-352. DR PDB; 3K3J; X-ray; 2.00 A; A=1-360. DR PDB; 3KF7; X-ray; 2.00 A; A=1-360. DR PDB; 3KQ7; X-ray; 1.80 A; A=1-360. DR PDB; 3L8S; X-ray; 2.35 A; A=2-360. DR PDB; 3L8X; X-ray; 2.15 A; A=2-360. DR PDB; 3LFA; X-ray; 2.10 A; A=2-360. DR PDB; 3LFB; X-ray; 2.60 A; A=2-360. DR PDB; 3LFC; X-ray; 2.80 A; A=2-360. DR PDB; 3LFD; X-ray; 3.40 A; A=2-360. DR PDB; 3LFE; X-ray; 2.30 A; A=2-360. DR PDB; 3LFF; X-ray; 1.50 A; A=2-360. DR PDB; 3LHJ; X-ray; 3.31 A; A=1-360. DR PDB; 3MGY; X-ray; 2.10 A; A=1-360. DR PDB; 3MH0; X-ray; 2.00 A; A=1-360. DR PDB; 3MH1; X-ray; 2.20 A; A=1-360. DR PDB; 3MH2; X-ray; 2.30 A; A=1-360. DR PDB; 3MH3; X-ray; 2.20 A; A=1-360. DR PDB; 3MPA; X-ray; 2.10 A; A=1-360. DR PDB; 3MPT; X-ray; 1.89 A; A=1-360. DR PDB; 3MVL; X-ray; 2.80 A; A/B=2-360. DR PDB; 3MVM; X-ray; 2.00 A; A/B=2-360. DR PDB; 3MW1; X-ray; 2.80 A; A=2-360. DR PDB; 3NEW; X-ray; 2.51 A; A=1-360. DR PDB; 3NNU; X-ray; 2.40 A; A=1-354. DR PDB; 3NNV; X-ray; 2.10 A; A=1-354. DR PDB; 3NNW; X-ray; 1.89 A; A=1-354. DR PDB; 3NNX; X-ray; 2.28 A; A=1-354. DR PDB; 3NWW; X-ray; 2.09 A; A=2-360. DR PDB; 3O8P; X-ray; 2.10 A; A=1-360. DR PDB; 3O8T; X-ray; 2.00 A; A=1-360. DR PDB; 3O8U; X-ray; 2.10 A; A=1-360. DR PDB; 3OBG; X-ray; 2.80 A; A=1-360. DR PDB; 3OBJ; X-ray; 2.40 A; A=1-360. DR PDB; 3OC1; X-ray; 2.59 A; A=1-360. DR PDB; 3OCG; X-ray; 2.21 A; A=2-360. DR PDB; 3OD6; X-ray; 2.68 A; X=1-360. DR PDB; 3ODY; X-ray; 2.20 A; X=1-360. DR PDB; 3ODZ; X-ray; 2.30 A; X=1-360. DR PDB; 3OEF; X-ray; 1.60 A; X=1-360. DR PDB; 3PG3; X-ray; 2.00 A; A=2-360. DR PDB; 3QUD; X-ray; 2.00 A; A=2-360. DR PDB; 3QUE; X-ray; 2.70 A; A=2-360. DR PDB; 3RIN; X-ray; 2.20 A; A=1-360. DR PDB; 3ROC; X-ray; 1.70 A; A=1-360. DR PDB; 3S3I; X-ray; 1.80 A; A=4-352. DR PDB; 3S4Q; X-ray; 2.27 A; A=2-360. DR PDB; 3U8W; X-ray; 2.15 A; A=1-360. DR PDB; 3UVP; X-ray; 2.40 A; A=2-360. DR PDB; 3UVQ; X-ray; 2.20 A; A=2-360. DR PDB; 3UVR; X-ray; 2.10 A; A=2-360. DR PDB; 3ZS5; X-ray; 1.60 A; A=2-360. DR PDB; 3ZSG; X-ray; 1.89 A; A=2-360. DR PDB; 3ZSH; X-ray; 2.05 A; A=2-360. DR PDB; 3ZSI; X-ray; 2.40 A; A=2-360. DR PDB; 3ZYA; X-ray; 1.90 A; A=1-360. DR PDB; 4A9Y; X-ray; 2.20 A; A=2-360. DR PDB; 4AA0; X-ray; 1.80 A; A=2-360. DR PDB; 4AA4; X-ray; 2.30 A; A=2-360. DR PDB; 4AA5; X-ray; 2.38 A; A=2-360. DR PDB; 4AAC; X-ray; 2.50 A; A=2-360. DR PDB; 4DLI; X-ray; 1.91 A; A=2-360. DR PDB; 4DLJ; X-ray; 2.60 A; A=2-360. DR PDB; 4E5A; X-ray; 1.87 A; X=1-360. DR PDB; 4E5B; X-ray; 2.00 A; A=1-360. DR PDB; 4E6A; X-ray; 2.09 A; A=1-360. DR PDB; 4E6C; X-ray; 2.39 A; A=1-360. DR PDB; 4E8A; X-ray; 2.70 A; A=1-360. DR PDB; 4EH2; X-ray; 2.00 A; A=2-360. DR PDB; 4EH3; X-ray; 2.40 A; A=2-360. DR PDB; 4EH4; X-ray; 2.50 A; A=2-360. DR PDB; 4EH5; X-ray; 2.00 A; A=2-360. DR PDB; 4EH6; X-ray; 2.10 A; A=2-360. DR PDB; 4EH7; X-ray; 2.10 A; A=2-360. DR PDB; 4EH8; X-ray; 2.20 A; A=2-360. DR PDB; 4EH9; X-ray; 2.10 A; A=2-360. DR PDB; 4EHV; X-ray; 1.60 A; A=2-360. DR PDB; 4EWQ; X-ray; 2.10 A; A=2-360. DR PDB; 4F9W; X-ray; 2.00 A; A=2-360. DR PDB; 4F9Y; X-ray; 1.85 A; A=2-360. DR PDB; 4FA2; X-ray; 2.00 A; A=2-360. DR PDB; 4GEO; X-ray; 1.66 A; A=2-360. DR PDB; 4KIN; X-ray; 1.97 A; A/B/C/D=2-360. DR PDB; 4KIP; X-ray; 2.27 A; A/B=2-360. DR PDB; 4KIQ; X-ray; 2.50 A; A/B/C/D=2-360. DR PDB; 4L8M; X-ray; 2.10 A; A=2-360. DR PDB; 4R3C; X-ray; 2.06 A; A=2-360. DR PDB; 4ZTH; X-ray; 2.15 A; A=2-360. DR PDB; 5ETA; X-ray; 2.80 A; A/B=1-360. DR PDB; 5ETC; X-ray; 2.42 A; A=1-360. DR PDB; 5ETF; X-ray; 2.40 A; A=1-360. DR PDB; 5ETI; X-ray; 2.80 A; A=1-360. DR PDB; 5ML5; X-ray; 1.90 A; A=1-360. DR PDB; 5MTX; X-ray; 1.80 A; A=1-360. DR PDB; 5MTY; X-ray; 2.31 A; A=1-360. DR PDB; 5MZ3; X-ray; 2.15 A; A=1-360. DR PDB; 5N63; X-ray; 2.40 A; A=1-360. DR PDB; 5N64; X-ray; 2.40 A; A=1-360. DR PDB; 5N65; X-ray; 2.00 A; A=1-360. DR PDB; 5N66; X-ray; 2.40 A; A=1-360. DR PDB; 5N67; X-ray; 1.90 A; A=1-360. DR PDB; 5N68; X-ray; 1.85 A; A=1-360. DR PDB; 5O8U; X-ray; 2.00 A; A=1-360. DR PDB; 5O8V; X-ray; 2.00 A; A=1-360. DR PDB; 5OMG; X-ray; 2.00 A; A=1-360. DR PDB; 5OMH; X-ray; 2.50 A; A=1-360. DR PDB; 5TBE; X-ray; 2.44 A; A=1-360. DR PDB; 5TCO; X-ray; 2.10 A; A=2-360. DR PDB; 5WJJ; X-ray; 1.60 A; A=1-360. DR PDB; 5XYX; X-ray; 2.61 A; A=1-360. DR PDB; 5XYY; X-ray; 1.70 A; A=1-360. DR PDB; 6ANL; X-ray; 2.00 A; A=1-360. DR PDB; 6HWT; X-ray; 1.70 A; A=2-360. DR PDB; 6HWU; X-ray; 2.30 A; A=2-360. DR PDB; 6HWV; X-ray; 1.70 A; A=2-360. DR PDB; 6M95; X-ray; 1.80 A; A=1-360. DR PDB; 6M9L; X-ray; 2.45 A; A=1-360. DR PDB; 6OHD; X-ray; 2.50 A; A=1-360. DR PDB; 6QDZ; X-ray; 1.73 A; A=1-360. DR PDB; 6QE1; X-ray; 1.85 A; A=1-360. DR PDB; 6QYX; X-ray; 1.66 A; A=1-166, A=197-360. DR PDB; 6RFO; X-ray; 1.70 A; A=167-196. DR PDB; 6SFI; X-ray; 1.60 A; A=1-360. DR PDB; 6SFJ; X-ray; 1.95 A; A=1-360. DR PDB; 6SFK; X-ray; 1.80 A; A=1-360. DR PDB; 6SFO; X-ray; 1.75 A; A=1-360. DR PDB; 6TCA; X-ray; 3.70 A; B/D/F/H=1-360. DR PDB; 6ZQS; X-ray; 1.95 A; A=1-360. DR PDB; 6ZWP; X-ray; 1.90 A; A=1-360. DR PDB; 8A8M; EM; 4.00 A; A=1-360. DR PDB; 8VXE; X-ray; 1.85 A; A=2-360. DR PDB; 8X3M; X-ray; 1.85 A; A=1-360. DR PDB; 8YD9; X-ray; 1.66 A; A=1-360. DR PDB; 9CJ1; X-ray; 1.80 A; A=1-360. DR PDB; 9CJ2; X-ray; 2.83 A; A/B=1-360. DR PDB; 9CJ3; X-ray; 1.95 A; A=1-360. DR PDB; 9CJ4; X-ray; 1.80 A; A=1-360. DR PDB; 9CJ5; X-ray; 3.30 A; A=1-360. DR PDB; 9MHB; X-ray; 1.65 A; A=2-360. DR PDB; 9NYT; X-ray; 2.16 A; A=1-360. DR PDB; 9O4L; X-ray; 2.27 A; A=1-360. DR PDBsum; 1A9U; -. DR PDBsum; 1BL6; -. DR PDBsum; 1BL7; -. DR PDBsum; 1BMK; -. DR PDBsum; 1DI9; -. DR PDBsum; 1IAN; -. DR PDBsum; 1KV1; -. DR PDBsum; 1KV2; -. DR PDBsum; 1M7Q; -. DR PDBsum; 1OUK; -. DR PDBsum; 1OUY; -. DR PDBsum; 1OVE; -. DR PDBsum; 1OZ1; -. DR PDBsum; 1R39; -. DR PDBsum; 1R3C; -. DR PDBsum; 1W7H; -. DR PDBsum; 1W82; -. DR PDBsum; 1W83; -. DR PDBsum; 1W84; -. DR PDBsum; 1WBN; -. DR PDBsum; 1WBO; -. DR PDBsum; 1WBS; -. DR PDBsum; 1WBT; -. DR PDBsum; 1WBV; -. DR PDBsum; 1WBW; -. DR PDBsum; 1WFC; -. DR PDBsum; 1YQJ; -. DR PDBsum; 1ZYJ; -. DR PDBsum; 1ZZ2; -. DR PDBsum; 1ZZL; -. DR PDBsum; 2BAJ; -. DR PDBsum; 2BAK; -. DR PDBsum; 2BAL; -. DR PDBsum; 2BAQ; -. DR PDBsum; 2FSL; -. DR PDBsum; 2FSM; -. DR PDBsum; 2FSO; -. DR PDBsum; 2FST; -. DR PDBsum; 2GFS; -. DR PDBsum; 2I0H; -. DR PDBsum; 2LGC; -. DR PDBsum; 2NPQ; -. DR PDBsum; 2OKR; -. DR PDBsum; 2ONL; -. DR PDBsum; 2QD9; -. DR PDBsum; 2RG5; -. DR PDBsum; 2RG6; -. DR PDBsum; 2Y8O; -. DR PDBsum; 2YIS; -. DR PDBsum; 2YIW; -. DR PDBsum; 2YIX; -. DR PDBsum; 2ZAZ; -. DR PDBsum; 2ZB0; -. DR PDBsum; 2ZB1; -. DR PDBsum; 3BV2; -. DR PDBsum; 3BV3; -. DR PDBsum; 3BX5; -. DR PDBsum; 3C5U; -. DR PDBsum; 3CTQ; -. DR PDBsum; 3D7Z; -. DR PDBsum; 3D83; -. DR PDBsum; 3DS6; -. DR PDBsum; 3DT1; -. DR PDBsum; 3E92; -. DR PDBsum; 3E93; -. DR PDBsum; 3FC1; -. DR PDBsum; 3FI4; -. DR PDBsum; 3FKL; -. DR PDBsum; 3FKN; -. DR PDBsum; 3FKO; -. DR PDBsum; 3FL4; -. DR PDBsum; 3FLN; -. DR PDBsum; 3FLQ; -. DR PDBsum; 3FLS; -. DR PDBsum; 3FLW; -. DR PDBsum; 3FLY; -. DR PDBsum; 3FLZ; -. DR PDBsum; 3FMH; -. DR PDBsum; 3FMJ; -. DR PDBsum; 3FMK; -. DR PDBsum; 3FML; -. DR PDBsum; 3FMM; -. DR PDBsum; 3FMN; -. DR PDBsum; 3FSF; -. DR PDBsum; 3FSK; -. DR PDBsum; 3GC7; -. DR PDBsum; 3GCP; -. DR PDBsum; 3GCQ; -. DR PDBsum; 3GCS; -. DR PDBsum; 3GCU; -. DR PDBsum; 3GCV; -. DR PDBsum; 3GFE; -. DR PDBsum; 3GI3; -. DR PDBsum; 3HA8; -. DR PDBsum; 3HEC; -. DR PDBsum; 3HEG; -. DR PDBsum; 3HL7; -. DR PDBsum; 3HLL; -. DR PDBsum; 3HP2; -. DR PDBsum; 3HP5; -. DR PDBsum; 3HRB; -. DR PDBsum; 3HUB; -. DR PDBsum; 3HUC; -. DR PDBsum; 3HV3; -. DR PDBsum; 3HV4; -. DR PDBsum; 3HV5; -. DR PDBsum; 3HV6; -. DR PDBsum; 3HV7; -. DR PDBsum; 3HVC; -. DR PDBsum; 3IPH; -. DR PDBsum; 3ITZ; -. DR PDBsum; 3IW5; -. DR PDBsum; 3IW6; -. DR PDBsum; 3IW7; -. DR PDBsum; 3IW8; -. DR PDBsum; 3K3I; -. DR PDBsum; 3K3J; -. DR PDBsum; 3KF7; -. DR PDBsum; 3KQ7; -. DR PDBsum; 3L8S; -. DR PDBsum; 3L8X; -. DR PDBsum; 3LFA; -. DR PDBsum; 3LFB; -. DR PDBsum; 3LFC; -. DR PDBsum; 3LFD; -. DR PDBsum; 3LFE; -. DR PDBsum; 3LFF; -. DR PDBsum; 3LHJ; -. DR PDBsum; 3MGY; -. DR PDBsum; 3MH0; -. DR PDBsum; 3MH1; -. DR PDBsum; 3MH2; -. DR PDBsum; 3MH3; -. DR PDBsum; 3MPA; -. DR PDBsum; 3MPT; -. DR PDBsum; 3MVL; -. DR PDBsum; 3MVM; -. DR PDBsum; 3MW1; -. DR PDBsum; 3NEW; -. DR PDBsum; 3NNU; -. DR PDBsum; 3NNV; -. DR PDBsum; 3NNW; -. DR PDBsum; 3NNX; -. DR PDBsum; 3NWW; -. DR PDBsum; 3O8P; -. DR PDBsum; 3O8T; -. DR PDBsum; 3O8U; -. DR PDBsum; 3OBG; -. DR PDBsum; 3OBJ; -. DR PDBsum; 3OC1; -. DR PDBsum; 3OCG; -. DR PDBsum; 3OD6; -. DR PDBsum; 3ODY; -. DR PDBsum; 3ODZ; -. DR PDBsum; 3OEF; -. DR PDBsum; 3PG3; -. DR PDBsum; 3QUD; -. DR PDBsum; 3QUE; -. DR PDBsum; 3RIN; -. DR PDBsum; 3ROC; -. DR PDBsum; 3S3I; -. DR PDBsum; 3S4Q; -. DR PDBsum; 3U8W; -. DR PDBsum; 3UVP; -. DR PDBsum; 3UVQ; -. DR PDBsum; 3UVR; -. DR PDBsum; 3ZS5; -. DR PDBsum; 3ZSG; -. DR PDBsum; 3ZSH; -. DR PDBsum; 3ZSI; -. DR PDBsum; 3ZYA; -. DR PDBsum; 4A9Y; -. DR PDBsum; 4AA0; -. DR PDBsum; 4AA4; -. DR PDBsum; 4AA5; -. DR PDBsum; 4AAC; -. DR PDBsum; 4DLI; -. DR PDBsum; 4DLJ; -. DR PDBsum; 4E5A; -. DR PDBsum; 4E5B; -. DR PDBsum; 4E6A; -. DR PDBsum; 4E6C; -. DR PDBsum; 4E8A; -. DR PDBsum; 4EH2; -. DR PDBsum; 4EH3; -. DR PDBsum; 4EH4; -. DR PDBsum; 4EH5; -. DR PDBsum; 4EH6; -. DR PDBsum; 4EH7; -. DR PDBsum; 4EH8; -. DR PDBsum; 4EH9; -. DR PDBsum; 4EHV; -. DR PDBsum; 4EWQ; -. DR PDBsum; 4F9W; -. DR PDBsum; 4F9Y; -. DR PDBsum; 4FA2; -. DR PDBsum; 4GEO; -. DR PDBsum; 4KIN; -. DR PDBsum; 4KIP; -. DR PDBsum; 4KIQ; -. DR PDBsum; 4L8M; -. DR PDBsum; 4R3C; -. DR PDBsum; 4ZTH; -. DR PDBsum; 5ETA; -. DR PDBsum; 5ETC; -. DR PDBsum; 5ETF; -. DR PDBsum; 5ETI; -. DR PDBsum; 5ML5; -. DR PDBsum; 5MTX; -. DR PDBsum; 5MTY; -. DR PDBsum; 5MZ3; -. DR PDBsum; 5N63; -. DR PDBsum; 5N64; -. DR PDBsum; 5N65; -. DR PDBsum; 5N66; -. DR PDBsum; 5N67; -. DR PDBsum; 5N68; -. DR PDBsum; 5O8U; -. DR PDBsum; 5O8V; -. DR PDBsum; 5OMG; -. DR PDBsum; 5OMH; -. DR PDBsum; 5TBE; -. DR PDBsum; 5TCO; -. DR PDBsum; 5WJJ; -. DR PDBsum; 5XYX; -. DR PDBsum; 5XYY; -. DR PDBsum; 6ANL; -. DR PDBsum; 6HWT; -. DR PDBsum; 6HWU; -. DR PDBsum; 6HWV; -. DR PDBsum; 6M95; -. DR PDBsum; 6M9L; -. DR PDBsum; 6OHD; -. DR PDBsum; 6QDZ; -. DR PDBsum; 6QE1; -. DR PDBsum; 6QYX; -. DR PDBsum; 6RFO; -. DR PDBsum; 6SFI; -. DR PDBsum; 6SFJ; -. DR PDBsum; 6SFK; -. DR PDBsum; 6SFO; -. DR PDBsum; 6TCA; -. DR PDBsum; 6ZQS; -. DR PDBsum; 6ZWP; -. DR PDBsum; 8A8M; -. DR PDBsum; 8VXE; -. DR PDBsum; 8X3M; -. DR PDBsum; 8YD9; -. DR PDBsum; 9CJ1; -. DR PDBsum; 9CJ2; -. DR PDBsum; 9CJ3; -. DR PDBsum; 9CJ4; -. DR PDBsum; 9CJ5; -. DR PDBsum; 9MHB; -. DR PDBsum; 9NYT; -. DR PDBsum; 9O4L; -. DR AlphaFoldDB; Q16539; -. DR BMRB; Q16539; -. DR EMDB; EMD-15233; -. DR SASBDB; Q16539; -. DR SMR; Q16539; -. DR BioGRID; 107819; 321. DR CORUM; Q16539; -. DR DIP; DIP-30987N; -. DR ELM; Q16539; -. DR FunCoup; Q16539; 4149. DR IntAct; Q16539; 185. DR MINT; Q16539; -. DR STRING; 9606.ENSP00000229795; -. DR BindingDB; Q16539; -. DR ChEMBL; CHEMBL260; -. DR DrugBank; DB02873; 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One. DR DrugBank; DB01948; 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One. DR DrugBank; DB02277; 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea. DR DrugBank; DB06882; 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea. DR DrugBank; DB08097; 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE. DR DrugBank; DB08395; 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE. DR DrugBank; DB03110; 2-Chlorophenol. DR DrugBank; DB07942; 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine. DR DrugBank; DB08093; 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE. DR DrugBank; DB08095; 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA. DR DrugBank; DB02195; 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine. DR DrugBank; DB02352; 3-(Benzyloxy)Pyridin-2-Amine. DR DrugBank; DB08730; 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE. DR DrugBank; DB08091; 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE. DR DrugBank; DB08092; 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide. DR DrugBank; DB04632; 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE. DR DrugBank; DB08522; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE. DR DrugBank; DB03980; 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole. DR DrugBank; DB07829; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE. DR DrugBank; DB02984; 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline. DR DrugBank; DB08521; 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine. DR DrugBank; DB07607; 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE. DR DrugBank; DB01761; 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine. DR DrugBank; DB07459; 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE. DR DrugBank; DB07832; 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde. DR DrugBank; DB01988; 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine. DR DrugBank; DB08352; 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine. DR DrugBank; DB08096; 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM. DR DrugBank; DB08424; [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE. DR DrugBank; DB08423; [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12140; Dilmapimod. DR DrugBank; DB03044; Doramapimod. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB01953; Inhibitor of P38 Kinase. DR DrugBank; DB05157; KC706. DR DrugBank; DB12270; Losmapimod. DR DrugBank; DB01017; Minocycline. DR DrugBank; DB08242; N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide. DR DrugBank; DB07833; N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide. DR DrugBank; DB08064; N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA. DR DrugBank; DB07834; N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide. DR DrugBank; DB01807; N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea. DR DrugBank; DB06991; N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide. DR DrugBank; DB08068; N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO. DR DrugBank; DB07811; N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide. DR DrugBank; DB08349; N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide. DR DrugBank; DB07307; N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide. DR DrugBank; DB08351; N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide. DR DrugBank; DB06940; N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. DR DrugBank; DB07138; Neflamapimod. DR DrugBank; DB07835; N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide. DR DrugBank; DB12017; Ozagrel. DR DrugBank; DB19169; Pamapimod. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB07941; PH-797804. DR DrugBank; DB06518; R-1487. DR DrugBank; DB04338; SB220025. DR DrugBank; DB07943; SD-0006. DR DrugBank; DB05412; Talmapimod. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugBank; DB04797; Triazolopyridine. DR DrugBank; DB05470; VX-702. DR DrugCentral; Q16539; -. DR GuidetoPHARMACOLOGY; 1499; -. DR GlyGen; Q16539; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q16539; -. DR MetOSite; Q16539; -. DR PhosphoSitePlus; Q16539; -. DR BioMuta; MAPK14; -. DR OGP; Q16539; -. DR CPTAC; CPTAC-1325; -. DR CPTAC; CPTAC-1355; -. DR CPTAC; CPTAC-1356; -. DR CPTAC; CPTAC-3005; -. DR CPTAC; CPTAC-3006; -. DR CPTAC; CPTAC-878; -. DR CPTAC; CPTAC-879; -. DR CPTAC; non-CPTAC-5408; -. DR CPTAC; non-CPTAC-5699; -. DR CPTAC; non-CPTAC-5700; -. DR CPTAC; non-CPTAC-5701; -. DR jPOST; Q16539; -. DR MassIVE; Q16539; -. DR PaxDb; 9606-ENSP00000229795; -. DR PeptideAtlas; Q16539; -. DR PRIDE; Q16539; -. DR ProteomicsDB; 60901; -. [Q16539-1] DR ProteomicsDB; 60902; -. [Q16539-2] DR ProteomicsDB; 60903; -. [Q16539-3] DR ProteomicsDB; 60904; -. [Q16539-4] DR Pumba; Q16539; -. DR ABCD; Q16539; 4 sequenced antibodies. DR Antibodypedia; 4142; 2328 antibodies from 55 providers. DR CPTC; Q16539; 3 antibodies. DR DNASU; 1432; -. DR Ensembl; ENST00000229794.9; ENSP00000229794.4; ENSG00000112062.14. [Q16539-1] DR Ensembl; ENST00000229795.8; ENSP00000229795.3; ENSG00000112062.14. [Q16539-2] DR Ensembl; ENST00000310795.8; ENSP00000308669.4; ENSG00000112062.14. [Q16539-4] DR GeneID; 1432; -. DR KEGG; hsa:1432; -. DR MANE-Select; ENST00000229794.9; ENSP00000229794.4; NM_139012.3; NP_620581.1. DR UCSC; uc003olp.4; human. [Q16539-1] DR AGR; HGNC:6876; -. DR ClinPGx; PA30621; -. DR CTD; 1432; -. DR DisGeNET; 1432; -. DR GeneCards; MAPK14; -. DR HGNC; HGNC:6876; MAPK14. DR HPA; ENSG00000112062; Low tissue specificity. DR MIM; 600289; gene. DR OpenTargets; ENSG00000112062; -. DR VEuPathDB; HostDB:ENSG00000112062; -. DR eggNOG; KOG0660; Eukaryota. DR GeneTree; ENSGT00940000155325; -. DR InParanoid; Q16539; -. DR OMA; NRYTDLN; -. DR OrthoDB; 9474812at2759; -. DR PAN-GO; Q16539; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q16539; -. DR BioCyc; MetaCyc:HS03507-MONOMER; -. DR BRENDA; 2.7.11.24; 2681. DR PathwayCommons; Q16539; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1. DR Reactome; R-HSA-432142; Platelet sensitization by LDL. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-525793; Myogenesis. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response. DR Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation. DR SignaLink; Q16539; -. DR SIGNOR; Q16539; -. DR Agora; ENSG00000112062; -. DR BioGRID-ORCS; 1432; 83 hits in 1217 CRISPR screens. DR ChiTaRS; MAPK14; human. DR EvolutionaryTrace; Q16539; -. DR GeneWiki; MAPK14; -. DR GenomeRNAi; 1432; -. DR Pharos; Q16539; Tchem. DR PRO; PR:Q16539; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q16539; protein. DR Bgee; ENSG00000112062; Expressed in buccal mucosa cell and 205 other cell types or tissues. DR ExpressionAtlas; Q16539; baseline and differential. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0034774; C:secretory granule lumen; TAS:Reactome. DR GO; GO:0000922; C:spindle pole; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB. DR GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc. DR GO; GO:0048273; F:mitogen-activated protein kinase p38 binding; IPI:UniProtKB. DR GO; GO:0051525; F:NFAT protein binding; ISS:BHF-UCL. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0070935; P:3'-UTR-mediated mRNA stabilization; TAS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0060348; P:bone development; IEA:Ensembl. DR GO; GO:0001502; P:cartilage condensation; IEA:Ensembl. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0007178; P:cell surface receptor protein serine/threonine kinase signaling pathway; IEA:Ensembl. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:MGI. DR GO; GO:0071223; P:cellular response to lipoteichoic acid; IMP:UniProtKB. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0098586; P:cellular response to virus; IMP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0006935; P:chemotaxis; TAS:ProtInc. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0046323; P:D-glucose import; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IEA:Ensembl. DR GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; ISS:BHF-UCL. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0035331; P:negative regulation of hippo signaling; IMP:FlyBase. DR GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0030316; P:osteoclast differentiation; ISS:BHF-UCL. DR GO; GO:0038066; P:p38MAPK cascade; IDA:UniProt. DR GO; GO:0001890; P:placenta development; IEA:Ensembl. DR GO; GO:0030168; P:platelet activation; TAS:Reactome. DR GO; GO:0090336; P:positive regulation of brown fat cell differentiation; IEA:Ensembl. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0031281; P:positive regulation of cyclase activity; IMP:CACAO. DR GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl. DR GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032735; P:positive regulation of interleukin-12 production; IMP:UniProtKB. DR GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome. DR GO; GO:0045663; P:positive regulation of myoblast differentiation; ISS:UniProtKB. DR GO; GO:1901741; P:positive regulation of myoblast fusion; ISS:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; ISS:UniProtKB. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IDA:CACAO. DR GO; GO:0030278; P:regulation of ossification; IEA:Ensembl. DR GO; GO:0099179; P:regulation of synaptic membrane adhesion; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0002021; P:response to dietary excess; IEA:Ensembl. DR GO; GO:0032868; P:response to insulin; IEA:Ensembl. DR GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IMP:BHF-UCL. DR GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl. DR GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB. DR GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IDA:UniProt. DR GO; GO:0090400; P:stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL. DR CDD; cd07877; STKc_p38alpha; 1. DR FunFam; 1.10.510.10:FF:000063; Mitogen-activated protein kinase 14; 1. DR FunFam; 3.30.200.20:FF:000769; Mitogen-activated protein kinase 14; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00280; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR003527; MAP_kinase_CS. DR InterPro; IPR050117; MAPK. DR InterPro; IPR038784; MAPK14. DR InterPro; IPR008352; MAPK_HOG-like. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR01773; P38MAPKINASE. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01351; MAPK; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Direct protein sequencing; Kinase; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Stress response; Transcription; KW Transcription regulation; Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801, FT ECO:0007744|PubMed:20068231" FT CHAIN 2..360 FT /note="Mitogen-activated protein kinase 14" FT /id="PRO_0000186291" FT DOMAIN 24..308 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOTIF 180..182 FT /note="TXY" FT ACT_SITE 168 FT /note="Proton acceptor" FT BINDING 30..38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 53 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 16 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 53 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21444723" FT MOD_RES 152 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21444723" FT MOD_RES 180 FT /note="Phosphothreonine; by MAP2K3, MAP2K4, MAP2K6 and FT autocatalysis" FT /evidence="ECO:0000269|PubMed:7535770, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 182 FT /note="Phosphotyrosine; by MAP2K3, MAP2K4, MAP2K6 and FT autocatalysis" FT /evidence="ECO:0000269|PubMed:7535770, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 263 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 323 FT /note="Phosphotyrosine; by ZAP70" FT /evidence="ECO:0000269|PubMed:15735648" FT VAR_SEQ 230..254 FT /note="DQLKLILRLVGTPGAELLKKISSES -> NQLQQIMRLTGTPPAYLINRMPS FT HE (in isoform CSBP1)" FT /evidence="ECO:0000303|PubMed:7997261" FT /id="VSP_004842" FT VAR_SEQ 255..360 FT /note="ARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHA FT YFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES -> V FT S (in isoform 5)" FT /evidence="ECO:0000303|PubMed:19906316" FT /id="VSP_057194" FT VAR_SEQ 255..307 FT /note="ARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHA FT Y -> LSTCWRRCLYWTQIRELQRPKPLHMPTLLSTTILMMNQWPILMISPLKAGTSL FT (in isoform Exip)" FT /evidence="ECO:0000303|PubMed:11866441" FT /id="VSP_004843" FT VAR_SEQ 281..360 FT /note="AVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDL FT LIDEWKSLTYDEVISFVPPPLDQEEMES -> GKLTIYPHLMDIELVMI (in FT isoform Mxi2)" FT /evidence="ECO:0000303|PubMed:7479834" FT /id="VSP_004844" FT VAR_SEQ 308..360 FT /note="Missing (in isoform Exip)" FT /evidence="ECO:0000303|PubMed:11866441" FT /id="VSP_004845" FT VARIANT 51 FT /note="A -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042270" FT VARIANT 322 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1765837157)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042271" FT VARIANT 343 FT /note="D -> G (in dbSNP:rs45496794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042272" FT MUTAGEN 34 FT /note="A->V: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 53 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 54 FT /note="K->R: Impairs MAP2K6/MKK6-dependent FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:11010976" FT MUTAGEN 69 FT /note="Y->H: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 168 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 175 FT /note="T->A: No effect on either the kinase activity or FT tyrosine phosphorylation." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 176 FT /note="D->A: Emulation of the active state. Increase in FT activity; when associated with S-327 or L-327." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 177 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 180 FT /note="T->E: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 182 FT /note="Y->F: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 320 FT /note="A->T: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 327 FT /note="F->L: Emulation of the active state. Increase in FT activity; when associated with A-176." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 327 FT /note="F->S: Emulation of the active state. Increase in FT activity; when associated with A-176." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 337 FT /note="W->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT CONFLICT 67 FT /note="R -> G (in Ref. 7; BAF84398)" FT /evidence="ECO:0000305" FT STRAND 8..13 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 16..21 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 24..29 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 31..33 FT /evidence="ECO:0007829|PDB:6SFI" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:3BV2" FT STRAND 38..43 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 44..47 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 48..54 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 62..77 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 87..90 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 96..98 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3LFF" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:4GEO" FT TURN 116..119 FT /evidence="ECO:0007829|PDB:3LFF" FT HELIX 124..143 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 153..155 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 156..158 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 160..162 FT /evidence="ECO:0007829|PDB:2RG6" FT STRAND 164..166 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:4GEO" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:1ZZL" FT TURN 176..179 FT /evidence="ECO:0007829|PDB:5XYY" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:3FMK" FT TURN 185..188 FT /evidence="ECO:0007829|PDB:3LFF" FT HELIX 191..194 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 197..199 FT /evidence="ECO:0007829|PDB:4EHV" FT HELIX 204..218 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 228..239 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 244..247 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 253..260 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 270..273 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 274..276 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 279..288 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 299..303 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 309..311 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 334..347 FT /evidence="ECO:0007829|PDB:2FST" SQ SEQUENCE 360 AA; 41293 MW; 286C81D0487618B3 CRC64; MSQERPTFYR QELNKTIWEV PERYQNLSPV GSGAYGSVCA AFDTKTGLRV AVKKLSRPFQ SIIHAKRTYR ELRLLKHMKH ENVIGLLDVF TPARSLEEFN DVYLVTHLMG ADLNNIVKCQ KLTDDHVQFL IYQILRGLKY IHSADIIHRD LKPSNLAVNE DCELKILDFG LARHTDDEMT GYVATRWYRA PEIMLNWMHY NQTVDIWSVG CIMAELLTGR TLFPGTDHID QLKLILRLVG TPGAELLKKI SSESARNYIQ SLTQMPKMNF ANVFIGANPL AVDLLEKMLV LDSDKRITAA QALAHAYFAQ YHDPDDEPVA DPYDQSFESR DLLIDEWKSL TYDEVISFVP PPLDQEEMES // ID MLH1_HUMAN Reviewed; 756 AA. AC P40692; B4DI13; B4DQ11; E9PCU2; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 252. DE RecName: Full=DNA mismatch repair protein Mlh1; DE AltName: Full=MutL protein homolog 1; GN Name=MLH1; Synonyms=COCA2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8145827; DOI=10.1038/368258a0; RA Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., RA Lescoe M.K., Kane M.F., Earibino C., Lipford J., Lindblom A., RA Tannergaard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjoeld M., RA Fishel R., Kolodner R.D., Liskay R.M.; RT "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated RT with hereditary non-polyposis colon cancer."; RL Nature 368:258-261(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Gall bladder; RX PubMed=8128251; DOI=10.1126/science.8128251; RA Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., RA Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., RA Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., RA Peltomaeki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., RA Vogelstein B.; RT "Mutation of a mutL homolog in hereditary colon cancer."; RL Science 263:1625-1629(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7812952; RA Kolodner R.D., Hall N.R., Lipford J.R., Kane M.F., Morrison P., Finan P.J., RA Burn J., Chapman P., Earabino C., Merchant E., Bishop D.T.; RT "Structure of the human MLH1 locus and analysis of a large hereditary RT nonpolyposis colorectal carcinoma kindred for mlh1 mutations."; RL Cancer Res. 55:242-248(1995). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYNCH2 LEU-542; PRO-574; RP VAL-582 AND THR-618. RX PubMed=7757073; DOI=10.1093/hmg/4.2.237; RA Han H.-J., Maruyama M., Baba S., Park J.-G., Nakamura Y.; RT "Genomic structure of human mismatch repair gene, hMLH1, and its mutation RT analysis in patients with hereditary non-polyposis colorectal cancer RT (HNPCC)."; RL Hum. Mol. Genet. 4:237-242(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-32; MET-213 AND RP VAL-219. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Brain, Corpus callosum, Kidney, and Substantia nigra; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP IDENTIFICATION OF MLH1 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [11] RP INTERACTION WITH MBD4. RX PubMed=10097147; DOI=10.1073/pnas.96.7.3969; RA Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., RA Matsumoto Y., Golemis E.A., Genuardi M., Neri G.; RT "MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA RT mismatch repair protein MLH1."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3969-3974(1999). RN [12] RP INTERACTION WITH EXO1 AND PMS2, CHARACTERIZATION OF VARIANTS LYNCH2 RP PRO-574; LYS-616 DEL; LEU-659 AND THR-681, AND CHARACTERIZATION OF VARIANT RP MMRCS1 LYS-616 DEL. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [13] RP INTERACTION WITH EXO1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT MET-117. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [14] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [15] RP INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [16] RP INVOLVEMENT IN MRTES. RX PubMed=8751876; RA Bapat B., Xia L., Madlensky L., Mitri A., Tonin P., Narod S.A., RA Gallinger S.; RT "The genetic basis of Muir-Torre syndrome includes the hMLH1 locus."; RL Am. J. Hum. Genet. 59:736-739(1996). RN [17] RP FUNCTION. RX PubMed=16873062; DOI=10.1016/j.cell.2006.05.039; RA Kadyrov F.A., Dzantiev L., Constantin N., Modrich P.; RT "Endonucleolytic function of MutLalpha in human mismatch repair."; RL Cell 126:297-308(2006). RN [18] RP FUNCTION. RX PubMed=18206974; DOI=10.1016/j.molcel.2007.10.030; RA Sacho E.J., Kadyrov F.A., Modrich P., Kunkel T.A., Erie D.A.; RT "Direct visualization of asymmetric adenine nucleotide-induced RT conformational changes in MutL alpha."; RL Mol. Cell 29:112-121(2008). RN [19] RP REVIEW. RX PubMed=16188885; DOI=10.1074/jbc.m509701200; RA Constantin N., Dzantiev L., Kadyrov F.A., Modrich P.; RT "Human mismatch repair: reconstitution of a nick-directed bidirectional RT reaction."; RL J. Biol. Chem. 280:39752-39761(2005). RN [20] RP REVIEW. RX PubMed=16873053; DOI=10.1016/j.cell.2006.07.003; RA Jiricny J.; RT "MutLalpha: at the cutting edge of mismatch repair."; RL Cell 126:239-241(2006). RN [21] RP REVIEW. RX PubMed=18157157; DOI=10.1038/cr.2007.115; RA Li G.M.; RT "Mechanisms and functions of DNA mismatch repair."; RL Cell Res. 18:85-98(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND MCM8, AND RP SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [31] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-33; LYS-241; LYS-361 AND LYS-377, RP DEACETYLATION BY HDAC6, AND MUTAGENESIS OF LYS-33; LYS-241; LYS-361 AND RP LYS-377. RX PubMed=30770470; DOI=10.1074/jbc.ra118.006374; RA Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B., RA Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.; RT "HDAC6 regulates DNA damage response via deacetylating MLH1."; RL J. Biol. Chem. 294:5813-5826(2019). RN [32] RP FUNCTION, UBIQUITINATION BY UBR4, DEUBIQUITINATION BY USP5, INTERACTION RP WITH PSM2, AND CHARACTERIZATION OF VARIANT LEU-574 AND ALA-589. RX PubMed=39032648; DOI=10.1016/j.jbc.2024.107592; RA Mao C., Li S., Che J., Liu D., Mao X., Rao H.; RT "The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the RT stability of DNA mismatch repair protein MLH1."; RL J. Biol. Chem. 300:107592-107592(2024). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 486-751. RA Dombrovsky L., Dong A., Wernimont A., Loppnau P., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Min J., Wu H.; RT "Crystal structure of MutL protein homolog 1 isoform 1."; RL Submitted (MAR-2011) to the PDB data bank. RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 3-196 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS. RX PubMed=26249686; DOI=10.1107/s2053230x15010183; RA Wu H., Zeng H., Lam R., Tempel W., Kerr I.D., Min J.; RT "Structure of the human MLH1 N-terminus: implications for predisposition to RT Lynch syndrome."; RL Acta Crystallogr. F 71:981-985(2015). RN [35] {ECO:0007744|PDB:5U5P} RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 467-476, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF LYS-471 AND ARG-472. RX PubMed=29175432; DOI=10.1016/j.biochi.2017.11.013; RA de Barros A.C., Takeda A.A.S., Dreyer T.R., Velazquez-Campoy A., Kobe B., RA Fontes M.R.M.; RT "DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus RT by a classical nuclear import pathway."; RL Biochimie 146:87-96(2018). RN [36] RP CHARACTERIZATION OF VARIANTS LYNCH2 CYS-31; LYS-37; HIS-38; LYS-38; PHE-44; RP ARG-67; PRO-109; PRO-111; MET-117; CYS-265; SER-265; GLN-443; PRO-550; RP GLY-578; PHE-582; ASP-589; ALA-618; CYS-646; LEU-648; LEU-654 AND PRO-659, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP AND FUNCTION. RX PubMed=20020535; DOI=10.1002/humu.21180; RA Drost M., Zonneveld J.B., van Dijk L., Morreau H., Tops C.M., Vasen H.F., RA Wijnen J.T., de Wind N.; RT "A cell-free assay for the functional analysis of variants of the mismatch RT repair protein MLH1."; RL Hum. Mutat. 31:247-253(2010). RN [37] RP CHARACTERIZATION OF VARIANTS LYNCH2 LEU-28; SER-29; 45-THR--ILE-47 DELINS RP CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; RP ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; GLN-443; ALA-460; PRO-550; RP 578-GLU--GLU-632 DEL; ASP-589; VAL-612 DEL; LYS-616 DEL; ALA-618; THR-618; RP 633-GLU--GLU-663 DEL; CYS-646; LEU-648; SER-648; LEU-654; GLN-659; PRO-659; RP THR-681 AND TRP-687, CHARACTERIZATION OF VARIANTS GLY-93; MET-213; VAL-219 RP AND MET-716, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [38] RP VARIANT LYNCH2 ARG-35. RX PubMed=8521398; RA Tannergaard P., Lipford J.R., Kolodner R., Froedin J.E., Nordenskjoeld M., RA Lindblom A.; RT "Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis RT colon cancer families."; RL Cancer Res. 55:6092-6096(1995). RN [39] RP VARIANT MMRCS1 LYS-616 DEL. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [40] RP VARIANT LYNCH2 LYS-616 DEL. RX PubMed=8571956; RA Wijnen J., Khan P.M., Vasen H., Menko F., van der Klift H., RA van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer E.J., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Kolodner R.D., Fodde R.; RT "Majority of hMLH1 mutations responsible for hereditary nonpolyposis RT colorectal cancer cluster at the exonic region 15-16."; RL Am. J. Hum. Genet. 58:300-307(1996). RN [41] RP VARIANTS LYNCH2 MET-117 AND LEU-226. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [42] RP VARIANTS LYNCH2 LYS-616 DEL AND THR-618, AND VARIANT CRC THR-492. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [43] RP VARIANTS LYNCH2 CYS-217; LEU-542; PRO-549 AND PRO-574. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [44] RP VARIANTS LEU-ASN-HIS-37 INS AND ASP-384. RX PubMed=8609062; DOI=10.1111/j.1349-7006.1996.tb03151.x; RA Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., RA Nakamura Y.; RT "Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic RT endometrial carcinomas with microsatellite instability."; RL Jpn. J. Cancer Res. 87:141-145(1996). RN [45] RP VARIANT LYNCH2 ALA-506. RX PubMed=8574961; DOI=10.1038/nm0296-169; RA Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., RA Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaeki P., RA de la Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W.; RT "Analysis of mismatch repair genes in hereditary non-polyposis colorectal RT cancer patients."; RL Nat. Med. 2:169-174(1996). RN [46] RP VARIANTS LYNCH2 LYS-62; SER-64; LYS-616 DEL; ALA-618 AND PRO-659, RP CHARACTERIZATION OF VARIANT LYNCH2 LYS-62, AND FUNCTION. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [47] RP VARIANT LYNCH2 LYS-616 DEL, AND VARIANT HIS-265. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [48] RP VARIANTS CRC GLU-54 AND VAL-244, AND VARIANTS VAL-219; GLN-325 AND ASN-406. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [49] RP VARIANTS LYNCH2 PRO-128 AND ASP-244, AND VARIANT VAL-219. RX PubMed=9218993; RX DOI=10.1002/(sici)1098-2264(199707)19:3<135::aid-gcc1>3.3.co;2-x; RA Pensotti V., Radice P., Presciuttini S., Calistri D., Gazzoli I., RA Grimalt Perez A.P., Mondini P., Buonsanti G., Sala P., Rossetti C., RA Ranzani G.N., Bertario L., Pierotti M.A.; RT "Mean age of tumor onset in hereditary nonpolyposis colorectal cancer RT (HNPCC) families correlates with the presence of mutations in DNA mismatch RT repair genes."; RL Genes Chromosomes Cancer 19:135-142(1997). RN [50] RP VARIANT LYNCH2 626-PHE-SER-627 DELINS SER-THR. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [51] RP VARIANT LYNCH2 PRO-329. RX PubMed=9272156; DOI=10.1007/s004390050517; RA Wang Y., Friedl W., Lamberti C., Ruelfs C., Kruse R., Propping P.; RT "Hereditary nonpolyposis colorectal cancer: causative role of a germline RT missense mutation in the hMLH1 gene confirmed by the independent occurrence RT of the same somatic mutation in tumour tissue."; RL Hum. Genet. 100:362-364(1997). RN [52] RP VARIANT LYNCH2 ARG-67, AND VARIANT VAL-219. RX PubMed=9067757; RX DOI=10.1002/(sici)1098-1004(1997)9:2<164::aid-humu9>3.0.co;2-9; RA Sasaki S., Tokino T., Miyatsu T., Muto T., Nakamura Y.; RT "Mutational analysis of the hMLH1 gene using an automated two-dimensional RT DNA typing system."; RL Hum. Mutat. 9:164-171(1997). RN [53] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [54] RP VARIANT LYNCH2 LEU-28. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [55] RP VARIANTS LYNCH2 GLY-182; THR-295 AND THR-551. RX PubMed=9399661; RX DOI=10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7; RA Wang Q., Desseigne F., Lasset C., Saurin J.-C., Navarro C., Yagci T., RA Keser I., Bagci H., Luleci G., Gelen T., Chayvialle J.-A., Puisieux A., RA Ozturk M.; RT "Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families."; RL Int. J. Cancer 73:831-836(1997). RN [56] RP VARIANT CRC TYR-77, AND VARIANT VAL-219. RX PubMed=9032648; DOI=10.1136/jmg.34.1.39; RA Tomlinson I.P.M., Beck N.E., Homfray T., Harocopos C.J., Bodmer W.F.; RT "Germline HNPCC gene variants have little influence on the risk for RT sporadic colorectal cancer."; RL J. Med. Genet. 34:39-42(1997). RN [57] RP VARIANTS LYNCH2 PHE-44 AND THR-441. RX PubMed=9326924; DOI=10.1038/ng1097-135; RA Hackman P., Tannergaerd P., Osei-Mensa S., Chen J., Kane M.F., RA Kolodner R.D., Lambert B., Hellgren D., Lindblom A.; RT "A human compound heterozygote for two MLH1 missense mutations."; RL Nat. Genet. 17:135-136(1997). RN [58] RP VARIANTS LYNCH2, AND VARIANTS. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [59] RP VARIANT CRC GLY-268. RX PubMed=9611074; DOI=10.1111/j.1399-0004.1998.tb02660.x; RA Liu T., Wahlberg S., Rubio C., Holmberg E., Groenberg H., Lindblom A.; RT "DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in RT 34 Swedish families with colorectal cancer."; RL Clin. Genet. 53:131-135(1998). RN [60] RP VARIANT LYNCH2 CYS-217. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [61] RP VARIANT ASP-384, AND ASSOCIATION WITH HNPCC. RX PubMed=9526167; DOI=10.1159/000022786; RA Wang Y., Friedl W., Lamberti C., Noethen M.M., Kruse R., Propping P.; RT "A novel missense mutation in the DNA mismatch repair gene hMLH1 present RT among East Asians but not among Europeans."; RL Hum. Hered. 48:87-91(1998). RN [62] RP VARIANT LYNCH2 LYS-69. RX PubMed=10627141; RX DOI=10.1002/(sici)1098-1004(1998)12:1<73::aid-humu20>3.0.co;2-f; RA Herfarth K.K.-F., Ogunbiyi O.A., Moley J.F., Kodner I.J., Wells S.A. Jr., RA Goodfellow P.J.; RT "Four new mutations in the DNA mismatch repair gene MLH1 in colorectal RT cancers with microsatellite instability."; RL Hum. Mutat. 12:73-73(1998). RN [63] RP VARIANTS LYNCH2 ARG-77 AND PRO-193. RX PubMed=10660333; RA Panariello L., Scarano M.I., de Rosa M., Capasso L., Renda A., Riegler G., RA Rossi G.B., Salvatore F., Izzo P.; RT "hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds."; RL Hum. Mutat. 12:216-217(1998). RN [64] RP VARIANT GLY-93. RX PubMed=10671064; RX DOI=10.1002/(sici)1098-1004(1998)12:6<433::aid-humu13>3.0.co;2-j; RA Quaresima B., Grandinetti C., Baudi F., Tassone P., Barbieri V., RA Conforti S., Avvedimento E.V., Costanzo F., Venuta S.; RT "Hereditary nonpolyposis colorectal cancer: identification of novel RT germline mutations in two kindreds not fulfilling the Amsterdam criteria."; RL Hum. Mutat. 12:433-433(1998). RN [65] RP VARIANTS LYNCH2 ARG-67; ILE-262 DEL; THR-551 AND PHE-565, AND VARIANTS RP VAL-219 AND MET-716. RX PubMed=9833759; RX DOI=10.1002/(sici)1097-0215(19981209)78:6<680::aid-ijc3>3.0.co;2-u; RA Hutter P., Couturier A., Membrez V., Joris F., Sappino A.-P., RA Chappuis P.O.; RT "Excess of hMLH1 germline mutations in Swiss families with hereditary non- RT polyposis colorectal cancer."; RL Int. J. Cancer 78:680-684(1998). RN [66] RP VARIANTS LYNCH2 ARG-67; ARG-117 AND GLU-485, AND VARIANT VAL-219. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [67] RP VARIANT LYNCH2 TRP-67. RX PubMed=9927034; RA Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., RA Ruano E., Puisieux A.; RT "Neurofibromatosis and early onset of cancers in hMLH1-deficient RT children."; RL Cancer Res. 59:294-297(1999). RN [68] RP VARIANTS HIS-265; ALA-326; PRO-385; ASN-406; THR-618 AND MET-716. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [69] RP VARIANTS LYNCH2 LEU-28; GLU-84 AND PRO-329. RX PubMed=10323887; DOI=10.1136/gut.44.6.839; RA Lamberti C., Kruse R., Ruelfs C., Caspari R., Wang Y., Jungck M., RA Mathiak M., Malayeri H.R.H., Friedl W., Sauerbruch T., Propping P.; RT "Microsatellite instability, a useful diagnostic tool to select patients at RT high risk for hereditary non-polyposis colorectal cancer: a study in RT different groups of patients with colorectal cancer."; RL Gut 44:839-843(1999). RN [70] RP VARIANTS LYNCH2 TRP-67; MET-117; GLY-182 AND LYS-616 DEL, AND VARIANT HNPCC RP TRP-755. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [71] RP VARIANT CRC GLY-578, AND VARIANT LYNCH2 ALA-618. RX PubMed=10598809; DOI=10.1007/s004390051127; RA Liu T., Tannergaerd P., Hackman P., Rubio C., Kressner U., Lindmark G., RA Hellgren D., Lambert B., Lindblom A.; RT "Missense mutations in hMLH1 associated with colorectal cancer."; RL Hum. Genet. 105:437-441(1999). RN [72] RP VARIANT LYNCH2 PHE-25, AND VARIANT TYR-718. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH2 TYR-264. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [74] RP VARIANTS LYNCH2 VAL-111 AND PRO-588, AND VARIANTS VAL-219 AND ASP-384. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANTS LYNCH2 HIS-607; ALA-618 AND LEU-659, AND VARIANT MET-213. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANT CRC ARG-260, AND VARIANT LYNCH2 VAL-304. RX PubMed=10882759; DOI=10.1136/jmg.37.7.e7; RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RT "Mutational germline analysis of hMSH2 and hMLH1 genes in early onset RT colorectal cancer patients."; RL J. Med. Genet. 37:E7-E7(2000). RN [77] RP ERRATUM OF PUBMED:10882759. RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RL J. Med. Genet. 40:472-472(2003). RN [78] RP VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635, VARIANTS LYNCH2 RP GLY-234; ILE-321; HIS-485 AND ALA-631, AND VARIANT CRC ILE-472. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [79] RP VARIANT HIS-607. RX PubMed=11369138; DOI=10.1016/s0304-3835(01)00448-7; RA Stone J.G., Coleman G., Gusterson B., Marossy A., Lakhani S.R., Ward A., RA Nash A., McKinna A., A'Hern R., Stratton M.R., Houlston R.S.; RT "Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in RT situ of the breast."; RL Cancer Lett. 167:171-174(2001). RN [80] RP INVOLVEMENT IN TUMORIGENESIS. RX PubMed=11389087; RA Vilkki S., Tsao J.-L., Loukola A., Poyhonen M., Vierimaa O., Herva R., RA Aaltonen L.A., Shibata D.; RT "Extensive somatic microsatellite mutations in normal human tissue."; RL Cancer Res. 61:4541-4544(2001). RN [81] RP VARIANTS LYNCH2 VAL-80; PRO-329; ARG-603; ALA-618; LEU-648; PRO-662 AND RP ARG-689. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [82] RP CHARACTERIZATION OF VARIANTS. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [83] RP VARIANT LYNCH2 ARG-751. RX PubMed=11139242; DOI=10.1002/1098-1004(2001)17:1<52::aid-humu6>3.0.co;2-e; RA Jakubowska A., Gorski B., Kurzawski G., Debniak T., Hadaczek P., RA Cybulski C., Kladny J., Oszurek O., Scott R.J., Lubinski J.; RT "Optimization of experimental conditions for RNA-based sequencing of MLH1 RT and MSH2 genes."; RL Hum. Mutat. 17:52-60(2001). RN [84] RP VARIANTS LYNCH2 HIS-622 AND TRP-687. RX PubMed=11748856; DOI=10.1002/humu.1240; RA Godino J., de La Hoya M., Diaz-Rubio E., Benito M., Caldes T.; RT "Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis RT colorectal cancer families from Spain."; RL Hum. Mutat. 18:549-549(2001). RN [85] RP VARIANTS LYNCH2 SER-338; ARG-603; THR-618 AND TYR-718. RX PubMed=12095971; DOI=10.1007/bf02573891; RA Rossi B.M., Lopes A., Oliveira Ferreira F., Nakagawa W.T., RA Napoli Ferreira C.C., Casali Da Rocha J.C., Simpson C.C., Simpson A.J.G.; RT "hMLH1 and hMSH2 gene mutation in Brazilian families with suspected RT hereditary nonpolyposis colorectal cancer."; RL Ann. Surg. Oncol. 9:555-561(2002). RN [86] RP VARIANTS LYNCH2 ASN-35; HIS-38; MET-117 AND ALA-618. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [87] RP VARIANTS VAL-219 AND VAL-655. RX PubMed=12115348; DOI=10.1002/cncr.10606; RA Baldinu P., Cossu A., Manca A., Satta M.P., Pisano M., Casula M., RA Dessole S., Pintus A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis of candidate genes in RT unselected Sardinian patients with endometrial carcinoma."; RL Cancer 94:3157-3168(2002). RN [88] RP CHARACTERIZATION OF VARIANTS LYNCH2 MET-117; GLY-185; CYS-217; ASP-244 AND RP ALA-326, AND CHARACTERIZATION OF VARIANTS VAL-219 AND HIS-265. RX PubMed=11781295; DOI=10.1053/gast.2002.30296; RA Trojan J., Zeuzem S., Randolph A., Hemmerle C., Brieger A., Raedle J., RA Plotz G., Jiricny J., Marra G.; RT "Functional analysis of hMLH1 variants and HNPCC-related mutations using a RT human expression system."; RL Gastroenterology 122:211-219(2002). RN [89] RP VARIANTS LYNCH2 CYS-385; HIS-607; THR-618 AND SER-648, AND VARIANT MET-213. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [90] RP CHARACTERIZATION OF VARIANTS LYNCH2 ARG-77; ARG-107 AND PRO-659, AND RP CHARACTERIZATION OF VARIANT GLY-93. RX PubMed=11793442; DOI=10.1002/gcc.1225.abs; RA Nystroem-Lahti M., Perrera C., Raeschle M., Panyushkina-Seiler E., RA Marra G., Curci A., Quaresima B., Costanzo F., D'Urso M., Venuta S., RA Jiricny J.; RT "Functional analysis of MLH1 mutations linked to hereditary nonpolyposis RT colon cancer."; RL Genes Chromosomes Cancer 33:160-167(2002). RN [91] RP VARIANT LYNCH2 PRO-662, AND VARIANT VAL-219. RX PubMed=11754112; DOI=10.1002/humu.9004; RA Krueger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kraemer H., RA Hinterseher I., Bier A., Kreuz F.R., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis RT colorectal cancer."; RL Hum. Mutat. 19:82-82(2002). RN [92] RP VARIANTS LYNCH2 MET-117 AND PRO-247, AND VARIANTS VAL-219; ALA-618 AND RP MET-716. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [93] RP VARIANT LYNCH2 CYS-646, AND VARIANT ALA-618. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [94] RP VARIANTS LYNCH2 PHE-19; LEU-28; MET-117; PRO-292; THR-681 AND TRP-687, AND RP VARIANT VAL-219. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [95] RP VARIANTS LYNCH2 SER-29; ARG-67; LEU-185 AND ASP-244. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [96] RP VARIANTS CRC 325-ARG--GLN-327 DEL; ARG-618 AND PRO-749. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [97] RP VARIANT LYNCH2 PRO-586. RX PubMed=12655562; DOI=10.1002/humu.9121; RA Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., RA Kreuz F.R., Theissig F., Aust D.E., Saeger H.D., Schackert H.K.; RT "Identification of six novel MSH2 and MLH1 germline mutations in HNPCC."; RL Hum. Mutat. 21:445-446(2003). RN [98] RP VARIANT CRC GLY-601. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [99] RP VARIANTS LYNCH2 CYS-18; ASP-101; LYS-182; CYS-379; ARG-559 AND LYS-616 DEL. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [100] RP VARIANT LYNCH2 SER-648. RX PubMed=15139004; DOI=10.1002/gcc.20040; RA Raevaara T.E., Gerdes A.-M., Loennqvist K.E., Tybjaerg-Hansen A., RA Abdel-Rahman W.M., Kariola R., Peltomaeki P., Nystroem-Lahti M.; RT "HNPCC mutation MLH1 P648S makes the functional protein unstable, and RT homozygosity predisposes to mild neurofibromatosis type 1."; RL Genes Chromosomes Cancer 40:261-265(2004). RN [101] RP VARIANTS LYNCH2 CYS-217; GLY-282; LEU-542; PRO-542; PRO-549; PRO-574; RP PRO-636; SER-640 AND MET-724. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [102] RP ERRATUM OF PUBMED:15365995. RA Shin Y.K., Heo S.C., Shin J.H., Hong S.H., Ku J.L., Yoo B.C., Kim I.J., RA Park J.G.; RL Hum. Mutat. 25:224-224(2005). RN [103] RP VARIANTS LYNCH2 GLY-41 AND ASN-VAL-PHE-HIS-ILE-719 INS. RX PubMed=15365996; DOI=10.1002/humu.9278; RA Krueger S., Bier A., Plaschke J., Hoehl R., Aust D.E., Kreuz F.R., RA Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., Schackert H.K.; RT "Ten novel MSH2 and MLH1 germline mutations in families with HNPCC."; RL Hum. Mutat. 24:351-352(2004). RN [104] RP VARIANTS LYNCH2 VAL-21; ARG-67; ASN-68 AND LYS-616 DEL. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [105] RP ERRATUM OF PUBMED:14961575. RA Cederquist K., Emanuelsson M., Goransson I., Holinski-Feder E., RA Muller-Koch Y., Golovleva I., Gronberg H.; RL Int. J. Cancer 115:1011-1011(2005). RN [106] RP INVOLVEMENT IN LYNCH2 BY EPIGENETIC INHERITANCE. RX PubMed=15064764; DOI=10.1038/ng1342; RA Suter C.M., Martin D.I.K., Ward R.L.; RT "Germline epimutation of MLH1 in individuals with multiple cancers."; RL Nat. Genet. 36:497-501(2004). RN [107] RP VARIANT HIS-132. RX PubMed=15184898; DOI=10.1038/ng1374; RA Lipkin S.M., Rozek L.S., Rennert G., Yang W., Chen P.-C., Hacia J., RA Hunt N., Shin B., Fodor S., Kokoris M., Greenson J.K., Fearon E., Lynch H., RA Collins F., Gruber S.B.; RT "The MLH1 D132H variant is associated with susceptibility to sporadic RT colorectal cancer."; RL Nat. Genet. 36:694-699(2004). RN [108] RP VARIANTS LYNCH2 LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; RP GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; RP PRO-329; ILE-330 DEL; PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; LEU-648; RP SER-648; LEU-654 AND PRO-659, VARIANTS SER-29; GLY-93; GLN-443; ALA-618; RP CYS-646; GLN-659; THR-681 AND MET-716, CHARACTERIZATION OF VARIANTS LYNCH2 RP LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; RP VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; RP PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; THR-618; LEU-648; SER-648; RP LEU-654 AND PRO-659, AND CHARACTERIZATION OF VARIANTS SER-29; GLY-93; RP MET-213; VAL-219; GLN-443; ALA-618; CYS-646; GLN-659; THR-681 AND MET-716. RX PubMed=16083711; DOI=10.1016/j.gastro.2005.06.005; RA Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., RA Loennqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., RA Gerdes A.-M., Peltomaeki P., Kohonen-Corish M., Mangold E., Macrae F., RA Greenblatt M., de la Chapelle A., Nystroem M.; RT "Functional significance and clinical phenotype of nontruncating mismatch RT repair variants of MLH1."; RL Gastroenterology 129:537-549(2005). RN [109] RP VARIANTS LYNCH2 LEU-28; LYS-35; ARG-67; VAL-111; MET-117; PRO-292; THR-441; RP LYS-618 DEL; PRO-623; ILE-657 DEL; THR-681; TRP-687 AND ARG-751. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [110] RP VARIANT MMRCS1 ASN-35. RX PubMed=17440981; DOI=10.1002/cncr.22697; RG Rotterdam initiative on gastrointestinal hereditary tumors; RA Poley J.-W., Wagner A., Hoogmans M.M.C.P., Menko F.H., Tops C., Kros J.M., RA Reddingius R.E., Meijers-Heijboer H., Kuipers E.J., Dinjens W.N.M.; RT "Biallelic germline mutations of mismatch-repair genes: a possible cause RT for multiple pediatric malignancies."; RL Cancer 109:2349-2356(2007). RN [111] RP VARIANTS LYNCH2 LYS-102 AND GLN-474. RX PubMed=17510385; DOI=10.1158/0008-5472.can-06-3509; RA Takahashi M., Shimodaira H., Andreutti-Zaugg C., Iggo R., Kolodner R.D., RA Ishioka C.; RT "Functional analysis of human MLH1 variants using yeast and in vitro RT mismatch repair assays."; RL Cancer Res. 67:4595-4604(2007). RN [112] RP INVOLVEMENT IN LYNCH2 BY GERMLINE EPIMUTATION. RX PubMed=17301300; DOI=10.1056/nejmoa064522; RA Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., RA Hawkins N.J., Ward R.L.; RT "Inheritance of a cancer-associated MLH1 germ-line epimutation."; RL N. Engl. J. Med. 356:697-705(2007). RN [113] RP VARIANTS CRC GLU-67 AND THR-681, AND VARIANTS ALA-22; GLY-93; SER-309; RP ASN-406; HIS-607; ALA-618; ARG-689; MET-716; TYR-718 AND ARG-751. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [114] RP VARIANTS LYNCH2 HIS-41; SER-101; ILE-330 DEL; PRO-619 AND ARG-689, AND RP VARIANTS ARG-67; ARG-77; SER-98; ASP-101; LYS-116; MET-117; ASN-126; RP MET-213; SER-215; SER-216; PHE-260; CYS-265; HIS-265; ASP-320; ALA-326; RP ILE-330 DEL; TRP-474; GLN-474; ASP-539; PRO-549; THR-551; ARG-585; ARG-603; RP HIS-607; SER-640; LEU-640; VAL-655; SER-656; ARG-666 AND THR-681. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [115] RP VARIANTS LYNCH2 CYS-233 DEL AND TRP-389, CHARACTERIZATION OF VARIANTS RP LYNCH2 LEU-28; LYS-37; HIS-38; LYS-38; PHE-44; ARG-67; PRO-109; PRO-111; RP MET-117; CYS-233 DEL; CYS-265; TRP-389; GLN-443; PRO-550; GLY-578; PHE-582; RP ASP-589; ALA-618; CYS-646; LEU-648; LEU-654; PRO-659 AND VAL-716 DEL, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP INTERACTION WITH PMS2, INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=22753075; DOI=10.1002/humu.22153; RA Andersen S.D., Liberti S.E., Luetzen A., Drost M., Bernstein I., RA Nilbert M., Dominguez M., Nystroem M., Hansen T.V., Christoffersen J.W., RA Jaeger A.C., de Wind N., Nielsen F.C., Toerring P.M., Rasmussen L.J.; RT "Functional characterization of MLH1 missense variants identified in Lynch RT syndrome patients."; RL Hum. Mutat. 33:1647-1655(2012). RN [116] RP VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND HIS-725, AND RP CHARACTERIZATION OF VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND RP HIS-725. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Heterodimerizes with PMS2 to form MutL alpha, a component of CC the post-replicative DNA mismatch repair system (MMR). DNA repair is CC initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to CC a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. CC Assembly of the MutL-MutS-heteroduplex ternary complex in presence of CC RFC and PCNA is sufficient to activate endonuclease activity of PMS2. CC It introduces single-strand breaks near the mismatch and thus generates CC new entry points for the exonuclease EXO1 to degrade the strand CC containing the mismatch. DNA methylation would prevent cleavage and CC therefore assure that only the newly mutated DNA strand is going to be CC corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp CC loader subunits of DNA polymerase III, suggesting that it may play a CC role to recruit the DNA polymerase III to the site of the MMR. Also CC implicated in DNA damage signaling, a process which induces cell cycle CC arrest and can lead to apoptosis in case of major DNA damages. CC Heterodimerizes with MLH3 to form MutL gamma which plays a role in CC meiosis. {ECO:0000269|PubMed:16873062, ECO:0000269|PubMed:18206974, CC ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:39032648, ECO:0000269|PubMed:9311737}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and CC MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) CC or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 CC to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). CC Interacts with PMS2; this interaction promotes MLH1 stability CC (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with CC MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, CC PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). CC Interacts with MTMR15/FAN1 (PubMed:20603073). CC {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:20603073, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:39032648}. CC -!- INTERACTION: CC P40692; P63261: ACTG1; NbExp=6; IntAct=EBI-744248, EBI-351292; CC P40692; P07355: ANXA2; NbExp=6; IntAct=EBI-744248, EBI-352622; CC P40692; Q10567-3: AP1B1; NbExp=3; IntAct=EBI-744248, EBI-11978055; CC P40692; P63010-2: AP2B1; NbExp=8; IntAct=EBI-744248, EBI-11529439; CC P40692; Q9BX63: BRIP1; NbExp=21; IntAct=EBI-744248, EBI-3509650; CC P40692; Q9BX70: BTBD2; NbExp=3; IntAct=EBI-744248, EBI-710091; CC P40692; Q5JTZ5: C9orf152; NbExp=3; IntAct=EBI-744248, EBI-18560658; CC P40692; Q8NA61: CBY2; NbExp=6; IntAct=EBI-744248, EBI-741724; CC P40692; Q8NA61-2: CBY2; NbExp=11; IntAct=EBI-744248, EBI-11524851; CC P40692; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-744248, EBI-740841; CC P40692; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-744248, EBI-17967022; CC P40692; Q96GN5: CDCA7L; NbExp=4; IntAct=EBI-744248, EBI-5278764; CC P40692; O76039: CDKL5; NbExp=4; IntAct=EBI-744248, EBI-1752465; CC P40692; P07858: CTSB; NbExp=6; IntAct=EBI-744248, EBI-715062; CC P40692; P17661: DES; NbExp=6; IntAct=EBI-744248, EBI-1055572; CC P40692; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-744248, EBI-744099; CC P40692; Q86W67: FAM228A; NbExp=3; IntAct=EBI-744248, EBI-12958227; CC P40692; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-744248, EBI-742802; CC P40692; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-744248, EBI-6658203; CC P40692; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-744248, EBI-741729; CC P40692; Q96NE9-2: FRMD6; NbExp=4; IntAct=EBI-744248, EBI-13213391; CC P40692; Q16658: FSCN1; NbExp=7; IntAct=EBI-744248, EBI-351076; CC P40692; P11142: HSPA8; NbExp=2; IntAct=EBI-744248, EBI-351896; CC P40692; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-744248, EBI-2557660; CC P40692; P52292: KPNA2; NbExp=9; IntAct=EBI-744248, EBI-349938; CC P40692; O15131: KPNA5; NbExp=3; IntAct=EBI-744248, EBI-540602; CC P40692; Q5T749: KPRP; NbExp=3; IntAct=EBI-744248, EBI-10981970; CC P40692; O95232-2: LUC7L3; NbExp=3; IntAct=EBI-744248, EBI-19157865; CC P40692; P43361: MAGEA8; NbExp=7; IntAct=EBI-744248, EBI-10182930; CC P40692; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-744248, EBI-12516603; CC P40692; O95243-2: MBD4; NbExp=3; IntAct=EBI-744248, EBI-6448717; CC P40692; Q9UJA3: MCM8; NbExp=2; IntAct=EBI-744248, EBI-8756095; CC P40692; Q9NXL9: MCM9; NbExp=5; IntAct=EBI-744248, EBI-2804985; CC P40692; Q9UHC1: MLH3; NbExp=7; IntAct=EBI-744248, EBI-3893094; CC P40692; Q6PF18: MORN3; NbExp=3; IntAct=EBI-744248, EBI-9675802; CC P40692; P29372-4: MPG; NbExp=3; IntAct=EBI-744248, EBI-10695618; CC P40692; P20585: MSH3; NbExp=5; IntAct=EBI-744248, EBI-1164205; CC P40692; P15173: MYOG; NbExp=12; IntAct=EBI-744248, EBI-3906629; CC P40692; P60323-2: NANOS3; NbExp=3; IntAct=EBI-744248, EBI-18012223; CC P40692; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-744248, EBI-5461341; CC P40692; Q14938-5: NFIX; NbExp=3; IntAct=EBI-744248, EBI-12024662; CC P40692; O00746: NME4; NbExp=3; IntAct=EBI-744248, EBI-744871; CC P40692; O15055: PER2; NbExp=3; IntAct=EBI-744248, EBI-1054296; CC P40692; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-744248, EBI-11532361; CC P40692; P54277: PMS1; NbExp=8; IntAct=EBI-744248, EBI-2893308; CC P40692; P54278: PMS2; NbExp=24; IntAct=EBI-744248, EBI-1162561; CC P40692; Q96KQ4: PPP1R13B; NbExp=3; IntAct=EBI-744248, EBI-1105153; CC P40692; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-744248, EBI-1567866; CC P40692; P25786: PSMA1; NbExp=5; IntAct=EBI-744248, EBI-359352; CC P40692; P26045: PTPN3; NbExp=3; IntAct=EBI-744248, EBI-1047946; CC P40692; Q6NSI4: RADX; NbExp=9; IntAct=EBI-744248, EBI-8634209; CC P40692; Q5RL73: RBM48; NbExp=3; IntAct=EBI-744248, EBI-473821; CC P40692; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-744248, EBI-6873025; CC P40692; Q6RVD6: SPATA8; NbExp=3; IntAct=EBI-744248, EBI-8635958; CC P40692; Q13813: SPTAN1; NbExp=6; IntAct=EBI-744248, EBI-351450; CC P40692; O95926: SYF2; NbExp=3; IntAct=EBI-744248, EBI-2557644; CC P40692; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-744248, EBI-745958; CC P40692; Q7Z6R9: TFAP2D; NbExp=5; IntAct=EBI-744248, EBI-11952651; CC P40692; Q08117-2: TLE5; NbExp=3; IntAct=EBI-744248, EBI-11741437; CC P40692; P62328: TMSB4X; NbExp=15; IntAct=EBI-744248, EBI-712598; CC P40692; Q96PP4: TSGA13; NbExp=3; IntAct=EBI-744248, EBI-12390276; CC P40692; Q01081: U2AF1; NbExp=3; IntAct=EBI-744248, EBI-632461; CC P40692; O94941: UBOX5; NbExp=7; IntAct=EBI-744248, EBI-751901; CC P40692; O75152: ZC3H11A; NbExp=8; IntAct=EBI-744248, EBI-748480; CC P40692; Q9NU63-3: ZFP57; NbExp=3; IntAct=EBI-744248, EBI-12879708; CC P40692; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-744248, EBI-11419867; CC P40692; Q9UDW3: ZMAT5; NbExp=3; IntAct=EBI-744248, EBI-7850213; CC P40692; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-744248, EBI-12272076; CC P40692; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-744248, EBI-1640204; CC P40692; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-744248, EBI-17269964; CC P40692; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-744248, EBI-10251462; CC P40692; P42843: SKP2; Xeno; NbExp=3; IntAct=EBI-744248, EBI-28370; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:30770470}. Chromosome CC {ECO:0000269|PubMed:26300262}. Note=Recruited to chromatin in a MCM9- CC dependent manner. {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P40692-1; Sequence=Displayed; CC Name=2; CC IsoId=P40692-2; Sequence=VSP_045201; CC Name=3; CC IsoId=P40692-3; Sequence=VSP_047023; CC -!- TISSUE SPECIFICITY: Colon, lymphocytes, breast, lung, spleen, testis, CC prostate, thyroid, gall bladder and heart. CC -!- PTM: Acetylated (PubMed:30770470). Deacetylated by HDAC6 which prevents CC the MutL alpha complex, formed by the MLH1-PMS2 heterodimer, from being CC recruited to the MutS alpha complex, formed by the MSH2-MSH6 CC heterodimer, leading to tolerance of DNA damage (PubMed:30770470). CC {ECO:0000269|PubMed:30770470}. CC -!- PTM: Ubiquitinated by UBR4; leading to proteasomal degradation. This CC ubiquitination is counteracted by the deubiquitinase USP5. CC {ECO:0000269|PubMed:39032648}. CC -!- DISEASE: Lynch syndrome 2 (LYNCH2) [MIM:609310]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10323887, ECO:0000269|PubMed:10375096, CC ECO:0000269|PubMed:10386556, ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10627141, ECO:0000269|PubMed:10660333, CC ECO:0000269|PubMed:10671064, ECO:0000269|PubMed:10713887, CC ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:10882759, CC ECO:0000269|PubMed:11139242, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:11748856, CC ECO:0000269|PubMed:11754112, ECO:0000269|PubMed:11781295, CC ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:11839723, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12095971, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655562, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14635101, ECO:0000269|PubMed:14961575, CC ECO:0000269|PubMed:15064764, ECO:0000269|PubMed:15139004, CC ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:15365996, CC ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17301300, ECO:0000269|PubMed:17510385, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8521398, CC ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:8571956, CC ECO:0000269|PubMed:8574961, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:8993976, CC ECO:0000269|PubMed:9048925, ECO:0000269|PubMed:9067757, CC ECO:0000269|PubMed:9218993, ECO:0000269|PubMed:9272156, CC ECO:0000269|PubMed:9298827, ECO:0000269|PubMed:9311737, CC ECO:0000269|PubMed:9326924, ECO:0000269|PubMed:9399661, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9718327, CC ECO:0000269|PubMed:9833759, ECO:0000269|PubMed:9927034, CC ECO:0000269|Ref.5}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 1 (MMRCS1) [MIM:276300]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:17440981, ECO:0000269|PubMed:7661930}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:8751876}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in MLH1 may contribute to lobular carcinoma in CC situ (LCIS), a non-invasive neoplastic disease of the breast. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Some epigenetic changes can be transmitted unchanged CC through the germline (termed 'epigenetic inheritance'). Evidence that CC this mechanism occurs in humans is provided by the identification of CC individuals in whom 1 allele of the MLH1 gene is epigenetically CC silenced throughout the soma (implying a germline event). These CC individuals are affected by Lynch syndrome but does not have CC identifiable mutations in MLH1, even though it is silenced, which CC demonstrates that an epimutation can phenocopy a genetic disease. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10882759, ECO:0000269|PubMed:12132870, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:14504054, CC ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8872463, CC ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9087566, CC ECO:0000269|PubMed:9611074}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/149/MLH1"; CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases MutL homolog 1 CC (E.coli) (MLH1); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/MLH1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07343; AAC50285.1; -; mRNA. DR EMBL; U07418; AAA17374.1; -; mRNA. DR EMBL; U40978; AAA82079.1; -; Genomic_DNA. DR EMBL; U40960; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40961; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40962; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40963; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40964; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40965; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40966; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40967; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40968; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40969; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40970; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40971; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40972; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40973; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40974; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40975; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40976; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40977; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U17857; AAA85687.1; -; Genomic_DNA. DR EMBL; U17839; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17840; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17841; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17842; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17843; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17844; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17845; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17846; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17847; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17848; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17849; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17851; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17852; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17853; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17854; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17855; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17856; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; AY217549; AAO22994.1; -; Genomic_DNA. DR EMBL; AK295359; BAG58325.1; -; mRNA. DR EMBL; AK298324; BAG60576.1; -; mRNA. DR EMBL; AK298583; BAG60773.1; -; mRNA. DR EMBL; AK316074; BAH14445.1; -; mRNA. DR EMBL; AK316264; BAH14635.1; -; mRNA. DR EMBL; AC006583; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64483.1; -; Genomic_DNA. DR EMBL; BC006850; AAH06850.1; -; mRNA. DR CCDS; CCDS2663.1; -. [P40692-1] DR CCDS; CCDS54562.1; -. [P40692-3] DR CCDS; CCDS54563.1; -. [P40692-2] DR PIR; S43085; S43085. DR RefSeq; NP_000240.1; NM_000249.4. [P40692-1] DR RefSeq; NP_001161089.1; NM_001167617.3. [P40692-3] DR RefSeq; NP_001161090.1; NM_001167618.3. [P40692-2] DR RefSeq; NP_001161091.1; NM_001167619.3. [P40692-2] DR RefSeq; NP_001245200.1; NM_001258271.1. DR RefSeq; NP_001245202.1; NM_001258273.2. [P40692-2] DR RefSeq; NP_001245203.1; NM_001258274.3. [P40692-2] DR RefSeq; NP_001341544.1; NM_001354615.2. [P40692-2] DR RefSeq; NP_001341545.1; NM_001354616.2. [P40692-2] DR RefSeq; NP_001341546.1; NM_001354617.2. [P40692-2] DR RefSeq; NP_001341547.1; NM_001354618.2. [P40692-2] DR RefSeq; NP_001341548.1; NM_001354619.2. [P40692-2] DR RefSeq; NP_001341549.1; NM_001354620.2. [P40692-3] DR RefSeq; XP_047304109.1; XM_047448153.1. [P40692-2] DR RefSeq; XP_047304110.1; XM_047448154.1. [P40692-2] DR RefSeq; XP_047304111.1; XM_047448155.1. [P40692-2] DR RefSeq; XP_054202541.1; XM_054346566.1. [P40692-2] DR RefSeq; XP_054202542.1; XM_054346567.1. [P40692-2] DR RefSeq; XP_054202543.1; XM_054346568.1. [P40692-2] DR PDB; 3RBN; X-ray; 2.16 A; A/B=486-751. DR PDB; 4P7A; X-ray; 2.30 A; A=1-347. DR PDB; 5U5P; X-ray; 2.17 A; B/C=467-476. DR PDB; 6WBA; X-ray; 2.15 A; B/C=466-476. DR PDB; 6WBB; X-ray; 2.66 A; B/C=466-476. DR PDB; 6WBC; X-ray; 2.15 A; B=466-476. DR PDB; 7M60; X-ray; 2.30 A; B/C=466-476. DR PDBsum; 3RBN; -. DR PDBsum; 4P7A; -. DR PDBsum; 5U5P; -. DR PDBsum; 6WBA; -. DR PDBsum; 6WBB; -. DR PDBsum; 6WBC; -. DR PDBsum; 7M60; -. DR AlphaFoldDB; P40692; -. DR SMR; P40692; -. DR BioGRID; 110438; 261. DR ComplexPortal; CPX-9901; MutLalpha endonuclease complex. DR ComplexPortal; CPX-9941; MutLabeta endonuclease complex. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR CORUM; P40692; -. DR DIP; DIP-27601N; -. DR FunCoup; P40692; 2633. DR IntAct; P40692; 232. DR MINT; P40692; -. DR STRING; 9606.ENSP00000231790; -. DR GlyCosmos; P40692; 1 site, 1 glycan. DR GlyGen; P40692; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P40692; -. DR MetOSite; P40692; -. DR PhosphoSitePlus; P40692; -. DR BioMuta; MLH1; -. DR DMDM; 730028; -. DR jPOST; P40692; -. DR MassIVE; P40692; -. DR PaxDb; 9606-ENSP00000231790; -. DR PeptideAtlas; P40692; -. DR ProteomicsDB; 19516; -. DR ProteomicsDB; 4266; -. DR ProteomicsDB; 55377; -. [P40692-1] DR Pumba; P40692; -. DR Antibodypedia; 4599; 923 antibodies from 47 providers. DR CPTC; P40692; 3 antibodies. DR DNASU; 4292; -. DR Ensembl; ENST00000231790.8; ENSP00000231790.3; ENSG00000076242.19. [P40692-1] DR Ensembl; ENST00000429117.6; ENSP00000407019.2; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000435176.5; ENSP00000402564.1; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000455445.6; ENSP00000398272.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000458205.6; ENSP00000402667.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000466900.6; ENSP00000519069.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000485889.2; ENSP00000518946.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000492474.6; ENSP00000518393.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000536378.5; ENSP00000444286.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000539477.6; ENSP00000443665.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000674019.1; ENSP00000501081.1; ENSG00000076242.19. [P40692-2] DR GeneID; 4292; -. DR KEGG; hsa:4292; -. DR MANE-Select; ENST00000231790.8; ENSP00000231790.3; NM_000249.4; NP_000240.1. DR UCSC; uc003cgl.4; human. [P40692-1] DR AGR; HGNC:7127; -. DR CIViC; 4292; 30 evidence items across 33 molecular profiles. DR ClinPGx; PA240; -. DR CTD; 4292; -. DR DisGeNET; 4292; -. DR GeneCards; MLH1; -. DR GeneReviews; MLH1; -. DR HGNC; HGNC:7127; MLH1. DR HPA; ENSG00000076242; Low tissue specificity. DR MalaCards; MLH1; -. DR MIM; 114500; phenotype. DR MIM; 120436; gene. DR MIM; 158320; phenotype. DR MIM; 276300; phenotype. DR MIM; 608089; phenotype. DR MIM; 609310; phenotype. DR OpenTargets; ENSG00000076242; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000076242; -. DR eggNOG; KOG1979; Eukaryota. DR GeneTree; ENSGT00800000124177; -. DR InParanoid; P40692; -. DR OMA; ANYHVKK; -. DR OrthoDB; 10263226at2759; -. DR PAN-GO; P40692; 4 GO annotations based on evolutionary models. DR PhylomeDB; P40692; -. DR PathwayCommons; P40692; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5545483; Defective Mismatch Repair Associated With MLH1. DR Reactome; R-HSA-5632987; Defective Mismatch Repair Associated With PMS2. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; P40692; -. DR SIGNOR; P40692; -. DR Agora; ENSG00000076242; -. DR BioGRID-ORCS; 4292; 15 hits in 1172 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH1; human. DR EvolutionaryTrace; P40692; -. DR GeneWiki; MLH1; -. DR GenomeRNAi; 4292; -. DR Pharos; P40692; Tbio. DR PRO; PR:P40692; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P40692; protein. DR Bgee; ENSG00000076242; Expressed in tibialis anterior and 210 other cell types or tissues. DR ExpressionAtlas; P40692; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005715; C:late recombination nodule; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032389; C:MutLalpha complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl. DR GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0007129; P:homologous chromosome pairing at meiosis; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; IEA:Ensembl. DR GO; GO:0007060; P:male meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0043060; P:meiotic metaphase I homologous chromosome alignment; IEA:Ensembl. DR GO; GO:0051257; P:meiotic spindle midzone assembly; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IGI:MGI. DR GO; GO:0045950; P:negative regulation of mitotic recombination; IEA:Ensembl. DR GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl. DR GO; GO:0048477; P:oogenesis; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0000712; P:resolution of meiotic recombination intermediates; IEA:Ensembl. DR GO; GO:0009617; P:response to bacterium; IEA:Ensembl. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03483; MutL_Trans_MLH1; 1. DR DisProt; DP03062; -. DR FunFam; 3.30.230.10:FF:000014; DNA mismatch repair protein Mlh1; 1. DR FunFam; 3.30.565.10:FF:000034; DNA mismatch repair protein mlh1, putative; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR032189; Mlh1_C. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF12; DNA MISMATCH REPAIR PROTEIN MLH1; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF16413; Mlh1_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle; KW Chromosome; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..756 FT /note="DNA mismatch repair protein Mlh1" FT /id="PRO_0000178000" FT REGION 355..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 400..491 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 410..650 FT /note="Interaction with EXO1" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, FT ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:22753075" FT MOTIF 471..474 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29175432" FT COMPBIAS 362..375 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 443..457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 82..84 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 100..104 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 33 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 241 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 361 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 377 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..241 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045201" FT VAR_SEQ 1..101 FT /note="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVK FT EGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRG -> MAF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047023" FT VARIANT 18 FT /note="R -> C (in LYNCH2; dbSNP:rs367654552)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022663" FT VARIANT 19 FT /note="I -> F (in LYNCH2; dbSNP:rs63750648)" FT /evidence="ECO:0000269|PubMed:12362047" FT /id="VAR_043383" FT VARIANT 21 FT /note="A -> V (in LYNCH2; dbSNP:rs63750706)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043384" FT VARIANT 22 FT /note="G -> A (in dbSNP:rs41295280)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038023" FT VARIANT 25 FT /note="I -> F (in LYNCH2; dbSNP:rs63749838)" FT /evidence="ECO:0000269|PubMed:10386556" FT /id="VAR_043385" FT VARIANT 28 FT /note="P -> L (in LYNCH2; loss of protein expression; FT normal interaction with PMS2 and EXO1; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63750792)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9298827" FT /id="VAR_004433" FT VARIANT 29 FT /note="A -> S (in LYNCH2; uncertain significance; acts FT functionally like the wild-type protein; dbSNP:rs63750656)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043386" FT VARIANT 31 FT /note="A -> C (in LYNCH2; decreased mismatch repair FT activity; requires 2 nucleotide substitutions; FT dbSNP:rs63749994)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076338" FT VARIANT 32 FT /note="I -> V (in dbSNP:rs2020872)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_014876" FT VARIANT 35 FT /note="M -> K (in LYNCH2; uncertain significance; FT dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043387" FT VARIANT 35 FT /note="M -> N (in MMRCS1; requires 2 nucleotide FT substitutions; dbSNP:rs121912965)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:17440981" FT /id="VAR_043388" FT VARIANT 35 FT /note="M -> R (in LYNCH2; dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:8521398" FT /id="VAR_004434" FT VARIANT 37 FT /note="E -> ELNH (found in an endometrial cancer sample; FT somatic mutation)" FT /id="VAR_004435" FT VARIANT 37 FT /note="E -> K (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; dbSNP:rs63751012)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076339" FT VARIANT 38 FT /note="N -> H (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63750580)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_043389" FT VARIANT 38 FT /note="N -> K (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs267607706)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076340" FT VARIANT 41 FT /note="D -> G (in LYNCH2; dbSNP:rs63751094)" FT /evidence="ECO:0000269|PubMed:15365996" FT /id="VAR_043390" FT VARIANT 41 FT /note="D -> H (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607713)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054522" FT VARIANT 44 FT /note="S -> F (in LYNCH2; no effect on MLH1 splicing; loss FT of mismatch repair activity; dbSNP:rs63751109)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9326924" FT /id="VAR_004436" FT VARIANT 45..47 FT /note="TSI -> CF (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_043391" FT VARIANT 54 FT /note="G -> E (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63751267)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012902" FT VARIANT 62 FT /note="Q -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751428)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004437" FT VARIANT 63 FT /note="D -> E (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs587778955)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043392" FT VARIANT 64 FT /note="N -> S (in LYNCH2; dbSNP:rs63750952)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004438" FT VARIANT 67 FT /note="G -> E (in CRC; dbSNP:rs63749939)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038024" FT VARIANT 67 FT /note="G -> R (in LYNCH2; no effect on MLH1 splicing; FT decreased mismatch repair activity; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14961575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9067757, ECO:0000269|PubMed:9833759" FT /id="VAR_004439" FT VARIANT 67 FT /note="G -> W (in LYNCH2; dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9927034" FT /id="VAR_012903" FT VARIANT 68 FT /note="I -> N (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750281)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_004440" FT VARIANT 69 FT /note="R -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751661)" FT /evidence="ECO:0000269|PubMed:10627141" FT /id="VAR_004441" FT VARIANT 71 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043393" FT VARIANT 77 FT /note="C -> R (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; normal interaction FT with PMS2; dbSNP:rs63749859)" FT /evidence="ECO:0000269|PubMed:10660333, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004442" FT VARIANT 77 FT /note="C -> Y (in CRC; sporadic; early onset; FT dbSNP:rs63750437)" FT /evidence="ECO:0000269|PubMed:9032648" FT /id="VAR_012904" FT VARIANT 80 FT /note="F -> V (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63749990)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012905" FT VARIANT 84 FT /note="K -> E (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750641)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012906" FT VARIANT 93 FT /note="S -> G (normal interaction with PMS2; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs41295282)" FT /evidence="ECO:0000269|PubMed:10671064, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_004443" FT VARIANT 98 FT /note="G -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607725)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054523" FT VARIANT 101 FT /note="G -> D (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607727)" FT /evidence="ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:18561205" FT /id="VAR_022664" FT VARIANT 101 FT /note="G -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607726)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054524" FT VARIANT 102 FT /note="E -> K (in LYNCH2; dbSNP:rs63750453)" FT /evidence="ECO:0000269|PubMed:17510385" FT /id="VAR_043394" FT VARIANT 106 FT /note="S -> R (in gastric cancer; uncertain significance; FT dbSNP:rs63750297)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043395" FT VARIANT 107 FT /note="I -> R (in LYNCH2; decreased mismatch repair FT activity; normal interaction with PMS2; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750507)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004444" FT VARIANT 109 FT /note="H -> P (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs587779004)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076341" FT VARIANT 109 FT /note="H -> Q (in gastric cancer; uncertain significance; FT dbSNP:rs63749803)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043396" FT VARIANT 111 FT /note="A -> P (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs587779005)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076342" FT VARIANT 111 FT /note="A -> V (in LYNCH2; dbSNP:rs63750539)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:16451135" FT /id="VAR_012907" FT VARIANT 116 FT /note="T -> K (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054525" FT VARIANT 116 FT /note="T -> R (no effect on protein expression; FT dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079812" FT VARIANT 117 FT /note="T -> M (in LYNCH2; decreased mismatch repair FT activity; no effect on MLH1 splicing; fails to interact FT with PMS2 and EXO1; loss of nuclear localization; FT dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:8566964" FT /id="VAR_004445" FT VARIANT 117 FT /note="T -> R (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_004446" FT VARIANT 126 FT /note="Y -> N (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs200076893)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054526" FT VARIANT 128 FT /note="A -> P (in LYNCH2; dbSNP:rs63750866)" FT /evidence="ECO:0000269|PubMed:9218993" FT /id="VAR_012908" FT VARIANT 132 FT /note="D -> H (decreased but not abolished ATPase activity; FT dbSNP:rs28930073)" FT /evidence="ECO:0000269|PubMed:15184898" FT /id="VAR_022665" FT VARIANT 155 FT /note="L -> R (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750891)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043397" FT VARIANT 182 FT /note="R -> G (in LYNCH2; incomplete; dbSNP:rs63750211)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9399661" FT /id="VAR_012909" FT VARIANT 182 FT /note="R -> K (in LYNCH2; dbSNP:rs587779021)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022666" FT VARIANT 185 FT /note="V -> G (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing; FT dbSNP:rs63750515)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004447" FT VARIANT 185 FT /note="V -> L (in LYNCH2; uncertain significance; FT dbSNP:rs63750012)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043398" FT VARIANT 193 FT /note="S -> P (in LYNCH2; dbSNP:rs63751021)" FT /evidence="ECO:0000269|PubMed:10660333" FT /id="VAR_004448" FT VARIANT 213 FT /note="V -> L (no effect on protein expression; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079813" FT VARIANT 213 FT /note="V -> M (no effect on MLH1 splicing; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944, FT ECO:0000269|Ref.5" FT /id="VAR_012910" FT VARIANT 215 FT /note="N -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607775)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054527" FT VARIANT 216 FT /note="I -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607776)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054528" FT VARIANT 217 FT /note="R -> C (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs4986984)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_004449" FT VARIANT 217 FT /note="R -> G (in dbSNP:rs4986984)" FT /id="VAR_020469" FT VARIANT 219 FT /note="I -> V (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs1799977)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:11754112, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9067757, FT ECO:0000269|PubMed:9087566, ECO:0000269|PubMed:9218993, FT ECO:0000269|PubMed:9833759, ECO:0000269|Ref.5" FT /id="VAR_004450" FT VARIANT 226..295 FT /note="Missing (in LYNCH2)" FT /id="VAR_004452" FT VARIANT 226 FT /note="R -> L (in LYNCH2; dbSNP:rs63751711)" FT /evidence="ECO:0000269|PubMed:8566964" FT /id="VAR_004451" FT VARIANT 233 FT /note="Missing (in LYNCH2; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076343" FT VARIANT 234 FT /note="E -> G (in LYNCH2; uncertain significance; FT dbSNP:rs63750696)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043399" FT VARIANT 244 FT /note="G -> D (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:9218993" FT /id="VAR_012911" FT VARIANT 244 FT /note="G -> V (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012912" FT VARIANT 247 FT /note="S -> P (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750948)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043400" FT VARIANT 260 FT /note="L -> F (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs63750642)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054529" FT VARIANT 260 FT /note="L -> R (in CRC; dbSNP:rs63751283)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043401" FT VARIANT 262 FT /note="Missing (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012913" FT VARIANT 264 FT /note="H -> L (no effect on protein expression; FT dbSNP:rs63751664)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079814" FT VARIANT 264 FT /note="H -> Y (in LYNCH2; dbSNP:rs63751597)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043402" FT VARIANT 265 FT /note="R -> C (in LYNCH2; results in partial MLH1 exon 10 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_054530" FT VARIANT 265 FT /note="R -> H (risk factor for LYNCH2; results in partial FT MLH1 exon 10 skipping on ex vivo splicing assay; decreased FT mismatch repair activity; dbSNP:rs63751448)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:8993976" FT /id="VAR_012914" FT VARIANT 265 FT /note="R -> S (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076344" FT VARIANT 268 FT /note="E -> G (in CRC; benign; dbSNP:rs63750650)" FT /evidence="ECO:0000269|PubMed:9611074" FT /id="VAR_012915" FT VARIANT 282 FT /note="A -> G (in LYNCH2; likely benign; dbSNP:rs63750360)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043403" FT VARIANT 292 FT /note="L -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750517)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043404" FT VARIANT 295 FT /note="S -> T (in LYNCH2; uncertain significance; FT dbSNP:rs63750144)" FT /evidence="ECO:0000269|PubMed:9399661" FT /id="VAR_012916" FT VARIANT 304 FT /note="D -> V (in LYNCH2; dbSNP:rs63750993)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043405" FT VARIANT 309 FT /note="P -> S (in dbSNP:rs267607808)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038025" FT VARIANT 320 FT /note="E -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607811)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054531" FT VARIANT 321 FT /note="S -> I (in LYNCH2; uncertain significance; FT dbSNP:rs63750286)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043406" FT VARIANT 325..327 FT /note="Missing (in CRC)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043407" FT VARIANT 325 FT /note="R -> Q (in dbSNP:rs63750268)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012917" FT VARIANT 326 FT /note="V -> A (in LYNCH2; benign; no decrease in mismatch FT repair activity; dbSNP:rs63751049)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205" FT /id="VAR_004453" FT VARIANT 329 FT /note="H -> P (in LYNCH2; loss of protein expression; loss FT of nuclear localization; dbSNP:rs63750710)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:9272156" FT /id="VAR_012918" FT VARIANT 330 FT /note="Missing (in LYNCH2; results in weak MLH1 exon 11 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; loss of protein expression; loss of FT nuclear localization; dbSNP:rs63751197)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_043408" FT VARIANT 338 FT /note="N -> S (in LYNCH2; dbSNP:rs63751467)" FT /evidence="ECO:0000269|PubMed:12095971" FT /id="VAR_043409" FT VARIANT 379 FT /note="Y -> C (in LYNCH2; dbSNP:rs143009528)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022667" FT VARIANT 384 FT /note="V -> D (probable risk factor for HNPCC in some FT populations; dbSNP:rs63750447)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:8609062, ECO:0000269|PubMed:9526167" FT /id="VAR_004454" FT VARIANT 385 FT /note="R -> C (in LYNCH2; uncertain significance; FT dbSNP:rs63750760)" FT /evidence="ECO:0000269|PubMed:11839723" FT /id="VAR_043410" FT VARIANT 385 FT /note="R -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750430)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043411" FT VARIANT 389 FT /note="R -> W (in LYNCH2; uncertain significance; no effect FT on nuclear localization; normal interaction with PMS2 and FT EXO1; dbSNP:rs61751644)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076345" FT VARIANT 403 FT /note="P -> S (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs587778897)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076346" FT VARIANT 406 FT /note="S -> N (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs41294980)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9087566" FT /id="VAR_012919" FT VARIANT 423 FT /note="R -> T (no effect on protein expression; FT dbSNP:rs370687064)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079815" FT VARIANT 441 FT /note="A -> T (in LYNCH2; benign; dbSNP:rs63750365)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:9326924" FT /id="VAR_012920" FT VARIANT 443 FT /note="K -> Q (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs34213726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043412" FT VARIANT 460 FT /note="E -> A (in LYNCH2; uncertain significance; FT dbSNP:rs202038499)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076347" FT VARIANT 472 FT /note="R -> I (in CRC; uncertain significance; FT dbSNP:rs63750498)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043413" FT VARIANT 474 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63751083)" FT /evidence="ECO:0000269|PubMed:17510385, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043414" FT VARIANT 474 FT /note="R -> W (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs147939838)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054532" FT VARIANT 485 FT /note="D -> E (in LYNCH2; dbSNP:rs63750956)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043415" FT VARIANT 485 FT /note="D -> H (in LYNCH2; uncertain significance; FT dbSNP:rs63750314)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043416" FT VARIANT 492 FT /note="A -> T (in LYNCH2; also found in sporadic colorectal FT cancer; dbSNP:rs63751145)" FT /evidence="ECO:0000269|PubMed:8872463" FT /id="VAR_004455" FT VARIANT 506 FT /note="V -> A (in LYNCH2; dbSNP:rs63749909)" FT /evidence="ECO:0000269|PubMed:8574961" FT /id="VAR_004456" FT VARIANT 539 FT /note="A -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607843)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054533" FT VARIANT 542 FT /note="Q -> L (in LYNCH2; type II; decreased mismatch FT repair activity; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004457" FT VARIANT 542 FT /note="Q -> P (in LYNCH2; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043417" FT VARIANT 549 FT /note="L -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750289)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:8797773" FT /id="VAR_012921" FT VARIANT 550 FT /note="L -> P (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750193)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043418" FT VARIANT 551 FT /note="N -> T (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750271)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9399661, ECO:0000269|PubMed:9833759" FT /id="VAR_012922" FT VARIANT 559 FT /note="L -> R (in LYNCH2; uncertain significance; FT dbSNP:rs63750059)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022668" FT VARIANT 565 FT /note="I -> F (in LYNCH2; dbSNP:rs63750062)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012923" FT VARIANT 574 FT /note="L -> P (in LYNCH2; type I; abrogates interaction FT with EXO1; loss of protein expression; dbSNP:rs63751608)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:39032648, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004458" FT VARIANT 578..632 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076348" FT VARIANT 578 FT /note="E -> G (in LYNCH2 and CRC; benign; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs63751612)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_004459" FT VARIANT 582 FT /note="L -> F (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076349" FT VARIANT 582 FT /note="L -> V (in LYNCH2; type II; dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:7757073" FT /id="VAR_004460" FT VARIANT 585 FT /note="L -> R (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607865)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054534" FT VARIANT 586 FT /note="A -> P (in LYNCH2; dbSNP:rs63751176)" FT /evidence="ECO:0000269|PubMed:12655562" FT /id="VAR_015689" FT VARIANT 588 FT /note="L -> P (in LYNCH2; dbSNP:rs63750575)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_012924" FT VARIANT 589 FT /note="A -> D (in LYNCH2; decreased mismatch repair FT activity; loss of interaction with PMS2 and EXO1; loss of FT protein expression; may lose nuclear localization; FT dbSNP:rs63750016)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:39032648" FT /id="VAR_043419" FT VARIANT 596 FT /note="Missing (in LYNCH2)" FT /id="VAR_043420" FT VARIANT 601 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63750718)" FT /evidence="ECO:0000269|PubMed:12655564" FT /id="VAR_043421" FT VARIANT 603 FT /note="P -> R (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs63750876)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18561205" FT /id="VAR_012925" FT VARIANT 607 FT /note="L -> H (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs41295284)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11369138, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012926" FT VARIANT 612 FT /note="Missing (in LYNCH2; loss of protein expression; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043422" FT VARIANT 616 FT /note="Missing (in LYNCH2 and MMRCS1; abrogates interaction FT with EXO1; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:7661930, FT ECO:0000269|PubMed:8571956, ECO:0000269|PubMed:8872463, FT ECO:0000269|PubMed:8993976, ECO:0000269|PubMed:9311737" FT /id="VAR_004461" FT VARIANT 618 FT /note="K -> A (in LYNCH2; benign; interacts weakly with FT PMS2; no decrease in mismatch repair activity; no effect on FT nuclear localization; requires 2 nucleotide substitutions; FT dbSNP:rs35502531)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004462" FT VARIANT 618 FT /note="K -> R (in CRC; likely benign; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043424" FT VARIANT 618 FT /note="K -> T (in LYNCH2; benign; type II; loss of nuclear FT localization; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:12095971, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8872463" FT /id="VAR_004463" FT VARIANT 618 FT /note="Missing (in LYNCH2; dbSNP:rs63751247)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043423" FT VARIANT 619 FT /note="A -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607866)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054535" FT VARIANT 622 FT /note="L -> H (in LYNCH2; dbSNP:rs63750693)" FT /evidence="ECO:0000269|PubMed:11748856" FT /id="VAR_012927" FT VARIANT 623 FT /note="A -> P (in LYNCH2; uncertain significance; FT dbSNP:rs587778951)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043425" FT VARIANT 626..627 FT /note="FS -> ST (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004464" FT VARIANT 631 FT /note="D -> A (in LYNCH2; uncertain significance; FT dbSNP:rs63750240)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043426" FT VARIANT 633..663 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2; loss of FT protein expression; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076350" FT VARIANT 635 FT /note="N -> K (in gastric cancer; uncertain significance; FT dbSNP:rs63751047)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043427" FT VARIANT 636 FT /note="L -> P (in LYNCH2; dbSNP:rs63750825)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043428" FT VARIANT 640 FT /note="P -> L (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607875)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054536" FT VARIANT 640 FT /note="P -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63749792)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043429" FT VARIANT 646 FT /note="Y -> C (in LYNCH2; defective in interaction with FT PMS2 and EXO1; no decrease in mismatch repair activity; FT dbSNP:rs35045067)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_043430" FT VARIANT 648 FT /note="P -> L (in LYNCH2; defective in interaction with FT PMS2 and EXO1; may lose nuclear localization; loss of FT protein expression; no decrease in mismatch repair FT activity; dbSNP:rs63750610)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_012928" FT VARIANT 648 FT /note="P -> S (in LYNCH2; the protein is unstable; loss of FT nuclear localization; loss of protein expression; no FT decrease in mismatch repair activity; dbSNP:rs63750899)" FT /evidence="ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:15139004, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_022669" FT VARIANT 654 FT /note="P -> L (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043431" FT VARIANT 655 FT /note="I -> V (in LYNCH2; likely benign; also found in an FT endometrial cancer sample; no effect on MLH1 splicing; FT dbSNP:rs55907433)" FT /evidence="ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043432" FT VARIANT 656 FT /note="F -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607876)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054537" FT VARIANT 657 FT /note="Missing (in LYNCH2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043433" FT VARIANT 659 FT /note="R -> L (in LYNCH2; dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11427529" FT /id="VAR_012929" FT VARIANT 659 FT /note="R -> P (in LYNCH2; interacts only very weakly with FT PMS2; abrogates interaction with EXO1; decreased mismatch FT repair activity; may lose nuclear localization; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004465" FT VARIANT 659 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043434" FT VARIANT 662 FT /note="T -> P (in LYNCH2; dbSNP:rs587778964)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11754112" FT /id="VAR_012930" FT VARIANT 666 FT /note="W -> R (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs267607887)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054538" FT VARIANT 681 FT /note="A -> T (in LYNCH2 and CRC; abrogates interaction FT with EXO1; no decrease in mismatch repair activity; FT dbSNP:rs63750217)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004466" FT VARIANT 687 FT /note="R -> W (in LYNCH2; dbSNP:rs63751275)" FT /evidence="ECO:0000269|PubMed:11748856, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012931" FT VARIANT 689 FT /note="Q -> R (in LYNCH2; benign; dbSNP:rs63750702)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012932" FT VARIANT 716 FT /note="V -> M (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs35831931)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9833759" FT /id="VAR_012933" FT VARIANT 718 FT /note="H -> Y (in LYNCH2; benign; dbSNP:rs2020873)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18033691" FT /id="VAR_004467" FT VARIANT 719 FT /note="I -> INVFHI (in LYNCH2)" FT /id="VAR_043435" FT VARIANT 724 FT /note="L -> M (in LYNCH2; dbSNP:rs63749875)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043436" FT VARIANT 725 FT /note="R -> H (reduces by 60% protein expression; FT dbSNP:rs566928243)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079816" FT VARIANT 729 FT /note="L -> V (in dbSNP:rs1800149)" FT /id="VAR_004468" FT VARIANT 749 FT /note="L -> P (in CRC; dbSNP:rs267607894)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043437" FT VARIANT 751 FT /note="K -> R (in LYNCH2; likely benign; FT dbSNP:rs140195825)" FT /evidence="ECO:0000269|PubMed:11139242, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691" FT /id="VAR_012934" FT VARIANT 755 FT /note="R -> W (in HNPCC; incomplete; dbSNP:rs267607900)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012935" FT MUTAGEN 33 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 241, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 33 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-241, R-361 and R- FT 377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-361 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 471 FT /note="K->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT MUTAGEN 472 FT /note="R->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT CONFLICT 352 FT /note="L -> H (in Ref. 6; BAG60773)" FT /evidence="ECO:0000305" FT CONFLICT 708..711 FT /note="Missing (in Ref. 4; AAA85687)" FT /evidence="ECO:0000305" FT HELIX 13..25 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 28..41 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 53..56 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 57..63 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 103..109 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 122..131 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 146..154 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 169..186 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 212..220 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 228..235 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 236..239 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 240..247 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 253..255 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 270..281 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 291..298 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 322..335 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 504..516 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 519..526 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 529..543 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 552..566 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 572..581 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 582..590 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 604..626 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 634..641 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 650..652 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 653..662 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 669..684 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 712..718 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 720..724 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 737..745 FT /evidence="ECO:0007829|PDB:3RBN" SQ SEQUENCE 756 AA; 84601 MW; C9231FC406C2CA20 CRC64; MSFVAGVIRR LDETVVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGFR GEALASISHV AHVTITTKTA DGKCAYRASY SDGKLKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EEYGKILEVV GRYSVHNAGI SFSVKKQGET VADVRTLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP QNVDVNVHPT KHEVHFLHEE SILERVQQHI ESKLLGSNSS RMYFTQTLLP GLAGPSGEMV KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS SGRARQQDEE MLELPAPAEV AAKNQSLEGD TTKGTSEMSE KRGPTSSNPR KRHREDSDVE MVEDDSRKEM TAACTPRRRI INLTSVLSLQ EEINEQGHEV LREMLHNHSF VGCVNPQWAL AQHQTKLYLL NTTKLSEELF YQILIYDFAN FGVLRLSEPA PLFDLAMLAL DSPESGWTEE DGPKEGLAEY IVEFLKKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPPL EGLPIFILRL ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SWKWTVEHIV YKALRSHILP PKHFTEDGNI LQLANLPDLY KVFERC // ID MLH3_HUMAN Reviewed; 1453 AA. AC Q9UHC1; P49751; Q56DK9; Q9P292; Q9UHC0; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 3. DT 28-JAN-2026, entry version 202. DE RecName: Full=DNA mismatch repair protein Mlh3; DE AltName: Full=MutL protein homolog 3; GN Name=MLH3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND RP VARIANTS ASP-826 AND LEU-844. RX PubMed=10615123; DOI=10.1038/71643; RA Lipkin S.M., Wang V., Jacoby R., Banerjee-Basu S., Baxevanis A.D., RA Lynch H.T., Elliott R.M., Collins F.S.; RT "MLH3: a DNA mismatch repair gene associated with mammalian microsatellite RT instability."; RL Nat. Genet. 24:27-35(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH MLH1, AND VARIANT ASP-826. RX PubMed=11292842; DOI=10.1093/nar/29.8.1695; RA Kondo E., Horii A., Fukushige S.; RT "The interacting domains of three MutL heterodimers in man: hMLH1 interacts RT with 36 homologous amino acid residues within hMLH3, hPMS1 and hPMS2."; RL Nucleic Acids Res. 29:1695-1702(2001). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-93; SER-120; GLN-231; RP ILE-420; VAL-492; GLN-600; PRO-606; GLN-624; CYS-647; CYS-720; ILE-723; RP PHE-741; HIS-797; ASP-826; LEU-844; GLY-845; ILE-942; PRO-966; ASN-1073; RP GLU-1105; ASP-1163 AND ARG-1319. RG NIEHS SNPs program; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1189-1453. RC TISSUE=Brain; RX PubMed=7596406; DOI=10.1038/375754a0; RA Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., RA Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.-F., RA Bruni A.C., Montesi M.P., Sorbi S., Rainero I., Pinessi L., Nee L., RA Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., RA da Silva H.A.R., Haines J.L., Pericak-Vance M.A., Tanzi R.E., Roses A.D., RA Fraser P.E., Rommens J.M., St George-Hyslop P.H.; RT "Cloning of a gene bearing missense mutations in early-onset familial RT Alzheimer's disease."; RL Nature 375:754-760(1995). RN [6] RP INVOLVEMENT IN SOMATIC COLORECTAL CANCER. RX PubMed=11317354; DOI=10.1002/humu.1114; RA Lipkin S.M., Wang V., Stoler D.L., Anderson G.R., Kirsch I., Hadley D., RA Lynch H.T., Collins F.S.; RT "Germline and somatic mutation analyses in the DNA mismatch repair gene RT MLH3: evidence for somatic mutation in colorectal cancers."; RL Hum. Mutat. 17:389-396(2001). RN [7] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [8] RP VARIANTS HNPCC7 GLU-24; SER-499; GLN-624; CYS-647; GLY-817; SER-981; RP SER-1007; THR-1394 AND LYS-1451. RX PubMed=11586295; DOI=10.1038/ng1001-137; RA Wu Y., Berends M.J.W., Sijmons R.H., Mensink R.G.J., Verlind E., Kooi K.A., RA van der Sluis T., Kempinga C., van der Zee A.G.J., Hollema H., RA Buys C.H.C.M., Kleibeuker J.H., Hofstra R.M.W.; RT "A role for MLH3 in hereditary nonpolyposis colorectal cancer."; RL Nat. Genet. 29:137-138(2001). CC -!- FUNCTION: Probably involved in the repair of mismatches in DNA. CC -!- SUBUNIT: Heterodimer of MLH1 and MLH3. Interacts with MTMR15/FAN1. CC {ECO:0000269|PubMed:11292842, ECO:0000269|PubMed:20603073}. CC -!- INTERACTION: CC Q9UHC1; P40692: MLH1; NbExp=7; IntAct=EBI-3893094, EBI-744248; CC Q9UHC1-2; G5E9A7: DMWD; NbExp=3; IntAct=EBI-9089845, EBI-10976677; CC Q9UHC1-2; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-9089845, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9UHC1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UHC1-2; Sequence=VSP_003290; CC -!- TISSUE SPECIFICITY: Ubiquitous. CC -!- DISEASE: Hereditary non-polyposis colorectal cancer 7 (HNPCC7) CC [MIM:614385]: An autosomal dominant disease associated with marked CC increase in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. HNPCC is reported to be the most common form of CC inherited colorectal cancer in the Western world. Clinically, HNPCC is CC often divided into two subgroups. Type I is characterized by hereditary CC predisposition to colorectal cancer, a young age of onset, and CC carcinoma observed in the proximal colon. Type II is characterized by CC increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical HNPCC is based on the Amsterdam CC criteria: 3 or more relatives affected by colorectal cancer, one a CC first degree relative of the other two; 2 or more generation affected; CC 1 or more colorectal cancers presenting before 50 years of age; CC exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' CC or 'incomplete HNPCC' can be used to describe families who do not or CC only partially fulfill the Amsterdam criteria, but in whom a genetic CC basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:11586295}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:11317354}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC42005.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAC42005.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF195657; AAF23904.1; -; mRNA. DR EMBL; AF195658; AAF23905.1; -; Genomic_DNA. DR EMBL; AB039667; BAA92353.1; -; mRNA. DR EMBL; AY963685; AAX59030.1; -; Genomic_DNA. DR EMBL; AL049780; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L40399; AAC42005.1; ALT_SEQ; mRNA. DR CCDS; CCDS32123.1; -. [Q9UHC1-1] DR CCDS; CCDS9837.1; -. [Q9UHC1-2] DR RefSeq; NP_001035197.1; NM_001040108.2. [Q9UHC1-1] DR RefSeq; NP_055196.2; NM_014381.3. [Q9UHC1-2] DR RefSeq; XP_006720179.1; XM_006720116.5. [Q9UHC1-1] DR RefSeq; XP_016876708.1; XM_017021219.3. [Q9UHC1-2] DR AlphaFoldDB; Q9UHC1; -. DR SMR; Q9UHC1; -. DR BioGRID; 117961; 62. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR FunCoup; Q9UHC1; 1826. DR IntAct; Q9UHC1; 48. DR MINT; Q9UHC1; -. DR STRING; 9606.ENSP00000348020; -. DR CarbonylDB; Q9UHC1; -. DR GlyGen; Q9UHC1; 2 sites, 1 N-linked glycan (1 site). DR iPTMnet; Q9UHC1; -. DR PhosphoSitePlus; Q9UHC1; -. DR BioMuta; MLH3; -. DR DMDM; 317373417; -. DR jPOST; Q9UHC1; -. DR MassIVE; Q9UHC1; -. DR PaxDb; 9606-ENSP00000348020; -. DR PeptideAtlas; Q9UHC1; -. DR ProteomicsDB; 84305; -. [Q9UHC1-1] DR ProteomicsDB; 84306; -. [Q9UHC1-2] DR Antibodypedia; 25763; 155 antibodies from 27 providers. DR DNASU; 27030; -. DR Ensembl; ENST00000355774.7; ENSP00000348020.2; ENSG00000119684.17. [Q9UHC1-1] DR Ensembl; ENST00000380968.6; ENSP00000370355.3; ENSG00000119684.17. [Q9UHC1-2] DR GeneID; 27030; -. DR KEGG; hsa:27030; -. DR MANE-Select; ENST00000355774.7; ENSP00000348020.2; NM_001040108.2; NP_001035197.1. DR UCSC; uc001xrd.1; human. [Q9UHC1-1] DR AGR; HGNC:7128; -. DR ClinPGx; PA30845; -. DR CTD; 27030; -. DR DisGeNET; 27030; -. DR GeneCards; MLH3; -. DR HGNC; HGNC:7128; MLH3. DR HPA; ENSG00000119684; Low tissue specificity. DR MalaCards; MLH3; -. DR MIM; 114500; phenotype. DR MIM; 604395; gene. DR MIM; 614385; phenotype. DR OpenTargets; ENSG00000119684; -. DR VEuPathDB; HostDB:ENSG00000119684; -. DR eggNOG; KOG1977; Eukaryota. DR GeneTree; ENSGT00800000124176; -. DR HOGENOM; CLU_002376_0_0_1; -. DR InParanoid; Q9UHC1; -. DR OMA; HIGREGH; -. DR OrthoDB; 429932at2759; -. DR PAN-GO; Q9UHC1; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHC1; -. DR PathwayCommons; Q9UHC1; -. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; Q9UHC1; -. DR Agora; ENSG00000119684; -. DR BioGRID-ORCS; 27030; 15 hits in 1154 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH3; human. DR GeneWiki; MLH3; -. DR GenomeRNAi; 27030; -. DR Pharos; Q9UHC1; Tbio. DR PRO; PR:Q9UHC1; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q9UHC1; protein. DR Bgee; ENSG00000119684; Expressed in monocyte and 191 other cell types or tissues. DR ExpressionAtlas; Q9UHC1; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0032300; C:mismatch repair complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0019237; F:centromeric DNA binding; IEA:Ensembl. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0030983; F:mismatched DNA binding; IEA:InterPro. DR GO; GO:0003696; F:satellite DNA binding; TAS:ProtInc. DR GO; GO:0007144; P:female meiosis I; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IBA:GO_Central. DR GO; GO:0007131; P:reciprocal meiotic recombination; NAS:UniProtKB. DR GO; GO:0007130; P:synaptonemal complex assembly; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03486; MutL_Trans_MLH3; 1. DR FunFam; 3.30.1370.100:FF:000003; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.230.10:FF:000028; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.565.10:FF:000031; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.1540.20:FF:000005; MutL homolog 3; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR Gene3D; 3.30.1540.20; MutL, C-terminal domain, dimerisation subdomain; 1. DR Gene3D; 3.30.1370.100; MutL, C-terminal domain, regulatory subdomain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR014790; MutL_C. DR InterPro; IPR042120; MutL_C_dimsub. DR InterPro; IPR042121; MutL_C_regsub. DR InterPro; IPR037198; MutL_C_sf. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF47; DNA MISMATCH REPAIR PROTEIN MLH3; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF08676; MutL_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SMART; SM00853; MutL_C; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF118116; DNA mismatch repair protein MutL; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW Alternative splicing; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleus; KW Proteomics identification; Reference proteome. FT CHAIN 1..1453 FT /note="DNA mismatch repair protein Mlh3" FT /id="PRO_0000178003" FT REGION 624..650 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 933..960 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 935..944 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 945..960 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 1215..1238 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_003290" FT VARIANT 24 FT /note="Q -> E (in HNPCC7; dbSNP:rs28937870)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012946" FT VARIANT 93 FT /note="R -> G (in dbSNP:rs28756978)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023338" FT VARIANT 120 FT /note="F -> S (in dbSNP:rs28756979)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023339" FT VARIANT 231 FT /note="K -> Q (in dbSNP:rs28756981)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023340" FT VARIANT 420 FT /note="V -> I (in dbSNP:rs28756982)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023341" FT VARIANT 492 FT /note="L -> V (in dbSNP:rs28756983)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023342" FT VARIANT 494 FT /note="H -> R (in dbSNP:rs760778201)" FT /id="VAR_010790" FT VARIANT 499 FT /note="N -> S (in HNPCC7; dbSNP:rs28937871)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012947" FT VARIANT 600 FT /note="R -> Q (in dbSNP:rs28756984)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023343" FT VARIANT 606 FT /note="T -> P (in dbSNP:rs28756985)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023344" FT VARIANT 624 FT /note="E -> Q (in HNPCC7; dbSNP:rs28756986)" FT /evidence="ECO:0000269|PubMed:11586295, ECO:0000269|Ref.3" FT /id="VAR_012948" FT VARIANT 647 FT /note="R -> C (in HNPCC7; dbSNP:rs28756987)" FT /evidence="ECO:0000269|PubMed:11586295, ECO:0000269|Ref.3" FT /id="VAR_012949" FT VARIANT 720 FT /note="Y -> C (in dbSNP:rs28756988)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023345" FT VARIANT 723 FT /note="V -> I (in dbSNP:rs28756989)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023346" FT VARIANT 741 FT /note="V -> F (in dbSNP:rs28756990)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023347" FT VARIANT 797 FT /note="R -> H (in dbSNP:rs28756991)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023348" FT VARIANT 817 FT /note="S -> G (in HNPCC7; dbSNP:rs143278116)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012950" FT VARIANT 826 FT /note="N -> D (in dbSNP:rs175081)" FT /evidence="ECO:0000269|PubMed:10615123, FT ECO:0000269|PubMed:11292842, ECO:0000269|Ref.3" FT /id="VAR_036781" FT VARIANT 844 FT /note="P -> L (in dbSNP:rs175080)" FT /evidence="ECO:0000269|PubMed:10615123, ECO:0000269|Ref.3" FT /id="VAR_023349" FT VARIANT 845 FT /note="S -> G (in dbSNP:rs28756992)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023350" FT VARIANT 942 FT /note="T -> I (in dbSNP:rs17102999)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023351" FT VARIANT 966 FT /note="S -> P (in dbSNP:rs17782839)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023352" FT VARIANT 981 FT /note="G -> S (in HNPCC7; dbSNP:rs377337763)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012951" FT VARIANT 1007 FT /note="N -> S (in HNPCC7; dbSNP:rs776639203)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012952" FT VARIANT 1073 FT /note="D -> N (in dbSNP:rs28756993)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023353" FT VARIANT 1105 FT /note="D -> E (in dbSNP:rs28757008)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023354" FT VARIANT 1163 FT /note="G -> D (in dbSNP:rs28757011)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023355" FT VARIANT 1319 FT /note="G -> R (in dbSNP:rs2139384512)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023356" FT VARIANT 1394 FT /note="A -> T (in HNPCC7; dbSNP:rs138006166)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012953" FT VARIANT 1451 FT /note="E -> K (in HNPCC7; dbSNP:rs28939071)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012954" SQ SEQUENCE 1453 AA; 163711 MW; 3D063427457DB033 CRC64; MIKCLSVEVQ AKLRSGLAIS SLGQCVEELA LNSIDAEAKC VAVRVNMETF QVQVIDNGFG MGSDDVEKVG NRYFTSKCHS VQDLENPRFY GFRGEALANI ADMASAVEIS SKKNRTMKTF VKLFQSGKAL KACEADVTRA SAGTTVTVYN LFYQLPVRRK CMDPRLEFEK VRQRIEALSL MHPSISFSLR NDVSGSMVLQ LPKTKDVCSR FCQIYGLGKS QKLREISFKY KEFELSGYIS SEAHYNKNMQ FLFVNKRLVL RTKLHKLIDF LLRKESIICK PKNGPTSRQM NSSLRHRSTP ELYGIYVINV QCQFCEYDVC MEPAKTLIEF QNWDTLLFCI QEGVKMFLKQ EKLFVELSGE DIKEFSEDNG FSLFDATLQK RVTSDERSNF QEACNNILDS YEMFNLQSKA VKRKTTAENV NTQSSRDSEA TRKNTNDAFL YIYESGGPGH SKMTEPSLQN KDSSCSESKM LEQETIVASE AGENEKHKKS FLEHSSLENP CGTSLEMFLS PFQTPCHFEE SGQDLEIWKE STTVNGMAAN ILKNNRIQNQ PKRFKDATEV GCQPLPFATT LWGVHSAQTE KEKKKESSNC GRRNVFSYGR VKLCSTGFIT HVVQNEKTKS TETEHSFKNY VRPGPTRAQE TFGNRTRHSV ETPDIKDLAS TLSKESGQLP NKKNCRTNIS YGLENEPTAT YTMFSAFQEG SKKSQTDCIL SDTSPSFPWY RHVSNDSRKT DKLIGFSKPI VRKKLSLSSQ LGSLEKFKRQ YGKVENPLDT EVEESNGVTT NLSLQVEPDI LLKDKNRLEN SDVCKITTME HSDSDSSCQP ASHILNSEKF PFSKDEDCLE QQMPSLRESP MTLKELSLFN RKPLDLEKSS ESLASKLSRL KGSERETQTM GMMSRFNELP NSDSSRKDSK LCSVLTQDFC MLFNNKHEKT ENGVIPTSDS ATQDNSFNKN SKTHSNSNTT ENCVISETPL VLPYNNSKVT GKDSDVLIRA SEQQIGSLDS PSGMLMNPVE DATGDQNGIC FQSEESKARA CSETEESNTC CSDWQRHFDV ALGRMVYVNK MTGLSTFIAP TEDIQAACTK DLTTVAVDVV LENGSQYRCQ PFRSDLVLPF LPRARAERTV MRQDNRDTVD DTVSSESLQS LFSEWDNPVF ARYPEVAVDV SSGQAESLAV KIHNILYPYR FTKGMIHSMQ VLQQVDNKFI ACLMSTKTEE NGEAGGNLLV LVDQHAAHER IRLEQLIIDS YEKQQAQGSG RKKLLSSTLI PPLEITVTEE QRRLLWCYHK NLEDLGLEFV FPDTSDSLVL VGKVPLCFVE REANELRRGR STVTKSIVEE FIREQLELLQ TTGGIQGTLP LTVQKVLASQ ACHGAIKFND GLSLQESCRL IEALSSCQLP FQCAHGRPSM LPLADIDHLE QEKQIKPNLT KLRKMAQAWR LFGKAECDTR QSLQQSMPPC EPP // ID MLKL_HUMAN Reviewed; 471 AA. AC Q8NB16; A6NCE4; Q8N6V0; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 28-JAN-2026, entry version 185. DE RecName: Full=Mixed lineage kinase domain-like protein {ECO:0000305}; DE Short=hMLKL {ECO:0000303|PubMed:12471243}; GN Name=MLKL {ECO:0000303|PubMed:22265413, ECO:0000312|HGNC:HGNC:26617}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND NOMENCLATURE. RX PubMed=12471243; DOI=10.1126/science.1075762; RA Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S.; RT "The protein kinase complement of the human genome."; RL Science 298:1912-1934(2002). RN [2] {ECO:0000305, ECO:0000312|EMBL:BAC03728.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Chondrocyte {ECO:0000312|EMBL:BAC03728.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [4] {ECO:0000305, ECO:0000312|EMBL:AAH28141.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Leukocyte {ECO:0000312|EMBL:AAH28141.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP FUNCTION, INTERACTION WITH RIPK3, ACTIVITY REGULATION, PHOSPHORYLATION AT RP THR-357 AND SER-358, AND MUTAGENESIS OF CYS-86; THR-357 AND SER-358. RX PubMed=22265413; DOI=10.1016/j.cell.2011.11.031; RA Sun L., Wang H., Wang Z., He S., Chen S., Liao D., Wang L., Yan J., Liu W., RA Lei X., Wang X.; RT "Mixed lineage kinase domain-like protein mediates necrosis signaling RT downstream of RIP3 kinase."; RL Cell 148:213-227(2012). RN [11] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK1 AND RIPK3. RX PubMed=22265414; DOI=10.1016/j.cell.2011.11.030; RA Wang Z., Jiang H., Chen S., Du F., Wang X.; RT "The mitochondrial phosphatase PGAM5 functions at the convergence point of RT multiple necrotic death pathways."; RL Cell 148:228-243(2012). RN [12] RP FUNCTION, AND INTERACTION WITH RIPK3. RX PubMed=22421439; DOI=10.1073/pnas.1200012109; RA Zhao J., Jitkaew S., Cai Z., Choksi S., Li Q., Luo J., Liu Z.G.; RT "Mixed lineage kinase domain-like is a key receptor interacting protein 3 RT downstream component of TNF-induced necrosis."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5322-5327(2012). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF LEU-58; ILE-76; RP LEU-162 AND LEU-165. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [14] RP INTERACTION WITH RIPK3. RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016; RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K., RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.; RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent RT proteasomal degradation."; RL Mol. Cell 70:920-935(2018). RN [15] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-358, SUBUNIT, REGION RP NBB, AND SUBCELLULAR LOCATION. RX PubMed=29883610; DOI=10.1016/j.molcel.2018.05.010; RA Dovey C.M., Diep J., Clarke B.P., Hale A.T., McNamara D.E., Guo H., RA Brown N.W. Jr., Cao J.Y., Grace C.R., Gough P.J., Bertin J., Dixon S.J., RA Fiedler D., Mocarski E.S., Kaiser W.J., Moldoveanu T., York J.D., RA Carette J.E.; RT "MLKL requires the inositol phosphate code to execute necroptosis."; RL Mol. Cell 70:936-948(2018). RN [16] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 189-471, ATP-BINDING, AND RP MUTAGENESIS OF LYS-230; LYS-331 AND GLU-351. RX PubMed=24219132; DOI=10.1042/bj20131270; RA Murphy J.M., Lucet I.S., Hildebrand J.M., Tanzer M.C., Young S.N., RA Sharma P., Lessene G., Alexander W.S., Babon J.J., Silke J., Czabotar P.E.; RT "Insights into the evolution of divergent nucleotide-binding mechanisms RT among pseudokinases revealed by crystal structures of human and mouse RT MLKL."; RL Biochem. J. 457:369-377(2014). RN [17] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 179-471. RX PubMed=24095729; DOI=10.1016/j.celrep.2013.08.044; RA Xie T., Peng W., Yan C., Wu J., Gong X., Shi Y.; RT "Structural insights into RIP3-mediated necroptotic signaling."; RL Cell Rep. 5:70-78(2013). RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] THR-52; GLU-100; PRO-132; GLN-146; LEU-169; RP PRO-291; MET-364; ILE-398 AND HIS-421. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Pseudokinase that plays a key role in TNF-induced CC necroptosis, a programmed cell death process (PubMed:22265413, CC PubMed:22265414, PubMed:22421439, PubMed:24316671). Does not have CC protein kinase activity (PubMed:22265413, PubMed:22265414, CC PubMed:22421439, PubMed:24316671). Activated following phosphorylation CC by RIPK3, leading to homotrimerization, localization to the plasma CC membrane and execution of programmed necrosis characterized by calcium CC influx and plasma membrane damage (PubMed:22265413, PubMed:22265414, CC PubMed:22421439, PubMed:24316671). In addition to TNF-induced CC necroptosis, necroptosis can also take place in the nucleus in response CC to orthomyxoviruses infection: following activation by ZBP1, MLKL is CC phosphorylated by RIPK3 in the nucleus, triggering disruption of the CC nuclear envelope and leakage of cellular DNA into the cytosol.following CC ZBP1 activation, which senses double-stranded Z-RNA structures, nuclear CC RIPK3 catalyzes phosphorylation and activation of MLKL, promoting CC disruption of the nuclear envelope and leakage of cellular DNA into the CC cytosol (By similarity). Binds to highly phosphorylated inositol CC phosphates such as inositolhexakisphosphate (InsP6) which is essential CC for its necroptotic function (PubMed:29883610). CC {ECO:0000250|UniProtKB:Q9D2Y4, ECO:0000269|PubMed:22265413, CC ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:22421439, CC ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883610}. CC -!- ACTIVITY REGULATION: Activated via binding to highly phosphorylated CC inositol phosphates such as inositolhexakisphosphate (InsP6) which CC mediates the release of an N-terminal auto-inhibitory region CC (PubMed:29883610). Activation requires not only RIPK3-dependent CC phosphorylation but also binding to highly phosphorylated inositol CC phosphates (PubMed:29883610). Inhibited by necrosulfonamide, a specific CC inhibitor of necroptosis that targets Cys-86 (PubMed:22265413). CC {ECO:0000269|PubMed:22265413, ECO:0000269|PubMed:29883610}. CC -!- SUBUNIT: Homooligomer (PubMed:29883610). Homotrimer; forms homotrimers CC on necroptosis induction (PubMed:24316671). Upon TNF-induced necrosis, CC forms in complex with PGAM5, RIPK1 and RIPK3 (PubMed:22265414). Within CC this complex, may play a role in the proper targeting of RIPK1-RIPK3 to CC its downstream effector PGAM5 (PubMed:22265414). Interacts with RIPK3; CC the interaction is direct and promotes its phosphorylation and CC subsequent activation (PubMed:22265413, PubMed:22421439, CC PubMed:29883609). {ECO:0000269|PubMed:22265413, CC ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:22421439, CC ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883609, CC ECO:0000269|PubMed:29883610}. CC -!- INTERACTION: CC Q8NB16; Q9Y572: RIPK3; NbExp=10; IntAct=EBI-1055040, EBI-298250; CC Q8NB16-1; Q8NB16-1: MLKL; NbExp=2; IntAct=EBI-16084674, EBI-16084674; CC Q8NB16-2; P20618: PSMB1; NbExp=3; IntAct=EBI-19046912, EBI-372273; CC Q8NB16-2; P60903: S100A10; NbExp=3; IntAct=EBI-19046912, EBI-717048; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24316671}. Cell CC membrane {ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883610}. CC Nucleus {ECO:0000250|UniProtKB:Q9D2Y4}. Note=Localizes to the cytoplasm CC and translocates to the plasma membrane on necroptosis induction CC (PubMed:24316671). Localizes to the nucleus in response to CC orthomyxoviruses infection (By similarity). CC {ECO:0000250|UniProtKB:Q9D2Y4, ECO:0000269|PubMed:24316671}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000303|PubMed:12471243, ECO:0000303|PubMed:14702039}; CC IsoId=Q8NB16-1; Sequence=Displayed; CC Name=2 {ECO:0000303|PubMed:15489334}; CC IsoId=Q8NB16-2; Sequence=VSP_052133, VSP_052134; CC -!- DOMAIN: The protein kinase domain is catalytically inactive but CC contains an unusual pseudoactive site with an interaction between Lys- CC 230 and Gln-356 residues (By similarity). Upon phosphorylation by CC RIPK3, undergoes an active conformation (By similarity). CC {ECO:0000250|UniProtKB:Q9D2Y4}. CC -!- DOMAIN: The coiled coil region 2 is responsible for homotrimerization. CC {ECO:0000269|PubMed:24316671}. CC -!- PTM: Phosphorylation by RIPK3 induces a conformational switch that is CC required for necroptosis (PubMed:22265413). It also induces CC homotrimerization and localization to the plasma membrane CC (PubMed:22265413). {ECO:0000269|PubMed:22265413}. CC -!- MISCELLANEOUS: Interaction with RIPK3 is species specific: human MLKL CC only interacts with human RIPK3 and not mouse RIPK3. CC {ECO:0000305|PubMed:22265413}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK091708; BAC03728.1; -; mRNA. DR EMBL; AC109599; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC028141; AAH28141.1; -; mRNA. DR CCDS; CCDS32487.1; -. [Q8NB16-1] DR CCDS; CCDS45528.1; -. [Q8NB16-2] DR RefSeq; NP_001135969.1; NM_001142497.3. [Q8NB16-2] DR RefSeq; NP_689862.1; NM_152649.4. [Q8NB16-1] DR RefSeq; XP_005255891.1; XM_005255834.5. [Q8NB16-1] DR RefSeq; XP_054235719.1; XM_054379744.1. [Q8NB16-1] DR PDB; 2MSV; NMR; -; A=1-154. DR PDB; 4M67; X-ray; 1.90 A; A=179-471. DR PDB; 4MWI; X-ray; 1.70 A; A=183-471. DR PDB; 5KNJ; X-ray; 2.88 A; A/B=191-471. DR PDB; 5KO1; X-ray; 2.16 A; A=191-471. DR PDB; 6BWK; X-ray; 2.79 A; A=190-471. DR PDB; 6D74; NMR; -; A=1-156. DR PDB; 6LK5; X-ray; 2.50 A; A=1-471. DR PDB; 6LK6; X-ray; 2.41 A; A=179-471. DR PDB; 6O5Z; X-ray; 2.29 A; A/B=190-471. DR PDB; 6UX8; X-ray; 2.50 A; A=5-154. DR PDB; 6ZLE; NMR; -; A=2-154. DR PDB; 6ZPR; NMR; -; A=2-154. DR PDB; 6ZVO; X-ray; 1.37 A; A/B/C=2-150. DR PDB; 6ZZ1; X-ray; 1.64 A; A/B=2-150. DR PDB; 7JW7; X-ray; 2.63 A; A=190-471. DR PDB; 7JXU; X-ray; 2.44 A; A/B=190-471. DR PDB; 7MON; X-ray; 2.23 A; A=190-471. DR PDB; 7NM2; NMR; -; A=2-154. DR PDB; 7NM4; NMR; -; A=2-154. DR PDB; 7NM5; NMR; -; A=2-154. DR PDB; 8SLZ; X-ray; 2.30 A; A=190-471. DR PDBsum; 2MSV; -. DR PDBsum; 4M67; -. DR PDBsum; 4MWI; -. DR PDBsum; 5KNJ; -. DR PDBsum; 5KO1; -. DR PDBsum; 6BWK; -. DR PDBsum; 6D74; -. DR PDBsum; 6LK5; -. DR PDBsum; 6LK6; -. DR PDBsum; 6O5Z; -. DR PDBsum; 6UX8; -. DR PDBsum; 6ZLE; -. DR PDBsum; 6ZPR; -. DR PDBsum; 6ZVO; -. DR PDBsum; 6ZZ1; -. DR PDBsum; 7JW7; -. DR PDBsum; 7JXU; -. DR PDBsum; 7MON; -. DR PDBsum; 7NM2; -. DR PDBsum; 7NM4; -. DR PDBsum; 7NM5; -. DR PDBsum; 8SLZ; -. DR AlphaFoldDB; Q8NB16; -. DR BMRB; Q8NB16; -. DR SMR; Q8NB16; -. DR BioGRID; 128244; 57. DR CORUM; Q8NB16; -. DR DIP; DIP-41782N; -. DR FunCoup; Q8NB16; 497. DR IntAct; Q8NB16; 25. DR MINT; Q8NB16; -. DR STRING; 9606.ENSP00000308351; -. DR BindingDB; Q8NB16; -. DR ChEMBL; CHEMBL1938217; -. DR DrugCentral; Q8NB16; -. DR GuidetoPHARMACOLOGY; 2106; -. DR TCDB; 1.A.105.1.1; the mixed lineage kinase domain-like (mlkl) family. DR GlyCosmos; Q8NB16; 4 sites, 1 glycan. DR GlyGen; Q8NB16; 4 sites, 1 O-linked glycan (4 sites). DR iPTMnet; Q8NB16; -. DR PhosphoSitePlus; Q8NB16; -. DR SwissPalm; Q8NB16; -. DR BioMuta; MLKL; -. DR DMDM; 74762545; -. DR CPTAC; CPTAC-895; -. DR CPTAC; CPTAC-896; -. DR jPOST; Q8NB16; -. DR MassIVE; Q8NB16; -. DR PaxDb; 9606-ENSP00000308351; -. DR PeptideAtlas; Q8NB16; -. DR ProteomicsDB; 72718; -. [Q8NB16-1] DR ProteomicsDB; 72719; -. [Q8NB16-2] DR Pumba; Q8NB16; -. DR ABCD; Q8NB16; 4 sequenced antibodies. DR Antibodypedia; 2097; 400 antibodies from 40 providers. DR DNASU; 197259; -. DR Ensembl; ENST00000306247.11; ENSP00000303118.7; ENSG00000168404.14. [Q8NB16-2] DR Ensembl; ENST00000308807.12; ENSP00000308351.7; ENSG00000168404.14. [Q8NB16-1] DR GeneID; 197259; -. DR KEGG; hsa:197259; -. DR MANE-Select; ENST00000308807.12; ENSP00000308351.7; NM_152649.4; NP_689862.1. DR UCSC; uc002fdb.3; human. [Q8NB16-1] DR AGR; HGNC:26617; -. DR ClinPGx; PA142671349; -. DR CTD; 197259; -. DR DisGeNET; 197259; -. DR GeneCards; MLKL; -. DR HGNC; HGNC:26617; MLKL. DR HPA; ENSG00000168404; Low tissue specificity. DR MalaCards; MLKL; -. DR MIM; 615153; gene. DR OpenTargets; ENSG00000168404; -. DR VEuPathDB; HostDB:ENSG00000168404; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00390000016453; -. DR HOGENOM; CLU_044216_0_0_1; -. DR InParanoid; Q8NB16; -. DR OMA; ESKVDWM; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q8NB16; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8NB16; -. DR PathwayCommons; Q8NB16; -. DR Reactome; R-HSA-3295583; TRP channels. DR Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-5675482; Regulation of necroptotic cell death. DR Reactome; R-HSA-9686347; Microbial modulation of RIPK1-mediated regulated necrosis. DR SignaLink; Q8NB16; -. DR SIGNOR; Q8NB16; -. DR Agora; ENSG00000168404; -. DR BioGRID-ORCS; 197259; 17 hits in 1193 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLKL; human. DR EvolutionaryTrace; Q8NB16; -. DR GenomeRNAi; 197259; -. DR Pharos; Q8NB16; Tchem. DR PRO; PR:Q8NB16; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q8NB16; protein. DR Bgee; ENSG00000168404; Expressed in granulocyte and 164 other cell types or tissues. DR ExpressionAtlas; Q8NB16; baseline and differential. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro. DR GO; GO:0051607; P:defense response to virus; ISS:UniProtKB. DR GO; GO:0097528; P:execution phase of necroptosis; IDA:UniProt. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0097527; P:necroptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0070207; P:protein homotrimerization; IDA:UniProtKB. DR CDD; cd21037; MLKL_NTD; 1. DR FunFam; 1.10.510.10:FF:000663; Mixed lineage kinase domain-like pseudokinase; 1. DR FunFam; 1.20.930.20:FF:000005; Mixed lineage kinase domain-like pseudokinase; 1. DR FunFam; 3.30.200.20:FF:000437; Mixed lineage kinase domain-like pseudokinase; 1. DR Gene3D; 1.20.930.20; Adaptor protein Cbl, N-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR036537; Adaptor_Cbl_N_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR059179; MLKL-like_MCAfunc. DR InterPro; IPR054000; MLKL_N. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR PANTHER; PTHR44329:SF298; MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF22215; MLKL_N; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Coiled coil; Cytoplasm; Membrane; Necrosis; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..471 FT /note="Mixed lineage kinase domain-like protein" FT /id="PRO_0000248239" FT DOMAIN 194..469 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..149 FT /note="N-terminal bundle and brace (NBB); mediates INSP6 FT binding" FT /evidence="ECO:0000269|PubMed:29883610" FT COILED 55..84 FT /evidence="ECO:0000255" FT COILED 139..180 FT /evidence="ECO:0000255" FT BINDING 209..217 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 230 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 86 FT /note="Target of necrosulfonamide inhibitor" FT /evidence="ECO:0000269|PubMed:22265413" FT MOD_RES 125 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976" FT MOD_RES 357 FT /note="Phosphothreonine; by RIPK3" FT /evidence="ECO:0000269|PubMed:22265413" FT MOD_RES 358 FT /note="Phosphoserine; by RIPK3" FT /evidence="ECO:0000269|PubMed:22265413, FT ECO:0000269|PubMed:29883610" FT MOD_RES 360 FT /note="Phosphoserine; by RIPK3" FT /evidence="ECO:0000250|UniProtKB:Q9D2Y4" FT VAR_SEQ 179..205 FT /note="YLPPKCMQEIPQEQIKEIKKEQLSGSP -> SLESSSGKSPLEISRFKVKNV FT KTGSAS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_052133" FT VAR_SEQ 206..413 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_052134" FT VARIANT 52 FT /note="S -> T (in dbSNP:rs34251827)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041350" FT VARIANT 100 FT /note="D -> E (in dbSNP:rs33987771)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041351" FT VARIANT 132 FT /note="S -> P (in dbSNP:rs35589326)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041352" FT VARIANT 146 FT /note="R -> Q (in dbSNP:rs34515646)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041353" FT VARIANT 169 FT /note="M -> L (in dbSNP:rs55929310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041354" FT VARIANT 291 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1313508921)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041355" FT VARIANT 364 FT /note="T -> M (in dbSNP:rs34389205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041356" FT VARIANT 398 FT /note="F -> I (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041357" FT VARIANT 421 FT /note="R -> H (in dbSNP:rs55987292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041358" FT MUTAGEN 58 FT /note="L->G: Does not affect formation of homotrimers, FT while translocation to the plasma membrane on necroptosis FT induction is impaired; when associated with G-76." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 76 FT /note="I->G: Does not affect formation of homotrimers, FT while translocation to the plasma membrane on necroptosis FT induction is impaired; when associated with G-58." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 86 FT /note="C->S: Abolishes binding to necrosulfonamide FT inhibitor." FT /evidence="ECO:0000269|PubMed:22265413" FT MUTAGEN 162 FT /note="L->G: Impairs formation of homotrimers and FT translocation to the plasma membrane on necroptosis FT induction; when associated with G-165." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 165 FT /note="L->G: Impairs formation of homotrimers and FT translocation to the plasma membrane on necroptosis FT induction; when associated with G-162." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 230 FT /note="K->M: Abolishes ATP-binding." FT /evidence="ECO:0000269|PubMed:24219132" FT MUTAGEN 331 FT /note="K->N: Impairs ATP-binding." FT /evidence="ECO:0000269|PubMed:24219132" FT MUTAGEN 351 FT /note="E->K: Binds ATP with an enhanced affinity." FT /evidence="ECO:0000269|PubMed:24219132" FT MUTAGEN 357..358 FT /note="TS->ED: Mimics phosphorylation state; acts as a FT dominant-negative mutant that impairs necroptosis." FT MUTAGEN 357 FT /note="T->A: No effect. Abolishes ability to mediate FT necroptosis; when associated with A-358." FT /evidence="ECO:0000269|PubMed:22265413" FT MUTAGEN 358 FT /note="S->A: No effect. Abolishes ability to mediate FT necroptosis; when associated with A-357." FT /evidence="ECO:0000269|PubMed:22265413" FT HELIX 2..20 FT /evidence="ECO:0007829|PDB:6ZVO" FT STRAND 22..24 FT /evidence="ECO:0007829|PDB:6ZZ1" FT HELIX 25..46 FT /evidence="ECO:0007829|PDB:6ZVO" FT HELIX 56..79 FT /evidence="ECO:0007829|PDB:6ZVO" FT HELIX 82..90 FT /evidence="ECO:0007829|PDB:6ZVO" FT STRAND 93..96 FT /evidence="ECO:0007829|PDB:2MSV" FT HELIX 99..120 FT /evidence="ECO:0007829|PDB:6ZVO" FT TURN 128..132 FT /evidence="ECO:0007829|PDB:2MSV" FT HELIX 133..148 FT /evidence="ECO:0007829|PDB:6ZVO" FT HELIX 198..201 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 202..204 FT /evidence="ECO:0007829|PDB:6O5Z" FT STRAND 207..211 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 213..222 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 225..232 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 240..256 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 265..271 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 274..276 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 278..284 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 291..297 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 303..322 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 337..339 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 349..352 FT /evidence="ECO:0007829|PDB:7MON" FT HELIX 353..359 FT /evidence="ECO:0007829|PDB:7MON" FT TURN 360..362 FT /evidence="ECO:0007829|PDB:7JXU" FT HELIX 373..376 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 379..383 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 391..407 FT /evidence="ECO:0007829|PDB:4MWI" FT TURN 411..414 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 417..425 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 435..437 FT /evidence="ECO:0007829|PDB:6O5Z" FT HELIX 439..448 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 453..455 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 459..467 FT /evidence="ECO:0007829|PDB:4MWI" SQ SEQUENCE 471 AA; 54479 MW; 005E7F7AB6D20649 CRC64; MENLKHIITL GQVIHKRCEE MKYCKKQCRR LGHRVLGLIK PLEMLQDQGK RSVPSEKLTT AMNRFKAALE EANGEIEKFS NRSNICRFLT ASQDKILFKD VNRKLSDVWK ELSLLLQVEQ RMPVSPISQG ASWAQEDQQD ADEDRRAFQM LRRDNEKIEA SLRRLEINMK EIKETLRQYL PPKCMQEIPQ EQIKEIKKEQ LSGSPWILLR ENEVSTLYKG EYHRAPVAIK VFKKLQAGSI AIVRQTFNKE IKTMKKFESP NILRIFGICI DETVTPPQFS IVMEYCELGT LRELLDREKD LTLGKRMVLV LGAARGLYRL HHSEAPELHG KIRSSNFLVT QGYQVKLAGF ELRKTQTSMS LGTTREKTDR VKSTAYLSPQ ELEDVFYQYD VKSEIYSFGI VLWEIATGDI PFQGCNSEKI RKLVAVKRQQ EPLGEDCPSE LREIIDECRA HDPSVRPSVD EILKKLSTFS K // ID MSH2_HUMAN Reviewed; 934 AA. AC P43246; B4E2Z2; O75488; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 255. DE RecName: Full=DNA mismatch repair protein Msh2; DE Short=hMSH2; DE AltName: Full=MutS protein homolog 2; GN Name=MSH2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8252616; DOI=10.1016/0092-8674(93)90546-3; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RT "The human mutator gene homolog MSH2 and its association with hereditary RT nonpolyposis colon cancer."; RL Cell 75:1027-1038(1993). RN [2] RP ERRATUM OF PUBMED:8252616. RX PubMed=8156592; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RL Cell 77:167-167(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LYNCH1 LEU-622 AND RP TYR-639. RX PubMed=8261515; DOI=10.1016/0092-8674(93)90330-s; RA Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Jen J., Parsons R., RA Peltomaeki P., Sistonen P., Aaltonen L.A., Nystroem-Lahti M., Guan X.-Y., RA Zhang J., Meltzer P.S., Yu J.-W., Kao F.-T., Chen D.J., Cerosaletti K.M., RA Fournier R.E.K., Todd S., Lewis T., Leach R.J., Naylor S.L., RA Weissenbach J., Mecklin J.-P., Jaervinen H., Petersen G.M., Hamilton S.R., RA Green J., Jass J., Watson P., Lynch H.T., Trent J.M., de la Chapelle A., RA Kinzler K.W., Vogelstein B.; RT "Mutations of a mutS homolog in hereditary nonpolyposis colorectal RT cancer."; RL Cell 75:1215-1225(1993). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN MRTES. RX PubMed=7713503; DOI=10.1006/geno.1994.1661; RA Kolodner R.D., Hall N.R., Lipford J., Kane M.F., Rao M.R.S., Morrison P., RA Wirth L., Finan P.J., Burn J., Chapman P., Earabino C., Merchant E., RA Bishop D.T.; RT "Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds RT for msh2 mutations."; RL Genomics 24:516-526(1994). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-96. RX PubMed=7726159; RA Wijnen J., Vasen H., Khan P.M., Menko F.H., van der Klift H., RA van Leeuwen C., van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer A., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Fodde R.; RT "Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing RT gradient-gel electrophoresis."; RL Am. J. Hum. Genet. 56:1060-1066(1995). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-8; CYS-43; SER-127; RP ASP-322 AND PHE-390. RG NIEHS SNPs program; RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 375-425. RC TISSUE=Blood; RA Corvello C.M., Bevilacqua R.A.U., Rossi B.M., Simpson A.J.G.; RT "A novel germline mutation at exon 7 of the hMSH2 gene (417 del G) in a RT large HNPCC Brazilian kindred."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [12] RP DNA-BINDING. RX PubMed=7923193; RA Fishel R., Ewel A., Lescoe M.K.; RT "Purified human MSH2 protein binds to DNA containing mismatched RT nucleotides."; RL Cancer Res. 54:5539-5542(1994). RN [13] RP DNA-BINDING. RX PubMed=8769132; DOI=10.1006/bbrc.1996.1168; RA Whitehouse A., Taylor G.R., Deeble J., Phillips S.E., Meredith D.M., RA Markham A.F.; RT "A carboxy terminal domain of the hMSH-2 gene product is sufficient for RT binding specific mismatched oligonucleotides."; RL Biochem. Biophys. Res. Commun. 225:289-295(1996). RN [14] RP INTERACTION WITH MSH3 AND MSH6. RX PubMed=8942985; DOI=10.1073/pnas.93.24.13629; RA Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., RA Kolodner R.D., Fishel R.; RT "hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6."; RL Proc. Natl. Acad. Sci. U.S.A. 93:13629-13634(1996). RN [15] RP INTERACTION WITH EXO1. RX PubMed=9788596; RA Schmutte C., Marinescu R.C., Sadoff M.M., Guerrette S., Overhauser J., RA Fishel R.; RT "Human exonuclease I interacts with the mismatch repair protein hMSH2."; RL Cancer Res. 58:4537-4542(1998). RN [16] RP FUNCTION. RX PubMed=9822680; DOI=10.1074/jbc.273.48.32055; RA Blackwell L.J., Martik D., Bjornson K.P., Bjornson E.S., Modrich P.; RT "Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is RT consistent with an ATP-dependent translocation mechanism."; RL J. Biol. Chem. 273:32055-32062(1998). RN [17] RP FUNCTION. RX PubMed=9822679; DOI=10.1074/jbc.273.48.32049; RA Blackwell L.J., Bjornson K.P., Modrich P.; RT "DNA-dependent activation of the hMutSalpha ATPase."; RL J. Biol. Chem. 273:32049-32054(1998). RN [18] RP FUNCTION, AND MUTAGENESIS OF LYS-675. RX PubMed=9564049; DOI=10.1093/emboj/17.9.2677; RA Iaccarino I., Marra G., Palombo F., Jiricny J.; RT "hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute RT differently to the ATPase activity of hMutSalpha."; RL EMBO J. 17:2677-2686(1998). RN [19] RP MISMATCH-BINDING, AND CHARACTERIZATION OF VARIANT LYNCH1 PRO-524. RX PubMed=9889267; DOI=10.1093/nar/27.3.736; RA Clark A.B., Cook M.E., Tran H.T., Gordenin D.A., Resnick M.A., Kunkel T.A.; RT "Functional analysis of human MutSalpha and MutSbeta complexes in yeast."; RL Nucleic Acids Res. 27:736-742(1999). RN [20] RP FUNCTION. RX PubMed=10078208; DOI=10.1016/s1097-2765(00)80316-0; RA Gradia S., Subramanian D., Wilson T., Acharya S., Makhov A., Griffith J., RA Fishel R.; RT "hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched RT DNA."; RL Mol. Cell 3:255-261(1999). RN [21] RP IDENTIFICATION OF MSH2 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [22] RP INTERACTION WITH EXO1, AND TISSUE SPECIFICITY. RX PubMed=10856833; DOI=10.1016/s0921-8777(00)00012-4; RA Rasmussen L.J., Rasmussen M., Lee B.-I., Rasmussen A.K., Wilson D.M. III, RA Nielsen F.C., Bisgaard H.C.; RT "Identification of factors interacting with hMSH2 in the fetal liver RT utilizing the yeast two-hybrid system. In vivo interaction through the C- RT terminal domains of hEXO1 and hMSH2 and comparative expression analysis."; RL Mutat. Res. 460:41-52(2000). RN [23] RP FUNCTION. RX PubMed=10660545; DOI=10.1074/jbc.275.6.3922; RA Gradia S., Acharya S., Fishel R.; RT "The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular RT switch."; RL J. Biol. Chem. 275:3922-3930(2000). RN [24] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=11306449; RA Schweizer P., Moisio A.L., Kuismanen S.A., Truninger K., Vierumaeki R., RA Salovaara R., Arola J., Butzow R., Jiricny J., Peltomaeki P., RA Nystroem-Lahti M.; RT "Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas RT in hereditary nonpolyposis colorectal cancer."; RL Cancer Res. 61:2813-2815(2001). RN [25] RP INTERACTION WITH EXO1. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [26] RP INTERACTION WITH EXO1. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [27] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [28] RP INVOLVEMENT IN MMRCS2. RX PubMed=12549480; DOI=10.1086/345297; RA Bougeard G., Charbonnier F., Moerman A., Martin C., Ruchoux M.M., RA Drouot N., Frebourg T.; RT "Early onset brain tumor and lymphoma in MSH2-deficient children."; RL Am. J. Hum. Genet. 72:213-216(2003). RN [29] RP INTERACTION WITH ATR, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [30] RP INTERACTION WITH EXO1. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [31] RP FUNCTION. RX PubMed=15064730; DOI=10.1038/sj.onc.1207462; RA Yang Q., Zhang R., Wang X.W., Linke S.P., Sengupta S., Hickson I.D., RA Pedrazzi G., Perrera C., Stagljar I., Littman S.J., Modrich P., RA Harris C.C.; RT "The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase."; RL Oncogene 23:3749-3756(2004). RN [32] RP PHOSPHORYLATION BY PRKCZ. RX PubMed=15808853; DOI=10.1016/j.jmb.2005.02.001; RA Hernandez-Pigeon H., Quillet-Mary A., Louat T., Schambourg A., Humbert O., RA Selves J., Salles B., Laurent G., Lautier D.; RT "hMutS alpha is protected from ubiquitin-proteasome-dependent degradation RT by atypical protein kinase C zeta phosphorylation."; RL J. Mol. Biol. 348:63-74(2005). RN [33] RP INVOLVEMENT IN MMRCS2. RX PubMed=16372347; DOI=10.1002/ajmg.a.31070; RA Mueller A., Schackert H.K., Lange B., Rueschoff J., Fuezesi L., Willert J., RA Burfeind P., Shah P., Becker H., Epplen J.T., Stemmler S.; RT "A novel MSH2 germline mutation in homozygous state in two brothers with RT colorectal cancers diagnosed at the age of 11 and 12 years."; RL Am. J. Med. Genet. A 140:195-199(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [35] RP FUNCTION. RX PubMed=17611581; DOI=10.1038/sj.jid.5700941; RA Seifert M., Scherer S.J., Edelmann W., Bohm M., Meineke V., Lobrich M., RA Tilgen W., Reichrath J.; RT "The DNA-mismatch repair enzyme hMSH2 modulates UV-B-induced cell cycle RT arrest and apoptosis in melanoma cells."; RL J. Invest. Dermatol. 128:203-213(2008). RN [36] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-555, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-921, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [40] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-845; LYS-847; LYS-871 AND LYS-892, RP DEACETYLATION BY HDAC6, UBIQUITINATION AT LYS-845; LYS-847; LYS-871 AND RP LYS-892, AND MUTAGENESIS OF LYS-845; LYS-847; LYS-871 AND LYS-892. RX PubMed=24882211; DOI=10.1016/j.molcel.2014.04.028; RA Zhang M., Xiang S., Joo H.Y., Wang L., Williams K.A., Liu W., Hu C., RA Tong D., Haakenson J., Wang C., Zhang S., Pavlovicz R.E., Jones A., RA Schmidt K.H., Tang J., Dong H., Shan B., Fang B., Radhakrishnan R., RA Glazer P.M., Matthias P., Koomen J., Seto E., Bepler G., Nicosia S.V., RA Chen J., Li C., Gu L., Li G.M., Bai W., Wang H., Zhang X.; RT "HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of RT MutSalpha."; RL Mol. Cell 55:31-46(2014). RN [41] RP FUNCTION, IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND RP MCM8, AND SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [42] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-430, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [43] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; MET-44; VAL-45; SER-127; RP MET-145; ASP-161; ARG-162; ARG-164; PRO-173; ARG-187; PRO-187; VAL-272; RP TYR-333; LEU-519; ASN-603; PRO-636; ALA-674; VAL-688; PHE-697; RP 745-ILE-ILE-746 DEL; LYS-749; THR-834; GLY-886 AND GLU-923, RP CHARACTERIZATION OF VARIANTS ASP-322 AND ILE-722, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [44] RP REVIEW. RX PubMed=8036718; DOI=10.1016/0168-9525(94)90093-0; RA Jiricny J.; RT "Colon cancer and DNA repair: have mismatches met their match?"; RL Trends Genet. 10:164-168(1994). RN [45] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [46] RP REVIEW. RX PubMed=17080293; DOI=10.1007/s10735-006-9062-5; RA Seifert M., Reichrath J.; RT "The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell RT cycle control and apoptosis: implications for pathogenesis, progression and RT therapy of cancer."; RL J. Mol. Histol. 37:301-307(2006). RN [47] RP INTERACTION WITH SMARCAD1. RX PubMed=18675275; DOI=10.1016/j.jmb.2008.07.031; RA Okazaki N., Ikeda S., Ohara R., Shimada K., Yanagawa T., Nagase T., RA Ohara O., Koga H.; RT "The novel protein complex with SMARCAD1/KIAA1122 binds to the vicinity of RT TSS."; RL J. Mol. Biol. 382:257-265(2008). RN [48] RP INTERACTION WITH SLX4. RX PubMed=19596235; DOI=10.1016/j.cell.2009.06.030; RA Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P., RA Elledge S.J., Harper J.W.; RT "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is RT required for DNA repair."; RL Cell 138:63-77(2009). RN [49] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=21642682; DOI=10.1001/jama.2011.743; RG French Cancer Genetics Network; RA Bonadona V., Bonaiti B., Olschwang S., Grandjouan S., Huiart L., Longy M., RA Guimbaud R., Buecher B., Bignon Y.J., Caron O., Colas C., Nogues C., RA Lejeune-Dumoulin S., Olivier-Faivre L., Polycarpe-Osaer F., Nguyen T.D., RA Desseigne F., Saurin J.C., Berthet P., Leroux D., Duffour J., RA Manouvrier S., Frebourg T., Sobol H., Lasset C., Bonaiti-Pellie C.; RT "Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 RT genes in Lynch syndrome."; RL JAMA 305:2304-2310(2011). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS). RX PubMed=17531815; DOI=10.1016/j.molcel.2007.04.018; RA Warren J.J., Pohlhaus T.J., Changela A., Iyer R.R., Modrich P.L., RA Beese L.S.; RT "Structure of the human MutSalpha DNA lesion recognition complex."; RL Mol. Cell 26:579-592(2007). RN [51] RP VARIANT LYNCH1 ASN-596 DEL. RX PubMed=7874129; RA Mary J.-L., Bishop T., Kolodner R.D., Lipford J.R., Kane M.F., Weber W., RA Torhorst J., Mueller H., Spycher M., Scott R.J.; RT "Mutational analysis of the hMSH2 gene reveals a three base pair deletion RT in a family predisposed to colorectal cancer development."; RL Hum. Mol. Genet. 3:2067-2069(1994). RN [52] RP VARIANTS PHE-390 AND LYS-419. RX PubMed=8690195; DOI=10.1053/gast.1996.v111.pm8690195; RA Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Onda A., RA Okumura Y., Kishi N., Iwama T., Mori T., Koike M., Ushio K., Chiba M., RA Nomizu S., Konishi F., Utsunomiya J., Miyaki M.; RT "Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, RT familial polyposis, and sporadic colon cancer."; RL Gastroenterology 111:307-317(1996). RN [53] RP VARIANT ASP-322. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [54] RP VARIANT LYNCH1 ASN-596 DEL, AND VARIANT HIS-167. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [55] RP VARIANT LYNCH1 TYR-506. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [56] RP VARIANT LYNCH1 GLN-46. RX PubMed=8700523; RA Bubb V.J., Curtis L.J., Cunningham C., Dunlop M.G., Carothers A.D., RA Morris R.G., White S., Bird C.C., Wyllie A.H.; RT "Microsatellite instability and the role of hMSH2 in sporadic colorectal RT cancer."; RL Oncogene 12:2641-2649(1996). RN [57] RP VARIANTS LYNCH1 THR-305; ASN-596 DEL AND THR-834. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [58] RP VARIANT LYNCH1 CYS-323. RX PubMed=9240418; DOI=10.1006/bbrc.1997.6942; RA Akiyama Y., Tsubouchi N., Yuasa Y.; RT "Frequent somatic mutations of hMSH3 with reference to microsatellite RT instability in hereditary nonpolyposis colorectal cancers."; RL Biochem. Biophys. Res. Commun. 236:248-252(1997). RN [59] RP VARIANTS LYNCH1 THR-110; ARG-639; LYS-647; HIS-656; THR-679; VAL-729 AND RP ILE-732. RX PubMed=9419403; RA Nakahara M., Yokozaki H., Yasui W., Dohi K., Tahara E.; RT "Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in RT Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Cancer Epidemiol. Biomarkers Prev. 6:1057-1064(1997). RN [60] RP VARIANT SER-596. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [61] RP VARIANT ASP-322. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [62] RP VARIANT LYNCH1 VAL-562. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [63] RP VARIANT LYNCH1 PHE-697, AND VARIANT ASP-322. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [64] RP VARIANT LYNCH1 265-VAL--GLN-314 DEL, AND VARIANTS GLY-641 AND VAL-770. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [65] RP VARIANT ARG-199. RX PubMed=9777949; DOI=10.1016/s0002-9440(10)65662-3; RA Leung S.Y., Chan T.L., Chung L.P., Chan A.S.Y., Fan Y.W., Hung K.N., RA Kwong W.K., Ho J.W.C., Yuen S.T.; RT "Microsatellite instability and mutation of DNA mismatch repair genes in RT gliomas."; RL Am. J. Pathol. 153:1181-1188(1998). RN [66] RP VARIANT CRC TYR-506, AND VARIANT LYNCH1 ILE-688. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [67] RP VARIANT ASP-322. RX PubMed=10023327; DOI=10.1016/s0959-8049(98)00217-2; RA Liu T., Stathopoulos P., Lindblom P., Rubio C., Wasteson Arver B., RA Iselius L., Holmberg E., Groenberg H., Lindblom A.; RT "MSH2 codon 322 Gly to Asp does not seem to confer an increased risk for RT colorectal cancer susceptibility."; RL Eur. J. Cancer 34:1981-1981(1998). RN [68] RP VARIANT LYNCH1 PHE-390. RX PubMed=9621522; DOI=10.1007/s100380050057; RA Okamura S., Koyama K., Miyoshi Y., Monden M., Takami M.; RT "Novel germline mutations of hMSH2 in a patient with hereditary RT nonpolyposis colorectal cancer 'HNPCC' and in a patient with six primary RT cancers."; RL J. Hum. Genet. 43:143-145(1998). RN [69] RP VARIANTS LYNCH1 SER-336 AND ASN-596 DEL. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [70] RP CHARACTERIZATION OF VARIANTS ASP-322; PHE-390; LYS-419; TYR-506; PRO-524; RP LEU-622 AND PHE-697. RX PubMed=10469597; DOI=10.1016/s0960-9822(99)80396-0; RA Drotschmann K., Clark A.B., Kunkel T.A.; RT "Mutator phenotypes of common polymorphisms and missense mutations in RT MSH2."; RL Curr. Biol. 9:907-910(1999). RN [71] RP VARIANTS LYNCH1 GLN-246; SER-596 AND THR-834, AND VARIANT ASP-322. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [72] RP VARIANT LYNCH1 PHE-390. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH1 PRO-636. RX PubMed=10528862; DOI=10.1136/jmg.36.10.792; RA Yuan Z.Q., Wong N., Foulkes W.D., Alpert L., Manganaro F., RA Andreutti-Zaugg C., Iggo R., Anthony K., Hsieh E., Redston M., Pinsky L., RA Trifiro M., Gordon P.H., Lasko D.; RT "A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC RT kindred: implications for clinical screening."; RL J. Med. Genet. 36:790-793(1999). RN [74] RP VARIANTS LYNCH1 ILE-688 AND GLU-845, AND VARIANT MET-8. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANT ASP-322. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANTS LYNCH1 ARG-692 AND ARG-697. RX PubMed=10612836; RX DOI=10.1002/(sici)1098-1004(200001)15:1<116::aid-humu24>3.0.co;2-q; RA Isidro G., Veiga I., Matos P., Almeida S., Bizarro S., Marshall B., RA Baptista M., Leite J., Regateiro F., Soares J., Castedo S., Boavida M.G.; RT "Four novel MSH2 / MLH1 gene mutations in Portuguese HNPCC families."; RL Hum. Mutat. 15:116-116(2000). RN [77] RP VARIANT LYNCH1 ASN-603, AND VARIANT ASP-322. RX PubMed=10829038; DOI=10.1200/jco.2000.18.11.2193; RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RT "Population-based molecular detection of hereditary nonpolyposis colorectal RT cancer."; RL J. Clin. Oncol. 18:2193-2200(2000). RN [78] RP ERRATUM OF PUBMED:10829038. RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RL J. Clin. Oncol. 18:3456-3456(2000). RN [79] RP VARIANTS GASTRIC CANCER PHE-17; GLU-824; ALA-868; GLY-870 AND GLY-873, AND RP VARIANTS LYNCH1 CYS-98; TYR-323; ILE-335; ARG-629 AND VAL-714. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [80] RP VARIANTS LYNCH1 ASP-161; VAL-216 AND ARG-554. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [81] RP CHARACTERIZATION OF VARIANTS ASP-322; LEU-622 AND TYR-639. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [82] RP VARIANT LYNCH1 VAL-813. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [83] RP VARIANTS LYNCH1 VAL-600 AND PHE-723. RX PubMed=11920458; DOI=10.1002/cncr.10332.abs; RA Furukawa T., Konishi F., Shitoh K., Kojima M., Nagai H., Tsukamoto T.; RT "Evaluation of screening strategy for detecting hereditary nonpolyposis RT colorectal carcinoma."; RL Cancer 94:911-920(2002). RN [84] RP VARIANTS LYNCH1 HIS-167; MET-393; PRO-524; ASN-596 DEL; LEU-622; SER-674 RP AND ARG-905, AND CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; MET-393; RP PRO-524; ASN-596 DEL; LEU-622; SER-674 AND ARG-905. RX PubMed=12124176; DOI=10.1016/s1535-6108(02)00073-9; RA Heinen C.D., Wilson T., Mazurek A., Berardini M., Butz C., Fishel R.; RT "HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch RT functions."; RL Cancer Cell 1:469-478(2002). RN [85] RP INVOLVEMENT IN MULTIPLE CAFE-AU-LAIT SPOTS WITH LEUKEMIA. RX PubMed=11809679; RA Whiteside D., McLeod R., Graham G., Steckley J.L., Booth K., RA Somerville M.J., Andrew S.E.; RT "A homozygous germ-line mutation in the human MSH2 gene predisposes to RT hematological malignancy and multiple cafe-au-lait spots."; RL Cancer Res. 62:359-362(2002). RN [86] RP VARIANT ASP-322. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [87] RP VARIANTS LYNCH1 MET-44; VAL-45; ASN-596 DEL; GLY-886 AND GLU-923. RX PubMed=12112654; DOI=10.1002/humu.10083; RA Bisgaard M.L., Jaeger A.C., Myrhoej T., Bernstein I., Nielsen F.C.; RT "Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype RT correlation between patients with and without identified mutation."; RL Hum. Mutat. 20:20-27(2002). RN [88] RP VARIANTS LYNCH1 ILE-102; ASP-163 AND ALA-564, AND VARIANT ASP-322. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [89] RP VARIANTS LYNCH1 HIS-167 AND SER-359. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [90] RP VARIANTS LYNCH1 LEU-92 DEL AND ALA-853, AND VARIANT ASP-322. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [91] RP VARIANTS LYNCH1 PRO-552; SER-583 AND PRO-636. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [92] RP VARIANTS CRC ILE-13 AND ILE-342, AND VARIANT ASP-322. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [93] RP VARIANT LYNCH1 SER-127. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [94] RP VARIANT LYNCH1 PRO-175. RX PubMed=12655568; DOI=10.1002/humu.9127; RA Bartosova Z., Fridrichova I., Bujalkova M., Wolf B., Ilencikova D., RA Krizan P., Hlavcak P., Palaj J., Lukac L., Lukacova M., Boeoer A., RA Haider R., Jiricny J., Nystroem-Lahti M., Marra G.; RT "Novel MLH1 and MSH2 germline mutations in the first HNPCC families RT identified in Slovakia."; RL Hum. Mutat. 21:449-449(2003). RN [95] RP VARIANTS LYNCH1 GLY-163 AND GLY-660. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [96] RP VARIANTS CRC SER-40; VAL-169; ARG-203; PHE-390; LYS-419; CYS-619 AND RP ARG-629, AND VARIANT MET-8. RX PubMed=12792735; RA Yamada K., Zhong X., Kanazawa S., Koike J., Tsujita K., Hemmi H.; RT "Oncogenic pathway of sporadic colorectal cancer with novel germline RT missense mutations in the hMSH2 gene."; RL Oncol. Rep. 10:859-866(2003). RN [97] RP VARIANT LYNCH1 THR-931. RX PubMed=15046096; RA Sun M.H., Cai Q., Fu G., Ren S., Mo S., Xu Y., Ding C., Zhang T., Zhu X., RA Xu X., Min D., Cai S., Luo D., Shi Y., Shi D.; RT "Gene symbol: hMSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 114:409-409(2004). RN [98] RP VARIANT LYNCH1 TYR-671. RX PubMed=15300854; DOI=10.1002/humu.9267; RA Sharp A., Pichert G., Lucassen A., Eccles D.; RT "RNA analysis reveals splicing mutations and loss of expression defects in RT MLH1 and BRCA1."; RL Hum. Mutat. 24:272-272(2004). RN [99] RP VARIANTS LYNCH1 LEU-440 DEL; TYR-506; ARG-629 AND ILE-688. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [100] RP VARIANT LYNCH1 ARG-839, AND VARIANT ARG-629. RX PubMed=15613555; DOI=10.1093/jjco/hyh121; RA Yuan Y., Huang Y.-Q., Cai S.-R., Song Y.-M., Zheng S., Zhang S.-Z.; RT "Genetic characterization of Chinese hereditary non-polyposis colorectal RT cancer by DHPLC and multiplex PCR."; RL Jpn. J. Clin. Oncol. 34:660-666(2004). RN [101] RP VARIANTS LYNCH1 LEU-349 AND ASN-596 DEL. RX PubMed=15342696; DOI=10.1136/jmg.2004.020651; RA Domingo E., Laiho P., Ollikainen M., Pinto M., Wang L., French A.J., RA Westra J., Frebourg T., Espin E., Armengol M., Hamelin R., Yamamoto H., RA Hofstra R.M.W., Seruca R., Lindblom A., Peltomaeki P., Thibodeau S.N., RA Aaltonen L.A., Schwartz S. Jr.; RT "BRAF screening as a low-cost effective strategy for simplifying HNPCC RT genetic testing."; RL J. Med. Genet. 41:664-668(2004). RN [102] RP VARIANT LYNCH1 PHE-93. RX PubMed=15896463; DOI=10.1016/j.canlet.2004.09.051; RA Baudi F., Fersini G., Lavecchia A., Terracciano R., Leone F., Quaresima B., RA Faniello M.C., De Paola L., Doldo P., Cuda G., Costanzo F., Venuta S.; RT "A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC RT family from Southern Italy."; RL Cancer Lett. 223:285-291(2005). RN [103] RP VARIANTS LYNCH1 VAL-169; PHE-390; ALA-564 AND ARG-629, AND VARIANT CRC RP LYS-419. RX PubMed=15996210; DOI=10.1111/j.1399-0004.2005.00469.x; RA Lee S.-C., Guo J.-Y., Lim R., Soo R., Koay E., Salto-Tellez M., Leong A., RA Goh B.-C.; RT "Clinical and molecular characteristics of hereditary non-polyposis RT colorectal cancer families in Southeast Asia."; RL Clin. Genet. 68:137-145(2005). RN [104] RP VARIANT LYNCH1 TYR-283. RX PubMed=15870828; DOI=10.1038/sj.ejhg.5201421; RA Wehner M., Mangold E., Sengteller M., Friedrichs N., Aretz S., Friedl W., RA Propping P., Pagenstecher C.; RT "Hereditary nonpolyposis colorectal cancer: pitfalls in deletion screening RT in MSH2 and MLH1 genes."; RL Eur. J. Hum. Genet. 13:983-986(2005). RN [105] RP VARIANT LYNCH1 ARG-162. RX PubMed=15991316; RA Kohonen-Corish M.R.J., Otway R., Tetlow N., Hornby J., Doe W.F.; RT "Gene symbol: MSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 116:539-539(2005). RN [106] RP VARIANTS LYNCH1 THR-2; LEU-92 DEL; MET-145; PHE-390 AND ALA-853, AND RP VARIANT ASP-322. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [107] RP VARIANTS LYNCH1 PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; RP TYR-333; ASN-603; PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, RP VARIANTS VAL-272; THR-834 AND GLU-923, CHARACTERIZATION OF VARIANTS LYNCH1 RP PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; TYR-333; ASN-603; RP PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, AND CHARACTERIZATION OF RP VARIANTS VAL-272; THR-834 AND GLU-923. RX PubMed=17101317; DOI=10.1053/j.gastro.2006.08.044; RA Ollila S., Sarantaus L., Kariola R., Chan P., Hampel H., Holinski-Feder E., RA Macrae F., Kohonen-Corish M., Gerdes A.-M., Peltomaeki P., Mangold E., RA de la Chapelle A., Greenblatt M., Nystroem M.; RT "Pathogenicity of MSH2 missense mutations is typically associated with RT impaired repair capability of the mutated protein."; RL Gastroenterology 131:1408-1417(2006). RN [108] RP VARIANT LYNCH1 ALA-162. RX PubMed=17128465; RA Leonardis D.; RT "Gene symbol: msh2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 119:675-675(2006). RN [109] RP VARIANT LYNCH1 ARG-674. RX PubMed=18625694; DOI=10.1136/gut.2008.156695; RA Ramsoekh D., Wagner A., van Leerdam M.E., Dinjens W.N., Steyerberg E.W., RA Halley D.J., Kuipers E.J., Dooijes D.; RT "A high incidence of MSH6 mutations in Amsterdam criteria II-negative RT families tested in a diagnostic setting."; RL Gut 57:1539-1544(2008). RN [110] RP VARIANTS GLN-46; LYS-106; ASP-322; SER-596; LEU-670; ILE-779; SER-807; RP HIS-835 AND ARG-911. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [111] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; SER-127; ASP-161; ARG-162; RP ARG-164; PRO-173; PRO-187; VAL-272; TYR-333; ASN-603; PRO-636; ALA-674; RP PHE-697; 745-ILE-ILE-746 DEL; LYS-749; THR-834 AND GLU-923, AND RP CHARACTERIZATION OF VARIANT ASP-322. RX PubMed=18951462; DOI=10.1002/humu.20893; RA Ollila S., Dermadi Bebek D., Jiricny J., Nystroem M.; RT "Mechanisms of pathogenicity in human MSH2 missense mutants."; RL Hum. Mutat. 29:1355-1363(2008). RN [112] RP VARIANTS LYNCH1 LEU-92 DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; RP GLU-645; LEU-696; TYR-748 AND GLN-839, VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723, CHARACTERIZATION OF VARIANTS LYNCH1 LEU-92 RP DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; GLU-645; LEU-696; TYR-748 RP AND GLN-839, AND CHARACTERIZATION OF VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [113] RP CHARACTERIZATION OF VARIANTS LYNCH1 ARG-162; HIS-167 AND SER-359. RX PubMed=18781619; DOI=10.1002/humu.20875; RA Belvederesi L., Bianchi F., Galizia E., Loretelli C., Bracci R., RA Catalani R., Amati M., Cellerino R.; RT "MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a RT human expression system."; RL Hum. Mutat. 29:E296-E309(2008). RN [114] RP CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; THR-305: LEU-622; ARG-639; RP ARG-674; PHE-697 AND THR-834. RX PubMed=18822302; DOI=10.1016/j.mrfmmm.2008.08.015; RA Lutzen A., de Wind N., Georgijevic D., Nielsen F.C., Rasmussen L.J.; RT "Functional analysis of HNPCC-related missense mutations in MSH2."; RL Mutat. Res. 645:44-55(2008). RN [115] RP CHARACTERIZATION OF VARIANTS LYNCH1 MET-44; VAL-45; HIS-167; THR-305; RP PHE-390; ASN-596 DEL; ARG-639; ARG-674; PHE-697; PHE-723 AND GLY-886, AND RP CHARACTERIZATION OF VARIANTS ASP-165; HIS-177; VAL-272; LEU-385; LEU-519; RP ALA-675; GLU-759; VAL-805; GLY-843 AND LEU-860. RX PubMed=22102614; DOI=10.1002/humu.22000; RA Drost M., Zonneveld J.B., van Hees S., Rasmussen L.J., Hofstra R.M., RA de Wind N.; RT "A rapid and cell-free assay to test the activity of lynch syndrome- RT associated MSH2 and MSH6 missense variants."; RL Hum. Mutat. 33:488-494(2012). RN [116] RP CHARACTERIZATION OF VARIANTS SER-127; MET-145; GLN-205; ASP-322; PRO-328; RP ILE-367; GLU-487 AND ILE-909. RX PubMed=22581703; DOI=10.1002/humu.22119; RA Kantelinen J., Kansikas M., Candelin S., Hampel H., Smith B., Holm L., RA Kariola R., Nystrom M.; RT "Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs RT found in cancer patients."; RL Hum. Mutat. 33:1294-1301(2012). RN [117] RP VARIANT LYNCH1 ARG-669. RX PubMed=22371642; DOI=10.3748/wjg.v18.i8.814; RA Zahary M.N., Kaur G., Abu Hassan M.R., Singh H., Naik V.R., Ankathil R.; RT "Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome RT patients."; RL World J. Gastroenterol. 18:814-820(2012). RN [118] RP VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839, AND CHARACTERIZATION RP OF VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Component of the post-replicative DNA mismatch repair system CC (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 CC heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA CC mismatches thereby initiating DNA repair. When bound, heterodimers bend CC the DNA helix and shields approximately 20 base pairs. MutS alpha CC recognizes single base mismatches and dinucleotide insertion-deletion CC loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion CC loops up to 13 nucleotides long. After mismatch binding, MutS alpha or CC beta forms a ternary complex with the MutL alpha heterodimer, which is CC thought to be responsible for directing the downstream MMR events, CC including strand discrimination, excision, and resynthesis. Recruits CC DNA helicase MCM9 to chromatin which unwinds the mismatch containing CC DNA strand (PubMed:26300262). ATP binding and hydrolysis play a pivotal CC role in mismatch repair functions. The ATPase activity associated with CC MutS alpha regulates binding similar to a molecular switch: mismatched CC DNA provokes ADP-->ATP exchange, resulting in a discernible CC conformational transition that converts MutS alpha into a sliding clamp CC capable of hydrolysis-independent diffusion along the DNA backbone. CC This transition is crucial for mismatch repair. MutS alpha may also CC play a role in DNA homologous recombination repair. In melanocytes may CC modulate both UV-B-induced cell cycle regulation and apoptosis. CC {ECO:0000269|PubMed:10078208, ECO:0000269|PubMed:10660545, CC ECO:0000269|PubMed:15064730, ECO:0000269|PubMed:17611581, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:26300262, CC ECO:0000269|PubMed:9564049, ECO:0000269|PubMed:9822679, CC ECO:0000269|PubMed:9822680}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC consisting of MSH2-MSH6 (MutS alpha) or MSH2-MSH3 (MutS beta) CC (PubMed:8942985). Both heterodimers form a ternary complex with MutL CC alpha (MLH1-PMS1) (PubMed:10856833, PubMed:11427529, PubMed:11429708, CC PubMed:12414623, PubMed:14676842, PubMed:9788596). Interacts with MCM9; CC the interaction recruits MCM9 to chromatin (PubMed:26300262). Interacts CC with MCM8 (PubMed:26300262). Interacts with EXO1 (PubMed:10856833, CC PubMed:11427529, PubMed:11429708, PubMed:12414623, PubMed:14676842, CC PubMed:9788596). Part of the BRCA1-associated genome surveillance CC complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 CC and the RAD50-MRE11-NBS1 protein complex (PubMed:10783165). This CC association could be a dynamic process changing throughout the cell CC cycle and within subnuclear domains (PubMed:10783165). Interacts with CC ATR (PubMed:14657349). Interacts with SLX4/BTBD12; this interaction is CC direct and links MutS beta to SLX4, a subunit of different structure- CC specific endonucleases (PubMed:19596235). Interacts with SMARCAD1 CC (PubMed:18675275). {ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:10856833, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:18675275, ECO:0000269|PubMed:19596235, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:8942985, CC ECO:0000269|PubMed:9788596}. CC -!- INTERACTION: CC P43246; Q92624: APPBP2; NbExp=3; IntAct=EBI-355888, EBI-743771; CC P43246; Q9UQ84-1: EXO1; NbExp=3; IntAct=EBI-355888, EBI-944694; CC P43246; P09429: HMGB1; NbExp=2; IntAct=EBI-355888, EBI-389432; CC P43246; P20585: MSH3; NbExp=14; IntAct=EBI-355888, EBI-1164205; CC P43246; P52701: MSH6; NbExp=11; IntAct=EBI-355888, EBI-395529; CC P43246; Q8IY92: SLX4; NbExp=5; IntAct=EBI-355888, EBI-2370740; CC P43246; P39875: EXO1; Xeno; NbExp=2; IntAct=EBI-355888, EBI-6738; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24882211, CC ECO:0000269|PubMed:26300262}. Chromosome {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P43246-1; Sequence=Displayed; CC Name=2; CC IsoId=P43246-2; Sequence=VSP_045536; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. CC {ECO:0000269|PubMed:10856833}. CC -!- PTM: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation CC by the ubiquitin-proteasome pathway. {ECO:0000269|PubMed:15808853}. CC -!- PTM: Sequentially deacetylated and polyubiquitinated by HDAC6, leading CC to MSH2 degradation. {ECO:0000269|PubMed:24882211}. CC -!- DISEASE: Lynch syndrome 1 (LYNCH1) [MIM:120435]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10375096, ECO:0000269|PubMed:10386556, CC ECO:0000269|PubMed:10528862, ECO:0000269|PubMed:10573010, CC ECO:0000269|PubMed:10612836, ECO:0000269|PubMed:10777691, CC ECO:0000269|PubMed:10829038, ECO:0000269|PubMed:11726306, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:11920458, CC ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:12655568, CC ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14635101, CC ECO:0000269|PubMed:15046096, ECO:0000269|PubMed:15300854, CC ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:15365995, CC ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15870828, CC ECO:0000269|PubMed:15896463, ECO:0000269|PubMed:15991316, CC ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:17128465, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18625694, CC ECO:0000269|PubMed:18781619, ECO:0000269|PubMed:18822302, CC ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:22371642, CC ECO:0000269|PubMed:7874129, ECO:0000269|PubMed:8261515, CC ECO:0000269|PubMed:8700523, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9048925, CC ECO:0000269|PubMed:9240418, ECO:0000269|PubMed:9298827, CC ECO:0000269|PubMed:9311737, ECO:0000269|PubMed:9419403, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9621522, CC ECO:0000269|PubMed:9718327, ECO:0000269|PubMed:9889267}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:7713503}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000305|PubMed:11306449, CC ECO:0000305|PubMed:21642682}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 2 (MMRCS2) [MIM:619096]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:12549480, CC ECO:0000269|PubMed:16372347}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12792735, CC ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:15996210, CC ECO:0000269|PubMed:9559627}. Note=Disease susceptibility may be CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutS family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC27930.1; Type=Frameshift; Note=The frameshift is caused by a single nucleotide deletion which is found in a HNPCC kindred.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/340/MSH2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U03911; AAA18643.1; -; mRNA. DR EMBL; U04045; AAA61870.1; -; mRNA. DR EMBL; U41221; AAA82080.1; ALT_SEQ; Genomic_DNA. DR EMBL; U41206; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41207; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41208; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41210; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41211; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41212; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41213; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41214; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41215; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41216; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41217; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41218; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41219; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41220; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; L47583; AAB59564.1; -; mRNA. DR EMBL; L47582; AAB59565.1; -; mRNA. DR EMBL; L47581; AAA76858.1; -; mRNA. DR EMBL; AY601851; AAS99351.1; -; Genomic_DNA. DR EMBL; AK304496; BAG65304.1; -; mRNA. DR EMBL; BX649122; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC079775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC138655; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC021566; AAH21566.1; -; mRNA. DR EMBL; AF066081; AAC27930.1; ALT_FRAME; Genomic_DNA. DR CCDS; CCDS1834.1; -. [P43246-1] DR CCDS; CCDS58709.1; -. [P43246-2] DR PIR; I64819; I64819. DR RefSeq; NP_000242.1; NM_000251.3. [P43246-1] DR RefSeq; NP_001245210.1; NM_001258281.1. [P43246-2] DR RefSeq; NP_001393570.1; NM_001406641.1. [P43246-1] DR PDB; 2O8B; X-ray; 2.75 A; A=1-934. DR PDB; 2O8C; X-ray; 3.37 A; A=1-934. DR PDB; 2O8D; X-ray; 3.00 A; A=1-934. DR PDB; 2O8E; X-ray; 3.30 A; A=1-934. DR PDB; 2O8F; X-ray; 3.25 A; A=1-934. DR PDB; 3THW; X-ray; 3.09 A; A=1-934. DR PDB; 3THX; X-ray; 2.70 A; A=1-934. DR PDB; 3THY; X-ray; 2.89 A; A=1-934. DR PDB; 3THZ; X-ray; 4.30 A; A=1-934. DR PDB; 8AG6; EM; 2.80 A; A=1-934. DR PDB; 8OLX; EM; 3.10 A; A=1-934. DR PDB; 8OM5; EM; 3.52 A; A=1-934. DR PDB; 8OM9; EM; 3.32 A; A=1-934. DR PDB; 8OMA; EM; 3.29 A; A=1-934. DR PDB; 8OMO; EM; 3.43 A; A=1-934. DR PDB; 8OMQ; EM; 3.11 A; A=1-934. DR PDB; 8R7C; X-ray; 2.82 A; A/E=1-930. DR PDB; 8R7E; X-ray; 2.78 A; A/E=1-930. DR PDB; 8R7V; EM; 3.12 A; A=1-934. DR PDB; 8RAU; X-ray; 2.33 A; A=1-934. DR PDB; 8RAV; X-ray; 2.63 A; A=1-934. DR PDB; 8RAW; X-ray; 2.69 A; A=1-934. DR PDB; 8RAX; X-ray; 3.16 A; A=1-934. DR PDB; 8RAZ; X-ray; 2.84 A; A=1-934. DR PDB; 8RB0; X-ray; 2.67 A; A=1-934. DR PDB; 8RB1; X-ray; 2.08 A; A=1-934. DR PDB; 8RB2; X-ray; 2.53 A; A/E=1-934. DR PDB; 8RZ7; EM; 3.37 A; A=1-934. DR PDB; 8RZ8; EM; 3.06 A; A=1-934. DR PDB; 8RZ9; EM; 3.02 A; A=1-934. DR PDBsum; 2O8B; -. DR PDBsum; 2O8C; -. DR PDBsum; 2O8D; -. DR PDBsum; 2O8E; -. DR PDBsum; 2O8F; -. DR PDBsum; 3THW; -. DR PDBsum; 3THX; -. DR PDBsum; 3THY; -. DR PDBsum; 3THZ; -. DR PDBsum; 8AG6; -. DR PDBsum; 8OLX; -. DR PDBsum; 8OM5; -. DR PDBsum; 8OM9; -. DR PDBsum; 8OMA; -. DR PDBsum; 8OMO; -. DR PDBsum; 8OMQ; -. DR PDBsum; 8R7C; -. DR PDBsum; 8R7E; -. DR PDBsum; 8R7V; -. DR PDBsum; 8RAU; -. DR PDBsum; 8RAV; -. DR PDBsum; 8RAW; -. DR PDBsum; 8RAX; -. DR PDBsum; 8RAZ; -. DR PDBsum; 8RB0; -. DR PDBsum; 8RB1; -. DR PDBsum; 8RB2; -. DR PDBsum; 8RZ7; -. DR PDBsum; 8RZ8; -. DR PDBsum; 8RZ9; -. DR AlphaFoldDB; P43246; -. DR EMDB; EMD-15417; -. DR EMDB; EMD-15518; -. DR EMDB; EMD-15519; -. DR EMDB; EMD-16964; -. DR EMDB; EMD-16969; -. DR EMDB; EMD-16971; -. DR EMDB; EMD-16972; -. DR EMDB; EMD-16973; -. DR EMDB; EMD-16974; -. DR EMDB; EMD-18992; -. DR EMDB; EMD-19605; -. DR EMDB; EMD-19606; -. DR EMDB; EMD-19607; -. DR SMR; P43246; -. DR BioGRID; 110573; 329. DR ComplexPortal; CPX-77; DNA mismatch repair MutSbeta complex. DR ComplexPortal; CPX-80; DNA mismatch repair MutSalpha complex. DR CORUM; P43246; -. DR DIP; DIP-35054N; -. DR FunCoup; P43246; 3266. DR IntAct; P43246; 111. DR MINT; P43246; -. DR STRING; 9606.ENSP00000233146; -. DR ChEMBL; CHEMBL4296019; -. DR GlyGen; P43246; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P43246; -. DR PhosphoSitePlus; P43246; -. DR SwissPalm; P43246; -. DR BioMuta; MSH2; -. DR DMDM; 1171032; -. DR jPOST; P43246; -. DR MassIVE; P43246; -. DR PaxDb; 9606-ENSP00000233146; -. DR PeptideAtlas; P43246; -. DR ProteomicsDB; 55601; -. [P43246-1] DR ProteomicsDB; 5866; -. DR Pumba; P43246; -. DR Antibodypedia; 4037; 803 antibodies from 50 providers. DR CPTC; P43246; 1 antibody. DR DNASU; 4436; -. DR Ensembl; ENST00000233146.7; ENSP00000233146.2; ENSG00000095002.17. [P43246-1] DR Ensembl; ENST00000543555.6; ENSP00000442697.1; ENSG00000095002.17. [P43246-2] DR GeneID; 4436; -. DR KEGG; hsa:4436; -. DR MANE-Select; ENST00000233146.7; ENSP00000233146.2; NM_000251.3; NP_000242.1. DR UCSC; uc002rvy.3; human. [P43246-1] DR AGR; HGNC:7325; -. DR CIViC; 4436; 8 evidence items across 9 molecular profiles. DR ClinPGx; PA31133; -. DR CTD; 4436; -. DR DisGeNET; 4436; -. DR GeneCards; MSH2; -. DR GeneReviews; MSH2; -. DR HGNC; HGNC:7325; MSH2. DR HPA; ENSG00000095002; Low tissue specificity. DR MalaCards; MSH2; -. DR MIM; 114500; phenotype. DR MIM; 120435; phenotype. DR MIM; 158320; phenotype. DR MIM; 608089; phenotype. DR MIM; 609309; gene. DR MIM; 619096; phenotype. DR OpenTargets; ENSG00000095002; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000095002; -. DR eggNOG; KOG0219; Eukaryota. DR GeneTree; ENSGT00550000074867; -. DR HOGENOM; CLU_002472_10_0_1; -. DR InParanoid; P43246; -. DR OMA; LVRFPQK; -. DR OrthoDB; 295033at2759; -. DR PAN-GO; P43246; 5 GO annotations based on evolutionary models. DR PhylomeDB; P43246; -. DR PathwayCommons; P43246; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5632927; Defective Mismatch Repair Associated With MSH3. DR Reactome; R-HSA-5632928; Defective Mismatch Repair Associated With MSH2. DR Reactome; R-HSA-5632968; Defective Mismatch Repair Associated With MSH6. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR SignaLink; P43246; -. DR SIGNOR; P43246; -. DR Agora; ENSG00000095002; -. DR BioGRID-ORCS; 4436; 27 hits in 1168 CRISPR screens. DR ChiTaRS; MSH2; human. DR EvolutionaryTrace; P43246; -. DR GeneWiki; MSH2; -. DR GenomeRNAi; 4436; -. DR Pharos; P43246; Tbio. DR PRO; PR:P43246; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P43246; protein. DR Bgee; ENSG00000095002; Expressed in secondary oocyte and 194 other cell types or tissues. DR ExpressionAtlas; P43246; baseline and differential. DR GO; GO:0000781; C:chromosome, telomeric region; HDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032301; C:MutSalpha complex; IDA:UniProtKB. DR GO; GO:0032302; C:MutSbeta complex; IDA:HGNC-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:Ensembl. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:HGNC-UCL. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0019237; F:centromeric DNA binding; IEA:Ensembl. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0032137; F:guanine/thymine mispair binding; IMP:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL. DR GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL. DR GO; GO:0019724; P:B cell mediated immunity; ISS:BHF-UCL. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006301; P:DNA damage tolerance; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; ISS:BHF-UCL. DR GO; GO:0043570; P:maintenance of DNA repeat elements; IMP:HGNC-UCL. DR GO; GO:0008584; P:male gonad development; ISS:BHF-UCL. DR GO; GO:0006298; P:mismatch repair; IDA:UniProtKB. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IEA:Ensembl. DR GO; GO:0006312; P:mitotic recombination; IBA:GO_Central. DR GO; GO:0045910; P:negative regulation of DNA recombination; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:BHF-UCL. DR GO; GO:0006119; P:oxidative phosphorylation; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0010224; P:response to UV-B; ISS:BHF-UCL. DR GO; GO:0010165; P:response to X-ray; ISS:BHF-UCL. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IEA:Ensembl. DR GO; GO:0016447; P:somatic recombination of immunoglobulin gene segments; ISS:BHF-UCL. DR GO; GO:0002204; P:somatic recombination of immunoglobulin genes involved in immune response; IBA:GO_Central. DR CDD; cd03285; ABC_MSH2_euk; 1. DR FunFam; 1.10.1420.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 1.10.1420.10:FF:000009; DNA mismatch repair protein; 1. DR FunFam; 3.30.420.110:FF:000002; DNA mismatch repair protein; 1. DR FunFam; 3.40.1170.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 3.40.50.300:FF:000523; DNA mismatch repair protein; 1. DR Gene3D; 1.10.1420.10; -; 2. DR Gene3D; 3.40.1170.10; DNA repair protein MutS, domain I; 1. DR Gene3D; 3.30.420.110; MutS, connector domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR IDEAL; IID00048; -. DR InterPro; IPR011184; DNA_mismatch_repair_Msh2. DR InterPro; IPR007695; DNA_mismatch_repair_MutS-lik_N. DR InterPro; IPR000432; DNA_mismatch_repair_MutS_C. DR InterPro; IPR007861; DNA_mismatch_repair_MutS_clamp. DR InterPro; IPR007696; DNA_mismatch_repair_MutS_core. DR InterPro; IPR016151; DNA_mismatch_repair_MutS_N. DR InterPro; IPR036187; DNA_mismatch_repair_MutS_sf. DR InterPro; IPR007860; DNA_mmatch_repair_MutS_con_dom. DR InterPro; IPR032642; Msh2_ATP-bd. DR InterPro; IPR045076; MutS. DR InterPro; IPR036678; MutS_con_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR NCBIfam; NF003810; PRK05399.1; 1. DR PANTHER; PTHR11361:SF35; DNA MISMATCH REPAIR PROTEIN MSH2; 1. DR PANTHER; PTHR11361; DNA MISMATCH REPAIR PROTEIN MUTS FAMILY MEMBER; 1. DR Pfam; PF01624; MutS_I; 1. DR Pfam; PF05188; MutS_II; 1. DR Pfam; PF05192; MutS_III; 1. DR Pfam; PF05190; MutS_IV; 1. DR Pfam; PF00488; MutS_V; 1. DR PIRSF; PIRSF005813; MSH2; 1. DR SMART; SM00534; MUTSac; 1. DR SMART; SM00533; MUTSd; 1. DR SUPFAM; SSF48334; DNA repair protein MutS, domain III; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS00486; DNA_MISMATCH_REPAIR_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; KW Hereditary nonpolyposis colorectal cancer; Isopeptide bond; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..934 FT /note="DNA mismatch repair protein Msh2" FT /id="PRO_0000115183" FT REGION 601..671 FT /note="Interaction with EXO1" FT BINDING 669..676 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 555 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 567 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P43247" FT MOD_RES 845 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 847 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 871 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 892 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 921 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 430 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 845 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 847 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 871 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 892 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:17974005" FT /id="VSP_045536" FT VARIANT 2 FT /note="A -> T (in LYNCH1; likely benign; dbSNP:rs63750466)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_054511" FT VARIANT 5 FT /note="P -> Q (decreases protein levels; dbSNP:rs56170584)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079822" FT VARIANT 8 FT /note="T -> M (in dbSNP:rs17217716)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:12792735, ECO:0000269|Ref.9" FT /id="VAR_013171" FT VARIANT 13 FT /note="S -> I (in CRC; uncertain significance; FT dbSNP:rs63749907)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043736" FT VARIANT 17 FT /note="V -> F (in gastric cancer; uncertain significance; FT cryptic acceptor splice site suppressed on ex vivo splicing FT assay; dbSNP:rs63750966)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043737" FT VARIANT 33 FT /note="T -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751107)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043738" FT VARIANT 40 FT /note="G -> S (in CRC; uncertain significance; FT dbSNP:rs63751260)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043739" FT VARIANT 43 FT /note="Y -> C (in dbSNP:rs17217723)" FT /evidence="ECO:0000269|Ref.9" FT /id="VAR_019233" FT VARIANT 44 FT /note="T -> M (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs587779085)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043740" FT VARIANT 45 FT /note="A -> V (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs63750285)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043741" FT VARIANT 46 FT /note="H -> Q (in LYNCH1; likely benign; dbSNP:rs33946261)" FT /evidence="ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:8700523" FT /id="VAR_004470" FT VARIANT 55 FT /note="R -> G (decreases protein levels; FT dbSNP:rs587782354)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079823" FT VARIANT 92 FT /note="Missing (in LYNCH1; uncertain significance)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18561205" FT /id="VAR_043742" FT VARIANT 93 FT /note="L -> F (in LYNCH1; dbSNP:rs63751429)" FT /evidence="ECO:0000269|PubMed:15896463" FT /id="VAR_043743" FT VARIANT 96 FT /note="R -> H (in dbSNP:rs63750002)" FT /evidence="ECO:0000269|PubMed:7726159" FT /id="VAR_004471" FT VARIANT 98 FT /note="Y -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750887)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043744" FT VARIANT 102 FT /note="V -> I (in LYNCH1; likely benign; FT dbSNP:rs193922373)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043745" FT VARIANT 106 FT /note="R -> K (in dbSNP:rs41295286)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038026" FT VARIANT 110 FT /note="K -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043746" FT VARIANT 127 FT /note="N -> S (in LYNCH1; benign; presumed to enhance FT cancer risk considerably when associated with P-328; shows FT significantly decreased repair efficiency when associated FT with variant P-328; dbSNP:rs17217772)" FT /evidence="ECO:0000269|PubMed:12655564, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22581703, ECO:0000269|Ref.9" FT /id="VAR_019234" FT VARIANT 139 FT /note="N -> S (in LYNCH1; dbSNP:rs1553350676)" FT /id="VAR_004472" FT VARIANT 145 FT /note="I -> M (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750124)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_004473" FT VARIANT 161 FT /note="V -> D (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750126)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012936" FT VARIANT 162 FT /note="G -> A (in LYNCH1; dbSNP:rs63750773)" FT /evidence="ECO:0000269|PubMed:17128465" FT /id="VAR_054512" FT VARIANT 162 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; associated with an abnormal subcellular FT localization pattern; affects protein stability; loss of FT protein expression; dbSNP:rs63750624)" FT /evidence="ECO:0000269|PubMed:15991316, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043747" FT VARIANT 163 FT /note="V -> D (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043748" FT VARIANT 163 FT /note="V -> G (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022670" FT VARIANT 164 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750582)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043749" FT VARIANT 165 FT /note="Y -> D (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779163)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067284" FT VARIANT 167 FT /note="D -> H (in LYNCH1; benign; shows reduced mismatch FT binding; does not show a decreased expression level of the FT MutS alpha complex; not associated with an abnormal FT subcellular localization pattern; normal mismatch repair FT activity; dbSNP:rs63750255)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:8872463" FT /id="VAR_004474" FT VARIANT 169 FT /note="I -> V (in LYNCH1 and CRC; likely benign; FT dbSNP:rs63750716)" FT /evidence="ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043750" FT VARIANT 173 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750070)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043751" FT VARIANT 175 FT /note="L -> P (in LYNCH1; dbSNP:rs63751291)" FT /evidence="ECO:0000269|PubMed:12655568" FT /id="VAR_043752" FT VARIANT 177 FT /note="E -> H (in LYNCH1; uncertain significance; normal FT mismatch repair activity; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067285" FT VARIANT 187 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043753" FT VARIANT 187 FT /note="L -> R (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076352" FT VARIANT 198 FT /note="E -> G (in dbSNP:rs63750327)" FT /id="VAR_054513" FT VARIANT 199 FT /note="C -> R (in LYNCH1; also found in a patient with FT glioma; no effect on MSH2 splicing; dbSNP:rs63751110)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9777949" FT /id="VAR_012937" FT VARIANT 203 FT /note="G -> R (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs587779973)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043754" FT VARIANT 205 FT /note="E -> Q (shows no defects; normal mismatch repair FT activity; dbSNP:rs63749984)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068705" FT VARIANT 216 FT /note="I -> V (in LYNCH1; uncertain significance; shows FT slightly reduced mismatch binding or release efficiency; FT dbSNP:rs63749936)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012938" FT VARIANT 246 FT /note="K -> Q (in LYNCH1; uncertain significance; FT dbSNP:rs63750881)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043755" FT VARIANT 265..314 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004475" FT VARIANT 272 FT /note="A -> V (in LYNCH1; benign; shows slightly reduced FT mismatch binding or release efficiency; results in partial FT MSH2 exon 5 skipping; normal mismatch repair activity; FT dbSNP:rs34136999)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043756" FT VARIANT 283 FT /note="D -> Y (in LYNCH1; dbSNP:rs63750381)" FT /evidence="ECO:0000269|PubMed:15870828" FT /id="VAR_043757" FT VARIANT 305 FT /note="A -> T (in LYNCH1; normal mismatch repair activity; FT dbSNP:rs63751454)" FT /evidence="ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004476" FT VARIANT 322 FT /note="G -> D (in dbSNP:rs4987188)" FT /evidence="ECO:0000269|PubMed:10023327, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703, FT ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:9087566, FT ECO:0000269|PubMed:9298827, ECO:0000269|Ref.9" FT /id="VAR_004477" FT VARIANT 323 FT /note="S -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:9240418" FT /id="VAR_012939" FT VARIANT 323 FT /note="S -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043758" FT VARIANT 328 FT /note="A -> P (shows significantly decreased repair FT efficiency when associated with variant S-127; presumed to FT enhance cancer risk considerably when associated with FT variant S-127; dbSNP:rs753237286)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068706" FT VARIANT 331 FT /note="N -> D (in LYNCH1; uncertain significance; no effect FT on MSH2 splicing; dbSNP:rs267607938)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054514" FT VARIANT 333 FT /note="C -> Y (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750828)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043759" FT VARIANT 335 FT /note="T -> I (in LYNCH1; uncertain significance; FT dbSNP:rs63750602)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043760" FT VARIANT 336 FT /note="P -> S (in LYNCH1; dbSNP:rs63751062)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043761" FT VARIANT 342 FT /note="V -> I (in CRC; uncertain significance; FT dbSNP:rs63749879)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043762" FT VARIANT 349 FT /note="P -> L (in LYNCH1; dbSNP:rs587779067)" FT /evidence="ECO:0000269|PubMed:15342696" FT /id="VAR_043763" FT VARIANT 359 FT /note="R -> S (in LYNCH1; shows a decreased expression FT level of the MutS alpha complex; associated with an FT abnormal subcellular localization pattern; FT dbSNP:rs63751617)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:18781619" FT /id="VAR_043764" FT VARIANT 367 FT /note="V -> I (shows no defects; normal mismatch repair FT activity; dbSNP:rs80285180)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068707" FT VARIANT 385 FT /note="P -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs564736113)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067286" FT VARIANT 390 FT /note="L -> F (in LYNCH1 and CRC; benign; may decrease FT mismatch repair activity; dbSNP:rs17224367)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:8690195, FT ECO:0000269|PubMed:9621522, ECO:0000269|Ref.9" FT /id="VAR_004478" FT VARIANT 393 FT /note="K -> M (in LYNCH1; dbSNP:rs1558478490)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_043765" FT VARIANT 419 FT /note="Q -> K (in CRC; likely benign; decreased mismatch FT repair activity; dbSNP:rs63750006)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15996210, FT ECO:0000269|PubMed:8690195" FT /id="VAR_012940" FT VARIANT 440 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043766" FT VARIANT 470 FT /note="V -> E (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607959)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054515" FT VARIANT 487 FT /note="D -> E (decreased mismatch repair activity; FT dbSNP:rs35107951)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068708" FT VARIANT 492 FT /note="M -> V (in LYNCH1)" FT /id="VAR_043767" FT VARIANT 506 FT /note="D -> Y (in LYNCH1 and CRC; sporadic early-onset CRC; FT decreased mismatch repair activity; dbSNP:rs63750492)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_012941" FT VARIANT 519 FT /note="F -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1371291280)" FT /evidence="ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614" FT /id="VAR_067287" FT VARIANT 524 FT /note="R -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751207)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:9889267" FT /id="VAR_004479" FT VARIANT 534 FT /note="R -> P (no effect on protein levels; FT dbSNP:rs587778523)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079824" FT VARIANT 552 FT /note="T -> P (in LYNCH1; dbSNP:rs63750838)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043768" FT VARIANT 554 FT /note="S -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751656)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012942" FT VARIANT 562 FT /note="E -> V (in LYNCH1; dbSNP:rs63750997)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004480" FT VARIANT 564 FT /note="T -> A (in LYNCH1; benign; dbSNP:rs55778204)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043769" FT VARIANT 583 FT /note="N -> S (in LYNCH1; dbSNP:rs201118107)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043770" FT VARIANT 596 FT /note="N -> S (in LYNCH1; uncertain significance; FT dbSNP:rs41295288)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8993976" FT /id="VAR_012943" FT VARIANT 596 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63749831)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:7874129, FT ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9311737" FT /id="VAR_004481" FT VARIANT 600 FT /note="A -> V (in LYNCH1; dbSNP:rs63751236)" FT /evidence="ECO:0000269|PubMed:11920458" FT /id="VAR_043771" FT VARIANT 603 FT /note="D -> N (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; affects protein stability; loss FT of protein expression; dbSNP:rs63750657)" FT /evidence="ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043772" FT VARIANT 610 FT /note="H -> N (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607980)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054516" FT VARIANT 619 FT /note="Y -> C (in CRC; uncertain significance; FT dbSNP:rs63749982)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043773" FT VARIANT 622 FT /note="P -> L (in LYNCH1; decreased mismatch repair FT activity; confers multiple biochemical defects; FT dbSNP:rs28929483)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:8261515" FT /id="VAR_004482" FT VARIANT 629 FT /note="Q -> R (in LYNCH1; benign; dbSNP:rs61756468)" FT /evidence="ECO:0000269|PubMed:12132870, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15996210" FT /id="VAR_043774" FT VARIANT 636 FT /note="A -> P (in LYNCH1; decreased mismatch binding FT activity; dbSNP:rs63750875)" FT /evidence="ECO:0000269|PubMed:10528862, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_012944" FT VARIANT 638 FT /note="R -> G (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607981)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054517" FT VARIANT 639 FT /note="H -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779116)" FT /evidence="ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9419403" FT /id="VAR_043775" FT VARIANT 639 FT /note="H -> Y (in LYNCH1; the equivalent substitution in FT yeast does not affect mismatch repair efficiency in vitro; FT dbSNP:rs28929484)" FT /evidence="ECO:0000269|PubMed:11555625, FT ECO:0000269|PubMed:8261515" FT /id="VAR_004483" FT VARIANT 641 FT /note="C -> G (in dbSNP:rs63749946)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004484" FT VARIANT 645 FT /note="Q -> E (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607982)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054518" FT VARIANT 647 FT /note="E -> K (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043776" FT VARIANT 656 FT /note="Y -> H (in LYNCH1; somatic mutation; FT dbSNP:rs1573567393)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043777" FT VARIANT 660 FT /note="D -> G (in LYNCH1; dbSNP:rs1085308057)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022671" FT VARIANT 669 FT /note="G -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751668)" FT /evidence="ECO:0000269|PubMed:22371642" FT /id="VAR_067761" FT VARIANT 670 FT /note="P -> L (in dbSNP:rs41294982)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038027" FT VARIANT 671 FT /note="N -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63751232)" FT /evidence="ECO:0000269|PubMed:15300854, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043778" FT VARIANT 674 FT /note="G -> A (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs267607996)" FT /evidence="ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_076353" FT VARIANT 674 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:18625694, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614" FT /id="VAR_067288" FT VARIANT 674 FT /note="G -> S (in LYNCH1; somatic mutation; FT dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004485" FT VARIANT 675 FT /note="K -> A (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; requires 2 nucleotide FT substitutions; dbSNP:rs587779128)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067289" FT VARIANT 679 FT /note="I -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043779" FT VARIANT 688 FT /note="M -> I (in LYNCH1; dbSNP:rs63750790)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:9559627" FT /id="VAR_012945" FT VARIANT 688 FT /note="M -> V (in LYNCH1; loss of protein expression; FT dbSNP:rs1573569964)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076354" FT VARIANT 692 FT /note="G -> R (in LYNCH1; dbSNP:rs63750232)" FT /evidence="ECO:0000269|PubMed:10612836" FT /id="VAR_009250" FT VARIANT 696 FT /note="P -> L (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607994)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054519" FT VARIANT 697 FT /note="C -> F (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; confers multiple FT biochemical defects; dbSNP:rs63750398)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9298827" FT /id="VAR_004486" FT VARIANT 697 FT /note="C -> R (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs63750961)" FT /evidence="ECO:0000269|PubMed:10612836, FT ECO:0000269|PubMed:18561205" FT /id="VAR_009251" FT VARIANT 714 FT /note="A -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63751224)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043780" FT VARIANT 722 FT /note="V -> I (in LYNCH1; dbSNP:rs587781996)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076355" FT VARIANT 723 FT /note="S -> F (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63750794)" FT /evidence="ECO:0000269|PubMed:11920458, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:22102614" FT /id="VAR_043781" FT VARIANT 729 FT /note="M -> V (in LYNCH1; somatic mutation; FT dbSNP:rs1558520059)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043782" FT VARIANT 732 FT /note="T -> I (in LYNCH1; somatic mutation; FT dbSNP:rs730881765)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043783" FT VARIANT 745..746 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043784" FT VARIANT 748 FT /note="D -> Y (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608007)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054520" FT VARIANT 749 FT /note="E -> K (in LYNCH1; decreased mismatch repair FT activity; no loss of protein expression; dbSNP:rs63751477)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043785" FT VARIANT 759 FT /note="G -> E (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; dbSNP:rs386833406)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067290" FT VARIANT 770 FT /note="I -> V (in dbSNP:rs63750684)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004487" FT VARIANT 779 FT /note="M -> I (in dbSNP:rs41295292)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038028" FT VARIANT 805 FT /note="L -> V (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs779182536)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067291" FT VARIANT 807 FT /note="T -> S (in dbSNP:rs41295294)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038029" FT VARIANT 813 FT /note="M -> I (no effect on protein levels; FT dbSNP:rs587781678)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079825" FT VARIANT 813 FT /note="M -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63749841)" FT /evidence="ECO:0000269|PubMed:12373605" FT /id="VAR_043786" FT VARIANT 824 FT /note="Q -> E (in gastric cancer; uncertain significance; FT dbSNP:rs63750623)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043787" FT VARIANT 834 FT /note="A -> T (in LYNCH1; likely benign; decreased mismatch FT repair activity; shows no functional defects in gel shift FT assay; dbSNP:rs63750757)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004488" FT VARIANT 835 FT /note="N -> H (in dbSNP:rs41295296)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038030" FT VARIANT 839 FT /note="H -> Q (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608016)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054521" FT VARIANT 839 FT /note="H -> R (in LYNCH1; decreases protein levels; FT dbSNP:rs63750027)" FT /evidence="ECO:0000269|PubMed:15613555, FT ECO:0000269|PubMed:28494185" FT /id="VAR_043788" FT VARIANT 843 FT /note="C -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1667495338)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067292" FT VARIANT 845 FT /note="K -> E (in LYNCH1; dbSNP:rs63750571)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_013172" FT VARIANT 853 FT /note="E -> A (in LYNCH1; uncertain significance; FT dbSNP:rs63750797)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043789" FT VARIANT 860 FT /note="S -> L (in LYNCH1; likely benign; normal mismatch FT repair activity; dbSNP:rs63750849)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067293" FT VARIANT 868 FT /note="P -> A (in gastric cancer; uncertain significance; FT dbSNP:rs63751400)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043790" FT VARIANT 870 FT /note="A -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750709)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043791" FT VARIANT 873 FT /note="C -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750795)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043792" FT VARIANT 886 FT /note="E -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750350)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043793" FT VARIANT 905 FT /note="T -> R (in LYNCH1; likely benign; FT dbSNP:rs267608022)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004489" FT VARIANT 909 FT /note="K -> I (found in a colorectal cancer sample; normal FT mismatch repair activity; dbSNP:rs34319539)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068709" FT VARIANT 911 FT /note="L -> R (in dbSNP:rs41295182)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038031" FT VARIANT 923 FT /note="V -> E (in LYNCH1; uncertain significance; FT dbSNP:rs146421227)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043794" FT VARIANT 931 FT /note="K -> T (in LYNCH1; dbSNP:rs267608023)" FT /evidence="ECO:0000269|PubMed:15046096" FT /id="VAR_043795" FT MUTAGEN 675 FT /note="K->R: No effect on mismatch binding, complete loss FT of DNA repair function when associated with MSH6 mutant R- FT 1140." FT /evidence="ECO:0000269|PubMed:9564049" FT MUTAGEN 845 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-847, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 847 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 871 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 892 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-871." FT /evidence="ECO:0000269|PubMed:24882211" FT CONFLICT 784 FT /note="F -> I (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT CONFLICT 836 FT /note="F -> S (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT HELIX 14..24 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 33..38 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 48..56 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 59..61 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 65..71 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 82..94 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 117..124 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 129..131 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 137..139 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 147..152 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 160..167 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 168..171 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 172..179 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 197..204 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 208..220 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 223..227 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 229..232 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 234..236 FT /evidence="ECO:0007829|PDB:8OLX" FT HELIX 237..244 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:8OLX" FT TURN 252..254 FT /evidence="ECO:0007829|PDB:2O8E" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 259..262 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 264..277 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 279..281 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 283..285 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 286..288 FT /evidence="ECO:0007829|PDB:8R7E" FT STRAND 289..293 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 296..298 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 304..309 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 321..323 FT /evidence="ECO:0007829|PDB:8OMA" FT HELIX 326..330 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 336..347 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 353..367 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 370..377 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 378..380 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 387..395 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 401..411 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 424..426 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 432..435 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 437..455 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 476..502 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 517..519 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 521..525 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 527..530 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 531..535 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 536..538 FT /evidence="ECO:0007829|PDB:8OMO" FT STRAND 540..544 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8OMQ" FT STRAND 549..552 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 556..563 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 564..567 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 568..585 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 589..613 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 615..617 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 623..625 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 631..637 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 640..644 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:8R7C" FT STRAND 653..658 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 659..661 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 664..668 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 671..674 FT /evidence="ECO:0007829|PDB:8OMO" FT HELIX 675..691 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 695..703 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 706..711 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 718..721 FT /evidence="ECO:0007829|PDB:8OMQ" FT HELIX 724..738 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 744..749 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 750..753 FT /evidence="ECO:0007829|PDB:8R7E" FT HELIX 756..772 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 777..783 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 785..792 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 797..807 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 810..820 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 827..833 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 838..850 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 851..855 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 875..892 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 896..898 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 901..917 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 921..928 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:8AG6" SQ SEQUENCE 934 AA; 104743 MW; 664A058C78242E05 CRC64; MAVQPKETLQ LESAAEVGFV RFFQGMPEKP TTTVRLFDRG DFYTAHGEDA LLAAREVFKT QGVIKYMGPA GAKNLQSVVL SKMNFESFVK DLLLVRQYRV EVYKNRAGNK ASKENDWYLA YKASPGNLSQ FEDILFGNND MSASIGVVGV KMSAVDGQRQ VGVGYVDSIQ RKLGLCEFPD NDQFSNLEAL LIQIGPKECV LPGGETAGDM GKLRQIIQRG GILITERKKA DFSTKDIYQD LNRLLKGKKG EQMNSAVLPE MENQVAVSSL SAVIKFLELL SDDSNFGQFE LTTFDFSQYM KLDIAAVRAL NLFQGSVEDT TGSQSLAALL NKCKTPQGQR LVNQWIKQPL MDKNRIEERL NLVEAFVEDA ELRQTLQEDL LRRFPDLNRL AKKFQRQAAN LQDCYRLYQG INQLPNVIQA LEKHEGKHQK LLLAVFVTPL TDLRSDFSKF QEMIETTLDM DQVENHEFLV KPSFDPNLSE LREIMNDLEK KMQSTLISAA RDLGLDPGKQ IKLDSSAQFG YYFRVTCKEE KVLRNNKNFS TVDIQKNGVK FTNSKLTSLN EEYTKNKTEY EEAQDAIVKE IVNISSGYVE PMQTLNDVLA QLDAVVSFAH VSNGAPVPYV RPAILEKGQG RIILKASRHA CVEVQDEIAF IPNDVYFEKD KQMFHIITGP NMGGKSTYIR QTGVIVLMAQ IGCFVPCESA EVSIVDCILA RVGAGDSQLK GVSTFMAEML ETASILRSAT KDSLIIIDEL GRGTSTYDGF GLAWAISEYI ATKIGAFCMF ATHFHELTAL ANQIPTVNNL HVTALTTEET LTMLYQVKKG VCDQSFGIHV AELANFPKHV IECAKQKALE LEEFQYIGES QGYDIMEPAA KKCYLEREQG EKIIQEFLSK VKQMPFTEMS EENITIKLKQ LKAEVIAKNN SFVNEIISRI KVTT // ID MSH6_HUMAN Reviewed; 1360 AA. AC P52701; B4DF41; B4E3I4; F5H2F9; O43706; O43917; Q8TCX4; Q9BTB5; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 2. DT 28-JAN-2026, entry version 259. DE RecName: Full=DNA mismatch repair protein Msh6 {ECO:0000250|UniProtKB:P54276}; DE Short=hMSH6 {ECO:0000303|PubMed:8942985}; DE AltName: Full=G/T mismatch-binding protein {ECO:0000303|PubMed:7604265}; DE Short=GTBP {ECO:0000303|PubMed:9455487}; DE Short=GTMBP {ECO:0000250|UniProtKB:P54276}; DE AltName: Full=MutS protein homolog 6 {ECO:0000312|HGNC:HGNC:7329}; DE AltName: Full=MutS-alpha 160 kDa subunit; DE Short=p160 {ECO:0000303|PubMed:7604264}; GN Name=MSH6 {ECO:0000312|HGNC:HGNC:7329}; Synonyms=GTBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT GLU-39, AND SUBUNIT. RX PubMed=8942985; DOI=10.1073/pnas.93.24.13629; RA Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., RA Kolodner R.D., Fishel R.; RT "hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6."; RL Proc. Natl. Acad. Sci. U.S.A. 93:13629-13634(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING. RX PubMed=9455487; DOI=10.1093/dnares/4.5.359; RA Shiwaku H.O., Wakatsuki S., Mori Y., Fukushige S., Horii A.; RT "Alternative splicing of GTBP in normal human tissues."; RL DNA Res. 4:359-362(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Cerebellum, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-39; VAL-396; ALA-623 RP AND VAL-886. RG NIEHS SNPs program; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 69-1360, AND PARTIAL PROTEIN SEQUENCE. RX PubMed=7604265; DOI=10.1126/science.7604265; RA Palombo F., Gallinari P., Iaccarino I., Lettieri T., Hughes M., RA D'Arrigo A., Truong O., Hsuan J.J., Jiricny J.; RT "GTBP, a 160-kilodalton protein essential for mismatch-binding activity in RT human cells."; RL Science 268:1912-1914(1995). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-116. RX PubMed=8838326; DOI=10.1006/geno.1996.0067; RA Nicolaides N.C., Palombo F., Kinzler K.W., Vogelstein B., Jiricny J.; RT "Molecular cloning of the N-terminus of GTBP."; RL Genomics 31:395-397(1996). RN [9] RP CHARACTERIZATION, PARTIAL PROTEIN SEQUENCE, AND SUBUNIT. RX PubMed=7604264; DOI=10.1126/science.7604264; RA Drummond J.T., Li G.-M., Longley M.J., Modrich P.; RT "Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair RT to tumor cells."; RL Science 268:1909-1912(1995). RN [10] RP FUNCTION. RX PubMed=9822680; DOI=10.1074/jbc.273.48.32055; RA Blackwell L.J., Martik D., Bjornson K.P., Bjornson E.S., Modrich P.; RT "Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is RT consistent with an ATP-dependent translocation mechanism."; RL J. Biol. Chem. 273:32055-32062(1998). RN [11] RP FUNCTION. RX PubMed=9822679; DOI=10.1074/jbc.273.48.32049; RA Blackwell L.J., Bjornson K.P., Modrich P.; RT "DNA-dependent activation of the hMutSalpha ATPase."; RL J. Biol. Chem. 273:32049-32054(1998). RN [12] RP FUNCTION, AND MUTAGENESIS OF LYS-1140. RX PubMed=9564049; DOI=10.1093/emboj/17.9.2677; RA Iaccarino I., Marra G., Palombo F., Jiricny J.; RT "hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute RT differently to the ATPase activity of hMutSalpha."; RL EMBO J. 17:2677-2686(1998). RN [13] RP MISMATCH-BINDING. RX PubMed=9889267; DOI=10.1093/nar/27.3.736; RA Clark A.B., Cook M.E., Tran H.T., Gordenin D.A., Resnick M.A., Kunkel T.A.; RT "Functional analysis of human MutSalpha and MutSbeta complexes in yeast."; RL Nucleic Acids Res. 27:736-742(1999). RN [14] RP FUNCTION. RX PubMed=10078208; DOI=10.1016/s1097-2765(00)80316-0; RA Gradia S., Subramanian D., Wilson T., Acharya S., Makhov A., Griffith J., RA Fishel R.; RT "hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched RT DNA."; RL Mol. Cell 3:255-261(1999). RN [15] RP FUNCTION. RX PubMed=10660545; DOI=10.1074/jbc.275.6.3922; RA Gradia S., Acharya S., Fishel R.; RT "The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular RT switch."; RL J. Biol. Chem. 275:3922-3930(2000). RN [16] RP FUNCTION. RX PubMed=15064730; DOI=10.1038/sj.onc.1207462; RA Yang Q., Zhang R., Wang X.W., Linke S.P., Sengupta S., Hickson I.D., RA Pedrazzi G., Perrera C., Stagljar I., Littman S.J., Modrich P., RA Harris C.C.; RT "The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase."; RL Oncogene 23:3749-3756(2004). RN [17] RP PHOSPHORYLATION BY PRKCZ. RX PubMed=15808853; DOI=10.1016/j.jmb.2005.02.001; RA Hernandez-Pigeon H., Quillet-Mary A., Louat T., Schambourg A., Humbert O., RA Selves J., Salles B., Laurent G., Lautier D.; RT "hMutS alpha is protected from ubiquitin-proteasome-dependent degradation RT by atypical protein kinase C zeta phosphorylation."; RL J. Mol. Biol. 348:63-74(2005). RN [18] RP IDENTIFICATION OF MSH6 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [19] RP INVOLVEMENT IN LYNCH5. RX PubMed=9354786; DOI=10.1038/ng1197-271; RA Miyaki M., Konishi M., Tanaka K., Kikuchi-Yanoshita R., Muraoka M., RA Yasuno M., Igari T., Koike M., Chiba M., Mori T.; RT "Germline mutation of MSH6 as the cause of hereditary nonpolyposis RT colorectal cancer."; RL Nat. Genet. 17:271-272(1997). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219; SER-227 AND SER-261, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-41 AND SER-43, RP VARIANT [LARGE SCALE ANALYSIS] GLU-39, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [22] RP INVOLVEMENT IN MMRCS. RX PubMed=17557300; DOI=10.1002/humu.20569; RA Auclair J., Leroux D., Desseigne F., Lasset C., Saurin J.C., Joly M.O., RA Pinson S., Xu X.L., Montmain G., Ruano E., Navarro C., Puisieux A., RA Wang Q.; RT "Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a RT likely cause of PMS2 gene inactivation."; RL Hum. Mutat. 28:1084-1090(2007). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-309, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-79; SER-91; SER-137; RP SER-200; SER-227; SER-252; SER-254; SER-256 AND SER-261, AND IDENTIFICATION RP BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-70 AND LYS-504, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-227 AND RP SER-830, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-219; RP SER-227; SER-252; SER-261; THR-269; SER-274; SER-275; SER-279; SER-280 AND RP SER-309, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-227; RP SER-252; SER-309; THR-488; SER-830; SER-935 AND THR-1010, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP CHARACTERIZATION OF VARIANTS LYNCH5 LEU-128; ILE-144; ARG-566; LEU-623; RP THR-728; GLY-881 DELINS LYS-SER; THR-1087; HIS-1095; LYS-1193 AND GLN-1354, RP CHARACTERIZATION OF VARIANT ARG-1087, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [33] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 UL12 (MICROBIAL INFECTION). RX PubMed=21957315; DOI=10.1128/jvi.05487-11; RA Mohni K.N., Mastrocola A.S., Bai P., Weller S.K., Heinen C.D.; RT "DNA mismatch repair proteins are required for efficient herpes simplex RT virus 1 replication."; RL J. Virol. 85:12241-12253(2011). RN [34] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-103 AND RP 105-TRP-TRP-106. RX PubMed=23622243; DOI=10.1016/j.cell.2013.03.025; RA Li F., Mao G., Tong D., Huang J., Gu L., Yang W., Li G.M.; RT "The histone mark H3K36me3 regulates human DNA mismatch repair through its RT interaction with MutSalpha."; RL Cell 153:590-600(2013). RN [35] RP IDENTIFICATION IN THE MMR COMPLEX, AND INTERACTION WITH MCM9. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [36] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS). RX PubMed=17531815; DOI=10.1016/j.molcel.2007.04.018; RA Warren J.J., Pohlhaus T.J., Changela A., Iyer R.R., Modrich P.L., RA Beese L.S.; RT "Structure of the human MutSalpha DNA lesion recognition complex."; RL Mol. Cell 26:579-592(2007). RN [37] RP VARIANTS VAL-1213 AND ILE-1260. RX PubMed=7604266; DOI=10.1126/science.7604266; RA Papadopoulos N., Nicolaides N.C., Liu B., Parsons R., Lengauer C., RA Palombo F., D'Arrigo A., Markowitz S., Willson J.K.V., Kinzler K.W., RA Jiricny J., Vogelstein B.; RT "Mutations of GTBP in genetically unstable cells."; RL Science 268:1915-1917(1995). RN [38] RP VARIANTS LYNCH5 ILE-144 AND CYS-850. RX PubMed=10521294; DOI=10.1086/302612; RA Wu Y., Berends M.J.W., Mensink R.G.J., Kempinga C., Sijmons R.H., RA van Der Zee A.G.J., Hollema H., Kleibeuker J.H., Buys C.H.C.M., RA Hofstra R.M.W.; RT "Association of hereditary nonpolyposis colorectal cancer-related tumors RT displaying low microsatellite instability with MSH6 germline mutations."; RL Am. J. Hum. Genet. 65:1291-1298(1999). RN [39] RP VARIANTS CRC ILE-285; ARG-566; GLY-803 AND THR-1087, AND VARIANTS GLU-39; RP ASP-220; VAL-396 AND LEU-800. RX PubMed=10537275; RA Kolodner R.D., Tytell J.D., Schmeits J.L., Kane M.F., Das Gupta R., RA Weger J., Wahlberg S., Fox E.A., Peel D., Ziogas A., Garber J.E., RA Syngal S., Anton-Culver H., Li F.P.; RT "Germ-line msh6 mutations in colorectal cancer families."; RL Cancer Res. 59:5068-5074(1999). RN [40] RP VARIANT LYNCH5 GLU-698. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [41] RP VARIANT CRC MET-1284. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [42] RP VARIANTS CRC VAL-20; ALA-878 AND HIS-901, AND VARIANTS ENDMC VAL-20; RP ALA-878 AND HIS-901. RX PubMed=11153917; DOI=10.1007/s004390000417; RA Charames G.S., Millar A.L., Pal T., Narod S., Bapat B.; RT "Do MSH6 mutations contribute to double primary cancers of the colorectum RT and endometrium?"; RL Hum. Genet. 107:623-629(2000). RN [43] RP VARIANTS GLU-39 AND SER-340. RX PubMed=10699937; RX DOI=10.1002/(sici)1097-0215(20000301)85:5<606::aid-ijc2>3.0.co;2-b; RA Plaschke J., Kruppa C., Tischler R., Bocker T., Pistorius S., Dralle H., RA Rueschoff J., Saeger H.D., Fishel R., Schackert H.K.; RT "Sequence analysis of the mismatch repair gene hMSH6 in the germline of RT patients with familial and sporadic colorectal cancer."; RL Int. J. Cancer 85:606-613(2000). RN [44] RP VARIANTS CRC ALA-685; GLN-772; ALA-800; MET-854; ALA-878; VAL-1031 AND RP ARG-1158. RX PubMed=11470537; DOI=10.1016/s0378-1119(01)00517-0; RA Ohmiya N., Matsumoto S., Yamamoto H., Baranovskaya S., Malkhosyan S.R., RA Perucho M.; RT "Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal RT cancers of the microsatellite mutator phenotype."; RL Gene 272:301-313(2001). RN [45] RP VARIANT LYNCH5 ALA-878. RX PubMed=11586295; DOI=10.1038/ng1001-137; RA Wu Y., Berends M.J.W., Sijmons R.H., Mensink R.G.J., Verlind E., Kooi K.A., RA van der Sluis T., Kempinga C., van der Zee A.G.J., Hollema H., RA Buys C.H.C.M., Kleibeuker J.H., Hofstra R.M.W.; RT "A role for MLH3 in hereditary nonpolyposis colorectal cancer."; RL Nat. Genet. 29:137-138(2001). RN [46] RP VARIANTS CRC ILE-144; ARG-522; MET-725; CYS-850; ALA-878; ASP-1021; RP MET-1100; ILE-1219 AND ASP-1248. RX PubMed=11709755; DOI=10.1086/337944; RA Berends M.J.W., Wu Y., Sijmons R.H., Mensink R.G.J., van der Sluis T., RA Hordijk-Hos J.M., de Vries E.G.E., Hollema H., Karrenbeld A., RA Buys C.H.C.M., van der Zee A.G.J., Hofstra R.M.W., Kleibeuker J.H.; RT "Molecular and clinical characteristics of MSH6 variants: an analysis of 25 RT index carriers of a germline variant."; RL Am. J. Hum. Genet. 70:26-37(2002). RN [47] RP VARIANT CRC HIS-976. RX PubMed=11807791; DOI=10.1002/ijc.10097; RA Plaschke J., Krueger S., Pistorius S., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Involvement of hMSH6 in the development of hereditary and sporadic RT colorectal cancer revealed by immunostaining is based on germline RT mutations, but rarely on somatic inactivation."; RL Int. J. Cancer 97:643-648(2002). RN [48] RP VARIANT LYNCH5 VAL-492. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [49] RP VARIANTS CRC HIS-1095 AND GLN-1354. RX PubMed=12522549; DOI=10.1007/s00439-002-0866-4; RA Kariola R., Otway R., Loennqvist K.E., Raevaara T.E., Macrae F., Vos Y.J., RA Kohonen-Corish M., Hofstra R.M.W., Nystroem-Lahti M.; RT "Two mismatch repair gene mutations found in a colon cancer patient - which RT one is pathogenic?"; RL Hum. Genet. 112:105-109(2003). RN [50] RP VARIANTS GLU-39; ALA-54; ALA-509; MET-854 AND ALA-878. RX PubMed=14520694; DOI=10.1002/ijc.11415; RA Peterlongo P., Nafa K., Lerman G.S., Glogowski E., Shia J., Ye T.Z., RA Markowitz A.J., Guillem J.G., Kolachana P., Boyd J.A., Offit K., RA Ellis N.A.; RT "MSH6 germline mutations are rare in colorectal cancer families."; RL Int. J. Cancer 107:571-579(2003). RN [51] RP VARIANTS LEU-128; LEU-623; THR-728 AND LYS-1193, AND CHARACTERIZATION OF RP VARIANTS LEU-128; LEU-623; THR-728 AND LYS-1193. RX PubMed=15354210; DOI=10.1038/sj.bjc.6602129; RA Kariola R., Hampel H., Frankel W.L., Raevaara T.E., de la Chapelle A., RA Nystroem-Lahti M.; RT "MSH6 missense mutations are often associated with no or low cancer RT susceptibility."; RL Br. J. Cancer 91:1287-1292(2004). RN [52] RP VARIANT LYNCH5 TRP-772. RX PubMed=14974087; DOI=10.1002/humu.9217; RG The German HNPCC consortium; RA Plaschke J., Krueger S., Dietmaier W., Gebert J., Sutter C., Mangold E., RA Pagenstecher C., Holinski-Feder E., Schulmann K., Moeslein G., RA Rueschoff J., Engel C., Evans G., Schackert H.K.; RT "Eight novel MSH6 germline mutations in patients with familial and RT nonfamilial colorectal cancer selected by loss of protein expression in RT tumor tissue."; RL Hum. Mutat. 23:285-285(2004). RN [53] RP VARIANT LYNCH5 VAL-1163. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [54] RP VARIANT CRC PRO-449, AND VARIANT ENDMC PRO-449. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [55] RP VARIANTS CRC ASN-99; ASP-619; VAL-787; ALA-878 AND CYS-1076. RX PubMed=15483016; DOI=10.1200/jco.2004.02.033; RA Plaschke J., Engel C., Krueger S., Holinski-Feder E., Pagenstecher C., RA Mangold E., Moeslein G., Schulmann K., Gebert J., von Knebel Doeberitz M., RA Rueschoff J., Loeffler M., Schackert H.K.; RT "Lower incidence of colorectal cancer and later age of disease onset in 27 RT families with pathogenic MSH6 germline mutations compared with families RT with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal RT cancer consortium."; RL J. Clin. Oncol. 22:4486-4494(2004). RN [56] RP VARIANTS [LARGE SCALE ANALYSIS] ASP-221 AND VAL-492. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [57] RP VARIANTS THR-13; LEU-65; ILE-144; HIS-468; CYS-503; LEU-580; ALA-878; RP LEU-1232 AND GLY-1321. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [58] RP CHARACTERIZATION OF VARIANT LYNCH5 VAL-20, CHARACTERIZATION OF VARIANTS CRC RP HIS-976 AND ASP-1021, AND CHARACTERIZATION OF VARIANTS SER-25; VAL-326; RP VAL-396; VAL-492; CYS-503; ARG-522; ASN-610; CYS-850; ALA-878; TYR-1026; RP SER-1087 AND MET-1225. RX PubMed=22102614; DOI=10.1002/humu.22000; RA Drost M., Zonneveld J.B., van Hees S., Rasmussen L.J., Hofstra R.M., RA de Wind N.; RT "A rapid and cell-free assay to test the activity of lynch syndrome- RT associated MSH2 and MSH6 missense variants."; RL Hum. Mutat. 33:488-494(2012). RN [59] RP CHARACTERIZATION OF VARIANTS PRO-435; PRO-585; THR-677; ALA-878; HIS-1095 RP AND GLN-1354. RX PubMed=22581703; DOI=10.1002/humu.22119; RA Kantelinen J., Kansikas M., Candelin S., Hampel H., Smith B., Holm L., RA Kariola R., Nystrom M.; RT "Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs RT found in cancer patients."; RL Hum. Mutat. 33:1294-1301(2012). CC -!- FUNCTION: Component of the post-replicative DNA mismatch repair system CC (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA CC mismatches thereby initiating DNA repair. When bound, MutS alpha bends CC the DNA helix and shields approximately 20 base pairs, and recognizes CC single base mismatches and dinucleotide insertion-deletion loops (IDL) CC in the DNA. After mismatch binding, forms a ternary complex with the CC MutL alpha heterodimer, which is thought to be responsible for CC directing the downstream MMR events, including strand discrimination, CC excision, and resynthesis. ATP binding and hydrolysis play a pivotal CC role in mismatch repair functions. The ATPase activity associated with CC MutS alpha regulates binding similar to a molecular switch: mismatched CC DNA provokes ADP-->ATP exchange, resulting in a discernible CC conformational transition that converts MutS alpha into a sliding clamp CC capable of hydrolysis-independent diffusion along the DNA backbone. CC This transition is crucial for mismatch repair. MutS alpha may also CC play a role in DNA homologous recombination repair. Recruited on CC chromatin in G1 and early S phase via its PWWP domain that specifically CC binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early CC recruitment to chromatin to be replicated allowing a quick CC identification of mismatch repair to initiate the DNA mismatch repair CC reaction. {ECO:0000269|PubMed:10078208, ECO:0000269|PubMed:10660545, CC ECO:0000269|PubMed:15064730, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:23622243, ECO:0000269|PubMed:9564049, CC ECO:0000269|PubMed:9822679, ECO:0000269|PubMed:9822680}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC consisting of MSH2-MSH6 (MutS alpha) (PubMed:7604264, PubMed:8942985). CC Forms a ternary complex with MutL alpha (MLH1-PMS1). Interacts with CC MCM9 (PubMed:26300262). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). {ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:7604264, CC ECO:0000269|PubMed:8942985}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1 CC protein UL12. {ECO:0000269|PubMed:21957315}. CC -!- INTERACTION: CC P52701; Q9NXL9: MCM9; NbExp=3; IntAct=EBI-395529, EBI-2804985; CC P52701; P43246: MSH2; NbExp=11; IntAct=EBI-395529, EBI-355888; CC P52701; P01106: MYC; NbExp=2; IntAct=EBI-395529, EBI-447544; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23622243}. Chromosome CC {ECO:0000269|PubMed:23622243}. Note=Associates with H3K36me3 via its CC PWWP domain. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=GTBP-N; CC IsoId=P52701-1; Sequence=Displayed; CC Name=GTBP-alt; CC IsoId=P52701-2; Sequence=VSP_003291, VSP_003292; CC Name=3; CC IsoId=P52701-3; Sequence=VSP_054419; CC Name=4; CC IsoId=P52701-4; Sequence=VSP_055020; CC -!- DOMAIN: The PWWP domain specifically recognizes and binds trimethylated CC 'Lys-36' of histone H3 (H3K36me3). {ECO:0000269|PubMed:23622243}. CC -!- PTM: The N-terminus is blocked. CC -!- PTM: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation CC by the ubiquitin-proteasome pathway. {ECO:0000269|PubMed:15808853}. CC -!- DISEASE: Lynch syndrome 5 (LYNCH5) [MIM:614350]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10521294, CC ECO:0000269|PubMed:11586295, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14974087, ECO:0000269|PubMed:15365995, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614, CC ECO:0000269|PubMed:9354786}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:11153917, CC ECO:0000269|PubMed:14961575}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 3 (MMRCS3) [MIM:619097]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:17557300}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10537275, ECO:0000269|PubMed:10699937, CC ECO:0000269|PubMed:11153917, ECO:0000269|PubMed:11470537, CC ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:11807791, CC ECO:0000269|PubMed:12522549, ECO:0000269|PubMed:14520694, CC ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:15483016, CC ECO:0000269|PubMed:22102614}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutS family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/344/MSH6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U73737; AAB47425.1; -; Genomic_DNA. DR EMBL; U73732; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73733; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73734; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73736; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; D89645; BAA23674.1; -; Genomic_DNA. DR EMBL; D89646; BAA23675.1; -; mRNA. DR EMBL; AK293921; BAG57302.1; -; mRNA. DR EMBL; AK304735; BAG65496.1; -; mRNA. DR EMBL; AY082894; AAL87401.1; -; Genomic_DNA. DR EMBL; AC006509; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC004246; AAH04246.1; -; mRNA. DR EMBL; U54777; AAB39212.2; -; mRNA. DR EMBL; U28946; AAC50461.1; -; mRNA. DR CCDS; CCDS1836.1; -. [P52701-1] DR CCDS; CCDS62906.1; -. [P52701-3] DR PIR; JC5839; JC5839. DR RefSeq; NP_000170.1; NM_000179.3. [P52701-1] DR RefSeq; NP_001268421.1; NM_001281492.2. [P52701-3] DR RefSeq; NP_001268422.1; NM_001281493.2. [P52701-4] DR RefSeq; NP_001268423.1; NM_001281494.2. [P52701-4] DR RefSeq; NP_001393725.1; NM_001406796.1. [P52701-1] DR RefSeq; NP_001393738.1; NM_001406809.1. [P52701-1] DR RefSeq; NP_001393740.1; NM_001406811.1. [P52701-4] DR RefSeq; NP_001393741.1; NM_001406812.1. [P52701-4] DR RefSeq; NP_001393743.1; NM_001406814.1. [P52701-4] DR RefSeq; NP_001393744.1; NM_001406815.1. [P52701-4] DR RefSeq; NP_001393745.1; NM_001406816.1. [P52701-4] DR RefSeq; NP_001393752.1; NM_001406823.1. [P52701-4] DR RefSeq; NP_001393758.1; NM_001406829.1. [P52701-4] DR PDB; 2GFU; NMR; -; A=68-201. DR PDB; 2O8B; X-ray; 2.75 A; B=341-1360. DR PDB; 2O8C; X-ray; 3.37 A; B=341-1360. DR PDB; 2O8D; X-ray; 3.00 A; B=341-1360. DR PDB; 2O8E; X-ray; 3.30 A; B=341-1360. DR PDB; 2O8F; X-ray; 3.25 A; B=341-1360. DR PDB; 6OQM; X-ray; 2.20 A; A=87-198. DR PDB; 8AG6; EM; 2.80 A; B=2-1360. DR PDBsum; 2GFU; -. DR PDBsum; 2O8B; -. DR PDBsum; 2O8C; -. DR PDBsum; 2O8D; -. DR PDBsum; 2O8E; -. DR PDBsum; 2O8F; -. DR PDBsum; 6OQM; -. DR PDBsum; 8AG6; -. DR AlphaFoldDB; P52701; -. DR EMDB; EMD-15417; -. DR SMR; P52701; -. DR BioGRID; 109211; 288. DR ComplexPortal; CPX-80; DNA mismatch repair MutSalpha complex. DR CORUM; P52701; -. DR DIP; DIP-32972N; -. DR ELM; P52701; -. DR FunCoup; P52701; 3882. DR IntAct; P52701; 103. DR MINT; P52701; -. DR STRING; 9606.ENSP00000234420; -. DR ChEMBL; CHEMBL4739849; -. DR CarbonylDB; P52701; -. DR GlyCosmos; P52701; 1 site, 1 glycan. DR GlyGen; P52701; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P52701; -. DR MetOSite; P52701; -. DR PhosphoSitePlus; P52701; -. DR SwissPalm; P52701; -. DR BioMuta; MSH6; -. DR DMDM; 68067672; -. DR CPTAC; CPTAC-544; -. DR jPOST; P52701; -. DR MassIVE; P52701; -. DR PaxDb; 9606-ENSP00000234420; -. DR PeptideAtlas; P52701; -. DR ProteomicsDB; 25957; -. DR ProteomicsDB; 4004; -. DR ProteomicsDB; 56502; -. [P52701-1] DR ProteomicsDB; 56503; -. [P52701-2] DR Pumba; P52701; -. DR ABCD; P52701; 6 sequenced antibodies. DR Antibodypedia; 3963; 880 antibodies from 46 providers. DR CPTC; P52701; 2 antibodies. DR DNASU; 2956; -. DR Ensembl; ENST00000234420.11; ENSP00000234420.5; ENSG00000116062.20. [P52701-1] DR Ensembl; ENST00000540021.6; ENSP00000446475.1; ENSG00000116062.20. [P52701-3] DR GeneID; 2956; -. DR KEGG; hsa:2956; -. DR MANE-Select; ENST00000234420.11; ENSP00000234420.5; NM_000179.3; NP_000170.1. DR UCSC; uc002rwd.5; human. [P52701-1] DR AGR; HGNC:7329; -. DR CIViC; 2956; 7 evidence items across 7 molecular profiles. DR ClinPGx; PA184; -. DR CTD; 2956; -. DR DisGeNET; 2956; -. DR GeneCards; MSH6; -. DR GeneReviews; MSH6; -. DR HGNC; HGNC:7329; MSH6. DR HPA; ENSG00000116062; Low tissue specificity. DR MalaCards; MSH6; -. DR MIM; 114500; phenotype. DR MIM; 600678; gene. DR MIM; 608089; phenotype. DR MIM; 614350; phenotype. DR MIM; 619097; phenotype. DR OpenTargets; ENSG00000116062; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000116062; -. DR eggNOG; KOG0217; Eukaryota. DR GeneTree; ENSGT00550000075024; -. DR HOGENOM; CLU_002472_1_3_1; -. DR InParanoid; P52701; -. DR OMA; TPMMAQY; -. DR OrthoDB; 10252754at2759; -. DR PAN-GO; P52701; 4 GO annotations based on evolutionary models. DR PhylomeDB; P52701; -. DR PathwayCommons; P52701; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5632928; Defective Mismatch Repair Associated With MSH2. DR Reactome; R-HSA-5632968; Defective Mismatch Repair Associated With MSH6. DR SignaLink; P52701; -. DR SIGNOR; P52701; -. DR Agora; ENSG00000116062; -. DR BioGRID-ORCS; 2956; 15 hits in 1169 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MSH6; human. DR EvolutionaryTrace; P52701; -. DR GeneWiki; MSH6; -. DR GenomeRNAi; 2956; -. DR Pharos; P52701; Tbio. DR PRO; PR:P52701; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P52701; protein. DR Bgee; ENSG00000116062; Expressed in ventricular zone and 219 other cell types or tissues. DR ExpressionAtlas; P52701; baseline and differential. DR GO; GO:0000785; C:chromatin; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0032301; C:MutSalpha complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:HGNC-UCL. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0140003; F:histone H3K36me3 reader activity; IDA:UniProtKB. DR GO; GO:0030983; F:mismatched DNA binding; IDA:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006281; P:DNA repair; IDA:BHF-UCL. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; ISS:BHF-UCL. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; ISS:BHF-UCL. DR GO; GO:0045190; P:isotype switching; ISS:BHF-UCL. DR GO; GO:0000710; P:meiotic mismatch repair; ISS:BHF-UCL. DR GO; GO:0006298; P:mismatch repair; IDA:UniProtKB. DR GO; GO:0045910; P:negative regulation of DNA recombination; IDA:BHF-UCL. DR GO; GO:0009411; P:response to UV; ISS:BHF-UCL. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; ISS:BHF-UCL. DR GO; GO:0016447; P:somatic recombination of immunoglobulin gene segments; ISS:BHF-UCL. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd05837; PWWP_MSH6; 1. DR FunFam; 1.10.1420.10:FF:000005; DNA mismatch repair protein; 1. DR FunFam; 1.10.1420.10:FF:000006; DNA mismatch repair protein; 1. DR FunFam; 2.30.30.140:FF:000069; DNA mismatch repair protein; 1. DR FunFam; 3.30.420.110:FF:000004; DNA mismatch repair protein; 1. DR FunFam; 3.40.1170.10:FF:000002; DNA mismatch repair protein; 1. DR FunFam; 3.40.50.300:FF:000645; DNA mismatch repair protein; 1. DR Gene3D; 1.10.1420.10; -; 2. DR Gene3D; 2.30.30.140; -; 1. DR Gene3D; 3.40.1170.10; DNA repair protein MutS, domain I; 1. DR Gene3D; 3.30.420.110; MutS, connector domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR IDEAL; IID00054; -. DR InterPro; IPR007695; DNA_mismatch_repair_MutS-lik_N. DR InterPro; IPR017261; DNA_mismatch_repair_MutS/MSH. DR InterPro; IPR000432; DNA_mismatch_repair_MutS_C. DR InterPro; IPR007861; DNA_mismatch_repair_MutS_clamp. DR InterPro; IPR007696; DNA_mismatch_repair_MutS_core. DR InterPro; IPR016151; DNA_mismatch_repair_MutS_N. DR InterPro; IPR036187; DNA_mismatch_repair_MutS_sf. DR InterPro; IPR007860; DNA_mmatch_repair_MutS_con_dom. DR InterPro; IPR045076; MutS. DR InterPro; IPR036678; MutS_con_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR000313; PWWP_dom. DR NCBIfam; NF003810; PRK05399.1; 1. DR PANTHER; PTHR11361:SF148; DNA MISMATCH REPAIR PROTEIN MSH6; 1. DR PANTHER; PTHR11361; DNA MISMATCH REPAIR PROTEIN MUTS FAMILY MEMBER; 1. DR Pfam; PF01624; MutS_I; 1. DR Pfam; PF05188; MutS_II; 1. DR Pfam; PF05192; MutS_III; 1. DR Pfam; PF05190; MutS_IV; 1. DR Pfam; PF00488; MutS_V; 1. DR Pfam; PF00855; PWWP; 1. DR PIRSF; PIRSF037677; DNA_mis_repair_Msh6; 1. DR SMART; SM00534; MUTSac; 1. DR SMART; SM00533; MUTSd; 1. DR SMART; SM00293; PWWP; 1. DR SUPFAM; SSF55271; DNA repair protein MutS, domain I; 1. DR SUPFAM; SSF48334; DNA repair protein MutS, domain III; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR SUPFAM; SSF63748; Tudor/PWWP/MBT; 1. DR PROSITE; PS00486; DNA_MISMATCH_REPAIR_2; 1. DR PROSITE; PS50812; PWWP; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome; KW Direct protein sequencing; Disease variant; DNA damage; DNA repair; KW DNA-binding; Hereditary nonpolyposis colorectal cancer; KW Host-virus interaction; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome. FT CHAIN 1..1360 FT /note="DNA mismatch repair protein Msh6" FT /id="PRO_0000115207" FT DOMAIN 92..154 FT /note="PWWP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00162" FT REGION 1..84 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 195..362 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33..51 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 198..209 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 219..230 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 240..249 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 263..273 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 320..351 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1134..1141 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243" FT MOD_RES 43 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243" FT MOD_RES 70 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 79 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 137 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 219 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:21406692" FT MOD_RES 227 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 254 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 256 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 261 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692" FT MOD_RES 269 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 274 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 275 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 279 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 280 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 309 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 488 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 504 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 830 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 935 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1010 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..302 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055020" FT VAR_SEQ 80..209 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054419" FT VAR_SEQ 1058..1068 FT /note="DVLLCLANYSR -> GKTLNKLVLRL (in isoform GTBP-alt)" FT /evidence="ECO:0000305" FT /id="VSP_003291" FT VAR_SEQ 1069..1360 FT /note="Missing (in isoform GTBP-alt)" FT /evidence="ECO:0000305" FT /id="VSP_003292" FT VARIANT 13 FT /note="K -> T (in dbSNP:rs41294988)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038032" FT VARIANT 20 FT /note="A -> V (in LYNCH5, CRC and ENDMC; likely benign; FT normal mismatch repair activity; dbSNP:rs63750664)" FT /evidence="ECO:0000269|PubMed:11153917, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043943" FT VARIANT 25 FT /note="A -> S (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs267608026)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067294" FT VARIANT 25 FT /note="A -> V (in dbSNP:rs35462442)" FT /id="VAR_038033" FT VARIANT 39 FT /note="G -> E (in dbSNP:rs1042821)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:10699937, ECO:0000269|PubMed:14520694, FT ECO:0000269|PubMed:8942985, ECO:0000269|Ref.4, FT ECO:0007744|PubMed:16964243" FT /id="VAR_004490" FT VARIANT 54 FT /note="G -> A (in dbSNP:rs63751098)" FT /evidence="ECO:0000269|PubMed:14520694" FT /id="VAR_043944" FT VARIANT 65 FT /note="S -> L (in dbSNP:rs41294984)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038034" FT VARIANT 99 FT /note="K -> N (in CRC; uncertain significance; FT dbSNP:rs63751258)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043945" FT VARIANT 128 FT /note="R -> L (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs63750143)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043946" FT VARIANT 144 FT /note="S -> I (in LYNCH5 and CRC; benign; normal mismatch FT repair activity; dbSNP:rs3211299)" FT /evidence="ECO:0000269|PubMed:10521294, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012955" FT VARIANT 220 FT /note="E -> D (in dbSNP:rs1800938)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012956" FT VARIANT 221 FT /note="E -> D (in dbSNP:rs41557217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042274" FT VARIANT 285 FT /note="S -> I (in CRC; uncertain significance; FT dbSNP:rs63750878)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012957" FT VARIANT 295 FT /note="K -> R (in multiple colorectal adenoma; FT dbSNP:rs267608051)" FT /id="VAR_043947" FT VARIANT 326 FT /note="A -> V (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs587779323)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067295" FT VARIANT 340 FT /note="F -> S (in dbSNP:rs61753793)" FT /evidence="ECO:0000269|PubMed:10699937" FT /id="VAR_043948" FT VARIANT 396 FT /note="L -> V (in LYNCH5; benign; normal mismatch repair FT activity; dbSNP:rs2020908)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:22102614, ECO:0000269|Ref.4" FT /id="VAR_012958" FT VARIANT 435 FT /note="L -> P (decreased mismatch repair activity; FT dbSNP:rs63751405)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068710" FT VARIANT 449 FT /note="L -> P (in CRC and ENDMC; dbSNP:rs63750741)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043949" FT VARIANT 468 FT /note="R -> H (in dbSNP:rs41295268)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038035" FT VARIANT 492 FT /note="M -> V (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs61754783)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:22102614" FT /id="VAR_042275" FT VARIANT 503 FT /note="S -> C (in LYNCH5; likely benign; normal mismatch FT repair activity; dbSNP:rs63750897)" FT /evidence="ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:22102614" FT /id="VAR_038036" FT VARIANT 509 FT /note="V -> A (in dbSNP:rs63751005)" FT /evidence="ECO:0000269|PubMed:14520694" FT /id="VAR_043950" FT VARIANT 522 FT /note="Q -> R (in CRC; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63751009)" FT /evidence="ECO:0000269|PubMed:11709755, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043951" FT VARIANT 538 FT /note="Y -> S (in dbSNP:rs728619)" FT /id="VAR_038037" FT VARIANT 566 FT /note="G -> R (in CRC and LYNCH5; decreased mismatch repair FT activity; loss of protein expression; dbSNP:rs63749973)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012959" FT VARIANT 580 FT /note="S -> L (in dbSNP:rs41295270)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038038" FT VARIANT 585 FT /note="L -> P (decreased mismatch repair activity; FT dbSNP:rs587779220)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068711" FT VARIANT 610 FT /note="K -> N (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs201735525)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067296" FT VARIANT 619 FT /note="E -> D (in CRC; uncertain significance; FT dbSNP:rs63751121)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043952" FT VARIANT 623 FT /note="P -> A (in dbSNP:rs3136334)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_029244" FT VARIANT 623 FT /note="P -> L (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs63750462)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043953" FT VARIANT 677 FT /note="S -> T (normal mismatch repair activity; FT dbSNP:rs587779224)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068712" FT VARIANT 685 FT /note="G -> A (in CRC; uncertain significance; FT dbSNP:rs63750358)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043954" FT VARIANT 698 FT /note="Q -> E (in HNPCC; uncertain significance; FT dbSNP:rs63750832)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012960" FT VARIANT 725 FT /note="I -> M (in CRC; uncertain significance; FT dbSNP:rs63750304)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043955" FT VARIANT 728 FT /note="K -> T (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs35552856)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043956" FT VARIANT 772 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs63750725)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043957" FT VARIANT 772 FT /note="R -> W (in LYNCH5; dbSNP:rs63750138)" FT /evidence="ECO:0000269|PubMed:14974087" FT /id="VAR_043958" FT VARIANT 787 FT /note="A -> V (in CRC; uncertain significance; FT dbSNP:rs63750637)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043959" FT VARIANT 800 FT /note="V -> A (in CRC; somatic mutation; dbSNP:rs63750895)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043960" FT VARIANT 800 FT /note="V -> L (in dbSNP:rs61748083)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012961" FT VARIANT 803 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63751450)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012962" FT VARIANT 850 FT /note="Y -> C (in LYNCH5 and CRC; uncertain significance; FT normal mismatch repair activity; dbSNP:rs63750389)" FT /evidence="ECO:0000269|PubMed:10521294, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:22102614" FT /id="VAR_012963" FT VARIANT 854 FT /note="K -> M (in CRC; uncertain significance; FT dbSNP:rs34374438)" FT /evidence="ECO:0000269|PubMed:11470537, FT ECO:0000269|PubMed:14520694" FT /id="VAR_043961" FT VARIANT 878 FT /note="V -> A (in LYNCH5, CRC and ENDMC; benign; normal FT mismatch repair activity; dbSNP:rs2020912)" FT /evidence="ECO:0000269|PubMed:11153917, FT ECO:0000269|PubMed:11470537, ECO:0000269|PubMed:11586295, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:14520694, FT ECO:0000269|PubMed:15483016, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:22581703" FT /id="VAR_012964" FT VARIANT 881 FT /note="G -> KS (in LYNCH5; uncertain significance; normal FT mismatch repair activity)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076356" FT VARIANT 886 FT /note="I -> V (in dbSNP:rs2020914)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014902" FT VARIANT 901 FT /note="R -> H (in CRC and ENDMC; uncertain significance; FT dbSNP:rs63749889)" FT /evidence="ECO:0000269|PubMed:11153917" FT /id="VAR_043962" FT VARIANT 976 FT /note="R -> H (in CRC; uncertain significance; sporadic; FT normal mismatch repair activity; dbSNP:rs63751113)" FT /evidence="ECO:0000269|PubMed:11807791, FT ECO:0000269|PubMed:22102614" FT /id="VAR_012965" FT VARIANT 1021 FT /note="A -> D (in CRC; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750287)" FT /evidence="ECO:0000269|PubMed:11709755, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043963" FT VARIANT 1026 FT /note="D -> Y (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs267608054)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067297" FT VARIANT 1031 FT /note="D -> V (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs63750804)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043964" FT VARIANT 1076 FT /note="R -> C (in CRC; dbSNP:rs63750617)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043965" FT VARIANT 1087 FT /note="P -> R (in dbSNP:rs63750753)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076357" FT VARIANT 1087 FT /note="P -> S (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750998)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067298" FT VARIANT 1087 FT /note="P -> T (in CRC and LYNCH5; uncertain significance; FT dbSNP:rs63750998)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012966" FT VARIANT 1095 FT /note="R -> H (in CRC and LYNCH5; uncertain significance; FT normal mismatch repair activity; dbSNP:rs63750253)" FT /evidence="ECO:0000269|PubMed:12522549, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_043966" FT VARIANT 1100 FT /note="T -> M (in CRC; uncertain significance; FT dbSNP:rs63750442)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043967" FT VARIANT 1158 FT /note="C -> R (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs63750157)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043968" FT VARIANT 1163 FT /note="E -> V (in LYNCH5; dbSNP:rs63750252)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043969" FT VARIANT 1193 FT /note="E -> K (in LYNCH5; decreased mismatch repair FT activity; displays marked impairment of heterodimerization FT with MSH2; dbSNP:rs63751328)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043970" FT VARIANT 1213 FT /note="D -> V (in dbSNP:rs2104526240)" FT /evidence="ECO:0000269|PubMed:7604266" FT /id="VAR_004491" FT VARIANT 1219 FT /note="T -> I (in CRC; uncertain significance; FT dbSNP:rs63750949)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043971" FT VARIANT 1225 FT /note="T -> M (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750370)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067299" FT VARIANT 1232 FT /note="V -> L (in dbSNP:rs41295276)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038039" FT VARIANT 1234 FT /note="E -> Q (in dbSNP:rs35717727)" FT /id="VAR_038040" FT VARIANT 1248 FT /note="H -> D (in CRC; uncertain significance; FT dbSNP:rs63750882)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043972" FT VARIANT 1260 FT /note="V -> I (in dbSNP:rs63750673)" FT /evidence="ECO:0000269|PubMed:7604266" FT /id="VAR_004492" FT VARIANT 1284 FT /note="T -> M (in CRC; uncertain significance; FT dbSNP:rs63750836)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043973" FT VARIANT 1321 FT /note="R -> G (in dbSNP:rs41295278)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038041" FT VARIANT 1354 FT /note="L -> Q (in CRC and LYNCH5; uncertain significance; FT normal mismatch repair activity; dbSNP:rs267608140)" FT /evidence="ECO:0000269|PubMed:12522549, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_043974" FT MUTAGEN 103 FT /note="Y->A: Abolishes binding to H3K36me3 and DNA mismatch FT repair activity." FT /evidence="ECO:0000269|PubMed:23622243" FT MUTAGEN 105..106 FT /note="WW->AA: Abolishes binding to H3K36me3 and DNA FT mismatch repair activity." FT /evidence="ECO:0000269|PubMed:23622243" FT MUTAGEN 1140 FT /note="K->R: No effect on mismatch binding, complete loss FT of DNA repair function when associated with MSH2 mutant R- FT 675." FT /evidence="ECO:0000269|PubMed:9564049" FT CONFLICT 36..57 FT /note="AAPGASPSPGGDAAWSEAGPGP -> GCPRGLSFPRRGCGLERGWAWA (in FT Ref. 2; BAA23674/BAA23675)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="M -> V (in Ref. 3; BAG65496)" FT /evidence="ECO:0000305" FT CONFLICT 1358..1360 FT /note="KEL -> D (in Ref. 4; AAL87401)" FT /evidence="ECO:0000305" FT STRAND 74..79 FT /evidence="ECO:0007829|PDB:2GFU" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 106..110 FT /evidence="ECO:0007829|PDB:6OQM" FT TURN 114..116 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 117..120 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 128..133 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 139..144 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 170..183 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 187..191 FT /evidence="ECO:0007829|PDB:2GFU" FT TURN 192..195 FT /evidence="ECO:0007829|PDB:2GFU" FT STRAND 197..199 FT /evidence="ECO:0007829|PDB:2GFU" FT HELIX 366..369 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 371..373 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 375..377 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 400..403 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 408..419 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 420..422 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 423..429 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 432..436 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 437..447 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 453..456 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 458..462 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 463..465 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 466..475 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 480..485 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 489..497 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 505..507 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 511..517 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 519..521 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 526..528 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 538..546 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 554..561 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 563..565 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 568..575 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 591..597 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 603..609 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 610..615 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 624..626 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 630..639 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 640..643 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 644..647 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 657..661 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 671..673 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 678..693 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 697..701 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 712..715 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 737..742 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 758..762 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 768..779 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 785..799 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 802..812 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 818..829 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 831..836 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 838..841 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 847..879 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 885..890 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 894..896 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 897..900 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 906..913 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 918..923 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 936..955 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 959..961 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 968..970 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 973..975 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 978..981 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 983..986 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 995..999 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1002..1005 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1008..1010 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1011..1041 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1044..1066 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1070..1072 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1082..1084 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1089..1094 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1111..1116 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1120..1122 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 1129..1133 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:2O8F" FT HELIX 1140..1154 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1155..1157 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1160..1167 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1171..1176 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1189..1203 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1209..1213 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1215..1218 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1221..1237 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1242..1246 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1250..1255 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1256..1258 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 1260..1269 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1285..1292 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1298..1305 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1310..1322 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1323..1326 FT /evidence="ECO:0007829|PDB:2O8F" FT TURN 1330..1332 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1347..1359 FT /evidence="ECO:0007829|PDB:8AG6" SQ SEQUENCE 1360 AA; 152786 MW; 4A4AA9F8ECB8FFE9 CRC64; MSRQSTLYSF FPKSPALSDA NKASARASRE GGRAAAAPGA SPSPGGDAAW SEAGPGPRPL ARSASPPKAK NLNGGLRRSV APAAPTSCDF SPGDLVWAKM EGYPWWPCLV YNHPFDGTFI REKGKSVRVH VQFFDDSPTR GWVSKRLLKP YTGSKSKEAQ KGGHFYSAKP EILRAMQRAD EALNKDKIKR LELAVCDEPS EPEEEEEMEV GTTYVTDKSE EDNEIESEEE VQPKTQGSRR SSRQIKKRRV ISDSESDIGG SDVEFKPDTK EEGSSDEISS GVGDSESEGL NSPVKVARKR KRMVTGNGSL KRKSSRKETP SATKQATSIS SETKNTLRAF SAPQNSESQA HVSGGGDDSS RPTVWYHETL EWLKEEKRRD EHRRRPDHPD FDASTLYVPE DFLNSCTPGM RKWWQIKSQN FDLVICYKVG KFYELYHMDA LIGVSELGLV FMKGNWAHSG FPEIAFGRYS DSLVQKGYKV ARVEQTETPE MMEARCRKMA HISKYDRVVR REICRIITKG TQTYSVLEGD PSENYSKYLL SLKEKEEDSS GHTRAYGVCF VDTSLGKFFI GQFSDDRHCS RFRTLVAHYP PVQVLFEKGN LSKETKTILK SSLSCSLQEG LIPGSQFWDA SKTLRTLLEE EYFREKLSDG IGVMLPQVLK GMTSESDSIG LTPGEKSELA LSALGGCVFY LKKCLIDQEL LSMANFEEYI PLDSDTVSTT RSGAIFTKAY QRMVLDAVTL NNLEIFLNGT NGSTEGTLLE RVDTCHTPFG KRLLKQWLCA PLCNHYAIND RLDAIEDLMV VPDKISEVVE LLKKLPDLER LLSKIHNVGS PLKSQNHPDS RAIMYEETTY SKKKIIDFLS ALEGFKVMCK IIGIMEEVAD GFKSKILKQV ISLQTKNPEG RFPDLTVELN RWDTAFDHEK ARKTGLITPK AGFDSDYDQA LADIRENEQS LLEYLEKQRN RIGCRTIVYW GIGRNRYQLE IPENFTTRNL PEEYELKSTK KGCKRYWTKT IEKKLANLIN AEERRDVSLK DCMRRLFYNF DKNYKDWQSA VECIAVLDVL LCLANYSRGG DGPMCRPVIL LPEDTPPFLE LKGSRHPCIT KTFFGDDFIP NDILIGCEEE EQENGKAYCV LVTGPNMGGK STLMRQAGLL AVMAQMGCYV PAEVCRLTPI DRVFTRLGAS DRIMSGESTF FVELSETASI LMHATAHSLV LVDELGRGTA TFDGTAIANA VVKELAETIK CRTLFSTHYH SLVEDYSQNV AVRLGHMACM VENECEDPSQ ETITFLYKFI KGACPKSYGF NAARLANLPE EVIQKGHRKA REFEKMNQSL RLFREVCLAS ERSTVDAEAV HKLLTLIKEL // ID MSRE_HUMAN Reviewed; 451 AA. AC P21757; D3DSP3; O60505; P21759; Q45F10; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 1. DT 28-JAN-2026, entry version 227. DE RecName: Full=Macrophage scavenger receptor types I and II; DE AltName: Full=Macrophage acetylated LDL receptor I and II; DE AltName: Full=Scavenger receptor class A member 1; DE AltName: CD_antigen=CD204; GN Name=MSR1; Synonyms=SCARA1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS I AND II), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=2251254; DOI=10.1073/pnas.87.23.9133; RA Matsumoto A., Naito M., Itakura H., Ikemoto S., Asaoka H., Hayakawa I., RA Kanamori H., Aburatani H., Takaku F., Suzuki H., Kobari Y., Miyai T., RA Takahashi K., Cohen E.H., Wydro R., Housman D.E., Kodama T.; RT "Human macrophage scavenger receptors: primary structure, expression, and RT localization in atherosclerotic lesions."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9133-9137(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM III), FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=9548586; RA Gough P.J., Greaves D.R., Gordon S.; RT "A naturally occurring isoform of the human macrophage scavenger receptor RT (SR-A) gene generated by alternative splicing blocks modified LDL uptake."; RL J. Lipid Res. 39:531-543(1998). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-23 AND ALA-275. RG NIEHS SNPs program; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM I). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 155-272. RX PubMed=8093617; DOI=10.1016/s0021-9258(18)53970-3; RA Emi M., Asaoka H., Matsumoto A., Itakura H., Kurihara Y., Wada Y., RA Kanamori H., Yazaki Y., Takahashi E., Lepert M.; RT "Structure, organization, and chromosomal mapping of the human macrophage RT scavenger receptor gene."; RL J. Biol. Chem. 268:2120-2125(1993). RN [8] RP DISULFIDE BONDS IN SRCR DOMAIN. RX PubMed=8900177; DOI=10.1074/jbc.271.43.26924; RA Resnick D., Chatterton J.E., Schwartz K., Slayter H., Krieger M.; RT "Structures of class A macrophage scavenger receptors. Electron microscopic RT study of flexible, multidomain, fibrous proteins and determination of the RT disulfide bond pattern of the scavenger receptor cysteine-rich domain."; RL J. Biol. Chem. 271:26924-26930(1996). RN [9] RP POSSIBLE INVOLVEMENT IN PC, AND VARIANTS ALA-36; TYR-41; ALA-113; TYR-174; RP ALA-275; SER-369 AND ARG-441. RX PubMed=12244320; DOI=10.1038/ng994; RA Xu J., Zheng S.L., Komiya A., Mychaleckyj J.C., Isaacs S.D., Hu J.J., RA Sterling D., Lange E.M., Hawkins G.A., Turner A., Ewing C.M., Faith D.A., RA Johnson J.R., Suzuki H., Bujnovszky P., Wiley K.E., DeMarzo A.M., RA Bova G.S., Chang B., Hall M.C., McCullough D.L., Partin A.W., RA Kassabian V.S., Carpten J.D., Bailey-Wilson J.E., Trent J.M., Ohar J., RA Bleecker E.R., Walsh P.C., Isaacs W.B., Meyers D.A.; RT "Germline mutations and sequence variants of the macrophage scavenger RT receptor 1 gene are associated with prostate cancer risk."; RL Nat. Genet. 32:321-325(2002). RN [10] RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8; RA Hillman R.T., Green R.E., Brenner S.E.; RT "An unappreciated role for RNA surveillance."; RL Genome Biol. 5:R8.1-R8.16(2004). RN [11] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-221. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [12] RP INVOLVEMENT IN BE, AND VARIANT VAL-254. RX PubMed=21791690; DOI=10.1001/jama.2011.1029; RA Orloff M., Peterson C., He X., Ganapathi S., Heald B., Yang Y.R., Bebek G., RA Romigh T., Song J.H., Wu W., David S., Cheng Y., Meltzer S.J., Eng C.; RT "Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett RT esophagus and esophageal adenocarcinoma."; RL JAMA 306:410-419(2011). RN [13] RP INTERACTION WITH MYO18A. RX PubMed=25965346; DOI=10.1371/journal.pone.0126576; RA Yang L., Carrillo M., Wu Y.M., DiAngelo S.L., Silveyra P., Umstead T.M., RA Halstead E.S., Davies M.L., Hu S., Floros J., McCormack F.X., RA Christensen N.D., Chroneos Z.C.; RT "SP-R210 (Myo18A) isoforms as intrinsic modulators of macrophage priming RT and activation."; RL PLoS ONE 10:E0126576-E0126576(2015). CC -!- FUNCTION: Membrane glycoproteins implicated in the pathologic CC deposition of cholesterol in arterial walls during atherogenesis. Two CC types of receptor subunits exist. These receptors mediate the CC endocytosis of a diverse group of macromolecules, including modified CC low density lipoproteins (LDL) (PubMed:2251254). Isoform III does not CC internalize acetylated LDL (PubMed:9548586). CC {ECO:0000269|PubMed:2251254, ECO:0000269|PubMed:9548586}. CC -!- SUBUNIT: Homotrimer (By similarity). Interacts with MYO18A CC (PubMed:25965346). {ECO:0000250|UniProtKB:P30204, CC ECO:0000269|PubMed:25965346}. CC -!- INTERACTION: CC P21757; P27449: ATP6V0C; NbExp=6; IntAct=EBI-1776976, EBI-721179; CC P21757; Q7L5A8: FA2H; NbExp=3; IntAct=EBI-1776976, EBI-11337888; CC P21757; Q86VS8: HOOK3; NbExp=4; IntAct=EBI-1776976, EBI-1777078; CC P21757; O95214: LEPROTL1; NbExp=4; IntAct=EBI-1776976, EBI-750776; CC P21757; Q6FHL7: LEPROTL1; NbExp=3; IntAct=EBI-1776976, EBI-10249700; CC P21757; Q13021: MALL; NbExp=6; IntAct=EBI-1776976, EBI-750078; CC P21757; Q16617: NKG7; NbExp=7; IntAct=EBI-1776976, EBI-3919611; CC P21757; Q96IW7: SEC22A; NbExp=7; IntAct=EBI-1776976, EBI-8652744; CC P21757; Q7TQ77: AABR07026291.1; Xeno; NbExp=2; IntAct=EBI-1776976, EBI-1777000; CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type II membrane protein. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=I; CC IsoId=P21757-1; Sequence=Displayed; CC Name=II; CC IsoId=P21757-2; Sequence=VSP_006229, VSP_006230; CC Name=III; CC IsoId=P21757-3; Sequence=VSP_036842; CC -!- TISSUE SPECIFICITY: Isoform I, isoform II and isoform III are expressed CC in monocyte-derived macrophages. Isoform I and isoform II are expressed CC in the liver, placenta and brain. {ECO:0000269|PubMed:2251254, CC ECO:0000269|PubMed:9548586}. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:12244320}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. MSR1 variants may play a role in CC susceptibility to prostate cancer. MSR1 variants have been found in CC individuals with prostate cancer and co-segregate with the disease in CC some families. CC -!- DISEASE: Barrett esophagus (BE) [MIM:614266]: A condition characterized CC by a metaplastic change in which normal esophageal squamous epithelium CC is replaced by a columnar and intestinal-type epithelium. Patients with CC Barrett esophagus have an increased risk of esophageal adenocarcinoma. CC The main cause of Barrett esophagus is gastroesophageal reflux. The CC retrograde movement of acid and bile salts from the stomach into the CC esophagus causes prolonged injury to the esophageal epithelium and CC induces chronic esophagitis, which in turn is believed to trigger the CC pathologic changes. {ECO:0000269|PubMed:21791690}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC Genetic variants in MSR1 have been found in individuals with Barrett CC esophagus and are thought to contribute to disease susceptibility. CC -!- MISCELLANEOUS: [Isoform II]: May be produced at very low levels due to CC a premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D90187; BAA14208.1; -; mRNA. DR EMBL; D90188; BAA14209.1; -; mRNA. DR EMBL; AF037351; AAC09251.1; -; mRNA. DR EMBL; DQ144993; AAZ38715.1; -; Genomic_DNA. DR EMBL; AC023396; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471080; EAW63832.1; -; Genomic_DNA. DR EMBL; CH471080; EAW63830.1; -; Genomic_DNA. DR EMBL; CH471080; EAW63833.1; -; Genomic_DNA. DR EMBL; CH471080; EAW63834.1; -; Genomic_DNA. DR EMBL; BC063878; AAH63878.1; -; mRNA. DR EMBL; D13263; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS5995.1; -. [P21757-1] DR CCDS; CCDS5996.1; -. [P21757-3] DR CCDS; CCDS5997.1; -. [P21757-2] DR PIR; A38415; A38415. DR PIR; B38415; B38415. DR RefSeq; NP_002436.1; NM_002445.4. [P21757-2] DR RefSeq; NP_619729.1; NM_138715.3. [P21757-1] DR RefSeq; NP_619730.1; NM_138716.3. [P21757-3] DR PDB; 7DPX; X-ray; 2.00 A; A=349-451. DR PDBsum; 7DPX; -. DR AlphaFoldDB; P21757; -. DR SMR; P21757; -. DR BioGRID; 110587; 27. DR FunCoup; P21757; 246. DR IntAct; P21757; 14. DR MINT; P21757; -. DR STRING; 9606.ENSP00000405453; -. DR BindingDB; P21757; -. DR ChEMBL; CHEMBL5811; -. DR GlyCosmos; P21757; 7 sites, No reported glycans. DR GlyGen; P21757; 7 sites, 10 N-linked glycans (2 sites). DR iPTMnet; P21757; -. DR PhosphoSitePlus; P21757; -. DR BioMuta; MSR1; -. DR DMDM; 127357; -. DR jPOST; P21757; -. DR MassIVE; P21757; -. DR PaxDb; 9606-ENSP00000262101; -. DR PeptideAtlas; P21757; -. DR ProteomicsDB; 53900; -. [P21757-1] DR ProteomicsDB; 53901; -. [P21757-2] DR ProteomicsDB; 53902; -. [P21757-3] DR Antibodypedia; 601; 953 antibodies from 41 providers. DR DNASU; 4481; -. DR Ensembl; ENST00000262101.10; ENSP00000262101.5; ENSG00000038945.16. [P21757-1] DR Ensembl; ENST00000350896.3; ENSP00000262100.3; ENSG00000038945.16. [P21757-3] DR Ensembl; ENST00000355282.6; ENSP00000347430.2; ENSG00000038945.16. [P21757-3] DR Ensembl; ENST00000381998.8; ENSP00000371428.4; ENSG00000038945.16. [P21757-2] DR GeneID; 4481; -. DR KEGG; hsa:4481; -. DR MANE-Select; ENST00000262101.10; ENSP00000262101.5; NM_138715.3; NP_619729.1. DR UCSC; uc003wwz.4; human. [P21757-1] DR AGR; HGNC:7376; -. DR ClinPGx; PA31181; -. DR CTD; 4481; -. DR DisGeNET; 4481; -. DR GeneCards; MSR1; -. DR HGNC; HGNC:7376; MSR1. DR HPA; ENSG00000038945; Tissue enriched (lung). DR MalaCards; MSR1; -. DR MIM; 153622; gene. DR MIM; 176807; phenotype. DR MIM; 614266; phenotype. DR OpenTargets; ENSG00000038945; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000038945; -. DR eggNOG; ENOG502QUW0; Eukaryota. DR GeneTree; ENSGT00950000183074; -. DR HOGENOM; CLU_041152_2_0_1; -. DR InParanoid; P21757; -. DR OMA; DDHWEIR; -. DR OrthoDB; 536948at2759; -. DR PAN-GO; P21757; 6 GO annotations based on evolutionary models. DR PhylomeDB; P21757; -. DR PathwayCommons; P21757; -. DR Reactome; R-HSA-3000480; Scavenging by Class A Receptors. DR SignaLink; P21757; -. DR SIGNOR; P21757; -. DR Agora; ENSG00000038945; -. DR BioGRID-ORCS; 4481; 14 hits in 1153 CRISPR screens. DR ChiTaRS; MSR1; human. DR GeneWiki; MSR1; -. DR GenomeRNAi; 4481; -. DR Pharos; P21757; Tbio. DR PRO; PR:P21757; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; P21757; protein. DR Bgee; ENSG00000038945; Expressed in right lung and 129 other cell types or tissues. DR ExpressionAtlas; P21757; baseline and differential. DR GO; GO:0005581; C:collagen trimer; IEA:UniProtKB-KW. DR GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0034362; C:low-density lipoprotein particle; IEA:UniProtKB-KW. DR GO; GO:0016020; C:membrane; NAS:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; ISS:ARUK-UCL. DR GO; GO:0001540; F:amyloid-beta binding; ISS:ARUK-UCL. DR GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL. DR GO; GO:0030169; F:low-density lipoprotein particle binding; ISS:BHF-UCL. DR GO; GO:0005044; F:scavenger receptor activity; TAS:ARUK-UCL. DR GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL. DR GO; GO:0030301; P:cholesterol transport; ISS:BHF-UCL. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0042953; P:lipoprotein transport; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL. DR GO; GO:0006911; P:phagocytosis, engulfment; ISS:ARUK-UCL. DR GO; GO:0034381; P:plasma lipoprotein particle clearance; ISS:BHF-UCL. DR GO; GO:0010886; P:positive regulation of cholesterol storage; ISS:BHF-UCL. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; ISS:BHF-UCL. DR GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL. DR FunFam; 3.10.250.10:FF:000011; Scavenger receptor class A member 5; 1. DR Gene3D; 3.10.250.10; SRCR-like domain; 1. DR InterPro; IPR008160; Collagen. DR InterPro; IPR003543; SR-AI/II. DR InterPro; IPR001190; SRCR. DR InterPro; IPR036772; SRCR-like_dom_sf. DR PANTHER; PTHR48071:SF16; MACROPHAGE SCAVENGER RECEPTOR TYPES I AND II; 1. DR PANTHER; PTHR48071; SRCR DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF01391; Collagen; 1. DR Pfam; PF03523; Macscav_rec; 1. DR Pfam; PF00530; SRCR; 1. DR PRINTS; PR01408; MACSCAVRCPTR. DR PRINTS; PR00258; SPERACTRCPTR. DR SMART; SM00202; SR; 1. DR SUPFAM; SSF56487; SRCR-like; 1. DR PROSITE; PS00420; SRCR_1; 1. DR PROSITE; PS50287; SRCR_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Coiled coil; Collagen; Disulfide bond; KW Endocytosis; Glycoprotein; LDL; Membrane; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Signal-anchor; KW Transmembrane; Transmembrane helix. FT CHAIN 1..451 FT /note="Macrophage scavenger receptor types I and II" FT /id="PRO_0000181627" FT TOPO_DOM 1..50 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 51..76 FT /note="Helical; Signal-anchor for type II membrane protein" FT /evidence="ECO:0000255" FT TOPO_DOM 77..451 FT /note="Extracellular" FT /evidence="ECO:0000255" FT DOMAIN 273..341 FT /note="Collagen-like" FT DOMAIN 350..450 FT /note="SRCR" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00196" FT REGION 77..109 FT /note="Spacer" FT /evidence="ECO:0000305" FT REGION 267..346 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 171..255 FT /evidence="ECO:0000255" FT MOD_RES 27 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P30204" FT CARBOHYD 82 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 102 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 143 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 221 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 249 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 267 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 375..439 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00196, FT ECO:0000269|PubMed:8900177" FT DISULFID 388..449 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00196, FT ECO:0000269|PubMed:8900177" FT DISULFID 419..429 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00196, FT ECO:0000269|PubMed:8900177" FT VAR_SEQ 345..408 FT /note="TPFTKVRLVGGSGPHEGRVEILHSGQWGTICDDRWEVRVGQVVCRSLGYPGV FT QAVHKAAHFGQG -> S (in isoform III)" FT /evidence="ECO:0000303|PubMed:9548586" FT /id="VSP_036842" FT VAR_SEQ 345..358 FT /note="TPFTKVRLVGGSGP -> RPVQLTDHIRAGPS (in isoform II)" FT /evidence="ECO:0000303|PubMed:2251254" FT /id="VSP_006229" FT VAR_SEQ 359..451 FT /note="Missing (in isoform II)" FT /evidence="ECO:0000303|PubMed:2251254" FT /id="VSP_006230" FT VARIANT 23 FT /note="F -> C (in dbSNP:rs35175081)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_025190" FT VARIANT 36 FT /note="P -> A (found in a family with prostate cancer; FT dbSNP:rs749666450)" FT /evidence="ECO:0000269|PubMed:12244320" FT /id="VAR_066581" FT VARIANT 41 FT /note="S -> Y (found in patients with prostate cancer; FT dbSNP:rs145597376)" FT /evidence="ECO:0000269|PubMed:12244320" FT /id="VAR_066582" FT VARIANT 113 FT /note="V -> A (found in patients with prostate cancer; FT dbSNP:rs117359034)" FT /evidence="ECO:0000269|PubMed:12244320" FT /id="VAR_066583" FT VARIANT 174 FT /note="D -> Y (found in patients with prostate cancer; FT dbSNP:rs72552387)" FT /evidence="ECO:0000269|PubMed:12244320" FT /id="VAR_066584" FT VARIANT 254 FT /note="L -> V (found in patients with Barrett esophagus; FT dbSNP:rs387906645)" FT /evidence="ECO:0000269|PubMed:21791690" FT /id="VAR_066585" FT VARIANT 269 FT /note="T -> I (in dbSNP:rs13306543)" FT /id="VAR_052061" FT VARIANT 275 FT /note="P -> A (in dbSNP:rs2229388)" FT /evidence="ECO:0000269|PubMed:12244320, ECO:0000269|Ref.3" FT /id="VAR_025191" FT VARIANT 369 FT /note="G -> S (found in a family with prostate cancer; FT dbSNP:rs776370129)" FT /evidence="ECO:0000269|PubMed:12244320" FT /id="VAR_066586" FT VARIANT 441 FT /note="H -> R (found in patients with prostate cancer; FT dbSNP:rs138749399)" FT /evidence="ECO:0000269|PubMed:12244320" FT /id="VAR_066587" FT STRAND 350..357 FT /evidence="ECO:0007829|PDB:7DPX" FT STRAND 360..367 FT /evidence="ECO:0007829|PDB:7DPX" FT STRAND 370..376 FT /evidence="ECO:0007829|PDB:7DPX" FT HELIX 381..390 FT /evidence="ECO:0007829|PDB:7DPX" FT STRAND 394..400 FT /evidence="ECO:0007829|PDB:7DPX" FT TURN 402..405 FT /evidence="ECO:0007829|PDB:7DPX" FT STRAND 412..418 FT /evidence="ECO:0007829|PDB:7DPX" FT HELIX 426..428 FT /evidence="ECO:0007829|PDB:7DPX" FT STRAND 429..432 FT /evidence="ECO:0007829|PDB:7DPX" FT HELIX 441..443 FT /evidence="ECO:0007829|PDB:7DPX" FT STRAND 446..450 FT /evidence="ECO:0007829|PDB:7DPX" SQ SEQUENCE 451 AA; 49762 MW; 915C03B56653BB41 CRC64; MEQWDHFHNQ QEDTDSCSES VKFDARSMTA LLPPNPKNSP SLQEKLKSFK AALIALYLLV FAVLIPLIGI VAAQLLKWET KNCSVSSTNA NDITQSLTGK GNDSEEEMRF QEVFMEHMSN MEKRIQHILD MEANLMDTEH FQNFSMTTDQ RFNDILLQLS TLFSSVQGHG NAIDEISKSL ISLNTTLLDL QLNIENLNGK IQENTFKQQE EISKLEERVY NVSAEIMAMK EEQVHLEQEI KGEVKVLNNI TNDLRLKDWE HSQTLRNITL IQGPPGPPGE KGDRGPTGES GPRGFPGPIG PPGLKGDRGA IGFPGSRGLP GYAGRPGNSG PKGQKGEKGS GNTLTPFTKV RLVGGSGPHE GRVEILHSGQ WGTICDDRWE VRVGQVVCRS LGYPGVQAVH KAAHFGQGTG PIWLNEVFCF GRESSIEECK IRQWGTRACS HSEDAGVTCT L // ID MUTYH_HUMAN Reviewed; 546 AA. AC Q9UIF7; D3DPZ4; Q15830; Q9UBP2; Q9UBS7; Q9UIF4; Q9UIF5; Q9UIF6; DT 07-JUN-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 216. DE RecName: Full=Adenine DNA glycosylase; DE EC=3.2.2.31 {ECO:0000269|PubMed:20418187}; DE AltName: Full=MutY homolog; DE Short=hMYH; GN Name=MUTYH; Synonyms=MYH; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM ALPHA-3). RX PubMed=8682794; DOI=10.1128/jb.178.13.3885-3892.1996; RA Slupska M.M., Baikalov C., Luther W.M., Chiang J.H., Wei Y.F., Miller J.H.; RT "Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY RT gene whose function is required for the repair of oxidative DNA damage."; RL J. Bacteriol. 178:3885-3892(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA-1; ALPHA-2; ALPHA-3; BETA-1; RP GAMMA-2 AND GAMMA-3), AND FUNCTION. RX PubMed=10684930; DOI=10.1093/nar/28.6.1355; RA Ohtsubo T., Nishioka K., Imaiso Y., Iwai S., Shimokawa H., Oda H., RA Fujikawa T., Nakabeppu Y.; RT "Identification of human MutY homolog (hMYH) as a repair enzyme for 2- RT hydroxyadenine in DNA and detection of multiple forms of hMYH located in RT nuclei and mitochondria."; RL Nucleic Acids Res. 28:1355-1364(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=20843780; DOI=10.1093/nar/gkq750; RA Wang W., Shen P., Thiyagarajan S., Lin S., Palm C., Horvath R., RA Klopstock T., Cutler D., Pique L., Schrijver I., Davis R.W., Mindrinos M., RA Speed T.P., Scharfe C.; RT "Identification of rare DNA variants in mitochondrial disorders with RT improved array-based sequencing."; RL Nucleic Acids Res. 39:44-58(2011). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-22; HIS-335; GLU-500; RP MET-526 AND GLN-531. RG NIEHS SNPs program; RL Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-3). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP STRUCTURE BY NMR OF 356-497. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the NUDIX domain from human A/G-specific adenine DNA RT glycosylase alpha-3 splice isoform."; RL Submitted (NOV-2005) to the PDB data bank. RN [9] RP VARIANTS FAP2 CYS-176 AND ASP-393. RX PubMed=11818965; DOI=10.1038/ng828; RA Al-Tassan N., Chmiel N.H., Maynard J., Fleming N., Livingston A.L., RA Williams G.T., Hodges A.K., Davies D.R., David S.S., Sampson J.R., RA Cheadle J.P.; RT "Inherited variants of MYH associated with somatic G:C-->T:A mutations in RT colorectal tumors."; RL Nat. Genet. 30:227-232(2002). RN [10] RP VARIANTS FAP2 ARG-128; CYS-176 AND ASP-393. RX PubMed=12853198; DOI=10.1016/s0140-6736(03)13805-6; RA Sampson J.R., Dolwani S., Jones S., Eccles D., Ellis A., Evans D.G., RA Frayling I., Jordan S., Maher E.R., Mak T., Maynard J., Pigatto F., RA Shaw J., Cheadle J.P.; RT "Autosomal recessive colorectal adenomatous polyposis due to inherited RT mutations of MYH."; RL Lancet 362:39-41(2003). RN [11] RP VARIANTS FAP2 CYS-176 AND ASP-393, AND VARIANTS MET-22; HIS-335 AND RP PHE-512. RX PubMed=12606733; DOI=10.1056/nejmoa025283; RA Sieber O.M., Lipton L., Crabtree M., Heinimann K., Fidalgo P., RA Phillips R.K.S., Bisgaard M.-L., Orntoft T.F., Aaltonen L.A., Hodgson S.V., RA Thomas H.J.W., Tomlinson I.P.M.; RT "Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line RT mutations in MYH."; RL N. Engl. J. Med. 348:791-799(2003). RN [12] RP VARIANTS FAP2 HIS-125; HIS-179 AND TRP-238. RX PubMed=15366000; DOI=10.1002/humu.9282; RA Isidro G., Laranjeira F., Pires A., Leite J., Regateiro F., RA Castro e Sousa F., Soares J., Castro C., Giria J., Brito M.J., Medeira A., RA Teixeira R., Morna H., Gaspar I., Marinho C., Jorge R., Brehm A., RA Ramos J.S., Boavida M.G.; RT "Germline MUTYH (MYH) mutations in Portuguese individuals with multiple RT colorectal adenomas."; RL Hum. Mutat. 24:353-354(2004). RN [13] RP VARIANTS GASC SER-402 AND ARG-411. RX PubMed=15273732; DOI=10.1038/sj.onc.1207574; RA Kim C.J., Cho Y.G., Park C.H., Kim S.Y., Nam S.W., Lee S.H., Yoo N.J., RA Lee J.Y., Park W.S.; RT "Genetic alterations of the MYH gene in gastric cancer."; RL Oncogene 23:6820-6822(2004). RN [14] RP VARIANTS FAP2 CYS-176; HIS-242; TRP-271; PRO-385; ASP-393; CYS-423 AND RP GLU-477 DEL, AND VARIANTS MET-22 AND HIS-335. RX PubMed=16134147; DOI=10.1002/humu.9370; RA Aceto G., Curia M.C., Veschi S., De Lellis L., Mammarella S., Catalano T., RA Stuppia L., Palka G., Valanzano R., Tonelli F., Casale V., Stigliano V., RA Cetta F., Battista P., Mariani-Costantini R., Cama A.; RT "Mutations of APC and MYH in unrelated Italian patients with adenomatous RT polyposis coli."; RL Hum. Mutat. 26:394-394(2005). RN [15] RP VARIANTS FAP2 CYS-176; SER-177; VAL-280; LEU-292; PRO-385 AND ASP-393, AND RP VARIANTS MET-22; HIS-335 AND PHE-512. RX PubMed=16941501; DOI=10.1002/humu.9460; RG PAFNORD Group; RA Lejeune S., Guillemot F., Triboulet J.P., Cattan S., Mouton C., Porchet N., RA Manouvrier S., Buisine M.P.; RT "Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in RT patients with multiple polyposis."; RL Hum. Mutat. 27:1064-1064(2006). RN [16] RP VARIANTS FAP2 ILE-TRP-148 INS; CYS-176; GLN-182; VAL-220; HIS-242 AND RP ASP-393, AND VARIANTS MET-22 AND HIS-335. RX PubMed=16287072; DOI=10.1002/ijc.21470; RA Russell A.M., Zhang J., Luz J., Hutter P., Chappuis P.O., Berthod C.R., RA Maillet P., Mueller H., Heinimann K.; RT "Prevalence of MYH germline mutations in Swiss APC mutation-negative RT polyposis patients."; RL Int. J. Cancer 118:1937-1940(2006). RN [17] RP VARIANTS FAP2 LEU-154; CYS-176; HIS-179; HIS-242; TRP-271; LEU-292; RP CYS-306; ASP-393; LEU-402; CYS-423; GLU-477 DEL AND PHE-490. RX PubMed=16557584; DOI=10.1002/ijc.21905; RA Aretz S., Uhlhaas S., Goergens H., Siberg K., Vogel M., Pagenstecher C., RA Mangold E., Caspari R., Propping P., Friedl W.; RT "MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations RT present with an attenuated or atypical phenotype."; RL Int. J. Cancer 119:807-814(2006). RN [18] RP VARIANTS FAP2 CYS-176; CYS-179; TRP-182 AND ASP-393. RX PubMed=18091433; DOI=10.1097/gim.0b013e31815bf940; RA Cattaneo F., Molatore S., Mihalatos M., Apessos A., Venesio T., Bione S., RA Grignani P., Nasioulas G., Ranzani G.N.; RT "Heterogeneous molecular mechanisms underlie attenuated familial RT adenomatous polyposis."; RL Genet. Med. 9:836-841(2007). RN [19] RP VARIANTS FAP2 GLU-213; SER-235 AND MET-474. RX PubMed=18515411; DOI=10.1136/gut.2007.145748; RA Dallosso A.R., Dolwani S., Jones N., Jones S., Colley J., Maynard J., RA Idziaszczyk S., Humphreys V., Arnold J., Donaldson A., Eccles D., Ellis A., RA Evans D.G., Frayling I.M., Hes F.J., Houlston R.S., Maher E.R., Nielsen M., RA Parry S., Tyler E., Moskvina V., Cheadle J.P., Sampson J.R.; RT "Inherited predisposition to colorectal adenomas caused by multiple rare RT alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3."; RL Gut 57:1252-1255(2008). RN [20] RP CHARACTERIZATION OF VARIANTS FAP2 ILE-TRP-148 INS; CYS-176; TRP-182; RP ASP-393 AND GLU-477 DEL, FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=20418187; DOI=10.1016/j.dnarep.2010.03.008; RA D'Agostino V.G., Minoprio A., Torreri P., Marinoni I., Bossa C., RA Petrucci T.C., Albertini A.M., Ranzani G.N., Bignami M., Mazzei F.; RT "Functional analysis of MUTYH mutated proteins associated with familial RT adenomatous polyposis."; RL DNA Repair 9:700-707(2010). RN [21] RP VARIANTS FAP2 ILE-TRP-148 INS; TRP-182 AND GLU-477 DEL, AND RP CHARACTERIZATION OF VARIANTS FAP2 ILE-TRP-148 INS; CYS-176; TRP-182; RP ASP-393 AND GLU-477 DEL. RX PubMed=19953527; DOI=10.1002/humu.21158; RA Molatore S., Russo M.T., D'Agostino V.G., Barone F., Matsumoto Y., RA Albertini A.M., Minoprio A., Degan P., Mazzei F., Bignami M., Ranzani G.N.; RT "MUTYH mutations associated with familial adenomatous polyposis: functional RT characterization by a mammalian cell-based assay."; RL Hum. Mutat. 31:159-166(2010). RN [22] RP CHARACTERIZATION OF VARIANTS FAP2 CYS-176; HIS-179; VAL-220; VAL-280; RP CYS-306; PRO-385; ASP-393; LEU-402 AND GLU-477 DEL, CHARACTERIZATION OF RP VARIANTS GLU-72; VAL-370 AND PHE-512, FUNCTION, AND MUTAGENESIS OF ASP-233. RX PubMed=20848659; DOI=10.1002/humu.21363; RA Goto M., Shinmura K., Nakabeppu Y., Tao H., Yamada H., Tsuneyoshi T., RA Sugimura H.; RT "Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant RT proteins found in patients with colorectal polyposis and cancer."; RL Hum. Mutat. 31:E1861-E1874(2010). RN [23] RP CHARACTERIZATION OF VARIANTS FAP2 LEU-18; HIS-125; ARG-128; LEU-154; RP CYS-176; CYS-179; HIS-179; GLN-182; GLU-186; VAL-220; TRP-238; HIS-242; RP TRP-271; GLU-283; LEU-292; CYS-306; THR-377; PRO-385; ASP-393; LEU-402; RP MET-417; CYS-423; ASP-470; THR-470; GLU-477 DEL; THR-486 AND PHE-490, RP CHARACTERIZATION OF VARIANTS GASC SER-402 AND ARG-411, CHARACTERIZATION OF RP VARIANTS MET-22; ASP-25; ARG-100; ASN-102; VAL-224; MET-231; CYS-242; RP PHE-243; TRP-287; HIS-335; ARG-335; GLN-434; PRO-434; GLU-500; PHE-512; RP LEU-513; MET-526 AND GLN-531, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=25820570; DOI=10.1002/humu.22794; RA Komine K., Shimodaira H., Takao M., Soeda H., Zhang X., Takahashi M., RA Ishioka C.; RT "Functional complementation assay for 47 MUTYH variants in a MutY-disrupted RT Escherichia coli strain."; RL Hum. Mutat. 36:704-711(2015). RN [24] RP CHARACTERIZATION OF VARIANT FAP2 SER-235, CHARACTERIZATION OF VARIANTS RP ASN-102; MET-231; GLY-244; ASN-319; HIS-520 AND ALA-536, FUNCTION, AND RP MUTAGENESIS OF ASP-121. RX PubMed=26694661; DOI=10.1002/humu.22949; RA Shinmura K., Kato H., Goto M., Yamada H., Tao H., Nakamura S., Sugimura H.; RT "Functional evaluation of nine missense-type variants of the human DNA RT glycosylase enzyme MUTYH in the Japanese population."; RL Hum. Mutat. 37:350-353(2016). CC -!- FUNCTION: Involved in oxidative DNA damage repair. Initiates repair of CC A*oxoG to C*G by removing the inappropriately paired adenine base from CC the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase CC activities. {ECO:0000269|PubMed:10684930, ECO:0000269|PubMed:20418187, CC ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, CC ECO:0000269|PubMed:26694661}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Hydrolyzes free adenine bases from 7,8-dihydro-8- CC oxoguanine:adenine mismatched double-stranded DNA, leaving an CC apurinic site.; EC=3.2.2.31; Evidence={ECO:0000269|PubMed:20418187}; CC -!- COFACTOR: CC Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883; Evidence={ECO:0000250}; CC Note=Binds 1 [4Fe-4S] cluster. The cluster does not appear to play a CC role in catalysis, but is probably involved in the proper positioning CC of the enzyme along the DNA strand. {ECO:0000250}; CC -!- INTERACTION: CC Q9UIF7-3; Q6RW13: AGTRAP; NbExp=3; IntAct=EBI-10321956, EBI-741181; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:25820570}. CC Mitochondrion {ECO:0000250|UniProtKB:Q99P21}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=Alpha-1; CC IsoId=Q9UIF7-1; Sequence=Displayed; CC Name=Alpha-2; CC IsoId=Q9UIF7-2; Sequence=VSP_010549; CC Name=Alpha-3; CC IsoId=Q9UIF7-3; Sequence=VSP_010550; CC Name=Beta-1; CC IsoId=Q9UIF7-4; Sequence=VSP_010548; CC Name=Gamma-2; CC IsoId=Q9UIF7-5; Sequence=VSP_010548, VSP_010549; CC Name=Gamma-3; CC IsoId=Q9UIF7-6; Sequence=VSP_010548, VSP_010550; CC -!- DISEASE: Familial adenomatous polyposis 2 (FAP2) [MIM:608456]: A CC condition characterized by the development of multiple colorectal CC adenomatous polyps, benign neoplasms derived from glandular epithelium. CC Some affected individuals may develop colorectal carcinoma. CC {ECO:0000269|PubMed:11818965, ECO:0000269|PubMed:12606733, CC ECO:0000269|PubMed:12853198, ECO:0000269|PubMed:15366000, CC ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, CC ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, CC ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:18515411, CC ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187, CC ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, CC ECO:0000269|PubMed:26694661}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15273732, CC ECO:0000269|PubMed:25820570}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. Somatic mutations contribute CC to the development of a sub-set of sporadic gastric cancers in carriers CC of Helicobacter pylori (PubMed:15273732). CC {ECO:0000269|PubMed:15273732}. CC -!- SIMILARITY: Belongs to the Nth/MutY family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA89339.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA89339.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=BAA89345.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA89345.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41464/mutyh-(muty-homolog-(e-coli))"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U63329; AAC50618.1; -; Genomic_DNA. DR EMBL; AB032920; BAA89336.1; -; mRNA. DR EMBL; AB032921; BAA89337.1; -; mRNA. DR EMBL; AB032922; BAA89338.1; -; mRNA. DR EMBL; AB032923; BAA89339.1; ALT_SEQ; mRNA. DR EMBL; AB032924; BAA89340.1; -; mRNA. DR EMBL; AB032925; BAA89341.1; -; mRNA. DR EMBL; AB032926; BAA89342.1; -; mRNA. DR EMBL; AB032927; BAA89343.1; -; mRNA. DR EMBL; AB032928; BAA89344.1; -; mRNA. DR EMBL; AB032929; BAA89345.1; ALT_SEQ; mRNA. DR EMBL; HQ205466; ADP90937.1; -; Genomic_DNA. DR EMBL; HQ205468; ADP90947.1; -; Genomic_DNA. DR EMBL; HQ205469; ADP90952.1; -; Genomic_DNA. DR EMBL; HQ205470; ADP90957.1; -; Genomic_DNA. DR EMBL; HQ205472; ADP90967.1; -; Genomic_DNA. DR EMBL; HQ205473; ADP90972.1; -; Genomic_DNA. DR EMBL; HQ205474; ADP90977.1; -; Genomic_DNA. DR EMBL; HQ205475; ADP90982.1; -; Genomic_DNA. DR EMBL; HQ205476; ADP90987.1; -; Genomic_DNA. DR EMBL; HQ205477; ADP90992.1; -; Genomic_DNA. DR EMBL; HQ205479; ADP91002.1; -; Genomic_DNA. DR EMBL; HQ205480; ADP91007.1; -; Genomic_DNA. DR EMBL; HQ205481; ADP91012.1; -; Genomic_DNA. DR EMBL; HQ205482; ADP91017.1; -; Genomic_DNA. DR EMBL; HQ205483; ADP91022.1; -; Genomic_DNA. DR EMBL; HQ205484; ADP91027.1; -; Genomic_DNA. DR EMBL; HQ205485; ADP91032.1; -; Genomic_DNA. DR EMBL; HQ205486; ADP91037.1; -; Genomic_DNA. DR EMBL; HQ205487; ADP91042.1; -; Genomic_DNA. DR EMBL; HQ205488; ADP91047.1; -; Genomic_DNA. DR EMBL; HQ205489; ADP91052.1; -; Genomic_DNA. DR EMBL; HQ205490; ADP91057.1; -; Genomic_DNA. DR EMBL; HQ205491; ADP91062.1; -; Genomic_DNA. DR EMBL; HQ205492; ADP91067.1; -; Genomic_DNA. DR EMBL; HQ205493; ADP91072.1; -; Genomic_DNA. DR EMBL; HQ205494; ADP91077.1; -; Genomic_DNA. DR EMBL; HQ205495; ADP91082.1; -; Genomic_DNA. DR EMBL; HQ205496; ADP91087.1; -; Genomic_DNA. DR EMBL; HQ205497; ADP91092.1; -; Genomic_DNA. DR EMBL; HQ205498; ADP91097.1; -; Genomic_DNA. DR EMBL; HQ205499; ADP91102.1; -; Genomic_DNA. DR EMBL; HQ205500; ADP91107.1; -; Genomic_DNA. DR EMBL; HQ205501; ADP91112.1; -; Genomic_DNA. DR EMBL; HQ205502; ADP91117.1; -; Genomic_DNA. DR EMBL; HQ205503; ADP91122.1; -; Genomic_DNA. DR EMBL; HQ205505; ADP91132.1; -; Genomic_DNA. DR EMBL; AF527839; AAM78555.1; -; Genomic_DNA. DR EMBL; AL359540; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX06993.1; -; Genomic_DNA. DR EMBL; CH471059; EAX06996.1; -; Genomic_DNA. DR EMBL; CH471059; EAX06997.1; -; Genomic_DNA. DR EMBL; BC003178; AAH03178.1; -; mRNA. DR CCDS; CCDS41321.1; -. [Q9UIF7-5] DR CCDS; CCDS41322.1; -. [Q9UIF7-6] DR CCDS; CCDS520.1; -. [Q9UIF7-1] DR CCDS; CCDS72776.1; -. [Q9UIF7-4] DR CCDS; CCDS72777.1; -. [Q9UIF7-2] DR RefSeq; NP_001041636.2; NM_001048171.2. [Q9UIF7-6] DR RefSeq; NP_001041637.1; NM_001048172.2. [Q9UIF7-5] DR RefSeq; NP_001041638.1; NM_001048173.2. [Q9UIF7-6] DR RefSeq; NP_001041639.1; NM_001048174.2. [Q9UIF7-6] DR RefSeq; NP_001121897.1; NM_001128425.1. DR RefSeq; NP_001280119.1; NM_001293190.2. [Q9UIF7-2] DR RefSeq; NP_001280120.1; NM_001293191.2. [Q9UIF7-4] DR RefSeq; NP_001280121.1; NM_001293192.1. DR RefSeq; NP_001280124.1; NM_001293195.2. [Q9UIF7-6] DR RefSeq; NP_001280125.1; NM_001293196.1. DR RefSeq; NP_001393999.1; NM_001407070.1. [Q9UIF7-6] DR RefSeq; NP_001394000.1; NM_001407071.1. [Q9UIF7-5] DR RefSeq; NP_001394001.1; NM_001407072.1. [Q9UIF7-6] DR RefSeq; NP_001394006.1; NM_001407077.1. [Q9UIF7-4] DR RefSeq; NP_001394007.1; NM_001407078.1. [Q9UIF7-5] DR RefSeq; NP_001394010.1; NM_001407081.1. [Q9UIF7-6] DR RefSeq; NP_001394015.1; NM_001407086.1. [Q9UIF7-5] DR RefSeq; NP_001394017.1; NM_001407088.1. [Q9UIF7-6] DR RefSeq; NP_001394018.1; NM_001407089.1. [Q9UIF7-6] DR RefSeq; NP_036354.1; NM_012222.3. [Q9UIF7-1] DR PDB; 1X51; NMR; -; A=356-497. DR PDB; 3N5N; X-ray; 2.30 A; X/Y=76-362. DR PDB; 8FAY; X-ray; 1.91 A; A/D=64-516. DR PDBsum; 1X51; -. DR PDBsum; 3N5N; -. DR PDBsum; 8FAY; -. DR AlphaFoldDB; Q9UIF7; -. DR SMR; Q9UIF7; -. DR BioGRID; 110681; 29. DR DIP; DIP-41972N; -. DR FunCoup; Q9UIF7; 1732. DR IntAct; Q9UIF7; 26. DR MINT; Q9UIF7; -. DR STRING; 9606.ENSP00000500891; -. DR iPTMnet; Q9UIF7; -. DR PhosphoSitePlus; Q9UIF7; -. DR BioMuta; MUTYH; -. DR DMDM; 48428272; -. DR jPOST; Q9UIF7; -. DR MassIVE; Q9UIF7; -. DR PaxDb; 9606-ENSP00000361170; -. DR PeptideAtlas; Q9UIF7; -. DR ProteomicsDB; 84500; -. [Q9UIF7-1] DR ProteomicsDB; 84501; -. [Q9UIF7-2] DR ProteomicsDB; 84502; -. [Q9UIF7-3] DR ProteomicsDB; 84503; -. [Q9UIF7-4] DR ProteomicsDB; 84504; -. [Q9UIF7-5] DR ProteomicsDB; 84505; -. [Q9UIF7-6] DR Pumba; Q9UIF7; -. DR Antibodypedia; 1869; 332 antibodies from 40 providers. DR CPTC; Q9UIF7; 1 antibody. DR DNASU; 4595; -. DR Ensembl; ENST00000354383.10; ENSP00000346354.6; ENSG00000132781.23. [Q9UIF7-5] DR Ensembl; ENST00000355498.6; ENSP00000347685.2; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000372098.7; ENSP00000361170.3; ENSG00000132781.23. [Q9UIF7-1] DR Ensembl; ENST00000372104.5; ENSP00000361176.1; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000372110.7; ENSP00000361182.3; ENSG00000132781.23. [Q9UIF7-2] DR Ensembl; ENST00000372115.7; ENSP00000361187.3; ENSG00000132781.23. [Q9UIF7-3] DR Ensembl; ENST00000435155.2; ENSP00000403655.2; ENSG00000132781.23. [Q9UIF7-4] DR Ensembl; ENST00000448481.5; ENSP00000409718.1; ENSG00000132781.23. [Q9UIF7-4] DR Ensembl; ENST00000456914.7; ENSP00000407590.2; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000672314.2; ENSP00000500828.2; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000672818.3; ENSP00000500891.1; ENSG00000132781.23. [Q9UIF7-1] DR Ensembl; ENST00000713750.1; ENSP00000519051.1; ENSG00000132781.23. [Q9UIF7-6] DR GeneID; 4595; -. DR KEGG; hsa:4595; -. DR MANE-Select; ENST00000456914.7; ENSP00000407590.2; NM_001048174.2; NP_001041639.1. [Q9UIF7-6] DR UCSC; uc001cnf.4; human. [Q9UIF7-1] DR AGR; HGNC:7527; -. DR ClinPGx; PA31328; -. DR CTD; 4595; -. DR DisGeNET; 4595; -. DR GeneCards; MUTYH; -. DR GeneReviews; MUTYH; -. DR HGNC; HGNC:7527; MUTYH. DR HPA; ENSG00000132781; Low tissue specificity. DR MalaCards; MUTYH; -. DR MIM; 604933; gene. DR MIM; 608456; phenotype. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000132781; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 247798; MUTYH-related polyposis. DR VEuPathDB; HostDB:ENSG00000132781; -. DR eggNOG; KOG2457; Eukaryota. DR GeneTree; ENSGT00510000047220; -. DR HOGENOM; CLU_012862_0_0_1; -. DR InParanoid; Q9UIF7; -. DR OMA; CRPGDFN; -. DR OrthoDB; 10248838at2759; -. DR PAN-GO; Q9UIF7; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9UIF7; -. DR PathwayCommons; Q9UIF7; -. DR Reactome; R-HSA-110330; Recognition and association of DNA glycosylase with site containing an affected purine. DR Reactome; R-HSA-110331; Cleavage of the damaged purine. DR Reactome; R-HSA-110357; Displacement of DNA glycosylase by APEX1. DR Reactome; R-HSA-9608287; Defective MUTYH substrate binding. [Q9UIF7-3] DR Reactome; R-HSA-9608290; Defective MUTYH substrate processing. DR SignaLink; Q9UIF7; -. DR SIGNOR; Q9UIF7; -. DR Agora; ENSG00000132781; -. DR BioGRID-ORCS; 4595; 18 hits in 1164 CRISPR screens. DR EvolutionaryTrace; Q9UIF7; -. DR GeneWiki; MUTYH; -. DR GenomeRNAi; 4595; -. DR Pharos; Q9UIF7; Tbio. DR PRO; PR:Q9UIF7; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9UIF7; protein. DR Bgee; ENSG00000132781; Expressed in cerebellar hemisphere and 95 other cell types or tissues. DR ExpressionAtlas; Q9UIF7; baseline and differential. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW. DR GO; GO:0034039; F:8-oxo-7,8-dihydroguanine DNA N-glycosylase activity; IBA:GO_Central. DR GO; GO:0035485; F:adenine/guanine mispair binding; IBA:GO_Central. DR GO; GO:0019104; F:DNA N-glycosylase activity; TAS:Reactome. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0032407; F:MutSalpha complex binding; IDA:HGNC-UCL. DR GO; GO:0032357; F:oxidized purine DNA binding; IBA:GO_Central. DR GO; GO:0000701; F:purine-specific mismatch base pair DNA N-glycosylase activity; IMP:UniProtKB. DR GO; GO:0006284; P:base-excision repair; IBA:GO_Central. DR GO; GO:0045007; P:depurination; TAS:Reactome. DR GO; GO:0006281; P:DNA repair; TAS:ProtInc. DR GO; GO:0006298; P:mismatch repair; IBA:GO_Central. DR GO; GO:0060546; P:negative regulation of necroptotic process; IEA:Ensembl. DR CDD; cd00056; ENDO3c; 1. DR CDD; cd03431; NUDIX_DNA_Glycosylase_C-MutY; 1. DR FunFam; 1.10.1670.10:FF:000002; Adenine DNA glycosylase; 1. DR FunFam; 1.10.340.30:FF:000002; Adenine DNA glycosylase; 1. DR FunFam; 3.90.79.10:FF:000026; Adenine DNA glycosylase; 1. DR Gene3D; 1.10.1670.10; Helix-hairpin-Helix base-excision DNA repair enzymes (C-terminal); 1. DR Gene3D; 1.10.340.30; Hypothetical protein, domain 2; 1. DR Gene3D; 3.90.79.10; Nucleoside Triphosphate Pyrophosphohydrolase; 1. DR InterPro; IPR011257; DNA_glycosylase. DR InterPro; IPR004036; Endonuclease-III-like_CS2. DR InterPro; IPR003651; Endonuclease3_FeS-loop_motif. DR InterPro; IPR004035; Endouclease-III_FeS-bd_BS. DR InterPro; IPR003265; HhH-GPD_domain. DR InterPro; IPR023170; HhH_base_excis_C. DR InterPro; IPR000445; HhH_motif. DR InterPro; IPR044298; MIG/MutY. DR InterPro; IPR029119; MutY_C. DR InterPro; IPR015797; NUDIX_hydrolase-like_dom_sf. DR InterPro; IPR000086; NUDIX_hydrolase_dom. DR PANTHER; PTHR42944; ADENINE DNA GLYCOSYLASE; 1. DR PANTHER; PTHR42944:SF1; ADENINE DNA GLYCOSYLASE; 1. DR Pfam; PF00633; HHH; 1. DR Pfam; PF00730; HhH-GPD; 1. DR Pfam; PF14815; NUDIX_4; 1. DR SMART; SM00478; ENDO3c; 1. DR SMART; SM00525; FES; 1. DR SUPFAM; SSF48150; DNA-glycosylase; 1. DR SUPFAM; SSF55811; Nudix; 1. DR PROSITE; PS00764; ENDONUCLEASE_III_1; 1. DR PROSITE; PS01155; ENDONUCLEASE_III_2; 1. DR PROSITE; PS51462; NUDIX; 1. PE 1: Evidence at protein level; KW 3D-structure; 4Fe-4S; Alternative splicing; Disease variant; DNA damage; KW DNA repair; Glycosidase; Hydrolase; Iron; Iron-sulfur; Metal-binding; KW Mitochondrion; Nucleus; Proteomics identification; Reference proteome; KW Tumor suppressor. FT CHAIN 1..546 FT /note="Adenine DNA glycosylase" FT /id="PRO_0000102239" FT DOMAIN 364..495 FT /note="Nudix hydrolase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00794" FT REGION 19..51 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 404..426 FT /note="Nudix box" FT ACT_SITE 131 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000250|UniProtKB:P83847" FT BINDING 287 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 294 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 297 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 303 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT SITE 233 FT /note="Transition state stabilizer" FT /evidence="ECO:0000250|UniProtKB:P83847" FT VAR_SEQ 1..14 FT /note="Missing (in isoform Beta-1, isoform Gamma-2 and FT isoform Gamma-3)" FT /evidence="ECO:0000303|PubMed:10684930" FT /id="VSP_010548" FT VAR_SEQ 53..63 FT /note="Missing (in isoform Alpha-3 and isoform Gamma-3)" FT /evidence="ECO:0000303|PubMed:10684930, FT ECO:0000303|PubMed:15489334" FT /id="VSP_010550" FT VAR_SEQ 53..62 FT /note="Missing (in isoform Alpha-2 and isoform Gamma-2)" FT /evidence="ECO:0000303|PubMed:10684930" FT /id="VSP_010549" FT VARIANT 18 FT /note="P -> L (in FAP2; uncertain significance; decreased FT function in DNA repair; dbSNP:rs79777494)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077640" FT VARIANT 22 FT /note="V -> M (does not affect function in DNA repair; FT dbSNP:rs3219484)" FT /evidence="ECO:0000269|PubMed:12606733, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:25820570, FT ECO:0000269|Ref.4" FT /id="VAR_018872" FT VARIANT 25 FT /note="G -> D (does not affect function in DNA repair; FT dbSNP:rs75321043)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077641" FT VARIANT 72 FT /note="V -> E (does not affect DNA glycosylase activity; FT dbSNP:rs1557487179)" FT /evidence="ECO:0000269|PubMed:20848659" FT /id="VAR_077642" FT VARIANT 100 FT /note="W -> R (found in sporadic hepatocellular carcinoma; FT uncertain significance; loss of function in DNA repair; FT dbSNP:rs1140507)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077643" FT VARIANT 102 FT /note="D -> N (found in multiple polyposis and sporadic FT colorectal cancer cases; uncertain significance; does not FT affect DNA glycosylase activity; does not affect function FT in DNA repair; dbSNP:rs587780746)" FT /evidence="ECO:0000269|PubMed:25820570, FT ECO:0000269|PubMed:26694661" FT /id="VAR_077644" FT VARIANT 125 FT /note="Y -> H (in FAP2; decreased function in DNA repair)" FT /evidence="ECO:0000269|PubMed:15366000, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026045" FT VARIANT 128 FT /note="W -> R (in FAP2; loss of function in DNA repair; FT dbSNP:rs730881832)" FT /evidence="ECO:0000269|PubMed:12853198, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026046" FT VARIANT 148 FT /note="G -> GIW (in FAP2; reduced DNA glycosylase activity; FT decreased DNA binding; loss of function in DNA repair)" FT /evidence="ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187" FT /id="VAR_064938" FT VARIANT 154 FT /note="P -> L (in FAP2; decreased function in DNA repair; FT dbSNP:rs777184451)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077646" FT VARIANT 176 FT /note="Y -> C (in FAP2; loss of DNA glycosylase activity; FT decreased DNA binding; loss of function in DNA repair; FT dbSNP:rs34612342)" FT /evidence="ECO:0000269|PubMed:11818965, FT ECO:0000269|PubMed:12606733, ECO:0000269|PubMed:12853198, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, FT ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:19953527, FT ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_018873" FT VARIANT 177 FT /note="Y -> S (in FAP2)" FT /evidence="ECO:0000269|PubMed:16941501" FT /id="VAR_077647" FT VARIANT 179 FT /note="R -> C (in FAP2; also found in multiple polyposis FT and colorectal cancer cases; loss of function in DNA FT repair; dbSNP:rs747993448)" FT /evidence="ECO:0000269|PubMed:18091433, FT ECO:0000269|PubMed:25820570" FT /id="VAR_064939" FT VARIANT 179 FT /note="R -> H (in FAP2; loss of DNA glycosylase activity; FT loss of function in DNA repair; dbSNP:rs143353451)" FT /evidence="ECO:0000269|PubMed:15366000, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026047" FT VARIANT 182 FT /note="R -> Q (in FAP2; loss of function in DNA repair; FT dbSNP:rs533899702)" FT /evidence="ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077648" FT VARIANT 182 FT /note="R -> W (in FAP2; loss of DNA glycosylase activity; FT loss of DNA binding; loss of function in DNA repair; FT dbSNP:rs750592289)" FT /evidence="ECO:0000269|PubMed:18091433, FT ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187" FT /id="VAR_064940" FT VARIANT 186 FT /note="G -> E (in FAP2; decreased function in DNA repair; FT dbSNP:rs754155145)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077649" FT VARIANT 213 FT /note="G -> E (in FAP2; dbSNP:rs768553551)" FT /evidence="ECO:0000269|PubMed:18515411" FT /id="VAR_077650" FT VARIANT 220 FT /note="I -> V (in FAP2; uncertain significance; reduced DNA FT glycosylase activity; no effect on function in DNA repair; FT dbSNP:rs200872702)" FT /evidence="ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570" FT /id="VAR_077651" FT VARIANT 224 FT /note="A -> V (decreased function in DNA repair; FT dbSNP:rs11545695)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077652" FT VARIANT 231 FT /note="V -> M (found in familial colorectal cancer; likely FT pathogenic; no significant effect on DNA glycosylase FT activity; slightly decreased function in DNA repair; FT dbSNP:rs200165598)" FT /evidence="ECO:0000269|PubMed:25820570, FT ECO:0000269|PubMed:26694661" FT /id="VAR_077653" FT VARIANT 235 FT /note="N -> S (in FAP2; loss of DNA glycosylase activity; FT loss of function in DNA repair; dbSNP:rs1057517765)" FT /evidence="ECO:0000269|PubMed:18515411, FT ECO:0000269|PubMed:26694661" FT /id="VAR_077654" FT VARIANT 238 FT /note="R -> W (in FAP2; uncertain significance; decreased FT function in DNA repair; dbSNP:rs34126013)" FT /evidence="ECO:0000269|PubMed:15366000, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026048" FT VARIANT 242 FT /note="R -> C (found in colorectal polyposis; likely FT pathogenic; decreased function in DNA repair; FT dbSNP:rs200495564)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077655" FT VARIANT 242 FT /note="R -> H (in FAP2; loss of function in DNA repair; FT dbSNP:rs140342925)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16287072, ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077656" FT VARIANT 243 FT /note="V -> F (does not affect function; FT dbSNP:rs587780749)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077657" FT VARIANT 244 FT /note="R -> G (reduced DNA glycosylase activity; decreased FT function in DNA repair; dbSNP:rs587782885)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077658" FT VARIANT 271 FT /note="R -> W (in FAP2; loss of function in DNA repair; FT dbSNP:rs769237459)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:25820570" FT /id="VAR_077659" FT VARIANT 280 FT /note="M -> V (in FAP2; reduced DNA glycosylase activity; FT dbSNP:rs876659676)" FT /evidence="ECO:0000269|PubMed:16941501, FT ECO:0000269|PubMed:20848659" FT /id="VAR_077660" FT VARIANT 283 FT /note="G -> E (in FAP2; uncertain significance; does not FT affect function in DNA repair; dbSNP:rs730881833)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077661" FT VARIANT 287 FT /note="C -> W (found in a case of sporadic lung cancer; FT uncertain significance; loss of function in DNA repair)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077662" FT VARIANT 292 FT /note="P -> L (in FAP2; also found in multiple polyposis FT cases; loss of function in DNA repair; dbSNP:rs374950566)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:25820570" FT /id="VAR_077663" FT VARIANT 306 FT /note="R -> C (in FAP2; uncertain significance; does not FT affect DNA glycosylase activity; slightly decreased FT function in DNA repair; dbSNP:rs138089183)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570" FT /id="VAR_077664" FT VARIANT 319 FT /note="S -> N (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs587781810)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077665" FT VARIANT 335 FT /note="Q -> H (does not affect function in DNA repair; FT dbSNP:rs3219489)" FT /evidence="ECO:0000269|PubMed:12606733, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:25820570, FT ECO:0000269|Ref.4" FT /id="VAR_018874" FT VARIANT 335 FT /note="Q -> R (found in a family with non-polyposis FT colorectal cancer-like syndrome; uncertain significance; FT does not affect function in DNA repair; dbSNP:rs199742231)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077666" FT VARIANT 370 FT /note="A -> V (does not affect DNA glycosylase activity; FT dbSNP:rs35352891)" FT /evidence="ECO:0000269|PubMed:20848659" FT /id="VAR_048262" FT VARIANT 377 FT /note="P -> T (in FAP2; decreased function in DNA repair)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077667" FT VARIANT 385 FT /note="L -> P (in FAP2; also found in multiple polyposis FT cases; loss of DNA glycosylase activity; loss of function FT in DNA repair; dbSNP:rs1060501335)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077668" FT VARIANT 393 FT /note="G -> D (in FAP2; reduced DNA glycosylase activity; FT decreased DNA binding; decreased function in DNA repair; FT dbSNP:rs36053993)" FT /evidence="ECO:0000269|PubMed:11818965, FT ECO:0000269|PubMed:12606733, ECO:0000269|PubMed:12853198, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, FT ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:19953527, FT ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_018875" FT VARIANT 402 FT /note="P -> L (in FAP2; also found in multiple polyposis FT and colorectal cancer cases; loss of DNA glycosylase FT activity; loss of function in DNA repair; FT dbSNP:rs529008617)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570" FT /id="VAR_077669" FT VARIANT 402 FT /note="P -> S (in GASC; sporadic; decreased function in DNA FT repair; dbSNP:rs121908382)" FT /evidence="ECO:0000269|PubMed:15273732, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026049" FT VARIANT 411 FT /note="Q -> R (in GASC; uncertain significance; does not FT affect function in DNA repair; dbSNP:rs121908383)" FT /evidence="ECO:0000269|PubMed:15273732, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026050" FT VARIANT 417 FT /note="L -> M (in FAP2; uncertain significance; also found FT in a family with non-polyposis colorectal cancer-like FT syndrome; uncertain significance; does not affect function FT in DNA repair; dbSNP:rs144079536)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077670" FT VARIANT 423 FT /note="R -> C (in FAP2; uncertain significance; does not FT affect function in DNA repair; dbSNP:rs150792276)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:25820570" FT /id="VAR_077671" FT VARIANT 434 FT /note="R -> P (found in sporadic colorectal cancer cases; FT uncertain significance; decreased function in DNA repair)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077672" FT VARIANT 434 FT /note="R -> Q (does not affect function in DNA repair; FT dbSNP:rs587782120)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077673" FT VARIANT 470 FT /note="A -> D (in FAP2; loss of function in DNA repair; FT dbSNP:rs200844166)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077674" FT VARIANT 470 FT /note="A -> T (found in patient with multiple polyposis; FT uncertain significance; does not affect function in DNA FT repair; dbSNP:rs192816572)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077675" FT VARIANT 474 FT /note="T -> M (in FAP2; uncertain significance; FT dbSNP:rs767747402)" FT /evidence="ECO:0000269|PubMed:18515411" FT /id="VAR_077676" FT VARIANT 477 FT /note="Missing (in FAP2; also found in a case of sporadic FT colorectal cancer; loss of DNA glycosylase activity; loss FT of DNA binding; loss of function in DNA repair)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:19953527, FT ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_064941" FT VARIANT 486 FT /note="A -> T (in FAP2; decreased function in DNA repair; FT dbSNP:rs587782263)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077677" FT VARIANT 490 FT /note="V -> F (in FAP2; uncertain significance; decreased FT function in DNA repair; dbSNP:rs587782228)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077678" FT VARIANT 500 FT /note="G -> E (decreased function in DNA repair; FT dbSNP:rs3219494)" FT /evidence="ECO:0000269|PubMed:25820570, ECO:0000269|Ref.4" FT /id="VAR_018876" FT VARIANT 512 FT /note="S -> F (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs140118273)" FT /evidence="ECO:0000269|PubMed:12606733, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026051" FT VARIANT 513 FT /note="P -> L (does not affect function in DNA repair; FT dbSNP:rs587778542)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077679" FT VARIANT 520 FT /note="R -> H (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs374655042)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077680" FT VARIANT 526 FT /note="L -> M (does not affect function in DNA repair; FT dbSNP:rs3219496)" FT /evidence="ECO:0000269|PubMed:25820570, ECO:0000269|Ref.4" FT /id="VAR_018877" FT VARIANT 531 FT /note="R -> Q (does not affect function in DNA repair; FT dbSNP:rs3219497)" FT /evidence="ECO:0000269|PubMed:25820570, ECO:0000269|Ref.4" FT /id="VAR_018878" FT VARIANT 536 FT /note="T -> A (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs151196169)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077681" FT MUTAGEN 121 FT /note="D->G: Does not affect DNA glycosylase activity. Does FT not affect function in DNA repair." FT /evidence="ECO:0000269|PubMed:26694661" FT MUTAGEN 233 FT /note="D->N: Loss of DNA glycosylase activity." FT /evidence="ECO:0000269|PubMed:20848659" FT HELIX 87..104 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 109..116 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 120..134 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 139..142 FT /evidence="ECO:0007829|PDB:8FAY" FT TURN 143..145 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 146..152 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 156..161 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 164..171 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 178..193 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 202..208 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 214..225 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 234..243 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 253..266 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 269..271 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 272..285 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 300..302 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 304..314 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 330..332 FT /evidence="ECO:0007829|PDB:3N5N" FT HELIX 348..354 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 358..360 FT /evidence="ECO:0007829|PDB:1X51" FT STRAND 365..376 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 383..388 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 391..393 FT /evidence="ECO:0007829|PDB:8FAY" FT TURN 394..397 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 403..405 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 410..425 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 430..432 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 434..442 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 444..456 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 470..474 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 475..479 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 481..483 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 485..497 FT /evidence="ECO:0007829|PDB:8FAY" SQ SEQUENCE 546 AA; 60069 MW; 6C79BDB34345DD10 CRC64; MTPLVSRLSR LWAIMRKPRA AVGSGHRKQA ASQEGRQKHA KNNSQAKPSA CDGMIAECPG APAGLARQPE EVVLQASVSS YHLFRDVAEV TAFRGSLLSW YDQEKRDLPW RRRAEDEMDL DRRAYAVWVS EVMLQQTQVA TVINYYTGWM QKWPTLQDLA SASLEEVNQL WAGLGYYSRG RRLQEGARKV VEELGGHMPR TAETLQQLLP GVGRYTAGAI ASIAFGQATG VVDGNVARVL CRVRAIGADP SSTLVSQQLW GLAQQLVDPA RPGDFNQAAM ELGATVCTPQ RPLCSQCPVE SLCRARQRVE QEQLLASGSL SGSPDVEECA PNTGQCHLCL PPSEPWDQTL GVVNFPRKAS RKPPREESSA TCVLEQPGAL GAQILLVQRP NSGLLAGLWE FPSVTWEPSE QLQRKALLQE LQRWAGPLPA THLRHLGEVV HTFSHIKLTY QVYGLALEGQ TPVTTVPPGA RWLTQEEFHT AAVSTAMKKV FRVYQGQQPG TCMGSKRSQV SSPCSRKKPR MGQQVLDNFF RSHISTDAHS LNSAAQ // ID NTRK3_HUMAN Reviewed; 839 AA. AC Q16288; B7Z4C5; E9PG56; H0YND1; O75682; Q12827; Q16289; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 06-MAR-2007, sequence version 2. DT 28-JAN-2026, entry version 243. DE RecName: Full=NT-3 growth factor receptor; DE EC=2.7.10.1; DE AltName: Full=GP145-TrkC; DE Short=Trk-C; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 3; DE AltName: Full=TrkC tyrosine kinase; DE Flags: Precursor; GN Name=NTRK3; Synonyms=TRKC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Fetal brain; RX PubMed=7806211; DOI=10.1006/geno.1994.1383; RA McGregor L.M., Baylin S.B., Griffin C.A., Hawkins A.L., Nelkin B.D.; RT "Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal RT assignment, and evidence for a splice variant."; RL Genomics 22:267-272(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND PARTIAL PROTEIN RP SEQUENCE. RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9778053; DOI=10.1038/sj.onc.1202100; RA Ichaso N., Rodriguez R.E., Martin-Zanca D., Gonzalez-Sarmiento R.; RT "Genomic characterization of the human trkC gene."; RL Oncogene 17:1871-1875(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [6] RP FUNCTION, PHOSPHORYLATION AT TYR-516, INVOLVEMENT IN CHD, VARIANTS PHE-21; RP VAL-71; MET-93; ILE-163; PHE-533 AND MET-817, CHARACTERIZATION OF VARIANTS RP MET-93; ILE-163; PHE-533 AND MET-817, AND MUTAGENESIS OF LYS-572. RX PubMed=25196463; DOI=10.1002/humu.22688; RA Werner P., Paluru P., Simpson A.M., Latney B., Iyer R., Brodeur G.M., RA Goldmuntz E.; RT "Mutations in NTRK3 suggest a novel signaling pathway in human congenital RT heart disease."; RL Hum. Mutat. 35:1459-1468(2014). RN [7] RP INTERACTION WITH PTPRS. RX PubMed=25385546; DOI=10.1038/ncomms6209; RA Coles C.H., Mitakidis N., Zhang P., Elegheert J., Lu W., Stoker A.W., RA Nakagawa T., Craig A.M., Jones E.Y., Aricescu A.R.; RT "Structural basis for extracellular cis and trans RPTPsigma signal RT competition in synaptogenesis."; RL Nat. Commun. 5:5209-5209(2014). RN [8] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 297-401, AND DISULFIDE BOND. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-149; CYS-306; LEU-307; GLN-336; RP TYR-677; GLN-678; ARG-768 AND LYS-781. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP VARIANTS SER-664; TYR-677; CYS-736; PRO-745 AND PHE-766. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). CC -!- FUNCTION: Receptor tyrosine kinase involved in nervous system and CC probably heart development. Upon binding of its ligand CC NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different CC signaling pathways, including the phosphatidylinositol 3-kinase/AKT and CC the MAPK pathways, that control cell survival and differentiation. CC {ECO:0000269|PubMed:25196463}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures (By similarity). Binds CC SH2B2. Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC with PTPRS (PubMed:25385546). Interacts with MAPK8IP3/JIP3 (By CC similarity). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:Q03351, ECO:0000269|PubMed:25385546}. CC -!- INTERACTION: CC Q16288; Q16832: DDR2; NbExp=2; IntAct=EBI-3936704, EBI-1381484; CC Q16288; Q6PKX4: DOK6; NbExp=3; IntAct=EBI-3936704, EBI-2880244; CC Q16288; Q15375: EPHA7; NbExp=2; IntAct=EBI-3936704, EBI-1383428; CC Q16288; P08581: MET; NbExp=2; IntAct=EBI-3936704, EBI-1039152; CC Q16288; P04629: NTRK1; NbExp=2; IntAct=EBI-3936704, EBI-1028226; CC Q16288; Q16620: NTRK2; NbExp=3; IntAct=EBI-3936704, EBI-3904881; CC Q16288; P18031: PTPN1; NbExp=2; IntAct=EBI-3936704, EBI-968788; CC Q16288; Q13332: PTPRS; NbExp=4; IntAct=EBI-3936704, EBI-711536; CC Q16288; P61619: SEC61A1; NbExp=2; IntAct=EBI-3936704, EBI-358919; CC Q16288; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-3936704, EBI-358766; CC Q16288; P31947: SFN; NbExp=2; IntAct=EBI-3936704, EBI-476295; CC Q16288; Q99523: SORT1; NbExp=2; IntAct=EBI-3936704, EBI-1057058; CC Q16288; P62258: YWHAE; NbExp=2; IntAct=EBI-3936704, EBI-356498; CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=A; CC IsoId=Q16288-1; Sequence=Displayed; CC Name=2; Synonyms=B; CC IsoId=Q16288-2; Sequence=VSP_002925, VSP_002926; CC Name=3; Synonyms=C; CC IsoId=Q16288-3; Sequence=VSP_002927; CC Name=4; Synonyms=D; CC IsoId=Q16288-4; Sequence=VSP_002924; CC Name=5; Synonyms=E; CC IsoId=Q16288-5; Sequence=VSP_002924, VSP_002927; CC -!- TISSUE SPECIFICITY: Widely expressed but mainly in nervous tissue. CC Isoform 2 is expressed at higher levels in adult brain than in fetal CC brain. CC -!- PTM: Ligand-mediated auto-phosphorylation. CC -!- DISEASE: Note=Defects in NTRK3 are associated with susceptibility to CC congenital heart defects (CHD). A disease characterized by congenital CC developmental abnormalities involving structures of the heart. CHD are CC the most common major birth defects and the leading cause of death from CC congenital malformations. {ECO:0000269|PubMed:25196463}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/433/NTRK3"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U05012; AAA75374.1; -; mRNA. DR EMBL; S76475; AAB33111.1; -; mRNA. DR EMBL; S76476; AAB33112.1; -; mRNA. DR EMBL; AJ224521; CAA12029.1; -; Genomic_DNA. DR EMBL; AJ224522; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224523; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224524; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224525; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224526; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224527; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224528; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224529; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224530; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224531; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224532; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224533; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224534; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224535; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AK297160; BAH12511.1; -; mRNA. DR EMBL; AC009711; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011966; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC021677; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS10340.1; -. [Q16288-3] DR CCDS; CCDS32322.1; -. [Q16288-1] DR CCDS; CCDS32323.1; -. [Q16288-2] DR CCDS; CCDS58399.1; -. [Q16288-5] DR PIR; A55178; A55178. DR PIR; I73632; I73632. DR PIR; I73633; I73633. DR RefSeq; NP_001007157.1; NM_001007156.3. [Q16288-2] DR RefSeq; NP_001012338.1; NM_001012338.3. [Q16288-1] DR RefSeq; NP_001230030.1; NM_001243101.2. [Q16288-5] DR RefSeq; NP_001307063.1; NM_001320134.1. DR RefSeq; NP_001307064.1; NM_001320135.1. DR RefSeq; NP_001362739.1; NM_001375810.1. [Q16288-1] DR RefSeq; NP_001362740.1; NM_001375811.1. [Q16288-3] DR RefSeq; NP_001362741.1; NM_001375812.1. [Q16288-5] DR RefSeq; NP_001362742.1; NM_001375813.1. [Q16288-2] DR RefSeq; NP_002521.2; NM_002530.4. [Q16288-3] DR RefSeq; XP_016877729.1; XM_017022240.2. [Q16288-3] DR RefSeq; XP_024305702.1; XM_024449934.2. [Q16288-2] DR RefSeq; XP_054234029.1; XM_054378054.1. [Q16288-3] DR RefSeq; XP_054234036.1; XM_054378061.1. [Q16288-2] DR PDB; 1WWC; X-ray; 1.90 A; A=297-422. DR PDB; 3V5Q; X-ray; 2.20 A; A/B=530-832. DR PDB; 4YMJ; X-ray; 2.00 A; A/B=530-839. DR PDB; 6KZC; X-ray; 2.00 A; A=528-839. DR PDB; 6KZD; X-ray; 1.71 A; A=528-839. DR PDBsum; 1WWC; -. DR PDBsum; 3V5Q; -. DR PDBsum; 4YMJ; -. DR PDBsum; 6KZC; -. DR PDBsum; 6KZD; -. DR AlphaFoldDB; Q16288; -. DR SMR; Q16288; -. DR BioGRID; 110971; 372. DR DIP; DIP-5723N; -. DR FunCoup; Q16288; 657. DR IntAct; Q16288; 355. DR MINT; Q16288; -. DR STRING; 9606.ENSP00000354207; -. DR BindingDB; Q16288; -. DR ChEMBL; CHEMBL5608; -. DR DrugBank; DB17191; Altiratinib. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB17140; JNJ-28312141. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16288; -. DR GuidetoPHARMACOLOGY; 1819; -. DR GlyCosmos; Q16288; 13 sites, No reported glycans. DR GlyGen; Q16288; 14 sites, 2 N-linked glycans (1 site). DR iPTMnet; Q16288; -. DR PhosphoSitePlus; Q16288; -. DR BioMuta; NTRK3; -. DR DMDM; 134035335; -. DR CPTAC; CPTAC-3001; -. DR CPTAC; CPTAC-3002; -. DR jPOST; Q16288; -. DR MassIVE; Q16288; -. DR PaxDb; 9606-ENSP00000354207; -. DR PeptideAtlas; Q16288; -. DR ProteomicsDB; 20249; -. DR ProteomicsDB; 40524; -. DR ProteomicsDB; 60850; -. [Q16288-1] DR ProteomicsDB; 60851; -. [Q16288-2] DR ProteomicsDB; 60852; -. [Q16288-3] DR ProteomicsDB; 60853; -. [Q16288-4] DR ABCD; Q16288; 8 sequenced antibodies. DR Antibodypedia; 3979; 851 antibodies from 42 providers. DR DNASU; 4916; -. DR Ensembl; ENST00000317501.9; ENSP00000318328.3; ENSG00000140538.18. [Q16288-2] DR Ensembl; ENST00000357724.6; ENSP00000350356.2; ENSG00000140538.18. [Q16288-4] DR Ensembl; ENST00000394480.6; ENSP00000377990.1; ENSG00000140538.18. [Q16288-3] DR Ensembl; ENST00000557856.5; ENSP00000453959.1; ENSG00000140538.18. [Q16288-5] DR Ensembl; ENST00000629765.3; ENSP00000485864.1; ENSG00000140538.18. [Q16288-1] DR Ensembl; ENST00000695462.1; ENSP00000511942.1; ENSG00000140538.18. [Q16288-1] DR GeneID; 4916; -. DR KEGG; hsa:4916; -. DR MANE-Select; ENST00000629765.3; ENSP00000485864.1; NM_001012338.3; NP_001012338.1. DR UCSC; uc059mwc.1; human. [Q16288-1] DR AGR; HGNC:8033; -. DR CIViC; 4916; 14 evidence items across 14 molecular profiles. DR ClinPGx; PA31819; -. DR CTD; 4916; -. DR DisGeNET; 4916; -. DR GeneCards; NTRK3; -. DR HGNC; HGNC:8033; NTRK3. DR HPA; ENSG00000140538; Tissue enhanced (brain). DR MalaCards; NTRK3; -. DR MIM; 191316; gene. DR OpenTargets; ENSG00000140538; -. DR Orphanet; 2665; Congenital mesoblastic nephroma. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2030; Fibrosarcoma. DR VEuPathDB; HostDB:ENSG00000140538; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155645; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16288; -. DR OMA; YREVTHP; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16288; 13 GO annotations based on evolutionary models. DR PhylomeDB; Q16288; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16288; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-388844; Receptor-type tyrosine-protein phosphatases. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9034013; NTF3 activates NTRK3 signaling. DR Reactome; R-HSA-9034015; Signaling by NTRK3 (TRKC). DR Reactome; R-HSA-9034793; Activated NTRK3 signals through PLCG1. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9603505; NTRK3 as a dependence receptor. DR SignaLink; Q16288; -. DR SIGNOR; Q16288; -. DR Agora; ENSG00000140538; -. DR BioGRID-ORCS; 4916; 12 hits in 1191 CRISPR screens. DR ChiTaRS; NTRK3; human. DR EvolutionaryTrace; Q16288; -. DR GeneWiki; TrkC_receptor; -. DR GenomeRNAi; 4916; -. DR Pharos; Q16288; Tclin. DR PRO; PR:Q16288; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q16288; protein. DR Bgee; ENSG00000140538; Expressed in Brodmann (1909) area 10 and 175 other cell types or tissues. DR ExpressionAtlas; Q16288; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl. DR GO; GO:0043121; F:neurotrophin binding; IBA:GO_Central. DR GO; GO:0005030; F:neurotrophin receptor activity; IDA:BHF-UCL. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0048677; P:axon extension involved in regeneration; IEA:Ensembl. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0090102; P:cochlea development; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IMP:UniProtKB. DR GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0048691; P:positive regulation of axon extension involved in regeneration; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0010976; P:positive regulation of neuron projection development; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0097107; P:postsynaptic density assembly; IEA:Ensembl. DR GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl. DR GO; GO:1905606; P:regulation of presynapse assembly; IEA:Ensembl. DR GO; GO:0051412; P:response to corticosterone; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR CDD; cd04971; IgI_TrKABC_d5; 1. DR CDD; cd05094; PTKc_TrkC; 1. DR FunFam; 1.10.510.10:FF:000701; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000251; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000265; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.10.10:FF:000035; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020446; NTRK3. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF66; NT-3 GROWTH FACTOR RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01942; NTKRECEPTOR3. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51450; LRR; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Developmental protein; KW Differentiation; Direct protein sequencing; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..31 FT CHAIN 32..839 FT /note="NT-3 growth factor receptor" FT /id="PRO_0000016731" FT TOPO_DOM 32..429 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 430..453 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 454..839 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 104..125 FT /note="LRR 1" FT REPEAT 128..149 FT /note="LRR 2" FT DOMAIN 160..209 FT /note="LRRCT" FT DOMAIN 210..300 FT /note="Ig-like C2-type 1" FT DOMAIN 309..382 FT /note="Ig-like C2-type 2" FT DOMAIN 538..839 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 679 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 834 FT /note="Interaction with PLC-gamma-1" FT /evidence="ECO:0000250" FT MOD_RES 493 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6VNS1" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:25196463" FT MOD_RES 705 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 709 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 710 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 72 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 79 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 133 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 163 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 203 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 218 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 232 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 267 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 272 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 294 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 375 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 388 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 32..38 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 36..45 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 164..189 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 166..207 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 231..284 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 320..362 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0007744|PDB:1WWC" FT VAR_SEQ 402..410 FT /note="ESTDNFILF -> V (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_002924" FT VAR_SEQ 529..612 FT /note="YVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLA FT ARKDFQREAELLTNLQHEHIVKFYGVCGDGDP -> WVFSNIDNHGILNLKDNRDHLVP FT STHYIYEEPEVQSGEVSYPRSHGFREIMLNPISLPGHSKPLNHGIYVEDVNVYFSKGRH FT GF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7823156" FT /id="VSP_002925" FT VAR_SEQ 613..839 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7823156" FT /id="VSP_002926" FT VAR_SEQ 712..725 FT /note="Missing (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7806211, ECO:0000303|PubMed:7823156" FT /id="VSP_002927" FT VARIANT 21 FT /note="V -> F (in dbSNP:rs200822610)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074601" FT VARIANT 71 FT /note="I -> V (found in patients with CHD; uncertain FT significance; dbSNP:rs200923715)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074602" FT VARIANT 93 FT /note="T -> M (found in patients with congenital heart FT defects; uncertain significance; significantly reduced FT autophosphorylation; decreased NTRK3 signaling and FT decreased apoptosis in absence of NTF3; dbSNP:rs147992979)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074603" FT VARIANT 149 FT /note="T -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs368222977)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041471" FT VARIANT 163 FT /note="N -> I (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; no effect on NTRK3 signaling; FT dbSNP:rs547862658)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074604" FT VARIANT 306 FT /note="R -> C (in dbSNP:rs56386352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041472" FT VARIANT 307 FT /note="V -> L (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1388363572)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041473" FT VARIANT 336 FT /note="L -> Q (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041474" FT VARIANT 533 FT /note="I -> F (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; changed NTRK3 signaling with decreased FT apoptosis in absence of NTF3; dbSNP:rs869112057)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074605" FT VARIANT 664 FT /note="A -> S (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046521" FT VARIANT 677 FT /note="H -> Y (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18293376" FT /id="VAR_041475" FT VARIANT 678 FT /note="R -> Q (in dbSNP:rs55890138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041476" FT VARIANT 735 FT /note="R -> F (in a lung large cell carcinoma sample; FT somatic mutation; requires 2 nucleotide substitutions)" FT /id="VAR_046770" FT VARIANT 736 FT /note="W -> C (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046522" FT VARIANT 745 FT /note="R -> P (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046523" FT VARIANT 766 FT /note="Y -> F (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046524" FT VARIANT 768 FT /note="K -> R (in dbSNP:rs55770052)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046771" FT VARIANT 781 FT /note="E -> K (in dbSNP:rs56393451)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046772" FT VARIANT 817 FT /note="I -> M (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; changed NTRK3 signaling with decreased FT apoptosis in absence of NTF3; dbSNP:rs869209165)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074606" FT MUTAGEN 572 FT /note="K->N: Loss of autophosphorylation and loss of NTRK3 FT signaling." FT /evidence="ECO:0000269|PubMed:25196463" FT CONFLICT 65 FT /note="S -> G (in Ref. 4; BAH12511)" FT /evidence="ECO:0000305" FT CONFLICT 70 FT /note="S -> N (in Ref. 2; AAB33111/AAB33112)" FT /evidence="ECO:0000305" FT CONFLICT 635 FT /note="D -> N (in Ref. 1; AAA75374)" FT /evidence="ECO:0000305" FT STRAND 318..326 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 332..337 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 345..354 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 356..367 FT /evidence="ECO:0007829|PDB:1WWC" FT HELIX 370..372 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 374..382 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 385..393 FT /evidence="ECO:0007829|PDB:1WWC" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 538..547 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 550..559 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 567..576 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 579..594 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 603..606 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 653..672 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 682..684 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 685..687 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 693..695 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 700..704 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 706..708 FT /evidence="ECO:0007829|PDB:4YMJ" FT HELIX 734..736 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 739..744 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 749..764 FT /evidence="ECO:0007829|PDB:6KZD" FT TURN 765..767 FT /evidence="ECO:0007829|PDB:6KZD" FT TURN 770..773 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 776..784 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 797..806 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 811..813 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 817..827 FT /evidence="ECO:0007829|PDB:6KZD" SQ SEQUENCE 839 AA; 94428 MW; 7FE8846830083C08 CRC64; MDVSLCPAKC SFWRIFLLGS VWLDYVGSVL ACPANCVCSK TEINCRRPDD GNLFPLLEGQ DSGNSNGNAS INITDISRNI TSIHIENWRS LHTLNAVDME LYTGLQKLTI KNSGLRSIQP RAFAKNPHLR YINLSSNRLT TLSWQLFQTL SLRELQLEQN FFNCSCDIRW MQLWQEQGEA KLNSQNLYCI NADGSQLPLF RMNISQCDLP EISVSHVNLT VREGDNAVIT CNGSGSPLPD VDWIVTGLQS INTHQTNLNW TNVHAINLTL VNVTSEDNGF TLTCIAENVV GMSNASVALT VYYPPRVVSL EEPELRLEHC IEFVVRGNPP PTLHWLHNGQ PLRESKIIHV EYYQEGEISE GCLLFNKPTH YNNGNYTLIA KNPLGTANQT INGHFLKEPF PESTDNFILF DEVSPTPPIT VTHKPEEDTF GVSIAVGLAA FACVLLVVLF VMINKYGRRS KFGMKGPVAV ISGEEDSASP LHHINHGITT PSSLDAGPDT VVIGMTRIPV IENPQYFRQG HNCHKPDTYV QHIKRRDIVL KRELGEGAFG KVFLAECYNL SPTKDKMLVA VKALKDPTLA ARKDFQREAE LLTNLQHEHI VKFYGVCGDG DPLIMVFEYM KHGDLNKFLR AHGPDAMILV DGQPRQAKGE LGLSQMLHIA SQIASGMVYL ASQHFVHRDL ATRNCLVGAN LLVKIGDFGM SRDVYSTDYY RLFNPSGNDF CIWCEVGGHT MLPIRWMPPE SIMYRKFTTE SDVWSFGVIL WEIFTYGKQP WFQLSNTEVI ECITQGRVLE RPRVCPKEVY DVMLGCWQRE PQQRLNIKEI YKILHALGKA TPIYLDILG // ID P53_HUMAN Reviewed; 393 AA. AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; AC Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; AC Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 4. DT 28-JAN-2026, entry version 313. DE RecName: Full=Cellular tumor antigen p53; DE AltName: Full=Antigen NY-CO-13; DE AltName: Full=Phosphoprotein p53; DE AltName: Full=Tumor suppressor p53; GN Name=TP53; Synonyms=P53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x; RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS RT cells."; RL EMBO J. 4:1251-1255(1985). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76. RX PubMed=2946935; DOI=10.1128/mcb.6.5.1379-1385.1986; RA Lamb P., Crawford L.; RT "Characterization of the human p53 gene."; RL Mol. Cell. Biol. 6:1379-1385(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3894933; DOI=10.1128/mcb.5.7.1601-1610.1985; RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; RT "Molecular cloning and in vitro expression of a cDNA clone for human RT cellular tumor antigen p53."; RL Mol. Cell. Biol. 5:1601-1610(1985). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3025664; DOI=10.1128/mcb.6.12.4650-4656.1986; RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; RT "Molecular basis for heterogeneity of the human p53 protein."; RL Mol. Cell. Biol. 6:4650-4656(1986). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5; RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; RT "A variation in the structure of the protein-coding region of the human p53 RT gene."; RL Gene 70:245-252(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS. RX PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; RT "p53 is frequently mutated in Burkitt's lymphoma cell lines."; RL EMBO J. 10:2879-2887(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=8316628; DOI=10.2307/3578196; RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., RA Mirzayans R.; RT "Isolation of two cell lines from a human malignant glioma specimen RT differing in sensitivity to radiation and chemotherapeutic drugs."; RL Radiat. Res. 134:349-354(1993). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX. RX PubMed=11058590; DOI=10.1074/jbc.m007140200; RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., RA Zevotek N.; RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that RT enhances tumor necrosis factor cytotoxicity."; RL J. Biol. Chem. 276:3361-3370(2001). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE RP SPLICING, INDUCTION, AND VARIANT ARG-72. RC TISSUE=Colon; RX PubMed=16131611; DOI=10.1101/gad.1339905; RA Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., RA Xirodimas D.P., Saville M.K., Lane D.P.; RT "p53 isoforms can regulate p53 transcriptional activity."; RL Genes Dev. 19:2122-2137(2005). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Chumakov P.M., Almazov V.P., Jenkins J.R.; RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Rozemuller E.H., Tilanus M.G.J.; RT "P53 genomic sequence. Corrections and polymorphism."; RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND RP ALA-366. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; RA Anderson C.W., Allalunis-Turner M.J.; RT "Human TP53 from the malignant glioma-derived cell lines M059J and M059K RT has a cancer-associated mutation in exon 8."; RL Radiat. Res. 154:473-476(2000). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309. RA Azuma K., Shichijo S., Itoh K.; RT "Identification of a tumor-rejection antigen recognized by HLA-B46 RT restricted CTL."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND RP PRO-155. RC TISSUE=Lung carcinoma; RX PubMed=14660794; DOI=10.1073/pnas.2536558100; RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., RA Varga J.L.; RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung RT carcinoma by antagonists of growth hormone-releasing hormone and RT bombesin."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393. RX PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x; RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; RT "Isolation and characterization of a human p53 cDNA clone: expression of RT the human p53 gene."; RL EMBO J. 3:3257-3262(1984). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185. RA Pan X.L., Zhang A.H.; RT "Study on the effect of tumor suppressor gene p53 in arsenism patients."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282. RC TISSUE=Blood; RA Nimri L.F., Owais W., Momani E.; RT "Detection of P53 gene mutations and serum p53 antibodies associated with RT cigarette smoking."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262. RC TISSUE=Ovarian adenocarcinoma; RA Filippini G., Soldati G.; RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases. RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RC TISSUE=Glial cell, and Glial tumor; RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., RA Salisbury J., Sibson D.R., Vergote I., Walker C.; RT "Mutation detection utilizing a novel PCR approach for amplification of the RT p53 gene from microdissected tissue: application to archival tumor RT samples."; RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., RA Lipsky P.E.; RT "Bcl6 and P53 gene mutations in tonsillar B cells."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR RP LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5, RP IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337. RX PubMed=19011621; DOI=10.1038/ncb1802; RA Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., RA La Thangue N.B.; RT "Arginine methylation regulates the p53 response."; RL Nat. Cell Biol. 10:1431-1439(2008). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366. RA Pinto E.M., Mendonca B.B., Latronico A.C.; RT "Allelic variant in intron 9 of TP53 gene."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [28] RP INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL RP INFECTION). RX PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8; RA Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.; RT "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 RT promotes the degradation of p53."; RL Cell 63:1129-1136(1990). RN [29] RP NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND RP LYS-321. RX PubMed=2156209; RA Addison C., Jenkins J.R., Sturzbecher H.-W.; RT "The p53 nuclear localisation signal is structurally linked to a p34cdc2 RT kinase motif."; RL Oncogene 5:423-426(1990). RN [30] RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. RX PubMed=2141171; DOI=10.1073/pnas.87.12.4766; RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990). RN [31] RP PHOSPHORYLATION. RX PubMed=1705009; DOI=10.1128/mcb.11.3.1598-1606.1991; RA Samad A., Carroll R.B.; RT "The tumor suppressor p53 is bound to RNA by a stable covalent linkage."; RL Mol. Cell. Biol. 11:1598-1606(1991). RN [32] RP DEPHOSPHORYLATION BY PP2A. RX PubMed=1848668; DOI=10.1128/mcb.11.4.1996-2003.1991; RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by RT protein phosphatase 2A: inhibition by small-t antigen."; RL Mol. Cell. Biol. 11:1996-2003(1991). RN [33] RP ALTERNATIVE SPLICING. RX PubMed=8632903; RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., RA Gilbert D., Iggo R., Frebourg T.; RT "The human tumour suppressor gene p53 is alternatively spliced in normal RT cells."; RL Oncogene 12:813-818(1996). RN [34] RP GLYCOSYLATION. RX PubMed=8632915; RA Shaw P., Freeman J., Bovey R., Iggo R.; RT "Regulation of specific DNA binding by p53: evidence for a role for O- RT glycosylation and charged residues at the carboxy-terminus."; RL Oncogene 12:921-930(1996). RN [35] RP PHOSPHORYLATION AT SER-33. RX PubMed=9372954; DOI=10.1128/mcb.17.12.7220; RA Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C., RA Pan Z.-Q.; RT "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner."; RL Mol. Cell. Biol. 17:7220-7229(1997). RN [36] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK. RX PubMed=9840937; DOI=10.1038/sj.onc.1202504; RA Schneider E., Montenarh M., Wagner P.; RT "Regulation of CAK kinase activity by p53."; RL Oncogene 17:2733-2741(1998). RN [37] RP SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386. RA Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., RA Scheffner M., Del Sal G.; RT "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1."; RL EMBO J. 18:6462-6471(1999). RN [38] RP PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1. RX PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6; RA Dumaz N., Milne D.M., Meek D.W.; RT "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior RT phosphorylation of serine 15."; RL FEBS Lett. 463:312-316(1999). RN [39] RP BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT RP ASN-305. RX PubMed=10551826; DOI=10.1074/jbc.274.46.32699; RA Liang S.H., Clarke M.F.; RT "A bipartite nuclear localization signal is required for p53 nuclear import RT regulated by a carboxyl-terminal domain."; RL J. Biol. Chem. 274:32699-32703(1999). RN [40] RP PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE, RP CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND RP 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2. RX PubMed=10570149; DOI=10.1073/pnas.96.24.13777; RA Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.; RT "Phosphorylation of Ser-20 mediates stabilization of human p53 in response RT to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999). RN [41] RP UBIQUITINATION. RX PubMed=10722742; DOI=10.1074/jbc.275.12.8945; RA Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.; RT "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and RT p53."; RL J. Biol. Chem. 275:8945-8951(2000). RN [42] RP ACETYLATION AT LYS-373 AND LYS-382. RX PubMed=10656795; DOI=10.1006/jmbi.1999.3415; RA Abraham J., Kelly J., Thibault P., Benchimol S.; RT "Post-translational modification of p53 protein in response to ionizing RT radiation analyzed by mass spectrometry."; RL J. Mol. Biol. 295:853-864(2000). RN [43] RP PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382; RP LEU-383 AND PHE-385. RX PubMed=10884347; DOI=10.1006/jmbi.2000.3830; RA Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.; RT "The C-terminal regulatory domain of p53 contains a functional docking site RT for cyclin A."; RL J. Mol. Biol. 300:503-518(2000). RN [44] RP FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION. RX PubMed=11025664; DOI=10.1038/35036365; RA Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.; RT "The function of PML in p53-dependent apoptosis."; RL Nat. Cell Biol. 2:730-736(2000). RN [45] RP INTERACTION WITH E4F1. RX PubMed=10644996; DOI=10.1038/sj.onc.1203250; RA Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., RA Schneider C., Del Sal G.; RT "p53 is involved in the p120E4F-mediated growth arrest."; RL Oncogene 19:188-199(2000). RN [46] RP PHOSPHORYLATION AT THR-18. RX PubMed=10951572; DOI=10.1038/sj.onc.1203709; RA Lopez-Borges S., Lazo P.A.; RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 RT within the mdm-2 binding site of the p53 tumour suppressor protein."; RL Oncogene 19:3656-3664(2000). RN [47] RP REVIEW ON ZINC-BINDING PROPERTIES. RX PubMed=11554448; DOI=10.1089/15230860152542961; RA Hainaut P., Mann K.; RT "Zinc binding and redox control of p53 structure and function."; RL Antioxid. Redox Signal. 3:611-623(2001). RN [48] RP PHOSPHORYLATION AT SER-15. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [49] RP DEACETYLATION AT LYS-382 BY SIRT1. RX PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x; RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., RA Guarente L., Weinberg R.A.; RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase."; RL Cell 107:149-159(2001). RN [50] RP MINIMAL REPRESSION DOMAIN. RX PubMed=11007800; DOI=10.1074/jbc.m008231200; RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; RT "p53 amino acids 339-346 represent the minimal p53 repression domain."; RL J. Biol. Chem. 276:1510-1515(2001). RN [51] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11447225; DOI=10.1074/jbc.m104157200; RA Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.; RT "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is RT mediated in part by polo-like kinase-3."; RL J. Biol. Chem. 276:36194-36199(2001). RN [52] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11551930; DOI=10.1074/jbc.m106050200; RA Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., RA Jhanwar-Uniyal M., Dai W.; RT "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at RT least in part via the p53 pathway."; RL J. Biol. Chem. 276:43305-43312(2001). RN [53] RP SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; RP LYS-386; THR-387 AND GLU-388. RX PubMed=11124955; DOI=10.1074/jbc.m009476200; RA Rodriguez M.S., Dargemont C., Hay R.T.; RT "SUMO-1 conjugation in vivo requires both a consensus modification motif RT and nuclear targeting."; RL J. Biol. Chem. 276:12654-12659(2001). RN [54] RP PHOSPHORYLATION BY PRPK. RX PubMed=11546806; DOI=10.1074/jbc.m105669200; RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.; RT "Cloning and characterization of a p53-related protein kinase expressed in RT interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and RT the testes."; RL J. Biol. Chem. 276:44003-44011(2001). RN [55] RP PHOSPHORYLATION AT SER-392. RX PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9; RA Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., RA Lozano G., Zhao Y., Lu H.; RT "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, RT and SSRP1."; RL Mol. Cell 7:283-292(2001). RN [56] RP INTERACTION WITH USP7. RX PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6; RA Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.; RT "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and RT in complex with ubiquitin aldehyde."; RL Cell 111:1041-1054(2002). RN [57] RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73. RX PubMed=11706030; DOI=10.1074/jbc.m108535200; RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.; RT "Differential effect of ik3-1/cables on p53- and p73-induced cell death."; RL J. Biol. Chem. 277:2951-2957(2002). RN [58] RP INTERACTION WITH HIPK2. RX PubMed=11925430; DOI=10.1074/jbc.m200153200; RA Kim E.-J., Park J.-S., Um S.-J.; RT "Identification and characterization of HIPK2 interacting with p73 and RT modulating functions of the p53 family in vivo."; RL J. Biol. Chem. 277:32020-32028(2002). RN [59] RP INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF RP SER-46 AND LYS-382. RX PubMed=11740489; DOI=10.1038/ncb715; RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., RA Will H., Schmitz M.L.; RT "Regulation of p53 activity by its interaction with homeodomain-interacting RT protein kinase-2."; RL Nat. Cell Biol. 4:1-10(2002). RN [60] RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46. RX PubMed=11780126; DOI=10.1038/ncb714; RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., RA Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., RA Appella E., Soddu S.; RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and RT mediates apoptosis."; RL Nat. Cell Biol. 4:11-19(2002). RN [61] RP INTERACTION WITH ING4. RX PubMed=12750254; RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.; RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity."; RL Cancer Res. 63:2373-2378(2003). RN [62] RP ACETYLATION AT LYS-305. RX PubMed=12724314; DOI=10.1074/jbc.m212574200; RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.; RT "Identification and characterization of a novel p300-mediated p53 RT acetylation site, lysine 305."; RL J. Biol. Chem. 278:25568-25576(2003). RN [63] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML, RP UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [64] RP INTERACTION WITH TP53INP1. RX PubMed=12851404; DOI=10.1074/jbc.m301979200; RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., RA Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.; RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are RT partners in regulating p53 activity."; RL J. Biol. Chem. 278:37722-37729(2003). RN [65] RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL. RX PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003; RA O'Keefe K., Li H., Zhang Y.; RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated RT cytoplasmic degradation but not ubiquitination."; RL Mol. Cell. Biol. 23:6396-6405(2003). RN [66] RP FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2. RX PubMed=12524540; DOI=10.1038/ng1070; RA Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., RA Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., RA Kuwabara P.E., Lu X.; RT "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to RT human."; RL Nat. Genet. 33:162-167(2003). RN [67] RP INTERACTION WITH HIPK1. RX PubMed=12702766; DOI=10.1073/pnas.0530308100; RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., RA Thukral S.K.; RT "Characterization of cells and gene-targeted mice deficient for the p53- RT binding kinase homeodomain-interacting protein kinase 1 (HIPK1)."; RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003). RN [68] RP INTERACTION WITH CDKN2AIP. RX PubMed=15109303; DOI=10.1042/bj20040337; RA Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., RA Kaul S.C.; RT "Alternative reading frame protein (ARF)-independent function of CARF RT (collaborator of ARF) involves its interactions with p53: evidence for a RT novel p53-activation pathway and its negative feedback control."; RL Biochem. J. 380:605-610(2004). RN [69] RP INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION. RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009; RA An W., Kim J., Roeder R.G.; RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional RT activation by p53."; RL Cell 117:735-748(2004). RN [70] RP INTERACTION WITH ANKRD2. RX PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071; RA Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V., RA Valle G., Faulkner G.; RT "The Ankrd2 protein, a link between the sarcomere and the nucleus in RT skeletal muscle."; RL J. Mol. Biol. 339:313-325(2004). RN [71] RP PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH RP TAF1. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [72] RP DEUBIQUITINATION BY USP7. RX PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1; RA Li M., Brooks C.L., Kon N., Gu W.; RT "A dynamic role of HAUSP in the p53-Mdm2 pathway."; RL Mol. Cell 13:879-886(2004). RN [73] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004; RA Ghosh A., Stewart D., Matlashewski G.; RT "Regulation of human p53 activity and cell localization by alternative RT splicing."; RL Mol. Cell. Biol. 24:7987-7997(2004). RN [74] RP METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372. RX PubMed=15525938; DOI=10.1038/nature03117; RA Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., RA McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.; RT "Regulation of p53 activity through lysine methylation."; RL Nature 432:353-360(2004). RN [75] RP ACETYLATION AT LYS-382. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [76] RP INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [77] RP INTERACTION WITH NQO1. RX PubMed=15687255; DOI=10.1101/gad.319905; RA Asher G., Tsvetkov P., Kahana C., Shaul Y.; RT "A mechanism of ubiquitin-independent proteasomal degradation of the tumor RT suppressors p53 and p73."; RL Genes Dev. 19:316-321(2005). RN [78] RP INTERACTION WITH NOC2L. RX PubMed=16322561; DOI=10.1101/gad.351205; RA Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N., RA Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A., RA Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.; RT "NIR is a novel INHAT repressor that modulates the transcriptional activity RT of p53."; RL Genes Dev. 19:2912-2924(2005). RN [79] RP RETRACTED PAPER. RX PubMed=15701641; DOI=10.1074/jbc.m413200200; RA Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RT "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine- RT serine-rich motif."; RL J. Biol. Chem. 280:16019-16029(2005). RN [80] RP RETRACTION NOTICE OF PUBMED:15701641. RX PubMed=32144153; DOI=10.1074/jbc.w120.012894; RA Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RL J. Biol. Chem. 295:3390-3390(2020). RN [81] RP INTERACTION WITH PTK2/FAK1. RX PubMed=15855171; DOI=10.1074/jbc.m414172200; RA Golubovskaya V.M., Finch R., Cance W.G.; RT "Direct interaction of the N-terminal domain of focal adhesion kinase with RT the N-terminal transactivation domain of p53."; RL J. Biol. Chem. 280:25008-25021(2005). RN [82] RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [83] RP PHOSPHORYLATION AT SER-15. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [84] RP INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [85] RP PHOSPHORYLATION AT THR-18. RX PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x; RA Blanco S., Klimcakova L., Vega F.M., Lazo P.A.; RT "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms RT determines their different effect on p53 stability in tumour cell lines."; RL FEBS J. 273:2487-2504(2006). RN [86] RP INTERACTION WITH YWHAZ. RX PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024; RA Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.; RT "Protein kinase A phosphorylates and regulates dimerization of 14-3-3 RT epsilon."; RL FEBS Lett. 580:305-310(2006). RN [87] RP PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG. RX PubMed=16377624; DOI=10.1074/jbc.m512074200; RA Yoshida K., Liu H., Miki Y.; RT "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor RT suppressor in the apoptotic response to DNA damage."; RL J. Biol. Chem. 281:5734-5740(2006). RN [88] RP FUNCTION, ACETYLATION AT LYS-120, VARIANTS ARG-120; GLU-120 AND MET-120, RP AND CHARACTERIZATION OF VARIANTS ARG-120; GLU-120 AND MET-120. RX PubMed=17189187; DOI=10.1016/j.molcel.2006.11.026; RA Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., RA McMahon S.B.; RT "Acetylation of the p53 DNA-binding domain regulates apoptosis induction."; RL Mol. Cell 24:841-851(2006). RN [89] RP METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370. RX PubMed=17108971; DOI=10.1038/nature05287; RA Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., RA Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.; RT "Repression of p53 activity by Smyd2-mediated methylation."; RL Nature 444:629-632(2006). RN [90] RP INTERACTION WITH DAXX. RX PubMed=16845383; DOI=10.1038/ncb1442; RA Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., RA El-Deiry W.S., Yang X.; RT "Critical role for Daxx in regulating Mdm2."; RL Nat. Cell Biol. 8:855-862(2006). RN [91] RP MOTIF, AND METHYLATION AT LYS-372. RX PubMed=16415881; DOI=10.1038/nsmb1045; RA Couture J.-F., Collazo E., Hauk G., Trievel R.C.; RT "Structural basis for the methylation site specificity of SET7/9."; RL Nat. Struct. Mol. Biol. 13:140-146(2006). RN [92] RP INTERACTION WITH POU4F2. RX PubMed=17145718; DOI=10.1093/nar/gkl878; RA Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., RA Morris P.J., Latchman D.S.; RT "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of RT cell cycle arrest by cooperating in trans-activation of bax expression."; RL Nucleic Acids Res. 34:6640-6652(2006). RN [93] RP PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37. RX PubMed=17254968; DOI=10.1016/j.cell.2006.11.050; RA Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., RA Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E., RA Han J.; RT "PRAK is essential for ras-induced senescence and tumor suppression."; RL Cell 128:295-308(2007). RN [94] RP INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175 RP AND PRO-175. RX PubMed=17719541; DOI=10.1016/j.cell.2007.06.013; RA Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.; RT "Hzf Determines cell survival upon genotoxic stress by modulating p53 RT transactivation."; RL Cell 130:624-637(2007). RN [95] RP UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION. RX PubMed=17170702; DOI=10.1038/sj.emboj.7601490; RA Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., RA Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., RA Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., RA Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., RA Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., RA Nakajima T.; RT "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident RT ubiquitin ligase 'Synoviolin'."; RL EMBO J. 26:113-122(2007). RN [96] RP INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C. RX PubMed=17245430; DOI=10.1038/sj.emboj.7601519; RA Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.; RT "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced RT dephosphorylation of p53 at Thr55."; RL EMBO J. 26:402-411(2007). RN [97] RP INTERACTION WITH ARMC10. RX PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025; RA Zhou X., Yang G., Huang R., Chen X., Hu G.; RT "SVH-B interacts directly with p53 and suppresses the transcriptional RT activity of p53."; RL FEBS Lett. 581:4943-4948(2007). RN [98] RP PHOSPHORYLATION AT SER-9. RX PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022; RA Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.; RT "Novel homeodomain-interacting protein kinase family member, HIPK4, RT phosphorylates human p53 at serine 9."; RL FEBS Lett. 581:5649-5657(2007). RN [99] RP DOMAIN. RX PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003; RA Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.; RT "Nine-amino-acid transactivation domain: establishment and prediction RT utilities."; RL Genomics 89:756-768(2007). RN [100] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=17121812; DOI=10.1074/jbc.m610793200; RA Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M., RA Wang W., Dicker D.T., El-Deiry W.S.; RT "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho- RT p53ser20 degradation."; RL J. Biol. Chem. 282:3273-3281(2007). RN [101] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=17317671; DOI=10.1074/jbc.m608974200; RA Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., RA Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., RA Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., RA Wazer D.E., Band H., Band V.; RT "The notch regulator MAML1 interacts with p53 and functions as a RT coactivator."; RL J. Biol. Chem. 282:11969-11981(2007). RN [102] RP PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND RP SUBCELLULAR LOCATION. RX PubMed=17591690; DOI=10.1242/jcs.03468; RA Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.; RT "Stabilization and activation of p53 induced by Cdk5 contributes to RT neuronal cell death."; RL J. Cell Sci. 120:2259-2271(2007). RN [103] RP INTERACTION WITH MORC3. RX PubMed=17332504; DOI=10.1091/mbc.e06-08-0747; RA Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H., RA Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.; RT "Dynamic regulation of p53 subnuclear localization and senescence by RT MORC3."; RL Mol. Biol. Cell 18:1701-1709(2007). RN [104] RP FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [105] RP DEMETHYLATION BY KDM1A. RX PubMed=17805299; DOI=10.1038/nature06092; RA Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., RA Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.; RT "p53 is regulated by the lysine demethylase LSD1."; RL Nature 449:105-108(2007). RN [106] RP METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382. RX PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012; RA Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., RA Dutta S., Appella E., Gozani O.; RT "Modulation of p53 function by SET8-mediated methylation at lysine 382."; RL Mol. Cell 27:636-646(2007). RN [107] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [108] RP ACETYLATION, AND DEACETYLATION BY SIRT2. RX PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114; RA Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.; RT "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of RT p53."; RL Biochem. Biophys. Res. Commun. 368:690-695(2008). RN [109] RP INTERACTION WITH SETD2. RX PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012; RA Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.; RT "Histone methyltransferase protein SETD2 interacts with p53 and selectively RT regulates its downstream genes."; RL Cell. Signal. 20:1671-1678(2008). RN [110] RP INTERACTION WITH NUPR1. RX PubMed=18690848; DOI=10.2174/156800908785133196; RA Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O., RA Shevde L.A.; RT "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues RT breast epithelial cells from doxorubicin-induced genotoxic stress."; RL Curr. Cancer Drug Targets 8:421-430(2008). RN [111] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031; RA Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., RA Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.; RT "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced RT p53 degradation."; RL Mol. Cell 29:9-22(2008). RN [112] RP INTERACTION WITH KAT7. RX PubMed=17954561; DOI=10.1128/mcb.00662-07; RA Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.; RT "Hbo1 Links p53-dependent stress signaling to DNA replication licensing."; RL Mol. Cell. Biol. 28:140-153(2008). RN [113] RP INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY RP ATM, AND MUTAGENESIS OF SER-15. RX PubMed=17967874; DOI=10.1128/mcb.00983-07; RA Shouse G.P., Cai X., Liu X.; RT "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and RT the tumor suppressor activity of B56gamma-specific protein phosphatase RT 2A."; RL Mol. Cell. Biol. 28:448-456(2008). RN [114] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [115] RP INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION RP AT LYS-291 AND LYS-292 BY MKRN1. RX PubMed=19536131; DOI=10.1038/emboj.2009.164; RA Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C., RA Lane D.P., Song J.; RT "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell RT cycle arrest and apoptosis."; RL EMBO J. 28:2100-2113(2009). RN [116] RP UBIQUITINATION BY TOPORS. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [117] RP UBIQUITINATION AT LYS-351 AND LYS-357, AND SUBCELLULAR LOCATION. RX PubMed=19033443; DOI=10.1074/jbc.m805658200; RA Kruse J.P., Gu W.; RT "MSL2 promotes Mdm2-independent cytoplasmic localization of p53."; RL J. Biol. Chem. 284:3250-3263(2009). RN [118] RP INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION. RX PubMed=19837670; DOI=10.1074/jbc.m109.056499; RA Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y., RA Rayala S.K., Kumar R.; RT "MTA1 coregulator regulates p53 stability and function."; RL J. Biol. Chem. 284:34545-34552(2009). RN [119] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=19776115; DOI=10.1128/jvi.00304-09; RA Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.; RT "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53- RT dependent transactivation by a mechanism different from that of IE2-86 RT protein."; RL J. Virol. 83:12388-12398(2009). RN [120] RP ACETYLATION AT LYS-120. RX PubMed=19854137; DOI=10.1016/j.molcel.2009.07.031; RA Li X., Wu L., Corsa C.A., Kunkel S., Dou Y.; RT "Two mammalian MOF complexes regulate transcription activation by distinct RT mechanisms."; RL Mol. Cell 36:290-301(2009). RN [121] RP INTERACTION WITH FBXO42. RX PubMed=19509332; DOI=10.1073/pnas.0901864106; RA Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., RA Yao X., Yi X., Shang Y.; RT "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 RT regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009). RN [122] RP FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24. RX PubMed=19556538; DOI=10.1073/pnas.0813177106; RA Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., RA Johnson R.L., Barton M.C.; RT "Trim24 targets endogenous p53 for degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009). RN [123] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [124] RP INTERACTION WITH TAF6 ISOFORMS 1 AND 4. RX PubMed=20096117; DOI=10.1186/1471-2199-11-10; RA Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M., RA Tora L., Benecke A., Bell B.; RT "TAF6delta orchestrates an apoptotic transcriptome profile and interacts RT functionally with p53."; RL BMC Mol. Biol. 11:10-10(2010). RN [125] RP UBIQUITINATION, AND DEUBIQUITINATION BY USP10. RX PubMed=20096447; DOI=10.1016/j.cell.2009.12.032; RA Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.; RT "USP10 regulates p53 localization and stability by deubiquitinating p53."; RL Cell 140:384-396(2010). RN [126] RP FUNCTION. RX PubMed=20673990; DOI=10.1016/j.cell.2010.06.040; RA Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., RA Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., RA Regev A., Lander E.S., Jacks T., Rinn J.L.; RT "A large intergenic noncoding RNA induced by p53 mediates global gene RT repression in the p53 response."; RL Cell 142:409-419(2010). RN [127] RP PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1. RX PubMed=20041275; DOI=10.1007/s00018-009-0236-7; RA Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.; RT "Isoform specific phosphorylation of p53 by protein kinase CK1."; RL Cell. Mol. Life Sci. 67:1105-1118(2010). RN [128] RP INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155; RP HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248. RX PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006; RA Lim S.O., Kim H., Jung G.; RT "p53 inhibits tumor cell invasion via the degradation of snail protein in RT hepatocellular carcinoma."; RL FEBS Lett. 584:2231-2236(2010). RN [129] RP INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR RP LOCATION. RX PubMed=19880522; DOI=10.1074/jbc.m109.064212; RA Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.; RT "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating RT cell proliferation and survival."; RL J. Biol. Chem. 285:1743-1753(2010). RN [130] RP METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373. RX PubMed=20118233; DOI=10.1074/jbc.m109.062588; RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RT "G9a and Glp methylate lysine 373 in the tumor suppressor p53."; RL J. Biol. Chem. 285:9636-9641(2010). RN [131] RP ERRATUM OF PUBMED:20118233. RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RL J. Biol. Chem. 285:18122-18122(2010). RN [132] RP PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5. RX PubMed=20124405; DOI=10.1074/jbc.m109.094243; RA Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.; RT "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA RT damage-induced apoptosis."; RL J. Biol. Chem. 285:12823-12830(2010). RN [133] RP INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382. RX PubMed=20228809; DOI=10.1038/ncb2038; RA Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., RA Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.; RT "BRD7 is a candidate tumour suppressor gene required for p53 function."; RL Nat. Cell Biol. 12:380-389(2010). RN [134] RP UBIQUITINATION BY RFWD3. RX PubMed=20173098; DOI=10.1073/pnas.0912094107; RA Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., RA O'Malley B.W., Gu W., Qin J., Wang Y.; RT "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in RT response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010). RN [135] RP INTERACTION WITH BRD7. RX PubMed=20660729; DOI=10.1073/pnas.1009559107; RA Burrows A.E., Smogorzewska A., Elledge S.J.; RT "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are RT critical regulators of p53 required for induction of replicative RT senescence."; RL Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010). RN [136] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [137] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [138] RP INTERACTION WITH MUL1, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-24 BY RP MUL1, AND MUTAGENESIS OF LYS-24. RX PubMed=21597459; DOI=10.1038/cdd.2011.57; RA Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., RA Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H.; RT "E3 ubiquitin ligase Hades negatively regulates the exonuclear function of RT p53."; RL Cell Death Differ. 18:1865-1875(2011). RN [139] RP FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183; RP SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF RP SER-183; SER-269 AND THR-284, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20959462; DOI=10.1074/jbc.m110.174755; RA Wu L., Ma C.A., Zhao Y., Jain A.; RT "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its RT DNA-binding domain and subsequent functional suppression."; RL J. Biol. Chem. 286:2236-2244(2011). RN [140] RP INTERACTION WITH ALDOB AND G6PD. RX PubMed=35122041; DOI=10.1038/s43018-020-0086-7; RA Li M., He X., Guo W., Yu H., Zhang S., Wang N., Liu G., Sa R., Shen X., RA Jiang Y., Tang Y., Zhuo Y., Yin C., Tu Q., Li N., Nie X., Li Y., Hu Z., RA Zhu H., Ding J., Li Z., Liu T., Zhang F., Zhou H., Li S., Yue J., Yan Z., RA Cheng S., Tao Y., Yin H.; RT "Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and RT pentose phosphate pathways."; RL Nat. Cancer 1:735-747(2020). RN [141] RP INVOLVEMENT IN BCC7. RX PubMed=21946351; DOI=10.1038/ng.926; RA Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., RA Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B., RA Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A., RA Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., RA Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., RA Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A., RA Rivera F., Planelles D., Soriano V., Requena C., Aben K.K., RA van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J., RA Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C., RA Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P., RA Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S., RA Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V., RA Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T., RA Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G., RA Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H., RA O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H., RA Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A., RA Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T., RA Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J., RA Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I., RA Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.; RT "A germline variant in the TP53 polyadenylation signal confers cancer RT susceptibility."; RL Nat. Genet. 43:1098-1103(2011). RN [142] RP INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [143] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF. RX PubMed=22726440; DOI=10.1016/j.cell.2012.05.014; RA Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.; RT "p53 opens the mitochondrial permeability transition pore to trigger RT necrosis."; RL Cell 149:1536-1548(2012). RN [144] RP INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT RP LYS-386. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [145] RP INTERACTION WITH NOP53. RX PubMed=22522597; DOI=10.1038/cdd.2012.40; RA Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., RA Park J.H.; RT "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal RT stresses."; RL Cell Death Differ. 19:1613-1622(2012). RN [146] RP INTERACTION WITH ZNF385B. RX PubMed=22945289; DOI=10.1002/eji.201242530; RA Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., RA Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.; RT "ZNF385B is characteristically expressed in germinal center B cells and RT involved in B-cell apoptosis."; RL Eur. J. Immunol. 42:3405-3415(2012). RN [147] RP METHYLATION AT LYS-370 AND LYS-382. RX PubMed=22864287; DOI=10.1038/nsmb.2353; RA Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., RA Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.; RT "PHF20 is an effector protein of p53 double lysine methylation that RT stabilizes and activates p53."; RL Nat. Struct. Mol. Biol. 19:916-924(2012). RN [148] RP FUNCTION. RX PubMed=24051492; DOI=10.1038/ncomms3444; RA Miki T., Matsumoto T., Zhao Z., Lee C.C.; RT "p53 regulates Period2 expression and the circadian clock."; RL Nat. Commun. 4:2444-2444(2013). RN [149] RP ACETYLATION AT LYS-120 AND LYS-382. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [150] RP INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [151] RP INTERACTION WITH S100A4, AND SUBCELLULAR LOCATION. RX PubMed=23752197; DOI=10.1038/onc.2013.213; RA Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graeslund T., RA Zhivotovsky B., Lehtioe J.; RT "S100A4 interacts with p53 in the nucleus and promotes p53 degradation."; RL Oncogene 32:5531-5540(2013). RN [152] RP FUNCTION. RX PubMed=24652652; DOI=10.1093/jnci/dju053; RA Polato F., Rusconi P., Zangrossi S., Morelli F., Boeri M., Musi A., RA Marchini S., Castiglioni V., Scanziani E., Torri V., Broggini M.; RT "DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that RT cooperates with p53 as oncosuppressor. [Corrected]."; RL J. Natl. Cancer Inst. 106:1-10(2014). RN [153] RP INTERACTION WITH UBD. RX PubMed=25422469; DOI=10.1073/pnas.1403383111; RA Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L., RA Chong S.S., Song J., Lee C.G.; RT "Disruption of FAT10-MAD2 binding inhibits tumor progression."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014). RN [154] RP INTERACTION WITH TTC5, AND SUBCELLULAR LOCATION. RX PubMed=25168243; DOI=10.1038/cdd.2014.135; RA Maniam S., Coutts A.S., Stratford M.R., McGouran J., Kessler B., RA La Thangue N.B.; RT "Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 RT activity through ATP synthase."; RL Cell Death Differ. 22:156-163(2015). RN [155] RP SUBCELLULAR LOCATION. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [156] RP UBIQUITINATION. RX PubMed=25591766; DOI=10.1159/000369691; RA Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.; RT "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation."; RL Cell. Physiol. Biochem. 35:237-245(2015). RN [157] RP INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION). RX PubMed=25772236; DOI=10.1038/onc.2015.63; RA Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E., RA Hay R.T., Dobner T., Schreiner S.; RT "PML isoforms IV and V contribute to adenovirus-mediated oncogenic RT transformation by functionally inhibiting the tumor-suppressor p53."; RL Oncogene 35:69-82(2016). RN [158] RP INTERACTION WITH FBXO22, AND UBIQUITINATION. RX PubMed=26868148; DOI=10.1038/ncomms10574; RA Johmura Y., Sun J., Kitagawa K., Nakanishi K., Kuno T., Naiki-Ito A., RA Sawada Y., Miyamoto T., Okabe A., Aburatani H., Li S., Miyoshi I., RA Takahashi S., Kitagawa M., Nakanishi M.; RT "SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates RT senescence."; RL Nat. Commun. 7:10574-10574(2016). RN [159] RP INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION. RX PubMed=27323408; DOI=10.18632/oncotarget.9959; RA Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J., RA Stiburek L.; RT "LACE1 interacts with p53 and mediates its mitochondrial translocation and RT apoptosis."; RL Oncotarget 7:47687-47698(2016). RN [160] RP INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION AT SER-15. RX PubMed=28842590; DOI=10.1038/s41598-017-09779-w; RA Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.; RT "DDX3 localizes to the centrosome and prevents multipolar mitosis by RT epigenetically and translationally modulating p53 expression."; RL Sci. Rep. 7:9411-9411(2017). RN [161] RP DEUBIQUITINATION BY USP3. RX PubMed=28807825; DOI=10.1016/j.bbrc.2017.08.036; RA Fu S., Shao S., Wang L., Liu H., Hou H., Wang Y., Wang H., Huang X., Lv R.; RT "USP3 stabilizes p53 protein through its deubiquitinase activity."; RL Biochem. Biophys. Res. Commun. 492:178-183(2017). RN [162] RP INTERACTION WITH DAZAP2. RX PubMed=33591310; DOI=10.1093/nar/gkab084; RA Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K., RA Aqeilan R.I., Lyko F., Hofmann T.G.; RT "DAZAP2 acts as specifier of the p53 response to DNA damage."; RL Nucleic Acids Res. 49:2759-2776(2021). RN [163] RP INVOLVEMENT IN BMFS5. RX PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020; RA Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C., RA Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y., RA Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M., RA Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S., RA Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S., RA Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S., RA Ito E.; RT "De novo mutations activating germline TP53 in an inherited bone-marrow- RT failure syndrome."; RL Am. J. Hum. Genet. 103:440-447(2018). RN [164] RP INTERACTION WITH MORN3, DEACETYLATION AT LYS-382, AND UBQIQUITINATION. RX PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010; RA Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D., RA Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S., RA Qian J., Chen Y., Fang J.Y., Xu J.; RT "A Designed Peptide Targets Two Types of Modifications of p53 with Anti- RT cancer Activity."; RL Cell Chem. Biol. 25:761-774.e5(2018). RN [165] RP ACETYLATION AT LYS-381, DEACETYLATION BY SIRT6, AND MUTAGENESIS OF LYS-381. RX PubMed=29474172; DOI=10.7554/elife.32127; RA Ghosh S., Wong S.K., Jiang Z., Liu B., Wang Y., Hao Q., Gorbunova V., RA Liu X., Zhou Z.; RT "Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6- RT deficient mice."; RL Elife 7:0-0(2018). RN [166] RP PHOSPHORYLATION AT THR-18 BY VRK1. RX PubMed=31527692; DOI=10.1038/s41598-019-49821-7; RA Martin-Doncel E., Rojas A.M., Cantarero L., Lazo P.A.; RT "VRK1 functional insufficiency due to alterations in protein stability or RT kinase activity of human VRK1 pathogenic variants implicated in neuromotor RT syndromes."; RL Sci. Rep. 9:13381-13381(2019). RN [167] RP DOMAIN, AND MUTAGENESIS OF SER-392. RX PubMed=31953488; DOI=10.1038/s41598-020-57521-w; RA Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., RA Nagatsugi F., Takahashi S.; RT "Liquid-like droplet formation by tumor suppressor p53 induced by RT multivalent electrostatic interactions between two disordered domains."; RL Sci. Rep. 10:580-580(2020). RN [168] RP INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN RP ORF45 (MICROBIAL INFECTION). RX PubMed=34523970; DOI=10.1128/jvi.01459-21; RA Alzhanova D., Meyo J.O., Juarez A., Dittmer D.P.; RT "The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an RT inhibitor of p53 signaling during viral reactivation."; RL J. Virol. 0:0-0(2021). RN [169] RP INTERACTION WITH ZNF768. RX PubMed=34404770; DOI=10.1038/s41467-021-24932-w; RA Villot R., Poirier A., Bakan I., Boulay K., Fernandez E., Devillers R., RA Gama-Braga L., Tribouillard L., Gagne A., Duchesne E., Caron D., RA Berube J.S., Berube J.C., Coulombe Y., Orain M., Gelinas Y., Gobeil S., RA Bosse Y., Masson J.Y., Elowe S., Bilodeau S., Manem V., Joubert P., RA Mallette F.A., Laplante M.; RT "ZNF768 links oncogenic RAS to cellular senescence."; RL Nat. Commun. 12:4841-4841(2021). RN [170] RP FUNCTION, DOMAIN, PHOSPHORYLATION AT SER-392, AND MUTAGENESIS OF SER-392. RX PubMed=35618207; DOI=10.1016/j.bbagrm.2022.194827; RA Dai Z., Li G., Chen Q., Yang X.; RT "Ser392 phosphorylation modulated a switch between p53 and transcriptional RT condensates."; RL Biochim. Biophys. Acta 1865:194827-194827(2022). RN [171] RP DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS LFS CYS-337; RP HIS-337 AND PRO-344, AND CHARACTERIZATION OF VARIANT PRO-337. RX PubMed=36108750; DOI=10.1016/j.ijbiomac.2022.09.087; RA Chen C., Fu G., Guo Q., Xue S., Luo S.Z.; RT "Phase separation of p53 induced by its unstructured basic region and RT prevented by oncogenic mutations in tetramerization domain."; RL Int. J. Biol. Macromol. 222:207-216(2022). RN [172] RP FUNCTION, AND DOMAIN. RX PubMed=36634798; DOI=10.1016/j.ijbiomac.2023.123221; RA Chen Q., Wu Y., Dai Z., Zhang Z., Yang X.; RT "Phosphorylation and specific DNA improved the incorporation ability of p53 RT into functional condensates."; RL Int. J. Biol. Macromol. 230:123221-123221(2023). RN [173] RP FUNCTION, DOMAIN, LACTYLATION AT LYS-120 AND LYS-139, AND CHARACTERIZATION RP OF VARIANTS GLU-120; GLN-120; ASN-139; THR-139; GLN-139 AND GLU-139. RX PubMed=38653238; DOI=10.1016/j.cell.2024.04.002; RA Zong Z., Xie F., Wang S., Wu X., Zhang Z., Yang B., Zhou F.; RT "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase RT that lactylates p53 and contributes to tumorigenesis."; RL Cell 187:2375-2392(2024). RN [174] RP STRUCTURE BY NMR OF 319-360. RX PubMed=8023159; DOI=10.1126/science.8023159; RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., RA Appella E., Gronenborn A.M.; RT "High-resolution structure of the oligomerization domain of p53 by RT multidimensional NMR."; RL Science 265:386-391(1994). RN [175] RP STRUCTURE BY NMR OF 325-355. RX PubMed=7773777; DOI=10.1038/nsb1294-877; RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; RT "Solution structure of the tetrameric minimum transforming domain of p53."; RL Nat. Struct. Biol. 1:877-890(1994). RN [176] RP STRUCTURE BY NMR OF 326-354. RX PubMed=9321402; DOI=10.1093/emboj/16.20.6230; RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., RA Halazonetis T.D.; RT "Hydrophobic side-chain size is a determinant of the three-dimensional RT structure of the p53 oligomerization domain."; RL EMBO J. 16:6230-6236(1997). RN [177] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. RX PubMed=8023157; DOI=10.1126/science.8023157; RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; RT "Crystal structure of a p53 tumor suppressor-DNA complex: understanding RT tumorigenic mutations."; RL Science 265:346-355(1994). RN [178] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. RX PubMed=7878469; DOI=10.1126/science.7878469; RA Jeffrey P.D., Gorina S., Pavletich N.P.; RT "Crystal structure of the tetramerization domain of the p53 tumor RT suppressor at 1.7 angstroms."; RL Science 267:1498-1502(1995). RN [179] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. RX PubMed=8875929; DOI=10.1126/science.274.5289.948; RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., RA Pavletich N.P.; RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor RT transactivation domain."; RL Science 274:948-953(1996). RN [180] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. RX PubMed=8875926; DOI=10.1126/science.274.5289.1001; RA Gorina S., Pavletich N.P.; RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains RT of 53BP2."; RL Science 274:1001-1005(1996). RN [181] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS, RP AND SUBUNIT. RX PubMed=14534297; DOI=10.1074/jbc.m309732200; RA Joerger A.C., Allen M.D., Fersht A.R.; RT "Crystal structure of a superstable mutant of human p53 core domain. RT Insights into the mechanism of rescuing oncogenic mutations."; RL J. Biol. Chem. 279:1291-1296(2004). RN [182] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015; RA Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., RA Haran T.E., Shakked Z.; RT "Structural basis of DNA recognition by p53 tetramers."; RL Mol. Cell 22:741-753(2006). RN [183] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND RP INTERACTION WITH USP7. RX PubMed=16474402; DOI=10.1038/nsmb1067; RA Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., RA Frappier L.; RT "Molecular recognition of p53 and MDM2 by USP7/HAUSP."; RL Nat. Struct. Mol. Biol. 13:285-291(2006). RN [184] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, RP MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7. RX PubMed=16402859; DOI=10.1371/journal.pbio.0040027; RA Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.; RT "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: RT implications for the regulation of the p53-MDM2 pathway."; RL PLoS Biol. 4:228-239(2006). RN [185] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382, RP MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1. RX PubMed=20870725; DOI=10.1074/jbc.m110.139527; RA West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E., RA Kutateladze T.G., Gozani O.; RT "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine RT 382 to target gene repression."; RL J. Biol. Chem. 285:37725-37732(2010). RN [186] RP REVIEW. RX PubMed=8266092; DOI=10.1126/science.8266092; RA Harris C.C.; RT "p53: at the crossroads of molecular carcinogenesis and risk assessment."; RL Science 262:1980-1981(1993). RN [187] RP REVIEW ON VARIANTS. RX PubMed=1905840; DOI=10.1126/science.1905840; RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; RT "p53 mutations in human cancers."; RL Science 253:49-53(1991). RN [188] RP REVIEW ON VARIANTS. RX PubMed=8829653; RX DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., RA Liao D., Soussi T., Kovach J.S., Sommer S.S.; RT "Database of mutations in the p53 and APC tumor suppressor genes designed RT to facilitate molecular epidemiological analyses."; RL Hum. Mutat. 7:202-213(1996). RN [189] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS. RX PubMed=17015838; DOI=10.1073/pnas.0607286103; RA Joerger A.C., Ang H.C., Fersht A.R.; RT "Structural basis for understanding oncogenic p53 mutations and designing RT rescue drugs."; RL Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006). RN [190] RP X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282. RX PubMed=18453682; DOI=10.1107/s0907444908003338; RA Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.; RT "Impact of low-frequency hotspot mutation R282Q on the structure of p53 RT DNA-binding domain as revealed by crystallography at 1.54 angstroms RT resolution."; RL Acta Crystallogr. D 64:471-477(2008). RN [191] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN RP COMPLEX WITH ZINC IONS AND PHIKAN083. RX PubMed=18650397; DOI=10.1073/pnas.0805326105; RA Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., RA Fersht A.R.; RT "Targeted rescue of a destabilized mutant of p53 by an in silico screened RT drug."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008). RN [192] RP X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN RP COMPLEX WITH DNA. RX PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063; RA Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., RA Frolow F., Liran A., Rotter V., Shakked Z.; RT "Structural basis of restoring sequence-specific DNA binding and RT transactivation to mutant p53 by suppressor mutations."; RL J. Mol. Biol. 385:249-265(2009). RN [193] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS. RX PubMed=19515728; DOI=10.1093/protein/gzp018; RA Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.; RT "Stabilising the DNA-binding domain of p53 by rational design of its RT hydrophobic core."; RL Protein Eng. Des. Sel. 22:421-430(2009). RN [194] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN RP COMPLEX WITH ZINC IONS. RX PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011; RA Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., RA Fersht A.R.; RT "Toward the rational design of p53-stabilizing drugs: probing the surface RT of the oncogenic Y220C mutant."; RL Chem. Biol. 17:46-56(2010). RN [195] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=20364130; DOI=10.1038/nsmb.1800; RA Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., RA Shakked Z.; RT "Diversity in DNA recognition by p53 revealed by crystal structures with RT Hoogsteen base pairs."; RL Nat. Struct. Mol. Biol. 17:423-429(2010). RN [196] {ECO:0007744|PDB:6T58} RP X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 17-56, AND INTERACTION WITH RP S100A4. RX PubMed=32442400; DOI=10.1016/j.str.2020.05.001; RA Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L.; RT "Structure Determination of the Transactivation Domain of p53 in Complex RT with S100A4Using Annexin A2 as a Crystallization Chaperone."; RL Structure 28:943-953.e4(2020). RN [197] RP VARIANT ARG-72. RX PubMed=1999338; DOI=10.1007/bf00201836; RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; RT "Characterization of a frequent polymorphism in the coding sequence of the RT Tp53 gene in colonic cancer patients and a control population."; RL Hum. Genet. 86:369-370(1991). RN [198] RP VARIANT LFS THR-133. RX PubMed=1933902; RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer RT family."; RL Cancer Res. 51:6385-6387(1991). RN [199] RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. RX PubMed=1978757; DOI=10.1126/science.1978757; RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., RA Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; RT "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, RT and other neoplasms."; RL Science 250:1233-1238(1990). RN [200] RP VARIANT LFS ASP-245. RX PubMed=2259385; DOI=10.1038/348747a0; RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family with RT Li-Fraumeni syndrome."; RL Nature 348:747-749(1990). RN [201] RP VARIANT LFS LEU-272. RX PubMed=1737852; DOI=10.1172/jci115630; RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., RA Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., RA Minna J.D.; RT "Hereditary and acquired p53 gene mutations in childhood acute RT lymphoblastic leukemia."; RL J. Clin. Invest. 89:640-647(1992). RN [202] RP VARIANTS LFS HIS-273 AND VAL-325. RX PubMed=1565144; DOI=10.1056/nejm199205143262002; RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., RA Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; RT "Germline mutations of the p53 tumor-suppressor gene in children and young RT adults with second malignant neoplasms."; RL N. Engl. J. Med. 326:1309-1315(1992). RN [203] RP VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285. RX PubMed=1694291; RA Bartek J., Iggo R., Gannon J., Lane D.P.; RT "Genetic and immunochemical analysis of mutant p53 in human breast cancer RT cell lines."; RL Oncogene 5:893-899(1990). RN [204] RP VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273. RX PubMed=1699228; DOI=10.1073/pnas.87.19.7555; RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., RA Gannon J.V., Lane D.P.; RT "p53 mutations in colorectal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990). RN [205] RP VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. RX PubMed=2263646; DOI=10.1073/pnas.87.24.9958; RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; RT "Frequent mutation of the p53 gene in human esophageal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990). RN [206] RP VARIANTS SPORADIC CANCERS. RX PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f; RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., RA Wakui A., Yamazaki T.; RT "Mutations of the P53 gene, including an intronic point mutation, in RT colorectal tumors."; RL Biochem. Biophys. Res. Commun. 177:901-906(1991). RN [207] RP VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. RX PubMed=1868473; RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; RT "p53 gene mutations in Barrett's epithelium and esophageal cancer."; RL Cancer Res. 51:4495-4499(1991). RN [208] RP VARIANTS SPORADIC CANCERS IN CHINA. RX PubMed=1849234; DOI=10.1038/350427a0; RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; RT "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; RL Nature 350:427-428(1991). RN [209] RP VARIANTS SPORADIC CANCERS IN SOUTH AFRICA. RX PubMed=1672732; DOI=10.1038/350429a0; RA Bressac B., Kew M., Wands J., Ozturk M.; RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma from RT southern Africa."; RL Nature 350:429-431(1991). RN [210] RP VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. RX PubMed=1394225; RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., RA Casey G.; RT "Frequent p53 mutations in head and neck cancer."; RL Cancer Res. 52:5997-6000(1992). RN [211] RP VARIANTS SPORADIC CANCERS. RX PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x; RA Crook T., Vousden K.H.; RT "Properties of p53 mutations detected in primary and secondary cervical RT cancers suggest mechanisms of metastasis and involvement of environmental RT carcinogens."; RL EMBO J. 11:3935-3940(1992). RN [212] RP VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [213] RP VARIANT PRO-HIS-PRO-178 INS. RX PubMed=1303181; DOI=10.1093/hmg/1.3.207; RA Bhatia K., Guiterrez M.I., Magrath I.T.; RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; RL Hum. Mol. Genet. 1:207-208(1992). RN [214] RP VARIANTS SPORADIC CANCERS. RX PubMed=1437144; RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., RA Appella E., May P.; RT "p53 mutations in Raji cells: characterization and localization relative to RT other Burkitt's lymphomas."; RL Oncogene 7:2161-2167(1992). RN [215] RP VARIANT SPORADIC CANCER THR-280. RX PubMed=1631151; DOI=10.1073/pnas.89.14.6516; RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., RA Cao Y., Yao K.-T., Colburn N.H.; RT "An infrequent point mutation of the p53 gene in human nasopharyngeal RT carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992). RN [216] RP VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; RP GLN-248; LEU-248 AND HIS-273. RX PubMed=7682763; RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; RT "p53 alterations in human squamous cell carcinomas and carcinoma cell RT lines."; RL Am. J. Pathol. 142:1131-1139(1993). RN [217] RP VARIANTS SPORADIC CANCERS. RX PubMed=8402617; RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; RT "The incidence of p53 mutations increases with progression of head and neck RT cancer."; RL Cancer Res. 53:4477-4480(1993). RN [218] RP VARIANTS SPORADIC CANCERS. RX PubMed=8336944; RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; RT "Efficient screening of p53 mutations by denaturing gradient gel RT electrophoresis in colorectal tumors."; RL Oncogene 8:2213-2220(1993). RN [219] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8118819; RA Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., RA Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., RA Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., RA Santibanez-Koref M.F.; RT "Prevalence and diversity of constitutional mutations in the p53 gene among RT 21 Li-Fraumeni families."; RL Cancer Res. 54:1298-1304(1994). RN [220] RP CHARACTERIZATION OF VARIANT ALA-143. RX PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x; RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; RT "A temperature-sensitive mutant of human p53."; RL EMBO J. 13:2535-2544(1994). RN [221] RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. RX PubMed=7887414; RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., RA Fraumeni J.F. Jr., Li F.P., Friend S.H.; RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; RL Am. J. Hum. Genet. 56:608-615(1995). RN [222] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8718514; RA Eeles R.A.; RT "Germline mutations in the TP53 gene."; RL Cancer Surv. 25:101-124(1995). RN [223] RP VARIANT LFS HIS-175. RX PubMed=8825920; DOI=10.1136/jmg.32.12.942; RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 RT mutation in TP53."; RL J. Med. Genet. 32:942-945(1995). RN [224] RP VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. RX PubMed=8829627; RX DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., RA Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; RL Hum. Mutat. 7:109-113(1996). RN [225] RP VARIANTS SPORADIC CANCERS. RX PubMed=9101296; RX DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., RA Zeuthen J.; RT "Single-step DGGE-based mutation scanning of the p53 gene: application to RT genetic diagnosis of colorectal cancer."; RL Hum. Mutat. 9:348-355(1997). RN [226] RP VARIANT SPORADIC CANCER ILE-157. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [227] RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND RP SER-278. RX PubMed=9450901; RX DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., RA Raubenheimer E.J.; RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a RT black African population sample."; RL Hum. Mutat. 11:39-44(1998). RN [228] RP VARIANT NON-CLASSICAL LFS CYS-337. RX PubMed=9452042; DOI=10.1002/humu.1380110121; RA Luca J.W., Strong L.C., Hansen M.F.; RT "A germline missense mutation R337C in exon 10 of the human p53 gene."; RL Hum. Mutat. Suppl. 1:S58-S61(1998). RN [229] RP VARIANT LFS ILE-292. RX PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3; RA Gueran S., Tunca Y., Imirzalioglu N.; RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li- RT Fraumeni syndrome family."; RL Cancer Genet. Cytogenet. 113:145-151(1999). RN [230] RP VARIANTS. RX PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x; RA Hainaut P., Hollstein M.; RT "p53 and human cancer: the first ten thousand mutations."; RL Adv. Cancer Res. 77:81-137(2000). RN [231] RP VARIANT ADCC HIS-337. RX PubMed=11481490; DOI=10.1073/pnas.161479898; RA Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., RA Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., RA Stratakis C.A., Sandrini R.; RT "An inherited p53 mutation that contributes in a tissue-specific manner to RT pediatric adrenal cortical carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001). RN [232] RP INVOLVEMENT IN CPP. RX PubMed=12085209; DOI=10.1038/sj.bjc.6600269; RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., RA Lu X., Barnes D.M., Camplejohn R.S.; RT "Investigations on a clinically and functionally unusual and novel germline RT p53 mutation."; RL Br. J. Cancer 86:1592-1596(2002). RN [233] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; RP ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; RP TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [234] RP VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; RP ALA-241; MET-249; SER-251; TYR-259 AND CYS-273. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [235] RP VARIANTS. RX PubMed=17311302; DOI=10.1002/humu.20495; RA Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., RA Olivier M.; RT "Impact of mutant p53 functional properties on TP53 mutation patterns and RT tumor phenotype: lessons from recent developments in the IARC TP53 RT database."; RL Hum. Mutat. 28:622-629(2007). RN [236] RP CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION, RP PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2. RX PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066; RA Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S., RA Kim J., Wang L., Lou Z.; RT "DBC1 functions as a tumor suppressor by regulating p53 stability."; RL Cell Rep. 10:1324-1334(2015). RN [237] RP VARIANTS VAL-138; HIS-175; ILE-237; TRP-248 AND PRO-273. RX PubMed=27657329; DOI=10.1371/journal.pbio.1002555; RA Guan Y., Huang D., Chen F., Gao C., Tao T., Shi H., Zhao S., Liao Z., RA Lo L.J., Wang Y., Chen J., Peng J.; RT "Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle RT Progression through Def Recruitment of Calpain3."; RL PLoS Biol. 14:e1002555-e1002555(2016). CC -!- FUNCTION: Multifunctional transcription factor that induces cell cycle CC arrest, DNA repair or apoptosis upon binding to its target DNA sequence CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, CC PubMed:9840937). Acts as a tumor suppressor in many tumor types; CC induces growth arrest or apoptosis depending on the physiological CC circumstances and cell type (PubMed:11025664, PubMed:12524540, CC PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, CC PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, CC PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, CC PubMed:38653238, PubMed:9840937). Negatively regulates cell division by CC controlling expression of a set of genes required for this process CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:9840937). One of the activated genes is an CC inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be CC mediated either by stimulation of BAX and FAS antigen expression, or by CC repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its CC pro-apoptotic activity is activated via its interaction with CC PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this CC activity is inhibited when the interaction with PPP1R13B/ASPP1 or CC TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In CC cooperation with mitochondrial PPIF is involved in activating oxidative CC stress-induced necrosis; the function is largely independent of CC transcription. Induces the transcription of long intergenic non-coding CC RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in CC TP53-dependent transcriptional repression leading to apoptosis and CC seems to have an effect on cell-cycle regulation. Implicated in Notch CC signaling cross-over. Prevents CDK7 kinase activity when associated to CC CAK complex in response to DNA damage, thus stopping cell cycle CC progression. Isoform 2 enhances the transactivation activity of isoform CC 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses CC transactivation activity and impairs growth suppression mediated by CC isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates CC the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional CC activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, CC ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:35618207, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238, CC ECO:0000269|PubMed:9840937}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, CC ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, CC ECO:0000269|PubMed:20364130}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; CC -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds CC DNA as a homotetramer (PubMed:36108750). Interacts with AXIN1. Probably CC part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). CC Interacts with histone acetyltransferases EP300 and methyltransferases CC HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C- CC terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts CC with ING4; this interaction may be indirect. Found in a complex with CC CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts CC with WWOX. May interact with HCV core protein. Interacts with USP7 and CC SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit CC histone H1 and prevent transactivation activity (By similarity). CC Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. CC Interacts with YWHAZ; the interaction enhances TP53 transcriptional CC activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this CC interaction. Interacts (via DNA-binding domain) with MAML1 (via N- CC terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). CC Interacts with MDM2; leading to ubiquitination and proteasomal CC degradation of TP53. Directly interacts with FBXO42; leading to CC ubiquitination and degradation of TP53. Interacts (phosphorylated at CC Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates CC stress-induced TP53-dependent inhibition of cell proliferation. CC Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. CC Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 CC interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds CC to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. CC Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and CC NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes CC ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes CC ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the CC association implicates preferentially tetrameric TP53, is induced by CC oxidative stress and is impaired by cyclosporin A (CsA). Interacts with CC SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated CC ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with CC UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via CC DNA-binding domain) with ZNF385A; the interaction is direct and CC enhances p53/TP53 transactivation functions on cell-cycle arrest target CC genes, resulting in growth arrest. Interacts with ANKRD2. Interacts CC with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts CC with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts CC with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 CC isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via CC oligomerization region) with NOP53; the interaction is direct and may CC prevent the MDM2-mediated proteasomal degradation of TP53 CC (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial CC translocation of TP53 (PubMed:27323408). Interacts with UBD CC (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 CC (PubMed:20096117). Interacts with C10orf90/FATS; the interaction CC inhibits binding of TP53 and MDM2 (By similarity). Interacts with CC NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a CC complex with EP300 and NUPR1; this complex binds CDKN1A promoter CC leading to transcriptional induction of CDKN1A (PubMed:18690848). CC Interacts with PRMT5 in response to DNA damage; the interaction is CC TTC5/STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via CC SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic CC activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 CC and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity CC (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X CC and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading CC to inhibit histone acetyltransferase activity of KAT7/HBO1 CC (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein CC ligase MUL1; the interaction results in ubiquitination of cytoplasmic CC TP53 at Lys-24 and subsequent proteasomal degradation CC (PubMed:21597459). Interacts with S100A4; this interaction promotes CC TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CC BANP (By similarity). Interacts with TTC5/STRAP; the interaction may CC result in increased mitochondrial-dependent apoptosis CC (PubMed:25168243). Interacts with NQO1; this interaction is NADH- CC dependent, stabilizes TP53 in response to oxidative stress and protects CC it from ubiquitin-independent degradation by the 20S proteasome CC (PubMed:15687255). Interacts with DAZAP2 at TP53 target gene promoters; CC the interaction is triggered by DNA damage and leads to modulation of CC the expression of a subset of TP53 target genes, reducing DNA damage- CC induced cell death by limiting the expression of cell death-mediating CC TP53 target genes (PubMed:33591310). Interacts (via N-terminus) with CC ZNF768 (via zinc-finger domains); interaction might be facilitated by CC TP53 oligomerization state (PubMed:34404770). Forms a ternary complex CC with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the CC complex inhibiting G6PD activity and keeping oxidative pentose CC phosphate metabolism in check. Interacts with MORN3; the interactions CC mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1 CC (PubMed:29681526). Interacts with HSPA9/MOT-2; the interaction promotes CC the degradation of TP53 (PubMed:24625977). Interacts with FBXO22; this CC interaction promotes TP53 proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, CC ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, CC ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, CC ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, CC ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, CC ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, CC ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, CC ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, CC ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, CC ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, CC ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, CC ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, CC ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:26868148, CC ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, CC ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:32442400, CC ECO:0000269|PubMed:33591310, ECO:0000269|PubMed:34404770, CC ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:8875926, CC ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}. CC -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 CC viral proteins leading to ubiquitination and degradation of TP53 giving CC a possible model for cell growth regulation. This complex formation CC requires an additional factor, E6-AP, which stably associates with TP53 CC in the presence of E6. {ECO:0000269|PubMed:2175676}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human CC adenovirus 5 E1B-55K protein; this interaction leads to the inhibition CC of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}. CC -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma- CC associated herpesvirus/HHV-8 protein ORF45; this interaction results in CC the cytoplasmic localization of TP53 thereby decreasing its CC transcriptional activity. {ECO:0000269|PubMed:34523970}. CC -!- INTERACTION: CC P04637; P00519: ABL1; NbExp=2; IntAct=EBI-366083, EBI-375543; CC P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226; CC P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158; CC P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313; CC P04637; Q9UBL3: ASH2L; NbExp=8; IntAct=EBI-366083, EBI-540797; CC P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880; CC P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; CC P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695; CC P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694; CC P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195; CC P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810; CC P04637; P15056: BRAF; NbExp=4; IntAct=EBI-366083, EBI-365980; CC P04637; P38398: BRCA1; NbExp=2; IntAct=EBI-366083, EBI-349905; CC P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792; CC P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221; CC P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; CC P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461; CC P04637; P55212: CASP6; NbExp=3; IntAct=EBI-366083, EBI-718729; CC P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501; CC P04637; P48643: CCT5; NbExp=3; IntAct=EBI-366083, EBI-355710; CC P04637; P38936: CDKN1A; NbExp=6; IntAct=EBI-366083, EBI-375077; CC P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; CC P04637; Q03701: CEBPZ; NbExp=2; IntAct=EBI-366083, EBI-1046778; CC P04637; O14757: CHEK1; NbExp=2; IntAct=EBI-366083, EBI-974488; CC P04637; O96017: CHEK2; NbExp=3; IntAct=EBI-366083, EBI-1180783; CC P04637; Q8NHY2: COP1; NbExp=5; IntAct=EBI-366083, EBI-1176214; CC P04637; Q92793: CREBBP; NbExp=17; IntAct=EBI-366083, EBI-81215; CC P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; CC P04637; Q14999: CUL7; NbExp=19; IntAct=EBI-366083, EBI-308606; CC P04637; Q8IWT3: CUL9; NbExp=16; IntAct=EBI-366083, EBI-311123; CC P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911; CC P04637; Q9UER7: DAXX; NbExp=13; IntAct=EBI-366083, EBI-77321; CC P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; CC P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962; CC P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367; CC P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; CC P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850; CC P04637; Q09472: EP300; NbExp=22; IntAct=EBI-366083, EBI-447295; CC P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991; CC P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; CC P04637; P21333-2: FLNA; NbExp=3; IntAct=EBI-366083, EBI-9641086; CC P04637; P51114: FXR1; NbExp=2; IntAct=EBI-366083, EBI-713291; CC P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586; CC P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539; CC P04637; Q13547: HDAC1; NbExp=8; IntAct=EBI-366083, EBI-301834; CC P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; CC P04637; Q9H2X6: HIPK2; NbExp=3; IntAct=EBI-366083, EBI-348345; CC P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432; CC P04637; P41235: HNF4A; NbExp=3; IntAct=EBI-366083, EBI-1049011; CC P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185; CC P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731; CC P04637; Q9BUJ2: HNRNPUL1; NbExp=12; IntAct=EBI-366083, EBI-1018153; CC P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932; CC P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682; CC P04637; P42858: HTT; NbExp=19; IntAct=EBI-366083, EBI-466029; CC P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; CC P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540; CC P04637; O14920: IKBKB; NbExp=3; IntAct=EBI-366083, EBI-81266; CC P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509; CC P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037; CC P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; CC P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414; CC P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570; CC P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959; CC P04637; P13473-2: LAMP2; NbExp=3; IntAct=EBI-366083, EBI-21591415; CC P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739; CC P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835; CC P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; CC P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611; CC P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; CC P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; CC P04637; Q00987: MDM2; NbExp=119; IntAct=EBI-366083, EBI-389668; CC P04637; O15151: MDM4; NbExp=24; IntAct=EBI-366083, EBI-398437; CC P04637; Q15648: MED1; NbExp=3; IntAct=EBI-366083, EBI-394459; CC P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524; CC P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405; CC P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030; CC P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967; CC P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830; CC P04637; Q99608: NDN; NbExp=4; IntAct=EBI-366083, EBI-718177; CC P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; CC P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728; CC P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; CC P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992; CC P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579; CC P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; CC P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729; CC P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550; CC P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631; CC P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; CC P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016; CC P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491; CC P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968; CC P04637; P09874: PARP1; NbExp=5; IntAct=EBI-366083, EBI-355676; CC P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; CC P04637; Q7Z412: PEX26; NbExp=3; IntAct=EBI-366083, EBI-752057; CC P04637; P35232: PHB1; NbExp=6; IntAct=EBI-366083, EBI-354213; CC P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434; CC P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; CC P04637; Q92569: PIK3R3; NbExp=5; IntAct=EBI-366083, EBI-79893; CC P04637; Q13526: PIN1; NbExp=14; IntAct=EBI-366083, EBI-714158; CC P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768; CC P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890; CC P04637; A0A6Q8PF08: PMP22; NbExp=3; IntAct=EBI-366083, EBI-50433196; CC P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229; CC P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; CC P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163; CC P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388; CC P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156; CC P04637; O43741: PRKAB2; NbExp=3; IntAct=EBI-366083, EBI-1053424; CC P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279; CC P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546; CC P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142; CC P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; CC P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552; CC P04637; Q96PM5: RCHY1; NbExp=13; IntAct=EBI-366083, EBI-947779; CC P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159; CC P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313; CC P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193; CC P04637; Q9Y265: RUVBL1; NbExp=10; IntAct=EBI-366083, EBI-353675; CC P04637; Q8N488: RYBP; NbExp=4; IntAct=EBI-366083, EBI-752324; CC P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686; CC P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862; CC P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230; CC P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747; CC P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058; CC P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732; CC P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877; CC P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391; CC P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700; CC P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298; CC P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586; CC P04637; P31947: SFN; NbExp=5; IntAct=EBI-366083, EBI-476295; CC P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; CC P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965; CC P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141; CC P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671; CC P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459; CC P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525; CC P04637; P08047: SP1; NbExp=6; IntAct=EBI-366083, EBI-298336; CC P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; CC P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478; CC P04637; P31948: STIP1; NbExp=4; IntAct=EBI-366083, EBI-1054052; CC P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140; CC P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849; CC P04637; Q9HBM6: TAF9B; NbExp=2; IntAct=EBI-366083, EBI-751601; CC P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; CC P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224; CC P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460; CC P04637; P04637: TP53; NbExp=34; IntAct=EBI-366083, EBI-366083; CC P04637; Q12888: TP53BP1; NbExp=8; IntAct=EBI-366083, EBI-396540; CC P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649; CC P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642; CC P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; CC P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169; CC P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378; CC P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287; CC P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054; CC P04637; P63279: UBE2I; NbExp=5; IntAct=EBI-366083, EBI-80168; CC P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357; CC P04637; P09936: UCHL1; NbExp=3; IntAct=EBI-366083, EBI-714860; CC P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; CC P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638; CC P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105; CC P04637; Q93009: USP7; NbExp=23; IntAct=EBI-366083, EBI-302474; CC P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; CC P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146; CC P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; CC P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739; CC P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867; CC P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; CC P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832; CC P04637; P63104: YWHAZ; NbExp=3; IntAct=EBI-366083, EBI-347088; CC P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307; CC P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801; CC P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019; CC P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411; CC P04637; P45481: Crebbp; Xeno; NbExp=10; IntAct=EBI-366083, EBI-296306; CC P04637; P03120: E2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1779322; CC P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242; CC P04637; P04019: E6; Xeno; NbExp=2; IntAct=EBI-366083, EBI-1177232; CC P04637; P06463: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1186926; CC P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659; CC P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290; CC P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973; CC P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585; CC P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527; CC P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146; CC P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025; CC P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119; CC P04637; Q9PST7: znf585b.S; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562; CC P04637; P03070; Xeno; NbExp=25; IntAct=EBI-366083, EBI-617698; CC P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571; CC P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726; CC P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962; CC P04637-1; P55209: NAP1L1; NbExp=2; IntAct=EBI-3895849, EBI-356392; CC P04637-1; P03126: E6; Xeno; NbExp=2; IntAct=EBI-3895849, EBI-1177242; CC P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19033443, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus, PML body CC {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:36108750}. Endoplasmic reticulum CC {ECO:0000269|PubMed:17170702}. Mitochondrion matrix CC {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, CC ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000269|PubMed:28842590}. CC Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). CC Translocates to mitochondria upon oxidative stress (PubMed:22726440). CC Translocates to mitochondria in response to mitomycin C treatment CC (PubMed:27323408). Competitive inhibition of TP53 interaction with CC HSPA9/MOT-2 by UBXN2A results in increased protein abundance and CC subsequent translocation of TP53 to the nucleus (PubMed:24625977). CC {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:27323408}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear CC but localizes to the cytoplasm when expressed with isoform 4. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized CC in the nucleus in most cells but found in the cytoplasm in some cells. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. CC Note=Predominantly nuclear but translocates to the cytoplasm following CC cell stress. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized CC in both nucleus and cytoplasm in most cells. In some cells, forms foci CC in the nucleus that are different from nucleoli. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; CC Name=1; Synonyms=p53, p53alpha; CC IsoId=P04637-1; Sequence=Displayed; CC Name=2; Synonyms=I9RET, p53beta; CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; CC Name=3; Synonyms=p53gamma; CC IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; CC Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; CC IsoId=P04637-4; Sequence=VSP_040832; CC Name=5; Synonyms=Del40-p53beta; CC IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; CC Name=6; Synonyms=Del40-p53gamma; CC IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; CC Name=7; Synonyms=Del133-p53, Del133-p53alpha; CC IsoId=P04637-7; Sequence=VSP_040833; CC Name=8; Synonyms=Del133-p53beta; CC IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; CC Name=9; Synonyms=Del133-p53gamma; CC IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range CC of normal tissues but in a tissue-dependent manner. Isoform 2 is CC expressed in most normal tissues but is not detected in brain, lung, CC prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 CC is expressed in most normal tissues but is not detected in lung, CC spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is CC expressed in most normal tissues but is not detected in prostate, CC uterus, skeletal muscle and breast. Isoform 8 is detected only in CC colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is CC expressed in most normal tissues but is not detected in brain, heart, CC lung, fetal liver, salivary gland, breast or intestine. CC {ECO:0000269|PubMed:16131611}. CC -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not CC induced in tumor cells in response to stress. CC {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}. CC -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo CC liquid-liquid phase separation (LLPS) following homotetramerization and CC activation (PubMed:31953488, PubMed:35618207, PubMed:36108750, CC PubMed:36634798, PubMed:38653238). Post-translational modifications, CC such as phosphorylation or lactylation affect the ability to undergo CC LLPS (PubMed:31953488, PubMed:35618207, PubMed:36634798, CC PubMed:38653238). {ECO:0000269|PubMed:31953488, CC ECO:0000269|PubMed:35618207, ECO:0000269|PubMed:36108750, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238}. CC -!- DOMAIN: The nuclear export signal acts as a transcriptional repression CC domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) CC correspond both to 9aaTAD motifs which are transactivation domains CC present in a large number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:17467953}. CC -!- PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity CC (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). CC Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, CC PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 CC impairs its ability to induce proapoptotic program and modulate cell CC senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, CC PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce CC transcription activation in a AKT-dependent manner (PubMed:10656795, CC PubMed:15448695, PubMed:20228809, PubMed:23431171, PubMed:29681526). CC Acetylation at Lys-381 increases stability (PubMed:29474172). CC Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby CC regulating cell senescence (PubMed:29474172). Acetylated at Lys-120 by CC KAT5, KAT6A and KAT8; regulating its ability to induce proapoptotic CC program (PubMed:17189187, PubMed:19854137, PubMed:23431171). CC {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:19854137, CC ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:29474172, ECO:0000269|PubMed:29681526}. CC -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid CC phase separation (LLPS), thereby inhibiting transcription factor CC activity. {ECO:0000269|PubMed:38653238}. CC -!- PTM: Phosphorylation on Ser residues mediates transcriptional CC activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at CC Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. CC Phosphorylated on Thr-18 by VRK1, which may prevent the interaction CC with MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylated on Ser-20 CC by CHEK2 in response to DNA damage, which prevents ubiquitination by CC MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen CC species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on CC Thr-55 by TAF1, which promotes MDM2-mediated degradation. CC Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA CC damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. CC Phosphorylation on Ser-46 is required for acetylation by CREBBP. CC Phosphorylated on Ser-392 following UV but not gamma irradiation. CC Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to CC be mediated by STK11/LKB1 but it was later shown that it is indirect CC and that STK11/LKB1-dependent phosphorylation is probably mediated by CC downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly CC mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform CC 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 CC results in a reduction in ubiquitination by MDM2 and an increase in CC acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in CC response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser- CC 46, leading to accumulation of p53/TP53, particularly in the nucleus, CC thus inducing the transactivation of p53/TP53 target genes. CC Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. CC Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- CC damage. Phosphorylation at Ser-15 is required for interaction with CC DDX3X and gamma-tubulin (PubMed:28842590). Phosphorylation at Ser-392 CC regulates its ability to undergo liquid-liquid phase separation by CC increasing fluidity of TP53/p53 condensates (PubMed:35618207). CC {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, CC ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, CC ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, CC ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, CC ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, CC ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, CC ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:31527692, CC ECO:0000269|PubMed:9372954}. CC -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small CC T antigen inhibits the dephosphorylation by the AC form of PP2A. CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in CC EB-1 cell line. {ECO:0000269|PubMed:8632915}. CC -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal CC degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, CC PubMed:17170702, PubMed:19880522, PubMed:29681526). Ubiquitinated by CC RFWD3, which works in cooperation with MDM2 and may catalyze the CC formation of short polyubiquitin chains on p53/TP53 that are not CC targeted to the proteasome (PubMed:10722742, PubMed:12810724, CC PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which CC leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by CC USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by CC TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation CC (PubMed:19556538). Ubiquitination by TOPORS induces degradation CC (PubMed:19473992). Deubiquitination by USP7, leading to stabilization CC (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2- CC independent manner (PubMed:15340061). Ubiquitinated by COP1, which CC leads to proteasomal degradation (PubMed:19837670). Ubiquitination and CC subsequent proteasomal degradation is negatively regulated by CCAR2 CC (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, CC polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, CC leading to TP53 stabilization (By similarity). Polyubiquitinated by CC MUL1 at Lys-24 which leads to proteasomal degradation CC (PubMed:21597459). Deubiquitinated by USP3, leading to stabilization CC (PubMed:28807825). Ubiquitinated by MSL2, promoting its cytoplasmic CC localization (PubMed:19033443). Also ubiquitinated by the SCF(FBXO22)- CC KDMA4A complex; leading to proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19033443, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, CC ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, CC ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, CC ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823, CC ECO:0000269|PubMed:26868148, ECO:0000269|PubMed:28807825, CC ECO:0000269|PubMed:29681526}. CC -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and CC increased transcriptional activation (PubMed:15525938, CC PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to CC decreased DNA-binding activity and subsequent transcriptional CC regulation activity (PubMed:17108971). Lys-372 monomethylation prevents CC interaction with SMYD2 and subsequent monomethylation at Lys-370 CC (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 CC (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting CC interaction with L3MBTL1 and leading to repress transcriptional CC activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 CC diminishes p53 ubiquitination, through stabilizing association with the CC methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated CC Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53- CC mediated transcriptional activation (PubMed:17805299). Monomethylated CC at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; CC methylation is increased after DNA damage and might possibly affect CC TP53 target gene specificity (PubMed:19011621). CC {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, CC ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, CC ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}. CC -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. CC {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, CC ECO:0000269|Ref.37}. CC -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of CC transformed cells. TP53 is frequently mutated or inactivated in about CC 60% of cancers. TP53 defects are found in Barrett metaplasia a CC condition in which the normally stratified squamous epithelium of the CC lower esophagus is replaced by a metaplastic columnar epithelium. The CC condition develops as a complication in approximately 10% of patients CC with chronic gastroesophageal reflux disease and predisposes to the CC development of esophageal adenocarcinoma. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant CC familial cancer syndrome that in its classic form is defined by the CC existence of a proband affected by a sarcoma before 45 years with a CC first degree relative affected by any tumor before 45 years and another CC first degree relative with any tumor before 45 years or a sarcoma at CC any age. Other clinical definitions for LFS have been proposed and CC called Li-Fraumeni like syndrome (LFL). In these families affected CC relatives develop a diverse set of malignancies at unusually early CC ages. Four types of cancers account for 80% of tumors occurring in TP53 CC germline mutation carriers: breast cancers, soft tissue and bone CC sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. CC Less frequent tumors include choroid plexus carcinoma or papilloma CC before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, CC Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. CC {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, CC ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, CC ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, CC ECO:0000269|PubMed:36108750, ECO:0000269|PubMed:7887414, CC ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. Note=The gene represented in this entry is CC involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor CC of neuroectodermal origin that generally occurs in childhood, but has CC also been reported in adults. Although generally found within the CC ventricular system, choroid plexus papillomas can arise ectopically in CC the brain parenchyma or disseminate throughout the neuraxis. Patients CC present with signs and symptoms of increased intracranial pressure CC including headache, hydrocephalus, papilledema, nausea, vomiting, CC cranial nerve deficits, gait impairment, and seizures. CC {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant CC neoplasm of the adrenal cortex and a rare childhood tumor. It occurs CC with increased frequency in patients with Beckwith-Wiedemann syndrome CC and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant CC skin neoplasm that typically appears on hair-bearing skin, most CC commonly on sun-exposed areas. It is slow growing and rarely CC metastasizes, but has potentialities for local invasion and CC destruction. It usually develops as a flat, firm, pale area that is CC small, raised, pink or red, translucent, shiny, and waxy, and the area CC may bleed following minor injury. Tumor size can vary from a few CC millimeters to several centimeters in diameter. CC {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of CC bone marrow failure syndrome, a heterogeneous group of life-threatening CC disorders characterized by hematopoietic defects in association with a CC range of variable extra-hematopoietic manifestations. BMFS5 is an CC autosomal dominant form characterized by infantile onset of severe red CC cell anemia requiring transfusion. Additional features include CC hypogammaglobulinemia, poor growth with microcephaly, developmental CC delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}. CC -!- CAUTION: Interaction with BANP was reported to enhance phosphorylation CC on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the CC publication has been retracted due to image duplication and CC manipulation. Interaction with BANP has been confirmed in mouse studies CC (By similarity). Phosphorylation at Ser-15 has been confirmed by other CC studies (PubMed:10570149, PubMed:11554766, PubMed:15866171, CC PubMed:16219768, PubMed:17317671, PubMed:17954561, PubMed:20959462, CC PubMed:25772236). Its nuclear and cytoplasmic localization has been CC confirmed by other studies (PubMed:15340061, PubMed:17170702, CC PubMed:17591690, PubMed:18206965, PubMed:19011621, PubMed:21597459, CC PubMed:22726440). {ECO:0000250|UniProtKB:P02340, CC ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, CC ECO:0000305|PubMed:32144153}. CC -!- WEB RESOURCE: Name=The TP53 Database; CC URL="https://tp53.cancer.gov/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/88/P53"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry; CC URL="https://en.wikipedia.org/wiki/P53"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue CC 206 of August 2018; CC URL="https://www.proteinspotlight.org/back_issues/206/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X02469; CAA26306.1; -; mRNA. DR EMBL; M13121; AAA59987.1; -; Genomic_DNA. DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; K03199; AAA59989.1; -; mRNA. DR EMBL; M14694; AAA61211.1; -; mRNA. DR EMBL; M14695; AAA61212.1; -; mRNA. DR EMBL; M22898; AAA59988.1; -; Genomic_DNA. DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; X01405; CAA25652.1; -; mRNA. DR EMBL; X60011; CAA42626.1; -; mRNA. DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA. DR EMBL; X60013; CAA42628.1; -; mRNA. DR EMBL; X60014; CAA42629.1; -; mRNA. DR EMBL; X60015; CAA42630.1; -; mRNA. DR EMBL; X60016; CAA42631.1; -; mRNA. DR EMBL; X60017; CAA42632.1; -; mRNA. DR EMBL; X60018; CAA42633.1; -; mRNA. DR EMBL; X60019; CAA42634.1; -; mRNA. DR EMBL; X60020; CAA42635.1; -; mRNA. DR EMBL; AF307851; AAG28785.1; -; mRNA. DR EMBL; DQ186648; ABA29753.1; -; mRNA. DR EMBL; DQ186649; ABA29754.1; -; mRNA. DR EMBL; DQ186650; ABA29755.1; -; mRNA. DR EMBL; DQ186651; ABA29756.1; -; mRNA. DR EMBL; DQ186652; ABA29757.1; -; mRNA. DR EMBL; DQ191317; ABB80262.1; -; mRNA. DR EMBL; DQ286964; ABB80266.1; -; mRNA. DR EMBL; X54156; CAA38095.1; -; Genomic_DNA. DR EMBL; U94788; AAC12971.1; -; Genomic_DNA. DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA. DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA. DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA. DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA. DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA. DR EMBL; AB082923; BAC16799.1; -; mRNA. DR EMBL; AK312568; BAG35463.1; -; mRNA. DR EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90143.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90144.1; -; Genomic_DNA. DR EMBL; BC003596; AAH03596.1; -; mRNA. DR EMBL; AY429684; AAR10356.1; -; mRNA. DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA. DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA. DR EMBL; U63714; AAB39322.1; -; Genomic_DNA. DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA. DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA. DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA. DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA. DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA. DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA. DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA. DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA. DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA. DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA. DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA. DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA. DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA. DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA. DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA. DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA. DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA. DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA. DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA. DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA. DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA. DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA. DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA. DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA. DR CCDS; CCDS11118.1; -. [P04637-1] DR CCDS; CCDS45605.1; -. [P04637-3] DR CCDS; CCDS45606.1; -. [P04637-2] DR CCDS; CCDS73966.1; -. [P04637-7] DR CCDS; CCDS73967.1; -. [P04637-9] DR CCDS; CCDS73968.1; -. [P04637-8] DR CCDS; CCDS73969.1; -. [P04637-4] DR CCDS; CCDS73970.1; -. [P04637-6] DR CCDS; CCDS73971.1; -. [P04637-5] DR PIR; A25224; DNHU53. DR RefSeq; NP_000537.3; NM_000546.5. [P04637-1] DR RefSeq; NP_001119584.1; NM_001126112.3. [P04637-1] DR RefSeq; NP_001119585.1; NM_001126113.3. [P04637-3] DR RefSeq; NP_001119586.1; NM_001126114.3. [P04637-2] DR RefSeq; NP_001119587.1; NM_001126115.2. [P04637-7] DR RefSeq; NP_001119588.1; NM_001126116.2. [P04637-8] DR RefSeq; NP_001119589.1; NM_001126117.2. [P04637-9] DR RefSeq; NP_001119590.1; NM_001126118.2. [P04637-4] DR RefSeq; NP_001263624.1; NM_001276695.3. [P04637-6] DR RefSeq; NP_001263625.1; NM_001276696.3. [P04637-5] DR RefSeq; NP_001263626.1; NM_001276697.1. DR RefSeq; NP_001263627.1; NM_001276698.1. DR RefSeq; NP_001263628.1; NM_001276699.1. DR RefSeq; NP_001263689.1; NM_001276760.3. [P04637-4] DR RefSeq; NP_001263690.1; NM_001276761.3. [P04637-4] DR RefSeq; NP_001394191.1; NM_001407262.1. [P04637-1] DR RefSeq; NP_001394192.1; NM_001407263.1. [P04637-4] DR RefSeq; NP_001394193.1; NM_001407264.1. [P04637-1] DR RefSeq; NP_001394194.1; NM_001407265.1. [P04637-4] DR RefSeq; NP_001394195.1; NM_001407266.1. [P04637-1] DR RefSeq; NP_001394196.1; NM_001407267.1. [P04637-4] DR RefSeq; NP_001394197.1; NM_001407268.1. [P04637-2] DR RefSeq; NP_001394198.1; NM_001407269.1. [P04637-5] DR RefSeq; NP_001394199.1; NM_001407270.1. [P04637-2] DR RefSeq; NP_001394200.1; NM_001407271.1. [P04637-5] DR PDB; 1A1U; NMR; -; A/C=324-358. DR PDB; 1AIE; X-ray; 1.50 A; A=326-356. DR PDB; 1C26; X-ray; 1.70 A; A=325-356. DR PDB; 1DT7; NMR; -; X/Y=367-388. DR PDB; 1GZH; X-ray; 2.60 A; A/C=95-292. DR PDB; 1H26; X-ray; 2.24 A; E=376-386. DR PDB; 1HS5; NMR; -; A/B=324-357. DR PDB; 1JSP; NMR; -; A=367-386. DR PDB; 1KZY; X-ray; 2.50 A; A/B=95-289. DR PDB; 1MA3; X-ray; 2.00 A; B=372-389. DR PDB; 1OLG; NMR; -; A/B/C/D=319-360. DR PDB; 1OLH; NMR; -; A/B/C/D=319-360. DR PDB; 1PES; NMR; -; A/B/C/D=325-355. DR PDB; 1PET; NMR; -; A/B/C/D=325-355. DR PDB; 1SAE; NMR; -; A/B/C/D=319-360. DR PDB; 1SAF; NMR; -; A/B/C/D=319-360. DR PDB; 1SAK; NMR; -; A/B/C/D=319-360. DR PDB; 1SAL; NMR; -; A/B/C/D=319-360. DR PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1UOL; X-ray; 1.90 A; A/B=94-312. DR PDB; 1XQH; X-ray; 1.75 A; B/F=369-377. DR PDB; 1YC5; X-ray; 1.40 A; B=372-389. DR PDB; 1YCQ; X-ray; 2.30 A; B=13-29. DR PDB; 1YCR; X-ray; 2.60 A; B=15-29. DR PDB; 1YCS; X-ray; 2.20 A; A=94-292. DR PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 2ADY; X-ray; 2.50 A; A/B=94-293. DR PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293. DR PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293. DR PDB; 2B3G; X-ray; 1.60 A; B=33-60. DR PDB; 2BIM; X-ray; 1.98 A; A/B=94-312. DR PDB; 2BIN; X-ray; 1.90 A; A=94-312. DR PDB; 2BIO; X-ray; 1.90 A; A=94-312. DR PDB; 2BIP; X-ray; 1.80 A; A=94-312. DR PDB; 2BIQ; X-ray; 1.80 A; A=94-312. DR PDB; 2F1X; X-ray; 2.30 A; A/B=359-368. DR PDB; 2FEJ; NMR; -; A=94-297. DR PDB; 2FOJ; X-ray; 1.60 A; B=361-367. DR PDB; 2FOO; X-ray; 2.20 A; B=358-363. DR PDB; 2GS0; NMR; -; B=20-73. DR PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292. DR PDB; 2H2D; X-ray; 1.70 A; B=372-389. DR PDB; 2H2F; X-ray; 2.20 A; B=372-389. DR PDB; 2H4F; X-ray; 2.00 A; D=372-389. DR PDB; 2H4H; X-ray; 1.99 A; B=372-389. DR PDB; 2H4J; X-ray; 2.10 A; D=372-389. DR PDB; 2H59; X-ray; 1.90 A; D/E=372-389. DR PDB; 2J0Z; NMR; -; A/B/C/D=326-356. DR PDB; 2J10; NMR; -; A/B/C/D=326-356. DR PDB; 2J11; NMR; -; A/B/C/D=326-356. DR PDB; 2J1W; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J1X; X-ray; 1.65 A; A/B=94-312. DR PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293. DR PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J20; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J21; X-ray; 1.60 A; A/B=94-312. DR PDB; 2K8F; NMR; -; B=1-39. DR PDB; 2L14; NMR; -; B=13-61. DR PDB; 2LY4; NMR; -; B=1-93. DR PDB; 2MEJ; NMR; -; B=96-312. DR PDB; 2MWO; NMR; -; B=363-377. DR PDB; 2MWP; NMR; -; B=376-387. DR PDB; 2MWY; NMR; -; B=15-29. DR PDB; 2MZD; NMR; -; B=35-59. DR PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312. DR PDB; 2PCX; X-ray; 1.54 A; A=94-292. DR PDB; 2RUK; NMR; -; A=41-62. DR PDB; 2VUK; X-ray; 1.50 A; A/B=94-312. DR PDB; 2WGX; X-ray; 1.75 A; A/B=94-312. DR PDB; 2X0U; X-ray; 1.60 A; A/B=94-312. DR PDB; 2X0V; X-ray; 1.80 A; A/B=94-312. DR PDB; 2X0W; X-ray; 2.10 A; A/B=94-312. DR PDB; 2XWR; X-ray; 1.68 A; A/B=89-293. DR PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293. DR PDB; 2YDR; X-ray; 2.75 A; P=144-154. DR PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 3D05; X-ray; 1.70 A; A=94-293. DR PDB; 3D06; X-ray; 1.20 A; A=94-293. DR PDB; 3D07; X-ray; 2.20 A; A/B=94-293. DR PDB; 3D08; X-ray; 1.40 A; A=94-293. DR PDB; 3D09; X-ray; 1.90 A; A=94-293. DR PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29. DR PDB; 3DAC; X-ray; 1.80 A; B/P=17-37. DR PDB; 3IGK; X-ray; 1.70 A; A=94-293. DR PDB; 3IGL; X-ray; 1.80 A; A=94-293. DR PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291. DR PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293. DR PDB; 3LW1; X-ray; 1.28 A; P=385-393. DR PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386. DR PDB; 3PDH; X-ray; 1.80 A; D=372-389. DR PDB; 3Q01; X-ray; 2.10 A; A/B=94-356. DR PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356. DR PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354. DR PDB; 3SAK; NMR; -; A/B/C/D=319-360. DR PDB; 3TG5; X-ray; 2.30 A; B=365-375. DR PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356. DR PDB; 3ZME; X-ray; 1.35 A; A/B=94-312. DR PDB; 4AGL; X-ray; 1.70 A; A/B=94-312. DR PDB; 4AGM; X-ray; 1.52 A; A/B=94-312. DR PDB; 4AGN; X-ray; 1.60 A; A/B=94-312. DR PDB; 4AGO; X-ray; 1.45 A; A/B=94-312. DR PDB; 4AGP; X-ray; 1.50 A; A/B=94-312. DR PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312. DR PDB; 4BUZ; X-ray; 1.90 A; P=379-386. DR PDB; 4BV2; X-ray; 3.30 A; E/H=376-388. DR PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29. DR PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291. DR PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293. DR PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBV; X-ray; 2.10 A; A=94-293. DR PDB; 4IBW; X-ray; 1.79 A; A=94-293. DR PDB; 4IBY; X-ray; 1.45 A; A/B=94-293. DR PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293. DR PDB; 4IJT; X-ray; 1.78 A; A=94-293. DR PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312. DR PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312. DR PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312. DR PDB; 4LOF; X-ray; 2.00 A; A=94-312. DR PDB; 4MZI; X-ray; 1.25 A; A=94-292. DR PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358. DR PDB; 4QO1; X-ray; 1.92 A; B=92-312. DR PDB; 4RP6; X-ray; 1.70 A; Z=252-258. DR PDB; 4RP7; X-ray; 1.58 A; Z=253-258. DR PDB; 4X34; X-ray; 1.80 A; C/D=377-386. DR PDB; 4XR8; X-ray; 2.25 A; C/D=94-292. DR PDB; 4ZZJ; X-ray; 2.74 A; B=379-383. DR PDB; 5A7B; X-ray; 1.40 A; A/B=94-312. DR PDB; 5AB9; X-ray; 1.36 A; A/B=94-312. DR PDB; 5ABA; X-ray; 1.62 A; A/B=94-312. DR PDB; 5AOI; X-ray; 1.78 A; A/B=94-312. DR PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312. DR PDB; 5AOK; X-ray; 1.35 A; A/B=94-312. DR PDB; 5AOL; X-ray; 1.50 A; A/B=94-312. DR PDB; 5AOM; X-ray; 1.74 A; A/B=94-312. DR PDB; 5BUA; X-ray; 1.81 A; A=94-293. DR PDB; 5ECG; X-ray; 3.00 A; A/B=95-312. DR PDB; 5G4M; X-ray; 1.38 A; A/B=94-312. DR PDB; 5G4N; X-ray; 1.35 A; A/B=94-312. DR PDB; 5G4O; X-ray; 1.48 A; A/B=94-312. DR PDB; 5HOU; NMR; -; A=1-61. DR PDB; 5HP0; NMR; -; A=37-61. DR PDB; 5HPD; NMR; -; A=2-61. DR PDB; 5LAP; X-ray; 1.42 A; A/B=94-312. DR PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291. DR PDB; 5MCT; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MCU; X-ray; 1.70 A; A/B=94-293. DR PDB; 5MCV; X-ray; 1.60 A; A/B=94-293. DR PDB; 5MCW; X-ray; 1.90 A; A/B=94-293. DR PDB; 5MF7; X-ray; 1.59 A; A/B=94-293. DR PDB; 5MG7; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MHC; X-ray; 1.20 A; P=382-393. DR PDB; 5MOC; X-ray; 1.80 A; P=382-393. DR PDB; 5O1A; X-ray; 1.44 A; A/B=94-312. DR PDB; 5O1B; X-ray; 1.43 A; A/B=94-312. DR PDB; 5O1C; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1D; X-ray; 1.36 A; A/B=94-312. DR PDB; 5O1E; X-ray; 1.30 A; A/B=94-312. DR PDB; 5O1F; X-ray; 1.38 A; A/B=94-312. DR PDB; 5O1G; X-ray; 1.35 A; A/B=94-312. DR PDB; 5O1H; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1I; X-ray; 1.40 A; A/B=94-312. DR PDB; 5OL0; X-ray; 1.99 A; C/D=372-389. DR PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154. DR PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356. DR PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289. DR PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 6GGA; X-ray; 1.55 A; A/B=94-312. DR PDB; 6GGB; X-ray; 1.32 A; A/B=94-312. DR PDB; 6GGC; X-ray; 1.24 A; A/B=94-312. DR PDB; 6GGD; X-ray; 1.40 A; A/B=94-312. DR PDB; 6GGE; X-ray; 1.25 A; A/B=94-312. DR PDB; 6GGF; X-ray; 1.32 A; A/B=94-312. DR PDB; 6LHD; X-ray; 2.50 A; A/B=96-292. DR PDB; 6R5L; X-ray; 1.88 A; P=382-393. DR PDB; 6RJZ; X-ray; 1.58 A; P=382-393. DR PDB; 6RK8; X-ray; 1.60 A; P=382-393. DR PDB; 6RKI; X-ray; 1.88 A; P=382-393. DR PDB; 6RKK; X-ray; 1.88 A; P=382-393. DR PDB; 6RKM; X-ray; 1.88 A; P=382-393. DR PDB; 6RL3; X-ray; 1.30 A; P=382-393. DR PDB; 6RL4; X-ray; 1.60 A; P=382-393. DR PDB; 6RL6; X-ray; 1.60 A; P=382-393. DR PDB; 6RM5; X-ray; 1.88 A; P=382-393. DR PDB; 6RM7; X-ray; 1.60 A; P=382-393. DR PDB; 6RWH; X-ray; 1.68 A; P=382-393. DR PDB; 6RWI; X-ray; 1.65 A; P=382-393. DR PDB; 6RWS; X-ray; 1.53 A; P=382-393. DR PDB; 6RWU; X-ray; 1.46 A; P=382-393. DR PDB; 6RX2; X-ray; 1.82 A; P=382-393. DR PDB; 6RZ3; X-ray; 4.23 A; A=62-292. DR PDB; 6S39; X-ray; 1.88 A; P=382-393. DR PDB; 6S3C; X-ray; 2.00 A; P=382-393. DR PDB; 6S40; X-ray; 1.90 A; P=382-393. DR PDB; 6S9Q; X-ray; 1.69 A; P=382-393. DR PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311. DR PDB; 6SI0; X-ray; 1.53 A; A/B=94-312. DR PDB; 6SI1; X-ray; 1.44 A; A/B=94-312. DR PDB; 6SI2; X-ray; 1.50 A; A/B=94-312. DR PDB; 6SI3; X-ray; 1.40 A; A/B=94-312. DR PDB; 6SI4; X-ray; 1.80 A; A/B=94-312. DR PDB; 6SIN; X-ray; 1.64 A; P=382-393. DR PDB; 6SIO; X-ray; 1.60 A; P=382-393. DR PDB; 6SIP; X-ray; 1.60 A; P=382-393. DR PDB; 6SIQ; X-ray; 1.60 A; P=382-393. DR PDB; 6SL6; X-ray; 1.67 A; A=89-311. DR PDB; 6SLV; X-ray; 1.90 A; P=382-393. DR PDB; 6T58; X-ray; 3.10 A; A/B=17-56. DR PDB; 6V4F; X-ray; 1.35 A; B=14-29. DR PDB; 6V4H; X-ray; 1.53 A; B/D=14-29. DR PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176. DR PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176. DR PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176. DR PDB; 6VRM; X-ray; 2.61 A; P=168-176. DR PDB; 6VRN; X-ray; 2.46 A; P=168-176. DR PDB; 6W51; X-ray; 3.53 A; C/F/I/L=168-176. DR PDB; 6XRE; EM; 4.60 A; M=1-393. DR PDB; 6ZNC; X-ray; 1.64 A; A=94-293. DR PDB; 7B46; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7B47; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 7B48; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 7B49; X-ray; 1.42 A; A/B=94-293. DR PDB; 7B4A; X-ray; 1.90 A; A/B=94-293. DR PDB; 7B4B; X-ray; 1.76 A; A/B/C/D=94-293. DR PDB; 7B4C; X-ray; 1.71 A; A/B/C/D=94-293. DR PDB; 7B4D; X-ray; 1.85 A; A=94-293. DR PDB; 7B4E; X-ray; 1.58 A; A=94-293. DR PDB; 7B4F; X-ray; 1.78 A; A=94-293. DR PDB; 7B4G; X-ray; 1.86 A; A=94-293. DR PDB; 7B4H; X-ray; 1.39 A; A=94-293. DR PDB; 7B4N; X-ray; 1.32 A; A=94-293. DR PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356. DR PDB; 7DHY; X-ray; 2.15 A; A/B/C/D=94-293. DR PDB; 7DHZ; X-ray; 1.74 A; A/B=94-293. DR PDB; 7DVD; X-ray; 2.59 A; A/B/C/D=92-290. DR PDB; 7EAX; X-ray; 2.55 A; A/B/C/D=96-289. DR PDB; 7EDS; X-ray; 1.77 A; A=94-293. DR PDB; 7EEU; X-ray; 2.90 A; A/B/C/D/E/F/G/H=94-293. DR PDB; 7EL4; X-ray; 2.11 A; A=23-29. DR PDB; 7NMI; X-ray; 2.10 A; A=17-56. DR PDB; 7RM4; X-ray; 3.33 A; C/H/M/R=168-176. DR PDB; 7V97; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7XZX; EM; 4.53 A; K/L/M/N=94-293. DR PDB; 7XZZ; EM; 4.07 A; K/L/M/N=1-393. DR PDB; 7YGI; X-ray; 2.10 A; A/B=92-289. DR PDB; 8A31; X-ray; 1.46 A; A/B=94-312. DR PDB; 8A32; X-ray; 1.47 A; A/B=94-312. DR PDB; 8A92; X-ray; 1.37 A; A/B=94-312. DR PDB; 8CG7; X-ray; 1.53 A; A/B=94-312. DR PDB; 8DC4; X-ray; 2.40 A; A/B/C/D=94-312. DR PDB; 8DC6; X-ray; 1.60 A; A/B/C/D=94-312. DR PDB; 8DC7; X-ray; 1.99 A; A=94-312. DR PDB; 8DC8; X-ray; 1.72 A; A=94-312. DR PDB; 8E7A; X-ray; 1.30 A; A=93-312. DR PDB; 8E7B; X-ray; 2.50 A; A/B=93-312. DR PDB; 8GCR; EM; 3.38 A; B=94-312. DR PDB; 8HLL; X-ray; 2.62 A; A=95-290. DR PDB; 8HLM; X-ray; 2.52 A; A=95-290. DR PDB; 8HLN; X-ray; 2.35 A; A=95-290. DR PDB; 8J8N; EM; 9.02 A; A/B/C/D=92-292. DR PDB; 8OXM; EM; 3.30 A; E/F=11-22. DR PDB; 8OXO; EM; 3.00 A; E/F=11-22. DR PDB; 8QWK; X-ray; 1.69 A; A=94-312. DR PDB; 8QWL; X-ray; 1.65 A; A=94-312. DR PDB; 8QWM; X-ray; 1.54 A; A/B=94-312. DR PDB; 8QWN; X-ray; 1.44 A; A=94-312. DR PDB; 8QWO; X-ray; 1.38 A; A/B=94-312. DR PDB; 8QWP; X-ray; 2.10 A; A/B=94-312. DR PDB; 8R1F; EM; 3.67 A; C=1-393. DR PDB; 8R1G; EM; 3.99 A; C/F=1-393. DR PDB; 8RBA; X-ray; 1.57 A; A/B=94-312. DR PDB; 8RBB; X-ray; 1.69 A; A/B=94-312. DR PDB; 8RBC; X-ray; 2.06 A; A/B=94-312. DR PDB; 8RCI; X-ray; 1.50 A; A=94-294. DR PDB; 8UQR; X-ray; 1.22 A; A/B/C/D=326-356. DR PDB; 8WD2; X-ray; 1.85 A; A/B=94-312. DR PDB; 8XP5; X-ray; 2.55 A; A/B=95-292. DR PDB; 9BR3; X-ray; 1.90 A; A/B=94-312. DR PDB; 9BR4; X-ray; 1.70 A; A/B=94-312. DR PDB; 9C5S; X-ray; 1.01 A; A/B/C/D=17-30. DR PDB; 9CHT; EM; 3.54 A; B=1-312. DR PDB; 9FZB; X-ray; 1.44 A; A=94-294. DR PDBsum; 1A1U; -. DR PDBsum; 1AIE; -. DR PDBsum; 1C26; -. DR PDBsum; 1DT7; -. DR PDBsum; 1GZH; -. DR PDBsum; 1H26; -. DR PDBsum; 1HS5; -. DR PDBsum; 1JSP; -. DR PDBsum; 1KZY; -. DR PDBsum; 1MA3; -. DR PDBsum; 1OLG; -. DR PDBsum; 1OLH; -. DR PDBsum; 1PES; -. DR PDBsum; 1PET; -. DR PDBsum; 1SAE; -. DR PDBsum; 1SAF; -. DR PDBsum; 1SAK; -. DR PDBsum; 1SAL; -. DR PDBsum; 1TSR; -. DR PDBsum; 1TUP; -. DR PDBsum; 1UOL; -. DR PDBsum; 1XQH; -. DR PDBsum; 1YC5; -. DR PDBsum; 1YCQ; -. DR PDBsum; 1YCR; -. DR PDBsum; 1YCS; -. DR PDBsum; 2AC0; -. DR PDBsum; 2ADY; -. DR PDBsum; 2AHI; -. DR PDBsum; 2ATA; -. DR PDBsum; 2B3G; -. DR PDBsum; 2BIM; -. DR PDBsum; 2BIN; -. DR PDBsum; 2BIO; -. DR PDBsum; 2BIP; -. DR PDBsum; 2BIQ; -. DR PDBsum; 2F1X; -. DR PDBsum; 2FEJ; -. DR PDBsum; 2FOJ; -. DR PDBsum; 2FOO; -. DR PDBsum; 2GS0; -. DR PDBsum; 2H1L; -. DR PDBsum; 2H2D; -. DR PDBsum; 2H2F; -. DR PDBsum; 2H4F; -. DR PDBsum; 2H4H; -. DR PDBsum; 2H4J; -. DR PDBsum; 2H59; -. DR PDBsum; 2J0Z; -. DR PDBsum; 2J10; -. DR PDBsum; 2J11; -. DR PDBsum; 2J1W; -. DR PDBsum; 2J1X; -. DR PDBsum; 2J1Y; -. DR PDBsum; 2J1Z; -. DR PDBsum; 2J20; -. DR PDBsum; 2J21; -. DR PDBsum; 2K8F; -. DR PDBsum; 2L14; -. DR PDBsum; 2LY4; -. DR PDBsum; 2MEJ; -. DR PDBsum; 2MWO; -. DR PDBsum; 2MWP; -. DR PDBsum; 2MWY; -. DR PDBsum; 2MZD; -. DR PDBsum; 2OCJ; -. DR PDBsum; 2PCX; -. DR PDBsum; 2RUK; -. DR PDBsum; 2VUK; -. DR PDBsum; 2WGX; -. DR PDBsum; 2X0U; -. DR PDBsum; 2X0V; -. DR PDBsum; 2X0W; -. DR PDBsum; 2XWR; -. DR PDBsum; 2YBG; -. DR PDBsum; 2YDR; -. DR PDBsum; 2Z5S; -. DR PDBsum; 2Z5T; -. DR PDBsum; 3D05; -. DR PDBsum; 3D06; -. DR PDBsum; 3D07; -. DR PDBsum; 3D08; -. DR PDBsum; 3D09; -. DR PDBsum; 3D0A; -. DR PDBsum; 3DAB; -. DR PDBsum; 3DAC; -. DR PDBsum; 3IGK; -. DR PDBsum; 3IGL; -. DR PDBsum; 3KMD; -. DR PDBsum; 3KZ8; -. DR PDBsum; 3LW1; -. DR PDBsum; 3OQ5; -. DR PDBsum; 3PDH; -. DR PDBsum; 3Q01; -. DR PDBsum; 3Q05; -. DR PDBsum; 3Q06; -. DR PDBsum; 3SAK; -. DR PDBsum; 3TG5; -. DR PDBsum; 3TS8; -. DR PDBsum; 3ZME; -. DR PDBsum; 4AGL; -. DR PDBsum; 4AGM; -. DR PDBsum; 4AGN; -. DR PDBsum; 4AGO; -. DR PDBsum; 4AGP; -. DR PDBsum; 4AGQ; -. DR PDBsum; 4BUZ; -. DR PDBsum; 4BV2; -. DR PDBsum; 4HFZ; -. DR PDBsum; 4HJE; -. DR PDBsum; 4IBQ; -. DR PDBsum; 4IBS; -. DR PDBsum; 4IBT; -. DR PDBsum; 4IBU; -. DR PDBsum; 4IBV; -. DR PDBsum; 4IBW; -. DR PDBsum; 4IBY; -. DR PDBsum; 4IBZ; -. DR PDBsum; 4IJT; -. DR PDBsum; 4KVP; -. DR PDBsum; 4LO9; -. DR PDBsum; 4LOE; -. DR PDBsum; 4LOF; -. DR PDBsum; 4MZI; -. DR PDBsum; 4MZR; -. DR PDBsum; 4QO1; -. DR PDBsum; 4RP6; -. DR PDBsum; 4RP7; -. DR PDBsum; 4X34; -. DR PDBsum; 4XR8; -. DR PDBsum; 4ZZJ; -. DR PDBsum; 5A7B; -. DR PDBsum; 5AB9; -. DR PDBsum; 5ABA; -. DR PDBsum; 5AOI; -. DR PDBsum; 5AOJ; -. DR PDBsum; 5AOK; -. DR PDBsum; 5AOL; -. DR PDBsum; 5AOM; -. DR PDBsum; 5BUA; -. DR PDBsum; 5ECG; -. DR PDBsum; 5G4M; -. DR PDBsum; 5G4N; -. DR PDBsum; 5G4O; -. DR PDBsum; 5HOU; -. DR PDBsum; 5HP0; -. DR PDBsum; 5HPD; -. DR PDBsum; 5LAP; -. DR PDBsum; 5LGY; -. DR PDBsum; 5MCT; -. DR PDBsum; 5MCU; -. DR PDBsum; 5MCV; -. DR PDBsum; 5MCW; -. DR PDBsum; 5MF7; -. DR PDBsum; 5MG7; -. DR PDBsum; 5MHC; -. DR PDBsum; 5MOC; -. DR PDBsum; 5O1A; -. DR PDBsum; 5O1B; -. DR PDBsum; 5O1C; -. DR PDBsum; 5O1D; -. DR PDBsum; 5O1E; -. DR PDBsum; 5O1F; -. DR PDBsum; 5O1G; -. DR PDBsum; 5O1H; -. DR PDBsum; 5O1I; -. DR PDBsum; 5OL0; -. DR PDBsum; 5UN8; -. DR PDBsum; 5XZC; -. DR PDBsum; 6FF9; -. DR PDBsum; 6FJ5; -. DR PDBsum; 6GGA; -. DR PDBsum; 6GGB; -. DR PDBsum; 6GGC; -. DR PDBsum; 6GGD; -. DR PDBsum; 6GGE; -. DR PDBsum; 6GGF; -. DR PDBsum; 6LHD; -. DR PDBsum; 6R5L; -. DR PDBsum; 6RJZ; -. DR PDBsum; 6RK8; -. DR PDBsum; 6RKI; -. DR PDBsum; 6RKK; -. DR PDBsum; 6RKM; -. DR PDBsum; 6RL3; -. DR PDBsum; 6RL4; -. DR PDBsum; 6RL6; -. DR PDBsum; 6RM5; -. DR PDBsum; 6RM7; -. DR PDBsum; 6RWH; -. DR PDBsum; 6RWI; -. DR PDBsum; 6RWS; -. DR PDBsum; 6RWU; -. DR PDBsum; 6RX2; -. DR PDBsum; 6RZ3; -. DR PDBsum; 6S39; -. DR PDBsum; 6S3C; -. DR PDBsum; 6S40; -. DR PDBsum; 6S9Q; -. DR PDBsum; 6SHZ; -. DR PDBsum; 6SI0; -. DR PDBsum; 6SI1; -. DR PDBsum; 6SI2; -. DR PDBsum; 6SI3; -. DR PDBsum; 6SI4; -. DR PDBsum; 6SIN; -. DR PDBsum; 6SIO; -. DR PDBsum; 6SIP; -. DR PDBsum; 6SIQ; -. DR PDBsum; 6SL6; -. DR PDBsum; 6SLV; -. DR PDBsum; 6T58; -. DR PDBsum; 6V4F; -. DR PDBsum; 6V4H; -. DR PDBsum; 6VQO; -. DR PDBsum; 6VR1; -. DR PDBsum; 6VR5; -. DR PDBsum; 6VRM; -. DR PDBsum; 6VRN; -. DR PDBsum; 6W51; -. DR PDBsum; 6XRE; -. DR PDBsum; 6ZNC; -. DR PDBsum; 7B46; -. DR PDBsum; 7B47; -. DR PDBsum; 7B48; -. DR PDBsum; 7B49; -. DR PDBsum; 7B4A; -. DR PDBsum; 7B4B; -. DR PDBsum; 7B4C; -. DR PDBsum; 7B4D; -. DR PDBsum; 7B4E; -. DR PDBsum; 7B4F; -. DR PDBsum; 7B4G; -. DR PDBsum; 7B4H; -. DR PDBsum; 7B4N; -. DR PDBsum; 7BWN; -. DR PDBsum; 7DHY; -. DR PDBsum; 7DHZ; -. DR PDBsum; 7DVD; -. DR PDBsum; 7EAX; -. DR PDBsum; 7EDS; -. DR PDBsum; 7EEU; -. DR PDBsum; 7EL4; -. DR PDBsum; 7NMI; -. DR PDBsum; 7RM4; -. DR PDBsum; 7V97; -. DR PDBsum; 7XZX; -. DR PDBsum; 7XZZ; -. DR PDBsum; 7YGI; -. DR PDBsum; 8A31; -. DR PDBsum; 8A32; -. DR PDBsum; 8A92; -. DR PDBsum; 8CG7; -. DR PDBsum; 8DC4; -. DR PDBsum; 8DC6; -. DR PDBsum; 8DC7; -. DR PDBsum; 8DC8; -. DR PDBsum; 8E7A; -. DR PDBsum; 8E7B; -. DR PDBsum; 8GCR; -. DR PDBsum; 8HLL; -. DR PDBsum; 8HLM; -. DR PDBsum; 8HLN; -. DR PDBsum; 8J8N; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8QWK; -. DR PDBsum; 8QWL; -. DR PDBsum; 8QWM; -. DR PDBsum; 8QWN; -. DR PDBsum; 8QWO; -. DR PDBsum; 8QWP; -. DR PDBsum; 8R1F; -. DR PDBsum; 8R1G; -. DR PDBsum; 8RBA; -. DR PDBsum; 8RBB; -. DR PDBsum; 8RBC; -. DR PDBsum; 8RCI; -. DR PDBsum; 8UQR; -. DR PDBsum; 8WD2; -. DR PDBsum; 8XP5; -. DR PDBsum; 9BR3; -. DR PDBsum; 9BR4; -. DR PDBsum; 9C5S; -. DR PDBsum; 9CHT; -. DR PDBsum; 9FZB; -. DR AlphaFoldDB; P04637; -. DR BMRB; P04637; -. DR EMDB; EMD-0378; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-18809; -. DR EMDB; EMD-18810; -. DR EMDB; EMD-22294; -. DR EMDB; EMD-22827; -. DR EMDB; EMD-29941; -. DR EMDB; EMD-33533; -. DR EMDB; EMD-33535; -. DR EMDB; EMD-36075; -. DR EMDB; EMD-45601; -. DR EMDB; EMD-53478; -. DR EMDB; EMD-53532; -. DR EMDB; EMD-53536; -. DR EMDB; EMD-53537; -. DR EMDB; EMD-6791; -. DR EMDB; EMD-8926; -. DR EMDB; EMD-8927; -. DR SMR; P04637; -. DR BioGRID; 113010; 2577. DR ComplexPortal; CPX-6093; p53-MDM2-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-663; p53-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-759; p53-MDM2 transcriptional regulation complex. DR CORUM; P04637; -. DR DIP; DIP-368N; -. DR ELM; P04637; -. DR FunCoup; P04637; 3248. DR IntAct; P04637; 850. DR MINT; P04637; -. DR STRING; 9606.ENSP00000269305; -. DR BindingDB; P04637; -. DR ChEMBL; CHEMBL4096; -. DR DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. DR DrugBank; DB13010; 4-isothioureidobutyronitrile. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB17549; Alrizomadlin. DR DrugBank; DB05404; AZD 3355. DR DrugBank; DB17507; COTI-2. DR DrugBank; DB11684; Eprenetapopt. DR DrugBank; DB17039; Nutlin-3. DR DrugBank; DB12541; SAR-405838. DR DrugBank; DB16331; Siremadlin. DR DrugBank; DB16447; Thymoquinone. DR DrugBank; DB03347; Triethyl phosphate. DR DrugBank; DB01593; Zinc. DR DrugBank; DB14487; Zinc acetate. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MoonDB; P04637; Predicted. DR TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family. DR GlyCosmos; P04637; 1 site, 1 glycan. DR GlyGen; P04637; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P04637; -. DR MetOSite; P04637; -. DR PhosphoSitePlus; P04637; -. DR SwissPalm; P04637; -. DR BioMuta; TP53; -. DR DMDM; 269849759; -. DR CPTAC; CPTAC-5895; -. DR CPTAC; CPTAC-5896; -. DR CPTAC; CPTAC-951; -. DR jPOST; P04637; -. DR MassIVE; P04637; -. DR PaxDb; 9606-ENSP00000269305; -. DR PeptideAtlas; P04637; -. DR ProteomicsDB; 51728; -. [P04637-1] DR ProteomicsDB; 51729; -. [P04637-2] DR ProteomicsDB; 51730; -. [P04637-3] DR ProteomicsDB; 51731; -. [P04637-4] DR ProteomicsDB; 51732; -. [P04637-5] DR ProteomicsDB; 51733; -. [P04637-6] DR ProteomicsDB; 51734; -. [P04637-7] DR ProteomicsDB; 51735; -. [P04637-8] DR ProteomicsDB; 51736; -. [P04637-9] DR Pumba; P04637; -. DR ABCD; P04637; 67 sequenced antibodies. DR Antibodypedia; 3525; 9660 antibodies from 66 providers. DR CPTC; P04637; 2 antibodies. DR DNASU; 7157; -. DR Ensembl; ENST00000269305.9; ENSP00000269305.4; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000420246.6; ENSP00000391127.2; ENSG00000141510.20. [P04637-2] DR Ensembl; ENST00000445888.6; ENSP00000391478.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000455263.6; ENSP00000398846.2; ENSG00000141510.20. [P04637-3] DR Ensembl; ENST00000503591.2; ENSP00000426252.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000504290.5; ENSP00000484409.1; ENSG00000141510.20. [P04637-9] DR Ensembl; ENST00000504937.5; ENSP00000481179.1; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000508793.6; ENSP00000424104.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000509690.6; ENSP00000425104.2; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000510385.5; ENSP00000478499.1; ENSG00000141510.20. [P04637-8] DR Ensembl; ENST00000610292.4; ENSP00000478219.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000610538.4; ENSP00000480868.1; ENSG00000141510.20. [P04637-6] DR Ensembl; ENST00000619485.4; ENSP00000482537.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000620739.4; ENSP00000481638.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000622645.4; ENSP00000482222.1; ENSG00000141510.20. [P04637-5] DR Ensembl; ENST00000714357.1; ENSP00000519624.1; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000714359.1; ENSP00000519626.1; ENSG00000141510.20. [P04637-1] DR GeneID; 7157; -. DR KEGG; hsa:7157; -. DR MANE-Select; ENST00000269305.9; ENSP00000269305.4; NM_000546.6; NP_000537.3. DR UCSC; uc002gij.4; human. [P04637-1] DR AGR; HGNC:11998; -. DR CIViC; 7157; 387 evidence items across 280 molecular profiles. DR ClinPGx; PA36679; -. DR CTD; 7157; -. DR DisGeNET; 7157; -. DR GeneCards; TP53; -. DR GeneReviews; TP53; -. DR HGNC; HGNC:11998; TP53. DR HPA; ENSG00000141510; Low tissue specificity. DR MalaCards; TP53; -. DR MIM; 133239; phenotype. DR MIM; 151623; phenotype. DR MIM; 191170; gene+phenotype. DR MIM; 202300; phenotype. DR MIM; 211980; phenotype. DR MIM; 260500; phenotype. DR MIM; 275355; phenotype. DR MIM; 614740; phenotype. DR MIM; 618165; phenotype. DR OpenTargets; ENSG00000141510; -. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2). DR Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma. DR Orphanet; 251899; Choroid plexus carcinoma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 3318; Essential thrombocythemia. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 52688; Myelodysplastic syndrome. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 2807; Papilloma of choroid plexus. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000141510; -. DR eggNOG; ENOG502QVY3; Eukaryota. DR GeneTree; ENSGT00950000183153; -. DR InParanoid; P04637; -. DR OMA; HKKGEPC; -. DR OrthoDB; 5915660at2759; -. DR PAN-GO; P04637; 3 GO annotations based on evolutionary models. DR PhylomeDB; P04637; -. DR PathwayCommons; P04637; -. DR Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria. DR Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria. DR Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3232118; SUMOylation of transcription factors. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest. DR Reactome; R-HSA-6804754; Regulation of TP53 Expression. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69481; G2/M Checkpoints. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21. DR Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9723905; Loss of function of TP53 in cancer due to loss of tetramerization ability. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling. DR Reactome; R-HSA-9819196; Zygotic genome activation (ZGA). DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SABIO-RK; P04637; -. DR SignaLink; P04637; -. DR SIGNOR; P04637; -. DR Agora; ENSG00000141510; -. DR BioGRID-ORCS; 7157; 66 hits in 1218 CRISPR screens. DR CD-CODE; 1A18FFC4; Paraspeckle. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A1A97FAB; Synthetic Condensate 000191. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; E11B6BAB; Synthetic Condensate 000195. DR ChiTaRS; TP53; human. DR EvolutionaryTrace; P04637; -. DR GeneWiki; P53; -. DR GenomeRNAi; 7157; -. DR Pharos; P04637; Tchem. DR PRO; PR:P04637; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04637; protein. DR Bgee; ENSG00000141510; Expressed in ventricular zone and 144 other cell types or tissues. DR ExpressionAtlas; P04637; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0043073; C:germ cell nucleus; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA. DR GO; GO:0005657; C:replication fork; IEA:Ensembl. DR GO; GO:0035861; C:site of double-strand break; IEA:Ensembl. DR GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IPI:ComplexPortal. DR GO; GO:0071889; F:14-3-3 protein binding; EXP:DisProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0005507; F:copper ion binding; IDA:UniProtKB. DR GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0140296; F:general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA. DR GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; IPI:DisProt. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA. DR GO; GO:0002039; F:p53 binding; IPI:CAFA. DR GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB. DR GO; GO:0006914; P:autophagy; IMP:CAFA. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0048539; P:bone marrow development; IMP:UniProtKB. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl. DR GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:CAFA. DR GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; ISS:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB. DR GO; GO:0006983; P:ER overload response; IDA:MGI. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl. DR GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl. DR GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl. DR GO; GO:0000423; P:mitophagy; IEA:Ensembl. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0070266; P:necroptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO. DR GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1903451; P:negative regulation of G1 to G0 transition; IDA:CAFA. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB. DR GO; GO:1903799; P:negative regulation of miRNA processing; IEA:Ensembl. DR GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl. DR GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO. DR GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB. DR GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB. DR GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProt. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL. DR GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; IMP:UniProtKB. DR GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0010165; P:response to X-ray; IEA:Ensembl. DR GO; GO:0009303; P:rRNA transcription; IEA:Ensembl. DR GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:GO_Central. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0016032; P:viral process; IMP:CACAO. DR CDD; cd08367; P53; 1. DR DisProt; DP00086; -. DR FunFam; 2.60.40.720:FF:000003; Cellular tumor antigen p53; 1. DR FunFam; 4.10.170.10:FF:000003; Cellular tumor antigen p53; 1. DR Gene3D; 2.60.40.720; -; 1. DR Gene3D; 6.10.50.20; -; 1. DR Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1. DR IDEAL; IID00015; -. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf. DR InterPro; IPR057064; P53_central_site. DR InterPro; IPR011615; p53_DNA-bd. DR InterPro; IPR040926; p53_TAD2. DR InterPro; IPR036674; p53_tetramer_sf. DR InterPro; IPR010991; p53_tetrameristn. DR InterPro; IPR013872; p53_transactivation_domain. DR InterPro; IPR002117; p53_tumour_suppressor. DR PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1. DR PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1. DR Pfam; PF00870; P53; 1. DR Pfam; PF08563; P53_TAD; 1. DR Pfam; PF07710; P53_tetramer; 1. DR Pfam; PF18521; TAD2; 1. DR PRINTS; PR00386; P53SUPPRESSR. DR SUPFAM; SSF47719; p53 tetramerization domain; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS00348; P53; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative promoter usage; KW Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Disease variant; DNA-binding; KW Endoplasmic reticulum; Glycoprotein; Host-virus interaction; KW Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; KW Mitochondrion; Necrosis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc. FT CHAIN 1..393 FT /note="Cellular tumor antigen p53" FT /id="PRO_0000185703" FT DNA_BIND 102..292 FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT REGION 1..320 FT /note="Interaction with CCAR2" FT /evidence="ECO:0000269|PubMed:25732823" FT REGION 1..83 FT /note="Interaction with HRMT1L2" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 1..44 FT /note="Transcription activation (acidic)" FT REGION 50..96 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488" FT REGION 66..110 FT /note="Interaction with WWOX" FT REGION 100..370 FT /note="Interaction with HIPK1" FT /evidence="ECO:0000250" FT REGION 100..300 FT /note="Required for interaction with ZNF385A" FT /evidence="ECO:0000269|PubMed:17719541" FT REGION 113..236 FT /note="Required for interaction with FBXO42" FT /evidence="ECO:0000269|PubMed:19509332" FT REGION 116..292 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000250" FT REGION 241..248 FT /note="Interaction with the 53BP2 SH3 domain" FT REGION 256..294 FT /note="Interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10644996" FT REGION 273..280 FT /note="Interaction with DNA" FT REGION 282..325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 300..393 FT /note="Interaction with CARM1" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 319..360 FT /note="Interaction with HIPK2" FT REGION 325..356 FT /note="Oligomerization" FT REGION 351..393 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488, FT ECO:0000269|PubMed:36108750" FT REGION 359..363 FT /note="Interaction with USP7" FT REGION 368..387 FT /note="Basic (repression of DNA-binding)" FT REGION 374..393 FT /note="Interaction with MORN3" FT /evidence="ECO:0000269|PubMed:29681526" FT MOTIF 17..25 FT /note="TADI" FT MOTIF 48..56 FT /note="TADII" FT MOTIF 305..321 FT /note="Bipartite nuclear localization signal" FT MOTIF 339..350 FT /note="Nuclear export signal" FT MOTIF 370..372 FT /note="[KR]-[STA]-K motif" FT COMPBIAS 69..90 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..299 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 365..384 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 179 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 242 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT SITE 120 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT MOD_RES 9 FT /note="Phosphoserine; by HIPK4" FT /evidence="ECO:0000269|PubMed:18022393" FT MOD_RES 15 FT /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, FT ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, FT ECO:0000269|PubMed:28842590" FT MOD_RES 18 FT /note="Phosphothreonine; by CK1, VRK1 and VRK2" FT /evidence="ECO:0000269|PubMed:10606744, FT ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422, FT ECO:0000269|PubMed:31527692" FT MOD_RES 20 FT /note="Phosphoserine; by CHEK2, CK1 and PLK3" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, FT ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275" FT MOD_RES 33 FT /note="Phosphoserine; by CDK5 and CDK7" FT /evidence="ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:9372954" FT MOD_RES 37 FT /note="Phosphoserine; by MAPKAPK5" FT /evidence="ECO:0000269|PubMed:17254968" FT MOD_RES 46 FT /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG" FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, FT ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690" FT MOD_RES 55 FT /note="Phosphothreonine; by TAF1 and GRK5" FT /evidence="ECO:0000269|PubMed:15053879, FT ECO:0000269|PubMed:20124405" FT MOD_RES 120 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:19854137, ECO:0000269|PubMed:23431171" FT MOD_RES 120 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 139 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 183 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 269 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 284 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 305 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:12724314" FT MOD_RES 315 FT /note="Phosphoserine; by AURKA, CDK1 and CDK2" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:14702041" FT MOD_RES 321 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P02340" FT MOD_RES 333 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 335 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 337 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 370 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 370 FT /note="N6-methyllysine; by SMYD2; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 372 FT /note="N6-methyllysine; by SETD7" FT /evidence="ECO:0000269|PubMed:15525938, FT ECO:0000269|PubMed:16415881" FT MOD_RES 373 FT /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate" FT /evidence="ECO:0000269|PubMed:20118233" FT MOD_RES 373 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795" FT MOD_RES 381 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:29474172, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 382 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795, FT ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, FT ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29681526, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6-methyllysine; by KMT5A; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 392 FT /note="Phosphoserine; by CK2, CDK2 and NUAK1" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, FT ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662, FT ECO:0000269|PubMed:35618207" FT CROSSLNK 24 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:21597459" FT CROSSLNK 291 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 292 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 351 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 357 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 386 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11124955, FT ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37" FT VAR_SEQ 1..132 FT /note="Missing (in isoform 7, isoform 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040833" FT VAR_SEQ 1..39 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_040832" FT VAR_SEQ 332..346 FT /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, FT isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040560" FT VAR_SEQ 332..341 FT /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 FT and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006535" FT VAR_SEQ 342..393 FT /note="Missing (in isoform 2, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006536" FT VAR_SEQ 347..393 FT /note="Missing (in isoform 3, isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040561" FT VARIANT 5 FT /note="Q -> H (in a sporadic cancer; somatic mutation; FT abolishes strongly phosphorylation)" FT /id="VAR_044543" FT VARIANT 6 FT /note="S -> L (in a sporadic cancer; somatic mutation; FT reduces interaction with ZNF385A)" FT /id="VAR_044544" FT VARIANT 7 FT /note="D -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782646)" FT /id="VAR_005851" FT VARIANT 8 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044545" FT VARIANT 10 FT /note="V -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs535274413)" FT /id="VAR_044546" FT VARIANT 11 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044547" FT VARIANT 11 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044548" FT VARIANT 15 FT /note="S -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044549" FT VARIANT 16 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044550" FT VARIANT 17 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044551" FT VARIANT 24 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044552" FT VARIANT 28 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044553" FT VARIANT 29..30 FT /note="NN -> KD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047158" FT VARIANT 31 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs201753350)" FT /id="VAR_044554" FT VARIANT 33 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044555" FT VARIANT 34 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044556" FT VARIANT 35 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912661)" FT /id="VAR_005852" FT VARIANT 36 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781866)" FT /id="VAR_044557" FT VARIANT 37 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044558" FT VARIANT 37 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044559" FT VARIANT 39 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044560" FT VARIANT 39 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1353016807)" FT /id="VAR_044561" FT VARIANT 42 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044562" FT VARIANT 43 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005853" FT VARIANT 44 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501190)" FT /id="VAR_044563" FT VARIANT 44 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044564" FT VARIANT 44 FT /note="M -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044565" FT VARIANT 45 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044566" FT VARIANT 46 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044567" FT VARIANT 46 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs876659630)" FT /id="VAR_044568" FT VARIANT 47 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044569" FT VARIANT 47 FT /note="P -> S (in dbSNP:rs1800371)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_014632" FT VARIANT 48 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044570" FT VARIANT 49 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044571" FT VARIANT 49 FT /note="D -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044572" FT VARIANT 49 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044573" FT VARIANT 52 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044574" FT VARIANT 53 FT /note="W -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005854" FT VARIANT 53 FT /note="W -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044575" FT VARIANT 54 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526742)" FT /id="VAR_044576" FT VARIANT 54 FT /note="F -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044577" FT VARIANT 56 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044578" FT VARIANT 56 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044579" FT VARIANT 58 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044580" FT VARIANT 58 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044581" FT VARIANT 59 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1237722021)" FT /id="VAR_044582" FT VARIANT 59 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044583" FT VARIANT 59 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045783" FT VARIANT 60 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044584" FT VARIANT 60 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044585" FT VARIANT 60 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005855" FT VARIANT 61 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1460793472)" FT /id="VAR_044586" FT VARIANT 61 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044587" FT VARIANT 62 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044588" FT VARIANT 63 FT /note="A -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs876658902)" FT /id="VAR_044589" FT VARIANT 63 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs372201428)" FT /id="VAR_044590" FT VARIANT 65 FT /note="R -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501210)" FT /id="VAR_044591" FT VARIANT 66 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526711)" FT /id="VAR_044592" FT VARIANT 66 FT /note="M -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044593" FT VARIANT 67 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044594" FT VARIANT 67 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044595" FT VARIANT 67 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044596" FT VARIANT 68 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044597" FT VARIANT 68 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044598" FT VARIANT 69 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044599" FT VARIANT 69 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044600" FT VARIANT 69 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044601" FT VARIANT 69 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044602" FT VARIANT 70 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044603" FT VARIANT 71 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044604" FT VARIANT 72 FT /note="P -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882014)" FT /id="VAR_045784" FT VARIANT 72 FT /note="P -> G (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045785" FT VARIANT 72 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1042522)" FT /id="VAR_045786" FT VARIANT 72 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045787" FT VARIANT 72 FT /note="P -> R (in dbSNP:rs1042522)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, FT ECO:0000269|Ref.17" FT /id="VAR_005856" FT VARIANT 73 FT /note="V -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_044605" FT VARIANT 73 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044606" FT VARIANT 73 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782423)" FT /id="VAR_044607" FT VARIANT 74 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044608" FT VARIANT 75 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044609" FT VARIANT 75 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044610" FT VARIANT 75 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044611" FT VARIANT 76 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:2946935" FT /id="VAR_044612" FT VARIANT 76 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044613" FT VARIANT 77 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044614" FT VARIANT 78 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044615" FT VARIANT 79 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044616" FT VARIANT 79 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_005857" FT VARIANT 79 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044617" FT VARIANT 80 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044618" FT VARIANT 80 FT /note="P -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501204)" FT /id="VAR_044619" FT VARIANT 81 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044620" FT VARIANT 82 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs534447939)" FT /id="VAR_044621" FT VARIANT 82 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044622" FT VARIANT 83 FT /note="A -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044623" FT VARIANT 83 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044624" FT VARIANT 84 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044625" FT VARIANT 84 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044626" FT VARIANT 85 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044627" FT VARIANT 85 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044628" FT VARIANT 86 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044629" FT VARIANT 87 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005858" FT VARIANT 88 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044630" FT VARIANT 88 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526631)" FT /id="VAR_044631" FT VARIANT 89 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730881994)" FT /id="VAR_044632" FT VARIANT 89 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044633" FT VARIANT 90 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526625)" FT /id="VAR_044634" FT VARIANT 90 FT /note="S -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044635" FT VARIANT 91 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044636" FT VARIANT 92 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044637" FT VARIANT 92 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1210700121)" FT /id="VAR_044638" FT VARIANT 92 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044639" FT VARIANT 93 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044640" FT VARIANT 93 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044641" FT VARIANT 94 FT /note="S -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044642" FT VARIANT 94 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005859" FT VARIANT 95 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044643" FT VARIANT 95 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044644" FT VARIANT 96 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044645" FT VARIANT 96 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044646" FT VARIANT 96 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044647" FT VARIANT 97 FT /note="V -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044648" FT VARIANT 97 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044649" FT VARIANT 97 FT /note="V -> I (in familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs730882023)" FT /id="VAR_044650" FT VARIANT 98 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1245723119)" FT /id="VAR_044651" FT VARIANT 98 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044652" FT VARIANT 99 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044653" FT VARIANT 99 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044654" FT VARIANT 100 FT /note="Q -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044655" FT VARIANT 101 FT /note="K -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs878854069)" FT /id="VAR_044656" FT VARIANT 101 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044657" FT VARIANT 102 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786202717)" FT /id="VAR_044658" FT VARIANT 104 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044659" FT VARIANT 104 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044660" FT VARIANT 105 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044661" FT VARIANT 105 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587781504)" FT /id="VAR_044662" FT VARIANT 105 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044663" FT VARIANT 105 FT /note="G -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044664" FT VARIANT 105 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044665" FT VARIANT 106 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044666" FT VARIANT 106 FT /note="S -> R (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526581)" FT /id="VAR_044667" FT VARIANT 107 FT /note="Y -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782447)" FT /id="VAR_044668" FT VARIANT 107 FT /note="Y -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044669" FT VARIANT 107 FT /note="Y -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs368771578)" FT /id="VAR_044670" FT VARIANT 108 FT /note="G -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044671" FT VARIANT 108 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782461)" FT /id="VAR_044672" FT VARIANT 109 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044673" FT VARIANT 109 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044674" FT VARIANT 109 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796722)" FT /id="VAR_044675" FT VARIANT 110 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_005860" FT VARIANT 110 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044676" FT VARIANT 110 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /id="VAR_044677" FT VARIANT 110 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; does not induce SNAI1 degradation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_005861" FT VARIANT 110 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005862" FT VARIANT 110 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_044678" FT VARIANT 111 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044679" FT VARIANT 111 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044680" FT VARIANT 111 FT /note="L -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044681" FT VARIANT 111 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044682" FT VARIANT 112 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044683" FT VARIANT 112 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1423803759)" FT /id="VAR_044684" FT VARIANT 113 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005863" FT VARIANT 113 FT /note="F -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045788" FT VARIANT 113 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044685" FT VARIANT 113 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044686" FT VARIANT 113 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044687" FT VARIANT 113 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs587781642)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033033" FT VARIANT 115 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044688" FT VARIANT 116 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044689" FT VARIANT 116 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044690" FT VARIANT 116 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044691" FT VARIANT 117 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs755238756)" FT /id="VAR_044692" FT VARIANT 117 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526518)" FT /id="VAR_044693" FT VARIANT 118 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044694" FT VARIANT 118 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794141)" FT /id="VAR_044695" FT VARIANT 118 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044696" FT VARIANT 119 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044697" FT VARIANT 119 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044698" FT VARIANT 120 FT /note="K -> E (in sporadic cancers; somatic mutation; FT abolished acetylation; impaired ability to induce FT proapoptotic program; mimics lactylation, leading to FT decreased ability to undergo liquid-liquid phase separation FT and activate the transcription factor activity; FT dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:38653238" FT /id="VAR_044699" FT VARIANT 120 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044700" FT VARIANT 120 FT /note="K -> Q (in a sporadic cancer; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044701" FT VARIANT 120 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044702" FT VARIANT 121 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044703" FT VARIANT 122 FT /note="V -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044704" FT VARIANT 123 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526486)" FT /id="VAR_044705" FT VARIANT 123 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044706" FT VARIANT 124 FT /note="C -> G (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044707" FT VARIANT 124 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044708" FT VARIANT 124 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044709" FT VARIANT 124 FT /note="C -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_044710" FT VARIANT 124 FT /note="C -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044711" FT VARIANT 125 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044712" FT VARIANT 125 FT /note="T -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044713" FT VARIANT 125 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_005864" FT VARIANT 125 FT /note="T -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057520003)" FT /id="VAR_044714" FT VARIANT 125 FT /note="T -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044715" FT VARIANT 126 FT /note="Y -> C (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526335)" FT /id="VAR_044716" FT VARIANT 126 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005865" FT VARIANT 126 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044717" FT VARIANT 126 FT /note="Y -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045789" FT VARIANT 126 FT /note="Y -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044718" FT VARIANT 126 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005866" FT VARIANT 126 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044719" FT VARIANT 127 FT /note="S -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_044720" FT VARIANT 127 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_005867" FT VARIANT 127 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044721" FT VARIANT 127 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044722" FT VARIANT 127 FT /note="S -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044723" FT VARIANT 128 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044724" FT VARIANT 128 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044725" FT VARIANT 128 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044726" FT VARIANT 128 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005868" FT VARIANT 129 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005869" FT VARIANT 129 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044727" FT VARIANT 129 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1438095083)" FT /id="VAR_044728" FT VARIANT 129 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs137852792)" FT /id="VAR_044729" FT VARIANT 130 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044730" FT VARIANT 130 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044731" FT VARIANT 130 FT /note="L -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044732" FT VARIANT 130 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691013)" FT /id="VAR_044733" FT VARIANT 130 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005870" FT VARIANT 130 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044734" FT VARIANT 131 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044735" FT VARIANT 131 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044736" FT VARIANT 131 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691037)" FT /id="VAR_044737" FT VARIANT 131 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs769270327)" FT /id="VAR_005872" FT VARIANT 131 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005871" FT VARIANT 131 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044738" FT VARIANT 131 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs587782160)" FT /id="VAR_044739" FT VARIANT 132..133 FT /note="KM -> NL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047159" FT VARIANT 132 FT /note="K -> E (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs747342068)" FT /id="VAR_044740" FT VARIANT 132 FT /note="K -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045790" FT VARIANT 132 FT /note="K -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_005873" FT VARIANT 132 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs866775781)" FT /id="VAR_044741" FT VARIANT 132 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs747342068)" FT /evidence="ECO:0000269|PubMed:1694291" FT /id="VAR_005874" FT VARIANT 132 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044742" FT VARIANT 132 FT /note="K -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044743" FT VARIANT 132 FT /note="K -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045791" FT VARIANT 133 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795139)" FT /id="VAR_044744" FT VARIANT 133 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044745" FT VARIANT 133 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044746" FT VARIANT 133 FT /note="M -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044747" FT VARIANT 133 FT /note="M -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934873)" FT /evidence="ECO:0000269|PubMed:1933902" FT /id="VAR_005875" FT VARIANT 133 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057280220)" FT /id="VAR_044748" FT VARIANT 134 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs780442292)" FT /id="VAR_044749" FT VARIANT 134 FT /note="F -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044750" FT VARIANT 134 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs267605077)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036504" FT VARIANT 134 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044751" FT VARIANT 134 FT /note="F -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044752" FT VARIANT 135 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781991)" FT /id="VAR_005877" FT VARIANT 135 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044753" FT VARIANT 135 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044754" FT VARIANT 135 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_005876" FT VARIANT 135 FT /note="C -> T (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045792" FT VARIANT 135 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519976)" FT /id="VAR_044755" FT VARIANT 135 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)" FT /id="VAR_044756" FT VARIANT 136 FT /note="Q -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526268)" FT /id="VAR_005878" FT VARIANT 136 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs758781593)" FT /id="VAR_044757" FT VARIANT 136 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_005879" FT VARIANT 136 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044758" FT VARIANT 136 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044759" FT VARIANT 137 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044760" FT VARIANT 137 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044761" FT VARIANT 137 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005880" FT VARIANT 137 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044762" FT VARIANT 138 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044763" FT VARIANT 138 FT /note="A -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934875)" FT /id="VAR_005881" FT VARIANT 138 FT /note="A -> S (in LFS; germline mutation)" FT /id="VAR_044764" FT VARIANT 138 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044765" FT VARIANT 138 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs750600586)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:27657329" FT /id="VAR_033034" FT VARIANT 139 FT /note="K -> E (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs1212996409)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044766" FT VARIANT 139 FT /note="K -> N (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:38653238" FT /id="VAR_005882" FT VARIANT 139 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044767" FT VARIANT 139 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044768" FT VARIANT 139 FT /note="K -> T (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044769" FT VARIANT 140 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044770" FT VARIANT 140 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044771" FT VARIANT 140 FT /note="T -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs786202561)" FT /id="VAR_044772" FT VARIANT 140 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044773" FT VARIANT 140 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044774" FT VARIANT 141 FT /note="C -> A (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045793" FT VARIANT 141 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781288)" FT /id="VAR_005885" FT VARIANT 141 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_005884" FT VARIANT 141 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044775" FT VARIANT 141 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044776" FT VARIANT 141 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519977)" FT /id="VAR_044777" FT VARIANT 141 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587781288)" FT /id="VAR_005886" FT VARIANT 142 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044778" FT VARIANT 142 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045794" FT VARIANT 142 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044779" FT VARIANT 142 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs779196500)" FT /id="VAR_044780" FT VARIANT 142 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044781" FT VARIANT 142 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044782" FT VARIANT 142 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044783" FT VARIANT 143 FT /note="V -> A (in sporadic cancers; somatic mutation; FT strong DNA binding ability at 32.5 degrees Celsius; strong FT reduction of transcriptional activity at 37.5 degrees FT Celsius; severely represses interaction with ZNF385A)" FT /evidence="ECO:0000269|PubMed:17719541, FT ECO:0000269|PubMed:8013454" FT /id="VAR_005887" FT VARIANT 143 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044784" FT VARIANT 143 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526241)" FT /id="VAR_044785" FT VARIANT 143 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044786" FT VARIANT 143 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044787" FT VARIANT 144 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786201419)" FT /id="VAR_044788" FT VARIANT 144 FT /note="Q -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044789" FT VARIANT 144 FT /note="Q -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786203071)" FT /id="VAR_044790" FT VARIANT 144 FT /note="Q -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786203071)" FT /id="VAR_005888" FT VARIANT 144 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044791" FT VARIANT 145 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044792" FT VARIANT 145 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782197)" FT /id="VAR_005889" FT VARIANT 145 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005890" FT VARIANT 145 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044793" FT VARIANT 145 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044794" FT VARIANT 146 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044795" FT VARIANT 146 FT /note="W -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786203064)" FT /id="VAR_044796" FT VARIANT 146 FT /note="W -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044797" FT VARIANT 146 FT /note="W -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044798" FT VARIANT 146 FT /note="W -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044799" FT VARIANT 147 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044800" FT VARIANT 147 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005891" FT VARIANT 147 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044801" FT VARIANT 147 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044802" FT VARIANT 147 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1453167097)" FT /id="VAR_005892" FT VARIANT 147 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526226)" FT /id="VAR_044803" FT VARIANT 148 FT /note="D -> A (in a sporadic cancer; somatic mutation; FT dbSNP:rs1046611742)" FT /id="VAR_044804" FT VARIANT 148 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044805" FT VARIANT 148 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044806" FT VARIANT 148 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044807" FT VARIANT 148 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044808" FT VARIANT 148 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691007)" FT /id="VAR_044809" FT VARIANT 149 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526214)" FT /id="VAR_044810" FT VARIANT 149 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005893" FT VARIANT 149 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044811" FT VARIANT 150 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044812" FT VARIANT 150 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044813" FT VARIANT 150 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044814" FT VARIANT 150 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044815" FT VARIANT 150 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044816" FT VARIANT 150 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044817" FT VARIANT 151 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs28934874)" FT /id="VAR_005894" FT VARIANT 151 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044818" FT VARIANT 151 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044819" FT VARIANT 151 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044820" FT VARIANT 151 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005895" FT VARIANT 151 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /id="VAR_005896" FT VARIANT 152 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044821" FT VARIANT 152 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782705)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005897" FT VARIANT 152 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044822" FT VARIANT 152 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044823" FT VARIANT 152 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs767328513)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005898" FT VARIANT 152 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044824" FT VARIANT 153 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044825" FT VARIANT 153 FT /note="P -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045795" FT VARIANT 153 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044826" FT VARIANT 153 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044827" FT VARIANT 153 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044828" FT VARIANT 153 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795860)" FT /id="VAR_044829" FT VARIANT 153 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005899" FT VARIANT 154 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044830" FT VARIANT 154 FT /note="G -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044831" FT VARIANT 154 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs762846821)" FT /id="VAR_044832" FT VARIANT 154 FT /note="G -> I (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045796" FT VARIANT 154 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs137852789)" FT /id="VAR_044833" FT VARIANT 154 FT /note="G -> V (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs762846821)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005900" FT VARIANT 155 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs772683278)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005901" FT VARIANT 155 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044834" FT VARIANT 155 FT /note="T -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044835" FT VARIANT 155 FT /note="T -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786202752)" FT /id="VAR_044836" FT VARIANT 155 FT /note="T -> P (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:20385133" FT /id="VAR_044837" FT VARIANT 155 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786202752)" FT /id="VAR_044838" FT VARIANT 156 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs563378859)" FT /id="VAR_044839" FT VARIANT 156 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044840" FT VARIANT 156 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs371524413)" FT /id="VAR_044841" FT VARIANT 156 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044842" FT VARIANT 156 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005902" FT VARIANT 156 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044843" FT VARIANT 157 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691023)" FT /id="VAR_044844" FT VARIANT 157 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005903" FT VARIANT 157 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_005904" FT VARIANT 157 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044845" FT VARIANT 157 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012977" FT VARIANT 157 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044846" FT VARIANT 158 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780068)" FT /id="VAR_005905" FT VARIANT 158 FT /note="R -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045797" FT VARIANT 158 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005906" FT VARIANT 158 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782144)" FT /id="VAR_005907" FT VARIANT 158 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044847" FT VARIANT 158 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782144)" FT /id="VAR_044848" FT VARIANT 158 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044849" FT VARIANT 158 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044850" FT VARIANT 158 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045798" FT VARIANT 159 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044851" FT VARIANT 159 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882022)" FT /id="VAR_045799" FT VARIANT 159 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044852" FT VARIANT 159 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044853" FT VARIANT 159 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044854" FT VARIANT 159 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044855" FT VARIANT 159 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526131)" FT /id="VAR_044856" FT VARIANT 160..161 FT /note="MA -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047160" FT VARIANT 160..161 FT /note="MA -> IS (in sporadic cancers; somatic mutation)" FT /id="VAR_047161" FT VARIANT 160..161 FT /note="MA -> IT (in a sporadic cancer; somatic mutation)" FT /id="VAR_047162" FT VARIANT 160 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs772354334)" FT /id="VAR_005908" FT VARIANT 160 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044857" FT VARIANT 160 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044858" FT VARIANT 160 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs377274728)" FT /id="VAR_044859" FT VARIANT 161 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795691)" FT /id="VAR_044860" FT VARIANT 161 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045800" FT VARIANT 161 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044861" FT VARIANT 161 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044862" FT VARIANT 161 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005909" FT VARIANT 161 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs193920817)" FT /id="VAR_044863" FT VARIANT 161 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044864" FT VARIANT 162 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044865" FT VARIANT 162 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044866" FT VARIANT 162 FT /note="I -> N (in a breast cancer with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044867" FT VARIANT 162 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780069)" FT /id="VAR_005910" FT VARIANT 162 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044868" FT VARIANT 162 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_005911" FT VARIANT 163 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs148924904)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074" FT /id="VAR_033035" FT VARIANT 163 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044869" FT VARIANT 163 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044870" FT VARIANT 163 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005912" FT VARIANT 163 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044871" FT VARIANT 163 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044872" FT VARIANT 164 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs879254249)" FT /id="VAR_044873" FT VARIANT 164 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044874" FT VARIANT 164 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691034)" FT /id="VAR_005913" FT VARIANT 164 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005914" FT VARIANT 164 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044875" FT VARIANT 164 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044876" FT VARIANT 165 FT /note="Q -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044877" FT VARIANT 165 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044878" FT VARIANT 165 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_005915" FT VARIANT 165 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044879" FT VARIANT 165 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005916" FT VARIANT 166 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044880" FT VARIANT 166 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044881" FT VARIANT 166 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526101)" FT /id="VAR_005917" FT VARIANT 166 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044882" FT VARIANT 166 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044883" FT VARIANT 167..168 FT /note="QH -> HD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047163" FT VARIANT 167..168 FT /note="QH -> YL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047164" FT VARIANT 167 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044884" FT VARIANT 167 FT /note="Q -> K (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_044885" FT VARIANT 167 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044886" FT VARIANT 167 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044887" FT VARIANT 168..169 FT /note="HM -> LI (in a sporadic cancer; somatic mutation)" FT /id="VAR_047165" FT VARIANT 168 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044888" FT VARIANT 168 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044889" FT VARIANT 168 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044890" FT VARIANT 168 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044891" FT VARIANT 168 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044892" FT VARIANT 168 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs867114783)" FT /id="VAR_005918" FT VARIANT 168 FT /note="H -> V (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045801" FT VARIANT 168 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044893" FT VARIANT 169..170 FT /note="MT -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047166" FT VARIANT 169 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005919" FT VARIANT 169 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044894" FT VARIANT 169 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005920" FT VARIANT 169 FT /note="M -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044895" FT VARIANT 170 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587780729)" FT /id="VAR_044896" FT VARIANT 170 FT /note="T -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044897" FT VARIANT 170 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs779000871)" FT /id="VAR_005921" FT VARIANT 170 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044898" FT VARIANT 170 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005922" FT VARIANT 171 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044899" FT VARIANT 171 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044900" FT VARIANT 171 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044901" FT VARIANT 171 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587781845)" FT /id="VAR_044902" FT VARIANT 171 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044903" FT VARIANT 171 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044904" FT VARIANT 172 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_005923" FT VARIANT 172 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044905" FT VARIANT 172 FT /note="V -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1131691043)" FT /id="VAR_044906" FT VARIANT 172 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691021)" FT /id="VAR_044907" FT VARIANT 172 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044908" FT VARIANT 173 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044909" FT VARIANT 173 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_005924" FT VARIANT 173 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044910" FT VARIANT 173 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660754)" FT /id="VAR_005925" FT VARIANT 173 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876660754)" FT /id="VAR_005926" FT VARIANT 173 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045802" FT VARIANT 174 FT /note="R -> G (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs864622115)" FT /id="VAR_044911" FT VARIANT 174 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796681)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005927" FT VARIANT 174 FT /note="R -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044912" FT VARIANT 174 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044913" FT VARIANT 174 FT /note="R -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044914" FT VARIANT 174 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_044915" FT VARIANT 175 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs138729528)" FT /id="VAR_005928" FT VARIANT 175 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs138729528)" FT /id="VAR_005929" FT VARIANT 175 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; reduces interaction with ZNF385A; FT dbSNP:rs28934578)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473, FT ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920" FT /id="VAR_005932" FT VARIANT 175 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934578)" FT /id="VAR_005930" FT VARIANT 175 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17719541" FT /id="VAR_005931" FT VARIANT 175 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044916" FT VARIANT 175 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044917" FT VARIANT 176..177 FT /note="CP -> FS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047167" FT VARIANT 176 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005933" FT VARIANT 176 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044918" FT VARIANT 176 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044919" FT VARIANT 176 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs967461896)" FT /id="VAR_044920" FT VARIANT 176 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519980)" FT /id="VAR_005934" FT VARIANT 176 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /id="VAR_044921" FT VARIANT 177 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044922" FT VARIANT 177 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045803" FT VARIANT 177 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044923" FT VARIANT 177 FT /note="P -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045804" FT VARIANT 177 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /id="VAR_005935" FT VARIANT 177 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036505" FT VARIANT 177 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs147002414)" FT /id="VAR_044924" FT VARIANT 177 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044925" FT VARIANT 178..179 FT /note="HH -> QS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047168" FT VARIANT 178 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044926" FT VARIANT 178 FT /note="H -> HPHP (in a Burkitt lymphoma)" FT /evidence="ECO:0000269|PubMed:1303181" FT /id="VAR_005936" FT VARIANT 178 FT /note="H -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044927" FT VARIANT 178 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795203)" FT /id="VAR_044928" FT VARIANT 178 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526004)" FT /id="VAR_044929" FT VARIANT 178 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044930" FT VARIANT 178 FT /note="H -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044931" FT VARIANT 178 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044932" FT VARIANT 179 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044933" FT VARIANT 179 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044934" FT VARIANT 179 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044935" FT VARIANT 179 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044936" FT VARIANT 179 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs876660821)" FT /id="VAR_044937" FT VARIANT 179 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044938" FT VARIANT 179 FT /note="H -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780070)" FT /id="VAR_044939" FT VARIANT 180 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044940" FT VARIANT 180 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044941" FT VARIANT 180 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044942" FT VARIANT 180 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253911)" FT /id="VAR_044943" FT VARIANT 180 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044944" FT VARIANT 180 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044945" FT VARIANT 181 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782596)" FT /id="VAR_044946" FT VARIANT 181 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044947" FT VARIANT 181 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs397514495)" FT /id="VAR_044948" FT VARIANT 181 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs397514495)" FT /id="VAR_005937" FT VARIANT 181 FT /note="R -> P (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044949" FT VARIANT 181 FT /note="R -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782596)" FT /id="VAR_044950" FT VARIANT 182 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044951" FT VARIANT 182 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005938" FT VARIANT 182 FT /note="C -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044952" FT VARIANT 183 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525970)" FT /id="VAR_044953" FT VARIANT 183 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044954" FT VARIANT 184 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501209)" FT /id="VAR_044955" FT VARIANT 184 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044956" FT VARIANT 184 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs72661117)" FT /id="VAR_047169" FT VARIANT 184 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044957" FT VARIANT 184 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_005939" FT VARIANT 185 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044958" FT VARIANT 185 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044959" FT VARIANT 185 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044960" FT VARIANT 185 FT /note="S -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs150607408)" FT /id="VAR_044961" FT VARIANT 185 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044962" FT VARIANT 185 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044963" FT VARIANT 186 FT /note="D -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs375275361)" FT /id="VAR_044964" FT VARIANT 186 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044965" FT VARIANT 186 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044966" FT VARIANT 186 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501206)" FT /id="VAR_044967" FT VARIANT 186 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044968" FT VARIANT 186 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_005940" FT VARIANT 187 FT /note="G -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005941" FT VARIANT 187 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044969" FT VARIANT 187 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045805" FT VARIANT 187 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044970" FT VARIANT 187 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs776167460)" FT /id="VAR_005942" FT VARIANT 187 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044971" FT VARIANT 188 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1199893366)" FT /id="VAR_044972" FT VARIANT 188 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044973" FT VARIANT 189 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044974" FT VARIANT 189 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044975" FT VARIANT 189 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005943" FT VARIANT 189 FT /note="A -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525921)" FT /id="VAR_044976" FT VARIANT 189 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044977" FT VARIANT 189 FT /note="A -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912665)" FT /id="VAR_044978" FT VARIANT 190 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044979" FT VARIANT 190 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044980" FT VARIANT 190 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_005944" FT VARIANT 190 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_044981" FT VARIANT 190 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044982" FT VARIANT 190 FT /note="P -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876660254)" FT /id="VAR_044983" FT VARIANT 191 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044984" FT VARIANT 191 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044985" FT VARIANT 191 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044986" FT VARIANT 191 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs868590738)" FT /id="VAR_044987" FT VARIANT 191 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005945" FT VARIANT 192..193 FT /note="QH -> HN (in a sporadic cancer; somatic mutation)" FT /id="VAR_047170" FT VARIANT 192..193 FT /note="QH -> HY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047171" FT VARIANT 192 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044988" FT VARIANT 192 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044989" FT VARIANT 192 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044990" FT VARIANT 192 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044991" FT VARIANT 192 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs730882002)" FT /id="VAR_005946" FT VARIANT 193 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_005947" FT VARIANT 193 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044992" FT VARIANT 193 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044993" FT VARIANT 193 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044994" FT VARIANT 193 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044995" FT VARIANT 193 FT /note="H -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786201838)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005948" FT VARIANT 193 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044996" FT VARIANT 194 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587780071)" FT /id="VAR_044997" FT VARIANT 194 FT /note="L -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_044998" FT VARIANT 194 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044999" FT VARIANT 194 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_005949" FT VARIANT 194 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005950" FT VARIANT 194 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045000" FT VARIANT 195 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs942158624)" FT /id="VAR_045001" FT VARIANT 195 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047172" FT VARIANT 195 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045002" FT VARIANT 195 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045003" FT VARIANT 195 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005951" FT VARIANT 195 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045004" FT VARIANT 195 FT /note="I -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045806" FT VARIANT 196 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516435)" FT /id="VAR_045005" FT VARIANT 196 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045006" FT VARIANT 196 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352697)" FT /id="VAR_045007" FT VARIANT 196 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045008" FT VARIANT 196 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045009" FT VARIANT 197 FT /note="V -> E (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045010" FT VARIANT 197 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045011" FT VARIANT 197 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786204041)" FT /id="VAR_045012" FT VARIANT 197 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786204041)" FT /id="VAR_045013" FT VARIANT 198 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045014" FT VARIANT 198 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045015" FT VARIANT 198 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_005952" FT VARIANT 198 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045016" FT VARIANT 198 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045017" FT VARIANT 199 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045018" FT VARIANT 199 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045019" FT VARIANT 199 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045020" FT VARIANT 199 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525857)" FT /id="VAR_045021" FT VARIANT 200 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045022" FT VARIANT 200 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045023" FT VARIANT 200 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045024" FT VARIANT 200 FT /note="N -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045807" FT VARIANT 200 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045025" FT VARIANT 200 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045026" FT VARIANT 201..202 FT /note="LR -> FC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047173" FT VARIANT 201 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882024)" FT /id="VAR_045027" FT VARIANT 201 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045028" FT VARIANT 201 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045029" FT VARIANT 202 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045030" FT VARIANT 202 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045031" FT VARIANT 202 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045032" FT VARIANT 202 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045033" FT VARIANT 202 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045034" FT VARIANT 202 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045035" FT VARIANT 203..204 FT /note="VE -> LV (in a sporadic cancer; somatic mutation)" FT /id="VAR_047174" FT VARIANT 203 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045036" FT VARIANT 203 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045037" FT VARIANT 203 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045038" FT VARIANT 203 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882003)" FT /id="VAR_045039" FT VARIANT 203 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045808" FT VARIANT 204 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045040" FT VARIANT 204 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045041" FT VARIANT 204 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1260903787)" FT /id="VAR_045042" FT VARIANT 204 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045043" FT VARIANT 204 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045044" FT VARIANT 204 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045045" FT VARIANT 205 FT /note="Y -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_005953" FT VARIANT 205 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_005954" FT VARIANT 205 FT /note="Y -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_047175" FT VARIANT 205 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045046" FT VARIANT 205 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045047" FT VARIANT 205 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_045048" FT VARIANT 206 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045049" FT VARIANT 206 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045050" FT VARIANT 207..208 FT /note="DD -> EY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047176" FT VARIANT 207 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045051" FT VARIANT 207 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045052" FT VARIANT 207 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045053" FT VARIANT 207 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs923100890)" FT /id="VAR_045054" FT VARIANT 207 FT /note="D -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045055" FT VARIANT 207 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045056" FT VARIANT 208 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045057" FT VARIANT 208 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045058" FT VARIANT 208 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045059" FT VARIANT 208 FT /note="D -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045809" FT VARIANT 208 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045060" FT VARIANT 208 FT /note="D -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1464727668)" FT /id="VAR_045061" FT VARIANT 208 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045062" FT VARIANT 209 FT /note="R -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045063" FT VARIANT 209 FT /note="R -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045064" FT VARIANT 209 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045065" FT VARIANT 209 FT /note="R -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045066" FT VARIANT 210 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045067" FT VARIANT 210 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045068" FT VARIANT 210 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045069" FT VARIANT 210 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045070" FT VARIANT 210 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045071" FT VARIANT 210 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045072" FT VARIANT 210 FT /note="N -> Y (in a familial cancer not matching LFS; FT germline mutation; dbSNP:rs1060501200)" FT /id="VAR_045073" FT VARIANT 211 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501198)" FT /id="VAR_045074" FT VARIANT 211 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045075" FT VARIANT 211 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045076" FT VARIANT 211 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045077" FT VARIANT 211 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045078" FT VARIANT 212 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795766)" FT /id="VAR_045079" FT VARIANT 212 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045080" FT VARIANT 212 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045081" FT VARIANT 212 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045082" FT VARIANT 212 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045083" FT VARIANT 213 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516436)" FT /id="VAR_045084" FT VARIANT 213 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778720)" FT /id="VAR_045085" FT VARIANT 213 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036506" FT VARIANT 213 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /id="VAR_005955" FT VARIANT 213 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045086" FT VARIANT 214 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045087" FT VARIANT 214 FT /note="H -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045088" FT VARIANT 214 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs587781386)" FT /id="VAR_047177" FT VARIANT 214 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045089" FT VARIANT 214 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045090" FT VARIANT 215 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045091" FT VARIANT 215 FT /note="S -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs886039484)" FT /id="VAR_045092" FT VARIANT 215 FT /note="S -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045093" FT VARIANT 215 FT /note="S -> K (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045810" FT VARIANT 215 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045094" FT VARIANT 215 FT /note="S -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520001)" FT /id="VAR_045095" FT VARIANT 215 FT /note="S -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045096" FT VARIANT 216 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045097" FT VARIANT 216 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045098" FT VARIANT 216 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045099" FT VARIANT 216 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /id="VAR_045100" FT VARIANT 216 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005956" FT VARIANT 216 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045811" FT VARIANT 217 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045101" FT VARIANT 217 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045102" FT VARIANT 217 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045103" FT VARIANT 217 FT /note="V -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045104" FT VARIANT 217 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045105" FT VARIANT 217 FT /note="V -> M (in dbSNP:rs35163653)" FT /id="VAR_047178" FT VARIANT 218 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045106" FT VARIANT 218 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045107" FT VARIANT 218 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525743)" FT /id="VAR_045108" FT VARIANT 218 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045109" FT VARIANT 218 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs878854072)" FT /id="VAR_045110" FT VARIANT 219 FT /note="P -> C (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045812" FT VARIANT 219 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045111" FT VARIANT 219 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1420675064)" FT /id="VAR_045112" FT VARIANT 219 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045113" FT VARIANT 219 FT /note="P -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs879253894)" FT /id="VAR_045114" FT VARIANT 219 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045115" FT VARIANT 220 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912666)" FT /evidence="ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005957" FT VARIANT 220 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045116" FT VARIANT 220 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045117" FT VARIANT 220 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_005958" FT VARIANT 220 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045118" FT VARIANT 220 FT /note="Y -> S (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912666)" FT /id="VAR_005959" FT VARIANT 221 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045119" FT VARIANT 221 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045120" FT VARIANT 221 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045121" FT VARIANT 221 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201592)" FT /id="VAR_045122" FT VARIANT 221 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045123" FT VARIANT 222 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045124" FT VARIANT 222 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs146340390)" FT /id="VAR_045125" FT VARIANT 222 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045126" FT VARIANT 222 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045127" FT VARIANT 222 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501203)" FT /id="VAR_045128" FT VARIANT 222 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045129" FT VARIANT 223 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047179" FT VARIANT 223 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045130" FT VARIANT 223 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045131" FT VARIANT 223 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045132" FT VARIANT 223 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045133" FT VARIANT 223 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045134" FT VARIANT 224 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs267605076)" FT /id="VAR_045135" FT VARIANT 224 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045136" FT VARIANT 224 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525707)" FT /id="VAR_045137" FT VARIANT 224 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045138" FT VARIANT 225 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045139" FT VARIANT 225 FT /note="V -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045140" FT VARIANT 225 FT /note="V -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045141" FT VARIANT 225 FT /note="V -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045142" FT VARIANT 225 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045143" FT VARIANT 225 FT /note="V -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs746504075)" FT /id="VAR_045144" FT VARIANT 226 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045145" FT VARIANT 226 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047180" FT VARIANT 226 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045844" FT VARIANT 226 FT /note="G -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045146" FT VARIANT 226 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs970212462)" FT /id="VAR_045147" FT VARIANT 227 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045148" FT VARIANT 227 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045149" FT VARIANT 227 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045150" FT VARIANT 227 FT /note="S -> T (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045151" FT VARIANT 228 FT /note="D -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045152" FT VARIANT 228 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_005960" FT VARIANT 228 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045153" FT VARIANT 228 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045154" FT VARIANT 228 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045155" FT VARIANT 228 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045845" FT VARIANT 228 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045156" FT VARIANT 228 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045157" FT VARIANT 229 FT /note="C -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045158" FT VARIANT 229 FT /note="C -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045846" FT VARIANT 229 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794312)" FT /id="VAR_045159" FT VARIANT 229 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045160" FT VARIANT 229 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793603)" FT /id="VAR_045161" FT VARIANT 230 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045162" FT VARIANT 230 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005961" FT VARIANT 230 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045163" FT VARIANT 230 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045164" FT VARIANT 230 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045165" FT VARIANT 231 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045166" FT VARIANT 231 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525564)" FT /id="VAR_045167" FT VARIANT 231 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045168" FT VARIANT 231 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045169" FT VARIANT 232 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045170" FT VARIANT 232 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525562)" FT /id="VAR_045171" FT VARIANT 232 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045172" FT VARIANT 232 FT /note="I -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_045173" FT VARIANT 232 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587781589)" FT /id="VAR_005962" FT VARIANT 232 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045174" FT VARIANT 233 FT /note="H -> D (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045175" FT VARIANT 233 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045176" FT VARIANT 233 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045177" FT VARIANT 233 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045178" FT VARIANT 233 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs879254233)" FT /id="VAR_047181" FT VARIANT 233 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045179" FT VARIANT 234 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780073)" FT /id="VAR_005963" FT VARIANT 234 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045180" FT VARIANT 234 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045181" FT VARIANT 234 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_005964" FT VARIANT 234 FT /note="Y -> K (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045847" FT VARIANT 234 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045182" FT VARIANT 234 FT /note="Y -> Q (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045848" FT VARIANT 234 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780073)" FT /id="VAR_045183" FT VARIANT 235 FT /note="N -> D (in an adrenocortical carcinoma with no FT family history; germline mutation and in sporadic cancers; FT somatic mutation)" FT /id="VAR_047182" FT VARIANT 235 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045184" FT VARIANT 235 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs144340710)" FT /id="VAR_045185" FT VARIANT 235 FT /note="N -> M (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045849" FT VARIANT 235 FT /note="N -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs144340710)" FT /id="VAR_045186" FT VARIANT 235 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045187" FT VARIANT 235 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786204145)" FT /id="VAR_045188" FT VARIANT 236 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882026)" FT /id="VAR_045189" FT VARIANT 236 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045190" FT VARIANT 236 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045191" FT VARIANT 236 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045192" FT VARIANT 236 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045193" FT VARIANT 236 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882026)" FT /id="VAR_045194" FT VARIANT 237 FT /note="M -> I (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782664)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_005965" FT VARIANT 237 FT /note="M -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045195" FT VARIANT 237 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045196" FT VARIANT 237 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045197" FT VARIANT 237 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045198" FT VARIANT 237 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs730882004)" FT /id="VAR_045199" FT VARIANT 238 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882005)" FT /id="VAR_005966" FT VARIANT 238 FT /note="C -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519981)" FT /id="VAR_045200" FT VARIANT 238 FT /note="C -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045850" FT VARIANT 238 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519981)" FT /id="VAR_045201" FT VARIANT 238 FT /note="C -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882005)" FT /id="VAR_045202" FT VARIANT 238 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs193920789)" FT /id="VAR_045203" FT VARIANT 238 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882005)" FT /id="VAR_005967" FT VARIANT 239 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876660807)" FT /id="VAR_045204" FT VARIANT 239 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045205" FT VARIANT 239 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045206" FT VARIANT 239 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1057522275)" FT /id="VAR_045207" FT VARIANT 239 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045208" FT VARIANT 239 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045209" FT VARIANT 239 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045210" FT VARIANT 240 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045211" FT VARIANT 240 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045212" FT VARIANT 240 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_005968" FT VARIANT 240 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045213" FT VARIANT 240 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045214" FT VARIANT 240 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045215" FT VARIANT 240 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045216" FT VARIANT 241 FT /note="S -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033036" FT VARIANT 241 FT /note="S -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045217" FT VARIANT 241 FT /note="S -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934573)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1699228" FT /id="VAR_005969" FT VARIANT 241 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /id="VAR_045218" FT VARIANT 241 FT /note="S -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_047183" FT VARIANT 241 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045219" FT VARIANT 242 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:16959974" FT /id="VAR_005970" FT VARIANT 242 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519982)" FT /id="VAR_045220" FT VARIANT 242 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045221" FT VARIANT 242 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /id="VAR_045222" FT VARIANT 242 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs375874539)" FT /id="VAR_045223" FT VARIANT 242 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912655)" FT /id="VAR_045224" FT VARIANT 243..244 FT /note="MG -> IC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047184" FT VARIANT 243..244 FT /note="MG -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047185" FT VARIANT 243 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045225" FT VARIANT 243 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045226" FT VARIANT 243 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045227" FT VARIANT 243 FT /note="M -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045228" FT VARIANT 243 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882006)" FT /id="VAR_045229" FT VARIANT 243 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045230" FT VARIANT 244 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs985033810)" FT /id="VAR_047186" FT VARIANT 244 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045231" FT VARIANT 244 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057517983)" FT /id="VAR_045232" FT VARIANT 244 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045233" FT VARIANT 244 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045234" FT VARIANT 244 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045235" FT VARIANT 244 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs985033810)" FT /id="VAR_045236" FT VARIANT 245 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs121912656)" FT /id="VAR_005971" FT VARIANT 245 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1978757" FT /id="VAR_005972" FT VARIANT 245 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2259385" FT /id="VAR_005973" FT VARIANT 245 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045237" FT VARIANT 245 FT /note="G -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045851" FT VARIANT 245 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045852" FT VARIANT 245 FT /note="G -> L (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045853" FT VARIANT 245 FT /note="G -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045854" FT VARIANT 245 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934575)" FT /id="VAR_045238" FT VARIANT 245 FT /note="G -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_005974" FT VARIANT 245 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005975" FT VARIANT 246 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1019340046)" FT /id="VAR_045239" FT VARIANT 246 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045240" FT VARIANT 246 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352695)" FT /id="VAR_044020" FT VARIANT 246 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005976" FT VARIANT 246 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005977" FT VARIANT 246 FT /note="M -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352695)" FT /id="VAR_005978" FT VARIANT 247..248 FT /note="NR -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047187" FT VARIANT 247..248 FT /note="NR -> KW (in sporadic cancers; somatic mutation)" FT /id="VAR_047188" FT VARIANT 247 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1452189221)" FT /id="VAR_045241" FT VARIANT 247 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045855" FT VARIANT 247 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_005980" FT VARIANT 247 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045242" FT VARIANT 247 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_045243" FT VARIANT 247 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_047189" FT VARIANT 247 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045244" FT VARIANT 248 FT /note="R -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045245" FT VARIANT 248 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs121912651)" FT /id="VAR_005981" FT VARIANT 248 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:7682763" FT /id="VAR_005982" FT VARIANT 248 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /id="VAR_045246" FT VARIANT 248 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005983" FT VARIANT 248 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912651)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:8829627" FT /id="VAR_005984" FT VARIANT 249..250 FT /note="RP -> SA (in a sporadic cancer; somatic mutation)" FT /id="VAR_047190" FT VARIANT 249..250 FT /note="RP -> SS (in sporadic cancers; somatic mutation)" FT /id="VAR_047191" FT VARIANT 249 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_005985" FT VARIANT 249 FT /note="R -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045247" FT VARIANT 249 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045248" FT VARIANT 249 FT /note="R -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033037" FT VARIANT 249 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045856" FT VARIANT 249 FT /note="R -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation; dbSNP:rs28934571)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133" FT /id="VAR_005986" FT VARIANT 249 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045249" FT VARIANT 249 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_045250" FT VARIANT 250 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045251" FT VARIANT 250 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045857" FT VARIANT 250 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045252" FT VARIANT 250 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794311)" FT /id="VAR_047192" FT VARIANT 250 FT /note="P -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045858" FT VARIANT 250 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045253" FT VARIANT 250 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045254" FT VARIANT 250 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045255" FT VARIANT 251 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045256" FT VARIANT 251 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882007)" FT /id="VAR_045257" FT VARIANT 251 FT /note="I -> M (in LFS; germline mutation; FT dbSNP:rs878854074)" FT /id="VAR_045258" FT VARIANT 251 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_005987" FT VARIANT 251 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882027)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033038" FT VARIANT 251 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045259" FT VARIANT 251 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045260" FT VARIANT 252 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045261" FT VARIANT 252 FT /note="L -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045262" FT VARIANT 252 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045263" FT VARIANT 252 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912653)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005988" FT VARIANT 252 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045264" FT VARIANT 253 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045265" FT VARIANT 253 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045266" FT VARIANT 253 FT /note="T -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525465)" FT /id="VAR_045267" FT VARIANT 253 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_047193" FT VARIANT 253 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045268" FT VARIANT 254 FT /note="I -> D (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045859" FT VARIANT 254 FT /note="I -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045269" FT VARIANT 254 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045270" FT VARIANT 254 FT /note="I -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045271" FT VARIANT 254 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_017908" FT VARIANT 254 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1330865474)" FT /id="VAR_045272" FT VARIANT 254 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_017909" FT VARIANT 254 FT /note="I -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs746601313)" FT /id="VAR_045273" FT VARIANT 255 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519995)" FT /id="VAR_045274" FT VARIANT 255 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045275" FT VARIANT 255 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045276" FT VARIANT 255 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045277" FT VARIANT 255 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045278" FT VARIANT 255 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045279" FT VARIANT 256 FT /note="T -> I (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045280" FT VARIANT 256 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045281" FT VARIANT 256 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045282" FT VARIANT 256 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045283" FT VARIANT 257 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005989" FT VARIANT 257 FT /note="L -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934577)" FT /id="VAR_045284" FT VARIANT 257 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934577)" FT /id="VAR_045285" FT VARIANT 257 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045286" FT VARIANT 258 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045287" FT VARIANT 258 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005990" FT VARIANT 258 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501201)" FT /id="VAR_045288" FT VARIANT 258 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912652)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005991" FT VARIANT 258 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045860" FT VARIANT 258 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045289" FT VARIANT 258 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045290" FT VARIANT 259 FT /note="D -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047194" FT VARIANT 259 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045291" FT VARIANT 259 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs745425759)" FT /id="VAR_045292" FT VARIANT 259 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045293" FT VARIANT 259 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045294" FT VARIANT 259 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045861" FT VARIANT 259 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045862" FT VARIANT 259 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045295" FT VARIANT 259 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033039" FT VARIANT 260 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045296" FT VARIANT 260 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045297" FT VARIANT 260 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045298" FT VARIANT 260 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045299" FT VARIANT 260 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045300" FT VARIANT 260 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658916)" FT /id="VAR_045301" FT VARIANT 261 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045302" FT VARIANT 261 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045303" FT VARIANT 261 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045304" FT VARIANT 261 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045305" FT VARIANT 261 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045306" FT VARIANT 262..263 FT /note="GN -> PD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047195" FT VARIANT 262 FT /note="G -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045307" FT VARIANT 262 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047196" FT VARIANT 262 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045863" FT VARIANT 262 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045308" FT VARIANT 262 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691025)" FT /evidence="ECO:0000269|Ref.23" FT /id="VAR_045309" FT VARIANT 263 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs72661119)" FT /id="VAR_045310" FT VARIANT 263 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045311" FT VARIANT 263 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045312" FT VARIANT 263 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045313" FT VARIANT 263 FT /note="N -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045314" FT VARIANT 264 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045315" FT VARIANT 264 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525353)" FT /id="VAR_045316" FT VARIANT 264 FT /note="L -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045317" FT VARIANT 264 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045318" FT VARIANT 264 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045319" FT VARIANT 265 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045320" FT VARIANT 265 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253942)" FT /id="VAR_045321" FT VARIANT 265 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045322" FT VARIANT 265 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_047197" FT VARIANT 266 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045323" FT VARIANT 266 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045324" FT VARIANT 266 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519990)" FT /id="VAR_045325" FT VARIANT 266 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045326" FT VARIANT 267 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045327" FT VARIANT 267 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045328" FT VARIANT 267 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587780075)" FT /id="VAR_045329" FT VARIANT 267 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780075)" FT /id="VAR_045330" FT VARIANT 267 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs55832599)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036507" FT VARIANT 268 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045864" FT VARIANT 268 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045331" FT VARIANT 268 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045332" FT VARIANT 268 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045333" FT VARIANT 268 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045334" FT VARIANT 268 FT /note="N -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045335" FT VARIANT 269 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045336" FT VARIANT 269 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045337" FT VARIANT 269 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_047198" FT VARIANT 269 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045338" FT VARIANT 269 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045339" FT VARIANT 269 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045340" FT VARIANT 270 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045341" FT VARIANT 270 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045342" FT VARIANT 270 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519987)" FT /id="VAR_045343" FT VARIANT 270 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045344" FT VARIANT 270 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045345" FT VARIANT 270 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045346" FT VARIANT 271 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045347" FT VARIANT 271 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045348" FT VARIANT 271 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045349" FT VARIANT 271 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501191)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036508" FT VARIANT 271 FT /note="E -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045865" FT VARIANT 271 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045350" FT VARIANT 271 FT /note="E -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045866" FT VARIANT 271 FT /note="E -> V (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_047199" FT VARIANT 272 FT /note="V -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045351" FT VARIANT 272 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045352" FT VARIANT 272 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045353" FT VARIANT 272 FT /note="V -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912657)" FT /evidence="ECO:0000269|PubMed:1737852" FT /id="VAR_005992" FT VARIANT 272 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs121912657)" FT /id="VAR_045354" FT VARIANT 273 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121913343)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005993" FT VARIANT 273 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005994" FT VARIANT 273 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; abolishes sequence-specific DNA FT binding; does not induce SNAI1 degradation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14" FT /id="VAR_005995" FT VARIANT 273 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036509" FT VARIANT 273 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045867" FT VARIANT 273 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_045355" FT VARIANT 273 FT /note="R -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045356" FT VARIANT 273 FT /note="R -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121913343)" FT /id="VAR_045357" FT VARIANT 273 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045868" FT VARIANT 274 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045358" FT VARIANT 274 FT /note="V -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045359" FT VARIANT 274 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_005997" FT VARIANT 274 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_047200" FT VARIANT 274 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045360" FT VARIANT 274 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_045361" FT VARIANT 275 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045362" FT VARIANT 275 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045363" FT VARIANT 275 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519983)" FT /id="VAR_045364" FT VARIANT 275 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045365" FT VARIANT 275 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525279)" FT /id="VAR_005999" FT VARIANT 275 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs863224451)" FT /evidence="ECO:0000269|PubMed:7887414" FT /id="VAR_005998" FT VARIANT 276 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045366" FT VARIANT 276 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045367" FT VARIANT 276 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691029)" FT /id="VAR_045368" FT VARIANT 276 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045369" FT VARIANT 276 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045370" FT VARIANT 276 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045371" FT VARIANT 277 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs763098116)" FT /id="VAR_045372" FT VARIANT 277 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_006000" FT VARIANT 277 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_045373" FT VARIANT 277 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045374" FT VARIANT 277 FT /note="C -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_047201" FT VARIANT 277 FT /note="C -> Y (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs763098116)" FT /id="VAR_045375" FT VARIANT 278 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_006001" FT VARIANT 278 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045869" FT VARIANT 278 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_006002" FT VARIANT 278 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876659802)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_006003" FT VARIANT 278 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_045376" FT VARIANT 278 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901" FT /id="VAR_006004" FT VARIANT 278 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /id="VAR_006005" FT VARIANT 279 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793881)" FT /id="VAR_006006" FT VARIANT 279 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525248)" FT /id="VAR_045377" FT VARIANT 279 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045378" FT VARIANT 279 FT /note="G -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045379" FT VARIANT 280 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs753660142)" FT /id="VAR_045380" FT VARIANT 280 FT /note="R -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006008" FT VARIANT 280 FT /note="R -> K (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; no effect on interaction with CCAR2; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:25732823" FT /id="VAR_006007" FT VARIANT 280 FT /note="R -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045381" FT VARIANT 280 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045382" FT VARIANT 280 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1631151" FT /id="VAR_006009" FT VARIANT 281..282 FT /note="DR -> EW (in sporadic cancers; somatic mutation)" FT /id="VAR_047203" FT VARIANT 281 FT /note="D -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587781525)" FT /id="VAR_006010" FT VARIANT 281 FT /note="D -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519984)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_006011" FT VARIANT 281 FT /note="D -> G (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006012" FT VARIANT 281 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006013" FT VARIANT 281 FT /note="D -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs764146326)" FT /id="VAR_047202" FT VARIANT 281 FT /note="D -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045870" FT VARIANT 281 FT /note="D -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006014" FT VARIANT 281 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /id="VAR_045383" FT VARIANT 282 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934574)" FT /id="VAR_045384" FT VARIANT 282 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045385" FT VARIANT 282 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_006015" FT VARIANT 282 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_045386" FT VARIANT 282 FT /note="R -> Q (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882008)" FT /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22" FT /id="VAR_045387" FT VARIANT 282 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; dbSNP:rs28934574)" FT /evidence="ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:8829627" FT /id="VAR_006016" FT VARIANT 283 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs149633775)" FT /id="VAR_006017" FT VARIANT 283 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_006018" FT VARIANT 283 FT /note="R -> H (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs371409680)" FT /id="VAR_006019" FT VARIANT 283 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045388" FT VARIANT 283 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_006020" FT VARIANT 283 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs149633775)" FT /id="VAR_045389" FT VARIANT 284 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:20959462" FT /id="VAR_006021" FT VARIANT 284 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs863224685)" FT /id="VAR_045390" FT VARIANT 284 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045391" FT VARIANT 284 FT /note="T -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1204379654)" FT /id="VAR_006022" FT VARIANT 285 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045392" FT VARIANT 285 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045393" FT VARIANT 285 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045394" FT VARIANT 285 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs112431538)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:1694291" FT /id="VAR_006023" FT VARIANT 285 FT /note="E -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_006024" FT VARIANT 285 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs121912667)" FT /id="VAR_006025" FT VARIANT 286 FT /note="E -> A (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519985)" FT /id="VAR_006026" FT VARIANT 286 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_006027" FT VARIANT 286 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_006028" FT VARIANT 286 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:11023613, FT ECO:0000269|PubMed:8316628" FT /id="VAR_006029" FT VARIANT 286 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045871" FT VARIANT 286 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_006030" FT VARIANT 286 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_045395" FT VARIANT 287 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047204" FT VARIANT 287 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs748891343)" FT /id="VAR_045396" FT VARIANT 287 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045397" FT VARIANT 287 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782006)" FT /id="VAR_045398" FT VARIANT 287 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045399" FT VARIANT 288 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045400" FT VARIANT 288 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045401" FT VARIANT 288 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045402" FT VARIANT 288 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045403" FT VARIANT 288 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045404" FT VARIANT 289 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045405" FT VARIANT 289 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045406" FT VARIANT 289 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045407" FT VARIANT 289 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045408" FT VARIANT 289 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525154)" FT /id="VAR_045409" FT VARIANT 290 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs770374782)" FT /id="VAR_045410" FT VARIANT 290 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs55819519)" FT /id="VAR_045411" FT VARIANT 290 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_045412" FT VARIANT 291 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525126)" FT /id="VAR_045413" FT VARIANT 291 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045414" FT VARIANT 291 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs372613518)" FT /id="VAR_045415" FT VARIANT 291 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_047205" FT VARIANT 291 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs781490101)" FT /id="VAR_045416" FT VARIANT 291 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045417" FT VARIANT 292 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045418" FT VARIANT 292 FT /note="K -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045872" FT VARIANT 292 FT /note="K -> I (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs121912663)" FT /evidence="ECO:0000269|PubMed:10484981" FT /id="VAR_015819" FT VARIANT 292 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045419" FT VARIANT 292 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045420" FT VARIANT 292 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs121912663)" FT /id="VAR_045421" FT VARIANT 292 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045422" FT VARIANT 293 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045423" FT VARIANT 293 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780076)" FT /id="VAR_045424" FT VARIANT 293 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045425" FT VARIANT 293 FT /note="G -> W (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587780076)" FT /id="VAR_045426" FT VARIANT 294 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045427" FT VARIANT 294 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1305324490)" FT /id="VAR_045428" FT VARIANT 294 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045429" FT VARIANT 294 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_047206" FT VARIANT 294 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045430" FT VARIANT 294 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045431" FT VARIANT 295 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045432" FT VARIANT 295 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045433" FT VARIANT 295 FT /note="P -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045434" FT VARIANT 295 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691006)" FT /id="VAR_045435" FT VARIANT 296 FT /note="H -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045873" FT VARIANT 296 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045436" FT VARIANT 296 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_047207" FT VARIANT 296 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045437" FT VARIANT 296 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_006031" FT VARIANT 296 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045438" FT VARIANT 296 FT /note="H -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs483352696)" FT /id="VAR_045439" FT VARIANT 296 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs672601296)" FT /id="VAR_045440" FT VARIANT 297 FT /note="H -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045441" FT VARIANT 297 FT /note="H -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045442" FT VARIANT 297 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045443" FT VARIANT 297 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659477)" FT /id="VAR_045444" FT VARIANT 297 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045445" FT VARIANT 298 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045446" FT VARIANT 298 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045447" FT VARIANT 298 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045448" FT VARIANT 298 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045449" FT VARIANT 298 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045450" FT VARIANT 299 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045451" FT VARIANT 299 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045452" FT VARIANT 299 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045453" FT VARIANT 299 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045454" FT VARIANT 300 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045455" FT VARIANT 300 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs909643864)" FT /id="VAR_045456" FT VARIANT 300 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_006032" FT VARIANT 300 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045457" FT VARIANT 301 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045458" FT VARIANT 301 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525067)" FT /id="VAR_006033" FT VARIANT 301 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045459" FT VARIANT 301 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045460" FT VARIANT 301 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_047208" FT VARIANT 302 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045461" FT VARIANT 302 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501202)" FT /id="VAR_006034" FT VARIANT 302 FT /note="G -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs863224686)" FT /id="VAR_045462" FT VARIANT 302 FT /note="G -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_006035" FT VARIANT 303 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045463" FT VARIANT 303 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045464" FT VARIANT 303 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658714)" FT /id="VAR_045465" FT VARIANT 303 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045466" FT VARIANT 304 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587782654)" FT /id="VAR_045467" FT VARIANT 304 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045468" FT VARIANT 304 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045469" FT VARIANT 304 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_047209" FT VARIANT 305 FT /note="K -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045470" FT VARIANT 305 FT /note="K -> M (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045471" FT VARIANT 305 FT /note="K -> N (in sporadic cancers; somatic mutation; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:10551826" FT /id="VAR_045472" FT VARIANT 305 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045473" FT VARIANT 305 FT /note="K -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045474" FT VARIANT 306 FT /note="R -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045475" FT VARIANT 306 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1048095040)" FT /id="VAR_006036" FT VARIANT 307 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045476" FT VARIANT 307 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045477" FT VARIANT 307 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_006037" FT VARIANT 308 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045478" FT VARIANT 308 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045479" FT VARIANT 309 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045480" FT VARIANT 309 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1555525012)" FT /evidence="ECO:0000269|Ref.14" FT /id="VAR_006038" FT VARIANT 310 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045481" FT VARIANT 310 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045482" FT VARIANT 311 FT /note="N -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525007)" FT /id="VAR_045483" FT VARIANT 311 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045484" FT VARIANT 311 FT /note="N -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045485" FT VARIANT 311 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045486" FT VARIANT 312 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045487" FT VARIANT 312 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs145151284)" FT /id="VAR_045488" FT VARIANT 313 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045489" FT VARIANT 313 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045490" FT VARIANT 313 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045491" FT VARIANT 313 FT /note="S -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs1367492395)" FT /id="VAR_045492" FT VARIANT 314 FT /note="S -> F (in a sporadic cancer; somatic mutation; FT dbSNP:rs751440465)" FT /id="VAR_045493" FT VARIANT 315 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045494" FT VARIANT 315 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045495" FT VARIANT 315 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045496" FT VARIANT 316 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524979)" FT /id="VAR_045497" FT VARIANT 316 FT /note="P -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs772773208)" FT /id="VAR_045498" FT VARIANT 317 FT /note="Q -> H (in a kidney cancer with no family history; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs1060501199)" FT /id="VAR_045499" FT VARIANT 317 FT /note="Q -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs764735889)" FT /id="VAR_045500" FT VARIANT 317 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047210" FT VARIANT 317 FT /note="Q -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045501" FT VARIANT 317 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1159579789)" FT /id="VAR_045502" FT VARIANT 318 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555524975)" FT /id="VAR_045503" FT VARIANT 319 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045504" FT VARIANT 319 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045505" FT VARIANT 319 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045506" FT VARIANT 320 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045507" FT VARIANT 321 FT /note="K -> E (in kidney cancer; germline mutation)" FT /id="VAR_045508" FT VARIANT 321 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045509" FT VARIANT 322 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045510" FT VARIANT 322 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045511" FT VARIANT 323 FT /note="L -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045874" FT VARIANT 323 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045512" FT VARIANT 323 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045513" FT VARIANT 323 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045514" FT VARIANT 323 FT /note="L -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1432281680)" FT /id="VAR_047211" FT VARIANT 324 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045515" FT VARIANT 324 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045875" FT VARIANT 324 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045516" FT VARIANT 325 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045517" FT VARIANT 325 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045518" FT VARIANT 325 FT /note="G -> V (in LFS; germline mutation; FT dbSNP:rs121912659)" FT /evidence="ECO:0000269|PubMed:1565144" FT /id="VAR_006039" FT VARIANT 326 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045519" FT VARIANT 327 FT /note="Y -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045520" FT VARIANT 327 FT /note="Y -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045521" FT VARIANT 328 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045522" FT VARIANT 328 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045523" FT VARIANT 328 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045524" FT VARIANT 329 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs969930693)" FT /id="VAR_045525" FT VARIANT 329 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045526" FT VARIANT 330 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045527" FT VARIANT 330 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_047212" FT VARIANT 330 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045528" FT VARIANT 331 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11575996)" FT /id="VAR_045529" FT VARIANT 331 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045530" FT VARIANT 331 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795056)" FT /id="VAR_045531" FT VARIANT 332 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045532" FT VARIANT 334 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_006040" FT VARIANT 334 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs730882028)" FT /id="VAR_045533" FT VARIANT 335 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045534" FT VARIANT 335 FT /note="R -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs771939956)" FT /id="VAR_045535" FT VARIANT 335 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045536" FT VARIANT 337 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs587782529)" FT /evidence="ECO:0000269|PubMed:36108750, FT ECO:0000269|PubMed:9452042" FT /id="VAR_006041" FT VARIANT 337 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:11481490, FT ECO:0000269|PubMed:36108750" FT /id="VAR_035016" FT VARIANT 337 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs121912664)" FT /id="VAR_045537" FT VARIANT 337 FT /note="R -> P (in sporadic cancers; somatic mutation; FT impaired ability to tetramerize and undergo liquid-liquid FT phase separation; dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045538" FT VARIANT 338 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045539" FT VARIANT 338 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs150293825)" FT /id="VAR_045540" FT VARIANT 339 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022316" FT VARIANT 339 FT /note="E -> Q (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /id="VAR_045541" FT VARIANT 341 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045542" FT VARIANT 342 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045543" FT VARIANT 342 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_045544" FT VARIANT 342 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_047213" FT VARIANT 343 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045545" FT VARIANT 344 FT /note="L -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912662)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045546" FT VARIANT 344 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045547" FT VARIANT 346 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045548" FT VARIANT 347 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045549" FT VARIANT 347 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045550" FT VARIANT 348 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045551" FT VARIANT 348 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045552" FT VARIANT 349 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045553" FT VARIANT 352 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045554" FT VARIANT 353 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045555" FT VARIANT 354 FT /note="Q -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045556" FT VARIANT 354 FT /note="Q -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs755394212)" FT /id="VAR_045557" FT VARIANT 354 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs752142489)" FT /id="VAR_047214" FT VARIANT 356 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045558" FT VARIANT 356 FT /note="G -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_045559" FT VARIANT 358 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045560" FT VARIANT 358 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782237)" FT /id="VAR_045561" FT VARIANT 360 FT /note="G -> A (in dbSNP:rs35993958)" FT /id="VAR_045562" FT VARIANT 360 FT /note="G -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs35993958)" FT /id="VAR_045563" FT VARIANT 363 FT /note="R -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs876660285)" FT /id="VAR_045564" FT VARIANT 364 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045565" FT VARIANT 364 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045566" FT VARIANT 364 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045567" FT VARIANT 365 FT /note="H -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_047215" FT VARIANT 365 FT /note="H -> Y (in a familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs267605075)" FT /id="VAR_045568" FT VARIANT 366 FT /note="S -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs17881470)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022317" FT VARIANT 370 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045569" FT VARIANT 376 FT /note="S -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045570" FT VARIANT 376 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045571" FT VARIANT 379 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs863224682)" FT /id="VAR_045572" FT VARIANT 385 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524094)" FT /id="VAR_045573" FT VARIANT 389 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs587783064)" FT /id="VAR_045574" FT VARIANT 392 FT /note="S -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045575" FT MUTAGEN 15 FT /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND FT PPP2R1A." FT /evidence="ECO:0000269|PubMed:17967874" FT MUTAGEN 18 FT /note="T->A: No effect on interaction with MDM2 and FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->A: Abolishes phosphorylation site. Abolishes FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->D: Constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 22..23 FT /note="LW->QS: Loss of interaction with MDM2, leading to FT constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 24 FT /note="K->R: Abolishes ubiquitination by MUL1." FT /evidence="ECO:0000269|PubMed:21597459" FT MUTAGEN 37 FT /note="S->D: Abolishes phosphorylation by MAPKAPK5." FT /evidence="ECO:0000269|PubMed:17254968" FT MUTAGEN 46 FT /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2 FT and acetylation of K-382 by CREBBP." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 46 FT /note="Missing: Alters interaction with WWOX." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 55 FT /note="T->A: Blocks phosphorylation by TAF1." FT /evidence="ECO:0000269|PubMed:15053879" FT MUTAGEN 183 FT /note="S->A: Abolishes strongly phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 183 FT /note="S->E: Inhibits slightly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 248 FT /note="R->S: Does not induce SNAI1 degradation." FT /evidence="ECO:0000269|PubMed:20385133" FT MUTAGEN 269 FT /note="S->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 269 FT /note="S->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 284 FT /note="T->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 291..292 FT /note="KK->RR: Abolishes polyubiquitination by MKRN1." FT /evidence="ECO:0000269|PubMed:19536131" FT MUTAGEN 319 FT /note="K->A: Loss of nuclear localization; when associated FT with A-320 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 320 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 321 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-320." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 333..337 FT /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced FT nuclear localization. Decreased binding to promoters of FT target genes. Reduced transcriptional activity. Decrease in FT cell cycle arrest." FT /evidence="ECO:0000269|PubMed:19011621" FT MUTAGEN 359 FT /note="P->D: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 361 FT /note="G->E: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 362 FT /note="S->A: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 370 FT /note="K->R: Induces a decrease in methylation by SMYD2." FT /evidence="ECO:0000269|PubMed:17108971" FT MUTAGEN 372 FT /note="K->R: Induces a decrease in protein stabilization." FT /evidence="ECO:0000269|PubMed:15525938" FT MUTAGEN 373 FT /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2." FT /evidence="ECO:0000269|PubMed:20118233" FT MUTAGEN 381 FT /note="K->Q: Mimics acetylation, leading to increased FT stability." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 381 FT /note="K->R: Decreased acetylation." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 382 FT /note="K->A: Abolishes acetylation by CREBBP." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 382 FT /note="K->R: Abolishes monomethylation by KMT5A." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 383 FT /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin FT A." FT /evidence="ECO:0000269|PubMed:10884347" FT MUTAGEN 385 FT /note="F->A: Reduced SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11124955" FT MUTAGEN 386 FT /note="K->A: Abolishes SUMO1 conjugation, in vitro and in FT vivo." FT /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37" FT MUTAGEN 387 FT /note="T->A: No effect SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 388 FT /note="E->A: Abolishes SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 392 FT /note="S->D: Mimics phosphorylation; promotes ability to FT undergo liquid-liquid phase separation." FT /evidence="ECO:0000269|PubMed:35618207" FT MUTAGEN 392 FT /note="S->E: Abolished ability to undergo liquid-liquid FT phase separation." FT /evidence="ECO:0000269|PubMed:31953488" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:5HOU" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:5HOU" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:9C5S" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:5HPD" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:2L14" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 41..44 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 47..55 FT /evidence="ECO:0007829|PDB:2B3G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:7B49" FT TURN 105..108 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:3Q05" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:3Q05" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 128..131 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 132..135 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 141..146 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:5UN8" FT STRAND 156..165 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 177..180 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:4KVP" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:6GGC" FT STRAND 194..199 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 225..227 FT /evidence="ECO:0007829|PDB:2FEJ" FT STRAND 228..236 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:3D07" FT TURN 243..248 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 251..258 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:2ADY" FT STRAND 264..274 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:4HJE" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:3Q01" FT STRAND 327..334 FT /evidence="ECO:0007829|PDB:3Q01" FT HELIX 335..354 FT /evidence="ECO:0007829|PDB:1AIE" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:1YC5" SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64; MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD // ID PGFRB_HUMAN Reviewed; 1106 AA. AC P09619; B5A957; Q8N5L4; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1989, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=Platelet-derived growth factor receptor beta; DE Short=PDGF-R-beta; DE Short=PDGFR-beta; DE EC=2.7.10.1; DE AltName: Full=Beta platelet-derived growth factor receptor; DE AltName: Full=Beta-type platelet-derived growth factor receptor; DE AltName: Full=CD140 antigen-like family member B; DE AltName: Full=Platelet-derived growth factor receptor 1; DE Short=PDGFR-1; DE AltName: CD_antigen=CD140b; DE Flags: Precursor; GN Name=PDGFRB; Synonyms=PDGFR, PDGFR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PDGFB. RX PubMed=2835772; DOI=10.1073/pnas.85.10.3435; RA Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J., RA Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.; RT "Cloning and expression of a cDNA coding for the human platelet-derived RT growth factor receptor: evidence for more than one receptor class."; RL Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, GLYCOSYLATION, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH PDGFA AND PDGFB. RX PubMed=2850496; DOI=10.1128/mcb.8.8.3476-3486.1988; RA Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B., RA Oestman A., Betsholtz C., Heldin C.-H.; RT "cDNA cloning and expression of a human platelet-derived growth factor RT (PDGF) receptor specific for B-chain-containing PDGF molecules."; RL Mol. Cell. Biol. 8:3476-3486(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PHE-180. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569. RX PubMed=9285559; DOI=10.1038/sj.onc.1201267; RA Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P., Goustin A.S.; RT "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I- RT infected T-cells results in a novel tyrosine kinase product with RT transforming activity."; RL Oncogene 15:1051-1057(1997). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 559-1106 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CEP85L. RX PubMed=21938754; DOI=10.1002/gcc.20930; RA Chmielecki J., Peifer M., Viale A., Hutchinson K., Giltnane J., Socci N.D., RA Hollis C.J., Dean R.S., Yenamandra A., Jagasia M., Kim A.S., Dave U.P., RA Thomas R.K., Pao W.; RT "Systematic screen for tyrosine kinase rearrangements identifies a novel RT C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated RT myeloproliferative neoplasm."; RL Genes Chromosomes Cancer 51:54-65(2012). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106. RX PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3; RA Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.; RT "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes."; RL Cell 55:655-661(1988). RN [9] RP PROTEIN SEQUENCE OF 33-47. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [10] RP PHOSPHORYLATION AT TYR-751 AND TYR-857. RX PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2; RA Kazlauskas A., Cooper J.A.; RT "Autophosphorylation of the PDGF receptor in the kinase insert region RT regulates interactions with cell proteins."; RL Cell 58:1121-1133(1989). RN [11] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS, AND RP SUBCELLULAR LOCATION. RX PubMed=2554309; DOI=10.1073/pnas.86.21.8314; RA Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S., LaRochelle W.J., RA Ruggiero M., Aaronson S.A.; RT "Independent expression of human alpha or beta platelet-derived growth RT factor receptor cDNAs in a naive hematopoietic cell leads to functional RT coupling with mitogenic and chemotactic signaling pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989). RN [12] RP FUNCTION IN CELL PROLIFERATION; ACTIVATION OF PLCG1 AND IN PHOSPHORYLATION RP OF PLCG1 AND RASA1/GAP, AND MUTAGENESIS OF TYR-751 AND TYR-857. RX PubMed=1653029; DOI=10.1091/mbc.2.6.413; RA Kazlauskas A., Durden D.L., Cooper J.A.; RT "Functions of the major tyrosine phosphorylation site of the PDGF receptor RT beta subunit."; RL Cell Regul. 2:413-425(1991). RN [13] RP INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR PDGFA RP AND PDGFB, AND PHOSPHORYLATION AT TYR-857 AND TYR-751. RX PubMed=1709159; DOI=10.1016/s0021-9258(18)31541-2; RA Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A., RA Bowen-Pope D.F., Cooper J.A., Kazlauskas A.; RT "Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit RT dimerization and intersubunit trans-phosphorylation."; RL J. Biol. Chem. 266:8987-8992(1991). RN [14] RP FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBCELLULAR LOCATION, CATALYTIC RP ACTIVITY, AND MUTAGENESIS OF LYS-634. RX PubMed=1846866; DOI=10.1083/jcb.112.3.469; RA Sorkin A., Westermark B., Heldin C.H., Claesson-Welsh L.; RT "Effect of receptor kinase inactivation on the rate of internalization and RT degradation of PDGF and the PDGF beta-receptor."; RL J. Cell Biol. 112:469-478(1991). RN [15] RP FUNCTION IN ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY, RP INTERACTION WITH PIK3R1 AND RASA1, PHOSPHORYLATION AT TYR-740; TYR-751; RP TYR-771 AND TYR-857, AND MUTAGENESIS OF LYS-634; TYR-716; TYR-740; TYR-751; RP TYR-763; TYR-771; TYR-775; TYR-778 AND TYR-857. RX PubMed=1314164; DOI=10.1002/j.1460-2075.1992.tb05182.x; RA Kashishian A., Kazlauskas A., Cooper J.A.; RT "Phosphorylation sites in the PDGF receptor with different specificities RT for binding GAP and PI3 kinase in vivo."; RL EMBO J. 11:1373-1382(1992). RN [16] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND PHOSPHORYLATION OF RP PLCG1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-1009 AND TYR-1021, RP AND MUTAGENESIS OF TYR-1009 AND TYR-1021. RX PubMed=1396585; DOI=10.1002/j.1460-2075.1992.tb05484.x; RA Ronnstrand L., Mori S., Arridsson A.K., Eriksson A., Wernstedt C., RA Hellman U., Claesson-Welsh L., Heldin C.H.; RT "Identification of two C-terminal autophosphorylation sites in the PDGF RT beta-receptor: involvement in the interaction with phospholipase C-gamma."; RL EMBO J. 11:3911-3919(1992). RN [17] RP UBIQUITINATION, AND DEGRADATION. RX PubMed=1313434; DOI=10.1016/s0021-9258(18)42714-7; RA Mori S., Heldin C.H., Claesson-Welsh L.; RT "Ligand-induced polyubiquitination of the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 267:6429-6434(1992). RN [18] RP INTERACTION WITH PIK3R1 AND RASA1, AND MUTAGENESIS OF TYR-740; TYR-751 AND RP TYR-771. RX PubMed=1375321; DOI=10.1128/mcb.12.6.2534-2544.1992; RA Kazlauskas A., Kashishian A., Cooper J.A., Valius M.; RT "GTPase-activating protein and phosphatidylinositol 3-kinase bind to RT distinct regions of the platelet-derived growth factor receptor beta RT subunit."; RL Mol. Cell. Biol. 12:2534-2544(1992). RN [19] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION, PHOSPHORYLATION AT RP TYR-579 AND TYR-581; INTERACTION WITH SRC, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF TYR-579 AND TYR-581. RX PubMed=7685273; DOI=10.1002/j.1460-2075.1993.tb05879.x; RA Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A., RA Claesson-Welsh L., Heldin C.H.; RT "Identification of two juxtamembrane autophosphorylation sites in the PDGF RT beta-receptor; involvement in the interaction with Src family tyrosine RT kinases."; RL EMBO J. 12:2257-2264(1993). RN [20] RP INTERACTION WITH DGFA AND PDGFB. RX PubMed=7679113; DOI=10.1016/s0021-9258(18)53739-x; RA Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L., RA LaRochelle W.J., Giese N.A.; RT "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding RT to alpha and beta PDGF receptor."; RL J. Biol. Chem. 268:3625-3631(1993). RN [21] RP FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PTPN11, INTERACTION WITH RP PTPN11; PIK3R1; PLCG1 AND RASA1, AND MUTAGENESIS OF TYR-1009. RX PubMed=7691811; DOI=10.1016/s0021-9258(20)80562-6; RA Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S., Cooper J.A., RA Shoelson S.E., Walsh C.T., Neel B.G.; RT "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by RT its binding site, phosphotyrosine 1009, on the human platelet-derived RT growth factor receptor."; RL J. Biol. Chem. 268:21478-21481(1993). RN [22] RP INTERACTION WITH NCK1 AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF NCK1, AND RP MUTAGENESIS OF TYR-751. RX PubMed=7692233; DOI=10.1128/mcb.13.11.6889-6896.1993; RA Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J., RA Schlessinger J.; RT "Two signaling molecules share a phosphotyrosine-containing binding site in RT the platelet-derived growth factor receptor."; RL Mol. Cell. Biol. 13:6889-6896(1993). RN [23] RP INTERACTION WITH SHB. RX PubMed=8302579; RA Welsh M., Mares J., Karlsson T., Lavergne C., Breant B., Claesson-Welsh L.; RT "Shb is a ubiquitously expressed Src homology 2 protein."; RL Oncogene 9:19-27(1994). RN [24] RP INTERACTION WITH GRB7. RX PubMed=8940081; DOI=10.1074/jbc.271.48.30942; RA Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.; RT "Grb7 is a downstream signaling component of platelet-derived growth factor RT alpha- and beta-receptors."; RL J. Biol. Chem. 271:30942-30949(1996). RN [25] RP CHROMOSOMAL TRANSLOCATION WITH TRIP11. RX PubMed=9373237; RA Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.; RT "Fusion of the platelet-derived growth factor receptor beta to a novel gene RT CEV14 in acute myelogenous leukemia after clonal evolution."; RL Blood 90:4271-4277(1997). RN [26] RP INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716; RP TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021. RX PubMed=10454568; DOI=10.1128/mcb.19.9.6217; RA Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A., RA Swamy O.R., Leone M.E., Riedel H.; RT "Grb10, a positive, stimulatory signaling adapter in platelet-derived RT growth factor BB-, insulin-like growth factor I-, and insulin-mediated RT mitogenesis."; RL Mol. Cell. Biol. 19:6217-6228(1999). RN [27] RP INTERACTION WITH SH2B2/APS. RX PubMed=9989826; DOI=10.1038/sj.onc.1202326; RA Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., RA Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.; RT "APS, an adaptor protein containing PH and SH2 domains, is associated with RT the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis."; RL Oncogene 18:759-767(1999). RN [28] RP PHOSPHORYLATION AT TYR-562; TYR-751; TYR-763; TYR-771; TYR-775; TYR-778; RP TYR-857; TYR-1009 AND TYR-1021, AND DEPHOSPHORYLATION AT TYR-751; TYR-857; RP TYR-1009 AND TYR-1021 BY PTPRJ. RX PubMed=10821867; DOI=10.1074/jbc.275.21.16219; RA Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E., RA Vilella R., Bohmer F., Ostman A.; RT "Site-selective dephosphorylation of the platelet-derived growth factor RT beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1."; RL J. Biol. Chem. 275:16219-16226(2000). RN [29] RP INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [30] RP FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC. RX PubMed=11297552; DOI=10.1074/jbc.m101056200; RA Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., RA Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., RA Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.; RT "Platelet-derived growth factor C (PDGF-C), a novel growth factor that RT binds to PDGF alpha and beta receptor."; RL J. Biol. Chem. 276:27406-27414(2001). RN [31] RP FUNCTION AS A RECEPTOR FOR PDGFD. RX PubMed=11331881; DOI=10.1038/35074588; RA Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H., RA Alitalo K., Eriksson U.; RT "PDGF-D is a specific, protease-activated ligand for the PDGF beta- RT receptor."; RL Nat. Cell Biol. 3:512-516(2001). RN [32] RP CHROMOSOMAL TRANSLOCATION WITH ETV6. RX PubMed=12181402; DOI=10.1056/nejmoa020150; RA Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., RA Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., RA Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E., RA Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.; RT "Response to imatinib mesylate in patients with chronic myeloproliferative RT diseases with rearrangements of the platelet-derived growth factor receptor RT beta."; RL N. Engl. J. Med. 347:481-487(2002). RN [33] RP CHROMOSOMAL TRANSLOCATION WITH PDE4DIP. RX PubMed=12907457; DOI=10.1182/blood-2003-04-1150; RA Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C., Shipp M.A., RA Aguiar R.C.T.; RT "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated RT with eosinophilia: involvement of PDGFRB and response to imatinib."; RL Blood 102:4187-4190(2003). RN [34] RP CHROMOSOMAL TRANSLOCATION WITH SPECC1. RX PubMed=15087372; DOI=10.1158/0008-5472.can-03-4026; RA Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C., Locatelli F., RA Maserati E., Pasquali F., Panarello C.; RT "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic RT leukemia with t(5;17)(q33;p11.2)."; RL Cancer Res. 64:2649-2651(2004). RN [35] RP CHROMOSOMAL TRANSLOCATION WITH TP53BP1, AND ACTIVITY REGULATION. RX PubMed=15492236; DOI=10.1158/0008-5472.can-04-2005; RA Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J., RA Chase A.J., Cross N.C.; RT "p53-Binding protein 1 is fused to the platelet-derived growth factor RT receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib- RT responsive eosinophilic myeloproliferative disorder."; RL Cancer Res. 64:7216-7219(2004). RN [36] RP PHOSPHORYLATION AT TYR-579; TYR-751; TYR-771 AND TYR-1021, AND RP DEPHOSPHORYLATION AT TYR-579 AND TYR-1021 BY PTPN2. RX PubMed=14966296; DOI=10.1128/mcb.24.5.2190-2201.2004; RA Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B., RA Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H., Roennstrand L., RA Ostman A., Hellberg C.; RT "Site-selective regulation of platelet-derived growth factor beta receptor RT tyrosine phosphorylation by T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 24:2190-2201(2004). RN [37] RP PHOSPHORYLATION AT TYR-579; TYR-581; TYR-716; TYR-740; TYR-771; TYR-857; RP TYR-1009 AND TYR-1021. RX PubMed=15902258; DOI=10.1038/nature03587; RA Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S., RA Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., Kang S.W.; RT "Regulation of PDGF signalling and vascular remodelling by peroxiredoxin RT II."; RL Nature 435:347-353(2005). RN [38] RP INTERACTION WITH CBL, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-1021, AND RP UBIQUITINATION. RX PubMed=17620338; DOI=10.1074/jbc.m701797200; RA Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J., RA Naramura M., Band V., Band H.; RT "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived RT growth factor receptor beta provides a dual mechanism of negative RT regulation."; RL J. Biol. Chem. 282:29336-29347(2007). RN [39] RP FUNCTION AS PDGFD RECEPTOR. RX PubMed=21098708; DOI=10.1158/0008-5472.can-10-0511; RA Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M., Abrams J., RA Kim H.R.; RT "A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate RT cancer."; RL Cancer Res. 70:9631-9640(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF CBL; STAM; PDCD6IP/ALIX; PLCG1 AND PTPN11, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-634 AND TYR-857. RX PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004; RA Wardega P., Heldin C.H., Lennartsson J.; RT "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell RT proliferation but not migration."; RL Cell. Signal. 22:1363-1368(2010). RN [41] RP FUNCTION. RX PubMed=20529858; DOI=10.1074/jbc.m110.102566; RA Mendelson K., Swendeman S., Saftig P., Blobel C.P.; RT "Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) RT activates ADAM17 and promotes metalloproteinase-dependent cross-talk RT between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling RT pathways."; RL J. Biol. Chem. 285:25024-25032(2010). RN [42] RP FUNCTION IN SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION. RX PubMed=21733313; DOI=10.1017/s0007114511002571; RA Kim H.J., Cha B.Y., Choi B., Lim J.S., Woo J.T., Kim J.S.; RT "Glyceollins inhibit platelet-derived growth factor-mediated human arterial RT smooth muscle cell proliferation and migration."; RL Br. J. Nutr. 107:24-35(2012). RN [43] RP INTERACTION WITH SHC1 AND GRB2, AND FUNCTION IN PHOSPHORYLATION OF SHC1. RX PubMed=8195171; DOI=10.1016/s0021-9258(17)36611-5; RA Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H., RA Claesson-Welsh L.; RT "Direct interaction between Shc and the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 269:15337-15343(1994). RN [44] RP FUNCTION IN SMOOTH MUSCLE CELL MIGRATION AND NEOINTIMA FORMATION AFTER RP BLOOD VESSEL INJURY, AND MUTAGENESIS OF TYR-740; TYR-751 AND TYR-1021. RX PubMed=21679854; DOI=10.1016/j.jacc.2011.02.037; RA Caglayan E., Vantler M., Leppanen O., Gerhardt F., Mustafov L., RA Ten Freyhaus H., Kappert K., Odenthal M., Zimmermann W.H., Tallquist M.D., RA Rosenkranz S.; RT "Disruption of platelet-derived growth factor-dependent RT phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity abolishes RT vascular smooth muscle cell proliferation and migration and attenuates RT neointima formation in vivo."; RL J. Am. Coll. Cardiol. 57:2527-2538(2011). RN [45] RP INVOLVEMENT IN PENTT, VARIANT PENTT ALA-665, AND CHARACTERIZATION OF RP VARIANT PENTT ALA-665. RX PubMed=26279204; DOI=10.1016/j.ajhg.2015.07.009; RA Johnston J.J., Sanchez-Contreras M.Y., Keppler-Noreuil K.M., Sapp J., RA Crenshaw M., Finch N.A., Cormier-Daire V., Rademakers R., Sybert V.P., RA Biesecker L.G.; RT "A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome."; RL Am. J. Hum. Genet. 97:465-474(2015). RN [46] RP INVOLVEMENT IN KOGS, AND VARIANT KOGS ARG-584. RX PubMed=25454926; DOI=10.1016/j.jpeds.2014.10.015; RA Takenouchi T., Yamaguchi Y., Tanikawa A., Kosaki R., Okano H., Kosaki K.; RT "Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB RT mutation."; RL J. Pediatr. 166:483-486(2015). RN [47] RP CHARACTERIZATION OF VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND RP FUNCTION. RX PubMed=26599395; DOI=10.1371/journal.pone.0143407; RA Vanlandewijck M., Lebouvier T., Andaloussi Maee M., Nahar K., Hornemann S., RA Kenkel D., Cunha S.I., Lennartsson J., Boss A., Heldin C.H., Keller A., RA Betsholtz C.; RT "Functional characterization of germline mutations in PDGFB and PDGFRB in RT primary familial brain calcification."; RL PLoS ONE 10:E0143407-E0143407(2015). RN [48] RP REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION. RX PubMed=9739761; DOI=10.1016/s0304-419x(98)00015-8; RA Heldin C.H., Ostman A., Ronnstrand L.; RT "Signal transduction via platelet-derived growth factor receptors."; RL Biochim. Biophys. Acta 1378:F79-113(1998). RN [49] RP REVIEW. RX PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002; RA Ostman A.; RT "PDGF receptors-mediators of autocrine tumor growth and regulators of tumor RT vasculature and stroma."; RL Cytokine Growth Factor Rev. 15:275-286(2004). RN [50] RP REVIEW. RX PubMed=17419949; DOI=10.1016/s0065-230x(06)97011-0; RA Ostman A., Heldin C.H.; RT "PDGF receptors as targets in tumor treatment."; RL Adv. Cancer Res. 97:247-274(2007). RN [51] RP REVIEW ON FUNCTION; LIGANDS; ROLE IN DEVELOPMENT AND DISEASE AND ACTIVATION RP OF SIGNALING PATHWAYS. RX PubMed=18483217; DOI=10.1101/gad.1653708; RA Andrae J., Gallini R., Betsholtz C.; RT "Role of platelet-derived growth factors in physiology and medicine."; RL Genes Dev. 22:1276-1312(2008). RN [52] RP X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH PIK3R1, RP AND COMPARISON WITH NMR ANALYSIS. RX PubMed=11567151; DOI=10.1107/s0907444901012434; RA Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A., RA Rowsell S., Murshudov G.N.; RT "NMR trial models: experiences with the colicin immunity protein Im7 and RT the p85alpha C-terminal SH2-peptide complex."; RL Acta Crystallogr. D 57:1397-1404(2001). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH NHERF1, RP AND INTERACTION WITH NHERF1. RX PubMed=11882663; DOI=10.1074/jbc.m201507200; RA Karthikeyan S., Leung T., Ladias J.A.A.; RT "Structural determinants of the Na+/H+ exchanger regulatory factor RT interaction with the beta 2 adrenergic and platelet-derived growth factor RT receptors."; RL J. Biol. Chem. 277:18973-18978(2002). RN [54] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-314 IN COMPLEX WITH PDGFB, RP SUBUNIT, GLYCOSYLATION AT ASN-45; ASN-89; ASN-103; ASN-215; ASN-230; RP ASN-292 AND ASN-307, AND DISULFIDE BONDS. RX PubMed=20534510; DOI=10.1073/pnas.1000806107; RA Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.; RT "Structures of a platelet-derived growth factor/propeptide complex and a RT platelet-derived growth factor/receptor complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010). RN [55] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589; TYR-718 RP AND ILE-882. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [56] RP VARIANT IMF1 THR-660, AND INVOLVEMENT IN IMF1. RX PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024; RA Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O., RA Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E., RA Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D., Fournet J.C., RA Papp E., McPherson E.W., Zabel C., Vaksmann G., Morisot C., Keating B., RA Sleiman P.M., Cleveland J.A., Everman D.B., Zackai E., Hakonarson H.; RT "Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:1001-1007(2013). RN [57] RP VARIANT IMF1 CYS-561, AND INVOLVEMENT IN IMF1. RX PubMed=23731537; DOI=10.1016/j.ajhg.2013.04.026; RA Cheung Y.H., Gayden T., Campeau P.M., Leduc C.A., Russo D., Nguyen V.H., RA Guo J., Qi M., Guan Y., Albrecht S., Moroz B., Eldin K.W., Lu J.T., RA Schwartzentruber J., Malkin D., Berghuis A.M., Emil S., Gibbs R.A., RA Burk D.L., Vanstone M., Lee B.H., Orchard D., Boycott K.M., Chung W.K., RA Jabado N.; RT "A recurrent PDGFRB mutation causes familial infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:996-1000(2013). RN [58] RP VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND INVOLVEMENT IN IBGC4. RX PubMed=24065723; DOI=10.1093/brain/awt255; RG French IBGC Study Group; RA Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I., RA Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D., RA Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B., RA Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P., RA Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O., RA Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T., RA Campion D., Hannequin D.; RT "Phenotypic spectrum of probable and genetically-confirmed idiopathic basal RT ganglia calcification."; RL Brain 136:3395-3407(2013). RN [59] RP VARIANTS IBGC4 PRO-658 AND TRP-987, AND INVOLVEMENT IN IBGC4. RX PubMed=23255827; DOI=10.1212/wnl.0b013e31827ccf34; RA Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A., RA Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L., Augustin J., RA Martinaud O., Defebvre L., Krystkowiak P., Pariente J., Clanet M., RA Labauge P., Ayrignac X., Lefaucheur R., Le Ber I., Frebourg T., RA Hannequin D., Campion D.; RT "Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia RT calcification."; RL Neurology 80:181-187(2013). RN [60] RP VARIANT PENTT SER-666, CHARACTERIZATION OF VARIANT PENTT SER-666, AND RP INVOLVEMENT IN PENTT. RX PubMed=30573803; DOI=10.1038/s41431-018-0323-z; RA Bredrup C., Stokowy T., McGaughran J., Lee S., Sapkota D., Cristea I., RA Xu L., Tveit K.S., Hoevding G., Steen V.M., Roedahl E., Bruland O., RA Houge G.; RT "A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a RT progeria-like condition in the severe end of Penttinen syndrome."; RL Eur. J. Hum. Genet. 27:574-581(2019). RN [61] RP VARIANT OPDKD TYR-666, CHARACTERIZATION OF VARIANT OPDKD TYR-666, AND RP INVOLVEMENT IN OPDKD. RX PubMed=33450762; DOI=10.1093/hmg/ddab014; RA Bredrup C., Cristea I., Safieh L.A., Di Maria E., Gjertsen B.T., RA Tveit K.S., Thu F., Bull N., Edward D.P., Hennekam R.C.M., Hoevding G., RA Haugen O.H., Houge G., Roedahl E., Bruland O.; RT "Temperature-dependent autoactivation associated with clinical variability RT of PDGFRB Asn666 substitutions."; RL Hum. Mol. Genet. 30:72-77(2021). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA CC and PDGFB, and plays an essential role in the regulation of embryonic CC development, cell proliferation, survival, differentiation, chemotaxis CC and migration. Plays an essential role in blood vessel development by CC promoting proliferation, migration and recruitment of pericytes and CC smooth muscle cells to endothelial cells. Plays a role in the migration CC of vascular smooth muscle cells and the formation of neointima at CC vascular injury sites. Required for normal development of the CC cardiovascular system. Required for normal recruitment of pericytes CC (mesangial cells) in the kidney glomerulus, and for normal formation of CC a branched network of capillaries in kidney glomeruli. Promotes CC rearrangement of the actin cytoskeleton and the formation of membrane CC ruffles. Binding of its cognate ligands - homodimeric PDGFB, CC heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to CC the activation of several signaling cascades; the response depends on CC the nature of the bound ligand and is modulated by the formation of CC heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, CC PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the CC production of the cellular signaling molecules diacylglycerol and CC inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the CC activation of protein kinase C. Phosphorylation of PIK3R1, the CC regulatory subunit of phosphatidylinositol 3-kinase, leads to the CC activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or CC of the C-terminus of PTPN11, creates a binding site for GRB2, resulting CC in the activation of HRAS, RAF1 and down-stream MAP kinases, including CC MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation CC of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and CC STAM. Receptor signaling is down-regulated by protein phosphatases that CC dephosphorylate the receptor and its down-stream effectors, and by CC rapid internalization of the activated receptor. CC {ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11331881, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:1709159, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:20529858, ECO:0000269|PubMed:21098708, CC ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:21733313, CC ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:26599395, CC ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496, CC ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811, CC ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:7685273}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Binding of PDGFB and/or PDGFD leads to dimerization CC and activation by autophosphorylation on tyrosine residues. Inhibited CC by imatinib. {ECO:0000269|PubMed:15492236}. CC -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with CC heterodimers formed by PDGFA and PDGFB. May also interact with CC homodimeric PDGFC. Monomer in the absence of bound ligand. Interaction CC with homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or CC homodimeric PDGFD, leads to receptor dimerization, where both PDGFRA CC homodimers and heterodimers with PDGFRB are observed. Interacts with CC SH2B2/APS. Interacts directly (tyrosine phosphorylated) with SHB. CC Interacts (tyrosine phosphorylated) with PIK3R1 and RASA1. Interacts CC (tyrosine phosphorylated) with CBL. Interacts (tyrosine phosphorylated) CC with SRC and SRC family kinases. Interacts (tyrosine phosphorylated) CC with PIK3C2B, maybe indirectly. Interacts (tyrosine phosphorylated) CC with SHC1, GRB7, GRB10 and NCK1. Interaction with GRB2 is mediated by CC SHC1. Interacts (via C-terminus) with NHERF1. CC {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11567151, CC ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:1314164, CC ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17620338, CC ECO:0000269|PubMed:20534510, ECO:0000269|PubMed:2835772, CC ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7679113, CC ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233, CC ECO:0000269|PubMed:8195171, ECO:0000269|PubMed:8302579, CC ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9989826}. CC -!- INTERACTION: CC P09619; P05067: APP; NbExp=3; IntAct=EBI-641237, EBI-77613; CC P09619; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-641237, EBI-742887; CC P09619; P06241: FYN; NbExp=3; IntAct=EBI-641237, EBI-515315; CC P09619; Q14451: GRB7; NbExp=4; IntAct=EBI-641237, EBI-970191; CC P09619; P14778: IL1R1; NbExp=2; IntAct=EBI-641237, EBI-525905; CC P09619; P35968: KDR; NbExp=2; IntAct=EBI-641237, EBI-1005487; CC P09619; Q53G59: KLHL12; NbExp=6; IntAct=EBI-641237, EBI-740929; CC P09619; Q5T749: KPRP; NbExp=3; IntAct=EBI-641237, EBI-10981970; CC P09619; Q15323: KRT31; NbExp=3; IntAct=EBI-641237, EBI-948001; CC P09619; O76011: KRT34; NbExp=3; IntAct=EBI-641237, EBI-1047093; CC P09619; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-641237, EBI-10172052; CC P09619; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-641237, EBI-11953334; CC P09619; O94898: LRIG2; NbExp=3; IntAct=EBI-641237, EBI-2830372; CC P09619; O75581: LRP6; NbExp=3; IntAct=EBI-641237, EBI-910915; CC P09619; O14745: NHERF1; NbExp=5; IntAct=EBI-641237, EBI-349787; CC P09619; Q15599: NHERF2; NbExp=2; IntAct=EBI-641237, EBI-1149760; CC P09619; P01127: PDGFB; NbExp=16; IntAct=EBI-641237, EBI-1554925; CC P09619; P27986: PIK3R1; NbExp=21; IntAct=EBI-641237, EBI-79464; CC P09619; O00459: PIK3R2; NbExp=3; IntAct=EBI-641237, EBI-346930; CC P09619; P19174: PLCG1; NbExp=7; IntAct=EBI-641237, EBI-79387; CC P09619; P60484: PTEN; NbExp=3; IntAct=EBI-641237, EBI-696162; CC P09619; P18031: PTPN1; NbExp=3; IntAct=EBI-641237, EBI-968788; CC P09619; Q06124: PTPN11; NbExp=8; IntAct=EBI-641237, EBI-297779; CC P09619; Q05209: PTPN12; NbExp=3; IntAct=EBI-641237, EBI-2266035; CC P09619; P23470: PTPRG; NbExp=2; IntAct=EBI-641237, EBI-2258115; CC P09619; Q12913: PTPRJ; NbExp=4; IntAct=EBI-641237, EBI-2264500; CC P09619; P20936: RASA1; NbExp=3; IntAct=EBI-641237, EBI-1026476; CC P09619; Q13239: SLA; NbExp=4; IntAct=EBI-641237, EBI-726214; CC P09619; Q15654: TRIP6; NbExp=3; IntAct=EBI-641237, EBI-742327; CC P09619; P07947: YES1; NbExp=3; IntAct=EBI-641237, EBI-515331; CC P09619; P0CK45: E5; Xeno; NbExp=2; IntAct=EBI-641237, EBI-7015490; CC P09619; P35918: Kdr; Xeno; NbExp=4; IntAct=EBI-641237, EBI-1555005; CC P09619; Q28619: NHERF1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-7073613; CC P09619; P23727: PIK3R1; Xeno; NbExp=6; IntAct=EBI-641237, EBI-520244; CC P09619; P08487: PLCG1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-8013886; CC P09619; P41499: Ptpn11; Xeno; NbExp=4; IntAct=EBI-641237, EBI-7180604; CC P09619; P25020: V-SRC; Xeno; NbExp=4; IntAct=EBI-641237, EBI-8636140; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand CC binding, the autophosphorylated receptor is ubiquitinated and CC internalized, leading to its degradation. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P09619-1; Sequence=Displayed; CC Name=2; CC IsoId=P09619-2; Sequence=VSP_056008, VSP_056009; CC -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding. CC Autophosphorylation occurs in trans, i.e. one subunit of the dimeric CC receptor phosphorylates tyrosine residues on the other subunit. CC Phosphorylation at Tyr-579, and to a lesser degree, at Tyr-581, is CC important for interaction with SRC family kinases. Phosphorylation at CC Tyr-740 and Tyr-751 is important for interaction with PIK3R1. CC Phosphorylation at Tyr-751 is important for interaction with NCK1. CC Phosphorylation at Tyr-771 and Tyr-857 is important for interaction CC with RASA1/GAP. Phosphorylation at Tyr-857 is important for efficient CC phosphorylation of PLCG1 and PTPN11, resulting in increased CC phosphorylation of AKT1, MAPK1/ERK2 and/or MAPK3/ERK1, PDCD6IP/ALIX and CC STAM, and in increased cell proliferation. Phosphorylation at Tyr-1009 CC is important for interaction with PTPN11. Phosphorylation at Tyr-1009 CC and Tyr-1021 is important for interaction with PLCG1. Phosphorylation CC at Tyr-1021 is important for interaction with CBL; PLCG1 and CBL CC compete for the same binding site. Dephosphorylated by PTPRJ at Tyr- CC 751, Tyr-857, Tyr-1009 and Tyr-1021. Dephosphorylated by PTPN2 at Tyr- CC 579 and Tyr-1021. {ECO:0000269|PubMed:10821867, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:14966296, ECO:0000269|PubMed:15902258, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144, CC ECO:0000269|PubMed:7685273}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20534510, CC ECO:0000269|PubMed:2850496}. CC -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is CC polyubiquitinated, leading to its degradation. CC {ECO:0000269|PubMed:1313434, ECO:0000269|PubMed:17620338}. CC -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found in a CC form of chronic myelomonocytic leukemia (CMML). Translocation CC t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal CC myeloid proliferation and by progression to acute myelogenous leukemia CC (AML). CC -!- DISEASE: Myeloproliferative disorder chronic with eosinophilia (MPE) CC [MIM:131440]: A hematologic disorder characterized by malignant CC eosinophils proliferation. Note=The gene represented in this entry may CC be involved in disease pathogenesis. Chromosomal aberrations involving CC PDGFRB have been found in many instances of chronic myeloproliferative CC disorder with eosinophilia. Translocation t(5;12) with ETV6 on CC chromosome 12 creating an PDGFRB-ETV6 fusion protein (PubMed:12181402). CC Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 CC fusion protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that CC forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457). Translocation CC t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end of CEP85L (isoform CC 4) to the 3'-end of PDGFRB (PubMed:21938754). CC {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457, CC ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. A chromosomal aberration involving PDGFRB has been found CC in a patient with AML. Translocation t(5;14)(q33;q32) with TRIP11 CC (PubMed:9373237). {ECO:0000269|PubMed:9373237}. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The gene represented in this entry may be involved in CC disease pathogenesis. A chromosomal aberration involving PDGFRB has CC been found in a patient with JMML. Translocation t(5;17)(q33;p11.2) CC with SPECC1 (PubMed:15087372). {ECO:0000269|PubMed:15087372}. CC -!- DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4) CC [MIM:615007]: A form of basal ganglia calcification, an autosomal CC dominant condition characterized by symmetric calcification in the CC basal ganglia and other brain regions. Affected individuals can either CC be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, CC including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, CC seizures, and chronic headache. Serum levels of calcium, phosphate, CC alkaline phosphatase and parathyroid hormone are normal. The CC neuropathological hallmark of the disease is vascular and pericapillary CC calcification, mainly of calcium phosphate, in the affected brain CC areas. {ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, CC ECO:0000269|PubMed:26599395}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare CC mesenchymal disorder characterized by the development of benign tumors CC in the skin, striated muscles, bones, and, more rarely, visceral CC organs. Subcutaneous or soft tissue nodules commonly involve the skin CC of the head, neck, and trunk. Skeletal and muscular lesions occur in CC about half of the patients. Lesions may be solitary or multicentric, CC and they may be present at birth or become apparent in early infancy or CC occasionally in adult life. Visceral lesions are associated with high CC morbidity and mortality. {ECO:0000269|PubMed:23731537, CC ECO:0000269|PubMed:23731542}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Kosaki overgrowth syndrome (KOGS) [MIM:616592]: A syndrome CC characterized by somatic overgrowth, distinctive facial features, CC hyperelastic and fragile skin, and progressive neurologic deterioration CC with white matter lesions on brain imaging. CC {ECO:0000269|PubMed:25454926}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Premature aging syndrome, Penttinen type (PENTT) [MIM:601812]: CC An autosomal dominant syndrome characterized by a prematurely aged CC appearance with lipoatrophy, epidermal and dermal atrophy along with CC hypertrophic lesions that resemble scars, thin hair, proptosis, CC underdeveloped cheekbones, and marked acro-osteolysis. CC {ECO:0000269|PubMed:26279204, ECO:0000269|PubMed:30573803}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Ocular pterygium-digital keloid dysplasia syndrome (OPDKD) CC [MIM:621091]: An autosomal dominant disorder that presents in childhood CC with aggressive ingrowth of vascularized connective tissue on the CC cornea, ultimately leading to loss of vision. Later, affected CC individuals develop keloids on digits after minor trauma, but are CC otherwise healthy. {ECO:0000269|PubMed:33450762}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/21/PDGFRB"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J03278; AAA60049.1; -; mRNA. DR EMBL; M21616; AAA36427.1; -; mRNA. DR EMBL; EU826595; ACF47631.1; -; mRNA. DR EMBL; AC005895; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032224; AAH32224.1; -; mRNA. DR EMBL; U33172; AAC51675.1; -; Genomic_DNA. DR CCDS; CCDS4303.1; -. [P09619-1] DR PIR; A28206; PFHUGB. DR RefSeq; NP_002600.1; NM_002609.4. [P09619-1] DR PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106. DR PDB; 1H9O; X-ray; 1.79 A; B=751-755. DR PDB; 1SHA; X-ray; 1.50 A; B=751-755. DR PDB; 2IUI; X-ray; 2.40 A; C/D=748-758. DR PDB; 2L6W; NMR; -; A/B=526-563. DR PDB; 2PLD; NMR; -; B=1018-1029. DR PDB; 2PLE; NMR; -; B=1018-1029. DR PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314. DR PDBsum; 1GQ5; -. DR PDBsum; 1H9O; -. DR PDBsum; 1SHA; -. DR PDBsum; 2IUI; -. DR PDBsum; 2L6W; -. DR PDBsum; 2PLD; -. DR PDBsum; 2PLE; -. DR PDBsum; 3MJG; -. DR AlphaFoldDB; P09619; -. DR BMRB; P09619; -. DR EMDB; EMD-6426; -. DR SMR; P09619; -. DR BioGRID; 111185; 211. DR ComplexPortal; CPX-2882; PDGF receptor beta - PDGF-BB complex. DR ComplexPortal; CPX-2883; PDGF receptor alpha-beta - PDGF-BB complex. DR ComplexPortal; CPX-2886; PDGF receptor beta - PDGF-AB complex. DR ComplexPortal; CPX-2888; PDGF receptor alpha-beta - PDGF-CC complex. DR ComplexPortal; CPX-2889; PDGF receptor beta - PDGF-DD complex. DR ComplexPortal; CPX-2890; PDGF receptor alpha-beta - PDGF-DD complex. DR ComplexPortal; CPX-2891; PDGF receptor beta - PDGF-CC complex. DR ComplexPortal; CPX-2892; PDGF receptor alpha-beta - PDGF-AB complex. DR CORUM; P09619; -. DR DIP; DIP-558N; -. DR FunCoup; P09619; 1764. DR IntAct; P09619; 390. DR MINT; P09619; -. DR STRING; 9606.ENSP00000261799; -. DR BindingDB; P09619; -. DR ChEMBL; CHEMBL1913; -. DR DrugBank; DB00102; Becaplermin. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB17041; PD-173952. DR DrugBank; DB02567; PD173955. DR DrugBank; DB12978; Pexidartinib. DR DrugBank; DB09221; Polaprezinc. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB08009; SU-11652. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB13093; TAK-593. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB09283; Trapidil. DR DrugBank; DB05146; XL820. DR DrugBank; DB05014; XL999. DR DrugCentral; P09619; -. DR GuidetoPHARMACOLOGY; 1804; -. DR TCDB; 8.A.23.1.37; the basigin (basigin) family. DR GlyConnect; 1967; 4 N-Linked glycans (3 sites). DR GlyCosmos; P09619; 11 sites, 4 glycans. DR GlyGen; P09619; 13 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P09619; -. DR PhosphoSitePlus; P09619; -. DR BioMuta; PDGFRB; -. DR DMDM; 129890; -. DR CPTAC; CPTAC-1630; -. DR CPTAC; CPTAC-3063; -. DR jPOST; P09619; -. DR MassIVE; P09619; -. DR PaxDb; 9606-ENSP00000261799; -. DR PeptideAtlas; P09619; -. DR ProteomicsDB; 52253; -. [P09619-1] DR Pumba; P09619; -. DR ABCD; P09619; 7 sequenced antibodies. DR Antibodypedia; 3424; 2244 antibodies from 49 providers. DR DNASU; 5159; -. DR Ensembl; ENST00000261799.9; ENSP00000261799.4; ENSG00000113721.15. [P09619-1] DR GeneID; 5159; -. DR KEGG; hsa:5159; -. DR MANE-Select; ENST00000261799.9; ENSP00000261799.4; NM_002609.4; NP_002600.1. DR UCSC; uc003lro.4; human. [P09619-1] DR AGR; HGNC:8804; -. DR CIViC; 5159; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA33148; -. DR CTD; 5159; -. DR DisGeNET; 5159; -. DR GeneCards; PDGFRB; -. DR GeneReviews; PDGFRB; -. DR HGNC; HGNC:8804; PDGFRB. DR HPA; ENSG00000113721; Low tissue specificity. DR MalaCards; PDGFRB; -. DR MIM; 131440; phenotype. DR MIM; 173410; gene. DR MIM; 228550; phenotype. DR MIM; 601626; phenotype. DR MIM; 601812; phenotype. DR MIM; 607785; phenotype. DR MIM; 615007; phenotype. DR MIM; 616592; phenotype. DR MIM; 621091; phenotype. DR OpenTargets; ENSG00000113721; -. DR Orphanet; 363665; Acroosteolysis-keloid-like lesions-premature aging syndrome. DR Orphanet; 1980; Bilateral striopallidodentate calcinosis. DR Orphanet; 86830; Chronic myeloproliferative disease, unclassifiable. DR Orphanet; 2591; Infantile myofibromatosis. DR Orphanet; 477831; Kosaki overgrowth syndrome. DR Orphanet; 168950; Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement. DR Orphanet; 314950; Primary hypereosinophilic syndrome. DR VEuPathDB; HostDB:ENSG00000113721; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000157138; -. DR HOGENOM; CLU_000288_49_0_1; -. DR InParanoid; P09619; -. DR OMA; WPEDQEF; -. DR OrthoDB; 9936425at2759; -. DR PAN-GO; P09619; 10 GO annotations based on evolutionary models. DR PhylomeDB; P09619; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P09619; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-186797; Signaling by PDGF. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P09619; -. DR SIGNOR; P09619; -. DR Agora; ENSG00000113721; -. DR BioGRID-ORCS; 5159; 18 hits in 1194 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PDGFRB; human. DR EvolutionaryTrace; P09619; -. DR GeneWiki; PDGFRB; -. DR GenomeRNAi; 5159; -. DR Pharos; P09619; Tclin. DR PRO; PR:P09619; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P09619; protein. DR Bgee; ENSG00000113721; Expressed in stromal cell of endometrium and 182 other cell types or tissues. DR ExpressionAtlas; P09619; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0160185; F:phospholipase C activator activity; IMP:UniProtKB. DR GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc. DR GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; IDA:UniProtKB. DR GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB. DR GO; GO:0005017; F:platelet-derived growth factor receptor activity; TAS:ProtInc. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0060981; P:cell migration involved in coronary angiogenesis; ISS:UniProtKB. DR GO; GO:0035441; P:cell migration involved in vasculogenesis; ISS:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB. DR GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB. DR GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB. DR GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB. DR GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB. DR GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0014805; P:smooth muscle adaptation; NAS:BHF-UCL. DR GO; GO:0071670; P:smooth muscle cell chemotaxis; ISS:BHF-UCL. DR CDD; cd00096; Ig; 1. DR CDD; cd05859; Ig4_PDGFR; 1. DR CDD; cd05861; IgI_PDGFR-alphabeta; 1. DR CDD; cd05107; PTKc_PDGFR_beta; 1. DR FunFam; 3.30.200.20:FF:000025; Platelet-derived growth factor receptor alpha; 1. DR FunFam; 1.10.510.10:FF:000140; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000223; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000572; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000715; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000814; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000982; Platelet-derived growth factor receptor beta; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 5. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR027288; PGFRB. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR PANTHER; PTHR24416:SF53; PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF25305; Ig_PDGFR_d4; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF500948; Beta-PDGF_receptor; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR PRINTS; PR01832; VEGFRECEPTOR. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Chemotaxis; KW Chromosomal rearrangement; Cytoplasmic vesicle; Developmental protein; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Lysosome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..32 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 33..1106 FT /note="Platelet-derived growth factor receptor beta" FT /id="PRO_0000016757" FT TOPO_DOM 33..532 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 533..553 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 554..1106 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 33..120 FT /note="Ig-like C2-type 1" FT DOMAIN 129..210 FT /note="Ig-like C2-type 2" FT DOMAIN 214..309 FT /note="Ig-like C2-type 3" FT DOMAIN 331..403 FT /note="Ig-like C2-type 4" FT DOMAIN 416..524 FT /note="Ig-like C2-type 5" FT DOMAIN 600..962 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1019..1106 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1043..1060 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1066..1088 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 826 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 606..614 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 634 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 527..528 FT /note="Breakpoint for insertion to form PDE4DIP-PDGFRB FT fusion protein" FT SITE 527..528 FT /note="Breakpoint for translocation to form TRIP11-PDGFRB" FT SITE 558..559 FT /note="Breakpoint for translocation to form the CEP85L- FT PDGFRB fusion protein" FT MOD_RES 562 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 579 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258, ECO:0000269|PubMed:7685273" FT MOD_RES 581 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:7685273" FT MOD_RES 686 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 716 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258" FT MOD_RES 740 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:15902258" FT MOD_RES 751 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 763 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 771 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT MOD_RES 775 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 778 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 857 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 934 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 970 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 1009 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:15902258" FT MOD_RES 1021 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT CARBOHYD 45 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 89 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 103 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 215 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 230 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 292 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 307 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 354 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 371 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 479 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 54..100 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 149..190 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 235..291 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 436..508 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 311..336 FT /note="VESGYVRLLGEVGTLQFAELHRSRTL -> RAATCGSWERWAHYNLLSCIGA FT GHCR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056008" FT VAR_SEQ 337..1106 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056009" FT VARIANT 29 FT /note="I -> F (in dbSNP:rs17110944)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_034377" FT VARIANT 180 FT /note="S -> F (in dbSNP:rs17853027)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_035125" FT VARIANT 282 FT /note="E -> K (in dbSNP:rs34586048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042027" FT VARIANT 345 FT /note="P -> S (in dbSNP:rs2229558)" FT /id="VAR_049717" FT VARIANT 485 FT /note="E -> K (in dbSNP:rs41287110)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042028" FT VARIANT 561 FT /note="R -> C (in IMF1; dbSNP:rs367543286)" FT /evidence="ECO:0000269|PubMed:23731537" FT /id="VAR_069925" FT VARIANT 584 FT /note="P -> R (in KOGS; dbSNP:rs863224946)" FT /evidence="ECO:0000269|PubMed:25454926" FT /id="VAR_075865" FT VARIANT 589 FT /note="Y -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042029" FT VARIANT 658 FT /note="L -> P (in IBGC4; no effect on protein abundance; FT loss of PDGF beta receptor activity; dbSNP:rs397509381)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069320" FT VARIANT 660 FT /note="P -> T (in IMF1; dbSNP:rs144050370)" FT /evidence="ECO:0000269|PubMed:23731542" FT /id="VAR_069926" FT VARIANT 665 FT /note="V -> A (in PENTT; gain of function in protein FT tyrosine kinase activity; shows ligand-independent FT constitutive signaling; dbSNP:rs1554108211)" FT /evidence="ECO:0000269|PubMed:26279204" FT /id="VAR_075866" FT VARIANT 666 FT /note="N -> S (in PENTT; likely pathogenic; gain-of- FT function variant resulting in constitutive FT autophosphorylation and increased phosphorylation of FT downstream signaling proteins; levels of protein FT phosphorylation are similar at 32 and 37 degrees Celsius; FT dbSNP:rs2113894766)" FT /evidence="ECO:0000269|PubMed:30573803" FT /id="VAR_090402" FT VARIANT 666 FT /note="N -> Y (in OPDKD; likely pathogenic; gain-of- FT function variant resulting in temperature-dependent FT constitutive autophosphorylation and increased FT phosphorylation of downstream signaling proteins; levels of FT protein phosphorylation at 32 degrees Celsius are higher FT than at 37 degrees; dbSNP:rs797044887)" FT /evidence="ECO:0000269|PubMed:33450762" FT /id="VAR_090403" FT VARIANT 718 FT /note="N -> Y (in dbSNP:rs35322465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042030" FT VARIANT 882 FT /note="T -> I (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042031" FT VARIANT 987 FT /note="R -> W (in IBGC4; decreased protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway; dbSNP:rs397509382)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069321" FT VARIANT 1071 FT /note="E -> V (in IBGC4; no effect on protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway)" FT /evidence="ECO:0000269|PubMed:24065723, FT ECO:0000269|PubMed:26599395" FT /id="VAR_075395" FT MUTAGEN 579 FT /note="Y->F: Loss of kinase activity; when associated with FT F-581. Strongly reduces interaction with SRC family FT kinases. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 581 FT /note="Y->F: Loss of kinase activity; when associated with FT F-579. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 634 FT /note="K->A,R: Loss of kinase activity. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825" FT MUTAGEN 716 FT /note="Y->F: No effect neither on interaction with GRB10 FT and RASA1 nor on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164" FT MUTAGEN 740 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-751. Strongly FT decreases phosphatidylinositol 3-kinase activity. No effect FT on interaction with GRB10 and RASA1." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:21679854" FT MUTAGEN 751 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-740. Abolishes FT phosphatidylinositol 3-kinase activity and interaction with FT NCK1, and slightly reduces interaction with RASA1. No FT effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:21679854, FT ECO:0000269|PubMed:7692233" FT MUTAGEN 763 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 771 FT /note="Y->F: Loss of interaction with GRB10. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321" FT MUTAGEN 775 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 778 FT /note="Y->F: Strongly reduces expression levels." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 857 FT /note="Y->F: Reduces kinase activity. No effect on FT interaction with GRB10. Abolishes interaction with RASA1. FT No effect on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, FT ECO:0000269|PubMed:20494825" FT MUTAGEN 1009 FT /note="Y->F: No effect on interaction with GRB10. Abolishes FT interaction with PLCG1; when associated with F-1021." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:7691811" FT MUTAGEN 1021 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation. Abolishes interaction with PLCG1; when FT associated with F-1009. No effect on interaction with FT GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:17620338, FT ECO:0000269|PubMed:21679854" FT CONFLICT 241 FT /note="E -> D (in Ref. 2; AAA36427)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 50..58 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 81..87 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 96..101 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 114..119 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 136..141 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 158..164 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 175..177 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 178..181 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 185..194 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 223..226 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 231..239 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 241..248 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 252..255 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 261..265 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 267..270 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 271..280 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 287..295 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 296..299 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 300..311 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 530..556 FT /evidence="ECO:0007829|PDB:2L6W" SQ SEQUENCE 1106 AA; 123968 MW; 038C15E531D6E89D CRC64; MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV EPEPELEQLP DSGCPAPRAE AEDSFL // ID PGFRL_HUMAN Reviewed; 375 AA. AC Q15198; A8K085; Q6FH04; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Platelet-derived growth factor receptor-like protein; DE Short=PDGFR-like protein; DE AltName: Full=PDGF receptor beta-like tumor suppressor; DE Flags: Precursor; GN Name=PDGFRL; Synonyms=PRLTS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANT CRC TYR-23, AND TISSUE SPECIFICITY. RC TISSUE=Fetal lung; RX PubMed=7898930; RA Fujiwara Y., Ohata H., Kuroki T., Koyama K., Tsuchiya E., Monden M., RA Nakamura Y.; RT "Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 RT that is homologous to an extracellular domain of the PDGF receptor beta RT gene."; RL Oncogene 10:891-895(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INTERACTION WITH GRB2 AND TNK2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [7] RP POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO BEHCET DISEASE. RX PubMed=22926996; DOI=10.1002/humu.22208; RA Hou S., Xiao X., Zhou Y., Zhu X., Li F., Kijlstra A., Yang P.; RT "Genetic variant on PDGFRL associated with Behcet disease in Chinese Han RT populations."; RL Hum. Mutat. 34:74-78(2013). CC -!- SUBUNIT: Forms a complex composed of PDGFRL, TNK2 and GRB2. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Expressed in colon, lung and liver. CC {ECO:0000269|PubMed:7898930}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:7898930}. Note=The gene CC represented in this entry is involved in disease pathogenesis. CC -!- DISEASE: Note=A polymorphism in PDGFRL has been reported to be CC associated with susceptibility to Behcet disease (PubMed:22926996). CC Behcet disease is a complex multiple-system disorder characterized by CC recurrent oral ulcerations, recurrent genital ulcerations, typical skin CC lesions, and uveitis. Behcet disease also involves joints, blood CC vessels, musculoskeletal, neurological systems, and the CC gastrointestinal tract. {ECO:0000269|PubMed:22926996}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D37965; BAA07179.1; -; mRNA. DR EMBL; CR541952; CAG46750.1; -; mRNA. DR EMBL; AK289450; BAF82139.1; -; mRNA. DR EMBL; CH471080; EAW63811.1; -; Genomic_DNA. DR EMBL; BC010927; AAH10927.1; -; mRNA. DR CCDS; CCDS6003.1; -. DR PIR; I60125; I60125. DR RefSeq; NP_001359002.1; NM_001372073.1. DR RefSeq; NP_006198.1; NM_006207.2. DR AlphaFoldDB; Q15198; -. DR BioGRID; 111183; 43. DR FunCoup; Q15198; 10. DR IntAct; Q15198; 49. DR MINT; Q15198; -. DR STRING; 9606.ENSP00000444211; -. DR TCDB; 8.A.23.1.55; the basigin (basigin) family. DR GlyConnect; 1609; 3 N-Linked glycans (1 site). DR GlyCosmos; Q15198; 2 sites, 2 glycans. DR GlyGen; Q15198; 2 sites, 3 N-linked glycans (1 site). DR iPTMnet; Q15198; -. DR PhosphoSitePlus; Q15198; -. DR BioMuta; PDGFRL; -. DR DMDM; 74762141; -. DR jPOST; Q15198; -. DR MassIVE; Q15198; -. DR PaxDb; 9606-ENSP00000444211; -. DR PeptideAtlas; Q15198; -. DR ProteomicsDB; 60488; -. DR Antibodypedia; 22286; 251 antibodies from 31 providers. DR DNASU; 5157; -. DR Ensembl; ENST00000251630.11; ENSP00000251630.4; ENSG00000104213.14. DR Ensembl; ENST00000541323.1; ENSP00000444211.1; ENSG00000104213.14. DR GeneID; 5157; -. DR KEGG; hsa:5157; -. DR MANE-Select; ENST00000251630.11; ENSP00000251630.4; NM_001372073.1; NP_001359002.1. DR UCSC; uc003wxr.3; human. DR AGR; HGNC:8805; -. DR ClinPGx; PA33149; -. DR CTD; 5157; -. DR DisGeNET; 5157; -. DR GeneCards; PDGFRL; -. DR HGNC; HGNC:8805; PDGFRL. DR HPA; ENSG00000104213; Tissue enhanced (ovary). DR MalaCards; PDGFRL; -. DR MIM; 114500; phenotype. DR MIM; 604584; gene. DR OpenTargets; ENSG00000104213; -. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR VEuPathDB; HostDB:ENSG00000104213; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00390000017153; -. DR HOGENOM; CLU_062833_0_0_1; -. DR InParanoid; Q15198; -. DR OMA; CWGQLCN; -. DR OrthoDB; 9864753at2759; -. DR PAN-GO; Q15198; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q15198; -. DR PathwayCommons; Q15198; -. DR SignaLink; Q15198; -. DR Agora; ENSG00000104213; -. DR BioGRID-ORCS; 5157; 10 hits in 1152 CRISPR screens. DR ChiTaRS; PDGFRL; human. DR GenomeRNAi; 5157; -. DR Pharos; Q15198; Tbio. DR PRO; PR:Q15198; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q15198; protein. DR Bgee; ENSG00000104213; Expressed in pericardium and 166 other cell types or tissues. DR ExpressionAtlas; Q15198; baseline and differential. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc. DR GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; TAS:ProtInc. DR FunFam; 2.60.40.10:FF:000223; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000907; Platelet-derived growth factor receptor-like protein; 1. DR FunFam; 2.60.40.10:FF:001395; Platelet-derived growth factor receptor-like protein; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR042495; PDGFRL. DR PANTHER; PTHR15360; PLATELET-DERIVED GROWTH FACTOR RECEPTOR LIKE; 1. DR PANTHER; PTHR15360:SF1; PLATELET-DERIVED GROWTH FACTOR RECEPTOR-LIKE PROTEIN; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF21339; VEGFR-1-like_Ig-like; 1. DR SMART; SM00409; IG; 2. DR SMART; SM00408; IGc2; 2. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR PROSITE; PS50835; IG_LIKE; 2. PE 1: Evidence at protein level; KW Disease variant; Disulfide bond; Glycoprotein; Immunoglobulin domain; KW Proteomics identification; Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..375 FT /note="Platelet-derived growth factor receptor-like FT protein" FT /id="PRO_0000233090" FT DOMAIN 62..159 FT /note="Ig-like C2-type 1" FT DOMAIN 272..375 FT /note="Ig-like C2-type 2" FT REGION 22..64 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 40..50 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 132 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 219 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 96..143 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 293..357 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VARIANT 23 FT /note="H -> Y (in CRC; somatic mutation; FT dbSNP:rs137853148)" FT /evidence="ECO:0000269|PubMed:7898930" FT /id="VAR_026052" FT CONFLICT 227 FT /note="M -> I (in Ref. 2; CAG46750)" FT /evidence="ECO:0000305" SQ SEQUENCE 375 AA; 41861 MW; DF7FE6EB3FB2A802 CRC64; MKVWLLLGLL LVHEALEDVT GQHLPKNKRP KEPGENRIKP TNKKVKPKIP KMKDRDSANS APKTQSIMMQ VLDKGRFQKP AATLSLLAGQ TVELRCKGSR IGWSYPAYLD TFKDSRLSVK QNERYGQLTL VNSTSADTGE FSCWVQLCSG YICRKDEAKT GSTYIFFTEK GELFVPSPSY FDVVYLNPDR QAVVPCRVTV LSAKVTLHRE FPAKEIPANG TDIVYDMKRG FVYLQPHSEH QGVVYCRAEA GGRSQISVKY QLLYVAVPSG PPSTTILASS NKVKSGDDIS VLCTVLGEPD VEVEFTWIFP GQKDERPVTI QDTWRLIHRG LGHTTRISQS VITVEDFETI DAGYYICTAQ NLQGQTTVAT TVEFS // ID PK3CA_HUMAN Reviewed; 1068 AA. AC P42336; Q14CW1; Q99762; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 2. DT 28-JAN-2026, entry version 242. DE RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; DE Short=PI3-kinase subunit alpha; DE Short=PI3K-alpha; DE Short=PI3Kalpha {ECO:0000303|PubMed:28676499}; DE Short=PtdIns-3-kinase subunit alpha; DE EC=2.7.1.137 {ECO:0000269|PubMed:23936502}; DE EC=2.7.1.153 {ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; DE AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; DE Short=PtdIns-3-kinase subunit p110-alpha; DE Short=p110alpha {ECO:0000303|PubMed:15135396}; DE AltName: Full=Phosphoinositide 3-kinase alpha {ECO:0000303|PubMed:28676499}; DE AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide; DE AltName: Full=Serine/threonine protein kinase PIK3CA; DE EC=2.7.11.1 {ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; GN Name=PIK3CA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-43 AND ARG-332. RX PubMed=7713498; DOI=10.1006/geno.1994.1655; RA Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R., Rocchi M., RA Waterfield M.; RT "Molecular cloning, cDNA sequence, and chromosomal localization of the RT human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene."; RL Genomics 24:472-477(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9043658; DOI=10.1016/s0968-0896(96)00196-4; RA Stirdivant S.M., Ahern J., Conroy R.R., Barnett S.F., Ledder L.M., RA Oliff A., Heimbrook D.C.; RT "Cloning and mutagenesis of the p110 alpha subunit of human RT phosphoinositide 3'-hydroxykinase."; RL Bioorg. Med. Chem. 5:65-74(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INTERACTION WITH APPL1. RX PubMed=10490823; DOI=10.1038/sj.onc.1203080; RA Mitsuuchi Y., Johnson S.W., Sonoda G., Tanno S., Golemis E.A., Testa J.R.; RT "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor RT molecule that interacts with the oncoprotein-serine/threonine kinase RT AKT2."; RL Oncogene 18:4891-4898(1999). RN [5] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15135396; DOI=10.1016/j.pep.2003.12.010; RA Meier T.I., Cook J.A., Thomas J.E., Radding J.A., Horn C., Lingaraj T., RA Smith M.C.; RT "Cloning, expression, purification, and characterization of the human Class RT Ia phosphoinositide 3-kinase isoforms."; RL Protein Expr. Purif. 35:218-224(2004). RN [6] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23936502; DOI=10.1371/journal.pone.0071337; RA Buchanan C.M., Dickson J.M., Lee W.J., Guthridge M.A., Kendall J.D., RA Shepherd P.R.; RT "Oncogenic mutations of p110alpha isoform of PI 3-kinase upregulate its RT protein kinase activity."; RL PLoS ONE 8:e71337-e71337(2013). RN [7] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=28676499; DOI=10.1074/jbc.m116.772426; RA Maheshwari S., Miller M.S., O'Meally R., Cole R.N., Amzel L.M., RA Gabelli S.B.; RT "Kinetic and structural analyses reveal residues in phosphoinositide 3- RT kinase alpha that are critical for catalysis and substrate recognition."; RL J. Biol. Chem. 292:13541-13550(2017). RN [8] RP FUNCTION IN INVADOPODIA FORMATION, AND CHARACTERIZATION OF VARIANTS LYS-545 RP AND ARG-1047. RX PubMed=21708979; DOI=10.1083/jcb.201009126; RA Yamaguchi H., Yoshida S., Muroi E., Yoshida N., Kawamura M., Kouchi Z., RA Nakamura Y., Sakai R., Fukami K.; RT "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} RT regulates invadopodia formation."; RL J. Cell Biol. 193:1275-1288(2011). RN [9] RP INVOLVEMENT IN MADAC, AND VARIANTS MADAC PRO-115; LYS-542; ARG-1047 AND RP LEU-1047. RX PubMed=23100325; DOI=10.1093/hmg/dds440; RA Rios J.J., Paria N., Burns D.K., Israel B.A., Cornelia R., Wise C.A., RA Ezaki M.; RT "Somatic gain-of-function mutations in PIK3CA in patients with RT macrodactyly."; RL Hum. Mol. Genet. 22:444-451(2013). RN [10] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [11] RP REVIEW ON CANCER. RX PubMed=18418043; DOI=10.4161/cc.7.9.5817; RA Huang C.-H., Mandelker D., Gabelli S.B., Amzel L.M.; RT "Insights into the oncogenic effects of PIK3CA mutations from the structure RT of p110alpha/p85alpha."; RL Cell Cycle 7:1151-1156(2008). RN [12] RP REVIEW ON FUNCTION, AND REVIEW ON CANCER. RX PubMed=18794883; DOI=10.1038/onc.2008.244; RA Zhao L., Vogt P.K.; RT "Class I PI3K in oncogenic cellular transformation."; RL Oncogene 27:5486-5496(2008). RN [13] RP REVIEW ON FUNCTION. RX PubMed=19200708; DOI=10.1016/j.ceb.2008.12.007; RA Jia S., Roberts T.M., Zhao J.J.; RT "Should individual PI3 kinase isoforms be targeted in cancer?"; RL Curr. Opin. Cell Biol. 21:199-208(2009). RN [14] RP INVOLVEMENT IN CLAPO, AND VARIANTS CLAPO SER-83; PRO-115; ARG-420; LYS-542 RP AND LEU-1047. RX PubMed=29446767; DOI=10.1038/gim.2017.200; RA Rodriguez-Laguna L., Ibanez K., Gordo G., Garcia-Minaur S., RA Santos-Simarro F., Agra N., Vallespin E., Fernandez-Montano V.E., RA Martin-Arenas R., Del Pozo A., Gonzalez-Pecellin H., Mena R., RA Rueda-Arenas I., Gomez M.V., Villaverde C., Bustamante A., Ayuso C., RA Ruiz-Perez V.L., Nevado J., Lapunzina P., Lopez-Gutierrez J.C., RA Martinez-Glez V.; RT "CLAPO syndrome: identification of somatic activating PIK3CA mutations and RT delineation of the natural history and phenotype."; RL Genet. Med. 20:882-889(2018). RN [15] RP INVOLVEMENT IN CCM4, AND VARIANTS CCM4 LYS-542; ARG-1047 AND LEU-1047. RX PubMed=34496175; DOI=10.1056/nejmoa2100440; RA Peyre M., Miyagishima D., Bielle F., Chapon F., Sierant M., Venot Q., RA Lerond J., Marijon P., Abi-Jaoude S., Le Van T., Labreche K., Houlston R., RA Faisant M., Clemenceau S., Boch A.L., Nouet A., Carpentier A., Boetto J., RA Louvi A., Kalamarides M.; RT "Somatic PIK3CA mutations in sporadic cerebral cavernous malformations."; RL N. Engl. J. Med. 385:996-996(2021). RN [16] RP INVOLVEMENT IN HFMH, VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047, AND RP CHARACTERIZATION OF VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047. RX PubMed=37712948; DOI=10.1084/jem.20230926; RA Bayard C., Segna E., Taverne M., Fraissenon A., Hennocq Q., Periou B., RA Zerbib L., Ladraa S., Chapelle C., Hoguin C., Kaltenbach S., Villarese P., RA Asnafi V., Broissand C., Nemazanyy I., Autret G., Goudin N., Legendre C., RA Authier F.J., Viel T., Tavitian B., Gitiaux C., Fraitag S., Duong J.P., RA Delcros C., Sergent B., Picard A., Dussiot M., Guibaud L., Khonsari R., RA Canaud G.; RT "Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of- RT function mutations and responds to pharmacological inhibition."; RL J. Exp. Med. 220:0-0(2023). RN [17] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1, AND DOMAINS. RX PubMed=18079394; DOI=10.1126/science.1150799; RA Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., RA Kinzler K.W., Vogelstein B., Gabelli S.B., Amzel L.M.; RT "The structure of a human p110alpha/p85alpha complex elucidates the effects RT of oncogenic PI3Kalpha mutations."; RL Science 318:1744-1748(2007). RN [18] RP STRUCTURE BY NMR OF 331-481. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C2 domain from human PI3-kinase p110 subunit RT alpha."; RL Submitted (APR-2008) to the PDB data bank. RN [19] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX WITH RP WORTMANNIN AND PIK3R1, INTERACTION WITH PIK3R1, CHARACTERIZATION OF VARIANT RP ARG-1047, AND DOMAINS. RX PubMed=19805105; DOI=10.1073/pnas.0908444106; RA Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., RA Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.; RT "A frequent kinase domain mutation that changes the interaction between RT PI3Kalpha and the membrane."; RL Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009). RN [20] RP VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047; LEU-1047 AND RP TYR-1065. RX PubMed=15289301; DOI=10.1158/0008-5472.can-04-1170; RA Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., RA McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H.; RT "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade RT astrocytomas, and medulloblastomas."; RL Cancer Res. 64:5048-5050(2004). RN [21] RP INVOLVEMENT IN OC, AND VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; RP ARG-1047 AND LEU-1047. RX PubMed=15520168; DOI=10.1158/0008-5472.can-04-2933; RA Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G., RA Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B., Phillips W.A.; RT "Mutation of the PIK3CA gene in ovarian and breast cancer."; RL Cancer Res. 64:7678-7681(2004). RN [22] RP VARIANT CANCER ARG-1047. RX PubMed=15016963; DOI=10.1126/science.1096502; RA Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., RA Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V., Markowitz S., RA Kinzler K.W., Vogelstein B., Velculescu V.E.; RT "High frequency of mutations of the PIK3CA gene in human cancers."; RL Science 304:554-554(2004). RN [23] RP VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025. RX PubMed=15924253; DOI=10.1007/s00401-005-1000-1; RA Hartmann C., Bartels G., Gehlhaar C., Holtkamp N., von Deimling A.; RT "PIK3CA mutations in glioblastoma multiforme."; RL Acta Neuropathol. 109:639-642(2005). RN [24] RP VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=15784156; DOI=10.1186/1471-2407-5-29; RA Li V.S.W., Wong C.W., Chan T.L., Chan A.S.W., Zhao W., Chu K.-M., So S., RA Chen X., Yuen S.T., Leung S.Y.; RT "Mutations of PIK3CA in gastric adenocarcinoma."; RL BMC Cancer 5:29-29(2005). RN [25] RP INVOLVEMENT IN CRC, AND CHARACTERIZATION OF VARIANTS CRC HIS-38; VAL-106; RP ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047. RX PubMed=15930273; DOI=10.1158/0008-5472.can-04-4114; RA Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., Ohta M., RA Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M., Kawabe T., RA Omata M.; RT "Functional analysis of PIK3CA gene mutations in human colorectal cancer."; RL Cancer Res. 65:4562-4567(2005). RN [26] RP VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007; HIS-1021; RP CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050; LYS-1052 AND RP LEU-1065. RX PubMed=16322209; DOI=10.1158/0008-5472.can-05-2620; RA Oda K., Stokoe D., Taketani Y., McCormick F.; RT "High frequency of coexistent mutations of PIK3CA and PTEN genes in RT endometrial carcinoma."; RL Cancer Res. 65:10669-10673(2005). RN [27] RP INVOLVEMENT IN CRC, AND VARIANTS CANCER LYS-542; GLY-545; LYS-545; RP GLN-1023; ARG-1047 AND LEU-1047. RX PubMed=15994075; DOI=10.1016/j.ejca.2005.04.022; RA Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., RA Schwartz S. Jr., Duval A., Carneiro F., Machado J.C., Hamelin R., RA Seruca R.; RT "The prevalence of PIK3CA mutations in gastric and colon cancer."; RL Eur. J. Cancer 41:1649-1654(2005). RN [28] RP VARIANTS CANCER LYS-545 AND ARG-1047. RX PubMed=15712344; DOI=10.1002/humu.9316; RA Wang Y., Helland A., Holm R., Kristensen G.B., Boerresen-Dale A.-L.; RT "PIK3CA mutations in advanced ovarian carcinomas."; RL Hum. Mutat. 25:322-322(2005). RN [29] RP VARIANT HCC ALA-545. RX PubMed=15608678; DOI=10.1038/sj.onc.1208304; RA Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., RA Lee J.Y., Yoo N.J., Lee S.H.; RT "PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular RT carcinomas."; RL Oncogene 24:1477-1480(2005). RN [30] RP VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047, AND VARIANT RP MET-391. RX PubMed=16533766; DOI=10.1158/1078-0432.ccr-05-2173; RA Qiu W., Schoenleben F., Li X., Ho D.J., Close L.G., Manolidis S., RA Bennett B.P., Su G.H.; RT "PIK3CA mutations in head and neck squamous cell carcinoma."; RL Clin. Cancer Res. 12:1441-1446(2006). RN [31] RP VARIANT CANCER ARG-1047. RX PubMed=16114017; DOI=10.1002/ijc.21444; RA Or Y.Y.-Y., Hui A.B.-Y., To K.-F., Lam C.N.-Y., Lo K.-W.; RT "PIK3CA mutations in nasopharyngeal carcinoma."; RL Int. J. Cancer 118:1065-1067(2006). RN [32] RP VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047. RX PubMed=16353168; DOI=10.1002/path.1908; RA Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D., Fresu G., RA Salvatore S., Cuccurullo F., Mezzetti A., Campani D., Marchetti A.; RT "PIK3CA mutation and histological type in breast carcinoma: high frequency RT of mutations in lobular carcinoma."; RL J. Pathol. 208:350-355(2006). RN [33] RP CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=16432179; DOI=10.1073/pnas.0510857103; RA Bader A.G., Kang S., Vogt P.K.; RT "Cancer-specific mutations in PIK3CA are oncogenic in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 103:1475-1479(2006). RN [34] RP VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047. RX PubMed=17673550; DOI=10.1073/pnas.0705218104; RA Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E., RA Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R., RA Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A., Real F.X.; RT "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic RT keratoses with a characteristic mutation pattern."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13450-13454(2007). RN [35] RP VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047. RX PubMed=22658544; DOI=10.1016/j.ajhg.2012.05.006; RA Kurek K.C., Luks V.L., Ayturk U.M., Alomari A.I., Fishman S.J., RA Spencer S.A., Mulliken J.B., Bowen M.E., Yamamoto G.L., Kozakewich H.P., RA Warman M.L.; RT "Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome."; RL Am. J. Hum. Genet. 90:1108-1115(2012). RN [36] RP VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL; RP LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043; TYR-1047 RP AND SER-1049. RX PubMed=22729224; DOI=10.1038/ng.2331; RA Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., RA Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., RA Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A., RA Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C., RA Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M., RA Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G., RA Weksberg R., Zirn B., Beaulieu C.L., Majewski J., Bulman D.E., RA O'Driscoll M., Shendure J., Graham J.M. Jr., Boycott K.M., Dobyns W.B.; RT "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA RT cause a spectrum of related megalencephaly syndromes."; RL Nat. Genet. 44:934-940(2012). RN [37] RP VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). RN [38] RP VARIANT MCAP ASN-112, CHARACTERIZATION OF VARIANT MCAP ASN-112, FUNCTION, RP AND SUBUNIT. RX PubMed=26593112; DOI=10.1002/humu.22933; RA Donato N.D., Rump A., Mirzaa G.M., Alcantara D., Oliver A., Schrock E., RA Dobyns W.B., O'Driscoll M.; RT "Identification and characterisation of a novel constitutional PIK3CA RT mutation in a child lacking the typical segmental overgrowth of 'PIK3CA- RT related overgrowth spectrum' (PROS)."; RL Hum. Mutat. 37:242-245(2016). CC -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) phosphorylates CC phosphatidylinositol (PI) and its phosphorylated derivatives at CC position 3 of the inositol ring to produce 3-phosphoinositides CC (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and CC PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate CC phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, CC PubMed:28676499). PIP3 plays a key role by recruiting PH domain- CC containing proteins to the membrane, including AKT1 and PDPK1, CC activating signaling cascades involved in cell growth, survival, CC proliferation, motility and morphology. Participates in cellular CC signaling in response to various growth factors. Involved in the CC activation of AKT1 upon stimulation by receptor tyrosine kinases CC ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in CC signaling via insulin-receptor substrate (IRS) proteins. Essential in CC endothelial cell migration during vascular development through VEGFA CC signaling, possibly by regulating RhoA activity. Required for lymphatic CC vasculature development, possibly by binding to RAS and by activation CC by EGF and FGF2, but not by PDGF. Regulates invadopodia formation CC through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in CC embryonic stem cells through a AKT1 pathway. Participates in CC vasculogenesis in embryonic stem cells through PDK1 and protein kinase CC C pathway. In addition to its lipid kinase activity, it displays a CC serine-protein kinase activity that results in the autophosphorylation CC of the p85alpha regulatory subunit as well as phosphorylation of other CC proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly CC others (PubMed:23936502, PubMed:28676499). Plays a role in the positive CC regulation of phagocytosis and pinocytosis (By similarity). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:15135396, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:23936502, CC ECO:0000269|PubMed:26593112, ECO:0000269|PubMed:28676499}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153; CC Evidence={ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293; CC Evidence={ECO:0000305|PubMed:15135396, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a CC 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP + CC H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216; CC EC=2.7.1.137; Evidence={ECO:0000269|PubMed:23936502}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710; CC Evidence={ECO:0000305|PubMed:23936502}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000305|PubMed:23936502, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:55632, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55633; CC Evidence={ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero- CC 3-phospho-1D-myo-inositol 4,5-bisphosphate + ATP = 1-octadecanoyl-2- CC (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo- CC inositol 3,4,5-triphosphate) + ADP + H(+); Xref=Rhea:RHEA:43396, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:77137, CC ChEBI:CHEBI:83243, ChEBI:CHEBI:456216; CC Evidence={ECO:0000305|PubMed:15135396}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43397; CC Evidence={ECO:0000305|PubMed:15135396}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=1.77 uM for PIP2 (1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate)) {ECO:0000269|PubMed:28676499}; CC KM=2.00 uM for ATP {ECO:0000269|PubMed:28676499}; CC Vmax=1.70 pmol/min/ng enzyme for the phosphorylation of PIP2 (1,2- CC dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)) CC {ECO:0000269|PubMed:28676499}; CC -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate CC biosynthesis. {ECO:0000305|PubMed:15135396, CC ECO:0000305|PubMed:28676499}. CC -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory CC subunit (PIK3R1, PIK3R2 or PIK3R3) (PubMed:26593112). Interacts with CC IRS1 in nuclear extracts (By similarity). Interacts with RUFY3 (By CC similarity). Interacts with RASD2 (By similarity). Interacts with CC APPL1. Interacts with HRAS and KRAS (By similarity). Interaction with CC HRAS/KRAS is required for PI3K pathway signaling and cell proliferation CC stimulated by EGF and FGF2 (By similarity). Interacts with FAM83B; CC activates the PI3K/AKT signaling cascade (PubMed:23676467). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:23676467, CC ECO:0000269|PubMed:26593112}. CC -!- INTERACTION: CC P42336; P54253: ATXN1; NbExp=3; IntAct=EBI-2116585, EBI-930964; CC P42336; P54252: ATXN3; NbExp=3; IntAct=EBI-2116585, EBI-946046; CC P42336; P21860: ERBB3; NbExp=18; IntAct=EBI-2116585, EBI-720706; CC P42336; P01100: FOS; NbExp=3; IntAct=EBI-2116585, EBI-852851; CC P42336; P62993: GRB2; NbExp=6; IntAct=EBI-2116585, EBI-401755; CC P42336; P42858: HTT; NbExp=3; IntAct=EBI-2116585, EBI-466029; CC P42336; P35568: IRS1; NbExp=42; IntAct=EBI-2116585, EBI-517592; CC P42336; P27986: PIK3R1; NbExp=63; IntAct=EBI-2116585, EBI-79464; CC P42336; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-2116585, EBI-9090282; CC P42336; O00459: PIK3R2; NbExp=49; IntAct=EBI-2116585, EBI-346930; CC P42336; Q92569: PIK3R3; NbExp=48; IntAct=EBI-2116585, EBI-79893; CC P42336; O43791: SPOP; NbExp=4; IntAct=EBI-2116585, EBI-743549; CC -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with the CC PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the CC recruitment to the plasma membrane. The inhibitory interactions with CC PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain CC with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type CC domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with CC the nSH2 (N-terminal SH2) region of PIK3R1. CC {ECO:0000269|PubMed:18079394, ECO:0000269|PubMed:19805105}. CC -!- DISEASE: Note=PIK3CA mutations are involved in various type of cancer. CC Most of the cancer-associated mutations are missense mutations and map CC to one of the three hotspots: Glu-542; Glu-545 and His-1047. Mutated CC isoforms participate in cellular transformation and tumorigenesis CC induced by oncogenic receptor tyrosine kinases (RTKs) and HRAS/KRAS. CC Interaction with HRAS/KRAS is required for Ras-driven tumor formation. CC Mutations increasing the lipid kinase activity are required for CC oncogenic signaling. The protein kinase activity may not be required CC for tumorigenesis. {ECO:0000269|PubMed:15016963, CC ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, CC ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, CC ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16114017, CC ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, CC ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, CC ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:19805105, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22658544, CC ECO:0000269|PubMed:22729224}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:16353168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15520168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC {ECO:0000269|PubMed:15608678}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign CC skin tumor. Seborrheic keratoses usually begin with the appearance of CC one or more sharply defined, light brown, flat macules. The lesions may CC be sparse or numerous. As they initially grow, they develop a velvety CC to finely verrucous surface, followed by an uneven warty surface with CC multiple plugged follicles and a dull or lackluster appearance. CC {ECO:0000269|PubMed:17673550}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Megalencephaly-capillary malformation-polymicrogyria syndrome CC (MCAP) [MIM:602501]: A syndrome characterized by a spectrum of CC anomalies including primary megalencephaly, prenatal overgrowth, brain CC and body asymmetry, cutaneous vascular malformations, digital anomalies CC consisting of syndactyly with or without postaxial polydactyly, CC connective tissue dysplasia involving the skin, subcutaneous tissue, CC and joints, and cortical brain malformations, most distinctively CC polymicrogyria. {ECO:0000269|PubMed:22729224, CC ECO:0000269|PubMed:26593112}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital lipomatous overgrowth, vascular malformations, and CC epidermal nevi (CLOVE) [MIM:612918]: A sporadically occurring, non- CC hereditary disorder characterized by asymmetric somatic hypertrophy and CC anomalies in multiple organs. It is defined by four main clinical CC findings: congenital lipomatous overgrowth, vascular malformations, CC epidermal nevi, and skeletal/spinal abnormalities. The presence of CC truncal overgrowth and characteristic patterned macrodactyly at birth CC differentiates CLOVE from other syndromic forms of overgrowth. CC {ECO:0000269|PubMed:22658544}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 5 (CWS5) [MIM:615108]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:23246288}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: CLAPO syndrome (CLAPO) [MIM:613089]: A syndrome characterized CC by capillary malformation of the lower lip, lymphatic malformation of CC the face and neck, asymmetry of face and limbs and partial or CC generalised overgrowth. {ECO:0000269|PubMed:29446767}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC The tissue distribution of the clinical manifestations in CLAPO seems CC to follow a pattern of somatic mosaicism. CC {ECO:0000269|PubMed:29446767}. CC -!- DISEASE: Macrodactyly (MADAC) [MIM:155500]: A congenital anomaly CC characterized by fibrofatty tissue enlargement and bony overgrowth CC affecting the digits or the entire hand or foot. CC {ECO:0000269|PubMed:23100325}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. The tissue CC distribution of the clinical manifestations in MADAC seems to follow a CC pattern of somatic mosaicism. {ECO:0000269|PubMed:23100325}. CC -!- DISEASE: Cerebral cavernous malformations 4 (CCM4) [MIM:619538]: A form CC of cerebral cavernous malformations, a congenital vascular anomaly of CC the central nervous system that can result in hemorrhagic stroke, CC seizures, recurrent headaches, and focal neurologic deficits. The CC lesions are characterized by grossly enlarged blood vessels consisting CC of a single layer of endothelium and without any intervening neural CC tissue, ranging in diameter from a few millimeters to several CC centimeters. CCM4 cases occur sporadically. CC {ECO:0000269|PubMed:34496175}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Hemifacial myohyperplasia (HFMH) [MIM:606773]: A rare disease CC characterized by facial asymmetry due to unilateral muscular CC hypertrophy mimicking spasm and orofacial dystonia. CC {ECO:0000269|PubMed:37712948}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an oncogene CC derived from PIK3CA. {ECO:0000305|PubMed:18418043}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE- CC ProRule:PRU00877, ECO:0000255|PROSITE-ProRule:PRU00879, CC ECO:0000255|PROSITE-ProRule:PRU00880}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/415/PIK3CA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z29090; CAA82333.1; -; mRNA. DR EMBL; U79143; AAB39753.1; -; mRNA. DR EMBL; BC113601; AAI13602.1; -; mRNA. DR EMBL; BC113603; AAI13604.1; -; mRNA. DR CCDS; CCDS43171.1; -. DR PIR; I38110; I38110. DR RefSeq; NP_006209.2; NM_006218.4. DR RefSeq; XP_006713721.1; XM_006713658.5. DR RefSeq; XP_054202817.1; XM_054346842.1. DR RefSeq; XP_054202818.1; XM_054346843.1. DR RefSeq; XP_054202819.1; XM_054346844.1. DR RefSeq; XP_054202820.1; XM_054346845.1. DR RefSeq; XP_054202821.1; XM_054346846.1. DR RefSeq; XP_054202822.1; XM_054346847.1. DR RefSeq; XP_054202823.1; XM_054346848.1. DR PDB; 2ENQ; NMR; -; A=331-481. DR PDB; 2RD0; X-ray; 3.05 A; A=1-1068. DR PDB; 3HHM; X-ray; 2.80 A; A=1-1068. DR PDB; 3HIZ; X-ray; 3.30 A; A=1-1068. DR PDB; 3ZIM; X-ray; 2.85 A; A=107-1046. DR PDB; 4JPS; X-ray; 2.20 A; A=1-1068. DR PDB; 4L1B; X-ray; 2.59 A; A=1-1068. DR PDB; 4L23; X-ray; 2.50 A; A=1-1068. DR PDB; 4L2Y; X-ray; 2.80 A; A=1-1068. DR PDB; 4OVU; X-ray; 2.96 A; A=1-1068. DR PDB; 4OVV; X-ray; 3.50 A; A=1-1068. DR PDB; 4TUU; X-ray; 2.64 A; A=105-1048. DR PDB; 4TV3; X-ray; 2.85 A; A=105-1048. DR PDB; 4WAF; X-ray; 2.39 A; A=2-1068. DR PDB; 4YKN; X-ray; 2.90 A; A=2-1068. DR PDB; 4ZOP; X-ray; 2.62 A; A=1-1068. DR PDB; 5DXH; X-ray; 3.00 A; A/D=2-1068. DR PDB; 5DXT; X-ray; 2.25 A; A=107-1068. DR PDB; 5FI4; X-ray; 2.50 A; A=1-1068. DR PDB; 5ITD; X-ray; 3.02 A; A=1-1068. DR PDB; 5SW8; X-ray; 3.30 A; A=1-1068. DR PDB; 5SWG; X-ray; 3.11 A; A=1-1068. DR PDB; 5SWO; X-ray; 3.50 A; A=1-1068. DR PDB; 5SWP; X-ray; 3.41 A; A=1-1068. DR PDB; 5SWR; X-ray; 3.31 A; A=1-1068. DR PDB; 5SWT; X-ray; 3.49 A; A=1-1068. DR PDB; 5SX8; X-ray; 3.47 A; A=1-1068. DR PDB; 5SX9; X-ray; 3.52 A; A=1-1068. DR PDB; 5SXA; X-ray; 3.35 A; A=1-1068. DR PDB; 5SXB; X-ray; 3.30 A; A=1-1068. DR PDB; 5SXC; X-ray; 3.55 A; A=1-1068. DR PDB; 5SXD; X-ray; 3.50 A; A=1-1068. DR PDB; 5SXE; X-ray; 3.51 A; A=1-1068. DR PDB; 5SXF; X-ray; 3.46 A; A=1-1068. DR PDB; 5SXI; X-ray; 3.40 A; A=1-1068. DR PDB; 5SXJ; X-ray; 3.42 A; A=1-1068. DR PDB; 5SXK; X-ray; 3.55 A; A=1-1068. DR PDB; 5UBR; X-ray; 2.40 A; A=107-1050. DR PDB; 5UK8; X-ray; 2.50 A; A=1-1068. DR PDB; 5UKJ; X-ray; 2.80 A; A=1-1068. DR PDB; 5UL1; X-ray; 3.00 A; A=1-1068. DR PDB; 5XGH; X-ray; 2.97 A; A=8-1055. DR PDB; 5XGI; X-ray; 2.56 A; A=8-1059. DR PDB; 5XGJ; X-ray; 2.97 A; A=8-1055. DR PDB; 6GVF; X-ray; 2.50 A; A=107-1051. DR PDB; 6GVG; X-ray; 3.00 A; A=107-1068. DR PDB; 6GVH; X-ray; 2.74 A; A=107-1068. DR PDB; 6GVI; X-ray; 2.90 A; A=107-1068. DR PDB; 6NCT; X-ray; 3.35 A; A=1-1068. DR PDB; 6OAC; X-ray; 3.15 A; A=105-1048. DR PDB; 6PYS; X-ray; 2.19 A; A=107-1051. DR PDB; 6VO7; X-ray; 2.31 A; A=157-300. DR PDB; 7JIU; X-ray; 2.12 A; A=107-1052. DR PDB; 7K6M; X-ray; 2.41 A; A=105-1048. DR PDB; 7K6N; X-ray; 2.77 A; A=105-1048. DR PDB; 7K6O; X-ray; 2.74 A; A=105-1048. DR PDB; 7K71; X-ray; 2.90 A; A=105-1048. DR PDB; 7L1B; X-ray; 2.04 A; C=1046-1054. DR PDB; 7L1C; X-ray; 1.96 A; C=1046-1054. DR PDB; 7L1D; X-ray; 3.11 A; C=1046-1054. DR PDB; 7MLK; X-ray; 2.91 A; A=105-1048. DR PDB; 7MYN; EM; 2.79 A; A=1-1068. DR PDB; 7MYO; EM; 2.92 A; A=1-1068. DR PDB; 7PG5; X-ray; 2.20 A; A=1-1068. DR PDB; 7PG6; X-ray; 2.50 A; A=1-1068. DR PDB; 7R9V; X-ray; 2.69 A; A=105-1048. DR PDB; 7R9Y; X-ray; 2.85 A; A=105-1048. DR PDB; 7RRG; X-ray; 2.12 A; C=1046-1054. DR PDB; 7TZ7; X-ray; 2.41 A; A=1-1068. DR PDB; 8AM0; X-ray; 2.82 A; A=1-1068. DR PDB; 8BFU; X-ray; 2.41 A; A=105-1048. DR PDB; 8DCP; EM; 2.41 A; A=1-1068. DR PDB; 8DCX; EM; 2.80 A; A=1-1068. DR PDB; 8DD4; EM; 3.10 A; A=1-1068. DR PDB; 8DD8; EM; 3.40 A; A=1-1068. DR PDB; 8EXL; X-ray; 1.99 A; A=7-1052. DR PDB; 8EXO; X-ray; 2.46 A; A=7-1052. DR PDB; 8EXU; X-ray; 2.68 A; A=7-1052. DR PDB; 8EXV; X-ray; 2.48 A; A=7-1052. DR PDB; 8GUA; EM; 2.77 A; A=1-1068. DR PDB; 8GUB; EM; 2.73 A; A=1-1068. DR PDB; 8GUD; EM; 2.62 A; A=1-1068. DR PDB; 8ILR; EM; 3.05 A; A=1-1068. DR PDB; 8ILS; EM; 3.10 A; A=1-1068. DR PDB; 8ILV; EM; 3.19 A; A=1-1068. DR PDB; 8OW2; X-ray; 2.57 A; A=105-1048. DR PDB; 8SBC; X-ray; 2.30 A; A=1-1068. DR PDB; 8SBJ; X-ray; 3.10 A; A=1-1068. DR PDB; 8TDU; X-ray; 3.11 A; A/C=1-1068. DR PDB; 8TGD; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8TS7; X-ray; 2.71 A; A=2-1053. DR PDB; 8TS8; X-ray; 2.72 A; A=2-1053. DR PDB; 8TS9; X-ray; 2.83 A; A=2-1050. DR PDB; 8TSA; X-ray; 2.51 A; A=2-1050. DR PDB; 8TSB; X-ray; 3.53 A; A=2-1053. DR PDB; 8TSC; X-ray; 3.62 A; A=2-1050. DR PDB; 8TSD; X-ray; 2.70 A; A=2-1053. DR PDB; 8TU6; EM; 3.12 A; A=2-1068. DR PDB; 8TWY; X-ray; 2.67 A; A=105-1048. DR PDB; 8V8H; X-ray; 3.58 A; A/C=1-1068. DR PDB; 8V8I; X-ray; 3.20 A; A/C=1-1068. DR PDB; 8V8J; X-ray; 3.35 A; A/C=1-1068. DR PDB; 8V8U; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8V8V; X-ray; 2.61 A; A/C=1-1068. DR PDB; 8VCL; X-ray; 2.40 A; C=1046-1054. DR PDB; 8W9A; EM; 2.70 A; A=1-1068. DR PDB; 8W9B; EM; 3.00 A; A=1-1068. DR PDB; 9ASF; X-ray; 1.77 A; C=1046-1054. DR PDB; 9ASG; X-ray; 2.03 A; C=1046-1054. DR PDB; 9B4S; X-ray; 3.10 A; A=105-1068. DR PDB; 9B4T; X-ray; 2.75 A; A=105-1068. DR PDB; 9B4U; X-ray; 2.21 A; A/B=157-300. DR PDB; 9C15; X-ray; 2.81 A; A=105-1068. DR PDB; 9CMK; X-ray; 1.75 A; A/B=160-300. DR PDB; 9CML; X-ray; 2.01 A; A/B=160-300. DR PDB; 9CMV; X-ray; 3.01 A; A=105-1068. DR PDB; 9E8M; X-ray; 2.83 A; A/B=157-300. DR PDBsum; 2ENQ; -. DR PDBsum; 2RD0; -. DR PDBsum; 3HHM; -. DR PDBsum; 3HIZ; -. DR PDBsum; 3ZIM; -. DR PDBsum; 4JPS; -. DR PDBsum; 4L1B; -. DR PDBsum; 4L23; -. DR PDBsum; 4L2Y; -. DR PDBsum; 4OVU; -. DR PDBsum; 4OVV; -. DR PDBsum; 4TUU; -. DR PDBsum; 4TV3; -. DR PDBsum; 4WAF; -. DR PDBsum; 4YKN; -. DR PDBsum; 4ZOP; -. DR PDBsum; 5DXH; -. DR PDBsum; 5DXT; -. DR PDBsum; 5FI4; -. DR PDBsum; 5ITD; -. DR PDBsum; 5SW8; -. DR PDBsum; 5SWG; -. DR PDBsum; 5SWO; -. DR PDBsum; 5SWP; -. DR PDBsum; 5SWR; -. DR PDBsum; 5SWT; -. DR PDBsum; 5SX8; -. DR PDBsum; 5SX9; -. DR PDBsum; 5SXA; -. DR PDBsum; 5SXB; -. DR PDBsum; 5SXC; -. DR PDBsum; 5SXD; -. DR PDBsum; 5SXE; -. DR PDBsum; 5SXF; -. DR PDBsum; 5SXI; -. DR PDBsum; 5SXJ; -. DR PDBsum; 5SXK; -. DR PDBsum; 5UBR; -. DR PDBsum; 5UK8; -. DR PDBsum; 5UKJ; -. DR PDBsum; 5UL1; -. DR PDBsum; 5XGH; -. DR PDBsum; 5XGI; -. DR PDBsum; 5XGJ; -. DR PDBsum; 6GVF; -. DR PDBsum; 6GVG; -. DR PDBsum; 6GVH; -. DR PDBsum; 6GVI; -. DR PDBsum; 6NCT; -. DR PDBsum; 6OAC; -. DR PDBsum; 6PYS; -. DR PDBsum; 6VO7; -. DR PDBsum; 7JIU; -. DR PDBsum; 7K6M; -. DR PDBsum; 7K6N; -. DR PDBsum; 7K6O; -. DR PDBsum; 7K71; -. DR PDBsum; 7L1B; -. DR PDBsum; 7L1C; -. DR PDBsum; 7L1D; -. DR PDBsum; 7MLK; -. DR PDBsum; 7MYN; -. DR PDBsum; 7MYO; -. DR PDBsum; 7PG5; -. DR PDBsum; 7PG6; -. DR PDBsum; 7R9V; -. DR PDBsum; 7R9Y; -. DR PDBsum; 7RRG; -. DR PDBsum; 7TZ7; -. DR PDBsum; 8AM0; -. DR PDBsum; 8BFU; -. DR PDBsum; 8DCP; -. DR PDBsum; 8DCX; -. DR PDBsum; 8DD4; -. DR PDBsum; 8DD8; -. DR PDBsum; 8EXL; -. DR PDBsum; 8EXO; -. DR PDBsum; 8EXU; -. DR PDBsum; 8EXV; -. DR PDBsum; 8GUA; -. DR PDBsum; 8GUB; -. DR PDBsum; 8GUD; -. DR PDBsum; 8ILR; -. DR PDBsum; 8ILS; -. DR PDBsum; 8ILV; -. DR PDBsum; 8OW2; -. DR PDBsum; 8SBC; -. DR PDBsum; 8SBJ; -. DR PDBsum; 8TDU; -. DR PDBsum; 8TGD; -. DR PDBsum; 8TS7; -. DR PDBsum; 8TS8; -. DR PDBsum; 8TS9; -. DR PDBsum; 8TSA; -. DR PDBsum; 8TSB; -. DR PDBsum; 8TSC; -. DR PDBsum; 8TSD; -. DR PDBsum; 8TU6; -. DR PDBsum; 8TWY; -. DR PDBsum; 8V8H; -. DR PDBsum; 8V8I; -. DR PDBsum; 8V8J; -. DR PDBsum; 8V8U; -. DR PDBsum; 8V8V; -. DR PDBsum; 8VCL; -. DR PDBsum; 8W9A; -. DR PDBsum; 8W9B; -. DR PDBsum; 9ASF; -. DR PDBsum; 9ASG; -. DR PDBsum; 9B4S; -. DR PDBsum; 9B4T; -. DR PDBsum; 9B4U; -. DR PDBsum; 9C15; -. DR PDBsum; 9CMK; -. DR PDBsum; 9CML; -. DR PDBsum; 9CMV; -. DR PDBsum; 9E8M; -. DR AlphaFoldDB; P42336; -. DR EMDB; EMD-24081; -. DR EMDB; EMD-24082; -. DR EMDB; EMD-27327; -. DR EMDB; EMD-27330; -. DR EMDB; EMD-27334; -. DR EMDB; EMD-27336; -. DR EMDB; EMD-34271; -. DR EMDB; EMD-34272; -. DR EMDB; EMD-34273; -. DR EMDB; EMD-35543; -. DR EMDB; EMD-35545; -. DR EMDB; EMD-35547; -. DR EMDB; EMD-37362; -. DR EMDB; EMD-37363; -. DR EMDB; EMD-41617; -. DR SMR; P42336; -. DR BioGRID; 111308; 178. DR ComplexPortal; CPX-1917; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85beta. DR ComplexPortal; CPX-1918; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55gamma. DR ComplexPortal; CPX-2384; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85alpha. DR ComplexPortal; CPX-5970; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55alpha. DR ComplexPortal; CPX-5971; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p50alpha. DR CORUM; P42336; -. DR DIP; DIP-42728N; -. DR FunCoup; P42336; 3134. DR IntAct; P42336; 216. DR MINT; P42336; -. DR STRING; 9606.ENSP00000263967; -. DR BindingDB; P42336; -. DR ChEMBL; CHEMBL4005; -. DR DrugBank; DB12015; Alpelisib. DR DrugBank; DB00171; ATP. DR DrugBank; DB11666; Buparlisib. DR DrugBank; DB00201; Caffeine. DR DrugBank; DB13051; CH-5132799. DR DrugBank; DB12483; Copanlisib. DR DrugBank; DB15275; Inavolisib. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB11772; Pilaralisib. DR DrugBank; DB14935; Serabelisib. DR DrugBank; DB12108; Taselisib. DR DrugBank; DB08059; Wortmannin. DR DrugBank; DB05241; XL765. DR DrugCentral; P42336; -. DR GuidetoPHARMACOLOGY; 2153; -. DR iPTMnet; P42336; -. DR MetOSite; P42336; -. DR PhosphoSitePlus; P42336; -. DR BioMuta; PIK3CA; -. DR DMDM; 126302584; -. DR CPTAC; CPTAC-1631; -. DR CPTAC; CPTAC-3127; -. DR CPTAC; CPTAC-3128; -. DR CPTAC; CPTAC-3129; -. DR jPOST; P42336; -. DR MassIVE; P42336; -. DR PaxDb; 9606-ENSP00000263967; -. DR PeptideAtlas; P42336; -. DR ProteomicsDB; 55509; -. DR Pumba; P42336; -. DR Antibodypedia; 1374; 746 antibodies from 44 providers. DR CPTC; P42336; 1 antibody. DR DNASU; 5290; -. DR Ensembl; ENST00000263967.4; ENSP00000263967.3; ENSG00000121879.7. DR GeneID; 5290; -. DR KEGG; hsa:5290; -. DR MANE-Select; ENST00000263967.4; ENSP00000263967.3; NM_006218.4; NP_006209.2. DR UCSC; uc003fjk.4; human. DR AGR; HGNC:8975; -. DR CIViC; 5290; 319 evidence items across 211 molecular profiles. DR ClinPGx; PA33308; -. DR CTD; 5290; -. DR DisGeNET; 5290; -. DR GeneCards; PIK3CA; -. DR GeneReviews; PIK3CA; -. DR HGNC; HGNC:8975; PIK3CA. DR HPA; ENSG00000121879; Low tissue specificity. DR MalaCards; PIK3CA; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 114550; phenotype. DR MIM; 155500; phenotype. DR MIM; 167000; phenotype. DR MIM; 171834; gene. DR MIM; 182000; phenotype. DR MIM; 602501; phenotype. DR MIM; 606773; phenotype. DR MIM; 612918; phenotype. DR MIM; 613089; phenotype. DR MIM; 615108; phenotype. DR MIM; 619538; phenotype. DR OpenTargets; ENSG00000121879; -. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 90308; Capillary-lymphatic-venous malformation with segmental distribution. DR Orphanet; 168984; CLAPO syndrome. DR Orphanet; 140944; CLOVES syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 221061; Familial cerebral cavernous malformation. DR Orphanet; 276280; Hemihyperplasia-multiple lipomatosis syndrome. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 295239; Macrodactyly of fingers, unilateral. DR Orphanet; 295243; Macrodactyly of toes, unilateral. DR Orphanet; 60040; Megalencephaly-capillary malformation-polymicrogyria syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 314662; Segmental progressive overgrowth syndrome with fibroadipose hyperplasia. DR VEuPathDB; HostDB:ENSG00000121879; -. DR eggNOG; KOG0904; Eukaryota. DR GeneTree; ENSGT00940000155531; -. DR HOGENOM; CLU_002191_1_1_1; -. DR InParanoid; P42336; -. DR OMA; RWSEWLN; -. DR OrthoDB; 67688at2759; -. DR PAN-GO; P42336; 9 GO annotations based on evolutionary models. DR PhylomeDB; P42336; -. DR BioCyc; MetaCyc:HS04527-MONOMER; -. DR BRENDA; 2.7.1.137; 2681. DR BRENDA; 2.7.1.153; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P42336; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-112399; IRS-mediated signalling. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-198203; PI3K/AKT activation. DR Reactome; R-HSA-201556; Signaling by ALK. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization. DR Reactome; R-HSA-373753; Nephrin family interactions. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-416476; G alpha (q) signalling events. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654689; PI-3K cascade:FGFR1. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654710; PI-3K cascade:FGFR3. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K). DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-912526; Interleukin receptor SHC signaling. DR Reactome; R-HSA-912631; Regulation of signaling by CBL. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9842640; Signaling by LTK in cancer. DR Reactome; R-HSA-9842663; Signaling by LTK. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9927354; Co-stimulation by ICOS. DR SABIO-RK; P42336; -. DR SignaLink; P42336; -. DR SIGNOR; P42336; -. DR UniPathway; UPA00220; -. DR Agora; ENSG00000121879; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5290; 275 hits in 1174 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PIK3CA; human. DR EvolutionaryTrace; P42336; -. DR GeneWiki; P110%CE%B1; -. DR GenomeRNAi; 5290; -. DR Pharos; P42336; Tclin. DR PRO; PR:P42336; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P42336; protein. DR Bgee; ENSG00000121879; Expressed in calcaneal tendon and 201 other cell types or tissues. DR ExpressionAtlas; P42336; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0014704; C:intercalated disc; ISS:BHF-UCL. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:BHF-UCL. DR GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; ISS:BHF-UCL. DR GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; IDA:UniProtKB. DR GO; GO:0005944; C:phosphatidylinositol 3-kinase complex, class IB; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB. DR GO; GO:0046934; F:1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IDA:UniProt. DR GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl. DR GO; GO:0030295; F:protein kinase activator activity; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0141068; P:autosome genomic imprinting; IEA:Ensembl. DR GO; GO:0086003; P:cardiac muscle cell contraction; ISS:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071464; P:cellular response to hydrostatic pressure; ISS:BHF-UCL. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0043542; P:endothelial cell migration; TAS:UniProtKB. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0030835; P:negative regulation of actin filament depolymerization; ISS:BHF-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB. DR GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; ISS:BHF-UCL. DR GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central. DR GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central. DR GO; GO:0030168; P:platelet activation; TAS:UniProtKB. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISS:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:1905477; P:positive regulation of protein localization to membrane; IDA:UniProt. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0032008; P:positive regulation of TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0110053; P:regulation of actin filament organization; ISS:BHF-UCL. DR GO; GO:0043457; P:regulation of cellular respiration; IEA:Ensembl. DR GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl. DR GO; GO:0055119; P:relaxation of cardiac muscle; ISS:BHF-UCL. DR GO; GO:0014823; P:response to activity; IEA:Ensembl. DR GO; GO:1903544; P:response to butyrate; IEA:Ensembl. DR GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl. DR GO; GO:0043201; P:response to L-leucine; IEA:Ensembl. DR GO; GO:0014870; P:response to muscle inactivity; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; ISS:BHF-UCL. DR GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome. DR GO; GO:0038203; P:TORC2 signaling; IMP:MGI. DR GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IGI:BHF-UCL. DR GO; GO:0001944; P:vasculature development; TAS:UniProtKB. DR CDD; cd08398; C2_PI3K_class_I_alpha; 1. DR CDD; cd00872; PI3Ka_I; 1. DR CDD; cd05175; PI3Kc_IA_alpha; 1. DR FunFam; 1.10.1070.11:FF:000006; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 1.25.40.70:FF:000001; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 2.60.40.150:FF:000041; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000055; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000074; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.30.1010.10:FF:000007; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR037704; PI3-kinase_alpha_cat. DR InterPro; IPR015433; PI3/4_kinase. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR002420; PI3K-type_C2_dom. DR InterPro; IPR003113; PI3K_ABD. DR InterPro; IPR001263; PI3K_accessory_dom. DR InterPro; IPR042236; PI3K_accessory_sf. DR InterPro; IPR000341; PI3K_Ras-bd_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR10048:SF107; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM; 1. DR PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF00792; PI3K_C2; 1. DR Pfam; PF02192; PI3K_p85B; 1. DR Pfam; PF00794; PI3K_rbd; 1. DR Pfam; PF00613; PI3Ka; 1. DR SMART; SM00142; PI3K_C2; 1. DR SMART; SM00143; PI3K_p85B; 1. DR SMART; SM00144; PI3K_rbd; 1. DR SMART; SM00145; PI3Ka; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS51547; C2_PI3K; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. DR PROSITE; PS51544; PI3K_ABD; 1. DR PROSITE; PS51546; PI3K_RBD; 1. DR PROSITE; PS51545; PIK_HELICAL; 1. PE 1: Evidence at protein level; KW 3D-structure; Angiogenesis; ATP-binding; Disease variant; Kinase; KW Lipid metabolism; Nucleotide-binding; Phagocytosis; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1068 FT /note="Phosphatidylinositol 4,5-bisphosphate 3-kinase FT catalytic subunit alpha isoform" FT /id="PRO_0000088785" FT DOMAIN 16..105 FT /note="PI3K-ABD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00877" FT DOMAIN 187..289 FT /note="PI3K-RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00879" FT DOMAIN 330..487 FT /note="C2 PI3K-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00880" FT DOMAIN 517..694 FT /note="PIK helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00878" FT DOMAIN 765..1051 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 771..777 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 912..920 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 931..957 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT SITE 776 FT /note="Implicated in the recognition of ATP as well as FT PIP2. Also crucial for autophosphorylation of the p85alpha FT subunit" FT /evidence="ECO:0000305|PubMed:23936502" FT VARIANT 38 FT /note="R -> H (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction between the PI3K-ABD domain and FT the N-terminal lobe of PI3K/PI4K kinase domain possibly FT affecting the conformation of the kinase domain; FT dbSNP:rs772110575)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026166" FT VARIANT 43 FT /note="I -> V (in dbSNP:rs1051399)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042942" FT VARIANT 81 FT /note="E -> K (in MCAP; dbSNP:rs1057519929)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069251" FT VARIANT 83 FT /note="F -> S (in CLAPO; uncertain significance; somatic FT mutation; dbSNP:rs1560137208)" FT /evidence="ECO:0000269|PubMed:29446767" FT /id="VAR_081475" FT VARIANT 88 FT /note="R -> Q (in MCAP; also found in a glioblastoma FT multiforme sample; dbSNP:rs121913287)" FT /evidence="ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026167" FT VARIANT 106 FT /note="G -> V (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT dbSNP:rs1057519930)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026168" FT VARIANT 112 FT /note="I -> N (in MCAP; increased phosphatidylinositol 3- FT kinase signaling; decreased interaction with p85 regulatory FT subunit; no effect on protein abundance; FT dbSNP:rs863225460)" FT /evidence="ECO:0000269|PubMed:26593112" FT /id="VAR_075634" FT VARIANT 115 FT /note="R -> P (in CLAPO and MADAC; uncertain significance; FT somatic mutation in CLAPO and MADAC patients; FT dbSNP:rs200018596)" FT /evidence="ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767" FT /id="VAR_081476" FT VARIANT 118 FT /note="G -> D (in CWS5; dbSNP:rs587777790)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069786" FT VARIANT 135 FT /note="E -> K (in CWS5; dbSNP:rs587777791)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069787" FT VARIANT 218 FT /note="E -> K (in CWS5; dbSNP:rs587777792)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069788" FT VARIANT 332 FT /note="S -> R (in dbSNP:rs1051407)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042943" FT VARIANT 343 FT /note="Y -> C (found in a cancer sample; uncertain FT significance; dbSNP:rs2108393253)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026169" FT VARIANT 356 FT /note="V -> I (in CWS5; dbSNP:rs587777793)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069789" FT VARIANT 364 FT /note="G -> R (in MCAP; dbSNP:rs1576935161)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069252" FT VARIANT 365 FT /note="E -> K (in MCAP; dbSNP:rs1064793732)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069253" FT VARIANT 378 FT /note="C -> Y (in MCAP; dbSNP:rs397514565)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069254" FT VARIANT 382 FT /note="R -> K (in CWS5; dbSNP:rs587777794)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069790" FT VARIANT 391 FT /note="I -> M (in dbSNP:rs2230461)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026170" FT VARIANT 420 FT /note="C -> R (in CLOVE, CRC and CLAPO; uncertain FT significance; somatic mutation in CLAPO patients; shows an FT increase in lipid kinase activity; may increase the FT affinity for lipid membranes; dbSNP:rs121913272)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:29446767" FT /id="VAR_026171" FT VARIANT 453 FT /note="E -> Q (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction of the C2 PI3K-type domain with FT the iSH2 region of the p85 regulatory subunit; FT dbSNP:rs1057519925)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026172" FT VARIANT 453 FT /note="Missing (in MCAP)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069255" FT VARIANT 542 FT /note="E -> K (in CLOVE, KERSEB, CRC, BC, CLAPO, MADAC, FT CCM4 and HFMH; somatic mutation; also found in glioblastoma FT multiforme and endometrial carcinoma; somatic mutation; FT shows an increase in lipid kinase activity; oncogenic in FT vivo; occurs in the interface between the PI3K helical FT domain and the nSH2 (N-terminal SH2) region of the p85 FT regulatory subunit and may reduce the inhibitory effect of FT p85; requires interaction with RAS to induce cellular FT transformation; increased AKT and RPS6 phosphorylation in FT HFMH patient's cells; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, FT ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, FT ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:22658544, FT ECO:0000269|PubMed:23100325, ECO:0000269|PubMed:29446767, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026173" FT VARIANT 542 FT /note="E -> Q (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026174" FT VARIANT 542 FT /note="E -> V (in BC; uncertain significance; FT dbSNP:rs1057519927)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026175" FT VARIANT 545 FT /note="E -> A (in CWS5 and HCC; also found in a FT glioblastoma multiforme sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15608678, FT ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:23246288" FT /id="VAR_026176" FT VARIANT 545 FT /note="E -> G (in KERSEB; also found in an endometrial FT carcinoma sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:17673550" FT /id="VAR_026177" FT VARIANT 545 FT /note="E -> K (in MCAP, KERSEB, CRC, BC and HFMH; somatic FT mutation; shows an increase in lipid kinase activity; FT oncogenic in vivo; occurs in the interface between the PI3K FT helical domain and the nSH2 (N-terminal SH2) region of the FT p85 regulatory subunit and may reduce the inhibitory effect FT of p85; requires interaction with RAS to induce cellular FT transformation; enhances invadopodia-mediated extracellular FT matrix degradation and invasion in breast cancer cells; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cells; dbSNP:rs104886003)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15712344, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22729224, FT ECO:0000269|PubMed:37712948" FT /id="VAR_026178" FT VARIANT 546 FT /note="Q -> E (in BC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026179" FT VARIANT 546 FT /note="Q -> K (in OC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026180" FT VARIANT 546 FT /note="Q -> P (found in an anaplastic astrocytoma sample; FT uncertain significance; dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026181" FT VARIANT 546 FT /note="Q -> R (in BC; uncertain significance; FT dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026182" FT VARIANT 726 FT /note="E -> K (in MCAP; dbSNP:rs867262025)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069256" FT VARIANT 914 FT /note="G -> R (in MCAP; dbSNP:rs587776932)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069257" FT VARIANT 1007 FT /note="G -> R (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1448660730)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026183" FT VARIANT 1021 FT /note="Y -> C (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913288)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026184" FT VARIANT 1021 FT /note="Y -> H (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026185" FT VARIANT 1021 FT /note="Y -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026186" FT VARIANT 1023 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs2108429549)" FT /evidence="ECO:0000269|PubMed:15994075" FT /id="VAR_026187" FT VARIANT 1025 FT /note="T -> A (in MCAP; dbSNP:rs397517202)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069258" FT VARIANT 1025 FT /note="T -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs1553826166)" FT /evidence="ECO:0000269|PubMed:15924253" FT /id="VAR_026188" FT VARIANT 1035 FT /note="A -> V (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs1242945375)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026189" FT VARIANT 1043 FT /note="M -> I (in MCAP and CRC; also found in an FT endometrial carcinoma sample; shows an increase in lipid FT kinase activity; dbSNP:rs121913283)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:22729224" FT /id="VAR_026190" FT VARIANT 1047 FT /note="H -> L (in BC, CLAPO, MADAC and CCM4; somatic FT mutation; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767, ECO:0000269|PubMed:34496175" FT /id="VAR_026191" FT VARIANT 1047 FT /note="H -> R (in CLOVE, KERSEB, CRC, BC, OC, MADAC, CCM4 FT and HFMH; also found in an endometrial carcinoma sample; FT somatic mutation; shows an increase in lipid kinase FT activity; oncogenic in vivo; requires binding to p85 FT regulatory subunit to induce cellular transformation but FT not interaction with RAS; may mimic the conformatitonal FT change triggered by the interaction with RAS; enhances FT invadopodia-mediated extracellular matrix degradation and FT invasion in breast cancer cells; may alter the interaction FT of the PI3K/PI4K kinase domain with the cell membrane; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cell; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15016963, FT ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16114017, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:21708979, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026192" FT VARIANT 1047 FT /note="H -> Y (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913281)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026193" FT VARIANT 1049 FT /note="G -> S (in MCAP; dbSNP:rs121913277)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069259" FT VARIANT 1050 FT /note="G -> D (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429937)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026194" FT VARIANT 1052 FT /note="T -> K (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429956)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026195" FT VARIANT 1065 FT /note="H -> L (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1560150596)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026196" FT VARIANT 1065 FT /note="H -> Y (found in brain tumors; uncertain FT significance; dbSNP:rs2108430115)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026197" FT CONFLICT 170 FT /note="N -> H (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 187 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 286..287 FT /note="ML -> KM (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="V -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 723 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 751 FT /note="F -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 767 FT /note="E -> K (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT STRAND 5..10 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 13..15 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 18..25 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 27..29 FT /evidence="ECO:0007829|PDB:8TSA" FT STRAND 31..37 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 42..52 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 59..61 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 65..67 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 69..74 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:4OVU" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 89..91 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 94..102 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5SXA" FT HELIX 108..121 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 126..129 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 134..142 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 144..154 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 155..159 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 160..166 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 179..182 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 183..185 FT /evidence="ECO:0007829|PDB:3HHM" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:8BFU" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 199..202 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 204..212 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 217..230 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:8V8V" FT HELIX 236..246 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 247..249 FT /evidence="ECO:0007829|PDB:7JIU" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8W9A" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8W9B" FT STRAND 263..265 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 267..269 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 271..279 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 284..289 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 290..294 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:5SXA" FT STRAND 323..326 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 332..343 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 348..350 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 353..362 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 365..368 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 378..380 FT /evidence="ECO:0007829|PDB:6PYS" FT STRAND 382..392 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 393..395 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 400..408 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 413..415 FT /evidence="ECO:0007829|PDB:8SBC" FT STRAND 420..430 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 434..436 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 439..444 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8GUA" FT STRAND 454..456 FT /evidence="ECO:0007829|PDB:6GVF" FT STRAND 458..460 FT /evidence="ECO:0007829|PDB:8V8V" FT STRAND 468..470 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 472..477 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 481..485 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 489..504 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 508..511 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:4TUU" FT TURN 520..522 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 525..536 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 539..541 FT /evidence="ECO:0007829|PDB:4TUU" FT HELIX 545..553 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 562..564 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 565..569 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 570..572 FT /evidence="ECO:0007829|PDB:8W9A" FT HELIX 577..588 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 595..598 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 599..602 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 603..605 FT /evidence="ECO:0007829|PDB:8GUD" FT HELIX 609..622 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 625..630 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 632..638 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 639..641 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 661..672 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 673..676 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 678..680 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 681..694 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 698..721 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 724..726 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 728..739 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 742..747 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 749..753 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 756..761 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 766..768 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 773..776 FT /evidence="ECO:0007829|PDB:8DCP" FT STRAND 779..784 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 786..789 FT /evidence="ECO:0007829|PDB:7MYN" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 795..805 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 808..826 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 838..842 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 845..849 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 852..856 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 857..860 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 863..865 FT /evidence="ECO:0007829|PDB:7K6N" FT STRAND 866..868 FT /evidence="ECO:0007829|PDB:8TSA" FT HELIX 869..871 FT /evidence="ECO:0007829|PDB:7K6N" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 876..884 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7JIU" FT HELIX 890..911 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 920..924 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 925..927 FT /evidence="ECO:0007829|PDB:8GUD" FT STRAND 929..931 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 935..937 FT /evidence="ECO:0007829|PDB:8W9B" FT TURN 938..941 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 948..950 FT /evidence="ECO:0007829|PDB:7K6M" FT STRAND 951..954 FT /evidence="ECO:0007829|PDB:7K6M" FT HELIX 958..964 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 965..967 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 971..973 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 975..993 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 995..1003 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1004..1007 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1013..1015 FT /evidence="ECO:0007829|PDB:8EXV" FT HELIX 1016..1025 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1026..1029 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 1032..1047 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1048..1050 FT /evidence="ECO:0007829|PDB:5SW8" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:3HHM" FT STRAND 1056..1058 FT /evidence="ECO:0007829|PDB:4JPS" SQ SEQUENCE 1068 AA; 124284 MW; 041487231A9A1207 CRC64; MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLITIKHELF KEARKYPLHQ LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFA IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPMD CFTMPSYSRR ISTATPYMNG ETSTKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF SSVVKFPDMS VIEEHANWSV SREAGFSYSH AGLSNRLARD NELRENDKEQ LKAISTRDPL SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME LLDCNYPDPM VRGFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK QEKKDETQKV QMKFLVEQMR RPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF LIVISKGAQE CTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA YIRKTLALDK TEQEALEYFM KQMNDAHHGG WTTKMDWIFH TIKQHALN // ID PRAP1_HUMAN Reviewed; 151 AA. AC Q96NZ9; B7ZL57; B7ZL58; E9KL31; Q5VWY4; Q7Z4X5; Q8IWR3; Q8NCS2; DT 11-SEP-2007, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 2. DT 28-JAN-2026, entry version 153. DE RecName: Full=Proline-rich acidic protein 1; DE AltName: Full=Epididymis tissue protein Li 178; DE AltName: Full=Uterine-specific proline-rich acidic protein; DE Flags: Precursor; GN Name=PRAP1; Synonyms=UPA; ORFNames=UNQ608/PRO1195; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 4), FUNCTION, INDUCTION, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND VARIANTS GLY-54; ARG-69 AND RP ARG-101. RX PubMed=14583459; RA Zhang J., Wong H., Ramanan S., Cheong D., Leong A., Hooi S.C.; RT "The proline-rich acidic protein is epigenetically regulated and inhibits RT growth of cancer cell lines."; RL Cancer Res. 63:6658-6665(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ARG-101, AND TISSUE RP SPECIFICITY. RC TISSUE=Epididymis; RX PubMed=20736409; DOI=10.1074/mcp.m110.001719; RA Li J., Liu F., Wang H., Liu X., Liu J., Li N., Wan F., Wang W., Zhang C., RA Jin S., Liu J., Zhu P., Liu Y.; RT "Systematic mapping and functional analysis of a family of human epididymal RT secretory sperm-located proteins."; RL Mol. Cell. Proteomics 9:2517-2528(2010). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-101. RA Zheng L.H., Yu L., Zhao S.Y.; RT "A novel human cDNA homologous to Mus musculus uterine-specific proline- RT rich acidic protein mRNA."; RL Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-101. RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-101. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4), NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 4-151 (ISOFORM 3), AND VARIANT ARG-101. RC TISSUE=Liver, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, AND INDUCTION. RX PubMed=23235459; DOI=10.1038/cddis.2012.180; RA Huang B.H., Zhuo J.L., Leung C.H., Lu G.D., Liu J.J., Yap C.T., Hooi S.C.; RT "PRAP1 is a novel executor of p53-dependent mechanisms in cell survival RT after DNA damage."; RL Cell Death Dis. 3:e442-e442(2012). RN [9] RP FUNCTION, INTERACTION WITH MAD1L1, AND TISSUE SPECIFICITY. RX PubMed=24374861; DOI=10.1002/path.4319; RA Sze K.M., Chu G.K., Mak Q.H., Lee J.M., Ng I.O.; RT "Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of RT MAD1 and has a suppressive role in mitotic checkpoint signalling in RT hepatocellular carcinoma."; RL J. Pathol. 233:51-60(2014). RN [10] RP TISSUE SPECIFICITY. RX PubMed=32629119; DOI=10.1016/j.jcmgh.2020.06.011; RA Wolfarth A.A., Liu X., Darby T.M., Boyer D.J., Spizman J.B., Owens J.A., RA Chandrasekharan B., Naudin C.R., Hanley K.Z., Robinson B.S., Ortlund E.A., RA Jones R.M., Neish A.S.; RT "Proline-Rich Acidic Protein 1 (PRAP1) Protects the Gastrointestinal RT Epithelium From Irradiation-Induced Apoptosis."; RL Cell. Mol. Gastroenterol. Hepatol. 10:713-727(2020). CC -!- FUNCTION: Lipid-binding protein which promotes lipid absorption by CC facilitating MTTP-mediated lipid transfer (mainly triglycerides and CC phospholipids) and MTTP-mediated apoB lipoprotein assembly and CC secretion (By similarity). Protects the gastrointestinal epithelium CC from irradiation-induced apoptosis (By similarity). May play an CC important role in maintaining normal growth homeostasis in epithelial CC cells (PubMed:14583459). Involved in p53/TP53-dependent cell survival CC after DNA damage (PubMed:23235459). May down-regulate the expression of CC MAD1L1 and exert a suppressive role in mitotic spindle assembly CC checkpoint in hepatocellular carcinomas (PubMed:24374861). CC {ECO:0000250|UniProtKB:Q80XD8, ECO:0000269|PubMed:14583459, CC ECO:0000269|PubMed:23235459, ECO:0000269|PubMed:24374861}. CC -!- SUBUNIT: Interacts with isoform 1 and isoform 3 of MAD1L1 CC (PubMed:24374861). Interacts with MTTP (By similarity). CC {ECO:0000250|UniProtKB:Q80XD8, ECO:0000269|PubMed:24374861}. CC -!- INTERACTION: CC Q96NZ9; Q8IVF2-3: AHNAK2; NbExp=3; IntAct=EBI-2116102, EBI-12078468; CC Q96NZ9; Q12797-6: ASPH; NbExp=3; IntAct=EBI-2116102, EBI-12092171; CC Q96NZ9; Q96LK0: CEP19; NbExp=3; IntAct=EBI-2116102, EBI-741885; CC Q96NZ9; P17066: HSPA6; NbExp=3; IntAct=EBI-2116102, EBI-355106; CC Q96NZ9; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-2116102, EBI-16439278; CC Q96NZ9; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-2116102, EBI-995714; CC Q96NZ9; O43765: SGTA; NbExp=9; IntAct=EBI-2116102, EBI-347996; CC Q96NZ9; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-2116102, EBI-744081; CC Q96NZ9; Q9UMX0: UBQLN1; NbExp=6; IntAct=EBI-2116102, EBI-741480; CC Q96NZ9; Q9UMX0-2: UBQLN1; NbExp=3; IntAct=EBI-2116102, EBI-10173939; CC Q96NZ9; Q9UHD9: UBQLN2; NbExp=6; IntAct=EBI-2116102, EBI-947187; CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:14583459}. CC Endoplasmic reticulum {ECO:0000250|UniProtKB:Q80XD8}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=PRAP; CC IsoId=Q96NZ9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96NZ9-2; Sequence=VSP_027661, VSP_027662; CC Name=3; Synonyms=PRAPV1; CC IsoId=Q96NZ9-3; Sequence=VSP_027660; CC Name=4; Synonyms=PRAPV2; CC IsoId=Q96NZ9-4; Sequence=VSP_027661; CC -!- TISSUE SPECIFICITY: Highly expressed in the intestinal epithelial cells CC (at protein level) (PubMed:32629119). Abundantly expressed in the CC epithelial cells of the liver, kidney and cervix. Significantly down- CC regulated in hepatocellular carcinoma and right colon adenocarcinoma CC compared with the respective adjacent normal tissues. Expressed in CC epididymis (at protein level). {ECO:0000269|PubMed:14583459, CC ECO:0000269|PubMed:20736409, ECO:0000269|PubMed:24374861, CC ECO:0000269|PubMed:32629119}. CC -!- INDUCTION: Up-regulated by butyrate, trichostatin A and 5'-aza-2' CC deoxycytidine (PubMed:14583459). Induced by DNA-damaging agents in a CC p53/TP53-dependent manner in HepG2 liver cancer cell line and HCT116 CC colon cancer cell line (PubMed:23235459). {ECO:0000269|PubMed:14583459, CC ECO:0000269|PubMed:23235459}. CC -!- SEQUENCE CAUTION: CC Sequence=AAP97247.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF421885; AAL16670.1; -; mRNA. DR EMBL; AY158074; AAN87018.1; -; mRNA. DR EMBL; AF123768; AAP97247.1; ALT_FRAME; mRNA. DR EMBL; AY358908; AAQ89267.1; -; mRNA. DR EMBL; GU727628; ADU87630.1; -; mRNA. DR EMBL; AL360181; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471211; EAW61336.1; -; Genomic_DNA. DR EMBL; BC029447; AAH29447.2; -; mRNA. DR EMBL; BC061643; AAH61643.1; -; mRNA. DR EMBL; BC071872; AAH71872.1; -; mRNA. DR EMBL; BC093853; AAH93853.1; -; mRNA. DR EMBL; BC101743; AAI01744.1; -; mRNA. DR EMBL; BC143590; AAI43591.1; -; mRNA. DR EMBL; BC143592; AAI43593.1; -; mRNA. DR EMBL; BC143591; AAI43592.1; -; mRNA. DR CCDS; CCDS44498.1; -. [Q96NZ9-4] DR CCDS; CCDS7679.1; -. [Q96NZ9-1] DR RefSeq; NP_001138673.1; NM_001145201.2. [Q96NZ9-4] DR RefSeq; NP_660203.3; NM_145202.4. [Q96NZ9-1] DR AlphaFoldDB; Q96NZ9; -. DR BioGRID; 125610; 18. DR FunCoup; Q96NZ9; 153. DR IntAct; Q96NZ9; 17. DR STRING; 9606.ENSP00000416126; -. DR BindingDB; Q96NZ9; -. DR ChEMBL; CHEMBL4879502; -. DR GlyCosmos; Q96NZ9; 1 site, 1 glycan. DR GlyGen; Q96NZ9; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q96NZ9; -. DR PhosphoSitePlus; Q96NZ9; -. DR BioMuta; PRAP1; -. DR DMDM; 317373269; -. DR jPOST; Q96NZ9; -. DR MassIVE; Q96NZ9; -. DR PaxDb; 9606-ENSP00000416126; -. DR PeptideAtlas; Q96NZ9; -. DR ProteomicsDB; 77584; -. [Q96NZ9-2] DR ProteomicsDB; 77585; -. [Q96NZ9-3] DR ProteomicsDB; 77586; -. [Q96NZ9-4] DR Antibodypedia; 48788; 69 antibodies from 18 providers. DR DNASU; 118471; -. DR Ensembl; ENST00000433452.6; ENSP00000416126.2; ENSG00000165828.16. [Q96NZ9-1] DR Ensembl; ENST00000463201.2; ENSP00000486265.1; ENSG00000165828.16. [Q96NZ9-4] DR GeneID; 118471; -. DR KEGG; hsa:118471; -. DR MANE-Select; ENST00000433452.6; ENSP00000416126.2; NM_145202.5; NP_660203.3. DR UCSC; uc001lmp.3; human. [Q96NZ9-1] DR AGR; HGNC:23304; -. DR ClinPGx; PA134981678; -. DR CTD; 118471; -. DR DisGeNET; 118471; -. DR GeneCards; PRAP1; -. DR HGNC; HGNC:23304; PRAP1. DR HPA; ENSG00000165828; Group enriched (intestine, liver). DR MIM; 609776; gene. DR OpenTargets; ENSG00000165828; -. DR VEuPathDB; HostDB:ENSG00000165828; -. DR eggNOG; ENOG502TDVH; Eukaryota. DR GeneTree; ENSGT00390000012626; -. DR InParanoid; Q96NZ9; -. DR OMA; WVETEDI; -. DR OrthoDB; 9938040at2759; -. DR PAN-GO; Q96NZ9; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q96NZ9; -. DR PathwayCommons; Q96NZ9; -. DR SignaLink; Q96NZ9; -. DR Agora; ENSG00000165828; -. DR BioGRID-ORCS; 118471; 9 hits in 1130 CRISPR screens. DR ChiTaRS; PRAP1; human. DR GenomeRNAi; 118471; -. DR Pharos; Q96NZ9; Tchem. DR PRO; PR:Q96NZ9; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q96NZ9; protein. DR Bgee; ENSG00000165828; Expressed in duodenum and 96 other cell types or tissues. DR ExpressionAtlas; Q96NZ9; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB. DR GO; GO:0005576; C:extracellular region; ISS:UniProtKB. DR GO; GO:0017129; F:triglyceride binding; ISS:UniProtKB. DR GO; GO:0071481; P:cellular response to X-ray; ISS:UniProtKB. DR GO; GO:1902426; P:deactivation of mitotic spindle assembly checkpoint; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:1904731; P:positive regulation of intestinal lipid absorption; ISS:UniProtKB. DR GO; GO:2001140; P:positive regulation of phospholipid transport; ISS:UniProtKB. DR GO; GO:1905885; P:positive regulation of triglyceride transport; ISS:UniProtKB. DR InterPro; IPR027922; PRAP. DR PANTHER; PTHR37861; PROLINE-RICH ACIDIC PROTEIN 1; 1. DR PANTHER; PTHR37861:SF1; PROLINE-RICH ACIDIC PROTEIN 1; 1. DR Pfam; PF15314; PRAP; 1. PE 1: Evidence at protein level; KW Alternative splicing; Endoplasmic reticulum; Lipid-binding; KW Proteomics identification; Reference proteome; Secreted; Signal. FT SIGNAL 1..20 FT /evidence="ECO:0000255" FT CHAIN 21..151 FT /note="Proline-rich acidic protein 1" FT /id="PRO_0000299416" FT REGION 71..151 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 43 FT /note="K -> NR (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_027660" FT VAR_SEQ 79..87 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14583459, FT ECO:0000303|PubMed:15489334" FT /id="VSP_027661" FT VAR_SEQ 95..151 FT /note="TEDTLGHVLSPEPDHDSLYHPPPEEDQGEERPRLWVMPNHQVLLGPEEDQDH FT IYHPQ -> SRARP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14583459" FT /id="VSP_027662" FT VARIANT 54 FT /note="E -> G (in dbSNP:rs1848687860)" FT /evidence="ECO:0000269|PubMed:14583459" FT /id="VAR_034815" FT VARIANT 69 FT /note="K -> R" FT /evidence="ECO:0000269|PubMed:14583459" FT /id="VAR_034816" FT VARIANT 81 FT /note="G -> S (in dbSNP:rs34780987)" FT /id="VAR_034817" FT VARIANT 101 FT /note="H -> R (in dbSNP:rs4369319)" FT /evidence="ECO:0000269|PubMed:12975309, FT ECO:0000269|PubMed:14583459, ECO:0000269|PubMed:15164054, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:20736409, FT ECO:0000269|Ref.3" FT /id="VAR_034818" SQ SEQUENCE 151 AA; 17208 MW; B751EDBFD24D08CA CRC64; MRRLLLVTSL VVVLLWEAGA VPAPKVPIKM QVKHWPSEQD PEKAWGARVV EPPEKDDQLV VLFPVQKPKL LTTEEKPRGQ GRGPILPGTK AWMETEDTLG HVLSPEPDHD SLYHPPPEED QGEERPRLWV MPNHQVLLGP EEDQDHIYHP Q // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID RASK_HUMAN Reviewed; 189 AA. AC P01116; A8K8Z5; B0LPF9; P01118; Q96D10; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 268. DE RecName: Full=GTPase KRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; DE AltName: Full=K-Ras 2; DE AltName: Full=Ki-Ras; DE AltName: Full=c-K-ras; DE AltName: Full=c-Ki-ras; DE Contains: DE RecName: Full=GTPase KRas, N-terminally processed; DE Flags: Precursor; GN Name=KRAS; Synonyms=KRAS2, RASK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RX PubMed=6308466; DOI=10.1038/304501a0; RA McGrath J.P., Capon D.J., Smith D.H., Chen E.Y., Seeburg P.H., RA Goeddel D.V., Levinson A.D.; RT "Structure and organization of the human Ki-ras proto-oncogene and a RT related processed pseudogene."; RL Nature 304:501-506(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Lung carcinoma; RX PubMed=6308465; DOI=10.1038/304497a0; RA Shimizu K., Birnbaum D., Ruley M.A., Fasano O., Suard Y., Edlund L., RA Taparowsky E., Goldfarb M., Wigler M.; RT "Structure of the Ki-ras gene of the human lung carcinoma cell line Calu- RT 1."; RL Nature 304:497-500(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Colon carcinoma, and Lung; RX PubMed=6308467; DOI=10.1038/304507a0; RA Capon D.J., Seeburg P.H., McGrath J.P., Hayflick J.S., Edman U., RA Levinson A.D., Goeddel D.V.; RT "Activation of Ki-ras2 gene in human colon and lung carcinomas by two RT different point mutations."; RL Nature 304:507-513(1983). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B), AND VARIANT COLON RP CANCER VAL-12. RC TISSUE=Colon carcinoma; RX PubMed=6092920; DOI=10.1128/mcb.4.8.1577-1582.1984; RA McCoy M.S., Bargmann C.I., Weinberg R.A.; RT "Human colon carcinoma Ki-ras2 oncogene and its corresponding proto- RT oncogene."; RL Mol. Cell. Biol. 4:1577-1582(1984). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2B). RX PubMed=3310850; RA Kahn S., Yamamoto F., Almoguera C., Winter E., Forrester K., Jordano J., RA Perucho M.; RT "The c-K-ras gene and human cancer (review)."; RL Anticancer Res. 7:639-652(1987). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG SeattleSNPs variation discovery resource; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT LUNG CARCINOMA RP CYS-12. RC TISSUE=Lung carcinoma; RX PubMed=6320174; DOI=10.1073/pnas.81.1.71; RA Nakano H., Yamamoto F., Neville C., Evans D., Mizuno T., Perucho M.; RT "Isolation of transforming sequences of two human lung carcinomas: RT structural and functional analysis of the activated c-K-ras oncogenes."; RL Proc. Natl. Acad. Sci. U.S.A. 81:71-75(1984). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96. RC TISSUE=Pancreatic carcinoma; RX PubMed=3855240; DOI=10.1016/s0006-291x(85)80140-6; RA Hirai H., Okabe T., Anraku Y., Fujisawa M., Urabe A., Takaku F.; RT "Activation of the c-K-ras oncogene in a human pancreas carcinoma."; RL Biochem. Biophys. Res. Commun. 127:168-174(1985). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT GASC VAL-12. RX PubMed=3034404; RA Deng G., Lu Y., Chen S., Miao J., Lu G., Li H., Cai H., Xu X., Zheng E., RA Liu P.; RT "Activated c-Ha-ras oncogene with a guanine to thymine transversion at the RT twelfth codon in a human stomach cancer cell line."; RL Cancer Res. 47:3195-3198(1987). RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36, AND VARIANT BLADDER/LUNG CANCER RP ARG-12. RC TISSUE=Lung carcinoma; RX PubMed=6695174; DOI=10.1126/science.6695174; RA Santos E., Martin-Zanca D., Reddy P.E., Pierotti M.A., Porta G., RA Barbacid M.; RT "Malignant activation of a K-ras oncogene in lung carcinoma but not in RT normal tissue of the same patient."; RL Science 223:661-664(1984). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=3932274; RA Sekiya T., Tokunaga A., Fushimi M.; RT "Essential region for transforming activity of human c-Ha-ras-1."; RL Jpn. J. Cancer Res. 76:787-791(1985). RN [17] RP PROTEIN SEQUENCE OF 1-41; 43-147 AND 150-161, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96. RC TISSUE=Lung carcinoma; RX PubMed=6096811; DOI=10.1093/nar/12.23.8873; RA Yamamoto F., Perucho M.; RT "Activation of a human c-K-ras oncogene."; RL Nucleic Acids Res. 12:8873-8885(1984). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [20] RP INTERACTION WITH RAP1GDS1. RX PubMed=20709748; DOI=10.1074/jbc.m110.129916; RA Berg T.J., Gastonguay A.J., Lorimer E.L., Kuhnmuench J.R., Li R., RA Fields A.P., Williams C.L.; RT "Splice variants of SmgGDS control small GTPase prenylation and membrane RT localization."; RL J. Biol. Chem. 285:35255-35266(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP ACETYLATION AT LYS-104, VARIANT VAL-12, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=22711838; DOI=10.1073/pnas.1201487109; RA Yang M.H., Nickerson S., Kim E.T., Liot C., Laurent G., Spang R., RA Philips M.R., Shan Y., Shaw D.E., Bar-Sagi D., Haigis M.C., Haigis K.M.; RT "Regulation of RAS oncogenicity by acetylation."; RL Proc. Natl. Acad. Sci. U.S.A. 109:10843-10848(2012). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDE6D. RX PubMed=23698361; DOI=10.1038/nature12205; RA Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., RA Hahn S.A., Triola G., Wittinghofer A., Bastiaens P.I., Waldmann H.; RT "Small molecule inhibition of the KRAS-PDE? interaction impairs oncogenic RT KRAS signalling."; RL Nature 497:638-642(2013). RN [24] RP FUNCTION, AND CHARACTERIZATION OF VARIANT COLON CANCER VAL-12. RX PubMed=24623306; DOI=10.7554/elife.02313; RA Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.; RT "A KRAS-directed transcriptional silencing pathway that mediates the CpG RT island methylator phenotype."; RL Elife 3:E02313-E02313(2014). RN [25] RP INTERACTION WITH RAP1GDS1, AND ISOPRENYLATION AT CYS-186. RX PubMed=24415755; DOI=10.1074/jbc.m113.527192; RA Schuld N.J., Vervacke J.S., Lorimer E.L., Simon N.C., Hauser A.D., RA Barbieri J.T., Distefano M.D., Williams C.L.; RT "The chaperone protein SmgGDS interacts with small GTPases entering the RT prenylation pathway by recognizing the last amino acid in the CAAX motif."; RL J. Biol. Chem. 289:6862-6876(2014). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [27] RP PALMITOYLATION AT CYS-180; LYS-182; LYS-184 AND LYS-185, DEPALMITOYLATION RP BY SIRT2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-180 AND RP 182-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [28] RP INTERACTION WITH GPR31. RX PubMed=28619714; DOI=10.1083/jcb.201609096; RA Fehrenbacher N., Tojal da Silva I., Ramirez C., Zhou Y., Cho K.J., RA Kuchay S., Shi J., Thomas S., Pagano M., Hancock J.F., Bar-Sagi D., RA Philips M.R.; RT "The G protein-coupled receptor GPR31 promotes membrane association of RT KRAS."; RL J. Cell Biol. 216:2329-2338(2017). RN [29] RP UBIQUITINATION AT LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [30] RP UBIQUITINATION. RX PubMed=30442766; DOI=10.1126/science.aap8210; RA Bigenzahn J.W., Collu G.M., Kartnig F., Pieraks M., Vladimer G.I., RA Heinz L.X., Sedlyarov V., Schischlik F., Fauster A., Rebsamen M., RA Parapatics K., Blomen V.A., Mueller A.C., Winter G.E., Kralovics R., RA Brummelkamp T.R., Mlodzik M., Superti-Furga G.; RT "LZTR1 is a regulator of RAS ubiquitination and signaling."; RL Science 362:1171-1177(2018). RN [31] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [32] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [33] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND CHARACTERIZATION OF RP VARIANT GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [34] RP INTERACTION WITH PPP1CA AND SHOC2, AND CHARACTERIZATION OF VARIANT GLN-61. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1-164 IN COMPLEX WITH THE GTP RP ANALOG GUANOSINE-5'-DIPHOSPHATE, AND ACTIVITY REGULATION. RX PubMed=22566140; DOI=10.1002/anie.201201358; RA Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., RA Lee T., Rossanese O.W., Fesik S.W.; RT "Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated RT activation."; RL Angew. Chem. Int. Ed. Engl. 51:6140-6143(2012). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 2-164 IN COMPLEX WITH GTP ANALOGS RP AND MAGNESIUM, FUNCTION, ACTIVITY REGULATION, INTERACTION WITH SOS1, AND RP SUBCELLULAR LOCATION. RX PubMed=22431598; DOI=10.1073/pnas.1116510109; RA Maurer T., Garrenton L.S., Oh A., Pitts K., Anderson D.J., Skelton N.J., RA Fauber B.P., Pan B., Malek S., Stokoe D., Ludlam M.J., Bowman K.K., Wu J., RA Giannetti A.M., Starovasnik M.A., Mellman I., Jackson P.K., Rudolph J., RA Wang W., Fang G.; RT "Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS- RT mediated nucleotide exchange activity."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5299-5304(2012). RN [37] {ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-164, ISOPRENYLATION AT CYS-186, RP AND METHYLATION AT CYS-186. RX PubMed=27791178; DOI=10.1073/pnas.1615316113; RA Dharmaiah S., Bindu L., Tran T.H., Gillette W.K., Frank P.H., Ghirlando R., RA Nissley D.V., Esposito D., McCormick F., Stephen A.G., Simanshu D.K.; RT "Structural basis of recognition of farnesylated and methylated KRAS4b by RT PDEdelta."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E6766-E6775(2016). RN [38] {ECO:0007744|PDB:7LC1, ECO:0007744|PDB:7LC2} RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) IN COMPLEX WITH MAPKAP1, INTERACTION RP WITH MAPKAP1, AND MUTAGENESIS OF ASP-38 AND TYR-40. RX PubMed=34380736; DOI=10.1073/pnas.2103261118; RA Castel P., Dharmaiah S., Sale M.J., Messing S., Rizzuto G., RA Cuevas-Navarro A., Cheng A., Trnka M.J., Urisman A., Esposito D., RA Simanshu D.K., McCormick F.; RT "RAS interaction with Sin1 is dispensable for mTORC2 assembly and RT activity."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [39] {ECO:0007744|PDB:7VVB} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH MAPKAP1, AND RP INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [40] RP VARIANT BREAST CANCER ASP-13. RX PubMed=3627975; DOI=10.1093/nar/15.15.5963; RA Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., RA Hynes N.E.; RT "The human c-Kirsten ras gene is activated by a novel mutation in codon 13 RT in the breast carcinoma cell line MDA-MB231."; RL Nucleic Acids Res. 15:5963-5971(1987). RN [41] RP VARIANT BLADDER CANCER THR-59. RX PubMed=1553789; DOI=10.1007/bf00296523; RA Grimmond S.M., Raghavan D., Russell P.J.; RT "Detection of a rare point mutation in Ki-ras of a human bladder cancer RT xenograft by polymerase chain reaction and direct sequencing."; RL Urol. Res. 20:121-126(1992). RN [42] RP VARIANTS PANCREATIC CARCINOMA ASP-12 AND VAL-12. RX PubMed=8439212; DOI=10.1097/00000658-199302000-00007; RA Motojima K., Urano T., Nagata Y., Shiku H., Tsurifune T., Kanematsu T.; RT "Detection of point mutations in the Kirsten-ras oncogene provides evidence RT for the multicentricity of pancreatic carcinoma."; RL Ann. Surg. 217:138-143(1993). RN [43] RP VARIANTS GASC SER-12 AND ASP-12. RX PubMed=7773929; RX DOI=10.1002/1097-0142(19950615)75:12<2794::aid-cncr2820751203>3.0.co;2-f; RA Lee K.H., Lee J.S., Suh C., Kim S.W., Kim S.B., Lee J.H., Lee M.S., RA Park M.Y., Sun H.S., Kim S.H.; RT "Clinicopathologic significance of the K-ras gene codon 12 point mutation RT in stomach cancer. An analysis of 140 cases."; RL Cancer 75:2794-2801(1995). RN [44] RP INVOLVEMENT IN AML, VARIANT GLY-10 INS, AND CHARACTERIZATION OF VARIANT RP GLY-10 INS. RX PubMed=8955068; DOI=10.1074/jbc.271.51.32491; RA Bollag G., Adler F., elMasry N., McCabe P.C., Conner E. Jr., Thompson P., RA McCormick F., Shannon K.; RT "Biochemical characterization of a novel KRAS insertion mutation from a RT human leukemia."; RL J. Biol. Chem. 271:32491-32494(1996). RN [45] RP VARIANTS GASC ASN-5; VAL-12; ASP-13 AND THR-59. RX PubMed=14534542; DOI=10.1038/sj.onc.1206749; RA Lee S.H., Lee J.W., Soung Y.H., Kim H.S., Park W.S., Kim S.Y., Lee J.H., RA Park J.Y., Cho Y.G., Kim C.J., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J.; RT "BRAF and KRAS mutations in stomach cancer."; RL Oncogene 22:6942-6945(2003). RN [46] RP VARIANT PYLOCYTIC ASTROCYTOMA ARG-13. RX PubMed=16247081; DOI=10.1212/01.wnl.0000180409.78098.d7; RA Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H.; RT "RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic RT astrocytoma."; RL Neurology 65:1335-1336(2005). RN [47] RP VARIANTS NS3 GLY-152 AND VAL-153 (ISOFORM 2). RX PubMed=16773572; DOI=10.1086/504394; RA Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I., Sarkozy A., RA Digilio C., Palleschi A., Pizzuti A., Grammatico P., Zampino G., RA Dallapiccola B., Gelb B.D., Tartaglia M.; RT "Germline missense mutations affecting KRAS Isoform B are associated with a RT severe Noonan syndrome phenotype."; RL Am. J. Hum. Genet. 79:129-135(2006). RN [48] RP VARIANTS LUNG CARCINOMA CYS-12; ASP-12; SER-12; VAL-12 AND HIS-61. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [49] RP VARIANT CFC2 ARG-60. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [50] RP VARIANTS NS3 ILE-14 AND ILE-58, VARIANT CFC2 ARG-34, AND CHARACTERIZATION RP OF VARIANTS NS3 ILE-14 AND ILE-58. RX PubMed=16474405; DOI=10.1038/ng1748; RA Schubbert S., Zenker M., Rowe S.L., Boell S., Klein C., Bollag G., RA van der Burgt I., Musante L., Kalscheuer V., Wehner L.-E., Nguyen H., RA West B., Zhang K.Y.J., Sistermans E., Rauch A., Niemeyer C.M., Shannon K., RA Kratz C.P.; RT "Germline KRAS mutations cause Noonan syndrome."; RL Nat. Genet. 38:331-336(2006). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-12; ASP-12; SER-12; VAL-12; ASP-13; RP ARG-61; ASN-117 AND THR-146. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS JMML ASP-12; SER-12 AND ASP-13. RX PubMed=17332249; DOI=10.1182/blood-2006-09-046649; RA Matsuda K., Shimada A., Yoshida N., Ogawa A., Watanabe A., Yajima S., RA Iizuka S., Koike K., Yanai F., Kawasaki K., Yanagimachi M., Kikuchi A., RA Ohtsuka Y., Hidaka E., Yamauchi K., Tanaka M., Yanagisawa R., Nakazawa Y., RA Shiohara M., Manabe A., Kojima S., Koike K.; RT "Spontaneous improvement of hematologic abnormalities in patients having RT juvenile myelomonocytic leukemia with specific RAS mutations."; RL Blood 109:5477-5480(2007). RN [53] RP VARIANT NS3 GLU-5. RX PubMed=17468812; DOI=10.1007/s10038-007-0146-1; RA Bertola D.R., Pereira A.C., Brasil A.S., Albano L.M., Kim C.A., RA Krieger J.E.; RT "Further evidence of genetic heterogeneity in Costello syndrome: RT involvement of the KRAS gene."; RL J. Hum. Genet. 52:521-526(2007). RN [54] RP VARIANTS NS3 ILE-14; ARG-22; LEU-34; GLN-34; MET-36; VAL-153 AND ILE-156 RP (ISOFORM 2), VARIANT CFC2 GLU-22, AND VARIANTS ASN-5 AND LEU-156 (ISOFORM RP 2). RX PubMed=17056636; DOI=10.1136/jmg.2006.046300; RA Zenker M., Lehmann K., Schulz A.L., Barth H., Hansmann D., Koenig R., RA Korinthenberg R., Kreiss-Nachtsheim M., Meinecke P., Morlot S., Mundlos S., RA Quante A.S., Raskin S., Schnabel D., Wehner L.E., Kratz C.P., Horn D., RA Kutsche K.; RT "Expansion of the genotypic and phenotypic spectrum in patients with KRAS RT germline mutations."; RL J. Med. Genet. 44:131-135(2007). RN [55] RP VARIANTS NS3 ILE-58 AND SER-60. RX PubMed=19396835; DOI=10.1002/ajmg.a.32786; RA Kratz C.P., Zampino G., Kriek M., Kant S.G., Leoni C., Pantaleoni F., RA Oudesluys-Murphy A.M., Di Rocco C., Kloska S.P., Tartaglia M., Zenker M.; RT "Craniosynostosis in patients with Noonan syndrome caused by germline KRAS RT mutations."; RL Am. J. Med. Genet. A 149:1036-1040(2009). RN [56] RP CHARACTERIZATION OF VARIANTS NS3 ILE-14; ARG-22; LEU-34; ILE-58 AND VAL-153 RP (ISOFORM 2), CHARACTERIZATION OF VARIANTS CFC2 GLU-22; ARG-34 AND ARG-60, RP CHARACTERIZATION OF VARIANTS ASN-5 AND LEU-156 (ISOFORM 2), FUNCTION, AND RP CATALYTIC ACTIVITY. RX PubMed=20949621; DOI=10.1002/humu.21377; RA Gremer L., Merbitz-Zahradnik T., Dvorsky R., Cirstea I.C., Kratz C.P., RA Zenker M., Wittinghofer A., Ahmadian M.R.; RT "Germline KRAS mutations cause aberrant biochemical and physical properties RT leading to developmental disorders."; RL Hum. Mutat. 32:33-43(2011). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, CHARACTERIZATION OF RP VARIANT VAL-12, AND MUTAGENESIS OF GLN-61. RX PubMed=39809765; DOI=10.1038/s41467-025-55967-y; RA Bernal Astrain G., Strakhova R., Jo C.H., Teszner E., Killoran R.C., RA Smith M.J.; RT "The small GTPase MRAS is a broken switch."; RL Nat. Commun. 16:647-647(2025). RN [58] RP VARIANTS CFC2 HIS-71 AND GLU-147. RX PubMed=21797849; DOI=10.1111/j.1399-0004.2011.01754.x; RA Stark Z., Gillessen-Kaesbach G., Ryan M.M., Cirstea I.C., Gremer L., RA Ahmadian M.R., Savarirayan R., Zenker M.; RT "Two novel germline KRAS mutations: expanding the molecular and clinical RT phenotype."; RL Clin. Genet. 81:590-594(2012). RN [59] RP VARIANTS OES ASP-13 AND PHE-19, AND INVOLVEMENT IN OES. RX PubMed=25808193; DOI=10.1002/ajmg.a.37048; RA Peacock J.D., Dykema K.J., Toriello H.V., Mooney M.R., Scholten D.J. II, RA Winn M.E., Borgman A., Duesbery N.S., Hiemenga J.A., Liu C., Campbell S., RA Nickoloff B.P., Williams B.O., Steensma M.; RT "Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS RT alterations."; RL Am. J. Med. Genet. A 167:1429-1435(2015). RN [60] RP VARIANTS OES THR-146 AND VAL-146, AND INVOLVEMENT IN OES. RX PubMed=26970110; DOI=10.1111/cge.12775; RA Boppudi S., Boegershausen N., Hove H.B., Percin E.F., Aslan D., Dvorsky R., RA Kayhan G., Li Y., Cursiefen C., Tantcheva-Poor I., Toft P.B., Bartsch O., RA Lissewski C., Wieland I., Jakubiczka S., Wollnik B., Ahmadian M.R., RA Heindl L.M., Zenker M.; RT "Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal RT syndrome and encephalocraniocutaneous lipomatosis."; RL Clin. Genet. 90:334-342(2016). RN [61] RP VARIANT SFM ASP-12, VARIANTS OES THR-146 AND VAL-146, INVOLVEMENT IN SFM, RP AND INVOLVEMENT IN OES. RX PubMed=30891959; DOI=10.1002/mgg3.625; RA Chacon-Camacho O.F., Lopez-Moreno D., Morales-Sanchez M.A., Hofmann E., RA Pacheco-Quito M., Wieland I., Cortes-Gonzalez V., Villanueva-Mendoza C., RA Zenker M., Zenteno J.C.; RT "Expansion of the phenotypic spectrum and description of molecular findings RT in a cohort of patients with oculocutaneous mosaic RASopathies."; RL Mol. Genet. Genomic Med. 7:E625-E625(2019). RN [62] RP VARIANTS ALA-12; ASP-12; CYS-12; VAL-12; ASN-117 AND THR-146. RX PubMed=34820593; DOI=10.1200/po.21.00223; RA van 't Erve I., Wesdorp N.J., Medina J.E., Ferreira L., Leal A., RA Huiskens J., Bolhuis K., van Waesberghe J.T.M., Swijnenburg R.J., RA van den Broek D., Velculescu V.E., Kazemier G., Punt C.J.A., Meijer G.A., RA Fijneman R.J.A.; RT "KRAS A146 mutations are associated with distinct clinical behavior in RT patients with colorectal liver metastases."; RL JCO Precis. Oncol. 5:0-0(2021). CC -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase CC activity (PubMed:20949621, PubMed:39809765). Plays an important role in CC the regulation of cell proliferation (PubMed:22711838, CC PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation CC and ultimately degradation of GJA1 (By similarity). Plays a role in CC promoting oncogenic events by inducing transcriptional silencing of CC tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a CC ZNF304-dependent manner (PubMed:24623306). CC {ECO:0000250|UniProtKB:P08644, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, CC ECO:0000269|PubMed:24623306, ECO:0000269|PubMed:39809765}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP (PubMed:22566140, PubMed:22431598, CC PubMed:39809765). Activated by a guanine nucleotide-exchange factor CC (GEF) and inactivated by a GTPase-activating protein (GAP) CC (PubMed:22711838). Interaction with SOS1 promotes exchange of bound GDP CC to GTP (PubMed:22566140, PubMed:22431598, PubMed:39809765). CC {ECO:0000269|PubMed:22431598, ECO:0000269|PubMed:22566140, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:39809765}. CC -!- SUBUNIT: Interacts with PHLPP (By similarity). Interacts (active GTP- CC bound form preferentially) with RGS14 (By similarity). Interacts (when CC farnesylated) with PDE6D; this promotes dissociation from the cell CC membrane (PubMed:23698361). Interacts with SOS1 (PubMed:22431598). CC Interacts (when farnesylated) with GPR31 (PubMed:28619714). Interacts CC with RAP1GDS1 (PubMed:20709748, PubMed:24415755). Interacts (active CC GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a CC tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they CC also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:35768504, CC PubMed:35830882, PubMed:35831509, PubMed:36175670). Interacts (GTP- CC bound form) with MAPKAP1/SIN1; inhibiting K-Ras/KRAS activity CC (PubMed:34380736, PubMed:35522713). {ECO:0000250|UniProtKB:P08644, CC ECO:0000269|PubMed:20709748, ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24415755, CC ECO:0000269|PubMed:28619714, ECO:0000269|PubMed:34380736, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:36175670}. CC -!- SUBUNIT: [Isoform 2B]: Interacts with GPR31; in a farnelysation- CC dependent manner. {ECO:0000269|PubMed:28619714}. CC -!- INTERACTION: CC P01116; Q96II5: ARAF; NbExp=3; IntAct=EBI-367415, EBI-9383168; CC P01116; Q99755: PIP5K1A; NbExp=9; IntAct=EBI-367415, EBI-726414; CC P01116; P04049: RAF1; NbExp=6; IntAct=EBI-367415, EBI-365996; CC P01116; P50749: RASSF2; NbExp=2; IntAct=EBI-367415, EBI-960081; CC P01116-2; P05067: APP; NbExp=3; IntAct=EBI-367427, EBI-77613; CC P01116-2; P49354: FNTA; NbExp=2; IntAct=EBI-367427, EBI-602336; CC P01116-2; O00270: GPR31; NbExp=4; IntAct=EBI-367427, EBI-34583813; CC P01116-2; P01116-2: KRAS; NbExp=6; IntAct=EBI-367427, EBI-367427; CC P01116-2; P04049: RAF1; NbExp=3; IntAct=EBI-367427, EBI-365996; CC P01116-2; Q04631: Fnta; Xeno; NbExp=3; IntAct=EBI-367427, EBI-602447; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:29239724}; Lipid-anchor CC {ECO:0000269|PubMed:29239724, ECO:0000305|PubMed:23698361}; Cytoplasmic CC side {ECO:0000305|PubMed:23698361}. Endomembrane system CC {ECO:0000269|PubMed:29239724}. Cytoplasm, cytosol CC {ECO:0000269|PubMed:23698361}. CC -!- SUBCELLULAR LOCATION: [Isoform 2B]: Cell membrane CC {ECO:0000269|PubMed:28619714}; Lipid-anchor CC {ECO:0000305|PubMed:28619714}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Isoforms differ in the C-terminal region which is encoded by CC two alternative exons (IVA and IVB).; CC Name=2A; Synonyms=K-Ras4A {ECO:0000303|PubMed:29239724}; CC IsoId=P01116-1; Sequence=Displayed; CC Name=2B; Synonyms=K-Ras4B; CC IsoId=P01116-2, P01118-1; CC Sequence=VSP_011140, VSP_011141; CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000269|PubMed:22711838, CC ECO:0000269|Ref.17}. CC -!- PTM: Palmitoylated at Lys-182, Lys-184 and Lys-185 (PubMed:29239724). CC Palmitoylation on lysine residues is promoted by palmitoylation at Cys- CC 180 (PubMed:29239724). Lysine-depalmitoylation by SIRT2 promotes its CC localization to endomembranes in endocytic pathways (PubMed:29239724). CC {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000305|PubMed:30442762, ECO:0000305|PubMed:30442766}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL. {ECO:0000269|PubMed:19744486}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC {ECO:0000269|PubMed:8955068}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, CC ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835, CC ECO:0000269|PubMed:20949621}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:14534542, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma CC (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord CC derived from glial cells which vary from histologically benign forms to CC highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}. CC -!- DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of CC cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder CC characterized by a distinctive facial appearance, heart defects and CC intellectual disability. Heart defects include pulmonic stenosis, CC atrial septal defects and hypertrophic cardiomyopathy. Some affected CC individuals present with ectodermal abnormalities such as sparse, CC friable hair, hyperkeratotic skin lesions and a generalized ichthyosis- CC like condition. Typical facial features are similar to Noonan syndrome. CC They include high forehead with bitemporal constriction, hypoplastic CC supraorbital ridges, downslanting palpebral fissures, a depressed nasal CC bridge, and posteriorly angulated ears with prominent helices. CFC2 CC patients often do not have the skin abnormalities, such as ichthyosis, CC hyperkeratosis, and hemangioma observed in CFC1. CC {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:21797849}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=KRAS mutations are involved in cancer development. CC {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, CC ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:24623306, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, CC ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, CC ECO:0000269|PubMed:7773929}. CC -!- DISEASE: Oculoectodermal syndrome (OES) [MIM:600268]: A syndrome CC characterized by the association of epibulbar dermoids and aplasia CC cutis congenita. Affected individuals show multiple, asymmetric, CC atrophic, non-scarring and hairless regions that may be associated with CC hamartomas. Ectodermal changes include linear hyperpigmentation that CC may follow the lines of Blaschko and rarely epidermal nevus-like CC lesions. Epibulbar dermoids may be uni-or bilateral. Additional ocular CC anomalies such as skin tags of the upper eyelid, rarely optic nerve or CC retinal changes, and microphthalmia can be present. The phenotypic CC expression is highly variable, and various other abnormalities have CC occasionally been reported including growth failure, lymphedema, CC cardiovascular defects, as well as neurodevelopmental symptoms like CC developmental delay, epilepsy, learning difficulties, and behavioral CC abnormalities. Benign tumor-like lesions such as nonossifying fibromas CC of the long bones and giant cell granulomas of the jaws have repeatedly CC been observed and appear to be age-dependent, becoming a common CC manifestation in individuals aged 5 years or older. CC {ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:26970110, CC ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/91/KRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L00049; AAB59444.1; -; Genomic_DNA. DR EMBL; L00045; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00048; AAB59445.1; -; Genomic_DNA. DR EMBL; L00045; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; M54968; AAB41942.1; -; mRNA. DR EMBL; AF493917; AAM12631.1; -; mRNA. DR EMBL; BT007153; AAP35817.1; -; mRNA. DR EMBL; AK292510; BAF85199.1; -; mRNA. DR EMBL; CH471094; EAW96511.1; -; Genomic_DNA. DR EMBL; CH471094; EAW96512.1; -; Genomic_DNA. DR EMBL; EU332849; ABY87538.1; -; Genomic_DNA. DR EMBL; BC013572; AAH13572.1; -; mRNA. DR EMBL; K01519; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; K01520; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M25876; AAA35683.1; -; Genomic_DNA. DR EMBL; M34904; AAA36149.1; -; Genomic_DNA. DR EMBL; M30539; AAA36557.1; -; Genomic_DNA. DR EMBL; X01669; CAA25828.1; -; Genomic_DNA. DR EMBL; X02825; CAA26593.1; -; Genomic_DNA. DR EMBL; K03210; AAA36554.1; -; Genomic_DNA. DR EMBL; K03209; AAA36554.1; JOINED; Genomic_DNA. DR CCDS; CCDS8702.1; -. [P01116-2] DR CCDS; CCDS8703.1; -. [P01116-1] DR PIR; A93311; TVHUK. DR PIR; B93311; TVHU2K. DR RefSeq; NP_001356715.1; NM_001369786.1. [P01116-1] DR RefSeq; NP_001356716.1; NM_001369787.1. [P01116-2] DR RefSeq; NP_004976.2; NM_004985.4. [P01116-2] DR RefSeq; NP_203524.1; NM_033360.4. [P01116-1] DR PDB; 1D8D; X-ray; 2.00 A; P=178-188. DR PDB; 1D8E; X-ray; 3.00 A; P=178-188. DR PDB; 1KZO; X-ray; 2.20 A; C=169-173. DR PDB; 1KZP; X-ray; 2.10 A; C=169-173. DR PDB; 1N4P; X-ray; 2.65 A; M/N=185-189. DR PDB; 1N4Q; X-ray; 2.40 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4R; X-ray; 2.80 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4S; X-ray; 2.60 A; M/N/O/P/Q/R=185-189. DR PDB; 2MSC; NMR; -; B=1-186. DR PDB; 2MSD; NMR; -; B=1-186. DR PDB; 2MSE; NMR; -; B=1-186. DR PDB; 3GFT; X-ray; 2.27 A; A/B/C/D/E/F=1-164. DR PDB; 4DSN; X-ray; 2.03 A; A=2-164. DR PDB; 4DSO; X-ray; 1.85 A; A=2-164. DR PDB; 4EPR; X-ray; 2.00 A; A=1-164. DR PDB; 4EPT; X-ray; 2.00 A; A=1-164. DR PDB; 4EPV; X-ray; 1.35 A; A=1-164. DR PDB; 4EPW; X-ray; 1.70 A; A=1-164. DR PDB; 4EPX; X-ray; 1.76 A; A=1-164. DR PDB; 4EPY; X-ray; 1.80 A; A=1-164. DR PDB; 4L8G; X-ray; 1.52 A; A=1-169. DR PDB; 4LDJ; X-ray; 1.15 A; A=1-164. DR PDB; 4LPK; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LRW; X-ray; 2.15 A; A/B=1-169. DR PDB; 4LUC; X-ray; 1.29 A; A/B=1-169. DR PDB; 4LV6; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LYF; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4LYH; X-ray; 1.37 A; A/B/C=1-169. DR PDB; 4LYJ; X-ray; 1.93 A; A=1-169. DR PDB; 4M1O; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4M1S; X-ray; 1.55 A; A/B/C=1-169. DR PDB; 4M1T; X-ray; 1.70 A; A/B/C=1-169. DR PDB; 4M1W; X-ray; 1.58 A; A/B/C=1-169. DR PDB; 4M1Y; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 4M21; X-ray; 1.94 A; A/B/C=1-169. DR PDB; 4M22; X-ray; 2.09 A; A/B/C=1-169. DR PDB; 4NMM; X-ray; 1.89 A; A=1-164. DR PDB; 4OBE; X-ray; 1.24 A; A/B=1-164. DR PDB; 4PZY; X-ray; 1.88 A; A/B=1-164. DR PDB; 4PZZ; X-ray; 1.40 A; A=1-164. DR PDB; 4Q01; X-ray; 1.29 A; A/B=1-164. DR PDB; 4Q02; X-ray; 1.70 A; A=1-164. DR PDB; 4Q03; X-ray; 1.20 A; A=1-164. DR PDB; 4QL3; X-ray; 1.04 A; A=1-11, A=13-164. DR PDB; 4TQ9; X-ray; 1.49 A; A/B=1-164. DR PDB; 4TQA; X-ray; 1.13 A; A/B=1-164. DR PDB; 4WA7; X-ray; 1.99 A; A=1-164. DR PDB; 5F2E; X-ray; 1.40 A; A=1-169. DR PDB; 5KYK; X-ray; 2.70 A; A/B/C=1-167. DR PDB; 5MLA; X-ray; 2.19 A; A=1-166. DR PDB; 5MLB; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2S; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2T; X-ray; 2.19 A; A=1-166. DR PDB; 5OCG; X-ray; 1.48 A; A=2-189. DR PDB; 5OCO; X-ray; 1.66 A; A/B/C/D/E/F=1-169. DR PDB; 5OCT; X-ray; 2.07 A; A/B/C/D/E/F=1-169. DR PDB; 5TAR; X-ray; 1.90 A; A=2-164. DR PDB; 5TB5; X-ray; 2.00 A; A/C=2-164. DR PDB; 5UFE; X-ray; 2.30 A; A=1-166. DR PDB; 5UFQ; X-ray; 2.20 A; A/B=1-166. DR PDB; 5UK9; X-ray; 1.89 A; A/B=1-166. DR PDB; 5UQW; X-ray; 1.50 A; A/B=1-164. DR PDB; 5US4; X-ray; 1.83 A; A/B=1-164. DR PDB; 5USJ; X-ray; 1.94 A; A/B/C/D/E/F=1-164. DR PDB; 5V6S; X-ray; 1.70 A; A=1-169. DR PDB; 5V6V; X-ray; 1.72 A; A/B=1-169. DR PDB; 5V71; X-ray; 2.23 A; A/B/C/D/E/F=1-167. DR PDB; 5V9L; X-ray; 1.98 A; A/B/C=1-167. DR PDB; 5V9O; X-ray; 1.56 A; A=1-167. DR PDB; 5V9U; X-ray; 1.38 A; A/B=1-169. DR PDB; 5VBM; X-ray; 1.49 A; A=1-169. DR PDB; 5VP7; X-ray; 1.70 A; A/F=1-169. DR PDB; 5VPI; X-ray; 1.62 A; A/B=1-169. DR PDB; 5VPY; X-ray; 2.00 A; A/B=1-169. DR PDB; 5VPZ; X-ray; 1.85 A; A/B=1-169. DR PDB; 5VQ0; X-ray; 2.30 A; A/B=1-169. DR PDB; 5VQ1; X-ray; 1.78 A; A/B=1-169. DR PDB; 5VQ2; X-ray; 1.96 A; A/B=1-169. DR PDB; 5VQ6; X-ray; 1.99 A; A/B=1-169. DR PDB; 5VQ8; X-ray; 2.30 A; A/B=1-169. DR PDB; 5W22; X-ray; 1.76 A; A/B=1-169. DR PDB; 5WHA; X-ray; 2.04 A; A/D/G/J=1-166. DR PDB; 5WHB; X-ray; 2.18 A; A/D/G/J=1-166. DR PDB; 5WHD; X-ray; 1.64 A; A/B/C/D=1-166. DR PDB; 5WHE; X-ray; 1.91 A; A/D/G/J=1-166. DR PDB; 5WLB; X-ray; 1.72 A; A/D=1-166. DR PDB; 5WPM; X-ray; 1.72 A; A=1-166. DR PDB; 5XCO; X-ray; 1.25 A; A=1-169. DR PDB; 5YXZ; X-ray; 1.70 A; A=1-169. DR PDB; 5YY1; X-ray; 1.69 A; A=1-169. DR PDB; 6ARK; X-ray; 1.75 A; A=1-169. DR PDB; 6ASA; X-ray; 2.54 A; A=1-167. DR PDB; 6ASE; X-ray; 1.55 A; A=1-169. DR PDB; 6B0V; X-ray; 1.29 A; A/B=1-169. DR PDB; 6B0Y; X-ray; 1.43 A; A/B=1-169. DR PDB; 6BOF; X-ray; 1.40 A; A/B=2-169. DR PDB; 6BP1; X-ray; 2.00 A; A=1-169. DR PDB; 6CC9; NMR; -; B=1-186. DR PDB; 6CCH; NMR; -; B=1-186. DR PDB; 6CCX; NMR; -; B=1-186. DR PDB; 6CU6; X-ray; 1.50 A; A/B/C=1-169. DR PDB; 6E6F; X-ray; 3.40 A; A/B=1-166. DR PDB; 6E6G; X-ray; 1.93 A; A=1-166. DR PDB; 6EPL; X-ray; 2.55 A; R=1-169. DR PDB; 6EPM; X-ray; 2.50 A; R=1-169. DR PDB; 6EPN; X-ray; 2.50 A; R=1-169. DR PDB; 6EPO; X-ray; 2.40 A; R=1-169. DR PDB; 6EPP; X-ray; 2.40 A; R=1-169. DR PDB; 6F76; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6FA1; X-ray; 1.97 A; A/C/D/F=1-167, B/E=1-169. DR PDB; 6FA2; X-ray; 2.60 A; A/B/C/D/E/F=1-167. DR PDB; 6FA3; X-ray; 1.82 A; A/B/C/D/E/F=1-167. DR PDB; 6FA4; X-ray; 2.02 A; A/B/C/D/E/F=1-169. DR PDB; 6GJ5; X-ray; 1.50 A; A/B=1-169. DR PDB; 6GJ6; X-ray; 1.76 A; A=1-169. DR PDB; 6GJ7; X-ray; 1.67 A; A=1-169. DR PDB; 6GJ8; X-ray; 1.65 A; A=1-167. DR PDB; 6GOD; X-ray; 1.71 A; A=2-173. DR PDB; 6GOE; X-ray; 1.60 A; A=2-169. DR PDB; 6GOF; X-ray; 1.98 A; A=2-173. DR PDB; 6GOG; X-ray; 2.05 A; A/B/C/D/E/F=1-169. DR PDB; 6GOM; X-ray; 1.63 A; A/B/C/D/E/F=1-167. DR PDB; 6GQT; X-ray; 1.69 A; A/B/C/D/E/F=1-167. DR PDB; 6GQW; X-ray; 2.80 A; A/B/C/D/E/F=1-167. DR PDB; 6GQX; X-ray; 2.20 A; A/B/C/D/E/F=1-167. DR PDB; 6GQY; X-ray; 2.75 A; A/B/C/D/E/F=1-167. DR PDB; 6H46; X-ray; 2.22 A; A=1-166. DR PDB; 6H47; X-ray; 1.70 A; A=1-166. DR PDB; 6JTN; X-ray; 1.90 A; C=10-19. DR PDB; 6JTO; X-ray; 1.70 A; C=10-19. DR PDB; 6JTP; X-ray; 1.90 A; C=10-18. DR PDB; 6M9W; X-ray; 1.50 A; A=2-169. DR PDB; 6MBQ; X-ray; 1.35 A; A=2-166. DR PDB; 6MBT; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MBU; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MNX; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6MQG; X-ray; 1.50 A; A=3-169. DR PDB; 6MQN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6MS9; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 6MTA; X-ray; 2.15 A; A/B/C=1-169. DR PDB; 6N2J; X-ray; 1.80 A; A=1-169. DR PDB; 6N2K; X-ray; 1.72 A; A=1-169. DR PDB; 6O36; X-ray; 2.00 A; A/B/C=1-167. DR PDB; 6O46; X-ray; 1.90 A; A/B/C=1-167. DR PDB; 6O4Y; X-ray; 1.58 A; C=7-14. DR PDB; 6O4Z; X-ray; 1.50 A; C=5-12. DR PDB; 6O51; X-ray; 1.55 A; C=6-14. DR PDB; 6O53; X-ray; 1.40 A; C=5-14. DR PDB; 6OB2; X-ray; 2.85 A; A/C=1-169. DR PDB; 6OB3; X-ray; 2.10 A; A/C=1-169. DR PDB; 6OIM; X-ray; 1.65 A; A=1-169. DR PDB; 6P0Z; X-ray; 1.01 A; A/B=2-169. DR PDB; 6P8W; X-ray; 2.10 A; A/B=1-169. DR PDB; 6P8X; X-ray; 2.11 A; A/B/C/D=1-169. DR PDB; 6P8Y; X-ray; 2.31 A; A/B=1-169. DR PDB; 6P8Z; X-ray; 1.65 A; A/B=1-169. DR PDB; 6PGO; X-ray; 1.60 A; A/B=1-169. DR PDB; 6PGP; X-ray; 1.50 A; A/B=1-169. DR PDB; 6PQ3; X-ray; 1.75 A; A=1-169. DR PDB; 6PTS; NMR; -; B=1-186. DR PDB; 6PTW; NMR; -; B=1-186. DR PDB; 6QUU; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUV; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUW; X-ray; 1.24 A; A/B=1-169. DR PDB; 6QUX; X-ray; 1.62 A; A/B=1-169. DR PDB; 6T5B; X-ray; 1.37 A; A=1-169. DR PDB; 6T5U; X-ray; 1.72 A; B=1-166. DR PDB; 6T5V; X-ray; 1.31 A; A=1-169. DR PDB; 6TAM; X-ray; 1.64 A; A=1-169. DR PDB; 6TAN; X-ray; 1.16 A; A=1-169. DR PDB; 6USX; X-ray; 2.27 A; A/B=1-169. DR PDB; 6USZ; X-ray; 2.03 A; A=1-169. DR PDB; 6UT0; X-ray; 1.94 A; A/B/C/D=1-169. DR PDB; 6V5L; NMR; -; A=1-169. DR PDB; 6V65; X-ray; 2.76 A; C=1-169. DR PDB; 6V6F; X-ray; 2.54 A; C=1-169. DR PDB; 6VC8; X-ray; 2.50 A; A/B/C=1-169. DR PDB; 6VJJ; X-ray; 1.40 A; A=1-169. DR PDB; 6W4E; NMR; -; B/C=2-186. DR PDB; 6W4F; NMR; -; B/C=2-186. DR PDB; 6WGN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6WS2; X-ray; 1.59 A; A/B/C/D=1-169. DR PDB; 6WS4; X-ray; 1.84 A; A/B/C/D=1-169. DR PDB; 6XGU; X-ray; 2.70 A; A=1-169. DR PDB; 6XGV; X-ray; 2.11 A; A=1-169. DR PDB; 6XHA; X-ray; 2.87 A; A=1-169. DR PDB; 6XHB; X-ray; 2.50 A; A=1-169. DR PDB; 6YR8; X-ray; 1.90 A; A=1-166. DR PDB; 6YXW; X-ray; 2.06 A; A/C=1-167. DR PDB; 6ZL5; X-ray; 1.65 A; A=1-169. DR PDB; 6ZLI; X-ray; 1.73 A; A/B=1-169. DR PDB; 7A1W; X-ray; 1.76 A; A=1-169. DR PDB; 7A1X; X-ray; 1.32 A; A=1-164. DR PDB; 7A1Y; X-ray; 2.00 A; A=1-164. DR PDB; 7A47; X-ray; 2.16 A; A/C/E=1-169. DR PDB; 7ACA; X-ray; 1.57 A; A/B/C/D=1-169. DR PDB; 7ACF; X-ray; 1.91 A; A/B/C/D=1-169. DR PDB; 7ACH; X-ray; 1.90 A; A/B=1-169. DR PDB; 7ACQ; X-ray; 1.86 A; A/B/C=1-169. DR PDB; 7C40; X-ray; 2.52 A; A=1-167. DR PDB; 7C41; X-ray; 2.28 A; A/G/J/M=1-167. DR PDB; 7EW9; X-ray; 2.13 A; A/B/C=1-169. DR PDB; 7EWA; X-ray; 2.25 A; A/B/C=1-169. DR PDB; 7EWB; X-ray; 1.99 A; A/B/C=1-169. DR PDB; 7EYX; X-ray; 1.82 A; A=2-169. DR PDB; 7F0W; X-ray; 1.39 A; A=2-169. DR PDB; 7KFZ; EM; 3.47 A; A/C=1-169. DR PDB; 7KMR; X-ray; 1.51 A; A=1-186. DR PDB; 7KYZ; NMR; -; A=1-189. DR PDB; 7LC1; X-ray; 2.35 A; A/C=1-169. DR PDB; 7LC2; X-ray; 2.70 A; A/B=1-169. DR PDB; 7LGI; NMR; -; A=1-169. DR PDB; 7LZ5; X-ray; 1.50 A; A=1-164. DR PDB; 7MDP; X-ray; 1.96 A; A=1-169. DR PDB; 7MQU; NMR; -; A=1-169. DR PDB; 7NY8; X-ray; 1.80 A; A/B=1-167. DR PDB; 7O70; X-ray; 1.18 A; A/D=1-169. DR PDB; 7OK3; X-ray; 1.60 A; A=1-169. DR PDB; 7OK4; X-ray; 1.70 A; A=1-169. DR PDB; 7OO7; X-ray; 1.48 A; A/D=1-164. DR PDB; 7Q9U; X-ray; 2.24 A; AAA/BBB=1-176. DR PDB; 7R0M; X-ray; 1.61 A; A/B=1-169. DR PDB; 7R0N; X-ray; 1.20 A; A=1-169. DR PDB; 7R0Q; X-ray; 1.95 A; A/B=1-169. DR PDB; 7ROV; X-ray; 1.32 A; A/B=1-189. DR PDB; 7RP2; X-ray; 2.20 A; A=1-169. DR PDB; 7RP3; X-ray; 2.00 A; A=2-169. DR PDB; 7RP4; X-ray; 2.15 A; A/B=2-169. DR PDB; 7RPZ; X-ray; 1.30 A; A=1-169. DR PDB; 7RSC; NMR; -; A/B=2-186. DR PDB; 7RSE; NMR; -; A/B=2-186. DR PDB; 7RT1; X-ray; 1.27 A; A=1-169. DR PDB; 7RT2; X-ray; 1.59 A; A=1-169. DR PDB; 7RT3; X-ray; 1.56 A; A=1-169. DR PDB; 7RT4; X-ray; 2.10 A; A=1-169. DR PDB; 7RT5; X-ray; 1.29 A; A=1-169. DR PDB; 7SCW; X-ray; 1.98 A; A=1-189. DR PDB; 7SCX; X-ray; 1.96 A; A=1-189. DR PDB; 7STF; EM; 3.14 A; C=7-16. DR PDB; 7T1F; X-ray; 2.20 A; A/B/C=1-169. DR PDB; 7T47; X-ray; 1.27 A; A=1-164. DR PDB; 7TLE; X-ray; 1.99 A; A=1-164. DR PDB; 7TLG; X-ray; 1.80 A; A/B=1-164. DR PDB; 7TLK; X-ray; 1.71 A; A/B=1-164. DR PDB; 7U8H; X-ray; 1.70 A; A/B/C/D=1-169. DR PDB; 7VVB; X-ray; 1.70 A; A=1-189. DR PDB; 7W5R; X-ray; 3.87 A; A/E/I/M/Q/U=1-167. DR PDB; 7YCC; X-ray; 1.79 A; A/B/C=1-169. DR PDB; 7YCE; X-ray; 1.80 A; A=1-169. DR PDB; 7YUZ; X-ray; 1.88 A; A=2-174. DR PDB; 7YV1; X-ray; 1.45 A; A=2-174. DR PDB; 8AFB; X-ray; 1.12 A; A=1-164. DR PDB; 8AFC; X-ray; 2.41 A; A/B=1-164. DR PDB; 8AFD; X-ray; 1.63 A; A/B/C/D=1-164. DR PDB; 8AQ5; X-ray; 1.80 A; A=1-169. DR PDB; 8AQ7; X-ray; 1.65 A; A/B=1-169. DR PDB; 8AZR; X-ray; 1.60 A; A=1-164. DR PDB; 8AZV; X-ray; 1.05 A; A=1-164. DR PDB; 8AZX; X-ray; 1.04 A; A=1-164. DR PDB; 8AZY; X-ray; 1.09 A; A=1-169. DR PDB; 8AZZ; X-ray; 1.02 A; A=1-164. DR PDB; 8B00; X-ray; 1.04 A; A=1-164. DR PDB; 8B69; X-ray; 3.07 A; B/D=1-169. DR PDB; 8B6I; X-ray; 1.70 A; A/B=1-169. DR PDB; 8B78; X-ray; 1.11 A; A=1-164. DR PDB; 8BE3; X-ray; 1.85 A; A/R=1-169. DR PDB; 8BE4; X-ray; 1.90 A; R=1-169. DR PDB; 8BE5; X-ray; 3.13 A; R=1-169. DR PDB; 8BLR; X-ray; 1.40 A; A=2-169. DR PDB; 8CPR; X-ray; 2.00 A; A=2-169. DR PDB; 8CX5; X-ray; 1.72 A; A/B=1-169. DR PDB; 8DGS; EM; 4.30 A; E=1-169. DR PDB; 8DGT; EM; 3.90 A; F=1-169. DR PDB; 8DNI; X-ray; 1.50 A; A=1-169. DR PDB; 8DNJ; X-ray; 1.81 A; A/B/C=1-169. DR PDB; 8DNK; X-ray; 2.23 A; A=1-169. DR PDB; 8DVG; X-ray; 2.59 A; C=7-16. DR PDB; 8EBZ; X-ray; 1.20 A; A=1-169. DR PDB; 8ECR; X-ray; 1.42 A; A/B=1-186. DR PDB; 8EDY; X-ray; 1.18 A; A=1-186. DR PDB; 8EER; X-ray; 1.18 A; A=1-186. DR PDB; 8EIE; X-ray; 1.41 A; A=1-186. DR PDB; 8EPW; X-ray; 2.00 A; A=1-169. DR PDB; 8EZG; X-ray; 2.52 A; A=1-167. DR PDB; 8F0M; X-ray; 2.44 A; A/C=1-169. DR PDB; 8FMI; X-ray; 1.12 A; A=1-169. DR PDB; 8FMJ; X-ray; 1.33 A; A=1-169. DR PDB; 8FMK; X-ray; 1.48 A; A=1-169. DR PDB; 8G42; EM; 3.02 A; B=1-169. DR PDB; 8G47; EM; 3.19 A; B=1-169. DR PDB; 8G4F; EM; 2.91 A; B=1-166. DR PDB; 8G4H; EM; 2.87 A; B=1-169. DR PDB; 8G9P; X-ray; 1.50 A; A/B=1-169. DR PDB; 8G9Q; X-ray; 1.40 A; A=1-169. DR PDB; 8I5C; X-ray; 3.34 A; C/H/M/R/W/b/g/l/q/v=8-16. DR PDB; 8I5D; X-ray; 3.30 A; P=8-16. DR PDB; 8I5E; X-ray; 2.20 A; P=8-16. DR PDB; 8JGD; X-ray; 1.60 A; A=1-169. DR PDB; 8JHL; X-ray; 2.10 A; A=1-169. DR PDB; 8JJS; X-ray; 1.53 A; A=2-174. DR PDB; 8K4T; X-ray; 2.30 A; C/F=7-16. DR PDB; 8K4V; X-ray; 3.10 A; C/F/I/L=7-16. DR PDB; 8K50; X-ray; 2.80 A; C/F/I/L=7-16. DR PDB; 8ONV; X-ray; 1.01 A; A=1-164. DR PDB; 8PI0; NMR; -; A=1-167. DR PDB; 8PIY; NMR; -; A=1-169. DR PDB; 8QU8; EM; 3.50 A; F=1-164. DR PDB; 8QUG; X-ray; 1.56 A; A=1-164. DR PDB; 8QVU; X-ray; 2.24 A; A/E=1-189. DR PDB; 8QW6; X-ray; 2.20 A; A/E=1-169. DR PDB; 8QW7; X-ray; 2.36 A; A/E=1-169. DR PDB; 8R7W; X-ray; 1.16 A; A/B=1-169. DR PDB; 8R7X; X-ray; 1.31 A; A/B=1-169. DR PDB; 8RNI; X-ray; 2.49 A; C=7-16. DR PDB; 8RRO; X-ray; 3.50 A; E/J/O/T/Y/d/i/n=7-16. DR PDB; 8S8C; X-ray; 1.90 A; A=1-169. DR PDB; 8STM; X-ray; 2.00 A; A/B/C/D=1-169. DR PDB; 8STN; X-ray; 2.03 A; A/B=1-169. DR PDB; 8T4V; X-ray; 1.47 A; A/B=1-169. DR PDB; 8T71; X-ray; 1.80 A; A/B=1-177. DR PDB; 8T72; X-ray; 1.60 A; A/B/C=1-177. DR PDB; 8T73; X-ray; 1.50 A; A/B=1-169. DR PDB; 8T74; X-ray; 1.65 A; A=1-177. DR PDB; 8T75; X-ray; 2.65 A; A/C/E/G=1-177. DR PDB; 8TBF; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBH; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBJ; X-ray; 1.45 A; A/B=1-169. DR PDB; 8TBK; X-ray; 1.26 A; A/B=1-169. DR PDB; 8TBL; X-ray; 1.88 A; A/B=1-169. DR PDB; 8TBM; X-ray; 1.57 A; A/B=1-169. DR PDB; 8TBN; X-ray; 1.46 A; A/B=1-169. DR PDB; 8TVK; X-ray; 1.04 A; A=1-169. DR PDB; 8TXE; X-ray; 1.35 A; A/B=1-169. DR PDB; 8TXG; X-ray; 1.50 A; A=1-169. DR PDB; 8TXH; X-ray; 1.20 A; A/B=1-169. DR PDB; 8TXJ; X-ray; 1.40 A; A=1-169. DR PDB; 8TXK; X-ray; 1.38 A; A=1-169. DR PDB; 8TY2; X-ray; 1.41 A; A=1-169. DR PDB; 8TY8; X-ray; 1.40 A; A=1-169. DR PDB; 8TY9; X-ray; 1.43 A; A=1-169. DR PDB; 8UDR; EM; 3.10 A; C=7-16. DR PDB; 8UN3; X-ray; 2.07 A; A/B/C/D=2-167. DR PDB; 8UN4; X-ray; 1.57 A; A=2-169. DR PDB; 8UN5; X-ray; 1.31 A; A/B=2-167. DR PDB; 8V39; X-ray; 2.10 A; A/B/C=1-169. DR PDB; 8V3A; X-ray; 1.67 A; A/B=1-169. DR PDB; 8VGQ; EM; 2.80 A; A=1-169. DR PDB; 8VJZ; X-ray; 1.90 A; C=7-16. DR PDB; 8VR9; EM; 3.06 A; C=8-16. DR PDB; 8VRA; EM; 3.12 A; C=7-16. DR PDB; 8VRB; EM; 3.25 A; C=7-16. DR PDB; 8WTE; X-ray; 2.17 A; G/J=8-16. DR PDB; 8WUL; X-ray; 2.36 A; K/N/Q/T=8-16. DR PDB; 8X6R; X-ray; 1.85 A; A/B/C/D/E/F=1-169. DR PDB; 8YIV; X-ray; 2.10 A; C=55-64. DR PDB; 8YJ2; X-ray; 2.26 A; C=55-64. DR PDB; 9AX6; X-ray; 1.65 A; A/B=1-169. DR PDB; 9BAI; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAJ; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAK; X-ray; 1.67 A; A/B/C/D=1-169. DR PDB; 9BFV; X-ray; 1.20 A; A/B=1-169. DR PDB; 9BFW; X-ray; 1.20 A; A=1-169. DR PDB; 9BFX; X-ray; 1.40 A; A/B=1-169. DR PDB; 9BFY; X-ray; 1.26 A; A/B=1-169. DR PDB; 9BFZ; X-ray; 1.80 A; A/B=1-169. DR PDB; 9BG1; X-ray; 1.51 A; A/B=1-169. DR PDB; 9BG2; X-ray; 1.64 A; A/B=1-169. DR PDB; 9BG4; X-ray; 1.14 A; A/B=1-169. DR PDB; 9BG5; X-ray; 1.67 A; A/B=1-164. DR PDB; 9BG6; X-ray; 1.66 A; A/B=1-169. DR PDB; 9BG7; X-ray; 1.60 A; A/B=1-169. DR PDB; 9BG9; X-ray; 1.58 A; A/B=1-164. DR PDB; 9BGA; X-ray; 1.41 A; A/B=1-169. DR PDB; 9BGB; X-ray; 1.68 A; A/B=1-164. DR PDB; 9BGC; X-ray; 1.87 A; A/B=1-169. DR PDB; 9BHO; X-ray; 1.89 A; A/C=1-169. DR PDB; 9BHP; X-ray; 2.10 A; A/C=1-169. DR PDB; 9BHQ; X-ray; 1.90 A; A/C=1-169. DR PDB; 9BI1; X-ray; 1.65 A; A/C=1-169. DR PDB; 9BI2; X-ray; 2.15 A; A/C=1-169. DR PDB; 9BL0; X-ray; 1.66 A; A/B=1-169. DR PDB; 9C15; X-ray; 2.81 A; B=1-169. DR PDB; 9DMM; X-ray; 1.90 A; A=1-169. DR PDB; 9E5D; X-ray; 1.36 A; A=1-169. DR PDB; 9E5F; X-ray; 1.35 A; A=1-169. DR PDB; 9E9H; X-ray; 1.65 A; A=1-169. DR PDB; 9E9I; X-ray; 1.18 A; A=1-169. DR PDB; 9G0Y; X-ray; 1.31 A; A=1-169. DR PDB; 9G4B; X-ray; 1.14 A; A=1-169. DR PDB; 9GBJ; X-ray; 1.71 A; A=1-169. DR PDB; 9GGT; X-ray; 1.71 A; A=1-169. DR PDB; 9GGU; X-ray; 1.60 A; A=1-169. DR PDB; 9GGV; X-ray; 1.19 A; A=1-169. DR PDB; 9GGW; X-ray; 1.82 A; A/B=1-169. DR PDB; 9GGX; X-ray; 1.30 A; A=1-169. DR PDB; 9GGY; X-ray; 1.27 A; A=1-169. DR PDB; 9GGZ; X-ray; 1.37 A; A=1-169. DR PDB; 9GH0; X-ray; 1.57 A; A=1-169. DR PDB; 9GH1; X-ray; 1.33 A; A=1-169. DR PDB; 9GH2; X-ray; 1.35 A; A=1-169. DR PDB; 9KPM; X-ray; 1.41 A; A=1-169. DR PDB; 9KPN; X-ray; 1.29 A; A/B=1-169. DR PDBsum; 1D8D; -. DR PDBsum; 1D8E; -. DR PDBsum; 1KZO; -. DR PDBsum; 1KZP; -. DR PDBsum; 1N4P; -. DR PDBsum; 1N4Q; -. DR PDBsum; 1N4R; -. DR PDBsum; 1N4S; -. DR PDBsum; 2MSC; -. DR PDBsum; 2MSD; -. DR PDBsum; 2MSE; -. DR PDBsum; 3GFT; -. DR PDBsum; 4DSN; -. DR PDBsum; 4DSO; -. DR PDBsum; 4EPR; -. DR PDBsum; 4EPT; -. DR PDBsum; 4EPV; -. DR PDBsum; 4EPW; -. DR PDBsum; 4EPX; -. DR PDBsum; 4EPY; -. DR PDBsum; 4L8G; -. DR PDBsum; 4LDJ; -. DR PDBsum; 4LPK; -. DR PDBsum; 4LRW; -. DR PDBsum; 4LUC; -. DR PDBsum; 4LV6; -. DR PDBsum; 4LYF; -. DR PDBsum; 4LYH; -. DR PDBsum; 4LYJ; -. DR PDBsum; 4M1O; -. DR PDBsum; 4M1S; -. DR PDBsum; 4M1T; -. DR PDBsum; 4M1W; -. DR PDBsum; 4M1Y; -. DR PDBsum; 4M21; -. DR PDBsum; 4M22; -. DR PDBsum; 4NMM; -. DR PDBsum; 4OBE; -. DR PDBsum; 4PZY; -. DR PDBsum; 4PZZ; -. DR PDBsum; 4Q01; -. DR PDBsum; 4Q02; -. DR PDBsum; 4Q03; -. DR PDBsum; 4QL3; -. DR PDBsum; 4TQ9; -. DR PDBsum; 4TQA; -. DR PDBsum; 4WA7; -. DR PDBsum; 5F2E; -. DR PDBsum; 5KYK; -. DR PDBsum; 5MLA; -. DR PDBsum; 5MLB; -. DR PDBsum; 5O2S; -. DR PDBsum; 5O2T; -. DR PDBsum; 5OCG; -. DR PDBsum; 5OCO; -. DR PDBsum; 5OCT; -. DR PDBsum; 5TAR; -. DR PDBsum; 5TB5; -. DR PDBsum; 5UFE; -. DR PDBsum; 5UFQ; -. DR PDBsum; 5UK9; -. DR PDBsum; 5UQW; -. DR PDBsum; 5US4; -. DR PDBsum; 5USJ; -. DR PDBsum; 5V6S; -. DR PDBsum; 5V6V; -. DR PDBsum; 5V71; -. DR PDBsum; 5V9L; -. DR PDBsum; 5V9O; -. DR PDBsum; 5V9U; -. DR PDBsum; 5VBM; -. DR PDBsum; 5VP7; -. DR PDBsum; 5VPI; -. DR PDBsum; 5VPY; -. DR PDBsum; 5VPZ; -. DR PDBsum; 5VQ0; -. DR PDBsum; 5VQ1; -. DR PDBsum; 5VQ2; -. DR PDBsum; 5VQ6; -. DR PDBsum; 5VQ8; -. DR PDBsum; 5W22; -. DR PDBsum; 5WHA; -. DR PDBsum; 5WHB; -. DR PDBsum; 5WHD; -. DR PDBsum; 5WHE; -. DR PDBsum; 5WLB; -. DR PDBsum; 5WPM; -. DR PDBsum; 5XCO; -. DR PDBsum; 5YXZ; -. DR PDBsum; 5YY1; -. DR PDBsum; 6ARK; -. DR PDBsum; 6ASA; -. DR PDBsum; 6ASE; -. DR PDBsum; 6B0V; -. DR PDBsum; 6B0Y; -. DR PDBsum; 6BOF; -. DR PDBsum; 6BP1; -. DR PDBsum; 6CC9; -. DR PDBsum; 6CCH; -. DR PDBsum; 6CCX; -. DR PDBsum; 6CU6; -. DR PDBsum; 6E6F; -. DR PDBsum; 6E6G; -. DR PDBsum; 6EPL; -. DR PDBsum; 6EPM; -. DR PDBsum; 6EPN; -. DR PDBsum; 6EPO; -. DR PDBsum; 6EPP; -. DR PDBsum; 6F76; -. DR PDBsum; 6FA1; -. DR PDBsum; 6FA2; -. DR PDBsum; 6FA3; -. DR PDBsum; 6FA4; -. DR PDBsum; 6GJ5; -. DR PDBsum; 6GJ6; -. DR PDBsum; 6GJ7; -. DR PDBsum; 6GJ8; -. DR PDBsum; 6GOD; -. DR PDBsum; 6GOE; -. DR PDBsum; 6GOF; -. DR PDBsum; 6GOG; -. DR PDBsum; 6GOM; -. DR PDBsum; 6GQT; -. DR PDBsum; 6GQW; -. DR PDBsum; 6GQX; -. DR PDBsum; 6GQY; -. DR PDBsum; 6H46; -. DR PDBsum; 6H47; -. DR PDBsum; 6JTN; -. DR PDBsum; 6JTO; -. DR PDBsum; 6JTP; -. DR PDBsum; 6M9W; -. DR PDBsum; 6MBQ; -. DR PDBsum; 6MBT; -. DR PDBsum; 6MBU; -. DR PDBsum; 6MNX; -. DR PDBsum; 6MQG; -. DR PDBsum; 6MQN; -. DR PDBsum; 6MS9; -. DR PDBsum; 6MTA; -. DR PDBsum; 6N2J; -. DR PDBsum; 6N2K; -. DR PDBsum; 6O36; -. DR PDBsum; 6O46; -. DR PDBsum; 6O4Y; -. DR PDBsum; 6O4Z; -. DR PDBsum; 6O51; -. DR PDBsum; 6O53; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6OIM; -. DR PDBsum; 6P0Z; -. DR PDBsum; 6P8W; -. DR PDBsum; 6P8X; -. DR PDBsum; 6P8Y; -. DR PDBsum; 6P8Z; -. DR PDBsum; 6PGO; -. DR PDBsum; 6PGP; -. DR PDBsum; 6PQ3; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6QUU; -. DR PDBsum; 6QUV; -. DR PDBsum; 6QUW; -. DR PDBsum; 6QUX; -. DR PDBsum; 6T5B; -. DR PDBsum; 6T5U; -. DR PDBsum; 6T5V; -. DR PDBsum; 6TAM; -. DR PDBsum; 6TAN; -. DR PDBsum; 6USX; -. DR PDBsum; 6USZ; -. DR PDBsum; 6UT0; -. DR PDBsum; 6V5L; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 6VC8; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6W4E; -. DR PDBsum; 6W4F; -. DR PDBsum; 6WGN; -. DR PDBsum; 6WS2; -. DR PDBsum; 6WS4; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6YR8; -. DR PDBsum; 6YXW; -. DR PDBsum; 6ZL5; -. DR PDBsum; 6ZLI; -. DR PDBsum; 7A1W; -. DR PDBsum; 7A1X; -. DR PDBsum; 7A1Y; -. DR PDBsum; 7A47; -. DR PDBsum; 7ACA; -. DR PDBsum; 7ACF; -. DR PDBsum; 7ACH; -. DR PDBsum; 7ACQ; -. DR PDBsum; 7C40; -. DR PDBsum; 7C41; -. DR PDBsum; 7EW9; -. DR PDBsum; 7EWA; -. DR PDBsum; 7EWB; -. DR PDBsum; 7EYX; -. DR PDBsum; 7F0W; -. DR PDBsum; 7KFZ; -. DR PDBsum; 7KMR; -. DR PDBsum; 7KYZ; -. DR PDBsum; 7LC1; -. DR PDBsum; 7LC2; -. DR PDBsum; 7LGI; -. DR PDBsum; 7LZ5; -. DR PDBsum; 7MDP; -. DR PDBsum; 7MQU; -. DR PDBsum; 7NY8; -. DR PDBsum; 7O70; -. DR PDBsum; 7OK3; -. DR PDBsum; 7OK4; -. DR PDBsum; 7OO7; -. DR PDBsum; 7Q9U; -. DR PDBsum; 7R0M; -. DR PDBsum; 7R0N; -. DR PDBsum; 7R0Q; -. DR PDBsum; 7ROV; -. DR PDBsum; 7RP2; -. DR PDBsum; 7RP3; -. DR PDBsum; 7RP4; -. DR PDBsum; 7RPZ; -. DR PDBsum; 7RSC; -. DR PDBsum; 7RSE; -. DR PDBsum; 7RT1; -. DR PDBsum; 7RT2; -. DR PDBsum; 7RT3; -. DR PDBsum; 7RT4; -. DR PDBsum; 7RT5; -. DR PDBsum; 7SCW; -. DR PDBsum; 7SCX; -. DR PDBsum; 7STF; -. DR PDBsum; 7T1F; -. DR PDBsum; 7T47; -. DR PDBsum; 7TLE; -. DR PDBsum; 7TLG; -. DR PDBsum; 7TLK; -. DR PDBsum; 7U8H; -. DR PDBsum; 7VVB; -. DR PDBsum; 7W5R; -. DR PDBsum; 7YCC; -. DR PDBsum; 7YCE; -. DR PDBsum; 7YUZ; -. DR PDBsum; 7YV1; -. DR PDBsum; 8AFB; -. DR PDBsum; 8AFC; -. DR PDBsum; 8AFD; -. DR PDBsum; 8AQ5; -. DR PDBsum; 8AQ7; -. DR PDBsum; 8AZR; -. DR PDBsum; 8AZV; -. DR PDBsum; 8AZX; -. DR PDBsum; 8AZY; -. DR PDBsum; 8AZZ; -. DR PDBsum; 8B00; -. DR PDBsum; 8B69; -. DR PDBsum; 8B6I; -. DR PDBsum; 8B78; -. DR PDBsum; 8BE3; -. DR PDBsum; 8BE4; -. DR PDBsum; 8BE5; -. DR PDBsum; 8BLR; -. DR PDBsum; 8CPR; -. DR PDBsum; 8CX5; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8DNI; -. DR PDBsum; 8DNJ; -. DR PDBsum; 8DNK; -. DR PDBsum; 8DVG; -. DR PDBsum; 8EBZ; -. DR PDBsum; 8ECR; -. DR PDBsum; 8EDY; -. DR PDBsum; 8EER; -. DR PDBsum; 8EIE; -. DR PDBsum; 8EPW; -. DR PDBsum; 8EZG; -. DR PDBsum; 8F0M; -. DR PDBsum; 8FMI; -. DR PDBsum; 8FMJ; -. DR PDBsum; 8FMK; -. DR PDBsum; 8G42; -. DR PDBsum; 8G47; -. DR PDBsum; 8G4F; -. DR PDBsum; 8G4H; -. DR PDBsum; 8G9P; -. DR PDBsum; 8G9Q; -. DR PDBsum; 8I5C; -. DR PDBsum; 8I5D; -. DR PDBsum; 8I5E; -. DR PDBsum; 8JGD; -. DR PDBsum; 8JHL; -. DR PDBsum; 8JJS; -. DR PDBsum; 8K4T; -. DR PDBsum; 8K4V; -. DR PDBsum; 8K50; -. DR PDBsum; 8ONV; -. DR PDBsum; 8PI0; -. DR PDBsum; 8PIY; -. DR PDBsum; 8QU8; -. DR PDBsum; 8QUG; -. DR PDBsum; 8QVU; -. DR PDBsum; 8QW6; -. DR PDBsum; 8QW7; -. DR PDBsum; 8R7W; -. DR PDBsum; 8R7X; -. DR PDBsum; 8RNI; -. DR PDBsum; 8RRO; -. DR PDBsum; 8S8C; -. DR PDBsum; 8STM; -. DR PDBsum; 8STN; -. DR PDBsum; 8T4V; -. DR PDBsum; 8T71; -. DR PDBsum; 8T72; -. DR PDBsum; 8T73; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8TBF; -. DR PDBsum; 8TBH; -. DR PDBsum; 8TBJ; -. DR PDBsum; 8TBK; -. DR PDBsum; 8TBL; -. DR PDBsum; 8TBM; -. DR PDBsum; 8TBN; -. DR PDBsum; 8TVK; -. DR PDBsum; 8TXE; -. DR PDBsum; 8TXG; -. DR PDBsum; 8TXH; -. DR PDBsum; 8TXJ; -. DR PDBsum; 8TXK; -. DR PDBsum; 8TY2; -. DR PDBsum; 8TY8; -. DR PDBsum; 8TY9; -. DR PDBsum; 8UDR; -. DR PDBsum; 8UN3; -. DR PDBsum; 8UN4; -. DR PDBsum; 8UN5; -. DR PDBsum; 8V39; -. DR PDBsum; 8V3A; -. DR PDBsum; 8VGQ; -. DR PDBsum; 8VJZ; -. DR PDBsum; 8VR9; -. DR PDBsum; 8VRA; -. DR PDBsum; 8VRB; -. DR PDBsum; 8WTE; -. DR PDBsum; 8WUL; -. DR PDBsum; 8X6R; -. DR PDBsum; 8YIV; -. DR PDBsum; 8YJ2; -. DR PDBsum; 9AX6; -. DR PDBsum; 9BAI; -. DR PDBsum; 9BAJ; -. DR PDBsum; 9BAK; -. DR PDBsum; 9BFV; -. DR PDBsum; 9BFW; -. DR PDBsum; 9BFX; -. DR PDBsum; 9BFY; -. DR PDBsum; 9BFZ; -. DR PDBsum; 9BG1; -. DR PDBsum; 9BG2; -. DR PDBsum; 9BG4; -. DR PDBsum; 9BG5; -. DR PDBsum; 9BG6; -. DR PDBsum; 9BG7; -. DR PDBsum; 9BG9; -. DR PDBsum; 9BGA; -. DR PDBsum; 9BGB; -. DR PDBsum; 9BGC; -. DR PDBsum; 9BHO; -. DR PDBsum; 9BHP; -. DR PDBsum; 9BHQ; -. DR PDBsum; 9BI1; -. DR PDBsum; 9BI2; -. DR PDBsum; 9BL0; -. DR PDBsum; 9C15; -. DR PDBsum; 9DMM; -. DR PDBsum; 9E5D; -. DR PDBsum; 9E5F; -. DR PDBsum; 9E9H; -. DR PDBsum; 9E9I; -. DR PDBsum; 9G0Y; -. DR PDBsum; 9G4B; -. DR PDBsum; 9GBJ; -. DR PDBsum; 9GGT; -. DR PDBsum; 9GGU; -. DR PDBsum; 9GGV; -. DR PDBsum; 9GGW; -. DR PDBsum; 9GGX; -. DR PDBsum; 9GGY; -. DR PDBsum; 9GGZ; -. DR PDBsum; 9GH0; -. DR PDBsum; 9GH1; -. DR PDBsum; 9GH2; -. DR PDBsum; 9KPM; -. DR PDBsum; 9KPN; -. DR AlphaFoldDB; P01116; -. DR BMRB; P01116; -. DR EMDB; EMD-18657; -. DR EMDB; EMD-22857; -. DR EMDB; EMD-29713; -. DR EMDB; EMD-29715; -. DR EMDB; EMD-29719; -. DR EMDB; EMD-29720; -. DR EMDB; EMD-42151; -. DR EMDB; EMD-43221; -. DR EMDB; EMD-43478; -. DR EMDB; EMD-43479; -. DR EMDB; EMD-43480; -. DR EMDB; EMD-70124; -. DR SASBDB; P01116; -. DR SMR; P01116; -. DR BioGRID; 110043; 3005. DR ComplexPortal; CPX-26355; SHOC2-KRAS-PPP1CA complex. DR CORUM; P01116; -. DR DIP; DIP-33951N; -. DR FunCoup; P01116; 3194. DR IntAct; P01116; 549. DR MINT; P01116; -. DR STRING; 9606.ENSP00000256078; -. DR BindingDB; P01116; -. DR ChEMBL; CHEMBL2189121; -. DR DrugBank; DB07771; [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID. DR DrugBank; DB15568; Adagrasib. DR DrugBank; DB07780; Farnesyl diphosphate. DR DrugBank; DB15569; Sotorasib. DR DrugCentral; P01116; -. DR GuidetoPHARMACOLOGY; 2824; -. DR GlyCosmos; P01116; 1 site, No reported glycans. DR GlyGen; P01116; 1 site. DR iPTMnet; P01116; -. DR PhosphoSitePlus; P01116; -. DR SwissPalm; P01116; -. DR BioMuta; KRAS; -. DR DMDM; 131875; -. DR CPTAC; CPTAC-1550; -. DR jPOST; P01116; -. DR MassIVE; P01116; -. DR PaxDb; 9606-ENSP00000256078; -. DR PeptideAtlas; P01116; -. DR ProteomicsDB; 51323; -. [P01116-1] DR ProteomicsDB; 51324; -. [P01116-2] DR Pumba; P01116; -. DR TopDownProteomics; P01116-2; -. [P01116-2] DR ABCD; P01116; 18 sequenced antibodies. DR Antibodypedia; 24248; 916 antibodies from 40 providers. DR CPTC; P01116; 6 antibodies. DR DNASU; 3845; -. DR Ensembl; ENST00000256078.10; ENSP00000256078.5; ENSG00000133703.15. [P01116-1] DR Ensembl; ENST00000311936.8; ENSP00000308495.3; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000685328.1; ENSP00000508921.1; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000688940.1; ENSP00000509238.1; ENSG00000133703.15. [P01116-2] DR GeneID; 3845; -. DR KEGG; hsa:3845; -. DR MANE-Select; ENST00000311936.8; ENSP00000308495.3; NM_004985.5; NP_004976.2. [P01116-2] DR UCSC; uc001rgp.3; human. [P01116-1] DR AGR; HGNC:6407; -. DR CIViC; 3845; 1 clinical assertion and 480 evidence items across 102 molecular profiles. DR ClinPGx; PA30196; -. DR CTD; 3845; -. DR DisGeNET; 3845; -. DR GeneCards; KRAS; -. DR GeneReviews; KRAS; -. DR HGNC; HGNC:6407; KRAS. DR HPA; ENSG00000133703; Low tissue specificity. DR MalaCards; KRAS; -. DR MIM; 163200; phenotype. DR MIM; 190070; gene. DR MIM; 600268; phenotype. DR MIM; 601626; phenotype. DR MIM; 607785; phenotype. DR MIM; 609942; phenotype. DR MIM; 613659; phenotype. DR MIM; 615278; phenotype. DR OpenTargets; ENSG00000133703; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2396; Encephalocraniocutaneous lipomatosis. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 3339; Oculoectodermal syndrome. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 268114; RAS-associated autoimmune leukoproliferative disease. DR VEuPathDB; HostDB:ENSG00000133703; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155871; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01116; -. DR OMA; CCGGCVI; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01116; 5 GO annotations based on evolutionary models. DR PhylomeDB; P01116; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01116; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-4086398; Ca2+ pathway. [P01116-2] DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF). DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SignaLink; P01116; -. DR SIGNOR; P01116; -. DR Agora; ENSG00000133703; -. DR BioGRID-ORCS; 3845; 259 hits in 1133 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; KRAS; human. DR EvolutionaryTrace; P01116; -. DR GeneWiki; KRAS; -. DR GenomeRNAi; 3845; -. DR Pharos; P01116; Tclin. DR PRO; PR:P01116; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; P01116; protein. DR Bgee; ENSG00000133703; Expressed in trigeminal ganglion and 218 other cell types or tissues. DR ExpressionAtlas; P01116; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IBA:GO_Central. DR GO; GO:0019002; F:GMP binding; IEA:Ensembl. DR GO; GO:0005525; F:GTP binding; IBA:GO_Central. DR GO; GO:0003924; F:GTPase activity; IMP:DisProt. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IDA:MGI. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl. DR GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0007565; P:female pregnancy; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:0035022; P:positive regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl. DR GO; GO:0009629; P:response to gravity; IEA:Ensembl. DR GO; GO:0035900; P:response to isolation stress; IEA:Ensembl. DR GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl. DR GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0060509; P:type I pneumocyte differentiation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP03860; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00176; RAN; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Ectodermal dysplasia; Glycoprotein; GTP-binding; KW Hydrolase; Intellectual disability; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase KRas" FT /id="PRO_0000082641" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.17" FT CHAIN 2..186 FT /note="GTPase KRas, N-terminally processed" FT /id="PRO_0000326480" FT PROPEP 187..189 FT /note="Removed in mature form" FT /evidence="ECO:0000305|PubMed:27791178" FT /id="PRO_0000281291" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 10..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase KRas; alternate" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase KRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 104 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22711838" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5" FT LIPID 180 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 182 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000269|PubMed:29239724" FT LIPID 184 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 185 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0000305|PubMed:24415755, ECO:0007744|PDB:5TAR, FT ECO:0007744|PDB:5TB5" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:30442762" FT VAR_SEQ 151..153 FT /note="RVE -> GVD (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011140" FT VAR_SEQ 165..189 FT /note="QYRLKKISKEEKTPGCVKIKKCIIM -> KHKEKMSKDGKKKKKKSKTKCVI FT M (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011141" FT VARIANT 5 FT /note="K -> E (in NS3; dbSNP:rs193929331)" FT /evidence="ECO:0000269|PubMed:17468812" FT /id="VAR_065144" FT VARIANT 5 FT /note="K -> N (in GASC; found also in a patient with FT Costello syndrome; exhibits only minor alterations in its FT in vitro biochemical behavior compared to wild-type FT protein; dbSNP:rs104894361)" FT /evidence="ECO:0000269|PubMed:14534542" FT /id="VAR_064849" FT VARIANT 10 FT /note="G -> GG (in AML; expression in 3T3 cell causes FT cellular transformation; expression in COS cells activates FT the Ras-MAPK signaling pathway; lower GTPase activity; FT faster GDP dissociation rate)" FT /evidence="ECO:0000269|PubMed:8955068" FT /id="VAR_034601" FT VARIANT 12 FT /note="G -> A (in colorectal cancer samples; somatic FT mutation; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036305" FT VARIANT 12 FT /note="G -> C (in lung carcinoma; somatic mutation; also FT found in metastatic colorectal cancer; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:34820593, ECO:0000269|PubMed:6320174" FT /id="VAR_006839" FT VARIANT 12 FT /note="G -> D (in GASC, JMML and SFM; somatic mutation; FT also found in pancreatic carcinoma and lung carcinoma; also FT found in metastatic colorectal cancer; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:30891959, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:7773929, ECO:0000269|PubMed:8439212" FT /id="VAR_016026" FT VARIANT 12 FT /note="G -> R (in lung cancer and bladder cancer; somatic FT mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:6695174" FT /id="VAR_016027" FT VARIANT 12 FT /note="G -> S (in GASC and JMML; also found in lung FT carcinoma; somatic mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:7773929" FT /id="VAR_016028" FT VARIANT 12 FT /note="G -> V (in GASC; also found in lung carcinoma, FT pancreatic carcinoma and colon cancer; also found in FT metastatic colorectal cancer; somatic mutation; it is FT constitutively activated and stimulates transcription FT activation of tumor suppressor genes in non-transformed FT fibroblasts; promotes GTP binding; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:24623306, FT ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:39809765, ECO:0000269|PubMed:6092920, FT ECO:0000269|PubMed:8439212" FT /id="VAR_006840" FT VARIANT 13 FT /note="G -> D (in GASC, JMML and OES; also found in a FT breast carcinoma cell line; somatic mutation; FT dbSNP:rs112445441)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:3627975" FT /id="VAR_016029" FT VARIANT 13 FT /note="G -> R (in pylocytic astrocytoma; somatic mutation; FT increase activation of the Ras pathway; dbSNP:rs121913535)" FT /evidence="ECO:0000269|PubMed:16247081" FT /id="VAR_065145" FT VARIANT 14 FT /note="V -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; characterized FT by a strong increase of both intrinsic and guanine FT nucleotide exchanged factor-catalyzed nucleotide exchange FT leading to an increased level of the activated state; FT dbSNP:rs104894365)" FT /evidence="ECO:0000269|PubMed:16474405" FT /id="VAR_026109" FT VARIANT 19 FT /note="L -> F (in OES; somatic mutation; FT dbSNP:rs121913538)" FT /evidence="ECO:0000269|PubMed:25808193" FT /id="VAR_083261" FT VARIANT 22 FT /note="Q -> E (in CFC2; exhibits an increase in intrinsic FT and guanine nucleotide exchange factor catalyzed nucleotide FT exchange in combination with an impaired GTPase-activating FT protein-stimulated GTP hydrolysis but functional in FT interaction with effectors; dbSNP:rs121913236)" FT /evidence="ECO:0000269|PubMed:17056636, FT ECO:0000269|PubMed:20949621" FT /id="VAR_064850" FT VARIANT 22 FT /note="Q -> R (in NS3; impairs GTPase-activating protein FT stimulated GTP hydrolysis with unaffected intrinsic FT functions and a virtually functional effector interaction; FT dbSNP:rs727503110)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064851" FT VARIANT 34 FT /note="P -> L (in NS3; characterized by a defective GTPase- FT activating protein sensitivity and a strongly reduced FT interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064852" FT VARIANT 34 FT /note="P -> Q (in NS3; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064853" FT VARIANT 34 FT /note="P -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026110" FT VARIANT 36 FT /note="I -> M (in NS3; dbSNP:rs727503109)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064854" FT VARIANT 58 FT /note="T -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; exhibits only FT minor alterations in its in vitro biochemical behavior FT compared to wild-type protein; dbSNP:rs104894364)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:19396835" FT /id="VAR_026111" FT VARIANT 59 FT /note="A -> T (in GASC; also found in bladder cancer; FT somatic mutation; dbSNP:rs121913528)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:1553789" FT /id="VAR_016030" FT VARIANT 60 FT /note="G -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026112" FT VARIANT 60 FT /note="G -> S (in NS3; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:19396835" FT /id="VAR_065146" FT VARIANT 61 FT /note="Q -> H (in lung carcinoma; dbSNP:rs17851045)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:16533793, ECO:0000269|Ref.7" FT /id="VAR_006841" FT VARIANT 61 FT /note="Q -> R (in a colorectal cancer sample; somatic FT mutation; promotes interaction with SHOC2 and PP1C; FT dbSNP:rs121913240)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509" FT /id="VAR_036306" FT VARIANT 71 FT /note="Y -> H (in CFC2; dbSNP:rs387907205)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069784" FT VARIANT 117 FT /note="K -> N (in colorectal cancer samples; somatic FT mutation; dbSNP:rs770248150)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036307" FT VARIANT 146 FT /note="A -> T (in OES; somatic mutation; also found in FT colorectal cancer samples; dbSNP:rs121913527)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:26970110, ECO:0000269|PubMed:30891959, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036308" FT VARIANT 146 FT /note="A -> V (in OES; somatic mutation; FT dbSNP:rs1057519725)" FT /evidence="ECO:0000269|PubMed:26970110, FT ECO:0000269|PubMed:30891959" FT /id="VAR_083262" FT VARIANT 147 FT /note="K -> E (in CFC2; dbSNP:rs387907206)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069785" FT MUTAGEN 38 FT /note="D->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 40 FT /note="Y->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 61 FT /note="Q->L: Promotes GTP binding." FT /evidence="ECO:0000269|PubMed:39809765" FT MUTAGEN 180 FT /note="C->S: Abolished palmitoylation on Cys; reduced FT palmitoylation on Lys residues." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 182..185 FT /note="KIKK->RIRR: In K-Ras-3KR; abolished lysine- FT palmitoylation." FT /evidence="ECO:0000269|PubMed:29239724" FT STRAND 3..9 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:6EPO" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 28..32 FT /evidence="ECO:0007829|PDB:7F0W" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:6H46" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 60..62 FT /evidence="ECO:0007829|PDB:4Q01" FT HELIX 66..73 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 87..91 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 93..104 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5VBM" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:4OBE" FT HELIX 127..137 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 141..143 FT /evidence="ECO:0007829|PDB:8ONV" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 169..172 FT /evidence="ECO:0007829|PDB:5OCG" FT STRAND 175..177 FT /evidence="ECO:0007829|PDB:4DSN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:5TB5" FT VARIANT P01116-2:152 FT /note="V -> G (in NS3; dbSNP:rs104894367)" FT /evidence="ECO:0000305" FT /id="VAR_082908" FT VARIANT P01116-2:153 FT /note="D -> V (in CFC2 and NS3; exhibits only minor FT alterations in its in vitro biochemical behavior compared FT to wild-type protein; dbSNP:rs104894360)" FT /evidence="ECO:0000305" FT /id="VAR_082909" FT VARIANT P01116-2:156 FT /note="F -> I (in NS3; the patient also has features of FT cardiofaciocutaneous syndrome; dbSNP:rs397517042)" FT /evidence="ECO:0000305" FT /id="VAR_082910" FT VARIANT P01116-2:156 FT /note="F -> L (found in a patient with Costello syndrome; FT exhibits an increase in intrinsic and guanine nucleotide FT exchange factor catalyzed nucleotide exchange in FT combination with an impaired GTPase-activating protein- FT stimulated GTP hydrolysis but functional in interaction FT with effectors; dbSNP:rs104894362)" FT /evidence="ECO:0000305" FT /id="VAR_082911" FT MUTAGEN P01116-2:185 FT /note="C->S: Abolished interaction with GPR131." FT /evidence="ECO:0000269|PubMed:28619714" SQ SEQUENCE 189 AA; 21656 MW; 973547B2E11C2C81 CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC VKIKKCIIM // ID RIPK1_HUMAN Reviewed; 671 AA. AC Q13546; A0AV89; B2RAG1; B4E3F9; Q13180; Q59H33; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 3. DT 28-JAN-2026, entry version 243. DE RecName: Full=Receptor-interacting serine/threonine-protein kinase 1; DE EC=2.7.11.1 {ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; DE AltName: Full=Cell death protein RIP {ECO:0000303|PubMed:8612133}; DE AltName: Full=Receptor-interacting protein 1 {ECO:0000303|PubMed:16603398}; DE Short=RIP-1 {ECO:0000303|PubMed:16603398}; GN Name=RIPK1 {ECO:0000312|HGNC:HGNC:10019}; GN Synonyms=RIP {ECO:0000303|PubMed:8612133}, GN RIP1 {ECO:0000303|PubMed:16603398}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-45, INTERACTION WITH TRADD; TRAF1; RP TRAF2 AND TRAF3, AND VARIANT VAL-438. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=8612133; DOI=10.1016/s1074-7613(00)80252-6; RA Hsu H., Huang J., Shu H.-B., Baichwal V.R., Goeddel D.V.; RT "TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 RT signaling complex."; RL Immunity 4:387-396(1996). RN [2] RP SEQUENCE REVISION TO 120. RA Huang J., Hsu H., Baichwal V.R., Goeddel D.V.; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 15-671 (ISOFORM 2). RC TISSUE=Adrenal gland, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-234. RG SeattleSNPs variation discovery resource; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-438. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-671. RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 300-671, AND VARIANT VAL-438. RC TISSUE=Leukemic T-cell; RX PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1; RA Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.; RT "RIP: a novel protein containing a death domain that interacts with RT Fas/APO-1 (CD95) in yeast and causes cell death."; RL Cell 81:513-523(1995). RN [9] RP INTERACTION WITH CRADD, AND DOMAIN. RX PubMed=9044836; RA Ahmad M., Srinivasula S.M., Wang L., Talanian R.V., Litwack G., RA Fernandes-Alnemri T., Alnemri E.S.; RT "CRADD, a novel human apoptotic adaptor molecule for caspase-2, and RT FasL/tumor necrosis factor receptor-interacting protein RIP."; RL Cancer Res. 57:615-619(1997). RN [10] RP CLEAVAGE BY CASP8, AND MUTAGENESIS OF ASP-324. RX PubMed=10521396; DOI=10.1101/gad.13.19.2514; RA Lin Y., Devin A., Rodriguez Y., Liu Z.-G.; RT "Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced RT apoptosis."; RL Genes Dev. 13:2514-2526(1999). RN [11] RP INTERACTION WITH SQSTM1 AND TRAF2, AND DOMAIN DEATH. RX PubMed=10356400; DOI=10.1093/emboj/18.11.3044; RA Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.; RT "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB RT activation."; RL EMBO J. 18:3044-3053(1999). RN [12] RP INTERACTION WITH RIPK3. RX PubMed=10358032; DOI=10.1074/jbc.274.24.16871; RA Sun X., Lee J., Navas T., Baldwin D.T., Stewart T.A., Dixit V.M.; RT "RIP3, a novel apoptosis-inducing kinase."; RL J. Biol. Chem. 274:16871-16875(1999). RN [13] RP INTERACTION WITH BNLF1. RX PubMed=10409763; DOI=10.1128/mcb.19.8.5759; RA Izumi K.M., Cahir McFarland E., Ting A.T., Riley E.A., Seed B., Kieff E.D.; RT "The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the RT tumor necrosis factor receptor-associated proteins TRADD and receptor- RT interacting protein (RIP) but does not induce apoptosis or require RIP for RT NF-kappaB activation."; RL Mol. Cell. Biol. 19:5759-5767(1999). RN [14] RP INTERACTION WITH IKBKG. RX PubMed=9927690; DOI=10.1073/pnas.96.3.1042; RA Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A., RA Wallach D., Horwitz M.S.; RT "Identification of a cell protein (FIP-3) as a modulator of NF-kappaB RT activity and as a target of an adenovirus inhibitor of tumor necrosis RT factor alpha-induced apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 96:1042-1047(1999). RN [15] RP FUNCTION. RX PubMed=11101870; DOI=10.1038/82732; RA Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., RA Bodmer J.L., Schneider P., Seed B., Tschopp J.; RT "Fas triggers an alternative, caspase-8-independent cell death pathway RT using the kinase RIP as effector molecule."; RL Nat. Immunol. 1:489-495(2000). RN [16] RP INTERACTION WITH EGFR. RX PubMed=11116146; DOI=10.1074/jbc.m008458200; RA Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S., RA Vartanian T.; RT "The epidermal growth factor receptor engages receptor interacting protein RT and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF- RT kappa B. Identification of a novel receptor-tyrosine kinase signalosome."; RL J. Biol. Chem. 276:8865-8874(2001). RN [17] RP INTERACTION WITH RNF216. RX PubMed=11854271; DOI=10.1074/jbc.m108675200; RA Chen D., Li X., Zhai Z., Shu H.-B.; RT "A novel zinc finger protein interacts with receptor-interacting protein RT (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B RT activation."; RL J. Biol. Chem. 277:15985-15991(2002). RN [18] RP RIP HOMOTYPIC INTERACTION MOTIF, AND INTERACTION WITH RIPK3. RX PubMed=11734559; DOI=10.1074/jbc.m109488200; RA Sun X., Yin J., Starovasnik M.A., Fairbrother W.J., Dixit V.M.; RT "Identification of a novel homotypic interaction motif required for the RT phosphorylation of receptor-interacting protein (RIP) by RIP3."; RL J. Biol. Chem. 277:9505-9511(2002). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-384, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [20] RP INTERACTION WITH ZFAND5. RX PubMed=14754897; DOI=10.1074/jbc.m309491200; RA Huang J., Teng L., Li L., Liu T., Li L., Chen D., Xu L.-G., Zhai Z., RA Shu H.-B.; RT "ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor of RT NFkappaB activation."; RL J. Biol. Chem. 279:16847-16853(2004). RN [21] RP INTERACTION WITH DAB2IP. RX PubMed=15310755; DOI=10.1074/jbc.m407617200; RA Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W.; RT "AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2- RT induced ASK1-JNK activation."; RL J. Biol. Chem. 279:44955-44965(2004). RN [22] RP UBIQUITINATION BY TRAF2, AND DEUBIQUITINATION BY TNFAIP3. RX PubMed=15258597; DOI=10.1038/nature02794; RA Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., RA Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M.; RT "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF- RT kappaB signalling."; RL Nature 430:694-699(2004). RN [23] RP INTERACTION WITH MAVS. RX PubMed=16127453; DOI=10.1038/ni1243; RA Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., RA Takeuchi O., Akira S.; RT "IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon RT induction."; RL Nat. Immunol. 6:981-988(2005). RN [24] RP UBIQUITINATION AT LYS-377, AND MUTAGENESIS OF LYS-377. RX PubMed=16603398; DOI=10.1016/j.molcel.2006.03.026; RA Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J.; RT "Activation of IKK by TNFalpha requires site-specific ubiquitination of RT RIP1 and polyubiquitin binding by NEMO."; RL Mol. Cell 22:245-257(2006). RN [25] RP INTERACTION WITH TAX1BP1, FUNCTION, AND UBIQUITINATION. RX PubMed=17703191; DOI=10.1038/sj.emboj.7601823; RA Shembade N., Harhaj N.S., Liebl D.J., Harhaj E.W.; RT "Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and RT LPS-mediated NF-kappaB and JNK signaling."; RL EMBO J. 26:3910-3922(2007). RN [26] RP REVIEW. RX PubMed=17301840; DOI=10.1038/sj.cdd.4402085; RA Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P.; RT "RIP1, a kinase on the crossroads of a cell's decision to live or die."; RL Cell Death Differ. 14:400-410(2007). RN [27] RP FUNCTION IN PHOSPHORYLATION OF DAB2IP, AND INTERACTION WITH DAB2IP. RX PubMed=17389591; DOI=10.1074/jbc.m701148200; RA Zhang H., Zhang H., Lin Y., Li J., Pober J.S., Min W.; RT "RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical RT for tumor necrosis factor-induced ASK1-JNK/p38 activation."; RL J. Biol. Chem. 282:14788-14796(2007). RN [28] RP INTERACTION WITH RBCK1. RX PubMed=17449468; DOI=10.1074/jbc.m701913200; RA Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P., Zhang M., RA Chen D.Y., Zhai Z.H., Shu H.B.; RT "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1- RT triggered NF-kappaB activation by targeting TAB2/3 for degradation."; RL J. Biol. Chem. 282:16776-16782(2007). RN [29] RP INTERACTION WITH RFFL, AND UBIQUITINATION BY RFFL. RX PubMed=18450452; DOI=10.1016/j.cub.2008.04.017; RA Liao W., Xiao Q., Tchikov V., Fujita K., Yang W., Wincovitch S., RA Garfield S., Conze D., El-Deiry W.S., Schuetze S., Srinivasula S.M.; RT "CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates RT TNF-induced NF-kappaB activation."; RL Curr. Biol. 18:641-649(2008). RN [30] RP MUTAGENESIS OF SER-161, INHIBITION BY NECROSTATIN-1, AND PHOSPHORYLATION AT RP SER-6; SER-20; SER-25; SER-161; SER-166; SER-303; SER-320 AND SER-333. RX PubMed=18408713; DOI=10.1038/nchembio.83; RA Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X., RA Abbott D., Cuny G.D., Yuan C., Wagner G., Hedrick S.M., Gerber S.A., RA Lugovskoy A., Yuan J.; RT "Identification of RIP1 kinase as a specific cellular target of RT necrostatins."; RL Nat. Chem. Biol. 4:313-321(2008). RN [31] RP INTERACTION WITH MURID HERPESVIRUS 1 PROTEIN RIR1. RX PubMed=18442983; DOI=10.1074/jbc.c800051200; RA Upton J.W., Kaiser W.J., Mocarski E.S.; RT "Cytomegalovirus M45 cell death suppression requires receptor-interacting RT protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RT RIP1."; RL J. Biol. Chem. 283:16966-16970(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, AND PHOSPHORYLATION. RX PubMed=19524513; DOI=10.1016/j.cell.2009.05.037; RA Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., RA Chan F.K.; RT "Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates RT programmed necrosis and virus-induced inflammation."; RL Cell 137:1112-1123(2009). RN [34] RP FUNCTION, AND INTERACTION WITH RIPK3. RX PubMed=19524512; DOI=10.1016/j.cell.2009.05.021; RA He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X.; RT "Receptor interacting protein kinase-3 determines cellular necrotic RT response to TNF-alpha."; RL Cell 137:1100-1111(2009). RN [35] RP INTERACTION WITH RNF34, AND UBIQUITINATION BY RNF34. RX DOI=10.1016/j.cub.2008.11.041; RA Liao W., Fujita K., Xiao Q., Tchikov V., Yang W., Gunsor M., Garfield S., RA Goldsmith P., El-Deiry W.S., Schuetze S., Srinivasula S.M.; RT "Response: CARP1 regulates induction of NF-kappaB by TNFalpha."; RL Curr. Biol. 19:R17-R19(2009). RN [36] RP REVIEW. RX PubMed=20354226; DOI=10.1126/scisignal.3115re4; RA Vandenabeele P., Declercq W., Van Herreweghe F., Vanden Berghe T.; RT "The role of the kinases RIP1 and RIP3 in TNF-induced necrosis."; RL Sci. Signal. 3:RE4-RE4(2010). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP UBIQUITINATION BY THE LUBAC COMPLEX. RX PubMed=21455173; DOI=10.1038/nature09816; RA Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E., RA Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W., Nachbur U., RA Gangoda L., Warnken U., Purcell A.W., Silke J., Walczak H.; RT "Linear ubiquitination prevents inflammation and regulates immune RT signalling."; RL Nature 471:591-596(2011). RN [39] RP UBIQUITINATION BY BIRC2/C-IAP1 AND BIRC3/C-IAP2, AND INTERACTION WITH RP BIRC2/C-IAP1; BIRC3/C-IAP2 AND XIAP/BIRC4. RX PubMed=21931591; DOI=10.1371/journal.pone.0022356; RA Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J., RA Gevaert K., Declercq W., Vandenabeele P.; RT "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin RT chains to receptor interacting proteins kinases 1 to 4 (RIP1-4)."; RL PLoS ONE 6:E22356-E22356(2011). RN [40] RP IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK3 AND MLKL. RX PubMed=22265414; DOI=10.1016/j.cell.2011.11.030; RA Wang Z., Jiang H., Chen S., Du F., Wang X.; RT "The mitochondrial phosphatase PGAM5 functions at the convergence point of RT multiple necrotic death pathways."; RL Cell 148:228-243(2012). RN [41] RP INTERACTION WITH ARHGEF2. RX PubMed=21887730; DOI=10.1002/ibd.21851; RA Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B., RA Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.; RT "Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1."; RL Inflamm. Bowel Dis. 18:603-612(2012). RN [42] RP INTERACTION WITH DDX24. RX PubMed=24204270; DOI=10.1371/journal.ppat.1003721; RA Ma Z., Moore R., Xu X., Barber G.N.; RT "DDX24 negatively regulates cytosolic RNA-mediated innate immune RT signaling."; RL PLoS Pathog. 9:e1003721-e1003721(2013). RN [43] RP PROTEOLYTIC CLEAVAGE. RX PubMed=22858542; DOI=10.1038/cdd.2012.98; RA van Raam B.J., Ehrnhoefer D.E., Hayden M.R., Salvesen G.S.; RT "Intrinsic cleavage of receptor-interacting protein kinase-1 by caspase- RT 6."; RL Cell Death Differ. 20:86-96(2013). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [45] RP FUNCTION, AND DEUBIQUITINATION BY USP7. RX PubMed=24144979; DOI=10.1128/mcb.00465-13; RA Zaman M.M., Nomura T., Takagi T., Okamura T., Jin W., Shinagawa T., RA Tanaka Y., Ishii S.; RT "Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor RT necrosis factor alpha-induced apoptosis."; RL Mol. Cell. Biol. 33:4971-4984(2013). RN [46] RP GLYCOSYLATION AT ARG-603 (MICROBIAL INFECTION). RX PubMed=23955153; DOI=10.1038/nature12436; RA Li S., Zhang L., Yao Q., Li L., Dong N., Rong J., Gao W., Ding X., Sun L., RA Chen X., Chen S., Shao F.; RT "Pathogen blocks host death receptor signalling by arginine GlcNAcylation RT of death domains."; RL Nature 501:242-246(2013). RN [47] RP INTERACTION WITH TNFRSF1A. RX PubMed=24130170; DOI=10.1093/carcin/bgt338; RA Kim T.W., Kang Y.K., Park Z.Y., Kim Y.H., Hong S.W., Oh S.J., Sohn H.A., RA Yang S.J., Jang Y.J., Lee D.C., Kim S.Y., Yoo H.S., Kim E., Yeom Y.I., RA Park K.C.; RT "SH3RF2 functions as an oncogene by mediating PAK4 protein stability."; RL Carcinogenesis 35:624-634(2014). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [49] RP REVIEW. RX PubMed=25459879; DOI=10.1016/j.molcel.2014.11.001; RA Weinlich R., Green D.R.; RT "The two faces of receptor interacting protein kinase-1."; RL Mol. Cell 56:469-480(2014). RN [50] RP INTERACTION WITH TICAM1. RX PubMed=25736436; DOI=10.15252/embr.201439637; RA Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B., RA Liu Y.; RT "WDFY1 mediates TLR3/4 signaling by recruiting TRIF."; RL EMBO Rep. 16:447-455(2015). RN [51] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 AND 2 PROTEIN RIR1 (MICROBIAL RP INFECTION). RX PubMed=25674983; DOI=10.1016/j.chom.2015.01.003; RA Guo H., Omoto S., Harris P.A., Finger J.N., Bertin J., Gough P.J., RA Kaiser W.J., Mocarski E.S.; RT "Herpes simplex virus suppresses necroptosis in human cells."; RL Cell Host Microbe 17:243-251(2015). RN [52] RP INTERACTION WITH MUMPS VIRUS PROTEIN SH (MICROBIAL INFECTION). RX PubMed=28659487; DOI=10.1128/jvi.01037-17; RA Franz S., Rennert P., Woznik M., Gruetzke J., Luedde A., Arriero Pais E.M., RA Finsterbusch T., Geyer H., Mankertz A., Friedrich N.; RT "Mumps virus SH protein inhibits NF-kappaB activation by interacting with RT tumor necrosis factor receptor 1, interleukin-1 receptor 1, and Toll-like RT receptor 3 complexes."; RL J. Virol. 91:0-0(2017). RN [53] RP INTERACTION WITH PELI1 AND RIPK3, AND UBIQUITINATION BY PELI1. RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016; RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K., RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.; RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent RT proteasomal degradation."; RL Mol. Cell 70:920-935(2018). RN [54] RP FUNCTION, SUBUNIT, MUTAGENESIS OF LYS-599, AND PHOSPHORYLATION AT SER-166. RX PubMed=29440439; DOI=10.1073/pnas.1722013115; RA Meng H., Liu Z., Li X., Wang H., Jin T., Wu G., Shan B., RA Christofferson D.E., Qi C., Yu Q., Li Y., Yuan J.; RT "Death-domain dimerization-mediated activation of RIPK1 controls RT necroptosis and RIPK1-dependent apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 115:E2001-E2009(2018). RN [55] RP INVOLVEMENT IN IMD57. RX PubMed=30026316; DOI=10.1126/science.aar2641; RA Cuchet-Lourenco D., Eletto D., Wu C., Plagnol V., Papapietro O., Curtis J., RA Ceron-Gutierrez L., Bacon C.M., Hackett S., Alsaleem B., Maes M., RA Gaspar M., Alisaac A., Goss E., AlIdrissi E., Siegmund D., Wajant H., RA Kumararatne D., AlZahrani M.S., Arkwright P.D., Abinun M., Doffinger R., RA Nejentsev S.; RT "Biallelic RIPK1 mutations in humans cause severe immunodeficiency, RT arthritis, and intestinal inflammation."; RL Science 361:810-813(2018). RN [56] RP REVIEW. RX PubMed=31457011; DOI=10.3389/fcell.2019.00163; RA Ang R.L., Chan M., Ting A.T.; RT "Ripoptocide - A Spark for Inflammation."; RL Front. Cell Dev. Biol. 7:163-163(2019). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-25, AND MUTAGENESIS OF RP SER-25 AND LYS-45. RX PubMed=30988283; DOI=10.1038/s41467-019-09690-0; RA Dondelinger Y., Delanghe T., Priem D., Wynosky-Dolfi M.A., Sorobetea D., RA Rojas-Rivera D., Giansanti P., Roelandt R., Gropengiesser J., RA Ruckdeschel K., Savvides S.N., Heck A.J.R., Vandenabeele P., Brodsky I.E., RA Bertrand M.J.M.; RT "Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in RT models of infection and inflammation."; RL Nat. Commun. 10:1729-1729(2019). RN [58] RP FUNCTION, PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), AND MUTAGENESIS OF RP 539-ILE--GLY-542. RX PubMed=32657447; DOI=10.15252/embj.2020104469; RA Ashida H., Sasakawa C., Suzuki T.; RT "A unique bacterial tactic to circumvent the cell death crosstalk induced RT by blockade of caspase-8."; RL EMBO J. 39:e104469-e104469(2020). RN [59] RP FUNCTION, AND INTERACTION WITH GRB2. RX PubMed=35831301; DOI=10.1038/s41420-022-01106-1; RA Hou B., Huang H., Li Y., Liang J., Xi Z., Jiang X., Liu L., Li E.; RT "Grb2 interacts with necrosome components and is involved in rasfonin- RT induced necroptosis."; RL Cell. Death. Discov. 8:319-319(2022). RN [60] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-294 IN COMPLEXES WITH RP NECROSTATIN-TYPE INHIBITORS, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND RP AUTOPHOSPHORYLATION. RX PubMed=23473668; DOI=10.1016/j.str.2013.01.016; RA Xie T., Peng W., Liu Y., Yan C., Maki J., Degterev A., Yuan J., Shi Y.; RT "Structural basis of RIP1 inhibition by necrostatins."; RL Structure 21:493-499(2013). RN [61] {ECO:0007744|PDB:5V7Z} RP STRUCTURE BY NMR OF 532-549 IN COMPLEX WITH RIPK3, SUBUNIT, INTERACTION RP WITH RIPK3, DOMAIN, AND MUTAGENESIS OF SER-536. RX PubMed=29681455; DOI=10.1016/j.cell.2018.03.032; RA Mompean M., Li W., Li J., Laage S., Siemer A.B., Bozkurt G., Wu H., RA McDermott A.E.; RT "The structure of the necrosome RIPK1-RIPK3 core, a human hetero-amyloid RT signaling complex."; RL Cell 173:1244-1253(2018). RN [62] {ECO:0007744|PDB:6AC5} RP X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 561-671, GLYCOSYLATION AT ARG-603 RP (MICROBIAL INFECTION), AND MUTAGENESIS OF ARG-603. RX PubMed=30979585; DOI=10.1016/j.molcel.2019.03.028; RA Ding J., Pan X., Du L., Yao Q., Xue J., Yao H., Wang D.C., Li S., Shao F.; RT "Structural and functional insights into host death domains inactivation by RT the bacterial arginine GlcNAcyltransferase effector."; RL Mol. Cell 74:922-935(2019). RN [63] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-64; ILE-81; VAL-220; SER-404; VAL-443 RP AND VAL-569. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [64] RP INVOLVEMENT IN AIEFL, VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324, RP CHARACTERIZATION OF VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324, CLEAVAGE RP BY CASP8, AND FUNCTION. RX PubMed=31827281; DOI=10.1038/s41586-019-1828-5; RA Lalaoui N., Boyden S.E., Oda H., Wood G.M., Stone D.L., Chau D., Liu L., RA Stoffels M., Kratina T., Lawlor K.E., Zaal K.J.M., Hoffmann P.M., RA Etemadi N., Shield-Artin K., Biben C., Tsai W.L., Blake M.D., Kuehn H.S., RA Yang D., Anderton H., Silke N., Wachsmuth L., Zheng L., Moura N.S., RA Beck D.B., Gutierrez-Cruz G., Ombrello A.K., Pinto-Patarroyo G.P., RA Kueh A.J., Herold M.J., Hall C., Wang H., Chae J.J., Dmitrieva N.I., RA McKenzie M., Light A., Barham B.K., Jones A., Romeo T.M., Zhou Q., RA Aksentijevich I., Mullikin J.C., Gross A.J., Shum A.K., Hawkins E.D., RA Masters S.L., Lenardo M.J., Boehm M., Rosenzweig S.D., Pasparakis M., RA Voss A.K., Gadina M., Kastner D.L., Silke J.; RT "Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory RT disease."; RL Nature 577:103-108(2020). RN [65] RP INVOLVEMENT IN AIEFL, VARIANTS AIEFL HIS-324 AND VAL-324, CHARACTERIZATION RP OF VARIANTS AIEFL HIS-324 AND VAL-324, FUNCTION, CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, PHOSPHORYLATION AT SER-166, AND CLEAVAGE BY CASP8. RX PubMed=31827280; DOI=10.1038/s41586-019-1830-y; RA Tao P., Sun J., Wu Z., Wang S., Wang J., Li W., Pan H., Bai R., Zhang J., RA Wang Y., Lee P.Y., Ying W., Zhou Q., Hou J., Wang W., Sun B., Yang M., RA Liu D., Fang R., Han H., Yang Z., Huang X., Li H., Deuitch N., Zhang Y., RA Dissanayake D., Haude K., McWalter K., Roadhouse C., MacKenzie J.J., RA Laxer R.M., Aksentijevich I., Yu X., Wang X., Yuan J., Zhou Q.; RT "A dominant autoinflammatory disease caused by non-cleavable variants of RT RIPK1."; RL Nature 577:109-114(2020). CC -!- FUNCTION: Serine-threonine kinase which is a key regulator of TNF- CC mediated apoptosis, necroptosis and inflammatory pathways CC (PubMed:17703191, PubMed:24144979, PubMed:31827280, PubMed:31827281, CC PubMed:32657447, PubMed:35831301). Exhibits kinase activity-dependent CC functions that regulate cell death and kinase-independent scaffold CC functions regulating inflammatory signaling and cell survival CC (PubMed:11101870, PubMed:19524512, PubMed:19524513, PubMed:29440439, CC PubMed:30988283). Has kinase-independent scaffold functions: upon CC binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling CC complex (TNF-RSC also known as complex I) where it acts as a scaffold CC protein promoting cell survival, in part, by activating the canonical CC NF-kappa-B pathway (By similarity). Kinase activity is essential to CC regulate necroptosis and apoptosis, two parallel forms of cell death: CC upon activation of its protein kinase activity, regulates assembly of CC two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), CC which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which CC drives necroptosis (By similarity). RIPK1 is required to limit CASP8- CC dependent TNFR1-induced apoptosis (By similarity). In normal CC conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, CC a process mediated by RIPK3 component of complex IIb, which catalyzes CC phosphorylation of MLKL upon induction by ZBP1 (PubMed:19524512, CC PubMed:19524513, PubMed:29440439, PubMed:30988283). Inhibits RIPK3- CC mediated necroptosis via FADD-mediated recruitment of CASP8, which CC cleaves RIPK1 and limits TNF-induced necroptosis (PubMed:19524512, CC PubMed:19524513, PubMed:29440439, PubMed:30988283). Required to inhibit CC apoptosis and necroptosis during embryonic development: acts by CC preventing the interaction of TRADD with FADD thereby limiting aberrant CC activation of CASP8 (By similarity). In addition to apoptosis and CC necroptosis, also involved in inflammatory response by promoting CC transcriptional production of pro-inflammatory cytokines, such as CC interleukin-6 (IL6) (PubMed:31827280, PubMed:31827281). Phosphorylates CC RIPK3: RIPK1 and RIPK3 undergo reciprocal auto- and trans- CC phosphorylation (PubMed:19524513). Phosphorylates DAB2IP at 'Ser-728' CC in a TNF-dependent manner, and thereby activates the MAP3K5-JNK CC apoptotic cascade (PubMed:15310755, PubMed:17389591). Required for CC ZBP1-induced NF-kappa-B activation in response to DNA damage (By CC similarity). {ECO:0000250|UniProtKB:Q60855, CC ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:15310755, CC ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17703191, CC ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:19524513, CC ECO:0000269|PubMed:24144979, ECO:0000269|PubMed:29440439, CC ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, CC ECO:0000269|PubMed:31827281, ECO:0000269|PubMed:32657447, CC ECO:0000269|PubMed:35831301}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; CC -!- ACTIVITY REGULATION: Serine-threonine kinase activity is inhibited by CC linear polyubiquitination ('Met-1'-linked) by the LUBAC complex (By CC similarity). Inhibited by necrostatins, including necrostatin-1, CC necrostatin-3 and necrostatin-4 (PubMed:23473668). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:23473668}. CC -!- SUBUNIT: Homodimer (PubMed:29440439, PubMed:29681455). Interacts (via CC RIP homotypic interaction motif) with RIPK3 (via RIP homotypic CC interaction motif); this interaction induces RIPK1 phosphorylation and CC formation of a RIPK1-RIPK3 necroptosis-inducing complex CC (PubMed:10358032, PubMed:11734559, PubMed:19524512, PubMed:29681455, CC PubMed:29883609). Upon TNF-induced necrosis, the RIPK1-RIPK3 dimer CC further interacts with PGAM5 and MLKL; the formation of this complex CC leads to PGAM5 phosphorylation and increase in PGAM5 phosphatase CC activity (PubMed:22265414). Interacts (via the death domain) with CC TNFRSF6 (via the death domain) and TRADD (via the death domain) CC (PubMed:8612133). Is recruited by TRADD to TNFRSF1A in a TNF-dependent CC process (PubMed:24130170). Binds RNF216, EGFR, IKBKG, TRAF1, TRAF2 and CC TRAF3 (PubMed:11116146, PubMed:11854271, PubMed:8612133, CC PubMed:9927690). Interacts with BNLF1 (PubMed:10409763). Interacts with CC SQSTM1 upon TNF stimulation (PubMed:10356400). May interact with CC MAVS/IPS1 (PubMed:16127453). Interacts with ZFAND5 (PubMed:14754897). CC Interacts with RBCK1 (PubMed:17449468). Interacts with ZBP1 (By CC similarity). Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 and XIAP/BIRC4 CC (PubMed:21931591). Interacts (via kinase domain) with DAB2IP (via Ras- CC GAP domain); the interaction occurs in a TNF-dependent manner CC (PubMed:15310755, PubMed:17389591). Interacts with ARHGEF2 CC (PubMed:21887730). Interacts (via protein kinase domain) with RFFL; CC involved in RIPK1 ubiquitination (PubMed:18450452). Interacts with CC RNF34; involved in RIPK1 ubiquitination (Ref.35). Interacts with TICAM1 CC and this interaction is enhanced in the presence of WDFY1 CC (PubMed:25736436). Interacts with PELI1 (PubMed:29883609). Interacts CC (via death domain) with CRADD (via death domain); the interaction is CC direct (PubMed:9044836). Component of complex IIa composed of at least CC RIPK1, FADD and CASP8 (By similarity). Component of the AIM2 CC PANoptosome complex, a multiprotein complex that drives inflammatory CC cell death (PANoptosis) (By similarity). Interacts with MAP3K7, CFLAR, CC CASP8, FADD and NEMO (By similarity). Interacts with TAX1BP1; this CC interaction negatively regulates RIPK1 ubiquitination CC (PubMed:17703191). Interacts with GRB2 (PubMed:35831301). Interacts CC with DDX24; this interaction disrupts RLR signaling activation of IFN- CC dependent transcription factor IRF7 (PubMed:24204270). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:10356400, CC ECO:0000269|PubMed:10358032, ECO:0000269|PubMed:10409763, CC ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11734559, CC ECO:0000269|PubMed:11854271, ECO:0000269|PubMed:14754897, CC ECO:0000269|PubMed:16127453, ECO:0000269|PubMed:17389591, CC ECO:0000269|PubMed:17449468, ECO:0000269|PubMed:17703191, CC ECO:0000269|PubMed:18450452, ECO:0000269|PubMed:19524512, CC ECO:0000269|PubMed:21887730, ECO:0000269|PubMed:21931591, CC ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:24130170, CC ECO:0000269|PubMed:24204270, ECO:0000269|PubMed:25736436, CC ECO:0000269|PubMed:29440439, ECO:0000269|PubMed:29681455, CC ECO:0000269|PubMed:29883609, ECO:0000269|PubMed:35831301, CC ECO:0000269|PubMed:8612133, ECO:0000269|PubMed:9044836, CC ECO:0000269|PubMed:9927690, ECO:0000269|Ref.35}. CC -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein SH; CC this interaction inhibits downstream NF-kappa-B pathway activation. CC {ECO:0000269|PubMed:28659487}. CC -!- SUBUNIT: (Microbial infection) Interacts with Murid herpesvirus 1 CC protein RIR1. {ECO:0000269|PubMed:18442983}. CC -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction CC motif) with herpes simplex virus 1/HHV-1 protein RIR1/ICP6 (via RIP CC homotypic interaction motif); this interaction prevents necroptosis CC activation. {ECO:0000269|PubMed:25674983}. CC -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction CC motif) with herpes simplex virus 2/HHV-2 protein RIR1/ICP10 (via RIP CC homotypic interaction motif); this interaction prevents necroptosis CC activation. {ECO:0000269|PubMed:25674983}. CC -!- INTERACTION: CC Q13546; P04083: ANXA1; NbExp=5; IntAct=EBI-358507, EBI-354007; CC Q13546; Q13490: BIRC2; NbExp=10; IntAct=EBI-358507, EBI-514538; CC Q13546; Q13489: BIRC3; NbExp=3; IntAct=EBI-358507, EBI-517709; CC Q13546; Q92851: CASP10; NbExp=2; IntAct=EBI-358507, EBI-495095; CC Q13546; Q14790: CASP8; NbExp=30; IntAct=EBI-358507, EBI-78060; CC Q13546; Q8IVM0: CCDC50; NbExp=2; IntAct=EBI-358507, EBI-723996; CC Q13546; P48729: CSNK1A1; NbExp=5; IntAct=EBI-358507, EBI-1383726; CC Q13546; Q13158: FADD; NbExp=12; IntAct=EBI-358507, EBI-494804; CC Q13546; P08238: HSP90AB1; NbExp=2; IntAct=EBI-358507, EBI-352572; CC Q13546; Q9Y6K9: IKBKG; NbExp=9; IntAct=EBI-358507, EBI-81279; CC Q13546; Q96AB6: NTAN1; NbExp=2; IntAct=EBI-358507, EBI-12401218; CC Q13546; Q9ULZ3: PYCARD; NbExp=2; IntAct=EBI-358507, EBI-751215; CC Q13546; Q13546: RIPK1; NbExp=11; IntAct=EBI-358507, EBI-358507; CC Q13546; Q9Y572: RIPK3; NbExp=27; IntAct=EBI-358507, EBI-298250; CC Q13546; P19438: TNFRSF1A; NbExp=7; IntAct=EBI-358507, EBI-299451; CC Q13546; Q15628: TRADD; NbExp=3; IntAct=EBI-358507, EBI-359215; CC Q13546; Q13077: TRAF1; NbExp=8; IntAct=EBI-358507, EBI-359224; CC Q13546; Q12933: TRAF2; NbExp=10; IntAct=EBI-358507, EBI-355744; CC Q13546; Q13114: TRAF3; NbExp=5; IntAct=EBI-358507, EBI-357631; CC Q13546; O00635: TRIM38; NbExp=2; IntAct=EBI-358507, EBI-2130415; CC Q13546; Q13107: USP4; NbExp=4; IntAct=EBI-358507, EBI-723290; CC Q13546; B7UI21: nleB1; Xeno; NbExp=4; IntAct=EBI-358507, EBI-16070376; CC Q13546; PRO_0000449629 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-358507, EBI-25475885; CC Q13546; U5TQE9: UL39; Xeno; NbExp=3; IntAct=EBI-358507, EBI-11894787; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q60855}. Cell CC membrane {ECO:0000250|UniProtKB:Q9ZUF4}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13546-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13546-2; Sequence=VSP_037690; CC -!- DOMAIN: The RIP homotypic interaction motif (RHIM) mediates interaction CC with the RHIM motif of RIPK1. Both motifs form a hetero-amyloid CC serpentine fold, stabilized by hydrophobic packing and featuring an CC unusual Cys-Ser ladder of alternating Ser (from RIPK1) and Cys (from CC RIPK3). {ECO:0000269|PubMed:29681455}. CC -!- DOMAIN: The death domain mediates dimerization and activation of its CC kinase activity during necroptosis and apoptosis (PubMed:29440439). It CC engages other DD-containing proteins as well as a central CC (intermediate) region important for NF-kB activation and RHIM-dependent CC signaling (PubMed:10356400). {ECO:0000269|PubMed:10356400, CC ECO:0000269|PubMed:29440439}. CC -!- PTM: (Microbial infection) Proteolytically cleaved by S.flexneri OspD3 CC within the RIP homotypic interaction motif (RHIM), leading to its CC degradation and inhibition of necroptosis. CC {ECO:0000269|PubMed:32657447}. CC -!- PTM: Proteolytically cleaved by CASP8 at Asp-324 (PubMed:10521396, CC PubMed:31827280, PubMed:31827281). Cleavage is crucial for limiting CC TNF-induced apoptosis, necroptosis and inflammatory response CC (PubMed:31827280, PubMed:31827281). Cleavage abolishes NF-kappa-B CC activation and enhances the interaction of TRADD with FADD CC (PubMed:10521396). Proteolytically cleaved by CASP6 during intrinsic CC apoptosis (PubMed:22858542). {ECO:0000250|UniProtKB:Q60855, CC ECO:0000269|PubMed:10521396, ECO:0000269|PubMed:31827280, CC ECO:0000269|PubMed:31827281}. CC -!- PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation CC (PubMed:18408713, PubMed:19524513, PubMed:31827280). Phosphorylation of CC Ser-161 by RIPK3 is necessary for the formation of the necroptosis- CC inducing complex (PubMed:18408713). Phosphorylation at Ser-25 represses CC its kinase activity and consequently prevents TNF-mediated RIPK1- CC dependent cell death (PubMed:30988283). Phosphorylated at Ser-320 by CC MAP3K7 which requires prior ubiquitination with 'Lys-63'-linked chains CC by BIRC2/c-IAP1 and BIRC3/c-IAP2 (By similarity). This phosphorylation CC positively regulates RIPK1 interaction with RIPK3 to promote CC necroptosis but negatively regulates RIPK1 kinase activity and its CC interaction with FADD to mediate apoptosis (By similarity). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:18408713, CC ECO:0000269|PubMed:19524513, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280}. CC -!- PTM: Deubiquitinated by USP7; this modification is required for TNF- CC induced apoptosis. {ECO:0000269|PubMed:24144979}. CC -!- PTM: Ubiquitinated with 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear- CC linked type ubiquitin (PubMed:15258597, PubMed:16603398, CC PubMed:17703191, PubMed:18450452, PubMed:21455173, PubMed:21931591, CC PubMed:29883609, Ref.35). Polyubiquitination with 'Lys-63'-linked CC chains by TRAF2 induces association with the IKK complex CC (PubMed:15258597). Deubiquitination of 'Lys-63'-linked chains and CC polyubiquitination with 'Lys-48'-linked chains by TNFAIP3 leads to CC RIPK1 proteasomal degradation and consequently down-regulates TNF- CC induced NF-kappa-B signaling (PubMed:15258597). 'Lys-48'-linked CC polyubiquitination by RFFL or RNF34 also promotes proteasomal CC degradation and negatively regulates TNF-induced NF-kappa-B signaling CC (PubMed:18450452, Ref.35). Linear polyubiquitinated; the head-to-tail CC linear polyubiquitination ('Met-1'-linked) is mediated by the LUBAC CC complex and decreases protein kinase activity (PubMed:21455173). CC Deubiquitination of linear polyubiquitin by CYLD promotes the kinase CC activity (By similarity). Polyubiquitinated with 'Lys-48' and 'Lys-63'- CC linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation CC of NF-kappa-B (PubMed:21931591). Ubiquitinated with 'Lys-63'-linked CC chains by PELI1 (PubMed:29883609). Ubiquitination at Lys-377 with 'Lys- CC 63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2 is essential for its CC phosphorylation at Ser-320 mediated by MAP3K7 (By similarity). This CC ubiquitination is required for NF-kB activation, suppresses RIPK1 CC kinase activity and plays a critical role in preventing cell death CC during embryonic development (By similarity). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:15258597, CC ECO:0000269|PubMed:16603398, ECO:0000269|PubMed:18450452, CC ECO:0000269|PubMed:21455173, ECO:0000269|PubMed:21931591, CC ECO:0000269|PubMed:29883609, ECO:0000269|Ref.35}. CC -!- PTM: (Microbial infection) Glycosylated at Arg-603 by enteropathogenic CC E.coli protein NleB1: arginine GlcNAcylation prevents CC homotypic/heterotypic death domain interactions. CC {ECO:0000305|PubMed:23955153}. CC -!- DISEASE: Immunodeficiency 57 with autoinflammation (IMD57) CC [MIM:618108]: An autosomal recessive primary immunodeficiency CC characterized by lymphopenia and recurrent viral, bacterial, and fungal CC infections. Patients exhibit early-onset inflammatory bowel disease CC involving the upper and lower gastrointestinal tract, and develop CC progressive polyarthritis. {ECO:0000269|PubMed:30026316}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. RIPK1-deficient immune cells from IMD57 patients have impaired CC proinflammatory signaling leading to dysregulated cytokine secretion CC and are prone to necroptosis. {ECO:0000269|PubMed:30026316}. CC -!- DISEASE: Autoinflammation with episodic fever and lymphadenopathy CC (AIEFL) [MIM:618852]: An autosomal dominant immunologic disorder CC characterized by early onset of recurrent episodes of unexplained CC fever, lymphadenopathy, hepatosplenomegaly, and increased levels of CC inflammatory cytokines and chemokines in patient serum. CC {ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG65471.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U50062; AAC32232.1; -; mRNA. DR EMBL; AK314176; BAG36858.1; -; mRNA. DR EMBL; AK304701; BAG65471.1; ALT_INIT; mRNA. DR EMBL; AY682848; AAT74626.1; -; Genomic_DNA. DR EMBL; AL031963; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC126254; AAI26255.1; -; mRNA. DR EMBL; BC126256; AAI26257.1; -; mRNA. DR EMBL; AB208926; BAD92163.1; -; mRNA. DR EMBL; U25994; AAC50137.1; -; mRNA. DR CCDS; CCDS4482.1; -. [Q13546-1] DR CCDS; CCDS93851.1; -. [Q13546-2] DR PIR; T09479; T09479. DR RefSeq; NP_001341859.1; NM_001354930.2. [Q13546-1] DR RefSeq; NP_001341860.1; NM_001354931.2. [Q13546-2] DR RefSeq; NP_003795.2; NM_003804.6. [Q13546-1] DR RefSeq; XP_047275403.1; XM_047419447.1. [Q13546-1] DR RefSeq; XP_047275404.1; XM_047419448.1. [Q13546-1] DR RefSeq; XP_054212622.1; XM_054356647.1. [Q13546-1] DR PDB; 4ITH; X-ray; 2.25 A; A/B=1-294. DR PDB; 4ITI; X-ray; 2.86 A; A/B=1-294. DR PDB; 4ITJ; X-ray; 1.80 A; A/B=1-294. DR PDB; 4NEU; X-ray; 2.57 A; A/B=1-324. DR PDB; 5HX6; X-ray; 2.23 A; A/B=1-294. DR PDB; 5TX5; X-ray; 2.56 A; A/B=1-294. DR PDB; 5V7Z; NMR; -; B/D/F/H=532-549. DR PDB; 6AC5; X-ray; 1.45 A; A=561-671. DR PDB; 6C3E; X-ray; 2.60 A; A/B=2-294. DR PDB; 6C4D; X-ray; 2.52 A; A/B/C/D=2-294. DR PDB; 6HHO; X-ray; 3.49 A; A/B=1-294. DR PDB; 6NW2; X-ray; 2.00 A; A/B=1-294. DR PDB; 6NYH; X-ray; 2.10 A; A/B=1-294. DR PDB; 6OCQ; X-ray; 2.79 A; A/B=1-294. DR PDB; 6R5F; X-ray; 3.25 A; A/B/C/D=1-294. DR PDB; 6RLN; X-ray; 2.87 A; A/B=1-294. DR PDB; 7CJB; X-ray; 2.80 A; D/H/L/P=189-203. DR PDB; 7FCZ; X-ray; 2.21 A; A/B=1-294. DR PDB; 7FD0; X-ray; 2.00 A; A/B=1-294. DR PDB; 7XMK; X-ray; 2.38 A; A/B=1-294. DR PDB; 7YDX; X-ray; 2.64 A; A/B=1-294. DR PDB; 8I2N; X-ray; 2.29 A; A/B=1-294. DR PDB; 8Z93; EM; 4.65 A; A/B/C=496-583. DR PDB; 9MZX; X-ray; 2.53 A; A/B=6-294. DR PDB; 9MZY; X-ray; 2.32 A; A/B=8-294. DR PDB; 9MZZ; X-ray; 2.68 A; A/B=7-294. DR PDBsum; 4ITH; -. DR PDBsum; 4ITI; -. DR PDBsum; 4ITJ; -. DR PDBsum; 4NEU; -. DR PDBsum; 5HX6; -. DR PDBsum; 5TX5; -. DR PDBsum; 5V7Z; -. DR PDBsum; 6AC5; -. DR PDBsum; 6C3E; -. DR PDBsum; 6C4D; -. DR PDBsum; 6HHO; -. DR PDBsum; 6NW2; -. DR PDBsum; 6NYH; -. DR PDBsum; 6OCQ; -. DR PDBsum; 6R5F; -. DR PDBsum; 6RLN; -. DR PDBsum; 7CJB; -. DR PDBsum; 7FCZ; -. DR PDBsum; 7FD0; -. DR PDBsum; 7XMK; -. DR PDBsum; 7YDX; -. DR PDBsum; 8I2N; -. DR PDBsum; 8Z93; -. DR PDBsum; 9MZX; -. DR PDBsum; 9MZY; -. DR PDBsum; 9MZZ; -. DR AlphaFoldDB; Q13546; -. DR BMRB; Q13546; -. DR EMDB; EMD-39853; -. DR SMR; Q13546; -. DR BioGRID; 114274; 207. DR ComplexPortal; CPX-1907; Ripoptosome. DR ComplexPortal; CPX-25723; sTNF-TNR1A receptor-ligand core complex, BIRC3 variant. DR ComplexPortal; CPX-25726; mTNF-TNR1A receptor-ligand core complex, BIRC3 variant. DR ComplexPortal; CPX-8828; sTNF-TNR1A receptor-ligand core complex, BIRC2 variant. DR ComplexPortal; CPX-8932; mTNF-TNR1A receptor-ligand core complex, BIRC2 variant. DR CORUM; Q13546; -. DR DIP; DIP-433N; -. DR FunCoup; Q13546; 1287. DR IntAct; Q13546; 138. DR MINT; Q13546; -. DR STRING; 9606.ENSP00000259808; -. DR BindingDB; Q13546; -. DR ChEMBL; CHEMBL5464; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16875; GSK-2982772. DR DrugBank; DB16492; SAR443122. DR DrugCentral; Q13546; -. DR GuidetoPHARMACOLOGY; 2189; -. DR GlyCosmos; Q13546; 3 sites, 1 glycan. DR GlyGen; Q13546; 6 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q13546; -. DR MetOSite; Q13546; -. DR PhosphoSitePlus; Q13546; -. DR BioMuta; RIPK1; -. DR DMDM; 60393639; -. DR CPTAC; CPTAC-1053; -. DR CPTAC; CPTAC-900; -. DR CPTAC; CPTAC-901; -. DR CPTAC; CPTAC-902; -. DR jPOST; Q13546; -. DR MassIVE; Q13546; -. DR PaxDb; 9606-ENSP00000259808; -. DR PeptideAtlas; Q13546; -. DR ProteomicsDB; 59527; -. [Q13546-1] DR ProteomicsDB; 59528; -. [Q13546-2] DR Pumba; Q13546; -. DR Antibodypedia; 4145; 668 antibodies from 45 providers. DR DNASU; 8737; -. DR Ensembl; ENST00000259808.9; ENSP00000259808.3; ENSG00000137275.17. [Q13546-1] DR Ensembl; ENST00000380409.3; ENSP00000369773.3; ENSG00000137275.17. [Q13546-2] DR GeneID; 8737; -. DR KEGG; hsa:8737; -. DR MANE-Select; ENST00000259808.9; ENSP00000259808.3; NM_001354930.2; NP_001341859.1. DR UCSC; uc003mux.4; human. [Q13546-1] DR AGR; HGNC:10019; -. DR ClinPGx; PA34394; -. DR CTD; 8737; -. DR DisGeNET; 8737; -. DR GeneCards; RIPK1; -. DR HGNC; HGNC:10019; RIPK1. DR HPA; ENSG00000137275; Low tissue specificity. DR MalaCards; RIPK1; -. DR MIM; 603453; gene. DR MIM; 618108; phenotype. DR MIM; 618852; phenotype. DR OpenTargets; ENSG00000137275; -. DR Orphanet; 529977; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome. DR VEuPathDB; HostDB:ENSG00000137275; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000159347; -. DR HOGENOM; CLU_017229_0_0_1; -. DR InParanoid; Q13546; -. DR OrthoDB; 535509at2759; -. DR PAN-GO; Q13546; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q13546; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13546; -. DR Reactome; R-HSA-140534; Caspase activation via Death Receptors in the presence of ligand. DR Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment. DR Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1. DR Reactome; R-HSA-2562578; TRIF-mediated programmed cell death. DR Reactome; R-HSA-3295583; TRP channels. DR Reactome; R-HSA-3371378; Regulation by c-FLIP. DR Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-5218900; CASP8 activity is inhibited. DR Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-5357956; TNFR1-induced NF-kappa-B signaling pathway. DR Reactome; R-HSA-5675482; Regulation of necroptotic cell death. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-69416; Dimerization of procaspase-8. DR Reactome; R-HSA-75893; TNF signaling. DR Reactome; R-HSA-9013957; TLR3-mediated TICAM1-dependent programmed cell death. DR Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10. DR Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1. DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9686347; Microbial modulation of RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-9692913; SARS-CoV-1-mediated effects on programmed cell death. DR Reactome; R-HSA-9693928; Defective RIPK1-mediated regulated necrosis. DR SignaLink; Q13546; -. DR SIGNOR; Q13546; -. DR Agora; ENSG00000137275; -. DR BioGRID-ORCS; 8737; 38 hits in 1199 CRISPR screens. DR ChiTaRS; RIPK1; human. DR EvolutionaryTrace; Q13546; -. DR GeneWiki; RIPK1; -. DR GenomeRNAi; 8737; -. DR Pharos; Q13546; Tchem. DR PRO; PR:Q13546; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q13546; protein. DR Bgee; ENSG00000137275; Expressed in granulocyte and 154 other cell types or tissues. DR ExpressionAtlas; Q13546; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0031264; C:death-inducing signaling complex; IDA:BHF-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL. DR GO; GO:0097342; C:ripoptosome; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0070513; F:death domain binding; IPI:BHF-UCL. DR GO; GO:0005123; F:death receptor binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004706; F:JUN kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:DisProt. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0035591; F:signaling adaptor activity; IEA:Ensembl. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:1990000; P:amyloid fibril formation; IDA:DisProt. DR GO; GO:0006915; P:apoptotic process; IMP:UniProtKB. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; ISS:ARUK-UCL. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IDA:ARUK-UCL. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0097527; P:necroptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0060546; P:negative regulation of necroptotic process; ISS:UniProtKB. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IEA:Ensembl. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0050729; P:positive regulation of inflammatory response; IMP:UniProtKB. DR GO; GO:0070105; P:positive regulation of interleukin-6-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; IMP:UniProtKB. DR GO; GO:1903800; P:positive regulation of miRNA processing; IDA:ARUK-UCL. DR GO; GO:0060545; P:positive regulation of necroptotic process; IMP:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0043068; P:positive regulation of programmed cell death; IMP:UniProtKB. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IMP:BHF-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; TAS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:BHF-UCL. DR GO; GO:1903265; P:positive regulation of tumor necrosis factor-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0097300; P:programmed necrotic cell death; ISS:ARUK-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0030163; P:protein catabolic process; IDA:UniProtKB. DR GO; GO:0006979; P:response to oxidative stress; IMP:BHF-UCL. DR GO; GO:0034612; P:response to tumor necrosis factor; IMP:BHF-UCL. DR GO; GO:0097343; P:ripoptosome assembly; IMP:UniProtKB. DR GO; GO:1901026; P:ripoptosome assembly involved in necroptotic process; IMP:DisProt. DR GO; GO:0070231; P:T cell apoptotic process; ISS:UniProtKB. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IC:BHF-UCL. DR CDD; cd08777; Death_RIP1; 1. DR CDD; cd14027; STKc_RIP1; 1. DR DisProt; DP04298; -. DR FunFam; 1.10.533.10:FF:000052; Putative receptor-interacting serine/threonine-protein kinase 1; 1. DR FunFam; 1.10.510.10:FF:000472; Receptor interacting serine/threonine kinase 1; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR000488; Death_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR037934; RIP1_Death. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR PANTHER; PTHR44329:SF6; RECEPTOR-INTERACTING SERINE_THREONINE-PROTEIN KINASE 1; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00531; Death; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00005; DEATH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50017; DEATH_DOMAIN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Cytoplasm; Disease variant; Glycoprotein; Host-virus interaction; KW Inflammatory response; Isopeptide bond; Kinase; Membrane; Necrosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Ubl conjugation. FT CHAIN 1..671 FT /note="Receptor-interacting serine/threonine-protein kinase FT 1" FT /id="PRO_0000086606" FT DOMAIN 17..289 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 583..669 FT /note="Death" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00064" FT REGION 290..582 FT /note="Interaction with SQSTM1" FT /evidence="ECO:0000269|PubMed:10356400" FT REGION 331..354 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 389..455 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 531..547 FT /note="RIP homotypic interaction motif (RHIM)" FT /evidence="ECO:0000269|PubMed:11734559, FT ECO:0000269|PubMed:29681455" FT COMPBIAS 331..348 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 428..444 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 23..31 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 45 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 324..325 FT /note="Cleavage; by CASP8" FT /evidence="ECO:0000269|PubMed:10521396, FT ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281" FT MOD_RES 6 FT /note="Phosphoserine; by IKKA and IKKB" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 20 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 25 FT /note="Phosphoserine; by IKKA and IKKB" FT /evidence="ECO:0000269|PubMed:18408713, FT ECO:0000269|PubMed:30988283" FT MOD_RES 161 FT /note="Phosphoserine; by RIPK3 and autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 166 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000255, ECO:0000269|PubMed:29440439, FT ECO:0000269|PubMed:31827280" FT MOD_RES 303 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 320 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000269|PubMed:18408713, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 331 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000250|UniProtKB:Q60855" FT MOD_RES 333 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 384 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:15144186" FT CARBOHYD 603 FT /note="(Microbial infection) N-beta-linked (GlcNAc) FT arginine" FT /evidence="ECO:0000269|PubMed:30979585, FT ECO:0000305|PubMed:23955153, ECO:0007744|PDB:6AC5" FT CROSSLNK 377 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16603398" FT VAR_SEQ 108..153 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037690" FT VARIANT 64 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs774996232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041039" FT VARIANT 81 FT /note="V -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs758268804)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041040" FT VARIANT 220 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs759012409)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041041" FT VARIANT 234 FT /note="E -> K (in dbSNP:rs17548383)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_021109" FT VARIANT 324 FT /note="D -> H (in AIEFL; prevents cleavage by CASP8; FT increased kinase activity; increased inflammatory response; FT dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827280, FT ECO:0000269|PubMed:31827281" FT /id="VAR_083518" FT VARIANT 324 FT /note="D -> N (in AIEFL; prevents cleavage by CASP8; FT changed inflammatory response; dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827281" FT /id="VAR_083519" FT VARIANT 324 FT /note="D -> V (in AIEFL; prevents cleavage by CASP8; FT increased kinase activity; increased inflammatory response; FT dbSNP:rs1760720924)" FT /evidence="ECO:0000269|PubMed:31827280" FT /id="VAR_084135" FT VARIANT 324 FT /note="D -> Y (in AIEFL; prevents cleavage by CASP8; FT changed inflammatory response; dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827281" FT /id="VAR_083520" FT VARIANT 404 FT /note="A -> S (in dbSNP:rs34872409)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041042" FT VARIANT 438 FT /note="A -> V (in dbSNP:rs3173519)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:7538908, ECO:0000269|PubMed:8612133" FT /id="VAR_058285" FT VARIANT 443 FT /note="A -> V (in dbSNP:rs35722193)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041043" FT VARIANT 569 FT /note="A -> V (in dbSNP:rs55861377)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041044" FT MUTAGEN 25 FT /note="S->D: Phophomimetic mutant. Significant loss of FT kinase activity." FT /evidence="ECO:0000269|PubMed:30988283" FT MUTAGEN 45 FT /note="K->A: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:30988283, FT ECO:0000269|PubMed:8612133" FT MUTAGEN 161 FT /note="S->A: Decreases RIPK1 kinase activity." FT /evidence="ECO:0000269|PubMed:18408713" FT MUTAGEN 161 FT /note="S->E: No effect on RIPK1 autophosphorylation." FT /evidence="ECO:0000269|PubMed:18408713" FT MUTAGEN 324 FT /note="D->K: Abolishes cleavage by caspase-8." FT /evidence="ECO:0000269|PubMed:10521396" FT MUTAGEN 377 FT /note="K->R: Abolishes RIP-mediated NF-Kappa-B activation." FT /evidence="ECO:0000269|PubMed:16603398" FT MUTAGEN 536 FT /note="S->C: Strongly reduced homodimerization and FT interaction with RIPK3." FT /evidence="ECO:0000269|PubMed:29681455" FT MUTAGEN 539..542 FT /note="IQIG->AAAA: Abolished cleavage by S.flexneri OspD3." FT /evidence="ECO:0000269|PubMed:32657447" FT MUTAGEN 599 FT /note="K->R: Blocks homodimerization, necroptosis and FT apoptosis." FT /evidence="ECO:0000269|PubMed:29440439" FT MUTAGEN 603 FT /note="R->A: Abolished GlcNAcylation by E.coli NleB1." FT /evidence="ECO:0000269|PubMed:30979585" FT CONFLICT 258 FT /note="R -> I (in Ref. 3; BAG36858)" FT /evidence="ECO:0000305" FT CONFLICT 286 FT /note="R -> S (in Ref. 3; BAG36858)" FT /evidence="ECO:0000305" FT CONFLICT 514 FT /note="T -> S (in Ref. 8; AAC50137)" FT /evidence="ECO:0000305" FT STRAND 10..12 FT /evidence="ECO:0007829|PDB:7FD0" FT HELIX 14..16 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:5HX6" FT STRAND 20..22 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 26..28 FT /evidence="ECO:0007829|PDB:7FD0" FT STRAND 30..36 FT /evidence="ECO:0007829|PDB:4ITJ" FT TURN 37..39 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 40..51 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 54..56 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 57..68 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 87..93 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 100..104 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 106..108 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 112..131 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 141..143 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 144..146 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 163..168 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 171..173 FT /evidence="ECO:0007829|PDB:4ITH" FT HELIX 190..192 FT /evidence="ECO:0007829|PDB:6NW2" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 201..203 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 207..223 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 228..230 FT /evidence="ECO:0007829|PDB:6C4D" FT HELIX 234..242 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 249..251 FT /evidence="ECO:0007829|PDB:4ITJ" FT TURN 252..255 FT /evidence="ECO:0007829|PDB:6C3E" FT HELIX 258..267 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 278..292 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:4NEU" FT HELIX 297..309 FT /evidence="ECO:0007829|PDB:4NEU" FT TURN 310..312 FT /evidence="ECO:0007829|PDB:4NEU" FT STRAND 533..542 FT /evidence="ECO:0007829|PDB:5V7Z" FT HELIX 575..577 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 584..593 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 599..604 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 609..618 FT /evidence="ECO:0007829|PDB:6AC5" FT TURN 619..622 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 624..643 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 659..668 FT /evidence="ECO:0007829|PDB:6AC5" SQ SEQUENCE 671 AA; 75931 MW; 976E2428D525A9B2 CRC64; MQPDMSLNVI KMKSSDFLES AELDSGGFGK VSLCFHRTQG LMIMKTVYKG PNCIEHNEAL LEEAKMMNRL RHSRVVKLLG VIIEEGKYSL VMEYMEKGNL MHVLKAEMST PLSVKGRIIL EIIEGMCYLH GKGVIHKDLK PENILVDNDF HIKIADLGLA SFKMWSKLNN EEHNELREVD GTAKKNGGTL YYMAPEHLND VNAKPTEKSD VYSFAVVLWA IFANKEPYEN AICEQQLIMC IKSGNRPDVD DITEYCPREI ISLMKLCWEA NPEARPTFPG IEEKFRPFYL SQLEESVEED VKSLKKEYSN ENAVVKRMQS LQLDCVAVPS SRSNSATEQP GSLHSSQGLG MGPVEESWFA PSLEHPQEEN EPSLQSKLQD EANYHLYGSR MDRQTKQQPR QNVAYNREEE RRRRVSHDPF AQQRPYENFQ NTEGKGTAYS SAASHGNAVH QPSGLTSQPQ VLYQNNGLYS SHGFGTRPLD PGTAGPRVWY RPIPSHMPSL HNIPVPETNY LGNTPTMPFS SLPPTDESIK YTIYNSTGIQ IGAYNYMEIG GTSSSLLDST NTNFKEEPAA KYQAIFDNTT SLTDKHLDPI RENLGKHWKN CARKLGFTQS QIDEIDHDYE RDGLKEKVYQ MLQKWVMREG IKGATVGKLA QALHQCSRID LLSSLIYVSQ N // ID RIR2B_HUMAN Reviewed; 351 AA. AC Q7LG56; B4E2N4; Q17R22; Q75PQ6; Q75PQ7; Q75PY8; Q75PY9; Q86YE3; Q9NPD6; AC Q9NTD8; Q9NUW3; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 197. DE RecName: Full=Ribonucleoside-diphosphate reductase subunit M2 B; DE EC=1.17.4.1; DE AltName: Full=TP53-inducible ribonucleotide reductase M2 B; DE AltName: Full=p53-inducible ribonucleotide reductase small subunit 2-like protein; DE Short=p53R2; GN Name=RRM2B; Synonyms=P53R2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, AND RP INDUCTION. RX PubMed=10716435; DOI=10.1038/35003506; RA Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., RA Takei Y., Nakamura Y.; RT "A ribonucleotide reductase gene involved in a p53-dependent cell-cycle RT checkpoint for DNA damage."; RL Nature 404:42-49(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5). RA Ugai H., Yokoyama K.K.; RT "Homo sapiens p53-inducible ribonucleotide reductase small subunit 2 RT splicing variants."; RL Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 1-351 (ISOFORM 6). RC TISSUE=Placenta, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP FUNCTION, AND SUBUNIT. RX PubMed=11517226; DOI=10.1074/jbc.m106088200; RA Guittet O., Haakansson P., Voevodskaya N., Fridd S., Graeslund A., RA Arakawa H., Nakamura Y., Thelander L.; RT "Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro RT with the R1 protein, which is expressed both in resting cells in response RT to DNA damage and in proliferating cells."; RL J. Biol. Chem. 276:40647-40651(2001). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, AND VARIANT LEU-115. RX PubMed=11719458; RA Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., RA Arakawa H.; RT "p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle RT checkpoint."; RL Cancer Res. 61:8256-8262(2001). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH TP53 AND RRM1. RX PubMed=12615712; RA Xue L., Zhou B., Liu X., Qiu W., Jin Z., Yen Y.; RT "Wild-type p53 regulates human ribonucleotide reductase by protein-protein RT interaction with p53R2 as well as hRRM2 subunits."; RL Cancer Res. 63:980-986(2003). RN [12] RP TISSUE SPECIFICITY. RX PubMed=14583450; RA Zhou B., Liu X., Mo X., Xue L., Darwish D., Qiu W., Shih J., Hwu E.B., RA Luh F., Yen Y.; RT "The human ribonucleotide reductase subunit hRRM2 complements p53R2 in RT response to UV-induced DNA repair in cells with mutant p53."; RL Cancer Res. 63:6583-6594(2003). RN [13] RP CATALYTIC ACTIVITY, AND SUBUNIT. RX PubMed=16376858; DOI=10.1016/j.bbrc.2005.12.019; RA Qiu W., Zhou B., Darwish D., Shao J., Yen Y.; RT "Characterization of enzymatic properties of human ribonucleotide reductase RT holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits."; RL Biochem. Biophys. Res. Commun. 340:428-434(2006). RN [14] RP INVOLVEMENT IN PEOA5. RX PubMed=19664747; DOI=10.1016/j.ajhg.2009.07.009; RA Tyynismaa H., Ylikallio E., Patel M., Molnar M.J., Haller R.G., RA Suomalainen A.; RT "A heterozygous truncating mutation in RRM2B causes autosomal-dominant RT progressive external ophthalmoplegia with multiple mtDNA deletions."; RL Am. J. Hum. Genet. 85:290-295(2009). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH IRON IONS, AND RP COFACTOR. RX PubMed=19728742; DOI=10.1021/bi9001425; RA Smith P., Zhou B., Ho N., Yuan Y.C., Su L., Tsai S.C., Yen Y.; RT "2.6 A X-ray crystal structure of human p53R2, a p53-inducible RT ribonucleotide reductase."; RL Biochemistry 48:11134-11141(2009). RN [17] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 20-322 IN COMPLEX WITH IRON IONS. RG Structural genomics consortium (SGC); RT "Human ribonucleotide reductase, subunit M2 B."; RL Submitted (FEB-2009) to the PDB data bank. RN [18] RP VARIANTS MTDPS8A ARG-64; GLU-85 DEL; GLY-194; LYS-194 AND PHE-236. RX PubMed=17486094; DOI=10.1038/ng2040; RA Bourdon A., Minai L., Serre V., Jais J.-P., Sarzi E., Aubert S., RA Chretien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., RA Munnich A., Roetig A.; RT "Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase RT (p53R2), causes severe mitochondrial DNA depletion."; RL Nat. Genet. 39:776-780(2007). RN [19] RP VARIANTS MTDPS8A SER-224; ILE-282 AND VAL-317. RX PubMed=18504129; DOI=10.1016/j.nmd.2008.04.006; RA Bornstein B., Area E., Flanigan K.M., Ganesh J., Jayakar P., Swoboda K.J., RA Coku J., Naini A., Shanske S., Tanji K., Hirano M., DiMauro S.; RT "Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene."; RL Neuromuscul. Disord. 18:453-459(2008). RN [20] RP VARIANTS MTDPS8B HIS-110 AND HIS-121. RX PubMed=19667227; DOI=10.1001/archneurol.2009.139; RA Shaibani A., Shchelochkov O.A., Zhang S., Katsonis P., Lichtarge O., RA Wong L.J., Shinawi M.; RT "Mitochondrial neurogastrointestinal encephalopathy due to mutations in RT RRM2B."; RL Arch. Neurol. 66:1028-1032(2009). RN [21] RP VARIANT SER-33. RX PubMed=26741492; DOI=10.1371/journal.pgen.1005679; RA Kohda M., Tokuzawa Y., Kishita Y., Nyuzuki H., Moriyama Y., Mizuno Y., RA Hirata T., Yatsuka Y., Yamashita-Sugahara Y., Nakachi Y., Kato H., RA Okuda A., Tamaru S., Borna N.N., Banshoya K., Aigaki T., Sato-Miyata Y., RA Ohnuma K., Suzuki T., Nagao A., Maehata H., Matsuda F., Higasa K., RA Nagasaki M., Yasuda J., Yamamoto M., Fushimi T., Shimura M., RA Kaiho-Ichimoto K., Harashima H., Yamazaki T., Mori M., Murayama K., RA Ohtake A., Okazaki Y.; RT "A comprehensive genomic analysis reveals the genetic landscape of RT mitochondrial respiratory chain complex deficiencies."; RL PLoS Genet. 12:E1005679-E1005679(2016). RN [22] RP VARIANT RCDFRD ASP-262, AND INVOLVEMENT IN RCDFRD. RX PubMed=32827185; DOI=10.1002/humu.24094; RA Roberts L., Julius S., Dawlat S., Yildiz S., Rebello G., Meldau S., RA Pillay K., Esterhuizen A., Vorster A., Benefeld G., da Rocha J., RA Beighton P., Sellars S.L., Thandrayen K., Pettifor J.M., Ramesar R.S.; RT "Renal dysfunction, rod-cone dystrophy, and sensorineural hearing loss RT caused by a mutation in RRM2B."; RL Hum. Mutat. 41:1871-1876(2020). CC -!- FUNCTION: Plays a pivotal role in cell survival by repairing damaged CC DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for CC DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free CC radical center required for catalysis. Forms an active ribonucleotide CC reductase (RNR) complex with RRM1 which is expressed both in resting CC and proliferating cells in response to DNA damage. CC {ECO:0000269|PubMed:10716435, ECO:0000269|PubMed:11517226, CC ECO:0000269|PubMed:11719458}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 2'-deoxyribonucleoside 5'-diphosphate + [thioredoxin]- CC disulfide + H2O = a ribonucleoside 5'-diphosphate + [thioredoxin]- CC dithiol; Xref=Rhea:RHEA:23252, Rhea:RHEA-COMP:10698, Rhea:RHEA- CC COMP:10700, ChEBI:CHEBI:15377, ChEBI:CHEBI:29950, ChEBI:CHEBI:50058, CC ChEBI:CHEBI:57930, ChEBI:CHEBI:73316; EC=1.17.4.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10014, CC ECO:0000269|PubMed:16376858}; CC -!- COFACTOR: CC Name=Fe cation; Xref=ChEBI:CHEBI:24875; CC Evidence={ECO:0000269|PubMed:19728742}; CC Note=Binds 2 iron ions per subunit. {ECO:0000269|PubMed:19728742}; CC -!- SUBUNIT: Heterotetramer with large (RRM1) subunit. Interacts with CC p53/TP53. Interacts with RRM1 in response to DNA damage. CC {ECO:0000269|PubMed:11517226, ECO:0000269|PubMed:12615712, CC ECO:0000269|PubMed:16376858, ECO:0000269|PubMed:19728742, CC ECO:0000269|Ref.17}. CC -!- INTERACTION: CC Q7LG56; Q13315: ATM; NbExp=3; IntAct=EBI-9009083, EBI-495465; CC Q7LG56; Q00987: MDM2; NbExp=2; IntAct=EBI-9009083, EBI-389668; CC Q7LG56; O43929: ORC4; NbExp=4; IntAct=EBI-9009083, EBI-374889; CC Q7LG56; Q9H4P4: RNF41; NbExp=3; IntAct=EBI-9009083, EBI-2130266; CC Q7LG56; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-9009083, EBI-9009083; CC Q7LG56-1; Q00987: MDM2; NbExp=2; IntAct=EBI-15741413, EBI-389668; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates from CC cytoplasm to nucleus in response to DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q7LG56-1; Sequence=Displayed; CC Name=2; Synonyms=Long form; CC IsoId=Q7LG56-2; Sequence=VSP_017670; CC Name=3; Synonyms=Short form gamma; CC IsoId=Q7LG56-3; Sequence=VSP_017669; CC Name=4; Synonyms=Short form beta; CC IsoId=Q7LG56-4; Sequence=VSP_017668; CC Name=5; Synonyms=Short form; CC IsoId=Q7LG56-5; Sequence=VSP_017671, VSP_017672; CC Name=6; CC IsoId=Q7LG56-6; Sequence=VSP_053585; CC -!- TISSUE SPECIFICITY: Widely expressed at a high level in skeletal muscle CC and at a weak level in thymus. Expressed in epithelial dysplasias and CC squamous cell carcinoma. {ECO:0000269|PubMed:14583450}. CC -!- INDUCTION: In response to DNA damage in a wild-type p53/TP53-dependent CC manner. {ECO:0000269|PubMed:10716435}. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8A (MTDPS8A) CC [MIM:612075]: A disorder due to mitochondrial dysfunction characterized CC by various combinations of neonatal hypotonia, neurological CC deterioration, respiratory distress, lactic acidosis, and renal CC tubulopathy. {ECO:0000269|PubMed:17486094, CC ECO:0000269|PubMed:18504129}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8B (MTDPS8B) CC [MIM:612075]: A disease due to mitochondrial dysfunction and CC characterized by ophthalmoplegia, ptosis, gastrointestinal dysmotility, CC cachexia, peripheral neuropathy. {ECO:0000269|PubMed:19667227}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA CC deletions, autosomal dominant, 5 (PEOA5) [MIM:613077]: A disorder CC characterized by progressive weakness of ocular muscles and levator CC muscle of the upper eyelid. In a minority of cases, it is associated CC with skeletal myopathy, which predominantly involves axial or proximal CC muscles and which causes abnormal fatigability and even permanent CC muscle weakness. Ragged-red fibers and atrophy are found on muscle CC biopsy. A large proportion of chronic ophthalmoplegias are associated CC with other symptoms, leading to a multisystemic pattern of this CC disease. Additional symptoms are variable, and may include cataracts, CC hearing loss, sensory axonal neuropathy, ataxia, depression, CC hypogonadism, and parkinsonism. {ECO:0000269|PubMed:19664747}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Rod-cone dystrophy, sensorineural deafness, and Fanconi-type CC renal dysfunction (RCDFRD) [MIM:268315]: An autosomal recessive disease CC characterized by visual impairment due to rod-cone dystrophy, CC sensorineural hearing loss, and Fanconi-type renal dysfunction CC resulting in rickets-like skeletal changes. Death may occur in CC childhood or young adulthood due to renal failure. Disease onset is CC before age 5 years. {ECO:0000269|PubMed:32827185}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the ribonucleoside diphosphate reductase small CC chain family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG65196.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=EAW91842.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB036063; BAA92434.1; -; mRNA. DR EMBL; AB036532; BAA92493.1; -; Genomic_DNA. DR EMBL; AB163437; BAD11774.1; -; mRNA. DR EMBL; AB163438; BAD11775.1; -; mRNA. DR EMBL; AB166669; BAD12265.1; -; mRNA. DR EMBL; AB166670; BAD12266.1; -; mRNA. DR EMBL; AB166671; BAD12267.1; -; mRNA. DR EMBL; AK001965; BAA92005.1; -; mRNA. DR EMBL; AK304354; BAG65196.1; ALT_INIT; mRNA. DR EMBL; DC308409; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AL137348; CAB70703.2; -; mRNA. DR EMBL; DQ027001; AAY29059.1; -; Genomic_DNA. DR EMBL; AP001328; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP002907; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW91842.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC042468; AAH42468.1; -; mRNA. DR EMBL; BC108261; AAI08262.1; -; mRNA. DR EMBL; BC117496; AAI17497.1; -; mRNA. DR EMBL; BC130628; AAI30629.1; -; mRNA. DR CCDS; CCDS34932.1; -. [Q7LG56-1] DR CCDS; CCDS55267.1; -. [Q7LG56-2] DR PIR; T46249; T46249. DR RefSeq; NP_001165948.1; NM_001172477.1. [Q7LG56-6] DR RefSeq; NP_001165949.1; NM_001172478.2. [Q7LG56-2] DR RefSeq; NP_056528.2; NM_015713.4. [Q7LG56-1] DR PDB; 2VUX; X-ray; 2.80 A; A/B=20-322. DR PDB; 3HF1; X-ray; 2.60 A; A/B=1-351. DR PDB; 4DJN; X-ray; 2.20 A; A/B=13-322. DR PDBsum; 2VUX; -. DR PDBsum; 3HF1; -. DR PDBsum; 4DJN; -. DR AlphaFoldDB; Q7LG56; -. DR SMR; Q7LG56; -. DR BioGRID; 119071; 74. DR ComplexPortal; CPX-369; Ribonucleoside-diphosphate reductase RR1 complex, RRM2B variant. DR CORUM; Q7LG56; -. DR DIP; DIP-24264N; -. DR DIP; DIP-48627N; -. DR FunCoup; Q7LG56; 2091. DR IntAct; Q7LG56; 34. DR STRING; 9606.ENSP00000251810; -. DR BindingDB; Q7LG56; -. DR ChEMBL; CHEMBL3301398; -. DR DrugBank; DB00242; Cladribine. DR DrugBank; DB00631; Clofarabine. DR DrugBank; DB12948; Didox. DR GlyGen; Q7LG56; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q7LG56; -. DR PhosphoSitePlus; Q7LG56; -. DR BioMuta; RRM2B; -. DR DMDM; 74727333; -. DR jPOST; Q7LG56; -. DR MassIVE; Q7LG56; -. DR PaxDb; 9606-ENSP00000251810; -. DR PeptideAtlas; Q7LG56; -. DR ProteomicsDB; 5837; -. DR ProteomicsDB; 68860; -. [Q7LG56-1] DR ProteomicsDB; 68861; -. [Q7LG56-2] DR ProteomicsDB; 68862; -. [Q7LG56-3] DR ProteomicsDB; 68863; -. [Q7LG56-4] DR ProteomicsDB; 68864; -. [Q7LG56-5] DR Pumba; Q7LG56; -. DR Antibodypedia; 3483; 343 antibodies from 38 providers. DR DNASU; 50484; -. DR Ensembl; ENST00000251810.8; ENSP00000251810.3; ENSG00000048392.14. [Q7LG56-1] DR Ensembl; ENST00000395912.6; ENSP00000379248.2; ENSG00000048392.14. [Q7LG56-2] DR Ensembl; ENST00000519317.5; ENSP00000430641.1; ENSG00000048392.14. [Q7LG56-3] DR Ensembl; ENST00000519962.5; ENSP00000429140.1; ENSG00000048392.14. [Q7LG56-4] DR Ensembl; ENST00000522394.1; ENSP00000429578.1; ENSG00000048392.14. [Q7LG56-5] DR GeneID; 50484; -. DR KEGG; hsa:50484; -. DR MANE-Select; ENST00000251810.8; ENSP00000251810.3; NM_015713.5; NP_056528.2. DR UCSC; uc003ykn.4; human. [Q7LG56-1] DR AGR; HGNC:17296; -. DR ClinPGx; PA34866; -. DR CTD; 50484; -. DR DisGeNET; 50484; -. DR GeneCards; RRM2B; -. DR GeneReviews; RRM2B; -. DR HGNC; HGNC:17296; RRM2B. DR HPA; ENSG00000048392; Low tissue specificity. DR MalaCards; RRM2B; -. DR MIM; 268315; phenotype. DR MIM; 604712; gene. DR MIM; 612075; phenotype. DR MIM; 613077; phenotype. DR OpenTargets; ENSG00000048392; -. DR Orphanet; 329336; Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy. DR Orphanet; 254892; Autosomal dominant progressive external ophthalmoplegia. DR Orphanet; 480; Kearns-Sayre syndrome. DR Orphanet; 255235; Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy. DR Orphanet; 298; Mitochondrial neurogastrointestinal encephalomyopathy. DR VEuPathDB; HostDB:ENSG00000048392; -. DR eggNOG; KOG1567; Eukaryota. DR GeneTree; ENSGT00390000013305; -. DR HOGENOM; CLU_035339_2_0_1; -. DR InParanoid; Q7LG56; -. DR OMA; LEPMFLG; -. DR OrthoDB; 10248373at2759; -. DR PAN-GO; Q7LG56; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q7LG56; -. DR BRENDA; 1.17.4.1; 2681. DR PathwayCommons; Q7LG56; -. DR Reactome; R-HSA-499943; Interconversion of nucleotide di- and triphosphates. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR SignaLink; Q7LG56; -. DR SIGNOR; Q7LG56; -. DR Agora; ENSG00000048392; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 50484; 17 hits in 1170 CRISPR screens. DR ChiTaRS; RRM2B; human. DR EvolutionaryTrace; Q7LG56; -. DR GeneWiki; RRM2B; -. DR GenomeRNAi; 50484; -. DR Pharos; Q7LG56; Tbio. DR PRO; PR:Q7LG56; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q7LG56; protein. DR Bgee; ENSG00000048392; Expressed in secondary oocyte and 188 other cell types or tissues. DR ExpressionAtlas; Q7LG56; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IEA:GOC. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005971; C:ribonucleoside-diphosphate reductase complex; ISS:ComplexPortal. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004748; F:ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor; IBA:GO_Central. DR GO; GO:0009265; P:2'-deoxyribonucleotide biosynthetic process; IDA:ComplexPortal. DR GO; GO:0009200; P:deoxyribonucleoside triphosphate metabolic process; IEA:Ensembl. DR GO; GO:0009263; P:deoxyribonucleotide biosynthetic process; IBA:GO_Central. DR GO; GO:0006281; P:DNA repair; IDA:ComplexPortal. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; NAS:ComplexPortal. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0006264; P:mitochondrial DNA replication; IMP:ComplexPortal. DR GO; GO:1902254; P:negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0070318; P:positive regulation of G0 to G1 transition; IDA:ComplexPortal. DR GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IDA:ComplexPortal. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0014075; P:response to amine; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl. DR GO; GO:0009185; P:ribonucleoside diphosphate metabolic process; IDA:ComplexPortal. DR CDD; cd01049; RNRR2; 1. DR FunFam; 1.10.620.20:FF:000004; Ribonucleoside-diphosphate reductase subunit M2 B; 1. DR Gene3D; 1.10.620.20; Ribonucleotide Reductase, subunit A; 1. DR InterPro; IPR009078; Ferritin-like_SF. DR InterPro; IPR012348; RNR-like. DR InterPro; IPR033909; RNR_small. DR InterPro; IPR030475; RNR_small_AS. DR InterPro; IPR000358; RNR_small_fam. DR PANTHER; PTHR23409; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SMALL CHAIN; 1. DR PANTHER; PTHR23409:SF19; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SUBUNIT M2 B; 1. DR Pfam; PF00268; Ribonuc_red_sm; 1. DR SUPFAM; SSF47240; Ferritin-like; 1. DR PROSITE; PS00368; RIBORED_SMALL; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Deafness; KW Deoxyribonucleotide synthesis; Disease variant; DNA damage; DNA repair; KW Iron; Metal-binding; Neuropathy; Nucleus; Oxidoreductase; KW Primary mitochondrial disease; Progressive external ophthalmoplegia; KW Proteomics identification; Reference proteome. FT CHAIN 1..351 FT /note="Ribonucleoside-diphosphate reductase subunit M2 B" FT /id="PRO_0000228150" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU10014" FT BINDING 100 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 134 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 194 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 228 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 231 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT VAR_SEQ 1..16 FT /note="MGDPERPEAAGLDQDE -> MLLLRLPPHRSHASPLDCKLQDRCRKCYSPRS FT GQACPPALAAAWLRRCERRGGRPRGGRRKELTLGLRPARCSAPGPAKDDAWRPQAG FT (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_053585" FT VAR_SEQ 17..301 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017668" FT VAR_SEQ 17..228 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017669" FT VAR_SEQ 17..68 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017670" FT VAR_SEQ 42..43 FT /note="FV -> SF (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017671" FT VAR_SEQ 44..351 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017672" FT VARIANT 33 FT /note="P -> S (found in a patient with combined respiratory FT complex deficiencies, muscle weakness and hearing loss; FT uncertain significance; dbSNP:rs387906892)" FT /evidence="ECO:0000269|PubMed:26741492" FT /id="VAR_076280" FT VARIANT 64 FT /note="W -> R (in MTDPS8A; dbSNP:rs515726182)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046217" FT VARIANT 85 FT /note="Missing (in MTDPS8A; dbSNP:rs515726184)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046218" FT VARIANT 110 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607025)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065122" FT VARIANT 115 FT /note="V -> L (in colorectal adenocarcinomas cell line; FT loss of ribonucleotide reductase activity)" FT /evidence="ECO:0000269|PubMed:11719458" FT /id="VAR_025699" FT VARIANT 121 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607024)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065123" FT VARIANT 194 FT /note="E -> G (in MTDPS8A; dbSNP:rs515726191)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046219" FT VARIANT 194 FT /note="E -> K (in MTDPS8A; dbSNP:rs121918308)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046220" FT VARIANT 224 FT /note="I -> S (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726196)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046221" FT VARIANT 236 FT /note="C -> F (in MTDPS8A; dbSNP:rs121918309)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046222" FT VARIANT 262 FT /note="E -> D (in RCDFRD; dbSNP:rs1810682433)" FT /evidence="ECO:0000269|PubMed:32827185" FT /id="VAR_086956" FT VARIANT 282 FT /note="M -> I (in MTDPS8A; without tubulopathy; FT dbSNP:rs182614164)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046223" FT VARIANT 317 FT /note="L -> V (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726198)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046224" FT CONFLICT 277 FT /note="M -> V (in Ref. 3; BAA92005)" FT /evidence="ECO:0000305" FT HELIX 29..31 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 37..39 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 42..44 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 50..61 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 74..78 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 83..109 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 111..114 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 118..145 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 149..156 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 158..161 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 163..177 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 183..195 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 199..210 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 215..240 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 248..267 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 272..275 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 279..296 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 310..312 FT /evidence="ECO:0007829|PDB:4DJN" SQ SEQUENCE 351 AA; 40737 MW; 6D008687EEF40994 CRC64; MGDPERPEAA GLDQDERSSS DTNESEIKSN EEPLLRKSSR RFVIFPIQYP DIWKMYKQAQ ASFWTAEEVD LSKDLPHWNK LKADEKYFIS HILAFFAASD GIVNENLVER FSQEVQVPEA RCFYGFQILI ENVHSEMYSL LIDTYIRDPK KREFLFNAIE TMPYVKKKAD WALRWIADRK STFGERVVAF AAVEGVFFSG SFAAIFWLKK RGLMPGLTFS NELISRDEGL HCDFACLMFQ YLVNKPSEER VREIIVDAVK IEQEFLTEAL PVGLIGMNCI LMKQYIEFVA DRLLVELGFS KVFQAENPFD FMENISLEGK TNFFEKRVSE YQRFAVMAET TDNVFTLDAD F // ID ROS1_HUMAN Reviewed; 2347 AA. AC P08922; Q15368; Q5TDB5; DT 01-NOV-1988, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 3. DT 28-JAN-2026, entry version 230. DE RecName: Full=Proto-oncogene tyrosine-protein kinase ROS; DE EC=2.7.10.1 {ECO:0000269|PubMed:11094073, ECO:0000269|PubMed:16885344}; DE AltName: Full=Proto-oncogene c-Ros; DE AltName: Full=Proto-oncogene c-Ros-1; DE AltName: Full=Receptor tyrosine kinase c-ros oncogene 1; DE AltName: Full=c-Ros receptor tyrosine kinase; DE Flags: Precursor; GN Name=ROS1; Synonyms=MCF3, ROS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-2213; GLN-2228 AND CYS-2229. RX PubMed=2352949; DOI=10.1073/pnas.87.12.4799; RA Birchmeier C., O'Neill K., Riggs M., Wigler M.; RT "Characterization of ROS1 cDNA from a human glioblastoma cell line."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4799-4803(1990). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1790-2260. RX PubMed=3023956; DOI=10.1128/mcb.6.8.3000-3004.1986; RA Matsushime H., Wang L.-H., Shibuya M.; RT "Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus RT encodes for a transmembrane receptorlike molecule."; RL Mol. Cell. Biol. 6:3000-3004(1986). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1854-2347. RX PubMed=3785223; DOI=10.1128/mcb.6.9.3109-3116.1986; RA Birchmeier C., Birnbaum D., Waitches G., Fasano O., Wigler M.; RT "Characterization of an activated human ros gene."; RL Mol. Cell. Biol. 6:3109-3116(1986). RN [5] RP TISSUE SPECIFICITY. RX PubMed=8143271; DOI=10.1016/0165-4608(94)90128-7; RA Watkins D., Dion F., Poisson M., Delattre J.Y., Rouleau G.A.; RT "Analysis of oncogene expression in primary human gliomas: evidence for RT increased expression of the ros oncogene."; RL Cancer Genet. Cytogenet. 72:130-136(1994). RN [6] RP FUNCTION, INTERACTION WITH VAV3, AND CATALYTIC ACTIVITY. RX PubMed=11094073; DOI=10.1128/mcb.20.24.9212-9224.2000; RA Zeng L., Sachdev P., Yan L., Chan J.L., Trenkle T., McClelland M., RA Welsh J., Wang L.H.; RT "Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase RT activity, modulates cell morphology, and induces cell transformation."; RL Mol. Cell. Biol. 20:9212-9224(2000). RN [7] RP DISEASE, CHROMOSOMAL TRANSLOCATION WITH GOPC, AND MUTAGENESIS OF LYS-1980. RX PubMed=12661006; DOI=10.1002/gcc.10207; RA Charest A., Lane K., McMahon K., Park J., Preisinger E., Conroy H., RA Housman D.; RT "Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with RT an interstitial del(6)(q21q21)."; RL Genes Chromosomes Cancer 37:58-71(2003). RN [8] RP PHOSPHORYLATION AT TYR-2274 AND TYR-2334, AND MUTAGENESIS OF TYR-2274 AND RP TYR-2334. RX PubMed=12538861; DOI=10.1073/pnas.242741799; RA Charest A., Kheifets V., Park J., Lane K., McMahon K., Nutt C.L., RA Housman D.; RT "Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus RT in a glioblastoma."; RL Proc. Natl. Acad. Sci. U.S.A. 100:916-921(2003). RN [9] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH PTPN11. RX PubMed=16885344; DOI=10.1158/0008-5472.can-06-1193; RA Charest A., Wilker E.W., McLaughlin M.E., Lane K., Gowda R., Coven S., RA McMahon K., Kovach S., Feng Y., Yaffe M.B., Jacks T., Housman D.; RT "ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase- RT 2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling RT axis to form glioblastoma in mice."; RL Cancer Res. 66:7473-7481(2006). RN [10] RP VARIANTS [LARGE SCALE ANALYSIS] SER-13; VAL-126; PRO-145; GLN-167; SER-224; RP CYS-338; PRO-370; HIS-419; MET-537; PHE-653; HIS-865; LEU-1109; PHE-1239; RP SER-1353; ARG-1370; GLY-1506; HIS-1776; LYS-1902; ASN-1999; ARG-2003; RP SER-2138; ASN-2203; GLU-2213; ASN-2213; GLN-2228; CYS-2229 AND LYS-2240. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase (RTK) that plays a role in CC epithelial cell differentiation and regionalization of the proximal CC epididymal epithelium. NELL2 is an endogenous ligand for ROS1. Upon CC endogenous stimulation by NELL2, ROS1 activates the intracellular CC signaling pathway and triggers epididymal epithelial differentiation CC and subsequent sperm maturation (By similarity). May activate several CC downstream signaling pathways related to cell differentiation, CC proliferation, growth and survival including the PI3 kinase-mTOR CC signaling pathway. Mediates the phosphorylation of PTPN11, an activator CC of this pathway. May also phosphorylate and activate the transcription CC factor STAT3 to control anchorage-independent cell growth. Mediates the CC phosphorylation and the activation of VAV3, a guanine nucleotide CC exchange factor regulating cell morphology. May activate other CC downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and CC PLCG2. {ECO:0000250|UniProtKB:Q78DX7, ECO:0000269|PubMed:11094073, CC ECO:0000269|PubMed:16885344}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000269|PubMed:11094073, ECO:0000269|PubMed:16885344}; CC -!- ACTIVITY REGULATION: Inhibited by dephosphorylation by PTPN6. CC {ECO:0000250|UniProtKB:Q78DX7}. CC -!- SUBUNIT: Interacts with PTPN6 (via SH2 1 domain); the interaction is CC direct and promotes ROS1 dephosphorylation (By similarity). Interacts CC with PTPN11; may activate the PI3 kinase-mTOR signaling pathway CC (PubMed:16885344). Interacts with VAV3; constitutive interaction CC mediating VAV3 phosphorylation (PubMed:11094073). CC {ECO:0000250|UniProtKB:Q78DX7, ECO:0000269|PubMed:11094073, CC ECO:0000269|PubMed:16885344}. CC -!- INTERACTION: CC P08922; P18031: PTPN1; NbExp=3; IntAct=EBI-7371065, EBI-968788; CC P08922; P29350: PTPN6; NbExp=4; IntAct=EBI-7371065, EBI-78260; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I CC membrane protein {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Expressed in brain. Expression is increased in CC primary gliomas. {ECO:0000269|PubMed:8143271}. CC -!- PTM: Phosphorylated. Probably autophosphorylates. Phosphorylation at CC Tyr-2274 is required for the interaction with PTPN6 that mediates ROS1 CC dephosphorylation. Phosphorylation at Tyr-2274 stimulates the kinase CC activity and the activation of the ERK1 signaling cascade (By CC similarity). Phosphorylation at Tyr-2274 and/or Tyr-2334 recruits CC PTPN11 (PubMed:12538861). {ECO:0000250|UniProtKB:Q78DX7, CC ECO:0000269|PubMed:12538861}. CC -!- DISEASE: Note=A chromosomal aberration involving ROS1 is found in a CC glioblastoma multiforme sample. An intra-chromosomal deletion CC del(6)(q21q21) is responsible for the formation of GOPC-ROS1 chimeric CC protein which is localized to the Golgi and has a constitutive receptor CC tyrosine kinase activity. A SLC34A2-ROS1 chimeric protein produced in CC non-small cell lung cancer cells also retains a constitutive kinase CC activity. A third type of chimeric protein CD74-ROS1 was also CC identified in those cells. {ECO:0000269|PubMed:12661006}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M34353; AAA60278.1; -; mRNA. DR EMBL; Z98880; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL132671; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M13599; AAA60277.1; -; Genomic_DNA. DR EMBL; M13368; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13591; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13592; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13593; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13594; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13595; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13596; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13597; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13598; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13880; AAA36580.1; -; mRNA. DR CCDS; CCDS5116.1; -. DR PIR; A35512; TVHURS. DR RefSeq; NP_002935.2; NM_002944.2. DR PDB; 3ZBF; X-ray; 2.20 A; A=1934-2232. DR PDB; 4UXL; X-ray; 2.40 A; A=1934-2232. DR PDB; 7Z5W; X-ray; 2.25 A; A/B=1930-2256. DR PDB; 7Z5X; X-ray; 2.04 A; A/B=1930-2256. DR PDB; 9QEK; X-ray; 2.21 A; A=1934-2232. DR PDBsum; 3ZBF; -. DR PDBsum; 4UXL; -. DR PDBsum; 7Z5W; -. DR PDBsum; 7Z5X; -. DR PDBsum; 9QEK; -. DR AlphaFoldDB; P08922; -. DR SMR; P08922; -. DR BioGRID; 112025; 94. DR CORUM; P08922; -. DR FunCoup; P08922; 69. DR IntAct; P08922; 108. DR MINT; P08922; -. DR STRING; 9606.ENSP00000357494; -. DR BindingDB; P08922; -. DR ChEMBL; CHEMBL5568; -. DR DrugBank; DB08865; Crizotinib. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12130; Lorlatinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; P08922; -. DR GuidetoPHARMACOLOGY; 1840; -. DR GlyCosmos; P08922; 33 sites, 1 glycan. DR GlyGen; P08922; 34 sites, 1 O-linked glycan (3 sites). DR iPTMnet; P08922; -. DR PhosphoSitePlus; P08922; -. DR BioMuta; ROS1; -. DR DMDM; 126302596; -. DR CPTAC; CPTAC-3062; -. DR jPOST; P08922; -. DR MassIVE; P08922; -. DR PaxDb; 9606-ENSP00000357494; -. DR PeptideAtlas; P08922; -. DR ProteomicsDB; 52177; -. DR ABCD; P08922; 2 sequenced antibodies. DR Antibodypedia; 32541; 706 antibodies from 37 providers. DR DNASU; 6098; -. DR Ensembl; ENST00000368508.7; ENSP00000357494.3; ENSG00000047936.12. DR GeneID; 6098; -. DR KEGG; hsa:6098; -. DR UCSC; uc003pxp.2; human. DR AGR; HGNC:10261; -. DR CIViC; 6098; 32 evidence items across 18 molecular profiles. DR ClinPGx; PA34633; -. DR CTD; 6098; -. DR DisGeNET; 6098; -. DR GeneCards; ROS1; -. DR HGNC; HGNC:10261; ROS1. DR HPA; ENSG00000047936; Group enriched (epididymis, lung). DR MalaCards; ROS1; -. DR MIM; 165020; gene. DR OpenTargets; ENSG00000047936; -. DR Orphanet; 70567; Cholangiocarcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR VEuPathDB; HostDB:ENSG00000047936; -. DR eggNOG; KOG1095; Eukaryota. DR GeneTree; ENSGT00940000160831; -. DR InParanoid; P08922; -. DR OrthoDB; 65481at2759; -. DR PAN-GO; P08922; 7 GO annotations based on evolutionary models. DR PhylomeDB; P08922; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P08922; -. DR SignaLink; P08922; -. DR SIGNOR; P08922; -. DR Agora; ENSG00000047936; -. DR BioGRID-ORCS; 6098; 8 hits in 1191 CRISPR screens. DR ChiTaRS; ROS1; human. DR EvolutionaryTrace; P08922; -. DR GeneWiki; ROS1_(gene); -. DR GenomeRNAi; 6098; -. DR Pharos; P08922; Tclin. DR PRO; PR:P08922; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; P08922; protein. DR Bgee; ENSG00000047936; Expressed in upper lobe of left lung and 59 other cell types or tissues. DR ExpressionAtlas; P08922; baseline and differential. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; ISS:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0002066; P:columnar/cuboidal epithelial cell development; ISS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0032006; P:regulation of TOR signaling; IDA:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB. DR CDD; cd00063; FN3; 7. DR CDD; cd05044; PTKc_c-ros; 1. DR FunFam; 1.10.510.10:FF:000341; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.120.10.30:FF:000038; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.120.10.30:FF:000042; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.120.10.30:FF:000044; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000882; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000984; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001018; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001024; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001074; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001237; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001816; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000301; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.120.10.30; TolB, C-terminal domain; 3. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011042; 6-blade_b-propeller_TolB-like. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000033; LDLR_classB_rpt. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF527; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 9. DR SMART; SM00135; LY; 4. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 5. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF63825; YWTD domain; 3. DR PROSITE; PS50853; FN3; 9. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell membrane; Chromosomal rearrangement; KW Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..2347 FT /note="Proto-oncogene tyrosine-protein kinase ROS" FT /id="PRO_0000016722" FT TOPO_DOM 28..1859 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 1860..1882 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1883..2347 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 101..196 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 197..285 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 557..671 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 947..1042 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1043..1150 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1450..1556 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1557..1656 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1658..1751 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1752..1854 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1945..2222 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 2284..2311 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2301..2311 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 2079 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 1951..1959 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 1980 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 1852..1853 FT /note="Breakpoint for translocation to form SLC34A2-ROS1 FT and CD74-ROS1 fusion proteins" FT /evidence="ECO:0000269|PubMed:12661006" FT SITE 1880..1881 FT /note="Breakpoint for translocation to form GOPC-ROS1 FT fusion protein" FT /evidence="ECO:0000269|PubMed:12661006" FT MOD_RES 2274 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:12538861" FT MOD_RES 2334 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:12538861" FT CARBOHYD 52 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 114 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 123 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 324 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 396 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 471 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 607 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 628 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 706 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 714 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 732 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 939 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 961 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1015 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1087 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1090 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1095 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1211 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1272 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1330 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1458 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1461 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1474 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1499 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1565 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1669 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1715 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1738 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1808 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VARIANT 13 FT /note="N -> S (in dbSNP:rs45606237)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041442" FT VARIANT 126 FT /note="G -> V (in dbSNP:rs34245787)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041443" FT VARIANT 145 FT /note="T -> P (in dbSNP:rs1998206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030648" FT VARIANT 167 FT /note="R -> Q (in dbSNP:rs2243380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030649" FT VARIANT 224 FT /note="P -> S (in dbSNP:rs55959124)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041444" FT VARIANT 338 FT /note="Y -> C (in dbSNP:rs55707658)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041445" FT VARIANT 370 FT /note="S -> P (in dbSNP:rs56274823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041446" FT VARIANT 419 FT /note="Y -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1444274116)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041447" FT VARIANT 537 FT /note="I -> M (in dbSNP:rs28639589)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041448" FT VARIANT 653 FT /note="S -> F (in dbSNP:rs34203286)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041449" FT VARIANT 790 FT /note="N -> S (in dbSNP:rs34582164)" FT /id="VAR_049712" FT VARIANT 865 FT /note="Q -> H (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041450" FT VARIANT 1109 FT /note="S -> L (in dbSNP:rs2229079)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030650" FT VARIANT 1239 FT /note="Y -> F (in dbSNP:rs56192249)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041451" FT VARIANT 1353 FT /note="Y -> S (in dbSNP:rs35269727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041452" FT VARIANT 1370 FT /note="C -> R (in dbSNP:rs36106063)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041453" FT VARIANT 1439 FT /note="F -> S (in dbSNP:rs17079086)" FT /id="VAR_030651" FT VARIANT 1506 FT /note="R -> G (in dbSNP:rs35841892)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041454" FT VARIANT 1776 FT /note="D -> H (in dbSNP:rs12664076)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030652" FT VARIANT 1902 FT /note="E -> K (in dbSNP:rs9489124)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030653" FT VARIANT 1999 FT /note="H -> N (in dbSNP:rs45569132)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041455" FT VARIANT 2003 FT /note="K -> R (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041456" FT VARIANT 2039 FT /note="R -> H (in dbSNP:rs3752566)" FT /id="VAR_030654" FT VARIANT 2138 FT /note="F -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041457" FT VARIANT 2203 FT /note="D -> N (in dbSNP:rs556427413)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041458" FT VARIANT 2213 FT /note="D -> E (in dbSNP:rs75510639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041459" FT VARIANT 2213 FT /note="D -> N (in dbSNP:rs529038)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2352949" FT /id="VAR_030655" FT VARIANT 2228 FT /note="K -> Q (in dbSNP:rs529156)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2352949" FT /id="VAR_041460" FT VARIANT 2229 FT /note="S -> C (in dbSNP:rs619203)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2352949" FT /id="VAR_030656" FT VARIANT 2240 FT /note="N -> K (in dbSNP:rs210968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030657" FT VARIANT 2328 FT /note="K -> R (in dbSNP:rs35932630)" FT /id="VAR_049713" FT MUTAGEN 1980 FT /note="K->M: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12661006" FT MUTAGEN 2274 FT /note="Y->F: Loss of phosphorylation at Y-2274 and loss of FT interaction with PTPN11." FT /evidence="ECO:0000269|PubMed:12538861" FT MUTAGEN 2334 FT /note="Y->F: Loss of phosphorylation at Y-2334 and loss of FT interaction with PTPN11." FT /evidence="ECO:0000269|PubMed:12538861" FT CONFLICT 2246..2260 FT /note="EDGDVICLNSDDIMP -> KFDSSEFSSFRCTVN (in Ref. 3; FT AAA60277)" FT /evidence="ECO:0000305" FT CONFLICT 2262 FT /note="A -> V (in Ref. 1; AAA60278)" FT /evidence="ECO:0000305" FT HELIX 1942..1944 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1945..1952 FT /evidence="ECO:0007829|PDB:7Z5X" FT TURN 1954..1956 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1959..1966 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1969..1971 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1974..1982 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 1988..2001 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2012..2016 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2018..2027 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2034..2043 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2053..2072 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2082..2084 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2085..2088 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2090..2094 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2098..2100 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2125..2127 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2130..2135 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2140..2155 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2161..2165 FT /evidence="ECO:0007829|PDB:7Z5W" FT HELIX 2167..2175 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2188..2197 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2202..2204 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2208..2224 FT /evidence="ECO:0007829|PDB:7Z5X" SQ SEQUENCE 2347 AA; 263915 MW; 98902B9A59ACB8F5 CRC64; MKNIYCLIPK LVNFATLGCL WISVVQCTVL NSCLKSCVTN LGQQLDLGTP HNLSEPCIQG CHFWNSVDQK NCALKCRESC EVGCSSAEGA YEEEVLENAD LPTAPFASSI GSHNMTLRWK SANFSGVKYI IQWKYAQLLG SWTYTKTVSR PSYVVKPLHP FTEYIFRVVW IFTAQLQLYS PPSPSYRTHP HGVPETAPLI RNIESSSPDT VEVSWDPPQF PGGPILGYNL RLISKNQKLD AGTQRTSFQF YSTLPNTIYR FSIAAVNEVG EGPEAESSIT TSSSAVQQEE QWLFLSRKTS LRKRSLKHLV DEAHCLRLDA IYHNITGISV DVHQQIVYFS EGTLIWAKKA ANMSDVSDLR IFYRGSGLIS SISIDWLYQR MYFIMDELVC VCDLENCSNI EEITPPSISA PQKIVADSYN GYVFYLLRDG IYRADLPVPS GRCAEAVRIV ESCTLKDFAI KPQAKRIIYF NDTAQVFMST FLDGSASHLI LPRIPFADVK SFACENNDFL VTDGKVIFQQ DALSFNEFIV GCDLSHIEEF GFGNLVIFGS SSQLHPLPGR PQELSVLFGS HQALVQWKPP ALAIGANVIL ISDIIELFEL GPSAWQNWTY EVKVSTQDPP EVTHIFLNIS GTMLNVPELQ SAMKYKVSVR ASSPKRPGPW SEPSVGTTLV PASEPPFIMA VKEDGLWSKP LNSFGPGEFL SSDIGNVSDM DWYNNSLYYS DTKGDVFVWL LNGTDISENY HLPSIAGAGA LAFEWLGHFL YWAGKTYVIQ RQSVLTGHTD IVTHVKLLVN DMVVDSVGGY LYWTTLYSVE STRLNGESSL VLQTQPWFSG KKVIALTLDL SDGLLYWLVQ DSQCIHLYTA VLRGQSTGDT TITEFAAWST SEISQNALMY YSGRLFWING FRIITTQEIG QKTSVSVLEP ARFNQFTIIQ TSLKPLPGNF SFTPKVIPDS VQESSFRIEG NASSFQILWN GPPAVDWGVV FYSVEFSAHS KFLASEQHSL PVFTVEGLEP YALFNLSVTP YTYWGKGPKT SLSLRAPETV PSAPENPRIF ILPSGKCCNK NEVVVEFRWN KPKHENGVLT KFEIFYNISN QSITNKTCED WIAVNVTPSV MSFQLEGMSP RCFIAFQVRA FTSKGPGPYA DVVKSTTSEI NPFPHLITLL GNKIVFLDMD QNQVVWTFSA ERVISAVCYT ADNEMGYYAE GDSLFLLHLH NRSSSELFQD SLVFDITVIT IDWISRHLYF ALKESQNGMQ VFDVDLEHKV KYPREVKIHN RNSTIISFSV YPLLSRLYWT EVSNFGYQMF YYSIISHTLH RILQPTATNQ QNKRNQCSCN VTEFELSGAM AIDTSNLEKP LIYFAKAQEI WAMDLEGCQC WRVITVPAML AGKTLVSLTV DGDLIYWIIT AKDSTQIYQA KKGNGAIVSQ VKALRSRHIL AYSSVMQPFP DKAFLSLASD TVEPTILNAT NTSLTIRLPL AKTNLTWYGI TSPTPTYLVY YAEVNDRKNS SDLKYRILEF QDSIALIEDL QPFSTYMIQI AVKNYYSDPL EHLPPGKEIW GKTKNGVPEA VQLINTTVRS DTSLIISWRE SHKPNGPKES VRYQLAISHL ALIPETPLRQ SEFPNGRLTL LVTRLSGGNI YVLKVLACHS EEMWCTESHP VTVEMFNTPE KPYSLVPENT SLQFNWKAPL NVNLIRFWVE LQKWKYNEFY HVKTSCSQGP AYVCNITNLQ PYTSYNVRVV VVYKTGENST SLPESFKTKA GVPNKPGIPK LLEGSKNSIQ WEKAEDNGCR ITYYILEIRK STSNNLQNQN LRWKMTFNGS CSSVCTWKSK NLKGIFQFRV VAANNLGFGE YSGISENIIL VGDDFWIPET SFILTIIVGI FLVVTIPLTF VWHRRLKNQK SAKEGVTVLI NEDKELAELR GLAAGVGLAN ACYAIHTLPT QEEIENLPAF PREKLTLRLL LGSGAFGEVY EGTAVDILGV GSGEIKVAVK TLKKGSTDQE KIEFLKEAHL MSKFNHPNIL KQLGVCLLNE PQYIILELME GGDLLTYLRK ARMATFYGPL LTLVDLVDLC VDISKGCVYL ERMHFIHRDL AARNCLVSVK DYTSPRIVKI GDFGLARDIY KNDYYRKRGE GLLPVRWMAP ESLMDGIFTT QSDVWSFGIL IWEILTLGHQ PYPAHSNLDV LNYVQTGGRL EPPRNCPDDL WNLMTQCWAQ EPDQRPTFHR IQDQLQLFRN FFLNSIYKSR DEANNSGVIN ESFEGEDGDV ICLNSDDIMP VALMETKNRE GLNYMVLATE CGQGEEKSEG PLGSQESESC GLRKEEKEPH ADKDFCQEKQ VAYCPSGKPE GLNYACLTHS GYGDGSD // ID SBP1_HUMAN Reviewed; 472 AA. AC Q13228; A6NML9; A6PVW9; B2RDR3; B4DKP6; B4E1F3; Q49AQ8; Q96GX7; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 29-MAY-2007, sequence version 2. DT 28-JAN-2026, entry version 195. DE RecName: Full=Methanethiol oxidase {ECO:0000303|PubMed:29255262}; DE Short=MTO {ECO:0000303|PubMed:29255262}; DE EC=1.8.3.4 {ECO:0000269|PubMed:29255262}; DE AltName: Full=56 kDa selenium-binding protein; DE Short=SBP56; DE Short=SP56; DE AltName: Full=Selenium-binding protein 1; GN Name=SELENBP1; Synonyms=SBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Heart; RX PubMed=9027582; RX DOI=10.1002/(sici)1097-4644(199702)64:2<217::aid-jcb5>3.0.co;2-#; RA Chang P.W.G., Tsui S.K.W., Liew C., Lee C., Waye M.M.Y., Fung K.; RT "Isolation, characterization, and chromosomal mapping of a novel cDNA clone RT encoding human selenium binding protein."; RL J. Cell. Biochem. 64:217-224(1997). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4). RC TISSUE=Colon, Lung, and Synovial cell; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Colon, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 255-276, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Brain, and Cajal-Retzius cell; RA Lubec G., Vishwanath V.; RL Submitted (MAR-2007) to UniProtKB. RN [8] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=9679983; RA Yang M., Sytkowski A.J.; RT "Differential expression and androgen regulation of the human selenium- RT binding protein gene hSP56 in prostate cancer cells."; RL Cancer Res. 58:3150-3153(1998). RN [9] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14991897; DOI=10.1002/path.1524; RA Chen G., Wang H., Miller C.T., Thomas D.G., Gharib T.G., Misek D.E., RA Giordano T.J., Orringer M.B., Hanash S.M., Beer D.G.; RT "Reduced selenium-binding protein 1 expression is associated with poor RT outcome in lung adenocarcinomas."; RL J. Pathol. 202:321-329(2004). RN [10] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16223876; DOI=10.1073/pnas.0507666102; RA Glatt S.J., Everall I.P., Kremen W.S., Corbeil J., Sasik R., Khanlou N., RA Han M., Liew C.-C., Tsuang M.T.; RT "Comparative gene expression analysis of blood and brain provides RT concurrent validation of SELENBP1 up-regulation in schizophrenia."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15533-15538(2005). RN [11] RP TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16380993; DOI=10.1002/ijc.21671; RA Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X., Ng W.-C., Bandera C.A., RA Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.; RT "Selenium binding protein 1 in ovarian cancer."; RL Int. J. Cancer 118:2433-2440(2006). RN [12] RP TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16645984; DOI=10.1002/pmic.200500629; RA Kim H., Kang H.J., You K.T., Kim S.H., Lee K.Y., Kim T.I., Kim C., RA Song S.Y., Kim H.-J., Lee C., Kim H.; RT "Suppression of human selenium-binding protein 1 is a late event in RT colorectal carcinogenesis and is associated with poor survival."; RL Proteomics 6:3466-3476(2006). RN [13] RP INTERACTION WITH USP33. RX PubMed=19118533; DOI=10.1016/j.bbrc.2008.12.110; RA Jeong J.Y., Wang Y., Sytkowski A.J.; RT "Human selenium binding protein-1 (hSP56) interacts with VDU1 in a RT selenium-dependent manner."; RL Biochem. Biophys. Res. Commun. 379:583-588(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-111 AND SER-371, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, TISSUE SPECIFICITY, INVOLVEMENT IN RP EHMTO, VARIANTS EHMTO TRP-225; TYR-329 AND 347-GLY--ILE-472 DEL, RP CHARACTERIZATION OF VARIANTS EHMTO TRP-225; TYR-329 AND 347-GLY--ILE-472 RP DEL, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=29255262; DOI=10.1038/s41588-017-0006-7; RA Pol A., Renkema G.H., Tangerman A., Winkel E.G., Engelke U.F., RA de Brouwer A.P.M., Lloyd K.C., Araiza R.S., van den Heuvel L., Omran H., RA Olbrich H., Oude Elberink M., Gilissen C., Rodenburg R.J., Sass J.O., RA Schwab K.O., Schaefer H., Venselaar H., Sequeira J.S., Op den Camp H.J.M., RA Wevers R.A.; RT "Mutations in SELENBP1, encoding a novel human methanethiol oxidase, cause RT extraoral halitosis."; RL Nat. Genet. 50:120-129(2018). CC -!- FUNCTION: Catalyzes the oxidation of methanethiol, an organosulfur CC compound known to be produced in substantial amounts by gut bacteria CC (PubMed:29255262). Selenium-binding protein which may be involved in CC the sensing of reactive xenobiotics in the cytoplasm. May be involved CC in intra-Golgi protein transport (By similarity). CC {ECO:0000250|UniProtKB:Q8VIF7, ECO:0000269|PubMed:29255262}. CC -!- CATALYTIC ACTIVITY: CC Reaction=methanethiol + O2 + H2O = hydrogen sulfide + formaldehyde + CC H2O2 + H(+); Xref=Rhea:RHEA:11812, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16007, CC ChEBI:CHEBI:16240, ChEBI:CHEBI:16842, ChEBI:CHEBI:29919; EC=1.8.3.4; CC Evidence={ECO:0000269|PubMed:29255262}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=4.8 nM for methanethiol {ECO:0000269|PubMed:29255262}; CC -!- PATHWAY: Organosulfur degradation. {ECO:0000269|PubMed:29255262}. CC -!- SUBUNIT: Interacts with USP33. {ECO:0000269|PubMed:19118533}. CC -!- INTERACTION: CC Q13228; Q9UJ68: MSRA; NbExp=3; IntAct=EBI-711619, EBI-19157918; CC Q13228; O43422: THAP12; NbExp=3; IntAct=EBI-711619, EBI-2828217; CC Q13228; Q15645: TRIP13; NbExp=6; IntAct=EBI-711619, EBI-358993; CC Q13228; Q8TEY7-2: USP33; NbExp=5; IntAct=EBI-711619, EBI-719307; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14991897}. Cytoplasm, CC cytosol {ECO:0000269|PubMed:14991897, ECO:0000269|PubMed:16223876}. CC Membrane {ECO:0000250|UniProtKB:Q8VIF7}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q8VIF7}. Note=May associate with Golgi membrane CC (By similarity). May associate with the membrane of autophagosomes (By CC similarity). {ECO:0000250|UniProtKB:Q8VIF7}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q13228-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13228-2; Sequence=VSP_038440; CC Name=3; CC IsoId=Q13228-3; Sequence=VSP_045425; CC Name=4; CC IsoId=Q13228-4; Sequence=VSP_055126; CC -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in liver, lung, CC colon, prostate, kidney and pancreas. In brain, present both in neurons CC and glia (at protein level). Down-regulated in lung adenocarcinoma, CC colorectal carcinoma and ovarian cancer. Two-fold up-regulated in brain CC and blood from schizophrenia patients. {ECO:0000269|PubMed:14991897, CC ECO:0000269|PubMed:16223876, ECO:0000269|PubMed:16380993, CC ECO:0000269|PubMed:16645984, ECO:0000269|PubMed:29255262, CC ECO:0000269|PubMed:9679983}. CC -!- INDUCTION: Down-regulated by androgen in prostate cancer cells. CC {ECO:0000269|PubMed:9679983}. CC -!- PTM: Phosphorylated. {ECO:0000305|PubMed:14991897}. CC -!- PTM: The N-terminus is blocked. {ECO:0000250}. CC -!- DISEASE: Extraoral halitosis due to methanethiol oxidase deficiency CC (EHMTO) [MIM:618148]: An autosomal recessive malodor condition CC characterized by extraoral blood-borne halitosis resulting from the CC accumulation of sulfur-containing metabolites. In extraoral blood-borne CC halitosis, malodorant compounds are carried to the lungs, where they CC enter the breath. Affected individuals have a cabbage-like breath odor, CC high levels of methanethiol and dimethylsulfide in oral and nasal CC breath, and elevated urinary excretion of dimethylsulfoxide in the CC absence of intake of dimethylsulfide-containing food or use of sulfur- CC containing medication, lower-gastrointestinal problems, and known CC metabolic defects, such as methionine adenosyltransferase deficiency CC and tyrosinemia. {ECO:0000269|PubMed:29255262}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the selenium-binding protein family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U29091; AAB02395.1; -; mRNA. DR EMBL; CR456852; CAG33133.1; -; mRNA. DR EMBL; AK296661; BAG59258.1; -; mRNA. DR EMBL; AK303815; BAG64765.1; -; mRNA. DR EMBL; AK315643; BAG38010.1; -; mRNA. DR EMBL; AL391069; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471121; EAW53443.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53445.1; -; Genomic_DNA. DR EMBL; BC009084; AAH09084.1; -; mRNA. DR EMBL; BC032997; AAH32997.1; -; mRNA. DR CCDS; CCDS58027.1; -. [Q13228-3] DR CCDS; CCDS60266.1; -. [Q13228-4] DR CCDS; CCDS995.1; -. [Q13228-1] DR PIR; G01872; G01872. DR RefSeq; NP_001245217.1; NM_001258288.2. [Q13228-3] DR RefSeq; NP_001245218.1; NM_001258289.2. [Q13228-4] DR RefSeq; NP_003935.2; NM_003944.3. [Q13228-1] DR AlphaFoldDB; Q13228; -. DR SMR; Q13228; -. DR BioGRID; 114472; 214. DR CORUM; Q13228; -. DR FunCoup; Q13228; 548. DR IntAct; Q13228; 108. DR MINT; Q13228; -. DR STRING; 9606.ENSP00000397261; -. DR GlyGen; Q13228; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13228; -. DR PhosphoSitePlus; Q13228; -. DR SwissPalm; Q13228; -. DR BioMuta; SELENBP1; -. DR DMDM; 148840437; -. DR REPRODUCTION-2DPAGE; IPI00012303; -. DR REPRODUCTION-2DPAGE; Q13228; -. DR jPOST; Q13228; -. DR MassIVE; Q13228; -. DR PaxDb; 9606-ENSP00000397261; -. DR PeptideAtlas; Q13228; -. DR ProteomicsDB; 1722; -. DR ProteomicsDB; 5753; -. DR ProteomicsDB; 59234; -. [Q13228-1] DR ProteomicsDB; 59235; -. [Q13228-2] DR Pumba; Q13228; -. DR Antibodypedia; 1584; 393 antibodies from 30 providers. DR DNASU; 8991; -. DR Ensembl; ENST00000368868.10; ENSP00000357861.5; ENSG00000143416.22. [Q13228-1] DR Ensembl; ENST00000426705.6; ENSP00000397261.2; ENSG00000143416.22. [Q13228-4] DR Ensembl; ENST00000447402.7; ENSP00000413960.3; ENSG00000143416.22. [Q13228-3] DR GeneID; 8991; -. DR KEGG; hsa:8991; -. DR MANE-Select; ENST00000368868.10; ENSP00000357861.5; NM_003944.4; NP_003935.2. DR UCSC; uc010pcy.4; human. [Q13228-1] DR AGR; HGNC:10719; -. DR ClinPGx; PA35641; -. DR CTD; 8991; -. DR DisGeNET; 8991; -. DR GeneCards; SELENBP1; -. DR HGNC; HGNC:10719; SELENBP1. DR HPA; ENSG00000143416; Tissue enhanced (intestine). DR MalaCards; SELENBP1; -. DR MIM; 604188; gene. DR MIM; 618148; phenotype. DR OpenTargets; ENSG00000143416; -. DR Orphanet; 562538; Autosomal recessive extra-oral halitosis. DR VEuPathDB; HostDB:ENSG00000143416; -. DR eggNOG; KOG0918; Eukaryota. DR GeneTree; ENSGT00390000014244; -. DR HOGENOM; CLU_032512_0_0_1; -. DR InParanoid; Q13228; -. DR OMA; AYDFWWH; -. DR OrthoDB; 10252446at2759; -. DR PAN-GO; Q13228; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q13228; -. DR PathwayCommons; Q13228; -. DR SABIO-RK; Q13228; -. DR SignaLink; Q13228; -. DR Agora; ENSG00000143416; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 8991; 20 hits in 1164 CRISPR screens. DR ChiTaRS; SELENBP1; human. DR GeneWiki; SELENBP1; -. DR GenomeRNAi; 8991; -. DR Pharos; Q13228; Tbio. DR PRO; PR:Q13228; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q13228; protein. DR Bgee; ENSG00000143416; Expressed in mucosa of transverse colon and 202 other cell types or tissues. DR ExpressionAtlas; Q13228; baseline and differential. DR GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0018549; F:methanethiol oxidase activity; IMP:FlyBase. DR GO; GO:0008430; F:selenium binding; TAS:ProtInc. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR InterPro; IPR008826; Se-bd. DR PANTHER; PTHR23300; METHANETHIOL OXIDASE; 1. DR PANTHER; PTHR23300:SF0; METHANETHIOL OXIDASE; 1. DR Pfam; PF05694; SBP56; 1. DR SUPFAM; SSF75011; 3-carboxy-cis,cis-mucoante lactonizing enzyme; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; Cytoplasm; Direct protein sequencing; KW Disease variant; Membrane; Nucleus; Oxidoreductase; Phosphoprotein; KW Protein transport; Proteomics identification; Reference proteome; Selenium; KW Transport. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..472 FT /note="Methanethiol oxidase" FT /id="PRO_0000174633" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P17563" FT VAR_SEQ 1..64 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_038440" FT VAR_SEQ 1 FT /note="M -> MRLEWGPRPAALPWPAGMCAAERAEGAFTLQSVAQPMRPIAST (in FT isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055126" FT VAR_SEQ 59..120 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045425" FT VARIANT 225 FT /note="G -> W (in EHMTO; loss of methanethiol oxidation in FT patient cells; dbSNP:rs758495626)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080207" FT VARIANT 329 FT /note="H -> Y (in EHMTO; loss of methanethiol oxidation in FT patient cells; dbSNP:rs1553204840)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080208" FT VARIANT 347..472 FT /note="Missing (in EHMTO; loss of methanethiol oxidation in FT patient cells)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080209" FT CONFLICT 80 FT /note="C -> Y (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 92 FT /note="T -> N (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 114..116 FT /note="RAP -> GPQ (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 135 FT /note="F -> C (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 260..262 FT /note="DAA -> SAT (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 270..273 FT /note="LSST -> SAPN (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 278 FT /note="Y -> C (in Ref. 3; BAG59258)" FT /evidence="ECO:0000305" FT CONFLICT 280..282 FT /note="NEG -> TRE (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 305..306 FT /note="EM -> GV (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 410 FT /note="D -> E (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 442 FT /note="F -> C (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" SQ SEQUENCE 472 AA; 52391 MW; 6DC68F9B45FEC1BC CRC64; MATKCGNCGP GYSTPLEAMK GPREEIVYLP CIYRNTGTEA PDYLATVDVD PKSPQYCQVI HRLPMPNLKD ELHHSGWNTC SSCFGDSTKS RTKLVLPSLI SSRIYVVDVG SEPRAPKLHK VIEPKDIHAK CELAFLHTSH CLASGEVMIS SLGDVKGNGK GGFVLLDGET FEVKGTWERP GGAAPLGYDF WYQPRHNVMI STEWAAPNVL RDGFNPADVE AGLYGSHLYV WDWQRHEIVQ TLSLKDGLIP LEIRFLHNPD AAQGFVGCAL SSTIQRFYKN EGGTWSVEKV IQVPPKKVKG WLLPEMPGLI TDILLSLDDR FLYFSNWLHG DLRQYDISDP QRPRLTGQLF LGGSIVKGGP VQVLEDEELK SQPEPLVVKG KRVAGGPQMI QLSLDGKRLY ITTSLYSAWD KQFYPDLIRE GSVMLQVDVD TVKGGLKLNP NFLVDFGKEP LGPALAHELR YPGGDCSSDI WI // ID SMAD4_HUMAN Reviewed; 552 AA. AC Q13485; A8K405; DT 04-MAY-2001, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 255. DE RecName: Full=SMAD family member 4 {ECO:0000312|HGNC:HGNC:6770}; DE Short=SMAD 4 {ECO:0000305}; DE Short=hSMAD4; DE AltName: Full=Deletion target in pancreatic carcinoma 4; DE AltName: Full=Mothers against decapentaplegic homolog 4; DE Short=MAD homolog 4; DE Short=Mothers against DPP homolog 4; GN Name=SMAD4 {ECO:0000312|HGNC:HGNC:6770}; Synonyms=DPC4, MADH4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT PANCREATIC CARCINOMA RP HIS-493. RC TISSUE=Fetal brain; RX PubMed=8553070; DOI=10.1126/science.271.5247.350; RA Hahn S.A., Schutte M., Shamsul Hoque A.T.M., Moskaluk C.A., da Costa L.T., RA Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E.; RT "DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1."; RL Science 271:350-353(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8774881; DOI=10.1038/383168a0; RA Zhang Y., Feng X.-H., Wu R.-Y., Derynck R.; RT "Receptor-associated Mad homologues synergize as effectors of the TGF-beta RT response."; RL Nature 383:168-172(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9098646; DOI=10.1097/00019606-199704000-00003; RA Moskaluk C.A., Hruban R.H., Schutte M., Lietman A.S., Smyrk T., Fusaro L., RA Fusaro R., Lynch J., Yeo C.J., Jackson C.E., Lynch H.T., Kern S.E.; RT "Genomic sequencing of DPC4 in the analysis of familial pancreatic RT carcinoma."; RL Diagn. Mol. Pathol. 6:85-90(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=9389648; DOI=10.1101/gad.11.23.3157; RA Liu F., Pouponnot C., Massague J.; RT "Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible RT transcriptional complexes."; RL Genes Dev. 11:3157-3167(1997). RN [8] RP SUBUNIT. RX PubMed=9670020; DOI=10.1093/emboj/17.14.4056; RA Kawabata M., Inoue H., Hanyu A., Imamura T., Miyazono K.; RT "Smad proteins exist as monomers in vivo and undergo homo- and hetero- RT oligomerization upon activation by serine/threonine kinase receptors."; RL EMBO J. 17:4056-4065(1998). RN [9] RP INTERACTION WITH CITED1. RX PubMed=9707553; DOI=10.1073/pnas.95.17.9785; RA Shioda T., Lechleider R.J., Dunwoodie S.L., Li H., Yahata T., RA de Caestecker M.P., Fenner M.H., Roberts A.B., Isselbacher K.J.; RT "Transcriptional activating activity of Smad4: roles of SMAD hetero- RT oligomerization and enhancement by an associating transactivator."; RL Proc. Natl. Acad. Sci. U.S.A. 95:9785-9790(1998). RN [10] RP INTERACTION WITH ZNF423. RX PubMed=10660046; DOI=10.1016/s0092-8674(00)81561-5; RA Hata A., Seoane J., Lagna G., Montalvo E., Hemmati-Brivanlou A., RA Massague J.; RT "OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP- RT Smad and Olf signaling pathways."; RL Cell 100:229-240(2000). RN [11] RP CHARACTERIZATION OF SAD DOMAIN. RX PubMed=10636916; DOI=10.1074/jbc.275.3.2115; RA de Caestecker M.P., Yahata T., Wang D., Parks W.T., Huang S., Hill C.S., RA Shioda T., Roberts A.B., Lechleider R.J.; RT "The Smad4 activation domain (SAD) is a proline-rich, p300-dependent RT transcriptional activation domain."; RL J. Biol. Chem. 275:2115-2122(2000). RN [12] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF STK11/LKB1 AND STK11IP, AND RP INTERACTION WITH STK11/LKB1 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [13] RP INTERACTION WITH COPS5. RX PubMed=11818334; DOI=10.1093/embo-reports/kvf024; RA Wan M., Cao X., Wu Y., Bai S., Wu L., Shi X., Wang N., Cao X.; RT "Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation."; RL EMBO Rep. 3:171-176(2002). RN [14] RP INTERACTION WITH ZNF8. RX PubMed=12370310; DOI=10.1128/mcb.22.21.7633-7644.2002; RA Jiao K., Zhou Y., Hogan B.L.M.; RT "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor, RT as a novel nuclear interaction partner of Smad1."; RL Mol. Cell. Biol. 22:7633-7644(2002). RN [15] RP INTERACTION WITH VPS39. RX PubMed=12941698; DOI=10.1093/emboj/cdg428; RA Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S., RA McNally J.G., Roberts A.B.; RT "TLP, a novel modulator of TGF-beta signaling, has opposite effects on RT Smad2- and Smad3-dependent signaling."; RL EMBO J. 22:4465-4477(2003). RN [16] RP INTERACTION WITH DACH1. RX PubMed=14525983; DOI=10.1074/jbc.m310021200; RA Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K., RA Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.; RT "DACH1 inhibits transforming growth factor-beta signaling through binding RT Smad4."; RL J. Biol. Chem. 278:51673-51684(2003). RN [17] RP INTERACTION WITH DLX1. RX PubMed=14671321; DOI=10.1073/pnas.2536757100; RA Chiba S., Takeshita K., Imai Y., Kumano K., Kurokawa M., Masuda S., RA Shimizu K., Nakamura S., Ruddle F.H., Hirai H.; RT "Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway RT from activin A in hematopoietic cells."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15577-15582(2003). RN [18] RP INTERACTION WITH ZNF521. RX PubMed=14630787; DOI=10.1182/blood-2003-07-2388; RA Bond H.M., Mesuraca M., Carbone E., Bonelli P., Agosti V., Amodio N., RA De Rosa G., Di Nicola M., Gianni A.M., Moore M.A., Hata A., Grieco M., RA Morrone G., Venuta S.; RT "Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse RT Evi3, is highly expressed in primitive human hematopoietic cells."; RL Blood 103:2062-2070(2004). RN [19] RP INTERACTION WITH TRIM33. RX PubMed=15820681; DOI=10.1016/j.cell.2005.01.033; RA Dupont S., Zacchigna L., Cordenonsi M., Soligo S., Adorno M., Rugge M., RA Piccolo S.; RT "Germ-layer specification and control of cell growth by Ectodermin, a Smad4 RT ubiquitin ligase."; RL Cell 121:87-99(2005). RN [20] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=15799969; DOI=10.1074/jbc.m500362200; RA Chen H.B., Rud J.G., Lin K., Xu L.; RT "Nuclear targeting of transforming growth factor-beta-activated Smad RT complexes."; RL J. Biol. Chem. 280:21329-21336(2005). RN [21] RP INTERACTION WITH TSC22D1. RX PubMed=15881652; DOI=10.1007/s11010-005-3456-7; RA Choi S.J., Moon J.H., Ahn Y.W., Ahn J.H., Kim D.U., Han T.H.; RT "Tsc-22 enhances TGF-beta signaling by associating with Smad4 and induces RT erythroid cell differentiation."; RL Mol. Cell. Biochem. 271:23-28(2005). RN [22] RP INTERACTION WITH ZMIZ1. RX PubMed=16777850; DOI=10.1074/jbc.m508365200; RA Li X., Thyssen G., Beliakoff J., Sun Z.; RT "The novel PIAS-like protein hZimp10 enhances Smad transcriptional RT activity."; RL J. Biol. Chem. 281:23748-23756(2006). RN [23] RP INTERACTION WITH RBPMS. RX PubMed=17099224; DOI=10.1093/nar/gkl914; RA Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J., Song H., RA Ye Q.; RT "Potentiation of Smad-mediated transcriptional activation by the RNA- RT binding protein RBPMS."; RL Nucleic Acids Res. 34:6314-6326(2006). RN [24] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND INTERACTION RP WITH PDPK1. RX PubMed=17327236; DOI=10.1074/jbc.m609279200; RA Seong H.A., Jung H., Kim K.T., Ha H.; RT "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth RT factor-beta-induced signaling in a kinase-dependent manner through physical RT interaction with Smad proteins."; RL J. Biol. Chem. 282:12272-12289(2007). RN [25] RP INTERACTION WITH WWTR1. RX PubMed=18568018; DOI=10.1038/ncb1748; RA Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B.M., RA Dembowy J., Yaffe M.B., Zandstra P.W., Wrana J.L.; RT "TAZ controls Smad nucleocytoplasmic shuttling and regulates human RT embryonic stem-cell self-renewal."; RL Nat. Cell Biol. 10:837-848(2008). RN [26] RP INTERACTION WITH USP9X, UBIQUITINATION, AND MUTAGENESIS OF LYS-519. RX PubMed=19135894; DOI=10.1016/j.cell.2008.10.051; RA Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M., RA Martello G., Stinchfield M.J., Soligo S., Morsut L., Inui M., Moro S., RA Modena N., Argenton F., Newfeld S.J., Piccolo S.; RT "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, RT controls Smad4 monoubiquitination."; RL Cell 136:123-135(2009). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-37; LYS-428 AND LYS-507, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP POSSIBLE INVOLVEMENT IN PULMONARY HYPERTENSION, AND VARIANT SER-13. RX PubMed=21898662; DOI=10.1002/humu.21605; RA Nasim M.T., Ogo T., Ahmed M., Randall R., Chowdhury H.M., Snape K.M., RA Bradshaw T.Y., Southgate L., Lee G.J., Jackson I., Lord G.M., Gibbs J.S., RA Wilkins M.R., Ohta-Ogo K., Nakamura K., Girerd B., Coulet F., Soubrier F., RA Humbert M., Morrell N.W., Trembath R.C., Machado R.D.; RT "Molecular genetic characterization of SMAD signaling molecules in RT pulmonary arterial hypertension."; RL Hum. Mutat. 32:1385-1389(2011). RN [30] RP INTERACTION WITH ZNF451, IDENTIFICATION IN A COMPLEX WITH ZNF451; SMAD3 AND RP SMAD2, AND SUBUNIT. RX PubMed=24324267; DOI=10.1074/jbc.m113.526905; RA Feng Y., Wu H., Xu Y., Zhang Z., Liu T., Lin X., Feng X.H.; RT "Zinc finger protein 451 is a novel Smad corepressor in transforming growth RT factor-beta signaling."; RL J. Biol. Chem. 289:2072-2083(2014). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [32] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [33] RP INTERACTION WITH CREB3L1. RX PubMed=25310401; DOI=10.1371/journal.pone.0108528; RA Chen Q., Lee C.E., Denard B., Ye J.; RT "Sustained induction of collagen synthesis by TGF-beta requires regulated RT intramembrane proteolysis of CREB3L1."; RL PLoS ONE 9:E108528-E108528(2014). RN [34] RP FUNCTION, INTERACTION WITH CREBBP; EP300; HDAC1 AND ZBTB7A, AND REGION. RX PubMed=25514493; DOI=10.1016/j.bbagrm.2014.12.008; RA Yang Y., Cui J., Xue F., Zhang C., Mei Z., Wang Y., Bi M., Shan D., RA Meredith A., Li H., Xu Z.Q.; RT "Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced RT transcriptional responses."; RL Biochim. Biophys. Acta 1849:270-281(2015). RN [35] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [36] RP INTERACTION WITH NUP93 AND IPO7. RX PubMed=26878725; DOI=10.1038/ng.3512; RA Braun D.A., Sadowski C.E., Kohl S., Lovric S., Astrinidis S.A., Pabst W.L., RA Gee H.Y., Ashraf S., Lawson J.A., Shril S., Airik M., Tan W., Schapiro D., RA Rao J., Choi W.I., Hermle T., Kemper M.J., Pohl M., Ozaltin F., Konrad M., RA Bogdanovic R., Buescher R., Helmchen U., Serdaroglu E., Lifton R.P., RA Antonin W., Hildebrandt F.; RT "Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid- RT resistant nephrotic syndrome."; RL Nat. Genet. 48:457-465(2016). RN [37] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 319-543. RX PubMed=9214508; DOI=10.1038/40431; RA Shi Y., Hata A., Lo R.S., Massague J., Pavletich N.P.; RT "A structural basis for mutational inactivation of the tumour suppressor RT Smad4."; RL Nature 388:87-93(1997). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 285-552. RX PubMed=10647180; DOI=10.1016/s0969-2126(00)88340-9; RA Qin B., Lam S.S., Lin K.; RT "Crystal structure of a transcriptionally active Smad4 fragment."; RL Structure 7:1493-1503(1999). RN [40] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) OF 273-552 OF WILD TYPE AND MUTANTS RP ARG-416; ARG-502 AND ARG-515 IN COMPLEX WITH SMAD3, SUBUNIT, AND RP MUTAGENESIS OF ARG-416; ARG-496; ARG-502 AND ARG-515. RX PubMed=11224571; DOI=10.1038/84995; RA Chacko B.M., Qin B., Correia J.J., Lam S.S., de Caestecker M.P., Lin K.; RT "The L3 loop and C-terminal phosphorylation jointly define Smad protein RT trimerization."; RL Nat. Struct. Biol. 8:248-253(2001). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 314-552 IN COMPLEX WITH SMAD2 OR RP SMAD3, AND SUBUNIT. RX PubMed=15350224; DOI=10.1016/j.molcel.2004.07.016; RA Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J., RA De Caestecker M., Lin K.; RT "Structural basis of heteromeric smad protein assembly in TGF-beta RT signaling."; RL Mol. Cell 15:813-823(2004). RN [42] RP VARIANT JPS CYS-361. RX PubMed=9811934; DOI=10.1093/hmg/7.12.1907; RA Houlston R., Bevan S., Williams A., Young J., Dunlop M., Rozen P., Eng C., RA Markie D., Woodford-Richens K., Rodriguez-Bigas M.A., Leggett B., Neale K., RA Phillips R., Sheridan E., Hodgson S., Iwama T., Eccles D., Bodmer W., RA Tomlinson I.; RT "Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only RT account for a minority of cases."; RL Hum. Mol. Genet. 7:1907-1912(1998). RN [43] RP VARIANTS JPS GLY-330 AND ARG-352. RX PubMed=12417513; DOI=10.1007/bf02557528; RA Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L., RA Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M., RA Vogelstein B., Howe J.R.; RT "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis."; RL Ann. Surg. Oncol. 9:901-906(2002). RN [44] RP VARIANTS JP/HHT ARG-352 AND ASP-386. RX PubMed=15031030; DOI=10.1016/s0140-6736(04)15732-2; RA Gallione C.J., Repetto G.M., Legius E., Rustgi A.K., Schelley S.L., RA Tejpar S., Mitchell G., Drouin E., Westermann C.J.J., Marchuk D.A.; RT "A combined syndrome of juvenile polyposis and hereditary haemorrhagic RT telangiectasia associated with mutations in MADH4 (SMAD4)."; RL Lancet 363:852-859(2004). RN [45] RP VARIANTS [LARGE SCALE ANALYSIS] SER-130; ASN-351 AND HIS-361, AND RP INVOLVEMENT IN COLORECTAL CANCER. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [46] RP VARIANTS MYHRS THR-500 AND VAL-500. RX PubMed=22243968; DOI=10.1016/j.ajhg.2011.12.011; RA Caputo V., Cianetti L., Niceta M., Carta C., Ciolfi A., Bocchinfuso G., RA Carrani E., Dentici M.L., Biamino E., Belligni E., Garavelli L., RA Boccone L., Melis D., Andria G., Gelb B.D., Stella L., Silengo M., RA Dallapiccola B., Tartaglia M.; RT "A restricted spectrum of mutations in the SMAD4 tumor-suppressor gene RT underlies Myhre syndrome."; RL Am. J. Hum. Genet. 90:161-169(2012). RN [47] RP VARIANTS MYHRS MET-500; THR-500 AND VAL-500, AND CHARACTERIZATION OF RP VARIANT MYHRS THR-500. RX PubMed=22158539; DOI=10.1038/ng.1016; RA Le Goff C., Mahaut C., Abhyankar A., Le Goff W., Serre V., Afenjar A., RA Destree A., di Rocco M., Heron D., Jacquemont S., Marlin S., Simon M., RA Tolmie J., Verloes A., Casanova J.L., Munnich A., Cormier-Daire V.; RT "Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre RT syndrome."; RL Nat. Genet. 44:85-88(2012). CC -!- FUNCTION: In muscle physiology, plays a central role in the balance CC between atrophy and hypertrophy. When recruited by MSTN, promotes CC atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 CC release and subsequent recruitment by the BMP pathway to promote CC hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with CC SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac- CC specific gene expression. Binds to SMAD binding elements (SBEs) (5'- CC GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating CC regions (By similarity). Common SMAD (co-SMAD) is the coactivator and CC mediator of signal transduction by TGF-beta (transforming growth CC factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that CC forms in the nucleus and is required for the TGF-mediated signaling CC (PubMed:25514493). Promotes binding of the SMAD2/SMAD4/FAST-1 complex CC to DNA and provides an activation function required for SMAD1 or SMAD2 CC to stimulate transcription. Component of the multimeric CC SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; CC required for synergistic transcriptional activity in response to TGF- CC beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase CC activity by stimulating its dissociation from the 14-3-3 protein YWHAQ CC which acts as a negative regulator. {ECO:0000250, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:25514493, CC ECO:0000269|PubMed:9389648}. CC -!- SUBUNIT: Monomer; in the absence of TGF-beta activation CC (PubMed:9670020). Heterotrimer; on TGF-beta activation CC (PubMed:15799969). Heterotrimer composed of two molecules of a C- CC terminally phosphorylated R-SMAD molecule, SMAD2 or SMAD3, and one CC molecule of SMAD4 to form the transcriptional active SMAD2/SMAD3-SMAD4 CC complex (PubMed:15350224, PubMed:15799969). Found in a ternary complex CC composed of SMAD4, STK11/LKB1 and STK11IP. Found in a complex with CC SMAD1 and YY1 (By similarity). Identified in a complex that contains at CC least ZNF451, SMAD2, SMAD3 and SMAD4 (PubMed:24324267). Interacts with CC ATF2, COPS5, DACH1, MSG1, SKI, STK11/LKB1, STK11IP and TRIM33. CC Associates with ZNF423 or ZNF521 in response to BMP2 leading to CC activate transcription of BMP target genes. Interacts with USP9X. CC Interacts (via the MH1 and MH2 domains) with RBPMS. Interacts with CC WWTR1 (via coiled-coil domain). Interacts with CITED1 and CITED2. CC Interacts with PDPK1 (via PH domain) (By similarity). Interacts with CC VPS39; this interaction affects heterodimer formation with SMAD3, but CC not with SMAD2, and leads to inhibition of SMAD3-dependent CC transcription activation. Interactions with VPS39 and SMAD2 may be CC mutually exclusive. Interacts (via MH2 domain) with ZNF451 (via N- CC terminal zinc-finger domains) (PubMed:24324267). Interacts with ZC3H3 CC (By similarity). Interacts weakly with ZNF8 (PubMed:12370310). CC Interacts with NUP93 and IPO7; translocates SMAD4 to the nucleus CC through the NPC upon BMP7 stimulation resulting in activation of SMAD4 CC signaling (PubMed:26878725). Interacts with CREB3L1, the interaction CC takes place upon TGFB1 induction and SMAD4 acts as a CREB3L1 CC coactivator to induce the expression of genes involved in the assembly CC of collagen extracellular matrix (PubMed:25310401). Interacts with DLX1 CC (PubMed:14671321). Interacts with ZBTB7A; the interaction is direct and CC stimulated by TGFB1 (PubMed:25514493). Interacts with CREBBP; the CC recruitment of this transcriptional coactivator is negatively regulated CC by ZBTB7A (PubMed:25514493). Interacts with EP300; the interaction with CC this transcriptional coactivator is negatively regulated by ZBTB7A CC (PubMed:25514493). Interacts with HDAC1 (PubMed:25514493). Interacts CC (via MH2 domain) with ZMIZ1 (via SP-RING-type domain); in the TGF-beta CC signaling pathway increases the activity of the SMAD3/SMAD4 CC transcriptional complex (PubMed:16777850). Interacts (via N-terminus) CC with TSC22D1 (PubMed:15881652). {ECO:0000250|UniProtKB:O70437, CC ECO:0000250|UniProtKB:P97471, ECO:0000269|PubMed:10660046, CC ECO:0000269|PubMed:11224571, ECO:0000269|PubMed:11741830, CC ECO:0000269|PubMed:11818334, ECO:0000269|PubMed:12370310, CC ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:14525983, CC ECO:0000269|PubMed:14630787, ECO:0000269|PubMed:14671321, CC ECO:0000269|PubMed:15350224, ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:15820681, ECO:0000269|PubMed:15881652, CC ECO:0000269|PubMed:16777850, ECO:0000269|PubMed:17099224, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:18568018, CC ECO:0000269|PubMed:19135894, ECO:0000269|PubMed:24324267, CC ECO:0000269|PubMed:25310401, ECO:0000269|PubMed:25514493, CC ECO:0000269|PubMed:26878725, ECO:0000269|PubMed:9670020, CC ECO:0000269|PubMed:9707553}. CC -!- INTERACTION: CC Q13485; P36896: ACVR1B; NbExp=4; IntAct=EBI-347263, EBI-1384128; CC Q13485; P31749: AKT1; NbExp=6; IntAct=EBI-347263, EBI-296087; CC Q13485; P05067: APP; NbExp=3; IntAct=EBI-347263, EBI-77613; CC Q13485; P10398: ARAF; NbExp=6; IntAct=EBI-347263, EBI-365961; CC Q13485; Q92747: ARPC1A; NbExp=6; IntAct=EBI-347263, EBI-1020827; CC Q13485; Q9Y2T1: AXIN2; NbExp=4; IntAct=EBI-347263, EBI-4400025; CC Q13485; Q9NXR7: BABAM2; NbExp=5; IntAct=EBI-347263, EBI-949389; CC Q13485; P62324: BTG1; NbExp=4; IntAct=EBI-347263, EBI-742279; CC Q13485; Q9Y297: BTRC; NbExp=2; IntAct=EBI-347263, EBI-307461; CC Q13485; Q96HB5: CCDC120; NbExp=4; IntAct=EBI-347263, EBI-744556; CC Q13485; P24385: CCND1; NbExp=4; IntAct=EBI-347263, EBI-375001; CC Q13485; Q00534: CDK6; NbExp=3; IntAct=EBI-347263, EBI-295663; CC Q13485; P17676: CEBPB; NbExp=2; IntAct=EBI-347263, EBI-969696; CC Q13485; Q969H4: CNKSR1; NbExp=5; IntAct=EBI-347263, EBI-741671; CC Q13485; Q9UI36: DACH1; NbExp=7; IntAct=EBI-347263, EBI-347111; CC Q13485; Q9NPI6: DCP1A; NbExp=5; IntAct=EBI-347263, EBI-374238; CC Q13485; Q92988: DLX4; NbExp=5; IntAct=EBI-347263, EBI-1752755; CC Q13485; P29320: EPHA3; NbExp=6; IntAct=EBI-347263, EBI-1641575; CC Q13485; P21860: ERBB3; NbExp=6; IntAct=EBI-347263, EBI-720706; CC Q13485; P43268-3: ETV4; NbExp=3; IntAct=EBI-347263, EBI-12130722; CC Q13485; Q01844: EWSR1; NbExp=3; IntAct=EBI-347263, EBI-739737; CC Q13485; Q00597: FANCC; NbExp=5; IntAct=EBI-347263, EBI-81625; CC Q13485; Q9NW38: FANCL; NbExp=6; IntAct=EBI-347263, EBI-2339898; CC Q13485; Q9GZV9: FGF23; NbExp=3; IntAct=EBI-347263, EBI-6594125; CC Q13485; Q12778: FOXO1; NbExp=5; IntAct=EBI-347263, EBI-1108782; CC Q13485; O43524: FOXO3; NbExp=12; IntAct=EBI-347263, EBI-1644164; CC Q13485; P98177: FOXO4; NbExp=2; IntAct=EBI-347263, EBI-4481939; CC Q13485; P23769: GATA2; NbExp=10; IntAct=EBI-347263, EBI-2806671; CC Q13485; Q14344: GNA13; NbExp=5; IntAct=EBI-347263, EBI-465387; CC Q13485; P78333: GPC5; NbExp=5; IntAct=EBI-347263, EBI-2558325; CC Q13485; P49841: GSK3B; NbExp=5; IntAct=EBI-347263, EBI-373586; CC Q13485; Q13547: HDAC1; NbExp=7; IntAct=EBI-347263, EBI-301834; CC Q13485; P20823: HNF1A; NbExp=5; IntAct=EBI-347263, EBI-636034; CC Q13485; P01112: HRAS; NbExp=5; IntAct=EBI-347263, EBI-350145; CC Q13485; P23458: JAK1; NbExp=5; IntAct=EBI-347263, EBI-1383438; CC Q13485; P52333: JAK3; NbExp=3; IntAct=EBI-347263, EBI-518246; CC Q13485; Q8WZ60: KLHL6; NbExp=6; IntAct=EBI-347263, EBI-6426464; CC Q13485; Q9P2J3: KLHL9; NbExp=3; IntAct=EBI-347263, EBI-2510152; CC Q13485; O95835: LATS1; NbExp=7; IntAct=EBI-347263, EBI-444209; CC Q13485; P61968: LMO4; NbExp=8; IntAct=EBI-347263, EBI-2798728; CC Q13485; Q8N653: LZTR1; NbExp=5; IntAct=EBI-347263, EBI-2350056; CC Q13485; Q96RN5: MED15; NbExp=2; IntAct=EBI-347263, EBI-394506; CC Q13485; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-347263, EBI-10271199; CC Q13485; Q9UBE8: NLK; NbExp=6; IntAct=EBI-347263, EBI-366978; CC Q13485; P29474: NOS3; NbExp=4; IntAct=EBI-347263, EBI-1391623; CC Q13485; Q04721: NOTCH2; NbExp=5; IntAct=EBI-347263, EBI-2652733; CC Q13485; P24468: NR2F2; NbExp=4; IntAct=EBI-347263, EBI-2795198; CC Q13485; Q16620: NTRK2; NbExp=4; IntAct=EBI-347263, EBI-3904881; CC Q13485; Q8TE49: OTUD7A; NbExp=4; IntAct=EBI-347263, EBI-1049564; CC Q13485; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-347263, EBI-2803703; CC Q13485; P42338: PIK3CB; NbExp=3; IntAct=EBI-347263, EBI-2609540; CC Q13485; P28340: POLD1; NbExp=7; IntAct=EBI-347263, EBI-716569; CC Q13485; Q16633: POU2AF1; NbExp=3; IntAct=EBI-347263, EBI-943588; CC Q13485; O00743: PPP6C; NbExp=4; IntAct=EBI-347263, EBI-359751; CC Q13485; P04049: RAF1; NbExp=6; IntAct=EBI-347263, EBI-365996; CC Q13485; Q8WWW0: RASSF5; NbExp=7; IntAct=EBI-347263, EBI-367390; CC Q13485; Q8NHQ8: RASSF8; NbExp=5; IntAct=EBI-347263, EBI-306805; CC Q13485; Q04206: RELA; NbExp=5; IntAct=EBI-347263, EBI-73886; CC Q13485; P21912: SDHB; NbExp=5; IntAct=EBI-347263, EBI-1056481; CC Q13485; O95754: SEMA4F; NbExp=5; IntAct=EBI-347263, EBI-20855345; CC Q13485; P29353: SHC1; NbExp=5; IntAct=EBI-347263, EBI-78835; CC Q13485; P12755: SKI; NbExp=16; IntAct=EBI-347263, EBI-347281; CC Q13485; P12757: SKIL; NbExp=6; IntAct=EBI-347263, EBI-2902468; CC Q13485; Q13309: SKP2; NbExp=5; IntAct=EBI-347263, EBI-456291; CC Q13485; Q15797: SMAD1; NbExp=18; IntAct=EBI-347263, EBI-1567153; CC Q13485; Q15796: SMAD2; NbExp=31; IntAct=EBI-347263, EBI-1040141; CC Q13485; P84022: SMAD3; NbExp=43; IntAct=EBI-347263, EBI-347161; CC Q13485; Q13485: SMAD4; NbExp=7; IntAct=EBI-347263, EBI-347263; CC Q13485; O15198: SMAD9; NbExp=4; IntAct=EBI-347263, EBI-748763; CC Q13485; O15198-2: SMAD9; NbExp=3; IntAct=EBI-347263, EBI-12273450; CC Q13485; O15524: SOCS1; NbExp=4; IntAct=EBI-347263, EBI-968198; CC Q13485; P08047: SP1; NbExp=2; IntAct=EBI-347263, EBI-298336; CC Q13485; Q08117-2: TLE5; NbExp=3; IntAct=EBI-347263, EBI-11741437; CC Q13485; Q9UPN9: TRIM33; NbExp=6; IntAct=EBI-347263, EBI-2214398; CC Q13485; P16473: TSHR; NbExp=6; IntAct=EBI-347263, EBI-13939599; CC Q13485; P63279: UBE2I; NbExp=6; IntAct=EBI-347263, EBI-80168; CC Q13485; Q93008: USP9X; NbExp=2; IntAct=EBI-347263, EBI-302524; CC Q13485; Q9UPY6: WASF3; NbExp=6; IntAct=EBI-347263, EBI-3907133; CC Q13485; Q15915: ZIC1; NbExp=3; IntAct=EBI-347263, EBI-11963196; CC Q13485; P70056: foxh1; Xeno; NbExp=2; IntAct=EBI-347263, EBI-9969973; CC Q13485; P70398: Usp9x; Xeno; NbExp=4; IntAct=EBI-347263, EBI-2214043; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:17327236}. Nucleus {ECO:0000269|PubMed:15799969}. CC Note=Cytoplasmic in the absence of ligand. Migrates to the nucleus when CC complexed with R-SMAD (PubMed:15799969). PDPK1 prevents its nuclear CC translocation in response to TGF-beta (PubMed:17327236). CC {ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:17327236}. CC -!- DOMAIN: The MH1 domain is required for DNA binding. CC -!- DOMAIN: The MH2 domain is required for both homomeric and heteromeric CC interactions and for transcriptional regulation. Sufficient for nuclear CC import. CC -!- PTM: Phosphorylated by PDPK1. {ECO:0000269|PubMed:17327236}. CC -!- PTM: Monoubiquitinated on Lys-519 by E3 ubiquitin-protein ligase CC TRIM33. Monoubiquitination hampers its ability to form a stable complex CC with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP CC signaling cascade. Deubiquitination by USP9X restores its competence to CC mediate TGF-beta signaling. {ECO:0000269|PubMed:19135894}. CC -!- DISEASE: Pancreatic cancer (PNCA) [MIM:260350]: A malignant neoplasm of CC the pancreas. Tumors can arise from both the exocrine and endocrine CC portions of the pancreas, but 95% of them develop from the exocrine CC portion, including the ductal epithelium, acinar cells, connective CC tissue, and lymphatic tissue. {ECO:0000269|PubMed:8553070}. Note=The CC gene represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal CC dominant gastrointestinal hamartomatous polyposis syndrome in which CC patients are at risk for developing gastrointestinal cancers. The CC lesions are typified by a smooth histological appearance, predominant CC stroma, cystic spaces and lack of a smooth muscle core. Multiple CC juvenile polyps usually occur in a number of Mendelian disorders. CC Sometimes, these polyps occur without associated features as in JPS; CC here, polyps tend to occur in the large bowel and are associated with CC an increased risk of colon and other gastrointestinal cancers. CC {ECO:0000269|PubMed:12417513, ECO:0000269|PubMed:9811934}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Juvenile polyposis/hereditary hemorrhagic telangiectasia CC syndrome (JP/HHT) [MIM:175050]: JP/HHT syndrome phenotype consists of CC the coexistence of juvenile polyposis (JIP) and hereditary hemorrhagic CC telangiectasia (HHT) [MIM:187300] in a single individual. JIP and HHT CC are autosomal dominant disorders with distinct and non-overlapping CC clinical features. The former, an inherited gastrointestinal malignancy CC predisposition, is caused by mutations in SMAD4 or BMPR1A, and the CC latter is a vascular malformation disorder caused by mutations in ENG CC or ACVRL1. All four genes encode proteins involved in the transforming- CC growth-factor-signaling pathway. Although there are reports of patients CC and families with phenotypes of both disorders combined, the genetic CC etiology of this association is unknown. {ECO:0000269|PubMed:15031030}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:16959974}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Note=SMAD4 variants may be associated with susceptibility to CC pulmonary hypertension, a disorder characterized by plexiform lesions CC of proliferating endothelial cells in pulmonary arterioles. The lesions CC lead to elevated pulmonary arterial pression, right ventricular CC failure, and death. The disease can occur from infancy throughout life CC and it has a mean age at onset of 36 years. Penetrance is reduced. CC Although familial pulmonary hypertension is rare, cases secondary to CC known etiologies are more common and include those associated with the CC appetite-suppressant drugs. {ECO:0000269|PubMed:21898662}. CC -!- DISEASE: Myhre syndrome (MYHRS) [MIM:139210]: An autosomal dominant CC syndrome characterized by pre- and postnatal growth deficiency, CC intellectual disability, generalized muscle hypertrophy and striking CC muscular build, decreased joint mobility, cryptorchidism, and unusual CC facies. Dysmorphic facial features include microcephaly, midface CC hypoplasia, prognathism, and blepharophimosis. Typical skeletal CC anomalies are short stature, square body shape, broad ribs, iliac CC hypoplasia, brachydactyly, flattened vertebrae, and thickened calvaria. CC Other features, such as congenital heart disease, may also occur. CC {ECO:0000269|PubMed:22158539, ECO:0000269|PubMed:22243968}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/371/SMAD4"; CC -!- WEB RESOURCE: Name=Mendelian genes SMAD family member 4 (SMAD4); CC Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/SMAD4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045447; AAC03051.1; -; Genomic_DNA. DR EMBL; AF045438; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045439; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045440; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045441; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045442; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045443; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045444; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045445; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045446; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; U44378; AAA91041.1; -; mRNA. DR EMBL; AK290770; BAF83459.1; -; mRNA. DR EMBL; CH471096; EAW62985.1; -; Genomic_DNA. DR EMBL; BC002379; AAH02379.1; -; mRNA. DR CCDS; CCDS11950.1; -. DR PIR; S71811; S71811. DR RefSeq; NP_001393970.1; NM_001407041.1. DR RefSeq; NP_001393971.1; NM_001407042.1. DR RefSeq; NP_005350.1; NM_005359.6. DR PDB; 1DD1; X-ray; 2.62 A; A/B/C=285-552. DR PDB; 1G88; X-ray; 3.00 A; A/B/C=285-552. DR PDB; 1MR1; X-ray; 2.85 A; A/B=319-552. DR PDB; 1U7F; X-ray; 2.60 A; B=314-552. DR PDB; 1U7V; X-ray; 2.70 A; B=314-549. DR PDB; 1YGS; X-ray; 2.10 A; A=319-552. DR PDB; 5C4V; X-ray; 2.60 A; A/C/E=314-549. DR PDB; 5MEY; X-ray; 2.05 A; A=10-140. DR PDB; 5MEZ; X-ray; 2.98 A; A/B=10-140. DR PDB; 5MF0; X-ray; 3.03 A; A/B=10-140. DR PDB; 5UWU; X-ray; 2.24 A; D=133-149. DR PDB; 6YIC; X-ray; 1.60 A; P=398-406. DR PDBsum; 1DD1; -. DR PDBsum; 1G88; -. DR PDBsum; 1MR1; -. DR PDBsum; 1U7F; -. DR PDBsum; 1U7V; -. DR PDBsum; 1YGS; -. DR PDBsum; 5C4V; -. DR PDBsum; 5MEY; -. DR PDBsum; 5MEZ; -. DR PDBsum; 5MF0; -. DR PDBsum; 5UWU; -. DR PDBsum; 6YIC; -. DR AlphaFoldDB; Q13485; -. DR SASBDB; Q13485; -. DR SMR; Q13485; -. DR BioGRID; 110264; 532. DR ComplexPortal; CPX-1; SMAD2-SMAD3-SMAD4 complex. DR ComplexPortal; CPX-3208; SMAD2-SMAD4 complex. DR ComplexPortal; CPX-3252; SMAD3-SMAD4 complex. DR ComplexPortal; CPX-54; SMAD1-SMAD4 complex. DR CORUM; Q13485; -. DR DIP; DIP-31512N; -. DR FunCoup; Q13485; 4708. DR IntAct; Q13485; 524. DR MINT; Q13485; -. DR STRING; 9606.ENSP00000341551; -. DR GlyCosmos; Q13485; 5 sites, 1 glycan. DR GlyGen; Q13485; 10 sites, 1 O-linked glycan (10 sites). DR iPTMnet; Q13485; -. DR MetOSite; Q13485; -. DR PhosphoSitePlus; Q13485; -. DR SwissPalm; Q13485; -. DR BioMuta; SMAD4; -. DR DMDM; 13959561; -. DR CPTAC; CPTAC-1268; -. DR CPTAC; CPTAC-1269; -. DR jPOST; Q13485; -. DR MassIVE; Q13485; -. DR PaxDb; 9606-ENSP00000341551; -. DR PeptideAtlas; Q13485; -. DR ProteomicsDB; 59479; -. DR Pumba; Q13485; -. DR Antibodypedia; 3711; 1151 antibodies from 45 providers. DR DNASU; 4089; -. DR Ensembl; ENST00000342988.8; ENSP00000341551.3; ENSG00000141646.18. DR Ensembl; ENST00000398417.6; ENSP00000381452.1; ENSG00000141646.18. DR Ensembl; ENST00000588860.6; ENSP00000465878.2; ENSG00000141646.18. DR Ensembl; ENST00000589076.6; ENSP00000466934.2; ENSG00000141646.18. DR Ensembl; ENST00000589941.2; ENSP00000465874.2; ENSG00000141646.18. DR Ensembl; ENST00000590061.2; ENSP00000464772.2; ENSG00000141646.18. DR GeneID; 4089; -. DR KEGG; hsa:4089; -. DR MANE-Select; ENST00000342988.8; ENSP00000341551.3; NM_005359.6; NP_005350.1. DR UCSC; uc010xdp.3; human. DR AGR; HGNC:6770; -. DR CIViC; 4089; 29 evidence items across 22 molecular profiles. DR ClinPGx; PA30527; -. DR CTD; 4089; -. DR DisGeNET; 4089; -. DR GeneCards; SMAD4; -. DR GeneReviews; SMAD4; -. DR HGNC; HGNC:6770; SMAD4. DR HPA; ENSG00000141646; Low tissue specificity. DR MalaCards; SMAD4; -. DR MIM; 114500; phenotype. DR MIM; 139210; phenotype. DR MIM; 174900; phenotype. DR MIM; 175050; phenotype. DR MIM; 260350; phenotype. DR MIM; 600993; gene. DR OpenTargets; ENSG00000141646; -. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli. DR Orphanet; 774; Hereditary hemorrhagic telangiectasia. DR Orphanet; 2588; Myhre syndrome. DR VEuPathDB; HostDB:ENSG00000141646; -. DR eggNOG; KOG3701; Eukaryota. DR GeneTree; ENSGT00940000157435; -. DR InParanoid; Q13485; -. DR OMA; CWIEVQI; -. DR OrthoDB; 5875866at2759; -. DR PAN-GO; Q13485; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q13485; -. DR PathwayCommons; Q13485; -. DR Reactome; R-HSA-1181150; Signaling by NODAL. DR Reactome; R-HSA-1502540; Signaling by Activin. DR Reactome; R-HSA-201451; Signaling by BMP. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-3311021; SMAD4 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8941326; RUNX2 regulates bone development. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription. DR Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes. DR Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes. DR Reactome; R-HSA-9733709; Cardiogenesis. DR Reactome; R-HSA-9735871; SARS-CoV-1 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9839394; TGFBR3 expression. DR Reactome; R-HSA-9844594; Transcriptional regulation of brown and beige adipocyte differentiation by EBF2. DR SignaLink; Q13485; -. DR SIGNOR; Q13485; -. DR Agora; ENSG00000141646; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4089; 81 hits in 1216 CRISPR screens. DR ChiTaRS; SMAD4; human. DR EvolutionaryTrace; Q13485; -. DR GeneWiki; Mothers_against_decapentaplegic_homolog_4; -. DR GenomeRNAi; 4089; -. DR Pharos; Q13485; Tbio. DR PRO; PR:Q13485; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; Q13485; protein. DR Bgee; ENSG00000141646; Expressed in ventricular zone and 198 other cell types or tissues. DR ExpressionAtlas; Q13485; baseline and differential. DR GO; GO:0032444; C:activin responsive factor complex; IDA:BHF-UCL. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0097542; C:ciliary tip; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0071144; C:heteromeric SMAD protein complex; IPI:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0071141; C:SMAD protein complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0005518; F:collagen binding; IEA:Ensembl. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:BHF-UCL. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0031005; F:filamin binding; IEA:Ensembl. DR GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IEA:Ensembl. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0043199; F:sulfate binding; IMP:CAFA. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB. DR GO; GO:0001222; F:transcription corepressor binding; IPI:HGNC-UCL. DR GO; GO:0032924; P:activin receptor signaling pathway; NAS:ComplexPortal. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0036302; P:atrioventricular canal development; ISS:BHF-UCL. DR GO; GO:0003190; P:atrioventricular valve formation; ISS:BHF-UCL. DR GO; GO:0007411; P:axon guidance; IEA:Ensembl. DR GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL. DR GO; GO:0003360; P:brainstem development; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0003161; P:cardiac conduction system development; NAS:BHF-UCL. DR GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0008283; P:cell population proliferation; IEA:Ensembl. DR GO; GO:0071773; P:cellular response to BMP stimulus; NAS:BHF-UCL. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IMP:BHF-UCL. DR GO; GO:0048589; P:developmental growth; IEA:Ensembl. DR GO; GO:0006351; P:DNA-templated transcription; IDA:ComplexPortal. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0060956; P:endocardial cell differentiation; ISS:BHF-UCL. DR GO; GO:0042118; P:endothelial cell activation; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:BHF-UCL. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; IEA:Ensembl. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0061040; P:female gonad morphogenesis; IEA:Ensembl. DR GO; GO:0048859; P:formation of anatomical boundary; IEA:Ensembl. DR GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0070102; P:interleukin-6-mediated signaling pathway; ISS:BHF-UCL. DR GO; GO:0006879; P:intracellular iron ion homeostasis; ISS:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IMP:CACAO. DR GO; GO:0003220; P:left ventricular cardiac muscle tissue morphogenesis; ISS:BHF-UCL. DR GO; GO:0048382; P:mesendoderm development; IEA:Ensembl. DR GO; GO:0072133; P:metanephric mesenchyme morphogenesis; IEA:Ensembl. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; ISS:BHF-UCL. DR GO; GO:1905305; P:negative regulation of cardiac myofibril assembly; ISS:BHF-UCL. DR GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:BHF-UCL. DR GO; GO:0072134; P:nephrogenic mesenchyme morphogenesis; IEA:Ensembl. DR GO; GO:0014033; P:neural crest cell differentiation; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IMP:BHF-UCL. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0003251; P:positive regulation of cell proliferation involved in heart valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:BHF-UCL. DR GO; GO:1901203; P:positive regulation of extracellular matrix assembly; IMP:BHF-UCL. DR GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IEA:Ensembl. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:GO_Central. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:0051797; P:regulation of hair follicle development; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0032909; P:regulation of transforming growth factor beta2 production; IMP:BHF-UCL. DR GO; GO:0001666; P:response to hypoxia; IMP:BHF-UCL. DR GO; GO:0071559; P:response to transforming growth factor beta; IDA:UniProtKB. DR GO; GO:0048733; P:sebaceous gland development; IEA:Ensembl. DR GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL. DR GO; GO:0072520; P:seminiferous tubule development; IEA:Ensembl. DR GO; GO:0007338; P:single fertilization; IEA:Ensembl. DR GO; GO:0060395; P:SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0032525; P:somite rostral/caudal axis specification; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0060065; P:uterus development; IEA:Ensembl. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd10492; MH1_SMAD_4; 1. DR CDD; cd10498; MH2_SMAD_4; 1. DR DisProt; DP00464; -. DR FunFam; 2.60.200.10:FF:000002; Mothers against decapentaplegic homolog; 1. DR FunFam; 3.90.520.10:FF:000002; Mothers against decapentaplegic homolog; 1. DR Gene3D; 2.60.200.10; -; 1. DR Gene3D; 3.90.520.10; SMAD MH1 domain; 1. DR IDEAL; IID00132; -. DR InterPro; IPR013790; Dwarfin. DR InterPro; IPR003619; MAD_homology1_Dwarfin-type. DR InterPro; IPR013019; MAD_homology_MH1. DR InterPro; IPR017855; SMAD-like_dom_sf. DR InterPro; IPR001132; SMAD_dom_Dwarfin-type. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR InterPro; IPR036578; SMAD_MH1_sf. DR PANTHER; PTHR13703:SF63; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG 4; 1. DR PANTHER; PTHR13703; SMAD; 1. DR Pfam; PF03165; MH1; 1. DR Pfam; PF03166; MH2; 1. DR SMART; SM00523; DWA; 1. DR SMART; SM00524; DWB; 1. DR SUPFAM; SSF56366; SMAD MH1 domain; 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS51075; MH1; 1. DR PROSITE; PS51076; MH2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Cytoplasm; Disease variant; DNA-binding; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation; Zinc. FT CHAIN 1..552 FT /note="SMAD family member 4" FT /id="PRO_0000090861" FT DOMAIN 18..142 FT /note="MH1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00438" FT DOMAIN 323..552 FT /note="MH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439" FT REGION 1..322 FT /note="Mediates interaction with ZBTB7A" FT /evidence="ECO:0000269|PubMed:25514493" FT REGION 44..69 FT /note="Required for interaction with TSC22D1" FT /evidence="ECO:0000269|PubMed:15881652" FT REGION 168..194 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 236..256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 275..320 FT /note="SAD" FT COMPBIAS 170..194 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 245..256 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 71 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 115 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 127 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT SITE 515 FT /note="Necessary for heterotrimerization" FT MOD_RES 37 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 428 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 507 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 113 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:28112733" FT CROSSLNK 519 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19135894" FT VARIANT 13 FT /note="N -> S (rare variant; found in a patient with FT pulmonary hypertension; uncertain significance; FT dbSNP:rs281875323)" FT /evidence="ECO:0000269|PubMed:21898662" FT /id="VAR_066870" FT VARIANT 130 FT /note="P -> S (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1555685186)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036475" FT VARIANT 330 FT /note="E -> G (in JPS; dbSNP:rs281875324)" FT /evidence="ECO:0000269|PubMed:12417513" FT /id="VAR_022833" FT VARIANT 351 FT /note="D -> N (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1057519739)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036476" FT VARIANT 352 FT /note="G -> R (in JP/HHT and JPS; dbSNP:rs121912581)" FT /evidence="ECO:0000269|PubMed:12417513, FT ECO:0000269|PubMed:15031030" FT /id="VAR_019571" FT VARIANT 361 FT /note="R -> C (in JPS; dbSNP:rs80338963)" FT /evidence="ECO:0000269|PubMed:9811934" FT /id="VAR_019572" FT VARIANT 361 FT /note="R -> H (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs377767347)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036477" FT VARIANT 386 FT /note="G -> D (in JP/HHT; dbSNP:rs121912580)" FT /evidence="ECO:0000269|PubMed:15031030" FT /id="VAR_019573" FT VARIANT 493 FT /note="D -> H (in pancreatic carcinoma; dbSNP:rs121912578)" FT /evidence="ECO:0000269|PubMed:8553070" FT /id="VAR_011380" FT VARIANT 500 FT /note="I -> M (in MYHRS; dbSNP:rs281875320)" FT /evidence="ECO:0000269|PubMed:22158539" FT /id="VAR_067602" FT VARIANT 500 FT /note="I -> T (in MYHRS; there is an enhanced levels of FT SMAD4 protein with lower levels of ubiquitinated SMAD4 FT fibroblasts compared to controls suggesting stabilization FT of the mutant protein; 8-fold increase in phosphorylated FT SMAD2 and SMAD3; 11-fold increase in phosphorylated SMAD1, FT SMAD5 and SMAD8 in cell nuclei compared to controls; FT dbSNP:rs281875321)" FT /evidence="ECO:0000269|PubMed:22158539, FT ECO:0000269|PubMed:22243968" FT /id="VAR_067603" FT VARIANT 500 FT /note="I -> V (in MYHRS; dbSNP:rs281875322)" FT /evidence="ECO:0000269|PubMed:22158539, FT ECO:0000269|PubMed:22243968" FT /id="VAR_067604" FT MUTAGEN 416 FT /note="R->S: No effect on heterotrimerization. Partially FT diminished transcriptional activation." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 496 FT /note="R->S: No effect on heterotrimerization. Partially FT diminished transcriptional activation." FT MUTAGEN 502 FT /note="R->S: No effect on heterotrimerization. Greatly FT reduced transcriptional activation." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 515 FT /note="R->S: Reduced heterotrimerization." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 519 FT /note="K->R: Abolishes ubiquitination." FT /evidence="ECO:0000269|PubMed:19135894" FT HELIX 16..24 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 29..31 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 33..47 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 51..62 FT /evidence="ECO:0007829|PDB:5MEY" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 82..84 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 87..89 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 91..99 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 109..111 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 143..145 FT /evidence="ECO:0007829|PDB:5UWU" FT STRAND 288..291 FT /evidence="ECO:0007829|PDB:1DD1" FT STRAND 321..330 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 333..342 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 346..353 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 359..363 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 364..366 FT /evidence="ECO:0007829|PDB:1U7F" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 381..385 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 387..392 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 393..395 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 396..401 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 403..405 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 407..410 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 412..416 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 417..419 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 434..438 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 440..454 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 455..458 FT /evidence="ECO:0007829|PDB:1DD1" FT HELIX 461..464 FT /evidence="ECO:0007829|PDB:1DD1" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 500..506 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 518..520 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 521..529 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 530..541 FT /evidence="ECO:0007829|PDB:1YGS" SQ SEQUENCE 552 AA; 60439 MW; 7EE3C4647712DA90 CRC64; MDNMSITNTP TSNDACLSIV HSLMCHRQGG ESETFAKRAI ESLVKKLKEK KDELDSLITA ITTNGAHPSK CVTIQRTLDG RLQVAGRKGF PHVIYARLWR WPDLHKNELK HVKYCQYAFD LKCDSVCVNP YHYERVVSPG IDLSGLTLQS NAPSSMMVKD EYVHDFEGQP SLSTEGHSIQ TIQHPPSNRA STETYSTPAL LAPSESNATS TANFPNIPVA STSQPASILG GSHSEGLLQI ASGPQPGQQQ NGFTGQPATY HHNSTTTWTG SRTAPYTPNL PHHQNGHLQH HPPMPPHPGH YWPVHNELAF QPPISNHPAP EYWCSIAYFE MDVQVGETFK VPSSCPIVTV DGYVDPSGGD RFCLGQLSNV HRTEAIERAR LHIGKGVQLE CKGEGDVWVR CLSDHAVFVQ SYYLDREAGR APGDAVHKIY PSAYIKVFDL RQCHRQMQQQ AATAQAAAAA QAAAVAGNIP GPGSVGGIAP AISLSAAAGI GVDDLRRLCI LRMSFVKGWG PDYPRQSIKE TPCWIEIHLH RALQLLDEVL HTMPIADPQP LD // ID SMYD5_HUMAN Reviewed; 418 AA. AC Q6GMV2; D6W5H3; Q13558; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 150. DE RecName: Full=Protein-lysine N-trimethyltransferase SMYD5 {ECO:0000305}; DE EC=2.1.1.- {ECO:0000269|PubMed:39048817, ECO:0000269|PubMed:39103523}; DE AltName: Full=Protein NN8-4AG; DE AltName: Full=Retinoic acid-induced protein 15 {ECO:0000303|PubMed:8754834}; DE AltName: Full=SET and MYND domain-containing protein 5 {ECO:0000303|PubMed:28951459}; DE AltName: Full=[histone H3]-lysine20 N-trimethyltransferase SMYD5; DE EC=2.1.1.372 {ECO:0000250|UniProtKB:Q3TYX3}; DE AltName: Full=[histone H4]-lysine36 N-trimethyltransferase SMYD5; DE EC=2.1.1.359 {ECO:0000250|UniProtKB:Q3TYX3}; GN Name=SMYD5 {ECO:0000303|PubMed:28951459, ECO:0000312|HGNC:HGNC:16258}; GN Synonyms=RAI15 {ECO:0000303|PubMed:8754834}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] OF 7-418. RC TISSUE=Brain; RX PubMed=8754834; DOI=10.1128/mcb.16.8.4337; RA Shago M., Giguere V.; RT "Isolation of a novel retinoic acid-responsive gene by selection of genomic RT fragments derived from CpG-island-enriched DNA."; RL Mol. Cell. Biol. 16:4337-4348(1996). RN [4] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [5] RP FUNCTION. RX PubMed=28951459; DOI=10.1158/0008-5472.can-17-0828; RA Kidder B.L., He R., Wangsa D., Padilla-Nash H.M., Bernardo M.M., Sheng S., RA Ried T., Zhao K.; RT "SMYD5 Controls Heterochromatin and Chromosome Integrity during Embryonic RT Stem Cell Differentiation."; RL Cancer Res. 77:6729-6745(2017). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=39103523; DOI=10.1038/s41422-024-01013-3; RA Miao B., Ge L., He C., Wang X., Wu J., Li X., Chen K., Wan J., Xing S., RA Ren L., Shi Z., Liu S., Hu Y., Chen J., Yu Y., Feng L., Flores N.M., RA Liang Z., Xu X., Wang R., Zhou J., Fan J., Xiang B., Li E., Mao Y., RA Cheng J., Zhao K., Mazur P.K., Cai J., Lan F.; RT "SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine RT methylation to enhance translation output and promote hepatocellular RT carcinoma."; RL Cell Res. 0:0-0(2024). RN [7] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INDUCTION, AND RP MUTAGENESIS OF TYR-351. RX PubMed=39048817; DOI=10.1038/s41586-024-07718-0; RA Park J., Wu J., Szkop K.J., Jeong J., Jovanovic P., Husmann D., RA Flores N.M., Francis J.W., Chen Y.C., Benitez A.M., Zahn E., Song S., RA Ajani J.A., Wang L., Singh K., Larsson O., Garcia B.A., Topisirovic I., RA Gozani O., Mazur P.K.; RT "SMYD5 methylation of rpL40 links ribosomal output to gastric cancer."; RL Nature 0:0-0(2024). CC -!- FUNCTION: Protein-lysine N-trimethyltransferase that specifically CC catalyzes trimethylation of 'Lys-22' of the RPL40/eL40 subunit of the CC 60S ribosome, thereby promoting translation elongation and protein CC synthesis (PubMed:39048817, PubMed:39103523). May also act as a histone CC methyltransferase in the context of histone octamers, but not on CC nucleosome substrates: trimethylates 'Lys-36' of histone H3 and 'Lys- CC 20' of histone H4 to form H3K36me3 and H4K20me3, respectively (By CC similarity). The histone methyltransferase activity, which is CC independent of its SET domain, is however unsure in vivo CC (PubMed:39048817, PubMed:39103523). In association with the NCoR CC corepressor complex, involved in the repression of toll-like receptor 4 CC (TLR4)-target inflammatory genes in macrophages, possibly by catalyzing CC the formation of H4K20me3 at the gene promoters (By similarity). Plays CC an important role in embryonic stem (ES) cell self-renewal and CC differentiation (By similarity). Maintains genome stability of ES cells CC during differentiation through regulation of heterochromatin formation CC and repression of endogenous repetitive DNA elements by promoting CC H4K20me3 marks (PubMed:28951459). Acts as a regulator of the CC hypothermia response: its degradation in response to mild hypothermia CC relieves the formation of H3K36me3 at gene promoters, allowing CC expression of the neuroprotective gene SP1 (By similarity). CC {ECO:0000250|UniProtKB:Q3TYX3, ECO:0000269|PubMed:28951459, CC ECO:0000269|PubMed:39048817, ECO:0000269|PubMed:39103523}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-lysyl-[protein] + 3 S-adenosyl-L-methionine = CC N(6),N(6),N(6)-trimethyl-L-lysyl-[protein] + 3 S-adenosyl-L- CC homocysteine + 3 H(+); Xref=Rhea:RHEA:54192, Rhea:RHEA-COMP:9752, CC Rhea:RHEA-COMP:13826, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, CC ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:61961; CC Evidence={ECO:0000269|PubMed:39048817, ECO:0000269|PubMed:39103523}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54193; CC Evidence={ECO:0000269|PubMed:39048817, ECO:0000269|PubMed:39103523}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-lysyl(20)-[histone H4] + 3 S-adenosyl-L-methionine = CC N(6),N(6),N(6)-trimethyl-L-lysyl(20)-[histone H4] + 3 S-adenosyl-L- CC homocysteine + 3 H(+); Xref=Rhea:RHEA:64456, Rhea:RHEA-COMP:15554, CC Rhea:RHEA-COMP:15998, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, CC ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:61961; CC EC=2.1.1.372; Evidence={ECO:0000250|UniProtKB:Q3TYX3}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-lysyl(36)-[histone H3] + 3 S-adenosyl-L-methionine = CC N(6),N(6),N(6)-trimethyl-L-lysyl(36)-[histone H3] + 3 S-adenosyl-L- CC homocysteine + 3 H(+); Xref=Rhea:RHEA:60324, Rhea:RHEA-COMP:9785, CC Rhea:RHEA-COMP:15536, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, CC ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:61961; CC EC=2.1.1.359; Evidence={ECO:0000250|UniProtKB:Q3TYX3}; CC -!- SUBUNIT: Interacts with the N-CoR complex (By similarity). Interacts CC with EHMT2 and CBX5 (By similarity). {ECO:0000250|UniProtKB:Q3TYX3}. CC -!- INTERACTION: CC Q6GMV2; Q8TAU3: ZNF417; NbExp=3; IntAct=EBI-11057552, EBI-740727; CC Q6GMV2; Q96SQ5: ZNF587; NbExp=3; IntAct=EBI-11057552, EBI-6427977; CC Q6GMV2; O70343: Ppargc1a; Xeno; NbExp=4; IntAct=EBI-11057552, EBI-1371053; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:39048817, CC ECO:0000269|PubMed:39103523}. CC -!- INDUCTION: Strongly up-regulated in gastric adenocarcinomas and CC hepatocellular carcinomas, driving malignant progression. CC {ECO:0000269|PubMed:39048817, ECO:0000269|PubMed:39103523}. CC -!- PTM: Ubiquitinated and degradaed by the proteasome in response to mild CC hypothermia (32 degrees Celsius), relieving repression of the SP1 gene. CC {ECO:0000250|UniProtKB:Q3TYX3}. CC -!- MISCELLANEOUS: Acts as a strong promoter of malignant progression of CC gastric adenocarcinoma and hepatocellular carcinoma via its ability to CC mediate trimethylation of 'Lys-22' of the RPL40/eL40 subunit of the 60S CC ribosome and increase protein synthesis (PubMed:39048817, CC PubMed:39103523). SMYD5 inhibition significantly decreases cancer CC progression, and renders cancer cells hypersensitive to inhibitors of CC PI3K and mTOR (PubMed:39048817, PubMed:39103523). CC {ECO:0000269|PubMed:39048817, ECO:0000269|PubMed:39103523}. CC -!- SIMILARITY: Belongs to the class V-like SAM-binding methyltransferase CC superfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH73806.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; CH471053; EAW99744.1; -; Genomic_DNA. DR EMBL; CH471053; EAW99745.1; -; Genomic_DNA. DR EMBL; BC073806; AAH73806.1; ALT_INIT; mRNA. DR EMBL; U50383; AAB38131.1; -; mRNA. DR CCDS; CCDS33221.2; -. DR PIR; G02453; G02453. DR RefSeq; NP_006053.2; NM_006062.3. DR AlphaFoldDB; Q6GMV2; -. DR SMR; Q6GMV2; -. DR BioGRID; 115606; 38. DR FunCoup; Q6GMV2; 507. DR IntAct; Q6GMV2; 14. DR MINT; Q6GMV2; -. DR STRING; 9606.ENSP00000374152; -. DR GlyGen; Q6GMV2; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6GMV2; -. DR PhosphoSitePlus; Q6GMV2; -. DR BioMuta; SMYD5; -. DR DMDM; 90101758; -. DR jPOST; Q6GMV2; -. DR MassIVE; Q6GMV2; -. DR PaxDb; 9606-ENSP00000374152; -. DR PeptideAtlas; Q6GMV2; -. DR ProteomicsDB; 66304; -. DR Pumba; Q6GMV2; -. DR Antibodypedia; 31318; 223 antibodies from 26 providers. DR DNASU; 10322; -. DR Ensembl; ENST00000389501.9; ENSP00000374152.4; ENSG00000135632.13. DR GeneID; 10322; -. DR KEGG; hsa:10322; -. DR MANE-Select; ENST00000389501.9; ENSP00000374152.4; NM_006062.3; NP_006053.2. DR UCSC; uc002siw.3; human. DR AGR; HGNC:16258; -. DR ClinPGx; PA34190; -. DR CTD; 10322; -. DR DisGeNET; 10322; -. DR GeneCards; SMYD5; -. DR HGNC; HGNC:16258; SMYD5. DR HPA; ENSG00000135632; Low tissue specificity. DR MIM; 619114; gene. DR OpenTargets; ENSG00000135632; -. DR VEuPathDB; HostDB:ENSG00000135632; -. DR eggNOG; KOG2084; Eukaryota. DR GeneTree; ENSGT00510000047420; -. DR HOGENOM; CLU_054216_0_0_1; -. DR InParanoid; Q6GMV2; -. DR OMA; LMAMYQQ; -. DR OrthoDB; 438641at2759; -. DR PAN-GO; Q6GMV2; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q6GMV2; -. DR PathwayCommons; Q6GMV2; -. DR SignaLink; Q6GMV2; -. DR Agora; ENSG00000135632; -. DR BioGRID-ORCS; 10322; 10 hits in 1166 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; SMYD5; human. DR EvolutionaryTrace; Q6GMV2; -. DR GenomeRNAi; 10322; -. DR Pharos; Q6GMV2; Tbio. DR PRO; PR:Q6GMV2; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q6GMV2; protein. DR Bgee; ENSG00000135632; Expressed in cortical plate and 127 other cell types or tissues. DR ExpressionAtlas; Q6GMV2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0140955; F:histone H3K36 trimethyltransferase activity; ISS:UniProtKB. DR GO; GO:0042799; F:histone H4K20 methyltransferase activity; ISS:UniProtKB. DR GO; GO:0140943; F:histone H4K20 trimethyltransferase activity; IEA:UniProtKB-EC. DR GO; GO:0016279; F:protein-lysine N-methyltransferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0032259; P:methylation; IEA:UniProtKB-KW. DR GO; GO:0045814; P:negative regulation of gene expression, epigenetic; ISS:UniProtKB. DR GO; GO:1900249; P:positive regulation of cytoplasmic translational elongation; IDA:UniProtKB. DR GO; GO:2000736; P:regulation of stem cell differentiation; IMP:UniProtKB. DR GO; GO:2000035; P:regulation of stem cell division; ISS:UniProtKB. DR GO; GO:0141005; P:transposable element silencing by heterochromatin formation; IMP:UniProtKB. DR CDD; cd10521; SET_SMYD5; 1. DR FunFam; 2.170.270.10:FF:000078; SMYD family member 5; 1. DR Gene3D; 1.10.220.160; -; 1. DR Gene3D; 6.10.140.2220; -; 1. DR Gene3D; 2.170.270.10; SET domain; 2. DR InterPro; IPR001214; SET_dom. DR InterPro; IPR046341; SET_dom_sf. DR InterPro; IPR044422; SMYD5_SET. DR PANTHER; PTHR46402:SF2; HISTONE-LYSINE N-TRIMETHYLTRANSFERASE SMYD5; 1. DR PANTHER; PTHR46402; SET AND MYND DOMAIN-CONTAINING PROTEIN 5; 1. DR Pfam; PF00856; SET; 1. DR SMART; SM00317; SET; 1. DR SUPFAM; SSF82199; SET domain; 1. DR PROSITE; PS50280; SET; 1. PE 1: Evidence at protein level; KW Cytoplasm; Metal-binding; Methyltransferase; Proteomics identification; KW Reference proteome; S-adenosyl-L-methionine; Transferase; Ubl conjugation; KW Zinc; Zinc-finger. FT CHAIN 1..418 FT /note="Protein-lysine N-trimethyltransferase SMYD5" FT /id="PRO_0000227788" FT DOMAIN 21..352 FT /note="SET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00190" FT ZN_FING 98..136 FT /note="MYND-type" FT REGION 385..418 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 351 FT /ligand="S-adenosyl-L-methionine" FT /ligand_id="ChEBI:CHEBI:59789" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00190, FT ECO:0000305|PubMed:39048817" FT MUTAGEN 351 FT /note="Y->A: Abolished trimethylation of 'Lys-22' of the FT RPL40/eL40 subunit of the 60S ribosome." FT /evidence="ECO:0000269|PubMed:39048817" FT CONFLICT 7 FT /note="D -> A (in Ref. 3; AAB38131)" FT /evidence="ECO:0000305" FT CONFLICT 280..281 FT /note="QL -> HV (in Ref. 3; AAB38131)" FT /evidence="ECO:0000305" SQ SEQUENCE 418 AA; 47341 MW; 11073818FF5EEB83 CRC64; MAASMCDVFS FCVGVAGRAR VSVEVRFVSS AKGKGLFATQ LIRKGETIFV ERPLVAAQFL WNALYRYRAC DHCLRALEKA EENAQRLTGK PGQVLPHPEL CTVRKDLHQN CPHCQVMYCS AECRLAATEQ YHQVLCPGPS QDDPLHPLNK LQEAWRSIHY PPETASIMLM ARMVATVKQA KDKDRWIRLF SQFCNKTANE EEEIVHKLLG DKFKGQLELL RRLFTEALYE EAVSQWFTPD GFRSLFALVG TNGQGIGTSS LSQWVHACDT LELKPQDREQ LDAFIDQLYK DIEAATGEFL NCEGSGLFVL QSCCNHSCVP NAETSFPENN FLLHVTALED IKPGEEICIS YLDCCQRERS RHSRHKILRE NYLFVCSCPK CLAEADEPNV TSEEEEEEEE EEEGEPEDAE LGDEMTDV // ID SPEG_HUMAN Reviewed; 3267 AA. AC Q15772; A8K0G6; A8MRU0; Q27J74; Q695L1; Q6FGA6; Q6ZQW1; Q6ZTL8; Q9P2P9; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 16-DEC-2008, sequence version 4. DT 28-JAN-2026, entry version 210. DE RecName: Full=Striated muscle preferentially expressed protein kinase; DE EC=2.7.11.1; DE AltName: Full=Aortic preferentially expressed protein 1; DE Short=APEG-1; GN Name=SPEG; Synonyms=APEG1, KIAA1297; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND INDUCTION. RX PubMed=8663449; DOI=10.1074/jbc.271.29.17354; RA Hsieh C.-M., Yoshizumi M., Endege W.O., Kho C.-J., Jain M.K., Kashiki S., RA de Los Santos R., Lee W.-S., Perrella M.A., Lee M.-E.; RT "APEG-1, a novel gene preferentially expressed in aortic smooth muscle RT cells, is down-regulated by vascular injury."; RL J. Biol. Chem. 271:17354-17359(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Cerebellum, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12-129 (ISOFORM 1), AND ALTERNATIVE PROMOTER RP USAGE. RX PubMed=16545539; DOI=10.1016/j.ygeno.2006.01.009; RA Tam J.L.Y., Triantaphyllopoulos K., Todd H., Raguz S., de Wit T., RA Morgan J.E., Partridge T.A., Makrinou E., Grosveld F., Antoniou M.; RT "The human desmin locus: gene organization and LCR-mediated transcriptional RT control."; RL Genomics 87:733-746(2006). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 130-3267 (ISOFORM 1), TISSUE SPECIFICITY, AND RP VARIANT THR-2687. RX PubMed=15185077; DOI=10.1007/s00427-004-0413-5; RA Sutter S.B., Raeker M.O., Borisov A.B., Russell M.W.; RT "Orthologous relationship of obscurin and Unc-89: phylogeny of a novel RT family of tandem myosin light chain kinases."; RL Dev. Genes Evol. 214:352-359(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 982-3267 (ISOFORM 1), AND VARIANT RP THR-2687. RC TISSUE=Brain; RX PubMed=10718198; DOI=10.1093/dnares/7.1.65; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVI. The RT complete sequences of 150 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:65-73(2000). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-488, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (0.96 ANGSTROMS) OF 864-962, AND SUBUNIT. RX PubMed=16354304; DOI=10.1186/1472-6807-5-21; RA Manjasetty B.A., Niesen F.H., Scheich C., Roske Y., Goetz F., Behlke J., RA Sievert V., Heinemann U., Bussow K.; RT "X-ray structure of engineered human aortic preferentially expressed RT protein-1 (APEG-1)."; RL BMC Struct. Biol. 5:21-21(2005). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-206; CYS-934; GLN-966; LEU-1103; RP VAL-1135; ASP-1178; TRP-1234; GLN-1340; CYS-1621; TRP-1903; THR-2687; RP MET-2742 AND ARG-3079. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP INTERACTION WITH MTM1, INVOLVEMENT IN CNM5, AND VARIANT CNM5 VAL-2757. RX PubMed=25087613; DOI=10.1016/j.ajhg.2014.07.004; RA Agrawal P.B., Pierson C.R., Joshi M., Liu X., Ravenscroft G., RA Moghadaszadeh B., Talabere T., Viola M., Swanson L.C., Haliloglu G., RA Talim B., Yau K.S., Allcock R.J., Laing N.G., Perrella M.A., Beggs A.H.; RT "SPEG interacts with myotubularin, and its deficiency causes centronuclear RT myopathy with dilated cardiomyopathy."; RL Am. J. Hum. Genet. 95:218-226(2014). CC -!- FUNCTION: Isoform 3 may have a role in regulating the growth and CC differentiation of arterial smooth muscle cells. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with MTM1. Isoform 3 is found as a monomer or CC homodimer. {ECO:0000269|PubMed:16354304, ECO:0000269|PubMed:25087613}. CC -!- INTERACTION: CC Q15772; Q99873: PRMT1; NbExp=3; IntAct=EBI-1384196, EBI-78738; CC Q15772-4; O75031: HSF2BP; NbExp=3; IntAct=EBI-12175897, EBI-7116203; CC Q15772-4; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-12175897, EBI-16439278; CC Q15772-4; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-12175897, EBI-79165; CC Q15772-4; Q99873-3: PRMT1; NbExp=3; IntAct=EBI-12175897, EBI-17165527; CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=4; CC Name=4; CC IsoId=Q15772-5; Sequence=Displayed; CC Name=2; CC IsoId=Q15772-3; Sequence=VSP_018259, VSP_018261, VSP_018262; CC Name=3; Synonyms=APEG1; CC IsoId=Q15772-4; Sequence=VSP_018258, VSP_018261, VSP_018262; CC Name=1; Synonyms=SPEG; CC IsoId=Q15772-1; Sequence=VSP_036071; CC -!- TISSUE SPECIFICITY: Isoform 1 is preferentially expressed in striated CC muscle. Non-kinase form such as isoform 3 is predominantly expressed in CC the aorta. Isoform 3 appears to be expressed only in highly CC differentiated ASMC in normal vessel walls and down-regulated in CC dedifferentiated ASMC in vivo. In response to vascular injuries ASMC CC dedifferentiate and change from a quiescent and contractile phenotype CC to a proliferative and synthetic phenotype. This proliferation of CC vascular smooth muscle cells is one of the most prominent features of CC atherosclerosis. {ECO:0000269|PubMed:15185077, CC ECO:0000269|PubMed:8663449}. CC -!- INDUCTION: Isoform 3 is quickly down-regulated in response to vascular CC injury, when ASMC cells change from a quiescent to a proliferative CC phenotype. {ECO:0000269|PubMed:8663449}. CC -!- PTM: May be autophosphorylated. CC -!- DISEASE: Myopathy, centronuclear, 5 (CNM5) [MIM:615959]: A form of CC centronuclear myopathy, a congenital muscle disorder characterized by CC progressive muscular weakness and wasting involving mainly limb girdle, CC trunk, and neck muscles. It may also affect distal muscles. Weakness CC may be present during childhood or adolescence or may not become CC evident until the third decade of life. Ptosis is a frequent clinical CC feature. The most prominent histopathologic features include high CC frequency of centrally located nuclei in muscle fibers not secondary to CC regeneration, radial arrangement of sarcoplasmic strands around the CC central nuclei, and predominance and hypotrophy of type 1 fibers. CNM5 CC features include severe neonatal hypotonia with respiratory CC insufficiency, difficulty feeding, and delayed motor development. Some CC patients die in infancy, and some develop dilated cardiomyopathy. CC {ECO:0000269|PubMed:25087613}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Expression is under the tight control of the locus CC control region (LCRs). CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative splicing. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAY15052.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=ABD61734.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U57099; AAC50599.1; -; mRNA. DR EMBL; AK126500; BAC86568.1; -; mRNA. DR EMBL; AK289531; BAF82220.1; -; mRNA. DR EMBL; CR542201; CAG46998.1; -; mRNA. DR EMBL; AC053503; AAY15052.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH471063; EAW70747.1; -; Genomic_DNA. DR EMBL; BC006346; AAH06346.1; -; mRNA. DR EMBL; DQ395348; ABD61734.1; ALT_FRAME; mRNA. DR EMBL; AY603755; AAT80901.1; -; mRNA. DR EMBL; AB037718; BAA92535.1; -; mRNA. DR CCDS; CCDS42824.1; -. [Q15772-5] DR CCDS; CCDS54432.1; -. [Q15772-4] DR RefSeq; NP_001166947.1; NM_001173476.2. [Q15772-4] DR RefSeq; NP_005867.3; NM_005876.4. [Q15772-5] DR RefSeq; XP_047298873.1; XM_047442917.1. [Q15772-3] DR RefSeq; XP_047298874.1; XM_047442918.1. [Q15772-3] DR RefSeq; XP_047298875.1; XM_047442919.1. [Q15772-3] DR RefSeq; XP_047298876.1; XM_047442920.1. [Q15772-3] DR RefSeq; XP_047298877.1; XM_047442921.1. [Q15772-4] DR RefSeq; XP_047298878.1; XM_047442922.1. [Q15772-4] DR RefSeq; XP_047298879.1; XM_047442923.1. [Q15772-4] DR RefSeq; XP_054196142.1; XM_054340167.1. [Q15772-3] DR RefSeq; XP_054196143.1; XM_054340168.1. [Q15772-3] DR RefSeq; XP_054196144.1; XM_054340169.1. [Q15772-3] DR RefSeq; XP_054196145.1; XM_054340170.1. [Q15772-3] DR RefSeq; XP_054196146.1; XM_054340171.1. [Q15772-4] DR RefSeq; XP_054196147.1; XM_054340172.1. [Q15772-4] DR RefSeq; XP_054196148.1; XM_054340173.1. [Q15772-4] DR PDB; 1U2H; X-ray; 0.96 A; A=864-960. DR PDBsum; 1U2H; -. DR SMR; Q15772; -. DR BioGRID; 115579; 21. DR FunCoup; Q15772; 144. DR IntAct; Q15772; 13. DR STRING; 9606.ENSP00000311684; -. DR GlyCosmos; Q15772; 1 site, 1 glycan. DR GlyGen; Q15772; 8 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q15772; -. DR PhosphoSitePlus; Q15772; -. DR BioMuta; SPEG; -. DR DMDM; 218512143; -. DR jPOST; Q15772; -. DR MassIVE; Q15772; -. DR PaxDb; 9606-ENSP00000311684; -. DR PeptideAtlas; Q15772; -. DR ProteomicsDB; 60751; -. [Q15772-5] DR ProteomicsDB; 60752; -. [Q15772-1] DR ProteomicsDB; 60753; -. [Q15772-3] DR ProteomicsDB; 60754; -. [Q15772-4] DR Pumba; Q15772; -. DR Antibodypedia; 11575; 81 antibodies from 22 providers. DR DNASU; 10290; -. DR Ensembl; ENST00000312358.12; ENSP00000311684.7; ENSG00000072195.15. [Q15772-5] DR Ensembl; ENST00000396686.5; ENSP00000379917.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396688.5; ENSP00000379919.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396689.2; ENSP00000379920.2; ENSG00000072195.15. [Q15772-4] DR GeneID; 10290; -. DR KEGG; hsa:10290; -. DR MANE-Select; ENST00000312358.12; ENSP00000311684.7; NM_005876.5; NP_005867.3. DR UCSC; uc002vlq.4; human. [Q15772-5] DR AGR; HGNC:16901; -. DR ClinPGx; PA142672598; -. DR CTD; 10290; -. DR DisGeNET; 10290; -. DR GeneCards; SPEG; -. DR HGNC; HGNC:16901; SPEG. DR HPA; ENSG00000072195; Tissue enhanced (intestine). DR MalaCards; SPEG; -. DR MIM; 615950; gene. DR MIM; 615959; phenotype. DR OpenTargets; ENSG00000072195; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR VEuPathDB; HostDB:ENSG00000072195; -. DR eggNOG; KOG0032; Eukaryota. DR eggNOG; KOG0613; Eukaryota. DR GeneTree; ENSGT00940000161126; -. DR HOGENOM; CLU_000381_0_0_1; -. DR InParanoid; Q15772; -. DR OrthoDB; 2570713at2759; -. DR PAN-GO; Q15772; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q15772; -. DR PathwayCommons; Q15772; -. DR SignaLink; Q15772; -. DR SIGNOR; Q15772; -. DR Agora; ENSG00000072195; -. DR BioGRID-ORCS; 10290; 9 hits in 1166 CRISPR screens. DR ChiTaRS; SPEG; human. DR EvolutionaryTrace; Q15772; -. DR GeneWiki; SPEG; -. DR GenomeRNAi; 10290; -. DR Pharos; Q15772; Tbio. DR PRO; PR:Q15772; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15772; protein. DR Bgee; ENSG00000072195; Expressed in popliteal artery and 171 other cell types or tissues. DR ExpressionAtlas; Q15772; baseline and differential. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0042692; P:muscle cell differentiation; IBA:GO_Central. DR GO; GO:0007517; P:muscle organ development; TAS:ProtInc. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR CDD; cd00063; FN3; 2. DR CDD; cd20975; IgI_APEG-1_like; 1. DR CDD; cd14108; STKc_SPEG_rpt1; 1. DR CDD; cd14111; STKc_SPEG_rpt2; 1. DR FunFam; 2.60.40.10:FF:000080; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 2.60.40.10:FF:000145; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 1.10.510.10:FF:000363; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000497; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000538; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000784; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:001056; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000428; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000513; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000539; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000541; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000601; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000302; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000312; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 1.10.510.10:FF:000344; striated muscle preferentially expressed protein kinase isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 11. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR47633; IMMUNOGLOBULIN; 1. DR PANTHER; PTHR47633:SF3; STRIATED MUSCLE PREFERENTIALLY EXPRESSED PROTEIN KINASE; 1. DR Pfam; PF07679; I-set; 9. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF16650; SPEG_u2; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 9. DR SMART; SM00408; IGc2; 9. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 9. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 8. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Differentiation; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..3267 FT /note="Striated muscle preferentially expressed protein FT kinase" FT /id="PRO_0000072666" FT DOMAIN 43..124 FT /note="Ig-like 1" FT DOMAIN 722..810 FT /note="Ig-like 2" FT DOMAIN 869..958 FT /note="Ig-like 3" FT DOMAIN 963..1057 FT /note="Ig-like 4" FT DOMAIN 1064..1152 FT /note="Ig-like 5" FT DOMAIN 1188..1278 FT /note="Ig-like 6" FT DOMAIN 1285..1382 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1384..1480 FT /note="Ig-like 7" FT DOMAIN 1485..1573 FT /note="Ig-like 8" FT DOMAIN 1601..1854 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 2583..2673 FT /note="Ig-like 9" FT DOMAIN 2680..2774 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 2966..3218 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 132..227 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 276..714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 812..872 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1157..1180 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1906..2060 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2074..2239 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2253..2325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2339..2399 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2411..2452 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2466..2564 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2771..2896 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2909..2966 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 156..195 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 298..314 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 400..418 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 434..443 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 505..517 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 619..633 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 658..675 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 815..825 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 850..864 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2171..2180 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2188..2201 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2214..2224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2343..2354 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2355..2366 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2384..2395 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2466..2484 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2521..2540 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2806..2815 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2910..2924 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2937..2954 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1719 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 3085 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1607..1615 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 1630 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2972..2980 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2995 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 139 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 378 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 381 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 419 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 449 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 488 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 506 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 526 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 549 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 1128 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1172 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1988 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2014 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2015 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2037 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2055 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2055 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2109 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2139 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2177 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2376 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2380 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2410 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2414 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2439 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2448 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2521 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2524 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2559 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2771 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2774 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2949 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT DISULFID 989..1041 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2605..2657 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..849 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:8663449, ECO:0000303|Ref.3" FT /id="VSP_018258" FT VAR_SEQ 1..792 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_018259" FT VAR_SEQ 961..962 FT /note="AH -> GE (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018261" FT VAR_SEQ 963..3267 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018262" FT VAR_SEQ 3209..3267 FT /note="LQDCLAHPWLQDAYLMKLRRQTLTFTTNRLKEFLGEQRRRRAEAATRHKVLL FT RSYPGGP -> SCLSVCHKEIKMASS (in isoform 1)" FT /evidence="ECO:0000303|PubMed:10718198, FT ECO:0000303|PubMed:15185077, ECO:0000303|PubMed:16545539" FT /id="VSP_036071" FT VARIANT 206 FT /note="R -> H (in dbSNP:rs55821435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041101" FT VARIANT 934 FT /note="R -> C (in dbSNP:rs34398769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041102" FT VARIANT 966 FT /note="R -> Q (in dbSNP:rs34861443)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041103" FT VARIANT 1103 FT /note="P -> L (in dbSNP:rs56334571)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041104" FT VARIANT 1135 FT /note="A -> V (in dbSNP:rs55670811)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041105" FT VARIANT 1178 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs757589345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041106" FT VARIANT 1234 FT /note="R -> W (in dbSNP:rs55916864)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041107" FT VARIANT 1340 FT /note="R -> Q (in dbSNP:rs34994343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041108" FT VARIANT 1621 FT /note="R -> C (in dbSNP:rs55646900)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041109" FT VARIANT 1903 FT /note="R -> W (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs762000831)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041110" FT VARIANT 2189 FT /note="P -> L (in dbSNP:rs10755037)" FT /id="VAR_059769" FT VARIANT 2687 FT /note="P -> T (in dbSNP:rs13026308)" FT /evidence="ECO:0000269|PubMed:10718198, FT ECO:0000269|PubMed:15185077, ECO:0000269|PubMed:17344846" FT /id="VAR_041111" FT VARIANT 2742 FT /note="V -> M (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs566841339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041112" FT VARIANT 2757 FT /note="G -> V (in CNM5; dbSNP:rs587777676)" FT /evidence="ECO:0000269|PubMed:25087613" FT /id="VAR_071808" FT VARIANT 3079 FT /note="H -> R (in dbSNP:rs12464085)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041113" FT CONFLICT 71 FT /note="Q -> H (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="S -> I (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 2047 FT /note="S -> G (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT CONFLICT 3005 FT /note="R -> P (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT STRAND 867..873 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 878..881 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 886..896 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 899..904 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 915..919 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 921..923 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 924..931 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 934..936 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 938..946 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 949..960 FT /evidence="ECO:0007829|PDB:1U2H" SQ SEQUENCE 3267 AA; 354289 MW; E67BEB5624144233 CRC64; MQKARGTRGE DAGTRAPPSP GVPPKRAKVG AGGGAPVAVA GAPVFLRPLK NAAVCAGSDV RLRVVVSGTP QPSLRWFRDG QLLPAPAPEP SCLWLRRCGA QDAGVYSCMA QNERGRASCE AVLTVLEVGD SETAEDDISD VQGTQRLELR DDGAFSTPTG GSDTLVGTSL DTPPTSVTGT SEEQVSWWGS GQTVLEQEAG SGGGTRRLPG SPRQAQATGA GPRHLGVEPL VRASRANLVG ASWGSEDSLS VASDLYGSAF SLYRGRALSI HVSVPQSGLR REEPDLQPQL ASEAPRRPAQ PPPSKSALLP PPSPRVGKRS PPGPPAQPAA TPTSPHRRTQ EPVLPEDTTT EEKRGKKSKS SGPSLAGTAE SRPQTPLSEA SGRLSALGRS PRLVRAGSRI LDKLQFFEER RRSLERSDSP PAPLRPWVPL RKARSLEQPK SERGAPWGTP GASQEELRAP GSVAERRRLF QQKAASLDER TRQRSPASDL ELRFAQELGR IRRSTSREEL VRSHESLRAT LQRAPSPREP GEPPLFSRPS TPKTSRAVSP AAAQPPSPSS AEKPGDEPGR PRSRGPAGRT EPGEGPQQEV RRRDQFPLTR SRAIQECRSP VPPPAADPPE ARTKAPPGRK REPPAQAVRF LPWATPGLEG AAVPQTLEKN RAGPEAEKRL RRGPEEDGPW GPWDRRGARS QGKGRRARPT SPELESSDDS YVSAGEEPLE APVFEIPLQN VVVAPGADVL LKCIITANPP PQVSWHKDGS ALRSEGRLLL RAEGERHTLL LREARAADAG SYMATATNEL GQATCAASLT VRPGGSTSPF SSPITSDEEY LSPPEEFPEP GETWPRTPTM KPSPSQNRRS SDTGSKAPPT FKVSLMDQSV REGQDVIMSI RVQGEPKPVV SWLRNRQPVR PDQRRFAEEA EGGLCRLRIL AAERGDAGFY TCKAVNEYGA RQCEARLEVR AHPESRSLAV LAPLQDVDVG AGEMALFECL VAGPTDVEVD WLCRGRLLQP ALLKCKMHFD GRKCKLLLTS VHEDDSGVYT CKLSTAKDEL TCSARLTVRP SLAPLFTRLL EDVEVLEGRA ARFDCKISGT PPPVVTWTHF GCPMEESENL RLRQDGGLHS LHIAHVGSED EGLYAVSAVN THGQAHCSAQ LYVEEPRTAA SGPSSKLEKM PSIPEEPEQG ELERLSIPDF LRPLQDLEVG LAKEAMLECQ VTGLPYPTIS WFHNGHRIQS SDDRRMTQYR DVHRLVFPAV GPQHAGVYKS VIANKLGKAA CYAHLYVTDV VPGPPDGAPQ VVAVTGRMVT LTWNPPRSLD MAIDPDSLTY TVQHQVLGSD QWTALVTGLR EPGWAATGLR KGVQHIFRVL STTVKSSSKP SPPSEPVQLL EHGPTLEEAP AMLDKPDIVY VVEGQPASVT VTFNHVEAQV VWRSCRGALL EARAGVYELS QPDDDQYCLR ICRVSRRDMG ALTCTARNRH GTQTCSVTLE LAEAPRFESI MEDVEVGAGE TARFAVVVEG KPLPDIMWYK DEVLLTESSH VSFVYEENEC SLVVLSTGAQ DGGVYTCTAQ NLAGEVSCKA ELAVHSAQTA MEVEGVGEDE DHRGRRLSDF YDIHQEIGRG AFSYLRRIVE RSSGLEFAAK FIPSQAKPKA SARREARLLA RLQHDCVLYF HEAFERRRGL VIVTELCTEE LLERIARKPT VCESEIRAYM RQVLEGIHYL HQSHVLHLDV KPENLLVWDG AAGEQQVRIC DFGNAQELTP GEPQYCQYGT PEFVAPEIVN QSPVSGVTDI WPVGVVAFLC LTGISPFVGE NDRTTLMNIR NYNVAFEETT FLSLSREARG FLIKVLVQDR LRPTAEETLE HPWFKTQAKG AEVSTDHLKL FLSRRRWQRS QISYKCHLVL RPIPELLRAP PERVWVTMPR RPPPSGGLSS SSDSEEEELE ELPSVPRPLQ PEFSGSRVSL TDIPTEDEAL GTPETGAATP MDWQEQGRAP SQDQEAPSPE ALPSPGQEPA AGASPRRGEL RRGSSAESAL PRAGPRELGR GLHKAASVEL PQRRSPSPGA TRLARGGLGE GEYAQRLQAL RQRLLRGGPE DGKVSGLRGP LLESLGGRAR DPRMARAASS EAAPHHQPPL ENRGLQKSSS FSQGEAEPRG RHRRAGAPLE IPVARLGARR LQESPSLSAL SEAQPSSPAR PSAPKPSTPK SAEPSATTPS DAPQPPAPQP AQDKAPEPRP EPVRASKPAP PPQALQTLAL PLTPYAQIIQ SLQLSGHAQG PSQGPAAPPS EPKPHAAVFA RVASPPPGAP EKRVPSAGGP PVLAEKARVP TVPPRPGSSL SSSIENLESE AVFEAKFKRS RESPLSLGLR LLSRSRSEER GPFRGAEEED GIYRPSPAGT PLELVRRPER SRSVQDLRAV GEPGLVRRLS LSLSQRLRRT PPAQRHPAWE ARGGDGESSE GGSSARGSPV LAMRRRLSFT LERLSSRLQR SGSSEDSGGA SGRSTPLFGR LRRATSEGES LRRLGLPHNQ LAAQAGATTP SAESLGSEAS ATSGSSAPGE SRSRLRWGFS RPRKDKGLSP PNLSASVQEE LGHQYVRSES DFPPVFHIKL KDQVLLEGEA ATLLCLPAAC PAPHISWMKD KKSLRSEPSV IIVSCKDGRQ LLSIPRAGKR HAGLYECSAT NVLGSITSSC TVAVARVPGK LAPPEVPQTY QDTALVLWKP GDSRAPCTYT LERRVDGESV WHPVSSGIPD CYYNVTHLPV GVTVRFRVAC ANRAGQGPFS NSSEKVFVRG TQDSSAVPSA AHQEAPVTSR PARARPPDSP TSLAPPLAPA APTPPSVTVS PSSPPTPPSQ ALSSLKAVGP PPQTPPRRHR GLQAARPAEP TLPSTHVTPS EPKPFVLDTG TPIPASTPQG VKPVSSSTPV YVVTSFVSAP PAPEPPAPEP PPEPTKVTVQ SLSPAKEVVS SPGSSPRSSP RPEGTTLRQG PPQKPYTFLE EKARGRFGVV RACRENATGR TFVAKIVPYA AEGKRRVLQE YEVLRTLHHE RIMSLHEAYI TPRYLVLIAE SCGNRELLCG LSDRFRYSED DVATYMVQLL QGLDYLHGHH VLHLDIKPDN LLLAPDNALK IVDFGSAQPY NPQALRPLGH RTGTLEFMAP EMVKGEPIGS ATDIWGAGVL TYIMLSGRSP FYEPDPQETE ARIVGGRFDA FQLYPNTSQS ATLFLRKVLS VHPWSRPSLQ DCLAHPWLQD AYLMKLRRQT LTFTTNRLKE FLGEQRRRRA EAATRHKVLL RSYPGGP // ID STK11_HUMAN Reviewed; 433 AA. AC Q15831; B2RBX7; E7EW76; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 245. DE RecName: Full=Serine/threonine-protein kinase STK11 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14976552}; DE AltName: Full=Liver kinase B1; DE Short=LKB1; DE Short=hLKB1; DE AltName: Full=Renal carcinoma antigen NY-REN-19; DE Flags: Precursor; GN Name=STK11 {ECO:0000312|HGNC:HGNC:11389}; Synonyms=LKB1, PJS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INVOLVEMENT IN PJS. RC TISSUE=Liver; RX PubMed=9425897; DOI=10.1038/ng0198-38; RA Jenne D.E., Reimann H., Nezu J., Friedl W., Loff S., Jeschke R., RA Mueller O., Back W., Zimmer M.; RT "Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine RT kinase."; RL Nat. Genet. 18:38-43(1998). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9537235; RA Bignell G.R., Barfoot R., Seal S., Collins N., Warren W., Stratton M.R.; RT "Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene RT in sporadic breast cancer."; RL Cancer Res. 58:1384-1386(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP IDENTIFICATION AS A RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=11212897; DOI=10.1023/a:1006442024874; RA Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K., Schackert G.; RT "Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 RT mutations in human carcinoma metastases to the brain."; RL J. Neurooncol. 49:187-195(2000). RN [9] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF SMAD4 AND STK11IP, AND RP INTERACTION WITH SMAD4 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [10] RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, FUNCTION, MUTAGENESIS OF LYS-78 RP AND THR-189, AND PHOSPHORYLATION AT THR-189. RX PubMed=11430832; DOI=10.1016/s1097-2765(01)00258-1; RA Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R., Brien T.P., RA Bozzuto C.D., Ooi D., Cantley L.C., Yuan J.; RT "The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell RT death."; RL Mol. Cell 7:1307-1319(2001). RN [11] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=12097271; RA Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., RA Engles J.M., Westra W.H., Herman J.G., Sidransky D.; RT "Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the RT lung."; RL Cancer Res. 62:3659-3662(2002). RN [12] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STRADA, PHOSPHORYLATION AT RP THR-336 AND THR-363, AND CHARACTERIZATION OF VARIANT SPORADIC CANCER RP TYR-176. RX PubMed=12805220; DOI=10.1093/emboj/cdg292; RA Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., RA Alessi D.R., Clevers H.C.; RT "Activation of the tumour suppressor kinase LKB1 by the STE20-like RT pseudokinase STRAD."; RL EMBO J. 22:3062-3072(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-194, IDENTIFICATION IN A RP COMPLEX WITH STRADA AND CAB39, AND INTERACTION WITH STRADA; STRADB; CAB39 RP AND CAB39L. RX PubMed=14517248; DOI=10.1093/emboj/cdg490; RA Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutkowski M., RA Prescott A.R., Clevers H.C., Alessi D.R.; RT "MO25alpha/beta interact with STRADalpha/beta enhancing their ability to RT bind, activate and localize LKB1 in the cytoplasm."; RL EMBO J. 22:5102-5114(2003). RN [14] RP FUNCTION IN CELL POLARITY. RX PubMed=15016379; DOI=10.1016/s0092-8674(04)00114-x; RA Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K., RA Peters P.J., Clevers H.C.; RT "Complete polarization of single intestinal epithelial cells upon RT activation of LKB1 by STRAD."; RL Cell 116:457-466(2004). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-194. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [16] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=15021901; DOI=10.1038/sj.onc.1207502; RA Carretero J., Medina P.P., Pio R., Montuenga L.M., Sanchez-Cespedes M.; RT "Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor RT suppressor gene."; RL Oncogene 23:4037-4040(2004). RN [17] RP FUNCTION. RX PubMed=15733851; DOI=10.1016/j.febslet.2005.01.042; RA Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A., RA Alessi D.R.; RT "Identification of the sucrose non-fermenting related kinase SNRK, as a RT novel LKB1 substrate."; RL FEBS Lett. 579:1417-1423(2005). RN [18] RP FUNCTION, INTERACTION WITH PTEN, SUBCELLULAR LOCATION, AND CHARACTERIZATION RP OF VARIANT PJS ASN-176. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TP53. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [20] RP INTERACTION WITH WDR6. RX PubMed=17216128; DOI=10.1007/s11010-006-9402-5; RA Xie X., Wang Z., Chen Y.; RT "Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell RT growth arrest and p27(Kip1) induction."; RL Mol. Cell. Biochem. 301:115-122(2007). RN [21] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17711506; DOI=10.1111/j.1349-7006.2007.00585.x; RA Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y., RA Mitsudomi T.; RT "LKB1 gene mutations in Japanese lung cancer patients."; RL Cancer Sci. 98:1747-1751(2007). RN [22] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17676035; DOI=10.1038/nature06030; RA Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., RA Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D., RA Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J., RA Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I., RA Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E., RA Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N., RA Sharpless N.E., Wong K.K.; RT "LKB1 modulates lung cancer differentiation and metastasis."; RL Nature 448:807-810(2007). RN [23] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17384680; DOI=10.1038/sj.onc.1210418; RA Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., RA Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J.; RT "Prevalence and specificity of LKB1 genetic alterations in lung cancers."; RL Oncogene 26:5911-5918(2007). RN [24] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=18594528; DOI=10.1038/sj.bjc.6604469; RA Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X., Naoki K., RA Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K., Richards W.G., RA Sugarbaker D.J., Johnson B.E., Janne P.A.; RT "Mutations in the LKB1 tumour suppressor are frequently detected in tumours RT from Caucasian but not Asian lung cancer patients."; RL Br. J. Cancer 99:245-252(2008). RN [25] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [26] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [27] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-44; LYS-48; LYS-96; LYS-97; RP LYS-296; LYS-311; LYS-416; LYS-423 AND LYS-431, AND MUTAGENESIS OF LYS-44; RP LYS-48; LYS-96 AND LYS-97. RX PubMed=18687677; DOI=10.1074/jbc.m805711200; RA Lan F., Cacicedo J.M., Ruderman N., Ido Y.; RT "SIRT1 modulation of the acetylation status, cytosolic localization, and RT activity of LKB1. Possible role in AMP-activated protein kinase RT activation."; RL J. Biol. Chem. 283:27628-27635(2008). RN [28] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, RP PHOSPHORYLATION AT SER-428, AND MUTAGENESIS OF SER-428. RX PubMed=18854309; DOI=10.1074/jbc.m806153200; RA Denison F.C., Hiscock N.J., Carling D., Woods A.; RT "Characterization of an alternative splice variant of LKB1."; RL J. Biol. Chem. 284:67-76(2009). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [30] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=20559149; DOI=10.1097/jto.0b013e3181e05016; RA Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y., RA Pao W., Chen H., Ji H.; RT "Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung RT adenocarcinomas."; RL J. Thorac. Oncol. 5:1130-1135(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP FUNCTION. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [33] RP REVIEW ON FUNCTION. RX PubMed=21396365; DOI=10.1016/j.febslet.2011.03.010; RA Alexander A., Walker C.L.; RT "The role of LKB1 and AMPK in cellular responses to stress and damage."; RL FEBS Lett. 585:952-957(2011). RN [34] RP REVIEW ON INVOLVEMENT IN LUNG CANCER. RX PubMed=21380642; DOI=10.1007/s13238-011-1021-6; RA Gao Y., Ge G., Ji H.; RT "LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor RT suppressor."; RL Protein Cell 2:99-107(2011). RN [35] RP ACTIVITY REGULATION, INTERACTION WITH NR4A1, AND SUBCELLULAR LOCATION. RX PubMed=22983157; DOI=10.1038/nchembio.1069; RA Zhan Y.Y., Chen Y., Zhang Q., Zhuang J.J., Tian M., Chen H.Z., Zhang L.R., RA Zhang H.K., He J.P., Wang W.J., Wu R., Wang Y., Shi C., Yang K., Li A.Z., RA Xin Y.Z., Li T.Y., Yang J.Y., Zheng Z.H., Yu C.D., Lin S.C., Chang C., RA Huang P.Q., Lin T., Wu Q.; RT "The orphan nuclear receptor Nur77 regulates LKB1 localization and RT activates AMPK."; RL Nat. Chem. Biol. 8:897-904(2012). RN [36] RP INTERACTION WITH NISCH, AND SUBCELLULAR LOCATION. RX PubMed=23572524; DOI=10.1074/jbc.m112.418103; RA Jain P., Baranwal S., Dong S., Struckhoff A.P., Worthylake R.A., RA Alahari S.K.; RT "Integrin-binding protein nischarin interacts with tumor suppressor liver RT kinase B1 (LKB1) to regulate cell migration of breast epithelial cells."; RL J. Biol. Chem. 288:15495-15509(2013). RN [37] RP SUBCELLULAR LOCATION (ISOFORM 2), AND PHOSPHORYLATION AT SER-399 (ISOFORM RP 2). RX PubMed=23612973; DOI=10.1074/jbc.m112.443580; RA Zhu H., Moriasi C.M., Zhang M., Zhao Y., Zou M.H.; RT "Phosphorylation of serine 399 in LKB1 protein short form by protein kinase RT Czeta is required for its nucleocytoplasmic transport and consequent AMP- RT activated protein kinase (AMPK) activation."; RL J. Biol. Chem. 288:16495-16505(2013). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31 AND SER-401, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [40] RP FUNCTION, AND INTERACTION WITH CDKN1A. RX PubMed=25329316; DOI=10.1371/journal.pgen.1004721; RA Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J., Grueso J., RA Hernandez-Losa J., Moline T., Canals F., Ferrer B., Cortes J., Bastian B., RA Cajal S.R.Y., Martin-Caballero J., Flores J.M., Vivancos A., RA Garcia-Patos V., Recio J.A.; RT "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating RT CDKN1A (p21WAF1/CIP1) degradation."; RL PLoS Genet. 10:E1004721-E1004721(2014). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 43-347 IN COMPLEX WITH STRADA AND RP CAB39, ACTIVITY REGULATION, CHARACTERIZATION OF VARIANTS SPORADIC CANCER RP MET-66; GLY-86; ARG-123; SER-157; ASP-163; PRO-170; SER-171; ARG-174; RP TYR-176; ASN-177; GLU-181; GLN-199; THR-205; PHE-216; VAL-223; PRO-230; RP PRO-232; ARG-245; PRO-250; HIS-272; TYR-277; GLN-285 AND SER-315, AND RP MUTAGENESIS OF ARG-74; ASP-194 AND PHE-204. RX PubMed=19892943; DOI=10.1126/science.1178377; RA Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.; RT "Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism RT of kinase activation."; RL Science 326:1707-1711(2009). RN [42] RP VARIANTS PJS 50-LEU--ASP-53 DEL; ASN-176 AND CYS-308, CHARACTERIZATION OF RP VARIANTS PJS PRO-67; ASN-176 AND CYS-308, AND MUTAGENESIS OF LYS-78. RX PubMed=9837816; DOI=10.1086/302159; RA Mehenni H., Gehrig C., Nezu J., Oku A., Shimane M., Rossier C., Guex N., RA Blouin J.L., Scott H.S., Antonarakis S.E.; RT "Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for RT allelic and locus heterogeneity."; RL Am. J. Hum. Genet. 63:1641-1650(1998). RN [43] RP VARIANT TGCT ASP-163. RX PubMed=9605748; RA Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A., Stenwig A.E., RA Fossaa S.D., Salovaara R., Aaltonen L.A.; RT "Somatic mutations in LKB1 are rare in sporadic colorectal and testicular RT tumors."; RL Cancer Res. 58:2087-2090(1998). RN [44] RP VARIANTS COLORECTAL CANCER SER-171; LYS-199; ASN-208; ASP-215; LEU-354 AND RP MET-367. RX PubMed=9731485; RA Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H., Park W.S., RA Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Kim S.Y., Yang Y.M., Kim S.H., RA Kim C.S., Lee J.Y.; RT "Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers RT syndrome gene in left-sided colon cancer."; RL Cancer Res. 58:3787-3790(1998). RN [45] RP VARIANT COLORECTAL CANCER HIS-314. RX PubMed=9809980; RA Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F., RA Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N., Ingrosso M., RA Rossini F.P., Tenconi R., Guanti G.; RT "STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer."; RL Cancer Res. 58:4799-4801(1998). RN [46] RP VARIANT PJS ASN-247 DEL. RX PubMed=9760200; DOI=10.1007/s004390050801; RA Nakagawa H., Koyama K., Miyoshi Y., Ando H., Baba S., Watatani M., RA Yasutomi M., Matsuura N., Monden M., Nakamura Y.; RT "Nine novel germline mutations of STK11 in ten families with Peutz-Jeghers RT syndrome."; RL Hum. Genet. 103:168-172(1998). RN [47] RP VARIANT GASTRIC CARCINOMA LEU-324. RX PubMed=9683800; RA Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G., RA Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z.; RT "Mutations of the STK11 gene in sporadic gastric carcinoma."; RL Int. J. Oncol. 13:601-604(1998). RN [48] RP VARIANTS PJS PRO-67 AND 303-ILE--GLN-306 DELINS ASN. RX PubMed=9428765; DOI=10.1038/34432; RA Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., RA Bignell G., Warren W., Aminoff M., Hoeglund P., Jaervinen H., Kristo P., RA Pelin K., Ridanpaeae M., Salovaara R., Toro T., Bodmer W., Olschwang S., RA Olsen A.S., Stratton M.R., de la Chapelle A., Aaltonen L.A.; RT "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome."; RL Nature 391:184-187(1998). RN [49] RP VARIANT LUNG CANCER VAL-194. RX PubMed=10079245; DOI=10.1016/s0002-9440(10)65314-x; RA Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M., RA Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K., Kokkola A., RA Jarvinen H., Aaltonen L.A.; RT "LKB1 somatic mutations in sporadic cancers."; RL Am. J. Pathol. 154:677-681(1999). RN [50] RP VARIANTS PJS 162-ASP--LEU-164 DELINS ASN-ASP-MET; ASN-194 AND LYS-297. RX PubMed=10408777; RX DOI=10.1002/(sici)1098-1004(1999)13:6<476::aid-humu7>3.0.co;2-2; RA Westerman A.M., Entius M.M., Boor P.P.C., Koole R., de Baar E., RA Offerhaus G.J.A., Lubinski J., Lindhout D., Halley D.J.J., de Rooij F.W.M., RA Wilson J.H.P.; RT "Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families."; RL Hum. Mutat. 13:476-481(1999). RN [51] RP CHARACTERIZATION OF VARIANT TGCT ASP-163. RX PubMed=9887330; DOI=10.1093/hmg/8.1.45; RA Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S., RA Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D., Neale K., RA Phillips R., Zauber P., Twama T., Sampson J., Jaervinen H., Maekelae T.P., RA Aaltonen L.A.; RT "Mutations and impaired function of LKB1 in familial and non-familial RT Peutz-Jeghers syndrome and a sporadic testicular cancer."; RL Hum. Mol. Genet. 8:45-51(1999). RN [52] RP VARIANT OVARIAN CARCINOMA LEU-281. RX PubMed=10429654; DOI=10.1111/j.1349-7006.1999.tb00793.x; RA Nishioka Y., Kobayashi K., Sagae S., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of STK11 gene in ovarian carcinomas."; RL Jpn. J. Cancer Res. 90:629-632(1999). RN [53] RP VARIANTS MELANOMA ASP-49 AND ARG-135. RX PubMed=10201537; DOI=10.1046/j.1523-1747.1999.00551.x; RA Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W., RA Tomlinson I.; RT "Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic RT malignant melanomas."; RL J. Invest. Dermatol. 112:509-511(1999). RN [54] RP VARIANT MELANOMA TYR-194. RX PubMed=10208439; DOI=10.1038/sj.onc.1202486; RA Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F., RA Zeuthen J.; RT "Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in RT malignant melanoma."; RL Oncogene 18:1777-1780(1999). RN [55] RP VARIANTS PJS CYS-239 AND SER-315. RX PubMed=12372054; DOI=10.1034/j.1399-0004.2002.620405.x; RA Scott R.J., Crooks R., Meldrum C.J., Thomas L., Smith C.J.A., Mowat D., RA McPhillips M., Spigelman A.D.; RT "Mutation analysis of the STK11/LKB1 gene and clinical characteristics of RT an Australian series of Peutz-Jeghers syndrome patients."; RL Clin. Genet. 62:282-287(2002). RN [56] RP VARIANTS CERVICAL CANCER LYS-14; PRO-160 AND LEU-231, AND VARIANT CERVICAL RP CARCINOMA MET-66. RX PubMed=12533684; DOI=10.1097/01.lab.0000049821.16698.d0; RA Kuragaki C., Enomoto T., Ueno Y., Sun H., Fujita M., Nakashima R., Ueda Y., RA Wada H., Murata Y., Toki T., Konishi I., Fujii S.; RT "Mutations in the STK11 gene characterize minimal deviation adenocarcinoma RT of the uterine cervix."; RL Lab. Invest. 83:35-45(2003). RN [57] RP VARIANT [LARGE SCALE ANALYSIS] LYS-87. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP VARIANT PJS GLY-16. RX PubMed=21411391; DOI=10.1016/j.clinre.2010.11.008; RA Liu L., Du X., Nie J.; RT "A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome RT patient significantly diminished p53 activity."; RL Clin. Res. Hepatol. Gastroenterol. 35:221-226(2011). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase that CC controls the activity of AMP-activated protein kinase (AMPK) family CC members, thereby playing a role in various processes such as cell CC metabolism, cell polarity, apoptosis and DNA damage response. Acts by CC phosphorylating the T-loop of AMPK family proteins, thus promoting CC their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, CC MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not CC MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN CC and possibly p53/TP53. Acts as a key upstream regulator of AMPK by CC mediating phosphorylation and activation of AMPK catalytic subunits CC PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition CC of signaling pathways that promote cell growth and proliferation when CC energy levels are low, glucose homeostasis in liver, activation of CC autophagy when cells undergo nutrient deprivation, and B-cell CC differentiation in the germinal center in response to DNA damage. Also CC acts as a regulator of cellular polarity by remodeling the actin CC cytoskeleton. Required for cortical neuron polarization by mediating CC phosphorylation and activation of BRSK1 and BRSK2, leading to axon CC initiation and specification. Involved in DNA damage response: CC interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to CC participate in transcription activation. Able to phosphorylate CC p53/TP53; the relevance of such result in vivo is however unclear and CC phosphorylation may be indirect and mediated by downstream STK11/LKB1 CC kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis CC via interaction with p53/TP53: translocates to the mitochondrion during CC apoptosis and regulates p53/TP53-dependent apoptosis pathways. CC Regulates UV radiation-induced DNA damage response mediated by CDKN1A. CC In association with NUAK1, phosphorylates CDKN1A in response to UV CC radiation and contributes to its degradation which is necessary for CC optimal DNA repair (PubMed:25329316). {ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:14517248, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15016379, CC ECO:0000269|PubMed:15733851, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:25329316}. CC -!- FUNCTION: [Isoform 2]: Has a role in spermiogenesis. {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC -!- ACTIVITY REGULATION: Activated by forming a complex with STRAD (STRADA CC or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): STRADA CC (or STRADB)-binding promotes a conformational change of STK11/LKB1 in CC an active conformation, which is stabilized by CAB39/MO25alpha (or CC CAB39L/MO25beta) interacting with the STK11/LKB1 activation loop. CC Sequestration in the nucleus by NR4A1 prevents it from phosphorylating CC and activating cytoplasmic AMPK. {ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157}. CC -!- SUBUNIT: Catalytic component of a trimeric complex composed of CC STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CC CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and CC stimulates its catalytic activity. Found in a ternary complex composed CC of SMAD4, STK11/LKB1 and STK11IP. Interacts with p53/TP53, SMAD4, CC STK11IP and WDR6. Interacts with NR4A1. Interacts with NISCH; this CC interaction may increase STK11 activity. Interacts with PTEN; leading CC to PTEN phosphorylation. Interacts with SIRT1; the interaction CC deacetylates STK11. Interacts with CDKN1A. CC {ECO:0000269|PubMed:11741830, ECO:0000269|PubMed:12805220, CC ECO:0000269|PubMed:14517248, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17216128, CC ECO:0000269|PubMed:18687677, ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157, ECO:0000269|PubMed:23572524, CC ECO:0000269|PubMed:25329316}. CC -!- INTERACTION: CC Q15831; Q9Y376: CAB39; NbExp=23; IntAct=EBI-306838, EBI-306905; CC Q15831; Q16543: CDC37; NbExp=6; IntAct=EBI-306838, EBI-295634; CC Q15831; Q9BT78: COPS4; NbExp=5; IntAct=EBI-306838, EBI-742413; CC Q15831; Q13451: FKBP5; NbExp=11; IntAct=EBI-306838, EBI-306914; CC Q15831; P07900: HSP90AA1; NbExp=6; IntAct=EBI-306838, EBI-296047; CC Q15831; P08238: HSP90AB1; NbExp=8; IntAct=EBI-306838, EBI-352572; CC Q15831; O95835: LATS1; NbExp=2; IntAct=EBI-306838, EBI-444209; CC Q15831; Q96L34: MARK4; NbExp=2; IntAct=EBI-306838, EBI-302319; CC Q15831; P26927: MST1; NbExp=2; IntAct=EBI-306838, EBI-6929133; CC Q15831; P54646: PRKAA2; NbExp=3; IntAct=EBI-306838, EBI-1383852; CC Q15831; Q7RTN6: STRADA; NbExp=23; IntAct=EBI-306838, EBI-1109114; CC Q15831; Q7RTN6-1: STRADA; NbExp=3; IntAct=EBI-306838, EBI-15787241; CC Q15831; Q9C0K7: STRADB; NbExp=14; IntAct=EBI-306838, EBI-306893; CC Q15831; Q8NFZ5: TNIP2; NbExp=5; IntAct=EBI-306838, EBI-359372; CC Q15831; Q9NNW5: WDR6; NbExp=3; IntAct=EBI-306838, EBI-1568315; CC Q15831; P63104: YWHAZ; NbExp=6; IntAct=EBI-306838, EBI-347088; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane {ECO:0000250}. CC Mitochondrion. Note=A small fraction localizes at membranes (By CC similarity). Relocates to the cytoplasm when bound to STRAD (STRADA or CC STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta). CC Translocates to the mitochondrion during apoptosis. PTEN promotes CC cytoplasmic localization. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:23612973}. Cytoplasm {ECO:0000269|PubMed:23612973}. CC Note=Predominantly nuclear, but translocates to the cytoplasm in CC response to metformin or peroxynitrite treatment. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LKB1(L); CC IsoId=Q15831-1; Sequence=Displayed; CC Name=2; Synonyms=LKB1(S); CC IsoId=Q15831-2; Sequence=VSP_041746; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Strongest expression in CC testis and fetal liver. CC -!- PTM: Phosphorylated by ATM at Thr-363 following ionizing radiation CC (IR). Phosphorylation at Ser-428 by RPS6KA1 and/or some PKA is required CC to inhibit cell growth. Phosphorylation at Ser-428 is also required CC during neuronal polarization to mediate phosphorylation of BRSK1 and CC BRSK2 (By similarity). Phosphorylation by PKC/PRKCZ at Ser-399 in CC isoform 2 promotes metformin (or peroxynitrite)-induced nuclear export CC of STK11 and activation of AMPK. UV radiation-induced phosphorylation CC at Thr-363 mediates CDKN1A degradation (By similarity). CC {ECO:0000250|UniProtKB:Q9WTK7, ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:18854309}. CC -!- PTM: Acetylated. Deacetylation at Lys-48 enhances cytoplasmic CC localization and kinase activity in vitro. CC {ECO:0000269|PubMed:18687677}. CC -!- DISEASE: Peutz-Jeghers syndrome (PJS) [MIM:175200]: An autosomal CC dominant disorder characterized by melanocytic macules of the lips, CC multiple gastrointestinal hamartomatous polyps and an increased risk CC for various neoplasms, including gastrointestinal cancer. CC {ECO:0000269|PubMed:10408777, ECO:0000269|PubMed:12372054, CC ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:21411391, CC ECO:0000269|PubMed:9425897, ECO:0000269|PubMed:9428765, CC ECO:0000269|PubMed:9760200, ECO:0000269|PubMed:9837816}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. CC {ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Defects in STK11 are associated with some sporadic CC cancers, especially lung cancers. Frequently mutated and inactivated in CC non-small cell lung cancer (NSCLC). Defects promote lung cancerigenesis CC process, especially lung cancer progression and metastasis. Confers CC lung adenocarcinoma the ability to trans-differentiate into squamous CC cell carcinoma. Also able to promote lung cancer metastasis, via both CC cancer-cell autonomous and non-cancer-cell autonomous mechanisms. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. LKB1 subfamily. {ECO:0000305}. CC -!- CAUTION: Its phosphorylation by PKC/PRKCZ at Ser-428 is reported to CC promote peroxynitrite-induced nuclear export of STK11, leading to PTEN CC activation and subsequent inhibition of PI3K/AKT signaling and CC induction of apoptosis in vein endothelial cells (PubMed:18321849). CC However this paper was withdrawn by the authors due to concerns of CC image duplication in the figures. Its phosphorylation by PKC/PRKCZ has CC been confirmed in other studies (PubMed:18854309, PubMed:23612973). CC {ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:18854309, CC ECO:0000269|PubMed:23612973, ECO:0000305|PubMed:31519760}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/292/STK11"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=PJS entry; CC URL="https://en.wikipedia.org/wiki/PJS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U63333; AAB05809.1; -; mRNA. DR EMBL; AF035625; AAC39527.1; -; mRNA. DR EMBL; AF032984; AAB97833.1; -; Genomic_DNA. DR EMBL; AF055327; AAC15742.1; -; Genomic_DNA. DR EMBL; AF055320; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055321; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055322; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055323; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055324; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055325; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055326; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AK314858; BAG37374.1; -; mRNA. DR EMBL; AC011544; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004221; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471139; EAW69540.1; -; Genomic_DNA. DR EMBL; BC007981; AAH07981.1; -; mRNA. DR EMBL; BC019334; AAH19334.1; -; mRNA. DR CCDS; CCDS45896.1; -. [Q15831-1] DR RefSeq; NP_000446.1; NM_000455.5. [Q15831-1] DR RefSeq; NP_001394184.1; NM_001407255.1. [Q15831-2] DR PDB; 2WTK; X-ray; 2.65 A; C/F=43-347. DR PDB; 4ZDR; X-ray; 2.90 A; A/B=333-340. DR PDB; 5WXN; X-ray; 2.93 A; C/D=331-343. DR PDB; 8VSU; EM; 2.86 A; C=1-433. DR PDBsum; 2WTK; -. DR PDBsum; 4ZDR; -. DR PDBsum; 5WXN; -. DR PDBsum; 8VSU; -. DR AlphaFoldDB; Q15831; -. DR EMDB; EMD-43506; -. DR SMR; Q15831; -. DR BioGRID; 112670; 322. DR ComplexPortal; CPX-2431; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADA variant. DR ComplexPortal; CPX-2845; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADA variant. DR ComplexPortal; CPX-2868; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADB variant. DR ComplexPortal; CPX-2869; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADB variant. DR CORUM; Q15831; -. DR DIP; DIP-31317N; -. DR FunCoup; Q15831; 3083. DR IntAct; Q15831; 222. DR MINT; Q15831; -. DR STRING; 9606.ENSP00000324856; -. DR BindingDB; Q15831; -. DR ChEMBL; CHEMBL5606; -. DR DrugCentral; Q15831; -. DR GlyGen; Q15831; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q15831; -. DR PhosphoSitePlus; Q15831; -. DR BioMuta; STK11; -. DR DMDM; 3024670; -. DR CPTAC; CPTAC-2999; -. DR CPTAC; CPTAC-3000; -. DR jPOST; Q15831; -. DR MassIVE; Q15831; -. DR PaxDb; 9606-ENSP00000324856; -. DR PeptideAtlas; Q15831; -. DR ProteomicsDB; 60780; -. [Q15831-1] DR ProteomicsDB; 60781; -. [Q15831-2] DR Pumba; Q15831; -. DR Antibodypedia; 2048; 1357 antibodies from 44 providers. DR CPTC; Q15831; 1 antibody. DR DNASU; 6794; -. DR Ensembl; ENST00000326873.12; ENSP00000324856.6; ENSG00000118046.19. [Q15831-1] DR Ensembl; ENST00000585465.3; ENSP00000490268.2; ENSG00000118046.19. [Q15831-2] DR Ensembl; ENST00000652231.1; ENSP00000498804.1; ENSG00000118046.19. [Q15831-2] DR GeneID; 6794; -. DR KEGG; hsa:6794; -. DR MANE-Select; ENST00000326873.12; ENSP00000324856.6; NM_000455.5; NP_000446.1. DR UCSC; uc002lrl.2; human. [Q15831-1] DR AGR; HGNC:11389; -. DR CIViC; 6794; 20 evidence items across 8 molecular profiles. DR ClinPGx; PA36198; -. DR CTD; 6794; -. DR DisGeNET; 6794; -. DR GeneCards; STK11; -. DR GeneReviews; STK11; -. DR HGNC; HGNC:11389; STK11. DR HPA; ENSG00000118046; Low tissue specificity. DR MalaCards; STK11; -. DR MIM; 175200; phenotype. DR MIM; 273300; phenotype. DR MIM; 602216; gene. DR OpenTargets; ENSG00000118046; -. DR Orphanet; 2869; Peutz-Jeghers syndrome. DR VEuPathDB; HostDB:ENSG00000118046; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000158050; -. DR HOGENOM; CLU_000288_1_2_1; -. DR InParanoid; Q15831; -. DR OMA; AYHYGSE; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q15831; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q15831; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15831; -. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes. DR SignaLink; Q15831; -. DR SIGNOR; Q15831; -. DR Agora; ENSG00000118046; -. DR BioGRID-ORCS; 6794; 153 hits in 1229 CRISPR screens. DR ChiTaRS; STK11; human. DR EvolutionaryTrace; Q15831; -. DR GeneWiki; STK11; -. DR GenomeRNAi; 6794; -. DR Pharos; Q15831; Tchem. DR PRO; PR:Q15831; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q15831; protein. DR Bgee; ENSG00000118046; Expressed in left testis and 156 other cell types or tissues. DR ExpressionAtlas; Q15831; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0140535; C:intracellular protein-containing complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:1902554; C:serine/threonine protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0002039; F:p53 binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:MGI. DR GO; GO:0043276; P:anoikis; IMP:BHF-UCL. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; IEA:Ensembl. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0097484; P:dendrite extension; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IMP:UniProtKB. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0030010; P:establishment of cell polarity; IMP:UniProtKB. DR GO; GO:0070314; P:G1 to G0 transition; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0051645; P:Golgi localization; IEA:Ensembl. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0060770; P:negative regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:1901610; P:positive regulation of vesicle transport along microtubule; IMP:UniProtKB. DR GO; GO:0045059; P:positive thymic T cell selection; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006470; P:protein dephosphorylation; IMP:UniProtKB. DR GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome. DR GO; GO:0001558; P:regulation of cell growth; ISS:UniProtKB. DR GO; GO:0048814; P:regulation of dendrite morphogenesis; IEA:Ensembl. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0030111; P:regulation of Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0010212; P:response to ionizing radiation; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0001944; P:vasculature development; ISS:UniProtKB. DR CDD; cd14119; STKc_LKB1; 1. DR FunFam; 1.10.510.10:FF:000245; serine/threonine-protein kinase STK11; 1. DR FunFam; 3.30.200.20:FF:000235; serine/threonine-protein kinase STK11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00613; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR039154; LKB1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF94; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Autophagy; Cell cycle; Cytoplasm; Differentiation; Disease variant; KW DNA damage; Kinase; Lipoprotein; Magnesium; Manganese; Membrane; KW Metal-binding; Methylation; Mitochondrion; Nucleotide-binding; Nucleus; KW Palmitate; Phosphoprotein; Prenylation; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Spermatogenesis; KW Transferase; Tumor suppressor. FT CHAIN 1..430 FT /note="Serine/threonine-protein kinase STK11" FT /id="PRO_0000086699" FT PROPEP 431..433 FT /note="Removed in mature form" FT /evidence="ECO:0000250" FT /id="PRO_0000422300" FT DOMAIN 49..309 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 45..90 FT /note="Sufficient for interaction with SIRT1" FT /evidence="ECO:0000269|PubMed:18687677" FT REGION 312..331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 397..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 316..326 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..433 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 176 FT /note="Proton acceptor" FT BINDING 55..63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 78 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 31 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 44 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 48 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 96 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 97 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 189 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11430832" FT MOD_RES 296 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 311 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9WTK7" FT MOD_RES 336 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 363 FT /note="Phosphothreonine; by ATM and autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 401 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 416 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 423 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 428 FT /note="Phosphoserine; by autocatalysis, PKA, PKC/PRKCZ and FT RPS6KA1" FT /evidence="ECO:0000269|PubMed:18854309" FT MOD_RES 430 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000250" FT MOD_RES 431 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT LIPID 418 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000250" FT LIPID 430 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000250" FT VAR_SEQ 371..433 FT /note="QVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAPNPARKACSASS FT KIRRLSACKQQ -> GEEASEAGLRAERGLQKSEGSDLSGEEASRPAPQ (in FT isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_041746" FT VARIANT 14 FT /note="E -> K (in cervical cancer; somatic mutation; FT dbSNP:rs2145404557)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065627" FT VARIANT 16 FT /note="E -> G (in PJS; dbSNP:rs2145404592)" FT /evidence="ECO:0000269|PubMed:21411391" FT /id="VAR_065628" FT VARIANT 49 FT /note="Y -> D (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853080)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033138" FT VARIANT 50..53 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071057" FT VARIANT 66 FT /note="V -> M (in cervical carcinoma; somatic mutation; FT dbSNP:rs1599915144)" FT /evidence="ECO:0000269|PubMed:12533684, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065629" FT VARIANT 67 FT /note="L -> P (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs137853077)" FT /evidence="ECO:0000269|PubMed:9428765, FT ECO:0000269|PubMed:9837816" FT /id="VAR_006202" FT VARIANT 86 FT /note="R -> G (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1057520039)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065630" FT VARIANT 87 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1568690463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041139" FT VARIANT 123 FT /note="Q -> R (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs764449808)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065631" FT VARIANT 135 FT /note="G -> R (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853081)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033139" FT VARIANT 157 FT /note="F -> S (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145424124)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065632" FT VARIANT 160 FT /note="L -> P (in cervical cancer; somatic mutation; FT dbSNP:rs2145424155)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065633" FT VARIANT 162..164 FT /note="DGL -> NDM (in PJS)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007920" FT VARIANT 163 FT /note="G -> D (in TGCT; a tumor with seminoma and teratoma FT components; somatic mutation; severely impaired but FT detectable kinase activity; impairs heterotrimeric complex FT assembly with STRADA and CAB39; predominantly nuclear FT localization; dbSNP:rs137853078)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330" FT /id="VAR_033140" FT VARIANT 170 FT /note="Q -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs876659972)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065634" FT VARIANT 171 FT /note="G -> S (in colorectal cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1599926499)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9731485" FT /id="VAR_065635" FT VARIANT 174 FT /note="H -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065636" FT VARIANT 176 FT /note="D -> N (in PJS; loss of kinase activity, leading to FT greatly reduced autophosphorylation; fails to phosphorylate FT PTEN in vitro; no significant effect on nucleocytoplasmic FT localization; dbSNP:rs730881979)" FT /evidence="ECO:0000269|PubMed:15987703, FT ECO:0000269|PubMed:9837816" FT /id="VAR_071058" FT VARIANT 176 FT /note="D -> Y (in sporadic cancer; somatic mutation; Loss FT of kinase activity)" FT /evidence="ECO:0000269|PubMed:12805220, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065637" FT VARIANT 177 FT /note="I -> N (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520041)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065638" FT VARIANT 181 FT /note="N -> E (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; requires 2 nucleotide substitutions; FT dbSNP:rs1568707668)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065639" FT VARIANT 194 FT /note="D -> N (in PJS; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007921" FT VARIANT 194 FT /note="D -> V (in lung cancer; somatic mutation; FT dbSNP:rs121913316)" FT /evidence="ECO:0000269|PubMed:10079245" FT /id="VAR_065640" FT VARIANT 194 FT /note="D -> Y (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10208439" FT /id="VAR_033141" FT VARIANT 199 FT /note="E -> K (in colorectal cancer; somatic mutation; FT impaired kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065641" FT VARIANT 199 FT /note="E -> Q (in sporadic cancer; somatic mutation; does FT not affect kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065642" FT VARIANT 205 FT /note="A -> T (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs730881981)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065643" FT VARIANT 208 FT /note="D -> N (in colorectal cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738372)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065644" FT VARIANT 215 FT /note="G -> D (in colorectal cancer; somatic mutation; FT dbSNP:rs1057520038)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065645" FT VARIANT 216 FT /note="S -> F (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520017)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065646" FT VARIANT 223 FT /note="E -> V (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2080776621)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065647" FT VARIANT 230 FT /note="T -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425367)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065648" FT VARIANT 231 FT /note="F -> L (in cervical cancer; somatic mutation; FT dbSNP:rs929783669)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065649" FT VARIANT 232 FT /note="S -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425398)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065650" FT VARIANT 239 FT /note="W -> C (in PJS; late onset suggests reduced FT penetrance; dbSNP:rs137853082)" FT /evidence="ECO:0000269|PubMed:12372054" FT /id="VAR_033142" FT VARIANT 245 FT /note="L -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065651" FT VARIANT 247 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9760200" FT /id="VAR_006203" FT VARIANT 250 FT /note="T -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1568709142)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065652" FT VARIANT 272 FT /note="Y -> H (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs2145427076)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065653" FT VARIANT 277 FT /note="D -> Y (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1555738692)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065654" FT VARIANT 281 FT /note="P -> L (in ovarian carcinoma; somatic mutation; FT dbSNP:rs121913322)" FT /evidence="ECO:0000269|PubMed:10429654" FT /id="VAR_065655" FT VARIANT 285 FT /note="L -> Q (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738724)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065656" FT VARIANT 297 FT /note="R -> K (in PJS; dbSNP:rs1568710381)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007922" FT VARIANT 303..306 FT /note="IRQH -> N (in PJS)" FT /id="VAR_033143" FT VARIANT 308 FT /note="W -> C (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs1057520042)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071059" FT VARIANT 314 FT /note="P -> H (in colorectal cancer; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs1064795752)" FT /evidence="ECO:0000269|PubMed:9809980" FT /id="VAR_065657" FT VARIANT 315 FT /note="P -> S (in PJS; uncertain significance; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs786202431)" FT /evidence="ECO:0000269|PubMed:12372054, FT ECO:0000269|PubMed:19892943" FT /id="VAR_033144" FT VARIANT 324 FT /note="P -> L (in gastric carcinoma; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs367807476)" FT /evidence="ECO:0000269|PubMed:9683800" FT /id="VAR_065658" FT VARIANT 354 FT /note="F -> L (in colorectal cancer; somatic mutation; FT dbSNP:rs59912467)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065659" FT VARIANT 367 FT /note="T -> M (in colorectal cancer; somatic mutation; FT dbSNP:rs587782835)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065660" FT MUTAGEN 44 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->Q: No effect on basal nucleocytoplasmic FT localization, but fails to translocate to the cytoplasm FT when coexpressed with SIRT1." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->R: Enhanced phosphorylation at Thr-336 and Ser- FT 428, enhanced cytoplasmic localization and increased kinase FT activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 74 FT /note="R->A: Impaired formation of a heterotrimeric complex FT with STRADA and CAB39; when associated with A-204." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 78 FT /note="K->I: Loss of kinase activity, leading to greatly FT reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 78 FT /note="K->M: Loss of kinase activity, leading to reduced FT autophosphorylation and acting as a dominant-negative FT mutant." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 96 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 97 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 189 FT /note="T->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:11430832" FT MUTAGEN 194 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14517248, FT ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:19892943" FT MUTAGEN 204 FT /note="F->A: No effect. Impaired formation of a FT heterotrimeric complex with STRADA and CAB39; when FT associated with A-74." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 428 FT /note="S->A,E: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18854309" FT STRAND 54..57 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 62..68 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 69..71 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 74..80 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 82..87 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 91..102 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 120..123 FT /evidence="ECO:0007829|PDB:8VSU" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 136..142 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 150..169 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 190..192 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 217..219 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 231..233 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 234..250 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 260..269 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 280..289 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 294..296 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 300..305 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 307..310 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 326..328 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:4ZDR" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:2WTK" FT MOD_RES Q15831-2:399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:23612973" SQ SEQUENCE 433 AA; 48636 MW; 6DF4C37AB7A89569 CRC64; MEVVDPQQLG MFTEGELMSV GMDTFIHRID STEVIYQPRR KRAKLIGKYL MGDLLGEGSY GKVKEVLDSE TLCRRAVKIL KKKKLRRIPN GEANVKKEIQ LLRRLRHKNV IQLVDVLYNE EKQKMYMVME YCVCGMQEML DSVPEKRFPV CQAHGYFCQL IDGLEYLHSQ GIVHKDIKPG NLLLTTGGTL KISDLGVAEA LHPFAADDTC RTSQGSPAFQ PPEIANGLDT FSGFKVDIWS AGVTLYNITT GLYPFEGDNI YKLFENIGKG SYAIPGDCGP PLSDLLKGML EYEPAKRFSI RQIRQHSWFR KKHPPAEAPV PIPPSPDTKD RWRSMTVVPY LEDLHGADED EDLFDIEDDI IYTQDFTVPG QVPEEEASHN GQRRGLPKAV CMNGTEAAQL STKSRAEGRA PNPARKACSA SSKIRRLSAC KQQ // ID STK26_HUMAN Reviewed; 416 AA. AC Q9P289; B2RAU2; Q3ZB77; Q8NC04; Q9BXC3; Q9BXC4; DT 16-AUG-2005, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 195. DE RecName: Full=Serine/threonine-protein kinase 26 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:11641781, ECO:0000269|PubMed:29232556}; DE AltName: Full=MST3 and SOK1-related kinase {ECO:0000303|PubMed:11741893}; DE AltName: Full=Mammalian STE20-like protein kinase 4 {ECO:0000303|PubMed:11641781}; DE Short=MST-4 {ECO:0000305}; DE Short=STE20-like kinase MST4 {ECO:0000305}; DE AltName: Full=Serine/threonine-protein kinase MASK {ECO:0000305}; GN Name=STK26 {ECO:0000312|HGNC:HGNC:18174}; GN Synonyms=MASK {ECO:0000303|PubMed:11741893}, GN MST4 {ECO:0000303|PubMed:11641781}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=11641781; DOI=10.1038/sj.onc.1204818; RA Lin J.-L., Chen H.-C., Fang H.-I., Robinson D., Kung H.-J., Shih H.-M.; RT "MST4, a new Ste20-related kinase that mediates cell growth and RT transformation via modulating ERK pathway."; RL Oncogene 20:6559-6569(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Fetal brain; RX PubMed=11306563; DOI=10.1074/jbc.m009323200; RA Qian Z., Lin C., Espinosa R., LeBeau M., Rosner M.R.; RT "Cloning and characterization of MST4, a novel Ste20-like kinase."; RL J. Biol. Chem. 276:22439-22445(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=11741893; DOI=10.1074/jbc.m110882200; RA Dan I., Ong S.E., Watanabe N.M., Blagoev B., Nielsen M.M., Kajikawa E., RA Kristiansen T.Z., Mann M., Pandey A.; RT "Cloning of MASK, a novel member of the mammalian germinal center kinase RT III subfamily, with apoptosis-inducing properties."; RL J. Biol. Chem. 277:5929-5939(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-178, INTERACTION WITH GOLGA2, RP AND ACTIVITY REGULATION. RX PubMed=15037601; DOI=10.1083/jcb.200310061; RA Preisinger C., Short B., De Corte V., Bruyneel E., Haas A., Kopajtich R., RA Gettemans J., Barr F.A.; RT "YSK1 is activated by the Golgi matrix protein GM130 and plays a role in RT cell migration through its substrate 14-3-3zeta."; RL J. Cell Biol. 164:1009-1020(2004). RN [10] RP INTERACTION WITH PDCD10, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17360971; DOI=10.1091/mbc.e06-07-0608; RA Ma X., Zhao H., Shan J., Long F., Chen Y., Chen Y., Zhang Y., Han X., RA Ma D.; RT "PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and RT transformation via modulation of the ERK pathway."; RL Mol. Biol. Cell 18:1965-1978(2007). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4 AND THR-178, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-300; SER-304 AND SER-306, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP INTERACTION WITH PDCD10. RX PubMed=19370760; DOI=10.1002/humu.20996; RA Voss K., Stahl S., Hogan B.M., Reinders J., Schleider E., RA Schulte-Merker S., Felbor U.; RT "Functional analyses of human and zebrafish 18-amino acid in-frame deletion RT pave the way for domain mapping of the cerebral cavernous malformation 3 RT protein."; RL Hum. Mutat. 30:1003-1011(2009). RN [14] RP INTERACTION WITH CTTNBP2NL, IDENTIFICATION IN STRIPAK COMPLEX, AND RP FUNCTION. RX PubMed=18782753; DOI=10.1074/mcp.m800266-mcp200; RA Goudreault M., D'Ambrosio L.M., Kean M.J., Mullin M.J., Larsen B.G., RA Sanchez A., Chaudhry S., Chen G.I., Sicheri F., Nesvizhskii A.I., RA Aebersold R., Raught B., Gingras A.C.; RT "A PP2A phosphatase high density interaction network identifies a novel RT striatin-interacting phosphatase and kinase complex linked to the cerebral RT cavernous malformation 3 (CCM3) protein."; RL Mol. Cell. Proteomics 8:157-171(2009). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-4; THR-178 AND SER-300, CLEAVAGE OF INITIATOR METHIONINE RP [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE RP SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-178, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [17] RP INTERACTION WITH PDCD10 AND GOLGA2, AND SUBCELLULAR LOCATION. RX PubMed=20332113; DOI=10.1242/jcs.061341; RA Fidalgo M., Fraile M., Pires A., Force T., Pombo C., Zalvide J.; RT "CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell RT orientation."; RL J. Cell Sci. 123:1274-1284(2010). RN [18] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-4, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE RP ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [20] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-4; SER-300; SER-304 AND SER-306, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4; THR-178; SER-325; THR-327 RP AND THR-328, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [24] RP FUNCTION, INTERACTION WITH RIPOR1, AND SUBCELLULAR LOCATION. RX PubMed=27807006; DOI=10.1242/jcs.198614; RA Mardakheh F.K., Self A., Marshall C.J.; RT "RHO binding to FAM65A regulates Golgi reorientation during cell RT migration."; RL J. Cell Sci. 129:4466-4479(2016). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-53. RX PubMed=29232556; DOI=10.1016/j.ccell.2017.11.005; RA Huang T., Kim C.K., Alvarez A.A., Pangeni R.P., Wan X., Song X., Shi T., RA Yang Y., Sastry N., Horbinski C.M., Lu S., Stupp R., Kessler J.A., RA Nishikawa R., Nakano I., Sulman E.P., Lu X., James C.D., Yin X.M., Hu B., RA Cheng S.Y.; RT "MST4 phosphorylation of ATG4B regulates autophagic activity, RT tumorigenicity, and radioresistance in glioblastoma."; RL Cancer Cell 32:840-855(2017). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 1-300 IN COMPLEX WITH QUINAZOLIN RP INHIBITOR, AND SUBUNIT. RX PubMed=20730082; DOI=10.1371/journal.pone.0011905; RA Record C.J., Chaikuad A., Rellos P., Das S., Pike A.C., Fedorov O., RA Marsden B.D., Knapp S., Lee W.H.; RT "Structural comparison of human mammalian ste20-like kinases."; RL PLoS ONE 5:E11905-E11905(2010). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-9; TRP-36 AND CYS-45. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a mediator of CC cell growth (PubMed:11641781, PubMed:17360971). Modulates apoptosis CC (PubMed:11641781, PubMed:17360971). In association with STK24 CC negatively regulates Golgi reorientation in polarized cell migration CC upon RHO activation (PubMed:27807006). Phosphorylates ATG4B at 'Ser- CC 383', thereby increasing autophagic flux (PubMed:29232556). Part of the CC striatin-interacting phosphatase and kinase (STRIPAK) complexes. CC STRIPAK complexes have critical roles in protein (de)phosphorylation CC and are regulators of multiple signaling pathways including Hippo, CC MAPK, nuclear receptor and cytoskeleton remodeling. Different types of CC STRIPAK complexes are involved in a variety of biological processes CC such as cell growth, differentiation, apoptosis, metabolism and immune CC regulation (PubMed:18782753). {ECO:0000269|PubMed:11641781, CC ECO:0000269|PubMed:17360971, ECO:0000269|PubMed:18782753, CC ECO:0000269|PubMed:27807006, ECO:0000269|PubMed:29232556}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:11641781, ECO:0000269|PubMed:29232556}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:11641781}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q9Y4P1}; CC -!- ACTIVITY REGULATION: Interaction with Golgi matrix protein GOLGA2 leads CC to autophosphorylation on Thr-178, possibly as a consequence of CC stabilization of dimer formation. May also be activated by C-terminal CC cleavage. {ECO:0000269|PubMed:15037601}. CC -!- SUBUNIT: Homodimer (PubMed:20730082). Interacts with PDCD10 CC (PubMed:17360971, PubMed:19370760, PubMed:20332113). Interacts with CC GOLGA2 (PubMed:15037601, PubMed:20332113). Interacts with CTTNBP2NL CC (PubMed:18782753). Interacts with RIPOR1 (via C-terminus); this CC interaction occurs in a PDCD10-dependent and Rho-independent manner CC (PubMed:27807006). Interacts with PDCD10; this interaction is required CC for the association of STK26 with RIPOR1 (PubMed:27807006). Part of the CC core of STRIPAK complexes composed of PP2A catalytic and scaffolding CC subunits, the striatins (PP2A regulatory subunits), the striatin- CC associated proteins MOB4, STRIP1 and STRIP2, PDCD10 and members of the CC STE20 kinases, such as STK24 and STK26 (PubMed:18782753). CC {ECO:0000269|PubMed:15037601, ECO:0000269|PubMed:17360971, CC ECO:0000269|PubMed:18782753, ECO:0000269|PubMed:19370760, CC ECO:0000269|PubMed:20332113, ECO:0000269|PubMed:20730082, CC ECO:0000269|PubMed:27807006}. CC -!- INTERACTION: CC Q9P289; Q9Y376: CAB39; NbExp=6; IntAct=EBI-618239, EBI-306905; CC Q9P289; P13569: CFTR; NbExp=6; IntAct=EBI-618239, EBI-349854; CC Q9P289; Q9P2B4: CTTNBP2NL; NbExp=6; IntAct=EBI-618239, EBI-1774273; CC Q9P289; Q08379: GOLGA2; NbExp=7; IntAct=EBI-618239, EBI-618309; CC Q9P289; Q9BUL8: PDCD10; NbExp=11; IntAct=EBI-618239, EBI-740195; CC Q9P289; Q9P289: STK26; NbExp=4; IntAct=EBI-618239, EBI-618239; CC Q9P289; Q5VSL9: STRIP1; NbExp=4; IntAct=EBI-618239, EBI-1773588; CC Q9P289-1; Q9Y376: CAB39; NbExp=10; IntAct=EBI-15996971, EBI-306905; CC Q9P289-1; Q9BUL8: PDCD10; NbExp=10; IntAct=EBI-15996971, EBI-740195; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17360971, CC ECO:0000269|PubMed:27807006}. Golgi apparatus CC {ECO:0000269|PubMed:15037601, ECO:0000269|PubMed:27807006}. CC Note=Colocalized with RIPOR1 in the Golgi of serum-starved cells and CC relocated to cytoplasmic punctae, probably vesicular compartments, CC along with RIPOR1 upon serum stimulation in a Rho- and PDCD10-dependent CC manner (PubMed:27807006). {ECO:0000269|PubMed:27807006}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9P289-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9P289-2; Sequence=VSP_041469; CC Name=3; Synonyms=MST4a; CC IsoId=Q9P289-3; Sequence=VSP_041470; CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF231012; AAK38484.1; -; mRNA. DR EMBL; AF344882; AAK29620.1; -; mRNA. DR EMBL; AF344883; AAK29621.1; -; mRNA. DR EMBL; AB040057; BAA92785.2; -; mRNA. DR EMBL; BT020099; AAV38902.1; -; mRNA. DR EMBL; AK075107; BAC11406.1; -; mRNA. DR EMBL; AK314356; BAG36989.1; -; mRNA. DR EMBL; AL109749; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471107; EAX11786.1; -; Genomic_DNA. DR EMBL; CH471107; EAX11787.1; -; Genomic_DNA. DR EMBL; BC098315; AAH98315.1; -; mRNA. DR EMBL; BC103503; AAI03504.1; -; mRNA. DR CCDS; CCDS14631.1; -. [Q9P289-1] DR CCDS; CCDS43995.1; -. [Q9P289-3] DR CCDS; CCDS48168.1; -. [Q9P289-2] DR RefSeq; NP_001035917.1; NM_001042452.2. [Q9P289-3] DR RefSeq; NP_001035918.1; NM_001042453.2. [Q9P289-2] DR RefSeq; NP_057626.2; NM_016542.3. [Q9P289-1] DR PDB; 3GGF; X-ray; 2.35 A; A/B=1-300. DR PDB; 3W8I; X-ray; 2.40 A; B=346-416. DR PDB; 4FZA; X-ray; 3.15 A; B=18-297. DR PDB; 4FZD; X-ray; 3.25 A; B=18-297, C=323-327. DR PDB; 4FZF; X-ray; 3.64 A; B=18-297. DR PDB; 4GEH; X-ray; 1.95 A; B/D=325-413. DR PDB; 5XY9; X-ray; 2.30 A; C/D=314-325. DR PDB; 5YF4; X-ray; 1.90 A; B=320-335. DR PDB; 7B36; X-ray; 2.11 A; A/C=1-300. DR PDBsum; 3GGF; -. DR PDBsum; 3W8I; -. DR PDBsum; 4FZA; -. DR PDBsum; 4FZD; -. DR PDBsum; 4FZF; -. DR PDBsum; 4GEH; -. DR PDBsum; 5XY9; -. DR PDBsum; 5YF4; -. DR PDBsum; 7B36; -. DR AlphaFoldDB; Q9P289; -. DR SMR; Q9P289; -. DR BioGRID; 119722; 244. DR CORUM; Q9P289; -. DR DIP; DIP-34049N; -. DR FunCoup; Q9P289; 1696. DR IntAct; Q9P289; 111. DR MINT; Q9P289; -. DR STRING; 9606.ENSP00000377867; -. DR BindingDB; Q9P289; -. DR ChEMBL; CHEMBL5941; -. DR DrugBank; DB07853; 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P289; -. DR GlyGen; Q9P289; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9P289; -. DR PhosphoSitePlus; Q9P289; -. DR SwissPalm; Q9P289; -. DR BioMuta; STK26; -. DR DMDM; 73621232; -. DR jPOST; Q9P289; -. DR MassIVE; Q9P289; -. DR PaxDb; 9606-ENSP00000377867; -. DR PeptideAtlas; Q9P289; -. DR ProteomicsDB; 83756; -. [Q9P289-1] DR ProteomicsDB; 83757; -. [Q9P289-2] DR ProteomicsDB; 83758; -. [Q9P289-3] DR Pumba; Q9P289; -. DR Antibodypedia; 30220; 299 antibodies from 38 providers. DR DNASU; 51765; -. DR Ensembl; ENST00000394334.7; ENSP00000377867.2; ENSG00000134602.17. [Q9P289-1] DR Ensembl; ENST00000394335.6; ENSP00000377868.2; ENSG00000134602.17. [Q9P289-2] DR Ensembl; ENST00000496850.1; ENSP00000419702.1; ENSG00000134602.17. [Q9P289-3] DR GeneID; 51765; -. DR KEGG; hsa:51765; -. DR MANE-Select; ENST00000394334.7; ENSP00000377867.2; NM_016542.4; NP_057626.2. DR UCSC; uc004ewk.2; human. [Q9P289-1] DR AGR; HGNC:18174; -. DR CTD; 51765; -. DR DisGeNET; 51765; -. DR GeneCards; STK26; -. DR HGNC; HGNC:18174; STK26. DR HPA; ENSG00000134602; Tissue enhanced (bone marrow, epididymis). DR MIM; 300547; gene. DR OpenTargets; ENSG00000134602; -. DR VEuPathDB; HostDB:ENSG00000134602; -. DR eggNOG; KOG0201; Eukaryota. DR GeneTree; ENSGT00940000157904; -. DR HOGENOM; CLU_000288_63_23_1; -. DR InParanoid; Q9P289; -. DR OrthoDB; 8693905at2759; -. DR PAN-GO; Q9P289; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P289; -. DR PathwayCommons; Q9P289; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR SignaLink; Q9P289; -. DR SIGNOR; Q9P289; -. DR Agora; ENSG00000134602; -. DR BioGRID-ORCS; 51765; 18 hits in 777 CRISPR screens. DR ChiTaRS; STK26; human. DR EvolutionaryTrace; Q9P289; -. DR GeneWiki; MST4; -. DR GenomeRNAi; 51765; -. DR Pharos; Q9P289; Tchem. DR PRO; PR:Q9P289; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q9P289; protein. DR Bgee; ENSG00000134602; Expressed in germinal epithelium of ovary and 175 other cell types or tissues. DR ExpressionAtlas; Q9P289; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0071944; C:cell periphery; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0090443; C:FAR/SIN/STRIPAK complex; IDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005798; C:Golgi-associated vesicle; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0012506; C:vesicle membrane; TAS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IMP:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:1903698; P:positive regulation of microvillus assembly; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR CDD; cd06640; STKc_MST4; 1. DR FunFam; 1.10.510.10:FF:000411; Probable Ste20-like kinase Don3; 1. DR FunFam; 1.10.12.70:FF:000004; Serine/threonine-protein kinase 26; 1. DR FunFam; 3.30.200.20:FF:000252; Serine/threonine-protein kinase 26; 1. DR Gene3D; 1.10.12.70; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR046409; PDC10_dimerisation_sf. DR InterPro; IPR048288; PDCD10_N. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050629; STE20/SPS1-PAK. DR InterPro; IPR035056; STK_MST4. DR PANTHER; PTHR48012:SF7; SERINE_THREONINE-PROTEIN KINASE 26; 1. DR PANTHER; PTHR48012; STERILE20-LIKE KINASE, ISOFORM B-RELATED; 1. DR Pfam; PF20929; PDCD10_N; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Golgi apparatus; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT CHAIN 2..416 FT /note="Serine/threonine-protein kinase 26" FT /id="PRO_0000086404" FT DOMAIN 24..274 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 297..340 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 144 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 30..38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 53 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:29232556" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT MOD_RES 4 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 178 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15037601, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 300 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692" FT MOD_RES 304 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 306 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 309 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q99JT2" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 327 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 328 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 15..91 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041469" FT VAR_SEQ 200..261 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11306563" FT /id="VSP_041470" FT VARIANT 9 FT /note="Q -> R (in dbSNP:rs56035648)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040844" FT VARIANT 36 FT /note="G -> W (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040845" FT VARIANT 45 FT /note="R -> C (in dbSNP:rs56044451)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040846" FT MUTAGEN 53 FT /note="K->E: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:29232556" FT HELIX 20..23 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 24..31 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 32..34 FT /evidence="ECO:0007829|PDB:4FZD" FT STRAND 36..43 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 44..46 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 49..56 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:4FZD" FT HELIX 61..63 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 64..76 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 85..91 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 94..100 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 104..106 FT /evidence="ECO:0007829|PDB:3GGF" FT HELIX 107..111 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 118..137 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 138..142 FT /evidence="ECO:0007829|PDB:3GGF" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 150..152 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 158..160 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:4FZD" FT TURN 172..174 FT /evidence="ECO:0007829|PDB:4FZA" FT TURN 176..178 FT /evidence="ECO:0007829|PDB:4FZA" FT HELIX 188..191 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 199..214 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 218..221 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 224..233 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 241..243 FT /evidence="ECO:0007829|PDB:4FZA" FT HELIX 245..254 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 265..268 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 272..277 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 282..296 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 329..331 FT /evidence="ECO:0007829|PDB:5YF4" FT HELIX 346..350 FT /evidence="ECO:0007829|PDB:3W8I" FT HELIX 352..355 FT /evidence="ECO:0007829|PDB:4GEH" FT HELIX 357..366 FT /evidence="ECO:0007829|PDB:4GEH" FT TURN 367..370 FT /evidence="ECO:0007829|PDB:3W8I" FT HELIX 372..391 FT /evidence="ECO:0007829|PDB:4GEH" FT HELIX 395..409 FT /evidence="ECO:0007829|PDB:4GEH" SQ SEQUENCE 416 AA; 46529 MW; 3E31B7E3CBDA5768 CRC64; MAHSPVAVQV PGMQNNIADP EELFTKLERI GKGSFGEVFK GIDNRTQQVV AIKIIDLEEA EDEIEDIQQE ITVLSQCDSS YVTKYYGSYL KGSKLWIIME YLGGGSALDL LRAGPFDEFQ IATMLKEILK GLDYLHSEKK IHRDIKAANV LLSEQGDVKL ADFGVAGQLT DTQIKRNTFV GTPFWMAPEV IQQSAYDSKA DIWSLGITAI ELAKGEPPNS DMHPMRVLFL IPKNNPPTLV GDFTKSFKEF IDACLNKDPS FRPTAKELLK HKFIVKNSKK TSYLTELIDR FKRWKAEGHS DDESDSEGSD SESTSRENNT HPEWSFTTVR KKPDPKKVQN GAEQDLVQTL SCLSMIITPA FAELKQQDEN NASRNQAIEE LEKSIAVAEA ACPGITDKMV KKLIEKFQKC SADESP // ID TEX14_HUMAN Reviewed; 1497 AA. AC Q8IWB6; A6NH19; Q7RTP3; Q8ND97; Q9BXT9; DT 25-JUL-2006, integrated into UniProtKB/Swiss-Prot. DT 25-JUL-2006, sequence version 2. DT 28-JAN-2026, entry version 183. DE RecName: Full=Inactive serine/threonine-protein kinase TEX14; DE AltName: Full=Protein kinase-like protein SgK307; DE AltName: Full=Sugen kinase 307; DE AltName: Full=Testis-expressed sequence 14; DE AltName: Full=Testis-expressed sequence 14 protein; GN Name=TEX14; Synonyms=SGK307; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 480-1497 (ISOFORM 3), AND TISSUE SPECIFICITY. RC TISSUE=Testis; RX PubMed=11279525; DOI=10.1038/86927; RA Wang P.J., McCarrey J.R., Yang F., Page D.C.; RT "An abundance of X-linked genes expressed in spermatogonia."; RL Nat. Genet. 27:422-426(2001). RN [5] RP IDENTIFICATION, AND ALTERNATIVE SPLICING (ISOFORM 2). RX PubMed=12711554; DOI=10.1016/s1567-133x(03)00036-x; RA Wu M.-H., Rajkovic A., Burns K.H., Yan W., Lin Y.-N., Matzuk M.M.; RT "Sequence and expression of testis-expressed gene 14 (Tex14): a gene RT encoding a protein kinase preferentially expressed during RT spermatogenesis."; RL Gene Expr. Patterns 3:231-236(2003). RN [6] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CEP55. RX PubMed=20176808; DOI=10.1128/mcb.01392-09; RA Iwamori T., Iwamori N., Ma L., Edson M.A., Greenbaum M.P., Matzuk M.M.; RT "TEX14 interacts with CEP55 to block cell abscission."; RL Mol. Cell. Biol. 30:2280-2292(2010). RN [7] RP PHOSPHORYLATION, AND MUTAGENESIS OF 614-SER--THR-618 AND 726-SER--THR-728. RX PubMed=22405274; DOI=10.1016/j.molcel.2012.01.013; RA Mondal G., Ohashi A., Yang L., Rowley M., Couch F.J.; RT "Tex14, a plk1-regulated protein, is required for kinetochore-microtubule RT attachment and regulation of the spindle assembly checkpoint."; RL Mol. Cell 45:680-695(2012). RN [8] RP INVOLVEMENT IN SPGF23, AND TISSUE SPECIFICITY. RX PubMed=28206990; DOI=10.1038/gim.2016.225; RA Gershoni M., Hauser R., Yogev L., Lehavi O., Azem F., Yavetz H., RA Pietrokovski S., Kleiman S.E.; RT "A familial study of azoospermic men identifies three novel causative RT mutations in three new human azoospermia genes."; RL Genet. Med. 19:998-1006(2017). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-88; GLU-321; CYS-443 AND MET-559. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP VARIANT SPGF23 1152-ARG--ASP-1497 DEL. RX PubMed=32741963; DOI=10.1038/s41436-020-0907-1; RA Krausz C., Riera-Escamilla A., Moreno-Mendoza D., Holleman K., Cioppi F., RA Algaba F., Pybus M., Friedrich C., Wyrwoll M.J., Casamonti E., RA Pietroforte S., Nagirnaja L., Lopes A.M., Kliesch S., Pilatz A., RA Carrell D.T., Conrad D.F., Ars E., Ruiz-Castane E., Aston K.I., RA Baarends W.M., Tuettelmann F.; RT "Genetic dissection of spermatogenic arrest through exome analysis: RT clinical implications for the management of azoospermic men."; RL Genet. Med. 22:1956-1966(2020). CC -!- FUNCTION: Required both for the formation of intercellular bridges CC during meiosis and for kinetochore-microtubule attachment during CC mitosis. Intercellular bridges are evolutionarily conserved structures CC that connect differentiating germ cells and are required for CC spermatogenesis and male fertility. Acts by promoting the conversion of CC midbodies into intercellular bridges via its interaction with CEP55: CC interaction with CEP55 inhibits the interaction between CEP55 and CC PDCD6IP/ALIX and TSG101, blocking cell abscission and leading to CC transform midbodies into intercellular bridges. Also plays a role CC during mitosis: recruited to kinetochores by PLK1 during early mitosis CC and regulates the maturation of the outer kinetochores and microtubule CC attachment. Has no protein kinase activity in vitro (By similarity). CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with KIF23 and RBM44. Interacts with CEP55; CC inhibiting interaction between CEP55 and PDCD6IP/ALIX and TSG101 (By CC similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q8IWB6; Q53EZ4: CEP55; NbExp=5; IntAct=EBI-6674697, EBI-747776; CC Q8IWB6; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-6674697, EBI-742054; CC Q8IWB6; Q9UBR4-2: LHX3; NbExp=5; IntAct=EBI-6674697, EBI-12039345; CC Q8IWB6; P61968: LMO4; NbExp=3; IntAct=EBI-6674697, EBI-2798728; CC Q8IWB6; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-6674697, EBI-16439278; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Midbody {ECO:0000250}. CC Chromosome, centromere, kinetochore {ECO:0000250}. Note=Detected in the CC intercellular bridges that connect male germ cell daughter cells after CC cell division. {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q8IWB6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8IWB6-2; Sequence=VSP_019868; CC Name=3; CC IsoId=Q8IWB6-3; Sequence=VSP_019868, VSP_019869; CC -!- TISSUE SPECIFICITY: Expression restricted to testis. CC {ECO:0000269|PubMed:11279525, ECO:0000269|PubMed:28206990}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- DOMAIN: The GPPX3Y motif mediates interaction with CEP55. CC -!- PTM: Phosphorylated on Thr residues by CDK1 during early phases of CC mitosis, promoting the interaction with PLK1 and recruitment to CC kinetochores. Phosphorylated on Ser-437 by PLK1 during late CC prometaphase promotes the rapid depletion from kinetochores and its CC subsequent degradation by the APC/C complex. CC {ECO:0000269|PubMed:22405274}. CC -!- DISEASE: Spermatogenic failure 23 (SPGF23) [MIM:617707]: An infertility CC disorder caused by spermatogenesis defects that result in non- CC obstructive azoospermia. {ECO:0000269|PubMed:28206990, CC ECO:0000269|PubMed:32741963}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC -!- CAUTION: Ser-376 is present instead of the conserved Asp which is CC expected to be an active site residue. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAK31980.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL834143; CAD38856.2; -; mRNA. DR EMBL; AC005666; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040526; AAH40526.1; -; mRNA. DR EMBL; AF285601; AAK31980.1; ALT_INIT; mRNA. DR EMBL; BK000998; DAA01359.1; -; mRNA. DR CCDS; CCDS32692.1; -. [Q8IWB6-3] DR CCDS; CCDS32693.1; -. [Q8IWB6-2] DR CCDS; CCDS56042.1; -. [Q8IWB6-1] DR RefSeq; NP_001188386.1; NM_001201457.2. [Q8IWB6-1] DR RefSeq; NP_112562.3; NM_031272.4. [Q8IWB6-3] DR RefSeq; NP_938207.2; NM_198393.4. [Q8IWB6-2] DR PDB; 3WUT; X-ray; 2.30 A; C/F/I/L=792-804. DR PDB; 3WUU; X-ray; 2.90 A; C/F/I/L=791-805. DR PDBsum; 3WUT; -. DR PDBsum; 3WUU; -. DR AlphaFoldDB; Q8IWB6; -. DR SMR; Q8IWB6; -. DR BioGRID; 121089; 33. DR ELM; Q8IWB6; -. DR FunCoup; Q8IWB6; 103. DR IntAct; Q8IWB6; 30. DR STRING; 9606.ENSP00000240361; -. DR TCDB; 8.A.23.1.18; the basigin (basigin) family. DR GlyGen; Q8IWB6; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q8IWB6; -. DR PhosphoSitePlus; Q8IWB6; -. DR BioMuta; TEX14; -. DR DMDM; 110816441; -. DR MassIVE; Q8IWB6; -. DR PaxDb; 9606-ENSP00000240361; -. DR PeptideAtlas; Q8IWB6; -. DR ProteomicsDB; 70835; -. [Q8IWB6-1] DR ProteomicsDB; 70836; -. [Q8IWB6-2] DR ProteomicsDB; 70837; -. [Q8IWB6-3] DR Antibodypedia; 31015; 88 antibodies from 24 providers. DR DNASU; 56155; -. DR Ensembl; ENST00000240361.12; ENSP00000240361.8; ENSG00000121101.17. [Q8IWB6-1] DR Ensembl; ENST00000349033.10; ENSP00000268910.8; ENSG00000121101.17. [Q8IWB6-3] DR Ensembl; ENST00000389934.7; ENSP00000374584.3; ENSG00000121101.17. [Q8IWB6-2] DR GeneID; 56155; -. DR KEGG; hsa:56155; -. DR MANE-Select; ENST00000349033.10; ENSP00000268910.8; NM_031272.5; NP_112562.3. [Q8IWB6-3] DR UCSC; uc002iwr.3; human. [Q8IWB6-1] DR AGR; HGNC:11737; -. DR ClinPGx; PA36454; -. DR CTD; 56155; -. DR DisGeNET; 56155; -. DR GeneCards; TEX14; -. DR HGNC; HGNC:11737; TEX14. DR HPA; ENSG00000121101; Tissue enriched (testis). DR MalaCards; TEX14; -. DR MIM; 605792; gene. DR MIM; 617707; phenotype. DR OpenTargets; ENSG00000121101; -. DR Orphanet; 399805; Male infertility with azoospermia or oligozoospermia due to single gene mutation. DR VEuPathDB; HostDB:ENSG00000121101; -. DR eggNOG; ENOG502QSZN; Eukaryota. DR GeneTree; ENSGT00390000015123; -. DR HOGENOM; CLU_004733_0_0_1; -. DR InParanoid; Q8IWB6; -. DR OMA; FGKAMPW; -. DR OrthoDB; 5962695at2759; -. DR PAN-GO; Q8IWB6; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q8IWB6; -. DR PathwayCommons; Q8IWB6; -. DR SignaLink; Q8IWB6; -. DR SIGNOR; Q8IWB6; -. DR Agora; ENSG00000121101; -. DR BioGRID-ORCS; 56155; 10 hits in 1171 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TEX14; human. DR EvolutionaryTrace; Q8IWB6; -. DR GenomeRNAi; 56155; -. DR Pharos; Q8IWB6; Tbio. DR PRO; PR:Q8IWB6; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q8IWB6; protein. DR Bgee; ENSG00000121101; Expressed in right testis and 97 other cell types or tissues. DR ExpressionAtlas; Q8IWB6; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0045171; C:intercellular bridge; ISS:UniProtKB. DR GO; GO:0000776; C:kinetochore; ISS:UniProtKB. DR GO; GO:0030496; C:midbody; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0008608; P:attachment of spindle microtubules to kinetochore; ISS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl. DR GO; GO:0043063; P:intercellular bridge organization; ISS:UniProtKB. DR GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0051306; P:mitotic sister chromatid separation; ISS:UniProtKB. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; ISS:UniProtKB. DR GO; GO:0032466; P:negative regulation of cytokinesis; IEA:Ensembl. DR CDD; cd14011; PK_SCY1_like; 1. DR FunFam; 1.10.510.10:FF:000428; inactive serine/threonine-protein kinase TEX14 isoform X1; 1. DR FunFam; 1.25.40.20:FF:000153; inactive serine/threonine-protein kinase TEX14 isoform X3; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR039339; Tex14. DR PANTHER; PTHR23060:SF1; INACTIVE SERINE_THREONINE-PROTEIN KINASE TEX14; 1. DR PANTHER; PTHR23060; TESTIS EXPRESSED GENE 14; 1. DR Pfam; PF12796; Ank_2; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR SMART; SM00248; ANK; 3. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ANK repeat; ATP-binding; Cell cycle; KW Cell division; Centromere; Chromosome; Cytoplasm; Kinetochore; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat. FT CHAIN 1..1497 FT /note="Inactive serine/threonine-protein kinase TEX14" FT /id="PRO_0000246995" FT REPEAT 27..54 FT /note="ANK 1" FT REPEAT 55..84 FT /note="ANK 2" FT REPEAT 88..117 FT /note="ANK 3" FT DOMAIN 227..518 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 848..877 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 963..1048 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1144..1174 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1348..1470 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 795..801 FT /note="GPPX3Y" FT MOTIF 852..860 FT /note="D-box" FT COMPBIAS 989..1020 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1037..1046 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1160..1174 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1348..1360 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1368..1406 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1428..1460 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 233..241 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 273 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 175 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1M5M3" FT MOD_RES 437 FT /note="Phosphoserine; by PLK1" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1M5M3" FT MOD_RES 665 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1M5M3" FT MOD_RES 1106 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 1404 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 1459 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 1496 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT VAR_SEQ 213..218 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:11279525, FT ECO:0000303|PubMed:17974005" FT /id="VSP_019868" FT VAR_SEQ 1064..1103 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11279525, FT ECO:0000303|PubMed:17974005" FT /id="VSP_019869" FT VARIANT 88 FT /note="D -> G (in dbSNP:rs56292204)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041388" FT VARIANT 321 FT /note="K -> E (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs2045795960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041389" FT VARIANT 443 FT /note="S -> C (in dbSNP:rs2144493686)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041390" FT VARIANT 559 FT /note="I -> M" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041391" FT VARIANT 1152..1497 FT /note="Missing (in SPGF23)" FT /evidence="ECO:0000269|PubMed:32741963" FT /id="VAR_087420" FT MUTAGEN 614..618 FT /note="SSPST->AAPAA: In PBD-1; reduced ability to interact FT with PLK1." FT /evidence="ECO:0000269|PubMed:22405274" FT MUTAGEN 726..728 FT /note="STT->AAA: In PBD-5; reduced ability to interact with FT PLK1." FT /evidence="ECO:0000269|PubMed:22405274" FT CONFLICT 1326 FT /note="H -> R (in Ref. 4; AAK31980)" FT /evidence="ECO:0000305" FT CONFLICT 1387 FT /note="L -> P (in Ref. 1; CAD38856)" FT /evidence="ECO:0000305" FT STRAND 797..800 FT /evidence="ECO:0007829|PDB:3WUT" SQ SEQUENCE 1497 AA; 167901 MW; D7DC446A1A18FC4D CRC64; MSRAVRLPVP CPVQLGTLRN DSLEAQLHEY VKQGNYVKVK KILKKGIYVD AVNSLGQTAL FVAALLGLRK FVDVLVDYGS DPNHRCFDGS TPVHAAAFSG NQWILSKLLD AGGDLRLHDE RGQNPKTWAL TAGKERSTQI VEFMQRCASH MQAIIQGFSY DLLKKIDSPQ RLVYSPSWCG GLVQGNPNGS PNRLLKAGVI SAQNIYSFGF GKAMPWFQFY LTGATQMAYL GSLPVIGEKE VIQADDEPTF SFFSGPYMVM TNLVWNGSRV TVKELNLPTH PHCSRLRLAD LLIAEQEHSS KLRHPYLLQL MAVCLSQDLE KTRLVYERIT IGTLFSVLHE RRSQFPVLHM EVIVHLLLQI SDALRYLHFQ GFIHRSLSSY AVHIISPGEA RLTNLEYMLE SEDRGVQRDL TRVPLPTQLY NWAAPEVILQ KAATVKSDIY SFSMIMQEIL TDDIPWKGLD GSVVKKAVVS GNYLEADVRL PKPYYDIVKS GIHVKQKDRT MNLQDIRYIL KNDLKDFTGA QRTQPTESPR VQRYGLHPDV NVYLGLTSEH PRETPDMEII ELKEMGSQPH SPRVHSLFTE GTLDPQAPDP CLMARETQNQ DAPCPAPFMA EEASSPSTGQ PSLCSFEINE IYSGCLILED DIEEPPGAAS SLEADGPNQV DELKSMEEEL DKMEREACCF GSEDESSSKA ETEYSFDDWD WQNGSLSSLS LPESTREAKS NLNNMSTTEE YLISKCVLDL KIMQTIMHEN DDRLRNIEQI LDEVEMKQKE QEERMSLWAT SREFTNAYKL PLAVGPPSLN YIPPVLQLSG GQKPDTSGNY PTLPRFPRML PTLCDPGKQN TDEQFQCTQG AKDSLETSRI QNTSSQGRPR ESTAQAKATQ FNSALFTLSS HRQGPSASPS CHWDSTRMSV EPVSSEIYNA ESRNKDDGKV HLKWKMEVKE MAKKAATGQL TVPPWHPQSS LTLESEAENE PDALLQPPIR SPENTDWQRV IEYHRENDEP RGNGKFDKTG NNDCDSDQHG RQPRLGSFTS IRHPSPRQKE QPEHSEAFQA SSDTLVAVEK SYSHQSMQST CSPESSEDIT DEFLTPDGEY FYSSTAQENL ALETSSPIEE DFEGIQGAFA QPQVSGEEKF QMRKILGKNA EILPRSQFQP VRSTEDEQEE TSKESPKELK EKDISLTDIQ DLSSISYEPD SSFKEASCKT PKINHAPTSV STPLSPGSVS SAASQYKDCL ESITFQVKTE FASCWNSQEF IQTLSDDFIS VRERAKKLDS LLTSSETPPS RLTGLKRLSS FIGAGSPSLV KACDSSPPHA TQRRSLPKVE AFSQHHIDEL PPPSQELLDD IELLKQQQGS STVLHENTAS DGGGTANDQR HLEEQETDSK KEDSSMLLSK ETEDLGEDTE RAHSTLDEDL ERWLQPPEES VELQDLPKGS ERETNIKDQK VGEEKRKRED SITPERRKSE GVLGTSEEDE LKSCFWKRLG WSESSRIIVL DQSDLSD // ID TGFR2_HUMAN Reviewed; 567 AA. AC P37173; B4DTV5; Q15580; Q6DKT6; Q99474; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 258. DE RecName: Full=TGF-beta receptor type-2; DE Short=TGFR-2; DE EC=2.7.11.30; DE AltName: Full=TGF-beta type II receptor; DE AltName: Full=Transforming growth factor-beta receptor type II; DE Short=TGF-beta receptor type II; DE Short=TbetaR-II; DE Flags: Precursor; GN Name=TGFBR2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-439, AND SUBCELLULAR RP LOCATION. RC TISSUE=Liver; RX PubMed=1310899; DOI=10.1016/0092-8674(92)90152-3; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RT "Expression cloning of the TGF-beta type II receptor, a functional RT transmembrane serine/threonine kinase."; RL Cell 68:775-785(1992). RN [2] RP ERRATUM OF PUBMED:1310899. RX PubMed=1525823; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RL Cell 70:1069-1069(1992). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Glial cell; RX PubMed=7959019; DOI=10.1016/0378-1119(94)90178-3; RA Nikawa J.; RT "A cDNA encoding the human transforming growth factor beta receptor RT suppresses the growth defect of a yeast mutant."; RL Gene 149:367-372(1994). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8812462; DOI=10.1006/geno.1996.0471; RA Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W.P., RA Harris C.C.; RT "The genomic structure of the gene encoding the human transforming growth RT factor beta type II receptor (TGF-beta RII)."; RL Genomics 36:341-344(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8840968; RA Lu S.-L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y.; RT "Genomic structure of the transforming growth factor beta type II receptor RT gene and its mutations in hereditary nonpolyposis colorectal cancers."; RL Cancer Res. 56:4595-4598(1996). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439. RC TISSUE=Liver; RX PubMed=8973329; DOI=10.1016/s0378-1119(96)00501-x; RA Ogasa H., Noma T., Murata H., Kawai S., Nakazawa A.; RT "Cloning of a cDNA encoding the human transforming growth factor-beta type RT II receptor: heterogeneity of the mRNA."; RL Gene 181:185-190(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION (ISOFORM 3), SUBUNIT RP (ISOFORM 3), AND SUBCELLULAR LOCATION (ISOFORM 3). RC TISSUE=Peripheral blood T-cell {ECO:0000303|PubMed:34568316}; RX PubMed=34568316; DOI=10.3389/fcell.2021.690397; RA Bertolio M.S., La Colla A., Carrea A., Romo A., Canziani G., Echarte S.M., RA Campisano S., Barletta G.P., Monzon A.M., Rodriguez T.M., Chisari A.N., RA Dewey R.A.; RT "A Novel Splice Variant of Human TGF-beta Type II Receptor Encodes a RT Soluble Protein and Its Fc-Tagged Version Prevents Liver Fibrosis in RT vivo."; RL Front. Cell Dev. Biol. 9:690397-690397(2021). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-36. RG NIEHS SNPs program; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 23-37. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [12] RP FUNCTION IN PHOSPHORYLATION OF TGFBR1. RX PubMed=7774578; DOI=10.1002/j.1460-2075.1995.tb07214.x; RA Wieser R., Wrana J.L., Massague J.; RT "GS domain mutations that constitutively activate T beta R-I, the RT downstream signaling component in the TGF-beta receptor complex."; RL EMBO J. 14:2199-2208(1995). RN [13] RP INTERACTION WITH CLU. RX PubMed=8555189; DOI=10.1021/bi951880a; RA Reddy K.B., Karode M.C., Harmony A.K., Howe P.H.; RT "Interaction of transforming growth factor beta receptors with RT apolipoprotein J/clusterin."; RL Biochemistry 35:309-314(1996). RN [14] RP ALTERNATIVE SPLICING (ISOFORM 2), AND FUNCTION (ISOFORMS 1 AND 2). RX PubMed=8635485; DOI=10.1006/excr.1996.0066; RA Hirai R., Fijita T.; RT "A human transforming growth factor-beta type II receptor that contains an RT insertion in the extracellular domain."; RL Exp. Cell Res. 223:135-141(1996). RN [15] RP INTERACTION WITH ZFYVE9. RX PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8; RA Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.; RT "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor."; RL Cell 95:779-791(1998). RN [16] RP HOMODIMERIZATION. RX PubMed=9472030; DOI=10.1083/jcb.140.4.767; RA Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.; RT "Oligomeric structure of type I and type II transforming growth factor beta RT receptors: homodimers form in the ER and persist at the plasma membrane."; RL J. Cell Biol. 140:767-777(1998). RN [17] RP INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-277. RX PubMed=11483955; DOI=10.1038/35087019; RA Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.; RT "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that RT facilitates JNK activation."; RL Nat. Cell Biol. 3:708-714(2001). RN [18] RP INTERACTION WITH VPS39. RX PubMed=12941698; DOI=10.1093/emboj/cdg428; RA Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S., RA McNally J.G., Roberts A.B.; RT "TLP, a novel modulator of TGF-beta signaling, has opposite effects on RT Smad2- and Smad3-dependent signaling."; RL EMBO J. 22:4465-4477(2003). RN [19] RP INTERACTION WITH DYNLT4. RX PubMed=16982625; DOI=10.1074/jbc.m608614200; RA Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T., RA McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.; RT "Identification of Tctex2beta, a novel dynein light chain family member RT that interacts with different transforming growth factor-beta receptors."; RL J. Biol. Chem. 281:37069-37080(2006). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP IDENTIFICATION IN A COMPLEX WITH TSC22D1 AND TGFBR1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [23] RP INTERACTION WITH SCUBE3. RX PubMed=21441952; DOI=10.1038/onc.2011.85; RA Wu Y.Y., Peck K., Chang Y.L., Pan S.H., Cheng Y.F., Lin J.C., Yang R.B., RA Hong T.M., Yang P.C.; RT "SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the RT epithelial-mesenchymal transition in lung cancer."; RL Oncogene 30:3682-3693(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUBCELLULAR LOCATION. RX PubMed=25893292; DOI=10.1038/onc.2015.100; RA Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H., Lee J.H.; RT "Syntenin regulates TGF-beta1-induced Smad activation and the epithelial- RT to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I RT receptor internalization."; RL Oncogene 35:389-401(2016). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 38-159 IN COMPLEX WITH TGF-BETA3, RP AND DISULFIDE BONDS. RX PubMed=11850637; DOI=10.1038/nsb766; RA Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P.; RT "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex."; RL Nat. Struct. Biol. 9:203-208(2002). RN [28] RP X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 49-159, AND DISULFIDE BONDS. RX PubMed=12121646; DOI=10.1016/s0969-2126(02)00780-3; RA Boesen C.C., Radaev S., Motyka S.A., Patamawenu A., Sun P.D.; RT "The 1.1 A crystal structure of human TGF-beta type II receptor ligand RT binding domain."; RL Structure 10:913-919(2002). RN [29] RP STRUCTURE BY NMR OF 38-159, AND DISULFIDE BONDS. RX PubMed=12939140; DOI=10.1021/bi034366a; RA Deep S., Walker K.P. III, Shu Z., Hinck A.P.; RT "Solution structure and backbone dynamics of the TGFbeta type II receptor RT extracellular domain."; RL Biochemistry 42:10126-10139(2003). RN [30] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 43-149 IN COMPLEX WITH TGFBR1 AND RP TGFB3, AND DISULFIDE BONDS. RX PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039; RA Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P., RA Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.; RT "Cooperative assembly of TGF-beta superfamily signaling complexes is RT mediated by two disparate mechanisms and distinct modes of receptor RT binding."; RL Mol. Cell 29:157-168(2008). RN [31] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 38-153 IN COMPLEX WITH TGFBR1 AND RP TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS. RX PubMed=20207738; DOI=10.1074/jbc.m109.079921; RA Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.; RT "Ternary complex of transforming growth factor-beta1 reveals isoform- RT specific ligand recognition and receptor recruitment in the superfamily."; RL J. Biol. Chem. 285:14806-14814(2010). RN [32] RP VARIANT HNPCC6 MET-315. RX PubMed=9590282; DOI=10.1038/ng0598-17; RA Lu S.-L., Kawabata M., Imamura T., Akiyama Y., Nomizu T., Miyazono K., RA Yuasa Y.; RT "HNPCC associated with germline mutation in the TGF-beta type II receptor RT gene."; RL Nat. Genet. 19:17-18(1998). RN [33] RP VARIANT ESOPHAGEAL CANCER GLN-526. RX PubMed=10789724; DOI=10.1054/bjoc.1999.1178; RA Tanaka S., Mori M., Mafune K., Ohno S., Sugimachi K.; RT "A dominant negative mutation of transforming growth factor-beta receptor RT type II gene in microsatellite stable oesophageal carcinoma."; RL Br. J. Cancer 82:1557-1560(2000). RN [34] RP VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452, AND RP CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND MET-452. RX PubMed=11212236; RA Luecke C.D., Philpott A., Metcalfe J.C., Thompson A.M., Hughes-Davies L., RA Kemp P.R., Hesketh R.; RT "Inhibiting mutations in the transforming growth factor beta type 2 RT receptor in recurrent human breast cancer."; RL Cancer Res. 61:482-485(2001). RN [35] RP VARIANT ILE-191. RX PubMed=12202987; DOI=10.1007/s100380200069; RA Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T., Matsumoto N., RA Ishikawa M., Niikawa N., Yoshiura K.; RT "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types RT of variations in genes for transforming growth factor-beta1 (TGF-beta1) and RT its signaling pathway."; RL J. Hum. Genet. 47:478-483(2002). RN [36] RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537, AND CHARACTERIZATION OF RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537. RX PubMed=15235604; DOI=10.1038/ng1392; RA Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N., RA Morisaki T., Allard D., Varret M., Claustres M., Morisaki H., Ihara M., RA Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G., Ohta T., RA Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C., Matsumoto N.; RT "Heterozygous TGFBR2 mutations in Marfan syndrome."; RL Nat. Genet. 36:855-860(2004). RN [37] RP VARIANTS LDS2 CYS-460 AND HIS-460. RX PubMed=16027248; DOI=10.1161/circulationaha.105.537340; RA Pannu H., Fadulu V.T., Chang J., Lafont A., Hasham S.N., Sparks E., RA Giampietro P.F., Zaleski C., Estrera A.L., Safi H.J., Shete S., RA Willing M.C., Raman C.S., Milewicz D.M.; RT "Mutations in transforming growth factor-beta receptor type II cause RT familial thoracic aortic aneurysms and dissections."; RL Circulation 112:513-520(2005). RN [38] RP VARIANTS LDS2 ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528. RX PubMed=15731757; DOI=10.1038/ng1511; RA Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., RA Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A., RA Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y., RA Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B., De Paepe A.M., RA Dietz H.C.; RT "A syndrome of altered cardiovascular, craniofacial, neurocognitive and RT skeletal development caused by mutations in TGFBR1 or TGFBR2."; RL Nat. Genet. 37:275-281(2005). RN [39] RP VARIANT LDS2 ASN-446. RX PubMed=16251899; DOI=10.1038/sj.ejhg.5201502; RA Disabella E., Grasso M., Marziliano N., Ansaldi S., Lucchelli C., Porcu E., RA Tagliani M., Pilotto A., Diegoli M., Lanzarini L., Malattia C., RA Pelliccia A., Ficcadenti A., Gabrielli O., Arbustini E.; RT "Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not RT associated with FBN1 gene defects."; RL Eur. J. Hum. Genet. 14:34-38(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328; ILE-373; RP MET-387 AND SER-490. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [42] RP VARIANTS LDS2 HIS-190; VAL-247; PRO-325; ARG-357 AND ILE-530. RX PubMed=19533785; DOI=10.1002/ajmg.a.32918; RA Chung B.H., Lam S.T., Tong T.M., Li S.Y., Lun K.S., Chan D.H., Fok S.F., RA Or J.S., Smith D.K., Yang W., Lau Y.L.; RT "Identification of novel FBN1 and TGFBR2 mutations in 65 probands with RT Marfan syndrome or Marfan-like phenotypes."; RL Am. J. Med. Genet. A 149A:1452-1459(2009). RN [43] RP VARIANT LDS2 SER-510. RX PubMed=19883511; DOI=10.1186/1750-1172-4-24; RA Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R., RA Calzavara-Pinton P.G., Barlati S., Colombi M.; RT "Loeys-Dietz syndrome type I and type II: clinical findings and novel RT mutations in two Italian patients."; RL Orphanet J. Rare Dis. 4:24-24(2009). RN [44] RP VARIANT LDS2 LYS-457. RX PubMed=20101701; DOI=10.1002/ajmg.a.33263; RA Muramatsu Y., Kosho T., Magota M., Yokotsuka T., Ito M., Yasuda A., RA Kito O., Suzuki C., Nagata Y., Kawai S., Ikoma M., Hatano T., Nakayama M., RA Kawamura R., Wakui K., Morisaki H., Morisaki T., Fukushima Y.; RT "Progressive aortic root and pulmonary artery aneurysms in a neonate with RT Loeys-Dietz syndrome type 1B."; RL Am. J. Med. Genet. A 152:417-421(2010). RN [45] RP VARIANTS LDS2 PRO-308 AND ARG-521. RX PubMed=20358619; DOI=10.1002/ajmg.a.33356; RA Kirmani S., Tebben P.J., Lteif A.N., Gordon D., Clarke B.L., Hefferan T.E., RA Yaszemski M.J., McGrann P.S., Lindor N.M., Ellison J.W.; RT "Germline TGF-beta receptor mutations and skeletal fragility: a report on RT two patients with Loeys-Dietz syndrome."; RL Am. J. Med. Genet. A 152:1016-1019(2010). RN [46] RP VARIANTS LDS2 GLN-306 DELINS HIS-GLU; ARG-377; PHE-449 AND ARG-514. RX PubMed=22113417; DOI=10.1038/jhg.2011.130; RA Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K., RA Lee H.J., Kim D.K.; RT "Clinical features and genetic analysis of Korean patients with Loeys-Dietz RT syndrome."; RL J. Hum. Genet. 57:52-56(2012). RN [47] RP VARIANTS LDS2 VAL-509 AND PHE-510. RX PubMed=21949523; DOI=10.3345/kjp.2011.54.6.272; RA Ha J.S., Kim Y.H.; RT "A sporadic case of Loeys-Dietz syndrome type I with two novel mutations of RT the TGFBR2 gene."; RL Korean J. Pediatr. 54:272-275(2011). CC -!- FUNCTION: Transmembrane serine/threonine kinase forming with the TGF- CC beta type I serine/threonine kinase receptor, TGFBR1, the non- CC promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. CC Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to CC the cytoplasm and thus regulates a plethora of physiological and CC pathological processes including cell cycle arrest in epithelial and CC hematopoietic cells, control of mesenchymal cell proliferation and CC differentiation, wound healing, extracellular matrix production, CC immunosuppression and carcinogenesis. The formation of the receptor CC complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound CC to the cytokine dimer results in the phosphorylation and activation of CC TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 CC phosphorylates SMAD2 which dissociates from the receptor and interacts CC with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the CC nucleus where it modulates the transcription of the TGF-beta-regulated CC genes. This constitutes the canonical SMAD-dependent TGF-beta signaling CC cascade. Also involved in non-canonical, SMAD-independent TGF-beta CC signaling pathways. {ECO:0000269|PubMed:7774578}. CC -!- FUNCTION: [Isoform 1]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 2]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 3]: Binds TGFB1, TGFB2 and TGFB3 in the picomolar CC affinity range without the participation of additional receptors. CC Blocks activation of SMAD2 and SMAD3 by TGFB1. CC {ECO:0000269|PubMed:34568316}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric CC ligands assemble a functional receptor composed of two TGFBR1 and CC TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The CC respective affinity of TGFRB1 and TGFRB2 for the ligands may modulate CC the kinetics of assembly of the receptor and may explain the different CC biological activities of TGFB1, TGFB2 and TGFB3. Component of a complex CC composed of TSC22D1 (via N-terminus), TGFBR1 and TGFBR2; the CC interaction between TSC22D1 and TGFBR1 is inhibited by SMAD7 and CC promoted by TGFB1 (PubMed:21791611). Interacts with DAXX. Interacts CC with DYNLT4. Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to CC the TGF-beta receptor. Interacts with and is activated by SCUBE3; this CC interaction does not affect TGFB1-binding to TGFBR2. Interacts with CC VPS39; this interaction is independent of the receptor kinase activity CC and of the presence of TGF-beta. Interacts with CLU (PubMed:8555189). CC {ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11850637, CC ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:16982625, CC ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738, CC ECO:0000269|PubMed:21441952, ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:8555189, ECO:0000269|PubMed:9865696}. CC -!- SUBUNIT: [Isoform 3]: Homodimer; disulfide-linked. CC {ECO:0000269|PubMed:34568316}. CC -!- INTERACTION: CC P37173; P54819: AK2; NbExp=3; IntAct=EBI-296151, EBI-1056291; CC P37173; P61966-2: AP1S1; NbExp=3; IntAct=EBI-296151, EBI-12067760; CC P37173; Q9NP61: ARFGAP3; NbExp=3; IntAct=EBI-296151, EBI-2875816; CC P37173; O75143-2: ATG13; NbExp=3; IntAct=EBI-296151, EBI-20151086; CC P37173; Q93084-2: ATP2A3; NbExp=3; IntAct=EBI-296151, EBI-21505448; CC P37173; P54253: ATXN1; NbExp=3; IntAct=EBI-296151, EBI-930964; CC P37173; P54252: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-946046; CC P37173; Q4VBR4: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-12928880; CC P37173; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-296151, EBI-742750; CC P37173; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-296151, EBI-747505; CC P37173; P40227: CCT6A; NbExp=3; IntAct=EBI-296151, EBI-356687; CC P37173; P12830: CDH1; NbExp=3; IntAct=EBI-296151, EBI-727477; CC P37173; Q8NE08: COL25A1; NbExp=3; IntAct=EBI-296151, EBI-25836642; CC P37173; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-296151, EBI-9087876; CC P37173; Q9UER7: DAXX; NbExp=2; IntAct=EBI-296151, EBI-77321; CC P37173; Q9UMR2: DDX19B; NbExp=3; IntAct=EBI-296151, EBI-719232; CC P37173; P49184: DNASE1L1; NbExp=3; IntAct=EBI-296151, EBI-20894690; CC P37173; O14531: DPYSL4; NbExp=3; IntAct=EBI-296151, EBI-719542; CC P37173; P26378-2: ELAVL4; NbExp=3; IntAct=EBI-296151, EBI-21603100; CC P37173; P15036: ETS2; NbExp=3; IntAct=EBI-296151, EBI-1646991; CC P37173; P09471: GNAO1; NbExp=3; IntAct=EBI-296151, EBI-715087; CC P37173; P51674: GPM6A; NbExp=3; IntAct=EBI-296151, EBI-7187133; CC P37173; P42858: HTT; NbExp=3; IntAct=EBI-296151, EBI-466029; CC P37173; O75874: IDH1; NbExp=3; IntAct=EBI-296151, EBI-715695; CC P37173; Q6PI98: INO80C; NbExp=3; IntAct=EBI-296151, EBI-722540; CC P37173; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-296151, EBI-2557660; CC P37173; P06756: ITGAV; NbExp=3; IntAct=EBI-296151, EBI-298282; CC P37173; P23276: KEL; NbExp=3; IntAct=EBI-296151, EBI-746662; CC P37173; O60259: KLK8; NbExp=3; IntAct=EBI-296151, EBI-3915857; CC P37173; Q96E93: KLRG1; NbExp=3; IntAct=EBI-296151, EBI-750770; CC P37173; Q8N448: LNX2; NbExp=3; IntAct=EBI-296151, EBI-2340947; CC P37173; Q7Z434: MAVS; NbExp=3; IntAct=EBI-296151, EBI-995373; CC P37173; Q93074: MED12; NbExp=3; IntAct=EBI-296151, EBI-394357; CC P37173; Q14728: MFSD10; NbExp=3; IntAct=EBI-296151, EBI-11337904; CC P37173; P01106: MYC; NbExp=3; IntAct=EBI-296151, EBI-447544; CC P37173; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-296151, EBI-3446748; CC P37173; Q99435-2: NELL2; NbExp=3; IntAct=EBI-296151, EBI-17754404; CC P37173; Q8TAT6: NPLOC4; NbExp=3; IntAct=EBI-296151, EBI-1994109; CC P37173; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-296151, EBI-22002759; CC P37173; Q96IY1: NSL1; NbExp=3; IntAct=EBI-296151, EBI-2554690; CC P37173; Q16549: PCSK7; NbExp=3; IntAct=EBI-296151, EBI-8059854; CC P37173; Q9NUD9: PIGV; NbExp=3; IntAct=EBI-296151, EBI-25836582; CC P37173; Q8TBJ4: PLPPR1; NbExp=3; IntAct=EBI-296151, EBI-18063495; CC P37173; Q07869: PPARA; NbExp=3; IntAct=EBI-296151, EBI-78615; CC P37173; Q13200: PSMD2; NbExp=3; IntAct=EBI-296151, EBI-357648; CC P37173; P21246: PTN; NbExp=3; IntAct=EBI-296151, EBI-473725; CC P37173; Q13702-2: RAPSN; NbExp=3; IntAct=EBI-296151, EBI-22012855; CC P37173; P52756: RBM5; NbExp=3; IntAct=EBI-296151, EBI-714003; CC P37173; Q6NTF9-3: RHBDD2; NbExp=3; IntAct=EBI-296151, EBI-17589229; CC P37173; Q96NA2: RILP; NbExp=3; IntAct=EBI-296151, EBI-2856119; CC P37173; P61513: RPL37A; NbExp=3; IntAct=EBI-296151, EBI-356793; CC P37173; Q8IX30: SCUBE3; NbExp=6; IntAct=EBI-296151, EBI-4479975; CC P37173; Q8NC51: SERBP1; NbExp=3; IntAct=EBI-296151, EBI-523558; CC P37173; Q16586: SGCA; NbExp=3; IntAct=EBI-296151, EBI-5663553; CC P37173; Q99720-4: SIGMAR1; NbExp=3; IntAct=EBI-296151, EBI-25831036; CC P37173; Q8NCS7: SLC44A5; NbExp=3; IntAct=EBI-296151, EBI-21504521; CC P37173; Q16560-2: SNRNP35; NbExp=3; IntAct=EBI-296151, EBI-12938570; CC P37173; Q7Z614-3: SNX20; NbExp=3; IntAct=EBI-296151, EBI-12336127; CC P37173; Q3SY56: SP6; NbExp=3; IntAct=EBI-296151, EBI-11175533; CC P37173; P46977: STT3A; NbExp=3; IntAct=EBI-296151, EBI-719212; CC P37173; O43463: SUV39H1; NbExp=3; IntAct=EBI-296151, EBI-349968; CC P37173; Q13428-5: TCOF1; NbExp=3; IntAct=EBI-296151, EBI-25832010; CC P37173; P01137: TGFB1; NbExp=11; IntAct=EBI-296151, EBI-779636; CC P37173; P10600: TGFB3; NbExp=8; IntAct=EBI-296151, EBI-1033020; CC P37173; Q9Y228: TRAF3IP3; NbExp=3; IntAct=EBI-296151, EBI-765817; CC P37173; Q96BQ3: TRIM43; NbExp=3; IntAct=EBI-296151, EBI-2129899; CC P37173; Q9UHP3: USP25; NbExp=3; IntAct=EBI-296151, EBI-2513462; CC P37173; Q969W3: VCF1; NbExp=3; IntAct=EBI-296151, EBI-10281506; CC P37173; P19544-6: WT1; NbExp=3; IntAct=EBI-296151, EBI-11745701; CC P37173; P25490: YY1; NbExp=3; IntAct=EBI-296151, EBI-765538; CC P37173; A2AGH6: Med12; Xeno; NbExp=3; IntAct=EBI-296151, EBI-5744969; CC P37173; P07200: TGFB1; Xeno; NbExp=2; IntAct=EBI-296151, EBI-907660; CC P37173-2; P02750: LRG1; NbExp=3; IntAct=EBI-16065370, EBI-9083443; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1310899, CC ECO:0000269|PubMed:25893292}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:1310899}. Membrane raft CC {ECO:0000269|PubMed:25893292}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted CC {ECO:0000269|PubMed:34568316}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=betaR-II {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-1; Sequence=Displayed; CC Name=2; Synonyms=betaR-IIB {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-2; Sequence=VSP_012157; CC Name=3; Synonyms=TbetaRII-SE {ECO:0000303|PubMed:34568316}; CC IsoId=P37173-3; Sequence=VSP_061513, VSP_061514; CC -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic domain. CC -!- DISEASE: Hereditary non-polyposis colorectal cancer 6 (HNPCC6) CC [MIM:614331]: An autosomal dominant disease associated with marked CC increase in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. HNPCC is reported to be the most common form of CC inherited colorectal cancer in the Western world. Clinically, HNPCC is CC often divided into two subgroups. Type I is characterized by hereditary CC predisposition to colorectal cancer, a young age of onset, and CC carcinoma observed in the proximal colon. Type II is characterized by CC increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical HNPCC is based on the Amsterdam CC criteria: 3 or more relatives affected by colorectal cancer, one a CC first degree relative of the other two; 2 or more generation affected; CC 1 or more colorectal cancers presenting before 50 years of age; CC exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' CC or 'incomplete HNPCC' can be used to describe families who do not or CC only partially fulfill the Amsterdam criteria, but in whom a genetic CC basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:9590282}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10789724}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Loeys-Dietz syndrome 2 (LDS2) [MIM:610168]: An aortic aneurysm CC syndrome with widespread systemic involvement, characterized by CC arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or CC cleft palate. Physical findings include prominent joint laxity, easy CC bruising, wide and atrophic scars, velvety and translucent skin with CC easily visible veins, spontaneous rupture of the spleen or bowel, and CC catastrophic complications of pregnancy, including rupture of the CC gravid uterus and the arteries, either during pregnancy or in the CC immediate postpartum period. Some patients have craniosynostosis, CC exotropy, micrognathia and retrognathia, structural brain CC abnormalities, and intellectual deficit. {ECO:0000269|PubMed:15235604, CC ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16027248, CC ECO:0000269|PubMed:16251899, ECO:0000269|PubMed:19533785, CC ECO:0000269|PubMed:19883511, ECO:0000269|PubMed:20101701, CC ECO:0000269|PubMed:20358619, ECO:0000269|PubMed:21949523, CC ECO:0000269|PubMed:22113417}. Note=The disease is caused by variants CC affecting the gene represented in this entry. TGFBR2 mutations Cys-460 CC and His-460 have been reported to be associated with thoracic aortic CC aneurysms and dissection (TAAD). This phenotype, also known as thoracic CC aortic aneurysms type 3 (AAT3), is distinguised from LDS2 by having CC aneurysms restricted to thoracic aorta. As individuals carrying these CC mutations also exhibit descending aortic disease and aneurysms of other CC arteries (PubMed:16027248), they have been considered as LDS2 by the CC OMIM resource. {ECO:0000269|PubMed:16027248}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M85079; AAA61164.1; -; mRNA. DR EMBL; D28131; BAA05673.1; -; mRNA. DR EMBL; U52246; AAB17553.1; -; Genomic_DNA. DR EMBL; U52240; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52241; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52242; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52244; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52245; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U69152; AAB40916.1; -; Genomic_DNA. DR EMBL; U69146; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69147; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69148; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69149; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69150; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69151; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; D50683; BAA09332.1; -; mRNA. DR EMBL; MW881156; UDE22710.1; -; mRNA. DR EMBL; AY675319; AAT70724.1; -; Genomic_DNA. DR EMBL; AK300383; BAG62117.1; -; mRNA. DR EMBL; CH471055; EAW64412.1; -; Genomic_DNA. DR CCDS; CCDS2648.1; -. [P37173-1] DR CCDS; CCDS33727.1; -. [P37173-2] DR PIR; A42100; A42100. DR RefSeq; NP_001020018.1; NM_001024847.3. [P37173-2] DR RefSeq; NP_003233.4; NM_003242.5. [P37173-1] DR PDB; 1KTZ; X-ray; 2.15 A; B=38-159. DR PDB; 1M9Z; X-ray; 1.05 A; A=49-159. DR PDB; 1PLO; NMR; -; A=38-159. DR PDB; 2PJY; X-ray; 3.00 A; B=42-149. DR PDB; 3KFD; X-ray; 3.00 A; E/F/G/H=38-153. DR PDB; 4P7U; X-ray; 1.50 A; A=49-159. DR PDB; 4XJJ; X-ray; 1.40 A; A=50-159. DR PDB; 5E8V; X-ray; 1.69 A; A=237-549. DR PDB; 5E8Y; X-ray; 2.05 A; A=237-549. DR PDB; 5E91; X-ray; 2.42 A; A=237-549. DR PDB; 5E92; X-ray; 2.08 A; A=237-549. DR PDB; 5QIN; X-ray; 1.57 A; A=237-549. DR PDB; 5TX4; X-ray; 1.88 A; A=38-153. DR PDB; 5TY4; EM; 2.90 A; A=47-149. DR PDB; 7DV6; X-ray; 2.39 A; A=237-549. DR PDB; 8G4K; X-ray; 1.24 A; B=45-155. DR PDB; 8YGZ; X-ray; 2.10 A; A=237-549. DR PDB; 9B9F; X-ray; 3.00 A; D/I=42-153. DR PDB; 9E9G; X-ray; 1.40 A; A=38-154. DR PDB; 9FDY; EM; 3.40 A; D/E=42-153. DR PDB; 9FK5; EM; 4.10 A; D=42-153. DR PDB; 9FKP; EM; 3.72 A; D/E=42-153. DR PDBsum; 1KTZ; -. DR PDBsum; 1M9Z; -. DR PDBsum; 1PLO; -. DR PDBsum; 2PJY; -. DR PDBsum; 3KFD; -. DR PDBsum; 4P7U; -. DR PDBsum; 4XJJ; -. DR PDBsum; 5E8V; -. DR PDBsum; 5E8Y; -. DR PDBsum; 5E91; -. DR PDBsum; 5E92; -. DR PDBsum; 5QIN; -. DR PDBsum; 5TX4; -. DR PDBsum; 5TY4; -. DR PDBsum; 7DV6; -. DR PDBsum; 8G4K; -. DR PDBsum; 8YGZ; -. DR PDBsum; 9B9F; -. DR PDBsum; 9E9G; -. DR PDBsum; 9FDY; -. DR PDBsum; 9FK5; -. DR PDBsum; 9FKP; -. DR AlphaFoldDB; P37173; -. DR BMRB; P37173; -. DR EMDB; EMD-50333; -. DR EMDB; EMD-50519; -. DR EMDB; EMD-50524; -. DR EMDB; EMD-8472; -. DR SMR; P37173; -. DR BioGRID; 112906; 202. DR ComplexPortal; CPX-2544; TGF-beta-3-TGFR complex. DR ComplexPortal; CPX-529; TGF-beta-1-TGFR complex. DR ComplexPortal; CPX-834; TGF-beta-2-TGFR complex. DR CORUM; P37173; -. DR DIP; DIP-5939N; -. DR FunCoup; P37173; 1304. DR IntAct; P37173; 185. DR MINT; P37173; -. DR STRING; 9606.ENSP00000351905; -. DR BindingDB; P37173; -. DR ChEMBL; CHEMBL4267; -. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P37173; -. DR GuidetoPHARMACOLOGY; 1795; -. DR GlyConnect; 1979; 9 N-Linked glycans (3 sites). DR GlyCosmos; P37173; 5 sites, 9 glycans. DR GlyGen; P37173; 7 sites, 11 N-linked glycans (3 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P37173; -. DR PhosphoSitePlus; P37173; -. DR SwissPalm; P37173; -. DR BioMuta; TGFBR2; -. DR DMDM; 116242818; -. DR jPOST; P37173; -. DR MassIVE; P37173; -. DR PaxDb; 9606-ENSP00000351905; -. DR PeptideAtlas; P37173; -. DR ProteomicsDB; 55264; -. [P37173-1] DR ProteomicsDB; 55265; -. [P37173-2] DR Pumba; P37173; -. DR Antibodypedia; 11570; 809 antibodies from 42 providers. DR DNASU; 7048; -. DR Ensembl; ENST00000295754.10; ENSP00000295754.5; ENSG00000163513.21. [P37173-1] DR Ensembl; ENST00000359013.4; ENSP00000351905.4; ENSG00000163513.21. [P37173-2] DR GeneID; 7048; -. DR KEGG; hsa:7048; -. DR MANE-Select; ENST00000295754.10; ENSP00000295754.5; NM_003242.6; NP_003233.4. DR UCSC; uc003cen.4; human. [P37173-1] DR AGR; HGNC:11773; -. DR ClinPGx; PA36486; -. DR CTD; 7048; -. DR DisGeNET; 7048; -. DR GeneCards; TGFBR2; -. DR GeneReviews; TGFBR2; -. DR HGNC; HGNC:11773; TGFBR2. DR HPA; ENSG00000163513; Low tissue specificity. DR MalaCards; TGFBR2; -. DR MIM; 133239; phenotype. DR MIM; 190182; gene. DR MIM; 610168; phenotype. DR MIM; 614331; phenotype. DR OpenTargets; ENSG00000163513; -. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 60030; Loeys-Dietz syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 284973; Marfan syndrome type 2. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000163513; -. DR eggNOG; KOG3653; Eukaryota. DR GeneTree; ENSGT00940000157527; -. DR HOGENOM; CLU_000288_8_3_1; -. DR InParanoid; P37173; -. DR OMA; QMPNLCK; -. DR OrthoDB; 547665at2759; -. DR PAN-GO; P37173; 12 GO annotations based on evolutionary models. DR PhylomeDB; P37173; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P37173; -. DR Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer. DR Reactome; R-HSA-3642279; TGFBR2 MSI Frameshift Mutants in Cancer. DR Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer. DR Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer. DR Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-9839389; TGFBR3 regulates TGF-beta signaling. DR SignaLink; P37173; -. DR SIGNOR; P37173; -. DR Agora; ENSG00000163513; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 7048; 45 hits in 1213 CRISPR screens. DR ChiTaRS; TGFBR2; human. DR EvolutionaryTrace; P37173; -. DR GeneWiki; TGF_beta_receptor_2; -. DR GenomeRNAi; 7048; -. DR Pharos; P37173; Tchem. DR PRO; PR:P37173; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P37173; protein. DR Bgee; ENSG00000163513; Expressed in pericardium and 211 other cell types or tissues. DR ExpressionAtlas; P37173; baseline and differential. DR GO; GO:0048179; C:activin receptor complex; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL. DR GO; GO:0070021; C:transforming growth factor beta ligand-receptor complex; IPI:ComplexPortal. DR GO; GO:0048185; F:activin binding; IBA:GO_Central. DR GO; GO:0016361; F:activin receptor activity, type I; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL. DR GO; GO:0019209; F:kinase activator activity; IEA:Ensembl. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL. DR GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL. DR GO; GO:0005024; F:transforming growth factor beta receptor activity; IDA:BHF-UCL. DR GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IDA:UniProt. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0032924; P:activin receptor signaling pathway; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; IMP:BHF-UCL. DR GO; GO:0003180; P:aortic valve morphogenesis; IMP:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0048844; P:artery morphogenesis; IMP:BHF-UCL. DR GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001568; P:blood vessel development; TAS:BHF-UCL. DR GO; GO:0007420; P:brain development; ISS:BHF-UCL. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; ISS:BHF-UCL. DR GO; GO:0060434; P:bronchus morphogenesis; IEA:Ensembl. DR GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL. DR GO; GO:0035162; P:embryonic hemopoiesis; ISS:BHF-UCL. DR GO; GO:0003274; P:endocardial cushion fusion; ISS:BHF-UCL. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0003430; P:growth plate cartilage chondrocyte growth; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:BHF-UCL. DR GO; GO:0001947; P:heart looping; ISS:BHF-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:1905317; P:inferior endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0061520; P:Langerhans cell differentiation; IEA:Ensembl. DR GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl. DR GO; GO:1990086; P:lens fiber cell apoptotic process; IEA:Ensembl. DR GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl. DR GO; GO:0060443; P:mammary gland morphogenesis; IEA:Ensembl. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:BHF-UCL. DR GO; GO:1990428; P:miRNA transport; ISS:BHF-UCL. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; ISS:BHF-UCL. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0002663; P:positive regulation of B cell tolerance induction; ISS:BHF-UCL. DR GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL. DR GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:BHF-UCL. DR GO; GO:0051138; P:positive regulation of NK T cell differentiation; ISS:BHF-UCL. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0002666; P:positive regulation of T cell tolerance induction; ISS:BHF-UCL. DR GO; GO:0002651; P:positive regulation of tolerance induction to self antigen; ISS:BHF-UCL. DR GO; GO:0042127; P:regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:2000736; P:regulation of stem cell differentiation; IMP:BHF-UCL. DR GO; GO:0072091; P:regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL. DR GO; GO:0009410; P:response to xenobiotic stimulus; IDA:BHF-UCL. DR GO; GO:0060021; P:roof of mouth development; IMP:BHF-UCL. DR GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL. DR GO; GO:0060395; P:SMAD protein signal transduction; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0060440; P:trachea formation; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001570; P:vasculogenesis; ISS:BHF-UCL. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd14055; STKc_TGFbR2_like; 1. DR CDD; cd23538; TFP_LU_ECD_TGFR2; 1. DR DisProt; DP01760; -. DR FunFam; 1.10.510.10:FF:000260; TGF-beta receptor type-2; 1. DR FunFam; 2.10.60.10:FF:000009; TGF-beta receptor type-2; 1. DR FunFam; 3.30.200.20:FF:000213; TGF-beta receptor type-2; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00414; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR InterPro; IPR017194; Transform_growth_fac-b_typ-2. DR InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto. DR PANTHER; PTHR23255:SF55; TGF-BETA RECEPTOR TYPE-2; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF08917; ecTbetaR2; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF037393; TGFRII; 1. DR PRINTS; PR00653; ACTIVIN2R. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis; KW ATP-binding; Cell membrane; Craniosynostosis; Differentiation; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Growth regulation; Hereditary nonpolyposis colorectal cancer; Kinase; KW Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Secreted; Serine/threonine-protein kinase; Signal; Transferase; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..22 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 23..567 FT /note="TGF-beta receptor type-2" FT /id="PRO_0000024426" FT TOPO_DOM 23..166 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 167..187 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 188..567 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 244..544 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 439..567 FT /note="Sufficient for interaction with CLU" FT /evidence="ECO:0000269|PubMed:8555189" FT ACT_SITE 379 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 250..258 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 277 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 409 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT MOD_RES 548 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 553 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT CARBOHYD 70 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 94 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 154 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 51..84 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 54..71 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 61..67 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 77..101 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 121..136 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 138..143 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT VAR_SEQ 31..32 FT /note="SV -> SDVEMEAQKDEIICPSCNRTAHPLRHI (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7959019" FT /id="VSP_012157" FT VAR_SEQ 68..80 FT /note="MSNCSITSICEKP -> FSKVHYEGKKKAW (in isoform 3)" FT /id="VSP_061513" FT VAR_SEQ 81..567 FT /note="Missing (in isoform 3)" FT /id="VSP_061514" FT VARIANT 36 FT /note="M -> V (in dbSNP:rs17025864)" FT /evidence="ECO:0000269|Ref.8" FT /id="VAR_020510" FT VARIANT 61 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041414" FT VARIANT 73 FT /note="I -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036070" FT VARIANT 190 FT /note="R -> H (in LDS2; dbSNP:rs780542125)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076167" FT VARIANT 191 FT /note="V -> I (in dbSNP:rs56105708)" FT /evidence="ECO:0000269|PubMed:12202987, FT ECO:0000269|PubMed:17344846" FT /id="VAR_017606" FT VARIANT 247 FT /note="D -> V (in LDS2; dbSNP:rs761231369)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076168" FT VARIANT 306 FT /note="Q -> HE (in LDS2)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066723" FT VARIANT 308 FT /note="L -> P (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs28934568)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:20358619" FT /id="VAR_022351" FT VARIANT 315 FT /note="T -> M (in HNPCC6; dbSNP:rs34833812)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9590282" FT /id="VAR_008156" FT VARIANT 325 FT /note="T -> P (in LDS2; dbSNP:rs2125435431)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076169" FT VARIANT 328 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs2125435491)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041415" FT VARIANT 336 FT /note="Y -> N (in LDS2; dbSNP:rs104893812)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022352" FT VARIANT 355 FT /note="A -> P (in LDS2; dbSNP:rs104893813)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022353" FT VARIANT 357 FT /note="G -> R (in LDS2)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076170" FT VARIANT 357 FT /note="G -> W (in LDS2; dbSNP:rs104893814)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022354" FT VARIANT 373 FT /note="M -> I (in dbSNP:rs35719192)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041416" FT VARIANT 377 FT /note="H -> R (in LDS2; dbSNP:rs1553630274)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066724" FT VARIANT 387 FT /note="V -> M (in a breast tumor; dbSNP:rs35766612)" FT /evidence="ECO:0000269|PubMed:11212236, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022355" FT VARIANT 435 FT /note="N -> S (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022356" FT VARIANT 439 FT /note="V -> A (in dbSNP:rs1050833)" FT /evidence="ECO:0000269|PubMed:1310899, FT ECO:0000269|PubMed:8812462, ECO:0000269|PubMed:8840968, FT ECO:0000269|PubMed:8973329" FT /id="VAR_028063" FT VARIANT 446 FT /note="D -> N (in LDS2; dbSNP:rs886039551)" FT /evidence="ECO:0000269|PubMed:16251899" FT /id="VAR_066725" FT VARIANT 447 FT /note="V -> A (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022357" FT VARIANT 449 FT /note="S -> F (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893807)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:22113417" FT /id="VAR_022358" FT VARIANT 452 FT /note="L -> M (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022359" FT VARIANT 457 FT /note="M -> K (in LDS2)" FT /evidence="ECO:0000269|PubMed:20101701" FT /id="VAR_066726" FT VARIANT 460 FT /note="R -> C (in LDS2; dbSNP:rs104893811)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029760" FT VARIANT 460 FT /note="R -> H (in LDS2; dbSNP:rs104893816)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029761" FT VARIANT 490 FT /note="N -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1699660823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041417" FT VARIANT 509 FT /note="G -> V (in LDS2; dbSNP:rs863223853)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066727" FT VARIANT 510 FT /note="I -> F (in LDS2; dbSNP:rs2125455070)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066728" FT VARIANT 510 FT /note="I -> S (in LDS2)" FT /evidence="ECO:0000269|PubMed:19883511" FT /id="VAR_066729" FT VARIANT 514 FT /note="C -> R (in LDS2; dbSNP:rs193922664)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066730" FT VARIANT 521 FT /note="W -> R (in LDS2; dbSNP:rs1575166666)" FT /evidence="ECO:0000269|PubMed:20358619" FT /id="VAR_066731" FT VARIANT 526 FT /note="E -> Q (in esophageal cancer; dbSNP:rs121918714)" FT /evidence="ECO:0000269|PubMed:10789724" FT /id="VAR_015816" FT VARIANT 528 FT /note="R -> C (in LDS2; dbSNP:rs104893810)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022360" FT VARIANT 528 FT /note="R -> H (in LDS2; dbSNP:rs104893815)" FT /evidence="ECO:0000269|PubMed:15731757, FT ECO:0000269|PubMed:16959974" FT /id="VAR_022361" FT VARIANT 530 FT /note="T -> I (in LDS2; dbSNP:rs1699708963)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076171" FT VARIANT 537 FT /note="R -> C (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893809)" FT /evidence="ECO:0000269|PubMed:15235604" FT /id="VAR_022362" FT MUTAGEN 277 FT /note="K->R: Abolishes kinase activity, TGF-beta signaling FT and interaction with DAXX." FT /evidence="ECO:0000269|PubMed:11483955" FT CONFLICT 381 FT /note="K -> N (in Ref. 6; BAA09332)" FT /evidence="ECO:0000305" FT STRAND 40..45 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 50..52 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 55..58 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 65..68 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 74..76 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 78..81 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 83..90 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 95..102 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 104..106 FT /evidence="ECO:0007829|PDB:5TY4" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:2PJY" FT TURN 114..117 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 119..122 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 124..126 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 131..138 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:1PLO" FT HELIX 143..145 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 146..148 FT /evidence="ECO:0007829|PDB:1M9Z" FT HELIX 151..153 FT /evidence="ECO:0007829|PDB:9E9G" FT STRAND 244..252 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 257..263 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 267..269 FT /evidence="ECO:0007829|PDB:7DV6" FT STRAND 272..280 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 281..283 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 284..294 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 297..299 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 307..315 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 318..326 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 333..339 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 344..362 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 382..384 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 385..387 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 393..395 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 410..413 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 422..424 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 427..430 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 440..459 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 473..477 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 484..491 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 492..494 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 502..506 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 508..520 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 531..539 FT /evidence="ECO:0007829|PDB:5QIN" SQ SEQUENCE 567 AA; 64568 MW; C541DA751FFBDBEB CRC64; MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE LEHLDRLSGR SCSEEKIPED GSLNTTK // ID TITIN_HUMAN Reviewed; 34350 AA. AC Q8WZ42; A0A0A0MTS7; A6NKB1; C9JQJ2; E7EQE6; E7ET18; K7ENY1; Q10465; Q10466; AC Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q4ZG20; Q6NSG0; Q6PDB1; Q6PJP0; Q7KYM2; AC Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8; Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; AC Q92761; Q92762; Q9UD97; Q9UP84; Q9Y6L9; DT 13-JUN-2006, integrated into UniProtKB/Swiss-Prot. DT 18-APR-2012, sequence version 4. DT 28-JAN-2026, entry version 220. DE RecName: Full=Titin; DE EC=2.7.11.1; DE AltName: Full=Connectin; DE AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14; GN Name=TTN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF RP 3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; MET-3261; ASN-3419; RP SER-3491; GLU-12679; ILE-19762; ILE-20718; ASN-23807; MET-24980 AND RP THR-27755. RC TISSUE=Skeletal muscle; RX PubMed=7569978; DOI=10.1126/science.270.5234.293; RA Labeit S., Kolmerer B.; RT "Titins, giant proteins in charge of muscle ultrastructure and RT elasticity."; RL Science 270:293-296(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS RP LEU-1295; GLN-1572; ILE-2610; ASN-2831; SER-3491; PRO-4215; PHE-4283 AND RP ARG-12383. RX PubMed=10850961; DOI=10.1161/01.res.86.11.1114; RA Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F., Centner T., RA Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C., Granzier H., Labeit S.; RT "Series of exon-skipping events in the elastic spring region of titin as RT the structural basis for myofibrillar elastic diversity."; RL Circ. Res. 86:1114-1121(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS LEU-1295; GLN-1572; RP ILE-2610; ASN-2831; SER-3491; PRO-4215 AND PHE-4283. RX PubMed=11717165; DOI=10.1161/hh2301.100981; RA Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M., McNabb M., RA Witt C.C., Labeit D., Gregorio C.C., Granzier H., Labeit S.; RT "The complete gene sequence of titin, expression of an unusual ~700 kDa RT titin isoform and its interaction with obscurin identify a novel Z-line to RT I-band linking system."; RL Circ. Res. 89:1065-1072(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350 (ISOFORM RP 3). RC TISSUE=Muscle, and Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2). RC TISSUE=Heart muscle; RX PubMed=8937992; DOI=10.1242/jcs.109.11.2747; RA Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.; RT "The central Z-disk region of titin is assembled from a novel repeat in RT variable copy numbers."; RL J. Cell Sci. 109:2747-2754(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY. RC TISSUE=Heart muscle; RX PubMed=7819249; DOI=10.1021/bi00002a021; RA Musco G., Tziatzos C., Schuck P., Pastore A.; RT "Dissecting titin into its structural motifs: identification of an alpha RT helix near the N-terminus."; RL Biochemistry 34:553-561(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-4215 AND RP PHE-4283. RX PubMed=10051295; DOI=10.1161/01.cir.99.8.1022; RA Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S., RA Benson D.W., Seidman J.G., Seidman C.E.; RT "Familial dilated cardiomyopathy locus maps to chromosome 2q31."; RL Circulation 99:1022-1026(1999). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5). RC TISSUE=Heart ventricle; RX PubMed=12785098; DOI=10.1023/a:1023410523184; RA Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.; RT "Species variations in cDNA sequence and exon splicing patterns in the RT extensible I-band region of cardiac titin: relation to passive tension."; RL J. Muscle Res. Cell Motil. 23:473-482(2002). RN [10] RP PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669; 26545-26553; RP 28758-28774 AND 32920-32928, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797. RC TISSUE=Embryonic rhabdomyosarcoma; RA Behrends U., Gotz C., Mautner J.; RT "Serological identification of rhabdomyosarcoma antigens."; RL Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE OF 14257-14543. RX PubMed=8351016; DOI=10.1212/wnl.43.8.1581; RA Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., RA Labeit S., Mygland A., Gilhus N.E., Aarli J.A.; RT "Titin antibodies in myasthenia gravis: identification of a major RT immunogenic region of titin."; RL Neurology 43:1581-1585(1993). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE [GENOMIC RP DNA] OF 23754-24284. RX PubMed=1582406; DOI=10.1002/j.1460-2075.1992.tb05222.x; RA Labeit S., Gautel M., Lakey A., Trinick J.; RT "Towards a molecular understanding of titin."; RL EMBO J. 11:1711-1716(1992). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION. RX PubMed=8404852; DOI=10.1002/j.1460-2075.1993.tb06061.x; RA Gautel M., Leonard K., Labeit S.; RT "Phosphorylation of KSF motifs in the C-terminal region of titin in RT differentiating myoblasts."; RL EMBO J. 12:3827-3834(1993). RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [16] RP INTERACTION WITH TCAP. RX PubMed=9645487; DOI=10.1016/s0014-5793(98)00501-8; RA Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.; RT "Two immunoglobulin-like domains of the Z-disc portion of titin interact in RT a conformation-dependent way with telethonin."; RL FEBS Lett. 428:111-114(1998). RN [17] RP INTERACTION WITH NEB. RX PubMed=12482578; DOI=10.1016/s0014-5793(02)03655-4; RA Ma K., Wang K.; RT "Interaction of nebulin SH3 domain with titin PEVK and myopalladin: RT implications for the signaling and assembly role of titin and nebulin."; RL FEBS Lett. 532:273-278(2002). RN [18] RP INTERACTION WITH FHL2. RX PubMed=12432079; DOI=10.1242/jcs.00181; RA Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W., RA Perriard J.-C., Ehler E.; RT "Subcellular targeting of metabolic enzymes to titin in heart muscle may be RT mediated by DRAL/FHL-2."; RL J. Cell Sci. 115:4925-4936(2002). RN [19] RP INTERACTION WITH ANK1. RX PubMed=12444090; DOI=10.1074/jbc.m209012200; RA Kontrogianni-Konstantopoulos A., Bloch R.J.; RT "The hydrophilic domain of small ankyrin-1 interacts with the two N- RT terminal immunoglobulin domains of titin."; RL J. Biol. Chem. 278:3985-3991(2003). RN [20] RP INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3. RX PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012; RA Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C., Watanabe K., RA Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.; RT "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family RT of titin filament-based stress response molecules."; RL J. Mol. Biol. 333:951-964(2003). RN [21] RP INTERACTION WITH CRYAB. RX PubMed=14676215; DOI=10.1074/jbc.m307473200; RA Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D., RA Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.; RT "Association of the chaperone alphaB-crystallin with titin in heart RT muscle."; RL J. Biol. Chem. 279:7917-7924(2004). RN [22] RP INTERACTION WITH TRIM63 AND TRIM55. RX PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021; RA Witt S.H., Granzier H., Witt C.C., Labeit S.; RT "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins RT redundantly: towards understanding MURF-dependent muscle ubiquitination."; RL J. Mol. Biol. 350:713-722(2005). RN [23] RP INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION. RX PubMed=16410549; DOI=10.1242/jcs.02728; RA Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.; RT "Nuclear titin interacts with A- and B-type lamins in vitro and in vivo."; RL J. Cell Sci. 119:239-249(2006). RN [24] RP REVIEW. RX PubMed=16537787; DOI=10.1152/ajpheart.00816.2005; RA Hoshijima M.; RT "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, RT titin, and associated structures."; RL Am. J. Physiol. 290:H1313-H1325(2006). RN [25] RP INTERACTION WITH CMYA5. RX PubMed=20634290; DOI=10.1074/jbc.m110.108720; RA Sarparanta J., Blandin G., Charton K., Vihola A., Marchand S., Milic A., RA Hackman P., Ehler E., Richard I., Udd B.; RT "Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to RT tibial and limb-girdle muscular dystrophies."; RL J. Biol. Chem. 285:30304-30315(2010). RN [26] RP STRUCTURE BY NMR OF 33483-33579. RX PubMed=7613868; DOI=10.1016/s0969-2126(01)00170-8; RA Pfuhl M., Pastore A.; RT "Tertiary structure of an immunoglobulin-like domain from the giant muscle RT protein titin: a new member of the I set."; RL Structure 3:391-401(1995). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND RP MUTAGENESIS OF LYS-32207 AND TYR-32341. RX PubMed=9804419; DOI=10.1038/27603; RA Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O., RA Wilmanns M., Gautel M.; RT "Structural basis for activation of the titin kinase domain during RT myofibrillogenesis."; RL Nature 395:863-869(1998). RN [28] RP STRUCTURE BY NMR OF 22283-22385. RX PubMed=9782056; DOI=10.1016/s0969-2126(98)00129-4; RA Goll C.M., Pastore A., Nilges M.; RT "The three-dimensional structure of a type I module from titin: a prototype RT of intracellular fibronectin type III domains."; RL Structure 6:1291-1302(1998). RN [29] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE BOND. RX PubMed=11525170; DOI=10.1016/s0969-2126(01)00591-3; RA Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.; RT "Structural evidence for a possible role of reversible disulphide bridge RT formation in the elasticity of the muscle protein titin."; RL Structure 9:331-340(2001). RN [30] RP X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP. RX PubMed=16407954; DOI=10.1038/nature04343; RA Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I., RA Mayans O.M., Gautel M., Wilmanns M.; RT "Palindromic assembly of the giant muscle protein titin in the sarcomeric RT Z-disk."; RL Nature 439:229-233(2006). RN [31] RP VARIANT CMH9 LEU-740. RX PubMed=10462489; DOI=10.1006/bbrc.1999.1221; RA Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.; RT "Structural analysis of the titin gene in hypertrophic cardiomyopathy: RT identification of a novel disease gene."; RL Biochem. Biophys. Res. Commun. 262:411-417(1999). RN [32] RP INVOLVEMENT IN LGMDR10, AND VARIANT TMD PRO-34315. RX PubMed=12145747; DOI=10.1086/342380; RA Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., RA De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.; RT "Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the RT gene encoding the giant skeletal-muscle protein titin."; RL Am. J. Hum. Genet. 71:492-500(2002). RN [33] RP VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS CYS-328; RP GLN-4084 AND PRO-4215, CHARACTERIZATION OF VARIANTS CMD1G MET-54 AND RP VAL-743, AND FUNCTION. RX PubMed=11846417; DOI=10.1006/bbrc.2002.6448; RA Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., RA Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F., RA Imaizumi T., Yasunami M., Kimura A.; RT "Titin mutations as the molecular basis for dilated cardiomyopathy."; RL Biochem. Biophys. Res. Commun. 291:385-393(2002). RN [34] RP VARIANT CMD1G ARG-976. RX PubMed=11788824; DOI=10.1038/ng815; RA Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., RA Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S., RA Frenneaux M., Thierfelder L.; RT "Mutations of TTN, encoding the giant muscle filament titin, cause familial RT dilated cardiomyopathy."; RL Nat. Genet. 30:201-204(2002). RN [35] RP VARIANT TMD ASN-34306. RX PubMed=12891679; DOI=10.1002/ana.10647; RA Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S., Richard I., RA Hackman P., Udd B.; RT "Tibial muscular dystrophy in a Belgian family."; RL Ann. Neurol. 54:248-251(2003). RN [36] RP VARIANT CMD1G GLN-32996. RX PubMed=16465475; DOI=10.1007/s10974-005-9018-5; RA Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S., Nakamura T., RA Arimura T., Nakamura K., Ashizawa N., Yasunami M., Ohe T., Yano K., RA Kimura A.; RT "Functional analysis of titin/connectin N2-B mutations found in RT cardiomyopathy."; RL J. Muscle Res. Cell Motil. 26:367-374(2005). RN [37] RP VARIANT MFM9 TRP-279, CHARACTERIZATION OF VARIANT MFM9 TRP-279, AND RP INTERACTION WITH NBR1. RX PubMed=15802564; DOI=10.1126/science.1110463; RA Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., RA Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., RA Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E., RA Udd B., Gautel M.; RT "The kinase domain of titin controls muscle gene expression and protein RT turnover."; RL Science 308:1599-1603(2005). RN [38] RP INVOLVEMENT IN CMYO5. RX PubMed=17444505; DOI=10.1002/ana.21089; RA Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S., Al Rayess M.M., RA Mukhtar M.M., Urtizberea J.A., Labeit S., Guicheney P., Leturcq F., RA Gautel M., Fardeau M., Campbell K.P., Richard I., Estournet B., RA Ferreiro A.; RT "C-terminal titin deletions cause a novel early-onset myopathy with fatal RT cardiomyopathy."; RL Ann. Neurol. 61:340-351(2007). RN [39] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360; ILE-498; RP MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137; GLU-1201; ALA-1202; RP LEU-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353; VAL-1393; CYS-1416; RP PRO-1441; VAL-1544; GLN-1572; GLY-1658; GLN-1664; ASP-1692; LEU-1744; RP GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118; THR-2164; TYR-2240; RP SER-2392; PHE-2432; ILE-2610; MET-2771; PHE-2823; ASN-2831; ILE-2930; RP ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261; GLN-3367; LYS-3482; RP LYS-3570; VAL-3590; VAL-3762; PHE-3877; LEU-3965; PRO-4215; TRP-4238; RP PHE-4283; THR-4291; ASP-4303; GLU-4427; GLU-12310; ALA-12469; CYS-12642; RP LYS-12657; GLU-12679; PHE-12720; CYS-12798; GLY-13049; LYS-13083; RP LEU-13096; ARG-13099; ALA-13297; MET-13399; THR-13418; VAL-13428; RP THR-13430; LYS-13434; ASN-13469; ASN-13495; SER-13785; HIS-13870; RP ILE-14109; GLN-14131; THR-14208; VAL-14728; THR-14999; THR-15021; RP VAL-15520; ILE-15555; GLN-15620; ILE-15629; CYS-15635; GLN-15700; RP PRO-15705; MET-15837; HIS-16058; ILE-16067; THR-16090; HIS-16195; RP CYS-16409; PRO-16424; MET-16629; ARG-16877; ASP-17060; VAL-17637; RP HIS-17838; ASN-17866; GLU-17906; ALA-18094; SER-18109; THR-18164; RP LEU-18221; THR-18222; GLN-18726; ALA-18835; LYS-18881; SER-18939; RP GLN-19000; GLN-19060; LYS-19091; SER-19224; ILE-19367; LYS-19392; RP SER-19480; GLY-19495; HIS-19665; ILE-19762; ARG-19947; MET-19956; RP GLN-19992; CYS-20057; LEU-20075; LYS-20179; THR-20198; VAL-20198; RP HIS-20331; THR-20408; LYS-20564; ILE-20718; PRO-20726; ASN-20892; RP ARG-20894; GLU-21125; SER-21403; CYS-21730; GLN-21747; ARG-21851; RP ARG-21851; ARG-21925; HIS-21995; VAL-22045; HIS-22149; ILE-22160; RP THR-22261; ASN-22306; HIS-22357; PRO-22408; HIS-22537; LEU-22584; RP PRO-22646; ALA-22670; ASP-22770; THR-22801; TRP-22823; GLN-22968; RP LEU-23074; PHE-23079; ASN-23282; TYR-23303; CYS-23306; SER-23515; RP GLN-23551; ASN-23807; ASN-23872; ALA-23891; HIS-23933; MET-23939; RP LEU-23952; GLY-24098; SER-24119; ILE-24133; ALA-24159; ALA-24239; RP LYS-24265; THR-24584; THR-24781; HIS-24799; HIS-24954; MET-24980; RP HIS-25659; THR-25679; ALA-25720; LYS-25821; LYS-25859; LYS-25879; RP VAL-25923; ILE-26045; GLU-26059; VAL-26134; CYS-26477; TYR-26843; RP ARG-27346; CYS-27652; VAL-27728; LEU-27754; THR-27755; VAL-27929; RP LEU-28132; GLN-28168; HIS-28538; THR-28572; THR-28948; VAL-28986; RP GLU-28993; VAL-28998; MET-29070; VAL-29090; CYS-29419; PRO-29479; RP LEU-29880; GLU-29976; GLY-30042; CYS-30107; PHE-30125; PRO-30211; RP THR-30412; SER-30617; ILE-30674; ILE-30809; ILE-30818; LYS-30825; RP THR-30856; ASP-30887; SER-30887; HIS-30897; HIS-30907; HIS-30946; RP PHE-31081; CYS-31107; GLY-31124; SER-31156; THR-31246; HIS-31330; RP ARG-31690; GLN-31724; ILE-31725; SER-31732; ILE-31886; CYS-32097; RP ASN-32171; ILE-32248; HIS-32281; HIS-32323; TRP-32411; VAL-32558; RP VAL-32610; VAL-32637; ALA-32922; ARG-32943; HIS-32953; LEU-33213; RP CYS-33242; MET-33387; ASP-33419; MET-33536; GLN-33568; LYS-33616; RP LEU-33620; VAL-33886; THR-33899; PRO-33904; ILE-33955 AND ALA-34115. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [40] RP VARIANTS VAL-16046 AND GLN-32742. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [41] RP VARIANTS PRO-2963 AND GLN-14750. RX PubMed=25173926; DOI=10.1161/circgenetics.113.000486; RA Girolami F., Iascone M., Tomberli B., Bardi S., Benelli M., Marseglia G., RA Pescucci C., Pezzoli L., Sana M.E., Basso C., Marziliano N., Merlini P.A., RA Fornaro A., Cecchi F., Torricelli F., Olivotto I.; RT "Novel alpha-actinin 2 variant associated with familial hypertrophic RT cardiomyopathy and juvenile atrial arrhythmias: a massively parallel RT sequencing study."; RL Circ. Cardiovasc. Genet. 7:741-750(2014). CC -!- FUNCTION: Key component in the assembly and functioning of vertebrate CC striated muscles. By providing connections at the level of individual CC microfilaments, it contributes to the fine balance of forces between CC the two halves of the sarcomere. The size and extensibility of the CC cross-links are the main determinants of sarcomere extensibility CC properties of muscle. In non-muscle cells, seems to play a role in CC chromosome condensation and chromosome segregation during mitosis. CC Might link the lamina network to chromatin or nuclear actin, or both CC during interphase. {ECO:0000269|PubMed:11846417, CC ECO:0000269|PubMed:9804419}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Full activation of the protein kinase domain CC requires both phosphorylation of Tyr-32341, preventing it from blocking CC the catalytic aspartate residue, and binding of Ca/CALM to the C- CC terminal regulatory tail of the molecule which results in ATP binding CC to the kinase. {ECO:0000269|PubMed:9804419}. CC -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin. Interacts CC with actin, primarily via the PEVK domains and with MYPN (By CC similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and CC LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform CC Mu17/ank1.5, via the first two N-terminal immunoglobulin domains. CC Interacts with TRIM63 and TRIM55, through several domains including CC immunoglobulin domains 141 and 142. Interacts with ANKRD1, ANKRD2 and CC ANKRD23, via the region between immunoglobulin domains 77 and 78 and CC interacts with CAPN3, via immunoglobulin domain 79. Interacts with NBR1 CC through the protein kinase domain. Interacts with CALM/calmodulin. CC Isoform 6 interacts with OBSCN isoform 3. Interacts with CMYA5. CC {ECO:0000250, ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:12432079, CC ECO:0000269|PubMed:12444090, ECO:0000269|PubMed:12482578, CC ECO:0000269|PubMed:14583192, ECO:0000269|PubMed:14676215, CC ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:15967462, CC ECO:0000269|PubMed:16407954, ECO:0000269|PubMed:16410549, CC ECO:0000269|PubMed:20634290, ECO:0000269|PubMed:9645487, CC ECO:0000269|PubMed:9804419}. CC -!- INTERACTION: CC Q8WZ42; P12814: ACTN1; NbExp=2; IntAct=EBI-681210, EBI-351710; CC Q8WZ42; P35609: ACTN2; NbExp=16; IntAct=EBI-681210, EBI-77797; CC Q8WZ42; P62158: CALM3; NbExp=2; IntAct=EBI-681210, EBI-397435; CC Q8WZ42; P20807: CAPN3; NbExp=4; IntAct=EBI-681210, EBI-5655000; CC Q8WZ42; O75953: DNAJB5; NbExp=4; IntAct=EBI-681210, EBI-5655937; CC Q8WZ42; O75923: DYSF; NbExp=17; IntAct=EBI-681210, EBI-2799016; CC Q8WZ42; P06733: ENO1; NbExp=3; IntAct=EBI-681210, EBI-353877; CC Q8WZ42; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-681210, EBI-373144; CC Q8WZ42; Q14324: MYBPC2; NbExp=14; IntAct=EBI-681210, EBI-5653200; CC Q8WZ42; Q13203: MYBPH; NbExp=3; IntAct=EBI-681210, EBI-5655165; CC Q8WZ42; P20929: NEB; NbExp=6; IntAct=EBI-681210, EBI-1049657; CC Q8WZ42; Q5VST9: OBSCN; NbExp=15; IntAct=EBI-681210, EBI-941850; CC Q8WZ42; O75147: OBSL1; NbExp=13; IntAct=EBI-681210, EBI-1223896; CC Q8WZ42; O15061: SYNM; NbExp=3; IntAct=EBI-681210, EBI-7843148; CC Q8WZ42; O15273: TCAP; NbExp=9; IntAct=EBI-681210, EBI-954089; CC Q8WZ42; Q969Q1: TRIM63; NbExp=3; IntAct=EBI-681210, EBI-5661333; CC Q8WZ42; Q8WZ42: TTN; NbExp=16; IntAct=EBI-681210, EBI-681210; CC Q8WZ42-3; O15273: TCAP; NbExp=2; IntAct=EBI-15564183, EBI-954089; CC Q8WZ42-3; Q8WZ42-3: TTN; NbExp=9; IntAct=EBI-15564183, EBI-15564183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:16410549}. Nucleus CC {ECO:0000269|PubMed:16410549}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Comment=A number of isoforms may be produced, ranging from 27000 to CC 33000 residues in different striated muscle tissues, the size of the CC full-length protein may be up to 38138 residues.; CC Name=1; CC IsoId=Q8WZ42-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WZ42-2; Sequence=VSP_019138; CC Name=3; Synonyms=Small cardiac N2-B; CC IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145; CC Name=4; Synonyms=Soleus; CC IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151; CC Name=5; CC IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149, CC VSP_019150, VSP_019152; CC Name=6; Synonyms=Small cardiac novex-3; CC IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146; CC Name=7; Synonyms=Cardiac novex-2; CC IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144; CC Name=8; Synonyms=Cardiac novex-1; CC IsoId=Q8WZ42-8; Sequence=VSP_019140; CC Name=9; CC IsoId=Q8WZ42-9; Sequence=VSP_019139, VSP_042903, VSP_019145; CC Name=10; CC IsoId=Q8WZ42-10; Sequence=VSP_019139, VSP_019140, VSP_019145; CC Name=11; CC IsoId=Q8WZ42-11; Sequence=VSP_019142; CC Name=12; CC IsoId=Q8WZ42-12; Sequence=VSP_045935, VSP_045929, VSP_045930, CC VSP_045931, VSP_045932, VSP_045933, CC VSP_045934; CC Name=13; CC IsoId=Q8WZ42-13; Sequence=VSP_047142; CC -!- TISSUE SPECIFICITY: Isoforms 3, 7 and 8 are expressed in cardiac CC muscle. Isoform 4 is expressed in vertebrate skeletal muscle. Isoform 6 CC is expressed in skeletal muscle (at protein level). CC {ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7819249}. CC -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus sites for CC ERK- and CDK-like protein kinases as well as multiple SP motifs. ZIS1 CC could adopt a closed conformation which would block the TCAP-binding CC site. CC -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain of CC structural folds and may also be an interaction site to other CC myofilament proteins to form interfilament connectivity in the CC sarcomere. CC -!- PTM: Autophosphorylated. {ECO:0000250}. CC -!- DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure CC (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by CC adulthood onset of weakness in proximal, distal, axial and respiratory CC muscles. Pelvic girdle weakness, foot drop and neck weakness are the CC main symptoms at onset, but ultimately the weakness usually involves CC the proximal compartment of both upper and lower limbs. Additional CC features include variable degrees of Achilles tendon contractures, CC spinal rigidity and muscle hypertrophy. Respiratory involvement often CC leads to requirement for non-invasive ventilation support. CC {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, familial hypertrophic, 9 (CMH9) [MIM:613765]: CC A hereditary heart disorder characterized by ventricular hypertrophy, CC which is usually asymmetric and often involves the interventricular CC septum. The symptoms include dyspnea, syncope, collapse, palpitations, CC and chest pain. They can be readily provoked by exercise. The disorder CC has inter- and intrafamilial variability ranging from benign to CC malignant forms with high risk of cardiac failure and sudden cardiac CC death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1G (CMD1G) [MIM:604145]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:11788824, CC ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: CC Autosomal dominant, late-onset distal myopathy. Muscle weakness and CC atrophy are usually confined to the anterior compartment of the lower CC leg, in particular the tibialis anterior muscle. Clinical symptoms CC usually occur at age 35-45 years or much later. CC {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 CC (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy CC characterized by progressive weakness of the pelvic and shoulder girdle CC muscles. Severe disability is observed within 20 years of onset. CC {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital myopathy 5 with cardiomyopathy (CMYO5) CC [MIM:611705]: An autosomal recessive, early-onset muscular disorder CC characterized by dilated cardiomyopathy, delayed motor development with CC generalized muscle weakness predominantly affecting proximal and distal CC lower limbs. Skeletal muscle biopsies show minicore-like lesions with CC mitochondrial depletion and sarcomere disorganization, centralized CC nuclei, and type 1 fiber predominance. Dystrophic changes become CC apparent in the second decade. Cardiac muscle biopsies show disruption CC of myocardial architecture, nuclear hypertrophy, and endomysial CC fibrosis. Sudden death may occurr due to cardiomyopathy. CC {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region there is CC a long PEVK duplicated region. On account of this region, it has been CC very difficult to sequence the whole protein. The length of this region CC (ranging from 183 to 2174 residues), may be a key elastic element of CC titin. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553.; Evidence={ECO:0000305}; CC Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627.; Evidence={ECO:0000305}; CC Sequence=CAA62188.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=CAD12455.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry; CC URL="https://en.wikipedia.org/wiki/Titin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X90568; CAA62188.1; ALT_FRAME; mRNA. DR EMBL; X90569; CAA62189.1; -; mRNA. DR EMBL; AJ277892; CAD12455.1; ALT_FRAME; Genomic_DNA. DR EMBL; AJ277892; CAD12456.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12457.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12458.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12459.1; -; Genomic_DNA. DR EMBL; AC009948; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010680; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC023270; AAX88844.1; -; Genomic_DNA. DR EMBL; FJ695199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF459616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013396; AAH13396.1; -; mRNA. DR EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA. DR EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA. DR EMBL; BC107797; AAI07798.1; -; mRNA. DR EMBL; X98114; CAA66795.1; -; mRNA. DR EMBL; X98115; CAA66796.1; -; mRNA. DR EMBL; X83270; CAA58243.1; -; mRNA. DR EMBL; AF058332; AAD22603.1; -; Genomic_DNA. DR EMBL; AF058332; AAD22604.1; -; Genomic_DNA. DR EMBL; AF525413; AAP80791.1; -; mRNA. DR EMBL; DQ248309; ABB55264.1; -; mRNA. DR EMBL; X64698; CAA45939.1; -; mRNA. DR EMBL; X64699; CAA45940.1; -; Genomic_DNA. DR EMBL; X64697; CAA45938.1; -; mRNA. DR EMBL; X69490; CAA49245.1; -; mRNA. DR EMBL; AL713647; CAD28458.1; -; mRNA. DR CCDS; CCDS33337.1; -. [Q8WZ42-6] DR CCDS; CCDS54421.1; -. [Q8WZ42-3] DR CCDS; CCDS54422.1; -. [Q8WZ42-9] DR CCDS; CCDS54423.1; -. [Q8WZ42-10] DR CCDS; CCDS54424.1; -. [Q8WZ42-11] DR CCDS; CCDS59435.1; -. [Q8WZ42-12] DR PIR; I38344; I38344. DR PIR; I38346; I38346. DR RefSeq; NP_001243779.1; NM_001256850.1. [Q8WZ42-1] DR RefSeq; NP_001254479.2; NM_001267550.2. [Q8WZ42-12] DR RefSeq; NP_003310.4; NM_003319.4. [Q8WZ42-3] DR RefSeq; NP_596869.4; NM_133378.4. [Q8WZ42-11] DR RefSeq; NP_596870.2; NM_133379.5. [Q8WZ42-6] DR RefSeq; NP_597676.3; NM_133432.3. [Q8WZ42-10] DR PDB; 1BPV; NMR; -; A=22283-22385. DR PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171. DR PDB; 1NCT; NMR; -; A=33483-33579. DR PDB; 1NCU; NMR; -; A=33483-33579. DR PDB; 1TIT; NMR; -; A=12680-12765. DR PDB; 1TIU; NMR; -; A=12680-12765. DR PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492. DR PDB; 1TNM; NMR; -; A=33489-33579. DR PDB; 1TNN; NMR; -; A=33489-33579. DR PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765. DR PDB; 1YA5; X-ray; 2.44 A; A/B=1-196. DR PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194. DR PDB; 2BK8; X-ray; 1.69 A; A=32497-32590. DR PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196. DR PDB; 2ILL; X-ray; 2.20 A; A=31854-32047. DR PDB; 2J8H; X-ray; 1.99 A; A=31854-32047. DR PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047. DR PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155. DR PDB; 2RQ8; NMR; -; A=12677-12765. DR PDB; 2WP3; X-ray; 1.48 A; T=34252-34350. DR PDB; 2WWK; X-ray; 1.70 A; T=34252-34350. DR PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350. DR PDB; 2Y9R; X-ray; 1.90 A; T=34252-34350. DR PDB; 3B43; X-ray; 3.30 A; A=7945-8511. DR PDB; 3KNB; X-ray; 1.40 A; A=34253-34350. DR PDB; 3LCY; X-ray; 2.50 A; A/B/C/D=31456-31649. DR PDB; 3LPW; X-ray; 1.65 A; A/B=22877-23070. DR PDB; 3PUC; X-ray; 0.96 A; A=33774-33871. DR PDB; 3Q5O; X-ray; 2.05 A; A/B=34253-34350. DR PDB; 3QP3; X-ray; 2.00 A; A/B/C=33294-33395. DR PDB; 4C4K; X-ray; 1.95 A; T=34252-34350. DR PDB; 4JNW; X-ray; 2.06 A; A/B=32172-32492. DR PDB; 4O00; X-ray; 1.85 A; A/B=14217-14319. DR PDB; 4QEG; X-ray; 2.00 A; A=2880-2967. DR PDB; 4UOW; X-ray; 3.30 A; 1/3/5/7/9/B/D/F/H/J/L/N/P/R/T/V/X/Z=7-99. DR PDB; 5BS0; X-ray; 2.40 A; C=24337-24345. DR PDB; 5JDD; X-ray; 1.53 A; A=2795-3053. DR PDB; 5JDE; X-ray; 1.90 A; A/B=2795-3053. DR PDB; 5JDJ; X-ray; 1.74 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2880-2967. DR PDB; 5JOE; X-ray; 2.00 A; A=9582-9671. DR PDB; 6DL4; NMR; -; A=1821-1931. DR PDB; 6FWX; X-ray; 3.00 A; A/B=1-243. DR PDB; 6H4L; X-ray; 1.60 A; A=33294-33395. DR PDB; 6HCI; X-ray; 2.12 A; A/B/C/D=32712-32816. DR PDB; 6I0Y; EM; 3.20 A; z=12677-12765. DR PDB; 6SDB; X-ray; 2.80 A; A/B/C/D/E=3-196. DR PDB; 6YGN; X-ray; 2.40 A; A/B=32046-32594. DR PDB; 7AHS; X-ray; 2.05 A; A/B/C/D=9582-9851. DR PDB; 7NIP; NMR; -; A=9504-9544. DR PDB; 8BNQ; X-ray; 2.30 A; A/B=23562-23862. DR PDB; 8BVO; X-ray; 2.55 A; A=14415-14609. DR PDB; 8BW6; X-ray; 1.95 A; A=14415-14509. DR PDB; 8BXR; X-ray; 2.70 A; A=14319-14615. DR PDB; 8G4L; EM; 6.40 A; am/an/bm/bn/m/n=22784-23867. DR PDB; 8OIY; X-ray; 2.10 A; A/B/C/D/E/F=14217-14319. DR PDB; 8OMW; X-ray; 1.05 A; A=16525-16630. DR PDB; 8OQ9; X-ray; 1.65 A; A/B/C=21497-21598. DR PDB; 8ORL; X-ray; 1.43 A; A/B/C=21497-21598. DR PDB; 8OS3; X-ray; 1.68 A; A=15210-15313. DR PDB; 8OSD; X-ray; 1.70 A; A/B=20511-20616. DR PDB; 8OT5; X-ray; 1.56 A; A/B/C/D/E/F=25430-25531. DR PDB; 8OTY; X-ray; 1.90 A; A/B/C/D=26124-26224. DR PDB; 8OVU; X-ray; 1.95 A; A/B=3500-3598. DR PDB; 8P35; X-ray; 2.20 A; A/B/C/D/E/F=3500-3598. DR PDBsum; 1BPV; -. DR PDBsum; 1G1C; -. DR PDBsum; 1NCT; -. DR PDBsum; 1NCU; -. DR PDBsum; 1TIT; -. DR PDBsum; 1TIU; -. DR PDBsum; 1TKI; -. DR PDBsum; 1TNM; -. DR PDBsum; 1TNN; -. DR PDBsum; 1WAA; -. DR PDBsum; 1YA5; -. DR PDBsum; 2A38; -. DR PDBsum; 2BK8; -. DR PDBsum; 2F8V; -. DR PDBsum; 2ILL; -. DR PDBsum; 2J8H; -. DR PDBsum; 2J8O; -. DR PDBsum; 2NZI; -. DR PDBsum; 2RQ8; -. DR PDBsum; 2WP3; -. DR PDBsum; 2WWK; -. DR PDBsum; 2WWM; -. DR PDBsum; 2Y9R; -. DR PDBsum; 3B43; -. DR PDBsum; 3KNB; -. DR PDBsum; 3LCY; -. DR PDBsum; 3LPW; -. DR PDBsum; 3PUC; -. DR PDBsum; 3Q5O; -. DR PDBsum; 3QP3; -. DR PDBsum; 4C4K; -. DR PDBsum; 4JNW; -. DR PDBsum; 4O00; -. DR PDBsum; 4QEG; -. DR PDBsum; 4UOW; -. DR PDBsum; 5BS0; -. DR PDBsum; 5JDD; -. DR PDBsum; 5JDE; -. DR PDBsum; 5JDJ; -. DR PDBsum; 5JOE; -. DR PDBsum; 6DL4; -. DR PDBsum; 6FWX; -. DR PDBsum; 6H4L; -. DR PDBsum; 6HCI; -. DR PDBsum; 6I0Y; -. DR PDBsum; 6SDB; -. DR PDBsum; 6YGN; -. DR PDBsum; 7AHS; -. DR PDBsum; 7NIP; -. DR PDBsum; 8BNQ; -. DR PDBsum; 8BVO; -. DR PDBsum; 8BW6; -. DR PDBsum; 8BXR; -. DR PDBsum; 8G4L; -. DR PDBsum; 8OIY; -. DR PDBsum; 8OMW; -. DR PDBsum; 8OQ9; -. DR PDBsum; 8ORL; -. DR PDBsum; 8OS3; -. DR PDBsum; 8OSD; -. DR PDBsum; 8OT5; -. DR PDBsum; 8OTY; -. DR PDBsum; 8OVU; -. DR PDBsum; 8P35; -. DR EMDB; EMD-0322; -. DR EMDB; EMD-29722; -. DR SASBDB; Q8WZ42; -. DR SMR; Q8WZ42; -. DR BioGRID; 113124; 328. DR ComplexPortal; CPX-101; Titin-Telethonin complex. DR CORUM; Q8WZ42; -. DR DIP; DIP-33449N; -. DR FunCoup; Q8WZ42; 665. DR IntAct; Q8WZ42; 167. DR MINT; Q8WZ42; -. DR STRING; 9606.ENSP00000467141; -. DR MoonDB; Q8WZ42; Predicted. DR CarbonylDB; Q8WZ42; -. DR GlyCosmos; Q8WZ42; 11 sites, 2 glycans. DR GlyGen; Q8WZ42; 39 sites, 3 O-linked glycans (22 sites). DR iPTMnet; Q8WZ42; -. DR MetOSite; Q8WZ42; -. DR PhosphoSitePlus; Q8WZ42; -. DR SwissPalm; Q8WZ42; -. DR BioMuta; TTN; -. DR jPOST; Q8WZ42; -. DR MassIVE; Q8WZ42; -. DR PaxDb; 9606-ENSP00000467141; -. DR PeptideAtlas; Q8WZ42; -. DR ProteomicsDB; 75209; -. [Q8WZ42-1] DR ProteomicsDB; 75210; -. [Q8WZ42-10] DR ProteomicsDB; 75211; -. [Q8WZ42-11] DR ProteomicsDB; 75212; -. [Q8WZ42-2] DR ProteomicsDB; 75213; -. [Q8WZ42-3] DR ProteomicsDB; 75214; -. [Q8WZ42-4] DR ProteomicsDB; 75215; -. [Q8WZ42-5] DR ProteomicsDB; 75216; -. [Q8WZ42-6] DR ProteomicsDB; 75217; -. [Q8WZ42-7] DR ProteomicsDB; 75218; -. [Q8WZ42-8] DR ProteomicsDB; 75219; -. [Q8WZ42-9] DR Pumba; Q8WZ42; -. DR ABCD; Q8WZ42; 2 sequenced antibodies. DR Antibodypedia; 2056; 211 antibodies from 28 providers. DR DNASU; 7273; -. DR Ensembl; ENST00000342992.11; ENSP00000343764.6; ENSG00000155657.29. [Q8WZ42-11] DR Ensembl; ENST00000359218.11; ENSP00000352154.5; ENSG00000155657.29. [Q8WZ42-10] DR Ensembl; ENST00000360870.10; ENSP00000354117.4; ENSG00000155657.29. [Q8WZ42-6] DR Ensembl; ENST00000412264.2; ENSP00000394672.2; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000460472.6; ENSP00000434586.1; ENSG00000155657.29. [Q8WZ42-3] DR Ensembl; ENST00000589042.5; ENSP00000467141.1; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000591111.5; ENSP00000465570.1; ENSG00000155657.29. [Q8WZ42-1] DR GeneID; 7273; -. DR KEGG; hsa:7273; -. DR MANE-Select; ENST00000589042.5; ENSP00000467141.1; NM_001267550.2; NP_001254479.2. [Q8WZ42-12] DR UCSC; uc002unb.4; human. [Q8WZ42-1] DR UCSC; uc031rqc.3; human. DR AGR; HGNC:12403; -. DR ClinPGx; PA37067; -. DR CTD; 7273; -. DR DisGeNET; 7273; -. DR GeneCards; TTN; -. DR GeneReviews; TTN; -. DR HGNC; HGNC:12403; TTN. DR HPA; ENSG00000155657; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TTN; -. DR MIM; 188840; gene. DR MIM; 600334; phenotype. DR MIM; 603689; phenotype. DR MIM; 604145; phenotype. DR MIM; 608807; phenotype. DR MIM; 611705; phenotype. DR MIM; 613765; phenotype. DR OpenTargets; ENSG00000155657; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR Orphanet; 466921; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome. DR Orphanet; 324604; Classic multiminicore myopathy. DR Orphanet; 707983; Early-onset autosomal recessive TTN-related distal myopathy. DR Orphanet; 289377; Early-onset myopathy with fatal cardiomyopathy. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 334; Hereditary atrial fibrillation. DR Orphanet; 178464; Hereditary myopathy with early respiratory failure. DR Orphanet; 293888; Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant. DR Orphanet; 293910; Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant. DR Orphanet; 293899; Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant. DR Orphanet; 609; Tibial muscular dystrophy. DR Orphanet; 140922; Titin-related limb-girdle muscular dystrophy R10. DR VEuPathDB; HostDB:ENSG00000155657; -. DR eggNOG; KOG0613; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT01150000286978; -. DR HOGENOM; CLU_000001_1_0_1; -. DR InParanoid; Q8WZ42; -. DR OMA; TSSWPEY; -. DR OrthoDB; 5969272at2759; -. DR PAN-GO; Q8WZ42; 0 GO annotations based on evolutionary models. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q8WZ42; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-390522; Striated Muscle Contraction. DR SignaLink; Q8WZ42; -. DR SIGNOR; Q8WZ42; -. DR Agora; ENSG00000155657; -. DR BioGRID-ORCS; 7273; 10 hits in 1181 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TTN; human. DR EvolutionaryTrace; Q8WZ42; -. DR GeneWiki; Titin; -. DR GenomeRNAi; 7273; -. DR Pharos; Q8WZ42; Tbio. DR PRO; PR:Q8WZ42; -. DR Proteomes; UP000005640; Chromosome 2. DR Bgee; ENSG00000155657; Expressed in gluteal muscle and 163 other cell types or tissues. DR ExpressionAtlas; Q8WZ42; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IEA:UniProtKB-ARBA. DR GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031674; C:I band; IDA:BHF-UCL. DR GO; GO:0031430; C:M band; IDA:BHF-UCL. DR GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL. DR GO; GO:1990733; C:titin-telethonin complex; IPI:ComplexPortal. DR GO; GO:0030018; C:Z disc; IDA:BHF-UCL. DR GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL. DR GO; GO:0042805; F:actinin binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0019887; F:protein kinase regulator activity; IMP:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI. DR GO; GO:0008307; F:structural constituent of muscle; IMP:BHF-UCL. DR GO; GO:0097493; F:structural molecule activity conferring elasticity; IDA:BHF-UCL. DR GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL. DR GO; GO:0055013; P:cardiac muscle cell development; IMP:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:BHF-UCL. DR GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL. DR GO; GO:0035995; P:detection of muscle stretch; IDA:MGI. DR GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL. DR GO; GO:0006936; P:muscle contraction; TAS:UniProtKB. DR GO; GO:0030049; P:muscle filament sliding; NAS:ComplexPortal. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA. DR GO; GO:0050714; P:positive regulation of protein secretion; IMP:CAFA. DR GO; GO:0010737; P:protein kinase A signaling; IMP:CAFA. DR GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL. DR GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL. DR GO; GO:0048769; P:sarcomerogenesis; IMP:BHF-UCL. DR GO; GO:0003009; P:skeletal muscle contraction; NAS:ComplexPortal. DR GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL. DR GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL. DR GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB. DR CDD; cd00063; FN3; 132. DR CDD; cd00096; Ig; 31. DR CDD; cd05748; Ig_Titin_like; 28. DR CDD; cd20974; IgI_1_Titin_Z1z2-like; 2. DR CDD; cd20972; IgI_2_Titin_Z1z2-like; 1. DR CDD; cd20951; IgI_titin_I1-like; 1. DR CDD; cd05747; IgI_Titin_like; 1. DR CDD; cd20927; IgI_Titin_M1-like; 1. DR CDD; cd14104; STKc_Titin; 1. DR DisProt; DP00072; -. DR FunFam; 2.60.40.10:FF:000022; Cardiac titin; 44. DR FunFam; 2.60.40.10:FF:000800; Cardiac titin; 1. DR FunFam; 2.60.40.10:FF:000345; Muscle M-line assembly protein unc-89; 1. DR FunFam; 2.60.40.10:FF:001284; Myomesin 2; 1. DR FunFam; 2.60.40.10:FF:000147; Myosin light chain kinase; 2. DR FunFam; 2.60.40.10:FF:000107; Myosin, light chain kinase a; 2. DR FunFam; 2.60.40.10:FF:000031; Myosin-binding protein C, slow type; 7. DR FunFam; 2.60.40.10:FF:001867; Titin; 1. DR FunFam; 2.60.40.10:FF:001911; Titin; 1. DR FunFam; 1.10.510.10:FF:000329; Titin a; 1. DR FunFam; 2.60.40.10:FF:000002; Titin a; 32. DR FunFam; 2.60.40.10:FF:000112; Titin a; 8. DR FunFam; 2.60.40.10:FF:000135; Titin a; 7. DR FunFam; 2.60.40.10:FF:000160; Titin a; 1. DR FunFam; 2.60.40.10:FF:000547; Titin a; 2. DR FunFam; 2.60.40.10:FF:000672; Titin a; 1. DR FunFam; 2.60.40.10:FF:000673; Titin a; 1. DR FunFam; 2.60.40.10:FF:000811; Titin a; 1. DR FunFam; 2.60.40.10:FF:000867; Titin a; 1. DR FunFam; 2.60.40.10:FF:000891; Titin a; 1. DR FunFam; 2.60.40.10:FF:000900; Titin a; 1. DR FunFam; 2.60.40.10:FF:000981; Titin a; 1. DR FunFam; 2.60.40.10:FF:001200; Titin a; 1. DR FunFam; 2.60.40.10:FF:001399; Titin a; 1. DR FunFam; 2.60.40.10:FF:001400; Titin a; 1. DR FunFam; 2.60.40.10:FF:001459; Titin a; 1. DR FunFam; 2.60.40.10:FF:001500; Titin a; 1. DR FunFam; 2.60.40.10:FF:001579; Titin a; 1. DR FunFam; 2.60.40.10:FF:001697; Titin a; 1. DR FunFam; 3.30.200.20:FF:000286; Titin a; 1. DR FunFam; 2.60.40.10:FF:000011; Titin b; 11. DR FunFam; 2.60.40.10:FF:000629; Titin b; 1. DR FunFam; 2.60.40.10:FF:000635; Titin b; 1. DR FunFam; 2.60.40.10:FF:000779; Titin b; 1. DR FunFam; 2.60.40.10:FF:000833; Titin b; 1. DR FunFam; 2.60.40.10:FF:000859; Titin b; 1. DR FunFam; 2.60.40.10:FF:000864; Titin b; 1. DR FunFam; 2.60.40.10:FF:000901; Titin b; 1. DR FunFam; 2.60.40.10:FF:000980; Titin b; 1. DR FunFam; 2.60.40.10:FF:000986; Titin b; 1. DR FunFam; 2.60.40.10:FF:001115; Titin b; 1. DR FunFam; 2.60.40.10:FF:001190; Titin b; 1. DR FunFam; 2.60.40.10:FF:001477; Titin b; 1. DR FunFam; 2.60.40.10:FF:000034; Titin isoform A; 26. DR FunFam; 2.60.40.10:FF:000050; Titin isoform B; 8. DR FunFam; 2.60.40.10:FF:000003; Titin isoform E; 22. DR FunFam; 2.60.40.10:FF:000012; titin isoform X1; 26. DR FunFam; 2.60.40.10:FF:000073; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000127; titin isoform X1; 4. DR FunFam; 2.60.40.10:FF:000148; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000214; titin isoform X1; 7. DR FunFam; 2.60.40.10:FF:000218; titin isoform X1; 6. DR FunFam; 2.60.40.10:FF:000659; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000697; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000770; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000792; titin isoform X1; 2. DR FunFam; 2.60.40.10:FF:000983; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001003; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001213; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001229; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001272; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001327; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001328; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001342; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001343; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001344; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001345; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001350; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001365; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001367; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001382; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001385; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001408; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001430; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001434; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001454; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001476; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001544; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001581; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001610; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001612; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001663; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000714; Titin novex-3; 3. DR FunFam; 2.60.40.10:FF:001082; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001089; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001098; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001116; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001804; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:001844; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002231; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002123; Titin, tandem duplicate 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 299. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR040849; MyBP-C_THB. DR InterPro; IPR004168; PPAK_motif. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR015129; Titin_Z_rpt. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1. DR PANTHER; PTHR14340:SF13; TITIN; 1. DR Pfam; PF00041; fn3; 132. DR Pfam; PF07679; I-set; 162. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF02818; PPAK; 9. DR Pfam; PF18362; THB; 1. DR Pfam; PF09042; Titin_Z; 2. DR SMART; SM00060; FN3; 132. DR SMART; SM00409; IG; 167. DR SMART; SM00408; IGc2; 148. DR SMART; SM00406; IGv; 23. DR SUPFAM; SSF49265; Fibronectin type III; 74. DR SUPFAM; SSF48726; Immunoglobulin; 167. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 132. DR PROSITE; PS50835; IG_LIKE; 143. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Calcium; KW Calmodulin-binding; Cardiomyopathy; Coiled coil; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Limb-girdle muscular dystrophy; Magnesium; KW Metal-binding; Myofibrillar myopathy; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..34350 FT /note="Titin" FT /id="PRO_0000239311" FT DOMAIN 6..96 FT /note="Ig-like 1" FT DOMAIN 104..192 FT /note="Ig-like 2" FT REPEAT 417..462 FT /note="Z-repeat 1" FT REPEAT 466..511 FT /note="Z-repeat 2" FT REPEAT 512..554 FT /note="Z-repeat 3" FT REPEAT 555..600 FT /note="Z-repeat 4" FT REPEAT 601..646 FT /note="Z-repeat 5" FT REPEAT 647..691 FT /note="Z-repeat 6" FT REPEAT 692..740 FT /note="Z-repeat 7" FT DOMAIN 943..1031 FT /note="Ig-like 3" FT DOMAIN 1082..1172 FT /note="Ig-like 4" FT DOMAIN 1291..1382 FT /note="Ig-like 5" FT DOMAIN 1457..1546 FT /note="Ig-like 6" FT DOMAIN 1556..1646 FT /note="Ig-like 7" FT DOMAIN 1703..1793 FT /note="Ig-like 8" FT DOMAIN 1841..1928 FT /note="Ig-like 9" FT DOMAIN 2078..2167 FT /note="Ig-like 10" FT DOMAIN 2171..2262 FT /note="Ig-like 11" FT DOMAIN 2264..2354 FT /note="Ig-like 12" FT DOMAIN 2353..2443 FT /note="Ig-like 13" FT DOMAIN 2430..2529 FT /note="Ig-like 14" FT DOMAIN 2620..2703 FT /note="Ig-like 15" FT DOMAIN 2880..2965 FT /note="Ig-like 16" FT DOMAIN 2968..3050 FT /note="Ig-like 17" FT DOMAIN 3058..3141 FT /note="Ig-like 18" FT DOMAIN 3239..3327 FT /note="Ig-like 19" FT DOMAIN 3344..3432 FT /note="Ig-like 20" FT DOMAIN 3503..3586 FT /note="Ig-like 21" FT DOMAIN 3621..3712 FT /note="Ig-like 22" FT DOMAIN 4289..4376 FT /note="Ig-like 23" FT DOMAIN 4383..4471 FT /note="Ig-like 24" FT DOMAIN 4478..4566 FT /note="Ig-like 25" FT DOMAIN 4571..4659 FT /note="Ig-like 26" FT DOMAIN 4664..4753 FT /note="Ig-like 27" FT DOMAIN 4758..4846 FT /note="Ig-like 28" FT DOMAIN 4851..4936 FT /note="Ig-like 29" FT DOMAIN 4943..5032 FT /note="Ig-like 30" FT DOMAIN 5040..5128 FT /note="Ig-like 31" FT DOMAIN 5133..5221 FT /note="Ig-like 32" FT DOMAIN 5225..5314 FT /note="Ig-like 33" FT DOMAIN 5320..5408 FT /note="Ig-like 34" FT DOMAIN 5413..5501 FT /note="Ig-like 35" FT DOMAIN 5505..5594 FT /note="Ig-like 36" FT DOMAIN 5602..5690 FT /note="Ig-like 37" FT DOMAIN 5695..5783 FT /note="Ig-like 38" FT DOMAIN 5788..5877 FT /note="Ig-like 39" FT DOMAIN 5882..5970 FT /note="Ig-like 40" FT DOMAIN 5975..6063 FT /note="Ig-like 41" FT DOMAIN 6067..6156 FT /note="Ig-like 42" FT DOMAIN 6164..6252 FT /note="Ig-like 43" FT DOMAIN 6257..6347 FT /note="Ig-like 44" FT DOMAIN 6350..6440 FT /note="Ig-like 45" FT DOMAIN 6444..6534 FT /note="Ig-like 46" FT DOMAIN 6537..6626 FT /note="Ig-like 47" FT DOMAIN 6630..6721 FT /note="Ig-like 48" FT DOMAIN 6727..6815 FT /note="Ig-like 49" FT DOMAIN 6820..6908 FT /note="Ig-like 50" FT DOMAIN 6912..7001 FT /note="Ig-like 51" FT DOMAIN 7005..7093 FT /note="Ig-like 52" FT DOMAIN 7102..7190 FT /note="Ig-like 53" FT DOMAIN 7198..7286 FT /note="Ig-like 54" FT DOMAIN 7291..7380 FT /note="Ig-like 55" FT DOMAIN 7385..7473 FT /note="Ig-like 56" FT DOMAIN 7478..7567 FT /note="Ig-like 57" FT DOMAIN 7571..7662 FT /note="Ig-like 58" FT DOMAIN 7668..7756 FT /note="Ig-like 59" FT DOMAIN 7761..7849 FT /note="Ig-like 60" FT DOMAIN 7853..7942 FT /note="Ig-like 61" FT DOMAIN 7946..8035 FT /note="Ig-like 62" FT DOMAIN 8042..8133 FT /note="Ig-like 63" FT DOMAIN 8138..8229 FT /note="Ig-like 64" FT DOMAIN 8232..8321 FT /note="Ig-like 65" FT DOMAIN 8326..8414 FT /note="Ig-like 66" FT DOMAIN 8419..8508 FT /note="Ig-like 67" FT DOMAIN 8512..8603 FT /note="Ig-like 68" FT DOMAIN 8609..8697 FT /note="Ig-like 69" FT DOMAIN 8702..8790 FT /note="Ig-like 70" FT DOMAIN 8794..8883 FT /note="Ig-like 71" FT DOMAIN 8888..8976 FT /note="Ig-like 72" FT DOMAIN 8984..9074 FT /note="Ig-like 73" FT DOMAIN 9079..9168 FT /note="Ig-like 74" FT DOMAIN 9176..9265 FT /note="Ig-like 75" FT DOMAIN 9272..9361 FT /note="Ig-like 76" FT DOMAIN 9366..9470 FT /note="Ig-like 77" FT DOMAIN 9660..9755 FT /note="Ig-like 78" FT DOMAIN 9760..9851 FT /note="Ig-like 79" FT REPEAT 10216..10242 FT /note="PEVK 1" FT REPEAT 10244..10270 FT /note="PEVK 2" FT REPEAT 10272..10298 FT /note="PEVK 3" FT REPEAT 10300..10326 FT /note="PEVK 4" FT REPEAT 10327..10353 FT /note="PEVK 5" FT REPEAT 10355..10381 FT /note="PEVK 6" FT REPEAT 10508..10534 FT /note="PEVK 7" FT REPEAT 10536..10562 FT /note="PEVK 8" FT REPEAT 10592..10618 FT /note="PEVK 9" FT REPEAT 10878..10904 FT /note="PEVK 10" FT REPEAT 10906..10930 FT /note="PEVK 11" FT REPEAT 10932..10958 FT /note="PEVK 12" FT REPEAT 10960..10986 FT /note="PEVK 13" FT REPEAT 10987..11014 FT /note="PEVK 14" FT REPEAT 11363..11396 FT /note="PEVK 15" FT REPEAT 11397..11421 FT /note="PEVK 16" FT REPEAT 11453..11479 FT /note="PEVK 17" FT REPEAT 11481..11507 FT /note="PEVK 18" FT REPEAT 11509..11535 FT /note="PEVK 19" FT REPEAT 11537..11563 FT /note="PEVK 20" FT REPEAT 11565..11591 FT /note="PEVK 21" FT REPEAT 11657..11683 FT /note="PEVK 22" FT REPEAT 11703..11729 FT /note="PEVK 23" FT REPEAT 11745..11771 FT /note="PEVK 24" FT REPEAT 11775..11801 FT /note="PEVK 25" FT REPEAT 11836..11862 FT /note="PEVK 26" FT REPEAT 11864..11890 FT /note="PEVK 27" FT REPEAT 11893..11919 FT /note="PEVK 28" FT REPEAT 11929..11955 FT /note="PEVK 29" FT REPEAT 11966..11992 FT /note="PEVK 30" FT REPEAT 11996..12022 FT /note="PEVK 31" FT DOMAIN 12041..12133 FT /note="Ig-like 80" FT DOMAIN 12138..12222 FT /note="Ig-like 81" FT DOMAIN 12233..12318 FT /note="Ig-like 82" FT DOMAIN 12499..12584 FT /note="Ig-like 83" FT DOMAIN 12590..12672 FT /note="Ig-like 84" FT DOMAIN 12766..12850 FT /note="Ig-like 85" FT DOMAIN 12945..13032 FT /note="Ig-like 86" FT DOMAIN 13120..13206 FT /note="Ig-like 87" FT DOMAIN 13210..13295 FT /note="Ig-like 88" FT DOMAIN 13299..13384 FT /note="Ig-like 89" FT DOMAIN 13388..13478 FT /note="Ig-like 90" FT DOMAIN 13479..13562 FT /note="Ig-like 91" FT DOMAIN 13565..13655 FT /note="Ig-like 92" FT DOMAIN 13659..13748 FT /note="Ig-like 93" FT DOMAIN 13749..13833 FT /note="Ig-like 94" FT DOMAIN 13927..14012 FT /note="Ig-like 95" FT DOMAIN 14019..14114 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14120..14215 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14221..14316 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14417..14513 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14517..14614 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14615..14708 FT /note="Ig-like 96" FT DOMAIN 14713..14806 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14812..14907 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14913..15007 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15010..15107 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15113..15207 FT /note="Fibronectin type-III 10" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15214..15310 FT /note="Fibronectin type-III 11" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15314..15402 FT /note="Ig-like 97" FT DOMAIN 15409..15503 FT /note="Fibronectin type-III 12" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15509..15604 FT /note="Fibronectin type-III 13" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15608..15724 FT /note="Ig-like 98" FT DOMAIN 15731..15826 FT /note="Fibronectin type-III 14" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15832..15926 FT /note="Fibronectin type-III 15" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15929..16025 FT /note="Fibronectin type-III 16" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16029..16119 FT /note="Ig-like 99" FT DOMAIN 16126..16218 FT /note="Fibronectin type-III 17" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16224..16318 FT /note="Fibronectin type-III 18" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16322..16420 FT /note="Ig-like 100" FT DOMAIN 16427..16522 FT /note="Fibronectin type-III 19" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16528..16628 FT /note="Fibronectin type-III 20" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16634..16734 FT /note="Fibronectin type-III 21" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16727..16834 FT /note="Ig-like 101" FT DOMAIN 16841..16934 FT /note="Fibronectin type-III 22" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16941..17041 FT /note="Fibronectin type-III 23" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17044..17139 FT /note="Ig-like 102" FT DOMAIN 17147..17240 FT /note="Fibronectin type-III 24" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17246..17345 FT /note="Fibronectin type-III 25" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17348..17445 FT /note="Fibronectin type-III 26" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17449..17536 FT /note="Ig-like 103" FT DOMAIN 17545..17640 FT /note="Fibronectin type-III 27" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17646..17741 FT /note="Fibronectin type-III 28" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17745..17834 FT /note="Ig-like 104" FT DOMAIN 17842..17935 FT /note="Fibronectin type-III 29" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17941..18036 FT /note="Fibronectin type-III 30" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18042..18139 FT /note="Fibronectin type-III 31" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18143..18228 FT /note="Ig-like 105" FT DOMAIN 18239..18333 FT /note="Fibronectin type-III 32" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18339..18431 FT /note="Fibronectin type-III 33" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18435..18526 FT /note="Ig-like 106" FT DOMAIN 18533..18632 FT /note="Fibronectin type-III 34" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18633..18727 FT /note="Fibronectin type-III 35" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18733..18829 FT /note="Fibronectin type-III 36" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18833..18924 FT /note="Ig-like 107" FT DOMAIN 18931..19025 FT /note="Fibronectin type-III 37" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19030..19124 FT /note="Fibronectin type-III 38" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19128..19219 FT /note="Ig-like 108" FT DOMAIN 19226..19321 FT /note="Fibronectin type-III 39" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19325..19420 FT /note="Fibronectin type-III 40" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19426..19527 FT /note="Fibronectin type-III 41" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19531..19617 FT /note="Ig-like 109" FT DOMAIN 19628..19722 FT /note="Fibronectin type-III 42" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19728..19823 FT /note="Fibronectin type-III 43" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19826..19914 FT /note="Ig-like 110" FT DOMAIN 19921..20017 FT /note="Fibronectin type-III 44" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20018..20116 FT /note="Fibronectin type-III 45" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20119..20217 FT /note="Fibronectin type-III 46" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20220..20311 FT /note="Ig-like 111" FT DOMAIN 20318..20411 FT /note="Fibronectin type-III 47" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20417..20512 FT /note="Fibronectin type-III 48" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20518..20613 FT /note="Fibronectin type-III 49" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20716..20813 FT /note="Fibronectin type-III 50" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20814..20908 FT /note="Fibronectin type-III 51" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20893..20996 FT /note="Ig-like 112" FT DOMAIN 21006..21101 FT /note="Fibronectin type-III 52" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21105..21200 FT /note="Fibronectin type-III 53" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21203..21299 FT /note="Fibronectin type-III 54" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21303..21395 FT /note="Ig-like 113" FT DOMAIN 21402..21495 FT /note="Fibronectin type-III 55" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21501..21596 FT /note="Fibronectin type-III 56" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21602..21697 FT /note="Fibronectin type-III 57" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21701..21793 FT /note="Ig-like 114" FT DOMAIN 21797..21891 FT /note="Fibronectin type-III 58" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21894..21986 FT /note="Fibronectin type-III 59" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21990..22083 FT /note="Ig-like 115" FT DOMAIN 22088..22182 FT /note="Fibronectin type-III 60" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22188..22283 FT /note="Fibronectin type-III 61" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22286..22382 FT /note="Fibronectin type-III 62" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22386..22477 FT /note="Ig-like 116" FT DOMAIN 22484..22578 FT /note="Fibronectin type-III 63" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22584..22679 FT /note="Fibronectin type-III 64" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22685..22781 FT /note="Fibronectin type-III 65" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22785..22874 FT /note="Ig-like 117" FT DOMAIN 22881..22976 FT /note="Fibronectin type-III 66" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22978..23071 FT /note="Fibronectin type-III 67" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23075..23163 FT /note="Ig-like 118" FT DOMAIN 23170..23264 FT /note="Fibronectin type-III 68" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23270..23364 FT /note="Fibronectin type-III 69" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23368..23463 FT /note="Fibronectin type-III 70" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23468..23555 FT /note="Ig-like 119" FT DOMAIN 23566..23660 FT /note="Fibronectin type-III 71" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23666..23761 FT /note="Fibronectin type-III 72" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23767..23863 FT /note="Fibronectin type-III 73" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23867..23954 FT /note="Ig-like 120" FT DOMAIN 23963..24057 FT /note="Fibronectin type-III 74" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24060..24153 FT /note="Fibronectin type-III 75" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24157..24241 FT /note="Ig-like 121" FT DOMAIN 24252..24346 FT /note="Fibronectin type-III 76" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24352..24446 FT /note="Fibronectin type-III 77" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24450..24546 FT /note="Fibronectin type-III 78" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24550..24641 FT /note="Ig-like 122" FT DOMAIN 24648..24742 FT /note="Fibronectin type-III 79" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24748..24843 FT /note="Fibronectin type-III 80" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24849..24945 FT /note="Fibronectin type-III 81" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24949..25038 FT /note="Ig-like 123" FT DOMAIN 25045..25139 FT /note="Fibronectin type-III 82" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25142..25235 FT /note="Fibronectin type-III 83" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25239..25325 FT /note="Ig-like 124" FT DOMAIN 25335..25428 FT /note="Fibronectin type-III 84" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25434..25529 FT /note="Fibronectin type-III 85" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25532..25627 FT /note="Fibronectin type-III 86" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25632..25722 FT /note="Ig-like 125" FT DOMAIN 25731..25825 FT /note="Fibronectin type-III 87" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25831..25926 FT /note="Fibronectin type-III 88" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25932..26028 FT /note="Fibronectin type-III 89" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26032..26121 FT /note="Ig-like 126" FT DOMAIN 26128..26222 FT /note="Fibronectin type-III 90" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26225..26318 FT /note="Fibronectin type-III 91" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26322..26410 FT /note="Ig-like 127" FT DOMAIN 26417..26510 FT /note="Fibronectin type-III 92" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26516..26611 FT /note="Fibronectin type-III 93" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26614..26710 FT /note="Fibronectin type-III 94" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26714..26801 FT /note="Ig-like 128" FT DOMAIN 26812..26906 FT /note="Fibronectin type-III 95" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26912..27007 FT /note="Fibronectin type-III 96" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27013..27107 FT /note="Fibronectin type-III 97" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27101..27196 FT /note="Ig-like 129" FT DOMAIN 27205..27296 FT /note="Fibronectin type-III 98" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27302..27392 FT /note="Fibronectin type-III 99" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27499..27593 FT /note="Fibronectin type-III 100" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27599..27694 FT /note="Fibronectin type-III 101" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27697..27793 FT /note="Fibronectin type-III 102" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27797..27888 FT /note="Ig-like 130" FT DOMAIN 27895..27989 FT /note="Fibronectin type-III 103" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27995..28090 FT /note="Fibronectin type-III 104" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28096..28192 FT /note="Fibronectin type-III 105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28196..28286 FT /note="Ig-like 131" FT DOMAIN 28295..28389 FT /note="Fibronectin type-III 106" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28392..28484 FT /note="Fibronectin type-III 107" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28488..28577 FT /note="Ig-like 132" FT DOMAIN 28583..28680 FT /note="Fibronectin type-III 108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28686..28781 FT /note="Fibronectin type-III 109" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28784..28879 FT /note="Fibronectin type-III 110" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28882..28974 FT /note="Ig-like 133" FT DOMAIN 28979..29071 FT /note="Fibronectin type-III 111" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29081..29177 FT /note="Fibronectin type-III 112" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29180..29278 FT /note="Fibronectin type-III 113" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29282..29367 FT /note="Ig-like 134" FT DOMAIN 29378..29473 FT /note="Fibronectin type-III 114" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29475..29568 FT /note="Fibronectin type-III 115" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29568..29663 FT /note="Ig-like 135" FT DOMAIN 29670..29764 FT /note="Fibronectin type-III 116" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29770..29865 FT /note="Fibronectin type-III 117" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29868..29967 FT /note="Fibronectin type-III 118" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29971..30059 FT /note="Ig-like 136" FT DOMAIN 30070..30163 FT /note="Fibronectin type-III 119" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30169..30265 FT /note="Fibronectin type-III 120" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30271..30367 FT /note="Fibronectin type-III 121" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30371..30460 FT /note="Ig-like 137" FT DOMAIN 30467..30561 FT /note="Fibronectin type-III 122" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30564..30658 FT /note="Fibronectin type-III 123" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30663..30754 FT /note="Ig-like 138" FT DOMAIN 30761..30855 FT /note="Fibronectin type-III 124" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30861..30956 FT /note="Fibronectin type-III 125" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30962..31058 FT /note="Fibronectin type-III 126" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31061..31150 FT /note="Ig-like 139" FT DOMAIN 31158..31254 FT /note="Fibronectin type-III 127" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31258..31354 FT /note="Fibronectin type-III 128" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31360..31455 FT /note="Fibronectin type-III 129" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31460..31548 FT /note="Ig-like 140" FT DOMAIN 31653..31748 FT /note="Fibronectin type-III 130" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31754..31849 FT /note="Fibronectin type-III 131" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31855..31945 FT /note="Ig-like 141" FT DOMAIN 31955..32046 FT /note="Ig-like 142" FT DOMAIN 32051..32144 FT /note="Fibronectin type-III 132" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 32178..32432 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 32496..32584 FT /note="Ig-like 143" FT DOMAIN 32617..32710 FT /note="Ig-like 144" FT DOMAIN 32722..32811 FT /note="Ig-like 145" FT DOMAIN 33301..33391 FT /note="Ig-like 146" FT DOMAIN 33488..33576 FT /note="Ig-like 147" FT DOMAIN 33645..33732 FT /note="Ig-like 148" FT DOMAIN 33779..33867 FT /note="Ig-like 149" FT DOMAIN 33963..34052 FT /note="Ig-like 150" FT DOMAIN 34061..34149 FT /note="Ig-like 151" FT DOMAIN 34256..34344 FT /note="Ig-like 152" FT REGION 244..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 253..341 FT /note="ZIS1" FT REGION 333..356 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 859..886 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1408..1443 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1410..1440 FT /note="ZIS5" FT REGION 4241..4272 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 9920..9945 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10039..10070 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10087..10109 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10207..10280 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10314..10361 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10412..10457 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10499..10566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10583..10617 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10661..10743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10882..11102 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11158..11193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11362..11636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11666..12032 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14216..14236 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14891..14921 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 15911..15939 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 16614..16654 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18614..18637 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18716..18743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 19304..19331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27090..27110 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 31238..31267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33213..33256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33432..33463 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33584..33638 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33749..33777 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 529..561 FT /evidence="ECO:0000255" FT COILED 2025..2052 FT /evidence="ECO:0000255" FT COILED 3462..3487 FT /evidence="ECO:0000255" FT COILED 9534..9577 FT /evidence="ECO:0000255" FT COMPBIAS 1408..1419 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 4245..4257 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9920..9938 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10041..10052 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10058..10070 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10087..10101 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10207..10224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10245..10265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10329..10347 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10349..10360 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10418..10430 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10440..10457 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10684..10701 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10702..10720 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10721..10737 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10882..10944 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10961..10972 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10989..11009 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11030..11101 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11164..11190 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11388..11416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11438..11453 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11454..11465 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11466..11479 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11496..11509 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11510..11521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11538..11549 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11550..11563 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11580..11591 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11592..11613 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11614..11626 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11678..11696 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11704..11715 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11730..11745 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11768..11803 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11816..11825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11834..11846 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11854..11875 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11882..11900 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11927..11936 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11948..11958 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11960..11971 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11972..11981 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11982..11995 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11996..12008 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14223..14236 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19318..19331 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31252..31262 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33231..33242 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33439..33450 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33594..33604 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33625..33634 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33749..33771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 32298 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32184..32192 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32207 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 267 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 6920 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 9122 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 11503 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12007 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 12009 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12022 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 30443 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 32341 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:9804419" FT MOD_RES 33245 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33247 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33602 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33614 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT DISULFID 964..1015 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1724..1777 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2109..2134 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:11525170" FT DISULFID 2196..2246 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 3259..3311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4404..4455 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4499..4550 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4592..4643 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4686..4737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4779..4830 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5061..5112 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5248..5299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5623..5674 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5810..5861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5903..5954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6185..6236 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6372..6423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6465..6516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6748..6799 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7027..7078 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7123..7174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7219..7270 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7313..7364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7406..7457 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7689..7740 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7968..8019 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8064..8115 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8160..8211 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8254..8305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8347..8398 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8630..8681 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8909..8960 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9005..9056 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9101..9152 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9294..9345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9693..9743 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12067..12117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12611..12660 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12966..13016 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13233..13283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13322..13372 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13411..13461 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13771..13821 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 31481..31532 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 32516..32568 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 33664..33718 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 555..646 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8937992" FT /id="VSP_019138" FT VAR_SEQ 556..601 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019139" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPKVQALDRQSSGKDVRESTKSQAVADSSFTKEESKISQKEI FT KSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTG FT EAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQF FT LTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045935" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPK (in isoform 8 and isoform 10)" FT /evidence="ECO:0000305" FT /id="VSP_019140" FT VAR_SEQ 3434 FT /note="E -> EVQALDRQSSGKDVRESAKSQAVADSSFTKEESKISQKEIKSFQGSS FT YEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTGEAPKIFL FT HLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQFLTICNVQ FT LVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 9)" FT /evidence="ECO:0000305" FT /id="VSP_042903" FT VAR_SEQ 3435..3645 FT /note="APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLSKINETLELLSE FT SPVYPTKFDSEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTP FT SADYKFVFDGDDHSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTET FT ESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAIFEYTVV -> VQALDRQSSGKDVR FT ESTKSQAVADSSFTKEESKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQL FT CHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDV FT TWTHEGAKIEESERLKQSQNGNIQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVE FT GAPESILHERIEQEIEMEMK (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019141" FT VAR_SEQ 3454..4380 FT /note="Missing (in isoform 4 and isoform 11)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019142" FT VAR_SEQ 3455..5604 FT /note="FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYPTKFDSEKEGTGPIFI FT KEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDDHSLIILFT FT KLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGPCPPHFL FT KELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENKQLCTSVYYTIIHNPNGSGTFIVND FT PQREDSGLYICKAENMLGESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLKG FT PAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAKANELSSQLPLGAQELQSIL FT EQDKLTPESTREFLCINGSIHFQPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAV FT LSDTEKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPMHSYLTSVAEEVLSP FT KEKTVSDTNREQRVTLQKQEAQSALILSQSLAEGHVESLQSPDVMISQVNYEPLVPSEH FT SCTEGGKILIESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEHSDNVVMPPD FT QIIESKREPVAIKKVQEVQGRDLLSKESLLSGIPEEQRLNLKIQICRALQAAVASEQPG FT LFSEWLRNIEKVEVEAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMANLKME FT LRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDSFSGSQKVEPITEPEVESKYLIS FT TEEVSYFNVQSRVKYLDATPVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVAT FT VKIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNAKEVNWYFENKLVPSDEK FT FKCLQDQNTYTLVIDKVNTEDHQGEYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEP FT LEVALGHLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYISSLEILRTQVVDC FT GEYTCKASNEYGSVSCTATLTVTEAYPPTFLSRPKSLTTFVGKAAKFICTVTGTPVIET FT IWQKDGAALSPSPNWRISDAENKHILELSNLTIQDRGVYSCKASNKFGADICQAELIII FT DKPHFIKELEPVQSAINKKVHLECQVDEDRKVTVTWSKDGQKLPPGKDYKICFEDKIAT FT LEIPLAKLKDSGTYVCTASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARLHC FT KLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDITDVKVEDSGSYSCEAVNDVGS FT DSCSTEIVIKEPPSFIKTLEPADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKY FT RLFSQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLKEPPTFVKKVDDLIAL FT GGQTVTLQAAVRGSEPISVTWMKGQEVIREDGKIKMSFSNGVAVLIIPDVQISFGGKYT FT CLAENEAGSQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTPELKPKWYKDG FT RPLVASKKYRISFKNNVAQLKFYSAELHDSGQYTFEISNEVGSSSCETTFTVLDRDIAP FT FFTKPLRNVDSVVNGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGTASLEI FT IRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSFVTKPGSKDVLPGSAVCLKSTFQG FT STPLTIRWFKGNKELVSGGSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS FT ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKITWFANDREIKESSKHRMS FT FVESTAVLRLTDVGIEDSGEYMCEAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEY FT DVMLLAEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILKFVAADAGEYQCRV FT TNEVGSSICSARVTLREPPSFIKKIESTSSLRGGTAAFQATLKGSLPITVTWLKDSDEI FT TEDDNIRMTFENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKEPATITEEA FT VSIDVTQGDPATLQVKFSGTKEITAKWFKDGQELTLGSKYKISVTDTVSILKIISTEKK FT DSGEYTFEVQNDVGRSSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFSDSE FT DIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKYVLEGEPVVFTCRLIACPTPEM FT TWFHNNRPIPTGLRRIIKAESDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTAS FT LLVIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRFTGSPFNKKQDVEQKGM FT MRTIHFKTMSSAKKTDYMYDEEYLESKSDIRGWLNVGESFLDKETKVKLQRLREARKTL FT MEKKKLSLLDTSSEISSRTLRSEASDKDILFSREDMKIRSMSDLAESYKVDHSAESIVQ FT NPHALSNQMDQNIESEELPTSFQTIVDEEIFQTEIRMSQEALVKESLPKDHLYGEILVN FT ENTQARGQLEEIMANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESFGTLVNV FT EESEEIASERIKKDDLRELQLSASTRIDEFKTEQKEENMRFFENSFRKRPQRCPPSFLQ FT EIESQEVYEGDSCNFVCHFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSVH FT HQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVPVFHDYLDEEEELALVFDQA FT KGAHPSMSQEGQTNLHLLKTNPPVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQ FT TEELEPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARCREGDSIILECLISG FT EPQPVVTWFQNGVLLKQNQKFQFEEVNCSHQLYIKDVNSQDSGKYKCVAENNSGAVESV FT SDLTVEPVTYRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGPFTPWTNVKE FT YSVRDYFQSLETIEQIDQKEQVRCIPSREKIPRFVHGASRTIKISKPIRAEFIQCQAEG FT KERHVSEKSKLHQAEGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQSDYLP FT NIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVKHRIIEFEKLHVEKGVLEKRPTR FT TSIVNPPQKKIDDKAFSLKQRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQ FT THKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFHTQIKHTDVKFQELDSGQ FT PEEAYFKIQHPADTENIVFDLKQMYSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQ FT PDTHNISKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKEVRHVQEQNLDIL FT KTDLSLKSFSEEIYSESCALLPTSSADIEETDLSEKSCPLENGGRSSISHLKKAASEEK FT PLGVGEMEEECTLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQLSLSQCFP FT LLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQNEASFSTLEGEMIETSFSQNIPKLDE FT AHTTEAAESETSLTQYLLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVYEY FT YNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTPPSSVEYFESPKSPDLYFNPS FT DITKQSSIHSGGETVERYSTPLGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGET FT LERYSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEALERYSIPTGGPNPTG FT TFKTYPSKIEREDGTPNEHFYTPTEERGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIE FT PLTKRKVYENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGNVCSLEISNIQ FT KGEGGEYMCHAVNIIGEAKSFANVDIMPQEERVVALPPPVTHQHVMEFDLEHTTSSRTP FT SPQEIVLEVELSEKDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNMDSREG FT EDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFKCSVIGIPTPEVKWYKEYMCIEPD FT NIKYVISEEKGSHTLKIRNVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK FT SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDCYAPIGTAAYFQCLVRGSP FT RPTVYWYKDGKLVQGRRFTVEESGTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAA FT LTLT (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019143" FT VAR_SEQ 3646..4380 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019144" FT VAR_SEQ 4474..11851 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019145" FT VAR_SEQ 5605..34350 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019146" FT VAR_SEQ 10382..10645 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019147" FT VAR_SEQ 10742..10931 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019148" FT VAR_SEQ 11015..11163 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019149" FT VAR_SEQ 11117 FT /note="I -> VPKKPVPEKKVPVPAPKKVEPPPPPKVPEI (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045929" FT VAR_SEQ 11133 FT /note="E -> EAPPAKVSVVPKKPEPEKKVPPPGLKKAV (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045930" FT VAR_SEQ 11223..11852 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019150" FT VAR_SEQ 11421 FT /note="K -> KAPEVPKKIVPEEKVREAVLKKPEVPPAKVPGMPKKSVQEEKSPIVI FT SEDTEMYIYEASEEAVLEEKVLVTQPQKTKPKLAKVPEPPKKVVPEDKIYVTIPKKRET FT PATKEPDTTRGIFPEVEPPEAIPEIPEHPPTEEFEVFKEVIPEGETPIVKRRKTPSPTV FT PESPREIVPVKETPMAAPLEIEIPPTKAPEAMKEVVPEMKIFEDVPEEPETPRMKTPEA FT PQEIIPAKTVPSKKREPPSVKVPEALQEIVPEKKTLVVPLRKPEVLPDEVPEALREVVP FT EKKVHPPQRAEVVPVKVHEAPKEIIPEKKVSVVPPKKPEVPPVKVPEASKEVIREEKVP FT LAPPKEPEVPPVKVPEPPKEVVPEKKAPVAPPKEPEVPPVKVPEAPKEVVPEKKVPVPP FT PKKPEVPPTKVPEVPKAAVPEKKLPEAIPPKPESPPPE (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045931" FT VAR_SEQ 11450 FT /note="P -> PKVPEAPKEVVLEKKASVAVPKKPEAPRAKVPEAAQEVVPEKKIPKA FT PIKKPEAPAVTVPEVPQEATEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKP FT EAPPATVPEVPQEIVPEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPSAPPKKPEVPP FT V (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045932" FT VAR_SEQ 11507 FT /note="E -> EVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKVPEAPKEVVLEKKASV FT AVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEVPQEAAEKEIPVAPPK FT KPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIVPEKKTLVLPKKPEVP FT PVTVPEAPKEVVLEKKVPSTPPKKPEVPPVKVPEAPKEVVPEKKVPVPPPKKPEVPPTK FT VPEVPKAAVPEKKVPEAIPPKPESPPPEVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKV FT PEAPKEVVLEKKVSVAVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEV FT PQEAAEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIV FT PEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPLAPPKKPEVPPVKVPEAPKEVVPEKK FT VPVTPPKKPEVPPVKVPEAPIEVVPEKKMPLAPPKKPEVPPVKVPEAPKEVVPEKKVPS FT APPKKPEVPPVK (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045933" FT VAR_SEQ 11507 FT /note="E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019151" FT VAR_SEQ 11790 FT /note="P -> PKEPEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVT FT KKPEVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKE FT TPPVEEREIEKYIKPEEPEPEPQPEEIPV (in isoform 13)" FT /evidence="ECO:0000305" FT /id="VSP_047142" FT VAR_SEQ 11793 FT /note="P -> PEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVTKKP FT EVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKETPP FT VEEREIEKYIKPEEPEPEPQPEEIPVKEP (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045934" FT VAR_SEQ 11985..12201 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019152" FT VARIANT 54 FT /note="V -> M (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs139517732)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026685" FT VARIANT 60 FT /note="D -> Y (in dbSNP:rs35683768)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040078" FT VARIANT 115 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs564777385)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040079" FT VARIANT 279 FT /note="R -> W (in MFM9; disrupts NBR1-binding; FT dbSNP:rs138060032)" FT /evidence="ECO:0000269|PubMed:15802564" FT /id="VAR_026634" FT VARIANT 328 FT /note="R -> C (in dbSNP:rs16866538)" FT /evidence="ECO:0000269|PubMed:11846417, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026686" FT VARIANT 360 FT /note="R -> T (in dbSNP:rs56128843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040080" FT VARIANT 498 FT /note="V -> I (in dbSNP:rs72647851)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040081" FT VARIANT 740 FT /note="R -> L (in CMH9; dbSNP:rs28933405)" FT /evidence="ECO:0000269|PubMed:10462489" FT /id="VAR_026687" FT VARIANT 743 FT /note="A -> V (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs267607157)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026688" FT VARIANT 799 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149061352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040082" FT VARIANT 811 FT /note="T -> I (in dbSNP:rs35813871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040083" FT VARIANT 922 FT /note="R -> H (in dbSNP:rs56046320)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040084" FT VARIANT 937 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040085" FT VARIANT 976 FT /note="W -> R (in CMD1G; dbSNP:rs267607155)" FT /evidence="ECO:0000269|PubMed:11788824" FT /id="VAR_026689" FT VARIANT 1081 FT /note="A -> T (in dbSNP:rs55914517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040086" FT VARIANT 1137 FT /note="G -> R (in dbSNP:rs72647870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040087" FT VARIANT 1201 FT /note="K -> E (in dbSNP:rs10497520)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040088" FT VARIANT 1202 FT /note="V -> A (in dbSNP:rs150667217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040089" FT VARIANT 1249 FT /note="S -> L (in dbSNP:rs1552280)" FT /id="VAR_056081" FT VARIANT 1295 FT /note="S -> L (in dbSNP:rs1552280)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040090" FT VARIANT 1345 FT /note="G -> D (in dbSNP:rs36021856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040091" FT VARIANT 1347 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267599092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040092" FT VARIANT 1350 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs539470256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040093" FT VARIANT 1353 FT /note="V -> L (in dbSNP:rs36062108)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040094" FT VARIANT 1393 FT /note="I -> V (in dbSNP:rs16866531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040095" FT VARIANT 1416 FT /note="R -> C (in dbSNP:rs72647875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040096" FT VARIANT 1441 FT /note="R -> P (in dbSNP:rs72647876)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040097" FT VARIANT 1544 FT /note="I -> V (in dbSNP:rs72647877)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040098" FT VARIANT 1572 FT /note="R -> Q (in dbSNP:rs12476289)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040099" FT VARIANT 1658 FT /note="R -> G (in dbSNP:rs56270960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040100" FT VARIANT 1664 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs375029799)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040101" FT VARIANT 1692 FT /note="G -> D (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs370004591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040102" FT VARIANT 1744 FT /note="P -> L (in dbSNP:rs75686037)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040103" FT VARIANT 1772 FT /note="S -> G (in dbSNP:rs150725992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040104" FT VARIANT 1907 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040105" FT VARIANT 1998 FT /note="R -> H (in dbSNP:rs144135510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040106" FT VARIANT 2107 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040107" FT VARIANT 2118 FT /note="I -> T (in dbSNP:rs56404770)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040108" FT VARIANT 2164 FT /note="A -> T (in dbSNP:rs56285559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040109" FT VARIANT 2240 FT /note="D -> Y" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040110" FT VARIANT 2392 FT /note="G -> S (in dbSNP:rs4894048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040111" FT VARIANT 2432 FT /note="L -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs571572592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040112" FT VARIANT 2610 FT /note="M -> I (in dbSNP:rs56142888)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040113" FT VARIANT 2771 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs576644663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040114" FT VARIANT 2823 FT /note="V -> F (in dbSNP:rs33917087)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040115" FT VARIANT 2831 FT /note="S -> N (in dbSNP:rs2306636)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040116" FT VARIANT 2930 FT /note="V -> I (in dbSNP:rs56373393)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040117" FT VARIANT 2963 FT /note="T -> P (in dbSNP:rs200875815)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074293" FT VARIANT 3026 FT /note="N -> I (in dbSNP:rs11900987)" FT /id="VAR_056082" FT VARIANT 3154 FT /note="K -> R (in dbSNP:rs4893853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040118" FT VARIANT 3191 FT /note="Q -> E (in dbSNP:rs33997263)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040119" FT VARIANT 3238 FT /note="P -> L (in a bladder carcinoma sample; somatic FT mutation; dbSNP:rs397517792)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040120" FT VARIANT 3250 FT /note="V -> G (in dbSNP:rs55634230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040121" FT VARIANT 3261 FT /note="V -> M (in dbSNP:rs2291311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040122" FT VARIANT 3367 FT /note="R -> Q (in dbSNP:rs34819099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040123" FT VARIANT 3419 FT /note="S -> N (in dbSNP:rs2291310)" FT /evidence="ECO:0000269|PubMed:7569978" FT /id="VAR_056083" FT VARIANT 3482 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040124" FT VARIANT 3491 FT /note="P -> S (in dbSNP:rs2627037)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7569978" FT /id="VAR_040125" FT VARIANT 3570 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040126" FT VARIANT 3590 FT /note="L -> V (in dbSNP:rs55853696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040127" FT VARIANT 3637 FT /note="P -> S (in dbSNP:rs757223770)" FT /id="VAR_056084" FT VARIANT 3762 FT /note="I -> V (in dbSNP:rs34070843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040128" FT VARIANT 3799 FT /note="S -> Y (in CMD1G)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026690" FT VARIANT 3877 FT /note="I -> F (in dbSNP:rs34618570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040129" FT VARIANT 3965 FT /note="I -> L (in dbSNP:rs56244420)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040130" FT VARIANT 4084 FT /note="R -> Q (in dbSNP:rs200431386)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026691" FT VARIANT 4215 FT /note="T -> P (in dbSNP:rs2562829)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:17344846" FT /id="VAR_026635" FT VARIANT 4238 FT /note="G -> W (in dbSNP:rs56030296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040131" FT VARIANT 4283 FT /note="L -> F (in dbSNP:rs1883085)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026636" FT VARIANT 4291 FT /note="I -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040132" FT VARIANT 4303 FT /note="G -> D (in dbSNP:rs55857742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040133" FT VARIANT 4427 FT /note="D -> E (in dbSNP:rs55906845)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040134" FT VARIANT 4465 FT /note="S -> N (in CMD1G; dbSNP:rs281864908)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026692" FT VARIANT 8288 FT /note="A -> V (in dbSNP:rs16866412)" FT /id="VAR_056085" FT VARIANT 8474 FT /note="I -> T (in dbSNP:rs4893852)" FT /id="VAR_056086" FT VARIANT 12310 FT /note="G -> E (in dbSNP:rs55723264)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040135" FT VARIANT 12383 FT /note="H -> R (in dbSNP:rs2288563)" FT /evidence="ECO:0000269|PubMed:10850961" FT /id="VAR_040136" FT VARIANT 12469 FT /note="V -> A (in dbSNP:rs34706299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040137" FT VARIANT 12642 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs199684560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040138" FT VARIANT 12657 FT /note="E -> K (in a Wilms tumor; somatic mutation; FT dbSNP:rs778634417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040139" FT VARIANT 12679 FT /note="K -> E (in dbSNP:rs6723526)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040140" FT VARIANT 12720 FT /note="S -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040141" FT VARIANT 12798 FT /note="R -> C (in dbSNP:rs200914097)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040142" FT VARIANT 13049 FT /note="E -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040143" FT VARIANT 13083 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1458591077)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040144" FT VARIANT 13096 FT /note="R -> L (in dbSNP:rs373298007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040145" FT VARIANT 13099 FT /note="Q -> R (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040146" FT VARIANT 13297 FT /note="V -> A (in dbSNP:rs571522834)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040147" FT VARIANT 13399 FT /note="I -> M (in dbSNP:rs74580375)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040148" FT VARIANT 13418 FT /note="A -> T (in dbSNP:rs144668626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040149" FT VARIANT 13428 FT /note="E -> V (in dbSNP:rs114331773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040150" FT VARIANT 13430 FT /note="I -> T (in dbSNP:rs184078045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040151" FT VARIANT 13434 FT /note="R -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040152" FT VARIANT 13469 FT /note="D -> N (in dbSNP:rs17354992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040153" FT VARIANT 13495 FT /note="K -> N (in dbSNP:rs72677225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040154" FT VARIANT 13785 FT /note="N -> S (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040155" FT VARIANT 13870 FT /note="Q -> H (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040156" FT VARIANT 14109 FT /note="V -> I (in dbSNP:rs72677232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040157" FT VARIANT 14131 FT /note="R -> Q (in dbSNP:rs72677233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040158" FT VARIANT 14208 FT /note="P -> T (in dbSNP:rs146181477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040159" FT VARIANT 14728 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040160" FT VARIANT 14750 FT /note="R -> Q (in dbSNP:rs200944827)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074294" FT VARIANT 14999 FT /note="S -> T (in dbSNP:rs55663050)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040161" FT VARIANT 15021 FT /note="N -> T (in dbSNP:rs36043230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040162" FT VARIANT 15520 FT /note="A -> V (in dbSNP:rs16866412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040163" FT VARIANT 15555 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751398376)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040164" FT VARIANT 15620 FT /note="R -> Q (in dbSNP:rs201825412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040165" FT VARIANT 15629 FT /note="S -> I (in dbSNP:rs200650668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040166" FT VARIANT 15635 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040167" FT VARIANT 15700 FT /note="R -> Q (in dbSNP:rs370390570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040168" FT VARIANT 15705 FT /note="L -> P (in dbSNP:rs755155531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040169" FT VARIANT 15837 FT /note="I -> M (in dbSNP:rs554368924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040170" FT VARIANT 16046 FT /note="G -> V (in dbSNP:rs780672348)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069432" FT VARIANT 16058 FT /note="R -> H (in dbSNP:rs72646808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040171" FT VARIANT 16067 FT /note="K -> I (in dbSNP:rs2303832)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040172" FT VARIANT 16090 FT /note="I -> T (in dbSNP:rs72646809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040173" FT VARIANT 16195 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs373526624)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040174" FT VARIANT 16409 FT /note="R -> C (in dbSNP:rs55734111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040175" FT VARIANT 16424 FT /note="R -> P (in dbSNP:rs375895183)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040176" FT VARIANT 16575 FT /note="V -> M (in dbSNP:rs3813243)" FT /id="VAR_056087" FT VARIANT 16629 FT /note="I -> M (in dbSNP:rs55809450)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040177" FT VARIANT 16877 FT /note="K -> R (in dbSNP:rs72646823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040178" FT VARIANT 17060 FT /note="N -> D (in dbSNP:rs1001238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040179" FT VARIANT 17637 FT /note="I -> V (in dbSNP:rs56025724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040180" FT VARIANT 17838 FT /note="R -> H (in dbSNP:rs2288569)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040181" FT VARIANT 17866 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040182" FT VARIANT 17906 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs374713701)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040183" FT VARIANT 18094 FT /note="E -> A (in dbSNP:rs769852851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040184" FT VARIANT 18109 FT /note="G -> S (in dbSNP:rs200732032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040185" FT VARIANT 18164 FT /note="R -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040186" FT VARIANT 18221 FT /note="P -> L (in dbSNP:rs16866406)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040187" FT VARIANT 18222 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040188" FT VARIANT 18726 FT /note="R -> Q (in dbSNP:rs141973925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040189" FT VARIANT 18835 FT /note="V -> A (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1336054298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040190" FT VARIANT 18881 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1204056923)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040191" FT VARIANT 18939 FT /note="N -> S (in dbSNP:rs1470758075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040192" FT VARIANT 19000 FT /note="R -> Q (in dbSNP:rs199895260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040193" FT VARIANT 19060 FT /note="L -> Q (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1383995916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040194" FT VARIANT 19091 FT /note="R -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040195" FT VARIANT 19224 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040196" FT VARIANT 19367 FT /note="T -> I (in dbSNP:rs72646850)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040197" FT VARIANT 19392 FT /note="E -> K (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040198" FT VARIANT 19480 FT /note="A -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040199" FT VARIANT 19495 FT /note="D -> G (in dbSNP:rs773075736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040200" FT VARIANT 19665 FT /note="R -> H (in dbSNP:rs202240487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040201" FT VARIANT 19762 FT /note="T -> I (in dbSNP:rs2042996)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040202" FT VARIANT 19947 FT /note="G -> R (in dbSNP:rs181717727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040203" FT VARIANT 19956 FT /note="V -> M (in dbSNP:rs150661999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040204" FT VARIANT 19992 FT /note="R -> Q (in dbSNP:rs141965360)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040205" FT VARIANT 20057 FT /note="R -> C (in dbSNP:rs72646861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040206" FT VARIANT 20075 FT /note="S -> L (in dbSNP:rs13021201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040207" FT VARIANT 20179 FT /note="T -> K" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040208" FT VARIANT 20198 FT /note="A -> T (in dbSNP:rs56378177)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040209" FT VARIANT 20198 FT /note="A -> V (in dbSNP:rs55948748)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040210" FT VARIANT 20331 FT /note="R -> H (in dbSNP:rs200217934)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040211" FT VARIANT 20359 FT /note="R -> K (in dbSNP:rs9808036)" FT /id="VAR_056088" FT VARIANT 20408 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040212" FT VARIANT 20564 FT /note="R -> K (in dbSNP:rs72646869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040213" FT VARIANT 20718 FT /note="V -> I (in dbSNP:rs2303838)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040214" FT VARIANT 20726 FT /note="S -> P (in dbSNP:rs72646873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040215" FT VARIANT 20892 FT /note="T -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040216" FT VARIANT 20894 FT /note="S -> R (in dbSNP:rs750847940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040217" FT VARIANT 21125 FT /note="D -> E (in dbSNP:rs534340303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040218" FT VARIANT 21403 FT /note="P -> S (in dbSNP:rs55980498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040219" FT VARIANT 21730 FT /note="R -> C (in dbSNP:rs56141309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040220" FT VARIANT 21747 FT /note="R -> Q (in dbSNP:rs55853138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040221" FT VARIANT 21851 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs55713867)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040222" FT VARIANT 21925 FT /note="G -> R (in dbSNP:rs55801134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040223" FT VARIANT 21995 FT /note="R -> H (in dbSNP:rs56071233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040224" FT VARIANT 22045 FT /note="A -> V (in dbSNP:rs55903402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040225" FT VARIANT 22149 FT /note="R -> H (in dbSNP:rs55677134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040226" FT VARIANT 22160 FT /note="V -> I (in dbSNP:rs55885640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040227" FT VARIANT 22261 FT /note="I -> T (in dbSNP:rs55837610)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040228" FT VARIANT 22306 FT /note="K -> N (in dbSNP:rs56019808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040229" FT VARIANT 22357 FT /note="R -> H (in dbSNP:rs10164753)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040230" FT VARIANT 22408 FT /note="L -> P (in dbSNP:rs56399205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040231" FT VARIANT 22537 FT /note="Q -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040232" FT VARIANT 22584 FT /note="P -> L (in dbSNP:rs55992239)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040233" FT VARIANT 22646 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040234" FT VARIANT 22670 FT /note="T -> A (in dbSNP:rs56201325)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040235" FT VARIANT 22770 FT /note="A -> D (in dbSNP:rs55991022)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040236" FT VARIANT 22801 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs764005465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040237" FT VARIANT 22823 FT /note="R -> W (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs369098292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040238" FT VARIANT 22968 FT /note="E -> Q (in dbSNP:rs55762754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040239" FT VARIANT 23074 FT /note="P -> L (in dbSNP:rs55713856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040240" FT VARIANT 23079 FT /note="L -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040241" FT VARIANT 23282 FT /note="D -> N (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040242" FT VARIANT 23303 FT /note="H -> Y (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040243" FT VARIANT 23306 FT /note="R -> C (in dbSNP:rs744426)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040244" FT VARIANT 23515 FT /note="A -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040245" FT VARIANT 23551 FT /note="E -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040246" FT VARIANT 23807 FT /note="S -> N (in dbSNP:rs3813243)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040247" FT VARIANT 23872 FT /note="D -> N (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040248" FT VARIANT 23891 FT /note="V -> A (in dbSNP:rs55984930)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040249" FT VARIANT 23933 FT /note="Y -> H (in dbSNP:rs3813245)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040250" FT VARIANT 23939 FT /note="T -> M (in dbSNP:rs56372592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040251" FT VARIANT 23952 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040252" FT VARIANT 24098 FT /note="A -> G (in dbSNP:rs56391938)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040253" FT VARIANT 24098 FT /note="A -> T (in dbSNP:rs4894028)" FT /id="VAR_056089" FT VARIANT 24119 FT /note="N -> S (in dbSNP:rs3813246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040254" FT VARIANT 24133 FT /note="V -> I (in dbSNP:rs56340968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040255" FT VARIANT 24159 FT /note="V -> A (in a head and neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040256" FT VARIANT 24239 FT /note="T -> A (in dbSNP:rs56018860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040257" FT VARIANT 24265 FT /note="E -> K (in dbSNP:rs56341835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040258" FT VARIANT 24584 FT /note="I -> T (in dbSNP:rs12463674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040259" FT VARIANT 24781 FT /note="I -> T (in dbSNP:rs3731745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040260" FT VARIANT 24799 FT /note="R -> H (in dbSNP:rs56044609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040261" FT VARIANT 24954 FT /note="D -> H (in dbSNP:rs56307213)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040262" FT VARIANT 24980 FT /note="T -> M (in dbSNP:rs3731746)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040263" FT VARIANT 25659 FT /note="R -> H (in dbSNP:rs55850344)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040264" FT VARIANT 25679 FT /note="A -> T (in dbSNP:rs56365600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040265" FT VARIANT 25720 FT /note="P -> A (in dbSNP:rs56137800)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040266" FT VARIANT 25821 FT /note="T -> K (in dbSNP:rs55933739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040267" FT VARIANT 25859 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs375422359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040268" FT VARIANT 25879 FT /note="N -> K (in dbSNP:rs56264840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040269" FT VARIANT 25923 FT /note="A -> V (in dbSNP:rs55634791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040270" FT VARIANT 26045 FT /note="V -> I (in dbSNP:rs56309296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040271" FT VARIANT 26059 FT /note="K -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040272" FT VARIANT 26134 FT /note="I -> V (in dbSNP:rs3829746)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040273" FT VARIANT 26477 FT /note="R -> C (in dbSNP:rs56057221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040274" FT VARIANT 26843 FT /note="D -> Y (in dbSNP:rs56330345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040275" FT VARIANT 27346 FT /note="K -> R (in dbSNP:rs1186947794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040276" FT VARIANT 27652 FT /note="R -> C (in dbSNP:rs191482653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040277" FT VARIANT 27728 FT /note="G -> V (in dbSNP:rs55898359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040278" FT VARIANT 27754 FT /note="F -> L (in dbSNP:rs55940667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040279" FT VARIANT 27755 FT /note="I -> T (in dbSNP:rs9808377)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040280" FT VARIANT 27929 FT /note="I -> V (in dbSNP:rs139506970)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040281" FT VARIANT 28132 FT /note="I -> L (in dbSNP:rs77853750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040282" FT VARIANT 28168 FT /note="R -> Q (in dbSNP:rs72648238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040283" FT VARIANT 28538 FT /note="R -> H (in dbSNP:rs149567378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040284" FT VARIANT 28572 FT /note="I -> T (in dbSNP:rs114026724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040285" FT VARIANT 28948 FT /note="A -> T (in dbSNP:rs148617456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040286" FT VARIANT 28986 FT /note="I -> V (in dbSNP:rs535151633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040287" FT VARIANT 28993 FT /note="G -> E (in dbSNP:rs376628842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040288" FT VARIANT 28998 FT /note="L -> V (in dbSNP:rs373049260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040289" FT VARIANT 29070 FT /note="V -> M (in dbSNP:rs747122)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040290" FT VARIANT 29090 FT /note="I -> V (in dbSNP:rs16866391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040291" FT VARIANT 29419 FT /note="R -> C (in dbSNP:rs750303653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040292" FT VARIANT 29479 FT /note="L -> P (in dbSNP:rs1310673663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040293" FT VARIANT 29880 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040294" FT VARIANT 29976 FT /note="D -> E (in dbSNP:rs72648256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040295" FT VARIANT 30042 FT /note="S -> G (in dbSNP:rs72648257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040296" FT VARIANT 30107 FT /note="R -> C (in dbSNP:rs142525903)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040297" FT VARIANT 30125 FT /note="S -> F (in dbSNP:rs191484894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040298" FT VARIANT 30211 FT /note="L -> P (in dbSNP:rs62621206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040299" FT VARIANT 30412 FT /note="I -> T (in dbSNP:rs62621236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040300" FT VARIANT 30617 FT /note="T -> S (in a renal chromophobe cancer sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040301" FT VARIANT 30674 FT /note="T -> I (in dbSNP:rs56027402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040302" FT VARIANT 30809 FT /note="V -> I (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs397517769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040303" FT VARIANT 30818 FT /note="F -> I (in dbSNP:rs56009327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040304" FT VARIANT 30825 FT /note="E -> K (in dbSNP:rs55915651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040305" FT VARIANT 30856 FT /note="I -> T (in dbSNP:rs55660660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040306" FT VARIANT 30887 FT /note="G -> D (in dbSNP:rs56066673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040307" FT VARIANT 30887 FT /note="G -> S (in dbSNP:rs56233675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040308" FT VARIANT 30897 FT /note="R -> H (in dbSNP:rs3731749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040309" FT VARIANT 30907 FT /note="R -> H (in dbSNP:rs55676195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040310" FT VARIANT 30946 FT /note="R -> H (in dbSNP:rs55704830)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040311" FT VARIANT 31081 FT /note="I -> F (in dbSNP:rs72648270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040312" FT VARIANT 31107 FT /note="R -> C (in dbSNP:rs72648272)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040313" FT VARIANT 31124 FT /note="A -> G (in dbSNP:rs72648273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040314" FT VARIANT 31156 FT /note="N -> S (in dbSNP:rs149001703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040315" FT VARIANT 31246 FT /note="P -> T (in dbSNP:rs55653324)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040316" FT VARIANT 31330 FT /note="R -> H (in dbSNP:rs4894028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040317" FT VARIANT 31690 FT /note="C -> R (in dbSNP:rs56061641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040318" FT VARIANT 31724 FT /note="R -> Q (in dbSNP:rs55742743)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040319" FT VARIANT 31725 FT /note="V -> I (in dbSNP:rs55675869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040320" FT VARIANT 31732 FT /note="G -> S (in dbSNP:rs55880786)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040321" FT VARIANT 31886 FT /note="V -> I (in dbSNP:rs2278196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040322" FT VARIANT 32097 FT /note="R -> C (in dbSNP:rs56273463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040323" FT VARIANT 32171 FT /note="T -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040324" FT VARIANT 32248 FT /note="V -> I (in dbSNP:rs34924609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040325" FT VARIANT 32281 FT /note="Q -> H (in dbSNP:rs55886356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040326" FT VARIANT 32323 FT /note="R -> H (in dbSNP:rs55669553)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040327" FT VARIANT 32411 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs756924372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040328" FT VARIANT 32558 FT /note="I -> V (in dbSNP:rs56347248)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040329" FT VARIANT 32610 FT /note="M -> V (in dbSNP:rs56173891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040330" FT VARIANT 32637 FT /note="G -> V (in dbSNP:rs3731752)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040331" FT VARIANT 32742 FT /note="E -> Q (in dbSNP:rs148525155)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069433" FT VARIANT 32922 FT /note="V -> A (in dbSNP:rs55945684)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040332" FT VARIANT 32943 FT /note="L -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040333" FT VARIANT 32953 FT /note="R -> H (in dbSNP:rs3829747)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040334" FT VARIANT 32996 FT /note="R -> Q (in CMD1G; dbSNP:rs199642423)" FT /evidence="ECO:0000269|PubMed:16465475" FT /id="VAR_026693" FT VARIANT 33213 FT /note="V -> L (in dbSNP:rs55866005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040335" FT VARIANT 33242 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1003158162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040336" FT VARIANT 33387 FT /note="T -> M (in dbSNP:rs56001826)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040337" FT VARIANT 33419 FT /note="E -> D (in dbSNP:rs56308529)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040338" FT VARIANT 33536 FT /note="V -> M (in dbSNP:rs55865284)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040339" FT VARIANT 33568 FT /note="K -> Q (in dbSNP:rs56365812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040340" FT VARIANT 33616 FT /note="E -> K (in dbSNP:rs56324595)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040341" FT VARIANT 33620 FT /note="P -> L (in dbSNP:rs16866380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040342" FT VARIANT 33886 FT /note="E -> V (in dbSNP:rs55725279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040343" FT VARIANT 33899 FT /note="I -> T (in dbSNP:rs55880440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040344" FT VARIANT 33904 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040345" FT VARIANT 33955 FT /note="T -> I (in dbSNP:rs55842557)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040346" FT VARIANT 34115 FT /note="V -> A (in dbSNP:rs16866378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040347" FT VARIANT 34306 FT /note="I -> N (in TMD; dbSNP:rs281864928)" FT /evidence="ECO:0000269|PubMed:12891679" FT /id="VAR_026694" FT VARIANT 34315 FT /note="L -> P (in TMD; dbSNP:rs267607156)" FT /evidence="ECO:0000269|PubMed:12145747" FT /id="VAR_026695" FT MUTAGEN 32207 FT /note="K->A: Disrupts catalytic activity." FT /evidence="ECO:0000269|PubMed:9804419" FT MUTAGEN 32341 FT /note="Y->E: No phosphorylation on tyrosine." FT /evidence="ECO:0000269|PubMed:9804419" FT CONFLICT 132 FT /note="T -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 255 FT /note="P -> H (in Ref. 3; CAD12455/CAD12456/CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT 1472..1474 FT /note="QTA -> ANC (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 1730 FT /note="G -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 3919 FT /note="P -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 4525 FT /note="R -> K (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 6619 FT /note="R -> E (in Ref. 1; CAA62189 and 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 7145 FT /note="D -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 7441 FT /note="S -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 8038 FT /note="A -> E (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8225 FT /note="Q -> H (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8850 FT /note="A -> P (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9693 FT /note="C -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9892 FT /note="I -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10205 FT /note="I -> V (in Ref. 3; CAD12456 and 9; AAP80791)" FT /evidence="ECO:0000305" FT CONFLICT 10305 FT /note="G -> R (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 10566 FT /note="R -> K (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10779 FT /note="R -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11424 FT /note="E -> D (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 11511 FT /note="A -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11626 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11838 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 12994 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 13795..13797 FT /note="YKF -> IQI (in Ref. 11)" FT /evidence="ECO:0000305" FT CONFLICT 14590 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 14792 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 15974 FT /note="E -> K (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 16234..16235 FT /note="TK -> QR (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17238 FT /note="R -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17423 FT /note="R -> S (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 19734 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20517 FT /note="G -> A (in Ref. 1; CAA62188 and 3; CAD12455)" FT /evidence="ECO:0000305" FT CONFLICT 20622 FT /note="L -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20775 FT /note="A -> P (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 21625 FT /note="Y -> I (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 21795..21800 FT /note="PGPVLN -> ARPSPQ (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 22176 FT /note="C -> W (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22816 FT /note="A -> D (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22837 FT /note="T -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 24176 FT /note="I -> M (in Ref. 1; CAA62188 and 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 24181 FT /note="S -> F (in Ref. 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 25731 FT /note="P -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26573 FT /note="M -> V (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26846..26848 FT /note="IVE -> HRK (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 27879 FT /note="G -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 28936 FT /note="D -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29222 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29518 FT /note="F -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29701 FT /note="T -> P (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29873 FT /note="E -> G (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29878 FT /note="T -> Q (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30209 FT /note="K -> E (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30256 FT /note="A -> R (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30496 FT /note="V -> I (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30534 FT /note="Y -> H (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30748 FT /note="S -> L (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 31303 FT /note="W -> V (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 32060 FT /note="V -> A (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33084 FT /note="D -> N (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33120 FT /note="R -> W (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33382 FT /note="A -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33424 FT /note="S -> P (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33526 FT /note="Q -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33633 FT /note="T -> I (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33716 FT /note="Y -> V (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33995 FT /note="V -> A (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 34071 FT /note="N -> G (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT CONFLICT 34082 FT /note="C -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 34253 FT /note="G -> R (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT STRAND 4..10 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 15..18 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 23..33 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 36..45 FT /evidence="ECO:0007829|PDB:2A38" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 55..59 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 62..69 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 87..98 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 102..108 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 113..116 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 119..131 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:1YA5" FT STRAND 147..155 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 158..166 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 168..170 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 172..180 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 183..194 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 199..205 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 225..233 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 236..241 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 1850..1852 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1858..1863 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1866..1869 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1871..1876 FT /evidence="ECO:0007829|PDB:6DL4" FT TURN 1891..1893 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1894..1899 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1908..1916 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1919..1929 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 2076..2082 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2087..2090 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2095..2105 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2108..2113 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2122..2130 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2133..2138 FT /evidence="ECO:0007829|PDB:1G1C" FT HELIX 2143..2145 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2147..2155 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2158..2169 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2797..2799 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2804..2807 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2812..2820 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2826..2829 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2838..2845 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2848..2853 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2858..2860 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2862..2868 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2871..2880 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2884..2886 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2891..2894 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2899..2907 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2914..2916 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2924..2932 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2935..2940 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2949..2955 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2958..2967 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2971..2973 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2978..2981 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2986..2994 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3000..3003 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3012..3019 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3022..3027 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 3032..3034 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3036..3042 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3045..3053 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3504..3507 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3512..3515 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3520..3527 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3533..3538 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3547..3554 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3557..3562 FT /evidence="ECO:0007829|PDB:8OVU" FT HELIX 3567..3569 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3571..3579 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3582..3593 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 7948..7951 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7956..7958 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7964..7975 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7977..7981 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7983..7986 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7991..7996 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8001..8008 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8011..8013 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8015..8023 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8026..8036 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8044..8047 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8052..8055 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8060..8071 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8073..8078 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8087..8094 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8097..8104 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8107..8109 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8111..8119 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8122..8133 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8140..8143 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8151..8154 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8156..8166 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8169..8174 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8183..8190 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8193..8201 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8203..8205 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8207..8215 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8218..8226 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8233..8236 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8244..8247 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8249..8261 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8263..8268 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8276..8284 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8287..8294 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8297..8299 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8301..8309 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8315..8320 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8335..8337 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8343..8354 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8358..8361 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8368..8377 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8380..8385 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8390..8392 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8394..8401 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8406..8415 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8420..8423 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8436..8444 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8451..8454 FT /evidence="ECO:0007829|PDB:3B43" FT TURN 8463..8465 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8466..8468 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8472..8481 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8488..8495 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8500..8507 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 9506..9510 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9518..9525 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9530..9543 FT /evidence="ECO:0007829|PDB:7NIP" FT STRAND 9582..9587 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9592..9595 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9600..9608 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9616..9619 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9628..9635 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9638..9643 FT /evidence="ECO:0007829|PDB:5JOE" FT HELIX 9648..9650 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9652..9658 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9661..9670 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9674..9676 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9681..9684 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9689..9697 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9703..9706 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9717..9722 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9725..9732 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9735..9737 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9739..9745 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9748..9757 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9763..9765 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9770..9772 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9778..9786 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9790..9795 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9803..9811 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9814..9819 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9824..9826 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9828..9835 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9841..9850 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 12680..12682 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12687..12690 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12691..12693 FT /evidence="ECO:0007829|PDB:6I0Y" FT STRAND 12695..12705 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12709..12712 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12719..12722 FT /evidence="ECO:0007829|PDB:1TIU" FT STRAND 12723..12728 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12731..12736 FT /evidence="ECO:0007829|PDB:1WAA" FT HELIX 12741..12743 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12745..12751 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12754..12763 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 14223..14228 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14232..14240 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14252..14259 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14275..14281 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14288..14296 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14308..14314 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14319..14322 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14325..14327 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14331..14334 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14339..14349 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14352..14357 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14368..14372 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14374..14381 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14386..14388 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14390..14397 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14402..14412 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14419..14424 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14431..14436 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14446..14455 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14462..14468 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14470..14475 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14484..14492 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14506..14509 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14522..14524 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14528..14534 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14549..14555 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14568..14576 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14584..14592 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 15216..15224 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15227..15233 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15245..15252 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15268..15273 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15282..15290 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15305..15307 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 16533..16538 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16541..16546 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16559..16566 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16585..16592 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16600..16609 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16623..16626 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 20520..20528 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20531..20537 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20549..20556 FT /evidence="ECO:0007829|PDB:8OSD" FT HELIX 20568..20570 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20573..20580 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20587..20594 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 21506..21509 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21515..21518 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21532..21539 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21546..21551 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21553..21560 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21568..21577 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 22291..22296 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22299..22303 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22319..22324 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22340..22345 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22354..22361 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22367..22377 FT /evidence="ECO:0007829|PDB:1BPV" FT HELIX 22381..22384 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22883..22890 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22895..22900 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22912..22919 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22926..22932 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22934..22939 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22947..22956 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22970..22972 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22982..22987 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22992..22996 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23009..23016 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23023..23035 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23043..23052 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23568..23575 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23581..23586 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23596..23605 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23612..23618 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23620..23625 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23633..23642 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23671..23676 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23679..23683 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23697..23704 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23711..23716 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23720..23725 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23733..23742 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23769..23776 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23781..23786 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23798..23805 FT /evidence="ECO:0007829|PDB:8BNQ" FT TURN 23806..23808 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23811..23815 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23820..23827 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23835..23843 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 25439..25443 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25448..25451 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25465..25472 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25479..25481 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25486..25493 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25501..25509 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25514..25517 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 26130..26137 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26142..26147 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26157..26166 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26173..26179 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26181..26186 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26194..26203 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26206..26212 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 31458..31464 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31469..31472 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31475..31487 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31490..31495 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31498..31500 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31504..31520 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31524..31526 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31528..31535 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31540..31555 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31563..31568 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31573..31583 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31586..31591 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31600..31606 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31608..31617 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31620..31623 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31625..31632 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31637..31647 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31856..31859 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31864..31867 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31872..31879 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31885..31890 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31893..31895 FT /evidence="ECO:0007829|PDB:2J8O" FT STRAND 31899..31907 FT /evidence="ECO:0007829|PDB:2J8H" FT TURN 31908..31910 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31911..31916 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31921..31923 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31925..31933 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31936..31952 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31956..31959 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 31961..31967 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31973..31982 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31985..31992 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31997..32000 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32002..32005 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32007..32013 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 32020..32022 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32024..32032 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32035..32046 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32053..32061 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32063..32070 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32076..32078 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 32082..32089 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32095..32111 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32117..32125 FT /evidence="ECO:0007829|PDB:6YGN" FT HELIX 32142..32154 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32167..32170 FT /evidence="ECO:0007829|PDB:6YGN" FT TURN 32175..32177 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32178..32186 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32188..32197 FT /evidence="ECO:0007829|PDB:1TKI" FT TURN 32198..32201 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32202..32209 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32214..32228 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32237..32243 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32246..32251 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32259..32263 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32265..32267 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32272..32291 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32301..32303 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32304..32310 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32314..32316 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32330..32336 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32338..32340 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32343..32346 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32353..32369 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32379..32388 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32395..32398 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32403..32410 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32417..32419 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32423..32428 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32430..32433 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32436..32438 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32447..32457 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32466..32472 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32474..32476 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32483..32489 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32504..32506 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32512..32520 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32526..32531 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32538..32547 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32550..32555 FT /evidence="ECO:0007829|PDB:2BK8" FT HELIX 32560..32562 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32564..32571 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32576..32585 FT /evidence="ECO:0007829|PDB:2BK8" FT TURN 32586..32588 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32720..32726 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32731..32734 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32739..32749 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32752..32757 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32765..32767 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32768..32773 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32774..32776 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32777..32784 FT /evidence="ECO:0007829|PDB:6HCI" FT HELIX 32787..32789 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32791..32799 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32802..32813 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 33294..33297 FT /evidence="ECO:0007829|PDB:3QP3" FT STRAND 33299..33305 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33310..33313 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33318..33328 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33331..33336 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33345..33352 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33355..33360 FT /evidence="ECO:0007829|PDB:6H4L" FT HELIX 33365..33367 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33369..33377 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33380..33391 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33489..33492 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33497..33503 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33509..33512 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33514..33516 FT /evidence="ECO:0007829|PDB:1TNM" FT STRAND 33523..33526 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33532..33538 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33540..33547 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33556..33560 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33571..33577 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33777..33783 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33788..33794 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33796..33806 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33809..33814 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33821..33830 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33833..33838 FT /evidence="ECO:0007829|PDB:3PUC" FT HELIX 33843..33845 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33847..33855 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33858..33869 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 34060..34071 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34078..34088 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34091..34096 FT /evidence="ECO:0007829|PDB:4UOW" FT TURN 34104..34106 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34107..34112 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34115..34122 FT /evidence="ECO:0007829|PDB:4UOW" FT HELIX 34125..34127 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34129..34136 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34138..34148 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34254..34258 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34263..34268 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34271..34283 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34286..34291 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34300..34302 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34304..34308 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34310..34319 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34322..34324 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34326..34334 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34337..34348 FT /evidence="ECO:0007829|PDB:3KNB" FT CONFLICT Q8WZ42-6:3732 FT /note="L -> F (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT Q8WZ42-6:5139 FT /note="R -> M (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" SQ SEQUENCE 34350 AA; 3816030 MW; DEB216410AD560D9 CRC64; MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV IDGAAGQQLP HKTPPRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDSRIKNY RILEGMGVTF HCKMSGYPLP KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE KLKNVNIKEG SRLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI EAHGKIYKLT VLNMMKDDEG KYTFYAGENM TSGKLTVAGG AISKPLTDQT VAESQEAVFE CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH DTVPVKWFHK SVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET LELLSESPVY PTKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT VTGTPVIETI WQKDGAALSP SPNWRISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA EPANAGKYIC QIKNDGGMRE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKARK LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD SCSAQLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK IHVAISKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKGVVTEE KITIVTQREE SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP KKIVVEEKVR VPEEPRVPPT KVPEVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG ELLRPSPTCE IKAEGGKRFL TLHKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPVTVKD QTCPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK EVRGTKLVVT GLKEGAFYKF RVRAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPGPPA FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI // ID TLK2_HUMAN Reviewed; 772 AA. AC Q86UE8; D3DU07; Q9UKI7; Q9Y4F7; DT 22-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 22-AUG-2003, sequence version 2. DT 28-JAN-2026, entry version 204. DE RecName: Full=Serine/threonine-protein kinase tousled-like 2; DE EC=2.7.11.1 {ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:9427565}; DE AltName: Full=HsHPK; DE AltName: Full=PKU-alpha {ECO:0000303|PubMed:9427565}; DE AltName: Full=Tousled-like kinase 2 {ECO:0000303|PubMed:10523312}; GN Name=TLK2 {ECO:0000312|HGNC:HGNC:11842}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), VARIANT ARG-6, FUNCTION, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Placenta {ECO:0000269|PubMed:9427565}, and RC Testis {ECO:0000269|PubMed:9427565}; RX PubMed=9427565; DOI=10.1016/s0378-1119(97)00495-2; RA Yamakawa A., Kameoka Y., Hashimoto K., Yoshitake Y., Nishikawa K., RA Tanihara K., Date T.; RT "cDNA cloning and chromosomal mapping of genes encoding novel protein RT kinases termed PKU-alpha and PKU-beta, which have nuclear localization RT signal."; RL Gene 202:193-201(1997). RN [2] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, MUTAGENESIS OF ASP-613, RP SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH TLK1, AND ACTIVITY RP REGULATION. RC TISSUE=Placenta {ECO:0000269|PubMed:10523312}; RX PubMed=10523312; DOI=10.1093/emboj/18.20.5691; RA Sillje H.H.W., Takahashi K., Tanaka K., Van Houwe G., Nigg E.A.; RT "Mammalian homologues of the plant tousled gene code for cell-cycle- RT regulated kinases with maximal activities linked to ongoing DNA RT replication."; RL EMBO J. 18:5691-5702(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 189-772 (ISOFORM 2/3), AND TISSUE RP SPECIFICITY. RX PubMed=9662073; DOI=10.1007/bf02258367; RA Huang A.M., Chang T.J., Cho W.L., Chou C.K.; RT "From mosquito to man: identification of a novel protein kinase, HsHPK, RT which is highly expressed in human hepatoma tissues."; RL J. Biomed. Sci. 5:135-140(1998). RN [6] RP SUBCELLULAR LOCATION, AND INTERACTION WITH YWHAZ. RX PubMed=10455159; DOI=10.1074/jbc.274.35.24865; RA Zhang S., Xing H., Muslin A.J.; RT "Nuclear localization of protein kinase U-alpha is regulated by 14-3-3."; RL J. Biol. Chem. 274:24865-24872(1999). RN [7] RP FUNCTION, AND MUTAGENESIS OF ASP-613. RX PubMed=11470414; DOI=10.1016/s0960-9822(01)00298-6; RA Sillje H.H.W., Nigg E.A.; RT "Identification of human Asf1 chromatin assembly factors as substrates of RT Tousled-like kinases."; RL Curr. Biol. 11:1068-1073(2001). RN [8] {ECO:0000305} RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=12660173; DOI=10.1093/emboj/cdg151; RA Groth A., Lukas J., Nigg E.A., Sillje H.H.W., Wernstedt C., Bartek J., RA Hansen K.; RT "Human tousled like kinases are targeted by an ATM- and Chk1-dependent DNA RT damage checkpoint."; RL EMBO J. 22:1676-1687(2003). RN [9] RP PHOSPHORYLATION AT SER-750, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=12955071; DOI=10.1038/sj.onc.1206691; RA Krause D.R., Jonnalagadda J.C., Gatei M.H., Sillje H.H.W., Zhou B.-B., RA Nigg E.A., Khanna K.; RT "Suppression of tousled-like kinase activity after DNA damage or RT replication block requires ATM, NBS1 and Chk1."; RL Oncogene 22:5927-5937(2003). RN [10] RP INTERACTION WITH FEZ1 AND FEZ2. RX PubMed=16484223; DOI=10.1074/jbc.m513280200; RA Assmann E.M., Alborghetti M.R., Camargo M.E.R., Kobarg J.; RT "FEZ1 dimerization and interaction with transcription regulatory proteins RT involves its coiled-coil region."; RL J. Biol. Chem. 281:9869-9881(2006). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94 AND SER-134, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP FUNCTION AS ASF1A AND ASF1B KINASE, AND ACTIVITY REGULATION. RX PubMed=20016786; DOI=10.1371/journal.pone.0008328; RA Pilyugin M., Demmers J., Verrijzer C.P., Karch F., Moshkin Y.M.; RT "Phosphorylation-mediated control of histone chaperone ASF1 levels by RT Tousled-like kinases."; RL PLoS ONE 4:E8328-E8328(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [19] RP FUNCTION. RX PubMed=22354037; DOI=10.1038/emboj.2012.36; RA McKnight N.C., Jefferies H.B., Alemu E.A., Saunders R.E., Howell M., RA Johansen T., Tooze S.A.; RT "Genome-wide siRNA screen reveals amino acid starvation-induced autophagy RT requires SCOC and WAC."; RL EMBO J. 31:1931-1946(2012). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-73; SER-94; SER-99; SER-115; RP SER-117 AND SER-134, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] {ECO:0007744|PDB:5O0Y} RP X-RAY CRYSTALLOGRAPHY (2.86 ANGSTROMS) OF 191-755 IN COMPLEX WITH ATP, RP FUNCTION, SUBUNIT, INTERACTION WITH DYNLL1/LC8 AND TLK1, SUBCELLULAR RP LOCATION, PHOSPHORYLATION, CHARACTERIZATION OF VARIANTS MRD57 ARG-493; RP ARG-518 AND ASN-629, AND MUTAGENESIS OF HIS-518; ASP-613; SER-617; SER-659; RP SER-686; THR-695 AND ARG-720. RX PubMed=29955062; DOI=10.1038/s41467-018-04941-y; RA Mortuza G.B., Hermida D., Pedersen A.K., Segura-Bayona S., Lopez-Mendez B., RA Redondo P., Ruther P., Pozdnyakova I., Garrote A.M., Munoz I.G., RA Villamor-Paya M., Jauset C., Olsen J.V., Stracker T.H., Montoya G.; RT "Molecular basis of Tousled-Like Kinase 2 activation."; RL Nat. Commun. 9:2535-2535(2018). RN [23] {ECO:0007744|PDB:7LO0} RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 3-23 IN COMPLEX WITH ASF1A, AND RP FUNCTION. RX PubMed=35136069; DOI=10.1038/s41467-022-28427-0; RA Simon B., Lou H.J., Huet-Calderwood C., Shi G., Boggon T.J., Turk B.E., RA Calderwood D.A.; RT "Tousled-like kinase 2 targets ASF1 histone chaperones through client RT mimicry."; RL Nat. Commun. 13:749-749(2022). RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-6; ASP-54; GLY-95; GLY-108; LEU-109; RP LEU-173 AND GLN-262. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [25] RP VARIANT MRD57 LEU-617. RX PubMed=21572417; DOI=10.1038/ng.835; RA O'Roak B.J., Deriziotis P., Lee C., Vives L., Schwartz J.J., Girirajan S., RA Karakoc E., Mackenzie A.P., Ng S.B., Baker C., Rieder M.J., Nickerson D.A., RA Bernier R., Fisher S.E., Shendure J., Eichler E.E.; RT "Exome sequencing in sporadic autism spectrum disorders identifies severe RT de novo mutations."; RL Nat. Genet. 43:585-589(2011). RN [26] RP VARIANT MRD57 720-ARG--ASN-772 DEL, AND INVOLVEMENT IN MRD57. RX PubMed=27479843; DOI=10.1038/nn.4352; RA Lelieveld S.H., Reijnders M.R., Pfundt R., Yntema H.G., Kamsteeg E.J., RA de Vries P., de Vries B.B., Willemsen M.H., Kleefstra T., Loehner K., RA Vreeburg M., Stevens S.J., van der Burgt I., Bongers E.M., Stegmann A.P., RA Rump P., Rinne T., Nelen M.R., Veltman J.A., Vissers L.E., Brunner H.G., RA Gilissen C.; RT "Meta-analysis of 2,104 trios provides support for 10 new genes for RT intellectual disability."; RL Nat. Neurosci. 19:1194-1196(2016). RN [27] RP VARIANTS MRD57 13-GLN--ASN-772 DEL; 61-ARG--ASN-772 DEL; 68-GLU--ASN-772 RP DEL; 259-TYR--ASN-772 DEL; 262-ARG--ASN-772 DEL; ASP-297; 303-ARG--ASN-772 RP DEL; 330-SER--ASN-772 DEL; GLN-339; TRP-339; LYS-447; ARG-493; ARG-518; RP TRP-568; 573-GLN--ASN-772 DEL; ASN-629; ARG-680; 720-ARG--ASN-772 DEL AND RP 746-ARG--ASN-772 DEL, AND INVOLVEMENT IN MRD57. RX PubMed=29861108; DOI=10.1016/j.ajhg.2018.04.014; RG Deciphering Developmental Disorders Study; RA Reijnders M.R.F., Miller K.A., Alvi M., Goos J.A.C., Lees M.M., RA de Burca A., Henderson A., Kraus A., Mikat B., de Vries B.B.A., Isidor B., RA Kerr B., Marcelis C., Schluth-Bolard C., Deshpande C., Ruivenkamp C.A.L., RA Wieczorek D., Baralle D., Blair E.M., Engels H., Luedecke H.J., Eason J., RA Santen G.W.E., Clayton-Smith J., Chandler K., Tatton-Brown K., Payne K., RA Helbig K., Radtke K., Nugent K.M., Cremer K., Strom T.M., Bird L.M., RA Sinnema M., Bitner-Glindzicz M., van Dooren M.F., Alders M., Koopmans M., RA Brick L., Kozenko M., Harline M.L., Klaassens M., Steinraths M., RA Cooper N.S., Edery P., Yap P., Terhal P.A., van der Spek P.J., Lakeman P., RA Taylor R.L., Littlejohn R.O., Pfundt R., Mercimek-Andrews S., RA Stegmann A.P.A., Kant S.G., McLean S., Joss S., Swagemakers S.M.A., RA Douzgou S., Wall S.A., Kuery S., Calpena E., Koelling N., McGowan S.J., RA Twigg S.R.F., Mathijssen I.M.J., Nellaker C., Brunner H.G., Wilkie A.O.M.; RT "De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and RT Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder."; RL Am. J. Hum. Genet. 102:1195-1203(2018). RN [28] RP VARIANTS MRD57 475-GLU--ASN-772 DEL AND GLY-551, CHARACTERIZATION OF RP VARIANTS MRD57 GLY-551 AND LEU-617, FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH TLK1; CHD7; CHD8 AND DYNLL1/LC8, AND MUTAGENESIS OF RP ASP-592. RX PubMed=33323470; DOI=10.1136/jmedgenet-2020-107281; RA Pavinato L., Villamor-Paya M., Sanchiz-Calvo M., Andreoli C., Gay M., RA Vilaseca M., Arauz-Garofalo G., Ciolfi A., Bruselles A., Pippucci T., RA Prota V., Carli D., Giorgio E., Radio F.C., Antona V., Giuffre M., RA Ranguin K., Colson C., De Rubeis S., Dimartino P., Buxbaum J.D., RA Ferrero G.B., Tartaglia M., Martinelli S., Stracker T.H., Brusco A.; RT "Functional analysis of TLK2 variants and their proximal interactomes RT implicates impaired kinase activity and chromatin maintenance defects in RT their pathogenesis."; RL J. Med. Genet. 59:170-179(2022). CC -!- FUNCTION: Serine/threonine-protein kinase involved in the process of CC chromatin assembly and probably also DNA replication, transcription, CC repair, and chromosome segregation (PubMed:10523312, PubMed:11470414, CC PubMed:12660173, PubMed:12955071, PubMed:29955062, PubMed:33323470, CC PubMed:9427565). Phosphorylates the chromatin assembly factors ASF1A CC and ASF1B (PubMed:11470414, PubMed:20016786, PubMed:29955062, CC PubMed:35136069). Phosphorylation of ASF1A prevents its proteasome- CC mediated degradation, thereby enhancing chromatin assembly CC (PubMed:20016786). Negative regulator of amino acid starvation-induced CC autophagy (PubMed:22354037). {ECO:0000269|PubMed:10523312, CC ECO:0000269|PubMed:11470414, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:12955071, ECO:0000269|PubMed:20016786, CC ECO:0000269|PubMed:22354037, ECO:0000269|PubMed:29955062, CC ECO:0000269|PubMed:33323470, ECO:0000269|PubMed:35136069, CC ECO:0000269|PubMed:9427565}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:9427565}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:9427565}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:9427565}; CC -!- ACTIVITY REGULATION: Cell cycle-regulated, with maximal activity in the CC S-phase (PubMed:10523312, PubMed:20016786). Rapidly and transiently CC inhibited by phosphorylation following the generation of DNA double- CC stranded breaks during S-phase, probably by CHEK1, possibly at Ser-750 CC (PubMed:12660173, PubMed:12955071). This inhibition is cell cycle CC checkpoint- and ATM-dependent (PubMed:12955071). CC {ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:12955071, ECO:0000269|PubMed:20016786}. CC -!- SUBUNIT: Monomer (PubMed:29955062). May form homodimers; CC homodimerization may enhance autophosphoylation and enzymatic activity CC (PubMed:29955062). Heterodimer with TLK1 (PubMed:10523312, CC PubMed:29955062, PubMed:33323470). Interacts with YWHAZ; association CC with 14-3-3 proteins such as YWHAZ regulates subcellular location CC (PubMed:10455159). May also interact with FEZ1/LZTS1 and FEZ2 CC (PubMed:16484223). Interacts with CHD7 and CHD8 (PubMed:33323470). CC Interacts with DYNLL1/LC8 (PubMed:29955062). CC {ECO:0000269|PubMed:10455159, ECO:0000269|PubMed:10523312, CC ECO:0000269|PubMed:16484223, ECO:0000269|PubMed:29955062, CC ECO:0000269|PubMed:33323470}. CC -!- INTERACTION: CC Q86UE8; Q9Y294: ASF1A; NbExp=10; IntAct=EBI-1047967, EBI-749553; CC Q86UE8; Q9NVP2: ASF1B; NbExp=8; IntAct=EBI-1047967, EBI-1055650; CC Q86UE8; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-1047967, EBI-739624; CC Q86UE8; Q9NPF5: DMAP1; NbExp=3; IntAct=EBI-1047967, EBI-399105; CC Q86UE8; P63167: DYNLL1; NbExp=11; IntAct=EBI-1047967, EBI-349105; CC Q86UE8; Q96FJ2: DYNLL2; NbExp=7; IntAct=EBI-1047967, EBI-742371; CC Q86UE8; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1047967, EBI-13213391; CC Q86UE8; Q96IK5: GMCL1; NbExp=3; IntAct=EBI-1047967, EBI-2548508; CC Q86UE8; Q15306: IRF4; NbExp=2; IntAct=EBI-1047967, EBI-751345; CC Q86UE8; Q92985: IRF7; NbExp=2; IntAct=EBI-1047967, EBI-968267; CC Q86UE8; Q02548: PAX5; NbExp=3; IntAct=EBI-1047967, EBI-296331; CC Q86UE8; P26367: PAX6; NbExp=3; IntAct=EBI-1047967, EBI-747278; CC Q86UE8; Q8TAQ2: SMARCC2; NbExp=3; IntAct=EBI-1047967, EBI-357418; CC Q86UE8; Q86UE8: TLK2; NbExp=3; IntAct=EBI-1047967, EBI-1047967; CC Q86UE8; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-1047967, EBI-10180829; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10455159, CC ECO:0000269|PubMed:29955062, ECO:0000269|PubMed:33323470, CC ECO:0000269|PubMed:9427565}. Nucleus, nucleoplasm CC {ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:33323470}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:10455159, CC ECO:0000269|PubMed:33323470}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:10455159}. Note=Colocalizes with the cytoplasmic CC intermediate filament system during the G1 phase of the cell cycle CC (PubMed:10455159). Present in the perinuclear region at S phase and in CC the nucleus at late G2 (PubMed:10455159). CC {ECO:0000269|PubMed:10455159}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1 {ECO:0000305}; CC IsoId=Q86UE8-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:10523312}; CC IsoId=Q86UE8-2; Sequence=VSP_050573; CC Name=3 {ECO:0000269|PubMed:9427565}; CC IsoId=Q86UE8-3; Sequence=VSP_050572, VSP_050573; CC -!- TISSUE SPECIFICITY: Detected in placenta, fetal liver, kidney, CC pancreas, heart and skeletal muscle (PubMed:9427565). Highly expressed CC in testis (PubMed:9427565, PubMed:9662073). Detected in spleen, thymus, CC colon, ovary, small intestine, prostate and peripheral blood leukocytes CC (PubMed:9662073). Almost undetectable in liver and lung CC (PubMed:9662073). {ECO:0000269|PubMed:9427565, CC ECO:0000269|PubMed:9662073}. CC -!- PTM: Phosphorylated at Ser-750, probably by CHEK1. CC {ECO:0000269|PubMed:12955071}. CC -!- PTM: Autophosphorylated; phosphorylation promotes the assembly of CC higher order oligomers and enzymatic activity. CC {ECO:0000269|PubMed:29955062}. CC -!- DISEASE: Intellectual developmental disorder, autosomal dominant 57 CC (MRD57) [MIM:618050]: A disorder characterized by significantly below CC average general intellectual functioning associated with impairments in CC adaptive behavior and manifested during the developmental period. MRD57 CC is characterized by delayed psychomotor development apparent in infancy CC or early childhood, and a variety of behavioral abnormalities. Affected CC individuals may have severe gastro-intestinal problems, and facial CC dysmorphism. {ECO:0000269|PubMed:21572417, ECO:0000269|PubMed:27479843, CC ECO:0000269|PubMed:29861108, ECO:0000269|PubMed:29955062, CC ECO:0000269|PubMed:33323470}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF03095.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=AAH44925.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAA20561.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB004884; BAA20561.1; ALT_INIT; mRNA. DR EMBL; AF162667; AAF03095.1; ALT_INIT; mRNA. DR EMBL; CH471109; EAW94346.1; -; Genomic_DNA. DR EMBL; CH471109; EAW94348.1; -; Genomic_DNA. DR EMBL; BC044925; AAH44925.2; ALT_INIT; mRNA. DR CCDS; CCDS11633.1; -. [Q86UE8-2] DR CCDS; CCDS45753.1; -. [Q86UE8-3] DR CCDS; CCDS62283.1; -. [Q86UE8-1] DR RefSeq; NP_001271262.1; NM_001284333.3. [Q86UE8-1] DR RefSeq; NP_001271292.1; NM_001284363.1. [Q86UE8-3] DR RefSeq; NP_001362199.1; NM_001375270.1. [Q86UE8-2] DR RefSeq; NP_001362200.1; NM_001375271.1. [Q86UE8-2] DR RefSeq; NP_001362201.1; NM_001375272.1. [Q86UE8-3] DR RefSeq; NP_001425132.1; NM_001438203.1. [Q86UE8-3] DR RefSeq; NP_001425133.1; NM_001438204.1. [Q86UE8-3] DR RefSeq; NP_006843.2; NM_006852.3. [Q86UE8-2] DR RefSeq; XP_011522518.1; XM_011524216.3. [Q86UE8-1] DR RefSeq; XP_011522524.1; XM_011524222.4. [Q86UE8-1] DR RefSeq; XP_024306321.1; XM_024450553.2. [Q86UE8-1] DR RefSeq; XP_047291135.1; XM_047435179.1. [Q86UE8-2] DR RefSeq; XP_047291138.1; XM_047435182.1. [Q86UE8-3] DR RefSeq; XP_054170761.1; XM_054314786.1. [Q86UE8-1] DR RefSeq; XP_054170762.1; XM_054314787.1. [Q86UE8-1] DR RefSeq; XP_054170763.1; XM_054314788.1. [Q86UE8-1] DR RefSeq; XP_054170767.1; XM_054314792.1. [Q86UE8-2] DR RefSeq; XP_054170775.1; XM_054314800.1. [Q86UE8-3] DR PDB; 5O0Y; X-ray; 2.86 A; A=191-755. DR PDB; 7LO0; X-ray; 2.71 A; I/J/K/L/M/N/O/P/Q/R/T/U/V/W/X/Y=3-23. DR PDBsum; 5O0Y; -. DR PDBsum; 7LO0; -. DR AlphaFoldDB; Q86UE8; -. DR SMR; Q86UE8; -. DR BioGRID; 116201; 170. DR FunCoup; Q86UE8; 4227. DR IntAct; Q86UE8; 220. DR MINT; Q86UE8; -. DR STRING; 9606.ENSP00000316512; -. DR BindingDB; Q86UE8; -. DR ChEMBL; CHEMBL5404; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q86UE8; -. DR GlyGen; Q86UE8; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q86UE8; -. DR PhosphoSitePlus; Q86UE8; -. DR BioMuta; TLK2; -. DR DMDM; 34222826; -. DR CPTAC; non-CPTAC-5682; -. DR CPTAC; non-CPTAC-5683; -. DR jPOST; Q86UE8; -. DR MassIVE; Q86UE8; -. DR PaxDb; 9606-ENSP00000316512; -. DR PeptideAtlas; Q86UE8; -. DR ProteomicsDB; 69811; -. [Q86UE8-1] DR ProteomicsDB; 69812; -. [Q86UE8-2] DR ProteomicsDB; 69813; -. [Q86UE8-3] DR Pumba; Q86UE8; -. DR Antibodypedia; 31236; 371 antibodies from 31 providers. DR DNASU; 11011; -. DR Ensembl; ENST00000326270.13; ENSP00000316512.9; ENSG00000146872.20. [Q86UE8-1] DR Ensembl; ENST00000343388.11; ENSP00000340800.7; ENSG00000146872.20. [Q86UE8-3] DR Ensembl; ENST00000346027.10; ENSP00000275780.7; ENSG00000146872.20. [Q86UE8-2] DR Ensembl; ENST00000682085.1; ENSP00000506744.1; ENSG00000146872.20. [Q86UE8-2] DR Ensembl; ENST00000683104.1; ENSP00000508242.1; ENSG00000146872.20. [Q86UE8-3] DR GeneID; 11011; -. DR KEGG; hsa:11011; -. DR MANE-Select; ENST00000346027.10; ENSP00000275780.7; NM_006852.6; NP_006843.2. [Q86UE8-2] DR UCSC; uc002izz.5; human. [Q86UE8-1] DR AGR; HGNC:11842; -. DR CIViC; 11011; 1 evidence item across 1 molecular profile. DR ClinPGx; PA36544; -. DR CTD; 11011; -. DR DisGeNET; 11011; -. DR GeneCards; TLK2; -. DR HGNC; HGNC:11842; TLK2. DR HPA; ENSG00000146872; Low tissue specificity. DR MalaCards; TLK2; -. DR MIM; 608439; gene. DR MIM; 618050; phenotype. DR OpenTargets; ENSG00000146872; -. DR VEuPathDB; HostDB:ENSG00000146872; -. DR eggNOG; KOG1151; Eukaryota. DR GeneTree; ENSGT00950000182984; -. DR InParanoid; Q86UE8; -. DR OMA; LPSMTWQ; -. DR OrthoDB; 346907at2759; -. DR PAN-GO; Q86UE8; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q86UE8; -. DR PathwayCommons; Q86UE8; -. DR SignaLink; Q86UE8; -. DR SIGNOR; Q86UE8; -. DR Agora; ENSG00000146872; -. DR BioGRID-ORCS; 11011; 259 hits in 1157 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; TLK2; human. DR GeneWiki; TLK2; -. DR GenomeRNAi; 11011; -. DR Pharos; Q86UE8; Tchem. DR PRO; PR:Q86UE8; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q86UE8; protein. DR Bgee; ENSG00000146872; Expressed in calcaneal tendon and 115 other cell types or tissues. DR ExpressionAtlas; Q86UE8; baseline and differential. DR GO; GO:0005882; C:intermediate filament; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB. DR GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW. DR GO; GO:0007059; P:chromosome segregation; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; NAS:BHF-UCL. DR GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0051647; P:nucleus localization; IMP:DisProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1902275; P:regulation of chromatin organization; IDA:UniProtKB. DR CDD; cd14041; STKc_TLK2; 1. DR DisProt; DP02475; -. DR FunFam; 1.10.510.10:FF:000037; Serine/threonine-protein kinase tousled-like 2; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22974; MIXED LINEAGE PROTEIN KINASE; 1. DR PANTHER; PTHR22974:SF20; SERINE_THREONINE-PROTEIN KINASE TOUSLED-LIKE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; KW Chromatin regulator; Coiled coil; Cytoplasm; Cytoskeleton; Disease variant; KW DNA damage; Intellectual disability; Kinase; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..772 FT /note="Serine/threonine-protein kinase tousled-like 2" FT /id="PRO_0000086754" FT DOMAIN 462..741 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 24..126 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 180..208 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 225..276 FT /note="Required for interaction with TLK1 and DYNLL1/LC8" FT /evidence="ECO:0000269|PubMed:29955062" FT REGION 342..385 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 225..276 FT /evidence="ECO:0000255" FT COILED 317..347 FT /evidence="ECO:0000255" FT COILED 403..451 FT /evidence="ECO:0000255" FT COMPBIAS 29..44 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 46..61 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 367..380 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 592 FT /note="Proton acceptor" FT BINDING 468..476 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 491 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 73 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 94 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 99 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 115 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 117 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 134 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine; by CHEK1" FT /evidence="ECO:0000305|PubMed:12955071" FT VAR_SEQ 90..121 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:9427565" FT /id="VSP_050572" FT VAR_SEQ 375..396 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10523312, FT ECO:0000303|PubMed:9427565" FT /id="VSP_050573" FT VARIANT 6 FT /note="H -> R (in dbSNP:rs45550140)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9427565" FT /id="VAR_041216" FT VARIANT 13..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081017" FT VARIANT 54 FT /note="E -> D" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041217" FT VARIANT 61..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081018" FT VARIANT 68..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081019" FT VARIANT 95 FT /note="A -> G (in dbSNP:rs2598147)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041218" FT VARIANT 108 FT /note="A -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041219" FT VARIANT 109 FT /note="R -> L (in dbSNP:rs1555617262)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041220" FT VARIANT 173 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1331331651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041221" FT VARIANT 259..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081020" FT VARIANT 262..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081021" FT VARIANT 262 FT /note="R -> Q (in dbSNP:rs762409144)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041222" FT VARIANT 297 FT /note="G -> D (in MRD57; uncertain significance; FT dbSNP:rs1555639254)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081022" FT VARIANT 303..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081023" FT VARIANT 330..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081024" FT VARIANT 339 FT /note="R -> Q (in MRD57; uncertain significance; FT dbSNP:rs1567948287)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081025" FT VARIANT 339 FT /note="R -> W (in MRD57; uncertain significance; FT dbSNP:rs1567948262)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081026" FT VARIANT 447 FT /note="E -> K (in MRD57; uncertain significance; FT dbSNP:rs1567959483)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081027" FT VARIANT 475..772 FT /note="Missing (in MRD57; uncertain significance)" FT /evidence="ECO:0000269|PubMed:33323470" FT /id="VAR_087040" FT VARIANT 493 FT /note="H -> R (in MRD57; reduced kinase activity; FT dbSNP:rs1567974030)" FT /evidence="ECO:0000269|PubMed:29861108, FT ECO:0000269|PubMed:29955062" FT /id="VAR_081028" FT VARIANT 518 FT /note="H -> R (in MRD57; severely reduced kinase activity; FT dbSNP:rs1567995650)" FT /evidence="ECO:0000269|PubMed:29861108, FT ECO:0000269|PubMed:29955062" FT /id="VAR_081029" FT VARIANT 551 FT /note="D -> G (in MRD57; uncertain significance; exhibits FT abnormal perinuclear localization instead of diffuse FT nuclear localization; mildly impairs kinase activity; FT reduced phosphorylation of ASF1A; dbSNP:rs2082811958)" FT /evidence="ECO:0000269|PubMed:33323470" FT /id="VAR_087041" FT VARIANT 568 FT /note="R -> W (in MRD57; dbSNP:rs1283838287)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081030" FT VARIANT 573..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081031" FT VARIANT 617 FT /note="S -> L (in MRD57; exhibits abnormal perinuclear FT localization instead of diffuse nuclear localization; FT impairs kinase activity; reduced phosphorylation of ASF1A; FT dbSNP:rs2082914686)" FT /evidence="ECO:0000269|PubMed:21572417, FT ECO:0000269|PubMed:33323470" FT /id="VAR_087042" FT VARIANT 629 FT /note="D -> N (in MRD57; reduced phosphorylation of ASF1A; FT dbSNP:rs1568006217)" FT /evidence="ECO:0000269|PubMed:29861108, FT ECO:0000269|PubMed:29955062" FT /id="VAR_081032" FT VARIANT 680 FT /note="P -> R (in MRD57; dbSNP:rs1568018905)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081033" FT VARIANT 720..772 FT /note="Missing (in MRD57; uncertain significance)" FT /evidence="ECO:0000269|PubMed:27479843, FT ECO:0000269|PubMed:29861108" FT /id="VAR_081034" FT VARIANT 746..772 FT /note="Missing (in MRD57; uncertain significance)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081035" FT MUTAGEN 518 FT /note="H->N: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 592 FT /note="D->V: Loss of kinase activity. No impact on FT interaction with ASF1A." FT /evidence="ECO:0000269|PubMed:33323470, FT ECO:0000269|PubMed:35136069" FT MUTAGEN 613 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:10523312, FT ECO:0000269|PubMed:11470414, ECO:0000269|PubMed:29955062" FT MUTAGEN 617 FT /note="S->A: Increase in autophosphorylation." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 617 FT /note="S->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 659 FT /note="S->A: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 686 FT /note="S->A: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 686 FT /note="S->D: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 695 FT /note="T->A: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 720 FT /note="R->A: Reduced phosphorylation of ASF1A." FT /evidence="ECO:0000269|PubMed:29955062" FT CONFLICT 1 FT /note="M -> I (in Ref. 1; BAA20561)" FT /evidence="ECO:0000305" FT CONFLICT 161 FT /note="T -> P (in Ref. 1; BAA20561)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="Q -> R (in Ref. 2; AAF03095)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="M -> I (in Ref. 1; BAA20561)" FT /evidence="ECO:0000305" FT CONFLICT 727 FT /note="E -> R (in Ref. 2; AAF03095)" FT /evidence="ECO:0000305" FT HELIX 10..21 FT /evidence="ECO:0007829|PDB:7LO0" FT STRAND 463..470 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 472..481 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 482..485 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 486..494 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 497..499 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 502..519 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 529..534 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 539..545 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 549..551 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 552..559 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 564..581 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 584..586 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 595..597 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 598..600 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 603..607 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 622..624 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 627..629 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 641..643 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 646..649 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 652..654 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 661..676 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 680..682 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 687..693 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 694..698 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 712..721 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 726..728 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 739..741 FT /evidence="ECO:0007829|PDB:5O0Y" SQ SEQUENCE 772 AA; 87661 MW; 765EE37ED4A4ADEC CRC64; MMEELHSLDP RRQELLEARF TGVGVSKGPL NSESSNQSLC SVGSLSDKEV ETPEKKQNDQ RNRKRKAEPY ETSQGKGTPR GHKISDYFEF AGGSAPGTSP GRSVPPVARS SPQHSLSNPL PRRVEQPLYG LDGSAAKEAT EEQSALPTLM SVMLAKPRLD TEQLAQRGAG LCFTFVSAQQ NSPSSTGSGN TEHSCSSQKQ ISIQHRQTQS DLTIEKISAL ENSKNSDLEK KEGRIDDLLR ANCDLRRQID EQQKMLEKYK ERLNRCVTMS KKLLIEKSKQ EKMACRDKSM QDRLRLGHFT TVRHGASFTE QWTDGYAFQN LIKQQERINS QREEIERQRK MLAKRKPPAM GQAPPATNEQ KQRKSKTNGA ENETPSSGNT ELKDTAPALG AHSLLRLTLA EYHEQEEIFK LRLGHLKKEE AEIQAELERL ERVRNLHIRE LKRIHNEDNS QFKDHPTLND RYLLLHLLGR GGFSEVYKAF DLTEQRYVAV KIHQLNKNWR DEKKENYHKH ACREYRIHKE LDHPRIVKLY DYFSLDTDSF CTVLEYCEGN DLDFYLKQHK LMSEKEARSI IMQIVNALKY LNEIKPPIIH YDLKPGNILL VNGTACGEIK ITDFGLSKIM DDDSYNSVDG MELTSQGAGT YWYLPPECFV VGKEPPKISN KVDVWSVGVI FYQCLYGRKP FGHNQSQQDI LQENTILKAT EVQFPPKPVV TPEAKAFIRR CLAYRKEDRI DVQQLACDPY LLPHIRKSVS TSSPAGAAIA STSGASNNSS SN // ID TRAK1_HUMAN Reviewed; 953 AA. AC Q9UPV9; E9PDS2; J3KNT7; Q63HR0; Q659B5; Q96B69; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 186. DE RecName: Full=Trafficking kinesin-binding protein 1; DE AltName: Full=106 kDa O-GlcNAc transferase-interacting protein; DE AltName: Full=Protein Milton {ECO:0000303|PubMed:24995978}; GN Name=TRAK1; Synonyms=KIAA1042, OIP106; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=10470851; DOI=10.1093/dnares/6.3.197; RA Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XIV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:197-205(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 1-508 (ISOFORM 3). RC TISSUE=Kidney, and Salivary gland; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP PROTEIN SEQUENCE OF 448-462; 535-552; 642-660; 676-685; 686-705; 717-728; RP 829-846 AND 932-945, FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, RP INTERACTION WITH KIF5B; OGT; RHOT1 AND RHOT2, SUBCELLULAR LOCATION, RP GLYCOSYLATION AT SER-447; SER-680; SER-719 AND THR-935, AND MUTAGENESIS OF RP SER-447; 658-PRO--THR-672; SER-829; SER-830 AND SER-938. RX PubMed=24995978; DOI=10.1016/j.cell.2014.06.007; RA Pekkurnaz G., Trinidad J.C., Wang X., Kong D., Schwarz T.L.; RT "Glucose regulates mitochondrial motility via Milton modification by O- RT GlcNAc transferase."; RL Cell 158:54-68(2014). RN [6] RP SUBCELLULAR LOCATION, INTERACTION WITH OGT, AND GLYCOSYLATION. RX PubMed=12435728; DOI=10.1074/jbc.m209384200; RA Iyer S.P.N., Akimoto Y., Hart G.W.; RT "Identification and cloning of a novel family of coiled-coil domain RT proteins that interact with O-GlcNAc transferase."; RL J. Biol. Chem. 278:5399-5409(2003). RN [7] RP INTERACTION WITH KIF5C, AND SUBCELLULAR LOCATION. RX PubMed=15644324; DOI=10.1074/jbc.m409095200; RA Brickley K., Smith M.J., Beck M., Stephenson F.A.; RT "GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain RT proteins: association in vivo and in vitro with kinesin."; RL J. Biol. Chem. 280:14723-14732(2005). RN [8] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOT1 AND RHOT2. RX PubMed=16630562; DOI=10.1016/j.bbrc.2006.03.163; RA Fransson S., Ruusala A., Aspenstroem P.; RT "The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in RT mitochondrial trafficking."; RL Biochem. Biophys. Res. Commun. 344:500-510(2006). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH HGS. RX PubMed=18675823; DOI=10.1016/j.jmb.2008.07.045; RA Webber E., Li L., Chin L.S.; RT "Hypertonia-associated protein Trak1 is a novel regulator of endosome-to- RT lysosome trafficking."; RL J. Mol. Biol. 382:638-651(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND MARKER FOR GASTRIC CANCER. RX PubMed=18986759; DOI=10.1016/j.canlet.2008.09.031; RA Zhang F., Ren G., Lu Y., Jin B., Wang J., Chen X., Liu Z., Li K., Nie Y., RA Wang X., Fan D.; RT "Identification of TRAK1 (Trafficking protein, kinesin-binding 1) as MGb2- RT Ag: a novel cancer biomarker."; RL Cancer Lett. 274:250-258(2009). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=19528298; DOI=10.1083/jcb.200811033; RA Li Y., Lim S., Hoffman D., Aspenstrom P., Federoff H.J., Rempe D.A.; RT "HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial RT distribution and transport."; RL J. Cell Biol. 185:1065-1081(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-919, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP INVOLVEMENT IN DEE68. RX PubMed=28364549; DOI=10.1093/brain/awx002; RA Barel O., Malicdan M.C.V., Ben-Zeev B., Kandel J., Pri-Chen H., Stephen J., RA Castro I.G., Metz J., Atawa O., Moshkovitz S., Ganelin E., Barshack I., RA Polak-Charcon S., Nass D., Marek-Yagel D., Amariglio N., Shalva N., RA Vilboux T., Ferreira C., Pode-Shakked B., Heimer G., Hoffmann C., RA Yardeni T., Nissenkorn A., Avivi C., Eyal E., Kol N., Glick Saar E., RA Wallace D.C., Gahl W.A., Rechavi G., Schrader M., Eckmann D.M., RA Anikster Y.; RT "Deleterious variants in TRAK1 disrupt mitochondrial movement and cause RT fatal encephalopathy."; RL Brain 140:568-581(2017). RN [15] RP INVOLVEMENT IN DEE68. RX PubMed=28940097; DOI=10.1007/s00439-017-1843-2; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Expanding the genetic heterogeneity of intellectual disability."; RL Hum. Genet. 136:1419-1429(2017). RN [16] RP ERRATUM OF PUBMED:28940097. RX PubMed=29288388; DOI=10.1007/s00439-017-1859-7; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Correction to: Expanding the genetic heterogeneity of intellectual RT disability."; RL Hum. Genet. 137:105-109(2018). RN [17] RP INVOLVEMENT IN DEE68, AND VARIANT DEE68 PRO-329. RX PubMed=29846532; DOI=10.1093/brain/awy129; RA Sagie S., Lerman-Sagie T., Maljevic S., Yosovich K., Detert K., Chung S.K., RA Rees M.I., Lerche H., Lev D.; RT "Expanding the phenotype of TRAK1 mutations: hyperekplexia and refractory RT status epilepticus."; RL Brain 141:E55-E55(2018). CC -!- FUNCTION: Involved in the regulation of endosome-to-lysosome CC trafficking, including endocytic trafficking of EGF-EGFR complexes and CC GABA-A receptors (PubMed:18675823). Involved in mitochondrial motility. CC When O-glycosylated, abolishes mitochondrial motility. Crucial for CC recruiting OGT to the mitochondrial surface of neuronal processes CC (PubMed:24995978). TRAK1 and RHOT form an essential protein complex CC that links KIF5 to mitochondria for light chain-independent, CC anterograde transport of mitochondria (By similarity). CC {ECO:0000250|UniProtKB:Q960V3, ECO:0000269|PubMed:18675823, CC ECO:0000269|PubMed:24995978}. CC -!- SUBUNIT: Interacts with RHOT1 and RHOT2 (PubMed:16630562). Found in a CC complex with KIF5B, OGT, RHOT1 and RHOT2 (PubMed:24995978). Interacts CC with HGS (PubMed:18675823). Interacts with GABRA1 (By similarity). CC Interacts with KIF5C (PubMed:15644324). Interacts with OGT; stable CC interaction is not required for glycosylation of this protein by OGT. CC Isoform 1 interacts with OGT (PubMed:12435728, PubMed:24995978). CC {ECO:0000250|UniProtKB:Q6PD31, ECO:0000269|PubMed:12435728, CC ECO:0000269|PubMed:15644324, ECO:0000269|PubMed:16630562, CC ECO:0000269|PubMed:18675823, ECO:0000269|PubMed:24995978}. CC -!- INTERACTION: CC Q9UPV9; Q12840: KIF5A; NbExp=4; IntAct=EBI-1105048, EBI-713468; CC Q9UPV9; O15294: OGT; NbExp=3; IntAct=EBI-1105048, EBI-539828; CC Q9UPV9; Q8IXI2: RHOT1; NbExp=8; IntAct=EBI-1105048, EBI-1396430; CC Q9UPV9; Q8IXI1: RHOT2; NbExp=4; IntAct=EBI-1105048, EBI-1396563; CC Q9UPV9; Q2PQA9: Kif5b; Xeno; NbExp=3; IntAct=EBI-1105048, EBI-920191; CC Q9UPV9; P56558: Ogt; Xeno; NbExp=6; IntAct=EBI-1105048, EBI-7614183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18986759}. Nucleus CC {ECO:0000269|PubMed:12435728}. Mitochondrion CC {ECO:0000269|PubMed:15644324, ECO:0000269|PubMed:16630562, CC ECO:0000269|PubMed:18675823, ECO:0000269|PubMed:19528298}. Early CC endosome {ECO:0000269|PubMed:18675823}. Endosome CC {ECO:0000269|PubMed:18675823}. Mitochondrion membrane CC {ECO:0000269|PubMed:24995978}. Cytoplasm, cell cortex CC {ECO:0000250|UniProtKB:Q6PD31}. Note=Predominantly associated with CC early endosome. The localization to early endosomes depends on its CC interaction with HGS/HRS (PubMed:18675823). Colocalizes with MGARP at CC the mitochondria (PubMed:19528298). {ECO:0000269|PubMed:18675823, CC ECO:0000269|PubMed:19528298}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Milton1 {ECO:0000303|PubMed:24995978}; CC IsoId=Q9UPV9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UPV9-2; Sequence=VSP_010839, VSP_010840, VSP_010841; CC Name=3; CC IsoId=Q9UPV9-3; Sequence=VSP_045558, VSP_045559, VSP_045560; CC -!- TISSUE SPECIFICITY: High expression in spinal cord and moderate CC expression in all other tissues and specific brain regions examined. CC Expressed in all cell lines examined. {ECO:0000269|PubMed:18986759}. CC -!- DOMAIN: The C-terminal region is required for the early endosomal and CC mitochondrial localization. CC -!- PTM: O-glycosylated (PubMed:12435728, PubMed:24995978). Glycosylated by CC OGT; glycosylation in response to increased extracellular glucose CC levels is required for and leads to regulation of mitochondrial CC motility by OGT (PubMed:24995978). {ECO:0000269|PubMed:12435728, CC ECO:0000269|PubMed:24995978}. CC -!- DISEASE: Developmental and epileptic encephalopathy 68 (DEE68) CC [MIM:618201]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. DEE68 is an autosomal recessive form characterized by CC onset of twitching and/or myoclonic jerks in infancy. The disorder CC progresses to refractory generalized tonic-clonic seizures, often CC resulting in status epilepticus, loss of developmental milestones, and CC early death. Other features include delayed development, axial CC hypotonia, spasticity of the limbs, and clonus. CC {ECO:0000269|PubMed:28364549, ECO:0000269|PubMed:28940097, CC ECO:0000269|PubMed:29846532}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Over-expressed in all investigated carcinomas, CC especially in gastric adenocarcinoma and signet-ring carcinoma and may CC serve as a marker of gastric cancer. CC -!- SIMILARITY: Belongs to the milton family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA82994.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB028965; BAA82994.2; ALT_INIT; mRNA. DR EMBL; BX647199; CAH56169.1; -; mRNA. DR EMBL; AL713787; CAH56394.1; -; mRNA. DR EMBL; AC018358; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC093414; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC137935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC015922; AAH15922.1; -; mRNA. DR CCDS; CCDS2695.1; -. [Q9UPV9-2] DR CCDS; CCDS43072.1; -. [Q9UPV9-1] DR CCDS; CCDS58826.1; -. [Q9UPV9-3] DR RefSeq; NP_001036111.1; NM_001042646.3. [Q9UPV9-1] DR RefSeq; NP_001252537.1; NM_001265608.1. DR RefSeq; NP_001252539.1; NM_001265610.1. [Q9UPV9-3] DR RefSeq; NP_055780.2; NM_014965.4. [Q9UPV9-2] DR RefSeq; XP_024309170.1; XM_024453402.2. [Q9UPV9-1] DR RefSeq; XP_054201670.1; XM_054345695.1. [Q9UPV9-1] DR AlphaFoldDB; Q9UPV9; -. DR SMR; Q9UPV9; -. DR BioGRID; 116570; 76. DR CORUM; Q9UPV9; -. DR FunCoup; Q9UPV9; 2545. DR IntAct; Q9UPV9; 71. DR MINT; Q9UPV9; -. DR STRING; 9606.ENSP00000328998; -. DR GlyCosmos; Q9UPV9; 8 sites, 1 glycan. DR GlyGen; Q9UPV9; 10 sites, 1 O-linked glycan (8 sites). DR iPTMnet; Q9UPV9; -. DR PhosphoSitePlus; Q9UPV9; -. DR BioMuta; TRAK1; -. DR DMDM; 13124654; -. DR jPOST; Q9UPV9; -. DR MassIVE; Q9UPV9; -. DR PaxDb; 9606-ENSP00000328998; -. DR PeptideAtlas; Q9UPV9; -. DR ProteomicsDB; 19736; -. DR ProteomicsDB; 85456; -. [Q9UPV9-1] DR ProteomicsDB; 85457; -. [Q9UPV9-2] DR ABCD; Q9UPV9; 1 sequenced antibody. DR Antibodypedia; 1603; 192 antibodies from 33 providers. DR DNASU; 22906; -. DR Ensembl; ENST00000327628.10; ENSP00000328998.5; ENSG00000182606.18. [Q9UPV9-1] DR Ensembl; ENST00000341421.7; ENSP00000340702.3; ENSG00000182606.18. [Q9UPV9-2] DR Ensembl; ENST00000449246.5; ENSP00000410717.1; ENSG00000182606.18. [Q9UPV9-3] DR GeneID; 22906; -. DR KEGG; hsa:22906; -. DR MANE-Select; ENST00000327628.10; ENSP00000328998.5; NM_001042646.3; NP_001036111.1. DR UCSC; uc003cky.5; human. [Q9UPV9-1] DR AGR; HGNC:29947; -. DR ClinPGx; PA128394593; -. DR CTD; 22906; -. DR DisGeNET; 22906; -. DR GeneCards; TRAK1; -. DR HGNC; HGNC:29947; TRAK1. DR HPA; ENSG00000182606; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TRAK1; -. DR MIM; 608112; gene. DR MIM; 618201; phenotype. DR OpenTargets; ENSG00000182606; -. DR Orphanet; 442835; Non-specific early-onset epileptic encephalopathy. DR VEuPathDB; HostDB:ENSG00000182606; -. DR eggNOG; KOG4360; Eukaryota. DR GeneTree; ENSGT00940000155697; -. DR HOGENOM; CLU_013450_0_0_1; -. DR InParanoid; Q9UPV9; -. DR OMA; PFDCRTP; -. DR OrthoDB; 10067624at2759; -. DR PAN-GO; Q9UPV9; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q9UPV9; -. DR PathwayCommons; Q9UPV9; -. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-9013419; RHOT2 GTPase cycle. DR Reactome; R-HSA-9013425; RHOT1 GTPase cycle. DR SignaLink; Q9UPV9; -. DR Agora; ENSG00000182606; -. DR BioGRID-ORCS; 22906; 14 hits in 1160 CRISPR screens. DR ChiTaRS; TRAK1; human. DR GeneWiki; TRAK1; -. DR GenomeRNAi; 22906; -. DR Pharos; Q9UPV9; Tbio. DR PRO; PR:Q9UPV9; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9UPV9; protein. DR Bgee; ENSG00000182606; Expressed in secondary oocyte and 212 other cell types or tissues. DR ExpressionAtlas; Q9UPV9; baseline and differential. DR GO; GO:1904115; C:axon cytoplasm; IEA:GOC. DR GO; GO:0044295; C:axonal growth cone; IEA:Ensembl. DR GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl. DR GO; GO:0050811; F:GABA receptor binding; IBA:GO_Central. DR GO; GO:0017022; F:myosin binding; IBA:GO_Central. DR GO; GO:0030911; F:TPR domain binding; IEA:Ensembl. DR GO; GO:0019896; P:axonal transport of mitochondrion; IEA:Ensembl. DR GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl. DR GO; GO:0008333; P:endosome to lysosome transport; IDA:UniProtKB. DR GO; GO:0048311; P:mitochondrion distribution; IBA:GO_Central. DR GO; GO:0022008; P:neurogenesis; IBA:GO_Central. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0006493; P:protein O-linked glycosylation; ISS:UniProtKB. DR GO; GO:0006605; P:protein targeting; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0047496; P:vesicle transport along microtubule; IBA:GO_Central. DR InterPro; IPR006933; HAP1_N. DR InterPro; IPR051946; Intracell_Traff-Reg. DR InterPro; IPR022154; TRAK1/2_C. DR PANTHER; PTHR15751; TRAFFICKING KINESIN-BINDING PROTEIN; 1. DR PANTHER; PTHR15751:SF11; TRAFFICKING KINESIN-BINDING PROTEIN 1; 1. DR Pfam; PF04849; HAP1_N; 1. DR Pfam; PF12448; Milton; 1. DR SMART; SM01424; HAP1_N; 1. DR SMART; SM01423; Milton; 1. PE 1: Evidence at protein level; KW Alternative splicing; Coiled coil; Cytoplasm; Direct protein sequencing; KW Disease variant; Endosome; Epilepsy; Glycoprotein; Membrane; Mitochondrion; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..953 FT /note="Trafficking kinesin-binding protein 1" FT /id="PRO_0000058037" FT DOMAIN 47..354 FT /note="HAP1 N-terminal" FT REGION 359..509 FT /note="Interaction with HGS" FT /evidence="ECO:0000269|PubMed:18675823" FT REGION 472..495 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 658..672 FT /note="Interaction with OGT" FT /evidence="ECO:0000269|PubMed:24995978" FT REGION 777..796 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 104..356 FT /evidence="ECO:0000255" FT COILED 492..532 FT /evidence="ECO:0000255" FT COMPBIAS 786..796 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6PD31" FT MOD_RES 719 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6PD31" FT MOD_RES 919 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CARBOHYD 447 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:24995978" FT CARBOHYD 680 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:24995978" FT CARBOHYD 719 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:24995978" FT CARBOHYD 935 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:24995978" FT VAR_SEQ 1..97 FT /note="MALVFQFGQPVRAQPLPGLCHGKLIRTNACDVCNSTDLPEVEIISLLEEQLP FT HYKLRADTIYGYDHDDWLHTPLISPDANIDLTTEQIEETLKYFLL -> MQKFIEADYY FT ELDWYYEECSDVL (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_045558" FT VAR_SEQ 1..96 FT /note="MALVFQFGQPVRAQPLPGLCHGKLIRTNACDVCNSTDLPEVEIISLLEEQLP FT HYKLRADTIYGYDHDDWLHTPLISPDANIDLTTEQIEETLKYFL -> MSLRDKGGEEE FT CFEYDCQDEERKPTHRQHDTQDLLEEV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_010839" FT VAR_SEQ 583..630 FT /note="SATLHHWQQLAQPHLGGILDPRPGVVTKGFRTLDVDLDEVYCLNDFEE -> FT DHAGPRPLSVLLGDSLWSLIHLRKAGHLCHAYSFFFRDSHPRCWFEFL (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_045559" FT VAR_SEQ 631..953 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_045560" FT VAR_SEQ 655..744 FT /note="AHHPGKCMSQTNSTFTFTTCRILHPSDELTRVTPSLNSAPTPACGSTSHLKS FT TPVATPCTPRRLSLAESFTNTRESTTTMSTSLGLVWLL -> GERSQARVTVSGSRSYP FT SRPQASPEEMQEPPAATEEEEEEEEEEGSGEGTTISPVNLAPFPEAEFWAILTSVPGTI FT RSGSLSVASARLCG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_010840" FT VAR_SEQ 745..953 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_010841" FT VARIANT 329 FT /note="L -> P (in DEE68; uncertain significance; FT dbSNP:rs770281448)" FT /evidence="ECO:0000269|PubMed:29846532" FT /id="VAR_081639" FT MUTAGEN 447 FT /note="S->A: Reduced O-glycosylation of this protein." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 658..672 FT /note="Missing: Loss of interaction with OGT, but interacts FT with KIF5B and RHOT1/2 and is able to localize to FT mitochondria. Increased O-glycosylation of this protein by FT OGT." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 829 FT /note="S->A: Reduced O-glycosylation of this protein; when FT associated with A-830." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 830 FT /note="S->A: Reduced O-glycosylation of this protein; when FT associated with A-829." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 938 FT /note="S->A: Reduced O-glycosylation of this protein." FT /evidence="ECO:0000269|PubMed:24995978" FT CONFLICT 503 FT /note="S -> P (in Ref. 2; CAH56169)" FT /evidence="ECO:0000305" FT CONFLICT 638 FT /note="S -> F (in Ref. 2; CAH56169)" FT /evidence="ECO:0000305" FT CONFLICT Q9UPV9-2:631 FT /note="E -> EE (in Ref. 2; CAH56169)" FT /evidence="ECO:0000305" FT CONFLICT Q9UPV9-2:631 FT /note="E -> EEE (in Ref. 4; AAH15922)" FT /evidence="ECO:0000305" SQ SEQUENCE 953 AA; 106040 MW; E834BE07CF41D9A4 CRC64; MALVFQFGQP VRAQPLPGLC HGKLIRTNAC DVCNSTDLPE VEIISLLEEQ LPHYKLRADT IYGYDHDDWL HTPLISPDAN IDLTTEQIEE TLKYFLLCAE RVGQMTKTYN DIDAVTRLLE EKERDLELAA RIGQSLLKKN KTLTERNELL EEQVEHIREE VSQLRHELSM KDELLQFYTS AAEESEPESV CSTPLKRNES SSSVQNYFHL DSLQKKLKDL EEENVVLRSE ASQLKTETIT YEEKEQQLVN DCVKELRDAN VQIASISEEL AKKTEDAARQ QEEITHLLSQ IVDLQKKAKA CAVENEELVQ HLGAAKDAQR QLTAELRELE DKYAECMEML HEAQEELKNL RNKTMPNTTS RRYHSLGLFP MDSLAAEIEG TMRKELQLEE AESPDITHQK RVFETVRNIN QVVKQRSLTP SPMNIPGSNQ SSAMNSLLSS CVSTPRSSFY GSDIGNVVLD NKTNSIILET EAADLGNDER SKKPGTPGTP GSHDLETALR RLSLRRENYL SERRFFEEEQ ERKLQELAEK GELRSGSLTP TESIMSLGTH SRFSEFTGFS GMSFSSRSYL PEKLQIVKPL EGSATLHHWQ QLAQPHLGGI LDPRPGVVTK GFRTLDVDLD EVYCLNDFEE DDTGDHISLP RLATSTPVQH PETSAHHPGK CMSQTNSTFT FTTCRILHPS DELTRVTPSL NSAPTPACGS TSHLKSTPVA TPCTPRRLSL AESFTNTRES TTTMSTSLGL VWLLKERGIS AAVYDPQSWD RAGRGSLLHS YTPKMAVIPS TPPNSPMQTP TSSPPSFEFK CTSPPYDNFL ASKPASSILR EVREKNVRSS ESQTDVSVSN LNLVDKVRRF GVAKVVNSGR AHVPTLTEEQ GPLLCGPPGP APALVPRGLV PEGLPLRCPT VTSAIGGLQL NSGIRRNRSF PTMVGSSMQM KAPVTLTSGI LMGAKLSKQT SLR // ID TRI31_HUMAN Reviewed; 425 AA. AC Q9BZY9; A6NLX6; A9R9Q4; Q53H52; Q5RI37; Q5SRJ7; Q5SRJ8; Q5SS28; Q96AK4; AC Q96AP8; Q99579; Q9BZY8; DT 06-JUN-2002, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 2. DT 28-JAN-2026, entry version 195. DE RecName: Full=E3 ubiquitin-protein ligase TRIM31 {ECO:0000305}; DE EC=2.3.2.27 {ECO:0000269|PubMed:18773414, ECO:0000269|PubMed:27929086}; DE AltName: Full=Tripartite motif-containing protein 31 {ECO:0000303|PubMed:11331580}; GN Name=TRIM31 {ECO:0000303|PubMed:11331580, ECO:0000312|HGNC:HGNC:16289}; GN Synonyms=C6orf13 {ECO:0000312|HGNC:HGNC:16289}, RNF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA). RX PubMed=11331580; DOI=10.1093/emboj/20.9.2140; RA Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., RA Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., RA Pelicci P.G., Ballabio A.; RT "The tripartite motif family identifies cell compartments."; RL EMBO J. 20:2140-2151(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA), AND VARIANT RP LYS-421. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). RC TISSUE=Colon; RA Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y., RA Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS CYS-118; RP ILE-232 AND LYS-421. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA), AND VARIANT RP LYS-421. RC TISSUE=Colon; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-236. RA Henry J., Ribouchon M.-T., Depetris D., Mattei M.-G., Offer C., RA Tazi-Ahnini R., Pantarotti P.; RT "Cloning, structural analysis and mapping of B30 and B7 family members, to RT the MHC and other chromosomal regions. Toward the identification of the RT ancestral major histocompatibility complex."; RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases. RN [7] RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8; RA Hillman R.T., Green R.E., Brenner S.E.; RT "An unappreciated role for RNA surveillance."; RL Genome Biol. 5:R8.1-R8.16(2004). RN [8] RP FUNCTION, OLIGOMERIZATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, RP AUTOUBIQUITINATION, AND PATHWAY. RX PubMed=18773414; DOI=10.1002/jcb.21908; RA Sugiura T., Miyamoto K.; RT "Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a RT novel RBCC protein."; RL J. Cell. Biochem. 105:1081-1091(2008). RN [9] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF CYS-16; CYS-31 AND 53-CYS--CYS-56. RX PubMed=27929086; DOI=10.1038/ncomms13727; RA Song H., Liu B., Huai W., Yu Z., Wang W., Zhao J., Han L., Jiang G., RA Zhang L., Gao C., Zhao W.; RT "The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by RT promoting proteasomal degradation of NLRP3."; RL Nat. Commun. 7:13727-13727(2016). RN [10] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=27992402; DOI=10.1038/ni.3641; RA Liu B., Zhang M., Chu H., Zhang H., Wu H., Song G., Wang P., Zhao K., RA Hou J., Wang X., Zhang L., Gao C.; RT "The ubiquitin E3 ligase TRIM31 promotes aggregation and activation of the RT signaling adaptor MAVS through Lys63-linked polyubiquitination."; RL Nat. Immunol. 18:214-224(2017). RN [11] RP STRUCTURE BY NMR OF 1-66. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the RING domain (1-66) from tripartite motif- RT containing protein 31."; RL Submitted (OCT-2007) to the PDB data bank. CC -!- FUNCTION: E3 ubiquitin-protein ligase that acts as a regulator of CC antiviral immune response and inflammation by mediating ubiquitination CC of substrates (PubMed:18773414, PubMed:27929086, PubMed:27992402). Acts CC as a regulator of innate immune defense against viruses by mediating CC 'Lys-63'-linked ubiquitination of MAVS, promoting MAVS polymerization CC and formation of three-stranded helical filaments on mitochondria CC (PubMed:27992402). Acts as a negative regulator of the NLRP3 CC inflammasome by catalyzing 'Lys-48'-linked ubiquitination of NLRP3, CC leading to its degradation (PubMed:27929086). Regulator of Src-induced CC anchorage independent cell growth (By similarity). CC {ECO:0000250|UniProtKB:Q8R0K2, ECO:0000269|PubMed:18773414, CC ECO:0000269|PubMed:27929086, ECO:0000269|PubMed:27992402}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:18773414, CC ECO:0000269|PubMed:27929086}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC {ECO:0000269|PubMed:18773414, ECO:0000269|PubMed:27929086}. CC -!- SUBUNIT: May form oligomers (PubMed:18773414). Interacts with isoform CC p52shc of SHC1 (By similarity). {ECO:0000250|UniProtKB:Q8R0K2, CC ECO:0000269|PubMed:18773414}. CC -!- INTERACTION: CC Q9BZY9; P40227: CCT6A; NbExp=3; IntAct=EBI-747544, EBI-356687; CC Q9BZY9; P43355: MAGEA1; NbExp=4; IntAct=EBI-747544, EBI-740978; CC Q9BZY9; P61086: UBE2K; NbExp=11; IntAct=EBI-747544, EBI-473850; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18773414}. CC Mitochondrion {ECO:0000269|PubMed:18773414, CC ECO:0000269|PubMed:27992402}. Note=Predominantly expressed in the CC cytoplasm but a fraction is associated with the mitochondria CC (PubMed:18773414). Recruited t omitochondria after viral infection CC (PubMed:27992402). {ECO:0000269|PubMed:18773414, CC ECO:0000269|PubMed:27992402}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Alpha {ECO:0000303|PubMed:11331580}; CC IsoId=Q9BZY9-1; Sequence=Displayed; CC Name=Beta {ECO:0000303|PubMed:11331580}; CC IsoId=Q9BZY9-2; Sequence=VSP_005764, VSP_005765; CC -!- TISSUE SPECIFICITY: Up-regulated in gastric adenocarcinomas. CC {ECO:0000269|PubMed:18773414}. CC -!- PTM: Auto-ubiquitinated (in vitro). {ECO:0000269|PubMed:18773414}. CC -!- MISCELLANEOUS: [Isoform Beta]: May be produced at very low levels due CC to a premature stop codon in the mRNA, leading to nonsense-mediated CC mRNA decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16866.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF230386; AAG50165.1; -; mRNA. DR EMBL; AF230387; AAG50166.1; -; mRNA. DR EMBL; BT006675; AAP35321.1; -; mRNA. DR EMBL; AK222729; BAD96449.1; -; mRNA. DR EMBL; AL669914; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL671859; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX322644; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CR753815; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC016866; AAH16866.1; ALT_INIT; mRNA. DR EMBL; BC017017; AAH17017.1; -; mRNA. DR EMBL; Y07828; CAA69165.1; -; mRNA. DR CCDS; CCDS34374.1; -. [Q9BZY9-1] DR RefSeq; NP_008959.3; NM_007028.4. [Q9BZY9-1] DR PDB; 2YSJ; NMR; -; A=1-56. DR PDB; 2YSL; NMR; -; A=1-66. DR PDBsum; 2YSJ; -. DR PDBsum; 2YSL; -. DR AlphaFoldDB; Q9BZY9; -. DR BMRB; Q9BZY9; -. DR SMR; Q9BZY9; -. DR BioGRID; 116257; 456. DR CORUM; Q9BZY9; -. DR FunCoup; Q9BZY9; 20. DR IntAct; Q9BZY9; 16. DR STRING; 9606.ENSP00000365924; -. DR GlyCosmos; Q9BZY9; 1 site, 2 glycans. DR GlyGen; Q9BZY9; 1 site, 2 O-linked glycans (1 site). DR iPTMnet; Q9BZY9; -. DR PhosphoSitePlus; Q9BZY9; -. DR SwissPalm; Q9BZY9; -. DR BioMuta; TRIM31; -. DR DMDM; 68068082; -. DR jPOST; Q9BZY9; -. DR MassIVE; Q9BZY9; -. DR PaxDb; 9606-ENSP00000365924; -. DR PeptideAtlas; Q9BZY9; -. DR ProteomicsDB; 79921; -. [Q9BZY9-1] DR ProteomicsDB; 79922; -. [Q9BZY9-2] DR Antibodypedia; 11702; 202 antibodies from 27 providers. DR DNASU; 11074; -. DR Ensembl; ENST00000357569.5; ENSP00000350182.5; ENSG00000137397.18. DR Ensembl; ENST00000376734.4; ENSP00000365924.3; ENSG00000204616.12. [Q9BZY9-1] DR Ensembl; ENST00000433864.2; ENSP00000390551.2; ENSG00000233573.9. DR Ensembl; ENST00000445679.2; ENSP00000409501.2; ENSG00000224168.9. [Q9BZY9-1] DR Ensembl; ENST00000449412.2; ENSP00000398677.2; ENSG00000223531.9. [Q9BZY9-1] DR Ensembl; ENST00000453266.2; ENSP00000391685.2; ENSG00000225130.9. [Q9BZY9-1] DR GeneID; 11074; -. DR KEGG; hsa:11074; -. DR MANE-Select; ENST00000376734.4; ENSP00000365924.3; NM_007028.5; NP_008959.3. DR UCSC; uc003npg.2; human. [Q9BZY9-1] DR AGR; HGNC:16289; -. DR ClinPGx; PA38117; -. DR CTD; 11074; -. DR DisGeNET; 11074; -. DR GeneCards; TRIM31; -. DR HGNC; HGNC:16289; TRIM31. DR HPA; ENSG00000204616; Tissue enhanced (intestine, stomach, urinary bladder). DR MIM; 609316; gene. DR OpenTargets; ENSG00000204616; -. DR VEuPathDB; HostDB:ENSG00000204616; -. DR eggNOG; KOG2177; Eukaryota. DR GeneTree; ENSGT00940000163585; -. DR HOGENOM; CLU_013137_6_1_1; -. DR InParanoid; Q9BZY9; -. DR OMA; FWALRIA; -. DR OrthoDB; 654191at2759; -. DR PAN-GO; Q9BZY9; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9BZY9; -. DR PathwayCommons; Q9BZY9; -. DR Reactome; R-HSA-877300; Interferon gamma signaling. DR SignaLink; Q9BZY9; -. DR SIGNOR; Q9BZY9; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000204616; -. DR BioGRID-ORCS; 11074; 11 hits in 1188 CRISPR screens. DR ChiTaRS; TRIM31; human. DR EvolutionaryTrace; Q9BZY9; -. DR GeneWiki; TRIM31; -. DR GenomeRNAi; 11074; -. DR Pharos; Q9BZY9; Tbio. DR PRO; PR:Q9BZY9; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q9BZY9; protein. DR Bgee; ENSG00000204616; Expressed in mucosa of transverse colon and 94 other cell types or tissues. DR ExpressionAtlas; Q9BZY9; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:ARUK-UCL. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0046597; P:host-mediated suppression of symbiont invasion; IMP:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0045087; P:innate immune response; IMP:UniProtKB. DR GO; GO:1900226; P:negative regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0032897; P:negative regulation of viral transcription; IDA:UniProtKB. DR GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:0019076; P:viral release from host cell; IMP:UniProtKB. DR CDD; cd19765; Bbox2_TRIM10-like; 1. DR CDD; cd16582; RING-HC_TRIM31_C-V; 1. DR FunFam; 3.30.40.10:FF:000699; E3 ubiquitin-protein ligase TRIM31; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR050143; TRIM/RBCC. DR InterPro; IPR000315; Znf_B-box. DR InterPro; IPR020457; Znf_B-box_chordata. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR24103; E3 UBIQUITIN-PROTEIN LIGASE TRIM; 1. DR Pfam; PF00643; zf-B_box; 1. DR Pfam; PF15227; zf-C3HC4_4; 1. DR PRINTS; PR01406; BBOXZNFINGER. DR SMART; SM00336; BBOX; 1. DR SMART; SM00184; RING; 1. DR SUPFAM; SSF57845; B-box zinc-binding domain; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50119; ZF_BBOX; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Antiviral defense; Coiled coil; KW Cytoplasm; Immunity; Inflammatory response; Innate immunity; Metal-binding; KW Mitochondrion; Proteomics identification; Reference proteome; Transferase; KW Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..425 FT /note="E3 ubiquitin-protein ligase TRIM31" FT /id="PRO_0000056245" FT ZN_FING 16..57 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT ZN_FING 90..131 FT /note="B box-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT REGION 328..360 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 126..162 FT /evidence="ECO:0000255" FT COILED 270..307 FT /evidence="ECO:0000255" FT COMPBIAS 336..360 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 95 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 98 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 117 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 123 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT VAR_SEQ 249..267 FT /note="DIKVVLCRSEEFQFLNPTP -> NWRKNSVKQNQDTTPSQGA (in FT isoform Beta)" FT /evidence="ECO:0000303|PubMed:11331580" FT /id="VSP_005764" FT VAR_SEQ 268..425 FT /note="Missing (in isoform Beta)" FT /evidence="ECO:0000303|PubMed:11331580" FT /id="VSP_005765" FT VARIANT 17 FT /note="P -> R (in dbSNP:rs36063651)" FT /id="VAR_052139" FT VARIANT 118 FT /note="R -> C (in dbSNP:rs3734838)" FT /evidence="ECO:0000269|PubMed:14574404" FT /id="VAR_022728" FT VARIANT 232 FT /note="V -> I (in dbSNP:rs2523989)" FT /evidence="ECO:0000269|PubMed:14574404" FT /id="VAR_022729" FT VARIANT 235 FT /note="L -> P (in dbSNP:rs35775852)" FT /id="VAR_052140" FT VARIANT 421 FT /note="E -> K (in dbSNP:rs1116221)" FT /evidence="ECO:0000269|PubMed:14574404, FT ECO:0000269|PubMed:15489334, ECO:0000269|Ref.2" FT /id="VAR_019962" FT MUTAGEN 16 FT /note="C->A: Abolished E3 ubiquitin-protein ligase activity FT and ability to ubiquitinate NLRP3; when associated with A- FT 31." FT /evidence="ECO:0000269|PubMed:27929086" FT MUTAGEN 31 FT /note="C->A: Abolished E3 ubiquitin-protein ligase activity FT and ability to ubiquitinate NLRP3; when associated with A- FT 16." FT /evidence="ECO:0000269|PubMed:27929086" FT MUTAGEN 53..56 FT /note="CPLC->APLA: Abolished E3 ubiquitin-protein ligase FT activity and ability to ubiquitinate MAVS." FT /evidence="ECO:0000269|PubMed:27929086" FT CONFLICT 37..38 FT /note="LK -> PQ (in Ref. 1; AAG50165/AAG50166 and 6; FT CAA69165)" FT /evidence="ECO:0000305" FT CONFLICT 62..63 FT /note="KN -> RD (in Ref. 1; AAG50165/AAG50166 and 6; FT CAA69165)" FT /evidence="ECO:0000305" FT CONFLICT 109 FT /note="D -> G (in Ref. 3; BAD96449)" FT /evidence="ECO:0000305" FT CONFLICT 219..236 FT /note="ASTEPQLNDLKKLVDSLK -> EIPLMPTVERSQEARCYP (in Ref. 6; FT CAA69165)" FT /evidence="ECO:0000305" FT TURN 17..19 FT /evidence="ECO:0007829|PDB:2YSJ" FT STRAND 24..28 FT /evidence="ECO:0007829|PDB:2YSL" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:2YSJ" FT HELIX 37..46 FT /evidence="ECO:0007829|PDB:2YSJ" FT STRAND 54..56 FT /evidence="ECO:0007829|PDB:2YSL" SQ SEQUENCE 425 AA; 48244 MW; 8CCC0D07F2DBB52D CRC64; MASGQFVNKL QEEVICPICL DILQKPVTID CGHNFCLKCI TQIGETSCGF FKCPLCKTSV RKNAIRFNSL LRNLVEKIQA LQASEVQSKR KEATCPRHQE MFHYFCEDDG KFLCFVCRES KDHKSHNVSL IEEAAQNYQG QIQEQIQVLQ QKEKETVQVK AQGVHRVDVF TDQVEHEKQR ILTEFELLHQ VLEEEKNFLL SRIYWLGHEG TEAGKHYVAS TEPQLNDLKK LVDSLKTKQN MPPRQLLEDI KVVLCRSEEF QFLNPTPVPL ELEKKLSEAK SRHDSITGSL KKFKDQLQAD RKKDENRFFK SMNKNDMKSW GLLQKNNHKM NKTSEPGSSS AGGRTTSGPP NHHSSAPSHS LFRASSAGKV TFPVCLLASY DEISGQGASS QDTKTFDVAL SEELHAALSE WLTAIRAWFC EVPSS // ID TRPM7_HUMAN Reviewed; 1865 AA. AC Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Transient receptor potential cation channel subfamily M member 7; DE EC=2.7.11.1 {ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; DE AltName: Full=Channel-kinase 1; DE AltName: Full=Long transient receptor potential channel 7 {ECO:0000303|PubMed:11385574}; DE Short=LTrpC-7; DE Short=LTrpC7; DE Contains: DE RecName: Full=TRPM7 kinase, cleaved form {ECO:0000250|UniProtKB:Q923J1}; DE Short=M7CK; DE Contains: DE RecName: Full=TRPM7 channel, cleaved form {ECO:0000250|UniProtKB:Q923J1}; GN Name=TRPM7; Synonyms=CHAK1, LTRPC7 {ECO:0000303|PubMed:11385574}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY RP REGULATION. RX PubMed=11385574; DOI=10.1038/35079092; RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RT "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell RT viability."; RL Nature 411:590-595(2001). RN [2] RP ERRATUM OF PUBMED:11385574. RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RL Nature 412:660-660(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RX PubMed=14594813; DOI=10.1074/jbc.m308820200; RA Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.; RT "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein RT kinase fused to the transient receptor potential ion channel."; RL J. Biol. Chem. 279:3708-3716(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT RP ILE-1482. RC TISSUE=Colon, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF LYS-1648 AND GLY-1799. RX PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7; RA Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R., RA Kurosaki T., Fleig A., Scharenberg A.M.; RT "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7."; RL Cell 114:191-200(2003). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15485879; DOI=10.1074/jbc.c400441200; RA Dorovkov M.V., Ryazanov A.G.; RT "Phosphorylation of annexin I by TRPM7 channel-kinase."; RL J. Biol. Chem. 279:50643-50646(2004). RN [8] RP INTERACTION WITH TRPM6. RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [9] RP INTERACTION WITH TRPM6. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18394644; DOI=10.1016/j.jmb.2008.02.057; RA Clark K., Middelbeek J., Lasonder E., Dulyaninova N.G., Morrice N.A., RA Ryazanov A.G., Bresnick A.R., Figdor C.G., van Leeuwen F.N.; RT "TRPM7 regulates myosin IIA filament stability and protein localization by RT heavy chain phosphorylation."; RL J. Mol. Biol. 378:790-803(2008). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP THR-1163; SER-1191; SER-1193; SER-1255; SER-1258; THR-1265; SER-1287; RP SER-1358; SER-1361; SER-1387; SER-1390; SER-1396; SER-1404; THR-1405; RP SER-1407; THR-1435; SER-1446; THR-1455; SER-1456; SER-1463; SER-1468; RP THR-1471; SER-1476; SER-1477; THR-1482; SER-1493; SER-1504; THR-1508; RP SER-1513; SER-1527; SER-1533; THR-1537; THR-1542; SER-1543; THR-1551; RP SER-1567; SER-1569; THR-1583; SER-1598; SER-1615; SER-1660; THR-1685; RP SER-1779; THR-1830 AND SER-1860. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390; RP SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [17] RP PALMITOYLATION AT CYS-1143; CYS-1144 AND CYS-1146, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=36027648; DOI=10.1016/j.ceca.2022.102639; RA Gao X., Kuo C.W., Main A., Brown E., Rios F.J., Camargo L.L., Mary S., RA Wypijewski K., Goek C., Touyz R.M., Fuller W.; RT "Palmitoylation regulates cellular distribution of and transmembrane Ca RT flux through TrpM7."; RL Cell Calcium 106:102639-102639(2022). RN [18] RP VARIANT ILE-1482, CHARACTERIZATION OF VARIANT ILE-1482, AND ACTIVITY RP REGULATION. RX PubMed=16051700; DOI=10.1073/pnas.0505149102; RA Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G., RA Haymer D.S., Garruto R.M.; RT "A TRPM7 variant shows altered sensitivity to magnesium that may contribute RT to the pathogenesis of two Guamanian neurodegenerative disorders."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005). RN [19] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720; RP VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND RP ILE-1482. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, VARIANT ASP-1046, RP CHARACTERIZATION OF VARIANT ASP-1046, AND INVOLVEMENT IN HYPOMAGNESEMIA RP WITH SECONDARY HYPOCALCEMIA. RX PubMed=35561741; DOI=10.1093/ndt/gfac182; RA Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V., RA van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M., RA Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.; RT "Possible role for rare TRPM7 variants in patients with hypomagnesemia with RT secondary hypocalcemia."; RL Nephrol. Dial. Transplant. 0:0-0(2022). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain. The channel is highly CC permeable to divalent cations, specifically calcium (Ca2+), magnesium CC (Mg2+) and zinc (Zn2+) and mediates their influx (PubMed:11385574, CC PubMed:12887921, PubMed:15485879, PubMed:24316671, PubMed:35561741, CC PubMed:36027648). Controls a wide range of biological processes such as CC Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel CC and intracellular Ca(2+) signaling, embryonic development, immune CC responses, cell motility, proliferation and differentiation (By CC similarity). The C-terminal alpha-kinase domain autophosphorylates CC cytoplasmic residues of TRPM7 (PubMed:18365021). In vivo, TRPM7 CC phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in CC activating SMAD signaling pathways. In vitro, TRPM7 kinase CC phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of CC proteins with diverse cellular functions (PubMed:15485879, CC PubMed:18394644). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:12887921, CC ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644, ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741, ECO:0000269|PubMed:36027648}. CC -!- FUNCTION: [TRPM7 channel, cleaved form]: The cleaved channel exhibits CC substantially higher current and potentiates Fas receptor signaling. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- FUNCTION: [TRPM7 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. In immune cells, the TRPM7 kinase domain is clipped from the CC channel domain by caspases in response to Fas-receptor stimulation. The CC cleaved kinase fragments can translocate to the nucleus, and bind CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones known to CC be functionally important for cell differentiation and embryonic CC development. {ECO:0000250|UniProtKB:Q923J1}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:12887921, ECO:0000269|PubMed:35561741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:36027648}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:Q923J1}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000250|UniProtKB:Q923J1}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q923J1}; CC -!- ACTIVITY REGULATION: Channel displays constitutive activity. Channel CC activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP CC (PubMed:11385574, PubMed:16051700). Channel activity is negatively CC regulated by low intracellular pH (By similarity). Resting free CC cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to CC block native TRPM7 channel activity (By similarity). TRPM7 channel CC activity is highly dependent on membrane levels of phosphatidylinositol CC 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 CC channel activity (By similarity). TRPM7 kinase activity does not affect CC channel activity (By similarity). The kinase activity is controlled CC through the autophosphorylation of a serine/threonine-rich region CC located N-terminal to the catalytic domain (PubMed:18365021). CC {ECO:0000250|UniProtKB:Q923J1, ECO:0000250|UniProtKB:Q925B3, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:16051700, CC ECO:0000269|PubMed:18365021}. CC -!- SUBUNIT: Homotetramer (By similarity). Interacts with PLCB1 (By CC similarity). Forms heteromers with TRPM6; heteromeric channels are CC functionally different from the homomeric channels (PubMed:14976260, CC PubMed:16636202). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000250|UniProtKB:Q925B3, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Cytoplasmic vesicle membrane CC {ECO:0000250|UniProtKB:Q923J1}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Note=Localized largely in intracellular CC Zn(2+)-storage vesicles. {ECO:0000250|UniProtKB:Q923J1}. CC -!- SUBCELLULAR LOCATION: [TRPM7 kinase, cleaved form]: Nucleus CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- PTM: Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 CC promotes TRPM7 trafficking from the Golgi to the surface membrane. CC {ECO:0000269|PubMed:36027648}. CC -!- PTM: Autophosphorylated; autophosphorylation of C-terminus regulates CC TRPM7 kinase activity towards its substrates. CC {ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminal kinase domain can be cleaved from the channel CC segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, CC dissociating the kinase from the ion-conducting pore. The cleaved CC kinase fragments (M7CKs) can translocate to the cell nucleus and binds CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 CC (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by CC chronic, progressive and uniformly fatal amyotrophic lateral sclerosis CC and parkinsonism-dementia. Both diseases are known to occur in the same CC kindred, the same sibship and even the same individual. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause CC of disease in patients suffering from seizures and muscle cramps due to CC magnesium deficiency and episodes of hypocalcemia. CC {ECO:0000269|PubMed:35561741}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY032950; AAK44211.1; -; mRNA. DR EMBL; AF346629; AAK19738.2; -; mRNA. DR EMBL; AK000124; BAA90958.1; -; mRNA. DR EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA. DR EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA. DR EMBL; BC051024; AAH51024.1; -; mRNA. DR CCDS; CCDS42035.1; -. DR RefSeq; NP_001288141.1; NM_001301212.1. DR RefSeq; NP_060142.3; NM_017672.5. DR AlphaFoldDB; Q96QT4; -. DR SMR; Q96QT4; -. DR BioGRID; 120177; 153. DR CORUM; Q96QT4; -. DR FunCoup; Q96QT4; 1775. DR IntAct; Q96QT4; 44. DR MINT; Q96QT4; -. DR STRING; 9606.ENSP00000495860; -. DR BindingDB; Q96QT4; -. DR ChEMBL; CHEMBL1250412; -. DR DrugBank; DB04447; 1,4-Dithiothreitol. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR DrugBank; DB06757; Manganese cation. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR GuidetoPHARMACOLOGY; 499; -. DR TCDB; 1.A.4.5.1; the transient receptor potential ca2+/cation channel (trp-cc) family. DR CarbonylDB; Q96QT4; -. DR iPTMnet; Q96QT4; -. DR PhosphoSitePlus; Q96QT4; -. DR SwissPalm; Q96QT4; -. DR BioMuta; TRPM7; -. DR DMDM; 56404941; -. DR jPOST; Q96QT4; -. DR MassIVE; Q96QT4; -. DR PaxDb; 9606-ENSP00000320239; -. DR PeptideAtlas; Q96QT4; -. DR ProteomicsDB; 77898; -. DR Pumba; Q96QT4; -. DR Antibodypedia; 24755; 465 antibodies from 40 providers. DR DNASU; 54822; -. DR Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16. DR GeneID; 54822; -. DR KEGG; hsa:54822; -. DR MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3. DR UCSC; uc001zyt.5; human. DR AGR; HGNC:17994; -. DR ClinPGx; PA38273; -. DR CTD; 54822; -. DR DisGeNET; 54822; -. DR GeneCards; TRPM7; -. DR HGNC; HGNC:17994; TRPM7. DR HPA; ENSG00000092439; Tissue enriched (parathyroid). DR MalaCards; TRPM7; -. DR MIM; 105500; phenotype. DR MIM; 605692; gene. DR OpenTargets; ENSG00000092439; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 90020; Parkinson-dementia complex of Guam. DR VEuPathDB; HostDB:ENSG00000092439; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000157091; -. DR InParanoid; Q96QT4; -. DR OMA; SSKDPHX; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q96QT4; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96QT4; -. DR PathwayCommons; Q96QT4; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q96QT4; -. DR SIGNOR; Q96QT4; -. DR Agora; ENSG00000092439; -. DR BioGRID-ORCS; 54822; 406 hits in 1198 CRISPR screens. DR ChiTaRS; TRPM7; human. DR GeneWiki; TRPM7; -. DR GenomeRNAi; 54822; -. DR Pharos; Q96QT4; Tchem. DR PRO; PR:Q96QT4; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96QT4; protein. DR Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 179 other cell types or tissues. DR ExpressionAtlas; Q96QT4; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0001726; C:ruffle; IEA:Ensembl. DR GO; GO:0003779; F:actin binding; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0017022; F:myosin binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IEA:Ensembl. DR GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0010961; P:intracellular magnesium ion homeostasis; ISS:UniProtKB. DR GO; GO:0010960; P:magnesium ion homeostasis; IDA:UniProtKB. DR GO; GO:0015693; P:magnesium ion transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0006829; P:zinc ion transport; ISS:UniProtKB. DR CDD; cd16971; Alpha_kinase_ChaK1_TRMP7; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029601; TRPM7_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF8; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 7; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 2. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium; KW Calcium channel; Calcium transport; Cell membrane; Coiled coil; KW Cytoplasmic vesicle; Disease variant; Ion channel; Ion transport; Kinase; KW Lipoprotein; Membrane; Metal-binding; Necrosis; Neurodegeneration; KW Nucleotide-binding; Nucleus; Palmitate; Parkinsonism; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Transmembrane; KW Transmembrane helix; Transport; Zinc. FT CHAIN 1..1865 FT /note="Transient receptor potential cation channel FT subfamily M member 7" FT /id="PRO_0000215331" FT CHAIN 1..? FT /note="TRPM7 channel, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461294" FT CHAIN ?..1865 FT /note="TRPM7 kinase, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461295" FT TOPO_DOM 1..850 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 851..876 FT /note="Helical; Name=1" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 877..882 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 883..904 FT /note="Helical; Name=2" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 905..923 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 924..943 FT /note="Helical; Name=3" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 944..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..980 FT /note="Helical; Name=4" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 981..999 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1000..1023 FT /note="Helical; Name=5" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1024..1025 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1026..1066 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1067..1069 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1070..1098 FT /note="Helical; Name=6" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1099..1865 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 1594..1824 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 544..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1386..1407 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1492..1511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1524..1543 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1836..1865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1198..1250 FT /evidence="ECO:0000250" FT COMPBIAS 544..555 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 560..573 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1386..1398 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1511 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1844..1865 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1767 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1621 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1622 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1623 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1624 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1648 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1720 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1721 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1723 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1753 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1810 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1812 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1816 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 101 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1163 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1191 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1193 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1255 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1258 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1265 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1287 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1301 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1358 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1361 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1386 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1387 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1390 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1396 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1404 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1405 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1407 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1435 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1446 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1455 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1456 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1463 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1467 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1468 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1471 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1476 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1477 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 1482 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1493 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1500 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1504 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1508 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1513 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1527 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1533 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1537 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1542 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1543 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1551 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1567 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1569 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1583 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1598 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1615 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1660 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1685 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1779 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1830 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1851 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1860 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT LIPID 1143 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1144 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT VARIANT 68 FT /note="G -> V (in dbSNP:rs56064201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042395" FT VARIANT 406 FT /note="S -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042396" FT VARIANT 459 FT /note="I -> T (in dbSNP:rs55924090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042397" FT VARIANT 574 FT /note="K -> N (in dbSNP:rs56040619)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042398" FT VARIANT 720 FT /note="T -> S (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1040254222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042399" FT VARIANT 830 FT /note="M -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042400" FT VARIANT 949 FT /note="F -> Y (in dbSNP:rs55681028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042401" FT VARIANT 1033 FT /note="A -> G (in dbSNP:rs34530969)" FT /id="VAR_052381" FT VARIANT 1046 FT /note="G -> D (found in a patient with hypomagnesemia and FT secondary hypocalcemia; likely pathogenic; de novo variant; FT causes severely reduced Mg(2+) uptake in transfected cells; FT dbSNP:rs2059709974)" FT /evidence="ECO:0000269|PubMed:35561741" FT /id="VAR_086707" FT VARIANT 1064 FT /note="Q -> R (in dbSNP:rs56298128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042402" FT VARIANT 1145 FT /note="I -> V (in dbSNP:rs34711809)" FT /id="VAR_052382" FT VARIANT 1211 FT /note="I -> T (in dbSNP:rs56090496)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042403" FT VARIANT 1254 FT /note="A -> V (in dbSNP:rs56288221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042404" FT VARIANT 1306 FT /note="D -> E (in dbSNP:rs55970334)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042405" FT VARIANT 1444 FT /note="R -> K (in dbSNP:rs55840070)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042406" FT VARIANT 1482 FT /note="T -> I (mutant channels are functional but show FT increased susceptibility to inhibition by intracellular FT Mg(2+) concentrations compared to wild-type channels; FT dbSNP:rs8042919)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846" FT /id="VAR_019967" FT MUTAGEN 1648 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT MUTAGEN 1799 FT /note="G->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT CONFLICT 573..575 FT /note="EKM -> KKK (in Ref. 4; BAD18773)" FT /evidence="ECO:0000305" FT CONFLICT 998 FT /note="A -> S (in Ref. 5)" FT /evidence="ECO:0000305" FT CONFLICT 1496 FT /note="Missing (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" FT CONFLICT 1520 FT /note="D -> V (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" SQ SEQUENCE 1865 AA; 212697 MW; BE732674D52D7485 CRC64; MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS VRLML // ID TRRAP_HUMAN Reviewed; 3859 AA. AC Q9Y4A5; A4D265; O75218; Q9Y631; Q9Y6H4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 226. DE RecName: Full=Transformation/transcription domain-associated protein; DE AltName: Full=350/400 kDa PCAF-associated factor; DE Short=PAF350/400; DE AltName: Full=STAF40; DE AltName: Full=Tra1 homolog; GN Name=TRRAP; Synonyms=PAF400; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION, RP SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND E2F1. RC TISSUE=Cervix carcinoma; RX PubMed=9708738; DOI=10.1016/s0092-8674(00)81479-8; RA McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D.; RT "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc RT and E2F oncoproteins."; RL Cell 94:363-374(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 41-90; 337-344; RP 369-387; 879-892; 997-1005; 1171-1184; 1237-1247; 1545-1560; 1815-1820; RP 1922-1934; 2211-2218; 2260-2275; 2534-2547; 2583-2594; 2706-2726; RP 2830-2844; 3567-3573; 3583-3598; 3604-3614; 3712-3730 AND 3822-3834, AND RP IDENTIFICATION IN THE PCAF COMPLEX WITH TADA2L; TADA3L; TAF5L; TAF6L; RP TAF10; SUPT3H; TAF12 AND TAF9. RC TISSUE=Fetal heart; RX PubMed=9885574; DOI=10.1016/s1097-2765(00)80301-9; RA Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J., RA Nakatani Y.; RT "The 400 kDa subunit of the PCAF histone acetylase complex belongs to the RT ATM superfamily."; RL Mol. Cell 2:869-875(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [6] RP SUBCELLULAR LOCATION, IDENTIFICATION IN THE STAGA COMPLEX WITH SUPT3H; RP GCN5L2; KIAA0764; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001; RA Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M., RA Kundu T.K., Chait B.T., Roeder R.G.; RT "Human STAGA complex is a chromatin-acetylating transcription coactivator RT that interacts with pre-mRNA splicing and DNA damage-binding factors in RT vivo."; RL Mol. Cell. Biol. 21:6782-6795(2001). RN [7] RP IDENTIFICATION IN THE TFTC-HAT COMPLEX WITH TAF5L; TAF6L; TADA3L; SUPT3H; RP TAF2; TAF4; TAF5; GCN5L2 AND TAF10. RX PubMed=10373431; DOI=10.1074/jbc.274.26.18285; RA Brand M., Yamamoto K., Staub A., Tora L.; RT "Identification of TATA-binding protein-free TAFII-containing complex RT subunits suggests a role in nucleosome acetylation and signal RT transduction."; RL J. Biol. Chem. 274:18285-18289(1999). RN [8] RP IDENTIFICATION IN THE TIP60 HAT COMPLEX WITH KAT5; RUVBL1 AND RUVBL2. RX PubMed=10966108; DOI=10.1016/s0092-8674(00)00051-9; RA Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., RA Scully R., Qin J., Nakatani Y.; RT "Involvement of the TIP60 histone acetylase complex in DNA repair and RT apoptosis."; RL Cell 102:463-473(2000). RN [9] RP INTERACTION WITH GCN5L2. RX PubMed=10611234; DOI=10.1128/mcb.20.2.556-562.2000; RA McMahon S.B., Wood M.A., Cole M.D.; RT "The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 RT to c-Myc."; RL Mol. Cell. Biol. 20:556-562(2000). RN [10] RP INTERACTION WITH E2F1 AND E2F4, AND FUNCTION. RX PubMed=11418595; DOI=10.1074/jbc.m102067200; RA Lang S.E., McMahon S.B., Cole M.D., Hearing P.; RT "E2F transcriptional activation requires TRRAP and GCN5 cofactors."; RL J. Biol. Chem. 276:32627-32634(2001). RN [11] RP DOMAIN. RX PubMed=11445536; DOI=10.1101/gad.900101; RA Park J., Kunjibettu S., McMahon S.B., Cole M.D.; RT "The ATM-related domain of TRRAP is required for histone acetyltransferase RT recruitment and Myc-dependent oncogenesis."; RL Genes Dev. 15:1619-1624(2001). RN [12] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=12138177; DOI=10.1128/mcb.22.16.5650-5661.2002; RA Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E., RA McMahon S.B.; RT "Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP RT acetyltransferase complexes."; RL Mol. Cell. Biol. 22:5650-5661(2002). RN [13] RP IDENTIFICATION IN THE BAF53 COMPLEX WITH BAF53A; RUVBL1 AND SMARCA4. RX PubMed=11839798; DOI=10.1128/mcb.22.5.1307-1316.2002; RA Park J., Wood M.A., Cole M.D.; RT "BAF53 forms distinct nuclear complexes and functions as a critical c-Myc- RT interacting nuclear cofactor for oncogenic transformation."; RL Mol. Cell. Biol. 22:1307-1316(2002). RN [14] RP FUNCTION. RX PubMed=12743606; DOI=10.1038/sj.onc.1206376; RA Lang S.E., Hearing P.; RT "The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone RT acetyltransferase complex."; RL Oncogene 22:2836-2841(2003). RN [15] RP FUNCTION. RX PubMed=12660246; DOI=10.1074/jbc.m211795200; RA Liu X., Tesfai J., Evrard Y.A., Dent S.Y.R., Martinez E.; RT "c-Myc transformation domain recruits the human STAGA complex and requires RT TRRAP and GCN5 acetylase activity for transcription activation."; RL J. Biol. Chem. 278:20405-20412(2003). RN [16] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE RP NUA4 COMPLEX. RX PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004; RA Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.; RT "Structural and functional conservation of the NuA4 histone RT acetyltransferase complex from yeast to humans."; RL Mol. Cell. Biol. 24:1884-1896(2004). RN [17] RP IDENTIFICATION IN STAGA COMPLEX. RX PubMed=18206972; DOI=10.1016/j.molcel.2007.12.011; RA Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S., RA Suzuki E., Le Guezennec X., Stunnenberg H.G., Krasnov A., Georgieva S.G., RA Schuele R., Takeyama K., Kato S., Tora L., Devys D.; RT "A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, RT coactivates nuclear receptors, and counteracts heterochromatin silencing."; RL Mol. Cell 29:92-101(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [19] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH NPAT. RX PubMed=17967892; DOI=10.1128/mcb.00607-07; RA DeRan M., Pulvino M., Greene E., Su C., Zhao J.; RT "Transcriptional activation of histone genes requires NPAT-dependent RT recruitment of TRRAP-Tip60 complex to histone promoters during the G1/S RT phase transition."; RL Mol. Cell. Biol. 28:435-447(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051 AND SER-2077, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3078, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [22] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP PROBABLE INVOLVEMENT IN MELANOMA, VARIANT PHE-722, AND CHARACTERIZATION OF RP VARIANT PHE-722. RX PubMed=21499247; DOI=10.1038/ng.810; RA Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S., RA Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W., Robinson S., RA Rosenberg S.A., Samuels Y.; RT "Exome sequencing identifies GRIN2A as frequently mutated in melanoma."; RL Nat. Genet. 43:442-446(2011). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1628; SER-2051 AND SER-2077, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [29] RP FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX. RX PubMed=24463511; DOI=10.1038/nature12922; RA Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M., RA Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C., RA Hamiche A.; RT "ANP32E is a histone chaperone that removes H2A.Z from chromatin."; RL Nature 505:648-653(2014). RN [30] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-2543, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-893; GLY-1070; HIS-1669; HIS-1724; RP VAL-1925; LEU-1932; LEU-1947; GLY-2139; TRP-2302; GLY-2433; LEU-2690; RP ASP-2750; GLU-2801 AND MET-2931. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [32] RP INVOLVEMENT IN DEDDFA, AND VARIANT DEDDFA GLN-2004. RX PubMed=30424743; DOI=10.1186/s12881-018-0711-9; RA Mavros C.F., Brownstein C.A., Thyagrajan R., Genetti C.A., Tembulkar S., RA Graber K., Murphy Q., Cabral K., VanNoy G.E., Bainbridge M., Shi J., RA Agrawal P.B., Beggs A.H., D'Angelo E., Gonzalez-Heydrich J.; RT "De novo variant of TRRAP in a patient with very early onset psychosis in RT the context of non-verbal learning disability and obsessive-compulsive RT disorder: a case report."; RL BMC Med. Genet. 19:197-197(2018). RN [33] RP VARIANTS DEDDFA PHE-805; LEU-860; LEU-893; MET-1031; GLN-1035; ARG-1037; RP THR-1043; GLY-1104; LYS-1106; TRP-1111; ARG-1159; CYS-1859; CYS-1866; RP ARG-1866; ARG-1883; LEU-1932 AND GLN-3757. RX PubMed=30827496; DOI=10.1016/j.ajhg.2019.01.010; RG CAUSES Study; RG Deciphering Developmental Disorders study; RA Cogne B., Ehresmann S., Beauregard-Lacroix E., Rousseau J., Besnard T., RA Garcia T., Petrovski S., Avni S., McWalter K., Blackburn P.R., RA Sanders S.J., Uguen K., Harris J., Cohen J.S., Blyth M., Lehman A., RA Berg J., Li M.H., Kini U., Joss S., von der Lippe C., Gordon C.T., RA Humberson J.B., Robak L., Scott D.A., Sutton V.R., Skraban C.M., RA Johnston J.J., Poduri A., Nordenskjoeld M., Shashi V., Gerkes E.H., RA Bongers E.M.H.F., Gilissen C., Zarate Y.A., Kvarnung M., Lally K.P., RA Kulch P.A., Daniels B., Hernandez-Garcia A., Stong N., McGaughran J., RA Retterer K., Tveten K., Sullivan J., Geisheker M.R., Stray-Pedersen A., RA Tarpinian J.M., Klee E.W., Sapp J.C., Zyskind J., Holla O.L., Bedoukian E., RA Filippini F., Guimier A., Picard A., Busk O.L., Punetha J., Pfundt R., RA Lindstrand A., Nordgren A., Kalb F., Desai M., Ebanks A.H., Jhangiani S.N., RA Dewan T., Coban Akdemir Z.H., Telegrafi A., Zackai E.H., Begtrup A., RA Song X., Toutain A., Wentzensen I.M., Odent S., Bonneau D., Latypova X., RA Deb W., Redon S., Bilan F., Legendre M., Troyer C., Whitlock K., RA Caluseriu O., Murphree M.I., Pichurin P.N., Agre K., Gavrilova R., RA Rinne T., Park M., Shain C., Heinzen E.L., Xiao R., Amiel J., Lyonnet S., RA Isidor B., Biesecker L.G., Lowenstein D., Posey J.E., Denomme-Pichon A.S., RA Ferec C., Yang X.J., Rosenfeld J.A., Gilbert-Dussardier B., RA Audebert-Bellanger S., Redon R., Stessman H.A.F., Nellaker C., Yang Y., RA Lupski J.R., Goldstein D.B., Eichler E.E., Bolduc F., Bezieau S., Kuery S., RA Campeau P.M.; RT "Missense Variants in the Histone Acetyltransferase Complex Component Gene RT TRRAP Cause Autism and Syndromic Intellectual Disability."; RL Am. J. Hum. Genet. 104:530-541(2019). RN [34] RP VARIANTS DFNA75 CYS-171 AND ASN-394, VARIANT ASP-2750, AND INVOLVEMENT IN RP DFNA75. RX PubMed=31231791; DOI=10.1111/cge.13590; RA Xia W., Hu J., Ma J., Huang J., Wang X., Jiang N., Zhang J., Ma Z., Ma D.; RT "Novel TRRAP mutation causes autosomal dominant non-syndromic hearing RT loss."; RL Clin. Genet. 96:300-308(2019). CC -!- FUNCTION: Adapter protein, which is found in various multiprotein CC chromatin complexes with histone acetyltransferase activity (HAT), CC which gives a specific tag for epigenetic transcription activation. CC Component of the NuA4 histone acetyltransferase complex which is CC responsible for acetylation of nucleosomal histones H4 and H2A. Plays a CC central role in MYC transcription activation, and also participates in CC cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4- CC mediated transcription activation. Also involved in transcription CC activation mediated by the adenovirus E1A, a viral oncoprotein that CC deregulates transcription of key genes. Probably acts by linking CC transcription factors such as E1A, MYC or E2F1 to HAT complexes such as CC STAGA thereby allowing transcription activation. Probably not required CC in the steps following histone acetylation in processes of CC transcription activation. May be required for the mitotic checkpoint CC and normal cell cycle progression. Component of a SWR1-like complex CC that specifically mediates the removal of histone H2A.Z/H2AZ1 from the CC nucleosome. May play a role in the formation and maintenance of the CC auditory system (By similarity). {ECO:0000250|UniProtKB:A0A0R4ITC5, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:12660246, ECO:0000269|PubMed:12743606, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738}. CC -!- SUBUNIT: Interacts with MYC, E2F1 and E2F4 transcription factors. CC Interacts directly with p53/TP53. Interacts with GCN5L2. Component of CC various HAT complexes. Component of the PCAF complex, at least composed CC of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65- CC alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component CC of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L, CC SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5, CC TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase CC complex which contains the catalytic subunit KAT5/TIP60 and the CC subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, CC RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, CC MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of CC the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L, CC TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core CC complex is associated with a subcomplex required for histone CC deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the CC BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and CC TRRAP, which preferentially acetylates histone H4 (and H2A) within CC nucleosomes. Interacts with NPAT. Interaction with TELO2 and TTI1. CC Component of a SWR1-like complex. {ECO:0000269|PubMed:10373431, CC ECO:0000269|PubMed:10611234, ECO:0000269|PubMed:10966108, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:18206972, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738, CC ECO:0000269|PubMed:9885574}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:9708738}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9Y4A5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y4A5-2; Sequence=VSP_009102, VSP_009103; CC -!- DOMAIN: The PI3K/PI4K domain is required for the recruitment of HAT CC complexes, and the MYC-dependent transactivation. Although it is CC strongly related to the PI3/PI4-kinase family, it lacks the typical CC motifs that constitute the catalytic site of PI3/PI4-kinase proteins, CC and lacks such activity. {ECO:0000269|PubMed:11445536}. CC -!- DISEASE: Note=TRRAP mutation Phe-722 has been frequently found in CC cutaneous malignant melanoma, suggesting that TRRAP may play a role in CC the pathogenesis of melanoma. {ECO:0000269|PubMed:21499247}. CC -!- DISEASE: Developmental delay with or without dysmorphic facies and CC autism (DEDDFA) [MIM:618454]: An autosomal dominant neurodevelopmental CC disorder apparent from infancy or early childhood. Some patients CC present with intellectual disability and renal, cardiac, genitourinary CC systems, as well as structural brain abnormalities. In some cases, the CC phenotype is less severe, has no systemic involvement and is CC characterized by autism spectrum disorder and/or intellectual CC disability, sometimes associated with epilepsy. Affected individuals CC manifest variable dysmorphic features. {ECO:0000269|PubMed:30424743, CC ECO:0000269|PubMed:30827496}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778]: A form CC of non-syndromic deafness characterized by late-onset hearing loss that CC involves mid and high frequencies, and progresses to encompass all CC frequencies. {ECO:0000269|PubMed:31231791}. Note=The disease may be CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. TRA1 subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC62433.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF076974; AAD09420.1; -; mRNA. DR EMBL; AF110377; AAD04629.1; -; mRNA. DR EMBL; AC004893; AAC62433.1; ALT_SEQ; Genomic_DNA. DR EMBL; AC004991; AAC27675.2; -; Genomic_DNA. DR EMBL; CH471091; EAW76694.1; -; Genomic_DNA. DR EMBL; CH236956; EAL23887.1; -; Genomic_DNA. DR CCDS; CCDS5659.1; -. [Q9Y4A5-2] DR CCDS; CCDS59066.1; -. [Q9Y4A5-1] DR PIR; T02632; T02632. DR RefSeq; NP_001231509.1; NM_001244580.2. [Q9Y4A5-1] DR RefSeq; NP_003487.1; NM_003496.4. [Q9Y4A5-2] DR PDB; 7KTR; EM; 2.93 A; A=369-3859. DR PDB; 8H7G; EM; 3.70 A; C=1-3859. DR PDB; 8QRI; EM; 3.50 A; C=1-3859. DR PDB; 8XVG; EM; 9.40 A; L=1-3859. DR PDB; 8XVV; EM; 3.20 A; L=1-3859. DR PDB; 9C47; EM; 3.40 A; C=1-3859. DR PDB; 9CAD; EM; 3.05 A; D=1-3859. DR PDB; 9CAF; EM; 2.35 A; D=1-3859. DR PDBsum; 7KTR; -. DR PDBsum; 8H7G; -. DR PDBsum; 8QRI; -. DR PDBsum; 8XVG; -. DR PDBsum; 8XVV; -. DR PDBsum; 9C47; -. DR PDBsum; 9CAD; -. DR PDBsum; 9CAF; -. DR EMDB; EMD-18612; -. DR EMDB; EMD-18613; -. DR EMDB; EMD-18618; -. DR EMDB; EMD-18619; -. DR EMDB; EMD-34520; -. DR EMDB; EMD-38703; -. DR EMDB; EMD-38720; -. DR EMDB; EMD-45176; -. DR EMDB; EMD-45387; -. DR EMDB; EMD-45389; -. DR SMR; Q9Y4A5; -. DR BioGRID; 113900; 797. DR ComplexPortal; CPX-6802; SAGA complex, KAT2B variant. DR ComplexPortal; CPX-900; SAGA complex, KAT2A variant. DR ComplexPortal; CPX-903; TFTC histone acetylation complex. DR ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex. DR ComplexPortal; CPX-989; PCAF histone acetylase complex. DR CORUM; Q9Y4A5; -. DR DIP; DIP-28149N; -. DR FunCoup; Q9Y4A5; 1798. DR MINT; Q9Y4A5; -. DR STRING; 9606.ENSP00000352925; -. DR GlyGen; Q9Y4A5; 9 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (5 sites). DR iPTMnet; Q9Y4A5; -. DR MetOSite; Q9Y4A5; -. DR PhosphoSitePlus; Q9Y4A5; -. DR SwissPalm; Q9Y4A5; -. DR BioMuta; TRRAP; -. DR DMDM; 116242829; -. DR jPOST; Q9Y4A5; -. DR MassIVE; Q9Y4A5; -. DR PaxDb; 9606-ENSP00000352925; -. DR PeptideAtlas; Q9Y4A5; -. DR ProteomicsDB; 86142; -. [Q9Y4A5-1] DR ProteomicsDB; 86143; -. [Q9Y4A5-2] DR Pumba; Q9Y4A5; -. DR Antibodypedia; 16027; 189 antibodies from 23 providers. DR DNASU; 8295; -. DR Ensembl; ENST00000355540.7; ENSP00000347733.3; ENSG00000196367.15. [Q9Y4A5-2] DR Ensembl; ENST00000359863.8; ENSP00000352925.4; ENSG00000196367.15. [Q9Y4A5-1] DR GeneID; 8295; -. DR KEGG; hsa:8295; -. DR UCSC; uc003upp.3; human. [Q9Y4A5-1] DR AGR; HGNC:12347; -. DR ClinPGx; PA37020; -. DR CTD; 8295; -. DR DisGeNET; 8295; -. DR GeneCards; TRRAP; -. DR HGNC; HGNC:12347; TRRAP. DR HPA; ENSG00000196367; Low tissue specificity. DR MalaCards; TRRAP; -. DR MIM; 603015; gene. DR MIM; 618454; phenotype. DR MIM; 618778; phenotype. DR OpenTargets; ENSG00000196367; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000196367; -. DR eggNOG; KOG0889; Eukaryota. DR GeneTree; ENSGT00390000017961; -. DR InParanoid; Q9Y4A5; -. DR OrthoDB; 5570127at2759; -. DR PAN-GO; Q9Y4A5; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y4A5; -. DR PathwayCommons; Q9Y4A5; -. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3214847; HATs acetylate histones. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR SignaLink; Q9Y4A5; -. DR SIGNOR; Q9Y4A5; -. DR Agora; ENSG00000196367; -. DR BioGRID-ORCS; 8295; 773 hits in 1197 CRISPR screens. DR ChiTaRS; TRRAP; human. DR GenomeRNAi; 8295; -. DR Pharos; Q9Y4A5; Tbio. DR PRO; PR:Q9Y4A5; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9Y4A5; protein. DR Bgee; ENSG00000196367; Expressed in ventricular zone and 156 other cell types or tissues. DR ExpressionAtlas; Q9Y4A5; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0000786; C:nucleosome; IDA:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000124; C:SAGA complex; IDA:UniProtKB. DR GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB. DR GO; GO:0033276; C:transcription factor TFTC complex; IDA:UniProtKB. DR GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB. DR GO; GO:0140861; P:DNA repair-dependent chromatin remodeling; IBA:GO_Central. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:ComplexPortal. DR GO; GO:0042981; P:regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0051726; P:regulation of cell cycle; IMP:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0043484; P:regulation of RNA splicing; NAS:ComplexPortal. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR CDD; cd05163; PIKK_TRRAP; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR046807; Tra1_central. DR InterPro; IPR046805; Tra1_ring. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF1; TRANSFORMATION_TRANSCRIPTION DOMAIN-ASSOCIATED PROTEIN; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF20175; Tra1_central; 1. DR Pfam; PF20206; Tra1_ring; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; KW Autism spectrum disorder; Chromatin regulator; Deafness; KW Direct protein sequencing; Disease variant; Intellectual disability; KW Isopeptide bond; Non-syndromic deafness; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3859 FT /note="Transformation/transcription domain-associated FT protein" FT /id="PRO_0000088851" FT DOMAIN 2692..3275 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 3500..3823 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3827..3859 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 491..541 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2010..2388 FT /note="Interaction with TP53" FT /evidence="ECO:0000269|PubMed:12138177" FT REGION 2023..2044 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2543..2578 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 3506..3512 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3687..3695 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3707..3732 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 2047..2062 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 491..526 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 529..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2033..2044 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2543..2554 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 1628 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2051 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163" FT MOD_RES 2077 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 3078 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 2543 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1492..1509 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009102" FT VAR_SEQ 3001..3012 FT /note="GKPTWSGMHSSS -> A (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009103" FT VARIANT 171 FT /note="R -> C (in DFNA75; uncertain significance; FT dbSNP:rs200157211)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083794" FT VARIANT 394 FT /note="D -> N (in DFNA75; uncertain significance; FT dbSNP:rs1554407965)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083795" FT VARIANT 722 FT /note="S -> F (found in a cutaneous malignant melanoma FT sample; somatic mutation; induces cell transformation and FT confers resistance to apoptosis; dbSNP:rs147405090)" FT /evidence="ECO:0000269|PubMed:21499247" FT /id="VAR_067754" FT VARIANT 805 FT /note="L -> F (in DEDDFA; uncertain significance; FT dbSNP:rs1562940289)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082969" FT VARIANT 860 FT /note="F -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082970" FT VARIANT 878 FT /note="R -> L (in dbSNP:rs17161510)" FT /id="VAR_028359" FT VARIANT 893 FT /note="R -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041658" FT VARIANT 893 FT /note="R -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082971" FT VARIANT 1031 FT /note="I -> M (in DEDDFA; dbSNP:rs1187165148)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082972" FT VARIANT 1035 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs2116495143)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082973" FT VARIANT 1037 FT /note="S -> R (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082974" FT VARIANT 1043 FT /note="A -> T (in DEDDFA; dbSNP:rs1562945106)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082975" FT VARIANT 1070 FT /note="S -> G (in dbSNP:rs55920979)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041659" FT VARIANT 1104 FT /note="E -> G (in DEDDFA; dbSNP:rs1790257064)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082976" FT VARIANT 1106 FT /note="E -> K (in DEDDFA; dbSNP:rs1584324956)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082977" FT VARIANT 1111 FT /note="G -> W (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082978" FT VARIANT 1159 FT /note="G -> R (in DEDDFA; dbSNP:rs1790288810)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082979" FT VARIANT 1669 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs373632999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041660" FT VARIANT 1724 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs782203759)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041661" FT VARIANT 1859 FT /note="R -> C (in DEDDFA; dbSNP:rs1791432323)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082980" FT VARIANT 1866 FT /note="W -> C (in DEDDFA; uncertain significance; FT dbSNP:rs1562957576)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082981" FT VARIANT 1866 FT /note="W -> R (in DEDDFA; dbSNP:rs1562957569)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082982" FT VARIANT 1883 FT /note="G -> R (in DEDDFA)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082983" FT VARIANT 1925 FT /note="A -> V (in dbSNP:rs56197298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041662" FT VARIANT 1932 FT /note="P -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:30827496" FT /id="VAR_041663" FT VARIANT 1947 FT /note="R -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041664" FT VARIANT 2004 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs1562959030)" FT /evidence="ECO:0000269|PubMed:30424743" FT /id="VAR_082984" FT VARIANT 2139 FT /note="W -> G (in dbSNP:rs34185633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041665" FT VARIANT 2302 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs528967912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041666" FT VARIANT 2433 FT /note="S -> G (in dbSNP:rs35634065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041667" FT VARIANT 2690 FT /note="P -> L (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs753661271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041668" FT VARIANT 2750 FT /note="E -> D (in dbSNP:rs55755466)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:31231791" FT /id="VAR_041669" FT VARIANT 2801 FT /note="K -> E (in dbSNP:rs56341061)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041670" FT VARIANT 2931 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1294404368)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041671" FT VARIANT 3757 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs987263983)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082985" FT CONFLICT 660 FT /note="E -> D (in Ref. 2; AAD04629)" FT /evidence="ECO:0000305" FT HELIX 20..26 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 30..33 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 37..50 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 55..57 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 59..74 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 80..84 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 85..99 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 107..118 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 122..124 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 128..139 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 148..171 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 214..227 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 234..243 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 244..254 FT /evidence="ECO:0007829|PDB:9C47" FT TURN 255..259 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 276..293 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 294..298 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 307..319 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 320..322 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 325..338 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 342..345 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 347..351 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 365..367 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 371..385 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 387..389 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 392..406 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 413..434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 436..438 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 442..469 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 535..564 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 583..599 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 600..604 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 605..607 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 613..615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 627..639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 644..654 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 657..664 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 669..677 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 679..681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 682..695 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 698..702 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 704..723 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 725..732 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 736..747 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 774..779 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 780..782 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 783..795 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 821..827 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 828..835 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 839..855 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 858..865 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 869..879 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 885..898 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 899..903 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 923..927 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 929..931 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 934..938 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 940..951 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 952..955 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 957..973 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 981..988 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 992..995 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1005..1007 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1013..1029 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1032..1034 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1035..1057 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1058..1061 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1064..1066 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1067..1069 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1074..1076 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1080..1082 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1085..1087 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1091..1101 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1102..1104 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1107..1126 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1129..1132 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1136..1146 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1147..1150 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1151..1153 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1154..1170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1173..1193 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1194..1196 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1199..1201 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1202..1218 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1223..1225 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1228..1248 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1254..1271 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1275..1279 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1280..1285 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1287..1289 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1297..1299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1302..1315 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1317..1320 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1327..1329 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1330..1344 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1347..1351 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1354..1357 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1360..1362 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1363..1375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1376..1378 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1380..1382 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1383..1394 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1399..1413 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1415..1418 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1420..1431 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1435..1437 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1442..1454 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1456..1458 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1461..1484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1511..1523 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1524..1526 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1529..1531 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1532..1546 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1549..1551 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1555..1562 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1566..1573 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1576..1579 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1582..1592 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1594..1596 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1598..1605 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1609..1612 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1613..1615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1638..1653 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1657..1659 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1661..1672 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1674..1681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1692..1706 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1707..1709 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1710..1715 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1716..1718 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1719..1721 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1723..1725 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1728..1738 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1740..1743 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1746..1748 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1749..1758 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1760..1766 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1770..1773 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1774..1776 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1777..1786 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1804..1813 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1818..1820 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1828..1841 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1846..1853 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1854..1859 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1861..1870 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1877..1893 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1900..1911 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1913..1915 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1921..1925 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1928..1931 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1950..1964 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1966..1970 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1972..1974 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1976..1985 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1990..2000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2003..2016 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2021..2026 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2031..2042 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2045..2060 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2064..2073 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2077..2088 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2096..2099 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2105..2111 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2114..2118 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2120..2133 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2139..2141 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2146..2154 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2155..2157 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2158..2161 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2165..2182 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2184..2189 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2191..2200 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 2201..2203 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2205..2207 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 2212..2219 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2226..2232 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2233..2235 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2240..2251 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2257..2273 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2278..2286 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2287..2290 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2292..2294 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2295..2299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2301..2312 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2320..2331 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2340..2357 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2361..2375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2382..2384 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2389..2406 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2411..2426 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2429..2434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2435..2439 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2440..2448 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2452..2464 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2470..2478 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2483..2486 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2492..2500 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2506..2508 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2514..2516 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2523..2527 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2530..2538 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2586..2602 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2607..2618 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2622..2639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2642..2656 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2659..2666 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2671..2679 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2682..2684 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2690..2699 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2703..2714 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2718..2720 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2728..2730 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2742..2755 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2758..2768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2772..2781 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2782..2784 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2786..2806 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2811..2813 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2814..2830 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2834..2841 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2844..2847 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2849..2856 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2857..2859 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2862..2872 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2873..2875 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2878..2880 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2881..2894 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2904..2919 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2928..2930 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2931..2952 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2955..2957 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2961..2976 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2985..3000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3012..3020 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3028..3051 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3054..3062 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3063..3066 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3072..3089 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3090..3092 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3095..3106 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3115..3131 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3132..3134 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3135..3148 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3153..3170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3173..3186 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3192..3195 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3196..3205 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3206..3208 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3214..3222 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3224..3226 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 3228..3234 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3235..3242 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3247..3260 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3262..3283 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3284..3286 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3295..3310 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3312..3324 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3325..3328 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3332..3354 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3355..3358 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3365..3376 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3396..3407 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3411..3423 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3429..3432 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3434..3452 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3457..3460 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3461..3463 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3466..3470 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3473..3475 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3481..3484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3489..3491 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3495..3499 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3501..3507 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3509..3520 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3525..3531 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3536..3552 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3553..3557 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3562..3565 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3574..3578 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3581..3585 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3588..3592 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3593..3604 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3610..3625 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3631..3644 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3650..3658 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3662..3685 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3693..3695 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3696..3699 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3700..3702 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3705..3708 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3716..3718 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3719..3721 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3726..3729 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3733..3739 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3741..3745 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3747..3759 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3762..3764 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3766..3789 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3798..3800 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3804..3826 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3829..3831 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3834..3842 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3845..3848 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3853..3855 FT /evidence="ECO:0007829|PDB:7KTR" SQ SEQUENCE 3859 AA; 437600 MW; 391E467C0047B00B CRC64; MAFVATQGAT VVDQTTLMKK YLQFVAALTD VNTPDETKLK MMQEVSENFE NVTSSPQYST FLEHIIPRFL TFLQDGEVQF LQEKPAQQLR KLVLEIIHRI PTNEHLRPHT KNVLSVMFRF LETENEENVL ICLRIIIELH KQFRPPITQE IHHFLDFVKQ IYKELPKVVN RYFENPQVIP ENTVPPPEMV GMITTIAVKV NPEREDSETR THSIIPRGSL SLKVLAELPI IVVLMYQLYK LNIHNVVAEF VPLIMNTIAI QVSAQARQHK LYNKELYADF IAAQIKTLSF LAYIIRIYQE LVTKYSQQMV KGMLQLLSNC PAETAHLRKE LLIAAKHILT TELRNQFIPC MDKLFDESIL IGSGYTARET LRPLAYSTLA DLVHHVRQHL PLSDLSLAVQ LFAKNIDDES LPSSIQTMSC KLLLNLVDCI RSKSEQESGN GRDVLMRMLE VFVLKFHTIA RYQLSAIFKK CKPQSELGAV EAALPGVPTA PAAPGPAPSP APVPAPPPPP PPPPPATPVT PAPVPPFEKQ GEKDKEDKQT FQVTDCRSLV KTLVCGVKTI TWGITSCKAP GEAQFIPNKQ LQPKETQIYI KLVKYAMQAL DIYQVQIAGN GQTYIRVANC QTVRMKEEKE VLEHFAGVFT MMNPLTFKEI FQTTVPYMVE RISKNYALQI VANSFLANPT TSALFATILV EYLLDRLPEM GSNVELSNLY LKLFKLVFGS VSLFAAENEQ MLKPHLHKIV NSSMELAQTA KEPYNYFLLL RALFRSIGGG SHDLLYQEFL PLLPNLLQGL NMLQSGLHKQ HMKDLFVELC LTVPVRLSSL LPYLPMLMDP LVSALNGSQT LVSQGLRTLE LCVDNLQPDF LYDHIQPVRA ELMQALWRTL RNPADSISHV AYRVLGKFGG SNRKMLKESQ KLHYVVTEVQ GPSITVEFSD CKASLQLPME KAIETALDCL KSANTEPYYR RQAWEVIKCF LVAMMSLEDN KHALYQLLAH PNFTEKTIPN VIISHRYKAQ DTPARKTFEQ ALTGAFMSAV IKDLRPSALP FVASLIRHYT MVAVAQQCGP FLLPCYQVGS QPSTAMFHSE ENGSKGMDPL VLIDAIAICM AYEEKELCKI GEVALAVIFD VASIILGSKE RACQLPLFSY IVERLCACCY EQAWYAKLGG VVSIKFLMER LPLTWVLQNQ QTFLKALLFV MMDLTGEVSN GAVAMAKTTL EQLLMRCATP LKDEERAEEI VAAQEKSFHH VTHDLVREVT SPNSTVRKQA MHSLQVLAQV TGKSVTVIME PHKEVLQDMV PPKKHLLRHQ PANAQIGLME GNTFCTTLQP RLFTMDLNVV EHKVFYTELL NLCEAEDSAL TKLPCYKSLP SLVPLRIAAL NALAACNYLP QSREKIIAAL FKALNSTNSE LQEAGEACMR KFLEGATIEV DQIHTHMRPL LMMLGDYRSL TLNVVNRLTS VTRLFPNSFN DKFCDQMMQH LRKWMEVVVI THKGGQRSDG NESISECGRC PLSPFCQFEE MKICSAIINL FHLIPAAPQT LVKPLLEVVM KTERAMLIEA GSPFREPLIK FLTRHPSQTV ELFMMEATLN DPQWSRMFMS FLKHKDARPL RDVLAANPNR FITLLLPGGA QTAVRPGSPS TSTMRLDLQF QAIKIISIIV KNDDSWLASQ HSLVSQLRRV WVSENFQERH RKENMAATNW KEPKLLAYCL LNYCKRNYGD IELLFQLLRA FTGRFLCNMT FLKEYMEEEI PKNYSIAQKR ALFFRFVDFN DPNFGDELKA KVLQHILNPA FLYSFEKGEG EQLLGPPNPE GDNPESITSV FITKVLDPEK QADMLDSLRI YLLQYATLLV EHAPHHIHDN NKNRNSKLRR LMTFAWPCLL SKACVDPACK YSGHLLLAHI IAKFAIHKKI VLQVFHSLLK AHAMEARAIV RQAMAILTPA VPARMEDGHQ MLTHWTRKII VEEGHTVPQL VHILHLIVQH FKVYYPVRHH LVQHMVSAMQ RLGFTPSVTI EQRRLAVDLS EVVIKWELQR IKDQQPDSDM DPNSSGEGVN SVSSSIKRGL SVDSAQEVKR FRTATGAISA VFGRSQSLPG ADSLLAKPID KQHTDTVVNF LIRVACQVND NTNTAGSPGE VLSRRCVNLL KTALRPDMWP KSELKLQWFD KLLMTVEQPN QVNYGNICTG LEVLSFLLTV LQSPAILSSF KPLQRGIAAC MTCGNTKVLR AVHSLLSRLM SIFPTEPSTS SVASKYEELE CLYAAVGKVI YEGLTNYEKA TNANPSQLFG TLMILKSACS NNPSYIDRLI SVFMRSLQKM VREHLNPQAA SGSTEATSGT SELVMLSLEL VKTRLAVMSM EMRKNFIQAI LTSLIEKSPD AKILRAVVKI VEEWVKNNSP MAANQTPTLR EKSILLVKMM TYIEKRFPED LELNAQFLDL VNYVYRDETL SGSELTAKLE PAFLSGLRCA QPLIRAKFFE VFDNSMKRRV YERLLYVTCS QNWEAMGNHF WIKQCIELLL AVCEKSTPIG TSCQGAMLPS ITNVINLADS HDRAAFAMVT HVKQEPRERE NSESKEEDVE IDIELAPGDQ TSTPKTKELS EKDIGNQLHM LTNRHDKFLD TLREVKTGAL LSAFVQLCHI STTLAEKTWV QLFPRLWKIL SDRQQHALAG EISPFLCSGS HQVQRDCQPS ALNCFVEAMS QCVPPIPIRP CVLKYLGKTH NLWFRSTLML EHQAFEKGLS LQIKPKQTTE FYEQESITPP QQEILDSLAE LYSLLQEEDM WAGLWQKRCK YSETATAIAY EQHGFFEQAQ ESYEKAMDKA KKEHERSNAS PAIFPEYQLW EDHWIRCSKE LNQWEALTEY GQSKGHINPY LVLECAWRVS NWTAMKEALV QVEVSCPKEM AWKVNMYRGY LAICHPEEQQ LSFIERLVEM ASSLAIREWR RLPHVVSHVH TPLLQAAQQI IELQEAAQIN AGLQPTNLGR NNSLHDMKTV VKTWRNRLPI VSDDLSHWSS IFMWRQHHYQ GKPTWSGMHS SSIVTAYENS SQHDPSSNNA MLGVHASASA IIQYGKIARK QGLVNVALDI LSRIHTIPTV PIVDCFQKIR QQVKCYLQLA GVMGKNECMQ GLEVIESTNL KYFTKEMTAE FYALKGMFLA QINKSEEANK AFSAAVQMHD VLVKAWAMWG DYLENIFVKE RQLHLGVSAI TCYLHACRHQ NESKSRKYLA KVLWLLSFDD DKNTLADAVD KYCIGVPPIQ WLAWIPQLLT CLVGSEGKLL LNLISQVGRV YPQAVYFPIR TLYLTLKIEQ RERYKSDPGP IRATAPMWRC SRIMHMQREL HPTLLSSLEG IVDQMVWFRE NWHEEVLRQL QQGLAKCYSV AFEKSGAVSD AKITPHTLNF VKKLVSTFGV GLENVSNVST MFSSAASESL ARRAQATAQD PVFQKLKGQF TTDFDFSVPG SMKLHNLISK LKKWIKILEA KTKQLPKFFL IEEKCRFLSN FSAQTAEVEI PGEFLMPKPT HYYIKIARFM PRVEIVQKHN TAARRLYIRG HNGKIYPYLV MNDACLTESR REERVLQLLR LLNPCLEKRK ETTKRHLFFT VPRVVAVSPQ MRLVEDNPSS LSLVEIYKQR CAKKGIEHDN PISRYYDRLA TVQARGTQAS HQVLRDILKE VQSNMVPRSM LKEWALHTFP NATDYWTFRK MFTIQLALIG FAEFVLHLNR LNPEMLQIAQ DTGKLNVAYF RFDINDATGD LDANRPVPFR LTPNISEFLT TIGVSGPLTA SMIAVARCFA QPNFKVDGIL KTVLRDEIIA WHKKTQEDTS SPLSAAGQPE NMDSQQLVSL VQKAVTAIMT RLHNLAQFEG GESKVNTLVA AANSLDNLCR MDPAWHPWL // ID UFO_HUMAN Reviewed; 894 AA. AC P30530; Q8N5L2; Q9UD27; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 4. DT 28-JAN-2026, entry version 241. DE RecName: Full=Tyrosine-protein kinase receptor UFO; DE EC=2.7.10.1 {ECO:0000269|PubMed:28076778}; DE AltName: Full=AXL oncogene; DE Flags: Precursor; GN Name=AXL; Synonyms=UFO; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ROLE IN MYELOID LEUKEMIA. RC TISSUE=Fibroblast; RX PubMed=1656220; DOI=10.1128/mcb.11.10.5016-5031.1991; RA O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., RA Espinosa R., le Beau M.M., Earp H., Liu E.T.; RT "AXL, a transforming gene isolated from primary human myeloid leukemia RT cells, encodes a novel receptor tyrosine kinase."; RL Mol. Cell. Biol. 11:5016-5031(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG). RX PubMed=1834974; RA Janssen J.W.G., Schulz A.S., Steenvoorden A.C.M., Schmidberger M., RA Strehl S., Ambros P., Bartram C.R.; RT "A novel putative tyrosine kinase receptor with oncogenic potential."; RL Oncogene 6:2113-2120(1991). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 674-730. RX PubMed=8247543; RA Lee S.-T., Strunk K.M., Spritz R.A.; RT "A survey of protein tyrosine kinase mRNAs expressed in normal human RT melanocytes."; RL Oncogene 8:3403-3410(1993). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 677-730, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Colon tumor; RX PubMed=7896447; DOI=10.1002/ijc.2910600611; RA Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S., RA Varnum B., Liu E.T., Cance W.G.; RT "Receptor tyrosine kinases expressed in metastatic colon cancer."; RL Int. J. Cancer 60:791-797(1995). RN [8] RP INTERACTION WITH LIGAND GAS6. RX PubMed=7854420; DOI=10.1038/373623a0; RA Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D., Fridell Y.W., RA Hunt R.W., Trail G., Clogston C., Toso R.J., Yanagihara D., Bennett L., RA Silber M., Merewether L.A., Tseng A., Escobar E., Liu E.T., Yamane H.K.; RT "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein RT encoded by growth-arrest-specific gene 6."; RL Nature 373:623-626(1995). RN [9] RP INTERACTION WITH GAS6, AND ACTIVITY REGULATION. RX PubMed=8621659; DOI=10.1074/jbc.271.16.9785; RA Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.; RT "Characterization of Gas6, a member of the superfamily of G domain- RT containing proteins, as a ligand for Rse and Axl."; RL J. Biol. Chem. 271:9785-9789(1996). RN [10] RP PHOSPHORYLATION AT TYR-779; TYR-821 AND TYR-866, AND INTERACTION WITH GRB2; RP LCK; PIK3R1; PIK3R2 AND PLCG1. RX PubMed=9178760; DOI=10.1038/sj.onc.1201123; RA Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R., RA Ullrich A., Bartram C.R., Janssen J.W.; RT "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is RT mediated mainly by a multi-substrate docking-site."; RL Oncogene 14:2619-2631(1997). RN [11] RP ROLE IN PROSTATIC CARCINOMA. RX PubMed=10403904; DOI=10.1046/j.1525-1500.1999.99034.x; RA Jacob A.N., Kalapurakal J., Davidson W.R., Kandpal G., Dunson N., RA Prashar Y., Kandpal R.P.; RT "A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a RT modified differential display PCR are overexpressed in metastatic prostatic RT carcinoma cell line DU145."; RL Cancer Detect. Prev. 23:325-332(1999). RN [12] RP ROLE IN BREAST CANCER. RX PubMed=11484958; DOI=10.1023/a:1011126330233; RA Berclaz G., Altermatt H.J., Rohrbach V., Kieffer I., Dreher E., RA Andres A.C.; RT "Estrogen dependent expression of the receptor tyrosine kinase axl in RT normal and malignant human breast."; RL Ann. Oncol. 12:819-824(2001). RN [13] RP INTERACTION WITH NCK2; PIK3R3; SOCS1 AND TNS2. RX PubMed=12470648; DOI=10.1016/s0006-291x(02)02718-3; RA Hafizi S., Alindri F., Karlsson R., Dahlbaeck B.; RT "Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 RT domain-containing protein with homology to tensin."; RL Biochem. Biophys. Res. Commun. 299:793-800(2002). RN [14] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=12364394; DOI=10.1161/01.res.0000036753.50601.e9; RA D'Arcangelo D., Gaetano C., Capogrossi M.C.; RT "Acidification prevents endothelial cell apoptosis by Axl activation."; RL Circ. Res. 91:E4-12(2002). RN [15] RP ROLE IN THYROID CARCINOMAS. RX PubMed=12490074; DOI=10.1089/105072502320908303; RA Ito M., Nakashima M., Nakayama T., Ohtsuru A., Nagayama Y., Takamura N., RA Demedchik E.P., Sekine I., Yamashita S.; RT "Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in RT pediatric thyroid carcinomas around Chernobyl."; RL Thyroid 12:971-975(2002). RN [16] RP INTERACTION WITH CBL AND GAS6, AND UBIQUITINATION. RX PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086; RA Valverde P.; RT "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and RT downregulation."; RL Biochem. Biophys. Res. Commun. 333:180-185(2005). RN [17] RP ACTIVITY REGULATION, AND FUNCTION. RX PubMed=15507525; DOI=10.1182/blood-2004-04-1469; RA Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B., RA Avanzi G.C., Bussolino F.; RT "Inhibition of vascular endothelial growth factor receptor 2-mediated RT endothelial cell activation by Axl tyrosine kinase receptor."; RL Blood 105:1970-1976(2005). RN [18] RP FUNCTION IN PLATELET ACTIVATION AND THROMBOTIC RESPONSE REGULATION. RX PubMed=15733062; DOI=10.1111/j.1538-7836.2005.01186.x; RA Gould W.R., Baxi S.M., Schroeder R., Peng Y.W., Leadley R.J., RA Peterson J.T., Perrin L.A.; RT "Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate RT thrombotic responses."; RL J. Thromb. Haemost. 3:733-741(2005). RN [19] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=17005688; DOI=10.1128/jvi.01157-06; RA Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T., RA Jones S., Feldmann H., Kawaoka Y.; RT "Tyro3 family-mediated cell entry of Ebola and Marburg viruses."; RL J. Virol. 80:10109-10116(2006). RN [20] RP INTERACTION WITH GRB2; PIK3R1 AND PIK3R2, AND PHOSPHORYLATION AT TYR-779; RP TYR-821 AND TYR-866. RX PubMed=18346204; DOI=10.1111/j.1471-4159.2008.05343.x; RA Weinger J.G., Gohari P., Yan Y., Backer J.M., Varnum B., Shafit-Zagardo B.; RT "In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; RT in vitro mutagenesis defines the requisite binding sites for downstream Akt RT activation."; RL J. Neurochem. 106:134-146(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-884, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=18840707; DOI=10.1182/blood-2008-05-157073; RA Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A.; RT "The Axl/Gas6 pathway is required for optimal cytokine signaling during RT human natural killer cell development."; RL Blood 113:2470-2477(2009). RN [23] RP INTERACTION WITH GRB2 AND TNK2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [24] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21501828; DOI=10.1016/j.chom.2011.03.012; RA Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M., Chen I.S.; RT "The soluble serum protein Gas6 bridges virion envelope phosphatidylserine RT to the TAM receptor tyrosine kinase Axl to mediate viral entry."; RL Cell Host Microbe 9:286-298(2011). RN [25] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22156524; DOI=10.1128/jvi.06451-11; RA Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.; RT "Identification of cell surface molecules involved in dystroglycan- RT independent Lassa virus cell entry."; RL J. Virol. 86:2067-2078(2012). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22673088; DOI=10.1292/jvms.12-0176; RA Shimojima M., Kawaoka Y.; RT "Cell surface molecules involved in infection mediated by lymphocytic RT choriomeningitis virus glycoprotein."; RL J. Vet. Med. Sci. 74:1363-1366(2012). RN [27] RP FUNCTION (MICROBIAL INFECTION), AND REVIEW. RX PubMed=25277499; DOI=10.1016/j.virol.2014.09.009; RA Moller-Tank S., Maury W.; RT "Phosphatidylserine receptors: enhancers of enveloped virus entry and RT infection."; RL Virology 468:565-580(2014). RN [28] RP FUNCTION (MICROBIAL INFECTION), MUTAGENESIS OF LYS-567, CATALYTIC ACTIVITY, RP AND SUBCELLULAR LOCATION. RX PubMed=28076778; DOI=10.1016/j.celrep.2016.12.045; RA Meertens L., Labeau A., Dejarnac O., Cipriani S., Sinigaglia L., RA Bonnet-Madin L., Le Charpentier T., Hafirassou M.L., Zamborlini A., RA Cao-Lormeau V.M., Coulpier M., Misse D., Jouvenet N., Tabibiazar R., RA Gressens P., Schwartz O., Amara A.; RT "Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate RT Immune Responses."; RL Cell Rep. 18:324-333(2017). RN [29] RP INDUCTION BY MOSQUITO LYMPHOTOXIN BETA RECEPTOR INHIBITOR DURING ZIKA VIRUS RP INFECTION (MICROBIAL INFECTION). RX PubMed=29507355; DOI=10.1038/s41590-018-0063-9; RA Jin L., Guo X., Shen C., Hao X., Sun P., Li P., Xu T., Hu C., Rose O., RA Zhou H., Yang M., Qin C.F., Guo J., Peng H., Zhu M., Cheng G., Qi X., RA Lai R.; RT "Salivary factor LTRIN from Aedes aegypti facilitates the transmission of RT Zika virus by interfering with the lymphotoxin-beta receptor."; RL Nat. Immunol. 19:342-353(2018). RN [30] RP FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=29379210; DOI=10.1038/s41564-017-0092-4; RA Chen J., Yang Y.F., Yang Y., Zou P., Chen J., He Y., Shui S.L., Cui Y.R., RA Bai R., Liang Y.J., Hu Y., Jiang B., Lu L., Zhang X., Liu J., Xu J.; RT "AXL promotes Zika virus infection in astrocytes by antagonizing type I RT interferon signalling."; RL Nat. Microbiol. 3:302-309(2018). RN [31] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=31311882; DOI=10.1128/mbio.01372-19; RA Strange D.P., Jiyarom B., Pourhabibi Zarandi N., Xie X., Baker C., RA Sadri-Ardekani H., Shi P.Y., Verma S.; RT "Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human RT Sertoli Cells."; RL MBio 10:0-0(2019). RN [32] RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 33-227 IN COMPLEX WITH GAS6, RP MUTAGENESIS OF GLU-63; GLU-66 AND THR-84, AND SUBUNIT. RX PubMed=16362042; DOI=10.1038/sj.emboj.7600912; RA Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W., Ullrich A., RA Timpl R., Hohenester E.; RT "Structural basis for Gas6-Axl signalling."; RL EMBO J. 25:80-87(2006). RN [33] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; TRP-295; CYS-499 AND GLY-515. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the CC extracellular matrix into the cytoplasm by binding growth factor GAS6 CC and which is thus regulating many physiological processes including CC cell survival, cell proliferation, migration and differentiation. CC Ligand binding at the cell surface induces dimerization and CC autophosphorylation of AXL. Following activation by ligand, AXL binds CC and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, CC PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other CC downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. CC Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory CC subunits by AXL leads to the downstream activation of the AKT kinase. CC GAS6/AXL signaling plays a role in various processes such as CC endothelial cell survival during acidification by preventing apoptosis, CC optimal cytokine signaling during human natural killer cell CC development, hepatic regeneration, gonadotropin-releasing hormone CC neuron survival and migration, platelet activation, or regulation of CC thrombotic responses. Also plays an important role in inhibition of CC Toll-like receptors (TLRs)-mediated innate immune response. CC {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958, CC ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074, CC ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062, CC ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and CC lymphocytic choriomeningitis virus, possibly through GAS6 binding to CC phosphatidyl-serine at the surface of virion envelope. CC {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828, CC ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, CC possibly through GAS6 binding to phosphatidyl-serine at the surface of CC virion envelope. {ECO:0000269|PubMed:22673088}. CC -!- FUNCTION: (Microbial infection) Promotes Zika virus entry in glial CC cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210, CC PubMed:31311882). Additionally, Zika virus potentiates AXL kinase CC activity to antagonize type I interferon signaling and thereby promotes CC infection (PubMed:28076778). Interferon signaling inhibition occurs via CC an SOCS1-dependent mechanism (PubMed:29379210). CC {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210, CC ECO:0000269|PubMed:31311882}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:28076778}; CC -!- ACTIVITY REGULATION: Activated by GAS6-binding and subsequent CC autophosphorylation. {ECO:0000269|PubMed:15507525, CC ECO:0000269|PubMed:8621659}. CC -!- SUBUNIT: Heterodimer and heterotetramer with ligand GAS6. Interacts CC with CBL, GRB2, LCK, NCK2, PIK3R1, PIK3R2, PIK3R3, PLCG1, SOCS1 and CC TNS2. Part of a complex including AXL, TNK2 and GRB2, in which GRB2 CC promotes AXL recruitment by TNK2. {ECO:0000269|PubMed:12470648, CC ECO:0000269|PubMed:15958209, ECO:0000269|PubMed:16362042, CC ECO:0000269|PubMed:18346204, ECO:0000269|PubMed:19815557, CC ECO:0000269|PubMed:7854420, ECO:0000269|PubMed:8621659, CC ECO:0000269|PubMed:9178760}. CC -!- INTERACTION: CC P30530; P00533: EGFR; NbExp=5; IntAct=EBI-2850927, EBI-297353; CC P30530; P29317: EPHA2; NbExp=2; IntAct=EBI-2850927, EBI-702104; CC P30530; Q14393-2: GAS6; NbExp=8; IntAct=EBI-2850927, EBI-21517417; CC P30530; P62993: GRB2; NbExp=4; IntAct=EBI-2850927, EBI-401755; CC P30530; P08238: HSP90AB1; NbExp=3; IntAct=EBI-2850927, EBI-352572; CC P30530; Q01638: IL1RL1; NbExp=2; IntAct=EBI-2850927, EBI-993762; CC P30530; P27986: PIK3R1; NbExp=3; IntAct=EBI-2850927, EBI-79464; CC P30530; O43791: SPOP; NbExp=5; IntAct=EBI-2850927, EBI-743549; CC P30530; P0DTC2: S; Xeno; NbExp=9; IntAct=EBI-2850927, EBI-25474821; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28076778, CC ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:7896447}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:7896447}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; CC IsoId=P30530-1; Sequence=Displayed; CC Name=Short; CC IsoId=P30530-2; Sequence=VSP_005017; CC -!- TISSUE SPECIFICITY: Highly expressed in metastatic colon tumors. CC Expressed in primary colon tumors. Weakly expressed in normal colon CC tissue. {ECO:0000269|PubMed:7896447}. CC -!- INDUCTION: (Microbial infection) Up-regulated by Aedes aegypti CC lymphotoxin beta receptor inhibitor during Zika virus infection. CC {ECO:0000269|PubMed:29507355}. CC -!- PTM: Monoubiquitinated upon GAS6-binding. A very small proportion of CC the receptor could be subjected to polyubiquitination in a very CC transient fashion. {ECO:0000269|PubMed:15958209}. CC -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which CC activates kinase activity. {ECO:0000269|PubMed:18346204, CC ECO:0000269|PubMed:9178760}. CC -!- DISEASE: Note=AXL and its ligand GAS6 are highly expressed in thyroid CC carcinoma tissues, and might thus be involved in thyroid tumorigenesis. CC Overexpression of AXL and its ligand was also detected in many other CC cancers such as myeloproliferative disorders, prostatic carcinoma CC cells, or breast cancer. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/733/AXL"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M76125; AAA61243.1; -; mRNA. DR EMBL; S65125; AAB20305.1; -; mRNA. DR EMBL; X57019; CAA40338.1; -; mRNA. DR EMBL; AC011510; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032229; AAH32229.1; -; mRNA. DR CCDS; CCDS12574.1; -. [P30530-2] DR CCDS; CCDS12575.1; -. [P30530-1] DR PIR; A41527; A41527. DR RefSeq; NP_001690.2; NM_001699.5. [P30530-2] DR RefSeq; NP_068713.2; NM_021913.4. [P30530-1] DR PDB; 2C5D; X-ray; 3.30 A; C/D=33-227. DR PDB; 4RA0; X-ray; 3.07 A; C/D=33-227. DR PDB; 5U6B; X-ray; 2.84 A; A/B/C/D=514-818. DR PDB; 5VXZ; X-ray; 2.30 A; C/D=34-135. DR PDBsum; 2C5D; -. DR PDBsum; 4RA0; -. DR PDBsum; 5U6B; -. DR PDBsum; 5VXZ; -. DR AlphaFoldDB; P30530; -. DR SMR; P30530; -. DR BioGRID; 107036; 404. DR CORUM; P30530; -. DR FunCoup; P30530; 354. DR IntAct; P30530; 298. DR MINT; P30530; -. DR STRING; 9606.ENSP00000301178; -. DR BindingDB; P30530; -. DR ChEMBL; CHEMBL4895; -. DR DrugBank; DB12411; Bemcentinib. DR DrugBank; DB15187; Dubermatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12141; Gilteritinib. DR DrugBank; DB19201; Tamnorzatinib. DR DrugCentral; P30530; -. DR GuidetoPHARMACOLOGY; 1835; -. DR GlyConnect; 1983; 12 N-Linked glycans (4 sites). DR GlyCosmos; P30530; 8 sites, 12 glycans. DR GlyGen; P30530; 10 sites, 13 N-linked glycans (4 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P30530; -. DR PhosphoSitePlus; P30530; -. DR BioMuta; AXL; -. DR DMDM; 239938818; -. DR CPTAC; CPTAC-1766; -. DR CPTAC; CPTAC-2791; -. DR jPOST; P30530; -. DR MassIVE; P30530; -. DR PaxDb; 9606-ENSP00000301178; -. DR PeptideAtlas; P30530; -. DR ProteomicsDB; 54712; -. [P30530-1] DR ProteomicsDB; 54713; -. [P30530-2] DR Pumba; P30530; -. DR ABCD; P30530; 23 sequenced antibodies. DR Antibodypedia; 30709; 1302 antibodies from 46 providers. DR CPTC; P30530; 2 antibodies. DR DNASU; 558; -. DR Ensembl; ENST00000301178.9; ENSP00000301178.3; ENSG00000167601.13. [P30530-1] DR Ensembl; ENST00000359092.7; ENSP00000351995.2; ENSG00000167601.13. [P30530-2] DR GeneID; 558; -. DR KEGG; hsa:558; -. DR MANE-Select; ENST00000301178.9; ENSP00000301178.3; NM_021913.5; NP_068713.2. DR UCSC; uc010ehj.5; human. [P30530-1] DR AGR; HGNC:905; -. DR CIViC; 558; 1 evidence item across 1 molecular profile. DR ClinPGx; PA25197; -. DR CTD; 558; -. DR DisGeNET; 558; -. DR GeneCards; AXL; -. DR GeneReviews; AXL; -. DR HGNC; HGNC:905; AXL. DR HPA; ENSG00000167601; Low tissue specificity. DR MalaCards; AXL; -. DR MIM; 109135; gene. DR OpenTargets; ENSG00000167601; -. DR VEuPathDB; HostDB:ENSG00000167601; -. DR eggNOG; ENOG502QQQ3; Eukaryota. DR GeneTree; ENSGT00940000160232; -. DR InParanoid; P30530; -. DR OMA; WTIMSTL; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P30530; 13 GO annotations based on evolutionary models. DR PhylomeDB; P30530; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P30530; -. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR SignaLink; P30530; -. DR SIGNOR; P30530; -. DR Agora; ENSG00000167601; -. DR BioGRID-ORCS; 558; 17 hits in 1198 CRISPR screens. DR ChiTaRS; AXL; human. DR EvolutionaryTrace; P30530; -. DR GeneWiki; AXL_receptor_tyrosine_kinase; -. DR GenomeRNAi; 558; -. DR Pharos; P30530; Tchem. DR PRO; PR:P30530; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P30530; protein. DR Bgee; ENSG00000167601; Expressed in synovial joint and 206 other cell types or tissues. DR ExpressionAtlas; P30530; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IDA:FlyBase. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEP:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB. DR GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB. DR GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0021885; P:forebrain cell migration; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0001779; P:natural killer cell differentiation; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB. DR GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl. DR GO; GO:0010936; P:negative regulation of macrophage cytokine production; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl. DR GO; GO:0032689; P:negative regulation of type II interferon production; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl. DR GO; GO:0042698; P:ovulation cycle; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IDA:UniProtKB. DR GO; GO:0030168; P:platelet activation; IBA:GO_Central. DR GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0048549; P:positive regulation of pinocytosis; IMP:CACAO. DR GO; GO:1903902; P:positive regulation of viral life cycle; IMP:FlyBase. DR GO; GO:0032940; P:secretion by cell; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:CACAO. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome. DR CDD; cd00063; FN3; 2. DR CDD; cd20966; IgI_1_Axl_like; 1. DR CDD; cd05749; IgI_2_Axl_Tyro3_like; 1. DR CDD; cd05075; PTKc_Axl; 1. DR FunFam; 2.60.40.10:FF:000865; AXL receptor tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:000089; Tyrosine-protein kinase receptor TYRO3; 1. DR FunFam; 2.60.40.10:FF:000662; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000810; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 3.30.200.20:FF:000509; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000696; tyrosine-protein kinase receptor UFO isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR PANTHER; PTHR24416:SF323; TYROSINE-PROTEIN KINASE RECEPTOR UFO; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Differentiation; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Immunity; KW Immunoglobulin domain; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Oncogene; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..894 FT /note="Tyrosine-protein kinase receptor UFO" FT /id="PRO_0000024481" FT TOPO_DOM 26..451 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 452..472 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 473..894 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 27..128 FT /note="Ig-like C2-type 1" FT DOMAIN 139..222 FT /note="Ig-like C2-type 2" FT DOMAIN 227..331 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 336..428 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 536..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 26..92 FT /note="Interaction with GAS6" FT REGION 823..853 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 866..894 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 672 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 542..550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 703 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 779 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 821 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 866 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 884 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 157 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 339 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 401 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 56..117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 160..205 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 429..437 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:1656220" FT /id="VSP_005017" FT VARIANT 112 FT /note="T -> M (in dbSNP:rs35202236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045596" FT VARIANT 266 FT /note="D -> N (in dbSNP:rs7249222)" FT /id="VAR_057990" FT VARIANT 295 FT /note="R -> W (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs751738506)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045597" FT VARIANT 499 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs747576071)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041877" FT VARIANT 515 FT /note="S -> G (in dbSNP:rs1240393707)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041878" FT MUTAGEN 63 FT /note="E->R: Slightly reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 66 FT /note="E->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 84 FT /note="T->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 567 FT /note="K->M: Catalytically inactive mutant." FT /evidence="ECO:0000269|PubMed:28076778" FT CONFLICT 303 FT /note="T -> P (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 338 FT /note="E -> K (in Ref. 2; AAA61243)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="Q -> E (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 639 FT /note="D -> G (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 696 FT /note="K -> I (in Ref. 7; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 764 FT /note="Q -> R (in Ref. 5; AAH32229)" FT /evidence="ECO:0000305" FT STRAND 37..39 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 44..46 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 52..63 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 68..71 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 80..87 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 89..91 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 94..106 FT /evidence="ECO:0007829|PDB:5VXZ" FT HELIX 109..111 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 113..121 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 131..134 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 140..143 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 156..159 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 170..175 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 178..187 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 190..194 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 201..209 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 219..223 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 533..535 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 536..544 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 546..556 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 558..571 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 576..590 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 602..605 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 628..637 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 638..640 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 646..665 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 678..680 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 686..688 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 698..700 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 713..715 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 718..723 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 728..743 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 755..763 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 796..809 FT /evidence="ECO:0007829|PDB:5U6B" SQ SEQUENCE 894 AA; 98337 MW; 262D3659218E3202 CRC64; MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL TGTLRCQLQV QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS QLRITSLQLS DTGQYQCLVF LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV AANTPFNLSC QAQGPPEPVD LLWLQDAVPL ATAPGHGPQR SLHVPGLNKT SSFSCEAHNA KGVTTSRTAT ITVLPQQPRN LHLVSRQPTE LEVAWTPGLS GIYPLTHCTL QAVLSDDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF VHWQEPRAPL QGTLLGYRLA YQGQDTPEVL MDIGLRQEVT LELQGDGSVS NLTVCVAAYT AAGDGPWSLP VPLEAWRPGQ AQPVHQLVKE PSTPAFSWPW WYVLLGAVVA AACVLILALF LVHRRKKETR YGEVFEPTVE RGELVVRYRV RKSYSRRTTE ATLNSLGISE ELKEKLRDVM VDRHKVALGK TLGEGEFGAV MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLPTQMLV KFMADIASGM EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG DYYRQGRIAK MPVKWIAIES LADRVYTSKS DVWSFGVTMW EIATRGQTPY PGVENSEIYD YLRQGNRLKQ PADCLDGLYA LMSRCWELNP QDRPSFTELR EDLENTLKAL PPAQEPDEIL YVNMDEGGGY PEPPGAAGGA DPPTQPDPKD SCSCLTAAEV HPAGRYVLCP STTPSPAQPA DRGSPAAPGQ EDGA // ID WEE2_HUMAN Reviewed; 567 AA. AC P0C1S8; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 28-JUL-2009, sequence version 2. DT 28-JAN-2026, entry version 147. DE RecName: Full=Wee1-like protein kinase 2; DE EC=2.7.10.2; DE AltName: Full=Wee1-like protein kinase 1B; DE AltName: Full=Wee1B kinase; GN Name=WEE2; Synonyms=WEE1B; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=11029659; DOI=10.1046/j.1365-2443.2000.00367.x; RA Nakanishi M., Ando H., Watanabe N., Kitamura K., Ito K., Okayama H., RA Miyamoto T., Agui T., Sasaki M.; RT "Identification and characterization of human Wee1B, a new member of the RT Wee1 family of Cdk-inhibitory kinases."; RL Genes Cells 5:839-847(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] THR-8; LYS-332; HIS-398; GLU-470 AND RP ASP-526. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP INVOLVEMENT IN OZEMA5, VARIANT OZEMA5 HIS-234, CHARACTERIZATION OF VARIANT RP OZEMA5 HIS-234, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND RP PHOSPHORYLATION. RX PubMed=29606300; DOI=10.1016/j.ajhg.2018.02.015; RA Sang Q., Li B., Kuang Y., Wang X., Zhang Z., Chen B., Wu L., Lyu Q., Fu Y., RA Yan Z., Mao X., Xu Y., Mu J., Li Q., Jin L., He L., Wang L.; RT "Homozygous Mutations in WEE2 Cause Fertilization Failure and Female RT Infertility."; RL Am. J. Hum. Genet. 102:649-657(2018). CC -!- FUNCTION: Oocyte-specific protein tyrosine kinase that phosphorylates CC and inhibits CDK1/CDC2 and acts as a key regulator of meiosis during CC both prophase I and metaphase II (PubMed:29606300). Required to CC maintain meiotic arrest in oocytes during the germinal vesicle (GV) CC stage, a long period of quiescence at dictyate prophase I, by CC phosphorylating CDK1 at 'Tyr-15', leading to inhibit CDK1 activity and CC prevent meiotic reentry. Also required for metaphase II exit during egg CC activation by phosphorylating CDK1 at 'Tyr-15', to ensure exit from CC meiosis in oocytes and promote pronuclear formation (By similarity). CC {ECO:0000250|UniProtKB:Q66JT0, ECO:0000269|PubMed:29606300}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10027}; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11029659, CC ECO:0000269|PubMed:29606300}. CC -!- TISSUE SPECIFICITY: Expressed in oocytes (at protein level) CC (PubMed:29606300). May also be expressed in testis (PubMed:11029659). CC {ECO:0000269|PubMed:11029659, ECO:0000269|PubMed:29606300}. CC -!- PTM: Phosphorylated on serine residues (PubMed:29606300). CC Phosphorylation leads to increase its activity (By similarity). CC {ECO:0000250|UniProtKB:Q66JT0, ECO:0000269|PubMed:29606300}. CC -!- DISEASE: Oocyte/zygote/embryo maturation arrest 5 (OZEMA5) CC [MIM:617996]: An autosomal recessive infertility disorder characterized CC by oocyte inability to exit metaphase II, resulting in fertilization CC failure. {ECO:0000269|PubMed:29606300}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. WEE1 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131218; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC004918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS43660.1; -. DR RefSeq; NP_001099028.1; NM_001105558.1. DR PDB; 5VDK; X-ray; 2.70 A; A=202-492. DR PDBsum; 5VDK; -. DR AlphaFoldDB; P0C1S8; -. DR SMR; P0C1S8; -. DR BioGRID; 138978; 2. DR FunCoup; P0C1S8; 956. DR STRING; 9606.ENSP00000380675; -. DR BindingDB; P0C1S8; -. DR ChEMBL; CHEMBL5095; -. DR DrugCentral; P0C1S8; -. DR GlyGen; P0C1S8; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P0C1S8; -. DR PhosphoSitePlus; P0C1S8; -. DR BioMuta; WEE2; -. DR DMDM; 254763343; -. DR jPOST; P0C1S8; -. DR MassIVE; P0C1S8; -. DR PaxDb; 9606-ENSP00000380675; -. DR PeptideAtlas; P0C1S8; -. DR Antibodypedia; 32491; 120 antibodies from 24 providers. DR DNASU; 494551; -. DR Ensembl; ENST00000397541.6; ENSP00000380675.2; ENSG00000214102.8. DR Ensembl; ENST00000574659.5; ENSP00000459392.1; ENSG00000263042.5. DR GeneID; 494551; -. DR KEGG; hsa:494551; -. DR MANE-Select; ENST00000397541.6; ENSP00000380675.2; NM_001105558.1; NP_001099028.1. DR UCSC; uc003vwn.2; human. DR AGR; HGNC:19684; -. DR ClinPGx; PA134909633; -. DR CTD; 494551; -. DR DisGeNET; 494551; -. DR GeneCards; WEE2; -. DR HGNC; HGNC:19684; WEE2. DR HPA; ENSG00000214102; Not detected. DR MalaCards; WEE2; -. DR MIM; 614084; gene. DR MIM; 617996; phenotype. DR OpenTargets; ENSG00000214102; -. DR Orphanet; 488191; Female infertility due to oocyte meiotic arrest. DR VEuPathDB; HostDB:ENSG00000214102; -. DR eggNOG; KOG0601; Eukaryota. DR GeneTree; ENSGT00940000158803; -. DR HOGENOM; CLU_000288_25_1_1; -. DR InParanoid; P0C1S8; -. DR OMA; PLKDEMT; -. DR OrthoDB; 5337378at2759; -. DR PAN-GO; P0C1S8; 3 GO annotations based on evolutionary models. DR PhylomeDB; P0C1S8; -. DR PathwayCommons; P0C1S8; -. DR SignaLink; P0C1S8; -. DR SIGNOR; P0C1S8; -. DR Agora; ENSG00000214102; -. DR BioGRID-ORCS; 494551; 11 hits in 1174 CRISPR screens. DR GenomeRNAi; 494551; -. DR Pharos; P0C1S8; Tchem. DR PRO; PR:P0C1S8; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P0C1S8; protein. DR Bgee; ENSG00000214102; Expressed in primordial germ cell in gonad and 83 other cell types or tissues. DR ExpressionAtlas; P0C1S8; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0007143; P:female meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0035038; P:female pronucleus assembly; ISS:UniProtKB. DR GO; GO:0000278; P:mitotic cell cycle; IEA:InterPro. DR GO; GO:1900194; P:negative regulation of oocyte maturation; ISS:UniProtKB. DR GO; GO:0042327; P:positive regulation of phosphorylation; IEA:Ensembl. DR GO; GO:0080154; P:regulation of fertilization; IEA:Ensembl. DR GO; GO:0060631; P:regulation of meiosis I; ISS:UniProtKB. DR CDD; cd14139; PTKc_Wee1b; 1. DR FunFam; 3.30.200.20:FF:000115; Wee1-like kinase 2; 1. DR FunFam; 1.10.510.10:FF:000217; Wee1-like protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR017164; Wee1-like_protein_kinase. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR PANTHER; PTHR11042:SF75; WEE1-LIKE PROTEIN KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF037281; Wee1-like_protein_kinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Coiled coil; Disease variant; Kinase; Magnesium; KW Meiosis; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transferase; KW Tyrosine-protein kinase. FT CHAIN 1..567 FT /note="Wee1-like protein kinase 2" FT /id="PRO_0000248079" FT DOMAIN 212..486 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..117 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 514..567 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 494..519 FT /evidence="ECO:0000255" FT MOTIF 173..175 FT /note="Nuclear localization signal" FT /evidence="ECO:0000250" FT MOTIF 315..329 FT /note="Nuclear export signal" FT /evidence="ECO:0000250" FT COMPBIAS 1..12 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 25..35 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 42..51 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 64..77 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 339 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 218..226 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 241 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 344 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250" FT BINDING 380 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250" FT MOD_RES 76 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:A4PES0" FT VARIANT 8 FT /note="K -> T (in dbSNP:rs35672788)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041304" FT VARIANT 234 FT /note="D -> H (in OZEMA5; decreased WEE2 phosphorylation at FT serine residues; decreased CDK1/CDC2 phosphorylation at 'Y- FT 15'; dbSNP:rs1554415096)" FT /evidence="ECO:0000269|PubMed:29606300" FT /id="VAR_080992" FT VARIANT 332 FT /note="N -> K (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041305" FT VARIANT 398 FT /note="R -> H (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs200610853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041306" FT VARIANT 470 FT /note="D -> E (in dbSNP:rs55901099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041307" FT VARIANT 526 FT /note="Y -> D (in dbSNP:rs35683659)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041308" FT CONFLICT 351 FT /note="M -> V (in Ref. 2; AK131218)" FT /evidence="ECO:0000305" FT CONFLICT 529 FT /note="H -> Y (in Ref. 2; AK131218)" FT /evidence="ECO:0000305" FT HELIX 207..211 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 212..221 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 224..231 FT /evidence="ECO:0007829|PDB:5VDK" FT TURN 232..234 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 237..245 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 251..253 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 255..265 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 275..281 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 284..290 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 297..306 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 313..332 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 344..348 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 375..378 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 385..389 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 397..399 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 402..405 FT /evidence="ECO:0007829|PDB:5VDK" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 413..428 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 437..443 FT /evidence="ECO:0007829|PDB:5VDK" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 457..467 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 469..471 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:5VDK" SQ SEQUENCE 567 AA; 62925 MW; BC05DDFE96D87E3F CRC64; MDDKDIDKEL RQKLNFSYCE ETEIEGQKKV EESREASSQT PEKGEVQDSE AKGTPPWTPL SNVHELDTSS EKDKESPDQI LRTPVSHPLK CPETPAQPDS RSKLLPSDSP STPKTMLSRL VISPTGKLPS RGPKHLKLTP APLKDEMTSL ALVNINPFTP ESYKKLFLQS GGKRKIRGDL EEAGPEEGKG GLPAKRCVLR ETNMASRYEK EFLEVEKIGV GEFGTVYKCI KRLDGCVYAI KRSMKTFTEL SNENSALHEV YAHAVLGHHP HVVRYYSSWA EDDHMIIQNE YCNGGSLQAA ISENTKSGNH FEEPKLKDIL LQISLGLNYI HNSSMVHLDI KPSNIFICHK MQSESSGVIE EVENEADWFL SANVMYKIGD LGHATSINKP KVEEGDSRFL ANEILQEDYR HLPKADIFAL GLTIAVAAGA ESLPTNGAAW HHIRKGNFPD VPQELSESFS SLLKNMIQPD AEQRPSAAAL ARNTVLRPSL GKTEELQQQL NLEKFKTATL ERELREAQQA QSPQGYTHHG DTGVSGTHTG SRSTKRLVGG KSARSSSFTS GEREPLH //